<SEC-DOCUMENT>0001641172-25-020763.txt : 20250724
<SEC-HEADER>0001641172-25-020763.hdr.sgml : 20250724
<ACCEPTANCE-DATETIME>20250723215843
ACCESSION NUMBER:		0001641172-25-020763
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		143
FILED AS OF DATE:		20250724
DATE AS OF CHANGE:		20250723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288912
		FILM NUMBER:		251144371

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>forms-4.htm
<DESCRIPTION>S-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CYCC="http://cyclacel.com/20250331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_CYCC_cyclacel.com_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001130166 -->
<!-- Field: Set; Name: xdx; ID: xdx_079_XDX_forms%2D4.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_061_GBP_0_iso4217%2D%2DGBP -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_Segment_5_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000004" name="dei:EntityCentralIndexKey">0001130166</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0188" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:AccrualOfPreferredStockDividends" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0615" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" contextRef="AsOf2024-12-31" id="xdx2ixbrl0708" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0949" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0951" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0962" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0989" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1005" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1134" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:EffectiveIncomeTaxRateReconciliationOtherItemsAmount" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" contextRef="AsOf2024-12-31" id="xdx2ixbrl1153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" contextRef="AsOf2023-12-31" id="xdx2ixbrl1154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="xdx2ixbrl1163" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1171" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1194" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember54207687" id="xdx2ixbrl1222" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31_country_US" id="xdx2ixbrl1269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2025-03-31" id="xdx2ixbrl1332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl1354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="xdx2ixbrl1362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="xdx2ixbrl1363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl1376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl1377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl1381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl1382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl1386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl1387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl1393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl1399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-03-31" id="xdx2ixbrl1412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2025-01-012025-03-31_custom_ClinicalTrialSupplyMember" id="xdx2ixbrl1427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl1458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl1476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl1523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1579" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1590" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1594" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1598" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1656" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1664" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1672" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1679" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1680" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueTranslationAdjustment" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueTranslationAdjustment" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueTranslationAdjustment" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueTranslationAdjustment" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1689" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1692" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1693" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1695" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1702" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl1713" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1730" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl1755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1757" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl1758" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl1767" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIncomeTaxRefunds" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl1797" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" id="xdx2ixbrl1799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:AccrualOfPreferredStockDividends" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1805" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:AccrualOfPreferredStockDividends" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl1806" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl1837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl1857" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl1860" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2025-03-31" id="xdx2ixbrl1882" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:AccruedResearchAndDevelopmentCostCurrent" contextRef="AsOf2025-03-31" id="xdx2ixbrl1889" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CYCC:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" contextRef="AsOf2025-03-31" id="xdx2ixbrl1919" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1971" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1977" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1979" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1990" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl2001" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cycc-20250331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SixPercentConvertibleExchangeablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SixPercentConvertibleExchangeablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SixPercentConvertibleExchangeablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SixPercentConvertibleExchangeablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SixPercentConvertibleExchangeablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ClinicalTrialSupplyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CYCC:ClinicalTrialSupplyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialSupplyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CYCC:ClinicalTrialSupplyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ClinicalTrialSupplyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CYCC:ClinicalTrialSupplyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_ClinicalTrialSupplyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CYCC:ClinicalTrialSupplyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-292025-01-29_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-29</xbrli:startDate>
        <xbrli:endDate>2025-01-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-02_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-312025-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-31</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-042025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-04</xbrli:startDate>
        <xbrli:endDate>2025-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-052025-02-05_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_custom_HelenaSpecialOpportunitiesOneLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:HelenaSpecialOpportunitiesOneLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-05</xbrli:startDate>
        <xbrli:endDate>2025-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-062025-02-06_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-06</xbrli:startDate>
        <xbrli:endDate>2025-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-112025-02-11_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-11</xbrli:startDate>
        <xbrli:endDate>2025-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-11_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-112025-02-11_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-11</xbrli:startDate>
        <xbrli:endDate>2025-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-11_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-11</xbrli:startDate>
        <xbrli:endDate>2025-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-112025-02-11_custom_SeriesCAndDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCAndDConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-11</xbrli:startDate>
        <xbrli:endDate>2025-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-262025-02-26_custom_SeriesCAndDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCAndDConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-26</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-262025-02-26_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-26</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-262025-02-26_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-26</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-262025-02-26_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-26</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-102025-03-10_us-gaap_SubsequentEventMember_custom_CyclacelLimitedUnitedKingdomMember_custom_AssetsOfCyclacelLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CyclacelLimitedUnitedKingdomMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CYCC:AssetsOfCyclacelLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-10</xbrli:startDate>
        <xbrli:endDate>2025-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-212025-03-21_custom_SeriesEConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-21</xbrli:startDate>
        <xbrli:endDate>2025-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-21_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_custom_SeriesEConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_RombotisSettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:RombotisSettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_McBarronSettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:McBarronSettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_RombotisSettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:RombotisSettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_McBarronSettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:McBarronSettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-182023-12-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-18</xbrli:startDate>
        <xbrli:endDate>2023-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-242025-01-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-24</xbrli:startDate>
        <xbrli:endDate>2025-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:MdAndersonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:ClinicalCollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:MdAndersonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:ClinicalCollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OfficeEquipmentAndFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CYCC:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OfficeEquipmentAndFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CYCC:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_custom_OfficeEquipmentAndFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CYCC:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_custom_OfficeEquipmentAndFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CYCC:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnitedKingdomSubsidiaryCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CYCC:UnitedKingdomSubsidiaryCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_UnitedKingdomSubsidiaryCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CYCC:UnitedKingdomSubsidiaryCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_BerkeleyHeightsFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:BerkeleyHeightsFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DundeeScotlandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:DundeeScotlandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DundeeScotlandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:DundeeScotlandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BerkeleyHeightsFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:BerkeleyHeightsFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesDWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesDWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-30</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsAndCommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsAndCommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-30</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-022024-05-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-02</xbrli:startDate>
        <xbrli:endDate>2024-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-29_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-14_custom_RothCapitalPartnersLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:RothCapitalPartnersLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-30_custom_LadenburgThalmannCo.IncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:LadenburgThalmannCo.IncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember54201031">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-26_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CYCC:ChiefFinancialOfficerAndChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CYCC:ChiefFinancialOfficerAndChiefOperatingOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-21</xbrli:startDate>
        <xbrli:endDate>2023-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-21</xbrli:startDate>
        <xbrli:endDate>2023-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-122021-08-12_custom_CantorFitzgeraldCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CantorFitzgeraldCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-12</xbrli:startDate>
        <xbrli:endDate>2021-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CantorFitzgeraldCoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:August2021ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-12</xbrli:startDate>
        <xbrli:endDate>2022-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CantorFitzgeraldCoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:August2021ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-152022-08-15_custom_CantorFitzgeraldCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CantorFitzgeraldCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-15</xbrli:startDate>
        <xbrli:endDate>2022-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesCWarrantsMember_custom_November2024WarrantExerciseAndReloadAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesDWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAWarrantsMember_custom_April2024WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:April2024WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_custom_April2024WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:April2024WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_December2023PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DecemberTwoThousandTwentyThreePrivatePlacementMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreePrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_December2023PrivatePlacementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_December2023PlacementAgencyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PlacementAgencyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_December2023PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DecemberTwoThousandTwentyWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyWarrantMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DecemberTwoThousandTwentyWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AprilTwoThousandTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PlacementAgentWarrantsMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SeriesCWarrantsMember_custom_November2024WarrantExerciseAndReloadAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesDWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SeriesAWarrantsMember_custom_April2024WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:April2024WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_custom_April2024WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:April2024WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_December2023PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_DecemberTwoThousandTwentyThreePrivatePlacementMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreePrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_December2023PrivatePlacementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_December2023PlacementAgencyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PlacementAgencyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_December2023PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_December2023PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_DecemberTwoThousandTwentyWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_DecemberTwoThousandTwentyWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_DecemberTwoThousandTwentyWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_AprilTwoThousandTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-24_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_srt_MinimumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_srt_MaximumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-21_custom_EquityIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-13_custom_EquityIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EquityIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EquityIncentivePlan2018Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EquityIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:InducementEquityIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:InducementEquityIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_OptionsVestingOnThirdAnniversaryOfGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">CYCC:OptionsVestingOnThirdAnniversaryOfGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-06_custom_EquityIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_EquityIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_EquityIncentivePlan2018Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_EquityIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:InducementEquityIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_Plan401KMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">CYCC:Plan401KMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_Plan401KMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">CYCC:Plan401KMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_InternalRevenueServiceIRSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_InternalRevenueServiceIRSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember54207625">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember54207640">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember54207656">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember54207656">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember54207671">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember54207671">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember54207671">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember54207687">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStockWarrantsMember54207703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_GB">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_GB">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_country_GB">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_GB">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SingleReportableSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CYCC:SingleReportableSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SingleReportableSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CYCC:SingleReportableSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember54208953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember54208968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember54208968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember54208984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_SixPercentConvertibleExchangeablePreferredMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:SixPercentConvertibleExchangeablePreferredMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_SixPercentConvertibleExchangeablePreferredMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:SixPercentConvertibleExchangeablePreferredMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember54209000">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember54209015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember54209015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_CommonStockWarrantsMember54209031">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_DundeeScotlandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:DundeeScotlandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_DundeeScotlandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:DundeeScotlandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_KualaLumpurFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:KualaLumpurFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-192025-04-19_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-19</xbrli:startDate>
        <xbrli:endDate>2025-04-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-022025-04-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-02</xbrli:startDate>
        <xbrli:endDate>2025-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-29_us-gaap_SeriesEPreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-292025-04-29_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-29</xbrli:startDate>
        <xbrli:endDate>2025-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-06_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-06_custom_FittersDiversifiedBerhadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">CYCC:FittersDiversifiedBerhadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-072025-05-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-07</xbrli:startDate>
        <xbrli:endDate>2025-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>CYCC:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="GBP">
      <xbrli:measure>iso4217:GBP</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>CYCC:Segment</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> with the Securities and Exchange Commission
on July 23, 2025.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-_____</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20250101__20250331_zpBG6kufnhH8"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000013" name="dei:DocumentType">S-4</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20250101__20250331_zzNZdcTZUg83"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000014" name="dei:EntityRegistrantName">CYCLACEL
PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20250101__20250331_zRXFO6c39H8f"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:stateprovnameen" id="Fact000015" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20250101__20250331_zrLKSq15jtBe"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000016" name="dei:EntityTaxIdentificationNumber">93-2403210</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20250101__20250331_zdWrNcVe29bi"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000017" name="dei:EntityAddressAddressLine1">Level
10, Tower 11</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20250101__20250331_zspo6tANFN0a"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000018" name="dei:EntityAddressAddressLine2">Avenue 5, The Horizon</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine3_c20250101__20250331_zM2ngTL7RV6"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000019" name="dei:EntityAddressAddressLine3">Bangsar
South City, No. 8, Jalan Kerinchi</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressPostalZipCode_c20250101__20250331_zwzjbsD4EVB6"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000020" name="dei:EntityAddressPostalZipCode">59200</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressCityOrTown_c20250101__20250331_zmiiZKvOc1u3"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000021" name="dei:EntityAddressCityOrTown">Kuala Lumpur</ix:nonNumeric></span>, Malaysia</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
Of Principal Executive Offices And Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_90A_edei--CityAreaCode_c20250101__20250331_zT8yknZkmaZc"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000022" name="dei:CityAreaCode">(908)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20250101__20250331_z49dsi3sBHTk"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000023" name="dei:LocalPhoneNumber">517-7330</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--ContactPersonnelName_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zcuKrnkmkZJk"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" id="Fact000024" name="dei:ContactPersonnelName">Datuk
Dr. Doris Wong</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cyclacel
Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zglSRfDMUv7e"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" id="Fact000025" name="dei:EntityAddressAddressLine1">Level
10, Tower 11</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zQ3JgQCfXZ06"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" id="Fact000026" name="dei:EntityAddressAddressLine2">Avenue 5, The Horizon</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine3_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zJlfe0NBz0d5"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" id="Fact000027" name="dei:EntityAddressAddressLine3">Bangsar
South City, No. 8, Jalan Kerinchi</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zhyLVwSwqepf"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" id="Fact000028" name="dei:EntityAddressPostalZipCode">59200</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressCityOrTown_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zILHSfWzRNV3"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" id="Fact000029" name="dei:EntityAddressCityOrTown">Kuala Lumpur</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressCountry_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zwfFcBIxTLUk"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" format="ixt-sec:countrynameen" id="Fact000030" name="dei:EntityAddressCountry">Malaysia</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel.:
<span id="xdx_908_edei--CityAreaCode_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z06XSeHNebFi"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" id="Fact000031" name="dei:CityAreaCode">(908)</ix:nonNumeric></span> <span id="xdx_901_edei--LocalPhoneNumber_c20250101__20250331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zdh00hTmeJId"><ix:nonNumeric contextRef="From2025-01-012025-03-31_dei_BusinessContactMember" id="Fact000032" name="dei:LocalPhoneNumber">517-7330</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Copies
to:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debbie
A. Klis, Esq.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rimon
P.C.<br/>
1050 Connecticut Avenue, Suite 500<br/>
Washington, DC 20036<br/>
Tel.: 202-935-3390<br/>
debbie.klis@rimonlaw.com </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate
date of commencement of proposed sale to the public</b>: As soon as practicable after this Registration Statement becomes effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">If the securities
being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General
Instruction G, check the following box: &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityFilerCategory_c20250101__20250331_zjytoZ2EuVe5"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000033" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntitySmallBusiness_c20250101__20250331_zIW5LrWtX7m8"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleantrue" id="Fact000034" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20250101__20250331_zO65z9dDQl3k"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000035" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: Exchange Act
Rule 13e-4(i) (Cross-Border Issuer Tender Offer) &#9744; Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these
securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><b>Subject
    to Completion</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><b>Dated
    July 23, 2025</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>Preliminary
    Prospectus</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSED
TRANSACTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>YOUR
VOTE IS VERY IMPORTANT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders of Cyclacel Pharmaceuticals, Inc.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or &#8220;Parent&#8221;) and FITTERS Diversified Berhad, a Malaysia publicly-listed investment
holding company on Bursa Securities (KL: 9318) (&#8220;Fitters Parent&#8221;), which is the beneficial owner of all of the ordinary shares
(the &#8220;Company Ordinary Shares&#8221; or &#8220;Shares&#8221; and each, a &#8220;Share&#8221;) of Fitters Sdn. Bhd., a private limited
company incorporated in Malaysia (the &#8220;Company&#8221; or &#8220;Fitters Sdn. Bhd.&#8221;) entered into an Exchange Agreement dated
as of May 6, 2025, as amended on July 7, 2025 and as it may be further amended from time to time (collectively, the &#8220;Exchange
Agreement&#8221;) (&#8220;Fitters Parent&#8221; and &#8220;Parent&#8221; are sometimes referred to herein as the &#8220;Parties&#8221;
or each, a &#8220;Party&#8221;). The Parties thereto intend to effect a voluntary share exchange between Parent and Fitters Parent (the
&#8220;Exchange&#8221;), in which the Company will become a wholly-owned subsidiary of Parent, in accordance with the terms of the Exchange
Agreement and the rules under Delaware General Corporation Law (the &#8220;DGCL&#8221;) and the Malaysian Companies Act. The Company
has three wholly-owned subsidiaries: AHT NRG Asia Sdn. Bhd., FITTERS (Sarawak) Sdn. Bhd., and Modular Floor Systems (M) Sdn. Bhd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, and in accordance with the DGCL, at the Closing (as hereinafter
defined), Fitters Parent shall convey, assign, and transfer all of its right, title and interest to the Company Ordinary Shares to Parent.
The Shares transferred to Parent at the Closing shall constitute one hundred (100%) percent of the issued and outstanding capital shares
of the Company. As consideration for its acquisition of the Company Ordinary Shares, Parent shall pay an amount equal to $1,000,000
in cash and issue an amount of common stock, par value $0.001 per share (the &#8220;Parent Common Stock&#8221;) equal to nineteen
and ninety-nine hundreds percent (19.99%) of the issued and outstanding shares of Parent Common Stock as of the Closing Date (as defined
below) (the &#8220;Exchange Shares&#8221;) to Fitters Parent. In the event the value of the Exchange Shares is not mutually acceptable
to both Parties prior to the Closing Date, the parties have agreed to negotiate in good faith an adjustment to the Exchange Shares. If
the Transaction does not close by September 30, 2025, either party may terminate the Exchange Agreement and the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, the closing of the Exchange (the &#8220;Closing&#8221;)
shall take place no later than three business days after the date on which the conditions to Closing set forth in the Exchange Agreement
shall have been satisfied or, to the extent permitted thereunder, waived by the appropriate Party (other than those conditions that by
their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all
such conditions) or at such other time, date or location as the parties hereto agree. The date on which the Closing actually occurs and
the transactions contemplated in the Exchange Agreement become effective is hereinafter referred to as the &#8220;Closing Date.&#8221;
At the time of the Closing, Parent, Fitters Parent and the Company shall deliver the certificates and other documents and instruments
required to be delivered thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Exchange Agreement, at the Closing, the parties hereto shall (a) cause a Form Section 105 (Form of Transfer
of Securities) in substantially the form of Exhibit B to the Exchange Agreement (the &#8220;Malaysia Form of Transfer&#8221;) to be executed,
acknowledged and filed with the Companies Commission of Malaysia, as provided in sections 105 and 106 of the Malaysian Companies
Act and (b) take all such other and further actions as may be required by the Malaysian Companies Act or other applicable Law to make
the Exchange effective. The Exchange shall become effective as of the date and time of the filing of the Malaysia Form of Transfer or
at such later date or time as may be agreed by the Company and Parent in writing and specified in the Malaysia Form of Transfer in accordance
with relevant provisions of the Malaysian Companies Act. The date and time of such effectiveness are referred to herein as the &#8220;Effective
Time.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
U.S. federal income tax purposes, the Parties acknowledge and agree that the Exchange constitutes a taxable disposition of the Shares
by Fitters Parent and a corresponding acquisition by Parent. The Parties intend that the Exchange be treated in accordance with Sections
1001 and 1221 (or 1231, as applicable) of the Internal Revenue Code of 1986, as amended (the &#8220;<b>Code</b>&#8221;), and shall report
the transaction consistently with such treatment.&#160; If applicable, Parent may make an election under Section 338(g) of the Code with
respect to its acquisition of the Shares, and Fitters Parent shall cooperate with the making of such election by providing such information
that is reasonably requested by Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
after the Transaction, (a) current Parent&#8217;s stockholders are expected to own approximately 80.01% of the company and (b) Fitters
Parent is expected to own approximately 19.99% of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Cyclacel common stock are currently listed on The Nasdaq Capital Market under the symbol &#8220;CYCC.&#8221; After consummation of
the Transaction, Cyclacel will be renamed Bio Green Med Solution, Inc. and expects to trade on The Nasdaq Stock Market under the symbol
&#8220;BGMS.&#8221; On July 22, 2025, the last trading day before the date of this proxy statement/prospectus, the closing sale
price of Cyclacel common stock was $10.76 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
is holding a special meeting of stockholders, or the special meeting, in order to obtain the stockholder approvals necessary to complete
the Transaction and related matters. At the special meeting, which will be held virtually at 10:00 a.m., Eastern Time,
on September 4, 2025, unless postponed or adjourned to a later date, Cyclacel Pharmaceuticals will ask its stockholders to, among
other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
approve the issuance of shares of Cyclacel common stock to Fitters Parent pursuant to the terms of the Exchange Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
comply with Nasdaq Listing Rule 5635(a), the potential issuance of more than 20% of the issued and outstanding shares of Cyclacel common
stock in connection with the Transaction;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approve
an amendment to the amended and restated certificate of incorporation of Cyclacel Pharmaceuticals changing the Cyclacel Pharmaceuticals
corporate name to Bio Green Med Solution, Inc., permitting actions by stockholders by written consent and ratifying all prior action
by stockholder written consent and opt out of the business
combination provisions of Section 203 of the DGCL;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
consider and vote upon an adjournment of the special meeting, if necessary, to solicit additional proxies if there are not sufficient
votes in favor of the proposals set forth above; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
transact such other business as may properly come before the stockholders at the special meeting or any adjournment or postponement thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
careful consideration, the board of directors of Parent has unanimously approved the Exchange Agreement and the proposals described in
this proxy statement/prospectus, and the board of directors has determined that it is advisable to consummate the Transaction. Our board
of directors recommends that stockholders vote &#8220;FOR&#8221; the proposals described in the accompanying proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>More
information about Parent, Fitters Parent, the Company and its other subsidiaries, as well as the Transaction is contained in this proxy
statement/prospectus. You are urged to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR,
YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 21.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are excited about the opportunities the proposed Transaction brings to Cyclacel Pharmaceuticals&#8217; stockholders, and thank you for
your consideration and continued support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
Dr. Doris Wong</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer and Executive Director</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this proxy statement/prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying proxy statement/prospectus is dated ______, 2025, and is first being mailed to stockholders on or about ______, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
10, Tower 11, Avenue 5, The Horizon</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bangsar
South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTICE
OF SPECIAL MEETING OF STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>To
Be Held On September 4, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: left; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Time:</b></span></td>
  <td style="text-align: left">10:00 a.m., Eastern Time</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b>:</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 4,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
  2025</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place:</b>
The special meeting will be a virtual meeting via live audio webcast on the Internet. You will be able to attend the special
meeting, vote and submit your questions during the meeting by visiting www.proxyvote.com and entering the 16-digit control number
included in the Notice of Internet Availability or proxy card that you receive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purposes:
</b>For the holders of Parent&#8217;s common stock, par value $0.001 per share (&#8220;Common Stock&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            approve the issuance of shares of common stock of Cyclacel Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221;
                                            or &#8220;Parent&#8221;) to Fitters Parent pursuant to the terms of the Exchange Agreement
                                            between Cyclacel, Fitters Parent and the Company, dated as of May 6, 2025, as amended
                                            on July 7, 2025 and as it may be further amended from time to time, a copy of which is
                                            attached as <i>Annex A</i> and incorporated by reference herein, and is referred to as the
                                            Exchange Agreement;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            comply with Nasdaq Listing Rule 5635(a), the potential issuance of more than 20% of the issued
                                            and outstanding shares of Cyclacel common stock in connection with the Transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            approve an amendment to the amended and restated certificate of incorporation of Cyclacel
                                            (a) changing the Cyclacel Pharmaceuticals, Inc. corporate name to &#8220;Bio Green Med Solution,
                                            Inc.&#8221;, (b) permitting actions by stockholders by written consent and ratify all prior
                                            action by stockholder written consent, and (c) opting out of the business combination provisions of Section 203 of the DGCL,
                                            in the form attached as <i>Annex B</i>;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            consider and vote upon an adjournment of the special meeting, if necessary, to solicit additional
                                            proxies if there are not sufficient votes in favor of the proposals set forth above; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            transact such other business as may properly come before the stockholders at the special
                                            meeting or any adjournment or postponement thereof.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Record
Date: </b>The board of directors of Cyclacel has fixed July 10, 2025 as the record date for the determination of stockholders
entitled to notice of, and to vote at, the special meeting and any adjournment or postponement thereof. Only stockholders of record of
shares of Cyclacel common stock at the close of business on the record date are entitled to notice of, and to vote at, the special meeting.
At the close of business on the record date, [&#9679;] shares of common stock of Cyclacel were outstanding and entitled to vote at the
special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Your
vote is important. The affirmative vote of a majority in voting power of the issued and outstanding shares of Common Stock of Cyclacel,
entitled to vote on thereon is required for approval of Proposals 1, 2 and 4. The affirmative vote of the holders of a majority of the
outstanding shares of common stock entitled to vote on the record date for the special meeting is required for approval of Proposal 3.
Each of Proposals 1, 2, and 3 are conditioned upon each other and the approval of each such proposal is a condition to the completion
of the Transaction. Therefore, the Transaction cannot be consummated without the approval of Proposals 1, 2, and 3. You may change or
revoke your proxy at any time before it is voted at the special meeting.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS HAS DETERMINED THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, AND IN THE BEST INTERESTS OF, CYCLACEL AND ITS
STOCKHOLDERS AND HAS UNANIMOUSLY APPROVED EACH SUCH PROPOSAL. THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS OF CYCLACEL VOTE &#8220;FOR&#8221;
EACH OF THE PROPOSALS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
Order of the Board of Directors,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
Dr. Doris Wong</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer and Executive Director</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kuala
Lumpur, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">______,
2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REFERENCES
TO ADDITIONAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus incorporates important business and financial information about Cyclacel Pharmaceuticals that has been filed
with the Securities and Exchange Commission, or SEC, and that is not included in or delivered with this document. You may obtain this
information without charge through the SEC&#8217;s website (http://<i>www.sec.gov</i>) or upon your written or oral request by contacting
the secretary of Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, The Horizon Bangsar South City, No. 8, Jalan Kerinchi,
59200, Kuala Lumpur, Malaysia or by calling (908) 517-7330.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>To
ensure timely delivery of these documents, any request should be made no later than September <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2</b></span>, 2025 to receive them before the
special meeting.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional details about where you can find information about Cyclacel Pharmaceuticals, please see the section entitled &#8220;<i>Where
You Can Find More Information</i>&#8221; in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">TABLE
OF CONTENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_001">QUESTIONS AND ANSWERS ABOUT THE TRANSACTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_002">PROSPECTUS SUMMARY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_003">The Companies</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_004">The Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_005">Reasons for the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_006">Interests of the Directors and Executive Officers of Cyclacel Pharmaceuticals in the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_007">Interests of the Directors and Executive Officers of Fitters in the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_008">Continued Service with the Company</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_009">Fairness Opinion of the Fitters Sdn. Bhd. and its subsidiaries</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_010">Management Following the Closing of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_011">Overview of the Exchange Agreement and Agreements Related to the Exchange Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_012">Regulatory Approvals</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_013">Material U.S. Federal Income Tax Consequences of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_014">Nasdaq Stock Market Listing</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_015">Anticipated Accounting Treatment</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_016">Appraisal Rights</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_017">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_018">SELECTED HISTORICAL AND UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_019">Selected Historical Consolidated Financial Data of Cyclacel Pharmaceuticals</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_020">Comparative Historical and Unaudited Pro Forma Per Share Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_021">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_022">MARKET PRICE AND DIVIDEND INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_023">Parent Common Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_024">Fitters Parent Common Shares</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_025">RISK FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_026">Risks Related to the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_027">Risks Related to Cyclacel Pharmaceuticals</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_028">Risks Related to Fitters Sdn. Bhd.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_029">Risks Related to our Common Stock following the Effective Date of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_030">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_031">THE SPECIAL MEETING OF STOCKHOLDERS OF CYCLACEL PHARMACEUTICALS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_032">Date, Time and Place</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_033">Purposes of the Special Meeting</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_034">Recommendation of the Board of Directors of Cyclacel Pharmaceuticals</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_036">Record Date and Voting Power</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_037">Voting and Revocation of Proxies</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_038">Required Vote</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_039">Solicitation of Proxies</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_040">Other Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">61</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_041">THE TRANSACTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_042">Background of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#cs_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel Reasons for the Transaction</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#cs_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fairness Opinion of Strategic Capital Advisory Sdn Bhd of Fitters Sdn. Bhd. and its subsidiaries</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_044">Fitters Parent Reasons for the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_045">Interests of the Directors and Executive Officers of Cyclacel Pharmaceuticals in the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_046">Interests of the Directors and Executive Officers of Fitters Sdn. Bhd. in the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_047">Form of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_048">Transaction Consideration and Exchange Shares</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_049">Stock Options and Warrants</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_050">Closing Time of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_051">Regulatory Approvals</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_052">Material Malaysian Tax Considerations to the Company&#8217;s Shareholder Related to the Transaction</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_053">Material U.S. Federal Income Tax Consequences of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#ds_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Consequences of Ownership and Disposition of Cyclacel Pharmaceuticals Common Stock</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_056">Anticipated Accounting Treatment</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_057">Nasdaq Stock Market Listing</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_058">Appraisal Rights</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_059">THE EXCHANGE AGREEMENT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_060">Structure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_061">Completion and Effectiveness of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_062">Cyclacel Pharmaceuticals Common Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>95</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_063">Fractional Shares</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_064">Representations and Warranties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">95</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_065">Covenants; Conduct of Business Pending the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_066">Disclosure Documents</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_067">Meeting of Cyclacel Pharmaceuticals Stockholders</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_068">Regulatory Approvals</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_069">Nasdaq Stock Market Listing</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_070">Conditions to the Completion of the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_071">Termination of the Exchange Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">101</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_072">Amendment</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>101</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_073">Expenses</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">101</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_074">MATTERS BEING SUBMITTED TO A VOTE OF THE STOCKHOLDERS OF CYCLACEL</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_075">Proposal 1: Approval of the Issuance of Common Stock in the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_076">Proposal 2: Approval of the Potential Issuance of Greater than 20% in the Transaction</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_077">Proposal
    3: Approval of Amendment to Certificate of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">103</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_078">Proposal 4: Approval of Possible Adjournment of the Special Meeting</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_079">CYCLACEL PHARMACEUTICALS, INC. BUSINESS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_080">FITTERS SDN. BHD. BUSINESS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_081">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF CYCLACEL</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_082">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF FITTERS DIVERSIFIED BERHAD</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_083">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK OF CYCLACEL</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">153</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_084">MANAGEMENT FOLLOWING THE CLOSING OF THE TRANSACTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">154</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_085">Executive Officers and Directors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">154</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_088">Parent&#8217;s Board of Director Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">157</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_089">Parent Director and Executive Officer Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">157</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_090">Compensation Risk Management</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_091">Board of Directors of Fitters Sub Following the Transaction</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_092">Fitters Sdn. Bhd. Executive Officer and Director Compensation</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">159</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_093">Employment Benefits Plans</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">159</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_094">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_095">DESCRIPTION OF CAPITAL STOCK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_096">PRINCIPAL STOCKHOLDERS OF CYCLACEL</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">166</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_097">PRINCIPAL SHAREHOLDER OF FITTERS SDN. BHD.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">167</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_098">LEGAL MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">168</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_099">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">168</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_100">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">168</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_101">TRADEMARK NOTICE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">169</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_102">OTHER MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">169</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_103">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS OF CYCLACEL</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_104">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS OF FITTERS SDN. BHD.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-57</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEXES:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_105">ANNEX A&#8212; EXCHANGE AGREEMENT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_106">ANNEX B&#8212;AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>B-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#svv_107">ANNEX C&#8212; FAIRNESS OPINION OF STRATEGIC CAPITAL ADVISORY SDN. BHD. IN RELATION TO THE PROPOSED ACQUISITION OF THE ENTIRE EQUITY INTEREST IN FITTERS SDN BHD AND ITS SUBSIDIARIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C-1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-indent: -0.75in">&#160;</p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_001"></span>QUESTIONS
AND ANSWERS ABOUT THE TRANSACTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following section provides answers to frequently asked questions about the Transaction. This section, however, provides only summary
information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
What is the Transaction?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>Cyclacel Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or &#8220;Parent&#8221;) and FITTERS Diversified Berhad, a Malaysia publicly-listed
investment holding company on Bursa Securities (KL: 9318) (&#8220;Fitters Parent&#8221;), which is the beneficial owner of all of the
ordinary shares (the &#8220;Company Ordinary Shares&#8221; or &#8220;Shares&#8221; and each, a &#8220;Share&#8221;) of Fitters Sdn. Bhd.,
a private limited company incorporated in Malaysia (the &#8220;Company&#8221; or &#8220;Fitters Sdn. Bhd.&#8221;) entered into an Exchange
Agreement dated as of May 6, 2025, as amended on July 7, 2025 and as it may be further amended from time to time (collectively,
the &#8220;Exchange Agreement&#8221;) (&#8220;Fitters Parent&#8221; and &#8220;Parent&#8221; are sometimes referred to herein as the
&#8220;Parties&#8221; or each, a &#8220;Party&#8221;). The Parties thereto intend to effect a voluntary share exchange between Parent
and Fitters Parent (the &#8220;Exchange&#8221;), in which the Company will become a wholly-owned subsidiary of Parent, in accordance
with the terms of the Exchange Agreement and the rules under Delaware General Corporation Law (the &#8220;DGCL&#8221;) and the Malaysian
Companies Act. The Company has three wholly-owned subsidiaries: AHT NRG Asia Sdn. Bhd., FITTERS (Sarawak) Sdn. Bhd., and Modular Floor
Systems (M) Sdn. Bhd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, and in accordance with the DGCL, at the Closing (as hereinafter
defined), Fitters Parent shall convey, assign, and transfer all of its right, title and interest to the Company Ordinary Shares to Parent.
The Shares transferred to Parent at the Closing shall constitute one hundred (100%) percent of the issued and outstanding capital shares
of the Company. As consideration for its acquisition of the Company Ordinary Shares, Parent shall pay an amount equal to $1,000,000
in cash and issue an amount of common stock, par value $0.001 per share (the &#8220;Parent Common Stock&#8221;) equal to nineteen
and ninety-nine hundreds percent (19.99%) of the issued and outstanding shares of Parent Common Stock as of the Closing Date (as defined
below) (the &#8220;Exchange Shares&#8221;) to Fitters Parent. In the event the value of the Exchange Shares is not mutually acceptable
to both Parties prior to the Closing Date, the parties have agreed to negotiate in good faith an adjustment to the Exchange Shares. If
the Transaction does not close by September 30, 2025, either party may terminate the Exchange Agreement and the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, the closing of the Exchange (the &#8220;Closing&#8221;)
shall take place no later than three business days after the date on which the conditions to Closing set forth in the Exchange Agreement
shall have been satisfied or, to the extent permitted thereunder, waived by the appropriate Party (other than those conditions that by
their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all
such conditions) or at such other time, date or location as the parties hereto agree. The date on which the Closing actually occurs and
the transactions contemplated in the Exchange Agreement become effective is hereinafter referred to as the &#8220;Closing Date.&#8221;
At the time of the Closing, Parent, Fitters Parent and the Company shall deliver the certificates and other documents and instruments
required to be delivered thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of Cyclacel will continue to own and hold their existing shares of Cyclacel common stock. Immediately after the Transaction, (a) current
Parent&#8217;s stockholders are expected to own approximately 80.01% of the company and (b) Fitters Parent is expected to own approximately
19.99% of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
What will happen to Cyclacel if, for any reason, the Transaction does not close?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>If, for any reason, the Transaction does not close, our board of directors may elect to, among other things, attempt to complete
another strategic transaction like the Transaction or with a different structure or continue to primarily operate the business of Cyclacel
as a clinical-stage biopharmaceutical company working to develop innovative cancer medicines based on cell cycle, epigenetics and mitosis
biology. If Cyclacel were to continue its current business, without the completion of the Transaction or one of more additional alternative
transactions, it would likely need to identify, acquire and develop other products or product candidates in addition to its sole product
candidate presently, which includes an epigenetic/anti-mitotic program involving the evaluation of plogo, a PLK1 inhibitor, in solid
tumors and hematological malignancies. If Cyclacel decided to acquire and develop other products or product candidates, it would also
need to rebuild its workforce. In addition, if the Transaction does not close, our board of directors may elect to seek another target
company to acquire, though there is no assurance that such acquisition transaction would be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
Why are the two companies proposing to enter into the Transaction?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>Following the closing of the Transaction, Cyclacel and Fitters Parent believe that the combined company will have the following potential
advantages:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent,
after the Transaction, will be continue to be a publicly traded company specializing in supplying and trading protective and fire
safety equipment, including fire safety gear, fire doors, safety apparel, foam systems, and fire extinguishers. The strategic
alignment between Parent and the Company enables Parent to gain exposure to a high-growth industry, while concurrently enhancing the
Company&#8217;s access to US capital markets;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
the Company after the Transaction will be led by an experienced senior management team from the Company and the Cyclacel board of
directors; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
the Transaction, the combined company is expected to enhance its global brand profile, as Parent leverages the Company&#8217;s
established operational footprint in Southeast Asia, while the Company benefits from Parent&#8217;s market presence in North
America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
Why am I receiving this proxy statement/prospectus?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>You are receiving this proxy statement/prospectus because you have been identified as a stockholder of Cyclacel as of the record
date, and you are entitled to vote at the special meeting of stockholders to approve the matters set forth above. This document serves
as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
a proxy statement of Cyclacel used to solicit proxies for its special meeting of stockholders to vote on the matters set forth above;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
a prospectus of Cyclacel used to offer shares of Cyclacel common stock in exchange for the Company Ordinary Shares in the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
What approvals by the stockholders of Cyclacel are required to consummate the Transaction?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>To consummate the Transaction, stockholders of Cyclacel must approve the proposal numbers 1, 2 and 3. Pursuant to the terms of the
Exchange Agreement, Cyclacel is also requesting that stockholders approve proposal number 4 below, which is, collectively with proposal
numbers 1 through 4 (the &#8220;Proposals&#8221;). The Proposals include the following matters:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
the issuance of the Exchange Shares of Cyclacel to Fitters Parent pursuant to the terms of the Exchange Agreement between Cyclacel, Fitters
Parent and the Fitters Sdn. Bhd. dated as of May 6, 2025, as amended on July 7, 2025 and as it may be further amended from time to
time, a copy of which is attached as <i>Annex A</i>, which is referred to as the Exchange Agreement (Proposal 1);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
for purposes of complying with Nasdaq Listing Rule 5635(a), the potential issuance of more than 20% of the issued and outstanding
shares of Cyclacel common stock in connection with the Transaction (Proposal 2);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
an amendment to the amended and restated certificate of incorporation of Cyclacel (a) changing the Cyclacel corporate name to Bio Green
Med Solution, Inc., (b) permitting actions by stockholders by written consent <span style="font-weight: normal">and </span>ratification
of all prior action by stockholder written consent including without limitation, majority stockholder consents dated March 21, 2025,
May 12, 2025 and June 18, 2025, and (c) opting out of the business combination
provisions of Section 203 of the DGCL, in the form attached as <i>Annex B</i> (Proposal 3); and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
to consider and vote on an adjournment of the special meeting, if necessary, to solicit additional proxies if there are not
sufficient votes in favor of the proposals set forth above (Proposal 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
presence, in person or represented by proxy, at the special meeting of the holders of a majority of the shares of Cyclacel common stock
outstanding and entitled to vote at the special meeting is necessary to constitute a quorum at the meeting. Abstentions and broker non-votes
will be counted towards a quorum. The affirmative vote of the holders of a majority of the shares of Cyclacel common stock having voting
power present in person or represented by proxy at the special meeting, assuming a quorum is present, is required for approval of Proposals
1, 2 and 4. The affirmative vote of the holders of a majority of the outstanding shares of common stock entitled to vote on the record
date for the special meeting is required for approval of Proposal 3. Each of Proposals 1, 2, and 3 are conditioned upon each other and
the approval of each such proposal is a condition to the completion of the Transaction. Therefore, the Transaction cannot be consummated
without the approval of Proposals 1, 2, and 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Votes
will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221;
votes, abstentions and broker non-votes. Abstentions will be counted towards the vote total for each proposal and will have the same
effect as &#8220;AGAINST&#8221; votes for Proposal 3, but will have no effect on Proposals 1, 2 and 4. Similarly, broker non-votes will
have the same effect as &#8220;AGAINST&#8221; votes for Proposal 3, but will have no effect on Proposals 1, 2 and 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, the directors and executive officers of Cyclacel owned or controlled approximately 51.20 % of the outstanding
shares of Cyclacel common stock entitled to vote at the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adoption of the Exchange Agreement and the approval of the Transaction and related transactions has been approved by Fitters Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a more complete description of the closing conditions under the Exchange Agreement, you are urged to read the section entitled &#8220;<i>The
Exchange Agreement&#8212;Conditions to the Completion of the Transaction</i>&#8221; in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
What will Fitters Parent receive in the Transaction?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:</b>
As a result of the Transaction, Fitters Parent will become entitled to receive cash consideration equal to $1,000,000 (or such
other amount as mutually agreed upon prior to the Closing) and the Exchange Shares which equal approximately 19.99% of the
issued and outstanding Parent Common Stock on a pro forma basis, immediately prior to the closing of the Transaction, or such other
percentage agreed to by the Parties prior to the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a more complete description of what Fitters Parent will receive in the Transaction, please see the sections entitled &#8220;<i>Market
Price and Dividend Information</i>,&#8221; &#8220;<i>The Transaction&#8212;Transaction Consideration and Exchange Shares</i>&#8221; and
&#8220;<i>The Exchange Agreement&#8212;Transaction Consideration and Exchange Shares</i>&#8221; in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
Who will be the directors of Cyclacel following the Transaction?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:</b>
There is not anticipated to be any change in the current board of directors of Cyclacel, and immediately following the Transaction, the
board of directors of Cyclacel is expected to be composed of the following members of the board of directors of Cyclacel prior to the
Transaction, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwang
    Fock Chong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
Who will be the executive officers of Cyclacel immediately following the Transaction?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>There is not anticipated to be any change in the current officers of Cyclacel, and immediately following the Transaction, the executive
management of Cyclacel is expected to be composed of the following members of the executive management team prior to the Transaction,
as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
As a stockholder of Cyclacel, how does the board of directors recommend that I vote?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>After careful consideration, the board of directors of Cyclacel recommends that stockholders vote &#8220;FOR&#8221; all of the Proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
What risks should I consider in deciding whether to vote in favor of the Transaction?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>You should carefully review the section of this proxy statement/prospectus entitled &#8220;<i>Risk Factors,</i>&#8221; which sets
forth certain risks and uncertainties related to the Transaction, risks and uncertainties to which the combined company&#8217;s business,
following the closing of the Transaction will be subject, and risks and uncertainties to which each of Cyclacel and the Company is subject.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
When do you expect the Transaction to be consummated?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>The Transaction is anticipated to be consummated as early as the third quarter of 2025 after the special meeting of stockholders
of Cyclacel to be held on September 4, 2025, but the exact timing cannot be predicted. For more information, please see the section
entitled &#8220;<i>The Exchange Agreement&#8212;Conditions to the Completion of the Transaction</i>&#8221; in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
What do I need to do now?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>Cyclacel urges you to read this proxy statement/prospectus carefully, including its annexes, and to consider how the Transaction
affects you.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a stockholder of record, you may vote in one of the following ways:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <b>You
may vote by mail</b>. Complete, sign and date the proxy card that accompanies this proxy statement and return it promptly in the
postage-prepaid envelope provided (if you receive printed proxy materials). Your completed, signed and dated proxy card must be
received prior to the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<b>You may vote by telephone</b>. To vote over the telephone, dial toll-free 1-800-579-1639 using a touch-tone telephone and follow the
recorded instructions (have your Notice of Internet Availability or proxy card in hand when you call). You will be asked to provide the
company number and control number from your Notice of Internet Availability or proxy card. Telephone voting is available 24 hours a day,
7 days a week, until 11:59 p.m., Eastern Time, on September 3, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <b>You may vote via
the Internet</b>. To vote via the Internet, go to www.proxyvote.com to complete an electronic proxy card (have your Notice of Internet
Availability or proxy card in hand when you visit the website). You will be asked to provide the control number from your Notice of Internet
Availability or proxy card. Internet voting is available 24 hours a day, 7 days a week, until 11:59 p.m., Eastern Time, on September 3, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a beneficial owner of shares held of record by a broker, bank or other nominee, you will receive voting instructions from your
broker, bank or other nominee. You must follow the voting instructions provided by your broker, bank or other nominee in order to instruct
your broker, bank or other nominee on how to vote your shares. Beneficial owners of shares should generally be able to vote by returning
the voting instruction card, or by telephone or via the Internet. However, the availability of telephone or Internet voting will depend
on the voting process of your broker, bank, or other nominee. <b>If you are a beneficial owner, you may <i>not</i> vote your shares in
person at the special meeting unless you obtain a legal proxy from your broker, bank or other nominee.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
What happens if I do not return a proxy card or otherwise provide proxy instructions, as applicable?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:</b>
The failure to return your proxy card or otherwise provide proxy instructions will reduce the aggregate number of votes required to approve
Proposals 1, 2 and 4 and will have the same effect as voting against Proposal 3. Further, your shares will not be counted for purposes
of determining whether a quorum is present at the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
May I vote in person at the special meeting of stockholders?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>If your shares of common stock are registered directly in your name with our transfer agent, you are considered to be the stockholder
of record with respect to those shares, and the proxy materials and proxy card are being sent directly to you by Cyclacel. If you are
a stockholder of record, you may attend the special meeting of stockholders and vote your shares in person. Even if you plan to attend
the special meeting in person, Cyclacel requests that you sign and return the enclosed proxy card to ensure that your shares will be
represented at the special meeting if you are unable to attend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares of common stock are held in a brokerage account or by another nominee, you are considered the beneficial owner of shares
held in &#8220;street name,&#8221; and the proxy materials are being forwarded to you by your broker or other nominee together with a
voting instruction form. As the beneficial owner, you are also invited to attend the special meeting of stockholders. Because a beneficial
owner is not the stockholder of record, you may not vote these shares in person at the special meeting unless you obtain a legal proxy
from the broker, trustee or nominee that holds your shares, giving you the right to vote the shares at the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
When and where is the special meeting of stockholders being held?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>The special meeting of stockholders will be a virtual meeting via live audio webcast on the Internet. You will be able to attend
the special meeting, vote and submit your questions during the meeting by visiting www.proxyvote.com and entering the 16-digit control
number included in the Notice of Internet Availability or proxy card that you receive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
If my shares are held in &#8220;street name&#8221; by my broker, will my broker vote my shares for me?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:</b>
Unless your broker has discretionary authority to vote on certain matters, your broker will not be able to vote your shares of common
stock on matters requiring discretionary authority without instructions from you.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you do not give instructions to your broker, your broker can vote your shares with respect to &#8220;discretionary&#8221; items but not
with respect to &#8220;non-discretionary&#8221; items. Discretionary items are proposals considered routine under the rules applicable
to brokers on which your broker may vote shares held in &#8220;street name&#8221; in the absence of your voting instructions. On non-discretionary
items for which you do not give your broker instructions, the shares will be treated as broker non-votes. It is anticipated that Proposals
1 and 2 will be non-discretionary items. To make sure that your vote is counted, you should instruct your broker to vote your shares,
following the procedures provided by your broker.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
Can I change my vote or revoke my proxy?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>If you are a stockholder of record, you can change your vote or revoke your proxy at any time before the special meeting by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
By submitting a new proxy card with a date later than your previously delivered proxy and submitting it as instructed above or by
providing written notice of revocation to us before the special meeting at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi,
Kuala Lumpur, Malaysia 59200, Attention: Kiu Cu Seng, Chief Financial Officer, Executive Director and Secretary;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
By submitting a later proxy by Internet or by telephone as instructed above; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
By attending the special meeting and voting at the meeting. Attending the special meeting will not, in and of itself, change or
revoke a previously submitted proxy unless you specifically request it or vote at the special meeting. Your most current vote,
whether by telephone, Internet or proxy card is the one that will be counted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
Who is paying for this proxy solicitation?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone,
fax or email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and
other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to execute
proxies. We will then reimburse them for their expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged Laurel Hill Advisory Group, LLC, to act as our proxy solicitor in connection with the proposals to be acted upon at our
special meeting. Pursuant to our agreement, Laurel Hill Advisory Group, LLC will, among other things, provide advice regarding proxy
solicitation issues and solicit proxies from our stockholders on our behalf in connection with the special meeting. For these services,
we will pay a fee of approximately $20,000 plus expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q:
Who can help answer my questions?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A:
</b>If you are a stockholder of Cyclacel and would like additional copies of this proxy statement/prospectus without charge or if you
have questions about the Transaction, including the procedures for voting your shares, you should contact Laurel Hill Advisory Group,
LLC, 2 Robbins Lane, Suite 201, Jericho, NY 11753, or by phone: (516) 933-3100 or via email to dcarlo@laurelhill.com, or you may (1)
visit www.ProxyVote.com, (2) call 1-800-579-1639, or (3) send an email to <span style="text-decoration: underline">sendmaterial@proxyvote.com</span>. If you send an email, please
include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email
copy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_002"></span>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights selected information from this proxy statement/prospectus and may not contain all the information that is important
to you. To better understand the Transaction, the proposals being considered at the special meeting, you should read this entire proxy
statement/prospectus carefully, including the Exchange Agreement and the other annexes to which you are referred herein. For more information,
please see the section entitled </i>&#8220;<i>Where You Can Find More Information</i>&#8221; <i>in this proxy statement/prospectus. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_003"></span>The
Companies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CYCLACEL
PHARMACEUTICALS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11, Avenue 5, The Horizon</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bangsar
South City, No. 8, Jalan Kerinchi</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59200,
Kuala Lumpur, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
(908) 517-7330</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working to develop innovative cancer medicines based on cell cycle,
epigenetics and mitosis biology. We are a pioneer company in the field of cancer cell cycle biology with a vision to improve patient
healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient&#8217;s
overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
epigenetic/anti-mitotic program is evaluating plogo, a PLK1 inhibitor, in solid tumors and hematological malignancies. Our strategy is
to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have retained rights to commercialize our clinical development candidates and our business objective is to enter into selective partnership
arrangements with these programs. Substantially all our efforts to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. As part of the
Company&#8217;s efforts to reduce operating costs, it has determined to focus on the development of plogo only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FITTERS
DIVERSIFIED BERHAD</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
1, Jalan Tembaga SD 5/2</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bandar
Sri Damansara</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52200
Kuala Lumpur, Selangor, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
+60 3-6276 7155</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FITTERS
Diversified Berhad, a Malaysia publicly-listed investment holding company on Bursa Securities (KL: 9318) (&#8220;Fitters Parent&#8221;)
and its subsidiaries commenced its business operations as a fire protection and prevention solutions provider in the 1970s. On October
4, 1994, Fitters Parent gained official listing on the Second Board of Bursa Malaysia Securities Berhad (&#8220;Bursa Securities&#8221;)
and was subsequently promoted to the Main Board of Bursa Securities on July 4, 2007.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Parent&#8217;s subsidiary, Fitters Sdn. Bhd. (the &#8220;Company&#8221;) operates as Malaysia&#8217;s one-stop fire protection specialist
and is involved in the manufacturing, trading and specialized installation of fire-fighting equipment as well as the supply of fire safety
protection products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_004"></span>The
Transaction (see page 62)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Transaction is completed, Fitters Parent shall convey, assign, and transfer all of its right, title and interest to all of its ordinary
shares (the &#8220;Company Ordinary Shares&#8221; or &#8220;Shares&#8221; and each, a &#8220;Share&#8221;) of the Company to Parent.
The Shares transferred to Parent at the Closing shall constitute 100% percent of the issued and outstanding capital shares of the Company.
As consideration for its acquisition of the Shares, Parent shall pay an amount equal to $1,000,000 in cash (or such amount as mutually
agreed upon prior to the Closing) and issue an amount of common stock, par value $0.001 per share (the &#8220;Parent Common Stock&#8221;)
equal to nineteen and ninety-nine hundreds percent (19.99%) of the issued and outstanding shares of Parent Common Stock as of the Closing
Date (the &#8220;Exchange Shares&#8221;) to Fitters Parent. In the event the value of the Exchange Shares is not mutually acceptable
to both Parties prior to the Closing Date, the parties have agreed to negotiate in good faith an adjustment to the Exchange Shares. If
the Transaction does not close by September 30, 2025, either party may terminate the Exchange Agreement and the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of Cyclacel will continue to own and hold their existing shares of Cyclacel common stock. Immediately after the Transaction, (a) current
Parent&#8217;s stockholders are expected to own approximately 80.01% of the company and (b) Fitters Parent is expected to own approximately
19.99% of Parent, which amounts are subject to adjustment before the Closing. For a more complete description of the Transaction or the
Exchange Shares, please see the sections entitled &#8220;<i>The Transaction</i>&#8221; beginning on page 62 and &#8220;<i>The Exchange
Agreement&#8212;Transaction Consideration and Exchange Shares</i>&#8221; beginning on page 82.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction will be completed as promptly as practicable after all of the conditions to completion of the Transaction are satisfied or
waived, including the approval of the stockholders of Cyclacel. Cyclacel and Fitters Parent are working to complete the Transaction as
quickly as practicable. However, Cyclacel and Fitters Parent cannot predict the exact timing of the completion of the Transaction because
it is subject to various conditions. After completion of the Transaction, assuming Cyclacel receives the required stockholder approval
of Proposal 1 and Proposal 3, Cyclacel will be renamed Bio Green Med Solution, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_005"></span>Reasons
for the Transaction (see pages 67  and 70)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Transaction, the combined company will focus on the Company&#8217;s core program involving the provision of fire services. Cyclacel
believes that the combine company will have the following potential advantages:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; the
combined company, after the Transaction, will be a Nasdaq listed company focused on supplying and trading protective and fire safety
equipment, including fire safety gear, fire doors, safety apparel, foam systems, and fire extinguishers. The strategic alignment
between Parent and the Company enables Parent to gain exposure to a high-growth industry, while concurrently enhancing the
Company&#8217;s access to US capital markets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; the
Company, after the Transaction, will be led by an experienced senior management team from the Company and the Cyclacel board of directors;
and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
&#9679; following the Transaction, the combined company is expected to enhance its global brand profile, as Parent leverages the
Company&#8217;s established operational footprint in Southeast Asia, while the Company benefits from Parent&#8217;s market presence
in North America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the board of directors of Cyclacel and Fitters Parent also considered other reasons for the Transaction, as described in this proxy
statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, Cyclacel&#8217;s board of directors considered, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
pace of our ability to go to market through our program focused on epigenetics/mitosis control biology, which at present, in
Cyclacel&#8217;s efforts to reduce operating costs, has caused a change to focus on the development of the plogo clinical program
only while fadraciclib, Cyclacel&#8217;s subsidiary&#8217;s other drug development program, was being marketed for sale by
liquidators and will no longer be part of the assets of Cyclacel as of January 2025, which means that the likelihood that Cyclacel
could improve its revenue to benefit the stockholders of Cyclacel in the foreseeable future on a stand-alone basis is
limited;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the strategic alternatives of Cyclacel to the Transaction, including potential transactions that could have resulted from
discussions that management and its representatives conducted with other potential strategic partners;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
current market conditions, and Cyclacel&#8217;s current liquidity position, its depressed stock price and continuing net operating
losses;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
risks of continuing to operate Cyclacel on a stand-alone basis, including the need to rebuild its product candidate development
program, infrastructure and management to continue its operations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
management&#8217;s belief that it would be difficult to obtain additional equity or debt financing on acceptable terms, if at
all;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; the
opportunity as a result of the Transaction for Cyclacel stockholders to participate in the potential value that may result from
advancing the Company&#8217;s pipeline of services on a global basis as a fire safety and prevention company focused on the
provision of fire services and the potential increase in value of the company following the closing of the Transaction;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; the
terms and conditions of the draft Exchange Agreement and associated transactions, as well as the safeguards and protective
provisions included therein intended to mitigate risks; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; the
risk that Cyclacel is not able to successfully execute its business plan and commercialize its product candidate, plogo, on the
planned timeline or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Fitters Parent&#8217;s board of directors approved the Transaction based on a number of factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; The
Company&#8217;s need for capital to support the increase to the sales of its current services to new geographic areas by accessing
the United States&#8217; public market capital, including sources of capital from a broader range of investors than it could
otherwise obtain if it continued to operate as a subsidiary of Fitters Parent, which is listed on the Main Board of Bursa Securities
(Malaysia);</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; the
expectation that the Transaction would be a more time-and cost-effective means to access capital than other options considered;
and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; the
fact that Exchange Shares of Cyclacel common stock issued to Fitters Parent will be registered pursuant to a registration statement
on Form S-4 by Cyclacel and will become freely tradable for Fitters Parent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_006"></span>Interests
of the Directors and Executive Officers of Cyclacel in the Transaction</b> (see page 79)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, the directors and executive officers of Cyclacel owned or controlled approximately 51.20 % of the outstanding
shares of Cyclacel common stock. In addition, Datuk Dr. Doris Wong, Cyclacel&#8217;s chief executive officer and executive director owns
approximately seven (7%) percent of the issued and outstanding ordinary shares of Fitters Parent. In considering the recommendation of
the board of directors that the stockholders vote to approve Proposal 1, stockholders should be aware that our current and former directors
and executive officers have interests in the Transaction that are different from, or in addition to, the interests of stockholders generally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interests are discussed in more detail in the section entitled &#8220;<i>The Transaction&#8212;Interests of the Directors and Executive
Officers of Cyclacel in the Transaction</i>&#8221; of this proxy statement/prospectus. The members of the board of directors were aware
of the different or additional interests described in such section and considered these interests, among other matters, in evaluating
and negotiating the Exchange Agreement and the Transaction, and in recommending to our stockholders that the Transaction be approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_007"></span>Interests
of the Directors and Executive Officers of Fitters Parent in the Transaction</b> (see page 82)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
stockholders should be aware that certain executive officers and directors of Fitters Parent have interests in the Transaction that may
be different from the interests of stockholders of Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_008"></span>Continued
Service with the Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of the directors of Fitters Parent are expected to remain directors of the Company after the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_009"></span>Fairness
Opinion of the Fitters Sdn. Bhd. and its subsidiaries (see page 70)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2025, Strategic Capital Advisory Sdn. Bhd. (&#8220;Strategic Capital Advisory&#8221;), a highly specialized corporate finance
services company retained by Cyclacel, rendered its written fairness opinion (the &#8220;Fairness Opinion&#8221;) to the Cyclacel board
of directors, that, as of the date of such opinion, and based upon the various assumptions, qualifications and limitations set forth
therein, that the fair value of entire equity interest of Fitters Parent and its subsidiaries RM92.27 million to RM107.71 million, that
translates to USD20.72 million to USD24.19 million (using the exchange rate of USD1.00 to RM4.453 as of the date of the written Fairness
Opinion. Accordingly, Strategic Capital Advisory concluded that the purchase consideration falls within the ranges of values derived
using the Discounted Free Cash Flow to Firm (&#8220;FCFF&#8221;) methodology, hence it is fair from a financial point of view, to the
stockholders of Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
full text of the written Fairness Opinion of Strategic Capital Advisory dated April 8, 2025 is attached as <i>Annex C</i> to this proxy
statement/prospectus and is incorporated by reference. Cyclacel encourages its stockholders to read the Fairness Opinion in its entirety
for the assumptions made, procedures followed, other matters considered and limits of the review by Strategic Capital Advisory. The summary
of the written opinion of Strategic Capital Advisory set forth elsewhere in the proxy statement/prospectus is qualified by reference
to the full text of the Fairness Opinion. Strategic Capital Advisory provided its Fairness Opinion for the sole benefit and use of the
board of directors of Cyclacel in its consideration of the Transaction. Strategic Capital Advisory&#8217;s Fairness Opinion is not a
recommendation to any stockholder as to how to vote with respect to the proposed Transaction or to take any other action in connection
with the Transaction or otherwise.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_010"></span>Management
Following the Closing of the Transaction</b> (see page 154)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the Transaction, the executive management team of Cyclacel will remain the same, as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 95%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 38%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Secretary and Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwang
    Fock Chong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">46</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b><br/>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_011"></span>Overview of the Exchange Agreement and Agreements Related to the Exchange Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transaction
Consideration and Exchange Shares </i></b>(see page 82)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Transaction, each outstanding ordinary share of Fitters held by Fitters Parent will be exchanged for the Exchange
Shares of Cyclacel, as described in more detail herein. No fractional shares of Cyclacel common stock will be issued in connection with
the Transaction. Instead, all fractional shares of Cyclacel common stock that are issuable to Fitters Parent will be aggregated and will
be rounded up into one full share of Cyclacel common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of Exchange Shares is calculated using a formula intended to allocate to Fitters Parent, a percentage of the combined
company. As consideration for its acquisition of the shares of Cyclacel common stock, Parent shall pay an amount equal to
$1,000,000 in cash (or such amount as mutually agreed upon prior to the Closing) and issue an amount of Parent Common Stock
equal to nineteen and ninety nine hundreds (19.99%) percent of the issued and outstanding shares of Parent Common Stock as of the
Closing Date to Fitters Parent by issuance of book-entry shares representing the Exchange Shares in accordance with the applicable
provisions of the DGCL, and instruct Cyclacel&#8217;s transfer agent to update the register of stockholders of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the estimates set forth above, following the completion of the Transaction, (a) current Cyclacel stockholders are expected to own
approximately 80.01% of the common stock of Cyclacel, and (b) Fitters Parent is expected to own approximately 19.99% of the common stock
of Cyclacel, which final percentages are subject to adjustment based on the number of Exchange Shares issued at the Closing, as set forth
in the Exchange Agreement. In the event the value of the Exchange Shares is not mutually acceptable to both Parties prior to the Closing
Date, the parties have agreed to negotiate in good faith an adjustment to the Exchange Shares. If the Transaction does not close by September
30, 2025, either party may terminate the Exchange Agreement and the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
stock options that remain unexercised prior to the effective time of the Transaction will remain outstanding following the effective
time of the Transaction. Likewise, any outstanding warrants to purchase shares of Cyclacel common stock that are outstanding immediately
prior to the effective time of the Transaction will remain outstanding following the effective time of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conditions
to the Completion of the Transaction </i></b>(see page  98)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
complete the Transaction, each of the closing conditions set forth in the Exchange Agreement must be satisfied or waived including without
limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No
                                            Injunctions</b>. No temporary restraining Order, preliminary or permanent injunction issued
                                            by any court of competent jurisdiction preventing or prohibiting the consummation of the
                                            Exchange or the other transactions contemplated the Exchange Agreement shall be in effect;
                                            provided, however, that each Party shall have used its commercially reasonable efforts to
                                            prevent the entry of any such Orders or injunctions and to appeal as promptly as possible
                                            any such Orders or injunctions and to appeal as promptly as possible any such Orders or injunctions
                                            that may be entered.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
                                            Approval</b>. Parent shall have obtained the Parent Stockholder Exchange Vote and the Company
                                            shall have obtained the Required Company Shareholder Vote, each as defined below (and in
                                            the Exchange Agreement).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effectiveness
                                            of Registration Statement</b>. The Registration Statement shall have become effective in
                                            accordance with the provisions of the Securities Act, and shall not be subject to any stop
                                            order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect
                                            to the Registration Statement that has not been withdrawn. Any material state securities
                                            laws applicable to the issuance of the shares of Parent Common Stock in connection with the
                                            transactions contemplated under the Exchange Agreement shall have been complied with and
                                            no stop order (or similar order) shall have been issued or threatened in writing in respect
                                            of thereof by any applicable state securities commissioner or court of competent jurisdiction.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing</b>.
                                            The shares of Parent Common Stock to be issued in the Exchange pursuant to the Exchange Agreement
                                            shall have been approved for listing (subject to official notice of issuance) on Nasdaq as
                                            of the Closing.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing closing conditions, the obligations of Parent and the obligations of Fitters Parent and the Company to consummate
the transactions contemplated under the Exchange Agreement are also subject to the satisfaction or waiver in writing prior to the Effective
Time of the certain conditions as discussed in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the Exchange Agreement, &#8220;Parent Stockholder Exchange Vote&#8221; means the affirmative vote of a majority of the shares
of Parent Common Stock properly cast being the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary
to approve the Exchange Agreement and thereby approve the transactions contemplated under the Exchange Agreement, including the issuance
of the Exchange Shares to Fitters Parent pursuant to the terms of the Exchange Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination
of the Exchange Agreement</i></b> (see page 101)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
of Fitters Parent or Cyclacel can terminate the Exchange Agreement under certain specified circumstances, which would prevent the Transaction
from being consummated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_012"></span>Regulatory
Approvals </b>(see page 98)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, Cyclacel must comply with applicable federal and state securities laws and the rules and regulations of The Nasdaq
Stock Market in connection with the issuance of shares of Cyclacel common stock and the filing of this proxy statement/prospectus with
the Securities and Exchange Commission. As of the date hereof, the registration statement on Form S-4 of which this proxy statement/prospectus
is a part, has not become effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Malaysia, Fitters Parent shall have complied with all applicable Bursa Malaysia Securities Berhad Main Market Listing Requirements, including
any required notices to Bursa Malaysia and other necessary approvals regarding the transactions contemplated under this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_013"></span>Material
U.S. Federal Income Tax Consequences of the Transaction </b>(see page 152)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exchange of the Company Ordinary Shares by Fitters Parent for the Transaction consideration will be treated as an exchange described
in Section 1001 of the Code, the material U.S. federal income tax consequences of which should be as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; Fitters Parent
will recognize gain or loss upon the conveyance, assignment, and transfer of all of its right, title and interest to the Company Ordinary
Shares to Parent by delivering to Parent executed and transferrable Share certificates pursuant to the Transaction but such gain or loss
will be taxable in the U.S. only if the gain or loss is effectively connected with a trade or business of Fitters Parent in the United
States; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; Even if Fitters
Parent has a trade or business in the United States to which such gain is effectively connected, it will not be subject to tax if Fitters
Parent is eligible for the benefits of a comprehensive income tax treaty with the United States and such trade or business does not also
constitute a permanent establishment under the treaty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
matters are very complicated; accordingly, you should consult your tax advisor for a full understanding of the tax consequences of the
Transaction to you, including the applicability and effect of federal, state, and non-U.S. income and other tax laws. For more information,
please see the section entitled &#8220;<i>The Transaction&#8212;Material U.S. Federal Income Tax Consequences of the Transaction</i>&#8221;
of this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction will not result in any material tax consequences to holders of Cyclacel common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_014"></span>Nasdaq
Stock Market Listing </b>(see page 98)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
anticipates that the company&#8217;s common stock will continue to be listed on The Nasdaq Stock Market following the closing of the
Transaction under the trading symbol &#8220;BGMS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_015"></span>Anticipated
Accounting Treatment </b>(see page 93)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction will be recorded as a business combination under the acquisition method of accounting in accordance with U.S. GAAP and IFRS
(i.e., ASC 805/IFRS 3) The Transaction will be treated by Cyclacel as a business combination under the acquisition method of accounting
for business combinations in accordance with accounting principles generally accepted in the United States, or U.S. GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
accounting purposes, Cyclacel is considered to be acquiring Fitters Sdn. Bhd. (the &#8220;Company&#8221;) in the Transaction due to Cyclacel&#8217;s
control over the Company after the Closing under U.S. GAAP, as defined in Accounting Standards Codification (&#8220;ASC 805-10&#8221;).
ASC 805 applies to public and privately held entities and is applicable to all transactions or other events that meet the definition
of a business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_016"></span>Appraisal
Rights </b>(see page 93)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Cyclacel common stock are not entitled to appraisal rights in connection with the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_017"></span>Risk
Factors </b>(see page 21)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
Cyclacel and the Company are subject to various risks associated with their businesses and their industries. In addition, the Transaction,
including the possibility that the Transaction may not be completed, poses a number of risks to each company and its respective securityholders,
including the following risks:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of Exchange Shares may be adjusted prior to the Closing upon mutual agreement of the
                                            Parties to the Exchange Agreement based on the market price of Cyclacel common stock so the
                                            Transaction consideration at the closing may have a greater or lesser value than at the time
                                            the Exchange Agreement was signed;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to complete the Transaction may result in harm to the common stock price of Cyclacel and
                                            future business and operations of each of the Parties;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the conditions to the Transaction are not met, the Transaction may not occur;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Transaction may be completed even though material adverse changes may result from the announcement
                                            of the Transaction, industry-wide changes and other causes;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">some
                                            Cyclacel and Fitters Parent executive officers and directors have interests in the Transaction
                                            that are different from yours and that may influence them to support or approve the Transaction
                                            without regard to your interests;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            market price of Cyclacel common stock following the Transaction may decline as a result of
                                            the Transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
                                            securityholders will have a reduced ownership and voting interest in, and will exercise less
                                            influence over the management of, the combined company as compared to their current ownership
                                            and voting interest in the respective companies following the completion of the Transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                            provisions of the Exchange Agreement may discourage third parties from submitting competing
                                            proposals, including proposals that may be superior to the arrangements contemplated by the
                                            Exchange Agreement; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
                                            Parent may receive consideration in the Transaction that is less than the fair market value
                                            of the Company&#8217;s common shares and/or Cyclacel may pay more than the fair market value
                                            of the Company&#8217;s ordinary shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
risks and other risks are discussed in greater detail under the section entitled &#8220;<i>Risk Factors</i>&#8221; in this proxy statement/prospectus.
Cyclacel and Fitters Parent both encourage you to read and consider all of these risks carefully.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_018"></span>SELECTED
HISTORICAL AND UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_019"></span>Selected
Historical Consolidated Financial Data of Cyclacel</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes our selected consolidated financial data for the periods and as of the dates indicated. We have derived the consolidated
statement of operations data for the years ended December 31, 2024, 2023 and 2022 and the consolidated balance sheet data as of December
31, 2024 and 2023 from our audited consolidated financial statements included elsewhere in this proxy statement/prospectus. The selected
statement of operations data for the years ended December 31, 2021 and 2020 are derived from our consolidated financial statements or
unaudited interim condensed consolidated financial statements not included in this proxy statement/prospectus. Our unaudited interim
condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles on the
same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting
only of normal recurring adjustments, necessary for a fair statement of our financial position as of March 31, 2025 and 2024 and our
results of our operations for the three months ended March 31, 2025 and 2024. The results for the three months ended March 31, 2025 are
not necessarily indicative of results to be expected for the year ended December 31, 2025 any other interim periods or any future period
or year. This historical financial data should be read in conjunction with the section entitled &#8220;<i>Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations of Cyclacel</i>&#8221; and with our audited and unaudited consolidated
financial statements and their related notes, which are included elsewhere in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended March 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="18" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    The Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands, except share and per share amounts)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="18" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands, except share and per share amounts)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Operations Data:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">822</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,802</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,655</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,155</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,274</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,759</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,676</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,582</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,392</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,718</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,382</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,461</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,877</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance
    costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">538</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,036</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,384</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,047</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,873</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,656</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,389</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,036</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,004</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,453</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,656</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,389</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(81</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,946</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,198</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,457</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,445</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss attributable to common stockholders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(81</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,946</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,756</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,399</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,658</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,421</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share - basic and diluted (common stockholders)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(545.35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(502.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,419.18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,887.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,526.42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,310.21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share - basic and diluted (redeemable common stockholders)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,538.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average
    common shares outstanding - basic and diluted (common stockholders)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">365,231</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,314</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,545</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,740</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,479</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average
    common shares outstanding - basic and diluted (redeemable common stockholders)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">386</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For The Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">(in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="18" style="font: 10pt Times New Roman, Times, Serif; text-align: center">(in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Consolidated Balance Sheet Data:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">3,450</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">2,798</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">3,137</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">3,378</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">18,345</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">36,559</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">33,406</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Working capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,051</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,515</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,594</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(717</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,900</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">35,529</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32,983</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,734</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,165</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,094</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,805</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,050</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43,136</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36,802</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in-capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">443,318</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">429,919</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">438,202</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">429,796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">422,981</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">422,960</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">400,071</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(440,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(431,228</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(439,494</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(428,282</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(405,727</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(384,529</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(366,072</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total stockholders&#8217; equity (deficit)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,062</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,206</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,174</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">607</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,939</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">37,693</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33,259</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_020"></span>Comparative
Historical and Unaudited Pro Forma Per Share Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information below reflects the historical net loss and book value per share of Cyclacel common stock and the historical net loss and
book value per share of the Company ordinary shares in comparison with the unaudited pro forma net loss and book value per share
after giving effect to the Transaction on a pro forma basis. The pro forma amounts are presented for illustrative purposes only and are
not necessarily indicative of what the financial position, results of operations or per share information of the company would have been
if Cyclacel and Fitters Parent had effected the Transaction as of or for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the information below in conjunction with the audited and unaudited consolidated financial statements of each of Cyclacel
and the Company included in this proxy statement/prospectus and the related notes and the unaudited pro forma condensed combined financial
information and notes related to such financial statements included elsewhere in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">March 31, 2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year
Ended</p>
                                                                                                  <p style="margin-top: 0; margin-bottom: 0">December 31, 2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cyclacel Historical Per Common Share Data:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Basic and diluted net loss per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(0.22</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(502.46</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Book value per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(58.90</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Fitters Parent Historical Per Common Share Data:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">RM</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">RM</td><td style="text-align: right">(0.12</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Book value per share</td><td>&#160;</td>
    <td style="text-align: left">RM</td><td style="text-align: right">3.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">RM</td><td style="text-align: right">3.84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cyclacel and Fitters Parent Combined Unaudited Pro Forma Data:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(27.13</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Book value per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.19</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_021"></span>UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or &#8220;Parent&#8221;) and FITTERS Diversified Berhad, a Malaysia publicly-listed investment
holding company on Bursa Securities (KL: 9318) (&#8220;Fitters Parent&#8221;), which is the beneficial owner of all of the ordinary shares
(the &#8220;Company Ordinary Shares&#8221; or &#8220;Shares&#8221; and each, a &#8220;Share&#8221;) of Fitters Sdn. Bhd., a private limited
company incorporated in Malaysia (the &#8220;Company&#8221; or &#8220;Fitters Sdn. Bhd.&#8221;) entered into an Exchange Agreement dated
as of May 6, 2025, as amended on July 7, 2025 and as it may be further amended from time to time (collectively, the &#8220;Exchange
Agreement&#8221;) (&#8220;Fitters Parent&#8221; and &#8220;Parent&#8221; are sometimes referred to herein as the &#8220;Parties&#8221;
or each, a &#8220;Party&#8221;). The Parties thereto intend to effect a voluntary share exchange between Parent and Fitters Parent (the
&#8220;Exchange&#8221;), in which the Company will become a wholly-owned subsidiary of Parent, in accordance with the terms of the Exchange
Agreement and the rules under Delaware General Corporation Law (the &#8220;DGCL&#8221;) and the Malaysian Companies Act. The Company
has three wholly-owned subsidiaries: AHT NRG Asia Sdn. Bhd., FITTERS (Sarawak) Sdn. Bhd., and Modular Floor Systems (M) Sdn. Bhd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, and in accordance with the DGCL, at the Closing (as hereinafter
defined), Fitters Parent shall convey, assign, and transfer all of its right, title and interest to the Company Ordinary Shares to Parent.
The Shares transferred to Parent at the Closing shall constitute one hundred (100%) percent of the issued and outstanding capital shares
of the Company. As consideration for its acquisition of the Company Ordinary Shares, Parent shall pay an amount equal to $1,000,000
in cash and issue an amount of common stock, par value $0.001 per share (the &#8220;Parent Common Stock&#8221;) equal to nineteen
and ninety-nine hundreds percent (19.99%) of the issued and outstanding shares of Parent Common Stock as of the Closing Date (as defined
below) (the &#8220;Exchange Shares&#8221;) to Fitters Parent. In the event the value of the Exchange Shares is not mutually acceptable
to both Parties prior to the Closing Date, the parties have agreed to negotiate in good faith an adjustment to the Exchange Shares. If
the Transaction does not close by September 30, 2025, either party may terminate the Exchange Agreement and the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, the closing of the Exchange (the &#8220;Closing&#8221;)
shall take place no later than three business days after the date on which the conditions to Closing set forth in the Exchange Agreement
shall have been satisfied or, to the extent permitted thereunder, waived by the appropriate Party (other than those conditions that by
their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all
such conditions) or at such other time, date or location as the parties hereto agree. The date on which the Closing actually occurs and
the transactions contemplated in the Exchange Agreement become effective is hereinafter referred to as the &#8220;Closing Date.&#8221;
At the time of the Closing, Parent, Fitters Parent and the Company shall deliver the certificates and other documents and instruments
required to be delivered thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following unaudited pro forma condensed combined financial statements give effect to the exchange of all of the outstanding ordinary
shares of the Company for newly-issued shares of common stock of Cyclacel in the Transaction, pursuant to the Exchange Agreement between
the parties, and were prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).
Cyclacel was determined to be the accounting acquirer based upon the terms of the Transaction and other factors including: (i) Cyclacel&#8217;s
security holders will own 80.01% of the company, (ii) Cyclacel directors will hold all of the board seats in the combined company, and
(iii) Cyclacel management will hold all key positions in the management of the combined company, immediately following the closing of
the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the unaudited pro forma condensed combined financial statements, the Transaction will be recorded as a business combination using the
acquisition method of accounting under accounting principles generally accepted in the United States, or &#8220;U.S. GAAP&#8221;. The
Transaction will be accounted for as Cyclacel as the accounting acquirer, and it will record the assets acquired and liabilities assumed
by Cyclacel in the Transaction at their fair values as of the acquisition date. Cyclacel and Fitters Parent have determined a preliminary
estimated purchase price calculated as described in Note 2 to the unaudited pro forma condensed combined financial statements. The net
tangible and intangible assets acquired and liabilities assumed in connection with the Transaction are recorded at their estimated acquisition
date fair values. A final determination of these estimated fair values will be based on the estimated net tangible and intangible assets
and liabilities of Cyclacel that exist as of the date of completion of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined balance sheet as of March 31, 2025 gives effect to the Transaction as if it took place on March
31, 2025 and combines the historical balance sheets of Cyclacel and the Company as of such date. The unaudited pro forma condensed combined
statements of operations for the three months ended March 31, 2025 and for the year ended December 31, 2024 gives effect to the Transaction
as if it took place as of January 1, 2025, and combines the historical results of Cyclacel and the Company for each period. The historical
financial statements of Cyclacel and the Company have been adjusted to give pro forma effect to events that are (i) directly attributable
to the Transaction, (ii) factually supportable, and (iii) with respect to the unaudited pro forma condensed combined statements of operations,
at the date hereof are expected to have a continuing impact on the combined companies&#8217; results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying
notes. The unaudited pro forma condensed combined financial statements and pro forma adjustments have been prepared based on preliminary
estimates of fair value of assets acquired and liabilities assumed. Differences between these preliminary estimates and the final acquisition
accounting are likely to occur and these differences could be material as compared to the accompanying unaudited pro forma condensed
combined financial statements and the combined companies&#8217; future results of operations and financial position. The actual amounts
recorded as of the completion of the Transaction may also differ materially from the information presented in these unaudited condensed
combined pro forma financial statements as a result of, among other factors, the amount of capital raised by the Company between entering
the Exchange Agreement and closing of the Transaction; the amount of cash used in Cyclacel&#8217;s operations between the signing of
the Exchange Agreement and the closing of the Transaction; the timing of closing of the Transaction; changes in the fair value of Cyclacel
common stock; and other changes in the Cyclacel assets and liabilities that occur prior to the completion of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions,
regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies,
if any. The unaudited pro forma condensed combined financial information is preliminary and has been prepared for informational purposes
only and is not necessarily indicative of the financial position or results of operations in future periods or the results that actually
would have been realized had Cyclacel and the Company been a combined company during the specified periods. The actual results reported
in periods following the transaction are expected to differ significantly from those reflected in the unaudited pro forma condensed combined
financial information presented herein for a number of reasons, including, but not limited to, the termination of Cyclacel clinical trials
and the related reduction in work force in March 2025, sales of assets and actual differences from the assumptions used to prepare the
pro forma financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information, including the notes thereto, should be read in conjunction with the separate
Cyclacel and Company historical financial statements, and their respective management&#8217;s discussion and analysis of financial condition
and results of operations included elsewhere in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
Condensed Pro Forma Combined Balance Sheet as of March 31, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
    Pharmaceuticals, Inc.</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
    Accounting</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    Forma</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Historical)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Historical)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Combined</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="15" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Assets</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,450</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">593</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(1,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,043</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,005</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,005</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">767</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">767</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    Tax</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    &amp; other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,421</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,685</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,714</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,865</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,579</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
    And Other Assets</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
    plant and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
    Asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Goodwill</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">1,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">1,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,190</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Assets</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,734</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,035</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,769</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    payables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">181</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">295</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">549</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,228</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,777</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">663</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,409</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,072</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    income tax liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&#8217;
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">680</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(680</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">443,318</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,413</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">445,731</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    other comprehensive loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(440,461</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,929</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,764</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(440,296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217; Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,062</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,578</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,640</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholders&#8217; equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,734</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,035</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,769</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
Condensed Pro Forma Combined Statement of Operations for the Three Months Ended March 31, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Cyclacel Pharmaceuticals, Inc.</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Fitters</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Transaction Accounting </td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Pro Forma </td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Historical)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(Historical)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Adjustments</b></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Combined</b></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in thousands)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Sales Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">365</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">365</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Clinical Trial Supply</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of Sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General &amp; administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,344</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">822</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">822</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,036</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,090</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,955</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">34</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,989</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Loss before taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Basic and diluted earnings per common share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per share, continuing operations &#8211; basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.22</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.13</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average common shares outstanding - basic &amp; diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365,231</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,604,256</td><td style="text-align: left">)(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,975</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
Condensed Pro Forma Combined Statement of Operations for the Year Ended December 31, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
    Pharmaceuticals, Inc.</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
    Accounting </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    Forma </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Historical)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Historical)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Adjustments</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Combined</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="15" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in thousands)</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,755</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,755</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Trial Supply</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,755</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,798</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of Sales</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,368</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,368</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    &amp; administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,392</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">648</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,090</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,655</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,655</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,004</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,314</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense), net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">168</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">178</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    before taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,136</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">782</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">782</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,344</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted earnings per common share:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share, continuing operations &#8211; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(502.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.03</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average common shares outstanding - basic &amp; diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,314</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,604,256</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">418,058</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Unaudited Pro Forma Condensed Combined Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial statements have been prepared using the acquisition method and pursuant to the rules
and regulations of the SEC and present the pro forma financial position and results of operations of the combined company based upon
historical financial information after giving effect to the transactions, the Fitters acquisition by Cyclacel Pharmaceuticals Inc., and
transactions and adjustments described in these footnotes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition method is based on ASC 805, Business Combinations (&#8216;&#8216;ASC 805&#8217;&#8217;) and uses the fair value concepts
defined in ASC 820, Fair Value Measurements (&#8220;ASC 820&#8221;). ASC 805 requires, among other things, that most assets acquired
and liabilities assumed be recognized at their fair values as of the acquisition date. In addition, ASC 805 establishes that the consideration
transferred is measured at current market price at the consummation of an acquisition. Due to fluctuations in the market price of Cyclacel
Pharmaceuticals Inc.&#8217;s common stock, this requirement will likely result in a valuation of the actual equity consideration that
is different from the valuation presented in this unaudited condensed combined pro forma financial information. Certain footnote disclosures
normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules
and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial statements are presented for informational purposes only. These unaudited pro forma
condensed combined financial statements are not necessarily indicative of the results of operations that would have been achieved had
the transaction actually taken place at the dates indicated and do not purport to be indicative of Cyclacel Pharmaceuticals Inc&#8217;s
future financial position or operating results. The unaudited pro forma condensed combined financial statements should be read in conjunction
with the historical financial statements described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2. Estimate of Purchase Consideration</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a preliminary estimate of the consideration expected to be transferred to effect the acquisition of Fitters:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span style="text-decoration: underline">Preliminary allocation of purchase consideration</span></b></p>

<p style="font: 12pt/115% Arial, Helvetica, Sans-Serif; margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; padding-bottom: 2.5pt">Common Stock of CYCC Shares O/S as of July 7, 2025</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">1,583,965</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>19.99% of CYCC Shares: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,965</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock Price as of June 7, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">3.57</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Cash consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Estimated Purchase Consideration </td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,412,805</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">593,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,004,908</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">766,916</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,073</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid &amp; other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,420,807</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,324</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">ROU Asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,509</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,032</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(181,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,228,025</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,906</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred income tax liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37,347</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Bargain Purchase</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(165,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Estimated Fair Value of Net Assets Acquired &#160; </td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,412,805</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3. Pro Forma Adjustments for the Acquisition </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial statements give effect to the transaction described above as if it had occurred on March
31, 2025 for purposes of the unaudited pro forma condensed combined balance sheet and January 1, 2024 for purposes of the unaudited pro
forma condensed combined statements of operations. The unaudited pro forma condensed combined statements of operations do not include
any material non-recurring charges that will arise as a result of the transactions described above. Adjustments in the unaudited pro
forma condensed combined financial statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
                                            adjustment reflects the elimination of the historical equity of Fitters and reflects the
                                            new equity structure of the combined company, including:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
                                            of 395,744 shares of common stock to Fitters Parent at a share price of $3.57,
                                            being the closing stock price as of July 7, 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition
                                            of $165,499 bargain purchase as a result of the fair value of net assets exceeding
                                            the estimated purchase consideration.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
                                            adjustment reflects the issuance of new common stock arising as a result of equity consideration:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Weighted average shares CYCC</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">365,231</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares Fitters</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">395,744</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares Combined</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">760,975</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average shares Combined</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less Historical shares CYCC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(365,231</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less Historical shares Fitters</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,000,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Transaction Accounting Adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,604,256</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimate
                                            for additional Audit fees at $12,500 per quarter</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
                                            adjustment reflects the elimination of the historical equity of Fitters and reflects the
                                            new equity structure of the combined company, including:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
                                            of 395,744 shares of common stock to Fitters Parent at a share price of $3.57,
                                            being the closing stock price as of July 7, 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Weighted average shares CYCC</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">22,314</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares Fitters</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">395,744</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares Combined</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">418,058</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average shares Combined</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418,058</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less Historical shares CYCC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,314</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less Historical shares Fitters</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,000,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Transaction Accounting Adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,604,256</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimate
                                            for additional Audit fees at $50,000 for full year</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_022"></span>MARKET
PRICE AND DIVIDEND INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_023"></span>Parent
Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;CYCC.&#8221; Following the completion of the Transaction,
the Parent Common Stock will continue to be listed on The Nasdaq Stock Market and will trade under the combined company&#8217;s
new name, &#8220;Bio Green Med Solution, Inc.&#8221; and new trading symbol, &#8220;BGMS.&#8221; The following table presents, for the
periods indicated, the range of high and low per share sales prices for Parent Common Stock as reported on The Nasdaq Capital
Market for each of the periods set forth below, as adjusted for reverse stock splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Quarter Ended</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Low Sales Price of Parent Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">High Sales Price of Parent Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31%; text-align: left">March 31, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 31%; text-align: right">64.79</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 30%; text-align: right">213.58</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">74.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">597.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">228.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">448.76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">June 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">311.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">959.92</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">436.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">875.93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">527.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,720.14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,007.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,165.47</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,798.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,758.99</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing price of Parent Common Stock on May 5, 2025, the last trading day prior to the public announcement of the Transaction,
was $4.80 per share, as reported on The Nasdaq Capital Market. Because the market price of Parent Common Stock is subject to fluctuation,
the market value of the shares of Parent Common Stock that Fitters Parent will be entitled to receive in the Transaction may increase
or decrease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, there were __ registered holders of our common stock. This number does not include stockholders for whom shares
were held in &#8220;nominee&#8221; or &#8220;street name.&#8221; For information regarding the beneficial ownership of some stockholders
of Parent and Fitters Parent, see the section entitled &#8220;<i>Principal Stockholders of Parent</i>&#8221; of this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_024"></span>Fitters
Parent Ordinary Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Parent ordinary shares are listed on the Main Market of Bursa Malaysia Securities Berhad under the stock name: FITTERS and Stock Code:
9318. The following table presents, for the periods indicated, the range of high and low per share sales prices for Fitters Parent ordinary
shares as reported on the Main Market of Bursa Malaysia Securities Berhad for each of the periods set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Quarter Ended</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Low Sales Price of Parent Ordinary
    Shares (in MYR)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">High Sales Price of Parent Ordinary
    Shares (in MYR)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31%; text-align: left">March 31, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"/><td style="width: 31%; text-align: right">0.025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"/><td style="width: 30%; text-align: right">0.025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">June 31, 2024</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.06</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing price of Fitters Parent ordinary shares on May 5, 2025, the last trading day prior to the public announcement of the Transaction,
was MYR 0.025 per share, as reported on Main Market of Bursa Malaysia Securities Berhad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_025"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which
will be beyond its control. In addition to the other information contained in this proxy statement/prospectus, you should carefully consider
the material risks described below before deciding how to vote your shares of Parent Common Stock. In addition, you should read
and consider the risks associated with the business of Cyclacel Pharmaceuticals, Inc. because these risks may also affect the company
following the Transaction&#8212;these risks can be found in Cyclacel Pharmaceuticals, Inc.&#8217;s Annual Report on Form 10-K, as updated
by subsequent Quarterly Reports on Form 10-Q, all of which are filed with the SEC. You should also read and consider the other information
in this proxy statement/prospectus. Please see the section entitled </i>&#8220;<i>Where You Can Find More Information</i>&#8221; <i>in
this proxy statement/prospectus.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_026"></span>RISKS
RELATED TO THE TRANSACTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
number of Exchange Shares may be adjusted prior to the Closing upon mutual agreement of the Parties to the Exchange Agreement based on
the market price of Cyclacel common stock at that time; thus, the Transaction consideration at the Closing may have a greater or lesser
value than at the time the Exchange Agreement was signed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Closing of the Transaction, Fitters Parent shall convey, assign, and transfer all of its right, title and interest to the Company
Ordinary Shares to Parent in exchange for the cash consideration and the Exchange Shares. The number of Exchange Shares may be
adjusted prior to the Closing upon mutual agreement of the Parties to the Exchange Agreement based on the market price of Cyclacel common
stock so the Transaction consideration at the closing may have a greater or lesser value than at the time the Exchange Agreement was
signed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company Ordinary Shares to be transferred to Parent at the Closing shall constitute 100% percent of the issued and outstanding capital
shares of the Company. As part consideration for its acquisition of the Shares, Parent shall issue an amount of Exchange Shares
equal to nineteen and ninety-nine hundreds percent (19.99%) of the issued and outstanding shares of Parent Common Stock as of the Closing
Date to Fitters Parent by issuance of book-entry shares representing the Exchange Shares in accordance with the applicable provisions
of the DGCL, and instruct the Transfer Agent to update the register of stockholders of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of Cyclacel will continue to own and hold their existing shares of Cyclacel common stock. Immediately after the Transaction, (a) current
Parent&#8217;s stockholders are expected to own approximately 80.01% of the company and (b) Fitters Parent is expected to own approximately
19.99% of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to complete the Transaction could harm the common stock price of Parent and future business and operations of each company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Transaction is not completed, Parent and Fitters Parent are subject to the following risks:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price of Parent Common Stock may decline and remain volatile;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parties to the Exchange Agreement will have incurred significant expenses related to the Transaction, such as legal and accounting
    fees, many of which must be paid even if the Transaction is not completed; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
    Common Stock could be delisted from The Nasdaq Capital Market if it is unable to comply with the applicable Nasdaq listing requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Exchange Agreement is terminated and the board of directors of Parent or Fitters Parent determines to seek another business
combination, there can be no assurance that either Parent or Fitters Parent will be able to find a partner willing to provide equivalent
or more attractive consideration than the consideration to be provided by each party in the Transaction or any partner at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the conditions to the closing of the Transaction are not met, the Transaction may not occur.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the Transaction and related issuance of the Exchange Shares are approved by the stockholders of Parent, specified conditions must
be satisfied or waived to complete the Transaction. These conditions are set forth in the Exchange Agreement and described in the section
entitled &#8220;<i>The Exchange Agreement&#8212;Conditions to the Completion of the Transaction</i>&#8221; in this proxy statement/prospectus.
Parent and Fitters Parent cannot assure you that all of the conditions will be satisfied or waived. If the conditions are not satisfied
or waived, the Transaction may not occur or will be delayed, and Parent and Fitters Parent each may lose some or all the intended benefits
of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Transaction may be completed even though material adverse changes may result from the announcement of the Transaction, industry-wide
changes and other causes.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, either Parent or Fitters Parent can refuse to complete the Transaction if there is a material adverse change affecting Parent or the Company between May 6, 2025, the date of the Exchange Agreement, and the closing of the Transaction. However, certain types of changes
do not permit either party to refuse to complete the Transaction, even if such change could be said to have a material adverse effect
on Parent or the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
adverse change, event, development or effect arising from or relating to any of the following shall not be taken into account in determining
whether there has been a Material Adverse Effect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
general business or economic conditions,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
national or international political or social conditions, including the engagement by the United States or Malaysia in hostilities, whether
or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack upon the United
States or Malaysia, respectively, or any of its territories, possessions, or diplomatic or consular offices or upon any military installation,
equipment or personnel of the United States or Malaysia, respectively,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
financial, banking, or securities markets (including any disruption thereof and any decline in the price of any security or any market
index),</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
changes in US GAAP or IFRS,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
changes in laws, rules, regulations, orders, or other binding directives issued by any Governmental Entity, or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
the taking of any action required by the Exchange Agreement and the other agreements contemplated hereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
adverse changes occur and Parent and Fitters Parent still complete the Transaction, the stock price of Cyclacel following the closing
of the Transaction may suffer. This in turn may reduce the value of the Transaction to the stockholders of Parent, Fitters or
both.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Some
executive officers and directors of Parent and Fitters Parent have interests in the Transaction that are different from yours and that
may influence them to support or approve the Transaction without regard to your interests.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
officers and directors of Parent and Fitters Parent are parties to arrangements that provide them with interests in the Transaction that
are different from yours, including, among others, service as an officer or director of the Company following the closing of the Transaction,
severance and retention benefits, the acceleration of equity award vesting, and continued indemnification. For more information regarding
the interests of the Parent and Fitters Parent executive officers and directors in the Transaction, see the sections entitled &#8220;<i>The
Transaction&#8212;Interests of the Directors and Executive Officers of Parent in the Transaction</i>&#8221; and &#8220;<i>The Transaction&#8212;Interests
of the Directors and Executive Officers of Fitters Parent in the Transaction</i>&#8221; of this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of Parent Common Stock following the Transaction may decline as a result of the Transaction.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of Parent Common Stock may decline as a result of the Transaction for a number of reasons, including if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
investors react negatively to the prospects of the combined company&#8217;s business and prospects following the Closing of the
Transaction;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the effect of the Transaction on
the combined company&#8217;s business and prospects following the Closing of the Transaction is not consistent with the expectations
of financial or industry analysts; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
combined company does not achieve the perceived benefits of the Transaction as rapidly or to the extent anticipated by stockholders or
financial or industry analysts.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fitters
Parent and Parent securityholders will have a reduced ownership and voting interest in, and will exercise less influence over the management
of, the combined company following the Closing of the Transaction as compared to their current ownership and voting interest in the respective
companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the completion of the Transaction, the current securityholders of Fitters Parent and Parent will own a smaller percentage of the Company
and Cyclacel, respectively than the ownership in their respective companies prior to the Transaction. Immediately after the Transaction,
it is currently estimated that Fitters Parent will own approximately 19.99% of the common stock of Parent, with Parent securityholders,
whose shares of Parent Common Stock will remain outstanding after the Transaction, will own approximately 80.01% of the common stock
of Parent, calculated on a pro forma basis including after giving effect to the Transaction.
These estimates are based on the anticipated number of Exchange Shares and are subject to adjustment as provided in the Exchange Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the five member board of directors of the combined company will initially consist of the current directors of Parent. The
post-Transaction board of directors of Fitters Sdn. Bhd. will consist of one current member of the board of directors with the addition
of Datuk Dr. Doris Wong, Chief Executive Office and Executive Director of Parent. Consequently, securityholders of Parent will be able
to have continuity of the management and policies of the combined company following the Closing of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
provisions of the Exchange Agreement may discourage third parties from submitting competing proposals, including proposals that may be
superior to the arrangements contemplated by the Exchange Agreement.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the Exchange Agreement prohibit each of Parent and Fitters Parent from soliciting competing proposals or cooperating with persons
making unsolicited takeover proposals, except in limited circumstances when such party&#8217;s board of directors determines in good
faith, after consultation with its independent financial advisor, if any, and outside counsel, that an unsolicited competing proposal
constitutes, or would reasonably be expected to result in, a superior competing proposal and that failure to take such action would be
reasonably likely to result in a breach of the fiduciary duties of the board of directors. In addition, if Parent or Fitters Parent terminate
the Exchange Agreement under specified circumstances, the Parties will still be obligated to pay expenses related to the Transaction,
which may discourage third parties from submitting competing proposals to Parent or Fitters Parent or their stockholders, and may cause
the respective boards of directors to be less inclined to recommend a competing proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the lack of a public market for Fitters capital shares makes it difficult to evaluate the fairness of the Transaction, Fitters Parent
may receive consideration in the Transaction that is less than the fair market value of Fitters&#8217; capital shares and/or Parent may
pay more than the fair market value of Fitters capital shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The outstanding capital shares of Fitters is
privately held as a subsidiary of Fitters Parent. The lack of a public market for the capital shares of Fitters makes it extremely difficult
to determine its fair market value. Because the percentage of Parent equity to be issued to Fitters Parent as consideration for 100% of
the capital shares of Fitters was determined based on negotiations between the Parties, it is possible that the value of Parent Common
Stock to be received by Fitters Parent will be less than the fair market value of the capital shares of Fitters, or Parent may pay more
than the aggregate fair market value for Fitters capital shares. To mitigate this risk, the parties procured the Fairness Opinion of Strategic
Capital Advisory Sdn Bhd., as discussed throughout this proxy statement/prospectus.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_027"></span>RISKS
RELATED TO CYCLACEL PHARMACEUTICALS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unless
the context requires otherwise, references in the following &#8220;Risks Related to Parent&#8221; in this proxy statement/prospectus
to &#8220;Cyclacel,&#8221; &#8220;Parent&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; are to Cyclacel Pharmaceuticals,
Inc., a Delaware corporation.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Evaluation of Strategic Alternatives</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
activities to evaluate and pursue strategic alternatives may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, Parent announced that it was in the process of exploring and reviewing strategic alternatives on an expedited basis in
order to preserve Parent&#8217;s cash, including a potential transaction with investor David Lazar of Activist Investing, LLC (&#8220;Lazar&#8221;).
Parent&#8217;s Board of Directors reviewed a range of appropriate strategies to realize value from its assets. The Board directed management
to reduce operating costs, which included the liquidation of Parent&#8217;s wholly-owned United Kingdom subsidiary, Cyclacel Limited,
while such alternatives were being explored.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2025, the creditors voluntary liquidation of Cyclacel Limited was announced in the London Gazette, one of the official public
records of the government of the United Kingdom. As part of Cyclacel&#8217;s efforts to reduce operating costs it has determined to focus
on the development of the plogo clinical program only. On March 10, 2025, Cyclacel entered into an Agreement for the Sale and Purchase
of certain assets related to plogo with Cyclacel Limited and the joint liquidator. Therefore, fadraciclib, the Subsidiary&#8217;s other
drug development program, is being marketed for sale by the joint liquidator through Hilco Appraisals Limited, a firm of professional
valuation agents and will no longer be part of the assets of Cyclacel as of January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged ARC Group Limited, as a financial advisor to assist us in pursuing strategic alternatives, and on May 6, 2025 we announced
that we had entered into the Exchange Agreement. We continue to evaluate additional strategic alternatives in order to enhance stockholder
value, including the possibility of the sale of our assets related to plogo, and we have suspended many of our research and development
activities to reduce operating expenses while we evaluate and pursue these opportunities. We have and expect to continue to devote significant
time and resources to identifying and evaluating strategic alternatives, including the Transaction; however, there can be no assurance
that the Transaction or other such activities will enhance stockholder value. In addition, potential strategic transactions that require
stockholder approval, such as the Transaction and the related matters stockholders are being asked to approve in this proxy statement/prospectus,
may not be approved by our stockholders. Further, any strategic transaction that is completed ultimately may not deliver the anticipated
benefits or enhance stockholder value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
strategic transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may
pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial
results. For example, these transactions may entail numerous operational and financial risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to unknown liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher than expected acquisition and integration costs;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">write downs of assets or goodwill or impairment charges;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased amortization expenses;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to sell assets; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to retain key employees of our company or any acquired businesses.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
although there can be no assurance that we will undertake or successfully complete any strategic transactions of the nature described
above. Any transactions that we complete may be subject to the foregoing or other risks and could have a material adverse effect on our
business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business to date has been almost entirely dependent on the success of our product candidates and we have recently decided to discontinue
further development of fadraciclib in the U.S. and Europe, and devote significant time and resources to the further development of plogo
and identifying and evaluating strategic alternatives, which may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company working to develop innovative cancer medicines based on cell cycle, epigenetics and mitosis
biology. We are a pioneer company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating
insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient&#8217;s overall survival. The
epigenetic/anti-mitotic program is evaluating plogo, a PLK1 inhibitor, in solid tumors and hematological malignancies. Our strategy is
to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have retained rights to commercialize our clinical development candidates and our business objective is to enter into selective partnership
arrangements with these programs. Substantially all our efforts to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. As part of Cyclacel&#8217;s
efforts to reduce operating costs, it has determined to focus on the development of plogo only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are evaluating and pursuing strategic alternatives with a goal to enhance stockholder value, including the Transaction and have suspended
most of our research and development activities, other than our plogo program, to reduce operating expenses while we focus on closing
the Transaction and pursuing other strategic alternatives with respect to the sale of assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that our efforts to sell certain of our assets will result in any definitive offer to buy such assets or if made,
what the terms thereof will be or that the Transaction or any asset sale will be approved or consummated. In addition, there can be no
assurance that any transactions, involving our company and/or assets, that is consummated would enhance stockholder value. There also
can be no assurance that we will conduct additional research or development activities in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are substantially dependent on our remaining employees to facilitate the consummation of a strategic transaction. We could lose such
key employees, in particular, as a result of the plogo data and the reduction in our workforce in recent years.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, we instituted expense reductions to conserve capital, including a workforce reduction including of our former Chief Medical
Officer. Our cash conservation activities may cause remaining employees to seek alternative employment. Our ability to successfully complete
a strategic transaction, including the Transaction, depends in large part on our ability to retain certain of our remaining personnel,
particularly Datuk Dr. Doris Wong, Chief Executive Office and Executive Director, and Kiu Cu Seng, our Chief Financial Officer, Executive
Director and Secretary. Despite our efforts to retain these officers, one or more may terminate their employment with us on short notice.
The loss of the services of any of these officers could potentially harm our ability to evaluate and pursue strategic alternatives, as
well as fulfill our reporting obligations as a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
among emerging companies for qualified employees is intense, and the ability to retain our key employees is critical to our ability
to effectively manage our resources and to consummate a strategic transaction. Although we have suspended most of our research and development
activities, if we continue the development of plogo or of new products, such development requires expertise from a number of different
disciplines, some of which are not widely available. The failure of the development of plogo in clinical trials will likely make it more
challenging to retain qualified personnel and difficult to recruit personnel in the future, if necessary. The inability to recruit or
loss of the services of any executive, key employee, consultant or advisor may impede our ability to identify and execute on a strategic
path forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
key employees have a significant amount of know-how and experience in our company, and the loss of one or more of them could have a material
and adverse effect on our operations or ability to consummate a strategic transaction. While we have taken steps to retain our employees,
including the granting of equity awards, paying competitive salaries and implementing appropriate bonus programs, these factors may not
be enough to retain the employees that we need, particularly in light of the recent scaling back of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loss of the services of existing personnel or the failure to recruit additional, suitable key scientific, managerial, clinical, regulatory,
operational and other personnel in a timely manner, if required, could harm our business. We may experience difficulty in hiring and
retaining highly-skilled employees with appropriate qualifications as needed. If we fail to retain and motivate our current personnel
or fail to attract new personnel, our business and future growth prospects and our ability to consummate a strategic transaction would
be harmed. The inability to recruit or loss of the services of any executive, key employee, consultant or advisor may impede our ability
to identify and execute on our strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a history of operating losses, and we expect to incur losses for the foreseeable future. We may never become profitable. Our stock
is a highly speculative investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred operating losses in each year since beginning operations in 1996 due to costs incurred in connection with our research
and development activities and selling, general and administrative costs associated with our operations, we expect to incur significant
losses for the next several years and we may never achieve profitability. As of March 31, 2025, we had an accumulated deficit of $440.5
million. As of December 31, 2024 and December 31, 2023, our accumulated deficit was $439.5 million and $428.3 million, respectively.
Net cash used in operating activities increased by $2.7 million, from $0.5 million for the three months ended March 31, 2024 to $3.2
million for the three months ended March 31, 2025. The increase in cash used by operating activities was primarily the result of a change
in working capital of $5.5 million as result of the change of control and offset by $1.7 million of stock compensation expense. Our net
loss was $11.2 million and $22.5 million for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
remaining drug candidate, plogo, is in the early- to mid-stages of clinical testing and we must conduct significant additional clinical
trials before we can seek the regulatory approvals necessary to begin commercial sales of our drugs. We expect to incur continued losses
for several years as we continue our research and development of our drug candidates, seek regulatory approvals and commercialize any
approved drugs. If our remaining drug candidate is unsuccessful in clinical trials or we are unable to obtain regulatory approvals, or
if our drugs are unsuccessful in the market, we will not be profitable. If we fail to become and remain profitable, or if we are unable
to fund our continuing losses, particularly in light of the current economic conditions, you could lose all or part of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is substantial doubt regarding our ability to continue as a going concern. Our ability to raise additional capital in the future may
not be available to us on reasonable terms, if at all, when or as we require additional funding. If we issue additional shares of our
common stock or other securities that may be convertible into, or exercisable or exchangeable for, our common stock, our existing stockholders
would experience further dilution. If we fail to obtain additional funding, we may be unable to complete the development and commercialization
of our lead drug candidates or continue to fund our research and development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have funded all of our operations and capital expenditures with proceeds from the issuance of public equity securities, private placements
of our securities, interest on investments, licensing revenue, government grants, research and development tax credits and product revenue.
In order to conduct the lengthy and expensive research, preclinical testing and clinical trials necessary to complete the development
and marketing of our drug candidates, we will require substantial additional funds. We may have insufficient public equity available
for issue to raise the required additional substantial funds to implement our operating plan and we may not be able to obtain the appropriate
stockholder approvals necessary to increase our available public equity for issuance within a time that we may require additional funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2025, we used net cash of $3.2 million to fund our operating activities. We had cash and cash equivalents
of $3.5 million as of March 31, 2025. As of December 31, 2024, our cash and cash equivalents were $3.1 million. Based on our current
operating plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date
that our financial statements for the year ended December 31, 2024 are issued. To meet our long-term financing requirements, we may raise
funds through public or private equity offerings, debt financings or strategic alliances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
additional funds by issuing equity or convertible debt securities may cause our stockholders to experience substantial dilution in their
ownership interests and new investors may have rights superior to the rights of our other stockholders. To the extent equity valuations,
including the trading price of our common stock, are depressed as a result of economic disruptions or other uncertainties, for example
due to rising inflationary pressures, ongoing military conflicts or other factors, the potential magnitude of this dilution will increase.
Raising additional funds through debt financing, if available, may involve covenants that restrict our business activities and options.
To the extent that we raise additional funds through collaborations and licensing arrangements, we may have to relinquish valuable rights
to our drug discovery and other technologies, research programs or drug candidates, or grant licenses on terms that may not be favorable
to us. Additional funding may not be available to us on favorable terms, or at all, particularly in light of the current economic conditions.
If we are unable to obtain additional funds, we may be forced to delay or terminate our current clinical trials and the development and
marketing of our remaining drug candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unstable
market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerns
over energy costs, geopolitical issues, the U.S. mortgage market and a deteriorating real estate market, unstable global credit markets
and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished liquidity and credit
availability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations
of slower global economic growth, increased unemployment rates, and increased credit defaults in recent years. Our general business strategy
may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic
and market conditions. There can be no assurance that further deterioration in credit and financial markets and confidence in economic
conditions will not continue to occur. Our general business strategy may be adversely affected by any such economic downturn, volatile
business environment or continued unpredictable and unstable market conditions. If the current financial markets deteriorate, or do not
improve, it may make any necessary financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing
in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock
price and could require us to delay or abandon clinical development or other operating or strategic plans for our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inadequate
funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel,
prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from
performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other
government agencies on which our operations may rely, including those that fund research and development activities is subject to the
political process, which is inherently fluid and unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,
which would adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the
FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, upon
completion of this offering and in our operations as a public company, future government shutdowns could impact our ability to access
the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, independent contractors, principal investigators, contract research organizations, consultants or vendors may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk that our employees, independent contractors, principal investigators, contract research organizations, consultants
or vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or
negligent conduct or disclosure of unauthorized activities to us that violates: FDA regulations, including those laws requiring the reporting
of true, complete and accurate information to the FDA; manufacturing standards; federal and state health care fraud and abuse laws and
regulations; or laws that require the true, complete and accurate reporting of financial information or data. In addition, sales, marketing
and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks,
self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve
the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our nonclinical
studies or clinical trials, which could result in regulatory sanctions and serious harm to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect
and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally,
we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are
instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant
impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion
from participation in Medicare, Medicaid and other federal health care programs, contractual damages, reputational harm, diminished potential
profits and future earnings, and curtailment of our operations, any of which could adversely affect our business, financial condition,
results of operations or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to compete successfully in our marketplace, it will harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are existing products in the marketplace that compete with our products. Companies may develop new products that compete with our products.
Certain competitors and potential competitors have longer operating histories, substantially greater product development capabilities
and financial, scientific, marketing and sales resources. Competitors and potential competitors may also develop products that are safer,
more effective or have other potential advantages compared to our products. In addition, research, development and commercialization
efforts by others could render our products obsolete or non-competitive. Certain competitors and potential competitors have broader product
offerings and extensive customer bases, allowing them to adopt aggressive pricing policies that would enable them to gain market share.
Competitive pressure could result in price reductions, reduced margins and loss of market share. We could encounter potential customers
that, due to existing relationships with our competitors, are committed to products offered by those competitors. As a result, those
potential customers may not consider purchasing our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are at an early stage of development as a company and we do not have, and may never have, any products that generate significant revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are at an early stage of development as a company and have a limited operating history on which to evaluate our business and prospects.
We cannot guarantee that our sole product candidate currently in development will ever become marketable. We must demonstrate that our
drug candidate satisfies rigorous standards of safety and efficacy for their intended uses before the FDA, EMA and other regulatory authorities
in the United States, the European Union and elsewhere. Significant additional research, preclinical testing and clinical testing is
required before we can file applications with the FDA or EMA for approval of plogo or any of our future drug candidates. In addition,
to compete effectively, our drugs must be easy to administer, cost-effective and economical to manufacture on a commercial scale. We
may not achieve any of these objectives. We cannot be certain that the clinical development of our drug candidates in preclinical testing
or clinical development will be successful, that we will receive regulatory approvals required to commercialize them or that any of our
other research and drug discovery programs will yield a drug candidate suitable for investigation through clinical trials. Our commercial
revenues from our product candidate currently in development, if any, will be derived from sales of drugs that will not become marketable
for several years, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted and the price
of our common stock and our ability to access the capital markets could be negatively impacted. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed for trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;). We must satisfy Nasdaq&#8217;s continued
listing requirements, including, among other things, a minimum stockholders&#8217; equity of&#8201;$2.5 million and a minimum bid price
for our common stock of&#8201;$1.00 per share, or risk delisting, which would have a material adverse effect on our business. In order
to maintain our listing, we must also maintain continued business operations so that we are not characterized as a &#8220;public shell
company.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
delisting of our common stock from The Nasdaq Capital Market could materially reduce the liquidity of our common stock and result in
a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through
alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors,
suppliers, customers and employees and fewer business development opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
effected a 15:1 reverse stock split of our common stock on December 18, 2023 (the &#8220;Reverse Stock Split&#8221;), which enabled us
to regain compliance with Nasdaq&#8217;s minimum bid price requirements. On February 25, 2025, Nasdaq notified Cyclacel that it has regained
compliance with the equity requirement in Listing Rule 5550(b)(1) (the &#8220;Equity Rule&#8221;), as required by the Nasdaq Hearing
Panel&#8217;s decision dated October 22, 2024. As previously reported by Cyclacel on Form 8-K, filed with the SEC on October 24, 2024,
on October 15, 2024, Cyclacel met with the Nasdaq Hearings Panel regarding its potential delisting from Nasdaq as a result of its non-compliance
with the Equity Rule. On October 22, 2024, Cyclacel received the Nasdaq Hearings Panel decision which granted Cyclacel until December
24, 2024 to regain compliance with the Equity Rule. Following Cyclacel&#8217;s regaining compliance with the Equity Rule pursuant to
the February 25, 2025, Cyclacel will be subject to a Mandatory Panel Monitor for a period of one year from February 25, 2025 pursuant
to Listing Rule 5815(d)(4)(B).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, we effected a 16:1 reverse stock split, primarily to meet the minimum bid price requirements of Nasdaq, which reverse stock
split was approved by Cyclacel&#8217;s stockholders at a special meeting of its stockholders on February 6, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2025, Cyclacel received a minimum bid price compliance letter from Nasdaq confirming that Cyclacel has regained compliance with
Listing Rule 5550(a)(2), and that the matter is now closed. Notwithstanding the minimum bid price compliance letter from Nasdaq, we cannot
be sure that our share price will continue to comply with the requirements for continued listing of our common stock on The Nasdaq Capital
Market in the future, or that we will continue to comply with the other continued listing requirements. If our shares of common stock
lose their status on The Nasdaq Capital Market, we believe that our shares of common stock would likely be eligible to be quoted on the
inter-dealer electronic quotation and trading system operated by Pink OTC Markets Inc., commonly referred to as the Pink Sheets and now
known as the OTCQB market. These markets are generally not considered to be as efficient as,
and not as broad as, The Nasdaq Capital Market. Selling our shares of common stock on these markets could be more difficult because smaller
quantities of shares would likely be bought and sold, and transactions could be delayed. In addition, in the event our shares of common
stock are delisted, broker-dealers have certain regulatory burdens imposed upon them, which may discourage broker-dealers from effecting
transactions in our common stock, further limiting the liquidity of our common stock. These factors could result in lower prices and
larger spreads in the bid and ask prices for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
the extent we elect to fund the development of a drug candidate or the commercialization of a drug at our expense, we will need substantial
additional funding.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to market drugs on our own, with or without a partner, that can be effectively commercialized and sold in concentrated markets that
do not require a large sales force to be competitive. To achieve this goal, we will need to establish our own specialized sales force,
marketing organization and supporting distribution capabilities. The development and commercialization of our drug candidates is very
expensive. To the extent we elect to fund the full development of a drug candidate or the commercialization of a drug at our expense,
we will need to raise substantial additional funding to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fund
    research and development and clinical trials connected with our research;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fund
    clinical trials and seek regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">build
    or access manufacturing and commercialization capabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement
    additional internal control systems and infrastructure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercialize
    and secure coverage, payment and reimbursement of our drug candidates, if any such candidates receive regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    defend and expand the scope of our intellectual property; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional management, sales and scientific personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future funding requirements will depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress and cost of our clinical trials and other research and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of seeking and obtaining regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with establishing sales and marketing capabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring or investing in businesses, products and technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    payment, other terms and timing of any strategic alliance, licensing or other arrangements that we may establish.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to secure additional funding when needed, especially in light of the current economic conditions and financial market
turmoil, we may have to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs
or future commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include
property, general liability, employment benefits liability, workers&#8217; compensation, products liability and clinical trials (U.S.
and foreign), and directors&#8217; and officers&#8217;, employment practices and fiduciary liability insurance. We do not know, however,
if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay
substantial amounts, which would adversely affect our financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Funding
constraints may negatively impact our research and development, forcing us to delay our efforts to develop Plogo, which may prevent us
from commercializing our product candidate as quickly as possible.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development is an expensive process. As part of our operating plan, we have decided to concentrate our clinical development strategy
on our single remaining product candidate, plogo, an ongoing, hemato-oncology clinical program in transcriptional regulation and mitosis
control biology, which include our areas of historical expertise in PLK inhibitor. Because we have to prioritize our development candidate
as a result of budget constraints, we may not be able to fully realize the value of our product candidate in a timely manner, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Security
incidents, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing
critical information and expose us to liability, which could adversely affect our business and our reputation. Our business and operations
would suffer in the event of system failures.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, intellectual property and proprietary business information
owned or controlled by ourselves or our customers. This data encompasses a wide variety of business-critical information including research
and development information, commercial information, and business and financial information. We face four primary risks related to protecting
this critical information: loss of access; unauthorized disclosure; unauthorized modification; and inadequate monitoring of our controls
over the first three risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize information technology, or IT, systems and networks to process, transmit and store electronic information in connection with
our business activities. The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations
and business strategy, and we devote significant resources to protecting such information. As use of digital technologies has increased,
cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased
in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability
and integrity of our data. There can be no assurance that we will be successful in preventing cybersecurity incidents or successfully
mitigating their effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal and cloud-based computer systems and those of our contractors and consultants are
vulnerable to damage from such cybersecurity incidents, including computer viruses, social engineering, unauthorized access, natural
disasters, terrorism, war and telecommunication and electrical failures. Such an event could cause interruption of our operations. For
example, the loss of data from ongoing or completed clinical trials for our product candidate could result in delays in our regulatory
approval efforts and significantly increase our costs. In addition, there can be no assurance that we will promptly detect any such disruption
or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of or damage to our data,
or inappropriate disclosure of confidential or proprietary information, we could suffer material legal claims and liability, damage to
our reputation, suffer loss or harm to our intellectual property rights and the further research, development and commercial efforts
of our products and product candidate could be delayed. The loss of drug development or clinical trial data could result in delays in
our regulatory approval efforts and significantly increase our costs to recover or reproduce the data and could adversely impact our
business and operations, and could result in financial, legal, operational or reputational harm to us, loss of competitive advantage
or loss of consumer confidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely, and expect to continue to rely, on third parties to conduct some aspects of our product formulation, research, preclinical, and
clinical studies, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of
such formulation, research or testing.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, contracted laboratories
and third-party CROs, to conduct our preclinical studies and clinical trials, as well as certain product candidate discovery and development
activities, in accordance with applicable regulatory requirements and to monitor and manage data for our ongoing preclinical and clinical
programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of
their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the
applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve
us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GLP and GCP requirements,
as applicable, which are regulations and guidelines enforced by the FDA, the EMA and other comparable foreign regulatory authorities
for all of our products in clinical development. Regulatory authorities enforce these GLP and GCP regulations through periodic inspections
of laboratories conducting GLP studies, and clinical trial sponsors, principal investigators, CROs, and trial sites when auditing for
GCP compliance. If we, our investigators or any of our CROs or contracted laboratories fail to comply with applicable GLP and GCP regulations,
as applicable, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, the EMA or other
comparable foreign regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving
our marketing applications for our therapeutic product candidates. We cannot assure you that upon inspection by a given regulatory authority,
such regulatory authority will determine that any of our preclinical studies or clinical trials comply with applicable GLP or GCP regulations.
In addition, our clinical trials must be conducted with product manufactured in compliance with applicable cGMP regulations. Our failure
to comply with these regulations may require us to repeat preclinical studies or clinical trials, which would delay the regulatory approval
process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
these laboratories, investigators and CROs are not our employees, and we will not be able to control, other than by contract, the amount
of resources, including time which they devote to plogo or and of our future product candidate and clinical trials. If independent laboratories,
investigators or CROs fail to devote sufficient resources to the development of our product candidate, or if their performance is substandard,
it may delay or compromise the prospects for approval and commercialization of plogo or any future product candidates that we develop.
In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could
increase the risk that this information will be misappropriated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives.
If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able to enter
into arrangements with alternative laboratories, CROs or investigators or to do so in a timely manner or on commercially reasonable terms.
If laboratories, CROs or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected
deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure
to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical studies or clinical
trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize
our product candidate. As a result, our results of operations and the commercial prospects for our product candidate would be harmed,
our costs could increase and our ability to generate revenues could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switching
or adding additional laboratories or CROs (or investigators) involves additional costs and requires management time and focus. In addition,
there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact
our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our contracted laboratories
and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges
will not have a material adverse impact on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, clinical investigators may serve as scientific advisors or consultants to us from time to time and may receive cash compensation
in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest,
or the FDA concludes that the financial relationship may have affected the interpretation of the preclinical study or clinical trial,
the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the utility of the
preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay
or rejection could prevent us from commercializing our clinical-stage product candidate or any future therapeutic product candidates
it may develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third-party supply and manufacturing partners for drug supplies for our late-stage clinical activities and may do the same for
any commercial supplies of our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third-party contract manufacturing organizations, or CMOs, for our preclinical and future clinical trial product materials and
commercial supplies. We do not intend to produce any meaningful quantity of plogo or any of our future product candidates for preclinical
and clinical development through our internal resources, and we do not currently own manufacturing facilities for producing such supplies.
While we intend to try to avoid sole-source arrangements with any of our manufacturing, supply and testing vendors, it may not always
be possible to do so. We cannot assure you that our preclinical or future clinical development product supplies and commercial supplies
will not be limited or interrupted, especially with respect to any sole source third-party manufacturing and supply partners or will
be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could
require significant effort and expertise because there may be a limited number of qualified replacements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
complying with the manufacturing regulations of the FDA and other comparable foreign regulatory authorities, we and our third-party suppliers
must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality
control to assure that the products meet applicable specifications and other regulatory requirements. Suppliers and manufacturers must
meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities
in order to comply with regulatory standards, such as cGMP. Although our agreements with our CMOs require them to perform according to
certain cGMP requirements such as those relating to quality control, quality assurance and qualified personnel, we cannot control the
conduct of our CMOs to implement and maintain these standards. In the event that any of our current or future manufacturers fails to
comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components
or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which
we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able
to do on commercially reasonable terms, or at all. In some cases, the technical skills or technology required to manufacture our future
product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology
to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require
us to obtain a license from such manufacturer in order to have another third party manufacture our product candidate. If we are required
to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that
comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new
manufacturer could negatively affect our ability to develop product candidate in a timely manner or within budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our CMOs are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of
any of plogo and thereafter are subject to ongoing inspection from time to time. Our CMOs may not be able to comply with applicable cGMP
regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers,
to comply with applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations,
warning letters or sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or
withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal
prosecutions, any of which could significantly and adversely affect supplies of our products. Any such failure by us or any of our CMOs
would significantly impact our ability to develop, obtain regulatory approval for or, if approved, market our product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing,
or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations
in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance.
If we are unable to obtain or maintain third-party manufacturing for product candidate, or to do so on commercially reasonable terms,
we may not be able to develop and commercialize our product candidate successfully. Our or a third-party&#8217;s failure to execute our
manufacturing requirements could adversely affect our business in a number of ways, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to initiate or continue clinical trials of plogo under development, which may impact our potential economic benefits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in submitting regulatory applications, or receiving regulatory approvals, for plogo or any future product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of the cooperation of a collaborator;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
    plogo or any future of our product candidate to additional inspections by regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to cease distribution or to recall batches of plogo or any future of our product candidate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of approval to market and commercialize plogo or any future product candidate, an inability to meet commercial demands
    for our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to enter into and maintain successful strategic alliances for our drug candidates, we may have to reduce or delay our drug candidate
development or increase our expenditures.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
important element of our strategy for developing, manufacturing and commercializing our drug candidates is entering into strategic alliances
with pharmaceutical companies, research institutions or other industry participants to advance our programs and enable us to maintain
our financial and operational capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate alliances. We may not be able to negotiate alliances on acceptable terms, if at all.
In addition, these alliances may be unsuccessful. If we fail to create and maintain suitable alliances, we may have to limit the size
or scope of, or delay, one or more of our drug development or research programs. If we elect to fund drug development or research programs
on our own, we will have to increase our expenditure and will need to obtain additional funding, which may be unavailable or available
only on unfavorable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
the extent we are able to enter into strategic transactions, we will be exposed to risks related to those collaborations and alliances.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to enter into strategic transactions to complete the development and commercialization of some of our drug candidates, including
but not limited to after the Phase 2 stage of clinical testing. These arrangements may place the development of our drug candidates outside
our control, may require us to relinquish important rights, or may otherwise be on terms unfavorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dependence
on collaborative arrangements or strategic alliances will subject us to a number of risks, including the risks that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to control the amount and timing of resources that our collaborators may devote to the drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    collaborators may experience financial difficulties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to relinquish important rights such as marketing and distribution rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    combinations or significant changes in a collaborator&#8217;s business strategy may also adversely affect a collaborator&#8217;s
    willingness or ability to complete its obligations under any arrangement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration
    with others, including our competitors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborative
    arrangements are often terminated or allowed to expire, which would delay development and may increase the cost of developing our
    drug candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to enforce adequately or defend our intellectual property rights, our business may be harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in large part on obtaining and maintaining patent and trade secret protection for our drug candidates, the
methods used to manufacture those drug candidates and the methods for treating patients using those drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain patents is uncertain because legal means afford only limited protections and may not adequately protect our rights
or permit us to gain or keep any competitive advantage. Some legal principles remain unresolved and the breadth or interpretation of
claims allowed in patents in the United States, the European Union or elsewhere can still be difficult to ascertain or predict. In addition,
the specific content of patents and patent applications that are necessary to support and interpret patent claims is highly uncertain
due to the complex nature of the relevant legal, scientific and factual issues. Changes in either patent laws or in interpretations of
patent laws in the United States, the European Union or elsewhere may diminish the value of our intellectual property or narrow the scope
of our patent protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from
practicing our technologies or from developing competing products and technologies. In addition, we generally do not control the patent
prosecution of subject matter that we license from others and have not controlled the earlier stages of the patent prosecution. Accordingly,
we are unable to exercise the same degree of control over this intellectual property as we would over our own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if patents are issued regarding our drug candidates or methods of using them, those patents can be challenged by our competitors who
may argue such patents are invalid and/or unenforceable. Patents also will not protect our drug candidates if competitors devise ways
of making or using plogo or any future of our product candidates without legally infringing our patents. The FDA and FDA regulations
and policies and equivalents in other jurisdictions provide incentives to manufacturers to challenge patent validity or create modified,
non-infringing versions of a drug in order to facilitate the approval of abbreviated new drug applications for generic substitutes. These
same types of incentives encourage manufacturers to submit NDAs that rely on literature and clinical data not prepared for or by the
drug sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proprietary
trade secrets and unpatented know-how are also very important to our business. We rely on trade secrets to protect our technology, especially
where we do not believe that patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Our employees,
consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our confidential
information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure
of confidential information. Enforcing a claim that a third-party obtained illegally and is using trade secrets is expensive and time
consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.
Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain protection under the Hatch-Waxman Act and similar legislation outside of the United States by extending the patent terms
and obtaining data exclusivity for our product candidate, our business may be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA marketing approval of our product candidate, if any, one or more of our United States
patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred
to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term
lost during product development and the FDA regulatory review process. However, we may not be granted an extension because, for example,
of failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy
applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request.
If we are unable to obtain patent term extension or the term of any such extension is less than what we request, the period during which
we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products
following our patent expiration, and our revenue could be reduced, possibly materially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of former
employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we
have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation
may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper or prevent
our ability to commercialize certain potential drugs, which could severely harm our business. Even if we are successful in defending
against these claims, litigation could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Confidentiality
agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and
may not adequately protect our intellectual property, which could limit our ability to compete.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we operate in the highly technical field of drug discovery and development of small molecule drugs, we rely in part on trade secret protection
in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We enter into confidentiality
and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators,
sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose
to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#8217;s
relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services
to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property
rights to us. Enforcing a claim that a party illegally obtained and is using our trade secrets is difficult, expensive and time consuming,
and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. The failure
to obtain or maintain trade secret protection could adversely affect our competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights of third parties may increase our costs or delay or prevent us from being able to commercialize our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk that we are infringing or will infringe on the proprietary rights of third parties because patents and pending applications
belonging to third parties exist in the United States, the European Union and elsewhere in the world in the areas of our research. Others
might have been the first to make the inventions covered by each of our or our licensors&#8217; pending patent applications and issued
patents and might have been the first to file patent applications for these inventions. We are aware of several published patent applications,
and understand that others may exist, that could support claims that, if granted and held valid, could cover various aspects of our developmental
programs, including in some cases particular uses of our drug candidate, plogo, or substances, processes and techniques that we use in
the course of our research and development and manufacturing processes. We are aware that other patents exist that claim substances,
processes, techniques and methods of use, which, if held valid, could potentially restrict the scope of our research, development or
manufacturing operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we understand that other applications and patents exist relating to potential uses of plogo that are not part of our current
clinical programs for these compounds. Numerous third-party United States and foreign issued patents and pending applications exist in
the area of kinases, including PLK for which we have a research program. For example, some pending patent applications contain broad
claims that could represent freedom to operate limitations for some of our kinase programs should they be issued unchanged. Although
we intend to continue to monitor these applications, we cannot predict what claims will ultimately be allowed and if allowed what their
scope would be. In addition, because the patent application process can take several years to complete, there may be currently pending
applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use
of our drug candidates. If we wish to use the technology or compound claimed in issued and unexpired patents owned by others, we will
need to obtain a license from the owner, enter into litigation to challenge the validity of the patents or incur the risk of litigation
in the event that the owner asserts that we infringe its patents. In one case we have opposed a European patent relating to human aurora
kinase and the patent was finally revoked (with no appeal filed).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and
biotechnology industries. Defending against third party claims, including litigation in particular, would be costly and time-consuming
and would divert management&#8217;s attention from our business, which could lead to delays in our development or commercialization efforts.
If third parties are successful in their claims, we might have to pay substantial damages or take other actions that are adverse to our
business. As a result of intellectual property infringement claims, or to avoid potential claims, we might:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    prohibited from selling or licensing any product that we may develop unless the patent holder licenses the patent to us, which it
    is not required to do;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    required to pay substantial royalties or grant a cross license to our patents to another patent holder; decide to locate some of
    our research, development or manufacturing operations outside of Europe or the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    required to pay substantial damages for past infringement, which we may have to pay if a court determines that our product candidate
    or technologies infringe a competitor&#8217;s patent or other proprietary rights; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    required to redesign the manufacturing process or formulation of a drug candidate so it does not infringe, which may not be possible
    or could require substantial funds and time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or company
has the right to ask the court to rule that such patents are invalid or should not be enforced against that third party. These lawsuits
are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful
in stopping the infringement of such patents. In addition, there is a risk that the court will decide that such patents are not valid
and that we do not have the right to stop the other party from using the inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is also a risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that
such other party&#8217;s activities do not infringe our rights to such patents. In addition, the United States Supreme Court has recently
modified some tests used by the United States Patent and Trademark Office (&#8220; USPTO&#8221;), in granting patents over the past 20
years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents
we obtain or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid
to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents
and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel
to pay these fees. The USPTO and various non-United States governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other
professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance
with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might
be able to enter the market and this circumstance would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
patent applications of pharmaceutical and biotechnology companies involve highly complex legal and factual questions, which, if determined
adversely to us, could negatively impact our patent position.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions.
The standards of the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) are uncertain and could change in the future. Consequently,
the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented.
U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to <i>Inter Partes
</i>Review (IPR), Post Grant Review (PGR) or reexamination proceedings in the USPTO (and foreign patents may be subject to opposition
or comparable proceedings in the corresponding foreign patent office), which proceedings could result in either loss of the patent or
denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application.
Similarly, opposition or invalidity proceedings could result in loss of rights or reduction in the scope of one or more claims of a patent
in foreign jurisdictions. In addition, such interference, reexamination and opposition proceedings may be costly. Accordingly, rights
under any issued patents may not provide us with sufficient protection against competitive products or processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to obtain and maintain patent protection and trade secret protection of plogo or any of our future product candidates, proprietary
technologies and their uses, we could lose our competitive advantage and competition we face would increase, reducing our potential revenues
and adversely affecting our ability to attain or maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Securities Regulations and Investment in Our Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to achieve and maintain internal controls in accordance with Sections 302 and 404 of the Sarbanes-Oxley Act of 2002 could have a material
adverse effect on our business and stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404 of the Sarbanes-Oxley Act of 2002 requires that we maintain internal control over financial reporting that meets applicable standards.
As with many smaller companies with small staff, material weaknesses in our financial controls and procedures may be discovered. If we
fail to maintain our internal controls or fail to implement required new or improved controls, as such control standards are modified,
supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal controls
over financial reporting. Effective internal controls are necessary for us to produce reliable financial reports and are important in
the prevention of financial fraud. If we cannot produce reliable financial reports or prevent fraud, our business and operating results
could be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur increased costs and management resources as a result of being a public company, and we may fail to comply with public company obligations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we face and will continue to face increased legal, accounting, administrative and other costs and expenses that we
would not incur as a private company. Compliance with the Sarbanes Oxley Act of 2002, as well as other rules of the SEC, the Public Company
Accounting Oversight Board and Nasdaq resulted in a significant initial cost to us as well as an ongoing compliance cost. As a public
company, we are subject to Section 404 of the Sarbanes Oxley Act relating to internal control over financial reporting. We have completed
a formal process to evaluate our internal controls for purposes of Section 404, and we concluded that as of December 31, 2024, our internal
control over financial reporting was effective. As our business grows and changes, there can be no assurances that we can maintain the
effectiveness of our internal controls over financial reporting. In addition, our independent certified public accounting firm has not
provided an opinion on the effectiveness of our internal controls over financial reporting for the year ended December 31, 2024 because
we are a smaller reporting company. In the event our independent auditor is required to provide an opinion on such controls in the future,
there is a risk that the auditor would conclude that such controls are ineffective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our operating
results could be harmed. We have completed a formal process to evaluate our internal control over financial reporting. However, guidance
from regulatory authorities in the area of internal controls continues to evolve and substantial uncertainty exists regarding our on-going
ability to comply by applicable deadlines. Any failure to implement required new or improved controls, or difficulties encountered in
their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. Ineffective internal controls
could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading
price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>An
active trading market for our common stock has not developed and it may have a volatile public trading price, thus, purchasers of our
common stock could incur substantial losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
active public market for our common stock has not developed. Our stock can trade in small volumes, which may make the price of our stock
highly volatile. The last reported price of our stock may not represent the price at which you would be able to buy or sell the stock.
The market prices for securities of companies comparable to us have been highly volatile. Often, these stocks have experienced significant
price and volume fluctuations for reasons that are both related and unrelated to the operating performance of the individual companies.
In addition, the stock market as a whole and biotechnology and other life science stocks in particular have experienced significant recent
volatility. Like our common stock, these stocks have experienced significant price and volume fluctuations for reasons unrelated to the
operating performance of the individual companies. Factors giving rise to this volatility may include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosure
    of actual or potential clinical results with respect to the product candidate we are developing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    developments in both the United States and abroad;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning proprietary rights, including patents and litigation matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    concern about the safety or efficacy of our product candidate or technology, or related technology, or new technologies generally;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">concern
    about the safety or efficacy of our product candidate or technology, or related technology, or new technologies generally;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    announcements by our competitors or others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions and comments by securities analysts and investors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fluctuations
in our operating losses could adversely affect the price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating losses may fluctuate significantly on a quarterly basis. Some of the factors that may cause our operating losses to fluctuate
on a period-to-period basis include the status of our preclinical and clinical development programs, level of expenses incurred in connection
with our preclinical and clinical development programs, implementation or termination of collaboration, licensing, manufacturing or other
material agreements with third parties, non-recurring revenue or expenses under any such agreement, and compliance with regulatory requirements.
Period-to-period comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them
as an indication of future performance. Our fluctuating losses may fail to meet the expectations of securities analysts or investors.
Our failure to meet these expectations may cause the price of our common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about us, if they change their recommendations regarding our stock
adversely or if our operating results do not meet their expectations, our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us.
If analysts do not publish research reports or one or more of these analysts who were publishing research cease coverage of us or fail
to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading
volume to decline. Moreover, if one or more of the analysts who cover us downgrade our stock or if our operating results do not meet
their expectations, our stock price could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to facilitate our growth strategy by identifying or completing transactions with attractive acquisition candidates, which
could limit our revenues and profitability. Future acquisitions may result in significant transaction expenses and may involve significant
costs. We may experience integration and consolidation risks associated with future acquisitions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
element of our growth strategy is to selectively pursue, on an opportunistic basis, acquisitions of businesses or assets of businesses
that complement our existing business and footprint. We may also consider other potential strategic transactions, including dispositions,
which are also subject to claims by third parties and by the buyers under the terms of our disposition agreements. We have no current
agreement for any acquisition of a business or assets. The success of this element of our growth strategy depends, in part, on selecting
strategic acquisition candidates at attractive prices and effectively integrating their businesses into our own, including with respect
to financial reporting and regulatory matters. We cannot assure you that we will be able to identify attractive acquisition candidates
or complete the acquisition of any identified candidates at favorable prices and upon advantageous terms and conditions, including financing
alternatives. We expect to face competition for acquisition candidates, which may limit the number of acquisition opportunities and lead
to higher acquisition costs. We may not have the financial resources necessary to consummate any acquisitions or the ability to obtain
the necessary funds on satisfactory terms. Any acquisitions in the future may result in significant transaction expenses and risks associated
with entering new markets and dilution for our existing stockholders. We may also be subject to claims by third parties related to the
operations of these businesses prior to our acquisition and by sellers under the terms of our acquisition agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Anti-takeover provisions in our charter
documents and provisions of Delaware law may make an acquisition more difficult and could result in the entrenchment of management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are incorporated in Delaware. Anti-takeover
provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws may make a change
in control or efforts to remove management more difficult. Also, under Delaware law, our Board of Directors may adopt additional anti-takeover
measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have the authority to issue up to 5 million
shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. If the
Board of Directors exercises this power to issue preferred stock, it could be more difficult for a third party to acquire a majority
of our outstanding voting stock and vote the stock they acquire to remove management or directors. Our amended and restated certificate
of incorporation and amended and restated bylaws also provides staggered terms for the members of our Board of Directors. Under Section
141 of the Delaware General Corporation Law, our directors may be removed by stockholders only for cause and only by vote of the holders
of a majority of voting shares then outstanding. These provisions may prevent stockholders from replacing the entire board in a single
proxy contest, making it more difficult for a third party to acquire control of us without the consent of our Board of Directors. These
provisions could also delay the removal of management by the Board of Directors with or without cause. In addition, our directors may
only be removed for cause and amended and restated bylaws limit the ability of our stockholders to call special meetings of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of the foregoing provisions could
limit the price that investors might be willing to pay in the future for shares of our common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
the event of an acquisition of our common stock, we cannot assure our common stockholders that we will be able to negotiate terms that
would provide for a price equivalent to, or more favorable than, the price at which our shares of common stock may be trading at such
time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not effect a consolidation or merger with another entity without the vote or consent of the holders of at least a majority of the
shares of our preferred stock (in addition to the approval of our common stockholders), unless the preferred stock that remains outstanding
and its rights, privileges and preferences are unaffected or are converted into or exchanged for preferred stock of the surviving entity
having rights, preferences and limitations substantially similar, but no less favorable, to our convertible preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the event a third party seeks to acquire our company or acquire control of our company by way of a merger, but the terms
of such offer do not provide for our preferred stock to remain outstanding or be converted into or exchanged for preferred stock of the
surviving entity having rights, preferences and limitations substantially similar, but no less favorable, to our preferred stock, the
terms of the Certificate of Designations of our preferred stock provide for an adjustment to the conversion ratio of our preferred stock
such that, depending on the terms of any such transaction, preferred stockholders may be entitled, by their terms, to receive up to $10.00
per share in common stock, causing our common stockholders not to receive as favorable a price as the price at which such shares may
be trading at the time of any such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 6, 2025, we had 135,273 shares of our 6% Convertible Exchangeable Preferred Stock issued and outstanding. If the transaction
were one in which proceeds were received by us for distribution to stockholders, and the terms of the Certificate of Designations governing
the preferred stock were strictly complied with, approximately $1.7 million would be paid to the preferred holders before any distribution
to the common stockholders, although the form of transaction could affect how the holders of preferred stock are treated. In such an
event, although such a transaction would be subject to the approval of our holders of common stock, we cannot assure our common stockholders
that we will be able to negotiate terms that would provide for a price equivalent to, or more favorable than, the price at which our
shares of common stock may be trading at such time. Thus, the terms of our preferred stock might hamper a third party&#8217;s acquisition
of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have limited ability to pay cash dividends on our preferred stock, and there is no assurance that future quarterly dividends will
be declared.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware
law may limit our ability to pay cash dividends on our preferred stock. Under Delaware law, cash dividends on our preferred stock may
only be paid from surplus or, if there is no surplus, from the corporation&#8217;s net profits for the current or preceding fiscal year.
Delaware law defines &#8220;surplus&#8221; as the amount by which the total assets of a corporation, after subtracting its total liabilities,
exceed the corporation&#8217;s capital, as determined by its board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we are not profitable, our ability to pay cash dividends will require the availability of an adequate surplus. Even if adequate surplus
is available to pay cash dividends on our preferred stock, we may not have sufficient cash to pay dividends on the preferred stock or
we may choose not to declare the dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common and preferred stock may experience extreme price and volume fluctuations, which could lead to costly securities-related
litigation, including securities class action litigation or securities-related investigations, which could make an investment in us less
appealing.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider an investment in our common stock and preferred stock to be risky, and you should invest in our common stock and
preferred stock only if you can withstand a significant loss and wide fluctuations in the market value of your investment. Some factors
that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this &#8220;Risk Factors&#8221;
section and elsewhere in this Annual Report on Form 10-K, are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of technological innovations or new products or services by us or our competitors; announcements concerning our competitors or the
    biotechnology industry in general;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    regulatory pronouncements and changes in regulatory guidelines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    and industry-specific economic conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or departures of our key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our common stock or preferred stock by our stockholders, executives and directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financings to conduct and complete research and development activities including, but not limited to, our clinical
    trials, and other business activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure resources and the necessary personnel to conduct clinical trials on our desired schedule;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our submission for studies or product approvals or adverse regulatory decisions, including failure to receive regulatory
    approval for our product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigations related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates or recommendations by securities analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our quarterly results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    about our collaborators or licensors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles or in applicable laws, rules, regulations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which may be out of our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock markets have from time-to-time experienced significant price and volume fluctuations that have affected the market prices for publicly
traded securities. The market prices of the securities of biotechnology companies, particularly companies like us without product revenues
and earnings, have been highly volatile and are likely to remain highly volatile in the future. This volatility has often been unrelated
to the performance of particular companies. In the past, companies that experience volatility in the market price of their securities
have often faced securities class action and derivative litigation, and as a public company, we could be subject to sanctions or investigations
by Nasdaq, the SEC or other regulatory authorities. Moreover, market prices for stocks of biotechnology-related and technology companies
frequently reach levels that bear no relationship to the performance of these companies. These market prices generally are not sustainable
and are highly volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not meritorious, litigation brought against us could result in substantial costs, divert our management&#8217;s attention and resources,
and harm our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
future sale of our common and convertible preferred stock and future issuances of our common stock upon conversion of our preferred stock
could negatively affect our stock price and cause dilution to existing holders of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common or preferred stockholders sell substantial amounts of our stock in the public market, or the market perceives that such sales
may occur, the market price of our common stock and preferred stock could fall. If additional holders of convertible preferred
stock elect to convert their shares to shares of common stock at renegotiated prices, such conversion as well as the sale of substantial
amounts of our common stock, could cause dilution to existing holders of our common stock, thereby also negatively affecting the price
of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay cash dividends on our common stock in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying cash dividends on our common stock in the foreseeable future. Any payment of cash dividends will depend on our
financial condition, results of operations, capital requirements, the outcome of the review of our strategic alternatives and other factors
and will be at the discretion of our Board of Directors. Accordingly, investors will have to rely on capital appreciation, if any, to
earn a return on their investment in our common stock. Furthermore, we may in the future become subject to contractual restrictions on,
or prohibitions against, the payment of dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
number of shares of common stock which are registered is
significant in relation to our currently outstanding common stock and could cause downward pressure on the market price for our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock registered for resale is significant in relation to the number of shares of common stock currently
outstanding. If the security holder determines to sell a substantial number of shares into the market at any given time, there may
not be sufficient demand in the market to purchase the shares without a decline in the market price for our common stock. Moreover,
continuous sales into the market of a number of shares in excess of the typical trading volume for our common stock, or even the
availability of such a large number of shares, could depress the trading market for our common stock over an extended period of
time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
persons engage in short sales of our common stock the price of our common stock may decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
short is a technique used by a stockholder to take advantage of an anticipated decline in the price of a security. A significant number of short sales or a large volume of other sales within a relatively short period of time can
create downward pressure on the market price of a security. You could, therefore, experience
a decline in the value of your investment as a result of short sales of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are exposed to risks related to the marketable securities we may purchase.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may invest cash that is not required to meet short-term obligations in short term marketable securities. We may purchase securities in
United States government, government-sponsored agencies and highly rated corporate and asset-backed securities subject to an approved
investment policy. Historically, investment in these securities has been highly liquid and has experienced only very limited defaults.
However, recent volatility in the financial markets has created additional uncertainty regarding the liquidity and safety of these investments.
Although we believe our marketable securities investments are safe and highly liquid, we cannot guarantee that our investment portfolio
will not be negatively impacted by recent or future market volatility or credit restrictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Claims
for indemnification by our directors and officers may reduce our available funds to satisfy successful stockholder claims against us
and may reduce the amount of money available to us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
permitted by Section 102(b)(7) of the Delaware General Corporation Law, our restated certificate of incorporation limits the liability
of our directors to the fullest extent permitted by law. In addition, as permitted by Section 145 of the Delaware General Corporation
Law, our restated certificate of incorporation and restated bylaws provide that we shall indemnify, to the fullest extent authorized
by the Delaware General Corporation Law, each person who is involved in any litigation or other proceeding because such person is or
was a director or officer of our company or is or was serving as an officer or director of another entity at our request, against all
expense, loss or liability reasonably incurred or suffered in connection therewith. Our restated certificate of incorporation provides
that the right to indemnification includes the right to be paid expenses incurred in defending any proceeding in advance of its final
disposition, provided, however, that such advance payment will only be made upon delivery to us of an undertaking, by or on behalf of
the director or officer, to repay all amounts so advanced if it is ultimately determined that such director is not entitled to indemnification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not pay a proper claim for indemnification in full within 60 days after we receive a written claim for such indemnification, except
in the case of a claim for an advancement of expenses, in which case such period is 20 days, our restated certificate of incorporation
and our restated bylaws authorize the claimant to bring an action against us and prescribe what constitutes a defense to such action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the Delaware General Corporation Law permits a corporation to indemnify any director or officer of the corporation against expenses
(including attorney&#8217;s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with
any action, suit or proceeding brought by reason of the fact that such person is or was a director or officer of the corporation, if
such person acted in good faith and in a manner that he reasonably believed to be in, or not opposed to, the best interests of the corporation,
and, with respect to any criminal action or proceeding, if he or she had no reason to believe his or her conduct was unlawful. In a derivative
action, (i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses actually and reasonably
incurred by any director or officer in connection with the defense or settlement of such an action or suit if such person acted in good
faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, except that
no indemnification shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only to the
extent that the court in which the action or suit was brought shall determine that the defendant is fairly and reasonably entitled to
indemnity for such expenses despite such adjudication of liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights conferred in the restated certificate of incorporation and the restated bylaws are not exclusive, and we are authorized to enter
into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.
We have entered into indemnification agreements with each of our officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above limitations on liability and our indemnification obligations limit the personal liability of our directors and officers for monetary
damages for breach of their fiduciary duty as directors by shifting the burden of such losses and expenses to us. Although we obtained
coverage under our directors&#8217; and officers&#8217; liability insurance, certain liabilities or expenses covered by our indemnification
obligations may not be covered by such insurance or the coverage limitation amounts may be exceeded. As a result, we may need to use
a significant amount of our funds to satisfy our indemnification obligations, which could severely harm our business and financial condition
and limit the funds available to stockholders who may choose to bring a claim against our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_028"></span>RISKS
RELATED TO FITTERS SDN. BHD. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
in the following passage to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Fitters,&#8221; &#8220;Fitters Sdn. Bhd.&#8221;
and the &#8220;Company&#8221;, under this heading &#8220;Risks Related to Fitters Sdn. Bhd. Business,&#8221; refer to Fitters Sdn. Bhd.
only. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
performance is tied to customer demand for fire suppression equipment and materials, the decrease of which could adversely affect our
Fitters Sdn. Bhd.&#8217;s performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Sdn. Bhd. currently recognizes revenue from, among other things, its trading and installation of fire safety materials and equipment.
It is the holding company for Fitters (Sarawak) Sdn Bhd (&#8220;FSSB&#8221;), AHT NRG Asia Sdn Bhd (&#8220;AHT&#8221;) and Modular Floor
System (M) Sdn Bhd (&#8220;MSF&#8221;). FSSB is also involved in the trading of fire safety materials and equipment whereas both AHT
and MSF have ceased operations. The demand for Fitters&#8217; fire protection equipment is driven by rapid industrialization, urbanization,
and increasing safety awareness. In the March 31, 2025 financial year, our top four customers collectively accounted for 55% of the company&#8217;s
total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively. Accordingly, Fitters relies on a limited
number of customers from whom it generates most of its revenue. Dependence on a few customers could make it difficult to negotiate attractive
prices for our products and could expose us to the risk of substantial losses if a single dominant customer stops purchasing our products.
We have not entered into long-term supply contracts with either of these major customers. Therefore, there can be no assurance that we
will maintain or improve our relationships with our major customers, or that we will be able to continue to supply these customers at
current levels or at all. If we cannot maintain long-term relationships with these major customers, the loss of sales could have an adverse
effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of our customers fail to pay us, our profit and cash flow may be affected as a result.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our customers are slow in their payment process, their delayed payments may adversely affect our cash flow and our ability to
fund our operations out of our operating cash flow. In addition, although we attempt to establish appropriate reserves for our receivables,
those reserves may not prove to be adequate in view of actual levels of bad debts. The failure of our customers to pay us in a timely
manner could negatively affect our working capital, which could in turn adversely affect our cash flow. Although no customer has failed
to pay us even though their payments were delayed, there is no assurance that they will be able to pay in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Historical
financial results do not include significant amounts of compensation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical financial results do not include significant amounts of compensation at the Fitters level. Although the lack of salaries and
bonuses was appropriate for a company wholly-owned by public company, in the future, we will compensate our employees and executives
at market levels of compensation as determined by the board of directors and as a result our expenses will be increased in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may require financing in the future and our operations could be curtailed if we are unable to obtain required additional financing when
needed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to obtain additional debt or equity financing to fund future capital expenditures. While we do not anticipate seeking additional
financing in the immediate future, any additional equity may result in dilution to the holders of our outstanding shares of capital stock.
Additional debt financing may include conditions that would restrict our freedom to operate our business, such as conditions that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    our ability to pay dividends or require us to seek consent for the payment of dividends;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    our vulnerability to general adverse economic and industry conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    us to dedicate a portion of our cash flow from operations to payments on our debt, thereby reducing the availability of our cash
    flow to fund capital expenditures, working capital and other general corporate purposes; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    our flexibility in planning for, or reacting to, changes in our business and our industry.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that we will be able to obtain any additional financing on terms that are acceptable to us, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
cannot guarantee that we will be able to obtain any additional financing on terms that are acceptable to us, or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
disruptions in the capital and credit markets may adversely affect our business, including the availability and cost of short-term funds
for liquidity requirements, which could adversely affect our results of operations, cash flows and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the last two years, the global economy has experienced a contraction, which has affected the availability of business and consumer credit.
We may need to rely on the credit markets, particularly for short-term borrowings from banks in Malaysia or the United States, as well
as the capital markets, to meet our financial commitments and short-term liquidity needs if internal funds are not available from our
operations. Disruptions in the credit and capital markets, as have been experienced since mid-2008, could adversely affect our ability
to draw on such short-term bank facilities. Our access to funds under such credit facilities is dependent on the ability of the banks
that are parties to those facilities to meet their funding commitments, which may be dependent on governmental economic policies. Those
banks may not be able to meet their funding commitments to us if they experience shortages of capital and liquidity or if they experience
excessive volumes of borrowing requests from us and other borrowers within a short period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
disruptions in the credit and capital markets, similar to those that have been experienced since mid-2008, could result from uncertainty,
changing or increased regulation, reduced alternatives or failures of financial institutions and could adversely affect our access to
liquidity needed for our business. Any disruption could require us to take measures to conserve cash until the markets stabilize or until
alternative credit arrangements or other funding for our business needs can be arranged. Such measures could include deferring capital
expenditures, and reducing or eliminating discretionary uses of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continued
market disruptions could cause broader economic downturns, which may lead to lower demand for our products and increased likelihood that
our customers will be unable to pay for our products. Further, insolvencies or similar events by customers may cause us to incur bad
debt expense at levels higher than historically experienced. These events would adversely impact our results of operations, cash flows
and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
senior management lacks significant experience complying with laws applicable to operating as a wholly-owned subsidiary of a U.S. public
company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, Chin Yong Shing and Pang Wei Kang were the directors of Fitters, neither of them has experience applicable
to operating as a wholly-owned subsidiary of a U.S. public company. Mr. Chin began his career as a Project Engineer at FITTERS Engineering
Services Sdn. Bhd., a wholly owned subsidiary of FITTERS Diversified Berhad, on October 15 1992 and was promoted to Project Manager in
1998 and to General Manager in 2010. Mr. Chin is currently the Executive Director of Fitters, a position he has held since 2014. Mr.
Pang was appointed to the Board in January 2024 and brings experience in the food and beverage industry. Neither Mr. Chin nor Mr. Pang
have experience with the rules or regulations associated with being wholly-owned by U.S. public companies. In the process of taking these
steps to prepare Fitters for the Transaction, the company contemplates the appointment of Datuk Dr. Doris Wong as a director of Fitters.
Datuk Dr. Doris Wong has served as Chief Executive Officer and Executive Director of Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC)
since February 2025, which is a U.S. public company. Datuk Dr. Doris Wong also served as an independent director and member of the audit
committee and the compensation committee of Energem Corp from its initial public offering on November 16, 2021 until her appointment
as Executive Director on January 27, 2023, a former Nasdaq-listed special purpose acquisition company. Following Energem Corp&#8217;s
completion of a series of transactions that resulted in its business combination with Graphjet Technology Sdn. Bhd. (Nasdaq: GTI), a
Malaysian company that was subsequently acquired by a U.S. public company, on March 14, 2024 where she served as a director until her
resignation on January 6, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Transaction, Fitters will become subject to laws, regulations and obligations of the United States as a wholly-owned
subsidiary of Cyclacel that do not currently apply to it, and our senior management currently has no experience in complying with such
laws, regulations and obligations. These obligations can be burdensome and complicated, and failure to comply with such obligations could
have a material adverse effect on Fitters&#8217; profitability. In addition, we expect that the process of learning about such new obligations
as a wholly-owned subsidiary of a public company in the United States will require senior management to devote time and resources to
such efforts that might otherwise be spent on the operation of the business of fire enterprises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are substantially dependent upon our senior management and key research and development personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on our senior management to manage our business and operations. We also depend on our key personnel for the sales
and marketing of our products. We do not maintain key man life insurance on any of our senior management or key personnel. The loss of
any one of them would have a material adverse effect on our business and operations. Competition for senior management and our other
key personnel is intense and the pool of suitable candidates is limited. We may be unable to locate a suitable replacement for any senior
management or key personnel that we lose. In addition, if any member of our senior management or key personnel joins a competitor or
forms a competing company, they may compete with us for customers, business partners and other key professionals and staff members of
our company. Although each of our senior management and key personnel has signed a confidentiality and non-competition agreement in connection
with his employment with us, we cannot assure you that we will be able to successfully enforce these provisions in the event of a dispute
between us and any member of our senior management or key personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete for qualified personnel with other fire products businesses. Intense competition for these personnel could cause our compensation
costs to increase, which could have a material adverse effect on our results of operations. Our future success and ability to grow our
business will depend in part on the continued service of these individuals and our ability to identify, hire and retain additional qualified
personnel. If we are unable to attract and retain qualified employees, we may be unable to meet our business and financial goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not pay dividends.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that our operations will result in sufficient revenues to enable us to operate at profitable levels or to generate
positive cash flows. Furthermore, there is no assurance our Board of Directors will declare dividends even if we remain profitable. Dividend
policy is subject to the discretion of our Board of Directors and will depend on, among other things, our earnings, financial condition,
capital requirements and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not carry business interruption insurance so we could incur unrecoverable losses if our business is interrupted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to risks inherent to our business, including equipment failure, theft, natural disasters, labor disturbances, business interruptions,
property damage, and product liability. We do not carry any business interruption insurance or third-party liability insurance or other
insurance to cover risks associated with our business. As a result, if we suffer losses, damages or liabilities, including those caused
by natural disasters or other events beyond our control and we are unable to make a claim again a third party, we will be required to
bear all such losses from our own funds, which could have a material adverse effect on our business, financial condition and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
profitability is sensitive to general economic conditions and global supply chain conditions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be adversely affected by conditions in Malaysia, the U.S. and global economies. The Malaysian, U.S. and global financial
markets are susceptible to adverse geopolitical and macroeconomic developments, including rising inflation rates, the continuing adverse
impact of the COVID-19 outbreak, the imposition of tariffs, the Ukrainian/Russian and Israeli/Palestinian conflicts and related sanctions,
bank failures, and economic uncertainties related to these conditions. While the COVID-19 outbreak has abated, many of the consequences
of the COVID-19 outbreak continue to cause disruption and increased costs for businesses. We believe there continue to be, among other
things, supply chain disruptions that are causing delays in the delivery of equipment and inventory and staffing shortages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
inflation rates, particularly in the United States, have increased to levels not seen in years, and increased inflation may result in
increases in our operating costs (including our labor costs), reduced liquidity and limits on our ability to access credit or otherwise
raise capital on acceptable terms, if at all. In response to rising inflation, the U.S. Federal Reserve has raised, and may again raise,
interest rates, which, coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing
economic uncertainty and heightening these risks. Further, financial markets around the world experienced volatility following the invasion
of Ukraine by Russia in February 2022 and the eruption of the Israeli/Palestinian conflict in October 2023, including as a result of
economic sanctions and export controls against Russia and countermeasures taken by Russia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
full economic and social impact of these sanctions and countermeasures, in addition to the ongoing military conflicts in Ukraine and
Gaza, which could conceivably expand, remains uncertain; however, both the conflicts and related sanctions have resulted and could continue
to result in disruptions to trade, commerce, pricing stability, credit availability, and/or supply chain continuity, in both Europe and
globally, and has introduced significant uncertainty into global markets. While we do not currently operate in Russia, Ukraine or the
Middle East, as the adverse effects of these conflicts continue to develop, our business and results of operations may be adversely affected.
Any of the foregoing could harm our business. Any resulting financial impact cannot be reasonably estimated at this time but may materially
affect our business and financial condition. The extent to which the foregoing impacts our results will depend on future developments,
which are highly uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business may be negatively affected by labor issues and higher labor costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to maintain our workforce depends on our ability to attract and retain new and existing employees. As of the date of this proxy
statement/prospectus, none of our employees are covered by collective bargaining agreements and we consider our labor relations to be
acceptable. However, we could experience workforce dissatisfaction which could trigger bargaining issues, employment discrimination liability
issues as well as wage and benefit consequences, especially during critical operation periods. We could also experience a work stoppage
or other disputes which could disrupt our operations and could harm our operating results. In addition, legislation or changes in regulations
could result in labor shortages and higher labor costs. There can be no assurance that we may not experience labor issues that negatively
impact our operations or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Global
economic conditions could negatively affect our prospects for growth and operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
prospects for growth and operating results will be directly affected by the general global economic conditions of the industries in which
our suppliers, partners and customer groups operate. Our business will be highly dependent on the economic and market conditions in each
of the geographic areas in which we operate. These conditions affect our business by reducing the demand for fire prevention products
in times of economic downturn and increasing the price of our products in times of increasing demand. There can be no assurance that
global economic conditions will not negatively impact our liquidity, growth prospects and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
changes in political, economic and regulatory conditions in Malaysia and the United States could materially affect our financials and
prospects. Political, economic and regulatory uncertainties include, amongst others, risks of war, changes in political state, changes
in economic conditions, changes in governmental policies such as changes to labour laws, introduction of new rules or regulations, interest
rates, tariff rates, fiscal and monetary policies and method of taxation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations rely on information technology and communications networks, and operations that are vulnerable to damage or disturbance
from a variety of sources. Regardless of protection measures, essentially all systems are susceptible to disruption due to failure, vandalism,
computer viruses, security breaches, natural disasters, power outages and other events. In addition, cybersecurity threats are evolving
and include, among others, malicious software, attempts to gain unauthorized access to data, and other electronic security breaches that
could lead to disruptions in our systems, unauthorized release of confidential or otherwise protected information and corruption of data.
We also have a concentration of operations in certain sites, e.g., production, and shared services centers, where business interruptions
could cause material damage and costs. Transport of goods from suppliers, and to customers, could also be hampered for the reasons stated
above. Although we have assessed these risks, implemented controls, and performed business continuity planning, we cannot be sure that
interruptions with material adverse effects will not occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to execute our financial strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a capital-intensive industry and the amount we spend on capital expenditures may exceed current expectations, which could
require us to obtain additional funding for our operations or impair our ability to grow our business. Our financial strategy is dependent
on our ability to generate sufficient cash flow to reinvest in our existing business, fund internal growth, acquire other businesses,
pay dividends, reduce indebtedness and minimize borrowings, and take other actions to enhance shareholder value. We cannot assure you
that we will be successful in executing our pricing programs, that we will generate sufficient cash flow to execute our financial strategy,
that we will be able to pay cash dividends at our present rate, that we will be able to increase the amount of such dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to remain competitive and to grow and expand our operations largely depends on our cash flow from operations and access to capital.
If our operations are unable to offset the impact of inflation and business growth, it may be necessary to increase the amount we spend.
Additionally, if we make acquisitions or further expand our operations, the amount we expend on capital expenditures will increase. Our
cash needs also will increase if the expenditures increase above our current estimates, which may occur over a long period due to changes
in federal, state or local government requirements and other factors beyond our control. Increases in expenditures would negatively impact
our cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to market risks due to fluctuations in interest rates on our debt. Increases in interest rates will increase the cost of
new borrowings and our interest expense. Accordingly, fluctuations in interest rates can lead to significant fluctuations in the fair
value of our debt instruments. We do not use any derivative instruments to manage our interest rate risk exposure. We have not been subject
to nor do we anticipate being exposed to material risks due to changes in interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Exchange Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the Malaysian Ringgit against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes
in Malaysian and global political and economic conditions. Historically, Bank Negara Malaysia (&#8220;BNM&#8221;) is mandated by law
to promote monetary stability conducive to the sustainable growth of the Malaysian economy. As an open economy, the Ringgit is affected
by both domestic and global developments. Domestically, stronger economic prospects will attract more demand for the Ringgit while global
developments including interest rate differential and terms of trade will affect demand as well; the Ringgit exchange rate is based on
how much foreign investors, businesses and individuals demand the Ringgit in the foreign exchange market, for a given supply. We do not
believe that Malaysia currently have any significant direct foreign exchange risk and have not hedged our exposure to foreign currency
exchange risk. All of our revenues and expenses are denominated in Ringgit. Fluctuations in the exchange rate will also affect the relative
value of any dividend we pay to investors outside Malaysia and earnings from, and the value of, any foreign currency-denominated investments
we may make in the future. In addition, as the net proceeds from this offering will be denominated in U.S. dollars, fluctuations in the
exchange rate between the U.S. dollar and the Ringgit will affect the relative purchasing power of these proceeds if they are not converted
into Ringgit in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Inflation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2025, Malaysia&#8217;s Consumer Price Index (&#8220;CPI&#8221;) is projected to increase within a moderate range of 2.0% to 3.5%, according
to Bank Negara Malaysia. This is driven by factors like moderating global costs and a moderate level of demand. The headline CPI is expected
to be around 2.3%, and the core CPI around 2.8%. Specifically, April 2025 saw the annual inflation rate hit 2.3%, according to CNBC.<sup>1</sup>
Although we have not been materially affected by inflation since our inception, we may be affected in the future by higher rates of inflation.
For example, certain operating costs and expenses, such as personnel expenses, real estate leasing expenses, travel expenses and office
operating expenses may increase as a result of higher inflation. Additionally, because a substantial portion of our assets consists of
cash and cash equivalents and short-term investments, high inflation could significantly reduce the value and purchasing power of these
assets. We are not able to hedge our exposures to higher inflation in Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
litigation or governmental proceedings could result in material adverse consequences, including judgments or settlements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in lawsuits, regulatory inquiries, and governmental and other legal proceedings arising out of the
ordinary course of our business. Many of these matters raise difficult and complicated factual and legal issues and are subject to uncertainties
and complexities. The timing of the final resolutions to lawsuits, regulatory inquiries, and governmental and other legal proceedings
is uncertain. Additionally, the possible outcomes or resolutions to these matters could include adverse judgments or settlements, either
of which could require substantial payments, adversely affecting our consolidated financial condition, results of operations and cash
flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>
See CNBC, &#8220;<i>Annual inflation rate hit 2.3% in April, less than expected and lowest since 2021</i>,&#8221; May 13, 2025, <span style="text-decoration: underline">CPI
inflation April 2025: Rate hits 2.3%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to additional foreign government regulation in the future that may adversely affect our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our business expands outside of the current jurisdictions of Malaysia, Singapore and British Virgin Island, our operations would be subject
to the laws of the countries where we do business, including permitting and compliance requirements that address the similar risks as
do the laws in the United States, as well as international legal requirements such as those applicable to our industry. Depending on
the country or region, these laws could be more or less stringent. Compliance with these requirements will cause our business to incur
costs, and failure to comply with these requirements could adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to manage our growth effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
growth strategy places significant demands on our financial, operational and management resources. To continue our growth, we may need
to add administrative and other personnel, and will need to make additional investments in operations and systems. We cannot assure you
that we will be able to find and train qualified personnel, or do so on a timely basis, or expand our operations and systems to the extent,
and in the time, required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to execute our acquisition growth strategy. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to execute our growth strategy depends in part on our ability to identify and acquire desirable acquisition candidates as well
as our ability to successfully consolidate acquired operations into our business. The consolidation of our operations with those of acquired
companies may present significant challenges to our management. In addition, competition among our competitors for acquisition candidates
may prevent us from acquiring certain acquisition candidates. As such, we cannot assure you that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
  </span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">desirable
  acquisition candidates exist or will be identified;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
  </span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
  will be able to acquire any of the candidates identified;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
  </span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
  will effectively consolidate companies we acquire; or</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
  </span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
  acquisitions will be profitable or accretive to our earnings.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the aforementioned factors force us to alter our growth strategy, our growth prospects could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Businesses
we acquire may have undisclosed liabilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
pursuing any future acquisition strategy, our due diligence investigations of the acquisition candidates may fail to discover certain
undisclosed liabilities of the acquisition candidates. If we acquire a company having undisclosed liabilities such as environmental,
remediation or contractual, as a successor owner we may be responsible for such undisclosed liabilities. We expect to try to minimize
our exposure to such liabilities by conducting due diligence, by obtaining indemnification from each of the sellers of the acquired companies,
by deferring payment of a portion of the purchase price as security for the indemnification and by acquiring only specified assets. However,
we cannot assure you that we will be able to obtain indemnification or that any indemnification obtained will be enforceable, collectible
or sufficient in amount, scope or duration to fully offset any undisclosed liabilities arising from our acquisitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to compete successfully in our markets could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
provides products and services into competitive markets. We believe the principal points of competition in our markets are product performance,
reliability and innovation, application expertise, brand reputation, product life cycle cost, timeliness of delivery, proximity of service
centers, effectiveness of our distribution channels and price. Maintaining and improving our competitive position will require continued
investment by us in manufacturing, research and development, engineering, marketing, customer service and support, and our distribution
networks. We may not be successful in maintaining our competitive position. Our competitors may develop products that are superior to
our products, or may develop more efficient or effective methods of providing products and services or may adapt more quickly than we
do to new technologies or evolving customer requirements. Pricing pressures also could cause us to adjust the prices of certain products
to stay competitive. We may not be able to compete successfully with our existing or new competitors. Failure to continue competing successfully
could adversely affect our business, financial condition, results of operations and cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in our effective tax rates may adversely affect our financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
sell our products in three countries presently and plan to continue to grow globally in the future. Domestic income tax is calculated
at the Malaysian statutory income tax rate of 24% of the estimated assessable profit for the financial year. Taxation for other jurisdictions
is calculated at the rates prevailing in the respective jurisdictions. Given the intended global nature of our business, a number of
factors may increase our future effective tax rates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  jurisdictions in which profits are determined to be earned and taxed;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sustainability
  of historical income tax rates in the jurisdictions in which we conduct business;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  resolution of issues arising from tax audits with various tax authorities; and</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the valuation of our deferred tax assets and liabilities, and changes in deferred tax
                                            valuation allowances.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
significant increase in our future effective tax rates could reduce net income for future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with the U.S. Foreign Corrupt Practices Act or other applicable anti-corruption legislation could result in fines, criminal
penalties and an adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a number of countries throughout the world, including countries known to have a reputation for corruption. We are committed
to doing business in accordance with applicable anti-corruption laws. We are subject, however, to the risk that we, our affiliated entities
or our or their respective officers, directors, employees and agents may take action determined to be in violation of such anti-corruption
laws, including the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act of 2010 and others. Any such violation could result
in substantial fines, sanctions, civil and/or criminal penalties, and curtailment of operations in certain jurisdictions, and might adversely
affect our business, results of operations or financial condition. In addition, actual or alleged violations could damage our reputation
and ability to do business. Furthermore, detecting, investigating, and resolving actual or alleged violations is expensive and can consume
significant time and attention of our senior management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fitters&#8217;
results of operations and financial condition may be adversely affected by global economic and financial market conditions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete in various geographic and product markets including Malaysia, Singapore and British Virgin Island. We expect revenue from these
markets to be significant for the foreseeable future. Important factors impacting our businesses include the overall strength of these
economies and our customers&#8217; confidence in both local and global macro-economic conditions; industrial and federal, state, local
and municipal governmental spending; the strength of the residential and commercial real estate markets; interest rates; availability
of commercial financing for our customers and end-users; and unemployment rates. A slowdown or downturn in these financial or macro-economic
conditions could have a significant adverse effect on our business, financial condition, results of operations and cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced and expect to continue to experience fluctuations in revenues and operating results due to economic and business cycles,
particularly within the portion of our business that provides products and services used in residential and commercial buildings. We
believe our level of business activity is influenced by residential and commercial building starts and renovations, which are heavily
influenced by interest rates, consumer debt levels, changes in disposable income, employment growth and consumer confidence. Credit market
conditions greatly affect the ability of residential and commercial builders to obtain the necessary capital to complete and begin new
projects. We closely monitor the credit worthiness of our customers, and evaluate their financial ability to pay for those products and
services we provide to them. As it relates to our customers&#8217; ability to pay for products and services, we have not experienced
any significant negative impact as a result of the recent economic downturn. If market conditions worsen, it may result in a delay or
cancellation of orders from our customers or potential customers and adversely affect our revenues and our ability to manage inventory
levels, collect customer receivables and maintain current levels of profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Economic
and other risks associated with international sales and operations could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Transaction, we expect our international operations and export sales to constitute a significant portion of our revenue. Both our
sales from international operations and export sales are subject in varying degrees to risks inherent to doing business outside of Malaysia
and the United States. These risks include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">possibility
  of unfavorable circumstances arising from host country laws or regulations;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">currency
  exchange rate fluctuations and restrictions on currency repatriation;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
  negative consequences from changes to taxation policies;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
  of operations from labor and political disturbances;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
  in tariff and trade barriers and import and export licensing requirements; and</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurrection
  or war.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
payment of distributions, loans or advances to us by our foreign subsidiaries could be subject to restrictions on, or taxation of, dividends
on repatriation of earnings under applicable local law, monetary transfer restrictions and foreign currency exchange regulations in the
jurisdictions in which our subsidiaries operate. In addition to the general risks that we face outside Malaysia and the United States,
we now conduct more of our operations in emerging markets than we have in the past, which could involve additional uncertainties for
us, including risks that governments may impose limitations on our ability to repatriate funds; governments may impose withholding or
other taxes on remittances and other payments to us, or the amount of any such taxes may increase; an outbreak or escalation of any insurrection
or armed conflict may occur; governments may seek to nationalize our assets; or governments may impose or increase investment barriers
or other restrictions affecting our business. In addition, emerging markets pose other uncertainties, including the protection of our
intellectual property, pressure on the pricing of our products, and risks of political instability. We cannot predict the impact such
future, largely unforeseeable events might have on our business, financial condition, results of operations and cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fitters&#8217;
business could be adversely affected by significant movements in foreign currency exchange rates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to fluctuations in foreign currency exchange rates, which causes foreign currency risk related to the fluctuation in fair
value or future cash flows of a financial instrument as a result of changes in foreign exchange rates. Fitters has transactional currency
exposures arising from sales or purchases that are denominated in a currency other than the respective functional currencies of Group
entities. Approximately 0.01% in 2024 of Fitters&#8217; sales are denominated in foreign currencies whilst almost 83% (2024: 80%) of
costs are denominated in the respective functional currencies of Fitters entities. Fitters&#8217; trade receivable and trade payable
balances at the reporting date have similar exposures. Fitters did not hold any cash and/or cash equivalents denominated in foreign currencies
for working capital purpose. Any significant change in the value of currencies of the countries in which we do business relative to the
value of the Malaysian Ringgit (MYR), could affect our ability to sell products competitively and control our cost structure, which could
have a material adverse effect on our business, financial condition, results of operations and cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
industry is very competitive and some of our products are commodities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
faces competition from both new entrants and existing competitors in the fire services industries. The businesses are competitive due
to the presence of other local and international producers and suppliers of fire protection systems. The competitors may affect the Company&#8217;s
revenue and market share, which may in turn affect the financial performance of the Company. In this respect, the competitors from the
fire protection systems are constantly developing more advanced technology and product formulations in order to gain a larger market
share and a competitive edge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the barriers to entry for new distributors of fire protection equipment are low as they can source products or systems that
already have the relevant product certifications obtained by the respective manufacturer or supplier. As such, the competition that the
Company faces face may result in, among others, reduction in the prices of the Company&#8217;s products thus affecting the Company&#8217;s
profit margins, increase in the Company&#8217;s marketing activities and thus expenses, and/ or loss of business due to competitors&#8217;
offerings, which may adversely affect the Company&#8217;s business operations and financial performance. There can be no assurance that
the Company will continue to compete effectively in the industries and failure to do so may adversely affect its growth prospects and
financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no assurance that Fitters&#8217; existing projects will not be delayed or terminated and there can also be no certainty that Fitters&#8217;
order book will be continually maintained at such level in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters&#8217;
revenue for the fire services division is largely dependent on the sustainability of the Company&#8217;s order book, which is in turn
affected by the business and economic condition in Malaysia, as well as the Company&#8217;s ability to tender for the new projects by
competing against other competitors in terms of pricing, timely delivery and quality. There is no assurance that the Company&#8217;s
existing projects will not be delayed or terminated and there can also be no certainty that the Company&#8217;s order book will be continually
maintained at such level in the future. The sustainability of our order book refers to the long-term viability and success of our business,
which relies on fulfilling orders. A sustainable order book is characterized by consistent demand, effective operations, and adaptability
to changing market conditions and relates to ensuring the business can continue to receive and process orders in a way that is
profitable and environmentally responsible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>An
increase in labor costs could reduce the Company&#8217;s profit margin, which could impact our financial position, results of operations,
or cash flows.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters&#8217;
profitability may be affected by an increase in labour costs which will reduce the Company&#8217;s profit margin if the Company is unable
to fully pass on increases in the labour costs to its customers. The fire protection systems industry is labor intensive. The fire services
business requires extensive manpower to operate. Fitters faces difficulty in recruiting local workers and has to resort to the employment
of foreign workers. The shortage of foreign workers has been exacerbated in recent years by the increased demand for foreign workers.
As such, the Company is required to comply with the policies imposed by the Government and any future changes to such policies may adversely
affect the ability of the Company to employ foreign workers. Although the Company has sought to limit some of these risks, no assurance
can be given that any change to these factors will not have a material adverse effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have recorded a significant amount of goodwill and other identifiable intangible assets, and we may never realize the full value of our
intangible assets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company expects to recognise goodwill arising from the proposed Transaction, the amount of which will depend on the Transaction
Consideration <i>vis-&#224;-vis</i> the fair value of Fitters&#8217; identifiable assets and liabilities acquired as at the closing
of the proposed Transaction. Any subsequent fair value adjustments allocated to the identifiable assets acquired and liabilities assumed,
and the effects of amortisation of the fair value adjustments, if any, may materially affect the combined company&#8217;s financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the goodwill, will be subjected to periodic impairment testing and any downward adjustment to the goodwill may materially and adversely
affect the financial position and results of the combined company. Nevertheless, the combined company will continuously monitor the financial
performance of Fitters to ensure that the goodwill is supported by the operations of the relevant cash generating units at all times.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to product liability or warranty claims that could require us to make significant payments.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
would be exposed to product liability claims in the event that the use of our products results, or is alleged to result, in bodily injury
and/or property damage. There is a risk that we will experience product liability or warranty losses in the future or that we will incur
significant costs to defend such claims. Such losses and costs may be material. While we currently have product liability insurance,
our product liability insurance coverage may not be adequate for any liabilities that may ultimately be incurred or the coverage may
not continue to be available on terms acceptable to us. A successful claim brought against us in excess of our available insurance coverage
could require us to make significant payments or a requirement to participate in a product recall which may harm our reputation or profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compliance
with the United States securities laws and regulations is likely to make it more difficult and expensive for us to obtain directors&#8217;
and officers&#8217; liability insurance and to attract and retain qualified members of our board of directors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the Sarbanes-Oxley Act and the rules and regulations subsequently implemented by the SEC and the Public Company Accounting Oversight
Board to continue to impose significant compliance burdens and costs on the operations of the business. Those rules and regulations may
make it more difficult and expensive for us to maintain director and officer liability insurance, and we may be required to accept reduced
coverage or incur substantially higher costs to maintain coverage. These rules and regulations could also make it more difficult for
us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee, and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Combined Company following the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
determining whether you should approve the Transaction, the issuance of shares of Parent Common Stock and other matters related
to the Transaction you should carefully read the following risk factors in addition to the risks described above.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of its common stock may drop
following the Transaction.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of the common stock of Cyclacel following the Transaction could be subject to significant fluctuations. Market prices for
securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile.
Some of the factors that may cause the market price of the company&#8217;s common stock to fluctuate include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports
                                            on the progress of the combined company&#8217;s sales of the products and services and their
                                            growth or the lack thereof;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to maintain its existing customers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            by the company to prosecute, maintain, or enforce its intellectual property rights;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in laws or regulations applicable to its products and services;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            inability to obtain adequate supply of its products and services or the inability to do so
                                            at acceptable prices;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
                                            regulatory authority decisions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
                                            of new products, services, or technologies by its competitors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to meet or exceed financial and development projections that the company may provide to the
                                            public;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to meet or exceed the financial and development projections of the investment community;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            perception of the company&#8217;s products and services among the fire safety industry and
                                            green energy industry by the public, legislatures, regulators and the investment community;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            of significant acquisitions, strategic collaborations, joint ventures, or capital commitments
                                            by the company or its competitors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                            or other developments relating to proprietary rights, including intellectual property, litigation
                                            matters, and its ability to obtain protection for its technologies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
                                            or departures of key personnel;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            lawsuits, including patent or stockholder litigation;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            securities or industry analysts do not publish research or reports about its business, or
                                            if they issue adverse or misleading opinions regarding its business and stock;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the market valuations of similar companies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            market or macroeconomic conditions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                            of common stock by Cyclacel or its stockholders in the future;</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
                                            volume of Cyclacel common stock;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            introduction of technological innovations or new therapies that compete with potential products
                                            of the company;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the structure of health care payment systems; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">period-to-period
                                            fluctuations in the company&#8217;s financial results.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual
companies. These broad market fluctuations may also adversely affect the trading price of the company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class
action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion
of management attention and resources, which could significantly harm the company&#8217;s profitability and reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
a decrease in the stock price of the company may cause the company&#8217;s common stock to no longer satisfy the continued listing standards
of The Nasdaq Capital Market. If the company is not able to maintain the requirements for listing on The Nasdaq Capital Market, it could
be delisted, which could have a materially adverse effect on its ability to raise additional funds as well as the price and liquidity
of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
combined company will incur costs and demands upon management as a result of complying with the laws and regulations affecting public
companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company will incur significant legal, accounting and other expenses including costs associated with being a Nasdaq-listed public
company and the corresponding reporting and compliance requirements by Nasdaq, the Securities and Exchange Commission and other federal
regulators in the United States. In addition, the company will also incur costs associated with corporate governance requirements, including
requirements under the Sarbanes-Oxley Act, as well as new rules implemented by the SEC and Nasdaq. These rules and regulations may also
make it difficult and expensive for the combined company to obtain directors&#8217; and officers&#8217; liability insurance. As a result,
it may be more difficult for the combined company to attract and retain qualified individuals to serve on its board of directors or as
executive officers of the combined company, which may adversely affect investor confidence in the combined company and could cause the
company&#8217;s business or stock price to suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
company may experience adverse consequences because of required indemnification of officers and directors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of the company&#8217;s amended and restated certificate of incorporation and bylaws provide that it will indemnify any director and officer
as to liabilities incurred in their capacity as a director or officer and on those terms and conditions set forth therein to the fullest
extent of Delaware law. Further, the company may purchase and maintain insurance on behalf of any such persons whether or not the company
would have the power to indemnify such person against the liability insured against. The foregoing could result in substantial expenditures
by the company and prevent any recovery from its officers, directors, agents and employees for losses incurred by the company as a result
of their actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Parent
does not anticipate that the company will pay any cash dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current expectation is that the company will retain its future earnings, if any, to fund the development and growth of the company&#8217;s
business. As a result, capital appreciation, if any, of the common stock of the company will be your sole source of gain, if any, for
the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>An
active trading market for the post-Transaction combined company&#8217;s common stock may not develop and its stockholders may not be
able to resell their shares of common stock for a profit, if at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the Transaction, an active trading market for the combined company&#8217;s shares of common stock may never develop or
be sustained. If an active market for the company&#8217;s common stock does not develop or is not sustained, it may be difficult for
stockholders to sell their shares at an attractive price or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the ownership of Cyclacel common stock is highly concentrated, it may prevent you and other stockholders from influencing
significant corporate decisions and may result in conflicts of interest that could cause Cyclacel stock price to
decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
officers and directors of Cyclacel and their affiliates and entities that are related to such officers and directors, and Fitters
Parent are expected to beneficially own or control approximately [___]% of the outstanding shares of common stock of the combined
company following the completion of the Transaction. Accordingly, these executive officers, directors and their affiliates, and
Fitters Parent acting as a group, will have substantial influence over the outcome of corporate actions requiring stockholder
approval, including the election of directors, any merger, consolidation or sale of all or substantially all of the company assets
or any other significant corporate transactions. These stockholders may also delay or prevent a change of control of the company,
even if such a change of control would benefit the other stockholders of the company. The significant concentration of stock
ownership may adversely affect the trading price of the company&#8217;s common stock due to investors&#8217; perception that
conflicts of interest may exist or arise, and may adversely affect the liquidity of the our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports about the company, its business
or its market, its stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for the company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish
about it and its business. Equity research analysts may elect not to provide research coverage of the company&#8217;s common stock after
the completion of the Transaction, and such lack of research coverage may adversely affect the market price of its common stock. In the
event it does have equity research analyst coverage, the company will not have any control over the analysts or the content and opinions
included in their reports. The price of the company&#8217;s common stock could decline if one or more equity research analysts downgrade
its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the company or
fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading
volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on
a timely basis could be impaired.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
post-Transaction combined company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and
Nasdaq rules and regulations. The Sarbanes-Oxley Act requires, among other things, that the combined company maintain effective
disclosure controls and procedures and internal control over financial reporting. Effective internal control over financial
reporting is necessary for the combined company to provide reliable financial reports and, together with adequate disclosure
controls and procedures, is designed to prevent fraud.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company must perform system and process evaluation and testing of its internal control over financial reporting to allow
management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form 10-K for
each year, as required by Section 404 of the Sarbanes-Oxley Act, or Section 404. As a private company and subsidiary of Fitters
Parent, Fitters has never been required to test its internal controls within a specified period. This will require significant
management efforts and will require the combined company to incur substantial professional fees and internal costs to expand its
accounting and finance functions. The combined company may experience difficulty in meeting these reporting requirements in a timely
manner. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause
the combined company to fail to meet its reporting obligations. In addition, any testing by the combined company, as and when
required, conducted in connection with Section 404, or any subsequent testing by the combined company&#8217;s independent registered
public accounting firm, as and when required, may reveal deficiencies in the combined company&#8217;s internal control over
financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or
retroactive changes to its financial statements or identify other areas for further attention or improvement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the combined company remains an emerging growth company, the combined company will not be required to include an attestation report
on internal control over financial reporting issued by its independent registered public accounting firm as required by Section 404.
There is a risk that neither the combined company, nor Cyclacel&#8217;s independent registered public accounting firm once the
combined company is required to obtain an attestation report on internal control over financial reporting from such firm, will be
able to conclude within the prescribed timeframe that the combined company&#8217;s internal control over financial reporting is
effective as required by Section 404. If the combined company is not able to comply with the requirements of Section 404 of the
Sarbanes-Oxley Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to
produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it
could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_029"></span>RISKS
RELATED TO OUR COMMON STOCK FOLLOWING THE EFFECTIVE DATE OF THE TRANSACTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unless
the context requires otherwise, references in the following &#8220;Risks Related to our Common Stock following the Effective Date of
the Transaction&#8221; in this proxy statement/prospectus to &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; are to the Parent
after the Effective Date of the Transaction, which is to be renamed Bio Green Med Solution, Inc. with a ticker symbol of &#8220;BGMS&#8221;.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial
losses for investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock has been and is likely to continue to be highly volatile. Our common stock began trading March 16, 2004
and is traded on The Nasdaq Capital Market. On March 27, 2006, in connection with the name change from Xcyte to Cyclacel, we changed
the symbol under which our common stock trades to &#8220;CYCC,&#8221; previously &#8220;XCYT.&#8221; Our preferred stock
currently trades on the Nasdaq Capital Market under the symbol &#8220;CYCCP,&#8221; previously &#8220;XCYTP.&#8221; As
with any public company, some investors hold a short position in our common stock. Such investors have published and distributed information
about our company including on past and recent clinical trials. Activities by these investors may increase the volatility of the market
price of our common stock, and may affect our ability to raise additional funds and to complete any potential future clinical trials
or transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stock price could be subject to wide fluctuations due to many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any potential strategic options that we pursue, including the Transaction;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
government approvals relating to products in development;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in governmental regulations or in the status of regulatory approvals or applications;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
disputes or other developments with respect to our intellectual property rights or the intellectual property rights of others;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
product liability claims or other litigation, including intellectual property or securities litigation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
sales of large blocks of our common stock, including sales by our executive officers and directors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in earnings estimates or recommendations by securities analysts;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to meet investors&#8217; expectations regarding our future operating performance;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
media exposure of our products or products of our competitors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
volume and timing of sales of products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the introduction of new products or product enhancements by us or our competitors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to develop, obtain regulatory clearance or approval for and market new and enhanced products, if any, on a timely basis;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
quarterly variations in our or our competitors&#8217; results of operations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
developments in our industry; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of
our competitors.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, an active and liquid market may not develop or persist, and you may not be able to sell your shares quickly or at a price that
is higher than what you paid for them. These and other factors may make the price of our stock volatile and subject to unexpected fluctuations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale
of a substantial number of shares of our common stock by existing stockholders or by us may cause the price of our common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock into the public market or the perception that these sales might occur could depress
the market price of our common stock and could impair our ability to raise adequate capital through the sale of additional equity securities.
We are unable to predict the effect that sales may have on the prevailing market price of our common stock. In addition, in the past
two years, we have filed registration statements on Form S-8 registering a total of 2,083 shares of common stock subject to options
or reserved for future issuance pursuant to Cyclacel&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), providing for
an automatic increase in the number of Common Stock reserved for issuance under the applicable plan on April 17, 2025, and an additional
666 shares of its common stock under the 2018 Plan on July 31, 2024, and an additional 250 shares of its common stock under
the 2018 Plan on July 23, 2024. Shares registered under these registration statements are available for sale in the public market subject
to vesting arrangements, the exercise of such options and, in the case of our affiliates, the restrictions of Rule 144.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, options to purchase 1,360 shares of common stock issuable upon the exercise of options outstanding
at a weighted average exercise price of $2,515.85 per share, 9 shares of common stock issuable upon vesting of
restricted stock units outstanding at a weighted average exercise price of $3,240.00 per share, and 23,746 shares of
common stock issuable pursuant to the vesting of Restricted Options at a weighted average exercise price of $79.20 per
share, were exercisable. To the extent we raise additional capital by selling and issuing common stock, convertible securities or
other equity securities, it may result in material dilution to our existing stockholders and new investors could gain rights
superior to our existing stockholders. Sales by us or by our current stockholders also could cause the price of our common stock to
fall and make it more difficult for you to sell shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions in our amended and restated certificate of incorporation and our amended and restated bylaws, as well as Delaware law, could
discourage a takeover.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation, bylaws, and Delaware law, contain provisions that might enable our management to resist
a takeover, and might make it more difficult for an investor to acquire a substantial block of our common stock. These provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
authorize our board of directors to issue, without further action by our stockholders, up to 5,000,000 shares of undesignated preferred
stock;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
specify that special meetings of our stockholders can be called only by the Board of Directors, the chairman of the board or the president;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
specify that our bylaws of may be adopted, amended or repealed by the stockholders entitled to vote;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
require in general the approval of a supermajority (66-2/3%) vote of our outstanding capital shares to amend or repeal certain provisions
of our amended and restated certificate of incorporation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including
proposed nominations of persons for election to our board of directors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
provide that directors may be removed only for cause by a majority of the board of directors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;
establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered
terms;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
provide that vacancies on our board of directors may be filled only by a majority of directors then in office; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
provide that in general the number of directors on our board may only be fixed from time to time by a majority vote of our directors
then in office.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions might discourage, delay or prevent a change in control of our company or a change in our management. The existence of these
provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to
pay in the future for shares of our common stock. Anti-takeover provisions and other provisions under Delaware law could discourage,
delay or prevent a transaction involving a change in control of our company, even if doing so would benefit our stockholders. These provisions
could also discourage proxy contests and make it more difficult for you and other stockholders to elect or remove directors of your choosing
and to cause us to take other corporate actions you desire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have not paid dividends on our common stock in the past and do not expect to pay dividends in the future, and any return on investment
may be limited to the value of our stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable
future. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic
factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, our stock may be less
valuable because a positive return on your investment will only occur if our stock price appreciates.<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_030"></span>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus and the documents incorporated by reference into this proxy statement/prospectus contain forward-looking statements.
These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could
cause actual results to differ materially from expectations. These forward-looking statements should not be relied upon as predictions
of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur.
You can identify forward-looking statements by the use of forward-looking terminology including &#8220;believes,&#8221; &#8220;expects,&#8221;
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro
forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of
these words and phrases or comparable terminology. All statements other than statements of historical fact are statements that could
be deemed forward-looking statements. For example, forward-looking statements include, but are not limited to statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the strategies, prospects, plans, expectations and objectives of management for future operations of the combined company following the
closing of the Transaction;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the progress, scope or duration of the development of product candidates or programs;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the benefits that may be derived from product candidates or the commercial or market opportunity in any target indication;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the ability of Parent and the Company to protect their intellectual property rights;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the ability of Parent to maintain compliance with Nasdaq listing standards;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the anticipated operations, financial position, losses, costs or expenses of Parent or the Company following the closing of the Transaction;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
statements regarding future economic conditions or performance and/or its products and services;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the approval and closing of the Transaction, including the timing of the Transaction, the ability of Parent to solicit a sufficient number
of proxies to approve the Transaction, other conditions to the completion of the Transaction and relative ownership levels as of the
closing of the Transaction;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the expected benefits of and potential value created by the Transaction for the stockholders of Parent; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
statements of belief and any statement of assumptions underlying any of the foregoing.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a discussion of the factors that may cause Parent or the Company&#8217;s actual results, performance or achievements following closing
of the proposed Transaction to differ materially from any future results, performance or achievements expressed or implied in such forward-looking
statements, or for a discussion of risk associated with the ability of Parent and Fitters Parent to complete the Transaction and the
effect of the Transaction on the business of Parent and the Company following the completion of the Transaction, see &#8220;<i>Risk Factors</i>&#8221;
above in this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed
in the forward-looking statements are discussed in reports filed with the SEC by Parent. See &#8220;<i>Where You Can Find More Information</i>&#8221;.
There can be no assurance that the Transaction will be completed, or if it is completed, that it will close within the anticipated time
period or that the expected benefits of the Transaction will be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these risks or uncertainties materializes or any of these assumptions proves incorrect, the results of Parent or the Company following
completion of the Transaction could differ materially from the forward-looking statements. All forward-looking statements in this proxy
statement/prospectus are current only as of the date on which the statements were made. Parent and the Company do not undertake any obligation
(and expressly disclaim any such obligation to) to publicly update any forward-looking statement to reflect events or circumstances after
the date on which any statement is made or to reflect the occurrence of unanticipated events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_031"></span>THE
SPECIAL MEETING OF STOCKHOLDERS OF PARENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_032"></span>Date,
Time and Place</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
special meeting will be held virtually at 10:00 a.m., Eastern Time, on September 4, 2025. Parent is sending this
proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by the board of directors for use at the
special meeting and any adjournments or postponements of the special meeting. This proxy statement/prospectus is first being furnished
to stockholders on or about July 25, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_033"></span>Purposes
of the Special Meeting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purposes of the special meeting are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Proposal
                                            1</span>: to approve the issuance of shares of Cyclacel common stock to Fitters
                                            Parent pursuant to the terms of the Exchange Agreement (Proposal 1);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Proposal
                                            2</span>: for purposes of complying with Nasdaq Listing Rule 5635(a), the potential issuance
                                            of more than 20% of the issued and outstanding shares of Cyclacel common stock in connection
                                            with the Transaction (Proposal 2);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Proposal
                                            3</span>: to approve an amendment to the amended and restated certificate of incorporation of
                                            Cyclacel Pharmaceuticals (a) changing the Cyclacel corporate name to &#8220;Bio Green Med
                                            Solution, Inc.&#8221;, (b) permitting actions by stockholders by written consent and ratify
                                            all prior action by stockholder written consent, and (c) opting out of the business combination provisions of Section 203
                                            of the DGCL (Proposal 3); and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Proposal
                                            4</span>: to consider and vote upon an adjournment of the special meeting, if necessary, to
                                            solicit additional proxies if there are not sufficient votes in favor of the proposals set
                                            forth above (Proposal 4).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the special meeting, Parent may transact such other business as may properly come before the stockholders at the special meeting or
any adjournment or postponement thereof. After careful consideration, the board of directors of Parent has unanimously approved the
Exchange Agreement and the proposals described in this proxy statement/prospectus, and the board of directors has determined that it
is advisable to consummate the Transaction. Our board of directors recommends that stockholders vote &#8220;FOR&#8221; the proposals
described in the accompanying proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Proposals 1, 2 and 3 are conditioned upon each other and the approval of each such proposal is a condition to the completion of the
Transaction. Therefore, the Transaction cannot be consummated without the approval of Proposals 1, 2 and 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_034"></span>Recommendation
of the Board of Directors of Cyclacel Pharmaceuticals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            board of directors has determined and believes that the issuance of shares of Parent Common
                                            Stock pursuant to the Exchange Agreement is fair to, and in the best interests of, Parent
                                            and its stockholders and has unanimously approved such items. The board of directors recommends
                                            that stockholders vote &#8220;FOR&#8221; Proposals 1 and 2 to approve the issuance of shares
                                            of Parent Common Stock pursuant to the Exchange Agreement and the potential issuance
                                            of greater than 20% of Parent Common Stock resulting from the Transaction.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            board of directors has determined and believes that the amendment to the amended and restated
                                            certificate of incorporation of Parent to (a) change the name of Parent to &#8220;Bio Green
                                            Med Solution, Inc.&#8221;, (b) permit actions by stockholders by written consent, and ratify
                                            all prior action by stockholder written consent including without limitation, majority stockholder
                                            consents dated March 21, 2025 and May 12, 2025, and (c) opt out of the business combination provisions of Section 203 of the DGCL,
                                            is advisable to, and in the best interests of, Parent and its stockholders and has unanimously
                                            approved such amendment. The board of directors recommends that stockholders vote &#8220;FOR&#8221;
                                            Proposal 3 to approve the amendment and ratification.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            board of directors has determined and believes that adjourning the special meeting, if necessary,
                                            to solicit additional proxies if there are not sufficient votes in favor of Proposals 1,
                                            2, and 3 is fair to, and in the best interests of, Parent and its stockholders and has unanimously approved
                                            and adopted the proposal. The board of directors recommends that stockholders vote &#8220;FOR&#8221;
                                            Proposal 4 to adjourn the special meeting, if necessary, to solicit additional proxies if
                                            there are not sufficient votes in favor of Proposals 1, 2, and 3.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_036"></span>Record
Date and Voting Power</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
holders of record of Parent Common Stock at the close of business on the record date, July 10, 2025, are entitled to notice
of, and to vote at, the special meeting. At the close of business on the record date, there were [&#9679;] shares of Parent Common
Stock issued and outstanding. Each share of common stock entitles the holder thereof to one vote on each matter submitted for stockholder
approval. See the section entitled &#8220;<i>Principal Stockholders of Parent</i>&#8221; in this proxy statement/prospectus for information
regarding persons known to the management of Parent to be the beneficial owners of more than 5% of the outstanding shares of Parent
Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_037"></span>Voting
and Revocation of Proxies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proxy accompanying this proxy statement/prospectus is solicited on behalf of the board of directors for use at the special meeting. If
you are a stockholder of record, you may vote in one of the following ways:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<b>You may vote by mail</b>. Complete, sign and date the proxy card that accompanies this proxy statement and return it promptly in the
postage-prepaid envelope provided (if you receive printed proxy materials). Your completed, signed and dated proxy card must be received
prior to the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<b>You may vote by telephone</b>. To vote over the telephone, dial toll-free 1-800-579-1639 using a touch-tone telephone and follow the
recorded instructions (have your Notice of Internet Availability or proxy card in hand when you call). You will be asked to provide the
company number and control number from your Notice of Internet Availability or proxy card. Telephone voting is available 24 hours a day,
7 days a week, until 11:59 p.m., Eastern Time, on September 3, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<b>You may vote via the Internet</b>. To vote via the Internet, go to www.proxyvote.com to complete an electronic proxy card (have your
Notice of Internet Availability or proxy card in hand when you visit the website). You will be asked to provide the control number from
your Notice of Internet Availability or proxy card. Internet voting is available 24 hours a day, 7 days a week, until 11:59 p.m., Eastern
Time, on September 3, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a beneficial owner of shares held of record by a broker, bank or other nominee, you will receive voting instructions from your
broker, bank or other nominee. You must follow the voting instructions provided by your broker, bank or other nominee in order to instruct
your broker, bank or other nominee on how to vote your shares. Beneficial owners of shares should generally be able to vote by returning
the voting instruction card, or by telephone or via the Internet. However, the availability of telephone or Internet voting will depend
on the voting process of your broker, bank, or other nominee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a beneficial owner of shares held of record by a broker, bank or other nominee, you will receive voting instructions from your
broker, bank or other nominee. You must follow the voting instructions provided by your broker, bank or other nominee in order to instruct
your broker, bank or other nominee on how to vote your shares. Beneficial owners of shares should generally be able to vote by returning
the voting instruction card, or by telephone or via the Internet. However, the availability of telephone or Internet voting will depend
on the voting process of your broker, bank, or other nominee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a stockholder of record, you can change your vote or revoke your proxy at any time before the special meeting by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
By submitting a new proxy card with a date later than your previously delivered proxy and submitting it as instructed above or by providing
written notice of revocation to us before the special meeting at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia
59200, Attention: Kiu Cu Seng, Chief Financial Officer, Executive Director and Secretary;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
By submitting a later proxy by Internet or by telephone as instructed above; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
By attending the special meeting and voting at the meeting. Attending the special meeting will not, in and of itself, change or revoke
a previously submitted proxy unless you specifically request it or vote at the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
most current vote, whether by telephone, Internet or proxy card is the one that will be counted. If you are the beneficial owner of your
shares, you must contact the broker, bank or other nominee holding your shares and follow their instructions to change your vote or revoke
your proxy. All properly executed proxies that are not revoked will be voted at the special meeting and at any adjournments or postponements
of the special meeting in accordance with the instructions contained in the proxy. If a stockholder executes and returns a proxy and
does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; Proposal 1 to approve the issuance of
shares of Parent Common Stock in the Transaction, &#8220;FOR&#8221; Proposal 2 to approve the potential issuance of greater than
20% of the Parent Common Stock resulting from the Transaction, &#8220;FOR&#8221; Proposal 3 to approve an amendment to the amended
and restated certificate of incorporation of Parent changing the company&#8217;s name to &#8220;Bio Green Med Solution, Inc.,&#8221;
and &#8220;FOR&#8221; Proposal 4 to adjourn the special meeting, if necessary, to solicit additional proxies if there are not sufficient
votes in favor of Proposals 1, 2, and 3 in accordance with the recommendation of the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_038"></span>Required
Vote</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
vote is important. The affirmative vote of a majority in voting power of the issued and outstanding shares of common stock of Cyclacel
(the &#8220;Parent Common Stock&#8221;), entitled to vote on thereon is required for approval of Proposals 1, 2 and 4. The affirmative
vote of the holders of a majority of the outstanding shares of common stock entitled to vote on the record date for the special meeting
is required for approval of Proposal 3. Each of Proposals 1, 2, and 3 are conditioned upon each other and the approval of each such proposal
is a condition to the completion of the Transaction. Therefore, the Transaction cannot be consummated without the approval of Proposals
1, 2, and 3. You may change or revoke your proxy at any time before it is voted at the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Votes
will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221;
votes, abstentions and broker non-votes. Abstentions will be counted towards the vote total for each proposal and will have the same
effect as &#8220;AGAINST&#8221; votes on Proposal 3, but will have no effect on Proposals 1 and 2. Similarly, broker non-votes will have
the same effect as &#8220;AGAINST&#8221; votes on Proposal 3, but will have no effect on Proposals 1 and 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, the directors and executive officers of Parent owned or controlled 51.20% of the outstanding shares of
common stock entitled to vote at the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_039"></span>Solicitation
of Proxies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to solicitation by mail, the directors, officers, employees and agents of Parent may solicit proxies from stockholders by personal
interview, telephone, telegram or otherwise. We have engaged Laurel Hill Advisory Group, LLC, to act as our proxy solicitor in connection
with the proposals to be acted upon at our special meeting. Pursuant to our agreement, Laurel Hill Advisory Group, LLC will, among other
things, provide advice regarding proxy solicitation issues and solicit proxies from our stockholders on our behalf in connection with
the special meeting. For these services, we will pay a fee of approximately $20,000 plus expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_040"></span>Other
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this proxy statement/prospectus, the board of directors does not know of any business to be presented at the special meeting
other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before
the special meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with
the judgment of the persons voting the proxies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_041"></span>THE
TRANSACTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
section and the section entitled </i>&#8220;<i>The Exchange Agreement</i>&#8221; <i>in this proxy statement/prospectus describe the material
aspects of the Transaction, including the Exchange Agreement. While Parent and the Company believe that this description covers the
material terms of the Transaction and the Exchange Agreement, it may not contain all of the information that is important to you. You
should read carefully this entire proxy statement/prospectus for a more complete understanding of the Transaction and the Exchange Agreement,
including the Exchange Agreement, and the other documents to which you are referred herein. See the section entitled </i>&#8220;<i>Where
You Can Find More Information</i>&#8221; <i>in this proxy statement/prospectus.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_042"></span>Background
of the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="svv_043"></span>Historical
Background of Parent</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or &#8220;Parent&#8221;) is a clinical-stage biopharmaceutical company working to develop
innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. It operates in the field of cancer cell cycle biology
with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and
ultimately increase a patient&#8217;s overall survival. The epigenetic/anti-mitotic program is evaluating plogo, a PLK1 inhibitor, in
solid tumors and hematological malignancies. Cyclacel&#8217;s strategy is to build a diversified biopharmaceutical business based on
a pipeline of novel drug candidates addressing oncology and hematology indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of Cyclacel&#8217;s to date have been devoted to performing research and development, conducting clinical trials, developing and
acquiring intellectual property, raising capital and recruiting and training personnel. As part of Cyclacel&#8217;s efforts to reduce
operating costs, it has determined to focus on the development of plogo only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel&#8217;s
pipeline of innovative medicines aims to provide safe and effective anticancer treatment options to patients combined with the convenience
of oral administration. Cyclacel&#8217;s preclinical and clinical studies suggests that daily dosing by the oral route is a preferred
strategy for both our drugs. We also conducted certain early clinical studies using intravenous (&#8220;i.v.&#8221;) administration.
The aim of the current streamlined studies is to assess safety and identify signals of clinical activity which may lead to registration-enabling
outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel&#8217;s
clinical development strategy is focused on our program in epigenetics/mitosis control biology. As part of its efforts to reduce operating
costs it has determined to focus on the development of the plogo clinical program only. Fadraciclib, Cyclacel&#8217;s subsidiary&#8217;s
other drug development program, is being marketed for sale by the joint liquidators through Hilco Appraisals Limited, a firm of professional
valuation agents and will no longer be part of the assets of Cyclacel as of January 2025. Cyclacel has retained worldwide rights to commercialize
plogo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
currently retains virtually all marketing rights to the compounds associated with plogo&#8217;s clinical-stage drug program. To optimize
its commercial return, Cyclacel intends to enter into selected partnering arrangements and to retain co-promotion rights as appropriate.
Generally, Cyclacel plans to develop compounds through the Phase 2 proof-of-efficacy stage before seeking a partner. Cyclacel may enter
into partnering arrangements earlier than Phase 2 proof-of-concept trials where appropriate, or in connection with drug programs outside
our core competency in oncology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
its initial assessment of strategic options, Cyclacel fielded outreach from a number of private companies seeking a potential merger,
and made the assessment that a reverse merger or other strategic transaction would likely result in a more favorable outcome for its
stockholders than a liquidation of the company or acquiring products and funding their development. During this time, Cyclacel also pro-actively
sought out additional strategic advisors and discussions ensued with a number of investment banks. ARC Group Limited
(&#8220;ARC&#8221;) presented its qualifications to act as a financial advisor to the Chief Executive Officer of Cyclacel by way of
a telephone conference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
continued an active dialogue with ARC and thereafter entered into an investment banking agreement with ARC, pursuant to which
ARC agreed to act as exclusive financial advisor to Cyclacel to assist in the review of the company&#8217;s business and assets and explore
strategic opportunities for enhancing stockholder value, including a potential business combination with an unaffiliated third party.
During this time, Cyclacel also continued to explore potential strategic alliances or other ways to monetize its plogo-related assets,
with interest being expressed by three parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial screening process for potential business combination candidates involved ARC making outreach to a portfolio of four companies
that had the potential to meet certain criteria. These companies consisted of private companies considering an initial public offering,
or IPO, private companies not in the IPO queue, private companies that had failed in earlier attempts at an IPO, publicly-traded companies
on exchanges outside the U.S. seeking a Nasdaq listing, and public companies in the U.S. that were believed to have a strategic fit with
Cyclacel or were seeking a business combination transaction as a de facto financing event. See also &#8220;<i>History of Cyclacel Strategic
Alternatives and Significant Corporate Events</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there was interest from companies known to the management and board of directors of Cyclacel, and unsolicited enquiries received by the
various parties. For instance, Cyclacel first became aware of the four companies when these profiles of these parties were presented
by ARC to management of Cyclacel. Likewise, Cyclacel first became acquainted with Fitters Parent in late 2021 when Hoo Swee Guan (&#8220;Mr.
Hoo&#8221;) was appointed to the Board of Fitters Parent on November 26, 2021, as an Executive Director. Cyclacel&#8217;s Chief Executive
Officer and Mr. Hoo previously were affiliated in connection with their service on a previous Nasdaq listed company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
their review of potential strategic partners, ARC and Cyclacel focused on biotechnology, green energy, waste solutions and manufacturing
companies possessing (i) a perceived lower financing risk at closing, (ii) a strong product pipeline with multiple mid-to-late or commercial-stage
assets, (iii) strong news flows, (iv) an experienced management team, (v) high-quality existing investors or new investors willing to
support a potential transaction, (vi) a capital structure with no debt or a clear path to restructuring existing debt, and (vii) audited
financial statements or the ability to produce audited financial statements for the last two fiscal years. Prospective strategic partners
were removed from consideration if their valuation was considered to be too high, they possessed a single asset in a high-risk space
or their management team was not viewed as optimal to operate as a publicly traded company in the United States following a potential
transaction. See also &#8220;<i>History of Cyclacel Strategic Alternatives and Significant Corporate Events</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
review of the candidates by ARC and Cyclacel, one company submitted a formal proposal by the end of March 2025 detailing potential
financial and structural terms of a transaction. Cyclacel management and ARC carried out a detailed analysis of potential strategic
partners involved. In evaluating this formal proposal from the potential counterparty (see in this regard the discussions below with
respect to Cyclacel&#8217;s engagement with Fitters Parent), Cyclacel ultimately concluded that (x) one or more desired elements
were missing from the remaining three potential strategic partners (for example, that the counterparty did not have sufficient
resources to achieve potentially meaningful development milestones within its business plan or an ability to enter into an agreement
in the near-term for a combination with a public company), (y) the terms expected to be available to Cyclacel and its stockholders
in a potential combination, including as represented by the potential share of the post-transaction company that might be owned by
the pre-transaction Cyclacel stockholders immediately following a combination would likely not be fair or appropriate to the
pre-transaction Cyclacel stockholders, and/or (z) Cyclacel should pursue a transaction with Fitters Parent to the exclusion of other
potential strategic partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of its process, Fitters Parent was the only party with which Cyclacel ultimately reached a mutual understanding on deal terms,
including the potential share of the company that would be owned by the legacy Cyclacel stockholders immediately following a proposed
transaction, and moved forward with negotiating a definitive agreement. A more detailed chronological description of the Transaction
process follows below under the section below entitled &#8220;<i>The Transaction&#8212;Background of the Transaction&#8212;History of
Cyclacel Strategic Alternatives and Significant Corporate Events</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>History
of Cyclacel Strategic Alternatives and Significant Corporate Events</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the detailed analysis of the four potential strategic partners, three companies had one or more of the desired elements missing (for
example, the potential strategic partner did not have sufficient resources to achieve potentially meaningful development milestones within
its portfolio of product development candidates or an ability to enter into an agreement in the near-term for a transaction with a public
company).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2025, ARC Group reviewed with management of Cyclacel the proposals received to date, the application of the proposed selection
criteria to each of the potential strategic partners and the proposed financial terms offered by each of the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
that period management of Cyclacel also had numerous calls with representatives of ARC Group regarding the candidate companies under
review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
assistance from ARC Group, the Cyclacel management team selected one potential target company which management felt best fit the pre-established
selection criteria. The selected potential target company&#8217;s parent company, Fitters Parent was invited to submit presentations and other materials about its subsidiary, Fitters Sdn. Bhd (the &#8220;Company&#8221;) in connection
with their merits to be considered by Cyclacel for a potential strategic transaction. On March 19, 2025, Cyclacel management team concluded
that, it would enter into a further phase of due diligence and discussion regarding the potential for entering into a strategic transaction
with Fitters Parent, to acquire its wholly-owned subsidiary, which was the most desired candidate to retain listing of the Cyclacel common
stock on The Nasdaq Stock Market following the closing of a potential transaction and to provide the basis for a successful outcome for
its stockholders following the closing of a transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
Fitters Parent selected as the proposed strategic partner, Cyclacel management and ARC Group sent a draft of a non-binding letter of
intent (&#8220;LOI&#8221;) to representatives of Fitters Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
March 19, 2025, and March 25, 2025, ARC Group and Cyclacel drafted a form LOI for use in a proposed reverse merger with Fitters Parent.
On March 25, 2025, ARC Group sent a draft of the LOI proposing a reverse merger to representatives between Cyclacel and the Company.
During this period of time, Cyclacel continued due diligence discussions and LOI negotiations with Fitters Parent from March 19, 2025
through April 4, 2025. The LOI negotiations with Fitters Parent, for the most part, focused on valuations, investor support and management
teams in the case of the Company and Fitters Parent and cash balances and liabilities in the case of Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2025, Cyclacel and ARC Group held a telephone conference to discuss the Company and Fitters Parent and matters related to the
LOI to discuss initial terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2025, representatives of Fitters Parent sent a revised draft of the LOI to ARC Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on April 2, 2025, representatives of ARC Group and Cyclacel held a telephone conference to discuss the revised draft LOI received from
Fitters Parent. With respect to the revised LOI from Fitters Parent, the parties discussed the valuations of the companies, the relative
ownership of the legacy stockholders of each company following the closing of a proposed transaction, the size, timing and certainty
of a concurrent investment in Fitters Parent, timing and other matters related to financial statements required to be included in a proxy
statement/prospectus, and shareholder approval and other matters under Malaysian law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2025, ARC Group sent a revised draft LOI to representatives of Fitters Parent to address uncertainty around the Company&#8217;s
valuation, which was now to be determined in a business combination agreement, and to extend the intended closing date from 30 days to
90 days after the date of stockholder approval to build in sufficient time for closing to occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2025, Cyclacel and Fitters Parent executed the LOI. The LOI contemplated the exploration of Cyclacel acquiring the Company,
a wholly-owned subsidiary of Fitters Parent. The LOI contemplated the acquisition by Cyclacel of all of the issued and outstanding capital
stock of the Company in the form of purchase consideration to be mutually agreed upon by the Company and Fitters Parent subject to further
negotiation and agreement among the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the execution of the LOI on April 4, 2025, Cyclacel engaged Rimon, P.C. (&#8220;Rimon&#8221;) to serve as counsel to Cyclacel with
respect to the Transaction. Commencing on April 3, 2025, representatives from Rimon, Arc Group (&#8220;ARC&#8221;) and Cyclacel held
weekly conference calls on April 10, 2025, April 17, 2025, April 24, 2025 and April 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2025, Fitters Parent engaged Messrs. Ong, Ric &amp; Partners based in Kuala Lumpur (&#8220;ORP&#8221;) to serve as counsel to
Fitters Parent and its subsidiaries with respect to the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2025, Rimon circulated the first draft of an Agreement and Plan of Merger to representatives of Fitters Sdn. Bhd., a Malaysia
private limited company and a wholly-owned subsidiary of Fitters Parent (the &#8220;Company&#8221;), Cyclacel, Fitters Parent, ARC and
ORP. The draft of the Agreement and Plan of Merger contemplated a reverse triangular merger whereby a newly formed Fitters Merger Acquisition
Sub, Sdn. Bhd., a Malaysia private limited company and wholly-owned subsidiary of Cyclacel (&#8220;Merger Sub&#8221;), in accordance
with the Delaware General Corporation Law (&#8220;DGCL&#8221;) and Malaysian Companies Act, would be merged with and into the Company
and the separate corporate existence of Merger Sub would cease, and the Company would continue as the surviving corporation and succeed
to and assume all the rights, properties, liabilities and obligations of the Company in accordance with the Malaysian Companies Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representatives
of Fitters Parent, the Company, Cyclacel, ARC and Rimon held a conference call on April 10, 2025, whereby the parties discussed the
structure of the Transaction. Given certain matters related to Malaysian law and because the Company is wholly-owned by Fitters
Parent, the parties agreed to change the structure from a reverse triangular merger to a share exchange. Fitters Parent launched a
dataroom on April 16, 2025, with access links given to Rimon, ARC and Cyclacel representatives. Also on April 16, 2025, ORP
circulated a revised version of the Agreement and Plan of Merger in the form of an exchange agreement (the &#8220;Exchange
Agreement&#8221;) with the principal comments reflecting the structure change to a share exchange, whereby Fitters Parent would
exchange all of their capital shares in the Company for shares of common stock of Cyclacel, following which, the Company would become a wholly-owned subsidiary of Cyclacel. The revised draft also clarified that there are no statutory
rights for appraisal under the Malaysian Companies Act and that Fitters Parent had no outstanding preference shares and identified
Fitters Parent&#8217;s subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
April 16, 2025 and April 19, 2025, Rimon and ORP exchanged email communications regarding a list of open issues, including additional
due diligence items related to potential material contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 18, 2025, Rimon requested additional due diligence through tendering a due diligence request list to ORP while discussions continued
between Cyclacel and Fitters Parent and their respective representatives throughout April 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2025, Rimon circulated a revised draft of the Exchange Agreement to representatives of Cyclacel, the Company, Fitters Parent,
ARC and ORP which revised draft reflected additional conforming changes under the DGCL to accommodate the new acquisition structure in
lieu of a reverse triangular merger and also conforming changes under Malaysian law as to the transfer of securities at close of the
Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the weekly calls with representatives with Rimon, ARC and Cyclacel on April 17, 2025, April 24, 2025 and April 30, 2025, representatives
of Fitters Parent, the Company and ORP were invited to the calls to discuss the acquisition structure, the valuation of the Company and
its subsidiaries, the results of the Fairness Opinion, the timing of due diligence review and missing items to the due diligence request
and composition of officers and directors of the Company after the potential closing of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the April 24, 2025 conference call, representatives from Cyclacel, Fitters Parent, the Company, Rimon, ORP and ARC discussed the
status of the execution of the Exchange Agreement, disclosure schedules and related documentation. Included in this discussion was
the preparedness for the drafting of the proxy statement/prospectus on Form S-4. Representatives from ORP and Rimon stated that the
Exchange Agreement and related documentation was close to final form with the signing of such documentation being able to occur
within the next week. Representatives from Cyclacel, Fitters Parent, the Company, Rimon, and ORP agreed to turn drafts over the
weekend for a status update on these various matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2025, ORP circulated feedback on behalf of Fitters Parent to the due diligence request list and advised Rimon, Cyclacel and
ARC that the Fitters Parent dataroom had been updated with all necessary documents including the banking facility documents requested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2025, Rimon sent additional due diligence questions and requests for clarifications to ORP and Fitters Parent including, regarding
the outstanding CIMB Group Holdings Berhad facility, a Malaysian universal bank headquartered in Kuala Lumpur (the &#8220;CIMB facility&#8221;)
and the effectiveness of a corporate guarantee to Malayan Banking Berhad (&#8220;MBB&#8221;) and whether a waiver from MBB was needed
to authorize the sale of the securities, and in addition, whether a Company director services agreement needed to be amended to allow
for termination at the closing of the Transaction, and any intentions to dissolve certain of the Company&#8217;s dormant subsidiaries
prior to the closing of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 27, 2025, ORP circulated feedback to Rimon&#8217;s inquiries from April 26, 2025, advising that the current CIMB facility is still
effective but no drawdown was done by Fitters Parent or its subsidiaries. ORP advised further that the corporate guarantee to MBB is
a form of security in relation to a tradeline offered by MBB to the Company, which is still effective but there has been no drawdown
by the Company and provided corroborating documentation of the zero balance. ORP added that Fitters Parent will notify CIMB and MBB to
inform the banks regarding the disposal of shares in the Transaction and to seek consent for the disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2025, ORP advised that Fitters Parent and ORP had no further comments to the Exchange Agreement and tendered the Fitters
Parent Disclosure Schedules for Cyclacel and Rimon&#8217;s review and comments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2025, Rimon circulated another draft of the Exchange Agreement to Fitters Parent and ORP with certain clean up changes including
the determination of consideration for Cyclacel&#8217;s acquisition of Fitters Parent&#8217;s conveyance and transfer all of its right,
title and interest to all of the ordinary shares of the Company, Cyclacel shall issue an amount of its common stock equal to nineteen
and ninety nine hundreds (19.99%) percent of the issued and outstanding shares of its common stock as of the closing date (the &#8220;Exchange
Shares&#8221;) to Fitters Parent. In addition, the Exchange Agreement included a final termination date of September 30, 2025,
if the Transaction has not been consummated by such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2025, Rimon circulated a semi-final draft of the Exchange Agreement to Fitters Parent and ORP to include certain conditions
to closing required to meet Fitters Parent&#8217;s compliance and reporting obligations to the Bursa Malaysia Securities Berhad Main
Market stock exchange. Also on April 28, 2025, Rimon circulated comments on the Fitters Parent Disclosure Schedules for ORP and Fitters
Parent&#8217;s review and comment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2025, Rimon and ORP continued to exchange due diligence requests and responses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 2, 2025, the board of directors of Cyclacel held a meeting by telephone conference that representatives of Rimon and ARC attended
at the invitation of the board of directors. During the meeting, a member of the management team and a representative of Rimon reviewed
the key terms of the proposed Transaction between Cyclacel and Fitters Parent, including: structure and timing considerations; the formula
for determining the Exchange Shares for the exchange of the Company&#8217;s capital shares held by Fitters Parent into Cyclacel common
stock as well as the relative percentages of ownership of the existing Cyclacel stockholders, on the one hand, and Fitters Parent on
the other hand, following the completion of the proposed Transaction; the closing conditions in the draft Exchange Agreement and the
termination provisions set forth in the draft Exchange Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representatives
of ARC then reviewed with the board of directors ARC&#8217;s analysis of the Exchange Shares and discussed the findings of Strategic
Capital Advisory Sdn. Bhd. (&#8220;Strategic Capital Advisory&#8221;), a highly specialized corporate finance services company
retained by Cyclacel, which rendered its written fairness opinion (the &#8220;Fairness Opinion&#8221;) to the Cyclacel board of
directors, that, as of the date of such opinion, and based upon the various assumptions, qualifications and limitations set forth
therein, that the fair value of entire equity interest of Fitters Parent and its subsidiaries is RM92.27 million to RM107.71
million, that translates to USD20.72 million to USD24.19 million, using the exchange rate of USD1.00 to RM4.453 as of the date of
the written Fairness Opinion. Accordingly, Strategic Capital Advisory concluded that the purchase consideration falls within the
ranges of values derived using the Discounted FCFF methodology, hence it is fair from a financial point of view, to the stockholders
of Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representatives
from Rimon reviewed with Cyclacel&#8217;s board of directors the fiduciary duties of the board members in the context of the proposed
Transaction. During the various discussions, members of the board of directors asked questions and discussed the terms and features of
the proposed Transaction, including provisions of the draft Exchange Agreement and related documentation, as well as Cyclacel&#8217;s
cash forecast and ability to satisfy its obligations prior to the projected closing date in light of the net cash expectations contained
in the draft Exchange Agreement and its impact on the relative valuations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
further discussion among Cyclacel&#8217;s board of directors, the board unanimously (i) determined that the Transaction and the other
transactions contemplated by the Exchange Agreement were fair to and in the best interests of Cyclacel and its stockholders, (ii) approved
and adopted the Exchange Agreement and the transactions contemplated thereby, subject to finalization of the Exchange Agreement and ancillary
documents by management of Cyclacel in consultation with legal counsel, with such changes thereto as management deemed to be in the best
interests of Cyclacel and its stockholders, and (iii) resolved to recommend that the stockholders of Cyclacel vote to approve the Transaction,
adopt the Exchange Agreement and approve and/or adopt the other transactions and arrangements as contemplated by the Exchange Agreement,
including the issuance of shares of Cyclacel common stock in the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
April 28, 2025 and May 5, 2025, members of Cyclacel&#8217;s and Fitters Parent&#8217;s management teams continued to negotiate and finalize
the Exchange Agreement and related transaction documents, together with representatives of Rimon and ORP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 2, 2025, Rimon circulated an execution version of the Exchange Agreement to Cyclacel, the Company, Fitters Parent, ORP and ARC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 5, 2025, representatives from Cyclacel, the Company, Fitters Parent, Rimon, ORP, and ARC exchanged email correspondence to discuss
the execution of the Exchange Agreement, final disclosure schedules and related documentation. ORP provided certain date revisions to
the Exchange Agreement and the representatives agreed to execute the Exchange Agreement on May 6, 2025 and discussed consistent times
in Malaysia and in the U.S. to issue press releases. In addition, representatives stated that the necessary approvals for the Exchange
Agreement and related documentation were obtained and that Cyclacel and Fitters Parent were in a position to sign definitive documentation
as of the completion thereof. On May 6, 2025, Cyclacel, Fitters Parent and the Company entered into the Exchange Agreement and related
transaction documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Between
June 20, 2025 and June 30, 2025, Cyclacel and Fitters Parent negotiated a $1,000,000 cash payment as additional consideration for the
Transaction due to the decrease in valuation of Cyclacel from May 6, 2025 to the end of June. On July 7, 2025, Cyclacel, Fitters Parent
and the Company entered into Amendment No. 1 to Exchange Agreement to reflect this additional consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="cs_001"></span>Cyclacel
Reasons for the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating the Transaction, the Cyclacel board consulted with Cyclacel management, as well as its independent legal counsel and its financial
advisors and, in the course of reaching its decision (i) to approve and declare advisable the Exchange Agreement, the Transaction and
other transactions contemplated thereby and (ii) subject to the terms and conditions of the Exchange Agreement, to recommend that the
Cyclacel stockholders approve the issuance of Cyclacel common stock, the Cyclacel board considered a number of factors including these
key factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Strong
                                            Market Position</span>. The Cyclacel board considered the Company and its subsidiaries&#8217;
                                            industry-leading position within its key business line involving the manufacturing and trading
                                            of safety, firefighting equipment, industrial products, installation and maintenance of the
                                            Fire Department&#8217;s privatized Computerized Fire Alarm Monitoring System (&#8220;CMS&#8221;),
                                            contract for mechanical and electrical engineering works, corrective and preventive maintenance
                                            within the fire industry and specialty construction industry fire retardants;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Large
                                            and Growing Market Opportunity</span>. The Cyclacel board considered the Company and its subsidiaries&#8217;
                                            long-term market opportunity and growth potential within the Company&#8217;s key business
                                            lines;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Preferred
                                            Supplier to Multiple Key Customers</span>. The Cyclacel board considered the Company and its
                                            subsidiaries&#8217; long-standing relationships with key customers within its key business
                                            lines including fire retardants, renewable and waste-to-energy and property development and
                                            construction growth; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Innovation
                                            and Research and Development Track-record</span>. The Cyclacel board also considered the Company and its subsidiaries&#8217;
                                            long-standing track-record of innovation and customer value-enhancement, including the Company&#8217;s
                                            in-house research and development capabilities relating to both its products and the associated equipment
                                            including research and development that can be used to protect and keep people safe from
                                            risk of fire hazards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Cyclacel board also considered these material factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            opportunity for Cyclacel&#8217;s stockholders to participate in the benefits that are expected
                                            to result from the Transaction, including the expectation that the Transaction will create
                                            a premier fire services company better than either Cyclacel or the Company could do on their
                                            own;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
                                            management&#8217;s assessment that the proposed Transaction between Cyclacel and Fitters
                                            Parent is expected to benefit consumers by resulting in (i) greater capacity for the combined
                                            company to develop innovative fire services and products, (ii) expanded sales opportunity
                                            globally through expanded name recognition, and (iii) enhancement of the combined company&#8217;s
                                            technologies and capabilities, will allow the combined company to deliver a comprehensive
                                            offering to address diverse customer needs;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
                                            management&#8217;s belief that the Transaction would result in deleveraging of Cyclacel with
                                            cash generation to further strengthen the combined company&#8217;s financial profile and
                                            drive accelerated debt reduction and shareholder value creation;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
                                            management&#8217;s belief that the combined company would have a strengthened balance sheet
                                            and increased cash flow, in part as a result of synergies and accelerated deleveraging, that
                                            management believes will provide both the financial strength and flexibility to weather competitive
                                            challenges and provide a foundation for future growth;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
                                            management&#8217;s belief that the Transaction will be accretive to the combined company&#8217;s
                                            earnings and cash flow beginning in year two after the Transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
                                            management&#8217;s belief that the Transaction will meaningfully increase the public float
                                            of the combined company, thereby improving the combined company&#8217;s capital markets positioning;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel&#8217;s
                                            assessment of alternatives to the Transaction and the expectation that the Transaction will
                                            create a more relevant, innovative, competitive and financially successful business than
                                            Cyclacel would be able to create on a standalone basis;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
                                            management&#8217;s assessment that the proposed Transaction between Cyclacel and Fitters
                                            Parent presented attributes necessary for a successful acquisition, including strategic fit,
                                            acceptable execution risk, and financial benefits to Cyclacel&#8217;s stockholders;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            the combined company will benefit from an experienced and highly motivated management team;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">historical
                                            information concerning Cyclacel and Fitters Parent&#8217;s respective businesses, financial
                                            performance and condition, operations, management, competitive positions and stock performance,
                                            which comparisons generally informed Cyclacel board&#8217;s determination as to the relative
                                            values of Cyclacel, the Company and the combined company;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Cyclacel forecasts and the Company&#8217;s forecasts;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of Cyclacel&#8217;s due diligence review of the Company&#8217;s businesses and operations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            financial analyses presented by Strategic Capital Advisory Sdn. Bhd. (&#8220;Strategic Capital
                                            Advisory&#8221;), a highly specialized corporate finance services company retained by Cyclacel,
                                            rendered its written fairness opinion (the &#8220;Fairness Opinion&#8221;) to the Cyclacel
                                            board of directors, that, as of the date of such opinion, and based upon the various assumptions,
                                            qualifications and limitations set forth therein, that the fair value of entire equity interest
                                            of Fitters Parent and its subsidiaries is RM92.27 million to RM107.71 million, that translates
                                            to USD20.72 million to USD24.19 million, using the exchange rate of USD1.00 to RM4.453 as
                                            of the date of the written Fairness Opinion;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
                                            Capital Advisory&#8217;s conclusion that the purchase consideration falls within the ranges
                                            of values derived using the Discounted FCFF methodology, hence it is fair from a financial
                                            point of view, to the stockholders of Cyclacel. The full text of the written Fairness Opinion
                                            of Strategic Capital Advisory, dated April 8, 2025, which sets forth, among other things,
                                            the assumptions made, procedures followed, matters considered and limitations on the review
                                            undertaken by Strategic Capital Advisory in preparing its opinion, is attached as <i>Annex
                                            C</i> to this proxy statement/prospectus and is incorporated herein by reference. The summary
                                            of the Fairness Opinion of Strategic Capital Advisory set forth in this proxy statement/prospectus
                                            is qualified in its entirety by reference to the full text thereof;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            terms and conditions in the Exchange Agreement, including (i) that the parties agreed to
                                            use reasonable best efforts to obtain certain regulatory approvals related to the Transaction,
                                            (ii) that Datuk Dr. Doris Wong, Chief Executive Officer and acting Chair of the Cyclacel
                                            board, will serve on the Board of the Company, and (iii) that Cyclacel&#8217;s stockholders
                                            will own approximately 80.01% of the combined company immediately following the completion
                                            of the Transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the course of its deliberations, the Cyclacel board also considered the following risks and
                                            other countervailing factors related to entering into the Exchange Agreement that had previously
                                            been identified and discussed by Cyclacel management and the Cyclacel board:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential upside in Cyclacel&#8217;s stand-alone strategic plan to develop plogo and any
                                            other product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 63pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possibility of encountering difficulties in successfully integrating the Company&#8217;s
                                            business, operations with those of Cyclacel and in achieving the synergies and other benefits
                                            anticipated to result from the Transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk that the parties may not receive the necessary or advisable regulatory approvals or
                                            clearances to complete the Transaction, or the receipt thereof may materially delay consummation
                                            of the Transaction, or that governmental authorities could attempt to condition their approvals
                                            or clearances of the Transaction on one or more of the parties&#8217; compliance with certain
                                            burdensome terms or conditions that may cause one of the closing conditions to not be satisfied;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 63pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            fact that the Exchange Shares included in the Exchange Agreement provides for an amount of
                                            Exchange Shares of Parent Common Stock that are subject to adjustment before the Closing
                                            on mutual agreement of the Parties, which means Cyclacel cannot be sure of the market value
                                            of the Transaction consideration that it will pay to Fitters Parent in the Transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 63pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possibility that the Transaction might not be consummated for an extended period of time,
                                            which could lead to substantial costs incurred that could still result in a termination of
                                            the Exchange Agreement;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possibility that the Transaction might not be consummated, and the fact that if it is not
                                            consummated: (i) Cyclacel&#8217;s directors, executives and senior management will have expended
                                            extensive time and effort and will have experienced significant distractions from their work
                                            during the pendency of the transactions; (ii) Cyclacel will have incurred significant transaction
                                            expenses and opportunity costs; (iii) Cyclacel&#8217;s efforts to develop plogo in the interim
                                            period until the closing may be adversely affected; (iv) the trading price of Cyclacel&#8217;s
                                            stock could be adversely affected; (v) the market&#8217;s perceptions of Cyclacel and its
                                            prospects could be adversely affected; and (vi) Cyclacel&#8217;s business may be subject
                                            to significant disruptions and decline;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            diversion of the attention of the combined company&#8217;s management and other key employees
                                            by the integration process after the Closing of the Transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            substantial charges to be incurred in connection with the Transaction, including the costs
                                            of integrating the businesses of Cyclacel and the Company;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            challenge of integrating the workforces of Cyclacel and the Company while maintaining focus
                                            on providing consistent, high quality customer service and running the efficient operation
                                            of the combined company;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk that despite the Company&#8217;s and Cyclacel&#8217;s efforts and the efforts of the
                                            combined company after the Transaction, the Company, Cyclacel, and the combined company may
                                            not be able to retain key personnel;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            litigation may occur in connection with the Transaction and that such litigation could prevent
                                            the Transaction or increase costs related to the Transaction; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            other risks described above in the section entitled &#8220;Risk Factors&#8221; above in this
                                            proxy statement/prospectus.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing discussion of the information and factors considered by the Cyclacel board is not intended to be exhaustive but includes the
material factors considered by the Cyclacel board. In reaching its decision to approve and declare advisable the Exchange Agreement,
the Transaction and other transactions contemplated thereby, the Cyclacel board did not quantify or assign any relative weight to the
factors considered, and individual directors may have given different weights to different factors. The Cyclacel board considered all
these factors as a whole and overall considered the factors to be favorable to, and to support, its determination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Cyclacel board also realized that there can be no assurance regarding future results, including results expected or considered
in the factors listed above. However, the Cyclacel board concluded that the potential positive factors outweighed the risks and other
potentially negative factors associated with the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the reasons set forth above, the Cyclacel board unanimously (i) approved the terms of the Exchange Agreement and the Transaction, (ii)
determined that it is advisable to enter into the Exchange Agreement, (iii) approved the execution and delivery by Cyclacel of the Exchange
Agreement, the performance by Cyclacel of its covenants and agreements contained in the Exchange Agreement and the consummation of the
Transaction upon the terms and subject to the conditions contained therein, including the issuance of Cyclacel common stock, and (iv)
resolved to submit the issuance of Parent Common Stock to the stockholders of Cyclacel and to recommend approval of such stock
issuance in connection with the Transaction by the stockholders of Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
should be noted that the explanation of the reasoning of the Cyclacel board and certain information presented in this section are forward-looking
in nature and should be read in light of the factors set forth in the section entitled &#8220;Cautionary Statement Regarding Forward-Looking
Statements&#8221; above in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="cs_002"></span>Fairness
Opinion of Fitters Sdn. Bhd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
Capital Advisory Sdn. Bhd. (&#8220;Strategic Capital&#8221;) was appointed by the Board of Directors (&#8220;Board&#8221;) of Parent
as an expert to undertake an evaluation of the proposed acquisition of the entire equity interest in Fitters Sdn. Bhd. and its
subsidiaries for a purchase consideration of approximately USD22.50 million (the &#8220;Purchase Consideration&#8221;). On April 8,
2025, Strategic Capital Advisory rendered its written fairness opinion (the &#8220;Fairness Opinion&#8221;) to the Board, that, as
of the date of such opinion, and based upon the various assumptions, qualifications and limitations set forth therein, that the fair
value of entire equity interest of Fitters Parent and its subsidiaries is RM92.27 million to RM107.71 million, that translates to
USD20.72 million to USD24.19 million, using the exchange rate of USD1.00 to RM4.453 as of the date of the written Fairness Opinion.
Accordingly, Strategic Capital concluded that the purchase consideration falls within the ranges of values derived using the
Discounted Free Cash Flow to Firm (&#8220;FCFF&#8221;) methodology, hence it is fair from a financial point of view, to the
stockholders of Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sources of information which Strategic Capital used in its evaluation of Fitters Sdn. Bhd.. and its subsidiaries (&#8220;Target Co&#8221;)
are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audited
                                            financial statements of the Target Co for the financial year ended 31 March (&#8220;FYE&#8221;)
                                            2024;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Target Co&#8217;s management accounts for the 9-month financial period ended 31 December
                                            2024 (&#8220;9M-FPE 2024&#8221;);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Letter of Intent issued by Master Pyroserve Sdn Bhd (&#8220;MPSB&#8221;) to the Target Co
                                            for the maintenance service under the Sistem Pengawasan Kebakaran Automatik (&#8220;SPKA&#8221;)
                                            (&#8220;LOI&#8221;);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            financial forecast and projection of the Target Co from the FYEs 31 December 2025 to 31 December
                                            2031 (&#8220;Future Financials&#8221;) prepared by the management of the Target Co (&#8220;Management&#8221;);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation
                                            and explanation by the Management; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            publicly available information in respect of the industry that the Target Co is involved
                                            in.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
also &#8220;&#8212; Bases and Assumptions for Future Financials&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
Capital considered the following key developments in the Malaysian economy as extracted from quarterly bulletin for the fourth quarter
of 2024 (&#8220;4Q2024&#8221;) published by Bank Negara Malaysia,<sup>2</sup> as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Higher
                                            Gross Domestic Product growth of 5.0% in the 4Q2024, driven by domestic demand. Strong investment
                                            was underpinned by the continued realisation of new and existing projects. The factors supporting
                                            the growth in the 4Q2024 includes:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 45pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
                                            expansion in overall investment activities;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 45pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continued
                                            growth in exports of goods and services; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 45pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustained
                                            household spending.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            unemployment rate declined further to 3.2% in 4Q2024 (3Q2024: 3.2%). Employment rose to 16.8
                                            million persons in 4Q2024 (3Q2024: 16.7 million persons) amid continued demand for labour.
                                            Labour supply remained forthcoming as the labour force participation rate remained at a historical
                                            high of 70.6% in 4Q2024 (3Q2024: 70.5%);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
                                            headline and core inflation declined to 1.8% and 1.7%, respectively. Lower inflation
                                            was observed during the quarter for mobile communication services and petrol (RON97) but
                                            this was offset by higher inflation for food and beverages;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
                                            forward, the Malaysian economy is expected to remain resilient in 2025. Growth will be driven
                                            by robust expansion in investment activity, resilient household spending and continued expansion
                                            in exports. Investment activities will be driven by continued progress of multi-year projects
                                            in both the private and public sectors, higher realisation of approved investments and the
                                            implementation of catalytic initiatives under the national master plans. Employment and wage
                                            growth as well as policy measures, including the upward revision of the minimum wage and
                                            civil servant salaries, would remain supportive of household spending. Exports are expected
                                            to be supported by the global tech upcycle, continued growth in non-electrical and electronics
                                            goods and higher tourist spending. The growth outlook is subject to downside risks if growth
                                            in major trading partners slowed amid heightened risk of trade and investment restrictions,
                                            and lower-than-expected commodity production. Nevertheless, growth could potentially be higher
                                            from greater spillovers from the tech upcycle, more robust tourism activities, and faster
                                            implementation of investment project; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
                                            to date, both headline and core inflation averaged at 1.8%. Moving into 2025, inflation is
                                            expected to remain manageable amid easing global cost conditions and the absence of excessive
                                            domestic demand pressures. Global commodity prices are expected to continue to trend lower,
                                            contributing to moderate cost conditions in the near-term. In this environment, the overall
                                            impact of the recently announced domestic policy measures1 is expected to be contained.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bases
and Assumptions for Future Financials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
set forth in the Fairness Opinion, the Future Financials were prepared based on a set of assumptions made by Fitters Sdn. Bhd. (the &#8220;Management&#8221;),
which includes assumptions about future events and outlook that may or may not necessarily occur. In particular, the Future Financials
are dependent on the achievability of the specific assumptions as set out below. The FCFF for each financial year in the Future Financials
used to derive at the Discounted FCFF valuation are extracted from the estimate, forecast and projections based on the Management&#8217;s
best estimate, and includes the existing contracts as well as quotations provided to its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, we wish to highlight that the Discounted FCFF valuation is based on prevailing economic, market and other conditions as of
the date of the Fairness Opinion for valuation parameters, in addition to publicly available information and information provided by
the Target Co. Such conditions may change significantly over a short period of time. The resultant effect of such changes may materially
and/or adversely affect the valuation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup>
Source: <i>Bank Negara Malaysia (&#8220;BNM&#8221;) Quarterly Bulletin 4Q2024</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, the Future Financials are dependent on the achievability of the specific assumptions as set out below. The results of the
Future Financials can be materially affected by economic and other circumstances. The actual results may vary considerably from the Future
Financials. The Future Financials have been prepared on the bases consistent with the historical information provided by the Management,
of which the specific key assumptions are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Future Financials of the Target Co as provided by the Management are set out as follows:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2027</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2028</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2031</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,185</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,121</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,858</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,922</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91,121</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,776</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
    growth</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.7</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.3</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.8</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.6</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.2</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.2</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of sales</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,424</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,482</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33,481</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(46,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(67,395</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(98,329</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,511</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,761</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,639</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,377</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,726</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,446</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit margin</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenditure</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,400</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,599</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,830</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,422</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    before taxation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,798</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,912</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,141</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,813</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(179</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,631</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,227</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,579</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,114</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,933</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,195</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    after taxation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">568</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,166</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,218</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,027</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,623</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,618</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*Any
discrepancies in the table between the amount listed and totals thereof are due to rounding.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Target Co&#8217;s revenue can be further discussed in the following geographical manner:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2027</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2028</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FYE
    2031</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM&#8217;000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPKA</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,866</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,903</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,074</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FSSB</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">950</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">979</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,008</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,038</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,069</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,134</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyco</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,375</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,563</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,344</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemguard
    form</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,761</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,475</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,241</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,327</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
    apparel</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,107</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,972</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,554</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,550</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,185</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,121</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,858</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,922</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91,121</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,776</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Target Co has received the LOI from MPSB in relation to the SPKA Project, of which MPSB will
                                            award the maintenance services of the SPKA Project to the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            revenue contribution from FSSB is expected to grow by 3.0% per annum throughout the projected
                                            period;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
                                            of Tyco&#8217;s fire product. The Management has estimated an increase of 50.0% per annum
                                            throughout the projected period due to the booming of the data centers in Malaysia, particularly
                                            in Johor Bahru;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
                                            of Chemguard form concentrates. The Management has estimated an increase of 15.0% per annum
                                            throughout the projected period to serve the oil and gas industry; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
                                            of safety apparels of which the Management has estimated an increase of 60.0% per annum throughout
                                            the projected period.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
                                            profit margin is estimated to range from 20.0% to 34.2% throughout the projected period.
                                            gradually increase from approximately 61.5%.for the FYE 2025 to 64.3% for the FYE 2027. For
                                            information, the historical gross profit margin for the Target Co for the FYE 2024 and 9M-FPE
                                            2024 were 22.4% and 21.8%, respectively.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 58.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Target Co&#8217;s receivables and payables turnover days are estimated to be within 45 days
                                            and 45 days respectively, based on Management&#8217;s best estimate. For information, the
                                            historical receivables turnover days for the FYE 2024 and 9M-FPE 2024 were 87 days and 117
                                            days, whereas the historical payable turnover days for the FYE 2024 and 9M-FPE 2024 were
                                            36 days and 65 days. The Management represented that it will improve its cash management
                                            system in the future to mitigate its liquidity risk.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            operating cost comprises salaries which are expected to increase by 5.0% per annum throughout
                                            the projected period. Selling and distribution expenses are expected to increase by 30.0%
                                            per annum throughout the projected period. Others comprise administrative expenses, rental,
                                            professional fees, travelling expenses and premise cost are expected to increase by 10% per
                                            annum throughout the projected period.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 58.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
                                            expense is estimated based on the Malaysia&#8217;s corporate tax rate of 24.0%.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 58.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
                                            represented that there is no capital expenditure needed for the growth of the Target Co.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 58.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
Assumptions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no significant changes in the principal activities, key management personal, operating
                                            policies, accounting and business policies presently adopted by the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Future Financials have been prepared based on prevailing economic conditions and information
                                            available as at the date of its preparation and does not encompass any assessment of the
                                            potential for future changes in the economic conditions in Malaysia, Southeast Asia and globally;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no significant changes to the prevailing economic, political and market conditions
                                            in Malaysia, Southeast Asia and elsewhere that will have direct and indirect effects on the
                                            activities and performance of the Target Co and the business of the Target Co&#8217;s customers
                                            and suppliers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no material changes to the present legislation and government&#8217;s regulations
                                            and other operation regulations or restrictions affecting the Target Co&#8217;s activities
                                            or the market in which it operates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no significant changes in the credit period granted or received by the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            statutory income tax rate and other relevant duty and tax rate for the Target Co will remain
                                            at their respective existing rates with no significant changes in the bases of taxation and
                                            there will be no significant changes in the structure which would adversely affect the cash
                                            flows of the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no material adverse effect from service disruptions, equipment or network breakdown
                                            or other similar occurrences, wars, epidemic, terrorist attacks and other natural risks,
                                            both domestic and foreign, which will adversely affect the operations, income and expenditure
                                            of the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            rate of inflation will not fluctuate significantly from their projected levels;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.65pt; text-align: justify; text-indent: -28.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            exchange rate between RM and the various currencies in which the Target Co derives its income/expenses
                                            in will not fluctuate significantly from their projected levels;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            than the estimation made by the Management, there will be no substantial impairment to the
                                            carrying value of the Target Co&#8217;s investment, property, plant and equipment and other
                                            assets;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no significant changes in wages, supplies, administration, overhead expenses and
                                            other costs other than those forecasted and projected;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no termination of any significant agreements or contracts from which the legal rights
                                            accruing to the Target Co, in respect of the principal activities are derived; Such agreements
                                            or contracts are assumed to be renewed based on current terms upon expiry;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be adequate supply of manpower and other relevant resources to the Target Co for its
                                            business activities; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 50.85pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no major legal proceedings against the Target Co which will adversely affect the
                                            activities or performance of the Target Co or give rise to any contingent liability which
                                            will materially affect the financial position or business of the Target Co.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fire
Protection System Market Size</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Fairness Opinion, Strategic Capital wrote that the global fire protection system market size was valued at USD 68.90 billion in 2024.
The market is projected to grow from USD 71.97 billion in 2025 to USD 111.38 billion by 2032, exhibiting a compounded annual growth rate
(&#8220;CAGR&#8221;) of 6.4% during the forecast period. North America dominated the global market with a share of 35.63% in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
fire protection system is a comprehensive set of equipment, devices, and strategies designed to detect, control, suppress, and mitigate
fire hazards in buildings, structures, or various areas. It is an integrated network of devices and measures implemented to detect fire,
alert occupants, control smoke, suppress flames, and facilitate safe evacuation, with the ultimate goals of protecting life, minimizing
property damage, and reducing the impact of fire incidents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapid
urbanization and the development of commercial, industrial, and residential infrastructures necessitate the installation of fire protection
systems to ensure safety. The expansion of the construction industry, particularly in emerging economies, is leading to increased installations
of both active fire protection and passive fire protection systems in new buildings and structures. For instance, according to the Ceramic
World Web report, the construction sector in India increased by 13.3% in 2023 compared to 2022. Moreover, a rising number of fire cases
registered across the globe, which resulted in several injuries and deaths in recent years, creates the demand for such systems to ensure
safety in commercial and industrial premises. For instance, according to the National Safety Council, in the year 2022, around 1504,500
fire cases were registered globally, which caused 13,250 injuries and 3,790 deaths. Such a surge in the rising number of fire cases globally
drives the market growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Source:
https://www.fortunebusinessinsights.com/fire-protection-system-market-104820) </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
Methodology </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing its Fairness Opinion regarding the fairness of the Purchase Consideration, Strategic Capital has considered various methodologies,
which are commonly used for valuation, taking into consideration the Target Co&#8217;s business sustainability, subsequent income generating
capabilities as well as associated risks affecting its business. Amongst the vast variety of valuation methodologies, Strategic Capital
has considered and selected the Discounted Free Cash Flow to Firm (&#8220;FCFF&#8221;) to form an opinion on the fairness of the Purchase
Consideration as the underlying value of Target Co is likely to be derived from its future business operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
Capital also considered other valuation methodologies and found that the following methodologies are not suitable in forming an opinion
on the fairness of the Purchase Consideration based on the following factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Relative
                                            Valuation Analysis (&#8220;RVA&#8221;)</span> &#8212; RVA method seeks to compare a company&#8217;s
                                            implied trading multiple to that of comparable companies to determine the firm&#8217;s financial
                                            worth. Based on the Target Co&#8217;s audited financial statements for the FYE 2024, the
                                            Target Co registered a profit after tax of approximately RM357,135. As the Target Co is in
                                            the growth stage and has recently received the LOI from MPSB of which MPSB has participated
                                            in the tender for &#8220;<i>Perkhidmatan, Merancang, Menbangun, Membekal, Memasang, Menguji,
                                            Mentauliah, Mengoperasi, Menyelenggara dan Menaiktaraf SPKA kepada Jabatan Bomba dan Penyelamat
                                            Malaysia</i>&#8221; (&#8220;SPKA Project&#8221;). Management represented that the chance
                                            of securing such contract is encouraging. Hence, Strategic Capital opined that the RVA method
                                            is not appropriate to be used in this Proposed Evaluation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revalued
                                            Net Asset Valuation (&#8220;RNAV&#8221;)</span> &#8212; RNAV method seeks to adjust the net
                                            asset value of a company to take into consideration the valuation of assets of a company
                                            to determine the adjusted value of the firm&#8217;s financial value. Based on the Target
                                            Co&#8217;s audited financial statements as at 31 March 2024, the Target Co&#8217;s property,
                                            plant and equipment attributed to approximately 2.6% of its total assets. Hence, RNAV may
                                            not accurately reflect the potential and market value of the Target Co.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Discounted
FCFF Methodology </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Discounted FCFF Methodology is a commonly used investment appraisal technique to evaluate the attractiveness of an investment opportunity
which takes into consideration, amongst others, the time value of money as well as future cash flows to be derived from the business
over a specific period of time. Discounted FCFF Methodology is a valuation method which considers both the time value of money and the
projected net cash flow generated discounted at a specified discount rate to derive at the valuation of the subject matter. It is based
on discounted cash flows, involving the application of an appropriately selected discount rate applied on the projected future cash flows
to be earned by the capital contributors of a company, i.e., equity shareholders and debt capital providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Discounted FCFF methodology entails the discounting of future cash flows to be generated from the business at a specified discount
rate to arrive at the fair value of the investment, the risk involved in generating such cash flows will also be taken into consideration.
FCFF is the free cash flows available to be paid to the capital contributors of the company after all expenses and reinvestment cost.
The projected FCFF as determined annually based on the Future Financials shall be discounted using the WACC. The WACC formula is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>WACC
= [Cost of Equity X Equity / Capital] + [Cost of Debt X Debt / Capital X (1 &#8211; Corporate Tax Rate)]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of equity takes into account a combination of risk factors associated with the industry in which the Target Co are involved in,
namely, the systematic risk, i.e., the inherent market risk such as the interest rate fluctuation, and the capital structure,
i.e., the financing risk. These risks are translated into the cost of equity which is built upon the Capital Asset Pricing Model
(&#8220;CAPM&#8221;). The cost of equity formula is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of equity = Risk-Free Rate + [Re-geared Beta X (Market Return &#8211; Risk-Free Rate)] </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of the Discounted FCFF methodology, reference was made to valuation of public listed companies on Bursa Malaysia Securities
Berhad (&#8220;Bursa Securities&#8221;) and the stock exchanges in Southeast Asia which are principally engaged in the trading of fire
material and equipment and related products. Based on the above criteria, three (3) comparable companies listed on Bursa Securities,
Shenzhen Stock Exchange (&#8220;SZSE&#8221;) and the Stock Exchange of Thailand (&#8220;SET&#8221;) were selected on the basis that the
risks and structure of the industry of which Target Co is operating in are similar (&#8220;Comparable Companies&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Analysis
of Selected Publicly Traded Companies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
arriving at the appropriate discount rate for the Target Co, Strategic Capital applied the prevailing risk-free rate and market risk
premium, as well as adopted the betas of available Comparable Companies with relevant adjustments made taking into consideration the
gearing and the risk profile as well as other risk factors that may affect the Target Co. All information obtained was sourced from S&amp;P
Capital IQ as of the date of the Fairness Opinion unless stated otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of determining the fairness of the Purchase Consideration, the Comparable Companies&#8217; beta is adjusted (de-geared) for
its gearing ratio, and then re-geared based on the median net gearing level of the Comparable Companies. It is important to note that
the Comparable Companies tabulated in the Fairness Opinion are by no means exhaustive and may differ from the Target Co in terms of,
<i>inter alia</i>, composition of business activities, scale of operations, geographical location of operations, profit track record,
financial profile, risk profile, future prospects, capital structure, marketability of their securities and other criteria. One should
also note that any comparisons made with respect to the Comparable Companies are merely to provide an indication to the implied valuation
of the Target Co and the selection of Comparable Companies and adjustments made are highly subjective and judgmental and the selected
companies may not be entirely comparable due to various factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Comparable Companies and the input parameters for CAPM as of the date of the Fairness Opinion are set out as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparable
    Companies</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    activities</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unique
    Fire Holdings Berhad (&#8220;Unique&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bursa
    Securities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engages
    in the manufacture, assembly, and distribution of active fire protection systems, equipment, and accessories for the built environment.
    The company offers filling series for fire extinguisher; fire extinguishers; fire hose reels; fire hydrant systems; sprinkler systems;
    fire detection and alarm devices; fire suppression systems; carbon dioxide fire extinguishing system; wet chemical fire suppression
    systems; fire blanket and smoke curtain; home safety kit; design fire extinguisher; unique5112 systems; wet and dry riser systems,
    and hydrant; fire hoses; and batteries, cabinets, and fire blankets, as well as home safety kits. It also provides dry chemical fire
    extinguisher refilling machines, as well as fire protection equipment services.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jade
    Bird Fire Co., Ltd (&#8220;Jade&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SZSE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develops,
    manufactures, and sells professional fire safety electronic products and fire safety systems in China and internationally. The company
    offers fire safety system products, including automatic fire alarm and linkage control; electricity fire safety system products,
    such as gas fire monitoring, automatic gas fire extinguishing, and gas detection and monitoring systems, as well as fire cloud platform.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harn
    Engineering Solutions Public Company Limited (&#8220;Harn&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SET</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Design,
    install, designs, and distributes fire protection systems and fire suppression products in Thailand. It offers sprinklers, fire hose
    cabinets, floor control valves, pump room, and fire extinguishers for fire protection and safety</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Comparable Company</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market Cap<br/>
 (RM million)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Levered Beta</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Debt/ Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unlevered Beta</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Unique</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">148.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1.21</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1.45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Jade</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,350.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.58</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.03</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Harn</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">159.91</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15.03</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.62</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Median</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">13.58</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1.03</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of the Fairness of the Purchase Considerations </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fairness of the Purchase Consideration, and based on the Discounted FCFF Methodology using the Future Financials as provided
by the Management and the inputs from the Comparable Companies, the following were noted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 1in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WACC
    Inputs</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
    Net Debt/Equity Ratio of Comparable Companies</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.36%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free
    Rate<sup>[1]</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.76%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    return<sup>[2]</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.54%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-geared
    Beta<sup>[3]</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Illiquidity
    Premium<sup>[4]</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.00%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of equity derived using CAPM</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.39%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of debt<sup>[5]</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.75%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WACC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.30%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enterprise
    Value (&#8220;EV&#8221;) of the Target Co @ RM</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM97.42
    million</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-left: #84E290 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EV
    of the Target Co @ USD<sup>[6]</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD21.88
    million</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on the risk-free rate for Malaysia as extracted from http://www.bnm.gov.my. This risk-free
                                            rate is based on the yield of ten (10) years Malaysian Government Securities as of the date
                                            of the Fairness Opinion.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[2]</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on the historical average market return for Malaysia as extracted from Bloomberg. The historical
                                            average market return is based on the average return of FTSE Bursa Malaysia Top 100 Index
                                            for the past ten (10) years extracted on the date of the Fairness Opinion.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[3]</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-geared
                                            beta is arrived at based on the net debt/equity ratio of Comparable Companies.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[4]</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            illiquidity premium of 4.0% had been applied to derive the discount rate using CAPM to account
                                            for the lack of marketability and unsystematic risk as extracted from:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">http://people.stern.nyu.edu/adamodar/pdfiles/country/illiquidity.pdf</span>.</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[5]</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on the lending rate as extracted from Bank Negara Malaysia.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[6]</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on the exchange rate extracted from Bank Negara Malaysia as of the date of the Fairness Opinion
                                            of USD1.00: RM4.4530</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the underlying assumptions of the Future Financials, Strategic Capital performed a sensitivity analysis on three key parameters, namely
the discount rate, terminal value and FCFF as these assumptions have significant impact on the implied valuation of the Target Co. Strategic
Capital stress tested the Future Financials by varying the values adopted in the discount rate, terminal value and FCFF on a 0.5% and
3.0% upward and downward variance respectively on the midpoint of the valuation to arrive at a reasonable range of equity valuation of
the Target Co. The variance parameters for the discount rate, terminal value and FCFF are selected after considering the followings:-</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">World
                                            Bank had projected that Malaysia&#8217;s GDP to grow by 4.3% in 2024;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27.35pt; text-align: justify; text-indent: -9.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headline
                                            and core inflation are projected to remain moderate between 2% &#8210; 3.5% and 2.0% &#8210;
                                            3.0%, respectively. (<i>Source: Economic and Financial Developments in Malaysia in the First
                                            Quarter of 2024: Bank Negara Malaysia</i>);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27.35pt; text-align: justify; text-indent: -9.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            average annual real GDP growth for Malaysia from year 2014 to 2023 is 4.1% as extracted from
                                            the World Bank. Malaysia&#8217;s GDP growth for 2021, 2022 and 2023 were 3.3%, 8.7% and 3.7%
                                            respectively; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27.35pt; text-align: justify; text-indent: -9.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            average annual inflation rate for Malaysia from year 2014 to 2023 is 2.0% as extracted from
                                            World Bank. Malaysia&#8217;s inflation rate for 2021, 2022 and 2023 were 2.5%, 3.4% and 2.5%,
                                            respectively.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the above, Strategic Capital is of the opinion that the 0.5% and 3.0% upward and downward variance adopted for the discount rate,
terminal value and FCFF is reasonable to take into consideration the range of possible fluctuations in the business to not only take
into consideration the potential upsides but also the downturn due to unforeseen circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
    of the sensitivity test is as shown below:-</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic
    value</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitivity
    test Parameters</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
    range of value <br/>RM million</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High
    range of value RM million</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement
    in discount rate used (&#177;0.5%)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95.06</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement
    in terminal value (&#177;3.0%) and discount rate (&#177;0.5%)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93.43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement
    in FCFF (&#177;3.0%) and discount rate (&#177;0.5%)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107.71</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conclusion</span>
- Premised on the above, Strategic Capital concluded that the fair value of entire equity interest of the Target Co ranges from RM92.27
million to RM107.71 million, this shall translate to USD20.72 million to USD24.19 million using the exchange rate of USD1.00: RM4.453
as at the date of the Fairness Opinion. Strategic Capital concluded that the Purchase Consideration falls within the ranges of values
derived using the Discounted FCFF methodology, hence it is FAIR from a financial point of view to the holders of the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_044"></span>Fitters
Parent Reasons for the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of reaching its decision to approve the Transaction, the board of Fitters Parent (the &#8220;Fitters Parent Board&#8221;)
consulted with its senior management, financial advisors and legal counsel, reviewed a significant amount of information and
considered a number of factors including its due diligence of Cyclacel. In reaching its decision to approve the Exchange Agreement
and the transactions contemplated by the Exchange Agreement, Fitters Parent Board considered a range of factors, including, but not
limited to, the factors discussed below. In light of the complexity of such factors, Fitters Parent Board, as a whole, did not
consider it practicable nor did it attempt to quantify or otherwise assign relative weights to the specific factors it took into
account in reaching its decision. Individual members of Fitters Parent Board may have given different weight to different factors.
The explanation of the reasons for the approval by Fitters Parent Board of the Transaction, and all other information presented in
this section, is forward-looking in nature and, therefore, should be read in light of the factors discussed in the section entitled
&#8220;<i>Cautionary Note Regarding Forward-Looking Statements.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
reaching its decision, the Fitters Parent Board discussed the results of the due diligence conducted by Fitters Parent&#8217;s
management and legal counsel, which included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            expectation that the Transaction would be a more time- and cost-effective means to access
                                            capital than other options considered;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential to provide its current shareholders with greater liquidity by owning stock in a
                                            public company;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            fact that Exchange Shares of Parent Common Stock issued to Fitters Parent will be
                                            registered pursuant to a registration statement on Form S-4 by Parent and will become freely
                                            tradable for Fitters Parent;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            likelihood that the Transaction will be consummated on a timely basis;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Fitters Parent Board&#8217;s belief that Parent has a strong management team experienced in its
                                            industry, which is expected to remain with the post-Transaction combined company to seek
                                            to execute the Company&#8217;s strategic and growth goals;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            financial and other terms of the Exchange Agreement and the fact that such terms and conditions
                                            are reasonable and were the product of arm&#8217;s length negotiations between the Parties
                                            thereto;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
                                            of Parent&#8217;s material contracts, intellectual property, financial, tax, legal, and accounting
                                            due diligence;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meetings
                                            and calls with the management team and advisors of Parent regarding operations and forecasts;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consultations
                                            with Parent&#8217;s management and legal and financial advisor, ARC;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
                                            of Parent&#8217;s audited and unaudited financial statements;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
                                            on comparable transactions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            expenses to be incurred in connection with the Transaction and related administrative challenges
                                            associated with combining the companies; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">various
                                            other risks associated with the company and the Transaction, including the risks described
                                            in the section entitled &#8220;<i>Risk Factors</i>&#8221; in this proxy statement/prospectus.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
considering the valuation reached by Strategic Capital of RM92.27 million to RM107.71 million (that translates to USD20.72 million to
USD24.19 million using the exchange rate of USD1.00: RM4.453), the Fitters Parent Board primarily relied upon on the Fitters Parent&#8217;s
management and legal counsel research and due-diligence based perspective that the transaction would provide its shareholders with an
approximate 19.99% ownership interest in the combined company. Fitters Parent&#8217;s management conveyed to the Fitters Parent Board
their perspective that the purchase price for Fitters Parent, in combination with Fitters Parent&#8217;s projected financial performance
based on the Fitters Parent&#8217;s management due diligence, would result in greater returns for Fitters Parent&#8217;s shareholders
over a ten-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Fitters Parent Board further considered and discussed the assumptions underlying the Fitters Parent&#8217;s management long-term
financial projections including the assumptions for long-term (i) Fire Safety volume growth, (ii) Fire Safety price growth, (iii)
Fire Safety new business initiatives, and (iv) productivity (cost). In approving the Transaction, Fitters Parent Board determined to
rely on the Fairness Opinion from Strategic Capital, a highly specialized corporate finance services company retained by Cyclacel
rather than procuring its own valuation or fairness opinion. In addition, the officers and directors of Fitters Parent have
substantial experience in evaluating the operating and financial merits of companies from a wide range of industries and concluded
that their experience and background enabled them to make the necessary analyses and determinations regarding the
Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing information and factors considered by Fitters Parent Board are not intended to be exhaustive, but are believed to include all
of the material factors considered by Fitters Parent Board. In considering the factors described above, individual members of Fitters
Parent Board may have given different weight to different factors. Fitters Parent Board conducted an overall analysis of the factors
described above, including thorough discussions with, and questioning of, Fitters Parent&#8217;s management and Fitters Parent&#8217;s
legal advisors, and considered the factors overall to be favorable to, and to support, its determination.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_045"></span>Interests
of the Directors and Executive Officers of Cyclacel Pharmaceuticals in the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
considering the recommendation of the Cyclacel board of directors that its stockholders vote to approve the Transaction, stockholders
should be aware that certain of our current directors and executive officers have interests in the Transaction that are different
from, or in addition to, the interests of our stockholders generally. Specifically, Datuk Dr. Doris Wong, Cyclacel&#8217;s chief executive
officer and executive director owns approximately seven (7%) percent of the issued and outstanding ordinary shares of Fitters Parent.
The members of the Cyclacel board of directors were aware of the different or additional interests and considered these interests, among
other matters, in evaluating and negotiating the Exchange Agreement, and in recommending to stockholders that the Transaction be approved.
See &#8220;<i>The Transaction&#8212;Cyclacel Reasons for the Transaction</i>&#8221; above in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
should take these interests into account in deciding whether to vote &#8220;<b>FOR</b>&#8221; the Proposals. These interests are described
in more detail below, and certain of them are quantified in the narrative and the tables below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Parent&#8217;s
Executive Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
names and positions of our executive officers as of the date of this proxy statement/prospectus are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk Dr. Doris Wong, Chief
  Executive Officer and Executive Director; and</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu Cu Seng, Chief Financial
  Officer, Executive Director and Secretary,</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Parent&#8217;s
Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
names of our non-employee independent directors as of the date of this proxy statement/prospectus are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwang Fock Chong;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dr. Satis Waran Nair Krishnan; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo Angel Laurduraj.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transactions
with Parent&#8217;s Executive Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2025, David E. Lazar, our previous interim co-Principal Financial Officer and Principal Accounting Officer and former interim
Chief Executive Officer, entered into a securities purchase agreement (the &#8220;Wong Purchase Agreement&#8221;) with Datuk Dr. Wong,
our Chief Executive Officer and Executive Director, pursuant to which Datuk Dr. Wong agreed to purchase 1,000,000 shares of Series C
Convertible Preferred Stock of the Company, $0.0001 par value per share (the &#8220;Series C&#8221;) and such number of the 2,100,000
shares of Series D Convertible Preferred Stock of the Company, $0.0001 par value per share (the &#8220;Series D&#8221;) held by Mr. Lazar
so that Datuk Dr. Wong shall hold seventy percent (70%) of the issued and outstanding shares of the Company, which resulted in the issuance
of 1,745,262 shares of Series D (collectively, the Series C and Series D are the &#8220;Lazar Securities&#8221;). The transaction contemplated
by the Wong Purchase Agreement closed on February 26, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the sale of the Lazar Securities, Datuk Dr. Wong delivered $6,300,000 less the holdback amount of $100,000 to the escrow
agent. The Purchase Price included a cash brokerage fee in the amount of $800,000 paid to Lighthouse Advisory Limited. The holdback amount
will be held back by Datuk Dr. Wong for 120 days from the closing date to satisfy any indemnity and other agreed upon claims and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Lazar Securities were convertible into shares of Common Stock at the election of Datuk Dr. Wong. On the closing date, Datuk Dr. Wong
exercised the conversion rights related to the Series C and Series D shares into Common Stock as follows: (i) the conversion of 1,000,000
shares of Series C into 2,650,000 shares of Common Stock; and (ii) the conversion of 1,745,262 shares of Series D into 799,911
shares of Common Stock, or an aggregate of 810,953 shares of Common Stock. The Lazar Securities were sold in a transaction exempt
from registration under Regulation S of the Securities Act of 1933, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the transaction, Datuk Dr. Wong had no affiliation with the Company. Datuk Dr. Wong is not in the business of purchasing and selling
securities and did not acquire the Series C and Series D with the intent to distribute them on behalf of the Company. The transaction
with Mr. Lazar was a negotiated arm&#8217;s length bona fide transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2025, David Lazar exercised his conversion rights with respect to his 354,738 Series D shares in exchange for 162,588
shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows grants of stock options outstanding on the last day of the fiscal year ended December 31, 2024, to former executive
officers of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Options Exercisable</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Options Unexercisable</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
                                            Exercise Price<sup>(1)</sup></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option
    Expiration Date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Spiro Rombotis</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"/><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup></sup></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"/><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,120.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">01/04/2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,552.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12/11/2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">52</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,420.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12/13/2031</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,088.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">06/27/2033</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Paul McBarron</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup></sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,120.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">01/04/2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,552.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12/11/2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,420.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12/13/2031</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,088.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">06/27/2033</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option exercise price is the closing price of our Common Stock on The Nasdaq Capital Market
                                            on the date the option was granted.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            options were granted on December 7, 2015, and vest ratably on a monthly basis over 36 months.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            performance criteria were deemed to have been met in 2018 and 2019, and as such, performance-based
                                            options granted in 2017 and 2018 vested.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            options were granted on January 4, 2019 and included part of the 2018 bonus award, and vest
                                            ratably on a monthly basis over 36 months.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            options were granted on December 11, 2020, and vest ratably on a monthly basis over 36 months.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            options were granted on December 13, 2021, and vest ratably on a monthly basis over 36 months.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            options were granted on June 27, 2023, are performance based vesting, and will lapse May
                                            7, 2025 due to performance criteria not being met.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
Payments Upon Termination or Change-in-Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
has entered into agreements that require us to make payments and/or provide benefits to certain of our executive officers in the event
of a termination of employment or change-in-control. Our 2006 Equity Incentive Plan, or 2006 Plan, our 2015 Equity Incentive Plan, or
2015 Plan, our 2018 Equity Incentive Plan, or 2018 Plan, and our 2020 Inducement Equity Incentive Plan, or 2020 Plan (and collectively
with the 2006 Plan, 2015 Plan, and 2018 Plan, &#8220;the Plans&#8221;) provide for payments to named executive officers in connection
with a termination or a change-in-control of the Company. All of such agreements that require us to make payments and/or provide benefits
to certain of our executive officers in the event of a termination of employment or change-in-control have terminated. The Transaction
will not be a sale of more than 50% of the total voting power of the stock of Parent and, therefore, will not be a change of control
for this purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive
Officer and Director Compensation </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with their service to the Cyclacel and on the board of directors, each of our executive officers and non-employee directors
was granted a monthly cash fee during the director&#8217;s service on the board of directors. None of the agreements with each of our
executive officers and non-employee directors provide for any severance payments or stock option awards upon termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Appointment
of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Parent&#8217;s 2025 Annual Meeting schedule for June 30, 2025, the Parent&#8217;s stockholders will be able to vote on whether to
re-elect each of Datuk Dr. Doris Wong, Kiu Cu Seng, Kwang Fock Chong, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj, nominees
to our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Indemnification
of Directors and Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) provides, in general, that a corporation incorporated under the
laws of the State of Delaware, as we are, may indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding (other than a derivative action by or in the right of the corporation) by reason of the
fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys&#8217; fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding
if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the
corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was
unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of a derivative action, a Delaware corporation may indemnify any such person against expenses (including attorneys&#8217; fees)
actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted
in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, except
that no indemnification will be made in respect of any claim, issue or matter as to which such person will have been adjudged to be liable
to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or any other court in which such
action was brought determines such person is fairly and reasonably entitled to indemnity for such expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VIII of our certificate of incorporation, as amended, states that to the fullest extent permitted by the DGCL, a director of the corporation
shall not be liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Article IX of our certificate of incorporation, any person who was or is made a party or is threatened to be made a party to or is in
any way involved in any threatened, pending or completed action suit or proceeding, whether civil, criminal, administrative or investigative,
including any appeal therefrom, by reason of the fact that he is or was a director or officer of ours or was serving at our request as
a director or officer of another entity or enterprise (including any subsidiary), may be indemnified and held harmless by us, and we
may advance all expenses incurred by such person in defense of any such proceeding prior to its final determination, if this person acted
in good faith and in a manner reasonably believed to be in and not opposed to our best interest, and, with respect to any criminal action
or proceeding, the indemnified party had no reason to believe his or her conduct was unlawful. The indemnification provided in our bylaws
is not exclusive of any other rights to which those seeking indemnification may otherwise be entitled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out
of claims based on acts or omissions in their capacities as directors or officers. Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or
otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
Employment Agreements Following the Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange Agreement does not impose any requirements on Parent regarding retention or compensation of its employees such as our
executive officers. At this time, it is expected that certain of our executive officers may enter into employment, consulting or compensation
agreements with Parent or Fitters Parent between the date of this proxy statement/prospectus and the closing of the Transaction. The
terms of these potential arrangements have not been finalized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_046"></span>Interests
of the Directors and Executive Officers of Fitters Sdn. Bhd. in the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Parent should be aware that certain members of the board of directors of Fitters may have an interest in the Transaction that
may differ from, or be in addition to, interests of Fitters Parent or its directors and executive officers. Fitters Parent&#8217;s board
of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching their respective
decisions to approve the Exchange Agreement, the Transaction and related transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of Fitters&#8217; directors is expected to serve after the Closing of the Transaction with the addition of Datuk Dr. Doris Wong, our
chief executive officer, who currently holds Fitters Parent common shares. The table below sets forth the anticipated ownership of Fitters
Parent common shares by the Company&#8217;s directors and executive officers immediately prior to the closing of the Transaction based
on their ownership of as of July 10, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Fitters
    Parent Director or Officer Name</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Company<br/>
    Shares<br/> Owned Prior to the Closing</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Parent<br/>
    Common Stock to be<br/> issued at the Closing</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Chin Yong Shing</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pang Wei Kang</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management
Following the Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described elsewhere in this proxy statement/prospectus, including in the section entitled &#8220;<i>Management Following the Closing
of the Transaction</i>&#8221; of this proxy statement/prospectus, certain of the Company&#8217;s directors are expected to remain directors
of the Company after the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_047"></span>Form
of the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Transaction, each outstanding Company Ordinary Shares will be exchanged for Parent Common Stock as described
in more detail in this proxy statement/prospectus. After completion of the Transaction, assuming the Proposals are approved by Parent
stockholders at the special meeting, Cyclacel will be renamed &#8220;Bio Green Med Solution, Inc.&#8221; and it is expected that the
common stock of the company will trade on The Nasdaq Stock Market under the symbol &#8220;BGMS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_048"></span>Transaction
Consideration and the Exchange Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Transaction, $1,000,000 in cash consideration, or such other amount as mutually agreed upon, will be paid to Fitters Parent and each outstanding ordinary
share of the Company will be exchanged for shares of Parent Common Stock (the &#8220;Exchange Shares&#8221;). No fractional shares
of Parent Common Stock will be issued in connection with the Transaction. Instead, all fractional shares of Parent Common Stock
issuable to Fitters Parent will be aggregated and will be rounded up into one full share of Parent Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of Exchange Shares is calculated using a formula intended to allocate to Fitters Parent, a percentage of the company. The number
of Exchange Shares has been estimated to result in Fitters Parent owning approximately 19.99% of Parent Common Stock and current
Parent stockholders are expected to own approximately 80.01% of Parent Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_049"></span>Stock
Options and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
stock options that are outstanding immediately prior to the effective time will remain outstanding following the effective time of the
Transaction. Parent warrants to purchase shares of Parent Common Stock that are outstanding immediately prior to the effective
time of the Transaction will remain outstanding following the effective time of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_050"></span>Closing
Time of the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction will be completed as promptly as practicable after all of the conditions to completion of the Transaction are satisfied or
waived, including the approval of the stockholders of Cyclacel. Cyclacel and Fitters Parent are working to complete the Transaction as
quickly as practicable. However, Cyclacel and Fitters Parent cannot predict the exact timing of the completion of the Transaction because
it is subject to various conditions. After completion of the Transaction, assuming Cyclacel receives the required stockholder approval
of the Proposals, Cyclacel will be renamed &#8220;Bio Green Med Solution, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_051"></span>Regulatory
Approvals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
must comply with applicable federal and state securities laws and the rules and regulations of The Nasdaq Stock Market in connection
with the issuance of shares of Parent Common Stock in the Transaction and the filing of this proxy statement/prospectus with the
SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Malaysia, Fitters Parent shall have complied with all applicable Bursa Malaysia Securities Berhad Main Market Listing Requirements, including
any required notices to Bursa Malaysia and other necessary approvals regarding the transactions contemplated under this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_052"></span>Material
Malaysian Tax Considerations to the Company&#8217;s Shareholder Related to the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the expected material Malaysian tax consequences of the Transaction to Fitters Parent. The summary
does not purport to be a comprehensive description of all of the tax considerations that may be relevant to the Company&#8217;s shareholder.
The summary is based on Malaysian tax law and the practice of the Inland Revenue Board of Malaysia currently in force in Malaysia. Legislative,
administrative or judicial changes may modify the tax consequences described below, possibly with retrospective effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary deals with shareholder of the Company who legally and beneficially own shares in the Company. The summary does not constitute
tax or legal advice and the comments below are of a general nature only. Fitters Parent should consult its professional
advisers on the Malaysian tax implications of the Transaction and the tax implications in other relevant jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary does not address the Malaysian tax consequences resulting from shares being attributable to (i) a permanent establishment outside
of the shareholder&#8217;s country of residence, or (ii) a permanent representative outside of the shareholder&#8217;s country of residence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the discussion relates to matters of Malaysian tax law, it represents the opinion of our Malaysian counsel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax in Malaysia</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal legislation that governs an entity&#8217;s income tax in Malaysia is the Income Tax Act 1967 (the &#8220;ITA&#8221;). The regulatory
body implementing and enforcing the ITA is the Inland Revenue Board of Malaysia (&#8220;IRB&#8221;). Pursuant to Section 3 of the ITA,
income tax shall be charged for each year of assessment (&#8220;YA&#8221;) upon the income of any entity accruing in or derived from
Malaysia or received in Malaysia from outside Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 8 of the ITA, a company is a tax resident in Malaysia if its management and control are exercised in Malaysia. Management
and control are normally considered to be exercised at the place where the directors&#8217; meetings concerning management and control
of the company are held. The income tax rate payable by a resident company differs depending on the amount of the company&#8217;s paid-up
capital and its annual sale in relation to the particular YA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Fitters Parent&#8217;s main business activities are focused in Malaysia and its management and control are also in Malaysia, Fitters
Parent is categorized as a Resident company with its tax residency in Malaysia and is subject to pay an income tax at the rate of 24%
from its chargeable income for the particular YA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign-Sourced
Income &amp; Transaction Consideration</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia&#8217;s
taxation regime is territorial in principle, where income accruing in or derived from or received in Malaysia from outside Malaysia is
subject to income tax in Malaysia pursuant to Section 3 of the ITA. Previously, certain foreign-sourced income were exempted from income
tax due to the tax exemption pursuant to Paragraph 28, Schedule 6 of the ITA. This was subsequently removed with effect from January
1, 2022 pursuant to an announcement on the Malaysian Budget 2022. Therefore for the purposes of the Transaction, income derived by a
Malaysian Resident company from an overseas entity or from overseas activities outside Malaysia are taxable under the ITA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
view of the nature of the Transaction, Fitters Parent do not anticipate any income tax to be payable under Section 3 of the ITA for receiving
the Transaction Consideration in the form of common stock of Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
Gains Tax at the Time of the Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Malaysian Budget 2024 has introduced a new form of tax to Malaysia&#8217;s tax landscape now known as the Capital Gains Tax (&#8220;CGT&#8221;).
The CGT was gazetted via the Finance (No. 2) Act 2023 which made amendments to the ITA and came into effect beginning January 1, 2024
which was designed to levy taxes on profits derived from the sale of capital assets, including stocks, bonds, real estate and other investments.
For the purpose of the Transaction, the disposal of the common shares in the Company is known as a disposal of shares in an unlisted
Malaysian company which falls under the category of CGT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prevailing rate of CGT currently stands at 10% of the net gain of the disposal of the capital asset while there would be no CGT chargeable
for any loss or lack of net gain on disposal of the capital asset. Under Malaysian tax law, the Transaction is considered as a disposition
of the Company shares at fair market value and the acquisition of shares of Parent Common Stock at the same value, therefore the
net effect of the Transaction would result in a zero net gain for Fitters Parent. In view of the above, Fitters Parent opines that there
would be no CGT chargeable on the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stamp
Duty</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Stamp Duty is a form of tax chargeable on all transactional or non-transactional legal, commercial and/or financial instruments in Malaysia
pursuant to the Stamp Act 1949. Fitters Parent anticipates to be responsible for the <i>ad valorem </i>stamp duty on the transfer of
share form at the prevailing rate of 0.3% or a rate to be assessed by the IRB premised on the book value of the ordinary shares of the
Company or from the market value of the Transaction Consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_053"></span>Material
U.S. Federal Income Tax Consequences of the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 92; Options: NewSection; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a discussion of material U.S. federal income tax consequences of the Transaction applicable to Cyclacel (Parent), Fitters
Parent, and holders, immediately prior to the Transaction, of Fitters Parent shares. It is
not a complete analysis of all potential tax effects of the Transaction. The effects of other U.S. federal tax laws, such as estate and
gift tax laws, and of applicable state, local, and non-U.S. tax laws, are not discussed. This discussion is based on the Internal Revenue
Code of 1986, as amended, or the Code, U.S. Treasury Regulations promulgated thereunder, or the Regulations, judicial decisions, and
published rulings and administrative pronouncements of the Internal Revenue Service, or the IRS, each in effect as of the date of this
registration statement. Such authorities may change or be subject to differing interpretations, and any such change may be applied retroactively
in a manner that could adversely affect a holder of the Company common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the discussion in this section (<i>Material U.S. Federal Income Tax Consequences of the Transaction</i>) relates to the
treatment of the Transaction as a taxable sale or other disposition within the meaning of Section 1001 of the Code and to the
U.S. federal income tax consequences of the Transaction to Holders of Parent shares immediately before the Transaction, it represents
the opinion of our United States counsel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
counsel expresses no opinion with respect to the tax consequences to any other person, including Fitters Parent or any indirect
Fitters Parent U.S. Holders, or with respect to any other matter of aspect of the Transaction or any related transactions. Parent has
not sought and does not intend to seek a ruling from the U.S. Internal Revenue Service, or IRS, regarding the intended tax treatment
of the Transaction and there can be no assurance that the IRS will not challenge the intended tax treatment of the Transaction and, if
challenged, that a court would not sustain the IRS&#8217; position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Discussion
Limited to Shares held as a Capital Asset</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
it relates to Fitters Parent&#8217;s holdings of the Company common shares and Fitters Parents shareholders&#8217; holdings of
Fitters Parent shares, this discussion is limited to such shares that are, in each case, held as a &#8220;capital asset&#8221; within
the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal
income tax consequences relevant to the particular circumstances of Fitters Parent or a shareholder of Fitters Parent. In addition, it
does not address consequences relevant to Fitters Parent or Fitters Parent shareholders that may be subject to special rules, including,
without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
persons subject to the alternative minimum tax;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
persons whose functional currency is not the U.S. dollar;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
persons holding the Company common or preferred stock as part of a hedge, straddle, or other risk reduction strategy or as part of a
conversion transaction or other integrated investment;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
banks, insurance companies, and other financial institutions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
real estate investment trusts and regulated investment companies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
brokers, dealers, and traders in securities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
tax-exempt organizations and governmental organizations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
persons deemed to sell the Company common shares under the constructive sale provisions of the Code;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
persons who hold or receive the Company common shares pursuant to the exercise of any employee stock options or otherwise as compensation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
persons who hold the Company common shares that is &#8220;section 306 stock&#8221; within the meaning of Section 306(c) of the Code;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
persons required to accelerate the recognition of any item of gross income for U.S. federal income tax purposes with respect to the Company
common shares as a result of such item being taken into account in an applicable financial statement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
persons holding the Company common shares who exercise dissenters&#8217; rights; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
tax-qualified retirement plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 93; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Person</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, a U.S. Person is:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
an individual who is a citizen or resident of the United States;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a corporation created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
an estate the income of which is subject to U.S. federal income tax regardless of its source; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 23.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a trust if either a court within the United States is able to exercise primary supervision over the administration of such trust and
one or more United States persons (within the meaning of Section 7701(a)(30) of the Code) have the authority to control all substantial
decisions of such trust, or the trust has a valid election in effect under applicable Regulations to be treated as a United States person
for U.S. federal income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Holder,
Company U.S. Holder and Fitters U.S. Holder</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Holder.
</i>For purposes of this discussion, except where specified, with respect to shares of the Company or Fitters Parent, a Holder
is a beneficial owner of such shares immediately before the Transaction and with respect to shares of Parent Common Stock, a Holder is
a beneficial owner of such stock immediately after the Transaction. With respect to shares held by an entity or other arrangement that
is taxable for U.S. federal income tax purposes as a partnership, a Holder refers to any person treated for U.S. federal income tax purposes
as a partner in such entity or other arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Holder and Non-U.S. Holder.</i> In each case, a U.S. Holder is a U.S. Person who is a Holder of shares of the indicated entity. A Non-U.S.
Holder is a person who is not a U.S. Person and who is a Holder of shares of the indicated entity. With respect to shares held by an
entity or other arrangement that is taxable for U.S. federal income tax purposes as a partnership, the terms U.S. Holder or Non-U.S.
Holder are applied with respect to the status (as a U.S. Person or otherwise) of each person treated for U.S. federal income tax purposes
as a partner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds Fitters Parent shares, the tax treatment
of a partner in the partnership will depend in part on the status of the partner, the activities of the partnership, and certain determinations
made at the partner level. Accordingly, partnerships holding Fitters Parent common shares and the partners in such partnerships should
consult their tax advisors regarding the U.S. federal income tax consequences to them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion does not address any tax consequences of transactions effectuated before, after, or at the same time as the Transaction,
whether or not they are undertaken in connection with the Transaction, including, without limitation, transactions in which Company shares
are acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
Characterization of the Transaction for U.S. Federal Income Tax Purposes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction should qualify as a taxable sale or other disposition within the meaning of Section 1001 of the Code. The material
U.S. federal income tax consequences of the Transaction to the Parent, Fitters Parent and Fitters Parent U.S. Holders are described below
under the applicable heading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
U.S. Federal Income Tax Consequences of the Transaction to Cyclacel (Parent)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of Parent Common Stock in exchange for Company Ordinary Shares is not a taxable event to Parent for federal income tax purposes.
The basis for federal income tax purposes of the Company Ordinary Shares in the hands of Parent immediately after the Transaction will
be </span>equal to the Transaction consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Parent may make an election pursuant to Section 338(g) of the Code pursuant, in which case
the Company would be treated, for U.S. federal income tax purposes, as having (i.e., the Company would be deemed to have) sold all of
its assets at fair market value on the date of the Transaction, and the Company would be treated as a new corporation which purchased
all of the assets of the Company as of the beginning of the next day. If Parent makes the Section 338(g) election, Parent&#8217;s future
U.S. tax determinations with respect to the Company would be based on the assumption that the deemed transaction had occurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
U.S. Federal Income Tax Consequences of the Transaction to Parent&#8217;s Shareholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction should have no U.S. federal income tax consequences to persons who are Parent&#8217;s shareholders immediately before the
Transaction by virtue of their ownership of shares in Parent. Immediately after the Transaction Fitters Parent will be a shareholder
of Parent and certain United States federal income tax consequences of such ownership are discussed below. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 94; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
U.S. Federal Income Tax Consequences of the Transaction to Fitters Parent as the Sole Holder of the Company Ordinary Shares Immediately
Prior to the Transaction </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Transaction, for United States income tax purposes, Fitters Parent should not recognize gain or loss solely as a result
of the Transaction. Fitters Parent should have, immediately after the transaction, a tax basis in its Parent Common Stock
that is equal to the fair market value of Parent shares as of the time of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Federal Income Tax Reporting by Fitters Parent</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Company shareholder (i.e., Fitters Parent) that is required to file a U.S. federal income tax return and that owns (immediately before
the effectiveness of the Transaction) at least five percent (5%) (by vote or value) of the total outstanding stock of the Company is
required, for the taxable year in which the Transaction is effective, to attach to such U.S. federal income tax return a statement that
contains the information listed in Regulations Section 1.368-3(b). Such statement must include, among other information, the shareholder&#8217;s
tax basis in the Company common shares exchanged and the fair market value of such stock at the time of the exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
U.S. Federal Income Tax Consequences of the Transaction to Fitters Parent U.S. Holders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
provided in U.S. federal income tax rules applicable to passive foreign investment companies (&#8220;PFICs&#8221;) under Section 1291
of the Code, a U.S. Holder of stock in a PFIC is generally subject to tax, including an interest charge, on gain recognized upon a disposition
of such stock. These rules are discussed in greater detail below. If Fitters Parent is or was treated as a PFIC with respect to a U.S.
Holder, and if the Company or any of its subsidiaries is also treated as a PFIC with respect to such holder, PFIC status of the
Company or one of its subsidiaries may be attributed to the U.S. Holder under the look-through rules of Treasury Regulation &#167;&#8239;1.1291-8.
In such case, the disposition of the ordinary shares of the Company  by Fitters Parent, including in a transaction that is
otherwise non-taxable, may be subject to and taxable pursuant to these PFIC rules unless an exception applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
an exception, no gain or loss is expected to be recognized by a U.S. Holder as a result of the exchange of the ordinary shares of
the Company  for Parent voting stock, provided the following conditions, as provided in Proposed Treasury Regulation &#167;&#8239;1.1291-6(c)(2),
are satisfied:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
                                            the Transaction, the ordinary shares of the Company will be owned
                                            or considered as owned by a U.S. person; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent&#8217;s
                                            United States federal income tax basis in the Company&#8217;s ordinary shares immediately after the Transaction is no greater than the such tax basis of the ordinary
                                            shares of the Company in the hands of Fitters Parent immediately before the Transaction;
                                            </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent&#8217;s
                                            holding period of the ordinary shares of the Company  immediately after the Transaction
                                            is treated for United States federal income tax purposes as being at least as long as such
                                            holding period of the Company&#8217;s stock in the hands of Fitters Parent determined immediately
                                            before the Transaction; and, </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applying
                                            the indirect ownership rules of Treasury Regulation 1.1291-8, the aggregate indirect
                                            ownership of the Company ordinary shares by the Fitters Parent U.S. Holder
                                            is no less after the Transaction than before the Transaction. </span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the fourth requirement just above, in the case of a Fitters Parent U.S. Holder, the indirect ownership rules attribute shares through
a U.S. corporation only if the shareholder of the U.S. corporation owns at least 50% of the stock of the U.S. corporation. In the Transaction,
Fitters Parent will acquire only approximately 20% of the common stock of Parent, and thus the ordinary shares of
the Company to be owned by Parent after the Transaction will not be attributed to Fitters Parent and then to a Fitters
Parent U.S. Holder. The exception therefore cannot apply and if Company and Fitters Parent meet are or have been classified as PFICs,
such that the conditions elaborated upon here exist, Fitters Parent U.S. Holders  may be required to recognize gain without the receipt
of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
Treasury Regulations 1.1291-6, while not finalized and therefore of uncertain applicability, are generally relied upon by taxpayers and
the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Fitters Parent U.S. Holder recognized gain pursuant to the PFIC rules, the U.S. Holder would be required to report that gain on IRS
Form 8621, <i>Information Return by a Shareholder of a Passive Foreign Investment Company or a Qualified Electing Fund</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 95; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PFIC
Considerations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Definition
of a PFIC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. corporation will be classified as a PFIC for U.S. federal income tax purposes if either (i)&#160;at least 75% of its gross income
in a taxable year, including its pro&#160;rata share of the gross income of any corporation in which it is considered to own at least
25% of the shares by value, is passive income or (ii)&#160;at least 50% of its assets in a taxable year (generally determined based on
fair market value and averaged quarterly over the year) are held for the production of, or produce, passive income. Passive income generally
includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business)
and gains from the disposition of passive assets. For purposes of these rules, interest income is generally considered to be passive
income and cash held by a Non-U.S. corporation is considered to be a passive asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PFIC
Status of Fitters Parent, Company, or Subsidiaries of the Company</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
does not have information on whether Fitters Parent, Company, or subsidiaries of the Company are now or have at any time in the
past been a PFIC. Fitters Parent U.S. Holders should consult with their tax advisors and Fitters Parent to evaluate this possibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effect
of PFIC Rules on the Transaction</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&#160;1291(f)
of the Code requires that, to the extent provided in Treasury Regulations, a United States person who disposes of stock of a PFIC recognizes
gain notwithstanding any other provision of the Code. No final Treasury Regulations are currently in effect under Section&#160;1291(f)
of the Code. However, proposed Treasury Regulations under Section&#160;1291(f) of the Code have been promulgated with a retroactive effective
date. If finalized in their current form, those proposed Treasury Regulations may require gain recognition in the following circumstances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a U.S. shareholder owns stock of a foreign corporation (such as Fitters Parent), and that foreign corporation disposes of stock of another
foreign corporation (such as Company or a subsidiary of the Company), then the U.S. shareholder may be treated as indirectly disposing
of the Company shares&#8212;and must recognize gain&#8212;if Fitters Parent is or was a PFIC during the shareholder&#8217;s holding period
and Company (or a subsidiary of the Company) was also a PFIC during the period the shareholder indirectly held shares of the Company
(or the subsidiary of the Company), and no QEF election was made for Company (or such subsidiary). However, if the upper-tier foreign
corporation has never been a PFIC and is not a controlled foreign corporation, the U.S. shareholder is not treated under the PFIC rules
as owning shares of the lower-tier PFIC and no gain or inclusion results to the U.S. shareholder from disposition of the Company
by Fitters Parent. In the present circumstances no MTM election may be made for Company because it is not publicly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
these rules apply to cause a Fitters Parent U.S. Holder to recognize gain upon the disposition of the Company by Fitters Parent,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. Holder&#8217;s gain will be allocated ratably over the U.S. Holder&#8217;s indirect holding period for such U.S. Holder&#8217;s
    Company (or the subsidiary of the Company) shares;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of gain allocated to the U.S. Holder&#8217;s taxable year in which the U.S. Holder recognized the gain, or to the period in
    the U.S. Holder&#8217;s holding period before the first day of the first taxable year in which Company (or its subsidiary)
    was a PFIC, will be taxed as ordinary income;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of gain allocated to other taxable&#160;years (or portions thereof) of the U.S. Holder and included in such U.S. Holder&#8217;s
    holding period would be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder in respect
    of the tax attributable to each such other taxable year of such U.S. Holder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is difficult to predict whether, in what form and with what effective date, final Treasury Regulations under Section&#160;1291(f) of
the Code may be adopted or how any such Treasury Regulations would apply. Therefore, U.S. Holders of Fitters Parent shares that have
not made a timely QEF Election (or a QEF Election along with a purging election) or a&#160;mark-to-market&#160;election (each as defined
below) with respect to the Company (or any subsidiary of the Company) that was a PFIC during such period may, pursuant to the
proposed Treasury Regulations, be subject to taxation under the PFIC rules upon the Transaction. An Electing Shareholder (as defined
below) generally would not be subject to the adverse PFIC rules discussed above with respect to their Fitters Parent stock but rather
would include annually in gross income its pro&#160;rata share of the ordinary earnings and net capital gain of Fitters Parent, whether
or not such amounts are actually distributed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
gain recognized pursuant to PFIC rules by a Fitters Parent U.S. Holder as a result of the Transaction would be taxable income to such
U.S. Holder, taxed under the PFIC rules in the manner set forth above, with no corresponding receipt of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 96; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>QEF
Election and&#160;Mark-to-Market&#160;Election</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">The impact of the PFIC
rules on a U.S. shareholder of Fitters Parent will depend on whether Fitters Parent is or has been a PFIC at any time during such
U.S. Holder&#8217;s holding period for Fitters Parent shares, and similarly whether the Company (or a subsidiary of the Company)
has been a PFIC at any time during such U.S. Holder&#8217;s indirect holding period of the Company (or a subsidiary of the
Company) shares, and whether the U.S. Holder has made a timely and effective election to treat the Company (or a subsidiary of
the Company) as a &#8220;qualified electing fund&#8221; under Section&#160;1295 of the Code for the taxable year that is the first
year in the U.S. Holder&#8217;s indirect holding period of the Company (or a subsidiary of the Company) shares during which
Fitters Parent qualified as a PFIC (a &#8220;QEF Election&#8221;) or, if in a later taxable year, the U.S. Holder made a QEF Election
along with a purging election. A purging election creates a deemed sale of the Company shares by Fitters Parent for purposes of
calculating the Fitters Parent U.S. Holder&#8217;s income and gain with respect to the Company (or a subsidiary of the Company)
under the PFIC rules. As a result of any such purging election, the a Fitters parent U.S. Holder would have a new basis and holding period
in its Fitters Parent Stock. U.S. Holders are urged to consult their own tax advisors as to the application of the rules governing purging
elections to their particular circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder&#8217;s ability to make a QEF Election (or a QEF Election along with a purging election) with respect to Company is contingent
upon, among other things, the provision by Fitters Parent of a &#8220;PFIC Annual Information Statement&#8221; to such U.S. Holder. A
Fitters Parent U.S. Holder that made a QEF Election (or a QEF Election along with a purging election) may be referred to as an &#8220;Electing
Shareholder&#8221; and a U.S. Holder that did not make a QEF Election may be referred to as a&#160;&#8220;Non-Electing&#160;Shareholder.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>THE
RULES DEALING WITH PFICS ARE VERY COMPLEX AND ARE IMPACTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. ALL FITTERS PARENT
U.S. HOLDERS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS REGARDING THE CONSEQUENCES TO THEM OF THE PFIC RULES, INCLUDING, WITHOUT LIMITATION,
WHETHER A QEF ELECTION (OR A QEF ELECTION ALONG WITH A PURGING ELECTION), A MARK-TO-MARKET&#160;ELECTION OR ANY OTHER ELECTION IS AVAILABLE
AND THE CONSEQUENCES TO THEM OF ANY SUCH ELECTION, AND THE IMPACT OF ANY PROPOSED OR FINAL PFIC TREASURY REGULATIONS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
PRECEDING DISCUSSION DOES NOT PURPORT TO BE A COMPLETE ANALYSIS OR DISCUSSION OF ALL OF THE TRANSACTION&#8217;S POTENTIAL TAX EFFECTS.
FITTERS PARENT SHOULD CONSULT ITS TAX ADVISORS WITH RESPECT TO THE APPLICATION OF U.S. FEDERAL INCOME TAX LAWS TO ITS PARTICULAR SITUATION
AS WELL AS ANY TAX CONSEQUENCES OF THE TRANSACTION, INCLUDING TAX REPORTING REQUIREMENTS, AND THE OWNERSHIP AND DISPOSITION OF THE PARENT
COMMON STOCK RECEIVED, ARISING UNDER THE U.S. FEDERAL, STATE, LOCAL, AND OTHER APPLICABLE INCOME, ESTATE, GIFT OR OTHER TAX LAWS OR UNDER
ANY APPLICABLE INCOME TAX TREATY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
PERSONS WHO OWN FITTERS PARENT STOCK SHOULD CONSULT THEIR TAX ADVISORS AS TO THE SPECIFIC TAX CONSEQUENCES TO THEM OF THE TRANSACTION,
INCLUDING TAX RETURN REPORTING REQUIREMENTS AND THE APPLICABILITY AND EFFECT OF FEDERAL, STATE, LOCAL, AND OTHER APPLICABLE TAX LAWS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 97; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_001"></span>Material
Consequences of Post-Transaction Ownership and Disposition of Cyclacel Pharmaceuticals Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consequences
to the U.S. Holders Parent of Post-Transaction Ownership of Parent Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distributions
on Parent Common Stock to Parent U.S. Holders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
after the Transaction,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Parent makes
distributions of cash or property on its common stock, those payments would constitute dividends for U.S. federal income tax
purposes to the extent paid from current or accumulated earnings and profits, as determined under U.S. federal income tax
principles. To the extent such distributions exceeded both current and accumulated earnings and profits, the excess would constitute
a return of capital and would first reduce any U.S. Holder&#8217;s tax basis of Parent,  in Parent Common Stock,
but not below zero, and then would be treated by the U.S. Holder of Parent as gain from the sale of Parent Common
Stock as described below under &#8220;&#8212;<i>Gain on Disposition of Common Stock of the Parent by the Company U.S.
Holders</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
paid to any U.S. Holder of Parent Common Stock that is a taxable corporation generally would qualify for a dividends received
deduction if the requisite holding period were satisfied. With certain exceptions (including, but not limited to, dividends treated as
investment income for purposes of investment interest deduction limitations), and provided the Parent Common Stock was held for
more than 60 days during the 121-day period beginning 60 days before the ex-dividend date and certain other holding period requirements
were met, dividends paid to a non-corporate Parent U.S. Holder generally would constitute &#8220;qualified dividends&#8221; that
would be subject to tax at the maximum tax rate accorded to long-term capital gains. Dividends paid by Parent generally would be treated
as income from U.S. sources. The U.S. Holders of Parent Common Stock should consult their own tax advisors regarding the
holding period and other requirements that must be satisfied in order to qualify for the reduced maximum tax rate on dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gain
on Disposition of Common Stock of the Parent by the Company U.S. Holders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any U.S. Holder of Parent Common Stock sells or otherwise disposes of Parent Common Stock in a taxable transaction, the
U.S. Holder of Parent Common Stock will generally recognize capital gain or loss equal to the difference between the amount realized
and the Company U.S. Holder&#8217;s adjusted tax basis in the Parent Common Stock. The capital gain or loss will be long-term
capital gain or loss if the U.S. Holders of Parent Common Stock holding period for the Parent Common Stock is more than
one year at the time of the disposition. Long-term capital gain of a non-corporate U.S. Holder of Parent Common Stock is generally
taxed at preferential rates. The deductibility of capital losses is subject to limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Information
Reporting and Backup Withholding</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Parent U.S. Holders may be subject to information
withholding and/or backup withholding with respect to gross proceeds from the disposition of securities or from payments of dividends.
Backup withholding (currently at the rate of 24%) may apply under certain circumstances if any Parent U.S. Holder (1) fails to furnish
a social security or other taxpayer identification number, or a TIN, (2) furnishes an incorrect TIN, (3) fails to report interest or
dividends properly, or (4) fails to provide a certified statement on IRS Form W-9, signed under penalties of perjury, that the TIN provided
is correct, that the Parent U.S. Holder is not subject to backup withholding, and that the Parent U.S. Holder is a U.S. person for U.S.
federal income tax purposes. Any amount withheld from a payment under the backup withholding rules is allowable as a credit against (and
may entitle any Parent U.S. Holder to a refund with respect to) such Parent U.S. Holder&#8217;s federal income tax liability, provided
that the required information is timely furnished to the IRS. Certain persons, including corporations and certain financial institutions,
that demonstrate this fact if requested are exempt from information reporting and backup withholding. The Parent U.S. Holders should
consult with tax advisors as to their qualification for exemption from information reporting and backup withholding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consequences
to the Non-U.S. Holders of Ownership of Parent Common Stock, including Fitters Parent after the Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distributions
on Parent Common Stock to any Non-U.S. Holder of Parent Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Parent made distributions of cash or property on Parent Common Stock, those payments would constitute dividends for U.S. federal
income tax purposes to the extent paid from current or accumulated earnings and profits, as determined under U.S. federal income tax
principles. To the extent such distributions exceeded both current and accumulated earnings and profits, the excess would constitute
a return of capital and would first reduce any Non-U.S. Holder&#8217;s tax basis in Parent Common Stock, but not below zero, and
then would be treated by any Non-U.S. Holder as gain from the sale of stock as described below under &#8220;&#8212;<i>Gain on Disposition
of Parent Common Stock by the Non-U.S. Holders</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 98; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below of effectively-connected income, backup withholding, and FATCA, a dividend paid to any Non-U.S. Holder of
Parent Common Stock generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend
or such lower rate as may be specified by an applicable income tax treaty. The United States does not maintain a comprehensive income
tax treaty with Malaysia. To receive a reduced treaty rate, any Non-U.S. Holder of Parent Common Stock must provide an appropriate
IRS Form W-8 (or applicable successor form) and certify qualification for the reduced rate. If any Non-U.S. Holder is eligible for a
reduced rate of U.S. withholding tax pursuant to an income tax treaty, such  Non-U.S. Holder may obtain a refund or credit of any
excess amounts withheld by timely filing an appropriate claim with the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
that are received by any Non-U.S. Holder of Parent Common Stock and that are (a) effectively connected with such Non-U.S. Holder&#8217;s
conduct of a trade or business in the United States but, (b) not eligible for relief from United States taxation under the business profits
article of an applicable income tax treaty between such Non-U.S. Holder&#8217;s country of residence and the United States (such relief
is generally available if the dividend is not attributable to a permanent establishment or a fixed base maintained by such Non-U.S.
Holder in the United States), (c) are generally exempt from the 30% withholding tax if certain certification and disclosure requirements
are satisfied. To obtain this exemption, any Non-U.S. Holder of Parent Common Stock must provide an IRS Form W-8ECI (or applicable
successor form) properly certifying such exemption. However, such effectively connected dividends, although not subject to withholding
tax, generally are taxed at the same U.S. federal income tax rates as are applicable to U.S. persons, net of certain deductions and credits.
In addition, dividends received by a corporate Non-U.S. Holder of Parent Common Stock that are effectively connected with the
conduct of a trade or business in the U.S. may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be
specified by an applicable income tax treaty. Non-U.S. Holders of Parent Common Stock should consult tax advisors regarding any
applicable income tax or other treaties that may provide for different rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
documentation provided to an applicable withholding agent may need to be updated in certain circumstances. The certification requirements
described above also may require any Non-U.S. Holder of Parent Common Stock to provide a United States taxpayer identification
number.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional withholding rules that may apply to dividends, including dividends paid to foreign financial institutions (as specifically
defined by the applicable rules) or to certain other foreign entities that have substantial direct or indirect United States owners,
see the discussion below under the headings &#8220;&#8212;<i>Information Reporting and Backup Withholding</i>&#8221; and &#8220;&#8212;<i>Withholdable
Payments to Foreign Financial Institutions and Other Foreign Entities</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gain
on Disposition of Parent Common Stock by the Non-U.S. Holders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below under the headings &#8220;&#8212;<i>Information Reporting and Backup Withholding</i>&#8221; and &#8220;&#8212;<i>Withholdable
Payments to Foreign Financial Institutions and Other Foreign Entities</i>,&#8221; any Non-U.S. Holder of Parent Common Stock (such
as Fitters Parent) generally will not be required to pay U.S. federal income tax or withholding tax on any gain recognized upon the
sale, exchange or other taxable disposition of Parent Common Stock unless:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                                                                                                                                                                                                                          gain was effectively connected with the conduct by the Non-U.S. Holder of a trade or business within the United States
                                                                                                                                                                                                                                          provided that, if a tax treaty applied, the gain was not exempt from tax under the business profits article of the treaty (such
                                                                                                                                                                                                                                          relief is generally available under an applicable tax treaty if the gain is  not attributable to a
                                                                                                                                                                                                                                          permanent establishment or fixed place of business maintained by the Non-U.S. Holder in the United States;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the case of certain capital gains of any Non-U.S. Holder of Parent Common Stock that
                                            is an individual, such holder is present in the United States for 183 days or more during
                                            the taxable year in which the capital gain is recognized and certain other conditions are
                                            met; or Parent Common Stock constitutes a United States real property interest by
                                            reason of Parent having the status of a &#8220;United States real property holding corporation&#8221;
                                            (a &#8220;USRPHC&#8221;), for U.S. federal income tax purposes at any time within the shorter
                                            of the five-year period preceding such Non-U.S. Holder&#8217;s disposition of such Parent
                                            Common Stock and the Non-U.S. Holder&#8217;s holding period, in which case the Non-U.S.
                                            Holder of Parent Common Stock generally will be taxed on net gain derived from the
                                            sale or disposition at the rates applicable to U.S. persons.</span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
does not believe that it currently is or will become a USRPHC, and the remainder of this discussion assumes that is the case. However,
because the determination of whether a corporation is a USRPHC depends on the fair market value of its U.S. real property relative to
the fair market value of its other business assets, there can be no assurance that Parent will not become a USRPHC in the future. The
Non-U.S. Holders of Parent Common Stock should consult their tax advisors regarding any applicable income tax or other treaties
that may provide for different rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 99; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Information
Reporting and Backup Withholding </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
or the applicable paying agent must report annually to the IRS the amount of dividends on Parent Common Stock paid to the Non-U.S.
Holders and the amount of tax withheld, if any. A similar report will be sent to each the Non-U.S. Holder. Copies of this information
reporting may also be made available under the provisions of a specific income tax treaty or agreement with the tax authorities in any
Non-U.S. Holder&#8217;s country of residence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Non-U.S. Holders will generally be subject to backup withholding for dividends on Parent Common Stock paid to such Non-U.S. Holders
unless an exemption is established by, for example, properly certifying non-United States status on an appropriate IRS Form W-8 (or applicable
successor form). Notwithstanding the foregoing, backup withholding and information reporting nevertheless may apply if either Parent
or its paying agent has actual knowledge, or reason to know, that a holder of Parent Common Stock is a United States person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
reporting and backup withholding generally are not required with respect to the amount of any proceeds from the sale or other disposition
of Parent Common Stock by any Non-U.S. Holder outside the United States through a foreign office of a foreign broker that does
not have certain specified connections to the U.S. However, if any Non-U.S. Holder sells or otherwise disposes of shares of Parent Common
Stock through a U.S. broker or the U.S. offices of a foreign broker, the broker will generally be required to report to the IRS the
amount of proceeds paid to such Non-U.S. Holder and also to backup withhold on that amount unless the broker is provided with appropriate
certification of the Non-U.S. Holder&#8217;s status as a non-United States person, or an exemption is otherwise established. Information
reporting will also apply if any Non-U.S. Holder sells shares of common stock through a foreign broker deriving more than a specified
percentage of its income from U.S. sources or having certain other connections to the U.S., unless such broker has documentary evidence
in its records that such Non-U.S. Holder of Parent Common Stock is a non-U.S. person and certain other conditions are met, or
an exemption is otherwise established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld from a payment under the backup withholding rules may be refunded or credited
against any Non-U.S. Holders of Parent Common Stock U.S. federal income tax liability, if any, provided that an appropriate
claim is timely filed with the IRS. The Non-U.S. Holders of Parent Common Stock should consult their tax advisors
regarding the application of the information reporting and backup withholding rules to investment in Parent Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Withholdable
Payments to Foreign Financial Institutions and Other Foreign Entities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Account Tax Compliance Act, or FATCA, imposes a U.S. federal withholding tax of 30% on certain payments to &#8220;foreign financial
institutions&#8221; (as specifically defined under these rules) and certain other non-U.S. persons that fail to comply with certain information
reporting and certification requirements pertaining to their direct and indirect U.S. security holders and/or U.S. account holders. Such
payments include dividends on Parent Common Stock. Under certain circumstances, any Non-U.S. Holder of Parent Common Stock
may be eligible for refunds or credits of such taxes. Notwithstanding the foregoing, the IRS has issued proposed Regulations upon which
taxpayers may generally rely, that exclude gross proceeds from the sale or other disposition of stock from the application of the withholding
tax imposed under FATCA. An intergovernmental agreement between the U.S. and an applicable foreign country may modify the requirements
described in this paragraph. The Non-U.S. Holders of Parent Common Stock should consult with tax advisors regarding the
possible implications of this legislation and any applicable intergovernmental agreements on investment in Parent Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Federal Estate Tax</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Parent Common Stock that are owned or treated as owned by an individual who is not a citizen or resident of the United States
(as specially defined for U.S. federal estate tax purposes) at the time of death are considered U.S. situs assets and will be included
in the individual&#8217;s gross estate for U.S. federal estate tax purposes. Such shares, therefore, may be subject to U.S. federal estate
tax, unless an applicable estate tax or other treaty provides otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIS
SUMMARY IS NOT INTENDED TO BE CONSTRUED AS LEGAL ADVICE. FITTERS PARENT AND ALL U.S. HOLDERS AND NON-U.S. HOLDERS OF FITTERS PARENT STOCK
ARE URGED TO CONSULT WITH TAX ADVISORS WITH RESPECT TO THE APPLICATION OF U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATION,
AS WELL AS, IN THE CASE OF FITTERS PARENT, ANY TAX CONSEQUENCES OF THE RECEIPT, OWNERSHIP, AND DISPOSITION OF PARENT COMMON STOCK ARISING
UNDER THE LAWS OF ANY STATE, LOCAL, NON-UNITED STATES OR OTHER TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY, INCLUDING THE
CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 100; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_056"></span>Anticipated
Accounting Treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction will be recorded as a business combination under the acquisition method of accounting in accordance with U.S. GAAP and IFRS
(i.e., ASC 805/IFRS 3) The Transaction will be treated by Cyclacel as a business combination under the acquisition method of accounting
for business combinations in accordance with accounting principles generally accepted in the United States, or U.S. GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
accounting purposes, Cyclacel is considered to be acquiring Fitters Sdn. Bhd. (the &#8220;Company&#8221;) in the Transaction due to Cyclacel&#8217;s
control over the Company after the Closing under U.S. GAAP, as defined in Accounting Standards Codification (&#8220;ASC 805-10&#8221;).
ASC 805 applies to public and privately held entities and is applicable to all transactions or other events that meet the definition
of a business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
of Parent and the Company have determined a preliminary estimate of the purchase price calculated, as described in Note 2 to the unaudited
pro forma condensed combined financial statements. The net tangible assets acquired and liabilities assumed in connection with the Transaction
are recorded at their estimated acquisition date fair values. The acquisition method of accounting is dependent upon certain valuations
and any other studies and calculations deemed necessary that have yet to commence or progress to a stage where there is sufficient information
for a definitive measurement. A final determination of these estimated fair values, which cannot be made prior to the completion of the
Transaction, will be based on the actual net tangible assets of Parent that exist as of the date of completion of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_057"></span>Nasdaq
Stock Market Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
Common Stock currently is listed on The Nasdaq Capital Market under the symbol &#8220;CYCC.&#8221; Parent has agreed to use commercially
reasonable efforts to (i) maintain its existing listing on The Nasdaq Capital Market, (ii) prepare and submit to The Nasdaq Stock Market
a notification form for the additional listing of the shares of Parent Common Stock to be issued to Fitters Parent pursuant to
the Transaction, and (iii) cause such shares to be approved for listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Exchange Agreement, each of the Company&#8217;s and Parent&#8217;s obligation to complete the Transaction is subject
to the satisfaction or waiver by each of the parties, at or prior to the Transaction, of various conditions, including that the existing
shares of Parent Common Stock must have been continually listed on The Nasdaq Capital Market, Parent must have caused the shares
of Parent Common Stock to be issued in the Transaction to be approved for listing on The Nasdaq Stock Market as of the effective
time of the Transaction. Parent anticipates that its common stock will be listed on The Nasdaq Stock Market following the closing of
the Transaction under the trading symbol &#8220;BGMS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_058"></span>Appraisal
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Parent Common Stock are not entitled to appraisal rights in connection with the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 101; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_059"></span>THE
EXCHANGE AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following is a summary of the material terms of the Exchange Agreement. A copy of the Exchange Agreement is attached as Annex A to this
proxy statement/prospectus and is incorporated by reference into this proxy statement/prospectus. The Exchange Agreement has been attached
to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual
information about Parent or the Company. The following description does not purport to be complete and is qualified in its entirety by
reference to the Exchange Agreement. You should refer to the full text of the Exchange Agreement for details of the Transaction and the
terms and conditions of the Exchange Agreement.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Exchange Agreement contains representations and warranties that Parent, on the one hand, and the Company and its stockholders, on the
other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the
other parties to the Exchange Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one
of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties
are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Exchange Agreement.
While Parent and the Company do not believe that these disclosure schedules contain information required to be publicly disclosed under
the applicable securities laws, other than information that has already been disclosed, the disclosure schedules do contain information
that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Exchange Agreement. Accordingly,
you should not rely on the representations and warranties as current characterizations of factual information about Parent or the Company,
because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Parent, the Company and its
stockholders and are modified by the disclosure schedules.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_060"></span>Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or &#8220;Parent&#8221;) and FITTERS Diversified Berhad, a Malaysia publicly-listed investment
holding company on Bursa Securities (KL: 9318) (&#8220;Fitters Parent&#8221;), which is the beneficial owner of all of the issued and
outstanding ordinary shares (the &#8220;Company Ordinary Shares&#8221; or &#8220;Shares&#8221; and each, a &#8220;Share&#8221;) of Fitters
Sdn. Bhd., a private limited company incorporated in Malaysia (the &#8220;Company,&#8221; &#8220;Fitters&#8221; or &#8220;Fitters Sdn.
Bhd.&#8221;) entered into an Exchange Agreement dated as of May 6, 2025, as amended on July 7, 2025 and as it may be further amended
from time to time (collectively, the &#8220;Exchange Agreement&#8221;) (&#8220;Fitters Parent&#8221; and &#8220;Parent&#8221; are
sometimes referred to herein as the &#8220;Parties&#8221; or each, a &#8220;Party&#8221;). The Parties thereto intend to effect a voluntary
share exchange transaction between Parent and Fitters Parent (the &#8220;Exchange&#8221;), in which the Company will become a wholly-owned
subsidiary of Parent, in accordance with the terms of the Exchange Agreement and the rules under Delaware General Corporation Law (the
&#8220;DGCL&#8221;) and the Malaysian Companies Act. The Company has three wholly-owned subsidiaries: AHT NRG Asia Sdn. Bhd., FITTERS
(Sarawak) Sdn. Bhd., and Modular Floor Systems (M) Sdn. Bhd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, and in accordance with the DGCL, at the Closing (as
hereinafter defined), Fitters Parent shall convey, assign, and transfer all of its right, title and interest to the Company Ordinary
Shares to Parent. The Shares transferred to Parent at the Closing shall constitute one hundred (100%) percent of the issued and
outstanding capital shares of the Company. As consideration for its acquisition of the Company Ordinary Shares, Parent shall pay
an amount equal to $1,000,000 in cash (or such amount as mutually agreed upon prior to the Closing) and issue an amount of
common stock, par value $0.001 per share (the &#8220;Parent Common Stock&#8221;) equal to nineteen and ninety-nine hundreds percent
(19.99%) of the issued and outstanding shares of Parent Common Stock as of the Closing Date (as defined below) (the &#8220;Exchange
Shares&#8221;) to Fitters Parent. In the event the value of the Exchange Shares is not mutually acceptable to both Parties prior to
the Closing Date, the parties have agreed to negotiate in good faith an adjustment to the Exchange Shares. If the Transaction does
not close by September 30, 2025, either party may terminate the Exchange Agreement and the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, the closing of the Exchange (the &#8220;Closing&#8221;)
shall take place no later than three business days after the date on which the conditions to Closing set forth in the Exchange Agreement
shall have been satisfied or, to the extent permitted thereunder, waived by the appropriate Party (other than those conditions that by
their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all
such conditions) or at such other time, date or location as the parties hereto agree. The date on which the Closing actually occurs and
the transactions contemplated in the Exchange Agreement become effective is hereinafter referred to as the &#8220;Closing Date.&#8221;
At the time of the Closing, Parent, Fitters Parent and the Company shall deliver the certificates and other documents and instruments
required to be delivered thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 102; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_061"></span>Completion
and Effectiveness of the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction will be completed as promptly as practicable after all of the conditions to completion of the Transaction are satisfied or
waived, including the approval of the stockholders of Cyclacel. Cyclacel and Fitters Parent are working to complete the Transaction as
quickly as practicable. However, Cyclacel and Fitters Parent cannot predict the exact timing of the completion of the Transaction because
it is subject to various conditions. After completion of the Transaction, assuming Cyclacel receives the required stockholder approval
of the Proposals, Cyclacel will be renamed &#8220;Bio Green Med Solution, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_062"></span>Cyclacel Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
stock options that are outstanding immediately prior to the effective time of the Transaction will remain outstanding following the effective time of the Transaction. Likewise, any outstanding warrants to purchase shares of Cyclacel common stock that are outstanding immediately prior to the
effective time of the Transaction will remain outstanding following the effective time of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
after the Transaction, it is estimated Cyclacel securityholders will own approximately 80.01% of Cyclacel common stock at the
Closing of the Transaction and subject to adjustment as provided in the Exchange Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_063"></span>Fractional
Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of Cyclacel common stock will be issued in connection with the Transaction. Instead, all fractional shares of Cyclacel
common stock that are issuable to Fitters Parent will be aggregated and will be rounded up into one full share of Cyclacel common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_064"></span>Representations
and Warranties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange Agreement contains customary representations and warranties made by Cyclacel, Fitters Parent and the Company relating to their
respective businesses, as well as other facts pertinent to the Transaction. These representations and warranties are subject to materiality,
knowledge and other similar qualifications in many respects and expire at the effective time of the Transaction or termination of the
Exchange Agreement, as further described below. The representations and warranties of each of Cyclacel, Fitters Parent and the Company
have been made solely for the benefit of the other parties and those representations and warranties should not be relied on by any other
person. In addition, those representations and warranties may be intended not as statements of actual fact, but rather as a way of allocating
risk among the parties, may have been modified by the disclosure schedules delivered in connection with the Exchange Agreement, are subject
to the materiality standard described in the Exchange Agreement, which may differ from what may be viewed as material by you, will not
survive completion of the Transaction and cannot be the basis for any claims under the Exchange Agreement by the other parties after
termination of the Exchange Agreement, and were made only as of the date of the Exchange Agreement or another date as is specified in
the Exchange Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Parent and the Company jointly and severally made a number of representations and warranties to Cyclacel in the Exchange Agreement, including
representations and warranties relating to the following matters:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization,
                                            Standing and Corporate Power;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
                                            Structure of the Company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
                                            Authority; Noncontravention;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
                                            Authorization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            Statements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence
                                            of Certain Changes or Events;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            Fees;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation;
                                            Labor Matters; Compliance with Laws;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits
                                            Plans;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
                                            Returns and Tax Payments;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 103; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
                                            Matters;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
                                            Contracts Defaults;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
                                            Receivable;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
                                            Property;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
                                            Recommendation and Affirmative Vote;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
                                            Information;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undisclosed
                                            Liabilities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
                                            with Affiliates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            Business Practices;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
                                            Investigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Other Representations or Warranties; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
                                            of Information.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
portions of Fitters Parent and the Company&#8217;s representations and warranties are qualified as to &#8220;materiality&#8221; or &#8220;material
adverse effect.&#8221; Under the Exchange Agreement, a material adverse effect means, with respect to any Person, a material adverse
effect on the condition (financial or otherwise), business, assets, liabilities or the results of operations of such Person and its Subsidiaries
taken as a whole; provided, however, that any adverse change, event, development or effect arising from or relating to any of the following
shall not be taken into account in determining whether there has been a Material Adverse Effect: (a) general business or economic conditions,
(b) national or international political or social conditions, including the engagement by the United States or Malaysia in hostilities,
whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack upon
the United States or Malaysia, respectively, or any of its territories, possessions, or diplomatic or consular offices or upon any military
installation, equipment or personnel of the United States or Malaysia, respectively, (c) financial, banking, or securities markets (including
any disruption thereof and any decline in the price of any security or any market index), (d) changes in IFRS, (e) changes in laws, rules,
regulations, orders, or other binding directives issued by any Governmental Entity or (f) the taking of any action required by the Exchange
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
made a number of representations and warranties to Fitters Parent and the Company in the Exchange Agreement, including representations
and warranties relating to the following subject matters:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization,
                                            Standing and Corporate Power;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
                                            Structure of the Company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
                                            Authority; Noncontravention;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
                                            Authorization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
                                            Documents; Undisclosed Liabilities; Financial Statements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence
                                            of Certain Changes or Events;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            Fees;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation;
                                            Labor Matters; Compliance with Laws;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits
                                            Plans;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
                                            Returns and Tax Payments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
                                            Matters;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
                                            Contracts Defaults;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
                                            Receivable;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
                                            Property;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
                                            Determination and Vote Required;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required
                                            Parent Share Issuance Approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undisclosed
                                            Liabilities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
                                            with Affiliates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
                                            Investigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Other Representations or Warranties; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
                                            of Information.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to Fitters Parent and the Company&#8217;s representations and warranties, significant portions of Cyclacel&#8217;s representations and
warranties are qualified as to &#8220;materiality&#8221; or &#8220;material adverse effect,&#8221; as defined above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 104; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_065"></span>Covenants;
                                            Conduct of Business Pending the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
the date of the Exchange Agreement until the earlier of the Effective Time or the termination of the Agreement in accordance with its
terms, the Company and Cyclacel each agreed that it will conduct its business in the ordinary course and in compliance with all applicable
laws, rules, regulations, and certain material contracts and will provide the other party with prompt notice upon the occurrence of certain
events or discovery of certain conditions, facts or circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also agreed that prior to the earlier of termination and the Effective Time of the Transaction, subject to certain limited exceptions
set forth in the Exchange Agreement, without the consent of Cyclacel, it would not and would not permit any of its subsidiaries to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage
                                            in any transaction except in the ordinary course of business, or create or suffer to exist
                                            any material lien or other encumbrance upon any of its assets which will not be discharged
                                            in full prior to the Effective Time;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
                                            assign or otherwise transfer any of its assets, or cancel or compromise any debts or claims
                                            relating to its assets, other than in each case in the ordinary course of business and consistent
                                            with past practice;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
                                            to use reasonable efforts to preserve intact its present business organization, keep available
                                            the services of its employees and preserve its material relationships with customers, suppliers,
                                            licensors, licensees, distributors and others having business relationships with it, to the
                                            end that its good will and ongoing business will not be materially impaired prior to the Effective
                                            Time;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intentionally
                                            permit any Material Adverse Effect to occur with respect to the Company;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any material change in its accounting or bookkeeping methods, principles or practices, except
                                            as required by IFRS;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
                                            as required to give effect to anything in contemplation of the Closing, or effect or be a
                                            party to any merger, consolidation, share exchange, business combination, recapitalization,
                                            reclassification of shares, stock split, reverse stock split or similar transaction except,
                                            for the avoidance of doubt, the transactions contemplated under the Exchange Agreement; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
authorize any of, or commit or agree to take any of, the foregoing actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
also agreed that From the date of the Exchange Agreement until earlier of the Effective Time or the termination of the Exchange Agreement
in accordance with its terms, Parent shall not unless consented to in writing by the Company (which consent shall not be unreasonably
withheld, delayed, denied, or conditioned), expressly contemplated by the Exchange Agreement, including in connection with a reverse
stock split, as required by applicable Law, or as set forth on Schedule 5.2 of the Exchange Agreement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage
                                            in any transaction except in the ordinary course of business, or create or suffer to exist
                                            any material lien or other encumbrance upon any of its assets which will not be discharged
                                            in full prior to the Effective Time;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
                                            assign or otherwise transfer any of its assets, or cancel or compromise any debts or claims
                                            relating to its assets, other than in each case in the ordinary course of business and consistent
                                            with past practice;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
                                            to use reasonable efforts to preserve intact its present business organizations, keep available
                                            the services of its employees and preserve its material relationships with customers, suppliers,
                                            licensors, licensees, distributors and others having business relationships with it, to the
                                            end that its good will and ongoing business will not be materially impaired prior to the
                                            Effective Time;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intentionally
                                            permit any Material Adverse Effect to occur with respect to Parent;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any material change with respect in its accounting or bookkeeping methods, principles or
                                            practices, except as required by GAAP; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
                                            any of, or commit or agree to take any of, the foregoing actions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 105; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_066"></span>Disclosure
Documents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
promptly as practicable following the date of the Exchange Agreement, the parties agreed to prepare and file with the SEC this proxy
statement/prospectus and Cyclacel agreed to prepare and file with the SEC a registration statement on Form S-4, of which this proxy statement/prospectus
is a part, in connection with the registration under the Securities Act of the shares of the Exchange Shares to be issued pursuant to
the Transaction. Cyclacel agreed to use its commercially reasonable efforts to cause the registration statement to become effective as
promptly as practicable, and take all or any action required under any applicable federal and state securities and other laws in connection
with the issuance of shares of Cyclacel common stock pursuant to the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Cyclacel, Fitters Parent and the Company agreed to use their commercially reasonable efforts to cause the registration statement on
Form S-4, of which this proxy statement/prospectus is a part, to comply with the applicable rules and regulations promulgated by the
SEC in all material respects. Each of Fitters Parent and the Company shall reasonably cooperate with Parent and provide, and cause its
representatives to provide, Parent and its representatives, with all true, correct and complete information regarding the Company that
is required by law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration
Statement. Cyclacel agreed to mail this proxy statement/prospectus to its stockholders promptly after the registration statement on Form
S-4 is declared effective by the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_067"></span>Meeting
of Cyclacel Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
is obligated under the Exchange Agreement to call, give notice of and hold a meeting of its stockholders for the purposes of voting on
the Proposals. The Cyclacel stockholders&#8217; meeting will be held (on a date selected by Cyclacel in consultation with the Company)
not later than 45 days after the effective date of the registration statement on Form S-4 pursuant to the Exchange Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_068"></span>Regulatory
Approvals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Cyclacel nor the Company is required to make any filings or to obtain approvals or clearances from any antitrust regulatory authorities
in the United States or other countries to complete the Transaction. In the United States, Cyclacel must comply with applicable federal
and state securities laws and the rules and regulations of The Nasdaq Stock Market LLC in connection with the issuance of shares of Cyclacel
common stock in the Transaction, including the filing with the SEC of this proxy statement/prospectus. The Exchange Agreement provides
that the Company and Cyclacel shall respond as promptly as is practicable in compliance with: (i) any inquiries or requests received
from the Federal Trade Commission or the Department of Justice for information or documentation; and (ii) any inquiries or requests received
from any other governmental body in connection with antitrust or competition matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_069"></span>Nasdaq
Stock Market Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
common stock currently is listed on The Nasdaq Capital Market under the symbol &#8220;CYCC.&#8221; Cyclacel has agreed to use commercially
reasonable efforts to (i) maintain its existing listing on The Nasdaq Capital Market, (ii) prepare and submit to The Nasdaq Stock Market
a notification form for the listing of the Exchange Shares to be issued to Fitters Parent pursuant to the Transaction, and (iii) cause
such shares to be approved for listing on The Nasdaq Capital Market. In addition, under the Exchange Agreement, each of the Parties&#8217;
obligation to complete the Transaction is subject to the satisfaction or waiver by each of the parties, at or prior to the Transaction,
of various conditions, including that the existing shares of Cyclacel common stock must have been continually listed on The Nasdaq Capital
Market, and Cyclacel must have caused the shares of Cyclacel common stock to be issued in the Transaction to be approved for listing
on The Nasdaq Stock Market as of the effective time of the Transaction. For further information, see the section entitled &#8220;<i>Risk
Factors&#8212;Risks Related to Being a Public Company</i>.&#8221; Cyclacel anticipates that its common stock will be listed on The Nasdaq
Stock Market following the closing of the Transaction under the trading symbol &#8220;BGMS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_070"></span>Conditions
to the Completion of the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
respective obligations of Parent, Fitters Parent and the Company to consummate the Transactions are subject to the satisfaction or waiver
in writing prior to the Effective Time of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">No
                                            Injunctions</span>. No temporary restraining Order, preliminary or permanent injunction issued
                                            by any court of competent jurisdiction preventing or prohibiting the consummation of the
                                            Transaction contemplated shall be in effect; provided, however, that each Party shall have
                                            used its commercially reasonable efforts to prevent the entry of any such Orders or injunctions
                                            and to appeal as promptly as possible any such Orders or injunctions and to appeal as promptly
                                            as possible any such Orders or injunctions that may be entered.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stockholder
                                            Approval</span>. Parent shall have obtained the Parent Stockholder Exchange Vote and the Company
                                            shall have obtained the Required Company Shareholder Vote.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 106; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notice
                                            to Bursa Malaysia</span>. Fitters Parent shall have complied with all applicable Bursa Malaysia
                                            Securities Berhad Main Market Listing Requirements, including any required notices to Bursa
                                            Malaysia and other necessary approvals regarding the transactions contemplated under the
                                            Exchange Agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Effectiveness
                                            of Registration Statement</span>. The Registration Statement shall have become effective in
                                            accordance with the provisions of the Securities Act, and shall not be subject to any stop
                                            order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect
                                            to the Registration Statement that has not been withdrawn. Any material state securities
                                            laws applicable to the issuance of the shares of Parent Common Stock in connection with the
                                            transactions contemplated under the Exchange Agreement shall have been complied with and
                                            no stop order (or similar order) shall have been issued or threatened in writing in respect
                                            of thereof by any applicable state securities commissioner or court of competent jurisdiction.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Listing</span>.
                                            The shares of Parent Common Stock to be issued in the Exchange pursuant to the Exchange Agreement
                                            shall have been approved for listing (subject to official notice of issuance) on Nasdaq as
                                            of the Closing.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Value
                                            of Exchange Shares</span>. Parent and Fitters Parent shall agree in writing that the Exchange
                                            Shares represent mutually acceptable consideration for the acquisition of the Shares. In
                                            the event the value of the Exchange Shares is not mutually acceptable to both Parties, the
                                            Parties agree to negotiate in good faith an adjustment to the Exchange Shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of Parent to consummate the Transaction are also subject to the satisfaction or waiver in writing prior to the Effective
Time of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Representations
                                            and Warranties</span>. The representations and warranties of each of Fitters Parent and the
                                            Company contained in the Exchange Agreement and in any certificate delivered to Parent pursuant
                                            hereto shall be true and correct as of immediately prior to the Effective Time with the same
                                            force and effect as if made at and as of such time (except those representations and warranties
                                            that address matters only as of a particular date, which shall be true and correct as of
                                            that date), except where the failure of such representations and warranties to be so true
                                            and correct would not reasonably be expected to have, individually or in the aggregate, a
                                            Material Adverse Effect on the Company, and Parent shall have received a certificate to such
                                            effect signed by the President and the Chief Executive Officer of Fitters Parent and the
                                            Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Agreements
                                            and Covenants</span>. Each of Fitters Parent and the Company shall have performed in all material
                                            respects, or complied with in all material respects, all agreements and covenants required
                                            by the Exchange Agreement to be performed or complied with by them prior to the Effective
                                            Time, and Parent shall have received a certificate to such effect signed by the President
                                            and Chief Executive Officer of Fitters Parent and the Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certificate
                                            of Secretary</span>. Each of Fitters Parent and the Company shall have delivered to Parent a
                                            certificate executed by the Secretary of Fitters Parent and the Company, respectively, certifying:
                                            (i) resolutions duly adopted by the Board of Directors and shareholders of Fitters Parent
                                            and the Company, respectively, authorizing the Exchange Agreement and the Exchange; (ii)
                                            only with respect to the Company, the Governing Documents of the Company as in effect immediately
                                            prior to the Effective Time, including all amendments thereto; and (iii) the incumbency of
                                            the officers of Fitters Parent and the Company, respectively, executing the Exchange Agreement
                                            and all agreements and documents contemplated hereby.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Consents
                                            Obtained</span>. All consents, waivers, approvals, authorizations or Orders required to be obtained,
                                            and all filings required to be made, by the Company for the authorization, execution and
                                            delivery of the Exchange Agreement and the consummation by it of the transactions contemplated
                                            hereby shall have been obtained and made by the Company, except for such consents, waivers,
                                            approvals, authorizations and Orders, and such filings, which would not be reasonably likely
                                            to have a Material Adverse Effect on the Company or the Parent.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Absence
                                            of Material Adverse Effect</span>. Since the date of the Exchange Agreement, there shall not
                                            have been any Material Adverse Effect with respect to the Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Company
                                            Shareholder Written Consent</span>. The Company Shareholder Written Consent executed by the
                                            shareholders of the Company shall be in full force and effect.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Trademark
                                            License Agreement</span>. The Company and Fitters Parent shall enter into a trademark license
                                            agreement for use of the &#8220;FITTERS&#8221; mark and logo, as applicable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 107; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of Fitters Parent and the Company to consummate the Transaction are also subject to the satisfaction or waiver in writing
prior to the Effective Time of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Representations
                                            and Warranties</span>. The representations and warranties of Parent contained in the Exchange
                                            Agreement and in any certificate delivered to the Company pursuant hereto shall be true and
                                            correct as of immediately prior to the Effective Time with the same force and effect as if
                                            made at and as such time (except those representations and warranties that address matters
                                            only as of a particular date, which shall be true and correct as of that date), except where
                                            the failure of such representations and warranties to be so true and correct would not reasonably
                                            be expected to have, individually or in the aggregate, a Material Adverse Effect on Parent,
                                            and the Company shall have received a certificate to such effect signed by the Chief Executive
                                            Officer of Parent.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Agreements
                                            and Covenants</span>. Parent shall have performed in all material respects, or complied with
                                            in all material respects, all agreements and covenants required by the Exchange Agreement
                                            to be performed or complied with by them prior to the Effective Time, and the Company shall
                                            have received a certificate to such effect signed by the Chief Executive Officer of Parent.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certificate
                                            of Secretary</span>. Parent shall have delivered to the Company a certificate executed by the
                                            Secretary of Parent certifying: (i) resolutions duly adopted by the Board of Directors and
                                            stockholders of Parent authorizing the Exchange Agreement and the Exchange; (ii) the Certificate
                                            of Incorporation and Bylaws of Parent as in effect immediately prior to the Effective Time,
                                            including all amendments thereto; and (iii) the incumbency of the officers of Parent executing
                                            the Exchange Agreement and all agreements and documents contemplated hereby.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Consents
                                            Obtained</span>. All consents, waivers, approvals, authorizations or Orders required to be obtained,
                                            and all filings required to be made, by Parent for the authorization, execution and delivery
                                            of the Exchange Agreement and the consummation by it of the transactions contemplated hereby
                                            shall have been obtained and made by Parent, except for such consents, waivers, approvals,
                                            authorizations and Orders, and such filings, which would not be reasonably likely to have
                                            a Material Adverse Effect on Parent.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Absence
                                            of Material Adverse Effect</span>. Since the date of the Exchange Agreement, there shall not
                                            have been any Material Adverse Effect on Parent.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 108; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_071"></span>Termination
of the Exchange Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange Agreement may be terminated at any time prior to the Effective Time, whether before or after approval of the Exchange by the
shareholders of the Company and Parent, unless specified below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            mutual written agreement of the Company and Parent duly authorized by the Boards of Directors
                                            of the Company and Parent;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either the Company or Parent, if the other Party has breached any representation, warranty,
                                            covenant or agreement of such other Party set forth in the Exchange Agreement and such breach
                                            has resulted or is reasonably be expected to result in a Material Adverse Effect on such
                                            other Party or would prevent or materially delay the consummation of the Exchange;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either the Company or Parent, if all the conditions to the obligations of such Party for
                                            Closing the Exchange shall not have been satisfied or waived on or before the Final Date
                                            (as defined below); provided that in the event the SEC has declared effective under the Securities
                                            Act the Registration Statement by the Final Date, then either the Company or Parent shall
                                            be entitled to extend the Final Date for an additional sixty (60) days in order to hold the
                                            Parent Stockholder Meeting and obtain the Parent Stockholder Exchange Vote; provided, however,
                                            that the right to terminate the Exchange Agreement pursuant to Section 8.1(c) shall not be
                                            available to any Party whose breach of any representation, warranty, covenant or agreement
                                            set forth in the Exchange Agreement has been the cause of, or resulted in, such failure;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either the Company or Parent, if any Law, permanent injunction or other Order by any Governmental
                                            Entity which would make illegal or otherwise restrain or prohibit the consummation of the
                                            Exchange shall have been issued, entered, or enacted and shall have become final and nonappealable;
                                            provided, however, that the right to terminate the Exchange Agreement pursuant to Section
                                            8.1(d) shall not be available to any Party whose breach of any representation, warranty,
                                            covenant or agreement set forth in the Exchange Agreement has been the cause of, or resulted
                                            in, the issuance, entry, or enactment of any such Law or Order;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either the Company or Parent if (i) the Parent Stockholder Meeting (including any adjournments
                                            and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders
                                            shall have taken a final vote on the Parent Stockholder Matters, and (ii) the Parent Stockholder
                                            Exchange Approval Matter shall not have been approved at the Parent Stockholder Meeting (or
                                            at any adjournment or postponement thereof) by the Parent Stockholder Exchange Vote; provided,
                                            however, that the right to terminate the Exchange Agreement under Section 8.1(e) shall not
                                            be available to Parent where the failure to obtain the Parent Stockholder Exchange Vote shall
                                            have been caused by the action or failure to act of Parent and such action or failure to
                                            act constitutes a material breach by Parent of the Exchange Agreement; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            Parent if the Required Company Shareholder Vote shall not have been obtained within two (2)
                                            Business Days of the Registration Statement becoming effective in accordance with the provisions
                                            of the Securities Act; provided, however, that once the Required Company Shareholder Vote
                                            has been obtained, Parent may not terminate the Exchange Agreement pursuant to Section 8.1(d).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, the &#8220;Final Date&#8221; shall be September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_072"></span>Amendment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange Agreement may be amended with the approval of the respective boards of directors of Fitters Parent, the Company and Parent at
any time (whether before or after the adoption and approval of the Exchange Agreement by the Company&#8217;s shareholders or before or
after obtaining the Parent stockholder vote); provided, however, that after any such approval of the Exchange Agreement by a Party&#8217;s
stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of
such stockholders. The Exchange Agreement may not be amended except by an instrument in writing signed on behalf of each of Fitters Parent,
the Company, and Parent<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_073"></span>Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange Agreement provides that all fees and expenses incurred by any Party in connection with the Exchange Agreement and the transactions
contemplated hereby shall be paid by the Party incurring such fees and expenses. Fees and expenses incurred by any Party in connection
with the transactions contemplated by the Exchange Agreement shall include, without limitation, out-of-pocket fees and expenses incurred
for legal, financial, accounting and other advisors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 109; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_074"></span>MATTERS
BEING SUBMITTED TO A VOTE OF THE STOCKHOLDERS OF CYCLACEL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_075"></span>Proposal
1: Approval of the Issuance of Common Stock in the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the special meeting, stockholders will be asked to approve the issuance of Cyclacel common stock pursuant to the Exchange Agreement.
Immediately following the Transaction, (a) current Cyclacel stockholders are expected to own approximately 80.01% of the common stock
of Cyclacel and (b) Fitters Parent is expected to own approximately 19.99% of the common stock of Cyclacel, in each case calculated on
a pro forma basis after giving effect to the Transaction. These ownership percentages are estimates and are subject to adjustment prior
to Closing as set forth in the Exchange Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of, reasons for and other aspects of the Exchange Agreement, the Transaction and the issuance of the Exchange Shares of Cyclacel
pursuant to the Exchange Agreement are described in detail in the sections entitled &#8220;<i>The Exchange Agreement</i>&#8221; and &#8220;<i>The
Transaction</i>.&#8221; A copy of the Exchange Agreement is attached as <i>Annex A</i> to this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Required
Vote</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affirmative vote of the holders of a majority of the shares of Cyclacel common stock present in person or represented by proxy at the
special meeting is required to approve Proposal 1. <b>Each of Proposals 1, 2 and 3 are conditioned upon each other. Therefore, the Transaction
cannot be consummated without the approval of Proposals 1, 2 and 3.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recommendation
of Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL 1 TO APPROVE THE ISSUANCE OF CYCLACEL COMMON STOCK PURSUANT
TO THE EXCHANGE AGREEMENT.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_076"></span>Proposal
2: Approval of the Potential Issuance of Greater than 20% in the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the special meeting, stockholders will be asked to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential
issuance of more than 20% of the issued and outstanding shares of Cyclacel common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect
of Proposal on Current Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Nasdaq Proposal is adopted, Cyclacel could potentially issue shares representing more than 20% of the outstanding shares of our common
stock in connection with the Transaction. The current formula pursuant to the Exchange Agreement provides for a total number of Exchange
Shares to be issued to Fitters Parent equal to 19.99% of the outstanding stock of Cyclacel at the time of the Closing. Because the Exchange
Agreement provides for an adjustment of the number of Exchange Shares prior to Closing upon good faith negotiations between the Parties,
and the current amount is just under 20%, there is the possibility that the final number of Exchange Shares exceeds 20%. The issuance
of such shares would result in dilution to the Cyclacel stockholders and would afford such stockholders a smaller percentage interest
in the voting power, liquidation value and aggregate book value of Cyclacel. If the Nasdaq Proposal is adopted, Cyclacel would be able
to issue a higher percentage of Exchange Shares of common stock to Fitters Parent as consideration in the Transaction. We anticipate
that Fitters Parent will hold 19.99% of our outstanding shares of common stock, and the current Cyclacel stockholders will hold 80.01%
of our outstanding common stock immediately following completion of the Transaction but there is no certainty of the final percentages
until the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Proposal 2 is not approved and we need additional Exchange Shares to consummate the Transaction on its current terms, Cyclacel would
be unable to issue such Exchange Shares without being in violation of Nasdaq Listing Rule 5635(d), which could result in the delisting
of our securities from the Nasdaq Capital Market. If Nasdaq delists our securities from trading on its exchange, we could face significant
material adverse consequences, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a limited availability of market quotations for our securities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
reduced liquidity with respect to our securities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a determination that our shares are a &#8220;penny stock,&#8221; which will require brokers trading in our securities to adhere to more
stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our securities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a limited amount of news and analyst coverage for the post-transaction company; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a decreased ability to issue additional securities or obtain additional financing in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 110; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is a condition to the obligations of the Parties to close the Transaction that our common stock remain listed on The Nasdaq Capital Market.
As a result, if Proposal 2 is not adopted, the Transaction may not be completed unless the total number of Exchange Shares to be issued
to Fitters Parent equals 19.99% of the outstanding stock of Cyclacel at the time of the Closing. Additional terms of, reasons for and
other aspects of the computation of the number of Exchange Shares of Cyclacel pursuant to the Exchange Agreement are described in detail
in the sections entitled &#8220;<i>The Exchange Agreement</i>&#8221; and &#8220;<i>The Transaction</i>.&#8221; A copy of the Exchange
Agreement is attached as <i>Annex A</i> to this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Vote
Required for Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
that a quorum is present at the Meeting, the affirmative vote of holders of a majority of the total votes cast on this Proposal 2 is
required. Accordingly, neither a stockholder&#8217;s failure to vote online during the special meeting or by proxy, a broker non-vote
nor an abstention will be considered a &#8220;vote cast,&#8221; and thus will have no effect on the outcome of this proposal. <b>Each
of Proposals 1, 2 and 3 are conditioned upon each other. Therefore, the Transaction cannot be consummated without the approval of Proposals
1, 2 and 3.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recommendation
of Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL 2 TO APPROVE, FOR PURPOSES OF COMPLYING WITH NASDAQ LISTING
RULE 5635(D), THE POTENTIAL ISSUANCE OF MORE THAN 20% OF THE ISSUED AND OUTSTANDING SHARES OF CYCLACEL COMMON STOCK.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_077"></span>Proposal
3: Approval of Amendment to the Amended and Restated Certificate of Incorporation of the Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the special meeting, holders of Cyclacel common stock will be asked to approve the amendment to the amended and restated certificate
of incorporation of Cyclacel to (a) change the name of the corporation from &#8220;Cyclacel, Inc.&#8221; to &#8220;Bio Green Med Solution,
Inc.&#8221;, (b) permit actions by stockholders by written consent, and (c) opt out of the business combination provisions of
Section 203 of the DGCL, by filing an amendment to the amended and restated certificate of incorporation at the closing of the Transaction.
In addition, holders of Cyclacel common stock will be asked to approve and ratify all prior action by stockholder written consent including
without limitation, majority stockholder consents dated March 21, 2025, May 12, 2025 and June 18, 2025. A copy of the proposed
amendment to the amended and restated certificate of incorporation is attached as <i>Annex B </i>to this proxy statement/prospectus.
The primary reason for the corporate name change is that management believes this will allow for brand recognition of the Company&#8217;s
business line following the consummation of the Transaction and the reason to permit actions by stockholder written consent and ratification
of all prior actions by stockholder written consent is to provide more flexibility to management within the limits of applicable law
and allow a majority of stockholders to take action without the time and expense required to call a special meeting of stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Board believes that
opting out of the business combination provisions of Section 203 of the DGCL better aligns the Company with its principal stockholders
and investors and allows for cost efficiencies and operational flexibility.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Required
Vote</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affirmative vote of the holders of a majority of the outstanding shares of common stock entitled to vote on the record date for the special
meeting is required for approval of Proposal 3. <b>Each of Proposals 1, 2 and 3 are conditioned upon each other. Therefore, the Transaction
cannot be consummated without the approval of Proposals 1, 2 and 3.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recommendation
of Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL 3 TO APPROVE THE AMENDMENTS TO THE AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_078"></span>Proposal
4: Approval of Possible Adjournment of the Special Meeting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Cyclacel fails to receive a sufficient number of votes to approve Proposals 1, 2 and 3, Cyclacel may propose to adjourn the special meeting,
for a period of not more than 30 days, for the purpose of soliciting additional proxies to approve Proposals 1, 2 and 3. Cyclacel currently
does not intend to propose adjournment at the special meeting if there are sufficient votes to approve Proposals 1, 2 and 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Required
Vote</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affirmative vote of the holders of a majority of the shares of Cyclacel common stock present in person or represented by proxy at the
special meeting is required to approve Proposal 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recommendation
of Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL 4 TO ADJOURN THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT
ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSALS 1, 2 AND 3.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 111; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_079"></span>CYCLACEL
PHARMACEUTICALS, INC. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel,&#8221; we,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) is a Delaware corporation
formed in 1996. We are a clinical-stage biopharmaceutical company working to develop innovative cancer medicines based on cell cycle,
epigenetics and mitosis biology. We are a pioneer company in the field of cancer cell cycle biology with a vision to improve patient
healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient&#8217;s
overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
epigenetic/anti-mitotic program is evaluating plogo, a PLK1 inhibitor, in solid tumors and hematological malignancies. Our strategy is
to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have retained rights to commercialize our clinical development candidates and our business objective is to enter into selective partnership
arrangements with these programs. Substantially all our efforts to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. As part of the
Company&#8217;s efforts to reduce operating costs, it has determined to focus on the development of plogo only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recently established a wholly-owned subsidiary in Malaysia, BIGM Capital Sdn. Bhd., to act as an investment holding company and other
investment activities as deemed suitable at later stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell
Cycle Control Biology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polo
Kinases and other mitotic kinases were first discovered in fruit flies by our former Chief Scientist, Professor David Glover, PhD. PLK1
is a serine/threonine kinase playing a central role in cell division, or mitosis. In particular, PLK1 regulates mitotic entry, spindle
formation, mitotic exit and cytokinesis and is an important regulator of the DNA damage checkpoint. Cancer cells are much more sensitive
to PLK1 depletion than normal cells with intact cell cycle checkpoints. Inhibiting PLK1 blocks proliferation by prolonged mitotic arrest
followed by onset of cancer cell death. The lead drug in our anti-mitotic program is plogosertib, or plogo (formerly known as CYC140).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Development Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline of innovative medicines aims to provide safe and effective anticancer treatment options to patients combined with the convenience
of oral administration. Our preclinical and clinical studies suggests that daily dosing by the oral route is a preferred strategy for
both our drugs. We also conducted certain early clinical studies using intravenous (&#8220;i.v.&#8221;) administration. The aim of the
current streamlined studies is to assess safety and identify signals of clinical activity which may lead to registration-enabling outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our development programs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROGRAM</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; white-space: nowrap; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDICATION</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PHASE</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mitosis
    Regulation</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plogosertib
    PLK* inhibitor (oral)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solid
    tumors &#8211; multiple cohorts defined by tumor histology and a basket cohort</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1/2 to achieve proof of concept #</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
PLK: polo-like kinase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
Study to resume recruitment following introduction of new oral formulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently retain all global marketing rights to the compounds associated with our clinical-stage drug program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 112; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mitosis
Regulation Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Polo-Like-Kinase
inhibitor &#8212; Plogosertib</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our Polo-like Kinase, or PLK, inhibitor program, we have discovered potent and selective small molecule inhibitors of PLK1. Polo Kinase
was discovered by Professor David Glover, our former Chief Scientist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLK1
is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is an important regulator
of the DNA damage checkpoint. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian
and squamous cell cancers, as well as MYC amplified cancers including breast. Recent data with another PLK1 inhibitor in clinical development
suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plogo
is a novel, small molecule, selective, PLK1 inhibitor which has demonstrated an epigenetic mechanism, potent and selective target inhibition
(PLK1 IC50 approximately 3 nM) and impressive efficacy in human tumor xenografts at non-toxic doses. Plogo has improved pharmaceutical
properties over earlier, clinical stage, PLK inhibitors. Our translational biology program supports the development of plogo in solid
tumor and hematological malignancy indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
1/2 Study in advanced solid tumors and lymphomas (CYC140-101, orally dosed)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
open-label Phase 1/2 registration-directed study uses a streamlined design and initially seeks to determine the RP2D for single-agent
oral plogo in a dose escalation stage. Once RP2D has been established, the study will enter into proof-of-concept, cohort stage, using
a Simon 2-stage design. In this stage plogo will be administered to patients in up to seven mechanistically relevant cohorts including
patients with bladder, breast, colorectal (including KRAS mutant), hepatocellular and biliary tract, and lung cancers (both small cell
and non-small cell), as well as lymphomas. An additional basket cohort will enroll patients with biomarkers relevant to the drug&#8217;s
mechanism, including MYC amplified tumors. The protocol allows for expansion of individual cohorts based on response which may allow
acceleration of the clinical development and registration plan for plogo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifteen
patients have been treated at the first five dose escalation levels with no dose limiting toxicities observed. Stable disease has been
observed in pretreated patients with gastrointestinal, lung, and ovarian cancers. A new, alternative salt, oral formulation of plogo
with improved bioavailability is under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Published
preclinical data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data presented at the 2016 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium and at the 2017 Annual Meeting of
the American Association of Cancer Research demonstrated the therapeutic potential of plogo as a targeted anti-cancer agent. The data
demonstrated that plogo is a selective PLK1 inhibitor which is highly active against both solid and liquid cancer models, preferentially
induces growth inhibition and cell death in malignant versus non-malignant cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
of proliferating cells with plogo resulted in reduced phosphorylation of the PLK1 substrate phospho-nucleophosmin, accumulation of cells
in mitosis and an increase in the proportion of mitotic cells with monopolar spindles, which are all features consistent with PLK1 inhibition.
In a cell line panel derived from esophageal cancer and various non-malignant solid tissues, plogo was preferentially cytotoxic to malignant
cells. Malignant cells which are sensitive to plogo undergo complete growth inhibition and induction of cell death in response to treatment.
In contrast, non-malignant cells are only temporarily arrested and normal cell cycle transit is restored.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical development strategy is focused on our program in epigenetics/mitosis control biology. As part of the Company&#8217;s efforts
to reduce operating costs it has determined to focus on the development of the plogo clinical program only. Fadraciclib, the Company&#8217;s
other drug development program, is being marketed for sale by the joint liquidators through Hilco Appraisals Limited, a firm of professional
valuation agents and will no longer be part of the assets of the Company as of January 2025. We have retained worldwide rights to commercialize
plogo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 113; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Focus
on the cell cycle and cancer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
core area of expertise is in cell cycle biology and our senior management team has extensive experience in research, preclinical and
clinical development and sales and marketing. The novel, mechanism-targeted cell cycle drugs we are developing are designed to be highly
selective in comparison to conventional chemotherapies, potentially inducing death in cancer cells while sparing most normal cells which
may give rise to fewer side-effects. Thus, we believe that we are well placed to exploit the significant opportunities that this area
offers for new drug discovery and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Develop
anticancer drug candidates in all phases of the cell cycle and multiple compounds for particular cell cycle targets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Targeting
a broad development program focused on multiple phases of the cell cycle allows us to minimize risk while maximizing the potential for
success, and also to develop products that are complementary to one another.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Enter
into partnering arrangements selectively, while developing our own sales and marketing capability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently retain virtually all marketing rights to the compounds associated with our clinical-stage drug programs. To optimize our commercial
return, we intend to enter into selected partnering arrangements and to retain co-promotion rights as appropriate. Generally we plan
to develop compounds through the Phase 2 proof-of-efficacy stage before seeking a partner. We may enter into partnering arrangements
earlier than Phase 2 proof-of-concept trials where appropriate, or in connection with drug programs outside our core competency in oncology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our programs are based on technology licensed from others. Our breach of an existing license or failure to obtain a license to technology
that is required in order to develop, test and commercialize our products may seriously harm our business. In March 2023, we terminated
our license agreement with Daiichi Sankyo Co., Ltd. for patents and patent applications covering sapacitabine for commercial reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patents
and Proprietary Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Plogosertib
Patents and Proprietary Rights</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 10, 2025, we have 2 patents granted in the United States, 1 granted by the European Patent Office, or EPO, and 6 granted in other
countries worldwide. We have 2 patent applications filed in the United States, 2 filed at the EPO and 16 filed in other countries worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intellectual
Property Strategy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider intellectual property rights to be vital and use a variety of methods to secure, protect and evaluate these rights. These methods
include ownership and enforcement of patent rights, patent applications, license agreements with third parties, invention assignment,
confidentiality and non-compete agreements with key employees and consultants, material transfer agreements, and trademark protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
give priority to obtaining substance of matter claims in the United States, the EPO, Japan and other important markets if such protection
is available. We prefer composition of matter claims because they provide us with rights to the compounds themselves, and not merely
a particular use. In addition to composition of matter claims, we seek coverage for solid state forms, polymorphic and crystalline forms,
medical uses, combination therapies, specific regimens, pharmaceutical forms of our compounds and synthetic routes where available and
appropriate. Claims covering combination therapies, specific regimens and pharmaceutical forms can be valuable because the therapeutic
effect of pharmaceuticals used in the anticancer field is often enhanced when individual therapeutics are used in particular combinations
or dosed in a certain way. The availability of protection in these areas can, however, vary from jurisdiction to jurisdiction and combination
claims are particularly difficult to obtain for many inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
publications in scientific or patent literature often lag behind actual discoveries, we are not certain of being first to make the inventions
covered by each of our pending patent applications or the first to file those patent applications. Generally, patent applications are
maintained in secrecy for a period of 18 months or more, which increases the uncertainty we face. Moreover, the patent positions of biotechnology
and pharmaceutical companies are highly uncertain and involve complex legal and factual questions. As a result, we cannot predict the
breadth of claims allowed in biotechnology and pharmaceutical patents, or their enforceability. Third parties or competitors may challenge
or circumvent our patents or patent applications, if issued. Because of the extensive time required for development, testing and regulatory
review of a potential product, it is possible that before we commercialize any of our products, any related patent may expire, or remain
in existence for only a short period following commercialization, thus reducing any advantage of the patent and the commercial opportunity
of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 114; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
patents are issued to others containing valid claims that cover our compounds or their manufacture or use or screening assays related
thereto, we may be required to obtain licenses to these patents or to develop or obtain alternative technology. We are aware of several
published patent applications, and understand that others may exist, that could support claims that, if granted and held valid, would
cover various aspects of our developmental programs, including in some cases particular uses of our drug candidate plogo, or other therapeutic
candidates, or substances, processes and techniques that we use in the course of our research and development and manufacturing operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we understand that other applications and patents exist relating to potential uses of plogo which are not part of our current
clinical programs for those compounds. Although we intend to continue to monitor the pending applications, it is not possible to predict
whether these claims will ultimately be allowed or if they were allowed what their breadth would be. In addition, we may need to commence
litigation to enforce any patents issued to us or to determine the scope and validity of third-party proprietary rights. For example,
in one case we opposed a European patent relating to human aurora kinase and the patent was finally revoked (no appeal was filed). Litigation
would create substantial costs. We are aware that other patents exist that claim substances, processes, techniques and methods of use,
which, if held valid, could potentially restrict the scope of our research, development or manufacturing operations. If competitors prepare
and file patent applications in the United States that claim technology that we also claim, we may have to participate in interference
proceedings in the United States Patent and Trademark Office to determine which invention has priority. These proceedings could result
in substantial costs, even if the eventual outcome is favorable to us. An adverse outcome in litigation could subject us to significant
liabilities to third parties and require us to seek licenses of the disputed rights from third parties or to cease using the technology,
even a therapeutic product, if such licenses are unavailable or too expensive. Issued patents for plogo cover the United States, EPO
and six other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no in-house manufacturing capabilities and have no current plans to establish manufacturing facilities for significant clinical
or commercial production. We have no direct experience in manufacturing commercial quantities of any of our products, and we currently
lack the resources or capability to manufacture any of our products on a clinical or commercial scale. As a result, we are dependent
on corporate partners, licensees or other third parties for the manufacturing of clinical (and eventually commercial) scale quantities
of all of our products. We believe that this strategy will enable us to direct operational and financial resources to the development
of our product candidate rather than diverting resources to establishing a manufacturing infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory agencies in state and local jurisdictions, as well as in foreign countries, impose substantial regulatory
requirements upon the clinical development, manufacture, marketing and distribution of drugs. These agencies and other federal, state
and local authorities regulate research and development activities and the testing, manufacture, quality control, import, export, safety,
efficacy, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring,
and post-approval reporting of drug products, such as those we are developing. Along with our third-party contractors, we will be required
to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries
in which we wish to conduct studies or seek approval or licensure of plogo or any of its product candidates. The process of obtaining
regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require
the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, in the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act and its implementing regulations.
The process required by the FDA before our drug candidates may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                            of extensive nonclinical laboratory tests, which may include animal studies and formulation
                                            studies, all performed in accordance with the FDA&#8217;s good laboratory practice, or GLP,
                                            regulations;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 115; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of an investigational new drug application, or IND, which must become effective
                                            before clinical trials may begin and must be updated annually or when significant changes
                                            are made;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            by an Institutional Review Board (&#8220;IRB&#8221;) or ethics committee at each clinical
                                            site before the trial is initiated at such sites;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                            of adequate and well-controlled clinical trials in accordance with good clinical practice,
                                            or GCP, and other clinical-trial related regulations to establish the safety and efficacy
                                            of the drug candidate for each proposed indication;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
                                            and submission of a new drug application (&#8220;NDA&#8221;), to the FDA;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            determination by the FDA within 60 days of its receipt of an NDA to file the application
                                            for review;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA pre-approval inspection of the manufacturing facilities at which the
                                            product is produced to assess compliance with current good manufacturing practice requirements,
                                            or cGMP, regulations;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                            audit of selected clinical trial sites to assess compliance with GCP and the integrity of
                                            the clinical data submitted in support of the NDA; and</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            review and approval of the NDA to permit commercial marketing of the drug product for particular
                                            approved indications for use in the United States.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for
our drug candidates will be granted on a timely basis, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
testing any drug product candidate, including plogo, our sole current product candidate, in humans, the product candidate must undergo
rigorous preclinical testing. Preclinical and other nonclinical tests generally include laboratory evaluation of product chemistry, formulation
and stability, as well as studies to evaluate toxicity in animals. The Consolidated Appropriations Act for 2023, signed into law on December
29, 2022, (P.L. 117-328) amended the FDCA and the Public Health Service Act to specify that nonclinical testing for drugs may, but is
not required to, include in vivo animal testing. According to the amended language, a sponsor may fulfill nonclinical testing requirements
by completing various in vitro assays (e.g., cell-based assays, organ chips, or micro-physiological systems), in silico studies (i.e.,
computer modeling), other human or nonhuman biology-based tests (e.g., bioprinting), or in vivo animal tests. The conduct of preclinical
studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. Some long-term preclinical
testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after an IND for an investigational drug
candidate is submitted to the FDA and human clinical trials have been initiated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical tests, together with manufacturing information and analytical data, are submitted as part of an IND to the FDA.
An IND must become effective before human clinical trials begin. The IND automatically becomes effective 30 days after receipt by the
FDA, unless the FDA, within the 30-day time period, issues a notice expressly authorizing the proposed trial to proceed or raises concerns
or questions about the adequacy or safety of the preclinical testing or the proposed conduct of the clinical trial, including concerns
that human research subjects will be exposed to unreasonable health risks. If FDA raises concerns or places the trial on clinical hold,
the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Our submission of an IND, or those
of our collaborators, may therefore not result in FDA authorization to commence a clinical trial. A separate submission to an existing
IND must also be made for each successive clinical trial conducted during product development. Further, an independent institutional
review board, or IRB, for each medical center proposing to conduct the clinical trial (or a central IRB) must review and approve the
plan for any clinical trial before such trial commences at that site and the designated IRB must monitor the clinical trial until completed.
The FDA or the clinical trial sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive good clinical practice, or
GCP, requirements, including those relating to informed consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 116; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of an NDA submission, clinical trials are typically conducted in the following three sequential phases, which may overlap:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
                                            1</i>: The clinical trials are initially conducted in a limited population to test the drug
                                            candidate for safety, dose tolerance, absorption, metabolism, distribution and excretion
                                            in healthy humans. In the case of some products for severe or life-threatening diseases,
                                            such as cancer, especially when the product may be too inherently toxic to ethically administer
                                            to healthy volunteers, the initial human testing is often conducted in patients. Phase 1
                                            clinical trials can be designed to evaluate the impact of the drug candidate in combination
                                            with currently approved drugs.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
                                            2: </i>These clinical trials are generally conducted in a limited patient population to identify
                                            possible adverse effects and safety risks, to evaluate preliminary efficacy of the drug candidate
                                            for specific targeted indications and to determine dose tolerance and optimal dosage. Multiple
                                            Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning
                                            larger and more expensive Phase 3 clinical trial.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9632;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
                                            3: </i>These clinical trials are commonly referred to as pivotal clinical trials. If the
                                            Phase 2 clinical trials demonstrate that a dose range of the drug candidate is effective
                                            and has an acceptable safety profile, Phase 3 clinical trials are then undertaken in large
                                            patient populations to further evaluate dosage, to provide substantial evidence of clinical
                                            efficacy and to further test for safety in an expanded and diverse patient population at
                                            multiple, geographically dispersed clinical trial sites. These trials are intended to establish
                                            the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate
                                            basis for product labeling. Phase 3 trials typically include comparisons with placebo and/or
                                            other comparator treatments. The duration of treatment is often extended to mimic the actual
                                            use of a product during marketing.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, the FDA may condition approval of an NDA for a drug candidate on the sponsor&#8217;s agreement to conduct a Phase 4, which
includes additional clinical trials to further assess the drug&#8217;s safety and effectiveness after NDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Consolidated Appropriations Act for 2023, Congress amended the FDCA to require sponsors of a Phase 3 clinical trial, or other &#8220;pivotal
study&#8221; of a new drug to support marketing authorization, to submit a diversity action plan for such clinical trial. The action
plan must include the sponsor&#8217;s diversity goals for enrollment, as well as a rationale for the goals and a description of how the
sponsor will meet them. A sponsor must submit a diversity action plan to FDA by the time the sponsor submits the trial protocol to the
agency for review. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. It is unknown at this
time how the diversity action plan may affect Phase 3 trial planning and timing or what specific information FDA will expect in such
plans, but if FDA objects to a sponsor&#8217;s diversity action plan and requires the sponsor to amend the plan or take other actions,
it may delay trial initiation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if unexpected
serious adverse events, or SAEs, occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend
or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical
protocol, GCP, or other IRB requirements or if the drug has been associated with unexpected serious harm to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NDA
Submission and Review by the FDA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
preclinical studies and clinical trials are submitted to the FDA as part of an NDA requesting approval to market the product for one
or more indications. The NDA must contain proof of the product candidate&#8217;s safety and substantial evidence of effectiveness for
its proposed indication or indications in the form of relevant data available from pertinent preclinical and clinical studies, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry,
manufacturing, controls, and proposed labeling, among other things. In particular, a marketing application must demonstrate that the
manufacturing methods and quality controls used to produce the drug product are adequate to preserve the drug&#8217;s identity, strength,
quality, and purity. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the use of
the product, or from a number of alternative sources, including studies initiated by investigators. FDA approval of an NDA must be obtained
before the corresponding drug may be marketed in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 117; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews all NDAs submitted to determine if they are substantially complete before it accepts them for filing and may request additional
information rather than accepting a submission for filing. The FDA must make a decision on accepting an NDA for filing within 60 days
of receipt and must inform the sponsor by the 74th day after the FDA&#8217;s receipt of the submission whether the application is sufficiently
complete to permit substantive review. The FDA may refuse to file any submission that it deems incomplete or not properly reviewable
at the time of submission and may request additional information. In this event, the marketing application must be resubmitted with the
additional information requested by the agency. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the review process, the FDA reviews the NDA to determine, among other things, whether the product is safe and effective and whether the
facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued strength,
quality, and purity. The FDA may refer any NDA, including applications for novel drug candidates which present difficult questions of
safety or efficacy to an advisory committee to provide clinical insight on application review questions. Typically, an advisory committee
is a panel of independent experts, including clinicians and other scientific experts that reviews, evaluates and provides a recommendation
as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory
committee, but it considers such recommendations carefully when making final decisions on approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Pediatric Research Equity Act, or PREA, amendments to the FDCA, an NDA or supplement to an NDA must contain data that are adequate
to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric populations and to support
dosing and administration for each pediatric population for which the product is safe and effective. The FDA may grant deferrals for
submission of pediatric data or full or partial waivers. The PREA requires a sponsor that is planning to submit a marketing application
for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration
to submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase 2 meeting or, if there is no such meeting, as
early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the
pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and
statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments
or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and
the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes
to the pediatric plan need to be considered based on data collected from pre-clinical studies, early-phase clinical trials or other clinical
development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval is limited to the conditions of use (e.g., patient population, indication)
described in the application and may entail further limitations on the indicated uses for which such product may be marketed. For example,
the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication
guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and
other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case
basis. If the FDA concludes a REMS plan is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve an NDA
without a REMS, if one is required. The FDA also may condition approval on, among other things, changes to proposed labeling (e.g., adding
contraindications, warnings or precautions) or the development of adequate controls and specifications. Once approved, the FDA may withdraw
the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the
product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor
the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results
of these post-marketing studies. After approval, some types of changes to the approved product, such as adding new indications, manufacturing
changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. In addition, new government
requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could
delay or prevent regulatory approval of our products under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 118; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fast
Track, Priority Review, and Breakthrough Therapy Designations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#8217;s review and approval of new drugs
and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation
if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for
the condition. Fast track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical
development, in addition to the potential for rolling review once a marketing application is filed, meaning that the FDA may consider
for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule
for the submission of the sections of the application, the FDA agrees to accept the sections and determines that the schedule is acceptable,
and the sponsor pays any required user fees upon submission of the first section of the application. A fast track designated product
candidate may also qualify for accelerated approval (described below) or priority review, under which the FDA sets the target date for
FDA action on the NDA or BLA at six months after the FDA accepts the application for filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Priority
review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness
of the treatment, diagnosis, or prevention of a serious condition. Significant improvement may be illustrated by evidence of increased
effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented
enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new
subpopulation. If criteria are not met for priority review, the application is subject to the standard FDA review period of 10 months
after FDA accepts the application for filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended,
alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary
clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation
provides all the features of fast track designation in addition to intensive guidance on an efficient development program beginning as
early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced
review and regulatory staff in a proactive, collaborative, cross-disciplinary review, where appropriate. A drug designated as breakthrough
therapy is also eligible for accelerated approval if the relevant criteria are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. fast track, priority review and breakthrough
therapy designations do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval
but may expedite the development or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accelerated
Approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful
therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate
and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely
to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when it has an effect on an intermediate
clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably
likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition
and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic
receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical
endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet
the same statutory standards for safety and effectiveness as those granted traditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval
confirmatory studies to verify and describe the product candidate&#8217;s clinical benefit. As a result, a product candidate approved
on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical
trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted
clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of the product. As part of the
Consolidated Appropriations Act for 2023, Congress provided FDA additional statutory authority to mitigate potential risks to patients
from continued marketing of ineffective drugs or biologics previously granted accelerated approval. Under the act&#8217;s amendments
to the FDCA, FDA may require the sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval.
The sponsor must also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports
are published on FDA&#8217;s website. The amendments also give FDA the option of using expedited procedures to withdraw product approval
if the sponsor&#8217;s confirmatory trial fails to verify the claimed clinical benefits of the product. All promotional materials for
product candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 119; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Special
Protocol Assessment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Phase 2 clinical trial is the subject of discussion at an end-of-Phase 2 meeting with the FDA, a sponsor may be able to request a Special
Protocol Assessment, or SPA, the purpose of which is to reach agreement with the FDA on the design of the Phase 3 clinical trial protocol
design and analysis that will form the primary basis of an efficacy claim. If such an agreement is reached, it will be documented and
made part of the administrative record, and it will be binding on the FDA and may not be changed unless the sponsor fails to follow the
agreed-upon protocol, data supporting the request are found to be false or incomplete, or the FDA determines that a substantial scientific
issue essential to determining the safety or effectiveness of the drug was identified after the testing began. Even if an SPA is agreed
to, approval of the NDA is not guaranteed because a final determination that an agreed-upon protocol satisfies a specific objective,
such as the demonstration of efficacy, or supports an approval decision, will be based on a complete review of all the data in the NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Drugs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, defined as a
disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater
than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available
the drug in the United States will be recovered from sales in the United States for that drug. Orphan drug designation must be requested
before submitting a marketing application. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent
and its potential orphan use are disclosed publicly by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the
disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve
any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances,
such as a showing of clinical superiority to the product with orphan product exclusivity or if FDA finds that the holder of the orphan
product exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs
of patients with the disease or condition for which the drug was designated. Orphan product exclusivity does not prevent the FDA from
approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other
benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
term restoration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA approval of the use of our product candidate, some of our United States patents may be
eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to
five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term
restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product candidate&#8217;s approval date.
The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of
an NDA, plus the time between the submission date of the NDA and the approval of that application, except that the review period is reduced
by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product candidate
is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation
with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for
restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date,
depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 120; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-approval
requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including,
among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and
distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved
uses or patient populations (i.e., &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities.
The manufacturer and its products are also subject to similar post-approval requirements by regulatory authorities comparable to FDA
in jurisdictions outside of the United States where the products are approved. Although physicians may prescribe legally available products
for off-label uses, manufacturers may not market or promote such uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations
include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product
containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls,
records and reports and returned or salvaged products. The manufacturing facilities for our product candidate must meet applicable cGMP
requirements to the FDA&#8217;s or comparable foreign regulatory authorities&#8217; satisfaction before any product is approved and our
commercial products can be manufactured. We rely, and expect to continue to rely, on third parties for the production of clinical (and
ultimately commercial) quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations
that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation
to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of
approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic prescheduled
or unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers
must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Future inspections
by the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or
distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including
failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result
in restrictions on a product, manufacturer or holder of an approved NDA, including voluntary recall and regulatory sanctions as described
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval or clearance of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards
is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product,
including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory
requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or
clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential
consequences include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 11.5pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of the product, complete withdrawal of the product from
                                            the market or product recalls;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 11.5pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            warning letters or other enforcement-related letters or clinical holds on post-approval clinical
                                            trials;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 11.5pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            of the FDA to approve pending marketing applications or supplements to approved marketing
                                            authorizations, or suspension or revocation of product approvals;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 11.5pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 11.5pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties; and</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 11.5pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent
                                            decrees, corporate integrity agreements, debarment, or exclusion from federal health care
                                            programs; or mandated modification of promotional materials and labeling and the issuance
                                            of corrective information.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -24.5pt"></p>

<!-- Field: Page; Sequence: 121; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which
regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation
of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples
and impose requirements to ensure accountability in distribution. Most recently, the Drug Supply Chain Security Act, or DSCSA, was enacted
with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States. The
DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers
over a 10-year period that was initially expected to culminate in November 2023. In August 2023, the FDA announced &#8220;a 1-year stabilization
period to accommodate additional time&#8221; needed by pharmaceutical supply chain stakeholders. Since then, the deadline has been pushed
further with an additional year into 2025. The DSCSA&#8217;s new 2025 deadline for manufacturers and repackagers is May 27, 2025. From
time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the
approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory
changes will be enacted, whether FDA regulations, guidance or interpretations will be changed or what the impact of such changes, if
any, may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
U.S. health care laws and regulations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of states also have statutes or regulations similar to the aforementioned federal laws, some of which are broader in scope and
apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.
Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines,
or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information
related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements
that are more stringent than the Physician Payments Sunshine Act. State and foreign laws also govern the privacy and security of health
information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that business activities can be
subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid
change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal
and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers,
which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that business arrangements with third parties comply with applicable healthcare laws and regulations is costly and time consuming. If
business operations are found to be in violation of any of the laws described above or any other applicable governmental regulations
a pharmaceutical manufacturer may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement,
individual imprisonment, exclusion from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages,
reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity
agreement or other agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of operations,
any of which could adversely affect a pharmaceutical manufacturer&#8217;s ability to operate its business and the results of its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulation
outside of the United States</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial
sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we
must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the 28-member European
Union, before we commence clinical trials or market products in those countries or areas. The approval process and requirements governing
the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can
involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and
jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction
does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction
may negatively impact the regulatory process in others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 122; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>European
Union drug development, review and approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, our product candidate also may be subject to extensive regulatory requirements. As in the United States, medicinal
products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United
States, the various phases of pre-clinical and clinical research in the European Union are subject to significant regulatory controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP, and the related national implementing provisions of the individual
EU Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain
prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore,
the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion.
The clinical trial application must be accompanied by, among other documents, an IMPD (the Common Technical Document) with supporting
information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, and where relevant the implementing national provisions of the
individual EU Member States and further detailed in applicable guidance documents. All suspected unexpected serious adverse reactions
to the investigated drug that occurred during the clinical trial have to be reported to the competent national authority and the Ethics
Committee of the Member State where they occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the EU&#8217;s new Clinical Trials Regulation, which took effect in January 2022, there will be a centralized application procedure where
one EU Member State&#8217;s competent authority takes the lead in reviewing part I of the application, which contains scientific and
medicinal product documentation, and the other national authorities only have limited involvement. Part II, which contains the national
and patient-level documentation, will be assessed individually by each EU Member State. Strict deadlines have been established for the
assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be
governed by the national law of the competent EU Member State. Any substantial changes to the trial protocol or other information submitted
with the CTA must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical
trials must be manufactured in accordance with good manufacturing practices. Other national and EU-wide regulatory requirements may also
apply. Currently, the extent to which clinical trials will be governed by the Clinical Trials Regulation will depend on when the clinical
trial is initiated or on the duration of an ongoing trial. As of January 2023, all new clinical trials must comply with the Clinical
Trials Regulation. In addition, any clinical trial that was already under way as of January 1, 2023 and continues for more than three
years from the day on which the Clinical Trials Regulation becomes applicable (i.e., January 31, 2025), the Clinical Trials Regulation
will at that time begin to apply to the clinical trial. To obtain a marketing authorization of a drug in the European Union, we may submit
marketing authorization applications, or MAA, either under the so-called centralized or national authorization procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Centralized
procedure</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the European Medicines
Agency, or EMA, that is valid in all EU member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory
for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicines
(such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the
treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune
dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific
or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum
timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is
to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use, or the CHMP. Accelerated
assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest,
particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment
procedure is 150 days, excluding stop-clocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 123; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>National
authorization procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal
products that fall outside the scope of the centralized procedure:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decentralized
                                            procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization
                                            in more than one EU country of medicinal products that have not yet been authorized in any
                                            EU country and that do not fall within the mandatory scope of the centralized procedure.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37.9pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual
                                            recognition procedure. In the mutual recognition procedure, a medicine is first authorized
                                            in one EU Member State, in accordance with the national procedures of that country. Following
                                            this, further marketing authorizations can be sought from other EU countries in a procedure
                                            whereby the countries concerned agree to recognize the validity of the original, national
                                            marketing authorization.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37.9pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above described procedures, before granting the marketing authorization, the EMA or the competent authorities of the Member States
of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality,
safety and efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conditional
approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
specific circumstances, E.U. legislation (Article 14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing
Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining
the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted
for product candidates (including medicines designated as orphan medicinal products) if (1) the risk-benefit balance of the product candidate
is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3)
the product fulfills unmet medical needs and (4) the benefit to public health of the immediate availability on the market of the medicinal
product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization
may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion
of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid
for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional
or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to
the review by the CHMP of applications for a conditional marketing authorization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>European
Union regulatory exclusivity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and
an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar
applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for
a generic or biosimilar marketing authorization in the European Union during a period of eight years from the date on which the reference
product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant
from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the
EU. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten
years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific
evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>European
Union orphan designation and exclusivity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
criteria for designating an orphan medicinal product in the European Union, are similar in principle to those in the United States. Under
Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention
or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in
10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from orphan status,
would not generate sufficient return in the European Union to justify investment; and (3) there exists no satisfactory method of diagnosis,
prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will
be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible
for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years
of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application
for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation
has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation
does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 124; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth year, it is established that
the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not justifying
maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication
at any time if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 19.9pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            second applicant can establish that its product, although similar, is safer, more effective
                                            or otherwise clinically superior;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37.9pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 19.9pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            applicant consents to a second orphan medicinal product application; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37.9pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 19.9pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            applicant cannot supply enough orphan medicinal product.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37.9pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PRIME
designation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMA grants access to the Priority Medicines, or PRIME, program to investigational medicines for which it determines there to be preliminary
data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of
the program, the EMA provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up
their evaluation, aiming to bring promising treatments to patients sooner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Periods
of authorization and renewals</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis
of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end,
the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect
of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months
before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless
the European Commission or the competent authority decides on justified grounds relating to pharmacovigilance, to proceed with one additional
five-year renewal. Any authorization which is not followed by the actual placing of the drug on the E.U. market (in case of centralized
procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called
sunset clause).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Health
Care Reform</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidate. For example, Congress must reauthorize the FDA&#8217;s user fee
programs every five years and often makes changes to those programs in addition to policy or procedural changes that may be negotiated
between the FDA and industry stakeholders as part of this periodic reauthorization process. Congress most recently reauthorized the user
fee programs in September 2022 but without any substantive policy changes. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously mentioned, the primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and
other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical
products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies. For
example, the ACA, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate
Program; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans;
imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#8217; outpatient drugs coverage
under Medicare Part D; and established a Center for Medicare Innovation at the U.S. Centers for Medicare and Medicaid Services, or CMS,
to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 125; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that future changes or additions to the ACA, the Medicare and Medicaid programs and changes stemming from other healthcare reform
measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse
effect on the health care industry in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA that affect health care expenditures.
These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control
Act of 2011, which began in 2013 and was extended by the Consolidated Appropriations Act for 2023 and will remain in effect through 2032
unless additional Congressional action is taken.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which
has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things,
bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government
program reimbursement methodologies for drug products. Notably, on December 20, 2019, the Further Consolidated Appropriations Act for
2020 was signed into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access
to Equivalent Samples Act of 2019 (the &#8220;CREATES Act&#8221;), which provides a legislatively defined private right of action under
which eligible product developers can bring suit against companies who refuse to sell sufficient quantities of their branded products
on commercially reasonable, market-based terms to support such eligible product developers&#8217; marketing applications. The CREATES
Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly
restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and
biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to
conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay
in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits
a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially
reasonable, market-based terms.&#8221; Whether and how generic and biosimilar product developments will use this new pathway, as well
as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on
our future commercial products are unknown. We cannot currently predict the specific outcome or impact on our business of such regulatory
and legislative initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law, which is a measure from the Biden administration aimed
at reducing prescription drug costs and increasing access to innovative cell and gene therapies for Medicaid recipients. Among other
things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and
throughout the United States. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must
pay a rebate to the federal government if the drug product&#8217;s price increases faster than the rate of inflation. This calculation
is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on
the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate
drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate
drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation,
it is expected that the revenue generated from such drug will decrease. In addition to the IRA&#8217;s drug price negotiation provisions,
Executive Order 14087, issued in October 2022, called for the CMS innovation center to prepare and submit a report to the White House
on potential payment and delivery modes that would complement to IRA, lower drug costs, and promote access to innovative drugs. On his
first day in office, President Donald Trump repealed Executive Order 14087, which introduces uncertainty in federal drug pricing strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217;
ability to regulate pharmacy benefit managers (PBMs) and other members of the healthcare and pharmaceutical supply chain, an important
decision that appears to be leading to further and more aggressive efforts by states in this area. The Federal Trade Commission in mid-2022
also launched sweeping investigations into the practices of the PBM industry that could lead to additional federal and state legislative
or regulatory proposals targeting such entities&#8217; operations, pharmacy networks, or financial arrangements. Significant efforts
to change the PBM industry as it currently exists in the United States may affect the entire pharmaceutical supply chain and the business
of other stakeholders, including biopharmaceutical developers like us. In addition, regional healthcare authorities and individual hospitals
are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure
on our product pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria
and in additional downward pressure on the price that we receive for any approved drug, which could have an adverse effect on customers
for our product candidate. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction
in payments from private payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 126; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at
broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures
or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Such reforms could have an adverse effect on anticipated revenue from plogo and any of our future product candidates that we may successfully
develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and biopharmaceutical industries are rapidly changing and highly competitive. We are seeking to develop and market drug
candidates that will compete with other products and therapies that currently exist or are being developed. Other companies are actively
seeking to develop products that have disease targets similar to those we are pursuing. We face competition from many different sources,
including commercial, pharmaceutical and biotechnology companies, academic institutions, government agencies and private and public research
institutions. Many of our competitors have significantly greater financial, manufacturing, marketing and drug development resources than
we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. In addition,
competitors compete in the areas of recruiting and retaining qualified scientific and management personnel, establishing clinical trial
sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses. Some of these factors
can delay completion of recruitment into our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
large number of drug candidates are in development for the treatment of leukemia and lymphomas, MDS, gastrointestinal, genitourinary,
gynecological and thoracic cancers and other advanced solid tumors. Cardiff Oncology has a PLK1 inhibitor in clinical trials and we believe
that Arbutus, Boehringer Ingelheim, GlaxoSmithKline, Merck, Onconova, and Takeda have been and may continue to be evaluating PLK inhibitors
for hemato-oncology indications. Several companies are pursuing discovery and research activities in each of the other areas that are
the subject of our research and drug development program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Social and Government (&#8220;ESG&#8221;) Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize the importance of ESG matters, with a specific focus on Human Capital Management, as integral to creating a sustainable foundation
for our long-term business strategy. We support professional development at all levels. We also take reports of suspected violations
of our codes of conduct and take seriously appropriate action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we do not operate laboratories or manufacture products, we believe that our environmental impact is relatively small. We are involved
in office waste reduction practices. Our mostly remote workforce has further reduced our carbon footprint. We strive to offer excellent
benefits and long-term incentives to help retain our workforce.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
human capital resources and objectives include identifying, recruiting, retaining and incentivizing our existing and additional employees.
The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based
compensation awards in order to increase shareholder value and our success by motivating such individuals to perform to the best of their
abilities to achieve our objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that our industry is specialized and dynamic and a significant aspect of our success is our continued ability to execute our
human capital strategy of attracting, engaging, developing and retaining highly skilled talent. There is fierce competition both within
our industry and in the geographic locations in which we have offices for highly skilled talent, and we offer a robust set of benefits,
career-enhancing learning experiences and initiatives aligned with our mission, vision, and values in order to attract qualified prospective
employees and to retain and motivate our employees. We offer competitive compensation for our employees and strongly embrace a pay for
performance philosophy in setting and adjusting compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
codes of conduct clearly outline our commitment to diversity and inclusion, where all employees are welcomed in an environment designed
to make them feel comfortable, respected, and accepted regardless of their age, race, national origin, gender, religion, disability or
sexual orientation. We have a set of policies explicitly setting forth our expectations for nondiscrimination and a harassment-free work
environment. We are also a proud equal opportunity employer and cultivate a highly collaborative and entrepreneurial culture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 127; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_080"></span>FITTERS
SDN. BHD. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Sdn. Bhd. (&#8220;Fitters,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) is a Malaysian private limited company,
incorporated on August 20, 1982, specializing in the supply and trading of protective and fire safety equipment. Headquartered in Kuala
Lumpur, Malaysia, we provide a wide range of fire safety products, including fire extinguishers, foam system, fire-resistant doors, personal
protective equipment (&#8220;PPE&#8221;), and fire safety apparel. As a wholly-owned subsidiary of FITTERS Diversified Berhad, a company
listed on the Main Market of Bursa Malaysia Securities Berhad (Stock Code: 9318), we leverage the group&#8217;s expertise in fire protection
to serve domestic and international markets. Our mission is to deliver high-quality, certified safety solutions that enhance protection
across commercial, industrial, healthcare, and residential sectors. Our focus on trading and distribution positions us as a key player
in Malaysia&#8217;s fire safety market, with a reputation for reliability and compliance with stringent regulatory standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past four decades, we have expanded our product portfolio to include advanced fire-fighting equipment, foam system, PPE, and safety
apparel, establishing a strong presence in the industry. Our history of consistent growth reflects our commitment to quality and customer-centric
innovation, positioning us as a trusted name in fire safety equipment distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-4_001.jpg" alt="" style="height: 152px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Supply
and Trading of Protective and Fire Safety Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Sdn. Bhd. focuses on sourcing, supplying, and trading a comprehensive range of fire safety and protective equipment, serving diverse
industries with certified products that meet Malaysia&#8217;s regulatory standards. Our operations emphasize efficient distribution and
customer service, leveraging strategic partnerships with manufacturers and e-commerce platforms. The following discussion describes our
products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fire
Safety Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
distribute fire extinguishers, such as the FITTERS FIRE-X, designed for home and vehicle use, and other fire-fighting tools like foam
systems. Our products are approved by BOMBA and certified by SIRIM to ensure full compliance with safety regulations. Taking the necessary
fire safety precautions to protect any investment is a crucial factor in any business. Unexpected fires can end any livelihood in just
a matter of seconds. We offer a complete range of fire safety systems. With more than 30-years of experience in fire safety, we pride
ourselves as the &#8220;One-stop&#8221; fire protection specialist for businesses and individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-4_002.jpg" alt="" style="height: 152px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
range of Fire Safety Systems include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fire Sprinkler System</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprinkler
  head</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Flow
  Switch</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pressure
  Switch</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alarm
  Valve</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Butterfly
  Valve</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wet System Valve</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-action
  valve</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deluge
  valve</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gate
  Valve</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CO&#178; System</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CO&#178;
  cylinder complete with accessories</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fire Alarm System</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smoke
  detector</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heat
  detector</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 58.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wet
Chemical System / Kitchen Hood</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wet chemical cylinder complete with accessories</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Fire-Resistant
Doors and Components</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
supply fire-resistant doors under the &#8220;PYRODOR&#8221; brand, offering one-hour and two-hour fire resistance, along with
components like PYROFRAME and PYROBOARD. These are critical for commercial and industrial buildings, meeting strict safety codes. In
line with today&#8217;s stringent fire safety standards, PYRODOR offers high quality fire resistant door-sets &#8211; tested by
SIRIM in accordance with the latest MS1073 Part 2 &amp; 3 and approved by Fire &amp; Rescue Department, Malaysia. PYRODOR door-sets
are custom-made to accommodate stringent customer requirements.<sup>3</sup>Our total commitment to the protection of life and
property is hard to match. We maintain a well-planned program for continuous improvement to meet customers&#8217; requirements. We
have the one of the widest ranges of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved and tested one-hour
  fire rated metal frame and wooden frame door-sets, single leaf and double leaf doors with various locksets.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved and tested two-hour
  fire rated metal frame door-sets, single leaf and double leaf doors with various locksets.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
 </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 33%"><img src="forms-4_003.jpg" alt=""/></td>
  <td style="text-align: center; width: 34%"><img src="forms-4_004.jpg" alt=""/></td>
  <td style="text-align: center; width: 33%"><img src="forms-4_005.jpg" alt=""/></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sampling of PYRODOOR references include these commercial, governmental and residential developments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="forms-4_006.jpg" alt="" style="height: 151px; width: 670px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup></sup></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3</sup>
See pyrodor_brochure.pdf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<!-- Field: Page; Sequence: 129; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-4_007.jpg" alt="" style="height: 178px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img src="forms-4_008.jpg" alt="" style="height: 167px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Safety
Apparel; Personal Protective Equipment (PPE)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
PPE portfolio includes fire-retardant apparel and workwear uniform designed to serve clients in oil and gas industry as well as other
industrial sectors. We ensure that all products meet occupational safety standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide fire-retardant uniforms and reflective materials, such as Scotchlite, for workers in high-risk environments, enhancing visibility
and protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<img src="forms-4_009.jpg" alt="" style="height: 178px; width: 670px"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 49%">&#160;<img src="forms-4_010.jpg" alt="" style="height: 201px; width: 300px"/></td>
  <td style="width: 2%">&#160;</td>
  <td style="text-align: center; width: 49%"><img src="forms-4_011.jpg" alt="" style="height: 184px; width: 300px"/></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 130; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For protective and safety
garments, we understand the importance and need for fitted safety apparels. That is why we proudly offer custom-tailoring services for
our wide selection of apparels to meet the discerning demands of corporate or individual clients. Each garment is tailored with inherently
Flame Retardant fabric (Nomex or Daletec brand) , FR thread and accessories, the leading fabric for high risk heat and flame protection
that can withstand hazardous working conditions such as extreme heat, fires and corrosive chemicals. The advantages of PYROSUIT<b><sup>&#174;</sup></b>
and SAFEFITT<b><sup>&#174;</sup></b> Brand tailoring includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent,
  dependable protection</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Self-extinguishing
  and does not burn</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-break-open
  protection</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
  chemical resistance</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-wear
  life and lower cost</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduces
  static</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comfort</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-4_012.jpg" alt="" style="height: 131px; width: 620px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also the distributors of the following personal protection equipment
(PPE) products:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 49%"><img src="forms-4_013.jpg" alt=""/></td>
  <td style="text-align: center; width: 2%">&#160;</td>
  <td style="text-align: center; width: 49%"><img src="forms-4_014.jpg" alt=""/></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="forms-4_015.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 131; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-4_016.jpg" alt="" style="height: 494px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foam
Systems</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
foam blending facility allows for the manufacture of multiple foam concentrate products. Marketing all types of foam ancillary equipment
and valves, we are able to provide the designing, installation, testing and commissioning of all foam systems. We have a synergistic
agreement between Fitters Sdn. Bhd. and CHEMGUARD (USA) to operate its sole foam blending facility for supply to the entire Southeast
Asia region. CHEMGUARD&#8217;s leadership in the fire protection field is especially evident through the complete line of properly engineered
foam system foam products. All of CHEMGUARD foam concentrate products are earth-friendly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-4_017.jpg" alt="" style="height: 160px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 132; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fire-X
Fire Extinguishers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Big Extinguisher in a small can &#8211; more effective than a traditional fire extinguisher on most common fires. Our Fitters Fire-X
fire extinguishers are simple to use can and spray nozzle design makes fighting fires fast and easy. Our extinguishers serve commercial,
industrial, residential and government clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><img src="forms-4_018.jpg" alt="" style="height: 183px; width: 670px"/>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Big Extinguisher is recommended for all daily fire suppression needs including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><img src="forms-4_019.jpg" alt="" style="height: 153px; width: 670px"/></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth revenues from customers by Fitters&#8217; principal product lines:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Product</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For Year Ended<br/> March 31,<br/>
    2025 (USD)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For Year Ended<br/> March 31,<br/>
    2024 (USD)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Firefighting product income</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,472,290.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,626,561.39</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Safety apparel income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">413,478.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">474,877.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Maintenance income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,783.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,150.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Project Income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,015.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Sales Income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,921,568.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,116,589.59</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principal
Suppliers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the importance to our business of key products, the procurement and management are key activities for us. We carefully manage our purchasing
efforts and have established company policies involving product procurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted measures to reduce risks in products supply, including (i) obtaining better and innovative products, (ii) diversifying suppliers
and supply sources, and (iii) seeking long-term contracts with suppliers. Purchasing transactions are sometimes conducted in accordance
with a procedure for bidding invitations. Potential suppliers are evaluated on their proposed terms of technical specifications, price,
payment terms and timing for delivery. After validation of the various suppliers&#8217; service and capabilities for stable supply, we
acquire the needed materials from the suppliers offering the best terms. Our procurement department establishes an oversight process
by appointing individuals to conduct periodic market research of key price points. There is a standard procedure for conducting such
bidding process and accepting the bids to insure that all purchasing procedures are being strictly adhered to. We enter into long-term
contracts with some suppliers to lock in prices and send purchase orders for each delivery when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Major
Suppliers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table lists our top ten suppliers of materials and parts for products we manufacture as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Suppliers</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount Purchased in 2025 (In Thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Percentage of Total Purchase in 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">TYCO FIRE &amp; BUILDING PRODUCTS ASIA PTE LTD</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">957</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">63.94</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SAPPHIRE FINISHING MILLIS LTD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.98</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">TYCO FIRE PROTECTION PRODUCTS</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.82</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">KAWALAN API ENGINEERING SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.48</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">ANHUI YISHI REFLECTIVE MATERIAL CO.LTD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.52</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">IBENA SHANGHAI TECHNICAL TEXTILES CO LTD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.40</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;BESTARI VISION SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.39</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FORMOSA TAFFETA CO LTD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.02</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">SAMA MAJU MARINE &amp; INDUSTRY SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">HAI HUEI INTERNATIONAL CORP.</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.42</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82.42</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Customers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the fiscal year ended March 31, 2025, the Company achieved sales of USD$1,921,568.03, of which sales to the Company&#8217;s ten largest
customers amount to USD$1,365,248.74, constituting 71.05% of the Company&#8217;s total revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our ten largest customers as for the year ended March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer&#8217;s Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sales For Year Ended<br/> March 31, 2025<br/> (Thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage<br/> of Total<br/> Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">FITTERS ENGINEERING SERVICES SDN BHD</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">697</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">36.28</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">KAWALAN API ENGINEERING SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">PENTRONIC ENGINEERING SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.97</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">VERSUS SOLUTIONS SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.73</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">VALE MALAYSIA MINERALS SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.91</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">MARK JAYA ENGINEERING SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.17</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">GLOBE ENGINEERING SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.08</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FELVA SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">IMPREXIS SOLUTIONS &amp; ENGINEERING (M) SDN BHD</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.30</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">OLA INFINITI SDB BHD</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.87</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.05</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the March 31, 2025 financial year, our top four customers collectively accounted for 55% of the company&#8217;s total sales, with individual
contributions of 36%, 7%, 6%, and 6%, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Distribution
Channels</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
specialize in the distribution, trading, and installation of fire safety materials, equipment, and prevention systems and operate as
a &#8220;one-stop&#8221; protective clothing specialist and distribute fire retardant uniforms. Our distribution channels include direct
sales to commercial, industrial, healthcare, and residential sectors, as well as partnerships with other companies. We also distribute
products through traditional wholesale channels and e-commerce platforms like Shopee, Dropee, and Lapasar, broadening our reach to retail
and institutional customers. We offer installation services for fire protection and prevention systems, as part of our direct distribution
channel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 134; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Malaysian fire safety and protection industry plays a crucial role in safeguarding lives and property. This sector encompasses a wide
range of services, including fire detection, suppression, and prevention, as well as the manufacturing and maintenance of fire protection
equipment. The fire safety and protection industry in Malaysia operates within a robust economic and regulatory framework, driven by
global and regional market trends. Below, we outline key factors shaping the industry, as informed by analyses of the Malaysian economy,
fire protection systems, passive fire protection, and emerging fire safety challenges related to electric vehicles (EVs).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Malaysian
Economy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Malaysian economy demonstrated resilience in the fourth quarter of 2024 (&#8220;4Q2024&#8221;), with Gross Domestic Product (GDP) growth
of 5.0%, driven by strong domestic demand, according to Bank Negara Malaysia&#8217;s Quarterly Bulletin for 4Q2024. Key contributors
included robust investment from new and existing projects, sustained household spending, and continued export growth. The unemployment
rate declined to 3.2% in 4Q2024, with employment rising to 16.8 million persons and a labor force participation rate of 70.6%. Both headline
and core inflation moderated to 1.8% and 1.7%, respectively, despite higher food and beverage prices. Looking ahead, Malaysia&#8217;s
economy is expected to remain resilient in 2025, supported by investment in multi-year projects, wage growth, and policy measures like
minimum wage revisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2025, the Malaysian economy is projected to grow at a rate of 4.5% to 5.5%, with some analysts estimating a more modest growth of 4.0%.<sup>4</sup>
However, this growth is subject to various factors, including global trade tensions and domestic policy measures. Exports are projected
to benefit from the global tech upcycle and tourism, though risks include slower growth in trading partners or commodity production disruptions.
Inflation is expected to remain manageable in 2025, with global commodity prices trending lower, contributing to stable cost conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fire
Protection System Market</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global fire protection system market was valued at USD 68.90 billion in 2024 and is projected to grow from USD 71.97 billion in 2025
to USD 111.38 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.4% during the forecast period, according to Fortune
Business Insights. North America held a 35.63% share in 2024. Fire protection systems encompass equipment, devices, and strategies designed
to detect, control, suppress, and mitigate fire hazards in buildings and structures, aiming to protect lives, minimize property damage,
and facilitate safe evacuation. Rapid urbanization and infrastructure development, particularly in emerging economies, drive demand for
both active and passive fire protection systems. The construction sector&#8217;s growth, such as a 13.3% increase in India&#8217;s construction
industry in 2023, underscores this trend. Additionally, rising global fire incidents&#8212;1,504,500 cases in 2022, causing 13,250 injuries
and 3,790 deaths, per the National Safety Council&#8212;highlight the need for robust fire safety solutions in commercial and industrial
settings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Malaysia
Passive Fire Protection Market</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Malaysia passive fire protection market generated revenue of USD 45.8 million in 2023 and is expected to reach USD 56.6 million by 2030,
growing at a CAGR of 3.1% from 2024 to 2030, according to Grand View Research. Passive fire protection, including fire-resistant doors
and materials, is critical for containing fires and ensuring structural safety, complementing our product offerings like PYRODOR doors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup></sup></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>4</sup>
See Malaysia&#8217;s economy expected to grow 5-5.5 pct for 2023 to 2025: report-Xinhua.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;<img src="forms-4_020.jpg" alt="" style="height: 174px; width: 670px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Malaysia passive fire protection market generated a revenue of USD 45.8 million in 2023 and is expected to reach USD 56.6 million by
2030. The Malaysia market is expected to grow at a CAGR of 3.2% from 2024 to 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Source:
https://www.grandviewresearch.com/horizon/outlook/passive-fire-protection-market/malaysia</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Malaysia
passive fire protection market, 2018-2030 (US$M)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<img src="forms-4_021.jpg" alt="" style="height: 168px; width: 670px"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Source:
Horizon Grand View Research<b><sup>5</sup></b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fire
Safety Implications of Electric Vehicles (EVs) in Malaysia</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rise of EVs in Malaysia presents new fire safety challenges, as outlined by the Malaysian Fire Protection Association on February 17,
2025. EV sales surged to 10,664 units in the first half of 2024, a 148% year-on-year increase, representing 2.6% of vehicle sales. Lithium-ion
battery systems in EVs pose unique fire hazards, burning at higher temperatures than conventional vehicle fires and risking structural
damage to steel and concrete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growing EV infrastructure in Malaysia adds complexity to the fire risk landscape. As of June 25, 2024, the country has installed 2,585
EV charging units, spanning all states and federal territories except Labuan. These include 610 direct current (DC) fast chargers and
1,975 alternating current (AC) chargers. Selangor leads with 867 chargers, followed by Kuala Lumpur (675), Penang (277), and Johor (251).
With the number of EV charging points steadily increasing&#8212;up 12.5% since the first quarter of 2024&#8212; fire safety at these
stations becomes a critical issue. The Ministry of Investment, Trade and Industry (MITI) has projected that Malaysia will reach 10,000
public EV charging points by 2025, a key part of the Low Carbon Mobility Blueprint 2021-2030. However, as the EV fleet grows, ensuring
these charging points are equipped to handle potential fire hazards is essential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notable
incidents, such as a December 31, 2023, EV fire in Johor, Malaysia that destroyed 90% of a vehicle and damaged a showroom, underscore
these risks, particularly in enclosed spaces like urban parking lots. Malaysia&#8217;s EV charging infrastructure grew to 2,585 units
by June 25, 2024, with 610 DC fast chargers and 1,975 AC chargers, and the Ministry of Investment, Trade and Industry projects 10,000
public charging points by 2025. These developments necessitate advanced fire suppression systems and specialized training for first responders
to mitigate EV-related fire risks, creating opportunities for our fire safety products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rise of EVs in Malaysia is an important step toward sustainability, but it also presents new fire safety challenges. As more EVs hit
the roads and charging infrastructure expands, fire safety professionals must stay ahead of these developments. Adopting advanced suppression
systems, improving building designs, and promoting safe charging practices are essential steps to ensure that the benefits of EV adoption
do not come at the cost of safety. Malaysia&#8217;s evolving infrastructure must be equipped to handle the growing presence of EVs. With
proactive measures in place, the fire safety community can help mitigate the risks and ensure a safer future as we transition to cleaner,
greener transportation solutions. To better prepare for these challenges, fire safety professionals must also receive specialized training.
Fire safety training services are designed to help first responders, building managers, and safety personnel understand the nuances of
lithium-ion battery fires and EV-specific risks. (<i>Source: Malaysian Fire Protection Association: The Rise of EVs and Its Fire Safety
Implications for Malaysia, posted on 17 February 2025</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup></sup></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>5</sup> See Malaysia Passive Fire Protection
Market Size &amp; Outlook, 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 136; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
the immediate threat to life, EV fires pose serious risks to infrastructure. Lithium-ion battery fires burn at higher temperatures than
conventional vehicle fires, potentially compromising the structural integrity of surrounding materials, including steel and concrete.
Other structural risks include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heat Intensity: The extreme
  heat from these fires can weaken load-bearing elements in buildings, particularly in enclosed spaces like underground parking lots.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toxic Smoke: Fires involving
  lithium-ion batteries release hazardous gases, such as hydrogen fluoride, which can quickly fill confined areas and pose health risks
  to both building occupants and first responders.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-Ignition Potential: One
  of the most dangerous aspects of lithium-ion battery fires is their tendency to reignite even after they appear to have been extinguished.
  This makes them particularly hazardous in enclosed or difficult-to-access spaces, where containment is challenging.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
dense urban areas or facilities with limited ventilation, such as underground garages, these risks are amplified. Poor ventilation and
inadequate fire suppression systems can lead to catastrophic outcomes. For fire safety professionals, adapting current protocols to address
the specific hazards of EV fires is critical. Existing systems designed for traditional vehicle fires may not be sufficient to combat
the unique risks of lithium-ion batteries. Key mitigation strategies include fire detection and suppression systems in high- risk areas,
such as underground parking lots, must be upgraded. Specialized equipment, such as water mist systems are required to effectively penetrate
battery casings and cool the cells, preventing thermal runaway from escalating.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
Relevance to Fitters Sdn. Bhd.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia&#8217;s
economic growth and infrastructure expansion drive demand for our fire safety equipment, particularly in construction and commercial
sectors. The global and Malaysian fire protection markets&#8217; growth supports our distribution of certified products like fire extinguishers
and PPE, while the EV trend highlights the need for innovative solutions, aligning with our strategic focus. However, price competition
and regulatory compliance remain challenges, which we address through quality certifications and supplier relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-4_022.jpg" alt="A close-up of a website&#10;&#10;AI-generated content may be incorrect." style="height: 231px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sources:
Bank Negara Malaysia Quarterly Bulletin 4Q2024; Fortune Business Insights, &#8220;Fire Protection System Market,&#8221; 2024; Grand View
Research, &#8220;Malaysia Passive Fire Protection Market Outlook,&#8221; 2023; Malaysian Fire Protection Association, &#8220;The Rise
of EVs and Its Fire Safety Implications for Malaysia,&#8221; February 17, 2025.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 137; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competitive
Strengths</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rapid growth of the construction industry is one of the major drivers of the fire protection systems market. The increasing demand for
new and innovative buildings is resulting in an increase in the number of fire incidents. Additionally, the increasing trend of green
building and the growing awareness of the importance of fire safety are also contributing to the growth of this market. Investment in
research and development (R&amp;D) is also a key factor driving the growth of this market. Various new technologies are being developed
to improve the performance of fire protection systems. This is resulting in increased innovation and adoption of new fire protection
systems. The increasing popularity of retrofitting fire protection systems is also contributing to the growth of this market. The retrofitting
option allows existing buildings to be upgraded without having to replace all of the existing infrastructure. This is resulting in significant
cost savings for businesses and governments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for fire protection systems is growing rapidly, as businesses and homeowners become increasingly aware of the importance of protecting
themselves and their property from fire. This is due to the increasing prevalence of fires in commercial and residential buildings, as
well as the increasing awareness of the dangers of fire. The market for fire protection systems is expected to grow rapidly over the
next few years, as businesses and homeowners become increasingly aware of the importance of protecting themselves and their property
from fire. This is due to the increasing prevalence of fires in commercial and residential buildings, as well as the increasing awareness
of the dangers of fire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the following strengths differentiate Fitters Sdn. Bhd. in the fire safety market include top quality products and excellent
customer service as well as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Established
  Industry Presence</b>: Since 1982, we have built a strong reputation as a reliable supplier of fire safety equipment, supported by
  our parent company&#8217;s market leadership.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certified
  Product Offerings</b>: Our product range&#8212;including top quality products such as PYRODOR doors and FITTERS FIRE-X&#8212;is approved
  by BOMBA and certified by SIRIM, while our safety apparel hold certifications from both SIRIM and DOSH. These certifications ensure
  compliance with regulatory standards and foster customer trust.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Broad
  Distribution Network</b>: Our use of e-commerce platforms, combined with partnerships with wholesalers and authorized distributors,
  expands market access, distinguishing us from traditional distributors.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategic
  Supplier Relationships</b>: Long-term agreements with reputable manufacturers ensure consistent product availability and quality, mitigating
  supply chain risks.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Customer-Centric
  Approach</b>: Our focus on meeting diverse customer needs, including fire safety apparel and industrial fire systems, supports loyalty
  and repeat business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strong
  Reputation</b>: We have built up a strong brand reputation.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Growth
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
growth strategy focuses on expanding market share and enhancing profitability. In order to expand company revenue and market share, we
will focus on the following growth strategies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market penetration - improving
  sales within existing markets by expanding reach and improving customer retention.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product development - developing
  new products and services to cater for existing and new customers&#8217; needs.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market Development - pursuing
  new geographic markets.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diversification- expanding
  our product categories.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic partnerships -
  collaboration with other companies to leverage their strengths and resources.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 138; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Drivers and Opportunities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are influenced by several market drivers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory Compliance</b>:
  BOMBA&#8217;s and SIRIM&#8217;s stringent standards drive demand for certified fire equipment, ensuring steady orders for our products.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Urban
  Development</b>: Malaysia&#8217;s construction boom, particularly in Kuala Lumpur, increases the need for fire-resistant doors and
  extinguishers in new buildings.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
  Growth</b>: The expansion of industrial sectors, such as oil and gas, construction, manufacturing, mining, and utilities, is driving
  significant growth in demand for fire safety apparel, particularly flame-retardant and fire-resistant clothing.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E-Commerce
  Trends</b>: Growing online shopping in Malaysia supports our digital distribution strategy, enabling broader customer reach.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Safety
  Awareness</b>: Increased focus on workplace and residential safety fuels demand for our fire safety apparel and equipment.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate from facilities in Malaysia to support our supply and trading activities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Head Office</b>: Wisma
  FITTERS, No. 1, Jalan Tembaga SD 5/2, Bandar Sri Damansara, 52200 Kuala Lumpur, Malaysia, serving as our operational and administrative
  hub.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registered
  Office</b>: Third Floor, No. 77, 79 &amp; 81, Jalan SS21/60, Damansara Utama, 47400 Petaling Jaya, Selangor, Malaysia.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Distribution
  Network</b>: We utilize regional warehouses and logistics partners across Malaysia, coordinated from our Kuala Lumpur head office,
  to ensure efficient product delivery. Specific warehouse locations are managed by FITTERS Diversified Berhad&#8217;s broader infrastructure.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
facilities support our ability to source, store, and distribute products effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own patents or have pending applications, relying on certifications and supplier agreements for competitive positioning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company had a total of 15 full-time employee in Malaysia, distributed across departments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NO</b></span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEPARTMENT</b></span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER
    OF STAFF MEMBERS</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPAREL</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAREHOUSE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRADING</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROJECT</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADMIN</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENANG</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TOTAL</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 139; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Customers
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
serve a diverse customer base including the following types:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercial and Industrial</b>:
  Developers and facility managers procure our fire extinguishers and PYRODOR doors for projects like offices and factories. Industrial
  clients in sectors like oil &amp; gas, construction, and manufacturing rely on our fire safety apparel to protect workers and meet
  regulatory requirements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
  Agencies</b>: Public sector clients source certified fire equipment for compliance with BOMBA and SIRIM/SOH standards.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Retail
  Consumers</b>: Individual buyers access our safety apparel via e-commerce platforms like Shopee for home and vehicle use.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
broad customer mix ensures revenue stability, with strong demand from healthcare and construction sectors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competitors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face competition in a crowded market:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Local Distributors</b>:
  Malaysian suppliers of BOMBA-certified fire equipment and SIRIM/DOSH-certified PPE compete on price and availability, challenging our
  margins.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>International Brands</b>:
  Global manufacturers with established names in fire safety and PPE, such as 3M, Dupont and Daletec, compete in Malaysia, requiring
  us to emphasize local expertise.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E-Commerce
  Rivals</b>: Online distributors on platforms like Shopee offer low-cost alternatives, increasing price pressure due to low entry barriers.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
counter competition through certified products, reliable supply chains, and e-commerce accessibility, though pricing remains a challenge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to Malaysian regulations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product Standards</b>:
  Fire equipment and PPE must comply with BOMBA and SIRIM standards, requiring regular certification. Non-compliance risks product bans
  or fines.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Occupational
  Safety</b>: PPE distribution adheres to regulations enforced by Malaysia&#8217;s Department of Occupational Safety and Health, ensuring
  end-user safety.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Labour
  Policies</b>: Foreign worker hiring for logistics is governed by immigration rules, which may raise costs or limit availability.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trade
  Regulations</b>: Import duties and supplier compliance affect the sourcing of international products, impacting pricing.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain strict compliance to avoid operational or reputational risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we are not involved in any material legal proceedings that, individually or in the aggregate, are expected
to significantly impact our business, financial condition, or results of operations. Routine disputes, such as supplier or customer contract
issues, may arise but are managed promptly with no anticipated material liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factors Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business faces several risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price
  Competition</b>: Intense rivalry from local and online distributors may force price cuts, reducing margins, especially for PPE and
  extinguishers.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Raw
  Material Costs</b>: Rising prices for plastics (for PPE) or steel could increase supplier costs, impacting profitability if not passed
  to customers.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
  Compliance</b>: Failure to maintain BOMBA/SIRIM certifications risks product recalls or market exclusion, disrupting sales.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
  Chain Disruptions</b>: Dependence on external manufacturers could lead to delays or shortages, affecting customer satisfaction.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E-Commerce
  Dependence</b>: Reliance on third-party platforms like Shopee exposes us to commission costs and platform policy changes.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Labor
  Constraints</b>: Foreign worker restrictions may hinder logistics efficiency, increasing operational costs.</span>


</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leadership</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of Fitters Sdn. Bhd.&#8217;s current key management include the following two directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Chin
Yong Shing, Executive Director (age 56) &#8212; </i></b>Mr. Chin Yong Shing (&#8220;Mr. Chin&#8221;) graduated from Polytechnic of Wales
(UK) with a Bachelor of Engineering (Mechanical). He started his career as a Project Engineer at FITTERS Engineering Services Sdn. Bhd.,
a wholly owned subsidiary of FITTERS Diversified Berhad, on 15 October 1992. He was promoted to Project Manager in 1998 and to General
Manager in 2010. Mr. Chin is currently the Executive Director of Fitters Engineering Services Sdn. Bhd., a position he holds since 2014<b><i>.
</i></b>Mr. Chin was appointed as Director of Fitters Sdn. Bhd. in January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pang
Wei Kang, Director (age 25) &#8212; </i></b>Mr. Pang Wei Kang (&#8220;Mr. Pang&#8221;) graduated from Kingston University with a Bachelor
of Science in Business Management. He has extensive experience in the food and beverage industry, with a strong background and deep knowledge
in this field. In his role, he oversees the Japanese fine dining restaurant&#8217;s daily operations, leads marketing efforts, and manages
finances, ensuring that all activities align with the Japanese fine dining restaurant&#8217;s overarching goals. Beyond operational management,
Mr. Pang excels in strategic marketing, creating innovative campaigns to enhance the Japanese fine dining restaurant&#8217;s brand presence
and engage the audience. His financial expertise is a key asset, as he navigates budgeting, cost control, and comprehensive financial
strategies to drive the Japanese fine dining restaurant&#8217;s growth and success. Mr. Pang was appointed to the Board in January 2024
and was appointed as Director of Fitters Sdn. Bhd. in January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 140; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_081"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF CYCLACEL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company incorporated in the State of Delaware on January 5, 1996 that focused on the development
of innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis control biology. Our principal
executive office is now located at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia, and our telephone number
is (908) 517-7330. Our website address is www.cyclacel.com. The information contained on, or that can be accessed through, our website
is not part of, and is not incorporated by reference into, this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, our primary focus has been on our transcriptional regulation program, which evaluated fadraciclib, a CDK2/9 inhibitor, in solid
tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating Plogo, a PLK1 inhibitor, in advanced cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2025, the Company&#8217;s wholly owned United Kingdom subsidiary Cyclacel Limited entered into a creditors voluntary liquidation.
Upon the commencement of the liquidation of the Cyclacel Limited, the Company lost operational and strategic control over the Cyclacel
Limited and the financial results of Cyclacel Limited have been deconsolidated from Company as of January 24, 2025. The deconsolidation
of the subsidiary resulted in a gain on deconsolidation of approximately $5.0 million shown as other income within the income statement
for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are <span style="background-color: white">a clinical-stage biopharmaceutical company developing innovative cancer medicines based on
cell cycle, transcriptional regulation, epigenetics and mitosis control biology. </span>We reported revenue of $0 for the three months
ended March 31, 2025, and revenues of $29,000 for the three months ended March 31, 2024. We do not expect to report a significant amount
of revenue for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Company&#8217;s efforts to reduce operating costs it has determined to focus on the development of the <span style="background-color: white">plogosertib</span>
(&#8220;Plogo&#8221;) clinical program only. Accordingly, on March 10, 2025, the Company repurchased certain assets related to Plogo
from Cyclacel Limited with the approval of the joint liquidator in exchange for approximately $0.3 million in cash. Fadraciclib, Cyclacel
Limited&#8217;s other drug development program, is being marketed for sale by the joint liquidator . The Company has no plans at this
time to repurchase any rights to or assets of the fadraciclib program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently retain all marketing rights worldwide to the compounds associated with our drug programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recently established a wholly-owned subsidiary in Malaysia, BIGM Capital Sdn. Bhd., to act as an investment holding company and other
investment activities as deemed suitable at later stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plogosertib
Phase 1/2 Study in Advanced Solid Tumors and Lymphoma (140-101; NCT#05358379)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
open-label Phase 1/2 registration-directed study uses a streamlined design and initially seeks to determine the RP2D for single-agent
oral plogosertib in a dose escalation stage. Once RP2D has been established, the study will enter into proof-of-concept, cohort stage,
using a Simon 2-stage design. In this stage plogosertib will be administered to patients in up to seven mechanistically relevant cohorts
including patients with bladder, breast, colorectal (including KRAS mutant), hepatocellular and biliary tract, and lung cancers (both
small cell and non-small cell), as well as lymphomas. An additional basket cohort will enroll patients with biomarkers relevant to the
drug&#8217;s mechanism, including MYC amplified tumors. The protocol allows for expansion of individual cohorts based on response which
may allow acceleration of the clinical development and registration plan for plogosertib.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifteen
patients have been treated at the first five dose escalation levels with no dose limiting toxicities observed. Stable disease has been
observed in pretreated patients with gastrointestinal, lung, and ovarian cancers. A new, alternative salt, oral formulation of plogosertib
with improved bioavailability is under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently retain all marketing rights worldwide to our product candidate Plogo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 141; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenues from product sales to date. Our product candidates will require significant additional research and development
efforts, including extensive preclinical and clinical testing. Plogo and any future product candidates that we advance to clinical testing
will require regulatory approval prior to commercial use and will require significant costs for commercialization. We have recognized
revenue of $43,000 for the year ended December 31, 2024 related to the recovery of clinical manufacturing costs associated with an investigator
sponsored study managed by Cedars Sinai Medical Center. We recognized $0.4 million of revenue for the year ended December 31, 2023. We
recognized $0 revenue for the three months ended March 31, 2025 and $29,000 for the three months ended March 31, 2024. This revenue is
related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center.
We do not expect to report revenue from plogo for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Funding
Requirements and Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had cash and cash equivalents of $3.1 million. We have incurred losses since our inception and as of December
31, 2024, we had an accumulated deficit of $439.5 million. We expect to continue to incur substantial operating losses in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2025, we used net cash of $8.2 million to fund our operating activities. We have cash and cash equivalents
of $3.5 million as of March 31, 2025, which will allow it to meet its liquidity requirements into the second quarter of 2025. However,
there remains substantial doubt about our ability to continue as a going concern. We are currently investigating ways to raise additional
capital through private equity financing or by entering into a strategic transaction. In the event that we are not able to secure funding,
we may be forced to curtail operations, delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, Nasdaq notified the Company that it has regained compliance with the equity requirement in Listing Rule 5550(b)(1)
(the &#8220;Equity Rule&#8221;), as required by the Nasdaq Hearing Panel&#8217;s decision dated October 22, 2024. As previously reported
by the Company on Form 8-K, filed with the SEC on October 24, 2024, on October 15, 2024, the Company met with the Nasdaq Hearings Panel
regarding its potential delisting from Nasdaq as a result of its non-compliance with the Equity Rule. On October 22, 2024, the Company
received the Nasdaq Hearings Panel decision which granted the Company until December 24, 2024 to regain compliance with the Equity Rule.
This date was subsequently extended to February 25, 2025. Following the Company&#8217;s regaining compliance with the Equity Rule, pursuant
to the Nasdaq notice on February 25, 2025, the Company will be subject to a Mandatory Panel Monitor for a period of one year from February
25, 2025 pursuant to Listing Rule 5815(d)(4)(B).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
auditors have issued a going concern opinion. This means that our auditors believe there is substantial doubt that we can continue as
an on-going business for the next twelve months. This is because we have not generated any revenues and no revenues are anticipated for
the foreseeable future. We cannot complete the development of plogo without obtaining additional financing. Accordingly, we must raise
cash from sources other than operations. Our only other source for cash at this time is investments by others in our company. We must
raise cash to implement our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the current difficult economic environment and our lack of funding to implement our business plan, our Board of Directors
has begun to analyze strategic alternatives available to the Company to continue as a going concern. Such alternatives include raising
additional debt or equity financing or consummating a merger or acquisition with a partner that may involve a change in our business
plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our Board of Directors&#8217; preference would be to obtain additional funding to implement our business plan, the Board believes that
it must consider all viable strategic alternatives that are in the best interests of our shareholders. Such strategic alternatives include
a merger, acquisition, share exchange, asset purchase, or similar transaction. We believe we would be an attractive candidate for such
a business combination due to the perceived benefits of being a publicly listed company, thereby providing a transaction partner access
to the public marketplace to raise capital, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
We plan to acquire and consolidate complimentary industrial assets. Typically, these assets are the core manufacturer and supplier of
specific bulk commodity minerals and chemicals distributed to the global manufacturer industry. Our consolidation strategy is to assemble
a portfolio of mature and value-add industrial commodities businesses to generate scalable enterprises with a large portfolio of products
and services addressing a common and stable customer base. We believe that smaller, legacy-owned industrial companies will benefit from
economies of scale and professional asset allocation. Our acquisition strategy seeks to capitalize on the price differential between
public company and private company valuations, while also providing the platform to access capital markets and professional management
oversight.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 142; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Our present intent is to identify and evaluate business opportunities that might prove to be a good match for the Company. We will not
be able to develop any identified business opportunities without additional financing. Our board of directors and management are actively
pursuing financing to maintain operations while we evaluate potential businesses. We will not restrict our consideration to any particular
business or industry segment, and might consider, among others, finance, brokerage, insurance, transportation, communications, research
and development, biotechnology, service, natural resources, manufacturing, or technology. Management recognizes that the Company&#8217;s
inadequate financial resources limit the scope and number of suitable business venture candidates that might otherwise be available.
The decision to participate in a specific business opportunity will be made upon management&#8217;s analysis of the quality of the other
firm&#8217;s management and personnel, the anticipated acceptability of new products or marketing concepts, the merit of technological
changes and numerous other factors which are difficult, if not impossible, to analyze through the application of any objective criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
In many instances, it is anticipated that the historical operations of a specific venture may not necessarily be indicative of the potential
for the future because of the necessity to substantially shift a marketing approach, expand operations, change product emphasis, change
or substantially augment management, or make other changes. We will to some extent be dependent upon the management of a business opportunity
to identify such problems and to implement or be primarily responsible for the implementation of, required changes. We will not acquire
or merge with any company for which audited financial statements could not be obtained. Nonetheless, it may be anticipated that any opportunity
in which we determine to participate would present certain risks to our shareholders. Risks might include the track record of management&#8217;s
effectiveness, failures to establish a consistent market for products or services, development stage, or to realize profits. Many more
of these risks may not be adequately identified prior to the selection of a specific opportunity, and our shareholders must, therefore,
depend on the ability of management to identify and evaluate such risks as such become evident.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become a party to a merger, consolidation, reorganization, joint venture, franchise or licensing agreement with another entity or
may purchase the stock or assets of an existing business. In the event a merger or acquisition were to occur, our shareholders would
in all likelihood hold a lesser percentage ownership interest in the Company following such merger or acquisition. The percentage ownership
of existing shareholders may be subject to a significant reduction in the event we acquire a target company with substantial assets.
Any merger or acquisition effected by the Company can be expected to have a significant substantial dilutive effect on the percentage
of shares held by the Company&#8217;s present shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have sufficient funds to complete development and commercialization of any of our drug candidates. Current business
and capital market risks could have a detrimental effect on the availability of sources of funding and our ability to access them in
the future, which may delay or impede our progress of advancing our drugs currently in the clinical pipeline to approval by the FDA or
EMA for commercialization. Additionally, we plan to continue to evaluate in-licensing and acquisition opportunities to gain access to
new drugs or drug targets that would fit with our strategy. Any such transaction would likely increase our funding needs in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future funding requirements will depend on many factors, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rate of progress and
  cost of our clinical trials, preclinical studies and other discovery and research and development activities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with
  establishing manufacturing and commercialization capabilities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of acquiring or
  investing in businesses, Plogo or any of our future product candidates and technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting,
  defending and enforcing any patent claims and other intellectual property rights;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of seeking
  and obtaining FDA and EMA approvals;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of competing technological
  and market developments; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the economic and other terms
  and timing of any collaboration, licensing or other arrangements into which we may enter.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 143; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance
future cash needs primarily through public or private equity offerings, debt financings or strategic collaborations. Although we are
not reliant on institutional credit finance and therefore not subject to debt covenant compliance requirements or potential withdrawal
of credit by banks, we are reliant on the availability of funds and activity in equity markets. We do not know whether additional funding
will be available on acceptable terms, or at all. If we are not able to secure additional funding when needed, we may have to delay,
reduce the scope of or eliminate one or more of our clinical trials or research and development programs or make changes to our operating
plan. In addition, we may have to partner one or more of our product candidate programs at an earlier stage of development, which would
lower the economic value of those programs to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have relied primarily on the proceeds from sales of common and preferred equity securities to finance our operations
and internal growth. Additional funding has come through research and development tax credits, government grants, the sale of product
rights, interest on investments, licensing revenue, royalty income, and a limited amount of product revenue from operations discontinued
in September 2012.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 1 of the Notes to the Consolidated Financial Statements accompanying this Annual Report on Form 10-K, under ASC Topic
205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there
are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a
going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration
the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements
are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Agreements
to Sell Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2024, Cyclacel Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into a letter agreement (the &#8220;Warrant Exercise
and Reload Agreement&#8221;) with the holder (the &#8220;Holder&#8221;) of its issued and outstanding Series B Warrants (the &#8220;Prior
Warrants&#8221;) to purchase an aggregate of 20,704 shares of common stock of the Company offering the Holder the opportunity
to exercise all of its Prior Warrants for cash at a reduced exercise price equal to $99.60 per share provided the Prior Warrants
were exercised in full for cash on or before 12:30 P.M. Eastern Time on the date of the Warrant Exercise and Reload Agreement. In consideration
for the exercise of the Prior Warrants, the Holder received new unregistered Series C Warrants (the &#8220;Series C Warrants&#8221;)
exercisable for up to an aggregate of 41,408 shares of common stock (the &#8220;Series C Warrant Shares&#8221;) and new unregistered
Series D Warrants (the &#8220;Series D Warrants&#8221; and, together with the Series C Warrants, the &#8220;New Warrants&#8221;) exercisable
for up to an aggregate of 41,408 shares of common stock (the &#8220;Series D Warrant Shares&#8221; and, together with the Series
C Warrant Shares, the &#8220;New Warrant Shares&#8221;). The Series C Warrants are exercisable beginning on the date upon which the Company
receives stockholder approval of the issuance of the New Warrant Shares and the Placement Agent Warrant Shares (the &#8220;Stockholder
Approval Date&#8221;) for a period of five and one-half (5.5) years following the Stockholder Approval Date and the Series D Warrants
are exercisable beginning on the Stockholder Approval Date for a period of eighteen (18) months following the Stockholder Approval Date.
The New Warrants each have an exercise price of $99.60 per share. The shares of common stock issued upon exercise of the Prior
Warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-279157).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2024, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor (the &#8220;Purchaser&#8221;) for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of (i)
604 shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to 20,100 shares of common stock
(the &#8220;Pre-Funded Warrants&#8221;), (iii) series A warrants to purchase up to 20,704 shares of common stock (the &#8220;Series
A Warrants&#8221;), and (iv) series B warrants to purchase up to 20,704 shares of common stock (the &#8220;Series B Warrants&#8221;
and together with the Series A Warrants, the &#8220;Common Warrants&#8221;). The purchase price of each share of common stock and associated
Common Warrants was $386.40 and the purchase price of each Pre-Funded Warrant and associated Common Warrants was $386.376.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants are exercisable immediately upon issuance at an exercise price of $326.40 per share. The Series A Warrants will
expire five and one-half years from the date of issuance and the Series B Warrants will expire eighteen months from the date of issuance.
The Pre-Funded Warrants are exercisable immediately upon issuance at an exercise price of $0.024 per share and may be exercised
at any time until the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its
affiliates) may not exercise any portion of such warrants to the extent that the holder would own more than 4.99% (or, at the election
of the holder 9.99%) of the Company&#8217;s outstanding common stock immediately after exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 144; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Private Placement, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
dated as of April 30, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) registering the resale of the securities issued in the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, we entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional
investors (the &#8220;Purchasers&#8221;). Pursuant to the Securities Purchase Agreement, we agreed to sell in a registered direct offering
(&#8220;Registered Direct Offering&#8221;) 702 shares (&#8220;Shares&#8221;) of our common stock and pre-funded warrants (&#8220;Pre-Funded
Warrants&#8221;) to purchase up to 915 shares of common stock. The Pre-Funded Warrants have an exercise price of $0.24
per share and are immediately exercisable and can be exercised at any time after their original issuance until such Pre-Funded Warrants
are exercised in full. Each Share was sold at a price of $795.60 and each Pre-Funded Warrant was sold at a price of $795.36
(equal to the purchase price per Share minus the exercise price of the Pre-Funded Warrant).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the &#8220;Offerings&#8221;),
we also agreed to issue to the Purchasers unregistered warrants (&#8220;Common Warrants&#8221;) to purchase up to 1,617 shares
of common stock. Each Common Warrant has an exercise price of $765.60 per share, is exercisable immediately following their original
issuance and will expire seven years from the original issuance date. The closing of the offering occurred on December 26, 2023, and
the net proceeds to us were approximately $1.0 million, after deducting placement agent fees and other offering expenses payable by us.
Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Placement Agent&#8221;) acted as the exclusive placement agent for the Offerings, pursuant
to a placement agency agreement dated December 21, 2023, by and between us and the Placement Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, in a separate concurrent insider private placement (the &#8220;Insider Private Placement&#8221;), we also entered
into a Securities Purchase Agreement with certain of our executive officers (the &#8220;Insider Securities Purchase Agreement&#8221;)
pursuant to which we agreed to sell in a private placement (i) 25 shares of common stock and warrants to purchase 25 shares
of common stock on the same terms as the Common Warrants issued to the Purchasers in the Offerings to Spiro Rombotis, our Chief Executive
Officer, and (ii) 8 shares of common stock and warrants to purchase 8 shares of common stock on the same terms as the Common
Warrants issued to the Purchasers in the Offerings to Paul McBarron, our Executive Vice President-Finance, Chief Financial Officer and
Chief Operating Officer. Each such share of common stock and accompanying warrant was sold at a purchase price of $795.60, which
was the same purchase price for the Shares sold in the Registered Direct Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2021, we entered into a Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald
&amp; Co. (&#8220;Cantor&#8221;), pursuant to which we could issue and sell, from time to time, shares of our common stock having an
aggregate offering price of up to $50.0 million through Cantor as the sales agent. Cantor could sell our common stock by any method permitted
by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2022, we became aware that the shelf registration statement on Form S-3 (file number 333-231923) (the &#8220;Registration
Statement&#8221;) associated with this Sales Agreement had expired on June 21, 2022. Prior to becoming aware of the expiration, but following
the expiration, we sold an aggregate of 552 shares of our common stock at market prices for aggregate proceeds of approximately
$2,721,187. The sale of these shares were subject to potential rescission rights by certain stockholders. As a result of these rescission
rights, we classified 866 shares (including 314 previously issued and outstanding shares sold for which the Company did
not receive proceeds and which were reclassified to temporary equity as of September 30, 2022), with an aggregate redemption value of
$4,494,496 of our common stock as stock outside stockholders equity. We also restated our loss per share as a result of $135,000 of associated
fees not initially accounted for as accretion to the maximum redemption amount of the shares subject to potential rescission. During
the third quarter of 2023, upon expiration of the rescission rights and with no claims or demands to exercise such rights, we reclassified
all 866 shares back to permanent equity. In all periods presented, the shares subject to the rescission rights were treated as
issued and outstanding for purposes of earnings per share and general financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 145; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
on Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 29, 2025, the Board of Directors of Cyclacel Pharmaceuticals, Inc. (the &#8220;Company&#8221;) passed a resolution to suspend
payment of the quarterly cash dividend on the Company&#8217;s 6% Convertible Exchangeable Preferred Stock (the &#8220;Preferred Stock&#8221;)
scheduled for February 1, 2025. The quarterly cash dividend payments were suspended for payments scheduled for May 1, 2024, August 1,
2024 and November 1, 2024. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized $0 revenue for the three months ended March 31, 2025 and $29,000 for the three months ended March 31, 2024. This revenue is
related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center.
We do not expect to report revenue for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the revenues for years ended December 31, 2024 and 2023 (in thousands except percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify; padding-bottom: 1pt">Clinical trial supply</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">43</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">420</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">(377</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">(90</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Total Revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">43</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">420</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(377</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(90</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized $43,000 of revenue for the year ended December 31, 2024. This revenue relates to recovery of clinical manufacturing costs
associated with an investigator sponsored study managed by Cedars-Sinai Medical Center. We recognized $420,000 of revenue for the comparative
period in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to report revenue for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expense all research and development costs as they are incurred. Research and development expenses primarily include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trial and regulatory-related
  costs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payroll and personnel-related
  expenses, including consultants and contract research organizations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical studies and materials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology license costs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation;
  and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent and facility expenses
  for our office.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information with respect to our research and development expenditures for the three months ended March 31, 2025
and 2024 (in $000s except percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Transcriptional Regulation (fadraciclib)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">389</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,752</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,363</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(78</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Anti-mitotic (plogosertib)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(603</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(63</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other research and development expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">87</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,980</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(71</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
research and development expenses represented 16% and 64% of our operating expenses for the three months ended March 31, 2025 and 2024,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 146; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses decreased by $2.0 million from $2.8 million for the three months ended March 31, 2024 to $0.8 million for the
three months ended March 31, 2025. Expenditure for the transcriptional regulation program ceased as a result of the Company&#8217;s UK
subsidiary, Cyclacel Limited, being liquidated on January 24, 2025. Research and development expenses relating to <span style="background-color: white">plogosertib</span>
decreased by $0.6 million relative to the respective comparative period whilst we continue to explore and develop an alternative salt,
oral formulation with improved bioavailability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information with respect to our research and development expenditures for the years ended December 31, 2024
and 2023 (in thousands except percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Transcriptional Regulation (fadraciclib)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,970</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">13,358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(8,388</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(63</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Anti-mitotic (plogo)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,566</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,421</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(69</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other research and development expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">810</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(691</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(85</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,155</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,500</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(65</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses represented 55% and 74% of our operating expenses for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses decreased by $12.5 million from $19.2 million for the year ended December 31, 2023 to $6.7 million for the year
ended December 31, 2024. Expenditure for the transcriptional regulation program decreased by $8.4 million for the year ending December
31, 2024 relative to the respective comparative period. This decrease was primarily due to a decrease in clinical trial costs of $2.4
million associated with the temporary halt in the Phase 1/2 study in hematological malignancies, the completion of a bioequivalence and
tox studies during the prior year of $2.1 million, reduction in manufacturing costs of $3.5 million and other non-clinical expenditure
of $0.4 million. Research and development expenses relating to Plogo decreased by $3.4 million for the year ending December 31, 2024
relative to the respective comparative period. This decrease was primarily due to a decrease in clinical trial costs of $1.6 million
associated with the progression of clinical trials for the evaluation of Plogo in Phase 1/2 studies, a decrease in manufacturing costs
of $0.5 million, employment costs of $0.6 million and other non-clinical expenditure of $0.7 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
future</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that overall research and development expenses for the year ended December 31, 2025 will decrease significantly compared to
the year ended December 31, 2024 as we focus on our Plogo clinical program. There will be no expenditure related to fadraciclib as the
program is being marketed for sale by the joint liquidator of the Subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the liquidation of the UK Subsidiary, and therefore the loss of ownership of our transcriptional regulation program, we anticipate that
overall research and development expenses for the year ended December 31, 2025 will decrease significantly compared to the year ended
December 31, 2024 as we focus only on the development of anti-mitotic program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
and administrative</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include costs for administrative personnel, legal and other professional expenses and general corporate expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the general and administrative expenses for the three months ended March 31, 2025 and 2024 (in $000s except
percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">4,214</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">1,582</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">2,632</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">166</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 147; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
general and administrative expenses represented 84% and 36% of our operating expenses for the three months ended March 31, 2025 and 2024,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by approximately $2.6 million from $1.6 million for the three months ended March 31, 2024 to $4.2
million for the three months ended March 31, 2025, due to several one-time costs associated with the change of control of the Company;
primarily stock compensation expense of $1.4 million, D&amp;O insurance costs of $0.7 million, compensation expense of $0.3 million and
legal costs of $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the total general and administrative expenses for the years ended December 31, 2024 and 2023 (in thousands
except percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify; padding-bottom: 2.5pt">Total general and administrative expenses</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">5,392</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">6,718</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(1,326</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(20</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
general and administrative expenses represented 45% and 26% of our operating expenses for the years ended December 31, 2024 and 2023,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenditures decreased by $1.3 million from $6.7 million for the year ended December 31, 2023 to $5.4 million
for the year ended December 31, 2024. This decrease was primarily due to reduction in stock compensation costs of $0.5 million, employment
related costs of $0.2 million, corporate reporting costs of $0.2 million and investor relation costs of $0.2 million against the comparative
prior period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
future</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect general and administrative expenditures for the year ended December 31, 2025 to be broadly in line with our expenditures for the
year ended December 31, 2024, as the Company begins to stabilize following a change of control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
expense, net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes other (expense) income, net for the three months ended March 31, 2025 and 2024 (in $000 except percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Foreign exchange losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(8</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(9</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(900</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on deconsolidation of subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">52</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(42</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(81</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other income (expense), net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,955</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,900</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,909</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
other income increased by $4.9 million from $55,000 for the three months ended March 31, 2024 to $5.0 million for the three months ended
March 31, 2025. The liquidation of our formerly wholly owned subsidiary and the subsequent deconsolidation thereof in January 2025 resulted
in a $5.0 million gain on deconsolidation. Other income for the three months ended March 31, 2025 relates to royalties receivable under
a December 2005 Asset Purchase Agreement, or APA, whereby Xcyte Therapies, Inc., or Xcyte (a business acquired by us in March 2006) sold
certain assets and intellectual property to ThermoFisher Scientific Company, or TSC (formerly Invitrogen Corporation) through the APA
and other related agreements. The assets and technology were not part of our product development plan following the transaction between
Xcyte and Cyclacel in March 2006. Accordingly, we presented $0 and $52,000 as other income arising from royalties from the APA during
each of the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 148; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the other income (expense) for years ended December 31, 2024 and 2023 (in thousands except percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Foreign exchange losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(54</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(414</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">360</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(87</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(254</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(95</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">52</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">50</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total other income (expense), net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(98</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(110</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
other expense, net, increased by $108,000 from an expense of $98,000 for the year ended December 31, 2023 to an income of $10,000 for
the year ended December 31, 2024. The decrease in other expense, net primarily relates to a reduction in interest income of $254,000
as a direct result of holding lower cash balances during 2024. Other income, net relates to royalties receivable under a December 2005
Asset Purchase Agreement, or APA, whereby Xcyte Therapies, Inc., or Xcyte (a business acquired by us in March 2006) sold through the
APA and other related agreements certain assets and intellectual property which are not related to our product development plans to ThermoFisher
Scientific Company, or TSC. Accordingly, we presented $52,000 and $50,000 as other income received from TSC during the years ended December
31, 2024 and 2023, respectively. We have no knowledge of TSC&#8217;s activities and cannot predict when we may receive income
under the APA, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
exchange losses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange losses increased by $9,000, from a gain of $1,000 for the three months ended March 31, 2024, to a loss of $8,000 for the three
months ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange losses increased by $360,000 to a loss of $54,000 for the year ended December 31, 2024 compared to a loss of $414,000 for the
year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have intercompany loans in place between our parent company based in New Jersey and our subsidiary based in Scotland. The intercompany
loans outstanding are not expected to be repaid in the foreseeable future and the nature of the funding advanced is of a long-term investment
nature. Therefore, all unrealized foreign exchange gains or losses arising on the intercompany loans are recognized in other comprehensive
income until repayment of the intercompany loan becomes foreseeable. Unfavorable unrealized foreign exchange movements related to intercompany
loans resulted in a loss of $2.9 million for the year ended December 31, 2024 compared to a gain of $12.6 million for the year ended
December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
future</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense), net will continue to be impacted by changes in foreign exchange rates and the receipt of income under the APA. As we
are not in control of sales made by TSC, we are unable to estimate the level and timing of income under the APA, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the liquidation of the UK subsidiary in January 2025, the intercompany loans will be written off as part of the deconsolidation
process. The accumulated translation adjustments currently recorded in other comprehensive income within equity will be reversed and
recorded as part of the gain/loss from deconsolidation of the subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
tax benefit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record research and development tax credits within income taxes. Credit is taken for research and development tax credits, which are
claimed from the United Kingdom&#8217;s taxation and customs authority (HMRC), in respect of qualifying research and development costs
incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes total income tax benefit for the three months ended March 31, 2025 and 2024 (in $000s except percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-bottom: 2.5pt">Total income tax benefit</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">1,354</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(1,354</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(100</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 149; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total income tax benefit, which comprised of research and development tax credits recoverable was $1.4 million, during the three months
ended March 31, 2024 to $0 for the three months ended March 31, 2025, following the liquidation of the UK Subsidiary and the subsequent
loss of eligibility for recoverable tax credits as a result thereof. The level of tax credits recoverable is linked directly to qualifying
research and development expenditure incurred in any one year and the availability of trading losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes total income tax benefit from such credits for the years ended December 31, 2024 and 2023 (in thousands except
percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify; padding-bottom: 2.5pt">Total income tax benefit</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">782</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">2,996</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(2,214</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(74</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax benefit decreased significantly by approximately $2.2 million, from $3.0 million for the year ended December 31, 2023 to $0.8
million for the year ended December 31, 2024, due to the ineligibility to recover qualifying research and developments expenditure incurred
during 2024. The $0.8 million tax benefit in 2024 relates to a deferred claim based on 2023 qualifying research and development expenditure.
The level of tax credits recoverable is linked directly to qualifying research and development expenditure incurred in any one year and
the availability of trading losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
future</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to continue to be eligible to receive United Kingdom research and development tax credits for the year ending December
31, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of our key liquidity measures as of December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-bottom: 2.5pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">3,137</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">3,378</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Working capital:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Current assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,444</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,268</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,161</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total working capital deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,594</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(717</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
from operating, investing and financing activities for the three months ended March 31, 2025 and 2024 is summarized as follows (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,247</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(483</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by (used in) operating, investing and financing activities for the years ended December 31, 2024 and 2023 is summarized as follows
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,990</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(16,112</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">848</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 150; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities increased by $2.8 million, from $0.5 million for the three months ended March 31, 2024 to $3.2 million
for the three months ended March 31, 2025. The increase in cash used by operating activities was primarily due toa change in working
capital of $7.1 million as result of the change of control of the Company, and offset by decrease in net loss of $2.8 million and increase
of $1.5 million of stock compensation expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities decreased by $8.1 million, from $16.1 million for the year ended December 31, 2023 to $8.0 million
for the year ended December 31, 2024. The decrease in cash used by operating activities was primarily the result of a decrease in net
loss of $11.3 million, offset by a change in working capital of $2.3 million and stock based compensation of $0.9 million. The $2.3 million
change in working capital was primarily due to receivables for research and development tax credits. A cash receipt of approximately
$3.7 million in research and development tax credit was received during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used by investing activities was $0 for each of the three months ended March 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no net cash used in investing activities for the year ended December 31, 2024 and $6,000 in capital expenditures on information technology
(&#8220;IT&#8221;) during the respective comparative period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing
activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $3.6 million for the three months ended March 31, 2025 as a direct result of receiving approximately
$3.6 million, net of expenses, from the issuance of preferred stock under a Securities Purchase Agreement following a change of control
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities was $79,000 for the three months ended March 31, 2024 primarily due to dividend payment of approximately
$50,000 to the holders of our 6% Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $7.8 million for the year ended December 31, 2024 as a direct result of receiving approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6.2 million, net of expenses,
  from the issuance of common stock and warrants under a Securities Purchase Agreement with an institutional investor,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.6 million in net proceeds
  from a warrant exercise and reload agreement</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $0.8 million for the year ended December 31, 2023 as a direct result of receiving approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.0 million in net proceeds
  from the issuance of common stock and pre-funded warrants pursuant to the Registered Direct Offering,</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">offset by dividend payments
  of approximately $0.2 million to the holders of our 6% Convertible Exchangeable Preferred Stock in 2023 that were not paid in 2024.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our long-term contractual obligations as of December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Payments Due by Period</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Less than</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">1 year</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">1 &#8211; 3 years</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">3 &#8211; 5 years</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>More than</b></span></p>
                                                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5 years</b></span></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Operating Lease Obligations</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease obligations relates to leasing office space at our Berkeley Heights, New Jersey location. The lease for our Berkeley Heights location,
which was entered into in April 2022, has been terminated, effective January 31, 2025. Effective March 1, 2025, the Company entered into
a two year lease agreement for our corporate headquarters at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur,
Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 151; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have not had any off-balance sheet arrangements or relationships with unconsolidated entities or financial partnerships,
such as entities often referred to as structured finance or variable interest entities, which are typically established for the purpose
of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see Note 2 to the consolidated financial statements for a discussion of the potential effects that recently issued, but not yet effective,
accounting standards will have on our financial statements when adopted in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires
us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent
assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other
factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. We believe the judgments
and estimates required by the following accounting policies to be critical in the preparation of our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are more fully described in Note 2 to our consolidated financial statements included elsewhere in this
report. We believe the following critical accounting policies reflect our more significant estimates and assumptions used in the preparation
of our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued
Research and Development Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
research and development costs comprise our best estimates related to the cost of clinical trials, laboratory, and manufacturing activities
that were incurred, but not paid or invoiced, as of the end of a reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
management and monitoring of our clinical trials are performed with the assistance of contract research organizations, or CROs, or clinical
research associates, or CRAs, in accordance with our standard operating procedures. Typically, CROs and CRAs bill monthly for services
performed, or based upon milestones achieved. We accrue unbilled clinical trial expenses based on estimates of the level of services
performed each period. Moreover, clinical trial costs related to patient enrollment are accrued as patients are entered into and progress
through the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also perform outsourced laboratory and manufacturing activities. We accrue for unbilled laboratory and manufacturing activities performed
by third parties based on estimates of their progress towards completing the requested tasks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we accrued $1.3 million research and development costs, that we have estimated to have been incurred as of year-end
but had not been invoiced. This represents approximately 20% of our total research and development expense for the year ended December
31, 2024. As of December 31, 2023, we accrued $3.7 million research and development costs, that we have estimated to have been incurred
as of year-end but had not been invoiced. This represents approximately 19% of our total research and development expense for the year
ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
recording these accruals, we must make judgments about the progress of our various clinical activities. We (as well as our CROs and CRAs)
are reliant on information being provided timely and accurately by the multitude of clinics and hospitals where the studies are being
conducted, some of which are located internationally. We must also make estimates about the progress our third-party vendors are making
towards completing laboratory and manufacturing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
grant stock options, restricted stock units and restricted stock to officers, employees, directors and consultants under our 2018 Equity
Incentive Plan (the 2018 Plan) and the 2020 Inducement Equity Incentive Plan. We measure compensation cost for all stock-based awards
at fair value on date of grant and recognize compensation over the requisite service period. The fair value of restricted stock and restricted
stock units is determined based on the number of shares granted and the quoted price of our common stock on the date of grant. The determination
of grant-date fair value for stock option awards is estimated using an option-pricing model, which includes variables such as the expected
volatility of our share price, the anticipated exercise behavior of our employees, interest rates, and dividend yields. These variables
are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in significant
adjustments to the costs recognized for share-based payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 152; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_082"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF FITTERS SDN. BHD. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of financial condition and results of operations should be read together with the consolidated financial
statements of Fitters Sdn. Bhd. (&#8220;Fitters&#8221;) and accompanying notes appearing elsewhere in this proxy statement/prospectus.
This discussion of Fitters&#8217; financial condition and results of operations contains certain statements that are not strictly historical
and are &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve
a high degree of risk and uncertainty. Actual results may differ materially from those projected in the forward-looking statements due
to risks and uncertainties that exist in Fitters&#8217; operations, development efforts and business environment, including those set
forth in the section entitled &#8220;Risk Factors&#8212;Risks Related to Fitters Sdn. Bhd.&#8221; in this proxy statement/prospectus,
the other risks and uncertainties described in the section entitled &#8220;Risk Factors&#8221; in this proxy statement/prospectus and
the other risks and uncertainties described elsewhere in this proxy statement/prospectus. All forward-looking statements included in
this proxy statement/prospectus are based on information available to Fitters as of the date hereof, and Fitters assumes no obligation
to update any such forward-looking statement.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Sdn. Bhd. (&#8220;Fitters,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) is a Malaysian private limited company,
incorporated on August 20, 1982, specializing in the supply and trading of protective and fire safety equipment. Headquartered in Kuala
Lumpur, Malaysia, we provide a wide range of fire safety products, including fire extinguishers, foam system, fire-resistant doors, personal
protective equipment (&#8220;PPE&#8221;), and fire safety apparel. As a wholly-owned subsidiary of FITTERS Diversified Berhad, a company
listed on the Main Market of Bursa Malaysia Securities Berhad (Stock Code: 9318), we leverage the group&#8217;s expertise in fire protection
to serve domestic and international markets. Our mission is to deliver high-quality, certified safety solutions that enhance protection
across commercial, industrial, healthcare, and residential sectors. Our focus on trading and distribution positions us as a key player
in Malaysia&#8217;s fire safety market, with a reputation for reliability and compliance with stringent regulatory standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past four decades, we have expanded our product portfolio to include advanced fire-fighting equipment, foam system, PPE, and safety
apparel, establishing a strong presence in the industry. Our history of consistent growth reflects our commitment to quality and customer-centric
innovation, positioning us as a trusted name in fire safety equipment distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or &#8220;Parent&#8221;) and FITTERS Diversified Berhad, a Malaysia publicly-listed investment
holding company on Bursa Securities (KL: 9318) (&#8220;Fitters Parent&#8221;), which is the beneficial owner of all of the ordinary shares
(the &#8220;Company Ordinary Shares&#8221; or &#8220;Shares&#8221; and each, a &#8220;Share&#8221;) of Fitters Sdn. Bhd., a private limited
company incorporated in Malaysia (the &#8220;Company&#8221; or &#8220;Fitters&#8221;) entered into an Exchange Agreement dated as of
May 6, 2025, as amended on July 7, 2025 and as it may be further amended from time to time (collectively, the &#8220;Exchange
Agreement&#8221;) (&#8220;Fitters Parent&#8221; and &#8220;Parent&#8221; are sometimes referred to herein as the &#8220;Parties&#8221;
or each, a &#8220;Party&#8221;). The Parties thereto intend to effect a voluntary share exchange between Parent and Fitters Parent (the
&#8220;Exchange&#8221;), in which the Company will become a wholly-owned subsidiary of Parent, in accordance with the terms of the Exchange
Agreement and the rules under Delaware General Corporation Law (the &#8220;DGCL&#8221;) and the Malaysian Companies Act. The Company
has three wholly-owned subsidiaries: AHT NRG Asia Sdn. Bhd., FITTERS (Sarawak) Sdn. Bhd., and Modular Floor Systems (M) Sdn. Bhd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Exchange Agreement, and in accordance with the DGCL, at the Closing (as hereinafter
defined), Fitters Parent shall convey, assign, and transfer all of its right, title and interest to the Company Ordinary Shares to Parent.
The Shares transferred to Parent at the Closing shall constitute one hundred (100%) percent of the issued and outstanding capital shares
of the Company. As consideration for its acquisition of the Company Ordinary Shares, Parent shall issue an amount of common stock, par
value $0.001 per share (the &#8220;Parent Common Stock&#8221;) equal to nineteen and ninety-nine hundreds percent (19.99%) of the issued
and outstanding shares of Parent Common Stock as of the Closing Date (as defined below) (the &#8220;Exchange Shares&#8221;) to Fitters
Parent. In the event the value of the Exchange Shares is not mutually acceptable to both Parties prior to the Closing Date, the parties
have agreed to negotiate in good faith an adjustment to the Exchange Shares. If the Transaction does not close by September 30,
2025, either party may terminate the Exchange Agreement and the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 153; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue is primarily generated through the sale of fire protection products, emergency response equipment, and related services, including
system installation, maintenance, and inspection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Administrative
Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
expenses consist primarily of personnel expenses, professional fees for legal, auditing, tax and business consulting services and travel
costs. Fitters expects that general and administrative expenses will increase in the future as Fitters expands its operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Fitters completes the Transaction, Fitters would become a subsidiary of an SEC registrant and would expect to incur costs associated
with being a SEC registrant. These increases will likely include legal fees, costs associated with Sarbanes-Oxley compliance, accounting
fees, and directors&#8217; and officers&#8217; liability insurance premiums.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
trends and outlook</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our products and services are driven primarily by the increasing demand for fire safety and emergency response solutions. This demand
is influenced by stricter regulatory standards, growing awareness of fire prevention, urban development, and the need for advanced technology
in firefighting and emergency management. Additionally, rising investments in public safety infrastructure and industrial risk management
continue to create opportunities for growth in both domestic and international markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe drivers of industry demand should remain favorable in most of our geographic markets. For more information regarding these industry
trends, see &#8220;Fitters Sdn. Bhd. Business - Industry Overview.&#8221; Our customer targeting efforts, product development projects,
aftermarket service offerings are focused on enhancing our exposure to these trends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
management discussion and analysis of financial condition and results of operations is based on Fitters&#8217; consolidated financial
statements including the accounts of the Company and its subsidiaries, which have been prepared in accordance with accounting principles
in the United States of America (&#8220;US GAAP&#8221;). Intercompany transactions and balances were eliminated in consolidation. The
preparation of these financial statements requires Fitters to make estimates and judgments that affect the reported amounts of assets,
liabilities and expenses. On an ongoing basis, Fitters evaluates these estimates and judgments. Fitters bases its estimates on historical
experience and on various assumptions that Fitters believes to be reasonable under the circumstances. These estimates and assumptions
form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily
apparent from other sources. Actual results may differ materially from these estimates. Fitters believes that the accounting policies
discussed below are critical to understanding Fitters&#8217; historical and future performance, as these policies relate to the more
significant areas involving its judgments and estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing these financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities
in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers short-term, highly liquid investments with an original maturity of 90 days or less to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
deposit in Malaysia banks are secured by Perbadanan Insurans Deposit Malaysia, compensating up to a limit of Malaysia Ringgit MYR250,000
per deposit per member bank, which is equivalent to $56,351, if any of our bank fail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 154; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
Receivable </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist primarily of accounts receivable. The Company
extends credit to its customers in the normal course of business and generally does not require collateral. The Company&#8217;s credit
terms are dependent upon the segment, and the customer. The Company assesses the probability of collection from each customer at the
outset of the arrangement based on a number of factors, including the customer&#8217;s payment history and its current creditworthiness.
If in management&#8217;s judgment collection is not probable, the Company does not record revenue until the uncertainty is removed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
performs ongoing credit evaluations, and the Company maintains an allowance for potential credit losses based upon its loss history and
its aging analysis. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of credit losses in existing
accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable is recognized and carried at the original invoice amount less an allowance for any uncollectible amounts. An estimate for
doubtful accounts receivable is made when collection of the full amount is no longer probable. Bad debts are written off as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
losses </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables
and other receivables. Management considers historical collection rates, the current financial status of the Company&#8217;s customers,
macroeconomic factors, and other industry-specific factors when evaluating current expected credit losses. Forward-looking information
is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of
accounts receivable, management believes that the carrying value, net of expected losses, approximates fair value and therefore, relies
more on historical and current analysis of such financial instruments, including its trade receivables and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
loss rate is determined by historical collection based on aging schedule, adjusted for current conditions using reasonable and supportable
forecasts. Based on the aging categorization and the adjusted loss rate per category, an allowance for credit losses is calculated by
multiplying the adjusted loss rate with the amortized cost in the respective age category.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
recognition </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries generate multiple streams of revenues and recognized upon customer obtained control of promised goods or
services and recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those services.
In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts
with customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under this standard, a contract is defined as an agreement
between two or more parties that creates enforceable rights and obligations. The Company identifies distinct goods or services promised
in the contract, which primarily include the sale of firefighting equipment and safety apparel, as well as the provision of installation
and maintenance services. The transaction price is determined based on the fixed consideration the Company expects to receive in exchange
for transferring the promised goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
currencies translation </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated
into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded
in the statement of operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of the Company is the United States Dollars (&#8220;US$&#8221; or &#8220;US dollars&#8221;) and the accompanying
financial statements have been expressed in US dollars. In addition, the Company&#8217;s subsidiary maintains its books and record in
Malaysia Ringgit (&#8220;MYR&#8221;), which is the respective functional currency as being the primary currency of the economic environment
in which the entity operates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 155; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US dollars are translated
into US dollars, in accordance with ASC Topic 830-30, &#8220;Translation of Financial Statement&#8221;, using the exchange rate on the
balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting
from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation
of amounts from the local currency of the Company into US$1 has been made at the following exchange rates for the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Period-end MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4.4365</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4.7225</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period-averaged MYR : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.5049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6414</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Related
parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties,
which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control
the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also
considered to be related if they are subject to common control or common significant influence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
value of financial instruments </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&#8217;s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables,
amount due to related parties, trade payables and other payables approximate at their fair values because of the short-term nature of
these financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also follows the guidance of the ASC Topic 820-10, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820-10&#8221;),
with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy
that prioritizes the inputs used in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 : Observable inputs such as quoted prices in active markets;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lease
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offices for fixed periods pre-emptive extension options. The Company recognizes lease payments for its short-term lease on a
straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. The
right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments
made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Costs associated
with operating lease assets are recognized on a straight-line basis within operating expenses over the term of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the present value of the unpaid lease payments, ASC 842 requires a lessee to discount its unpaid lease payments using the
interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company
leases do not provide an implicit rate, the Company uses its incremental borrowing rate as the discount rate for the lease. The Company
incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 156; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended March 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Difference</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Total Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,921,568</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2,116,590</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(195,022</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(9.2</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Total Cost of Revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,503,775</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,643,505</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(139,730</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8.5</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Gross Profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">417,793</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">473,085</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(55,292</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(11.7</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Selling, General and Administrative Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(585,293</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(687,075</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(101,782</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14.8</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">(Loss) from Operation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(167,500</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(213,990</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">46,490</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">21.7</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Interest Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,353</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,342</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,989</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37.2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">(Loss) before Income Tax</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(103,072</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(155,802</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">52,730</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">33.8</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Income Tax Benefits/(Expenses)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,986</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(38,136</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49,122</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">128.8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net (Loss)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(92,086</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(193,938</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">101,852</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">52.5</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Total
Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
revenue was $1,921,568 and $2,116,590 for the years ended March 31, 2025, and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decrease of revenue was primarily driven by market fluctuations and delayed customer procurement decisions. Despite this, demand for
core fire safety products, such as fire extinguishers, alarms, and personal protective equipment remained relatively steady.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Total
Cost of Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues was $1,503,775 and $1,643,505 for the years ended March 31, 2025, and 2024, respectively. It primarily consists of the cost
of fire safety products, such as fire extinguishers, alarms, and personal protective equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Total
Operating Costs and Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
operating costs and expenses were $588,646 and $692,417 for the years ended March 31, 2025, and 2024, respectively. They consist
of general and administrative expenses &#8220;G&amp;A&#8221; and interest expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative (&#8220;G&amp;A&#8221;) expenses were $585,293 and $687,075 for the years ended March 31, 2025, and 2024, respectively.
In 2025, our G&amp;A expenses primarily consisted of employees&#8217; salaries and allowances of $243,397, directors&#8217; salaries
of $26,681, administrative expenses $54,341, exchange gain $29,887 provision for credit losses of $274,970, provision for obsolete stock
$18,703, rent and rates of $7,467, and audit, legal, and other professional fees of $7,337. In 2024, our G&amp;A expenses primarily consisted
of employees&#8217; salaries and allowances of $270,578, directors&#8217; salaries of $38,812, administrative expenses of $34,903, provision
for credit losses of $122,322,impairment for cost of investment in subsidiary of $49,245, provision for obsolete stock $104,668, rent
and rates of $7,758, and audit, legal, and other professional fees of $7,297. The decreased G&amp;A expense of $101,782 was mainly derived
from the decrease of provision for obsolete stock $85,965, impairment for cost of investment in subsidiary $49,245, employees&#8217;
salaries and allowances of $27,201, directors&#8217; salaries of $11,931 offset by the increase of provision for credit losses $152,648,
administrative expenses $19438, exchange gain $29,887 during the same period from 2024 to 2025. We expect our G&amp;A expenses will slightly
increase due to global inflation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit decreased by 11% compared to FYE 31 March 2024, primarily due to reduced sales volumes and margin pressure in certain product
lines. However, operating expenses were well-managed, showing a notable 15% decline compared to previous financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax benefits were derived from reversal of over-provision made in the prior year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 157; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, the company recorded a lower net loss of USD92,086 for FYE 31 March 2025, compared to a loss of USD193,938 in the previous
year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the financial results reflect short-term headwinds, they also underscore the importance of ongoing cost discipline and operational agility.
The company remains focused on enhancing customer engagement, improving efficiency, and reinforcing its position in the fire services
trading sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of our key liquidity measures as of March 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">593,055</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">250,202</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Working capital:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,864,758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,720,380</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,409,067</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,321,790</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total working capital surplus</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,455,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,398,590</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
from operating, investing and financing activities for the year ended March 31, 2025 and 2024 is summarized as follows :</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year ended March 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Difference</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">US$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">US$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">US$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net cash provided by operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">393,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">60,264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">333,644</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">553.6</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,791</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(991</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80.7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in)/provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(70,356</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,539</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,817</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325.4</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the latest reporting year, the company maintains a strong liquidity position, supported by healthy cash flows from operations and
prudent working capital management, reflecting our ability to meet short-term obligations and finance day-to-day operations without reliance
on external funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
generated from the sale of fire safety products and trading activities continues to be the primary source of liquidity. This has enabled
us to fund inventory purchases, support receivables, and make timely payments to suppliers while maintaining a buffer for unforeseen
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have access to unutilized lines of credit and favorable supplier terms, providing additional financial flexibility. Our
capital resources are sufficient to support planned investments in inventory expansion, and market development initiatives without compromising
financial stability. We remain focused on maintaining a balanced capital structure and a conservative approach to leverage, ensuring
long-term financial resilience and the ability to capitalize on future growth opportunities in the fire protection&#160;market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by operating activities for the years ended March 31, 2025 and 2024 were amounting to $398,908 and $60,264, respectively.
The net cash provided by operating activities in 2025 primarily consisted of a net loss of $92,086, a provision of credit loss allowance
of $274,970, a decrease in account receivable of $60,632, a decrease in prepayment, deposits and other receivables of $229,050 and an
increase in tax assets of $60,243, while the net cash provided by operating activities in 2024 was mainly from, a provision for credit
loss allowance of $122,322, a decrease of accounts receivable and inventory of $141,468 and $228,940 respectively and offset by net loss
for the year of $193,938 and increase of prepayment, deposits and other receivables of $262,628.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
net expenses totaled $278,879 and $142,362 for the years ended March 31, 2025, and 2024, respectively.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 158; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
expenses, net was comprised of non-cash expenses from depreciation and amortization of $3,909, provision for credit losses of $274,970
for the year ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
expenses, net was comprised of non-cash expenses from depreciation and amortization of $20,040, provision for credit losses of $122,322
for the year ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred operating losses during the past two years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $1,791 and $991 for the year ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025 and 2024, the cash used in investing was both composed of the purchase of equipment.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities was $70,356 for the year ended March 31, 2025, as compared to net cash provided by financing activities
of $16,539 for the year ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025 and 2024, net cash used in/provided by financing activities was due to the advances to related parties of $70,356 and repayment
from related companies of $16,539, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2025, and 2024, the Company has the following transactions with related parties:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">For the year ended 31 March</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">US$</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">US$</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenue</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; text-align: left">- Fitters Engineering Services Sdn. Bhd.</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 20%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">697,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">816,676</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Fitters Engineering Services Sdn. Bhd. (Ipoh)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,894</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,754</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Master Pyroserve Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,094</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Fitters Marketing Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Fitters Diversified Berhad</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of Revenue</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Fitters Engineering Services Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Fitters Marketing Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(899</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Fitters Diversified Berhad</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(124</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other transactions</td><td>&#160;</td>
    <td style="text-align: center">Category</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Fitters Engineering Services Sdn. Bhd. (Ipoh)</td><td>&#160;</td>
    <td style="text-align: left">Rental income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,946</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Master Pyroserve Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: left">Commission income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Fitters Marketing Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: left">Warehouse rental</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,252</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,537</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Fitters Diversified Berhad</td><td>&#160;</td>
    <td style="text-align: left">Office rental</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42,085</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,684</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">649,180</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">851,485</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Diversified Berhad was the holding company of the Company before the share exchange transaction, while the other companies are under
the common control of Fitters Diversified Berhad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 159; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a trading business focused on fire safety products, our future capital requirements will primarily support inventory expansion, supply
chain optimization, and market penetration initiatives. We anticipate increased investment in working capital to maintain adequate stock
levels of high-demand items, particularly as we expand our product range to include advanced and internationally certified fire protection&#160;equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance&#160;Sheet
Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
has not entered into any&#160;off-balance&#160;sheet arrangements and does not have any holdings in variable interest entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03
Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income
Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements,
among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and
depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03
is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15,
2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively
to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing
the potential impact on the Company&#8217;s financial statement disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, the FASB issued ASU 2025-02, Liabilities (Topic 405): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 122, which removes certain SEC guidance related to obligations to safeguard crypto-assets. The Company does not engage in activities
involving crypto-assets; therefore, the adoption of this ASU is not expected to have a material impact on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews new accounting standards as issued. Management has not identified any other new standards that it believes will have
a significant impact on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
inflation has been relatively low in recent years and did not have a material impact on our results of operations during 2025 and 2024.
Although the impact of inflation has been insignificant in recent years, it is still a factor in the global economy and we tend to experience
inflationary pressure on the cost of raw materials and components used in our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quantitative
and qualitative disclosures about market risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently exposed to market risk from changes in foreign currency and changes in interest rates. From time to time, we may enter
into derivative financial instrument transactions to manage or reduce our market risk, but we do not enter into derivative transactions
for speculative purposes. A discussion of our market risk exposure in financial instruments follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Currency
exchange rates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a trading company engaged in the import and distribution of fire safety products, fluctuations in currency exchange rates can impact
our cost of goods sold and overall financial performance. The majority of our purchases are denominated in foreign currencies, including
USD and EUR, while revenues are primarily generated in the local currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the reporting period, foreign exchange rates remained relatively stable, resulting in minimal impact on margins. However, we continue
to monitor exchange rate volatility closely, particularly in light of global economic uncertainty and supply chain dynamics. A sustained
appreciation of foreign currencies against the local currency could increase procurement costs, while a depreciation would be favorable
to our purchasing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial team actively monitors exchange rate movements and provides periodic risk assessments to ensure informed procurement and pricing
decisions, helping to protect profitability and maintain competitive&#160;pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
rates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
rate movements can influence our borrowing costs and overall financial performance, particularly in relation to working capital financing
and any outstanding credit facilities. During the reporting period, interest rates remained relatively stable, and the impact on our
financial results was minimal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company maintains a conservative approach to debt, with limited reliance on external financing. Where financing is utilized&#8212;such
as short-term credit lines for inventory purchases&#8212;it is structured with competitive, floating interest rates. We continuously
monitor market conditions and central bank policy changes to assess potential impacts on financing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
interest rates rise significantly, borrowing costs could increase, potentially affecting profitability. However, given our strong liquidity
position and prudent financial management, we are well-positioned to absorb moderate fluctuations without material impact on operations
or growth plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 160; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_083"></span>QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK OF CYCLACEL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Sensitivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company used net cash of $8.2 million to fund our operating activities for the three months ended
March 31, 2025. We had cash and cash equivalents of $3.5 million as of March 31, 2025, which will allow it to meet its liquidity requirements
into the second quarter of 2025 and for working capital purposes. The Company does not enter into investments for trading or speculative
purposes. The Company does not believe that it has any material exposure to changes in the fair value of these investments as a result
of changes in interest rates due to their short-term nature. Declines or increases in interest rates, however, will reduce or increase
future investment income, respectively, to the extent the Company has funds available for investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Exchange Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied
to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
January 24, 2025, the assets and liabilities of the Company&#8217;s former international subsidiary, Cyclacel Limited, were translated
from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange
during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity
transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well
as unrealized foreign exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or
anticipated in the foreseeable future and that are of a long-term-investment nature, were recorded in other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has not entered into, and does not have any current plans to enter into, any foreign currency hedging transactions
or derivative financial transactions. The Company expects its transactions outside of the U.S. in the near-term will primarily entail
payments for clinical trials, and for vendors and consultants supporting those trials if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s exposure to foreign currency risk will fluctuate in future periods as our clinical trial activity in changes and if the
Transaction closes, in relation to the acquisition of Fitters Sdn. Bhd. and maintaining business operations and assets outside of the
U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currencies of the Company&#8217;s foreign subsidiaries if the Transaction closes are the local currencies. Accordingly, the
effects of exchange rate fluctuations on the net assets of these operations will be accounted for as translation gains or losses in accumulated
other comprehensive income within stockholders&#8217; equity. The Company currently has no foreign subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Effects
of Inflation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not believe that inflation and changing prices had a significant impact on its results of operations for any periods presented
herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 161; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_084"></span>MANAGEMENT
FOLLOWING THE CLOSING OF THE TRANSACTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_085"></span>Executive
Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="svv_086"></span>Current
Executive Officers of Parent</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employment of the executive officers of Cyclacel Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Parent&#8221;) is
expected to continue with the combined company following the completion of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive
Officers and Directors of the Combined Company Following the Closing of the Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Exchange Agreement, effective as of the effective time of the Transaction, the initial size of the board of directors of the combined
company will be five and the initial directors will be comprised of the five members of the current Parent board. The following table
lists the names, ages and positions of the individuals who are expected to serve as executive officers, and directors including non-employee&#160;directors
of the company upon completion of the Transaction:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwang
    Fock Chong</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="svv_087"></span>Parent
Executive Officers and Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Datuk
Dr. Doris Wong -- </i></b>Datuk Dr. Wong brings more than 20 years of management experience to her role as Chief Executive Officer of
the Company across various industries ranging from oil and gas, property development, solar, engineering, advertising, food and beverage,
raw materials and more. She specializes in business development, strategic consultancy and corporate advisory in mergers and acquisition
and joint venture across Malaysia, Singapore, China, Japan, Thailand and Indonesia. Since October 2020, Datuk Dr. Wong has been serving
as an Executive Director of Metronic Global Bhd, an investment holding company, where she has been optimizing financial operations, establishing
business goals, advising the board of directors on organizational activities and executing special business projects. She has also been
involved in various investment opportunities in business diversification, generating new revenue and increasing shareholders&#8217; wealth.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
Dr. Wong has also been serving as the Executive Director of BSL Corporation Berhad (KLSE: BSLCORP) since May 2024, a public listed company
with its business segments constituting stamping and manufacturing of precision metal parts and fabrication of tools and dies, printed
circuit boards (PCB) assembly of all types of electronics and electrical components, devices and systems, fabrication and forging of
base metal components for consumer products. Datuk Dr. Wong served as an independent director and member of the audit committee and the
compensation committee of Energem Corp from its initial public offering on November 16, 2021 until her appointment as Executive Director
on January 27, 2023. Following Energem Corp&#8217;s completion of a series of transactions that resulted in its business combination
with Graphjet Technology Sdn. Bhd. (Nasdaq: GTI), a Malaysian private limited company (&#8220;Graphjet&#8221;) on March 14, 2024, Datuk
Dr. Wong served as a director of Graphjet until January 6, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
February 2017, Datuk Dr. Wong has been a non-independent non-executive director at Trive Property Group Bhd (0118.KL). Previously, from
January 2019 to September 2020, Datuk Dr. Wong served as Chief Corporate Officer in Metronic Engineering Sdn. Bhd. (0043.KL) where she
oversaw HR operations, set objectives for the HR team and helped shape the brand strategy of the company. Datuk Dr. Wong served as General
Manager from 2015 to 2016 in Dai-Ichi Kikaku Sdn. Bhd. where she was overseeing and handling business development, client strategy and
direction, creative, production, media planning, procurement and research. From 2012 to 2015, Datuk Dr. Wong served as Strategic Business
Consultant for JLPW Law Firm where she handled mergers and acquisitions and joint venture deals internationally for various industries
and from 2002 to 2012, Datuk Dr. Wong started her career as a Managing Director at Niagamatic Sdn. Bhd., where she controlled all business
operations to give strategic guidance and directions to the board and staff to ensure the company achieved its financial vison, mission
and long-term goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 162; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kiu
Cu Seng -- </i></b>Mr. Kiu&#160;brings significant accounting and audit experience involving publicly listed companies during his years
working with accounting standards. Mr. Kiu served as Energem Corp&#8217;s Chief Financial Officer from August 12, 2021 through its completion
of a series of transactions that resulted in its business combination with Graphjet on March 14, 2024. Since March 2021, Mr. Kiu has
served as Group Accountant for BCM Alliance Bhd, Sanichi Technology Bhd. and Trive Property Group Bhd. His responsibility is on group
consolidation issues. From June 2019 to February 2021, Mr. Kiu served as Manager in SBY &amp; Partners PLT (formerly known as Siew Boon
Yeong &amp; Associates) an established professional accounting organization providing a comprehensive range of services ranging from
audit and assurance, taxation and accounting where he specialized in auditing matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
June 2017 to February 2019, Mr. Kiu served as a Senior Auditor with Siew Boon Yeong &amp; Associates. Prior to that, from December 2016
to June 2017, Mr. Kiu served as a semi-senior auditor at the corporate compliance firm, Z. AMIN and he started his career in 2013 until
December 2016 with YTS &amp; Associate. Mr. Kiu graduated from Infrastructure University Kuala Lumpur in the year 2013 with bachelor&#8217;s
degree (with Honors) in Accounting and from Kuala Lumpur Infrastructure University College with a Diploma in Accounting in 2009<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Non-Employee
Directors</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kwang
Fock Chong &#8211; </i></b>Mr. Chong&#160;is a Chartered Accountant in Malaysia, and brings nearly 20 years of the working experience
to the Company. He served as an Independent Director, Chair of the Audit Committee and member of the Compensation Committee of Energem
Corp since its initial public offering on November 16, 2021 until its business combination with Graphjet on March 14, 2024. His experience
includes auditing of public listed companies, multinationals and private limited companies in various industries. Other than conducting
statutory audit in Malaysia, he also performed audit for companies based in China and the AIPAC region. He was also involved in Reporting
Accountants&#8217; engagement on initial public offering exercise, due diligence, reviewing financial forecast and projections. Mr. Chong
also serves as Auditors and Partner of KHLC PLT where his main responsibility is reviewer and signing partner since October 2020. From
July 2014 to September 2020, Mr. Chong served as Auditor and Partner of SBY Partners PLT that provides audit and assurance services.
His main responsibility was to be reviewer and signing partner. Mr. Chong received his Diploma in 2002 from Tunku Abdul Rahman College
in Financial Accounting. He achieved his Association of Chartered Certified Accountants certification in 2005.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Satis Waran Nair Krishnan &#8211; </i></b>Dr. Nair is a Medical Doctor at Centric Health in Drogheda, County Louth, Ireland. Dr. Krishnan
is a highly experienced practitioner originally from Malaysia. Dr. Krishnan joined Centric Health in Ireland September 2023. Prior to
that, from 2010 to August 2023, Dr. Krishnan was a Doctor in the public health field for the Ministry of Health Malaysia, With a decade
of practice in Malaysia and training in Dermatology from the Association of Family Physicians of Malaysia (AFPM) and the Institute of
Dermatology in Bangkok, Thailand, Dr. Krishnan brings a wealth of expertise to our team. Dr. Nair is proficient in English, Russian and
Ukrainian, he is dedicated to providing patient-centered care and promoting overall well-being. Dr. Krishnan received his medical degree
in 2010 and Professional Diploma of General Dermatology in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inigo
Angel Laurduraj &#8211; </i></b>Ms. Laurduraj brings extensive audit and accounting services to the Company over her 20 years in that
industry. Ms. Laurduraj served as a Senior Accounting Manager at IOI Oleochemicals Sdn. Bhd., an edible oil refining and oleochemicals
company for 11 years from 2007 through 2018. Prior to that, she served from 2005 through 2005 as an Auditor for Moore Stephens (now Moore
Global), a global firm operating in 114 countries specializing in accounting and finance services, audit and assurance, fund services,
private client services, corporate services, and tax services. Ms. Laurduraj earned an Association of Chartered Certified Accountants
(ACCA) in 2015 and a Bachelor of Arts in Accounting in 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq&#8217;s
listing standards require that the Parent&#8217;s board of directors consist of a majority of independent directors, as determined under
the applicable rules and regulations of The Nasdaq Stock Market LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 163; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon information requested from and provided by each proposed director concerning his or her background, employment and affiliations,
including family relationships, Parent&#8217;s board of directors believes that each of Kwang Fock Chong, Dr. Satis Waran Nair
Krishnan, and Inigo Angel Laurduraj, will qualify as an independent director following the completion of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Committees
of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parents&#8217;
board of directors currently has, and following the completion of the Transaction will continue to have, the following committees: audit
committee, a compensation committee and a nominating and corporate governance committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board also determined that each of Kwang Fock Chong, Inigo Angel Laurduraj, and Dr. Satis Waran Nair Krishnan also satisfy the additional
requirements of financial literacy and audit committee independence for audit committee service under the applicable rules and regulations
of the SEC and the listing standards of Nasdaq.<br/>
<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee currently consists of Kwang Fock Chong, as Chair, Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, each
of whom is an independent, non-employee&#160;director. The Audit Committee selects, on behalf of Parent&#8217;s board of directors,
an independent public accounting firm to audit Parent&#8217;s financial statements, discusses with the independent auditors their independence,
reviews and discusses the audited financial statements with the independent auditors and management, recommends to Parent&#8217;s board
of directors whether the audited financials should be included in Parent&#8217;s annual reports to be filed with the SEC, and oversees
management&#8217;s identification, evaluation, and mitigation of major risks to Parent. The Audit Committee operates pursuant to a written
charter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee of the combined company is expected to retain these persons and their duties and responsibilities following completion
of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent&#8217;s
board of directors has determined Mr. Chong qualifies as an &#8220;audit committee financial expert&#8221; as defined in SEC
rules and regulations and also possesses the financial sophistication and requisite experience as required under Nasdaq listing
standards, as defined in Item 407(d)(5) of Regulation S-K. To qualify as independent to serve on Parent&#8217;s audit committee,
listing standards of The Nasdaq Stock Market and the applicable rules of the SEC require that a director not accept any consulting,
advisory, or other compensatory fee from Parent, other than for service as a director, or be an affiliated person of Parent.
Parent&#8217;s board of directors has concluded that the current composition of the audit committee meets the requirements for
independence under the rules and regulations of The Nasdaq Stock Market LLC and of the SEC. Parent believes that, following
completion of the Transaction, the composition of the audit committee will comply with the applicable requirements of the rules and
regulations of The Nasdaq Stock Market LLC and of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee currently consists of Inigo Angel Laurduraj, as Chair, Kwang Fock Chong and Dr. Satis Waran Nair Krishnan,
each of whom is an independent director. The Compensation Committee reviews and approves (1)&#160;the annual salaries and other compensation
of Parent&#8217;s executive officers and (2) individual stock and stock option grants. The Compensation Committee also provides
assistance and recommendations with respect to Parent&#8217;s compensation policies and practices, and assists with the administration
of Parent&#8217;s compensation plans. In evaluating executive officer compensation, the Compensation Committee may retain the services
of compensation consultants and considers recommendations from the Chief Executive Officer with respect compensation of the other executive
officers. The Compensation Committee also periodically reviews compensation for&#160;non-employee directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee of the company is expected to retain these duties and responsibilities following completion of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee of the combined company is expected to retain these persons and their duties and responsibilities following
completion of the Transaction. To qualify as independent to serve on Parent&#8217;s compensation committee, the listing standards of
The Nasdaq Stock Market require a director not to accept any consulting, advisory, or other compensatory fee from Parent, other than
for service on Parent&#8217;s board of directors, and that Parent&#8217;s board of directors consider whether a director is affiliated
with Parent and, if so, whether such affiliation would impair the director&#8217;s judgment as a member of Parent&#8217;s compensation
committee. Parent&#8217;s board of directors has concluded that the composition of the compensation committee meets the requirements
for independence under the rules and regulations of The Nasdaq Stock Market LLC and of the SEC. Parent believes that, after the completion
of the Transaction, the composition of the compensation committee will meet the requirements for independence under, and the functioning
of such compensation committee will comply with any applicable requirements of the rules and regulations of The Nasdaq Stock Market LLC
and of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 164; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
and Corporate Governance Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee currently consists of Dr. Satis Waran Nair Krishnan, as Chair,  Kwang Fock Chong and
Inigo Angel Laurduraj, each of whom was determined by the Parent board of directors to be an independent director. The Nominating and
Corporate Governance Committee assists the Parent board of directors in fulfilling its responsibilities by: identifying and approving
individuals qualified to serve as members of the Parent board of directors, selecting director nominees for Parent&#8217;s annual meetings
of stockholders, evaluating the performance of Parent&#8217;s board of directors, and developing and recommending to Parent&#8217;s board
of directors corporate governance guidelines and oversight procedures with respect to corporate governance and ethical conduct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
codes of conduct clearly outline our commitment to diversity and inclusion, where all employees are welcomed in an environment designed
to make them feel comfortable, respected, and accepted regardless of their age, race, national origin, gender, religion, disability or
sexual orientation. We have a set of policies explicitly setting forth our expectations for nondiscrimination and a harassment-free work
environment. We are also a proud equal opportunity employer and cultivate a highly collaborative and entrepreneurial culture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
identifying and evaluating candidates, the committee takes into consideration the criteria approved by Parent&#8217;s board of directors
and such other factors as it deems appropriate. These factors may include judgment, skill, diversity, experience with businesses and
other organizations of comparable size, the interplay of the candidate&#8217;s experience with the experience of other members of the
board of directors, and the extent to which the candidate would be a desirable addition to the board of directors and any committees
of the board of directors. The Nominating and Corporate Governance Committee will consider properly submitted stockholder nominations
for candidates for the board of directors. Following verification of the stockholder status of persons proposing candidates, recommendations
will be aggregated and considered by the Nominating and Corporate Governance Committee. If any materials are provided by a stockholder
in connection with the nomination of a director candidate, such materials will be forwarded to the Nominating and Corporate Governance
Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee of the combined company is expected to retain these persons and their duties and
responsibilities following completion of the Transaction and is expected to retain these duties and responsibilities following completion
of the Transaction. Parent believes that, after the completion of the Transaction, the composition of the corporate governance committee
will meet the requirements for independence under, and the functioning of such committee will comply with any applicable requirements
of the rules and regulations of The Nasdaq Stock Market LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_088"></span>Parent&#8217;s
Board of Director Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
does not currently have a director compensation policy. All of Parent&#8217;s directors, including those who also serve as employees
(<i>i.e., </i>Datuk Dr. Doris Wong and Kiu Cu Seng), received cash compensation for service under their management service contracts
with Parent during 2025 (see &#8220;<i>Parent Director and Executive Officer Compensation</i>&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_089"></span>Parent
Director and Executive Officer Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent&#8217;s
executive officers and directors presently, and who will serve as executive officers and directors of the combined company following
the Transaction, are referred to in this proxy statement/prospectus as the &#8220;named executive officers and directors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 165; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
Compensation Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding the named executive officers and directors who will serve as executive officers and directors
of the combined company. For the management of the combined company after the closing of the Transaction, as discussed further above
in this section titled &#8220;<i>Management Following the Closing of the Transaction</i>&#8221; beginning on page 154</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    and Principal Position</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal
    Year</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(1)</sup></b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus<br/>
    ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    awards<br/>
    ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    awards<br/>
    ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other compensation<br/>
    ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total<br/>
    $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 31%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong, <i>Chief</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Officer and</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng, <i>Chief Financial </i></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    and Executive Director</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwang
    Fock Chong,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation arrangements are expressed in USD.</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the consummation of the Transaction, Parent expects to undertake a comprehensive review of all elements of its executive officer and
director compensation program, including the function and design of its equity incentive programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_090"></span>Compensation
Risk Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
has considered the risk associated with its compensation policies and practices for all employees and believes it has designed its compensation
policies and practices in a manner that does not create incentives that could lead to excessive risk taking that would have a material
adverse effect on Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_091"></span>Board
of Directors of Fitters Following the Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the current members of the board of directors of Fitters Sdn. Bhd. (&#8220;Fitters&#8221;) is expected to continue to serve on the
board of directors of the Company after the Closing of the Transaction with the addition of Datuk Dr. Doris Wong, our chief executive
officer, who currently holds Fitters Parent ordinary shares, who will be appointed to the board of directors of the Company.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the anticipated directors the Company upon the closing of the Transaction:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fitters
    Sdn. Bhd. Director or Officer Name</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chin
    Yong Shing</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Fitters
Sdn. Bhd. Executive Officers and Directors</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Chin
Yong Shing, Executive Director (age 56) -- </i></b>Mr. Chin Yong Shing (&#8220;Mr. Chin&#8221;) graduated from Polytechnic of Wales (UK)
with a Bachelor of Engineering (Mechanical). He started his career as a Project Engineer at FITTERS Engineering Services Sdn. Bhd., a
wholly owned subsidiary of FITTERS Diversified Berhad, on 15 October 1992. He was promoted to Project Manager in 1998 and to General
Manager in 2010. Mr. Chin is currently the Executive Director of Fitters Engineering Services Sdn Bhd, a position he holds since 2014<b><i>.
</i></b>Mr. Chin was appointed as Director of Fitters Sdn. Bhd. in January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Datuk
Dr. Doris Wong &#8211; </i></b>For Datuk Dr. Wong&#8217;s biography, please see above under &#8220;<i>Management Following The Closing
Of The Transaction &#8211; Parent Executive Officers and Directors</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 166; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_092"></span>Fitters
Sdn. Bhd. Executive Officer and Director Compensation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
Compensation Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding the executive officers and directors of Fitters Sdn. Bhd. who will serve as executive
officers and directors of Fitters Sdn. Bhd. after the closing of the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 30%; font-weight: bold; text-align: center">Name and Principal Position</td><td style="padding-bottom: 1pt; text-align: center; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Fiscal Year</b></span></td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Salary<br/>
 ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center"/><td style="padding-bottom: 1pt; text-align: center; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 5%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Bonus<br/>
 ($)</b></span></td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 5%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Stock Awards<br/>
 ($)</b></span></td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 5%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Option Awards<br/>
 ($)</b></span></td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 5%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>All other compensation<br/>
 ($)</b></span></td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; width: 2%; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 6%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Total<br/>
$</b></span></td><td style="padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chin Yong Shing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">12,000</span></td><td style="text-align: left"/><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">12,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Datuk Dr. Doris Wong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    arrangements are expressed in USD.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_093"></span>Employment
Benefits Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Parent&#8217;s
Equity Incentive Plan and Inducement Equity Inventive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
grants stock options, restricted stock units and restricted stock to officers, employees, directors and consultants under our 2018 Equity
Incentive Plan and the 2020 Inducement Equity Incentive Plan. Parent measures compensation cost for all stock-based awards at fair value
on date of grant and recognize compensation over the requisite service period. The fair value of restricted stock and restricted stock
units is determined based on the number of shares granted and the quoted price of our common stock on the date of grant. The determination
of grant-date fair value for stock option awards is estimated using an option-pricing model, which includes variables such as the expected
volatility of our share price, the anticipated exercise behavior of our employees, interest rates, and dividend yields. These variables
are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in significant
adjustments to the costs recognized for share-based payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2018, the Company&#8217;s stockholders approved the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), under which Cyclacel
may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan replaced the 2015 Equity Incentive
Plan (the &#8220;2015 Plan&#8221;). The 2018 Plan allows for various types of award grants, including stock options and restricted stock
units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option awards granted under the Company&#8217;s equity incentive plans have a maximum life of 10 years and generally&#160;vest
over a one to four-year period from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2024, the Company&#8217;s stockholders approved an additional 666 shares of common stock that may be issued under the
2018 Plan. On June 13, 2023, the Company&#8217;s stockholders approved an additional 250 shares of common stock that may be issued
under the 2018 Plan. As of December 31, 2024, the Company has reserved approximately 820 shares of the Company&#8217;s common
stock under the 2018 Plan for future issuances. Stock option awards granted under the Company&#8217;s equity incentive plans have a maximum
life of 10 years and generally vest over a one&#160;to&#160;four-year&#160;period from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2025, the Company&#8217;s stockholders approved an amendment to the 2018 Plan to reserve an additional 500,000 shares of
Common Stock for issuance thereunder, which number would not be adjusted as a result of the Reverse Stock Split. As of March 31, 2025,
the Company has reserved approximately 499,000 shares of the Company&#8217;s common stock under the 2018 Plan for future issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2020
Inducement Equity Incentive Plan&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), became effective. Under the Inducement Plan,
Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder
approval). The Inducement Plan allows for the issuance of up to 55 shares of the Company&#8217;s common stock (or the equivalent
of such number). As of December 31, 2024, the reserve remains at 55 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 167; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_094"></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee reviews and approves in advance all related-party transactions. Except as described below, there have been no transactions
during our last two fiscal years with our directors and officers and beneficial owners of more than 5% of our voting securities
and their affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, in an insider private placement, we entered into an Insider Securities Purchase Agreement pursuant to which we agreed
to sell in a private placement (i) 25 shares of common stock and warrants to purchase 25 shares of common stock, on the
same terms as the unregistered warrants&#160;issued to certain institutional investors (the &#8220;Purchasers&#8221; and such warrants,
the &#8220;Private Warrants&#8221;), to Spiro Rombotis, our former Chief Executive Officer, and (ii) 8 shares of common stock
and warrants to purchase 8 shares of common stock on the same terms as the Private Warrants issued to the Purchasers in the Offerings
to Paul McBarron, our former Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer. Each such share of
common stock and accompanying warrant was sold at a purchase price of $795.60, which was the same purchase price for the shares
of common stock sold in a concurrent registered direct offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 2, 2025, we entered into a Securities Purchase Agreement (the &#8220;Lazar Purchase Agreement&#8221;) with David E. Lazar, our
former interim Chief Executive Officer, principal financial officer, principal accounting officer and secretary, pursuant to which he
agreed to purchase from the Company 1,000,000 shares of Series C Convertible Preferred Stock (the &#8220;Series C Preferred Stock&#8221;)
and 2,100,000 shares of Series D Convertible Preferred Stock (the &#8220;Series D Preferred Stock&#8221; and, together with the Series
C Preferred Stock, the &#8220;Preferred Stock&#8221;) of the Company at a purchase price of $1.00 per share for aggregate gross proceeds
of $3.1 million, subject to the terms and conditions of the Lazar Purchase Agreement. Mr. Lazar agreed to pay $1,000,000 at the initial
closing of the transactions under the Lazar Purchase Agreement in exchange for 1,000,000 shares of Series C Preferred Stock which occurred
on January 6, 2025. Upon Company February 6, 2025, Mr. Lazar paid an additional $2,100,000 in exchange for 2,100,000 shares of Series
D Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the signing of the Lazar Purchase Agreement, Mr. Spiro Rombotis and Mr. Paul McBarron resigned as Chief Executive Officer
and Chief Financial Officer, respectively, of the Company and Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth
Ferguson and Ms. Karin Walker (together, the &#8220;Resigning Directors&#8221;) also resigned as members of our board of directors effective
as of the signing of the Lazar Purchase Agreement. On January 2, 2025, the Company entered into settlement agreements with the Resigning
Directors effective as of the signing of the Lazar Purchase Agreement. Pursuant to the terms of such settlement agreements, each Resigning
Director resigned his or her position as a member of the Board of Directors, and any positions held on committees of the Board of Directors
and received his or her accrued Board fees in full consideration of the release of claims against the Company and other promises and
covenants set forth in such settlement agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 2, 2025, the Company entered into a settlement agreement with Mr. Rombotis whereby Mr. Rombotis agreed to provide transition
services to the Company in his capacity as a member of the Board of Directors through the filing of the Company&#8217;s Annual Report
on Form 10-K for the year ended 2024. On January 2, 2025, the Company also entered into a settlement agreement with Mr. McBarron, whereby
Mr. McBarron agreed to provide transition services to the Company in his capacity as a member of the Board of Directors through the filing
of the Company&#8217;s Annual Report on Form 10-K for the year ended 2024. In consideration for entering into such settlement agreements,
the Company agreed to pay Mr. Rombotis and Mr. McBarron payments of $279,415.50 and $165,164.50, respectively, as soon as practicable,
and three months later a further one-time payment of $279,415.50 and $165,164.50 either in cash or through the issuance of common stock,
respectively, in full consideration of the release of claims against the Company and other promises and covenants set forth in their
settlement agreements, respectively, and the Lazar Purchase Agreement.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February 11, 2025, Mr. Lazar entered into a securities purchase agreement (the &#8220;Wong Purchase Agreement&#8221;) with an investor,
Datuk Dr. Wong pursuant to which Datuk Wong agreed to purchase 1,000,000 shares of Series C Convertible Preferred Stock of the Company,
and 1,745,262 of the 2,100,000 shares of Series D Convertible Preferred Stock of the Company, currently held by Mr. Lazar so that Datuk
Wong would hold seventy percent (70%) of the fully diluted issued and outstanding shares of the Company. The Wong Purchase Agreement
closed on February 26, 2025 (the &#8220;Closing Date&#8221;). Additionally, Datuk Wong succeeded to all of Mr. Lazar&#8217;s rights and
interests under Lazar Purchase Agreement.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities were convertible into shares of the common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) of the Company
at the election of Datuk Wong as follows: (i) the 1,000,000 shares of the Series C wee convertible into 11,041 shares of Common
Stock, and (ii) 1,745,262 of the Series D were convertible into 799,911 shares of Common Stock. On the Closing Date, Datuk Wong
exercised the conversion rights related to the Series C and Series D shares into Common Stock in full resulting in Datuk Wong owning
810,953 shares of Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, Mr. Lazar, provided notice of his resignation as Chief Executive Officer and Secretary of the Company and agreed to
continue his role as co-principal financial officer and co-principal accounting officer to assist with the transition of the Company&#8217;s
new Chief Financial Officer, until the filing date of the Company&#8217;s annual report on Form 10-K for the fiscal year ended December
31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, on February 26, 2025, Samuel L. Barker resigned from our board of directors and entered into a settlement agreement with the
Company whereby the Company paid him all of his accrued board fees.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 168; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_095"></span>DESCRIPTION
OF CAPITAL STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized capital stock of Cyclacel consists of 600,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares
of preferred stock, $0.001 par value per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, there were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,583,965</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of common stock outstanding;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,135,537</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of preferred stock outstanding;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,360</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of common stock issuable upon the exercise of options outstanding at a weighted average
                                            exercise price of $2,515.85 per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of common stock issuable upon vesting of restricted stock units outstanding at a weighted
                                            average exercise price of $3,240 per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,746</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of common stock issuable pursuant to the vesting of Restricted Options at a weighted
                                            average exercise price of $79.20 per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,758,254</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of common stock reserved for future issuance under our 2018 Equity Incentive Plan
                                            (the &#8220;2018 Plan&#8221;);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">55
                                            shares of common stock reserved for future issuance under our inducement equity incentive
                                            plan;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,965,178</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of common stock issuable upon the exercise of warrants outstanding at a weighted-average
                                            exercise price of&#8201; $11.12 per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
shares of common stock issuable upon the conversion of 264 shares of our Series&#160;A Convertible Preferred Stock, par value $0.001
per share, outstanding; and</span>&#160;</p></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                                                                                          <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">654,000
                                            shares of common stock issuable upon the conversion of 3,000,000 shares of our Series F
                                            Convertible Preferred Stock, par value $0.001 per share, outstanding; and</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
                                            shares of common stock issuable upon the conversion of 135,273 shares of our 6% Convertible
                                            Exchangeable Preferred Stock, par value $0.001 per share.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of the capital stock of Cyclacel is not complete and may not contain all the information you should consider before
investing in Cyclacel capital stock. This description is summarized from, and qualified in its entirety by reference to, the amended
and restated certificate of incorporation of Cyclacel, which has been filed with the SEC. See &#8220;<i>Where You Can Find More Information</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2025, the Company filed an amendment to its Certificate of Incorporation (&#8220;Certificate of Amendment&#8221;) to
implement a one-for-sixteen reverse stock split. The effective date of the Certificate of Amendment was May 12, 2025 (the
&#8220;Effective Date&#8221;). The Board of Directors of the Company approved the amendment to the Company&#8217;s Certificate of
Incorporation primarily to meet the minimum bid price requirements of The Nasdaq Capital Market. The Company&#8217;s stockholders
approved the Certificate of Amendment at a special meeting of its stockholders held on February 6, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the reverse stock split, on the Effective Date, every sixteen shares of common stock then issued and outstanding automatically
combined into one share of common stock, with no change in par value per share. No fractional shares will be outstanding following the
reverse stock split, and any fractional shares that would have resulted from the reverse stock split will be (a) rounded up to the nearest
whole number for any shareholder who would otherwise be entitled to receive one-half or more of a fractional split-adjusted share, and
(b) rounded down to the nearest whole number for any shareholder who would otherwise be entitled to receive less than one-half of a fractional
split-adjusted share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2025, the Company filed an amendment to its Certificate of Incorporation (&#8220;July Certificate of Amendment&#8221;) to implement
a one-for-fifteen reverse stock split. The effective date of the July Certificate of Amendment was July 7, 2025 (the &#8220;July Effective
Date&#8221;). The Company&#8217;s common stock began trading on a split-adjusted basis when the market opened on the July Effective Date.
The Board of Directors of the Company approved the amendment to the Company&#8217;s July Certificate of Incorporation primarily to meet
the share bid price requirements of The Nasdaq Capital Market. The Company&#8217;s stockholders approved the July Certificate of Amendment
by majority written consent on May 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the reverse stock split, on the July Effective Date, every fifteen shares of common stock then issued and outstanding automatically
will be combined into one share of common stock, with no change in par value per share. No fractional shares will be outstanding following
the reverse stock split, and any fractional shares that would have resulted from the reverse stock split will be (a) rounded up to the
nearest whole number for any shareholder who would otherwise be entitled to receive one-half or more of a fractional split-adjusted share,
and (b) rounded down to the nearest whole number for any shareholder who would otherwise be entitled to receive less than one-half of
a fractional split-adjusted share.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 169; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, and do
not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders
of common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors
out of funds legally available for dividend payments. All outstanding shares of common stock are fully paid and non-assessable, and the
shares of common stock to be issued upon completion of this offering will be fully paid and non-assessable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of common stock have no preferences or rights of conversion, exchange, pre-emption or other subscription rights. There are no
redemption or sinking fund provisions applicable to the common stock. In the event of any liquidation, dissolution or winding-up of our
affairs, holders of common stock will be entitled to share ratably in our assets that are remaining after payment or provision for payment
of all of our debts and obligations and after liquidation payments to holders of outstanding shares of preferred stock, if any. The rights,
preferences and privileges of holders of common stock are subject to the rights of the holders of any outstanding shares of preferred
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Listing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for quotation on The Nasdaq Capital Market under the symbol &#8220;CYCC.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delaware
Law and Certain Charter and By-law Provisions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of (1) Delaware law, (2) our amended and restated certificate of incorporation, as amended, and (3) our amended and restated
bylaws discussed below could discourage or make it more difficult to accomplish a proxy contest or other change in our management or
the acquisition of control by a holder of a substantial amount of our voting stock. It is possible that these provisions could make it
more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their best interests or
in our best interests. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our
board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that may
involve an actual or threatened change of control of us. These provisions are designed to reduce our vulnerability to an unsolicited
acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. Such provisions
also may have the effect of preventing changes in our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 170; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Classified Board of Directors; Removal of
Directors for Cause</i></b>.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our amended and restated certificate of incorporation
and amended and restated bylaws provide that our board of directors is divided into three classes, each serving staggered three-year
terms ending at the annual meeting of our stockholders. All directors elected to our classified board of directors will serve until the
election and qualification of their respective successors or their earlier resignation or removal. The board of directors is authorized
to create new directorships and to fill such positions so created and is permitted to specify the class to which any such new position
is assigned. The person filling such position would serve for the term applicable to that class. The board of directors (or its remaining
members, even if less than a quorum) is also empowered to fill vacancies on the board of directors occurring for any reason for the remainder
of the term of the class of directors in which the vacancy occurred. Members of the board of directors may only be removed for cause.
These provisions are likely to increase the time required for stockholders to change the composition of the board of directors. For example,
in general, at least two annual meetings will be necessary for stockholders to effect a change in a majority of the members of the board
of directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance
Notice Provisions for Stockholder Proposals and Stockholder Nominations of Directors.</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws provide that, for nominations to the board of directors or for other business to be properly brought by a
stockholder before a meeting of stockholders, the stockholder must first have given timely notice of the proposal in writing to our Secretary.
For an annual meeting, a stockholder&#8217;s notice generally must be delivered not less than 45 days nor more than 75 days prior to
the anniversary of the mailing date of the proxy statement for the previous year&#8217;s annual meeting. For a special meeting, the notice
must generally be delivered by the later of 90 days prior to the special meeting or ten days following the day on which public announcement
of the meeting is first made. Detailed requirements as to the form of the notice and information required in the notice are specified
in the amended and restated bylaws. If it is determined that business was not properly brought before a meeting in accordance with our
bylaw provisions, such business will not be conducted at the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Special
Meetings of Stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
meetings of the stockholders may be called only by our board of directors pursuant to a resolution adopted by a majority of the total
number of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Super-Majority
Stockholder Vote Required for Certain Actions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter
is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless the corporation&#8217;s certificate of incorporation
or bylaws, as the case may be, requires a greater percentage. Our amended and restated certificate of incorporation requires the affirmative
vote of the holders of at least 66 2/3% of our outstanding voting stock to amend or repeal any of the anti-takeover provisions
discussed in this section. This 66 2/3% stockholder vote would be
in addition to any separate class vote that might in the future be required pursuant to the terms of any preferred stock that might then
be outstanding. In addition, a 66 2/3% vote is also required for any amendment to, or repeal of, our amended and restated bylaws by the
stockholders. Our amended and restated bylaws may be amended or repealed by a simple majority vote of the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 6, 2025, we had 135,273 shares of 6% Convertible Exchangeable Preferred Stock and 264 shares of Series A Preferred Stock issued
and outstanding and no shares of our Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D Convertible
Preferred Stock or Series E Convertible Preferred Stock were outstanding as of June 6, 2025 (see further descriptions of each of the
foregoing classes of preferred stock immediately below). The description of preferred stock provisions set forth below is not complete
and is subject to and qualified in its entirety by reference to our certificate of incorporation and the certificate of designations
relating to each respective series of preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 171; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the authority to issue up to 5 million shares of preferred stock and to determine the terms of those shares of stock without any
further action by our stockholders. The board of directors has the right, without the consent of holders of common stock, to designate
and issue one or more series of preferred stock, which may be convertible into common stock at a ratio determined by the board of directors.
A series of preferred stock may bear rights superior to common stock as to voting, dividends, redemption, distributions in liquidation,
dissolution, or winding up, and other relative rights and preferences. The board may set the following terms of any series of preferred
stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of shares constituting the series and the distinctive designation of the series;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
                                            rates, whether dividends are cumulative, and, if so, from what date; and the relative rights
                                            of priority of payment of dividends;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting
                                            rights and the terms of the voting rights;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conversion
                                            privileges and the terms and conditions of conversion, including provision for adjustment
                                            of the conversion rate;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">redemption
                                            rights and the terms and conditions of redemption, including the date or dates upon or after
                                            which shares may be redeemable, and the amount per share payable in case of redemption, which
                                            may vary under different conditions and at different redemption dates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sinking
                                            fund provisions for the redemption or purchase of shares;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">rights
                                            in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation,
                                            and the relative rights of priority of payment; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            other relative powers, preferences, rights, privileges, qualifications, limitations and restrictions
                                            of the series.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
on outstanding shares of preferred stock will be paid or declared and set apart for payment before any dividends may be paid or declared
and set apart for payment on the common stock with respect to the same dividend period. If, upon any voluntary or involuntary liquidation,
dissolution or winding up of the Company, the assets available for distribution to holders of preferred stock are insufficient to pay
the full preferential amount to which the holders are entitled, then the available assets will be distributed ratably among the shares
of all series of preferred stock in accordance with the respective preferential amounts (including unpaid cumulative dividends, if any)
payable with respect to each series.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of preferred stock will not be entitled to preemptive rights to purchase or subscribe for any shares of any class of capital stock of
the corporation. The preferred stock will, when issued, be fully paid and non-assessable. The rights of the holders of preferred stock
will be subordinate to those of our general creditors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Board of Directors exercises this power to issue preferred stock, it could be more difficult for a third party to acquire a
majority of our outstanding voting stock and vote the stock they acquire to remove management or directors. Our amended and restated
certificate of incorporation and amended and restated bylaws also provides staggered terms for the members of our Board of
Directors. Under Section 141 of the Delaware General Corporation Law, our directors may be removed by stockholders only for cause
and only by vote of the holders of a majority of voting shares then outstanding. These provisions may prevent stockholders from
replacing the entire board in a single proxy contest, making it more difficult for a third party to acquire control of us without
the consent of our Board of Directors. These provisions could also delay the removal of management by the Board of Directors with or
without cause. In addition, our directors may only be removed for cause and amended and restated bylaws limit the ability of our
stockholders to call special meetings of stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 172; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>April
2024 Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, warrants to purchase a total of 1,242 shares of common stock issued pursuant to a securities purchase
agreement in an April 2024 financing transaction (the &#8220;April 2024 Securities Purchase Agreement&#8221;) remained outstanding. A
total of 62,750 warrants were issued in pursuant to the April 2024 Securities Purchase Agreement. This consisted of i) pre-funded
warrants to purchase 20,100 of common stock, exercisable immediately from the date of issuance, and with no expiry date, at an
exercise price of $0.24 per warrant share, ii) series A warrants to purchase up to 20,704 shares of common stock, exercisable
immediately from the date of issuance for a period of five and a half years after the date of issuance, at an exercise price of $326.40
per warrant share, iii) series B warrants to purchase up to 20,704 shares of common stock, exercisable immediately from the date
of issuance for a period of eighteen months after the date of issuance, at an exercise price of $326.40 per warrant share. A further
1,242 warrants issued in a concurrent placement agency agreement, are exercisable immediately from the date of issuance for a
period of five and a half years after the date of issuance, at an exercise price of $124.512 per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 20,100 pre-funded warrants and 10,716 Series B warrants were exercised during the year ended December 31, 2024
and 9,988 Series B Shares in Abeyance were exercised during the three month period ending March 31, 2025. A further 20,704
warrants were exercised during the period April 1, 2025 to July 10, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>December
2023 Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, warrants to purchase a total of 1,750 shares of common stock issued pursuant to a securities purchase
agreement in a December 2023 financing transaction remained outstanding. A total of 1,651 warrants, including 33 warrants
issued in a concurrent private placement, are exercisable immediately from the date of issuance for a period of seven years after the
date of issuance, at an exercise price of $765.60 per warrant share. A further 99 warrants issued in a concurrent placement
agency agreement, are exercisable immediately from the date of issuance for a period of five years after the date of issuance, at an
exercise price of $994.50 per warrant share. There were no exercises of these warrants during the years ended December 31, 2024
or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>December
2020 Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 10, 2025, warrants to purchase 186 shares of common stock issued pursuant to a securities purchase agreement in
a December 2020 financing transaction remained outstanding. Each warrant shall be exercisable beginning on the 12-month anniversary of
the date of issuance for a period of five years after the date of issuance, at an exercise price of $14,868.00 per warrant share.
The exercise price of the warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split,
recapitalization, reorganization or similar transaction, as described in the warrants. The warrants may be exercised on a &#8220;cashless&#8221;
basis. There were no exercises of these warrants during the year ended December 31, 2024 or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent and Registrar</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. The transfer agent and registrar&#8217;s address is
48 Wall Street, 23rd floor, New York, NY 10043, USA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 173; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_096"></span>PRINCIPAL
STOCKHOLDERS OF CYCLACEL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the beneficial ownership of Cyclacel common stock and preferred stock as of July 10, 2025 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, who we know to beneficially own more than 5% of Cyclacel common stock;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our current directors; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current executive officers and directors as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentage ownership information shown in the table is based on an aggregate of 1,583,965 shares of our common stock and the
percentage of ownership of preferred stock is based on 3,135,537 shares of preferred stock outstanding as of July 10, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
We deem shares of Common Stock that may be acquired by an individual or group within 60 days of July 10, 2025 pursuant to the
exercise of options or warrants to be outstanding for the purpose of computing the percentage ownership of an individual or group but
do not deem them to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except
as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with
respect to all shares of stock shown to be beneficially owned by them based on information provided to us by these stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Beneficial Owners<sup>(1)</sup></b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of
    Shares of Common Stock Beneficially Owned</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<sup>(2)</sup></b></span></p></td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Shares of Preferred Stock Beneficially Owned <sup>(2)</sup></b></span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
    of Preferred Stock Owned <sup>(2)</sup></b></span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">David Lazar</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">162,588</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">10.26</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ong Yee Lung<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kua Khai Loon<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yap Kim Choy<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk Dr. Doris Wong Sing
    Ee<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">810,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kiu Cu Seng</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Kwang Fock Chong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Satis Waran Nair Krishnan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inigo Angel Laurduraj</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All current directors and executive officers as a group (5 people)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">810,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
  <td style="width: 0.25in">*</td>
  <td style="text-align: justify">Represents beneficial ownership of less than one percent of our outstanding shares
  of Common Stock.</td></tr>


</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 0.25in">(1)</td><td style="text-align: justify">Unless otherwise indicated, the address of each beneficial owner
                                  is c/o Cyclacel Pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5,
                                  No. 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia.</td></tr>
<tr style="vertical-align: top">
<td>(2)</td><td style="text-align: justify">Reflects the reverse stock split effective on May 12, 2025 and July 7, 2025.</td></tr>
<tr style="vertical-align: top">
<td>(3)</td><td style="text-align: justify">Each share of preferred stock is convertible into 3.27 shares of common stock representing
            a total of 218,000 shares of common stock following the July 7, 2025 stock split, subject to a 4.99% blocker or 111,674 shares
            of common stock on an as-converted basis.</td></tr>
<tr style="vertical-align: top">
<td>(4)</td><td style="text-align: justify">The Company&#8217;s Chief Executive Officer, Datuk Dr. Doris Wong Sing Ee is the Majority
            Consenting Stockholder referred to herein who controls the management and affairs of the Company, and currently can control
            matters requiring the approval by the Company&#8217;s stockholders, including the election of directors, any merger, consolidation
            or sale of all or substantially all of its assets, and any other significant corporate transaction.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 174; Value: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_097"></span>PRINCIPAL
SHAREHOLDERS OF FITTERS SDN. BHD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the beneficial ownership of the ordinary shares of Fitters Sdn. Bhd. as of July 10, 2025 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, who we know to beneficially own more than 5% of our common stock;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our current directors; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current executive officers and directors as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentage ownership information shown in the table is based on an aggregate of 3,000,000 ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
We deem shares of Common Stock that may be acquired by an individual or group within 60 days of July 10, 2025 pursuant to the
exercise of options or warrants to be outstanding for the purpose of computing the percentage ownership of an individual or group but
do not deem them to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. We believe
that the shareholder named in this table has sole voting and investment power with respect to all ordinary shares shown to be beneficially
owned by it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Number of Ordinary Shares of &#160;Beneficially Owned</td><td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Percentage of Ordinary Shares Beneficially Owned</td><td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic">5% Stockholders: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters Diversified Berhad<sup>(1)</sup> </span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Named Executive Officers and Directors:</i> <sup>(2)</sup> </span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chin Yong Shing </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Pang Wei Kang </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All current directors and executive officers as a group (2 people)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All shares are directly held by Fitters Diversified Berhad.
The head office address for Fitters Diversified Berhad is Wisma FITTERS, No. 1, Jalan Tembaga SD 5/2, Bandar Sri Damansara, 52200 Kuala
Lumpur, Malaysia.</span></td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
</table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            otherwise indicated, the address of each beneficial owner is c/o Cyclacel Pharmaceuticals,
                                            Inc., Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi,
                                            59200 Kuala Lumpur, Malaysia</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 175; Options: NewSection; Value: 167 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_098"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon
P.C., Washington, D.C., will pass upon the validity of the Cyclacel Pharmaceuticals, Inc. common stock offered by this proxy statement/prospectus.
The material U.S. federal income tax consequences of the Transaction will be passed upon by Rimon P.C. Messrs. Ong, Ric &amp; Partners,
Advocates &amp; Solicitors (Kuala Lumpur) is serving as legal counsel to Fitters Parent and Fitters Sdn. Bhd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_099"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The consolidated financial statements
of Cyclacel Pharmaceuticals, Inc. as of December 31, 2024, and for the year then ended, included in this registration statement/proxy
statement on Form S-4, have been audited by Bush &amp; Associates CPA LLC (&#8220;Bush &amp; Associates&#8221;), an independent registered
public accounting firm, as set forth in their report appearing elsewhere in this registration statement/proxy statement. That report
contains an explanatory paragraph regarding the retrospective adjustment of share and per share date to give effect to the reverse stock
splits described in Note 1 to the consolidated financial statements. Such consolidated financial statements have been included in reliance
upon the report of Bush &amp; Associates, given on their authority as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Fitters Sdn. Bhd. as of March 31, 2025 and 2024, and for the years then ended, included in this
proxy statement/prospectus, have been audited by JP Centurion &amp; Partners PLT, an independent accounting firm, as set forth in their
report appearing elsewhere herein. The inclusion of their report is made in reliance upon their authority as experts in accounting and
auditing, and JP Centurion &amp; Partners PLT has consented to such inclusion.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of
Cyclacel Pharmaceuticals, Inc. as of December 31, 2023 and for the year ended December 31, 2023 included in this Prospectus have been
audited by RSM US LLP, an independent registered public accounting firm, as stated in their report thereon (which report expresses an
unqualified opinion and includes an explanatory paragraph relating to substantial doubt about the Company&#8217;s ability to continue
as a going concern) and included in this Prospectus and Registration Statement in reliance upon such report and upon the authority of
such firm as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_100"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. files annual, quarterly and special reports, proxy statements and other information with the SEC. Cyclacel Pharmaceuticals,
Inc.&#8217;s SEC filings are also available to the public from commercial document retrieval services and on the website maintained by
the SEC at http://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this proxy statement/prospectus, Cyclacel Pharmaceuticals, Inc. has filed a registration statement on Form S-4 to register
with the SEC the common stock that Cyclacel Pharmaceuticals, Inc. will issue to Fitters Diversified Bhd. in the Transaction. This proxy
statement/prospectus is a part of that registration statement and constitutes a prospectus of Cyclacel Pharmaceuticals, Inc., as well
as a proxy statement of Cyclacel Pharmaceuticals, Inc. for the special meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. has supplied all information contained in this proxy statement/prospectus relating to Cyclacel Pharmaceuticals,
Inc., and Fitters Sdn. Bhd. has supplied all information contained in this proxy statement/prospectus relating to Fitters Sdn. Bhd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you would like to request documents from Cyclacel Pharmaceuticals, Inc. or Fitters Sdn. Bhd., please send a request in writing or by
telephone to either Cyclacel Pharmaceuticals, Inc. or Fitters Sdn. Bhd. at the following addresses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
                                            Pharmaceuticals, Inc.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    10, Tower 11, Avenue 5, No. 8</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jalan
    Kerinch</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59200
    Kuala Lumpur, Malaysia</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Corporate Secretary</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    (908) 517-7330</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
                                            Sdn. Bhd.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
    1, Jalan Tembaga SD 5/2,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bandar
    Sri Damansara<br/>
    52200 Kuala Lumpur, Malaysia</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Corporate Secretary</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    +(603) 6276 7155</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a stockholder of Cyclacel Pharmaceuticals, Inc. and would like additional copies, without charge, of this proxy statement/prospectus
or if you have questions about the Transaction, including the procedures for voting your shares, you should contact our proxy solicitor:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laurel
Hill Advisory Group, LLC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
1-888-742-1305 (toll free); 1-516-933-3100 (collect)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
carlo@laurelhill.com</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 176; Value: 167 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_101"></span>TRADEMARK
NOTICE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
third-party logos and product/trade names are registered trademarks or trade names of their respective companies. &#8220;Cyclacel&#8221;
and &#8220;CYCLACEL&#8221; are registered trademarks of Cyclacel Pharmaceuticals, Inc. and the Cyclacel logo is a trademark of Cyclacel
Pharmaceuticals, Inc. The name &#8220;FITTERS&#8221; and &#8220;FITTERS FIRE&#8221; are registered trademarks in Malaysia of Fitters
Parent. Except as set forth above and solely for convenience, the trademarks and tradenames in this proxy statement/prospectus are referred
to without the <sup>&#174;</sup> and <sup>TM</sup> symbols, but such references should not be construed as any indicator that their respective
owners will not assert, to the fullest extent under applicable law, their rights thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_102"></span>OTHER
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
16(a) Beneficial Ownership Reporting Compliance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires Cyclacel&#8217;s executive officers and directors, and persons who own more than 10% of a registered
class of our equity securities, to file reports of ownership and changes of ownership on Forms 3, 4 and 5 with the SEC. Such directors,
executive officers and 10% stockholders are required by SEC regulations to furnish Cyclacel with copies of all Section 16(a) forms they
file.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely on our review of the copies of such forms Cyclacel has received and written representations from certain reporting persons that
have filed all required reports, we believe that all of our officers, directors and greater than 10% stockholders complied with all Section
16(a) filing requirements applicable to them with respect to transactions during 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
Proposals for Inclusion in Proxy Statement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
may present proper proposals for inclusion in our proxy statement by submitting their proposals in writing to our corporate secretary
in a timely manner. For a stockholder proposal to be considered for inclusion in our proxy statement for our special meeting, our corporate
secretary must have received the written proposal at our principal executive offices not later than the close of business (5:30 p.m.
Pacific Time) on September 2, 2025. In addition, stockholder proposals must comply with the requirements of Rule 14a-8 under the
Exchange Act regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Proposals should be addressed to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11, Avenue 5, No. 8</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jalan
Kerinch</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59200
Kuala Lumpur, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Corporate Secretary</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
(908) 517-7330</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
Proposals and Director Nominations Not for Inclusion in Proxy Statement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws also establish an advance notice procedure for stockholders who wish to present a proposal before an annual meeting of stockholders,
but do not intend for the proposal to be included in our proxy statement and for stockholders to nominate directors for election at an
annual meeting of stockholders. In order to be properly brought before our 2026 annual meeting of stockholders, if such meeting is held,
the stockholder must have given timely notice of such proposal or nomination, in proper written form. To be timely for our 2026 annual
meeting of stockholders, if such meeting is held, a stockholder&#8217;s notice of a matter that the stockholder wishes to present, or
the person or persons the stockholder wishes to nominate as a director, must be delivered to the corporate secretary of Cyclacel at Cyclacel&#8217;s
principal executive offices not less than 90 days and not more than 120 days prior to the first anniversary of the date of the preceding
year&#8217;s annual meeting of stockholders. As a result, any written notice given by a stockholder pursuant to these provisions of our
bylaws must be received by our corporate secretary at our principal executive offices:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    earlier than March 2, 2026, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    later than April 1, 2026.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we hold our 2026 annual meeting of stockholders more than 30 days before or more than 30 days after the one-year anniversary
date of the 2025 annual meeting, then such written notice must be received no later than the close of business on the later of the following
two dates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            90th day prior to such annual meeting, or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            10th day following the day on which public announcement of the date of such meeting is first
                                            made.</span></td></tr></table>

<p style="margin: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>


<!-- Field: Page; Sequence: 177; Value: 167 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be in proper written form, a stockholder&#8217;s notice must include the specified information concerning the proposal or nominee as
described in our bylaws. Notices should be addressed to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11, Avenue 5, No. 8</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jalan
Kerinch</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59200
Kuala Lumpur, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Corporate Secretary</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
(908) 517-7330</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Communications
with the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
cases where stockholders or other interested parties wish to communicate directly with Cyclacel&#8217;s non-management directors, messages
can be sent to Cyclacel, Inc., Attention: Secretary, Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinch, 59200 Kuala Lumpur, Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel&#8217;s
secretary monitors these communications and will provide a summary of all received messages to the Cyclacel board of directors at each
regularly scheduled meeting of the board. Cyclacel&#8217;s board of directors generally meets on a quarterly basis. Where the nature
of a communication warrants it, Cyclacel&#8217;s secretary may determine, in his or her judgment, to obtain the more immediate attention
of the appropriate committee of the board of directors or non-management director, of independent advisors or of our management, as Cyclacel&#8217;s
secretary considers appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel&#8217;s
secretary may decide in the exercise of his or her judgment whether a response to any stockholder or interested party communication is
necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
procedure for stockholder and other interested party communications with the non-management directors is administered by our nominating
and governance committee. This procedure does not apply to (a) communications to non-management directors from our officers or directors
who are stockholders or (b) stockholder proposals submitted pursuant to Rule 14a-8 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 178; Value: 167 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_103"></span>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS OF CYCLACEL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Financial Statements</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fs_001">Report of Independent Registered Public Accounting Firm</a>&#160;(PCAOB ID:&#160;6797)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-2 </td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fs_003">Consolidated Balance Sheets as of December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fs_004">Consolidated
    Statements of Operations (Loss) for the years ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fs_005">Consolidated
    Statements of Comprehensive Loss for the years ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-7 </td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fs_006">Consolidated Statements of Stockholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fs_007">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fs_008">Notes&#160;to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
    Interim Condensed Consolidated Financial Statements</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Da_001">Balance Sheets as of March 31, 2025 and December 31, 2025</a> (unaudited)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Da_002">Statements of Operations for the three months ended March 31, 2025 and the three months ended March 31, 2024 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Da_003">Consolidated Statements of Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Da_004">Statements of Changes in Stockholders&#8217; Equity (Deficit) for the three months ended March 31, 2025 and the three months ended March 31, 2024 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>39</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Da_005">Statements of Cash Flows for the three months ended March 31, 2025 and the three months ended March 31, 2024 (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-40</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Da_006">Notes to Financial Statements (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-41</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 179; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fs_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and the Stockholders of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPINION
ON THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Cyclacel Pharmaceuticals, Inc. and its subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2024, and the related consolidated statements of operations (loss) and other comprehensive loss, stockholders&#8217;
equity and cash flows for the year then ended, and the related notes to the consolidated financial statements (collectively, the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31,
2024, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company as of and for the year ended December 31, 2023, before the retroactive adjustments described
in Note 1 with respect to the stock split of its common stock on May 12, 2025, and subsequently a one-for-fifteen reverse stock split
on July 7, 2025 were audited by other auditors whose report, dated March 21, 2024, expressed an unqualified opinion, with an explanatory
paragraph expressing substantial doubt regarding the Company&#8217;s ability to continue as a going concern, on those statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also audited the adjustments described in Note 1 that were applied retroactively to the 2023 and 2024 financial statements to reflect
the stock split of its common stock on May 12, 2025, and subsequently a one-for-fifteen reverse stock split on July 7, 2025 and the related
disclosures included therein. In our opinion, such adjustments and related disclosures are appropriate and have been properly applied.
We were not engaged to audit, review, or apply any procedures to the 2023 financial statements of the Company other than with respect
to the adjustments and disclosures referred to herein and, accordingly, we do not express an opinion or any other form of assurance on
the 2023 financial statements taken as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our opinion, the consolidated financial statements and the retrospective adjustments related to the reverse stock splits present fairly,
in all material respects, the financial position of the Company as of December 31, 2024, and results of its operations and its cash flows
for the year then ended in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 1 to the consolidated financial statements, the Company effected a one-for-sixteen reverse stock split of its common
stock on May 12, 2025, and subsequently effected a one-for-fifteen reverse stock split on July 7, 2025. All share and per share data
for all periods presented in the consolidated financial statements have been retrospectively adjusted to give effect to these reverse
stock splits, consistent with the treatment followed by other public companies in similar circumstances. The reverse stock splits were
implemented primarily to comply with Nasdaq listing requirements and did not affect the par value of the common stock or the Company&#8217;s
total market capitalization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUBSTANTIAL
DOUBT ABOUT THE COMPANY&#8217;S ABILITY TO CONTINUE AS A GOING CONCERN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1 to the financial statements, the Company does not currently have sufficient funds to complete development and commercialization
and has a limited cash balance as of December 31, 2024. This raises substantial doubt about the Company&#8217;s ability to continue as
a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BASIS
FOR OPINION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audit provides a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 180; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CRITICAL
AUDIT MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CRITICAL
TRIAL ACCRUAL AND EXPENSES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Notes 2 and 9 of the consolidated financial statements, the Company&#8217;s total accrued expenses for research and development
were $1.3 million at December 31, 2024, which included the estimated obligation for pre-clinical and clinical trial expenses incurred
as of December 31, 2024, but not paid as of that date. The Company&#8217;s clinical trial expenses are based on the Company&#8217;s estimates
of the level of services performed each period pursuant agreements with third parties that conduct research and development on the Company&#8217;s
behalf, which results in an accrual or prepaid at period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the Company&#8217;s accrued clinical trial expenses as a critical audit matter because auditing the application of significant
management judgment over the estimate of services provided but not yet invoiced required significant audit effort and a high degree of
auditor judgment and subjectivity to evaluate the audit evidence obtained. Specifically, the amount of accrued clinical trial expenses
recognized is dependent on the availability of information to make the estimate, including information from multiple sources, the level
of effort expended as of the balance sheet date and the associated cost of such services. Additionally, due to the timing of invoicing
received from third parties, the actual amounts incurred are not typically known on the date the Company issues its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit procedures to evaluate the Company&#8217;s estimate of services incurred as of period end pursuant to its clinical trials included,
among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            tested the accuracy and completeness of the underlying data used in the estimates and evaluated
                                            the significant assumptions stated above that are used by management to estimate the recorded
                                            amounts.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            evaluate the completeness and valuation of the accrual clinical trial expenses, we compared
                                            invoices received by the Company subsequent to December 31, 2024, to the amounts recognized
                                            by the Company as of that date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            inspected the Company&#8217;s contracts with third parties and any pending change orders
                                            to assess the impact to the amounts recorded.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Bush &amp; Associates CPA LLC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Henderson,
Nevada</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
2, 2025, except for Note 1, as to which the date is July 22, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCAOB
ID Number 6797</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fs_002"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and the Board of Directors of Cyclacel Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
on the Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited, before the effects of the adjustments to retrospectively apply the reverse stock splits effective May 12, 2025 and July
7, 2025 described in Note 1, the accompanying consolidated balance sheet of Cyclacel Pharmaceuticals, Inc. and its subsidiaries (the
Company) as of December 31, 2023, the related consolidated statements of operations (loss), other comprehensive loss, stockholders&#8217;
equity and cash flows for the year then ended, and the related notes to the consolidated financial statement (collectively, the financial
statements). The 2023 financial statements before the effects of the adjustments around the May 12, 2025 and July 7, 2025 reverse stock
splits described in Note 1 are not presented herein. In our opinion, before the effects of the adjustments to retrospectively apply the
reverse stock splits effective May 12, 2025 and July 7, 2025, the financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year then ended,
in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were not engaged to audit, review, or apply any procedures to retrospectively apply the changes in the Company&#8217;s disclosures related
to the reverse stock splits effective May 12, 2025 and July 7, 2025 described in Note 1, and accordingly we do not express an opinion
or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those adjustments were
audited by other auditors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantial
Doubt About the Company&#8217;s Ability to Continue as a Going Concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying 2023 consolidated financial statements were prepared assuming that the Company would continue as a going concern. As discussed
in Note 1 to the 2023 financial statements, the Company did not have sufficient funds to complete development and commercialization and
had a limited cash balance as of December 31, 2023. This raised substantial doubt about the Company&#8217;s ability to continue as a
going concern. Management&#8217;s plans in regard to these matters were also described in Note&#160;1 to the 2023 financial statements.
The 2023 financial statements did not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for Opinion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws
and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
RSM US LLP</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
served as the Company&#8217;s auditor from 2013 through 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
21, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 182; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fs_003"></span>CYCLACEL
PHARMACEUTICALS,&#160;INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_pn3n3_zaTeyoV2lqSi" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zi9zMOsqDAY6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December
    31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_zR2cFVjmz4r5" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December
    31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zwiZxDmWnjw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_zjmz8WYVw4cd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzzQE_zyhDtq5HeoIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,378</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzzQE_zRgNeIO5fxt5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000046" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,066</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i02TI_mtACzzQE_maAzaFr_zF7Rn9q8mpwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,444</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzaFr_zLIe2R4iFEz9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzaFr_zXwVoFPHsNxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use lease asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DepositsAssetsNoncurrent_i01I_maAzaFr_zvrpEcieJyu3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">412</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,259</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Assets_i01TI_mtAzaFr_zw4pSf2lhl2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000061" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zoK6bjJkEiL5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_i01B_zYmLhtpsDsO1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maLCz3Xm_zVXLLkMOPZOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,599</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,543</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCz3Xm_z0YuKVHruI32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,669</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i02TI_mtLCz3Xm_maLzeBn_zkka7uBPB2Tc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,161</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzeBn_znrdWBOkozpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0079">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_i01TI_maLASEz2Ln_mtLzeBn_zHGdT4ZiVmKd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityAbstract_iB_z96aiURbjEl2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity (deficit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Preferred stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zeWXYghUBMU2"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zHeBm6x0cdGj"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>
    par value; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zOZDMjChKG57"><span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zzzprzcjGXIa"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span> </span>shares authorized
    at December 31, 2024 and December 31, 2023;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zIe62YuPF2A5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zgRdhxxjtjj4"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact000094" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%
    Convertible Exchangeable preferred stock; <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zCgsRvT9CVyj"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,273</ix:nonFraction></span>
    shares issued and outstanding at December 31, 2024 and <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zeCpE2E8FbRb"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zbOykZMSJSRl"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact000096" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact000097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,273</ix:nonFraction></ix:nonFraction></span>
    </span>shares issued and outstanding at December 31, 2023. Aggregate preference in liquidation of&#8201; $<span id="xdx_900_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20241231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zS5LMrhyM4af"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,697,676</ix:nonFraction></span>
    as of December 31, 2024 and $<span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zE3wSQAqDV18"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2023-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,006,512</ix:nonFraction></span>
    as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgkkjJQKT8D9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A convertible preferred stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z9HOlCLV7gJ1"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000103" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
    par value; <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHtZ1eDpMisi"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000104" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></span>
    shares issued and outstanding at December 31, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0101">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0102">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQslEDsqQbci" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B convertible preferred stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zU4vXfdpaS88"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000108" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
    par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQifO02LbM75"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>
    shares issued and outstanding at December 31, 2024 and <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIjwHqcwhEkf"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,000</ix:nonFraction></span>
    shares issued and outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0106">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0107">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_maSEzGMH_zwshQbWieDbi" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preferred stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0112">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0113">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--CommonStockValue_i01I_maSEzGMH_zLyXrADrfAvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Common stock, $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zKl7YZdpIo2k"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> par
    value; <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zSg9KLGPMtr"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares authorized
    at December 31, 2024 and December 31, 2023; <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zaqHxIBp23bj"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,913</ix:nonFraction></span>
    shares issued and outstanding at December 31, 2024 and <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zBowrkQM7C9l"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,412</ix:nonFraction></span>
    shares issued and outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_i01I_maSEzGMH_zXTfs5BLeV2i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">438,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429,797</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maSEzGMH_zc5RBuJx829j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">891</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">908</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzGMH_zDdxFUIgACK3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">439,494</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">428,282</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i01TI_maLASEz2Ln_mtSEzGMH_z8QEfmTLFNm2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stockholders&#8217; equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,174</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">607</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz2Ln_zKJ7uZP45x3j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total liabilities and stockholders&#8217; equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 183; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fs_004"></span>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS (LOSS)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_pn3n3_zR7bcdctiOx1" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_496_20240101__20241231_zDyFofSkxz9b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_495_20230101__20231231_zMHHq3FheeD7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td colspan="5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--RevenuesAbstract_iB_z21KsJpH5N5h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--ClinicalTrialSupplyMember_zUiKtY7Po8Cb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    trial supply</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_ClinicalTrialSupplyMember" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialSupplyMember" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_maOILz2iG_zyUWbtzsRC84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zgSjyigKlNZ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzP2X_z7iv3xN2hJBb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,655</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,155</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzP2X_zVBHr2BUIf22" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,392</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,718</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpenses_i01T_mtOEzP2X_msOILz2iG_zRrzQkGbk6S7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,047</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,873</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_maILFCOzz17_mtOILz2iG_zV9VCNnKcSce" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,004</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25,453</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zhWitEiDyOak" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    expense:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maNIEz1LK_znUvcveGem5c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange losses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-012024-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-012023-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">414</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeconsolidationGainOrLossAmount_i01_maNIEz1LK_zt5zeUf9SFPb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gain on deconsolidation of subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestIncomeExpenseNet_i01_maNIEz1LK_zARJWPzK4Gme" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-012024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">266</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEz1LK_zmXQG4EL9D51" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_i01T_maILFCOzz17_mtNIEz1LK_z7lnQWUIuCDi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income (expense), net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">98</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzz17_maPLzTFy_zYbW4zz8Sycc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    before taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,994</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25,551</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msPLzTFy_zblm7TZlcUXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">782</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,996</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_iT_mtPLzTFy_maNILATzNHb_zLzfzSOgggMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,555</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_msNILATzNHb_zwFbQPrpiOa8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    on convertible exchangeable preferred shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0188">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">201</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzNHb_zccm8agvuZOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss applicable to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,756</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareAbstract_iB_zgA2KT1saNq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted earnings per common share:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share &#8211; basic and diluted (common shareholders)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_901_eus-gaap--EarningsPerShareDiluted_i01_pid_c20240101__20241231_zzoFtQhU6yZc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">502.46</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_900_eus-gaap--EarningsPerShareDiluted_i01_pid_c20230101__20231231_zBzevJBhcLX9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">6,419.07</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 184; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fs_005"></span>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_pn3n3_zWejRq7VVlV8" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_z40V5CooFDFl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_zTXVAUqmn4Re" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_maCINOTzssx_zD6CDMbnRq57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,555</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_maCINOTzssx_zTCDvc4yGJ32" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,916</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,142</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_maCINOTzssx_zKgJ7gLVQJe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized foreign exchange gain (loss) on intercompany loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,899</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzssx_zaaaKMXazgrb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,195</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,147</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 185; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fs_006"></span>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands, except share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_pn3n3_zvAo6IkkOHfj" summary="xdx: Statement - Consolidated Statements of Stockholders' Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Shares</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zrNw7mG8HObi" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Shares</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zZWSMj7MQQAe" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zu3Jdz6ekPmc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Capital</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zNt6R0uJMg25" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Loss</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zclKLzVLM5F7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Deficit</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BB_zDuKRW5Wzsdg" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Equity</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom">Additional</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom">Other</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom">Total</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Preferred Stock</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Common Stock</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">Paid-in</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">Comprehensive</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">Accumulated</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">Stockholders&#8217;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Shares</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Shares</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Amount</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Capital</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Loss</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Deficit</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Equity</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_430_c20230101__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zVVp61Ee9IPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Balances at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z1dO6EurJfQh" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">573,282</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0211">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEMzyMW2m2j" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,617</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">422,982</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000214" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,316</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">405,727</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,939</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_zY3H0eUtFKF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct
    Offering, net of expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVd4FH4SmNK5" title="Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct Offering, net of expenses, shares" style="text-align: right"><ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">735</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2023-01-012023-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,049</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zDOxE9pdhi7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of series B Preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfZMqtSB2YBi" title="Conversion of series B Preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">118,745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLpymO9rMb34" title="Series B Preferred stock conversions, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IncreaseInCarryingAmountOfRedeemableCommonStock_iN_di_zPH8UXFfEX5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reclassification of redeemable common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ReclassificationOfRedeemableCommonStockShares_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZeoUQTSXKFd" title="Reclassification of redeemable common stock, shares" style="text-align: right"><ix:nonFraction name="CYCC:ReclassificationOfRedeemableCommonStockShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,494</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z2VejfMLnwHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBRUTJweOkN2" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000253" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,473</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_iN_di_zB3oFPD3rC81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Preferred stock dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">201</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2023-01-012023-12-31" id="Fact000265" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">201</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_zTMdLC6UTle4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unrealized foreign exchange on intercompany loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,550</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zrVFVEX4N5Pj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,142</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,142</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zl4ECi6DZL1d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,555</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,555</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_z9tVOkzuhX71" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balances at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkspW9E3s73e" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">454,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTd1SEpaboGl" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,412</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000289" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429,797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">908</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">428,282</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">607</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zH2rmKn5OxHg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOzIZyQxXPT8" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">454,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8iTYBYwdjVg" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,412</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000301" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429,797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">908</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">428,282</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">607</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_zYsWXSwBINV2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIeCJvycReVf" title="Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct Offering, net of expenses, shares" style="text-align: right"><ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,944</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" contextRef="From2024-01-012024-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,209</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zZvG31SNneqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of series B Preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zelDwmlhRgHg" title="Conversion of series B Preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000326" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">119,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9ViMA0JdCvg" title="Series B Preferred stock conversions, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred_zQkaXdzXHN1j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of series <span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z51nk6UMGVt8"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000336" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction>%</span>
    Convertible Exchangeable Preferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrKynrezhwka" title="Conversion of series 6% Convertible Exchangeable Preferred, shares" style="text-align: right">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">200,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Gh46qr77pd" title="Conversion of series 6% Convertible Exchangeable Preferred, shares" style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zgSg8CVgGHT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z09hVolGI8Jb" title="Warrant Exercises, shares" style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000343" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,613</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zxLgVlZiIDih" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000353" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31" id="Fact000356" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">592</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_zlwYjZT0en66" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized foreign exchange on intercompany loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,899</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,899</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zILzIVnLMtPb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,916</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000370" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,916</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zO7dQG7iCsTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zwr7ljev0NRl" style="vertical-align: bottom; background-color: White">
    <td>Balances at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zY1Uo4XWk6Lc" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000386" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9WM4umwbAZ1" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000388" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,913</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000380" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">438,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000382" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">891</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000383" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">439,494</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,174</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_434_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zAGY55cWqnwg" style="display: none; vertical-align: bottom; background-color: White">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zAGwIpwe6g7c" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPeUL0knqmjh" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,913</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">438,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000393" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">891</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000394" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">439,494</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000395" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,174</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fs_007"></span>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_pn3n3_zwHNKShLxcxi" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zX13MkiX7n1g" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_z1hYXP2wEFT3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zM8b8wgv7GWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating activities:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_i01_maCzbUo_ziYIzGWk7K4j" style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,555</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_ztoWaDSOugL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Depreciation_i02_maCzbUo_zDnh193U6yig" style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000410" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i02_maCzbUo_zYIxlPg9rCCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000413" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000414" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maCzbUo_zA5OzY0cR1T4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">69</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z7I2X6423rbh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzbUo_zWDZhsCgQvEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-12-31" id="Fact000422" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,472</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,712</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_i03_maCzbUo_zKRR2xZrZK7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable, accrued and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,811</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzbUo_maCzSjz_z70cDlpPiQWj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,990</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,112</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z4BeF9M2OEe8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzrN4_zigvfTSogOO" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzrN4_maCzSjz_z1QB7AdQU2ti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zzVqVqlLoxLj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maCzUSm_zIF5PXENZdwf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-012024-12-31" id="Fact000443" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msCzUSm_zTifMcBiDZX2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Costs from issuing common stock and pre-funded
    warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"/><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"/></tr>
<tr id="xdx_40C_ecustom--ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts_i01_maCzUSm_zTLquGcScT01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from the exercise of stock options and warrants, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsOfDividendsPreferredStockAndPreferenceStock_i01N_di_msCzUSm_z4bSFytmrqc5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payment of preferred stock dividend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">201</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzUSm_maCzSjz_zQ9ZfbYH3uLb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used) in financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,822</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">848</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCzSjz_z3BPB7cOMC95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-01-012024-12-31" id="Fact000458" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">73</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-012023-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">303</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzSjz_z7tIBG1KkXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">241</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,967</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zwqs8JdhocXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents, beginning of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000464" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,345</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zp00bGpsyJw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents, end of period</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zf4Zabpbh0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash received during the period for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromInterestReceived_i01_z94u2ZlJVHR7" style="vertical-align: bottom; background-color: White">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromInterestReceived" contextRef="From2024-01-012024-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromInterestReceived" contextRef="From2023-01-012023-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">266</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIncomeTaxRefunds_i01_zWEFXgANsKtj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research &amp; development tax credits</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIncomeTaxRefunds" contextRef="From2024-01-012024-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,715</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIncomeTaxRefunds" contextRef="From2023-01-012023-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,846</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxesPaidNetAbstract_iB_zB3BKmU4tgQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid during the period for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestPaidNet_i01_zF2GA3tDgvud" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_zgJPoq0IlKtc" style="vertical-align: bottom; background-color: White">
    <td>Taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zWutjrNloE59" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccrualOfPreferredStockDividends_i01_zBhTy5kAoXYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrual of preferred stock dividends</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CYCC:AccrualOfPreferredStockDividends" contextRef="From2023-01-012023-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 187; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_045_c20240101__20241231_z5Bj4MysDsik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fs_008"></span>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 29, 2025, the Board of Directors of Cyclacel Pharmaceuticals, Inc. (the &#8220;Company&#8221;) passed a resolution to suspend
payment of the quarterly cash dividend on the Company&#8217;s <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250129__20250129__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmRz0TY1gZl5"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-292025-01-29_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact000493" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
Convertible Exchangeable Preferred Stock (the &#8220;Preferred Stock&#8221;) scheduled for February 1, 2025. The Board of Directors will
continue to evaluate the payment of a quarterly cash dividend on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
and Restructuring Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 2, 2025, the Company entered into a securities purchase agreement with investor David Lazar, pursuant to which he agreed to purchase
from the Company <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250102__20250102__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_z03j26vqxkal"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-022025-01-02_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C Convertible Preferred Stock and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250102__20250102__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zOYFJDKtSw16"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-022025-01-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000495" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series D Convertible Preferred Stock of Cyclacel
at a purchase price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zFK9eVLYj963"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000496" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for aggregate gross proceeds of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pn5n6_c20250102__20250102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zmxT5BuIhvj7"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000497" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, subject to the terms and conditions of the Agreement.
The proceeds of the transaction will be used to settle outstanding liabilities of the Company and other general corporate and operating
purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2025, the creditors voluntary liquidation of Cyclacel Limited was announced in the London Gazette, one of the official public
records of the government of the United Kingdom. As part of the Company&#8217;s efforts to reduce operating costs it has determined to
focus on the development of the Plogo clinical program only. Therefore fadraciclib, the Subsidiary&#8217;s other drug development program,
is being marketed for sale by the liquidators through Hilco Appraisals Limited, a firm of professional valuation agents and will no longer
be part of the assets of the Company as of January 2025. With the commencement of the liquidation of the Subsidiary, the Company will
no longer be considered to have control over the Subsidiary and the financial results of the Subsidiary will be deconsolidated from those
of the Company. The deconsolidation, which is anticipated to increase stockholders&#8217; equity by approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_ecustom--StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary_pn5n6_c20250131__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ze5ofKgIARm8"><ix:nonFraction name="CYCC:StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" contextRef="From2025-01-312025-01-31_us-gaap_SubsequentEventMember" id="Fact000498" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, will be reported in the Company&#8217;s
Form 10-Q for the three months ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2025, the Company entered into a securities purchase agreement with investor David Lazar, for the issuance and sale in a
private placement of up to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_ecustom--CommonStockValueAgreedToBeIssued_c20250204__20250204__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z5ty174STIH"><ix:nonFraction name="CYCC:CommonStockValueAgreedToBeIssued" contextRef="From2025-02-042025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of shares of common stock, par value $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250204__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ziliBlIe0rp3"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember" id="Fact000500" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of the Company. The Company shall have the right,
but not the obligation, to direct the Purchaser, by delivering written notice thereof from time to time and until September 30, 2026,
to purchase up to the Aggregate Purchase Price of Shares at a purchase price equal to the greater of (i) the consolidated closing bid
price immediately prior to the entry of this Agreement and (ii) the consolidated closing bid price on the business day immediately preceding
the applicable purchase date. Unless otherwise agreed by the Company and the Purchaser, the Company&#8217;s right to cause the Purchaser
to purchase the Shares pursuant to the Lazar Purchase Agreement must be exercised in either $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_ecustom--SharePurchaseAgreementIncrementExerciseLotOneValue_c20250204__20250204__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRTcw5G7rLT"><ix:nonFraction name="CYCC:SharePurchaseAgreementIncrementExerciseLotOneValue" contextRef="From2025-02-042025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_ecustom--SharePurchaseAgreementIncrementExerciseLotTwoValue_c20250204__20250204__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVti2cooRtlg"><ix:nonFraction name="CYCC:SharePurchaseAgreementIncrementExerciseLotTwoValue" contextRef="From2025-02-042025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 5, 2025, the Company entered into a securities purchase agreement with Helena Special Opportunities 1 Ltd. (&#8220;Helena&#8221;),
pursuant to which the Company, subject to the restrictions and satisfaction of the conditions in the purchase agreement, has the right,
but not the obligation, to sell to Helena, and Helena is obligated to purchase, up to the lesser of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20250205__20250205__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--HelenaSpecialOpportunitiesOneLtdMember_zqsqacGkqDOe"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-02-052025-02-05_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_custom_HelenaSpecialOpportunitiesOneLtdMember" id="Fact000503" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">25</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of newly issued shares of the Company&#8217;s Common
Stock and (ii) the Exchange Cap (as defined in the agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company held a special meeting of stockholders (the &#8220;Special Meeting&#8221;) on February 6, 2025 at which, among other matters,
the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to effect
a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20250206__20250206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZgPVdB2IoSl"><ix:nonNumeric contextRef="From2025-02-062025-02-06_us-gaap_SubsequentEventMember" id="Fact000504" name="us-gaap:StockholdersEquityReverseStockSplit">reverse
stock split at a ratio not less than 1:4 and not more than 1:16</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&#8220;2025 Reverse Stock Split&#8221;) such ratio and the implementation and timing of such Reverse Stock Split to be determined in
the discretion of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). The 2025 Reverse Stock Split is expected to be implemented
by the Board in or around May 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 188; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, David Lazar, the Company&#8217;s interim Chief Executive Officer, interim principal financial officer, interim principal
accounting officer, and Secretary, provided notice of his resignation as Chief Executive Officer and Secretary of the Company effective
February 26, 2025. Mr. Lazar will continue his role as co-principal financial officer and co-principal accounting officer to assist with
the transition of the Company&#8217;s new Chief Financial Officer, as discussed below. Mr Lazar&#8217;s resignation was not the result
of any disagreement between Mr. Lazar and the Company on any matter relating to the Company&#8217;s operations, policies or practices.
In connection with Mr. Lazar&#8217;s departure, he will not be eligible to receive any severance benefits or any performance based bonus
compensation for the 2025 partial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2025, David E. Lazar (the &#8220;Seller&#8221;), the interim Chief Executive Officer and Secretary of the Company, entered
into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an investor, Datuk Dr. Wong (the &#8220;Investor&#8221;)
pursuant to which the Investor agreed to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250211__20250211__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zbgKxyT1u663"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-02-112025-02-11_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000505" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C Convertible Preferred Stock of the Company,
$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250211__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zg0sMqISGGbj"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-02-11_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000506" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par value per share (the &#8220;Series C&#8221;) and such number
of the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250211__20250211__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zv6TMZEyMr97"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-02-112025-02-11_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000507" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series D Convertible Preferred Stock of the Company,
$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250211__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zKL1YpUmEYZj"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-02-11_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000508" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par value per share (the &#8220;Series D&#8221;) currently
held by Seller so that Purchaser shall hold seventy percent (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zEAyFvdmGBHk"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStock" contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000509" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)
of the issued and outstanding shares of the Company, which resulted in the issuance of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250211__20250211__us-gaap--StatementClassOfStockAxis__custom--SeriesCAndDConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zyKlpl0nrNJj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-02-112025-02-11_custom_SeriesCAndDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,745,262</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series D (collectively, the Series C and Series D
are the &#8220;Securities&#8221;). The transaction contemplated by the Purchase Agreement closed on February 26, 2025 (the &#8220;Closing
Date&#8221;). Additionally, the Investor purchased and succeeded to all of the Seller&#8217;s rights and interests under that certain
securities purchase agreement between the Seller and the Company dated January 2, 2025. On the Closing Date, the Seller issued written
notice to the Company to exercise the conversion rights related to the Series C and Series D shares into Common Stock of the Company
registered in the Investor&#8217;s name, as follows: (i) the conversion of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250226__20250226__us-gaap--StatementClassOfStockAxis__custom--SeriesCAndDConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zXiUsaKG9Xq6"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-02-262025-02-26_custom_SeriesCAndDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000511" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250226__20250226__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zLxriLZz38We"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-02-262025-02-26_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000512" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,041</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock of the Company; and (ii) the conversion
of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250226__20250226__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zL70xG5uqabg"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-02-262025-02-26_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000513" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,745,262</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series D into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250226__20250226__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zhuGcoLNbAN5"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-02-262025-02-26_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000514" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">799,911</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of February 26, 2025, the Board appointed Datuk Dr. Wong, as Chief Executive Officer and, in such role, she will serve as the Company&#8217;s
principal executive officer. Datuk Dr. Wong was also elected to the Board of the Company as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of February 26, 2025, the Board appointed Kiu Cu Seng, as Chief Financial Officer and, in such role, he will serve as the Company&#8217;s
co-principal financial officer and co-principal accounting officer along with David Lazar until the effective date of his resignation
on the earlier of the filing date of the Company&#8217;s annual report on Form 10-K for the fiscal year ended December 31, 2024 or March
31, 2025, as discussed above. The Company&#8217;s Board also appointed Mr. Kiu as Executive Director and Secretary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 10, 2025, the Company entered into an agreement for the Sale and Purchase of Certain Assets (the &#8220;Purchase Agreement&#8221;)
with Cyclacel Limited, a United Kingdom-based wholly owned subsidiary of the Company that is currently in liquidation (&#8220;Cyclacel
Limited&#8221;), along with the joint liquidator of Cyclacel Limited effective as of January 24, 2025 (the &#8220;Liquidators&#8221;).
Under the terms of the Purchase Agreement, the Company agreed to purchase, and Cyclacel Limited agreed to sell, with the approval of
the Liquidators, certain assets (the &#8220;Assets&#8221;) of Cyclacel Limited related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor
for treatment of advanced cancers and hematological malignancies (&#8220;Plogo&#8221;), for a purchase price of &#163;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_907_eus-gaap--AssetAcquisitionConsiderationTransferred_uGBP_c20250310__20250310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--CyclacelLimitedUnitedKingdomMember__us-gaap--AssetAcquisitionAxis__custom--AssetsOfCyclacelLimitedMember_zYMAlDMRVvy9"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="From2025-03-102025-03-10_us-gaap_SubsequentEventMember_custom_CyclacelLimitedUnitedKingdomMember_custom_AssetsOfCyclacelLimitedMember" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="GBP">250,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(exclusive of VAT).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2025, the Company entered into securities purchase agreements with a consortium of investors, pursuant to which they agreed
to purchase from the Company <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250321__20250321__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_zez1FGeI0vdc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-212025-03-21_custom_SeriesEConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000516" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series E Convertible Preferred Stock
of Cyclacel at a purchase price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zR6Zl6ONAWo3"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-03-21_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_custom_SeriesEConvertiblePreferredStockMember" id="Fact000517" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for aggregate gross proceeds of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_903_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pn5n6_c20250321__20250321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zr1jPQUrVyI"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-03-212025-03-21_custom_SeriesEConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" id="Fact000518" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, subject to the terms and conditions of the Agreements.
The proceeds of the transactions will be used for general corporate and operating purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 2, 2025, Mr. Spiro Rombotis resigned as Chief Executive Officer of the Company and the Board of Directors appointed Mr. Lazar
as interim Chief Executive Officer of the Company, effective as of the signing of the Purchase Agreement. Mr. Lazar will serve as the
Company&#8217;s principal executive officer and principal financial officer until his successor is appointed. On this date, the Board
also appointed Messrs. David Natan and Avraham Ben-Tzvi as members of the Board of Directors. Dr. Robert Spiegel, Dr. Christopher Henney,
Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the &#8220;Resigning Directors&#8221;) resigned effective as
of January 2, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 189; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 2, 2025, the Company entered into settlement agreements with the Resigning Directors effective as of the signing of the Purchase
Agreement. Pursuant to the terms of the Director Settlement Agreements, each Resigning Director resigned his or her position as a member
of the Board of Directors, and any positions held on committees of the Board of Directors. Each Resigning Director has received his or
her accrued Board fees in full consideration of the release of claims against the Company and other promises and covenants set forth
in the Director Settlement Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 2, 2025, the Company entered into a settlement agreement with Mr. Spiro Rombotis (the &#8220;Rombotis Settlement Agreement&#8221;).
Pursuant to the terms of the Rombotis Settlement Agreement, Mr. Rombotis resigned his position as President and Chief Executive Officer
of the Company effective as of the signing of the Purchase Agreement, and agreed to provide transition services to the Company in his
capacity as a member of the Board of Directors through the filing of the Company&#8217;s Annual Report on Form 10-K for the year ended
2024. On January 2, 2025, the Company also entered into a settlement agreement with Paul McBarron (together with Mr. Rombotis, the &#8220;Resigning
Officers&#8221;) effective immediately following the Initial Closing, as such term is defined in the Purchase Agreement (the &#8220;McBarron
Settlement Agreement&#8221; and together with the Rombotis Settlement Agreement, the &#8220;Executive Officer Settlement Agreements&#8221;
and together with the Director Settlement Agreements, the &#8220;Settlement Agreements&#8221;). Pursuant to the terms of the McBarron
Settlement Agreement, Mr. McBarron agreed to provide transition services to the Company in his capacity as a member of the Board of Directors
through the filing of the Company&#8217;s Annual Report on Form 10-K for the year ended 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Executive Officer Settlement Agreements, and subject to the Purchase Agreement, the Company will pay to Mr. Rombotis and Mr. McBarron
payments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_ecustom--SettlementPaymentSettlementAgreement_pp2d_c20250102__20250102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--RombotisSettlementAgreementMember_zXuDevqjfNJ7"><ix:nonFraction name="CYCC:SettlementPaymentSettlementAgreement" contextRef="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_RombotisSettlementAgreementMember" id="Fact000519" format="ixt:numdotdecimal" decimals="2" unitRef="USD">279,415.50</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_ecustom--SettlementPaymentSettlementAgreement_pp2d_c20250102__20250102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--McBarronSettlementAgreementMember_z62AYUQXVIgl"><ix:nonFraction name="CYCC:SettlementPaymentSettlementAgreement" contextRef="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_McBarronSettlementAgreementMember" id="Fact000520" format="ixt:numdotdecimal" decimals="2" unitRef="USD">165,164.50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, as soon as practicable, and three months later a further one-time payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_ecustom--FutureOneTimeSettlementPaymentSettlementAgreement_iI_pp2d_c20250102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--RombotisSettlementAgreementMember_z6YqUyvwi5Bj"><ix:nonFraction name="CYCC:FutureOneTimeSettlementPaymentSettlementAgreement" contextRef="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_RombotisSettlementAgreementMember" id="Fact000521" format="ixt:numdotdecimal" decimals="2" unitRef="USD">279,415.50</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_ecustom--FutureOneTimeSettlementPaymentSettlementAgreement_iI_pp2d_c20250102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--McBarronSettlementAgreementMember_zXPRftrtylb6"><ix:nonFraction name="CYCC:FutureOneTimeSettlementPaymentSettlementAgreement" contextRef="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_McBarronSettlementAgreementMember" id="Fact000522" format="ixt:numdotdecimal" decimals="2" unitRef="USD">165,164.50</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">either in cash or through the issuance of common stock, respectively,
in full consideration of the release of claims against the Company and other promises and covenants set forth in the Executive Officer
Settlement Agreements (the &#8220;Settlement Payments&#8221;) and the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Settlement Agreements, the Company will provide continuing indemnification to the Resigning Directors and Resigning
Officers in a manner consistent with that which was in place as of the effective date of the Settlement Agreements, and will cause to
be maintained in effect the Company&#8217;s existing director and officer liability insurance pursuant to the Company&#8217;s tail insurance
coverage and will not modify its governing documents to modify the Resigning Directors&#8217; and Resigning Officers&#8217; rights under
such policy, as further set forth in the Settlement Agreements. The Settlement Agreements contain a mutual non-disparagement clause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, the Company entered into settlement agreements with Dr. Barker. Pursuant to the terms of the settlement agreement,
Dr. Barker resigned his position as a member of the Board of Directors, and any positions held on committees of the Board of Directors.
In addition, Dr. Barker will receive his accrued Board fees in full consideration of the release of claims against the Company and other
promises and covenants set forth in the settlement agreement. Pursuant to the terms of the settlement agreement, the Company will provide
continuing indemnification to Dr. Barker in a manner consistent with that which was in place as of the effective date of the settlement
agreement, and will cause to be maintained in effect the Company&#8217;s existing director and officer liability insurance pursuant to
the Company&#8217;s tail insurance coverage and will not modify its governing documents to modify Dr. Barker&#8217;s rights under such
policy, as further set forth in the settlement agreement. The settlement agreement contains a mutual non-disparagement clause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, the following directors of the Company tendered their resignation or notice of resignation from the Board: (i) Dr.
Samuel L. Barker resigned as an independent director effectively immediately; (ii) Avraham Ben-Tzvi provided notice that his resignation
as an independent director will be effective upon the earlier of the filing date of the Company&#8217;s annual report on Form 10-K for
the fiscal year ended December 31, 2024 or March 31, 2025; (iii) Paul McBarron resigned as a non-independent director effective immediately;
(iv) David Natan provided notice that his resignation as an independent director will be effective upon the earlier of the filing date
of the Company&#8217;s annual report on Form 10-K for the fiscal year ended December 31, 2024 or March 31, 2025; and (iv) Spiro Rombotis
resigned as a non-independent director effective immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
nonvested stock based compensation awards were (or will be) forfeited immediately as of the dates of resignation. As the Company accounts
for forfeitures as they occur, the Company will report an adjustment to compensation expense in the first quarter of 2025 to reflect
the difference between the compensation expense recorded to date and the cost that should have been recorded given the number of awards
that ultimately vested. The Company does not expect the amount of this adjustment to be significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 190; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000524" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_znfds40WrRDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
Organization of the Company and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82C_z9TCUACedVif" style="display: none">Company
Overview</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or &#8220;the Company&#8221;) is a clinical-stage biopharmaceutical company developing
innovative cancer medicines based on cell cycle and mitosis control biology. Cyclacel is a pioneer company in the field of cancer cell
cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome
resistance and ultimately increase a patient&#8217;s overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, substantially all efforts of the Company to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited
to, the fact that drug candidates developed by the Company typically will require approvals or clearances from the U.S. Food and Drug
Administration, the European Medicines Agency or other similar regulatory agencies in other countries prior to commercial sales. There
can be no assurance that the Company&#8217;s drug candidates will receive any of the required approvals or clearances. If any of the
Company&#8217;s drug candidates are denied approval or clearance or such approval is delayed, or if the Company is unable to obtain the
necessary financing to complete development and approval, there will be a material adverse impact on the Company&#8217;s financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
December 31, 2024, the Company has funded all of its operations and capital expenditures with proceeds from the issuance of public equity
securities, private placements of securities, government grants, research and development tax credits, interest on investments, royalty
income, product revenue and licensing revenue. The Company has incurred recurring losses since its inception, including net losses of
$<span id="xdx_901_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_z7CYLlOgcdd8"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">11.2</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zk9yXx1P6kE"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000526" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">22.6</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company had an accumulated deficit of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zRTcx8aPX5F6"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">439.5</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company expects to continue to generate operating
losses for the foreseeable future due to, among other things, costs related to the clinical development of its drug candidate, its preclinical
programs and its administrative organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going
Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Accounting Standard Codification (ASC) 205-40, <i>Presentation of Financial Statements-Going Concern</i>, management
is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial
doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have
not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,
management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company&#8217;s
ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern for one year after the date that these financial statements are issued. In
performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40,
the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered
probable at this time because these plans are not entirely within the Company&#8217;s control nor have they been approved by the Board
of Directors as of the date of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s current operating plan, it is anticipated that cash and cash equivalents of $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zdm8vsc8Mgnc"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of December 31, 2024 will allow it to meet liquidity
requirements into the second quarter of 2025. The Company continues to work to raise additional capital, however, as of the date of these
financial statements there is no guarantee that the Company will be able to raise additional funds to extend operations beyond the second
quarter of 2025. The Company&#8217;s history of losses, negative cash flows from operations, liquid resources currently on hand, and
dependence on the ability to obtain additional financing to fund its operations, about which there can be no certainty, have resulted
in the assessment that there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at
least twelve months from the issuance date of these financial statements. While the Company has plans in place to mitigate this risk,
which primarily consist of raising additional capital through a combination of public or private equity or debt financings or by entering
into partnership agreements for further development of our drug candidates, there is no guarantee that it will be successful in these
mitigation efforts. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates
realization of assets and the satisfaction of liabilities in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 191; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America, or GAAP and include the financial statements of Cyclacel Pharmaceuticals, Inc. and all of the Company&#8217;s
wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20231218__20231218_zE0NtuWg5gx"><ix:nonNumeric contextRef="From2023-12-182023-12-18" id="Fact000529" name="us-gaap:StockholdersEquityReverseStockSplit">15:1</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse stock split of the Company&#8217;s common stock on
December 18, 2023 (the &#8220;Reverse Stock Split&#8221;). All share and per share information has been adjusted to give effect to the
Reverse Stock Split for all periods presented, unless otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company held a special meeting of stockholders (the &#8220;Special Meeting&#8221;) on February 6, 2025 at which, among other matters,
the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to effect
a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20250206__20250206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5x4FQ6t8Hd1"><ix:nonNumeric contextRef="From2025-02-062025-02-06_us-gaap_SubsequentEventMember" id="Fact000530" name="us-gaap:StockholdersEquityReverseStockSplit">reverse
stock split at a ratio not less than 1:4 and not more than 1:16</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&#8220;2025 Reverse Stock Split&#8221;) such ratio and the implementation and timing of such Reverse Stock Split to be determined in
the discretion of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). The 2025 Reverse Stock Split is expected to be implemented
by the Board in or around May 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd7x1WMim2fg" class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonNumeric contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember" id="Fact000531" name="us-gaap:StockholdersEquityReverseStockSplit">All references to issued and outstanding shares
all periods reflect: the 1-for-16 reverse stock split effective May 12, 2025, and the 1-for-15 reverse stock split effective July 7,
2025. As a result, all share numbers for all periods, including the number of shares underlying warrants, options, and other convertible
securities, and all exercise prices applicable to such warrants, options and convertible securities have been adjusted retrospectively
to give effect to the 1-for-16 and 1-for-15 reverse stock splits</ix:nonNumeric></span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000533" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zkPOm8snEPCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_824_zBrTlNiBQtY1">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000535" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zf22ZbzN9hBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_860_zORo9d23eFii" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and
the reported expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals and stock-based
compensation expense. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various
other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates.
Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the
Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000537" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zTsyEQTmcUjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zzBt6yywtCb9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency and Currency Translation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities of the Company&#8217;s international subsidiary are translated from its functional currency into United States
dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the
statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising
on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses
arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable future and that
are of a long-term-investment nature, are recorded in other comprehensive loss. As discussed in the subsequent events note, the foreign
subsidiary will be liquidated. Upon loss of control of the foreign subsidiary, the accumulated translation adjustments currently recorded
in other comprehensive income within equity will be reversed and recorded as part of the gain/loss from deconsolidation of the subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 192; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000539" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhPazvbBRD2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_868_zg5mNVQtEq1k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and Cash Equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds, to maintain sufficient
liquidity to meet Cyclacel&#8217;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial
institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is
exposed to any significant credit risk on cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash and cash equivalents balance at December 31, 2024 was $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z8mXOaPoUwya"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and it maintains its cash accounts in several entities
both within the United States and the United Kingdom. The cash balances for amounts held in the United States are insured by the Federal
Deposit Insurance Corporation, or FDIC up to $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20241231__srt--RangeAxis__srt--MaximumMember_ztFkYdx0KeVa"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per account. The Company has cash balances exceeding the balance
insured by the FDIC that totaled approximately $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zRYaqA6cTC64"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million at December 31, 2024. The cash balances for amounts
held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme, or FSCS up to &#163;<span id="xdx_907_ecustom--CashFinancialServicesCompensationSchemeInsuredAmount_iI_uGBP_c20241231__srt--RangeAxis__srt--MaximumMember_z8induwTekb5"><ix:nonFraction name="CYCC:CashFinancialServicesCompensationSchemeInsuredAmount" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="GBP">85,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per account. The Company does not have cash balances exceeding
the balance insured by the FSCS at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000545" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8XV9i7HEWC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zJXr7MejXSGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and Equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of
the related assets, which are generally three <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zKERt8IxurR8" style="display: none"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentMember" format="ixt-sec:duryear" id="Fact000546" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zS7NMRj7zts8"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentMember" format="ixt-sec:durwordsen" id="Fact000547" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">five
years</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Amortization of leasehold
improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life
of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are
removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss.
Expenditures for maintenance and repairs are charged to operating expenses as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000549" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zSYMxV5D0yt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zqSOuNl91Gt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets
by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment,
if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000551" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrUHKJjdqFV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86B_zqNibifhTxSh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy,
of which the first two are considered observable and the last is considered unobservable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1&#8201;&#8212;&#8201;Quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2&#8201;&#8212;&#8201;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that
are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3&#8201;&#8212;&#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining
the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 193; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values
due to the short-term nature of these assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000553" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZSdFDq0EjRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_z0RohBEsyXM9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is managed and operated as <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zTSW8xTZfz6a"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-012024-12-31" id="Fact000554" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business which is focused on using cell cycle, transcriptional
regulation and mitosis control biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire
business is managed by a single management team that reports to the Chief Executive Officer. Historically, the Company has not operated
separate lines of business with respect to any of its products or product candidates and the Company did not prepare discrete financial
information with respect to separate products or product candidates or by location through December 31, 2024. Accordingly, the Company
has viewed its business historically as <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zWLd0JQd0Sx3"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-012024-12-31" id="Fact000555" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reportable operating segment with development operations in
<span id="xdx_909_eus-gaap--NumberOfCountriesInWhichEntityOperates_iI_dc_uInteger_c20241231_zEdDnnew2oul"><ix:nonFraction name="us-gaap:NumberOfCountriesInWhichEntityOperates" contextRef="AsOf2024-12-31" id="Fact000556" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">two</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">geographic
areas, namely the United States and the United Kingdom. With the commencement of the liquidation of the Subsidiary, the Company will
no longer be considered to have control over the Subsidiary and the financial results of the Subsidiary will be deconsolidated from those
of the Company commencing with its first quarter 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000558" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zyfbuT5pdDSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zr7bBrD150F5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, <i>Revenue from Contracts with Customers</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not generated any revenues from product sales to date. However, the Company recognized $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zdRogL4upoDl"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenue for the year ended December 31, 2024. This revenue
relates to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center
(&#8220;CSMC&#8221;). There was $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230101__20231231_zJpEFhhMydod"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenues recognized for the comparative period in 2023.
All revenues from this customer are recognized at the point in time that the related clinical supply are transferred to CSMC and CSMC
obtains control over the goods. The arrangements with CSMC comprise a single performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not recognized any other sources of revenue during the years ended December 31 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invoices CSMC following the transfer of the clinical supply and provides CSMC with typical payment terms. The Company has collected
all amounts due from CSMC. As of December 31, 2024, December 31, 2023, and January, 1, 2023, the Company has not recognized any accounts
receivable from CSMC, credit loss allowances, contract assets, contract liabilities, or warranty provisions. There were <span id="xdx_905_eus-gaap--RevenueRemainingPerformanceObligation_iI_do_c20241231_zyystFxOLx5"><ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="AsOf2024-12-31" id="Fact000561" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining performance obligations outstanding as of December
31, 2024; however, CSMC may place additional orders for clinical supply in 2025 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000563" name="CYCC:OtherIncomePolicyTextBlock"><p id="xdx_84D_ecustom--OtherIncomePolicyTextBlock_z48CGyEtEVP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_864_zpPxy3yffl8d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part
of the Company&#8217;s ongoing operations and activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000565" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIW8polrH7g2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_869_zhV5KtObiUm7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs associated with the development of the Company&#8217;s product candidates, including
upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials,
costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development
are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000567" name="CYCC:ClinicalTrialAccountingPolicyTextBlock"><p id="xdx_84F_ecustom--ClinicalTrialAccountingPolicyTextBlock_zz39pDabBkt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86D_zboMqvkHKNq2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial Accounting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
management and monitoring of the Company&#8217;s clinical trials are performed with the assistance of contract research organizations,
or CROs or clinical research associates, or CRAs in accordance with the Company&#8217;s standard operating procedures. Typically, CROs
and CRAs bill monthly for services performed, and others bill based upon milestones achieved. The Company accrues unbilled clinical trial
expenses based on estimates of the level of services performed each period. Clinical trial costs related to patient enrollment are accrued
as patients are entered into and progress through the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000569" name="CYCC:PatentCostsPolicyTextBlock"><p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zghWh5wi7XVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_861_zGXaAhljvi39" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 194; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000571" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zaElcefeAcl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zBP3UW2DZHD" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease contracts in accordance with ASC 842. As of December 31, 2024 and 2023, all of the Company&#8217;s leases
are classified as operating leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#8217;s obligation to make lease payments under the lease. As the Company&#8217;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how a loan would be repaid (e.g.,
amortizing versus bullet), and the Company&#8217;s credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of
exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether
it is reasonably certain that the Company will exercise an option, the Company considers factors such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease payments due in any optional period;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
    for failure to exercise (or not exercise) the option;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    factors, such as the availability of similar assets and current rental rates for such assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature of the underlying leased asset and its importance to the Company&#8217;s operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    remaining useful lives of any related leasehold improvements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term and is reported as a component
of general and administrative expense. Variable lease payments, if any, are recognized in the period when the obligation to make those
payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed
lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000573" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw7hrtGvrsh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86C_zqnZce9J5QU" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date
of the grant and recognizes compensation expense of those awards over the requisite service period, which for the Company is the period
between the grant date and the date the award vests or becomes exercisable. Many awards granted by the Company vest ratably over three<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z2zvqtVyXwXj" style="display: none"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000574" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">3</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zJTSjJa78iD3"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact000575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">four
years</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. However, certain awards granted to members
of the Company&#8217;s Board of Directors vest in their entirety on the one<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_z8fUbfdTSME4" style="display: none"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_DirectorMember" format="ixt-sec:duryear" id="Fact000576" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">1</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only
service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain years,
the Company will grant share-based payment awards to employees that are dependent upon the fulfillment of certain clinical and financial
conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes compensation
expense when the award is probable of vesting (See Note 12&#8201;&#8212;&#8201;Stock-Based Compensation).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expenses in its statement of operations in the same manner in which the award recipient&#8217;s
payroll costs are classified. The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of restricted stock and restricted stock units is determined based on the number of shares granted and the quoted price of
the Company&#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated
using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#8217;s share price, expected
term of the award, interest rates, and dividend yields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 195; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on its historical volatility as an input to the option pricing model as management believes that this rate will be representative
of future volatility over the expected term of the options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average risk-free interest rate represents the interest rate for treasury constant maturities published by the Federal Reserve
Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel
interpolates a discount rate based on the two Federal Reserve securities closest to the expected term of the employee option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected dividend yield is zero, as the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends
on common stock in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000578" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z54Xjh3qPW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86C_zqR9Wghh5rvd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based
on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year
in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred
tax assets to the amounts expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the
amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained
upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not-to be sustained, the tax position
is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized
is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes
includes the effects of any resulting tax reserves for unrecognized tax benefits that are considered appropriate as well as the related
net interest and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records research and development tax credits within income taxes. Credit is taken in the accounting period for research and development
tax credits, when claimed from H.M. Revenue &amp; Customs, or HMRC, the United Kingdom&#8217;s taxation and customs authority, in respect
of qualifying research and development costs incurred in the same accounting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000580" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zg7mEvChTDKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zfnnR38qNFEf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss Per Common Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221;. Basic and diluted net loss
per common share was determined by dividing the net loss applicable to common stockholders by the weighted average number of common shares
outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common
stockholders is the same as basic net loss per share attributable to common stockholders since potentially dilutive common shares are
not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders
for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000582" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z1D5SLfGoCwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86F_zHxZvlU9nSie" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Comprehensive
Income (Loss)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported to arrive at comprehensive income (loss). There were <span id="xdx_905_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20230101__20231231_zgku0Qy7OIg9"><ix:nonFraction name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000583" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reclassifications out of other comprehensive income (loss)
during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 196; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000585" name="CYCC:RecentlyIssuedAccountingPronouncementsPolicyTextBlock"><p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_z4CYFimM2Iy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_866_zzVz1m4j8wpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2024-03, &#8220;<i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;. This standard will require
all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage
and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received)
disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions
for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods
beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation
of that information.</span></p>

</ix:nonNumeric><p id="xdx_85E_zSxsf6fBNRa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000587" name="CYCC:SignificantContractsDisclosureTextBlock"><p id="xdx_80B_ecustom--SignificantContractsDisclosureTextBlock_zG5SVzWD8z2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82A_zrJx7x7nmhb8">Significant Contracts</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution,
Licensing and Research Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into licensing and similar agreements with academic and research organizations. Under the terms of these agreements,
the Company has received licenses to technology and patent applications. The Company may be required to pay royalties on future sales
of products employing the technology or falling under claims of patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
a 2003 license agreement, the Company licensed certain patent rights for sapacitabine. The Company will not be pursuing further development
of sapacitabine and the license agreement was terminated effective as of March 23, 2023 for commercial reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three<span id="xdx_902_ecustom--TermOfAgreement_dtY_c20210901__20210930__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zJN1Y8Vra9Z6" style="display: none"><ix:nonNumeric contextRef="From2021-09-012021-09-30_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember" format="ixt-sec:duryear" id="Fact000588" name="CYCC:TermOfAgreement">3</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
term of the Clinical Collaboration Agreement, or CCA with The University of Texas MD Anderson Cancer Center, or MD Anderson ended in
September 2021, in accordance with its terms. The main objective of the CCA was to clinically evaluate the safety and efficacy of three
Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic
syndromes and other advanced leukemias. Under the terms of the CCA, MD Anderson conducted <span id="xdx_907_ecustom--ConductClinicalStudies_dc_uInteger_c20210901__20210930__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zX8BqBaVQNI5"><ix:nonFraction name="CYCC:ConductClinicalStudies" contextRef="From2021-09-012021-09-30_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember" id="Fact000589" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">four</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical studies and under the risk-sharing agreement MD Anderson
assumed the patient costs for all studies and Cyclacel, who is the sponsor, provided investigational drugs and other limited support.
The agreement provided that the Company would make certain payments to MD Anderson upon first commercial sale in specific indications
studied in the alliance. There were <span id="xdx_909_ecustom--LicenseAgreementPaymentEarned_iI_do_c20231231__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zXvQVl3uVxs4"><ix:nonFraction name="CYCC:LicenseAgreementPaymentEarned" contextRef="AsOf2023-12-31_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember" id="Fact000590" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such payments earned in 2024 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000592" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock"><p id="xdx_808_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zYZBZ7Fszs8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82B_zbwIypBARO7e">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000594" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zKGCPiHTH0vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash and cash equivalents at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zSET5jeIuAFb" style="display: none">Summary
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zCrSHJ6cUOUa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z3X01H23zeu9" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Cash_iI_pn3n3_maCACEAzyS5_zOQ4QyfcCAj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000596" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000597" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,303</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_maCACEAzyS5_ztNzonajCXL9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000600" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtCACEAzyS5_ztcDYgnqRxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000602" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000603" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zlpBK3rZKgqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents are made up entirely of money market funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 197; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000605" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zeQ0gULVRKzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_825_zPqp0YORJTqh">Fair Value of Financial Assets and Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000607" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zQMBDnQxiAIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zfWV7hPOTay2" style="display: none">Schedule
of Financial Assets and Liabilities Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwX5DJUCfoAc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    1</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgjTt48bL3B6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    2</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zfavjkQ0qZS8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    3</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z03y08eOqvN3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">Fair Value Measurements</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">as of December 31, 2024 Using:</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 1</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 2</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 3</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zoNhzn6SrTel" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000609" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,044</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000612" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,044</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zI3MZ1GRH2td" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000617" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,044</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVw0fayAHRdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zljm8svDHA5a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxVo90jidCB1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCFgvYNLB1Nd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">as of December 31, 2023 Using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zz6uWUGiipWl" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000619" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000622" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zs7yLDFJFqs1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AB_z4BNglRLtnA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000629" name="CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock"><p id="xdx_809_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zJiNGqNYU9Ca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
Prepaid Expenses and Other Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_829_zPuB703Js7B" style="display: none">Prepaid
Expenses and Other Current Assets</span></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000631" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zQgaOlf1dqf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of prepaid expenses and other current assets at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B3_zoCIaaOCdeBb" style="display: none">Schedule
of prepaid expenses and other current assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_z7lf3DnBHndi" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zKUsKElCmOml" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxesAndOtherTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zNaZJS6qlveb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development tax credit receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact000634" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,933</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zfR5pVGM24T6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepayments and VAT receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent" contextRef="AsOf2024-12-31" id="Fact000636" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">237</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">792</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQOL_zcBXTXszRPd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">341</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQOL_z5PJ3bmEwOj2" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other assets</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000643" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,066</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zulAoQBuRbql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000645" name="CYCC:NonCurrentAssetsTextBlock"><p id="xdx_805_ecustom--NonCurrentAssetsTextBlock_zeJZXRYmhcki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_825_zKmxr92m22H">Non-Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at December 31, 2024, the Company had non-current assets of $<span id="xdx_90A_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20241231_zm2zxTjof2Z6"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000646" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which comprised clinical trial deposits held by a
contract research organization in relation to the Company&#8217;s Phase 1/2 clinical trials. As at December 31, 2023, the Company had
non-current assets of $<span id="xdx_901_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20231231_zblFozQVrCq"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000647" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million,
which was wholly attributable to clinical trial deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000649" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRAliyO6pFj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_82F_zUSzh6bAoghk">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000651" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5FwiODQbG4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zA2wcsohQTJ3" style="display: none">Schedule
of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_zwww3daVkxr1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zApi9l4rFhx3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><b>Lives in</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zDPi9ChoS2B7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Leasehold improvements</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVSyesfIk2Xj"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" id="Fact000655" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">2</ix:nonNumeric></span>
    to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z60zWO360104"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" id="Fact000656" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zP0tiNECtJP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment and furniture</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zwbT4afEWMY2"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember_custom_OfficeEquipmentAndFurnitureMember" format="ixt-sec:duryear" id="Fact000660" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>
    to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_ztazAMISFTch"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember_custom_OfficeEquipmentAndFurnitureMember" format="ixt-sec:duryear" id="Fact000661" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_OfficeEquipmentAndFurnitureMember" id="Fact000658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_OfficeEquipmentAndFurnitureMember" id="Fact000659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">423</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_maPPAENzWpG_zblZiY2R2G18" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000663" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000664" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzWpG_zWafk7wLbO2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: accumulated depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000666" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">424</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzWpG_zSnlF9zZX9a9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000669" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zL4k8x7IAF6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 198; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000672" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80F_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zHc4nHN70Xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
Accrued and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_822_zzyIFd8uN2gb" style="display: none">Accrued
and Other Liabilities</span></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000674" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaF3qBcqwcx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
and other current liabilities consisted of the following at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zbG35D6tYoFb" style="display: none">Schedule
of Accrued and Other Current Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zaNSbn7pGCEe" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zWyxteIAyah1" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_pn3n3_maALCzjWX_zxdCwQ5F9Xhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="CYCC:AccruedResearchAndDevelopmentCostsCurrent" contextRef="AsOf2024-12-31" id="Fact000676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,299</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="CYCC:AccruedResearchAndDevelopmentCostsCurrent" contextRef="AsOf2023-12-31" id="Fact000677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,668</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzjWX_zYEd45USEZVb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-12-31" id="Fact000679" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact000680" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--OtherCurrentLiabilities_iI_pn3n3_maALCzjWX_zNaqeuRnK0Oj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:OtherCurrentLiabilities" contextRef="AsOf2024-12-31" id="Fact000682" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:OtherCurrentLiabilities" contextRef="AsOf2023-12-31" id="Fact000683" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">380</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzjWX_zdKU4QmktAa4" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000685" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,669</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000686" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zkwCvpwKGGCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at December 31, 2024, the Company had accounts payables of $<span id="xdx_902_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20241231_z0nvYC2wo6Ba"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.6</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, of which $<span id="xdx_90C_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--UnitedKingdomSubsidiaryCompanyMember_zdj93MkE06j5"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31_custom_UnitedKingdomSubsidiaryCompanyMember" id="Fact000688" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million related to the UK subsidiary. As at December 31, 2023,
the Company had accounts payables of $<span id="xdx_901_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20231231_zQFCi6UqWH2b"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000689" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, of which $<span id="xdx_909_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--UnitedKingdomSubsidiaryCompanyMember_zONXGAeXRTO"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_custom_UnitedKingdomSubsidiaryCompanyMember" id="Fact000690" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million related to the UK subsidiary.</span></p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000692" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAEWNduzmAte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_821_zNIoIndDsXm1">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to <i>Note 3&#8201;&#8212;&#8201;Significant Contracts</i> for further discussion of certain of the Company&#8217;s commitments
and contingencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, the Company extended the lease for its corporate headquarters facility in Berkeley Heights, New Jersey for a further <span id="xdx_90A_ecustom--LesseeOperatingLeaseTermOfContractExtension_dc_c20220401__20220430__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_z9dGR3SGzIS8"><ix:nonNumeric contextRef="From2022-04-012022-04-30_custom_BerkeleyHeightsFacilityMember" format="ixt-sec:durwordsen" id="Fact000693" name="CYCC:LesseeOperatingLeaseTermOfContractExtension">three
years</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, expiring in July 2025. In December 2024,
the Company terminated this lease, effective as of January 31, 2025. Effective March 1, 2025, the Company entered into a <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20241231__srt--StatementGeographicalAxis__custom--CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_zxR258m07qDb"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" format="ixt-sec:durwordsen" id="Fact000694" name="us-gaap:LesseeOperatingLeaseTermOfContract">two
year</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lease agreement for our corporate headquarters
at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia, which we believe will be adequate to accommodate
our business needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and December 31, 2023, the Company recognized operating lease expenses of $<span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zmXNvBr5nk46"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,830</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zeMeGg0KHhKi"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,218</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively, including $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zbWfZnQMwJb6"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_custom_DundeeScotlandMember" id="Fact000697" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,104</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20230101__20231231__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zs9wSo2B9ce4"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31_custom_DundeeScotlandMember" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,851</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively relating to a short term lease for offices in
Dundee, Scotland. The remaining lease term as of December 31, 2024 is <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dc_c20241231__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_zzfOXMvQYFUl"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_BerkeleyHeightsFacilityMember" format="ixt-sec:durwordsen" id="Fact000699" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">one
month</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the Berkeley Heights facility and no
remaining lease term for Dundee, Scotland. The discount rate used by the Company in determining the lease liability was <span id="xdx_901_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20241231__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_zzSwAo6pIW29"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2024-12-31_custom_BerkeleyHeightsFacilityMember" id="Fact000700" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000702" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z440AH7tNQMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s future contractual obligations and commitments relating to its facilities lease as at December
31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BC_zB11ngH9qKE2" style="display: none">Schedule
of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zrvqNs2ZDnBg" style="text-align: center; font-weight: bold">Operating Lease</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Obligation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zYSfO3aFolH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000704" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zwF0630Vo0yb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_zFHUvGgprMR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0708">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zXdwuRZhI9kd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000710" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z3kbC3utV7Md" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z148Y2pkKCnc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000714" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zMqrRRcp51j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000716" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zalWS0btNRB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_82F_zOaHl5fSNiFg">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has completed the following equity issuances during the periods presented in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 199; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>November
2024 Warrant Exercise and Reload Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2024, Cyclacel Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into a letter agreement (the &#8220;Warrant Exercise
and Reload Agreement&#8221;) with the holder (the &#8220;Holder&#8221;) of its issued and outstanding Series B Warrants (the &#8220;Prior
Warrants&#8221;) to purchase an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_zIthoNGmdFGf"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the Company offering the Holder the
opportunity to exercise all of its Prior Warrants for cash at a reduced exercise price equal to $<span id="xdx_90F_ecustom--ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zIw77kU1BSQj"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesBWarrantsMember" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">99.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share provided the Prior Warrants were exercised in full
for cash on or before 12:30 P.M. Eastern Time on the date of the Warrant Exercise and Reload Agreement. In consideration for the exercise
of the Prior Warrants, the Holder received new unregistered Series C Warrants (the &#8220;Series C Warrants&#8221;) exercisable for up
to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MaximumMember_z2nJt8iIEQ98"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember_srt_MaximumMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,408</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series C Warrant Shares&#8221;)
and new unregistered Series D Warrants (the &#8220;Series D Warrants&#8221; and, together with the Series C Warrants, the &#8220;New
Warrants&#8221;) exercisable for up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember__srt--RangeAxis__srt--MaximumMember_z7P5lyeVpbA3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember_srt_MaximumMember" id="Fact000720" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,408</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series D Warrant Shares&#8221;
and, together with the Series C Warrant Shares, the &#8220;New Warrant Shares&#8221;). The Series C Warrants are exercisable beginning
on the date upon which the Company receives stockholder approval of the issuance of the New Warrant Shares and the Placement Agent Warrant
Shares (as defined below) (the &#8220;Stockholder Approval Date&#8221;) for a period of five and one-half (<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zwphBe7Sx8v9"><ix:nonNumeric contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" id="Fact000721" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
years following the Stockholder Approval Date and the Series D Warrants are exercisable beginning on the Stockholder Approval Date for
a period of eighteen (<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zaK6EsTtSSx5"><ix:nonNumeric contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember" format="ixt-sec:durmonth" id="Fact000722" name="us-gaap:WarrantsAndRightsOutstandingTerm">18</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
months following the Stockholder Approval Date. The New Warrants each have an exercise price of $<span id="xdx_904_ecustom--ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zwleHMtS4Yqf"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesBWarrantsMember" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">99.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The shares of common stock issued upon exercise
of the Prior Warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-279157).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Securities Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2024, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor (the &#8220;Purchaser&#8221;) for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of (i)
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_zaKIA9oBY35f"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">604</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock, (ii) pre-funded
warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z5erFSmnQjh7"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,100</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Pre-Funded Warrants&#8221;),
(iii) series A warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_ztG73B9rt8jc"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesAWarrantsMember" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series A Warrants&#8221;),
and (iv) series B warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zcItD1sBQpn4"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesBWarrantsMember" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series B Warrants&#8221;
and together with the Series A Warrants, the &#8220;Common Warrants&#8221;). The purchase price of each share of common stock and associated
Common Warrants was $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNXTFLy0SvWi"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact000728" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">386.40</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the purchase price of each Pre-Funded Warrant and associated
Common Warrants was $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsAndCommonWarrantsMember_zCo8viJY06Ch"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsAndCommonWarrantsMember" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">386.376</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants are exercisable immediately upon issuance at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zMYaDXFUgKg6"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">326.40</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Series A Warrants will expire five and one-half
years<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zUiLe2DtvpE2" style="display: none"><ix:nonNumeric contextRef="AsOf2024-04-30_custom_SeriesAWarrantsMember" format="ixt-sec:duryear" id="Fact000731" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance and the Series B Warrants will expire
eighteen months from the date of issuance. The Pre-Funded Warrants are exercisable immediately upon issuance at an exercise price of
$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_znxWUrSAWMI3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.024</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and may be exercised at any time until the Pre-Funded
Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its affiliates) may not exercise any
portion of such warrants to the extent that the holder would own more than <span id="xdx_902_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zP1rZsr56qjb"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStock" contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
(or, at the election of the holder <span id="xdx_907_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zsnWwNxkiFPi"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)
of the Company&#8217;s outstanding common stock immediately after exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Private Placement, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
dated as of April 30, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) registering the resale of the securities issued in the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Placement closed on May 2, 2024. The gross proceeds to the Company from the Private Placement were approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240502__20240502_zSzPTAYzb5m8"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-05-022024-05-02" id="Fact000735" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, before deducting placement agent fees and estimated
offering expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the Company&#8217;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of April 29, 2024, between the Company and Wainwright (as amended, the
&#8220;Engagement Letter&#8221;). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to <span id="xdx_902_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20240429_zD4yCmuXVAf1"><ix:nonFraction name="CYCC:CashPlacementFeePercentage" contextRef="AsOf2024-04-29" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds of the Private Placement and (ii) a management fee of <span id="xdx_90D_ecustom--ManagementFeePercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240429_zhsfS6elTY21"><ix:nonFraction name="CYCC:ManagementFeePercentageToAggregateGrossProceeds" contextRef="AsOf2024-04-29" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued
to Wainwright or its designees warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zJEJFIefpf0j"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember" id="Fact000738" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,242</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price equal to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z2k13njyoMgh"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">124.512</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Placement Agent Warrants are exercisable immediately
upon issuance and have a term of exercise equal to five and a half years<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zS5z7m5Zd4J3" style="display: none"><ix:nonNumeric contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact000740" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company was required to compensate Roth Capital Partners, LLC, pursuant to a tail provision contained
in an engagement letter entered into on March 14, 2024, in an amount equal to <span id="xdx_90D_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240314__srt--CounterpartyNameAxis__custom--RothCapitalPartnersLlcMember_zDxCywiasD27"><ix:nonFraction name="CYCC:CompensationPercentageToAggregateGrossProceeds" contextRef="AsOf2024-03-14_custom_RothCapitalPartnersLlcMember" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate proceeds of the Private Placement plus the reimbursement of certain expenses. The Company was also required to compensate
Ladenburg Thalmann &amp; Co. Inc, pursuant to a tail provision contained in an engagement letter entered into on October 30, 2023, in
an amount equal to <span id="xdx_907_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20231030__srt--CounterpartyNameAxis__custom--LadenburgThalmannCo.IncMember_zclQRSY20Kw1"><ix:nonFraction name="CYCC:CompensationPercentageToAggregateGrossProceeds" contextRef="AsOf2023-10-30_custom_LadenburgThalmannCo.IncMember" id="Fact000742" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate proceeds of the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 200; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the instruments issued in the Private Placement have been classified and recorded as part of shareholders&#8217; equity (deficit).
The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective
instruments as follows:</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000744" name="CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_z7m7v6VBOkz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_z6NUgLOQ9Vi8" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zBIhHSrSJReb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Allocated
    Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq3QwXNUjED6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Common shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000746" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72,108</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zpODY3vap7N4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prefunded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_PreFundedWarrantsMember" id="Fact000748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,398,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWUkBjHcDr4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember" id="Fact000750" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,819,274</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_zCzqzHT8J5V4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net proceeds</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,290,213</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z25frHlhgXC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fair value of the Placement Agent Warrants was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zKhQ2wTFXwo5"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsMember" id="Fact000753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">609,179</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
These have been accounted for as a direct cost of the Private Placement, resulting in no net effect to overall shareholders&#8217; equity
(deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000755" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjUMBilXRxKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BE_zH2Kn3OlToH6" style="display: none">Schedule
of Fair value of Warrants Valuation Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Pre-Funded Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Common Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Placement Agent Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zQlb4fHHvBn"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000756" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zfxP64rao9gd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">103</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            - <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zmZIGElcjLW2"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">121</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z3gwiYo35EJ6"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">103</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGismNVQlp66" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1</ix:nonFraction></span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">year</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUPPyBSjAiy9" style="display: none"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_srt_MinimumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.5</ix:nonFraction></span></span>1&#189;
                                            - 5&#189; years<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zXeVsP78Db5d" style="display: none"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_srt_MaximumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact000762" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.5</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuHIcIE3sdjd" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.5</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#189;
                                            years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zn43bSaXZy6a"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.51</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zXt0T5Dj3Kec" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.57</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            - <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ztk2p9BCs8ig"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.51</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZ1tCBxmj8l3"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.57</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zSpvZGyUq6h4"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact000768" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJMWTO3OuCFf"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMBjP67BlMnj"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zKTss7DXffqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the common stock was determined using the closing price of the Company&#8217;s common stock as of May 2, 2024, which is
the date that the Private Placement closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2023 Registered Direct Offering Securities Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain
institutional investors (&#8220;Purchasers&#8221;). Pursuant to the Securities Purchase Agreement, the Company agreed to sell in a registered
direct offering (&#8220;Registered Direct Offering&#8221;) <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUSvaUf0eOp7"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">702</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (&#8220;Shares&#8221;) of the Company&#8217;s common
stock and pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z8f25EwLQJtl"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">915</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. The Pre-Funded Warrants have an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z3cYy5VF96pf"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and are immediately exercisable and can be exercised
at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each Share is being sold at an offering
price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z696kwAm0G3e"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember54201031" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">795.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and each Pre-Funded Warrant is being sold at an offering price
of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zO3rfrOkVtii"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">795.36</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(equal to the purchase price per Share minus the exercise price
of the Pre-Funded Warrant).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the &#8220;Offerings&#8221;),
the Company also agreed to issue to the Purchasers unregistered warrants (&#8220;Common Warrants&#8221;) to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zfhbyd13R8R"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,617</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. Each Common Warrant has an exercise
price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zxyKxYf2JjZf"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">765.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, is exercisable immediately following their original
issuance and will expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zLBW1gBg5sD"><ix:nonNumeric contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" format="ixt-sec:durwordsen" id="Fact000778" name="us-gaap:WarrantsAndRightsOutstandingTerm">seven
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the original issuance date. The closing
of the offering occurred on December 26, 2023, and the net proceeds to the Company were approximately $<span id="xdx_90E_ecustom--AggregateProceedsFromSaleOfStock_iI_pn5n6_c20231226__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zJHQ1MXWzG76"><ix:nonFraction name="CYCC:AggregateProceedsFromSaleOfStock" contextRef="AsOf2023-12-26_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact000779" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and other offering
expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, in a separate concurrent insider private placement (the &#8220;Insider Private Placement&#8221;), the Company also
entered into a Securities Purchase Agreement with certain of its executive officers (the &#8220;Insider Securities Purchase Agreement&#8221;)
pursuant to which the Company agreed to sell in a private placement (i) <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDbEsQKu9cN4"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_z3l9jhhwa6Th"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember_custom_CommonStockWarrantsMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Spiro Rombotis, the Company&#8217;s Chief Executive Officer, and (ii) <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember_zzfWOP4FHBU3"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zQcDV3K7eude"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember_custom_CommonStockWarrantsMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Paul McBarron, the Company&#8217;s Executive Vice President-Finance, Chief Financial Officer
and Chief Operating Officer. Each such share of common stock and accompanying warrant was sold at a purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_z59qt1SSJDYk"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">795.60</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was the same purchase price for the Shares sold in the Registered Direct Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 201; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg
Thalmann &amp; Co. Inc. (the &#8220;Placement Agent&#8221;) acted as the exclusive placement agent for the Offerings, pursuant to a placement
agency agreement (the &#8220;Placement Agency Agreement&#8221;), dated December 21, 2023, by and between the Company and the Placement
Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Placement Agency Agreement, the Company paid the Placement Agent a cash placement fee equal to <span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zxyTpFX2Zh2f"><ix:nonFraction name="CYCC:CashPlacementFeePercentage" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds raised in the Offerings from sales arranged for by the Placement Agent. Subject to certain conditions,
the Company also agreed to reimburse all reasonable travel and other out-of-pocket expenses of the Placement Agent in connection with
the Offerings, including but not limited to legal fees, up to a maximum of $<span id="xdx_90A_eus-gaap--ProfessionalFees_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zrNaBYwgRAFk"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact000786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In addition, the Placement Agent also received warrants that have substantially the same terms as the Warrants issued in the concurrent
private placement to the Purchasers in the Offerings to purchase that number of shares of common stock equal to <span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zoYkp4PnmHTl"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStock" contextRef="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate number of shares of common stock and Prefunded Warrants sold in the Offerings, or an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zpU5LIm5eA24"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z9Jp8Gp4Tmda"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">994.50</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (the &#8220;Placement Agent Warrants&#8221;). The
Placement Agent Warrants will be exercisable immediately following the date of issuance and will expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zNfBBPfsUow9"><ix:nonNumeric contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember" format="ixt-sec:durwordsen" id="Fact000790" name="us-gaap:WarrantsAndRightsOutstandingTerm">five
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from issuance. The Placement Agency Agreement
contains customary representations, warranties and agreements by the Company and customary conditions to closing. The Company has agreed
to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and liabilities arising
from breaches of representations and warranties contained in the Placement Agency Agreement, or to contribute to payments that the Placement
Agent may be required to make in respect of those liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the instruments issued in the Offerings and the Insider Private Placement have been classified and recorded as part of shareholders&#8217;
equity. The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values
of the respective instruments as follows:</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember" escape="true" id="Fact000792" name="CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock"><p id="xdx_89F_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4OcU6YuX39i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zY381SfL0bfd" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zyjBGzo64avj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Allocated
    Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHUGbPFf2sba" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Common Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_us-gaap_CommonStockMember" id="Fact000794" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">258,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSZmexFaegDa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Pre-Funded Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_custom_PreFundedWarrantsMember" id="Fact000796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzNFN989B3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Regular Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_custom_CommonStockWarrantsMember" id="Fact000798" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">470,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zQqPN6pWrAzk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net Proceeds</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember" id="Fact000800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,049,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zb4MaUITsIzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fair value of the Placement Agent Warrants was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zFMPYS5N4FH9"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsMember_custom_InsiderPrivatePlacementMember" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
These have been accounted for as a direct cost of the Offerings and Inside Private Placement, resulting in no net effect to overall shareholders&#8217;
equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember" escape="true" id="Fact000803" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4JNxJDtzfie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zWpLB9du8iUi" style="display: none">Schedule
of Fair value of Warrants Valuation Assumption</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pre-Funded Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Regular Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Placement Agent Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zgIRxBJJrZac"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember" id="Fact000804" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">134</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zymclqOdcvj7"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">96</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_ztxHj2RvY8S1"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember" id="Fact000806" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">99</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Contractual/expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z70PhkHMtHj5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1</ix:nonFraction></span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">month</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zKVZgEYRcRl8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember" id="Fact000808" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7</ix:nonFraction></span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zdZmDyp6Len2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5</ix:nonFraction></span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAoG8yfczVX5"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember" id="Fact000810" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.53</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z6gjOzFvrbt5"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.91</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zrQBxpZsYiS6"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.89</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zVXETncroDmk"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zvysFIElhW06"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIppfgQqqL54"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zdarbiT7nGxh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the common shares was determined using the closing price of the Company&#8217;s common stock as of December 26, 2023, which
is the date that the Offerings and the Insider Private Placement closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>August
2021 Controlled Equity Offering Sales Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor
Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), pursuant to which the Company could issue and sell, from time to time, shares of its common
stock having an aggregate offering price of up to $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210812__20210812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_zJMdMEFhmXR9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-08-122021-08-12_custom_CantorFitzgeraldCoMember" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million through Cantor as the sales agent. Cantor could sell
the Company&#8217;s common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule
415(a)(4) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 202; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2022, the Company became aware that the shelf registration statement on Form S-3 (file number 333-231923) (the &#8220;Registration
Statement&#8221;) associated with this Sales Agreement had expired on June 21, 2022. Prior to becoming aware of the expiration, the Company
sold an aggregate of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zsPeJM7cseI8"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">552</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock at the market price, following the
expiration of the Registration Statement and through August 12, 2022, for aggregate proceeds of approximately $<span id="xdx_902_ecustom--AggregateProceedsFromSaleOfStock_iI_c20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zopApQOCgqQ5"><ix:nonFraction name="CYCC:AggregateProceedsFromSaleOfStock" contextRef="AsOf2022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,721,187</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
There was no sale of shares post August 12, 2022. The sale of these shares were subject to potential rescission rights by certain shareholders.
As a result of these potential rescission rights, the Company reclassified <span id="xdx_901_ecustom--ReclassificationOfCommonStockShares_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zv03kIgeoAE2"><ix:nonFraction name="CYCC:ReclassificationOfCommonStockShares" contextRef="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">866</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (including <span id="xdx_90B_ecustom--ReclassificationOfCommonStockSharesNoProceedsReceived_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zHuX4PF4IDH4"><ix:nonFraction name="CYCC:ReclassificationOfCommonStockSharesNoProceedsReceived" contextRef="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">314</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares sold for which the Company did not receive any proceeds),
with an aggregate purchase price of $<span id="xdx_90C_ecustom--ReclassificationOfCommonStockValue_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_z0sRpDI1mmYa"><ix:nonFraction name="CYCC:ReclassificationOfCommonStockValue" contextRef="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember" id="Fact000821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,494,496</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of its common stock outside stockholders&#8217; equity as of
December 31, 2022. These shares have been treated as issued and outstanding for financial reporting purposes. The rescission rights for
these shares lapsed and the shares were reclassified back to permanent equity as of December 31, 2023. As of December 31, 2024, there
have been no claims or demands to exercise such rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2022, the Sales Agreement was mutually terminated. A total of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220815__20220815__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_z1l7eIi8F1pk"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-08-152022-08-15_custom_CantorFitzgeraldCoMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">911</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares, for gross proceeds of approximately $<span id="xdx_908_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20220815__20220815__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_zSEwHJLzhdM5"><ix:nonFraction name="CYCC:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2022-08-152022-08-15_custom_CantorFitzgeraldCoMember" id="Fact000823" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.6</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, had been sold pursuant to the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>November
2024 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, warrants to purchase a total of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_z5ioFWcPrz2e"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" id="Fact000824" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82,816</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in a November 2024 financing transaction (the &#8220;November 2024 Warrant Exercise and Reload Agreement&#8221;) remained outstanding.
A total of <span id="xdx_903_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zupPvhXsoch9"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82,816</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were issued in pursuant to the November 2024 Warrant
Exercise and Reload Agreement. This consisted of i) series C warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zO0lcJxyhHN5"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember" id="Fact000826" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,408</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_z0hd0si37Pki" style="display: none"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesCWarrantsMember_custom_November2024WarrantExerciseAndReloadAgreementMember" format="ixt-sec:duryear" id="Fact000827" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_z2FwheneL143"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">99.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, ii) series D warrants to purchase up to
<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zU3LMLXpr5Ya"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,408</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zUVO9AuNCVq1"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember" format="ixt-sec:durwordsen" id="Fact000830" name="us-gaap:WarrantsAndRightsOutstandingTerm">eighteen
months</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zadW48rwEWAi"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember" id="Fact000831" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">99.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_pid_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zOsFWFPc3GB8"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2023-01-012023-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" id="Fact000832" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercises of these warrants during the years ended December
31, 2024 or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, warrants to purchase a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zoJySxMJhdyf"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,934</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in an April 2024 financing transaction (the &#8220;April 2024 Securities Purchase Agreement&#8221;) remained outstanding. A
total of <span id="xdx_905_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zZXZ2TKx37kf"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember" id="Fact000834" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,750</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were issued in pursuant to the April 2024 Securities
Purchase Agreement. This consisted of i) pre-funded warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zEb1Z3rQ8K8d"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,100</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of common stock, exercisable immediately from the date of issuance,
and with no expiry date, at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zDZWOZonCYFa"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember" id="Fact000836" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, ii) series A warrants to purchase up to
<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPCecdUahTjj"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zsisPXuun5yi" style="display: none"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesAWarrantsMember_custom_April2024WarrantsMember" format="ixt-sec:duryear" id="Fact000838" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zByQEcmurQsh"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">326.40</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, iii) series B warrants to purchase up to
<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zcsaiDPTj29"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember" id="Fact000840" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zxZ3QjgQ4aRl"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember" format="ixt-sec:durwordsen" id="Fact000841" name="us-gaap:WarrantsAndRightsOutstandingTerm">eighteen
months</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zN6BwN8MCAZ7"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">326.40</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share. A further <span id="xdx_906_ecustom--ClassOfWarrantOrRightsExercisable_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zsZi8sUXM4Z6"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,242</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of five and a half years<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zgIk9ZfIUNl" style="display: none"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_custom_April2024WarrantsMember" format="ixt-sec:duryear" id="Fact000844" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zaZ6gP9cddB4"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">124.512</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercised_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zJvVogHkTsQk"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,100</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-funded warrants and <span id="xdx_901_ecustom--ClassOfWarrantOrRightExercised_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_zSuLSN8a4tU8"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantMember" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,716</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B warrants were exercised during the year ended December
31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2023 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, warrants to purchase a total of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zFDZ84J9sTpg"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,750</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in a December 2023 financing transaction remained outstanding. A total of <span id="xdx_90F_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zOCDhAz0VnX6"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,651</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants, including <span id="xdx_901_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreePrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zkRorAjArK25"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyThreePrivatePlacementMember_custom_PlacementAgentWarrantsMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in a concurrent private placement, are exercisable
immediately from the date of issuance for a period of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zy80jv03DSm9"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember" format="ixt-sec:durwordsen" id="Fact000851" name="us-gaap:WarrantsAndRightsOutstandingTerm">seven
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zGDvXea7VShe"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember" id="Fact000852" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">765.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share. A further <span id="xdx_902_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcZWXIlfGF9"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember_us-gaap_WarrantMember" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zkzgA2wgcZNh"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_December2023PlacementAgencyAgreementMember" format="ixt-sec:durwordsen" id="Fact000854" name="us-gaap:WarrantsAndRightsOutstandingTerm">five
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zHvYGsHpLMV2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_December2023PlacementAgencyAgreementMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">994.50</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_z1pM3Xf04aQd"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2023-01-012023-12-31_custom_December2023PrivatePlacementMember" id="Fact000856" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercises of these warrants during the years ended December
31, 2024 or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 203; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2020 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z0PZl1O7TLQa"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyWarrantMember" id="Fact000857" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in a December 2020 financing transaction remained outstanding. Each warrant shall be exercisable beginning on the 12-month
anniversary of the date of issuance for a period of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z2hbvJdrqlgk"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyWarrantMember" format="ixt-sec:durwordsen" id="Fact000858" name="us-gaap:WarrantsAndRightsOutstandingTerm">five
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zjRA4NuhW6w2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyWarrantMember" id="Fact000859" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,868.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share. The exercise price of the warrants will
be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar
transaction, as described in the warrants. The warrants may be exercised on a &#8220;cashless&#8221; basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, <span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercised_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfzBNRAkfqy1"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyWarrantMember_us-gaap_SeriesBPreferredStockMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants lapsed upon conversion of the associated Series B
Preferred Stock. There were <span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z3Rwgk9BzASg"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2023-01-012023-12-31_custom_DecemberTwoThousandTwentyWarrantMember" id="Fact000861" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercises of these warrants during the year ended December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2020 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zcg8CHGkLTfh"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">497</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in connection with an April 2020 equity financing
remained outstanding, each with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zQmvWkjnxcYj"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18,000.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The common warrants are immediately exercisable and will expire on the fifth anniversary of the original issuance date. The exercise
price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting the Company&#8217;s common stock. The common warrants were issued separately
from the common stock and were eligible for transfer immediately after issuance. A common warrant to purchase one share of common stock
was issued for every share of common stock purchased in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise
notice accompanied by payment in full for the number of shares of the Company&#8217;s common stock purchased upon such exercise (except
in the case of a cashless exercise). <span id="xdx_90E_eus-gaap--DebtInstrumentDescription_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zjHjUmnK3Cg9"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact000864" name="us-gaap:DebtInstrumentDescription">A
holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more
than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days prior notice from the holder
to the Company, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s common warrants
up to 9.99% of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the common warrants.</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, the
Company will round down to the next whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90B_ecustom--ClassOfWarrantOrRightExercised_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_z3cX5KcR4pDc"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111</ix:nonFraction></span> warrants were exercised during the year ended December 31, 2024. <span id="xdx_906_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zIxfkqhLW8zg"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2023-01-012023-12-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact000866" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were exercised during the year ended December 31,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
B Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNid3PIJiCs1"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">237,745</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s Series B Preferred Stock were
issued in a December 2020 Securities Purchase Agreement. Each share of Series B Preferred Stock shall initially be convertible into one
third (1/3) share of common stock (the &#8220;Conversion Shares&#8221;), subject to adjustment in accordance with the Certificate of
Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock
basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series
B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company
will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a)
alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Certificate
of Designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights
of the holders of Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, (e) pay certain
dividends or (f) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock does not have a preference
upon any liquidation, dissolution or winding-up of the Company. The Purchaser may convert shares of Series B Preferred Stock through
a conversion into shares of common stock if and solely to the extent that such conversion would not result in the Purchaser beneficially
owning in excess of <span id="xdx_90B_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbrVB1A6kuJk"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of then-outstanding common stock or aggregate voting power of the Company (such limitation, the &#8220;Ownership Limitation&#8221;) and
any portion in excess of such limitation will remain outstanding as Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 204; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z80ypU7lmqX3"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series B Preferred Stock was converted, at the option
of the holder, into <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zocqvnwoQRD6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. As of December 31, 2024, there were
<span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlostzkFR6zg"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000871" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining shares of the Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYBA5ymp05Hg"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,872</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s Series A Preferred Stock were
issued in a July 2017 Underwritten Public Offering. Each share of Series A Preferred Stock is convertible at any time at the option of
the holder thereof, into a number of shares of common stock determined by dividing $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHzzSK2nIpO6"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact000873" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by the initial conversion price of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2IYGWDYiHw4"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2017-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">144,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, subject to a <span id="xdx_90D_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLJFziQuW93g"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
blocker provision, or, upon election by a holder prior to the issuance of shares of Series A Preferred Stock, <span id="xdx_907_ecustom--ConvertiblePreferredStockConversionPercentage_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2BPEAHa2UZ2"><ix:nonFraction name="CYCC:ConvertiblePreferredStockConversionPercentage" contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0cm0Sof4318"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000877" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Series A Preferred Stock remain issued and outstanding.
The <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zw6z4u0mehFa"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series A Preferred Stock issued and outstanding at
December 31, 2024, are convertible into <span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoedssE9uV12"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000879" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock
basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends
in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted
basis. There is no restriction on the Company&#8217;s ability to repurchase shares of Series A Preferred Stock while there is an arrearage
in the payment of dividends on such shares, and there are no sinking fund provisions applicable to Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder
of the Series A Preferred Stock to convert all or part of such holder&#8217;s Series A Preferred Stock in the event that (i) the volume
weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds <span id="xdx_906_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKvYphkB3ODl"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">300</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations,
stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $<span id="xdx_900_eus-gaap--ConversionOfStockAmountConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSkscOcyJSWf"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000881" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">500,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per trading day and (iii) the holder is not in possession of
any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to
cause each holder of Series A Preferred Stock to convert all or part of such holder&#8217;s Series A Preferred Stock shall be exercised
ratably among the holders of the then outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains
no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common
stock in the distribution of assets, to the extent legally available for distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6%
Convertible Exchangeable Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zmW1tAtLncpl"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,273</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z2XPeCSRRKtd"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000883" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
Convertible Exchangeable, or Preferred Stock issued and outstanding at an issue price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zLGOPcPZlrKc"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. Dividends on the Preferred Stock are cumulative
from the date of original issuance at the annual rate of <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zOSxPD0ojie9"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000885" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the liquidation preference of the Preferred Stock, and if declared, payable quarterly on the first day of February, May, August and
November, commencing February 1, 2005. Any dividends must be declared by the Company&#8217;s Board of Directors and must come from funds
that are legally available for dividend payments. The Preferred Stock has a liquidation preference of $<span id="xdx_90E_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zLKfEnzExJoh"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, plus accrued and unpaid dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Board of Directors considers numerous factors in determining whether to declare the quarterly dividend pursuant to the
Certificate of Designations governing the terms of the Company&#8217;s Preferred Stock, including the requisite financial analysis and
determination of a surplus. Accumulated but unpaid dividends in arrears on preferred stock were $<span id="xdx_901_eus-gaap--PreferredStockAmountOfPreferredDividendsInArrears_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zIKtoRIgiTQ7"><ix:nonFraction name="us-gaap:PreferredStockAmountOfPreferredDividendsInArrears" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000887" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, or $<span id="xdx_90F_eus-gaap--PreferredStockPerShareAmountsOfPreferredDividendsInArrears_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zHVTZio9m3j"><ix:nonFraction name="us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.55</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, of preferred stock, as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 205; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Stock is convertible at the option of the holder at any time into the Company&#8217;s shares of common stock at a conversion
rate of approximately <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zOGNhn7UbHV"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.0000001</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for each share of Preferred Stock based
on a price of $<span id="xdx_90F_ecustom--ConvertiblePreferredStockConversionPricePerShare_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ztBeBzRoU1Ej"><ix:nonFraction name="CYCC:ConvertiblePreferredStockConversionPricePerShare" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">142,128,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company has reserved <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3IEihCHsAbi"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for issuance upon conversion of the
remaining shares of Preferred Stock outstanding at December 31, 2024. The shares of previously converted Preferred Stock have been retired,
cancelled and restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors
as shares of Preferred Stock of one or more series.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&#8217;s common stock has
exceeded $<span id="xdx_90D_ecustom--CommonStockClosingPriceThreshold_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zZTyEkWeG0jb"><ix:nonFraction name="CYCC:CommonStockClosingPriceThreshold" contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">213,192,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which is <span id="xdx_901_ecustom--PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zH3UxVhle3bb"><ix:nonFraction name="CYCC:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">150</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the conversion price of the Preferred Stock, for at least <span id="xdx_90D_ecustom--PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zq3xaJ5siC7a"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:durday" id="Fact000894" name="CYCC:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays">20</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading days during any <span id="xdx_90B_ecustom--PreferredStockConversionObligationNumberOfTradingDays_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ziudvZhBorI5"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:durday" id="Fact000895" name="CYCC:PreferredStockConversionObligationNumberOfTradingDays">30</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-day
trading period, ending within <span id="xdx_909_ecustom--PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z7qW4QFrgAj9" style="display: none"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:durday" id="Fact000896" name="CYCC:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion">5</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">five
trading days prior to notice of automatic conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock
for <span id="xdx_904_ecustom--DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_dc_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z0ty4fIsJuX9"><ix:nonFraction name="CYCC:DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000897" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">six</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quarterly periods, holders of Preferred Stock are entitled
to nominate and elect two directors to the Company&#8217;s Board of Directors. This right accrued to the holders of Preferred Stock as
of August 2, 2010 and two directors were nominated and elected at the annual meeting held on May 24, 2011.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption price of
$<span id="xdx_904_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zQ53MohjAj38"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November
1, 2005, or Exchange Date for the Company&#8217;s <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zphZvKjMwR6b"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000899" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
Convertible Subordinated Debentures, or Debentures at the rate of $<span id="xdx_908_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zK8Wfzuii8Rl"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">principal amount of Debentures for each share of Preferred
Stock. The Debentures, if issued, will mature <span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zkuYmJjsUAAf"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:duryear" id="Fact000901" name="us-gaap:DebtInstrumentTerm">25</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years after the Exchange Date and have terms substantially
similar to those of the Preferred Stock. No such exchanges have taken place as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, the company declared dividends of $<span id="xdx_90A_eus-gaap--PreferredStockDividendsPerShareDeclared_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zoIeHqACcAB8"><ix:nonFraction name="us-gaap:PreferredStockDividendsPerShareDeclared" contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.15</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share quarterly on its <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zUWFr7Wm18E7"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000903" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
Convertible Exchangeable Preferred Stock. These dividends were paid on February 1, 2024. No further dividends were declared or paid subsequent
to this.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000905" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_znQWdRcu69i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_821_zEM0MRbmF4ef" style="display: none">Stock
Based Compensation</span></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000907" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zXCK22xGcJEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the years ended 2024 and
2023 as shown in the following table (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zW9fimmMO287" style="display: none">Schedule
of Stock Based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z5J1LKCuPOd6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zoBc2yGOwLFk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zG7j9d9M17T4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">498</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000910" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,039</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5qIKuYJsX7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000913" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zUb79rLOxow5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31" id="Fact000915" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact000916" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zyYSPO1y2Ai9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2018
Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2018, the Company&#8217;s stockholders approved the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), under which Cyclacel
may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan replaced the 2015 Equity Incentive
Plan (the &#8220;2015 Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2018 Plan allows for various types of award grants, including stock options and restricted stock units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2024, the Company&#8217;s stockholders approved an additional <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240621__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zeFiU61TQvt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-06-21_custom_EquityIncentivePlan2018Member" id="Fact000917" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that may be issued under the 2018 Plan.
On June 13, 2023, the Company&#8217;s stockholders approved an additional <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230613__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z6ms7IFo8Lij"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-06-13_custom_EquityIncentivePlan2018Member" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that may be issued under the 2018 Plan.
As of December 31, 2024, the Company has reserved approximately <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z9agf1Z10yx5"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_EquityIncentivePlan2018Member" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">196,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock under the 2018 Plan
for future issuances. Stock option awards granted under the Company&#8217;s equity incentive plans have a maximum life of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member__srt--RangeAxis__srt--MaximumMember_zgbuIy9LIkuf"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EquityIncentivePlan2018Member_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000920" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and generally <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240101__20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z27qR6ke1CFl"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EquityIncentivePlan2018Member" id="Fact000921" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">vest
over a one to four-year period from the date of grant.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 206; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020
Inducement Equity Incentive Plan </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), became effective. Under the Inducement Plan,
Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder
approval). The Inducement Plan allows for the issuance of up to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20201031__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zy9d7OagRbpd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-10-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock (or the equivalent
of such number). As of December 31, 2024, the reserve remains at <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zVvOaQTEFAYk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember" id="Fact000923" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Grants and Exercises</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeIIfNY9BWz4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000924" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted during the year ended December 31, 2024, all
issued under the 2018 Plan. These options had a grant date fair value of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr01DMLhwYbe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000925" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">424.80</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per option. There were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCLNscJVcAu1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000926" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">181</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted during the year ended December 31, 2023. These
options had a grant date fair value ranging between $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zNpnvqTKb2te"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,516.80</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zpp49O0UskSl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,635.20</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the options granted during the year ended December 31, 2024, all vested <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0KzoUypebxi"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:durwordsen" id="Fact000929" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">six
months</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from their date of grant. Of the options
granted during the year ended December 31, 2023, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--OptionsVestingOnThirdAnniversaryOfGrantMember_zScAeDCVQIA5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_OptionsVestingOnThirdAnniversaryOfGrantMember" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">awards shall vest on the third anniversary of their date of
grant, or earlier if either of the certain performance conditions are met relating to enrollment goals for various clinical studies.
A further <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV64TXIKVcYc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted during the year ended December 31, 2023 were
forfeited during 2024 due to the holders&#8217; termination of employment with the Company. The Company had assumed that these awards
will vest after <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dc_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--OptionsVestingOnThirdAnniversaryOfGrantMember_zZuZYVw122Q1"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_OptionsVestingOnThirdAnniversaryOfGrantMember" format="ixt-sec:durwordsen" id="Fact000932" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">three
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as satisfaction of the performance conditions
is not probable at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the total remaining unrecognized compensation cost related to the non-vested stock options with service conditions
amounted to approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231_zKgpLL0nXbzc"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-12-31" id="Fact000933" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which will be amortized over the weighted-average
remaining requisite service period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_z8HmQwph5sce"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact000934" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.30</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Outstanding
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000936" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zYaETrg97Iuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the share option activity and related information is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zYiLYeCPA6tk" style="display: none">Schedule
of Share Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Exercise</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Remaining</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Aggregate</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Options</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Price Per</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Contractual</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Intrinsic</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Term (Years)</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value ($000)</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%">Options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZba66nJpzr1" title="Number of Options Outstanding, Balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">447</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpPSaXrFwvVa" title="Weighted Average Exercise Price, Balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">21,049.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6ihu0t7sqTc"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000941" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.34</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKlyebtltsKg" title="Aggregrate Intrinsic Value, Balance" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4uBx3qaHJJj" title="Number of Options Outstanding, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG6lVgIsPxrf" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,117.94</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjZg89pcq0ce" title="Number of Options Outstanding, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4rlVdRnM6O9" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0951">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zei0oYx5BAD2" title="Number of Options Outstanding, Cancelled/forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAp2gYljl4z3" title="Weighted Average Exercise Price, Cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">79,737.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW6MdwH7khT8" title="Number of Options Outstanding, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">595</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxNXXZznHXje" title="Weighted Average Exercise Price, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12,048.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmJ5D0fqqkT3"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000960" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.96</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1THMMqemkLb" title="Aggregrate Intrinsic Value, Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTDEG35BHJkf" title="Number of Options Outstanding, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKNNH2gjtHA2" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">547.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z45Oa4VM7lp9" title="Number of Options Outstanding, Cancelled/forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000968" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">153</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqB5l4LngxRl" title="Weighted Average Exercise Price, Cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000970" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12327.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1aMINQMRCJc" title="Number of Options Outstanding, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvHykPYxeNHh" title="Weighted Average Exercise Price, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10,658.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgOqXuyCcwD2"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000975" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.20</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXPhzx6MQkGi" title="Aggregrate Intrinsic Value, Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3wxdHLU6Wd4" title="Number of Options Outstanding, Unvested" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjrVZ71REUt4" title="Weighted Average Exercise Price, Unvested" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,250.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmh8LOODM46c"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000982" name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm">8.45</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTSjcDWGjEBi" title="Number of Options Outstanding, Vested and exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7JzNxuMInj7" title="Weighted Average Exercise Price, Vested and exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000986" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12,141.75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwcSRTTunONf"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000987" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">6.99</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDlk1p37R0C7" title="Aggregrate Intrinsic Value, Vested and Exerciseable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zHpzs7E0GNpb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 207; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000991" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLk6BC2Yaog5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B7_zuL5AUzeIOG2" style="display: none">Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Year ended</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Year ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdy05diIKDd6"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000992" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zi4hnL1Nbi65" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000993" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zWa2OUYvebgi"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000994" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr79fZTdLQOe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.995</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zPj9fqVcqaJ2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact000996" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.660</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            &#8201;&#8211;&#8201;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTCRQ6XLrwv5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.160</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6AtZ7wEbaLk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHPdnGuNw9Z6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact000999" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&#8201;&#8211;&#8201;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zD8iL2fdMt72"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact001000" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield over expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSyMhqwDeVMb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001001" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDBGHpXkRUOe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001002" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Resulting weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqLTmwaaiAih"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">424.80</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjDlkN8WLLZ5"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001004" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,591.20</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zkuTqvoTGAA" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSbXS9y0d0S9" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1005">no</span></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock options exercised during each of the years ended December
31, 2024 and 2023, respectively. The Company does not expect to be able to benefit from the deduction for stock option exercises that
may occur because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK3tmfhPqMs9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units during the year ended December 31, 2024.
These restricted stock units vest monthly over a six-month<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtM_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbiwy96lLcQb" style="display: none"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:durmonth" id="Fact001007" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">6</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">service period. These restricted stock units were valued at
$<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdQNw50UDo8d"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">547.20</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbKBK3EXdol5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001009" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units were issued in January 2023 vest on
the third anniversary of their date of grant, or earlier if certain defined clinical trial related performance targets are met. A three-year<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1s54avrM6Ee" style="display: none"><ix:nonNumeric contextRef="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001010" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">3</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vesting assumption was applied to these restricted stock units
as satisfaction of the performance conditions is not probable at this time. Each of these restricted stock units was valued at $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgQdUy0iVF2e"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-01-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001011" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,240.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date. During 2023, <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0krSL20mtli"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of these restricted stock units were forfeited as the recipient
voluntarily terminated employment with the Company. A further <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSdTTweCTRNh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001013" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units issued in June 2023 vest on the first
anniversary of the date of grant. Each of these restricted stock units were valued at $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pp2d_c20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWLOO99AkOpg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001014" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">2,121.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, an additional <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGyHbUH9o1x3"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of these restricted stock units have been forfeited due to
the holders&#8217; termination of employment with the Company.</span></p>
<!-- Field: Split-Segment; Name: 003 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001017" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z0y5of2jRFW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized
information for restricted stock units as of December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z3I6sU64j9Ca" style="display: none">Schedule
of Restricted Stock Units Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Restricted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Remaining</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Stock Units</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Term</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 51%; text-align: left">Restricted Stock Units outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4bnpsxRNzp5" title="Restricted Stock Units outstanding, Beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001019" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">38</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5vmvcpilDg8" title="Restricted Stock Units, Grant Date Value Per Share" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001021" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6,768.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFYiu1O9hNg" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001023" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zARNwFuag36h" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,870.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdkJjVayPsI5" title="Cancelled/forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001027" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRFRVJA2uDT2" title="Cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001029" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,240.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrWRPQXoR4yd" title="Restricted Stock Units outstanding, Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001031" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBGAA1hpRkl1" title="Restricted Stock Units, Grant Date Value Per Share" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001033" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,902.40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPxTjzhMzzX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001034" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">8.96</ix:nonNumeric></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRomSdcQm0g8" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJFqXxPzH1Ej" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">547.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkqh0qcxHcUi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001039" name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms">9.03</ix:nonNumeric></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAfRIpbwJTIk" title="Cancelled/forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001041" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">32</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD5MLF0pZK74" title="Cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,675.17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZrTIw89T5rl" title="Restricted Stock Units outstanding, Ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6AnS530vm5j" title="Restricted Stock Units, Grant Date Value Per Share" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,881.62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdrTMg2j6Qw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001048" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">8.30</ix:nonNumeric></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzrxrQL9jip3" title="Unvested" style="text-align: right"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztEIEWKXLf67" title="Unvested, Weighted Average Grant Date Value Per Share" style="text-align: right"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,280.09</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8A61gEZ9Bf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001053" name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms">8.06</ix:nonNumeric></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb6xI7zGQfe6" title="Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQYuj9KVPi75" title="Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,747.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdKSrMuFyqBb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001058" name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms">8.39</ix:nonNumeric></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z6vaINvgkkf5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 208; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001060" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z4JEEJEo67V9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_82E_zqDEuSLYSI8i">Employee Benefit Plans</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pension
Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates a defined contribution group personal pension plan for all of its UK based employees. Company contributions to the plan
totaled approximately $<span id="xdx_907_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20240101__20241231_z2dd5cvF5pd7"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2024-01-012024-12-31" id="Fact001061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_z2Whnnugw6F"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2023-01-012023-12-31" id="Fact001062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>401(k)
Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
401(k) Plan provides for matching contributions by the Company in an amount equal to the lesser of <span id="xdx_907_ecustom--DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_pid_dp_uPure_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zsBo8GLJzrd4"><ix:nonFraction name="CYCC:DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" contextRef="From2024-01-012024-12-31_custom_Plan401KMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the employee&#8217;s deferral or <span id="xdx_901_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pid_dp_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_z9kCUlpY4w7e"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="From2024-01-012024-12-31_custom_Plan401KMember" id="Fact001064" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the U.S. employee&#8217;s qualifying compensation. The 401(k) Plan is intended to qualify under Section 401(k) of the Internal Revenue
Code, so that contributions to the 401(k) Plan by employees or by the Company, and the investment earnings thereon, are not taxable to
the employees until they are withdrawn. Company matching contributions are tax deductible by the Company when made. In 2024, Company
employees could elect to reduce their current compensation by up to the statutorily prescribed annual limit of $<span id="xdx_90E_ecustom--DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_z2wXwLdjHdV"><ix:nonFraction name="CYCC:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" contextRef="From2024-01-012024-12-31_custom_Plan401KMember" id="Fact001065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if under 50 years old and $<span id="xdx_90C_ecustom--DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zFq0vlBb6pQ5"><ix:nonFraction name="CYCC:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" contextRef="From2024-01-012024-12-31_custom_Plan401KMember" id="Fact001066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,500</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if over 50 years old and to have those funds contributed to
the 401(k) Plan. The Company made contributions of approximately $<span id="xdx_906_eus-gaap--DefinedContributionPlanCostRecognized_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zNkj37no1lpl"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2024-01-012024-12-31_custom_Plan401KMember" id="Fact001067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pp0d_c20230101__20231231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_ztTBMIszXbdc"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2023-01-012023-12-31_custom_Plan401KMember" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the 401(k) Plan for the years ended December 31, 2024 and
2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001070" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_z0l3rkrmF2o1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_82C_z9ds2jaJjJoa">Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001072" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zi2SGX2EgT35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Loss)
income from continuing operations before taxes is comprised of the following components for the years ended December 31, 2024 and 2023
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_ziPhwKKQ7QD9" style="display: none">Schedule
of Components of (Loss) Income Before Taxes from Continuing Operations</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z40s8ijn56Sg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_z6hypnLtSc9c" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_zpbZuNxDOIb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2024-01-012024-12-31" id="Fact001074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-01-012023-12-31" id="Fact001075" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">806</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_zn0TTtefFfZ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2024-01-012024-12-31" id="Fact001077" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,030</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2023-01-012023-12-31" id="Fact001078" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24,745</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztT40wwpCbvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from continuing operations before taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact001080" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact001081" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25,551</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zgXzGKTTjWei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001083" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zP6uKjErOoEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
benefit (provision) for income taxes from continuing operations consists of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zzIQKg3SheM1" style="display: none">Schedule
of Benefit (Provision) for Income Taxes from Continuing Operations</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Current&#8201;&#8201;&#8211;&#8201;&#8201;domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20240101__20241231_zHkvjHh0ciX7" title="Current - domestic" style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001085" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230101__20231231_zDspSsLfAIQe" title="Current - domestic" style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001087" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current&#8201;&#8201;&#8211;&#8201;&#8201;foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20240101__20241231_z9oZ5jhlCOdj" title="Current - foreign" style="text-align: right"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">803</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20230101__20231231_z6Hfu5Pnc17b" title="Current - foreign" style="text-align: right"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current&#8201;&#8201;&#8211;&#8201;&#8201;total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zloeSjLyuHY7" title="Current - total" style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">782</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_z9VgN91v53Lk" title="Current - total" style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,996</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred&#8201;&#8201;&#8211;&#8201;&#8201;domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20240101__20241231_zQ2kfkKvaYm5" title="Deferred  -  domestic" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20230101__20231231_zSiCUsFkQC8k" title="Deferred  -  domestic" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1099">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20240101__20241231_z1GEgQ9Enx3h" title="Income tax benefit" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001101" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">782</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20230101__20231231_zwWKMtcDwWP7" title="Income tax benefit" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001103" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,996</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z0hVNo1lu5Ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a taxable loss in each of the operating periods since incorporation. The income tax credits of $<span id="xdx_90A_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231_zKVJoKduiR1d"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-12-31" id="Fact001104" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20231231_zWcBYe3D7Oyk"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2023-12-31" id="Fact001105" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for the years ended December 31, 2024 and 2023, respectively,
represent UK research and development (&#8220;R&amp;D&#8221;) tax credits for expenditures in the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 209; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001107" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zIXbJHNN5g85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory
federal tax rate to loss from continuing operations before income taxes is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BD_zGLXvuCpGWSa" style="display: none">Schedule
of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory
Federal Tax Rate to Loss Before Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z8pHbjV9u6k3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zHIcFpd8tN45" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_z4J0PexTZVJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Loss from continuing operations before taxes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact001109" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,994</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact001110" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25,551</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_z6JAAMhrd20f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax expense computed at statutory federal tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001112" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,527</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001113" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,366</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_zV1GNveNkmd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional research and development tax relief</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-01-012023-12-31" id="Fact001116" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,409</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_zyhfrwmzo8hf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss surrendered to generate R&amp;D credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2023-01-012023-12-31" id="Fact001119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,865</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_zZ68zSJfuL25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,798</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,261</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_zdz7HvdWK7cj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other foreign items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2024-01-012024-12-31" id="Fact001124" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,158</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2023-01-012023-12-31" id="Fact001125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">809</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_pn3n3_zvxQ78xJhSSe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Disallowed expenses and non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" contextRef="From2024-01-012024-12-31" id="Fact001127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" contextRef="From2023-01-012023-12-31" id="Fact001128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_zocg3OA9DKb3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2024-01-012024-12-31" id="Fact001130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-012023-12-31" id="Fact001131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_zkjIlTHWkJAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign items, including change in tax rates, and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationOtherItemsAmount_pn3n3_zI4jzmlThK9f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:EffectiveIncomeTaxRateReconciliationOtherItemsAmount" contextRef="From2024-01-012024-12-31" id="Fact001136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zrvdoTqNWRlb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Current - total</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001139" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">782</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001140" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,996</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zWX1gTWRmRj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001142" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTQBA6wBlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&#8217;s deferred tax assets are shown below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zaRTNnpL4Wy7" style="display: none">Schedule
of Significant Components of the Entity's Deferred Tax Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zYKpNA6rzTgb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zXMGekTlL4Cl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzNQW_z9WHoQsvbAp2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Net operating loss and tax credit carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59,417</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,074</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_iI_pn3n3_maDTAGzNQW_zgSYHJggyol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation, amortization and impairment of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" contextRef="AsOf2024-12-31" id="Fact001147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" contextRef="AsOf2023-12-31" id="Fact001148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzNQW_zkSqryKkSQNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_iI_pn3n3_maDTAGzNQW_zeB95xzQFgza" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseRightOfUseAsset_iI_pn3n3_maDTAGzNQW_zUcW5ieyLWNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CYCC:DeferredTaxAssetsLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001156" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CYCC:DeferredTaxAssetsLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001157" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsLeaseRightOfUseLiability_iI_pn3n3_maDTAGzNQW_zudO5YVuNRlc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:DeferredTaxAssetsLeaseRightOfUseLiability" contextRef="AsOf2024-12-31" id="Fact001159" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CYCC:DeferredTaxAssetsLeaseRightOfUseLiability" contextRef="AsOf2023-12-31" id="Fact001160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzNQW_zqg5xGjm4Fmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001162" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzNQW_maDTANzSsl_z8fPaw5CXOh7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59,820</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,323</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzSsl_zlMJjZXNVAXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation allowance for deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001168" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59,820</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzSsl_zET7nPL47GL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zJQF0WqlpXk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance has been established, as realization of such assets is uncertain. The Company&#8217;s management evaluated the positive
and negative evidence bearing upon the realizability of its deferred assets, and has determined that, at present, the Company may not
be able to recognize the benefits of the deferred tax assets under the more likely than not criteria. Accordingly, a valuation allowance
of approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20241231_zVgt0vwS60J6"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001173" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">59.8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million has been established at December 31, 2024. The valuation
allowance increased by approximately $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zjQ2QYDP92g1"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-012024-12-31" id="Fact001174" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
specified in the Tax Reform Act of 1986, due to ownership changes, the Company&#8217;s ability to utilize its net operating loss (&#8220;NOL&#8221;)
carryforwards may be limited. Utilization of the NOLs may be subject to a substantial annual limitation under Section 382 of the Internal
Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership
changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and
tax, respectively. The Company completed a Section 382 study and has concluded that an ownership change occurred on March 4, 2015 and
July 21, 2017. As a result of the ownership changes, the NOLs are limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company has federal NOLs of $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zjWiNCg79XT7"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_InternalRevenueServiceIRSMember" id="Fact001175" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zswJqJgLAcXf"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_InternalRevenueServiceIRSMember" id="Fact001176" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. The federal NOLs have an indefinite
life. As of December 31, 2024 and 2023, the Company has state NOLs of&#8201;$<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zcg5ohylH34"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001177" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ziCVmlso24De"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001178" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.3</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively, which will begin to expire in 2028.
As of December 31, 2024 and 2023, the Company had foreign NOLs of $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zJgjQM3J2bcc"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="Fact001179" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">230.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zcWSGz9BC0jk"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001180" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">220.1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. The Company&#8217;s foreign NOL&#8217;s
do not expire under UK tax law however the use of these NOLs is restricted to an annual &#163;<span id="xdx_906_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn6n6_uGBP_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zET1OBwkf7Zd"><ix:nonFraction name="us-gaap:OperatingLossCarryforwardsValuationAllowance" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="Fact001181" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="GBP">5.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million allowance in each standalone company or group and above
this allowance, there will be a <span id="xdx_90A_ecustom--PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_pid_dp_uPure_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z7JNT7IuFkw1"><ix:nonFraction name="CYCC:PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="Fact001182" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
restriction in the profits that can be covered by losses brought forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 210; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated all significant tax positions at December 31, 2024 and 2023 and concluded that there are no material uncertain tax positions.
The Company would recognize both interest and penalties related to unrecognized benefits in income tax expense. The Company has not recorded
any interest and penalties on any unrecognized tax benefits since its inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
years 2020 - 2023 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the
United Kingdom and the United States, as carryforward attributes generated in years past may still be adjusted upon examination by the
United Kingdom&#8217;s H.M. Revenue &amp; Customs, the Internal Revenue Service (&#8220;IRS&#8221;) or state tax authorities. The Company
is currently not under examination by the IRS or any other jurisdictions for any tax years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not provided a deferred tax liability on the cumulative amount of unremitted foreign earnings of international subsidiaries because
it is our intent to permanently reinvest such earnings outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an aggregate deficit in foreign earnings and therefore has not provided any deferred tax liability on its outside book-tax
basis difference in its foreign subsidiaries and because it is also our intent to permanently reinvest any earnings outside of the United
States. We would recognize this deferred tax liability if we were to experience a change in circumstances producing a change in that
intention. As a result of the repeal of Section 902 foreign tax credit under the Tax Act, future distributions would not be offset by
a foreign tax credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental
to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting
these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses
for tax years tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be
amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E
activities are broader in scope than qualified research activities that are considered under IRC Section 41 (relating to the research
tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that
the company does not have any R&amp;E expenses in the US. The company will continue to monitor this issue for future developments, but
it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001184" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zzhzGbR1nhnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
Net Loss Per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_823_zj1AqnScSNpl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Loss per Common Share</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001186" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaPgmkrAWcSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to common stockholders was calculated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zmPAJzP3Lbrl" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zApuHLCLafz8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zosuHDqHoUu3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Years ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_iB_zkye7KFpM8v1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pn3n3_zbSYFLhOBBbd" style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001191" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,555</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockDividendsIncomeStatementImpact_i01N_pn3n3_di_zWwGMIonyOHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend on convertible exchangeable preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31" id="Fact001195" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">201</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01_pn3n3_zZDaggpx6Wfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to common shareholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-012024-12-31" id="Fact001197" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-012023-12-31" id="Fact001198" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,756</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zpuiu0OGIyBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average number of common shares used in loss per share&#8201;&#8211;&#8201;basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_z2K08zwrNZj9"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact001202" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,314</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zU4gHRANFRC2"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,545</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss per share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zPueyGER5C51">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact001204" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">502.46</ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zHsdxXBu0y1h">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">6,419.07</ix:nonFraction></span></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zBdjnzCqCrA6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 211; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss
per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per
share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on
amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the
periods indicated because including them would have had an anti-dilutive effect:</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001207" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8A5qjK8ZPL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zMnLkR0Etvvg" style="display: none">Schedule
of antidilutive shares excluded from computation of diluted net loss per share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zk6Kqj4vAPUe" style="text-align: center">December 31,</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zlAdyJ4k5uG7" style="text-align: center">December 31,</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrCtIDMllqvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember54207625" id="Fact001209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">494</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember54207640" id="Fact001210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">595</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zR6bOlwu5J4h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember54207656" id="Fact001212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember54207656" id="Fact001213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zyDexCfFVXUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20231231_zrUem3V7owIj"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-12-31" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%
    convertible exchangeable preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember54207671" id="Fact001215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember54207671" id="Fact001216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zRFaUHnu69b4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember54207671" id="Fact001219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001220" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zCe0VYxg8vfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1222">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001223" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_ziemC2QSOQWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember54207703" id="Fact001225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">117,182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember" id="Fact001226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,648</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zVCB9AnJJVy5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total shares excluded from calculation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31" id="Fact001228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">117,842</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact001229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zP6iQB9a6Ofh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001231" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zFvFF9ZiFIz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_827_zCY0RQhiwx5l">Geographic and Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001233" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zhvSlWLPSFni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geographic
information for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zjd4R6VCOs8i" style="display: none">Schedule
of Geographic Information</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenue</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">United Kingdom</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z31mrJ5xVR5f" title="Revenue" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31_country_GB" id="Fact001235" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zYpp0Btyfs8h" title="Revenue" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31_country_GB" id="Fact001237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231_zmcpsLEtp13f" title="Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31" id="Fact001239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231_zkaLebsGMq57" title="Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact001241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United States</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z93MITdRGmJg" title="Net Loss" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_country_US" id="Fact001243" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zB8d1IKB0Y7b" title="Net Loss" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_country_US" id="Fact001245" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">808</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z9oQ8kHoVvNf" title="Net Loss" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_country_GB" id="Fact001247" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,175</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zRJ0Tzg31Vwf" title="Net Loss" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_country_GB" id="Fact001249" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,747</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Net Loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231_z9ia6vKOwEye" title="Net Loss" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001251" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231_zBLG7QHpFici" title="Net Loss" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001253" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,555</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_z4mkAC6qKjjd" title="Total Assets" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_country_US" id="Fact001255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,285</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_z3BUwgBWuDD3" title="Total Assets" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_country_US" id="Fact001257" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,938</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zIbAgLrDsWP9" title="Total Assets" style="text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_country_GB" id="Fact001259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">809</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zsxWshuvtgH" title="Total Assets" style="text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_country_GB" id="Fact001261" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,867</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20241231_zUlx5ZeC1M8j" title="Total Assets" style="text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact001263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20231231_zAJ7AObNigng" title="Total Assets" style="text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact001265" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long Lived Assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">United States</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_zCpCcEUOJzub" title="Long Lived Assets, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31_country_US" id="Fact001267" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_zJfAm2BtN2of" title="Long Lived Assets, net" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1269">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zSuaHLMaO2Nc" title="Long Lived Assets, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31_country_GB" id="Fact001271" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zKbX2ASHevdk" title="Long Lived Assets, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31_country_GB" id="Fact001273" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Long Lived Assets, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231_zTND4cTeXCu1" title="Long Lived Assets, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact001275" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231_zRyQfY2EJ2Nf" title="Long Lived Assets, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zsP8HMlkbOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 212; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as a single segment engaged in the development of innovative cancer medicines based on cell cycle, transcriptional regulation
and mitosis control biology. Consistent with our operational structure, our Chief Executive Officer (CEO), as the chief operating decision
maker, makes resource allocation and business process decisions globally across our consolidated business. Managing and allocating resources
at the consolidated level enables our CEO to assess the overall level of resources available and how to best deploy these resources across
functions, and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on
a geographic or some other basis. Consistent with this decision-making process, our CEO considers consolidated net loss, which is our
single segment&#8217;s principal measure of segment profit and loss, when evaluating performance and allocating company-wide resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
expenses are amounts that are regularly provided to our CEO and included in consolidated net loss, our primary measure of our single
segment&#8217;s profit or loss. Our CEO regularly reviews reported consolidated revenues, significant expenses and consolidated net loss,
in addition to forecasted revenues, significant expenses and net loss amounts for future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001279" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zKx9LsphFx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of our consolidated net loss for the years ended December 31, 2024 and 2023 is as follows, including the significant expenses
provided to and regularly reviewed by our CEO:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B0_z7QwPwziIp66" style="display: none">Schedule
of Summary of Consolidated Net Loss</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zGDczUfPKtg" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zp3qrFRvlZzk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zWylEmRgvbF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zMpaKm9T8JXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzPoy_zyBHG2eEx5zf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001287" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,155</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pn3n3_maOEzPoy_zmCmaBoierR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,392</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEzPoy_z6BXTAH0TEac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001293" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001294" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,873</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_pn3n3_maILFCOzkrX_z5BrWNbJ2yTb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001296" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,004</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001297" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25,453</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_maILFCOzkrX_z30IvRkRIle8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001300" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">98</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzkrX_maNILz14R_zBwzAszUDlab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001303" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25,551</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_di_msNILz14R_zQ2xcxeqceca" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001305" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">782</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001306" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,996</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz14R_zb1OinZBvAt1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember" id="Fact001308" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,212</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember" id="Fact001309" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,555</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zHmoeihOuKli" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><p id="xdx_814_zx590ujr6s5i" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 213; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I. FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1. Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Da_001"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
$000s, except share, per share, and liquidation preference amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_111_pn3n3_zxY8qSDRLuLf" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20250331_z5rl4UrrzJ72" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20241231_zq1koWvgtOy5" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_z5zimR61FOfh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_zcDDrtYRQTg2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact001317" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,450</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact001318" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,137</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zNYsg8P4BhHd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact001320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001321" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">537</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrent_i02TI_za1fuIOeKe5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-03-31" id="Fact001323" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,714</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,674</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zyoORnN5qLSg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-03-31" id="Fact001326" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact001327" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zdBktNwRoZil" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Right-of-use lease asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-03-31" id="Fact001329" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DepositsAssetsNoncurrent_i01I_zGmVytDYTrRb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    deposits</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1332">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact001333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">412</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--Assets_i01TI_zUUoSu1iFE54" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31" id="Fact001335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,734</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact001336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,094</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zKR0Oe8eDoHc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY (DEFICIT)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAbstract_i01B_zs7q67KnIG79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_zm83OS2uuHK4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-03-31" id="Fact001344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">114</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact001345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,599</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_i02I_zr2uNwUxKVs" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    and other current liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact001347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">549</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,669</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_z7acWnXTjzP5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact001350" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">663</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001351" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,268</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zwpaqhzKDxne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Lease liability</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-03-31" id="Fact001353" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1354">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_i01TI_z1R0MDBWXzr" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-03-31" id="Fact001356" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">672</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact001357" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,268</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityAbstract_iB_zCyIEGWbbnmf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; equity (deficit):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zNwDejvW1D42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Preferred stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zPpTtXJ8Rx06"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001364" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">par value; <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zbdAIk2CxeJk"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares authorized at March 31, 2025 and December 31, 2024; <span id="xdx_908_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zu2JQanhegF"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact001366" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif">%
    Convertible Exchangeable preferred stock; <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zTmVv0tUNBPf"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,273</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at March 31, 2025 and December 31, 2024. Aggregate
    preference in liquidation of&#8201; $<span id="xdx_900_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20250331__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_zmGduRCHj7Yh"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2025-03-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact001368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,717,967</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">as of March 31, 2025 and $<span id="xdx_900_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20241231__us-gaap--StatementClassOfStockAxis__custom--SixPercentConvertibleExchangeablePreferredStockMember_z3UvoRSNTHV7"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember" id="Fact001369" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,697,676</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">as of December&#160;31,&#160;2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1362">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1363">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zksOiVqjQ6Li" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A convertible preferred
    stock, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVwBaIHKWWO3"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">par value; <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDReBMkvZHei"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001374" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at March&#160;31,&#160;2025 and December&#160;31,&#160;2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1371">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1372">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zI4NFr4vNbLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B convertible preferred
    stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBf2pEkFoqyc"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001378" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zA0qwpYI3sm9"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at March&#160;31,&#160;2025 and December 31,
    2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1376">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1377">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqAMIYHOVg8h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C convertible preferred
    stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zLDt1jeggFKb"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z4DNVjdCo0Rg"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001384" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at March&#160;31,&#160;2025 and December 31,
    2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1381">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1382">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zAS4ucqWN714" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series D convertible preferred
    stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zUPGvdZNlVSe"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact001388" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">par value; <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zl8eqsuccgzj"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">354,738</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at March&#160;31,&#160;2025 and <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zXy70HcrBful"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact001390" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1387">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zVc3WgpMxDob" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series E convertible preferred
    stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zh9FTr0pYMo1"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact001394" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">par value; <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zd6q4JooR1l4"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at March&#160;31,&#160;2025 and <span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zPd5wRMt275k"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact001396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact001392" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1393">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zXtY5vIXoHA2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred stock, value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact001398" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1399">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--CommonStockValue_i01I_zK8XWwFZuapl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zXvYftmTzHv7"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001403" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">par value; <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250331_zA8E7FIlxvHj"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact001404" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares authorized at March 31, 2025 and <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zfpYV5ZDUfs7"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares authorized at December&#160;31,&#160;2024; <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250331_zmVHTSn3HBya"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">863,902</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at March&#160;31,&#160;2025 and <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zfHJ64XTohm"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,913</ix:nonFraction></span></span>
    <span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at December&#160;31,&#160;2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-03-31" id="Fact001401" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact001402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AdditionalPaidInCapital_i01I_z0AKM2aJmr0g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-03-31" id="Fact001409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">443,521</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact001410" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">438,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_zWZpR8FVUpE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated other comprehensive loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1412">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact001413" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">891</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_z6kZtf8ld5d5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated deficit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" id="Fact001415" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">440,461</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact001416" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">439,494</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i01TI_zxXVFYSaTNYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    stockholders&#8217; equity (deficit)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact001418" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,062</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact001419" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,174</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zwgkbjWlzEW1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&#8217; equity (deficit)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-03-31" id="Fact001421" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,734</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact001422" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,094</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 214; Options: NewSection; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Da_002"></span>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
$000s, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_pn3n3_znaGbZulVbm4" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20250101__20250331_zSk2DbDbCqjb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20240331_zl62XFeKaWx2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March&#160;31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--RevenuesAbstract_iB_zmhnOY57nHG2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Revenues:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--ClinicalTrialSupplyMember_zW6vk0vL3Jh2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Clinical
    trial supply</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1427">&#8212;</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-03-31_custom_ClinicalTrialSupplyMember" id="Fact001428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_i01_zaOuAiHgdFqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1430">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-03-31" id="Fact001431" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_zVgYdOdQxCfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_zJnmzsLKBdU2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-03-31" id="Fact001436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">822</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31" id="Fact001437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,802</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_zQ7y0AcddB1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31" id="Fact001439" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,214</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-03-31" id="Fact001440" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,582</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_i01T_z6oRLCMPsCU1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-03-31" id="Fact001442" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,036</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-03-31" id="Fact001443" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,384</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_zflYOUPoCw8l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact001445" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,036</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact001446" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,355</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zxy7OZyQPbAg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income (expense):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_zTWxvw03S52f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign exchange gains
    (losses)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-01-01to2025-03-31" id="Fact001451" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-012024-03-31" id="Fact001452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--InterestIncomeExpenseNet_i01_zrWl6tCJ9uX2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2025-01-01to2025-03-31" id="Fact001454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-012024-03-31" id="Fact001455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeconsolidationGainOrLossAmount_i01_zyipmslRydei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on deconsolidation
    of subsidiary</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2025-01-01to2025-03-31" id="Fact001457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,947</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1458">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OtherNonoperatingIncomeExpense_i01_zws5rsN8hAc4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income, net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-03-31" id="Fact001460" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-03-31" id="Fact001461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_i01T_zSM8T8P9Ju9i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    other income (expense), net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-03-31" id="Fact001463" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,955</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-03-31" id="Fact001464" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zAJVadvqwm1i" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-03-31" id="Fact001466" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-03-31" id="Fact001467" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,300</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iN_di_zDiA6FefeOE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Income tax benefit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1469">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-03-31" id="Fact001470" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,354</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_iT_zwffxq9LYfgi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31" id="Fact001472" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-03-31" id="Fact001473" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,946</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_zDAcy2PCIbAi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Dividend on convertible
    exchangeable preferred shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1475">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1476">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_ztofkPZ7NIai" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss applicable to common shareholders</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-01to2025-03-31" id="Fact001478" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-03-31" id="Fact001479" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,946</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareAbstract_iB_zC65TpM2YSS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted earnings
    per common share:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss per share &#8211; basic and diluted
    (common shareholders)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_90F_eus-gaap--EarningsPerShareDiluted_i01_pid_c20250101__20250331_zR76Nzu5QZn" style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-03-31" id="Fact001483" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.22</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_902_eus-gaap--EarningsPerShareDiluted_i01_pid_c20240101__20240331_zVvkhillZPn5" style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-03-31" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">545.33</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 215; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Da_003"></span>CONSOLIDATED
STATEMENTS OF COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
$000s)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_pn3n3_zTYHBpV6F4Tg" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20250101__20250331_zUCXdwzt5NH8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20240331_z6ApaGeB7rBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_znv7tv78uilc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact001486" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact001487" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,946</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zBts711Watx9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Translation adjustment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2025-01-01to2025-03-31" id="Fact001489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,272</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31" id="Fact001490" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,140</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_zO2rW8EjWYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Unrealized foreign exchange
    loss on intercompany loans</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2025-01-01to2025-03-31" id="Fact001492" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,380</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-03-31" id="Fact001493" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,130</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ComprehensiveIncomeNetOfTax_iT_zpgJ2Xes8hSl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-01to2025-03-31" id="Fact001495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">811</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"/><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-03-31" id="Fact001496" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,936</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 216; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Da_004"></span>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
$000s, except share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_pn3n3_z3STqAirfpkf" summary="xdx: Statement - Consolidated Statements of Stockholders' Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zJ9q0FMITP9j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_ztzTzz2x0i9l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z6de8rYxcwA9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_z9XiysWot2mi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Loss</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zTlvTeeLVtCe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_z3qMhyIQslz1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Deficit)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    Stockholders&#8217;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred&#160;Stock</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common&#160;Stock</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid-in</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Comprehensive</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Loss</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Deficit)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43D_c20240101__20240331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_z2T1hhSlLxr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balances at December 31, 2023</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2WN6Wj0YDw1" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">454,537</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1498">&#8212;</span></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8jnYZjYLGUj" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001507" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,412</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001499" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001500" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429,797</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001501" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">908</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact001502" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">428,282</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact001503" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">607</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zq8otVPnDp7k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issue costs on issuance
    of common stock upon conversion of pre-funded warrants in underwritten offering</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1509">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZSb3OnXYhq7" title="Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">915</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1510">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001511" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">80</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1512">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1513">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2024-01-012024-03-31" id="Fact001514" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">80</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z3zu0tT174od" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B Preferred stock
    conversions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z3IXtgfoelZb" title="Series B Preferred stock conversions, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="Fact001525" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">119,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1518">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ0BMYoGX3i7" title="Series B Preferred stock conversions, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact001527" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1519">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1520">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1521">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1522">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1523">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zkC89scs9Fc5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1529">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1530">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1532">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1533">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31" id="Fact001534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_zbuw3utd1uG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized foreign exchange
    on intercompany loans</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1536">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1537">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1538">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001539" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,130</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1540">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2024-01-012024-03-31" id="Fact001541" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,130</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zNrxWscra9ff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Translation adjustment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1543">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1544">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1545">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,140</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1547">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31" id="Fact001548" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,140</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_ziRYwtJ5fqCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the period</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1550">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1551">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1552">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1553">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact001554" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,946</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact001555" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,946</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_431_c20240101__20240331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zaXiWTYCsNH3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balances at March 31, 2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgF6ojkUQge7" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember" id="Fact001564" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,537</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1557">&#8212;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAHUxakViC96" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact001566" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,493</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact001558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001559" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429,920</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001560" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">898</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact001561" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">431,228</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31" id="Fact001562" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,206</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_431_c20250101__20250331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zzhXeupPiz86" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balances at December 31, 2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVfOgJ00VEe1" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact001575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,537</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1568">&#8212;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQymNEyMHKM8" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001577" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,913</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001569" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001570" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">438,211</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001571" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">891</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact001572" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">439,494</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact001573" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,174</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_439_c20250101__20250331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zYEGxC2ULGR1" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balances</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6tk5XSrryD8" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact001586" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,537</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1579">&#8212;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKBW8x3IsPog" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001588" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,913</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001580" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">438,211</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001582" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">891</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact001583" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">439,494</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact001584" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,174</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses_zYcFcZA2PCs6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issue costs on issuance
    of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1590">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1591">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001592" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">248</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1593">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1594">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" contextRef="From2025-01-01to2025-03-31" id="Fact001595" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">248</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueOther_zo0c2qZKB6H1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issue of Series C preferred
    stock in Securities Purchase Agreement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwgG0HNu9ZZj" title="Issue of Series C preferred stock in Securities Purchase Agreement, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001604" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001597" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1598">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">999</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1600">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1601">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-01to2025-03-31" id="Fact001602" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueSeriesCPreferredStockConversions_zs71Ru26E5I1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C Preferred stock
    conversions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhaZYEAbBQje" title="Series C Preferred stock conversions, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001613" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001606" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrmS26R8M8Y3" title="Series C Preferred stock conversions, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,042</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001607" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001608" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1609">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1610">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1611">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_zrHGdcSRkqOj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issue of Series D preferred
    stock in Securities Purchase Agreement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zULPE2DJhmAk" title="Issue of Series D preferred stock in Securities Purchase Agreement, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001624" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001617" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1618">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001619" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,892</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1620">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1621">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" contextRef="From2025-01-01to2025-03-31" id="Fact001622" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,894</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueSeriesDPreferredStockConversions_zGjywUBYlcQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series D Preferred stock
    conversions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuMH00CLapPi" title="Series D Preferred stock conversions, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001633" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,745,262</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001626" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXhT6KbkR2L7" title="Series D Preferred stock conversions, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">799,912</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001628" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1629">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1630">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1631">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_zSynK4Waqpyi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issue of Series D preferred
    stock in Securities Purchase Agreement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwmO1rwzGrEg" title="Issue of Series D preferred stock in Securities Purchase Agreement, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001644" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="Fact001637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1638">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">999</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1640">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1641">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" contextRef="From2025-01-01to2025-03-31" id="Fact001642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueIssueOnWarrantExercise_zTK0CIjRdlcl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Warrant Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1646">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesIssueOnWarrantExercise_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zolt9E7uBuMf" title="Warrant Exercise, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodSharesIssueOnWarrantExercise" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,277</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1647">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1648">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1649">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1650">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1651">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zhRjyesqYr0g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issue of common stock on
    Securities Purchase Agreement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1655">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSj3MsJq40M9" title="Issue of common stock on Securities Purchase Agreement, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001662" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">758</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1656">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1657">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1658">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1659">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1660">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zYMPUZkSwIB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1664">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1665">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001666" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1667">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1668">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-03-31" id="Fact001669" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary_zBzfJlVSLBQc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deconsolidation of Subsidiary</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1671">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1672">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1673">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001674" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">886</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact001675" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">886</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1676">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_zLEtGhJ3QfLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized foreign exchange
    on intercompany loans</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1678">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1679">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1680">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001681" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,380</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1682">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" contextRef="From2025-01-01to2025-03-31" id="Fact001683" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,380</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueTranslationAdjustment_zmtNtQA3Mrzi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Translation adjustment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1685">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1686">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1687">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueTranslationAdjustment" contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001688" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,385</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1689">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueTranslationAdjustment" contextRef="From2025-01-01to2025-03-31" id="Fact001690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,385</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zxzYdAS5gKA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the period</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1692">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1693">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1694">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1695">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact001696" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact001697" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_436_c20250101__20250331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z3BaI3iDdcBc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balances at March 31,&#160;2025</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zocV5MXnzT6d" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember" id="Fact001706" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,490,275</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember" id="Fact001699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2ZHxl8aXpf4" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact001708" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">863,902</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact001700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001701" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">443,521</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1702">&#8212;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact001703" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">440,461</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31" id="Fact001704" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,062</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_438_c20250101__20250331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zD7PLUDRZcI3" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balances</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMUqLKFSZwGl" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember" id="Fact001717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,490,275</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember" id="Fact001710" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj2wIraeluM1" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact001719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">863,902</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact001711" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">443,521</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1713">&#8212;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact001714" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">440,461</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31" id="Fact001715" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,062</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 217; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Da_005"></span>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
$000s)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_112_pn3n3_zc8bEGGMLWF3" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20250101__20250331_ztbbFILjoZS6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20240331_z71D9G4DjjI9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March&#160;31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zphVCXRNOv8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_zjQCBa84NOR" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact001724" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact001725" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,946</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zWOojKYdwlSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash
    used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--Depreciation_i02_zY1ikCXlxUM6" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1730">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-03-31" id="Fact001731" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_zMrlN20uTLm2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-03-31" id="Fact001733" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact001734" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_zss3yrzVeU6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-03-31" id="Fact001736" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-03-31" id="Fact001737" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zIYWJQ1TKcR2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_zdgIbTVtpzK6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and other assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-01-01to2025-03-31" id="Fact001742" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">658</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-03-31" id="Fact001743" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,020</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_i03_zMQZCYHFBW5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable, accrued
    and other current liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="From2025-01-01to2025-03-31" id="Fact001745" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,499</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="From2024-01-012024-03-31" id="Fact001746" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">254</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zdjctW86mm4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-03-31" id="Fact001748" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,247</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-03-31" id="Fact001749" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">483</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zsxZlhn9Ff2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_zULbCWwXCd8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Purchase of property,
    plant and equipment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1755">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_zd2SLwj4pF8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash used in investing
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1757">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1758">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zoAG5I33FoS1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_znmRIa5QJ0l1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Costs from issuing common stock and pre-funded
    warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-01to2025-03-31" id="Fact001763" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">248</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-012024-03-31" id="Fact001764" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_zh73SQjfruL1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds, net of issuance costs, from issuing
    common stock and pre-funded warrants, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-01to2025-03-31" id="Fact001766" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,894</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1767">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_zV6READcpB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by (used)
    in financing activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-03-31" id="Fact001769" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,646</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-03-31" id="Fact001770" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">79</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_ztcQw9PwqC1g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Effect of exchange rate
    changes on cash and cash equivalents</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2025-01-01to2025-03-31" id="Fact001772" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">86</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-01-012024-03-31" id="Fact001773" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zpUWmDqTB1V6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease) in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-03-31" id="Fact001775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">313</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-03-31" id="Fact001776" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">580</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zVndVRUEhEY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents,
    beginning of period</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact001778" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,137</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact001779" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,378</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zkSSJx4O4Vbc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents,
    end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-03-31" id="Fact001781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,450</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-03-31" id="Fact001782" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,798</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental cash flow information:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash received during the period for:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromInterestReceived_i01_zyFZkXUoyFol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromInterestReceived" contextRef="From2025-01-01to2025-03-31" id="Fact001787" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromInterestReceived" contextRef="From2024-01-012024-03-31" id="Fact001788" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIncomeTaxRefunds_i01_zqmlxAbR1dba" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research &amp; development
    tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIncomeTaxRefunds" contextRef="From2024-01-012024-03-31" id="Fact001791" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,925</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNetAbstract_iB_zmLEroJtw6x1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid during the period for:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InterestPaidNet_i01_zFqJo2adBP9e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-03-31" id="Fact001796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1797">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zo8u0M3dXDh2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1799">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" id="Fact001800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z8uxCX8rkXLf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Noncash financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--AccrualOfPreferredStockDividends_i01_zt1x2QtxQF52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Accrual of preferred stock dividends</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1805">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 218; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
PHARMACEUTICALS, INC.</b></span></p>

<p id="xdx_041_c20250101__20250331_zIGdI9On9cq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Da_006"></span>NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001808" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z4QVIQpJaImf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_825_z7y7QvXuEHO7">Company Overview</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company developing
innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis control biology. Cyclacel is a pioneer
company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology
into medicines that can overcome resistance and ultimately increase a patient&#8217;s overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2025, the Company&#8217;s wholly owned United Kingdom subsidiary Cyclacel Limited entered into a creditors voluntary liquidation.
Upon the commencement of the liquidation of the Cyclacel Limited, the Company lost operational and strategic control over the Cyclacel
Limited and the financial results of Cyclacel Limited have been deconsolidated from Company as of January 24, 2025. The deconsolidation
of the subsidiary resulted in a gain on deconsolidation of approximately $<span id="xdx_900_eus-gaap--DeconsolidationGainOrLossAmount_pn5n6_c20250124__20250124_zjpz5YHCYdUc"><ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2025-01-242025-01-24" id="Fact001809" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million shown as other income within the income statement for
the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 31, 2025, substantially all efforts of the Company to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001811" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zJwWmGnpsfP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_828_zTZG0jPxPjta">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001813" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z5SC1TKoNBg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86B_zkCZdtJqw1A2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated balance sheet as of March 31, 2025, the consolidated statements of operations, comprehensive loss, and stockholders&#8217;
equity (deficit) for the three months ended March 31, 2025 and 2024 and the consolidated statements of cash flows for the three months
ended March 31, 2025 and 2024, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance
sheet as of December 31, 2024 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K
for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 2, 2025.
The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States
(&#8220;GAAP&#8221;) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they
do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete
set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary
to present fairly the consolidated balance sheet as of March 31, 2025, and the results of operations, comprehensive loss, and changes
in stockholders&#8217; equity (deficit) for the three months ended March 31, 2025, and cash flows for the three months ended March 31,
2025, have been made. The interim results for three months ended March 31, 2025 are not necessarily indicative of the results to be expected
for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2024 that are included
in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on April 2, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001815" name="CYCC:GoingConcernPolicyTextBlock"><p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_z3jJ9Fw35e6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_860_zXCLHemlLPI" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Accounting Standard Codification (ASC) 205-40, <i>Presentation of Financial Statements-Going Concern</i>, management
is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial
doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have
not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,
management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company&#8217;s
ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern for one year after the date that these financial statements are issued. In
performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40,
the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered
probable at this time because these plans are not entirely within the Company&#8217;s control nor have they been approved by the Board
of Directors as of the date of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 219; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s current operating plan, it is anticipated that cash and cash equivalents of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zymioRMWspyf"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact001816" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of March 31, 2025, will allow it to meet its liquidity
requirements into the second quarter of 2025. The Company&#8217;s history of losses, negative cash flows from operations, liquidity resources
currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources
are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company&#8217;s
ability to <span id="xdx_90F_eus-gaap--SubstantialDoubtAboutGoingConcernWithinOneYear_pn5n6_dbTp_c20250101__20250331_zOlc6k16dxaj"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleantrue" id="Fact001817" name="us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear">continue</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a going concern for a period of at least twelve months from
the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist
of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will
be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations,
delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, Nasdaq notified the Company that it has regained compliance with the equity requirement in Listing Rule 5550(b)(1)
(the &#8220;Equity Rule&#8221;), as required by the Nasdaq Hearing Panel&#8217;s decision dated October 22, 2024. Following the Company&#8217;s
regaining compliance with the Equity Rule, the Company will be subject to a Mandatory Panel Monitor for a period of one year from February
25, 2025 pursuant to Listing Rule 5815(d)(4)(B).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets
and the satisfaction of liabilities in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001819" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9NhsWiwFzV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86F_zNiNRgXykyMj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Newly
Adopted Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2025, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740): Improvements
to Income Tax Disclosures&#8221;. This standard requires all entities to include specified captions when reconciling the statutory income
tax rate to the effective tax rate, on both a percentage and absolute dollar basis, in the annual financial statements. ASU 2023-09 also
requires entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and
foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts
from, exceed a defined threshold. The company does not anticipate the adoption of ASU 2023-09 will require significant adjustments to
the presentation of that information in the Company&#8217;s annual financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001821" name="CYCC:RecentlyIssuedAccountingPronouncementsPolicyTextBlock"><p id="xdx_848_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zxj2fc1u1Yq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_867_z8XQNyu0LXFb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2024-03, &#8220;<i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001823" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKMAUBis1ymd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86B_zSjmyuNmHdNa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts
payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 220; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001825" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zbBtUWjxgeO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86A_zKuGX21dU0w7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
Income (Loss)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). <span id="xdx_90E_eus-gaap--OtherComprehensiveIncomeLossTax_do_c20250101__20250331_zKmQocSIJAh8"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="From2025-01-01to2025-03-31" id="Fact001826" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">taxes were recorded on items of other comprehensive income
(loss). There were <span id="xdx_90F_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20250101__20250331_zmEZIzVWNKMf"><ix:nonFraction name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="From2025-01-01to2025-03-31" id="Fact001827" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reclassifications out of other comprehensive income (loss)
during the three months ended March 31, 2024. However, upon deconsolidation of the Company&#8217;s formerly wholly-owned subsidiary on
January 24, 2025, $<span id="xdx_901_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_pn5n6_do_c20250124_zKO3BurNZ4G5"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-01-24" id="Fact001828" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of accumulated comprehensive income (loss) was reclassified
into earnings as part of the gain on deconsolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001830" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_842_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z9r0BdZUBTpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86D_ztLasLFOULI3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency and Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied
to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
January 24, 2025, the assets and liabilities of the Company&#8217;s international subsidiary were translated from its functional currency
into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used
to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation
adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign
exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable
future and that are of a long-term-investment nature, were recorded in other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001832" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zvYatxd84zDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_860_zSNBLpn78rl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease contracts in accordance with ASC 842. As of March 31, 2025, the Company&#8217;s outstanding leases are classified
as operating leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#8217;s obligation to make lease payments under the lease. As the Company&#8217;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing
versus bullet), and the Company&#8217;s credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect
the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In
assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease payments due in any optional period;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
    for failure to exercise (or not exercise) the option;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    factors, such as the availability of similar assets and current rental rates for such assets;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature of the underlying leased asset and its importance to the Company&#8217;s operations; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    remaining useful lives of any related leasehold improvements.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 221; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized
in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded
as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and
the right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001834" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z0Y03lbdDMUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_864_znXMbcaOvK78" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company enters into contracts with customers, the Company recognizes revenue using the five step-model provided in ASC 606, <i>Revenue
from Contracts with Customers </i>(&#8220;ASC 606&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract with a customer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when, or as, the Company satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines
the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then
applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the
Company considers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    achievement of a development milestone is highly susceptible to factors outside the entity&#8217;s influence, such as milestones
    involving the judgment or actions of third parties, including regulatory bodies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    the Company can reasonably predict that a milestone will be achieved based on previous experience; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    complexity and inherent uncertainty underlying the achievement of the milestone.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The
best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions,
entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment
due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part
satisfied) performance obligations. Once the right to receive consideration is unconditional, that amount is presented as a receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
revenue received from organizations that are not the Company&#8217;s customers, such as charitable foundations or government agencies,
is presented as a reduction against the related research and development expenses.</span></p>

</ix:nonNumeric><p id="xdx_851_zISaSAnOQu58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 222; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001836" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_804_eus-gaap--RevenueFromContractWithCustomerTextBlock_zpHZwylWVeue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_820_zHz5eSwZwLtd">Revenue</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_dxL_c20250101__20250331_zoY26LBzUa2l" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1837">0</span></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue for the three months ended March 31, 2025 and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20240331_z4IUS3sB0iXe"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-03-31" id="Fact001838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the three months ended March 31, 2024. This revenue is
related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001840" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zpofJ7nei8Zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_824_zRM4uZwVOCvk">Net Loss per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (&#8220;ASC 260&#8221;). Basic
and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number
of shares of common stock outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001842" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zbzAXbJny5Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months
ended March 31, 2025 and 2024, as the result would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_z43J4DXcFng7" style="display: none">Schedule
of Earnings Per Share, Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250331_zSVobvtRXP52" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20240331_zZJFVDt0iGye" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWpMgCBotake" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember54208953" id="Fact001844" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,259</ix:nonFraction></p></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember54208968" id="Fact001845" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">619</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuyEMv5nfs8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember54208968" id="Fact001847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember54208984" id="Fact001848" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">187</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SixPercentConvertibleExchangeablePreferredMember_zYxhTPDB1Uue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">6% convertible exchangeable preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_custom_SixPercentConvertibleExchangeablePreferredMember" id="Fact001850" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_custom_SixPercentConvertibleExchangeablePreferredMember" id="Fact001851" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zmOM5NfdY59d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;A preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember54209000" id="Fact001853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001854" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesDPreferredStockMember_zOhr2In2vgyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;D preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember54209015" id="Fact001856" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,588</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1857">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zRfDUYCbGV05" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;E preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember54209015" id="Fact001859" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">458,333</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zXNf4hOm0ZY4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_custom_CommonStockWarrantsMember54209031" id="Fact001862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">101,905</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember" id="Fact001863" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,648</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zs36fcpXjAL4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total shares excluded
    from calculation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-03-31" id="Fact001865" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">748,224</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31" id="Fact001866" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,456</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_z4RvWrHKJQIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001868" name="CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock"><p id="xdx_80A_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_za2ce6ncCEFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_820_zeGrSPn69j39">Prepaid Expenses and Other Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001870" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_898_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zaAfOm0GuBpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zrrHepcxb5El" style="display: none">Schedule
of Prepaid Expenses and Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250331_zfFI1ZvlaPic" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20241231_zETxqZSOI6q3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPECzxNf_zZhhBXB2luka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Prepayments</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent" contextRef="AsOf2025-03-31" id="Fact001872" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent" contextRef="AsOf2024-12-31" id="Fact001873" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">237</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPECzxNf_zhNtmZdVkIt9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact001875" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001876" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseCurrent_iTI_pn3n3_mtPECzxNf_zon8974OLUTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-03-31" id="Fact001878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact001879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">537</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z9IxNttGV2P8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001881" name="CYCC:NonCurrentAssetsTextBlock"><p id="xdx_80A_ecustom--NonCurrentAssetsTextBlock_z5UduPuSn50f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_828_zNbPBkrz68y9">Non-Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_907_eus-gaap--DepositsAssetsNoncurrent_iI_dxL_c20250331_zzx61uyaNAXh" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1882">0</span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-current
assets as of March 31, 2025 and $<span id="xdx_908_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20241231_zZBshIPL6pF6"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact001883" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of December 31, 2024. The balance at December 31,
2024 primarily comprised of deposits held by a contract research organization in relation to the Company&#8217;s clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001885" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80E_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zvOj8T2jVOqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82F_znSHTrXHVLJl">Accrued and Other Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001887" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_ztbudYMeSXQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
and other current liabilities consisted of the following (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zi8hNVrt2Rpc" style="display: none">Schedule
of Accrued and Other Current Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250331_zZRyuple1Nz1" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_z6ahcDahe2xj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCostCurrent_iI_pn3n3_zLff99MwH0ji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1889">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:AccruedResearchAndDevelopmentCostCurrent" contextRef="AsOf2024-12-31" id="Fact001890" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,300</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_zBMIXPiwxp6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued legal and professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2025-03-31" id="Fact001892" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">532</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-12-31" id="Fact001893" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_zP40xWtPhJ6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other current liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact001895" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">284</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_zl7SdYb7Ozl6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued and other current
    liabilities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-03-31" id="Fact001898" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">549</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,671</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zqtmuHxKFHN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001901" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zV3IkZxjpg3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_82E_zNdrso9qbDLh">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has an operating lease liability relating to its facilities in Kuala Lumpur, Malaysia. The Company terminated its lease
agreement for its previous headquarters in Berkely Heights, New Jersey, effective January 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 223; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2025 and 2024, the Company recognized operating lease expenses of $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20250101__20250331_zfafTDQdbiAf"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-01to2025-03-31" id="Fact001902" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,176</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20240331_z2xbsuVlcEK5"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-03-31" id="Fact001903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,039</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively, including $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20250101__20250331__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_znOi1ut4nW03"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-012025-03-31_custom_DundeeScotlandMember" id="Fact001904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240101__20240331__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zMBdCNNRjAoe"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-03-31_custom_DundeeScotlandMember" id="Fact001905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,011</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively relating to a short term lease for offices in
Dundee, Scotland. Cash payments made during the three months ended March 31, 2025 and 2024 totaled $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20250101__20250331_zi1fw9t1Hfh1"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2025-01-01to2025-03-31" id="Fact001906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90E_eus-gaap--OperatingLeasePayments_c20240101__20240331_zXpJey0GUjUg"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-03-31" id="Fact001907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,037</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, and were presented within cash outflows from operating activities. The remaining lease term as of March 31, 2025 is approximately
<span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331__srt--StatementGeographicalAxis__custom--KualaLumpurFacilityMember_zZcGgK6QrlAe"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_KualaLumpurFacilityMember" format="ixt-sec:duryear" id="Fact001908" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.9</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years for the Kuala Lumpur facility. The discount rate used
by the Company in determining the lease liability was <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20250331_zJl1vjsFJsVh"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2025-03-31" id="Fact001909" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001911" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z7uw9TXndB96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining
lease payments for both facilities are as follows (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zVNt5lnBaftk" style="display: none">Schedule
of Remaining Lease Payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20250331_zn4xLC10bj1e" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzo6M_zxqWjMRO59ug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2025-03-31" id="Fact001913" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_pn3n3_maLOLLPzo6M_z9ML6eh0b3T1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" contextRef="AsOf2025-03-31" id="Fact001915" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_pn3n3_maLOLLPzo6M_z4w1j7Zt1rL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" contextRef="AsOf2025-03-31" id="Fact001917" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maLOLLPzo6M_zsCZr4fNrUng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1919">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzo6M_zDO9QjtMUjIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total future minimum
    lease obligation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-03-31" id="Fact001921" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zRRwrwyyhI1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001923" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z0M8qK40nSn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_826_zmTnXRsUqxkd">Stock Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the
Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based
awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods
when they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001925" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYtfZyMeRNhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended
March 31, 2025 and 2024 as shown in the following table (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zKQAAO8uuGuh" style="display: none">Schedule
of Stock Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250331_zpby0g2Vqtmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20240331_zxKy2IqfCBvg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March&#160;31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYy8HPBaUKN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001927" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,592</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001928" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zInBf5ZVuUYd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001930" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001931" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zu8nndUTR1i1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-03-31" id="Fact001933" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,666</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31" id="Fact001934" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zfbzK3CbrNwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2018
Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2018, the Company&#8217;s stockholders approved the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), under which Cyclacel
may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan allows for various types of award
grants, including stock options and restricted stock units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2025, the Company&#8217;s stockholders approved an amendment to the 2018 Plan to reserve an additional <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zOP6vKFv9OK1"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-02-06_custom_EquityIncentivePlan2018Member" id="Fact001935" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock for issuance thereunder, which number
would not be adjusted as a result of the Reverse Stock Split. As of March 31, 2025, the Company has reserved approximately <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zWr9O94r64a3"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-03-31_custom_EquityIncentivePlan2018Member" id="Fact001936" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">468,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock under the 2018 Plan
for future issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option awards granted under the Company&#8217;s equity incentive plans have a maximum life of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member__srt--RangeAxis__srt--MaximumMember_z1HQAHZ8ao32"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_EquityIncentivePlan2018Member_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001937" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and generally <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20250101__20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zD8btxalzYGl"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_EquityIncentivePlan2018Member" id="Fact001938" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">vest
over a one to four-year period from the date of grant.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2020
Inducement Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), became effective. Under the Inducement Plan,
Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder
approval). The Inducement Plan allows for the issuance of up to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20201031__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zenVrPqMNLYh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-10-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember" id="Fact001939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock (or the equivalent
of such number). As of March 31, 2025, there were no shares issued under the Inducement Plan, leaving a remaining reserve of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zECb1czm6h26"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember" id="Fact001940" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 224; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Awards Granted Outside of the 2018 Plan and Inducement Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
February 2025, the Company issued stock option awards to employees and consultants outside of the 2018 Plan and the Inducement Plan.
The shares underlying these options are not registered for resale. All of the options granted outside of the 2018 Plan and Inducement
Plan vest immediately upon grant and can be exercised beginning three months from the recipient&#8217;s Termination Date through the
expiry of the option awards, which is ten years from the grant date. The Termination Date is defined as the date on which an award recipient
ceases to be an employee, director or consultant of the Company or of an Affiliate for any reason other than the death or disability,
or termination of the recipient for cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Grants and Exercises</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpvnHevrbHue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001941" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,818</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted during the three months ended March 31, 2025.
Of these awards, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmNdTSemosNj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001942" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,068</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were issued under the 2018 Plan and the rest were issued outside
of the 2018 Plan and the Inducement Plan. Options granted during the three months ended March 31, 2025 had a grant date fair value ranging
between $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxMFXKlbm1q1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" id="Fact001943" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__srt--RangeAxis__srt--MaximumMember_zB252Sjpw7Qd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_srt_MaximumMember" id="Fact001944" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">72.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSywSSjd0i1b"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted under the 2018 Plan during the three months
ended March 31, 2024. These options had a grant date fair value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuwfH12Fjlq4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001946" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">424.80</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001948" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zk3oxX36nWv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span id="xdx_8BE_zYhg4KfeWeV2" style="display: none">Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three months
    ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three months
    ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqFUkCdCtZWf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001949" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTjpv8bpNTi5"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001950" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwUUjiySqPj" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001951" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zKsRwGExvwIf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" id="Fact001952" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.060</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            &#8201;&#8211;&#8201;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zse7pFP0qWPl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact001953" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.250</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztCBFHieoNN" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001954" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.995</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zJNe79AcKKUc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" id="Fact001955" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&#8201;&#8211;&#8201;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zepvyxBHtzrc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" id="Fact001956" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">107</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlentDg6UWHh" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001957" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield over expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrx1L8kJHrYh" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001958" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaXlxtGKKdpd" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001959" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Resulting weighted average grant date fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj7mjJsL01uf" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001960" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">69.60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNK8Lp6rs0V2" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001961" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">424.80</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zOU16x43Y1g3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_do_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5Hk5HSFpwW4"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001962" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock options exercised during each of the three months ended
March 31, 2025 and 2024, respectively. The Company does not expect to be able to benefit from the deduction for stock option exercises
that may occur because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Outstanding
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact001964" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zQQmAYU3aYkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the share option activity and related information is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8BD_zoZ4fKD31OYc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Share Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price
    Per Share</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term&#160;(Years)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value&#160;($000)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstwfN5m9aj6" title="Number of Options Outstanding, Balance" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001966" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">494</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zytlelT6Ae67" title="Weighted Average Exercise Price, Balance" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001968" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10,658.40</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9kHDuWSUJ9" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001969" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.20</ix:nonNumeric></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaEZNWTN3Ty1" title="Aggregrate Intrinsic Value, Balance" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1971">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z29rIEzredui" title="Number of Options Outstanding, Granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001973" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,818</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztxQ9q4xeaZ3" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001975" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">70.79</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zktzPgOv4HSh" title="Number of Options Outstanding, Exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1977">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQqUjyUxUUkh" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1979">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLjl4YGhFYG1" title="Number of Options Outstanding, Cancelled/forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001981" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZfT3AMOY5Ld" title="Weighted Average Exercise Price, Cancelled/forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001983" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,238.25</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNELwZ9Cktb" title="Number of Options Outstanding, Balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001985" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,259</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMdsAc4XTAV9" title="Weighted Average Exercise Price, Balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001987" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">276.67</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv863YW7rCB1" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001988" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.76</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zorV9XJzvHS1" title="Aggregrate Intrinsic Value, Balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1990">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYWebtg3xGp3" title="Number of Options Outstanding, Unvested" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001992" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1PDNg7ypaj1" title="Weighted Average Exercise Price, Unvested" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001994" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,094.84</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable
    at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpqjbPFISF37" title="Number of Options Outstanding, Vested and exercisable" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001996" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,238</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsebhVlWTaRe" title="Weighted Average Exercise Price, Vested and exercisable" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001998" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">275.17</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zProbUO1VJKc" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001999" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">9.77</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlEDaTXVzfdl" title="Aggregrate Intrinsic Value, Vested and Exerciseable" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl2001">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zvFMNAb2hnYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 225; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxZJr4GZCzJb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002002" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units were issued during the three months
ended March 31, 2025. The Company issued <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze5Ema5bMKsf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002003" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units during the three months ended March
31, 2024. These restricted stock units vested monthly over a six-month <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtM_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zT5g5dA4dah1" style="display: none"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:durmonth" id="Fact002004" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">6</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">service period. These restricted stock units were valued at
$<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_iI_c20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9WPBZCBmJH7"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002005" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">547.20</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze3MYAgYX9Gb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71.36</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units were issued in January 2023. These units
vest on the third anniversary of their date of grant, or earlier if certain defined clinical trial related performance targets are met.
A three-year <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLLZ7NDCWYqd" style="display: none"><ix:nonNumeric contextRef="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact002007" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">3</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vesting assumption was applied to these restricted stock units
as satisfaction of the performance conditions is not probable at this time. Each restricted stock unit was valued at $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbOWdnDFImp7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-01-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002008" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,240.00</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date. As of March 31, 2025, all but <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM4bwDq1qFh3"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002009" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the original awards granted have been forfeited due to the
recipient&#8217;s termination of service with the Company. In the three months ended March 31, 2025, the Company reduced stock compensation
cost, a component of selling general, and administrative expense, by approximately $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAWh4Ot3BwK4"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a result of forfeitures of these awards during that period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact002012" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zIlyBKat9Eci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized
information for restricted stock units as of March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zlz1nvtipnN9" style="display: none">Schedule
of Restricted Stock Units Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Restricted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Grant Date</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Units</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value
    per share</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units outstanding
    at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zccoDBjfXf64" title="Restricted Stock Units, Balance" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAVbyDwPg9b" title="Weighted Average Grant Date Value per share, Balance" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002016" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,882.40</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJBQIK9FaNrb" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact002017" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">8.30</ix:nonNumeric></span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zitdVZA2rNjd" title="Restricted Stock Units, Granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002019" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zylkNtvV5h7e" title="Weighted Average Grant Date Value per share, Granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002021" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbmenNYJpFbl" title="Restricted Stock Units, Cancelled/forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002023" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQf3PvJrKsG2" title="Weighted Average Grant Date Value per share, Cancelled/forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,300.00</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units
    outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC6Pc9nonvbf" title="Restricted Stock Units, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002027" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4ngbjnxOPEb" title="Weighted Average Grant Date Value per share, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002029" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,795.37</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEq554owd7ha" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact002030" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">8.09</ix:nonNumeric></span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested at March 31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAhgUkCLGvL3" title="Restricted Stock Units, unvested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002032" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgEvQltVVBR4" title="Weighted Average Grant Date Value per share, Unvested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002034" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,240.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTZDNVuDP0Oh" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact002035" name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms">7.82</ix:nonNumeric></span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Vested at March 31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2aBmLd5Wzh" title="Restricted Stock Units, Vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002037" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">123</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zU0TV8voZ7ze" title="Weighted Average Grant Date Value per share, Vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002039" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,747.11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlBhulV3rLeb" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact002040" name="CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms">8.12</ix:nonNumeric></span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AD_zkCzJRcHThC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact002042" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs4GUMLb48n9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82F_zBtRPV7o9WC9">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Common
Stock Equity Offerings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Securities Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2024, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor (the &#8220;Purchaser&#8221;) for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of (i)
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_zmVqw0jjT8y3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" id="Fact002043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">604</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock, (ii) pre-funded
warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zuymfjDHeJk1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact002044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,100</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Pre-Funded Warrants&#8221;),
(iii) series A warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zxgh8A3yNQFg"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesAWarrantsMember" id="Fact002045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series A Warrants&#8221;),
and (iv) series B warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z4wlJtWOymT8"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesBWarrantsMember" id="Fact002046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series B Warrants&#8221;
and together with the Series A Warrants, the &#8220;Common Warrants&#8221;). The purchase price of each share of common stock and associated
Common Warrants was $386.40 and the purchase price of each Pre-Funded Warrant and associated Common Warrants was $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsAndCommonWarrantsMember_zni0dunyKQna"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsAndCommonWarrantsMember" id="Fact002047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">386.376</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants are exercisable immediately upon issuance at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zFt1UcVulfog"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact002048" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">326.40</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Series A Warrants will expire five and one-half
years<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zeyPH0DhQ0uj" style="display: none"><ix:nonNumeric contextRef="AsOf2024-04-30_custom_SeriesAWarrantsMember" format="ixt-sec:duryear" id="Fact002049" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance and the Series B Warrants will expire
<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_z3Y1WYKLO0k1"><ix:nonNumeric contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesBWarrantsMember" format="ixt-sec:durwordsen" id="Fact002050" name="us-gaap:WarrantsAndRightsOutstandingTerm">eighteen
months</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance. The Pre-Funded
Warrants are exercisable immediately upon issuance at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zgo6sIDf7gT8"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact002051" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.024</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and may be exercised at any time until the Pre-Funded
Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its affiliates) may not exercise any
portion of such warrants to the extent that the holder would own more than <span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zp7eFIdS9X19"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStock" contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact002052" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
(or, at the election of the holder <span id="xdx_907_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zhBWHyy6vAGb"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact002053" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)
of the Company&#8217;s outstanding common stock immediately after exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 226; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Private Placement, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
dated as of April 30, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) registering the resale of the securities issued in the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Placement closed on May 2, 2024. The gross proceeds to the Company from the Private Placement were approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240502__20240502_zfXWsPjyzQxg"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-05-022024-05-02" id="Fact002054" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, before deducting placement agent fees and estimated
offering expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the Company&#8217;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of April 29, 2024, between the Company and Wainwright (as amended, the
&#8220;Engagement Letter&#8221;). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to <span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20240429_zBrA9gHcwGs"><ix:nonFraction name="CYCC:CashPlacementFeePercentage" contextRef="AsOf2024-04-29" id="Fact002055" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds of the Private Placement and (ii) a management fee of <span id="xdx_90E_ecustom--ManagementFeePercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240429_zByJDqWP4oP5"><ix:nonFraction name="CYCC:ManagementFeePercentageToAggregateGrossProceeds" contextRef="AsOf2024-04-29" id="Fact002056" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued
to Wainwright or its designees warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zmhBLE2axGt8"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember" id="Fact002057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,242</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price equal to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zKb8wEowljf"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember" id="Fact002058" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">124.512</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Placement Agent Warrants are exercisable immediately
upon issuance and have a term of exercise equal to five and a half years<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zuD3aEBuYzLa" style="display: none"><ix:nonNumeric contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact002059" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company was required to compensate Roth Capital Partners, LLC, pursuant to a tail provision contained
in an engagement letter entered into on March 14, 2024, in an amount equal to <span id="xdx_902_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240314__srt--CounterpartyNameAxis__custom--RothCapitalPartnersLlcMember_z5vZ5JiKyDN9"><ix:nonFraction name="CYCC:CompensationPercentageToAggregateGrossProceeds" contextRef="AsOf2024-03-14_custom_RothCapitalPartnersLlcMember" id="Fact002060" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate proceeds of the Private Placement plus the reimbursement of certain expenses. The Company was also required to compensate
Ladenburg Thalmann &amp; Co. Inc, pursuant to a tail provision contained in an engagement letter entered into on October 30, 2023, in
an amount equal to <span id="xdx_907_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20231030__srt--CounterpartyNameAxis__custom--LadenburgThalmannCo.IncMember_zPS9NG1TTRLf"><ix:nonFraction name="CYCC:CompensationPercentageToAggregateGrossProceeds" contextRef="AsOf2023-10-30_custom_LadenburgThalmannCo.IncMember" id="Fact002061" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate proceeds of the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the instruments issued in the Private Placement have been classified and recorded as part of shareholders&#8217; equity (deficit).
The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective
instruments as follows:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact002063" name="CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_zA78XcnVP3d9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zoHcCeHWglHg" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250101__20250331_zGjcrW70H7G8" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Allocated
    Amount</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuojg1Le9Ry5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%"><span style="font-family: Times New Roman, Times, Serif">Common shares</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact002065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72,108</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSSPmw9N1rvj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prefunded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2025-01-012025-03-31_custom_PreFundedWarrantsMember" id="Fact002067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,398,831</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYpsat2GSfXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2025-01-012025-03-31_custom_CommonStockWarrantsMember" id="Fact002069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,819,274</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zs3KLuTxpE01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2025-01-01to2025-03-31" id="Fact002071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,290,213</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zyL72AZbeih7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fair value of the Placement Agent Warrants was $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zO9gzZVzzPmj" title="Warrants exercise price"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-03-31_custom_PlacementAgentWarrantsMember" id="Fact002073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">609,179</ix:nonFraction></span>. These have been accounted for as a direct cost of the Private Placement,
resulting in no net effect to overall shareholders&#8217; equity (deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact002075" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zTUa68Prla6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zxPcTvzLnbz2" style="display: none">Schedule of Fair value of Warrants Valuation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded
    Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Placement
    Agent Warrants</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKuoTFVcMyZ1" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact002077" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100</ix:nonFraction></span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zDnR00CKxMGj" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="Fact002079" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">103</ix:nonFraction></span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zzNklfHgkJNh" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="Fact002081" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">121</ix:nonFraction></span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0huGRbp6ax3" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact002083" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">103</ix:nonFraction></span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0cu2bRSDefd" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact002085" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1</ix:nonFraction></span> year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 7pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zENaCO5e8ZGh" title="Contractual term"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_srt_MinimumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact002087" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.5</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif">1&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">- 5&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">years <span style="display: none; font-size: 7pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zO0bmRuNgBzl" title="Contractual term"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_srt_MaximumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact002089" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.5</ix:nonFraction></span></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">5&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">years <span style="display: none; font-size: 7pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPcIKiW6chD8"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact002090" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.5</ix:nonFraction></span></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztL9uwwXw2Z9" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact002092" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.51</ix:nonFraction></span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z6AfpudEkteh" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact002094" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.57</ix:nonFraction></span>% - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zWqD4S4fITBk" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact002096" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.51</ix:nonFraction></span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zF6xSJIXdgW8" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact002098" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.57</ix:nonFraction></span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxxy4WOQ6Ip" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact002100" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zb3qu8Q9Wg4e" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact002102" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcVi1mljH135" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact002104" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zIYAZP4KnbVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the common shares was determined using the closing price of the Company&#8217;s common stock as of May 2, 2024, which is
the date that the Private Placement closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 227; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2023 Registered Direct Offering Securities Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with
certain institutional investors (&#8220;Purchasers&#8221;). Pursuant to the Securities Purchase Agreement, the Company agreed to
sell in a registered direct offering (&#8220;Registered Direct Offering&#8221;) <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z7KSS8HvQImj"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact002105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">702</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
(&#8220;Shares&#8221;) of the Company&#8217;s common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXgX3pF9BFr5"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember54201031" id="Fact002106" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par
value per share (&#8220;Common Stock&#8221;), and pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z9GBVwRk7evk"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact002107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">915</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock. The Pre-Funded Warrants have an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zmbSw9wXVz5a"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact002108" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share and can be exercised at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each
Share is being sold at an offering price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI7XvSgnZLP9"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember54201031" id="Fact002109" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">795.60</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
each Pre-Funded Warrant is being sold at an offering price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zPmArmRugOCe"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact002110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">795.36</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(equal
to the purchase price per Share minus the exercise price of the Pre-Funded Warrant). The Pre-Funded Warrants have been included in
the calculation of basic and diluted loss per share for all periods outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the &#8220;Offerings&#8221;),
the Company also agreed to issue to the Purchasers unregistered warrants (&#8220;Common Warrants&#8221;) to purchase up to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zcGGNLguUNC7"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact002111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,617</ix:nonFraction></span>
shares of Common Stock. Each Common Warrant has an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zj0bFuWECwe3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact002112" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">765.60</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, is exercisable immediately following their original
issuance and will expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zlPI0n1FE893"><ix:nonNumeric contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" format="ixt-sec:durwordsen" id="Fact002113" name="us-gaap:WarrantsAndRightsOutstandingTerm">seven
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the original issuance date. The closing
of the offering occurred on December 26, 2023, and the net proceeds to the Company were approximately $<span id="xdx_907_ecustom--AggregateProceedsFromSaleOfStock_iI_pn5n6_c20231226__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zbokclLNzJ2g"><ix:nonFraction name="CYCC:AggregateProceedsFromSaleOfStock" contextRef="AsOf2023-12-26_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember" id="Fact002114" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and other offering
expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, in a separate concurrent insider private placement (the &#8220;Insider Private Placement&#8221;), the Company also
entered into a Securities Purchase Agreement with certain of its executive officers (the &#8220;Insider Securities Purchase Agreement&#8221;)
pursuant to which the Company agreed to sell in a private placement (i) <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJ5yYlv0H2Ec"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember" id="Fact002115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock and warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zFknP8RvmKu"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember_custom_CommonStockWarrantsMember" id="Fact002116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Spiro Rombotis, the Company&#8217;s Chief Executive Officer, and (ii) <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember_zrbeLsRQlMMe"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember" id="Fact002117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock and warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zhPBpDu4Boik"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember_custom_CommonStockWarrantsMember" id="Fact002118" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Paul McBarron, the Company&#8217;s Executive Vice President-Finance, Chief Financial Officer
and Chief Operating Officer. Each such share of Common Stock and accompanying warrant was sold at a purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zafyPJ2aQeXa"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" id="Fact002119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">795.60</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was the same purchase price for the Shares sold in the Registered Direct Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg
Thalmann &amp; Co. Inc. (the &#8220;Placement Agent&#8221;) acted as the exclusive placement agent for the Offerings, pursuant to a placement
agency agreement (the &#8220;Placement Agency Agreement&#8221;), dated December 21, 2023, by and between the Company and the Placement
Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Placement Agency Agreement, the Company paid the Placement Agent a cash placement fee equal to <span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zzaZoE0raod1" title="Cash placement fee, percentage"><ix:nonFraction name="CYCC:CashPlacementFeePercentage" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" id="Fact002121" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>% of the aggregate gross proceeds
raised in the Offerings from sales arranged for by the Placement Agent. Subject to certain conditions, the Company also agreed to reimburse
all reasonable travel and other out-of-pocket expenses of the Placement Agent in connection with the Offerings, including but not limited
to legal fees, up to a maximum of $<span id="xdx_90A_eus-gaap--ProfessionalFees_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zuCzCsxkXyD1" title="Professional fees"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact002123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span>. In addition, the Placement Agent also received warrants that have substantially the same terms
as the Warrants issued in the concurrent private placement to the Purchasers in the Offerings to purchase that number of shares of Common
Stock equal to <span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zhiD8vh866p5" title="Percentage of outstanding common stock"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStock" contextRef="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember" id="Fact002125" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></span>% of the aggregate number of shares of Common Stock and Prefunded Warrants sold in the Offerings, or an aggregate of
<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zL0ufWmxoJl9" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember" id="Fact002127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99</ix:nonFraction></span> shares of Common Stock, at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zRZ2qm2L5R0j" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember" id="Fact002129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">994.50</ix:nonFraction></span> per share (the &#8220;Placement Agent Warrants&#8221;). The Placement
Agent Warrants will be exercisable immediately following the date of issuance and will expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zgX4pa6bSZx4" title="Warrant outstanding Term"><ix:nonNumeric contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember" format="ixt-sec:durwordsen" id="Fact002131" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from issuance. The Placement
Agency Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The
Company has agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and
liabilities arising from breaches of representations and warranties contained in the Placement Agency Agreement, or to contribute to
payments that the Placement Agent may be required to make in respect of those liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the instruments issued in the Offerings and the Insider Private Placement have been classified and recorded as part of shareholders&#8217;
equity (deficit). The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying
values of the respective instruments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"></p><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember" escape="true" id="Fact002133" name="CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zZ8211qrMUHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zRuUJ2cLdkP8" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPyX9aCkusHa" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Allocated
    Amount</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjgcPPPJlqXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%"><span style="font-family: Times New Roman, Times, Serif">Common Shares</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_us-gaap_CommonStockMember" id="Fact002135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">258,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zlthtXzj474i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_custom_PreFundedWarrantsMember" id="Fact002137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGaGssgFOYu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Regular Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_custom_CommonStockWarrantsMember" id="Fact002139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">470,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zbraQ6ny1bE9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember" id="Fact002141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,049,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_z7Nfb6onCP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 228; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fair value of the Placement Agent Warrants was $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_znWVI7GjaHId" title="Warrants exercise price"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-03-31_custom_PlacementAgentWarrantsMember_custom_InsiderPrivatePlacementMember" id="Fact002143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,000</ix:nonFraction></span>. These have been accounted for as a direct cost of the Offerings and
Inside Private Placement, resulting in no net effect to overall shareholders&#8217; equity (deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember" escape="true" id="Fact002145" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIfFlUzMp4s4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zOuAHdkHrU5l" style="display: none">Schedule of Fair value of Warrants Valuation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded
    Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Regular Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Placement
    Agent Warrants</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zxKTq7hZhrd2" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember" id="Fact002147" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">134</ix:nonFraction></span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zFEVlJ8CHIyc" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember" id="Fact002149" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">96</ix:nonFraction></span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zpB6jZiLkPt7" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember" id="Fact002151" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">99</ix:nonFraction></span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual/ expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAkLJTwKcqFl" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember" id="Fact002153" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1</ix:nonFraction></span> month</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zs4ti35RRENe" title="Contractual term"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember" id="Fact002155" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7</ix:nonFraction></span> years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zc3OwhDykApd" title="Contractual term"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember" id="Fact002157" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5</ix:nonFraction></span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zJ5dZf57aYed" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember" id="Fact002159" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.53</ix:nonFraction></span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zfYtLFqlCxH9" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember" id="Fact002161" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.91</ix:nonFraction></span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPGIqLtKCXz1" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember" id="Fact002163" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.89</ix:nonFraction></span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zP2XHomOv7Xj" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember" id="Fact002165" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zGU7TLCKdSU4" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember" id="Fact002167" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zSfRb5M2gZ3e" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember" id="Fact002169" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zSGN6mLcGGn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the common shares was determined using the closing price of the Company&#8217;s common stock as of December 26, 2023, which
is the date that the Offerings and the Insider Private Placement closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>November
2024 Warrants (As Amended)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, warrants to purchase a total of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zkcMv1Hg4Pzj" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" id="Fact002171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,526</ix:nonFraction></span> shares of common stock issued pursuant to a securities purchase agreement
in a November 2024 financing transaction (the &#8220;November 2024 Warrant Exercise and Reload Agreement&#8221;) and as amended in a
January 2, 2025 Warrant Exchange Agreement, remained outstanding. A total of <span id="xdx_904_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_ziWMN0bG94Y1" title="Exercisable warrants"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" id="Fact002173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82,816</ix:nonFraction></span> warrants were issued in pursuant to the November
2024 Warrant Exercise and Reload Agreement. This consisted of i) series C warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zUvaaA4Bzeyb" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember" id="Fact002175" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,408</ix:nonFraction></span> shares of common stock,
exercisable immediately from the date of issuance for a period of five and a half years<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_zK1HsjILzh9a" title="Warrant outstanding Term" style="display: none"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_SeriesCWarrantsMember_custom_November2024WarrantExerciseAndReloadAgreementMember" format="ixt-sec:duryear" id="Fact002177" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span> after the date of issuance, at an exercise price
of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zKj2kuaJpwWf" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember" id="Fact002179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">99.60</ix:nonFraction></span> per warrant share, ii) series D warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zO2cbLs6sHJk" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember" id="Fact002181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,408</ix:nonFraction></span> shares of common stock, exercisable immediately from the
date of issuance for a period of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zJCntURLdsp7" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember" format="ixt-sec:durwordsen" id="Fact002183" name="us-gaap:WarrantsAndRightsOutstandingTerm">eighteen months</ix:nonNumeric></span> after the date of issuance, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zet3ZEStQ8il" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember" id="Fact002185" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">99.60</ix:nonFraction></span> per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_pid_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zd2eb2Y4cayb" title="Warrants exercised"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2025-01-012025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" id="Fact002187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,289</ix:nonFraction></span> of these warrants were exercised during the three months ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, warrants to purchase a total of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zX6nfLCSawN9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember" id="Fact002188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,934</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in an April 2024 financing transaction (the &#8220;April 2024 Securities Purchase Agreement&#8221;) remained outstanding. A
total of <span id="xdx_908_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zR2Zh0SwJdKg"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember" id="Fact002189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,750</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were issued in pursuant to the April 2024 Securities
Purchase Agreement. This consisted of i) pre-funded warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zeboZxC2BIsc"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember" id="Fact002190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,100</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of common stock, exercisable immediately from the date of issuance,
and with no expiry date, at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zHitqqljdRM6"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember" id="Fact002191" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, ii) series A warrants to purchase up to
<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zWlbvYD8z0P9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember" id="Fact002192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zPpXhQ9L5Zce" style="display: none"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_SeriesAWarrantsMember_custom_April2024WarrantsMember" format="ixt-sec:duryear" id="Fact002193" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zRlUHfrKaXyd"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember" id="Fact002194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">326.40</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, iii) series B warrants to purchase up to
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zuQAmXLNEec2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember" id="Fact002195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,704</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zJWatDmblluh"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember" format="ixt-sec:durwordsen" id="Fact002196" name="us-gaap:WarrantsAndRightsOutstandingTerm">eighteen
months</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zsqKtwHR50Bh"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember" id="Fact002197" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">326.40</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share. A further <span id="xdx_90E_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zts2BaHIU36j"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember" id="Fact002198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,242</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of five and a half years<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zUKwuRMeFo6l" style="display: none"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_custom_April2024WarrantsMember" format="ixt-sec:duryear" id="Fact002199" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxpGjAhPERKk"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember" id="Fact002200" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">124.512</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercised_pid_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_z7Q8K41fr22e" title="Warrants exercised"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantMember" id="Fact002202" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,988</ix:nonFraction></span> Series B warrants were exercised during the three months ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 229; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2023 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, warrants to purchase a total of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zHgpj8Ogb3ol" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember" id="Fact002204" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,750</ix:nonFraction></span> shares of common stock issued pursuant to a securities purchase agreement
in a December 2023 financing transaction remained outstanding. A total of <span id="xdx_901_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zNIZl9MpeXn7" title="Warrants exerciseable"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember" id="Fact002206" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,651</ix:nonFraction></span> warrants, including <span id="xdx_90C_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreePrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zYetQAMjqvn3" title="Warrants exerciseable"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2025-03-31_custom_DecemberTwoThousandTwentyThreePrivatePlacementMember_custom_PlacementAgentWarrantsMember" id="Fact002208" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33</ix:nonFraction></span> warrants issued in a concurrent
private placement, are exercisable immediately from the date of issuance for a period of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zftguHdWf4H3" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember" format="ixt-sec:durwordsen" id="Fact002210" name="us-gaap:WarrantsAndRightsOutstandingTerm">seven years</ix:nonNumeric></span> after the date of issuance, at an
exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zmYARZA6K7Zc" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember" id="Fact002212" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">765.60</ix:nonFraction></span> per warrant share. A further <span id="xdx_906_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPxWoeO6a9c3" title="Warrants exercisable"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightsExercisable" contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember_us-gaap_WarrantMember" id="Fact002214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99</ix:nonFraction></span> warrants issued in a concurrent placement agency agreement, are exercisable
immediately from the date of issuance for a period of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_z8V30rblwKr5" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_December2023PlacementAgencyAgreementMember" format="ixt-sec:durwordsen" id="Fact002216" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> after the date of issuance, at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zqSJ6PU1vsJg" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_December2023PlacementAgencyAgreementMember" id="Fact002218" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">994.50</ix:nonFraction></span> per warrant
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zRANP317UFZb" title="Warrants exercised"><span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zpV4ybVDiICk" title="Warrants exercised"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2025-01-012025-03-31_custom_December2023PrivatePlacementMember" id="Fact002220" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2024-01-012024-03-31_custom_December2023PrivatePlacementMember" id="Fact002222" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2020 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zYUBqq4swWmd" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-31_custom_DecemberTwoThousandTwentyWarrantMember" id="Fact002224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186</ix:nonFraction></span> shares of common stock issued pursuant to a securities purchase agreement in a December
2020 financing transaction remained outstanding (the &#8220;December 2020 Securities Purchase Agreement&#8221;). Each warrant shall be
exercisable beginning on the 12-month anniversary of the date of issuance for a period of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zX8zGeFh6K3i" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-03-31_custom_DecemberTwoThousandTwentyWarrantMember" format="ixt-sec:durwordsen" id="Fact002226" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> after the date of issuance, at an
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zPYRsqvitn9j" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_DecemberTwoThousandTwentyWarrantMember" id="Fact002228" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,868</ix:nonFraction></span> per warrant share. The exercise price of the warrants will be subject to adjustment in the event of any stock
dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the warrants. The
warrants may be exercised on a &#8220;cashless&#8221; basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zupY5LG7oIA1" title="Warrants exercised"><span id="xdx_904_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zr5RfpDPtfk5" title="Warrants exercised"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2025-01-012025-03-31_custom_DecemberTwoThousandTwentyWarrantMember" id="Fact002230" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2024-01-012024-03-31_custom_DecemberTwoThousandTwentyWarrantMember" id="Fact002232" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2020 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zS3hgIxDurTj" title="Warrant outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact002234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">497</ix:nonFraction></span> warrants issued pursuant to a securities purchase agreement in connection with an April 2020 equity financing
remained outstanding, each with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_z0kzxT9mVZG1" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact002236" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18,000.00</ix:nonFraction></span>. The common warrants are immediately exercisable and will expire on the fifth
anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject
to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company&#8217;s
common stock. The common warrants were issued separately from the common stock and were eligible for transfer immediately after issuance.
A common warrant to purchase one share of common stock was issued for every share of common stock purchased in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise
notice accompanied by payment in full for the number of shares of the Company&#8217;s common stock purchased upon such exercise (except
in the case of a cashless exercise). <span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zwoDOH4r2sX8" title="Debt description"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact002238" name="us-gaap:DebtInstrumentDescription">A holder (together with its affiliates) may not exercise any portion of the common warrant to the
extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least
61 days prior notice from the holder to the Company, the holder may increase the amount of ownership of outstanding stock after exercising
the holder&#8217;s common warrants up to 9.99% of the number of shares of the Company&#8217;s common stock outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants.</ix:nonNumeric></span> No fractional
shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, the Company
will round down to the next whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zvGypY5H1Vq8" title="Warrants exercised"><span id="xdx_902_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_znF2EDkHduS8" title="Warrants exercised"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact002240" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="CYCC:ClassOfWarrantOrRightExercised" contextRef="From2024-01-012024-03-31_custom_AprilTwoThousandTwentyWarrantsMember" id="Fact002242" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Preferred
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
E Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zpYmcvRxdd22" title="Number of share sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of the Company&#8217;s Series E Preferred Stock were issued pursuant to a March 2025 Securities Purchase Agreement
with certain accredited investors. The Company received proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zORkeXYmqnYi" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002246" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million, net of issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 230; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series E Preferred Stock is convertible into </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zPE19G3De40c"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.45833</ix:nonFraction></span>
shares of the Company&#8217;s common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zFYuxC1XNDC8"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002248" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (&#8220;Common Stock&#8221;). In no event will the
Series E Preferred Stock be convertible into Common Stock in a manner that would result in each Investor or their transferees or their
affiliates holding more than the lower of (i) the maximum percentage of the number of shares of Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series E Preferred Stock that can be issued
to the holder without requiring a vote of the stockholders of the Company under the rules and regulations of The Nasdaq Capital Market
(&#8220;Nasdaq&#8221;); and (ii) <span id="xdx_900_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zJc8SRYs2dQa"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002249" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the number of shares of Common Stock outstanding immediately before the original issue date (the &#8220;Series E Ownership Limitation&#8221;),
prior to the date that the Company&#8217;s stockholders approve the issuance of shares of Common Stock to the Investors upon conversion
of the Series E Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, the Company filed a certificate of designations (the &#8220;Series E Certificate of Designations&#8221;) with
the Secretary of State of Delaware designating the rights, preferences and limitations of the shares of the Series E Preferred Stock
on March 21, 2025. The Series E Certificate of Designations provides, in particular, that the Series E Preferred Stock will vote together
with the Common Stock on an as-converted basis, subject to the Series E Ownership Limitation, subject further to adjustments for any
stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series E Preferred Stock will be entitled to participate in any dividends made on shares of Common Stock (on an as-converted
basis) if and when such dividends are declared. Upon any liquidation or sale of the Company or all or substantially all of its assets,
the holders of the Series E Preferred Stock will be entitled to receive pari passu with the other holders of preferred stock, prior to
and in preference to any distribution to holders of Common Stock, an amount equal to $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zSkwpv9KbYka" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002251" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share, the stated value of the Series
E Preferred Stock, then held by them plus any accrued but unpaid dividends. Thereafter, the remaining assets of the Company will be distributed
to the holders of Common Stock until such holders receive a return of their capital originally contributed, and thereafter, any remaining
assets will be distributed to all holders of Common Stock and preferred stock pro rata based on the number of shares held on an as-converted
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z1tjIWXFGAW3" title="Preferred stock shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of the Series E Preferred Stock remain issued and outstanding. The <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zjgMHtKDXS6g" title="Preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of Series E Preferred
Stock issued and outstanding at March 31, 2025, are convertible into <span id="xdx_908_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zbG7ge5i7Wz" title="Conversion of shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember" id="Fact002257" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">458,333</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
C and Series D Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zb4CxxZfbd95" title="Number of share sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact002259" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of the Company&#8217;s Series C Preferred Stock and <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zutCw4YoU4Nf" title="Number of share sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact002261" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100,000</ix:nonFraction></span> shares of the Company&#8217;s Series D Preferred
Stock were issued pursuant to a January 2025 Securities Purchase Agreement with David E. Lazar, pursuant to which he agreed to purchase
from the Company <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zQU0TJCDrbA2" title="Number of share sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-03-31_custom_SeriesCConvertiblePreferredStockMember" id="Fact002263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of Series C Convertible Preferred Stock (the &#8220;Series C Preferred Stock&#8221;) and <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z0cVsNfTWDH6" title="Number of share sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-03-31_custom_SeriesDConvertiblePreferredStockMember" id="Fact002265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100,000</ix:nonFraction></span>
shares of Series D Convertible Preferred Stock (the &#8220;Series D Preferred Stock&#8221; and, together with the Series C Preferred
Stock, the &#8220;Preferred Stock&#8221;) of the Company at a purchase price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zLNqQfQwzW1f" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact002267" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for aggregate gross proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_ziSnJURRTme8" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact002269" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span>
million, subject to the terms and conditions of the Purchase Agreement. The proceeds of the transaction were used to repay and settle
outstanding liabilities of the Company and for other general corporate and operating purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt">Each share of
Series C Preferred Stock is convertible into <span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7ysKNX5ZqXg" title="Conversion of shares"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact002271" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.011</ix:nonFraction></span>
shares of the Company&#8217;s common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250331_zYU2fJn9LU1j" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact002273" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share (&#8220;Common Stock&#8221;), and each share of Series D Preferred Stock is convertible into <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z722kWYFLCmf" title="Conversion of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact002275" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.45833</ix:nonFraction></span>
shares of Common Stock. In no event will the Series C Preferred Stock be convertible into Common Stock in a manner that would result
in Mr. Lazar or his transferees or their affiliates holding more than the lower of (i) the maximum percentage of the number of
shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
conversion of the Preferred Stock that can be issued to the holder without requiring a vote of the stockholders of the Company under
the rules and regulations of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;); and (ii) <span id="xdx_90A_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zVLbTH6plbRc" title="Outstanding common stock at election of purchaser"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2025-01-012025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact002277" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of the number of shares of Common Stock outstanding immediately before the original issue date (the &#8220;Series C Ownership
Limitation&#8221;), prior to the date that the Company&#8217;s stockholders approve the issuance of shares of Common Stock to Mr.
Lazar upon conversion of the Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 231; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, prior to a Fundamental Transaction (as defined below), in no event will the Series D Preferred Stock be convertible into Common
Stock in a manner that would result in Mr. Lazar or his transferees or their affiliates holding more than the lower of (i) the maximum
percentage of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon conversion of the Preferred Stock that can be issued to the Holder without requiring a vote of the stockholders of
the Company under the rules and regulations of Nasdaq; and, (ii) <span id="xdx_904_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zk70bDflPDbl" title="Outstanding common stock at election of purchaser"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact002279" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">49.99</ix:nonFraction></span>% of the number of shares of the Common Stock outstanding immediately
before the original issue date (the &#8220;Series D Ownership Limitation&#8221;). The term &#8220;Fundamental Transaction,&#8221; means
when (i) the Company effects any merger of the Company with or into another entity and the Company is not the surviving entity, (ii)
any tender offer or exchange offer (whether by the Company or by another individual or entity, and approved by the Company) is completed
pursuant to which holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash
or property and the holders of at least 50% of the Common Stock accept such offer, or (iii) the Company effects any reclassification
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock). The certificate
of designations for each of the Series C Preferred Stock and Series D Preferred Stock further provide that even following a vote of the
stockholders of the Company in accordance with the rules and regulations of the trading market on which the Common Stock trades on such
date and applicable securities laws to approve the removal of the Series C Ownership Limitation, the Company shall not affect any conversion
of the Preferred Stock, and a holder of the Preferred Stock shall not have the right to convert any portion of the Preferred Stock, to
the extent that, after giving effect to the conversion, such holder (together with any other shares of Common Stock otherwise held by
such holder(s) or their affiliates) would beneficially own the number of shares of Common Stock, which would be in excess of any statutory
threshold pursuant to which the acquisition of such shares would trigger a compulsory offer requirement under applicable federal or state
tender offer rules for the holder and its affiliates to make a tender offer for all the shares of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2025, all of the Series C preferred shares were converted in conjunction with the Purchase Agreement. As of March 31, 2025
there were no remaining shares of the Series C Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2025, <span id="xdx_90F_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250224__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zMCO5G34RGRb" title="Conversion of shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-02-24_us-gaap_SeriesDPreferredStockMember" id="Fact002281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,745,262</ix:nonFraction></span> of the Series D preferred shares were converted in conjunction with the Purchase Agreement. As of March
31, 2025, <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zN3mCOEZFIu2" title="Preferred stock shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact002283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">354,738</ix:nonFraction></span> shares of the Series D Preferred Stock remain issued and outstanding. The <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zCH8jksCD2B9" title="Preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact002285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">354,738</ix:nonFraction></span> shares of Series D Preferred Stock
issued and outstanding at March 31, 2025, are convertible into <span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z6hjriCr2rc8" title="Conversion of shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember" id="Fact002287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,588</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLsRIdlcPqab" title="Number of share sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact002289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">237,745</ix:nonFraction></span> shares of the Company&#8217;s Series B Preferred Stock were issued pursuant to a December 2020 Securities Purchase Agreement.
Each share of Series B Preferred Stock was initially convertible into one third (1/3) share of common stock (the &#8220;Conversion Shares&#8221;),
subject to adjustment in accordance with the Certificate of Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPu9HnRo13u2" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact002291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,000</ix:nonFraction></span> shares of Series B Preferred Stock were converted, at the option of the holder, into <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zeyl6WJF2ak7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact002292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165</ix:nonFraction></span>
shares of common stock. As of March 31, 2025, there were <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_do_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkj3mD0PFwli" title="Conversion of shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact002294" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> remaining shares of the Series&#160;B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOOlbNWOJTJ3" title="Number of share sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact002296" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,872</ix:nonFraction></span> shares of the Company&#8217;s Series A Preferred Stock were issued in a July 2017 Underwritten Public Offering. Each share
of Series A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined
by dividing $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqBCZjQGWjf3" title="Stock value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact002298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span> by the initial conversion price of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsTURdQmFgKa" title="Conversion price of convertible preferred stock"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2017-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact002300" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">144,000.00</ix:nonFraction></span> per share, subject to a <span id="xdx_90D_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAESJnthatX" title="Outstanding common stock at election of purchaser"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact002302" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% blocker provision, or, upon election by a
holder prior to the issuance of shares of Series A Preferred Stock, <span id="xdx_90B_ecustom--ConvertiblePreferredStockConversionPercentage_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3PoyIUtBKNe" title="Conversion percentage"><ix:nonFraction name="CYCC:ConvertiblePreferredStockConversionPercentage" contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember" id="Fact002304" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>%, and is subject to adjustment for stock splits, stock dividends,
distributions, subdivisions and combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 and December 31, 2024, <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4mei2YiKrAd" title="Preferred stock shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact002306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></span> shares of the Series A Preferred Stock remain issued and outstanding. The <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_za8mkKWMRoOg" title="Preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact002308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></span> shares of
Series A Preferred Stock issued and outstanding at March 31, 2025, are convertible into <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVmvgQBjVWUa" title="Conversion of shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact002310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock
basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends
in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted
basis. There is no restriction on the Company&#8217;s ability to repurchase shares of Series A Preferred Stock while there is an arrearage
in the payment of dividends on such shares, and there are no sinking fund provisions applicable to Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 232; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder
of the Series A Preferred Stock to convert all or part of such holder&#8217;s Series A Preferred Stock in the event that (i) the volume
weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds <span id="xdx_908_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcTrwOmPwfBg" title="Outstanding common stock at election of purchaser"><ix:nonFraction name="CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser" contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact002312" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">300</ix:nonFraction></span>% of the initial conversion
price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends
and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $<span id="xdx_908_eus-gaap--ConversionOfStockAmountConverted1_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVyAW3bRuw8i" title="Conversion of amount"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact002314" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">500,000</ix:nonFraction></span> per trading
day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information
which was provided by the Company. The right to cause each holder of Series A Preferred Stock to convert all or part of such holder&#8217;s
Series A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains
no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common
stock in the distribution of assets, to the extent legally available for distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>6%
Convertible Exchangeable Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3WdMmP29BVd" title="Preferred stock shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002316" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,273</ix:nonFraction></span> shares of the Company&#8217;s <span id="xdx_907_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ze6pXP3PNsi2" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002318" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Convertible Exchangeable Preferred Stock (the &#8220;<span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zjsOuoDx1f7b" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002320" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred
Stock&#8221;) issued and outstanding at an issue price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ztLikzfrwhWg" title="Share issue price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002322" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share. Dividends on the <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zeKGc9t23jmk" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002324" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred Stock are cumulative from the
date of original issuance at the annual rate of <span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z5ldLMp0Zw1a" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002326" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% of the liquidation preference of the <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zCeU7ykmoW3d" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002328" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred Stock, payable quarterly on the
first day of February, May, August and November, commencing February 1, 2005. Any dividends must be declared by the Company&#8217;s board
of directors and must come from funds that are legally available for dividend payments. The <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zt7IYqiOti9d" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002330" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred Stock has a liquidation preference
of $<span id="xdx_902_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zkradnCESYi1" title="Liquidation preference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002332" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share, plus accrued and unpaid dividends. As of March 31, 2024, there were no accrued and unpaid dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may automatically convert the 6% Preferred Stock into common stock if the per share closing price of the Company&#8217;s common
stock has exceeded $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zinJmwiIaa2l" title="Conversion amount"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002334" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">213,192,000</ix:nonFraction></span>, which is <span id="xdx_90D_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zm7PD695dYbg" title="Conversion price percentage"><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002336" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">150</ix:nonFraction></span>% of the conversion price of the <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zU2NIHGoSfde" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002338" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred Stock, for at least 20 trading days during any
30 day trading period, ending within five trading days prior to notice of automatic conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zJGsK7OFNHo" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002340" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may, at its option, redeem the <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z4Jwz1yauNbf" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002342" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred Stock in whole or in part, out of funds legally available at the redemption price
of $<span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zaxlBPAqB1C3" title="Redemption price per share"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002344" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
6% Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on
November&#160;1, 2005 (the &#8220;Exchange Date&#8221;) for the Company&#8217;s <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zFYZg4Hm6QEj" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002346" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Convertible Subordinated Debentures (the &#8220;Debentures&#8221;)
at the rate of $<span id="xdx_908_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zVrdSenLYaai" title="Redemption price per share"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002348" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> principal amount of Debentures for each share of <span id="xdx_908_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z1xGOnD8mM64" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002350" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred Stock. The Debentures, if issued, will mature <span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zzRktYzy60nl" title="Debt instrument, term"><ix:nonNumeric contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:duryear" id="Fact002352" name="us-gaap:DebtInstrumentTerm">25</ix:nonNumeric></span>
years after the Exchange Date and have substantially similar terms to those of the <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zY3klpZtJJWj" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact002354" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Preferred Stock. No such exchanges have taken place
to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact002356" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zKLzuswfrDM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_822_zKfc4OaQw7g3">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends
on 6% Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2025, the board of directors of the Company declared a quarterly cash dividend on the Company&#8217;s <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250419__20250419__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zerVJoSVrM8b" title="Preferred stock, dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-04-192025-04-19_us-gaap_SubsequentEventMember" id="Fact002358" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% Convertible Exchangeable
Preferred Stock scheduled for May 1, 2025. The cash dividend was paid on May 1, 2025, to Preferred Stock stockholders of record as of
the close of business on April 29, 2025. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on
a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 233; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock Conversions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2025, all of the remaining <span id="xdx_909_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250402__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXp45eGMmaEa" title="Number of common shares issued upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-04-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember" id="Fact002360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">354,738</ix:nonFraction></span> shares of the Company&#8217;s Series D Preferred Stock was converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250402__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zumQM22wlBZk" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-04-022025-04-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember" id="Fact002362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,588</ix:nonFraction></span> shares
of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2025, all of the <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv2zE2pslVTg" title="Number of common shares issued upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-04-29_us-gaap_SeriesEPreferredStockMember_us-gaap_SubsequentEventMember" id="Fact002364" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of the Company&#8217;s Series E Preferred Stock was converted into <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250429__20250429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBBonK5PAX64" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-04-292025-04-29_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember" id="Fact002366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,833</ix:nonFraction></span> shares of
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Amendment to Amended and Restated
Certificate of Incorporation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 25, 2025, after obtaining the
approval of the Board of Directors and the Company&#8217;s majority stockholder, the Company filed a Certificate of Amendment to its Amended
and Restated Certificate of Incorporation to increase the number of authorized shares of the Company&#8217;s common stock from two hundred
fifty million (<span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20250424_zAc9tKH6mDb8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-04-24" id="Fact002368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span>) to six hundred million (<span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20250425_zlbcXLeMvJT7" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-04-25" id="Fact002370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000,000</ix:nonFraction></span>). The amendment did not result in any changes to the issued and outstanding
shares of the Company&#8217;s common stock, and only affects the number of shares that may be issued by the Company in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Proposed
Business Combination of FITTERS Diversified Berhad</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2025, the Company entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; &#8220;FITTERS&#8221;), an investment
holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention
systems, &#8220;Waste-To-Resource&#8221; services and real estate development and construction. Pursuant to the Exchange Agreement, all
of the ordinary shares owned by FITTERS of FITTERS&#8217; subsidiary, Fitters Sdn. Bhd., a Malaysia-based private limited company (&#8220;Fitters
Sub&#8221;) shall be exchanged for common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250506__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8rn5pZbpNz2"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-05-06_us-gaap_SubsequentEventMember" id="Fact002371" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
of the Company (the &#8220;Purchaser Stock&#8221;), and Fitters Sub shall be continuing as a wholly-owned subsidiary of the Company (the
&#8220;Transaction&#8221;). As part of the Transaction, Cyclacel shall issue an amount of Purchaser Stock equal to 19.99% percent, which
percentage may be subject to adjustment, of the issued and outstanding shares of Purchaser Stock as of the closing date to FITTERS. At
the closing, it is expected that Cyclacel stockholders will own approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20250506__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FittersDiversifiedBerhadMember_zKEj4G1rxi17"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-05-06_custom_FittersDiversifiedBerhadMember" id="Fact002372" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.01</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the combined company. Cyclacel expects that at the closing of the Transaction, its common shares will continue to be listed on the
Nasdaq Capital Market under a new ticker symbol and Cyclacel will be renamed Bio Green Med Solution, Inc. Among the termination rights,
both Cyclacel and FITTERS have the right to terminate the Exchange Agreement if the closing date of the Transaction has not occurred
on or before September 30, 2025. It is currently anticipated that at least one of the officers or directors of FITTERS or Fitters Sub
will be appointed to Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction is subject to approval from Cyclacel stockholders and FITTERS shareholders. The Exchange Agreement has been unanimously approved
by the Boards of Directors of each of Cyclacel, FITTERS and Fitters Sub.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2025, the Company filed an amendment to its Certificate of Incorporation (&#8220;Certificate of Amendment&#8221;)
to implement a <span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20250507__20250507_zOr33nZ0KVag" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-05-072025-05-07" id="Fact002374" name="us-gaap:StockholdersEquityReverseStockSplit">one-for-sixteen</ix:nonNumeric></span> reverse stock split. The effective date of the Certificate of Amendment is May 12, 2025 (the &#8220;Effective
Date&#8221;). The Company&#8217;s common stock began trading on a split-adjusted basis when the market opened on the Effective Date. The
Board of Directors of the Company approved the amendment to the Company&#8217;s Certificate of Incorporation primarily to meet the share
bid price requirements of The Nasdaq Capital Market. The Company&#8217;s stockholders approved the Certificate of Amendment at a special
meeting of its stockholders held on February 6, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
reverse stock split, on the Effective Date, every sixteen shares of common stock then issued and outstanding automatically was combined
into one share of common stock, with no change in par value per share. No fractional shares were outstanding following the reverse stock
split, and any fractional shares that would have resulted from the reverse stock split have been (a) rounded up to the nearest whole
number for any shareholder who would otherwise be entitled to receive one-half or more of a fractional split-adjusted share, and (b)
rounded down to the nearest whole number for any shareholder who would otherwise be entitled to receive less than one-half of a fractional
split-adjusted share.</p>

</ix:nonNumeric><p id="xdx_81B_zMsXKgPiOeQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 234; Value: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="svv_104"></span>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS OF FITTERS SDN. BHD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page
    </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audited
    Financial Statements</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_001">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_002">CONSOLIDATED BALANCE SHEETS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_003">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_004">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_005">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_006">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>63</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 235; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-4_023.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors and Stockholders of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fitters
Sdn. Bhd.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,
Jalan Tembaga SD 5/2</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bandar
Sri Damansara</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52200
Kuala Lumpur, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Opinion
on the Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Fitters Sdn. Bhd. and its subsidiaries (the &#8216;Company&#8217;) as of
March 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive income, consolidated statements of stockholders&#8217;
equity, and consolidated statements of cash flows for the years ended of March 31, 2025 and 2024, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of March 31, 2025 and 2024, and the results of its operations and its cash flows for the years
ended March 31, 2025 and 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis
for Opinion</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Critical
Audit Matters</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required
to be communicated to those charged with governance and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgements. We determined that there are no critical audit
matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="border-bottom: Black 1pt solid; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="aud_001.jpg" alt=""/></span></td>
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
  <td><span style="font-family: Times New Roman, Times, Serif">JP CENTURION &amp; PARTNERS PLT (PCAOB: 6723)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kuala
Lumpur, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
13, 2025</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 236; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1. Financial statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_002"></span>FITTERS
SDN. BHD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS
OF MARCH 31, 2025 AND 2024 (Audited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares or otherwise stated)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audited</b></span></td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audited</b></span></td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">593,055</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,202</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,004,908</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">926,931</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable, net
    (including $616,858 and $735,855 of accounts receivable to related parties as of March 31, 2025 and 2024, respectively)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">766,916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,037,591</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepayment, deposits and
    other receivables (including $5,565 and $2,402 of other receivables to a related party as of March 31, 2025 and 2024, respectively)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">572,642</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">759,476</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Amount due from a related
    party</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">848,164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">729,362</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Tax
    assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">79,073</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,818</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,864,758</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,720,380</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,846</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Right-of-use
    assets, net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,509</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,329</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total non-current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">169,865</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">163,175</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,034,623</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,883,555</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES
    AND STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable (including
    nil and $225 of accounts payable to a related party as of March 31, 2025 and 2024, respectively)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">181,042</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">132,683</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other payables and accrued
    liabilities (including $987 and $1,017 of accruals to a related party as of March 31, 2025 and 2024, respectively)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,721</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,493</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Amount due to related parties</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,169,929</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,098,755</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liability &#8211; current portion</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,375</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,859</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,409,067</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,321,790</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Lease liability &#8211;
    non-current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,906</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,679</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,347</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,085</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total non-current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">47,253</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,764</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,456,320</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,373,554</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common stock, paid up MYR3,000,000;
    3,000,000 and 3,000,000 shares issued and outstanding as of March 31, 2025 and March 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">679,810</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">679,810</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated other comprehensive
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(30,508</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(190,896</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Retained
    earning</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,929,001</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,021,087</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL STOCKHOLDERS&#8217;
    EQUITY</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,578,303</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,510,001</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,034,623</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,883,555</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 237; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_003"></span>FITTERS
SDN. BHD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED MARCH 31, 2025 AND 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
United States Dollars (&#8220;US$&#8221; or &#8220;$&#8221;), except for number of shares or as otherwise stated)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/> March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/> March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">REVENUE (including $708,782 and
    $889,659 of revenue to related parties for the year ended March 31, 2025 and 2024, respectively)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,568</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,116,590</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">COST OF REVENUE (including
    $788 and $899 of cost of revenue to related parties for the years ended March 31, 2025 and 2024, respectively)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,503,775</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,643,505</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">GROSS PROFIT</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">417,793</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">473,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">SELLING, GENERAL AND ADMINISTRATIVE
    EXPENSES (including $58,814 and $37,275 of selling, general and administrative expenses to related parties for the
    years ended March 31, 2025 and 2024, respectively)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(585,293</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>)</td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(687,075</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(LOSS) FROM OPERATION</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(167,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>)</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(213,990</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">INTEREST INCOME</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,781</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,530</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">INTEREST EXPENSE</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,353</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,342</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(LOSS) BEFORE INCOME TAX</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(103,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>)</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(155,802</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">INCOME TAX BENEFITS (EXPENSES)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,986</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(38,136</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">NET (LOSS)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(92,086</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>)</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(193,938</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other comprehensive income:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">- Foreign currency translation
    (loss)/income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(160,388</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>)</td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,203</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    COMPREHENSIVE LOSS</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(252,474</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>)</td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(75,735</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">NET (LOSS)/INCOME PER
    SHARE, BASIC AND DILUTED</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.03</span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">WEIGHTED AVERAGE NUMBER
    OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 238; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_004"></span>FITTERS
SDN. BHD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED MARCH 31, 2025 AND 2024 (Audited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
United States Dollars (&#8220;US$&#8221; or &#8220;$&#8221;), except for number of shares or as otherwise stated)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMON
    STOCK</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUMBER
    OF SHARES</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMOUNT</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RETAINTED
    EARNING</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACCUMULATED
    OTHER COMPREHENSIVE LOSS</b> &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>TOTAL</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STOCKHOLDERS&#8217;</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b>
                                            &#160;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of March 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">679,810</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">679,810</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,215,025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(72,693</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,822,142</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss for the year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(193,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(193,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(118,203</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(118,203</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of March 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">679,810</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">679,810</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,021,087</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(190,896</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,510,001</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss for the year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(92,086</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(92,086</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,388</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,388</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of March 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">679,810</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">679,810</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,929,001</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,508</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,578,303</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 239; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_005"></span>FITTERS
SDN. BHD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED MARCH 31, 2025 AND 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
United States Dollars (&#8220;US$&#8221; or &#8220;$&#8221;), except for number of shares or as otherwise stated)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31,</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Audited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Audited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING
    ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net (loss)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(92,086</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(193,938</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Impairment of investment
    in subsidiaries</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,246</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash
    used in operating activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,909</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,040</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Provision for credit loss
    allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">274,970</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">122,322</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,632</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">141,468</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,945</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">228,940</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepayment, deposits and
    other receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">229,050</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(262,628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,201</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,482</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other payables and accrued
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40,849</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(42,428</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(60,243</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,929</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,298</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change in right-of-use
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,625</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,204</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in lease liability</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(35,356</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,559</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by operating activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">393,908</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,264</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM INVESTING
    ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Purchase
    of property, plant and equipment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,791</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(991</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,791</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(991</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM FINANCING
    ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Advances
    from related companies</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(70,356</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,539</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash (used in)/provided by financing activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(70,356</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,539</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Effect of exchange rate
    changes in cash and cash equivalents</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,092</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,624</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net changes in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">342,853</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">62,188</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents,
    beginning of year</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,202</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,014</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">CASH
    AND CASH EQUIVALENTS, END OF YEAR</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">593,055</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,202</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SUPPLEMENTAL CASH FLOWS
    INFORMATION</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash paid for income
    taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,058</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54,883</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash paid for interest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,353</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,342</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 240; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_006"></span>FITTERS
SDN. BHD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED MARCH 31, 2025 AND 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
United States Dollars (&#8220;US$&#8221; or &#8220;$&#8221;), except for number of shares or as otherwise stated)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span style="text-decoration: underline">ORGANIZATION AND BUSINESS BACKGROUND</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Sdn. Bhd. is a private limited company incorporated in Malaysia on August 20, 1982 and is a wholly-owned subsidiary of Fitters Diversified
Berhad before the share exchange transaction. (&#8220;the Company&#8221;)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
(Sarawak) Sdn. Bhd. is a private limited company incorporated in Malaysia on November 7, 1995 and is a wholly-owned subsidiary of Fitters
Sdn. Bhd..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AHT
NRG Asia Sdn. Bhd. is a private limited company incorporated in Malaysia on June 14, 1991 and is a wholly-owned subsidiary of Fitters
Sdn. Bhd..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modular
Floor Systems (M) Sdn. Bhd. is a private limited company incorporated in Malaysia on July 4, 2001 and is a wholly-owned subsidiary of
Fitters Sdn. Bhd..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2025, Cyclacel Pharmaceuticals, Inc., a Delaware corporation, entered into a share exchange agreement (the &#8220;Exchange Agreement&#8221;)
with Fitters Diversified Berhad, a Malaysian publicly listed company and Fitters Sdn. Bhd. for the disposal of 3,000,000 ordinary shares
in the capital of Fitters Sdn. Bhd.. Following the closing of the Transaction, Fitters Sdn. Bhd. will become a wholly-owned subsidiary
of the Cyclacel Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth details of the Company&#8217;s subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiary</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
    Name</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
                                            place of business /</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
                                            of incorporation</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Activities</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
    Sdn. Bhd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    and installation of fire safety materials and equipment, manufacture and assembly of firefighting protection and
    prevention systems and equipment</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
    (Sarawak) Sdn. Bhd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    of fire safety materials and equipment</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AHT
    NRG Asia Sdn. Bhd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renewable
    Energy Development</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modular
    Floor Systems (M) Sdn. Bhd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacture
    And trading of raised access-flooring systems</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 241; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span style="text-decoration: underline">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States
of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances were
eliminated in consolidation. The Company has adopted March 31 as its fiscal year end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries which the Company
controls and entities for which the Company is the primary beneficiary. Acquired businesses are included in the consolidated financial
statements from the date on which control is transferred to the Company. Subsidiaries are deconsolidated from the date that control ceases.
All inter-company accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is the organization chart of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="forms-4_024.jpg" alt=""/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing these financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities
in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 242; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers short-term, highly liquid investments with an original maturity of 90 days or less to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
deposit in Malaysia banks are secured by Perbadanan Insurans Deposit Malaysia, compensating up to a limit of Malaysia Ringgit MYR250,000
per deposit per member bank, which is equivalent to $56,351, if any of our bank fail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Accounts
Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist primarily of accounts receivable. The Company
extends credit to its customers in the normal course of business and generally does not require collateral. The Company&#8217;s credit
terms are dependent upon the segment, and the customer. The Company assesses the probability of collection from each customer at the
outset of the arrangement based on a number of factors, including the customer&#8217;s payment history and its current creditworthiness.
If in management&#8217;s judgment collection is not probable, the Company does not record revenue until the uncertainty is removed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
performs ongoing credit evaluations, and the Company maintains an allowance for potential credit losses based upon its loss history and
its aging analysis. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of credit losses in existing
accounts receivable. Management reviews the allowance for doubtful accounts each reporting period based on a detailed analysis of trade
receivables. In the analysis, management primarily considers the age of the customer&#8217;s receivable, and also considers the creditworthiness
of the customer, the economic conditions of the customer&#8217;s industry, general economic conditions and trends, and the business relationship
and history with its customers, among other factors. If any of these factors change, the Company may also change its original estimates,
which could impact the level of the Company&#8217;s future allowance for doubtful accounts. If judgments regarding the collectability
of receivables were incorrect, adjustments to the allowance may be required, which would reduce profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable is recognized and carried at the original invoice amount less an allowance for any uncollectible amounts. An estimate for
doubtful accounts receivable is made when collection of the full amount is no longer probable. Bad debts are written off as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Credit
losses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables
and other receivables. Management considers historical collection rates, the current financial status of the Company&#8217;s customers,
macroeconomic factors, and other industry-specific factors when evaluating current expected credit losses. Forward-looking information
is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of
accounts receivable, management believes that the carrying value, net of expected losses, approximates fair value and therefore, relies
more on historical and current analysis of such financial instruments, including its trade receivables and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
loss rate is determined by historical collection based on aging schedule, adjusted for current conditions using reasonable and supportable
forecasts. Based on the aging categorization and the adjusted loss rate per category, an allowance for credit losses is calculated by
multiplying the adjusted loss rate with the amortized cost in the respective age category.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Property,
Plant and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment are stated at cost, with depreciation and amortization provided using the straight-line method over the following
periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset
    Categories</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; background-color: white; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Depreciation
    Rate</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plant
    &amp; Machinery</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    Vehicle</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EDP
    Equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printer
    &amp; Software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    &amp; Fittings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Air
    Conditioner</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2%</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 243; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Revenue
recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries generate multiple streams of revenues and recognized upon customer obtained control of promised goods or
services and recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those services.
In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts
with customers. The Company applies the following five-step model in order to determine this amount:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Identify contract with customer;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Identify distinct performance obligations in contract, including promises if any;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Measurement of the transaction price, including the constraint on variable consideration;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Allocation of the transaction price to the performance obligations; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
Recognition of revenue when (or as) the Company satisfies each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under this standard, a contract is defined as an agreement
between two or more parties that creates enforceable rights and obligations. The Company identifies distinct goods or services promised
in the contract, which primarily include the sale of firefighting equipment and safety apparel, as well as the provision of installation
and maintenance services. The transaction price is determined based on the fixed consideration the Company expects to receive in exchange
for transferring the promised goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue
from trading of firefighting equipment and safety apparel</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from the sale of firefighting equipment and safety apparel is recognized at a point in time, typically upon delivery and the transfer
of control to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue
from installation and maintenance services</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from installation and maintenance services, including project-related work such as system installation, testing, and commissioning, is
recognized over time, as the customer simultaneously receives and consumes the benefits of the Company&#8217;s performance. Progress
toward satisfaction of these performance obligations is measured using an input method, based on costs incurred to date relative to the
total estimated costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Cost
of revenue</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenue includes direct costs associated with purchases of raw materials and finished goods such as fire safety equipment, fire extinguishers,
safety apparel, and direct costs associated with provision of contract services such as maintenance and installation services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Inventory</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of finished goods and are stated at the lower of cost, determined on a weighted average basis, or net realizable value. Net
realizable value is the estimated selling price in the ordinary course of business less the estimated cost of completion and the estimated
costs necessary to make the sale. When inventories are sold, their carrying amount is charged to expense in the period in which the revenue
is recognized. Write-downs for declines in net realizable value or for losses of inventories are recognized as an expense in the period
the impairment or loss occurs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 244; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Income
tax expense</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are determined in accordance with the provisions of ASC Topic 740, &#8220;Income Taxes&#8221; (&#8220;ASC Topic 740&#8221;). Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities
are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
in the period that includes the enactment date. The Company also adopted ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to
Income Tax Disclosures&#8221;, which requires disaggregated information about the reporting entity&#8217;s effective tax rate reconciliation
as well as information on income taxes paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements
uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the
financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax
positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of
being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Foreign
currencies translation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated
into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded
in the statement of operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of the Company is the United States Dollars (&#8220;US$&#8221; or &#8220;US dollars&#8221;) and the accompanying
financial statements have been expressed in US dollars. In addition, the Company&#8217;s subsidiary maintains its books and record in
Malaysia Ringgit (&#8220;MYR&#8221;), which is the respective functional currency as being the primary currency of the economic environment
in which the entity operates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US dollars are translated
into US dollars, in accordance with ASC Topic 830-30, &#8220;Translation of Financial Statement&#8221;, using the exchange rate on the
balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting
from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation
of amounts from the local currency of the Company into US$1 has been made at the following exchange rates for the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the years ended</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
    31</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period-end
    MYR : US$1 exchange rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4365</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7225</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period-average
    MYR : US$1 exchange rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5049</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6414</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 245; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Related
parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties,
which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control
the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also
considered to be related if they are subject to common control or common significant influence.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Fair
value of financial instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&#8217;s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables,
amount due to related parties, trade payables and other payables approximate at their fair values because of the short-term nature of
these financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also follows the guidance of the ASC Topic 820-10, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820-10&#8221;),
with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy
that prioritizes the inputs used in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 : Observable inputs such as quoted prices in active markets;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Net
Income/(Loss) per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates net income/(loss) per share in accordance with ASC Topic 260, &#8220;Earnings per Share.&#8221; Basic income/(loss)
per share is computed by dividing the net income/(loss) by the weighted-average number of common shares outstanding during the period.
Diluted income per share is computed similar to basic income/(loss) per share except that the denominator is increased to include the
number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if
the additional common shares were dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Lease</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offices for fixed periods pre-emptive extension options. The Company recognizes lease payments for its short-term lease on a
straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. The
right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments
made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Costs associated
with operating lease assets are recognized on a straight-line basis within operating expenses over the term of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the present value of the unpaid lease payments, ASC 842 requires a lessee to discount its unpaid lease payments using the
interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company
leases do not provide an implicit rate, the Company uses its incremental borrowing rate as the discount rate for the lease. The Company
incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance of ASC 280, &#8220;Segment Reporting&#8221;, which establishes standards for reporting information about
operating segments on a basis consistent with the Company&#8217;s internal organization structure as well as information about services
categories, business segments and major customers in financial statements. For the years ended March 31, 2025 and 2024, the Company has
two reportable segments based on business unit, trading business and contract services, and two reportable segments based on region,
West Malaysia and East Malaysia. The Company also adopted ASU 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures&#8221;, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced
disclosures about significant segment expenses.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 246; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Recently
accounting pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03
Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income
Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements,
among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and
depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03
is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15,
2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively
to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing
the potential impact on the Company&#8217;s financial statement disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, the FASB issued ASU 2025-02, Liabilities (Topic 405): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 122, which removes certain SEC guidance related to obligations to safeguard crypto-assets. The Company does not engage in activities
involving crypto-assets; therefore, the adoption of this ASU is not expected to have a material impact on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews new accounting standards as issued. Management has not identified any other new standards that it believes will have
a significant impact on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
INVENTORY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">274,682</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">276,643</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">122,736</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">115,197</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">775,090</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">680,511</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Provision for obsolete</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(167,600</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(145,420</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,004,908</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">926,931</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span style="text-decoration: underline">ACCOUNTS RECEIVABLE, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">337,938</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">411,531</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable &#8211; related party</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">848,603</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">760,991</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Provision for expected credit loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(136,113</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(91,643</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Provision for expected credit loss &#8211;
    related party</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(231,745</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,136</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Provision for doubtful
    debts</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(51,767</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,152</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable,
    net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">766,916</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,037,591</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span style="text-decoration: underline">PREPAYMENT, DEPOSITS AND OTHER RECEIVABLES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,700</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,587</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">577,118</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">755,672</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">701</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">659</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Provision for expected
    credit loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,877</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,442</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">572,642</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">759,476</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 247; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses include utility prepayment, project in progress and Wize platform retainer fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
receivables comprise rental receivables, staff advances, and a loan to a third-party company. The loan carries an interest rate of 8%
per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
deposits primarily include utility deposits, such as TNB, Syabas, and electricity deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 and 2024, the Company has other receivables of $12,442 and $5,844 respectively due from the common control company,
Fitters Engineering Services Sdn. Bhd. (Ipoh). Provisions for expected credit losses of $6,877 and $3,442 were recorded against these
balances, resulting in net receivables of $5,565 and $2,402 as of March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span style="text-decoration: underline">PROPERTY, PLANT AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant &amp; Machinery</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">109,578</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">102,942</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Motor Vehicle</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,582</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office Equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,532</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,197</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">EDP Equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,408</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,172</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Printer &amp; Software</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,560</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,066</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture &amp; Fittings</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">960</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">902</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Air Conditioner</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,554</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Renovation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,766</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">59,904</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Property</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">184,963</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">173,762</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">413,972</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">387,193</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: Accumulated depreciation (excluded property)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(226,686</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(211,096</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less: Accumulated depreciation
    (only property)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(62,930</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(57,251</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total property, plant
    and equipment, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,356</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,846</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                                                               the year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment in printer &amp; software</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">991</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Investment in air conditioner</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">642</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total investment in
    property, plant and equipment</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,791</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">991</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation for the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,909</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,040</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
with carrying amount of $122,033 is generate rental income from related party at the amount of $6,127 and $5,946 for March 31, 2025 and
2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span style="text-decoration: underline">ACCOUNTS PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">181,042</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">132,683</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">181,042</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">132,683</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 and 2024, the Company had accounts payable due to related party of $0 and $225, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 248; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span style="text-decoration: underline">OTHER PAYABLES AND ACCRUED LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,529</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53,258</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,191</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,753</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deposit received</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,578</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,482</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Receipt in advance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,423</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,721</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,493</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consist of outstanding audit fee, statutory contributions, and GST liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
payables include primarily payable to third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposits
received include rental deposits and utilities deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipt
in advance consist of monies received from customer but have yet to satisfied performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 and 2024, the Company has accrued expenses of $987 and $1,017 respectively due to a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span style="text-decoration: underline">AMOUNT DUE FROM/TO RELATED PARTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 and 2024 the Company has an outstanding amount due from a related party, in aggregate amounted $848,164 and $729,362,
respectively. These balances relate to miscellaneous expenses made by this related party on behalf of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 and 2024, the Company has an outstanding amount due to several related companies under common control companies in
aggregate amounted $1,169,929 and $1,098,755, respectively. These balances relate to miscellaneous expenses made by these related
parties on behalf of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aforementioned
amount is unsecured, non-interest bearing and payable on demand from 30 days to 2,000 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span style="text-decoration: underline">LEASE RIGHT-OF-USE ASSET AND LEASE LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Right-Of-Use Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of April 1, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,965</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">New right-of-use assets recognized</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33,399</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Amortization for the year ended March 31,
    2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28,779</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Adjustment for non-exercising option</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Adjustment for foreign
    currency translation difference</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,256</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of March 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,329</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lease Liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of April 1, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,062</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">New lease liability recognized</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33,399</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Imputed interest for the year ended March
    31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,163</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Gross repayment for the year ended March
    31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(30,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Adjustment for non-exercising option</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Adjustment for foreign
    currency translation difference</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,500</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of March
    31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,538</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease liability current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,859</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease liability non-current
    portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,679</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Right-Of-Use Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of April 1, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,329</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">New right-of-use assets recognized</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,264</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Amortization for the year ended March 31,
    2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32,633</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Adjustment for non-exercising option</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Adjustment for foreign
    currency translation difference</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,355</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of March 31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,509</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lease Liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of April 1, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,538</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">New lease liability recognized</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,264</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Imputed interest for the year ended March
    31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,237</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Gross repayment for the year ended March
    31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(39,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Adjustment for non-exercising option</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Adjustment for foreign
    currency translation difference</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,648</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of March
    31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,281</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease liability current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,375</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease liability non-current
    portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,906</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/> March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for amounts included in the measurement
    of lease liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating cash flow to operating
    lease</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">33,384</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,553</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remaining lease term for operating lease (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average discount
    rate for operating lease</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.68</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2025 and 2024, the Company incurred rental expenses of $36,669 and $30,586 to related party, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 249; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span style="text-decoration: underline">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2025 and 2024, the Company has the following transactions with related parties:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/> March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/> March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Engineering Services
    Sdn. Bhd.</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">697,664</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">816,676</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Engineering Services Sdn. Bhd. (Ipoh)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,894</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,754</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Master Pyroserve Sdn. Bhd.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,157</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,094</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Marketing Sdn. Bhd.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Diversified Berhad</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Cost of Revenue</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Engineering Services Sdn. Bhd.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Marketing Sdn. Bhd.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Diversified Berhad</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(124</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other transactions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Engineering Services Sdn. Bhd. (Ipoh)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,127</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,946</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Master Pyroserve Sdn. Bhd.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,396</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Marketing Sdn. Bhd.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,252</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(22,537</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">- Fitters Diversified Berhad</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(42,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,684</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">649,180</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">851,485</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitters
Diversified Berhad was the holding company of the Company before the share exchange transaction, while the other companies are under
the common control of Fitters Diversified Berhad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span style="text-decoration: underline">REVENUE FROM CONTRACTS WITH CUSTOMERS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s revenues are derived from the sale of fire-fighting equipment, the sale of safety apparel, and the provision of maintenance
and contract services. The breakdown of each revenue stream is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sale of fire-fighting equipment</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,472,290</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,626,561</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sale of safety apparel</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">413,478</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">474,878</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Maintenance services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,784</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,151</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Contract services</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,016</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total revenue</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,568</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,116,590</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2025 and 2024, the revenue including $708,782 and $889,659 of revenue to related parties, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>13.
<span style="text-decoration: underline">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loss before income taxes of the Company for the years ended March 31, 2025 and 2024 were comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the years ended March 31</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax jurisdictions from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">- Local (Malaysia)</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(103,072</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(155,802</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">(Loss) before income
    taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(103,072</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(155,802</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 250; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
for income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the years ended March 31</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax benefits/(expenses):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">- Local</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,986</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(38,136</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">- Local</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">- Local</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,347</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax payable:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">- Local</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">- Local</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">79,073</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,818</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Malaysia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Malaysian companies are subject to the Malaysian corporate tax laws at a two-tier corporate income tax rate based on amount of paid-up
capital. The 2024 tax rate for company with paid-up capital of MYR 2,500,000 (approximately $563,507) or less and that are not part of
a group containing a company exceeding this capitalization threshold is 15% on first chargeable income of MYR 150,000 (approximately
$33,810), 17% on remaining chargeable income up to MYR 600,000 (approximately $135,242) and any chargeable income beyond MYR 600,000
(approximately $135,242) will be subject to the corporate tax rate of 24%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">14.
CONCENTRATION OF RISK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Customer
Concentration</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2025 and 2024, one customer accounted for more than 10% of the Company&#8217;s revenues. The customers who accounted
for more than 10% of the Company&#8217;s revenues and its outstanding receivable balance at period-end is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>revenues</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>receivable,
                                            trade</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer A</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">697,971</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">823,990</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">759,057</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">653,859</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">697,971</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">823,990</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">759,057</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">653,859</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Vendor
Concentration</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2025 and 2024, there were one and two vendors respectively who accounted for more than 10% of the Company&#8217;s
cost of revenue. The vendors who accounted for more than 10% of the Company&#8217;s cost of revenue and its outstanding payable balance
at period-end is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended<br/>
 March 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost
    of revenue</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost
                                            of revenue</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>payable,
                                            trade</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vendor A</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">957,788</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">781,108</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,770</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vendor B</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">206,188</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">957,788</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">987,296</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,770</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 251; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
<span style="text-decoration: underline">FOREIGN CURRENCY EXCHANGE RATE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company cannot guarantee that the current exchange rate will remain stable, therefore there is a possibility that the Company could post
the same amount of income for two comparable periods and because of the fluctuating exchange rate post higher or lower income depending
on exchange rate converted into US dollars at the end of the financial year. The exchange rate could fluctuate depending on changes in
political and economic environments without notice.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span style="text-decoration: underline">SEGMENT REPORTING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
280, &#8220;Segment Reporting&#8221; establishes standards for reporting information about operating segments on a basis consistent with
the Company&#8217;s internal organization structure as well as information about services categories, business segments and major customers
in financial statements. The Company has two reportable segments based on business unit, trading business and contract services, and
two reportable segments based on region, West Malaysia and East Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted the ASU 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221;, which expands
annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the &#8220;Segment Reporting&#8221; Topic of the ASC, the Company&#8217;s chief operating decision maker has been identified
as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing
performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements
to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers,
and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation
under &#8220;Segment Reporting&#8221; due to their similar customer base and similarities in economic characteristics; nature of products
and services; and procurement, manufacturing and distribution processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the Year Ended and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of March 31, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">By
    Business Unit</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Trading
    Business</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contract
    Services</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,885,768</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,800</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,568</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cost of revenue</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,484,378</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,397</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,503,775</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">401,390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,403</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">417,793</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Selling, general and administrative
    expenses and other income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(585,293</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(585,293</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">(Loss) from operations</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(183,903</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,403</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(167,500</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,033,616</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,007</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,034,623</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Capital expenditure</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,356</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,356</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the Year Ended and</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
    of March 31, 2025</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    Region</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>West
    Malaysia</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>East
    Malaysia</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,737,289</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,279</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,921,568</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of revenue</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,391,765</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(112,010</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,503,775</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345,524</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,269</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">417,793</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
    general and administrative expenses and other income</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(489,842</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(95,451</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(585,293</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Loss)
    from operations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(144,318</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23,182</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(167,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,828,879</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">205,744</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,034,623</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    expenditure</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124,356</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124,356</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 252; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the Year Ended and</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
    of March 31, 2024</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    Business Unit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Business</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract
    Services</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,101,439</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,151</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,116,590</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of revenue</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,640,402</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,103</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,643,505</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">461,037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,048</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">473,085</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
    general and administrative expenses and other income</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(687,075</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(687,075</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Loss)
    from operations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(226,038</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,048</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(213,990</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,883,555</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,883,555</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    expenditure</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118,846</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118,846</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the Year Ended and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
                                            of March 31, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">By
    Region</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">West
    Malaysia</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">East
    Malaysia</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,986,698</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">129,892</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,116,590</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cost of revenue</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,563,741</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(79,764</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,643,505</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">422,957</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,128</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">473,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Selling, general and administrative
    expenses and other income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(513,422</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(173,653</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(687,075</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">(Loss) from operations</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(90,465</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(123,525</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(213,990</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,688,003</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">195,552</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,883,555</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Capital expenditure</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,837</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,846</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span style="text-decoration: underline">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC Topic 855, &#8220;Subsequent Events&#8221;, which establishes general standards of accounting for and disclosure
of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or
transactions that occurred after March 31, 2025 up through the date the Company presented these audited financial statements and there
are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, &#8220;Subsequent Events.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 253; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_105"></span>Annex
A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXCHANGE
AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>by
and among</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cyclacel
Pharmaceuticals, Inc.,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FITTERS
Diversified Berhad,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>and</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FITTERS
Sdn. Bhd.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>dated
as of May 5, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 254; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    1</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE EXCHANGE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    Exchange</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects
    of the Exchange</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    Time of the Exchange</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    and Officers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    2</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND
    FITTERS PARENT</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization,
    Standing and Corporate Power</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    Structure of the Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Authority; Noncontravention</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Authorization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence
    of Certain Changes or Events</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Fees</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation;
    Labor Matters; Compliance with Laws</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit
    Plans</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Returns and Tax Payments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
    Matters</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    Contract Defaults</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    Receivable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
    Property</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
    Recommendation and Affirmative Vote</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undisclosed
    Liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
    Information</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    with Affiliates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Business Practices</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Investigation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Other Representations or Warranties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
    Disclosure</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 255; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    3</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS AND WARRANTIES OF PARENT</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization,
    Standing and Corporate Power</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in">11</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    Structure of Parent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Authority; Noncontravention</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
    Authorization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    Documents; Undisclosed Liabilities; Financial Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence
    of Certain Changes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Fees</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation;
    Labor Matters; Compliance with Laws</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit
    Plans</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Returns and Tax Payments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
    Matters</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    Contract Defaults</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    Receivable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
    Property</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
    Determination and Vote Required</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required
    Parent Share Issuance Approval</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undisclosed
    Liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Investigation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Other Representations or Warranties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
    Disclosure</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    4</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVENANTS OF THE COMPANY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    of the Company Business</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction
    of Conditions Precedent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Other Negotiations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notification
    of Certain Matters</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    5</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVENANTS OF PARENT</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
    of Parent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    of the Parent Business</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 256 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notification
    of Certain Matters</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction
    of Conditions Precedent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    16 Matters</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    other Negotiations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    6</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVENANTS OF PARENT AND THE COMPANY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
    of Certain Events</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Announcements; Confidentiality</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
    Taxes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonable
    Efforts</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    and Expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legends</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Statement; Proxy Statement</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Shareholder Written Consent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
    Stockholder Meeting</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    7</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDITIONS TO EXCHANGE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condition
    to Obligation of Each Party to Effect the Exchange</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Conditions to Obligations of Parent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Conditions to Obligations of the Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    8</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERMINATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
    of Termination</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Termination</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    9</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
    10</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENERAL PROVISIONS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    or Indulgence Not Waiver; Remedies Cumulative</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire
    Agreement</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
    In Interest</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
    Law</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorneys&#8217;
    Fees</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drafting</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit A &#8211; Certain Definitions</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit B &#8211; Malaysia Form of Transfer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit C &#8211; Post-Closing Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C-1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 257 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXCHANGE
AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
EXCHANGE AGREEMENT (this or the &#8220;<b>Agreement</b>&#8221; is made and entered into as of May 5, 2025, by and among Cyclacel Pharmaceuticals,
Inc., a Delaware corporation (&#8220;<b>Parent</b>&#8221;), FITTERS Diversified Berhad, a Malaysian publicly listed company (&#8220;<b>Fitters
Parent</b>&#8221;) and FITTERS Sdn. Bhd., a Malaysia private limited company and a wholly-owned subsidiary of Fitters Parent (the &#8220;<b>Company</b>&#8221;
and together with Parent, and Fitters Parent, the &#8220;<b><span style="text-decoration: underline">Parties</span></b>&#8221; and each, a &#8220;<b><span style="text-decoration: underline">Party</span></b>&#8221;).
Certain other capitalized terms used in this Agreement are defined in <span style="text-decoration: underline">Exhibit A</span> attached hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RECITALS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS,
</b>Parent is a Delaware corporation listed on the Nasdaq under the symbol &#8220;CYCC;&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the Parties hereto intend to effect a share exchange between Parent and Fitters Parent (the &#8220;<b>Exchange</b>&#8221;), in which
the Company will become a wholly-owned subsidiary of Parent, in accordance with this Agreement and the DGCL and Malaysian Companies Act;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the Board of Directors of Parent has (a) determined that this Agreement, the Exchange and the transactions contemplated under this Agreement
is in the best interest of Parent and its stockholders, (b) approved the Exchange, (c) adopted this Agreement, and (d) determined to
recommend that its stockholders adopt, authorize and approve this Agreement, the Exchange and the transactions contemplated under this
Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the respective Boards of Directors of Fitters Parent and the Company have (a) determined that this Agreement, the Exchange and the transactions
contemplated under this Agreement is in the best interest of each company and its respective shareholders, (b) approved the Exchange,
(c) adopted this Agreement and (d) determined to recommend that its shareholders adopt, authorize and approve this Agreement, the Exchange
and the transactions contemplated under this Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
each of Parent, Fitters Parent and the Company desires to make certain representations, warranties, covenants and agreements in connection
with the Exchange and the other transactions contemplated by this Agreement and also to prescribe various conditions to the consummation
thereof; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
for U.S. federal income Tax purposes, the Parties intend, and each of Parent, Purchaser and the Company acknowledges, that the Exchange
will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a)(1)(B) of the Internal Revenue Code of 1986, as amended
(the &#8220;<b>Code</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 258; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the foregoing and the mutual promises, representations, warranties, covenants and agreements herein contained,
the parties hereto, intending to be legally bound, hereby agree as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
1</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
<br/></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
EXCHANGE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.1
Share Exchange</b>. Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, at the
Closing (as hereinafter defined), the Parties shall do the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Fitters Parent shall convey, assign, and transfer all of its right, title and interest to the Company Ordinary Shares (individually,
a &#8220;<b>Share</b>&#8221;; and collectively, the &#8220;<b>Shares</b>&#8221;) to Parent by delivering to Parent executed and transferrable
Share certificates endorsed in blank (or accompanied by duly executed stock powers endorsed in blank) in proper form for transfer. The
Shares transferred to Parent at the Closing shall constitute a one hundred (100%) percent of the issued and outstanding shares of capital
stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
As consideration for its acquisition of the Shares, Parent shall issue an amount of Parent Common Stock equal to nineteen and ninety
nine hundreds (19.99%) percent of the issued and outstanding shares of Parent Common Stock as of the Closing Date (the &#8220;<b>Exchange
Shares</b>&#8221;) to Fitters Parent by issuance of book-entry shares representing the Exchange Shares in accordance with the applicable
provisions of the DGCL, and instruct the Transfer Agent to update the register of stockholders of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
For U.S. federal income Tax purposes, the Exchange is intended to constitute a transaction that qualifies as a &#8220;reorganization&#8221;
within the meaning of Section 368(a) of the Code and the Treasury Regulations promulgated thereunder, and the Parties shall report the
transactions contemplated under this Agreement consistent with such intent and shall take no position in any tax filing or legal proceeding
inconsistent therewith. The Parties to this Agreement hereby adopt this Agreement as a &#8220;plan of reorganization&#8221; within the
meaning of Sections 1.368-2(g) and 1.368-3(a) of the U.S. Treasury Regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.2
Effects of the Exchange. </b>The Exchange shall have the effects set forth in the applicable provisions of the DGCL and Malaysian Companies
Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.3
Closing</b>. Upon the terms and subject to the conditions set forth herein and unless this Agreement has been terminated pursuant to
its terms, the closing of the Exchange (the &#8220;<b>Closing</b>&#8221;) shall take place remotely, at the date and time to be specified
by the Parties hereto, which date shall be no later than three (3) Business days after the date on which the conditions to Closing set
forth in <span style="text-decoration: underline">Article 8</span> of this Agreement shall have been satisfied or, to the extent permitted hereunder, waived by the appropriate
Party (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the
extent permitted hereunder, waiver of all such conditions) or at such other time, date or location as the parties hereto agree. The date
on which the Closing actually occurs and the transactions contemplated hereby become effective is hereinafter referred to as the &#8220;<b>Closing
Date</b>.&#8221; At the time of the Closing, Parent, Fitters Parent and the Company shall deliver the certificates and other documents
and instruments required to be delivered hereunder<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.4
Effective Time of the Exchange.</b> Subject to the provisions of this Agreement, at the Closing, the parties hereto shall (a) cause a
Form Section 105 (Form of Transfer of Securities) in substantially the form of <span style="text-decoration: underline">Exhibit B</span> (the &#8220;<b>Malaysia Form of Transfer</b>&#8221;)
to be executed, acknowledged and filed with the Companies Commission of Malaysia, as provided in s 105 and 106 of the Malaysian Companies
Act and (b) take all such other and further actions as may be required by the Malaysian Companies Act or other applicable Law to make
the Exchange effective. The Exchange shall become effective as of the date and time of the filing of the Malaysia Form of Transfer or
at such later date or time as may be agreed by the Company and Parent in writing and specified in the Malaysia Form of Transfer in accordance
with relevant provisions of the Malaysian Companies Act. The date and time of such effectiveness are referred to herein as the &#8220;<b>Effective
Time</b>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 259 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.5
Directors and Officers.</b> The directors of the Company and its Subsidiaries shall, from and after the Effective Time, be as set forth
on <span style="text-decoration: underline">Exhibit C</span> attached hereto, until their successors shall have been duly elected or appointed and qualified or until their earlier
death, resignation or removal in accordance with the Malaysian Companies Act and the Company Governing Documents. The officers of the
Company and its Subsidiaries shall, from and after the Effective Time remain the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
2</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPRESENTATIONS
AND WARRANTIES OF THE COMPANY AND FITTERS PARENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Fitters Parent and the Company jointly and severally represents and warrants to Parent that, except as set forth in the disclosure
schedules delivered by the Company to Parent (the &#8220;<b>Company Disclosure Schedule</b>&#8221;) prior to the execution of this Agreement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.1
Organization, Standing and Corporate Power</b>. The Company is duly organized, validly existing and in good standing under the Malaysian
Companies Act and has the requisite corporate power and authority to own, lease and operate its properties and carry on its business
as now being conducted. The Company holds, to the extent legally required to operate its business as such business is being operated
as of the date hereof, all Permits, except for any Permits for which the failure to obtain or hold would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect on the Company. The Company is duly qualified or licensed to do business
and is in good standing in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes
such qualification or licensing necessary, other than in such jurisdictions where the failure to be so qualified or licensed or to be
in good standing (individually or in the aggregate) would not have a Material Adverse Effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.2
Subsidiaries. </b>The Company has three (3) wholly-owned subsidiaries: AHT NRG Asia Sdn. Bhd., FITTERS (Sarawak) Sdn. Bhd., and Modular
Floor Systems (M) Sdn. Bhd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.3
Capital Structure of the Company.</b> As of the date of this Agreement, the number of shares and type of all authorized, issued and outstanding
capital shares of the Company, and all capital shares reserved for issuance under the Company&#8217;s various option and incentive plans
is specified on <span style="text-decoration: underline">Schedule 2.3</span>. All outstanding capital shares of the Company are duly authorized, validly issued, fully paid and
nonassessable and, except as set forth in <span style="text-decoration: underline">Schedule 2.3</span>, not subject to preemptive rights. Except for the Company Ordinary Shares
and as set forth on <span style="text-decoration: underline">Schedule 2.3</span>, there are no outstanding bonds, debentures, notes or other indebtedness or other securities
of the Company having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters.
As of immediately prior to the Effective Time, there will be no outstanding indebtedness of the Company convertible into capital shares
of the Company. Except as set forth in <span style="text-decoration: underline">Schedule 2.3</span>, there are no outstanding securities, options, warrants, calls, rights, commitments,
agreements, arrangements or undertakings of any kind to which the Company is a party or by which it is bound obligating the Company to
issue, deliver or sell, or cause to be issued, delivered or sold, additional capital shares or other equity or voting securities of the
Company or obligating the Company to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment,
agreement, arrangement or undertaking. There are no outstanding contractual obligations, commitments, understandings or arrangements
of the Company to repurchase, redeem or otherwise acquire or make any payment in respect of any capital shares of the Company. Except
as set forth on <span style="text-decoration: underline">Schedule 2.3</span>, there are no agreements or arrangements pursuant to which the Company is or could be required to
register Company Ordinary Shares or other securities under the Securities Act or other agreements or arrangements with or among any security
holders of the Company with respect to securities of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 260 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.4
Corporate Authority; Noncontravention.</b> The Company has all requisite corporate power and authority to enter into this Agreement and,
subject to receipt of the approval of its shareholders and the filing of the Malaysia Form of Transfer with the Companies Commission
of Malaysia, to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by the Company
and the consummation by the Company of the transactions contemplated hereby have been (or at Closing will have been) duly authorized
by all necessary corporate action on the part of the Company. This Agreement has been duly executed and when delivered by the Company
shall constitute a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except
as such enforcement may be limited by bankruptcy, insolvency or other similar Laws affecting the enforcement of creditors&#8217; rights
generally or by general principles of equity. The execution and delivery of this Agreement do not, and the consummation of the transactions
contemplated by this Agreement and compliance with the provisions hereof will not, conflict with, or result in any breach or violation
of, or Default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration
of or &#8220;put&#8221; right with respect to any obligation or to a loss of a material benefit under, or result in the creation of any
Lien upon any of the properties or Assets of the Company under, (i) the Governing Documents of the Company, (ii) any loan or credit agreement,
note, bond, mortgage, indenture, lease or other agreement, instrument, Permit, concession, franchise or license applicable to the Company,
its properties or Assets, or (iii) subject to the governmental filings and other matters referred to in the following sentence, any judgment,
Order, decree, statute, Law, ordinance, rule, regulation or arbitration award applicable to the Company, its properties or Assets, other
than, in the case of clauses (ii) and (iii), any such conflicts, breaches, violations, Defaults, rights, losses or Liens that individually
or in the aggregate would not have a Material Adverse Effect with respect to the Company or would not prevent, hinder or materially delay
the ability of the Company to consummate the transactions contemplated by this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.5
Governmental Authorization. </b>No consent, approval, Order or authorization of, or registration, declaration or filing with, or notice
to, any Governmental Entity is required to be obtained or made by the Company in connection with the execution and delivery of this Agreement
by the Company or the consummation by the Company of the transactions contemplated hereby, except any filings required under the Malaysian
Companies Act, the DGCL, the Securities Act, the Exchange Act, or any applicable United States state securities or &#8220;blue sky&#8221;
laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.6
Financial Statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
At or prior to Closing, Parent will have received a copy of the audited financial statements of the Company for the fiscal years ended
December 31, 2023 and 2024 (collectively, the &#8220;<b>Company Financial Statements</b>&#8221;). The Company Financial Statements fairly
present in all material respects the financial position of the Company at the dates indicated and its results of operations and cash
flows for the periods then ended and, to the Knowledge of the Company, except as indicated therein, reflect, as of the dates indicated,
all debts and liabilities of the Company, fixed or contingent, and of a nature required to be disclosed on a balance sheet, that are,
individually or in the aggregate, material to the business, results of operation, or financial condition of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Since January 1, 2025 (the &#8220;<b>Company Balance Sheet Date</b>&#8221;), there has been no Material Adverse Effect with respect to
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as set forth on <span style="text-decoration: underline">Schedule 2.6</span> or as contemplated by this Agreement, since the Company Balance Sheet Date, the Company has
not (i) issued, sold or otherwise disposed of, or agreed to issue, sell or otherwise dispose of, any capital shares or any other security
of the Company or (ii) granted, or agreed to grant, any option, warrant or other right to subscribe for or to purchase any capital shares
or any other security of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 261 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.7
Absence of Certain Changes or Events</b>. Except as set forth on <span style="text-decoration: underline">Schedule 2.7</span> or in connection with the execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby, since the Company Balance Sheet Date, the Company has
conducted its business only in the ordinary course consistent with past practice and there is not and has not been any:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
event, which, if it had taken place following the execution of this Agreement, would not have been permitted by <span style="text-decoration: underline">Section 4.1</span> without
prior consent of Parent;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
condition, event or occurrence which could reasonably be expected to prevent, hinder or materially delay the ability of the Company to
consummate the transactions contemplated by this Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
incurrence, assumption or guarantee by the Company of any indebtedness for borrowed money other than in the ordinary course and in amounts
and on terms consistent with past practices;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
creation or other incurrence by the Company of any Lien on any asset other than in the ordinary course consistent with past practices;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
labor dispute, other than routine, individual grievances, or, to the Knowledge of the Company, any activity or proceeding by a labor
union or representative thereof to organize any employees of the Company or any lockouts, strikes, slowdowns, work stoppages or, to the
Knowledge of the Company, threats by or with respect to such employees to do any of the foregoing;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
payment, prepayment or discharge of any material liability other than in the ordinary course of business or any failure to pay any material
liability when due;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
material write-offs or write-downs of any Assets of the Company;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
damage, destruction or loss of any Assets of the Company having, or reasonably expected to have, a Material Adverse Effect on the Company;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
other condition, event or occurrence which individually or in the aggregate could reasonably be expected to have a Material Adverse Effect
with respect to the Company; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
agreement or commitment to do any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.8
Certain Fees</b>. Except as set forth on <span style="text-decoration: underline">Schedule 2.8</span>, no brokerage or finder&#8217;s fees or commissions are or will be payable
by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other person with
respect to the transactions contemplated by this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.9
Litigation; Labor Matters; Compliance with Laws.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As of the date of this Agreement, there is no suit, action or proceeding or, to the Knowledge of the Company, investigation pending or,
to the Knowledge of the Company, threatened against or affecting the Company, or, to the Knowledge of the Company, any basis for any
such suit, action, proceeding or investigation, in each case that, individually or in the aggregate, could reasonably be expected to
have a Material Adverse Effect with respect to the Company or prevent, hinder or materially delay the ability of the Company to consummate
the transactions contemplated by this Agreement, nor is there any judgment, decree, injunction, or Order of any Governmental Entity or
arbitrator outstanding against the Company having, or which, insofar as reasonably could be foreseen by the Company, in the future could
have, any such effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 262 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company is not a party to, or bound by, any collective bargaining agreement, Contract or other agreement or understanding with a
labor union or labor organization, nor is it, as of the date of this Agreement, the subject of any proceeding asserting that it has committed
an unfair labor practice or seeking to compel it to bargain with any labor organization as to wages or conditions of employment nor,
as of the date of this Agreement, is there any strike, work stoppage or other labor dispute involving it pending or, to its Knowledge,
threatened, in each case that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect with
respect to Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company is in compliance with all statutes, Laws, regulations, ordinances, rules, judgments, Orders, decrees or arbitration awards
applicable to the Company or by which the Company or any of its businesses or properties is bound, except for such non-compliance that
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.10
Benefit Plans</b>. Except as set forth on <span style="text-decoration: underline">Schedule 2.10</span>, the Company is not a party to any Benefit Plan under which the Company
currently has an obligation to provide benefits to any current or former employee, officer or director of the Company. As used herein,
&#8220;<b>Benefit Plans</b>&#8221; shall mean any employee benefit plan, program, or arrangement of any kind, including any defined benefit
or defined contribution plan, share ownership plan, executive compensation program or arrangement, bonus plan, incentive compensation
plan or arrangement, profit sharing plan or arrangement, deferred compensation plan, agreement or arrangement, supplemental retirement
plan or arrangement, vacation pay, sickness, disability, or death benefit plan (whether provided through insurance, on a funded or unfunded
basis, or otherwise), medical or life insurance plan providing benefits to employees, retirees, or former employees or any of their dependents,
survivors, or beneficiaries, employee share option or share purchase plan, severance pay, termination, salary continuation, or employee
assistance plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.11
Tax Returns and Tax Payments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company has timely filed with the appropriate taxing authorities all material Tax Returns required to be filed by it (taking into
account all applicable extensions). All such Tax Returns are true, correct and complete in all material respects. All material Taxes
due and owing by the Company have been paid (whether or not shown on any Tax Return and whether or not any Tax Return was required).
Except as set forth on <span style="text-decoration: underline">Schedule 2.11</span>, the Company is not currently the beneficiary of any extension of time within which to file
any Tax Return or pay any Tax. No claim has ever been made in writing or, to the Knowledge of the Company, otherwise addressed to the
Company by a taxing authority in a jurisdiction where the Company does not file Tax Returns that it is or may be subject to taxation
by that jurisdiction. The unpaid Taxes of the Company did not, as of the Company Balance Sheet Date, materially exceed the reserve for
Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth
on the face of the most recent balance sheet included in the Company Financial Statements (rather than in any notes thereto). Since the
Company Balance Sheet Date, the Company has not incurred any material liability for Taxes outside the ordinary course of business consistent
with past practice. As of the Closing Date, the unpaid Taxes of the Company will not materially exceed the reserve for Tax liability
(excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the books
and records of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
No material claim for unpaid Taxes has been made or asserted in writing against the Company or become a Lien against the property of
the Company, no audit of any Tax Return of the Company is being conducted by a tax authority, and no extension of the statute of limitations
on the assessment of any Taxes has been granted by the Company and is currently in effect. The Company has withheld and paid all material
Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor,
shareholder or other third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 263 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
As used herein, &#8220;<b>Tax Return</b>&#8221; shall mean any return, report or statement required to be filed with any governmental
authority with respect to Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.12
Environmental Matters.</b> Except for such matters as would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect on the Company: (i) the Company is in compliance with all Environmental Laws; (ii) the Company has not received any written
notice regarding any violation of any Environmental Laws, including any investigatory, remedial or corrective obligations; (iii) the
Company holds all Permits and authorizations required under applicable Environmental Laws, and is in compliance with all terms, conditions
and provisions of all such Permits and authorizations; (iv) no releases of Hazardous Materials have occurred at, from, in, to, on or
under any real property currently or formerly owned, operated or leased by the Company or any predecessor thereof and no Hazardous Materials
are present in, on, about or migrating to or from any such property; (v) the Company has not transported or arranged for the treatment,
storage, handling, disposal, or transportation of any Hazardous Material to any off-site location; (vi) the Company has no liability,
absolute or contingent, under any Environmental Law; and (vii) there are no past, pending or, to the Knowledge of the Company, threatened
claims under Environmental Laws against the Company and Company is not aware of any facts or circumstances that could reasonably be expected
to result in a liability or claim against the Company pursuant to Environmental Laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.13
Material Contract Defaults</b>. Except as set forth on <span style="text-decoration: underline">Schedule 2.13</span>, the Company is not, and has not received any written notice
or has any Knowledge that any other Party is, in Material Contract Default under any Company Material Contract; and, to the Knowledge
of the Company, there has not occurred any event that with the lapse of time or the giving of notice or both would constitute such a
Material Contract Default under any Company Material Contract. For purposes of this Agreement, a &#8220;<b>Company Material Contract</b>&#8221;
means any Contract that is in effect as of the Closing Date to which the Company is a party (i) with expected receipts or expenditures
in excess of $100,000, (ii) requiring the Company to indemnify any person, other than any Contract providing for indemnification of customers
or other Persons pursuant to Contracts entered into in the ordinary course of business, (iii) granting exclusive rights to any party,
or (iv) evidencing indebtedness for borrowed or loaned money in excess of $100,000, including guarantees of such indebtedness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.14
Accounts Receivable.</b> All of the accounts receivable of the Company that are reflected on the most recent balance sheet included in
the Company Financial Statements or the accounting records of the Company as of the Closing (collectively, the &#8220;<b>Accounts Receivable</b>&#8221;)
represent or will represent valid obligations arising from sales actually made or services actually performed in the ordinary course
of business and are not subject to any defenses, counterclaims, or rights of set off other than those arising in the ordinary course
of business and for which adequate reserves have been established. The Accounts Receivable are fully collectible to the extent not reserved
for on the balance sheet on which they are shown or on the accounting records of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.15
Properties</b>. Except as set forth on <span style="text-decoration: underline">Schedule 2.15</span>, the Company has valid land use rights for all real property that is material
to its business and good, clear and marketable title to all the tangible properties and tangible Assets reflected in the latest balance
sheet included in the Company Financial Statements as being owned by the Company or acquired after the date thereof which are, individually
or in the aggregate, material to the Company&#8217;s business (except properties sold or otherwise disposed of since the date thereof
in the ordinary course of business), free and clear of all Material Liens. Any real property and facilities held under lease by the Company
is held by it under valid, subsisting and enforceable leases of which the Company is in compliance, except as could not, individually
or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 264 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.16
Intellectual Property.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As used in this Agreement, &#8220;<b>Intellectual Property</b>&#8221; means all right, title and interest in or relating to all intellectual
property, whether protected, created or arising under the laws of the United States or any other jurisdiction or under any international
convention, including, but not limited to the following: (a) service marks, trademarks, trade names, trade dress, logos and corporate
names (and any derivations, modifications or adaptations thereof), Internet domain names and Internet websites (and content thereof),
together with the goodwill associated with any of the foregoing, and all applications, registrations, renewals and extensions thereof
(collectively, &#8220;<b>Marks</b>&#8221;); (b) patents and patent applications, including all continuations, divisionals, continuations-in-part
and provisionals and patents issuing thereon, and all reissues, reexaminations, substitutions, renewals and extensions thereof (collectively,
&#8220;<b>Patents</b>&#8221;); (c) copyrights, works of authorship and moral rights, and all registrations, applications, renewals, extensions
and reversions thereof (collectively, &#8220;<b>Copyrights</b>&#8221;); (d) confidential and proprietary information, trade secrets and
non-public discoveries, concepts, ideas, research and development, technology, know-how, formulae, inventions (whether or not patentable
and whether or not reduced to practice), compositions, processes, techniques, technical data and information, procedures, designs, drawings,
specifications, databases, customer lists, supplier lists, pricing and cost information, and business and marketing plans and proposals,
in each case excluding any rights in respect of any of the foregoing that comprise or are protected by Patents (collectively, &#8220;<b>Trade
Secrets</b>&#8221;); and (e) Technology. For purposes of this Agreement, &#8220;<b>Technology</b>&#8221; means all Software, information,
designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs,
subroutines, tools, materials, specifications, processes, inventions (whether or not patentable and whether or not reduced to practice),
apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings,
and other embodiments of any of the foregoing, in any form or media whether or not specifically listed herein. Further, for purposes
of this Agreement, &#8220;<b>Software</b>&#8221; means any and all computer programs, whether in source code or object code; databases
and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize
and develop any of the foregoing; and all documentation, including user manuals and other training documentation, related to any of the
foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<span style="text-decoration: underline">Schedule 2.16</span> sets forth a list, as of the date of this Agreement, of all: (a) Company-Owned IP that is the subject of any issuance,
registration, certificate, application or other filing by, to or with any Governmental Authority or authorized private registrar, including
registered Marks, registered Copyrights, issued Patents, domain name registrations and pending applications for any of the foregoing;
(b) material unregistered Company-Owned IP, including, but not limited to all Software developed by or for the Company; and (c) any Software
not exclusively owned by the Company and incorporated, embedded or bundled with any Software listed in clause (b) above (except for commercially
available software and so-called &#8220;shrink wrap&#8221; software licensed to the Company on reasonable terms through commercial distributors
or in consumer retail stores for a license fee of no more than $20,000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company is the exclusive owner of or, to the Knowledge of the Company, has a valid and enforceable right to use all Intellectual
Property listed for the Company in <span style="text-decoration: underline">Schedule 2.16</span> (and any other Intellectual Property required to be listed in <span style="text-decoration: underline">Schedule 2.16</span>)
as the same are used, sold, licensed and otherwise commercially exploited by the Company, free and clear of all Material Liens, and no
such Intellectual Property has been abandoned, except in each case as would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect on the Company. To the Knowledge of the Company, the Company-Owned IP and the material Intellectual
Property licensed to it pursuant to, to the Knowledge of the Company, valid and enforceable written license agreements include all of
the material Intellectual Property necessary and sufficient to enable the Company to conduct its business in substantially the manner
in which such business is currently being conducted. To the Knowledge of the Company, its rights in and to the Company-Owned IP are valid
and enforceable, except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 265 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company has not received, and is not aware of, any written or oral notice of any reasonable basis for an allegation against the Company
of any infringement, misappropriation, or violation by the Company of any rights of any third party with respect to any Intellectual
Property, and the Company is not aware of any reasonable basis for any claim challenging the ownership, use, validity or enforceability
of any Intellectual Property owned, used or held for use by the Company, in each case except for such allegations or claims that would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company. To the Knowledge of the
Company, no third party is infringing, misappropriating, or otherwise violating (or has infringed, misappropriated or violated) any Company-Owned
IP or Intellectual Property exclusively licensed to the Company, except as would not be reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Except as would not be reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company, (a)
the conduct of the business of the Company is not infringing, misappropriating or otherwise violating any Intellectual Property rights
of any third parties, and (b) the Company is not aware of any infringement, misappropriation or violation of any third-party rights which
will occur as a result of the continued operation of the Company as presently operated and/or the consummation of the transaction contemplated
by this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company has taken reasonable measures to protect the confidentiality and value of its Trade Secrets (and any confidential information
owned by a third party to whom the Company has a confidentiality obligation), except where the failure to take such actions would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
To the Knowledge of the Company, the consummation of the transactions contemplated by this Agreement will not adversely affect the right
of the Company to own or use any Intellectual Property owned, used or held for use by it), except for any such effect as would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
To the Knowledge of the Company, all necessary registration, maintenance, renewal and other relevant filing fees in connection with any
of the Company-Owned IP listed (or required to be listed) on <span style="text-decoration: underline">Schedule 2.16</span> have been timely paid and all necessary registrations,
documents, certificates and other relevant filings in connection with such Company-Owned IP have been timely filed with the relevant
governmental authorities in the United States or foreign jurisdictions, as the case may be, for the purpose of maintaining such Company-Owned
IP and all issuances, registrations and applications therefor, except in each case where the failure to take such actions would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company. To the Knowledge of the Company, there
are no material annuities, payments, fees, responses to office actions or other filings necessary to be made and having a due date with
respect to any such Company-Owned IP within ninety (90) days after the date of this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17
Board Recommendation and Affirmative Vote.</b> The Boards of Directors of Fitters Parent and the Company have determined that the terms
of the Exchange are fair to and in the best interests of the shareholders of Fitters Parent and the Company and recommended that the
Company&#8217;s shareholders approve the Exchange. The affirmative vote (or written consent) of the holders of a majority of the capital
shares of the Company outstanding on the record date and entitled to vote thereon, voting as a single class on an as-converted basis
is required to approve the Exchange and this Agreement (the &#8220;<b>Required Company Shareholder Vote</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 266 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.18
Undisclosed Liabilities.</b> The Company has no liabilities or monetary obligations of any nature (whether fixed or unfixed, secured
or unsecured, known or unknown and whether absolute, accrued, contingent, or otherwise) except for such liabilities or obligations (i)
reflected or reserved against in the Company Financial Statements, (ii) incurred in the ordinary course of business after the Company
Balance Sheet Date, (iii) incurred in connection with the transactions contemplated by this Agreement, (iv) disclosed in <span style="text-decoration: underline">Schedule
2.18</span>, or (v) would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.19
Reserved</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.20
Parent Information.</b> Each of Fitters Parent and the Company acknowledges that it has had access to the documents filed by Parent under
the Exchange Act, since the end of its most recently completed fiscal year to the date hereof, and has carefully reviewed the same (&#8220;<b>Exchange
Act Documents</b>&#8221;). Each of Fitters Parent and the Company has carefully considered the potential risks relating to Parent and
investing in the Parent Common Stock, and fully understands that such securities are speculative investments, which involve a high degree
of risk of loss of the Company and its shareholders&#8217; entire investment. Among others, each of Fitters Parent and the Company has
carefully considered each of the risks identified under the caption &#8220;Risk Factors&#8221; in the Exchange Act Documents, which &#8220;Risk
Factors&#8221; are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.21
Transactions with Affiliates. </b><span style="text-decoration: underline">Schedule 2.21</span> describes any material transactions or relationships between, on the one hand,
the Company and, on the other hand, any (i) executive officer or director of the Company or any such executive officer&#8217;s or director&#8217;s
immediate family members, (ii) owner of more than 5% of the voting power of the outstanding capital shares of the Company, or (iii) to
the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item 404 of Regulation S-K under the Securities
Act) of any such officer, director or owner (other than the Company) in the case of each of clauses (i), (ii) or (iii) that is of the
type that would be required to be disclosed under Item 404 of Regulations S-K under the Securities Act. <span style="text-decoration: underline">Schedule 2.21</span> lists each
shareholders&#8217; agreement, voting agreement, registration rights agreement, co-sale agreement or other similar Company Material Contract
between the Company and any holders of capital share of the Company, including any such Contract granting any Person investor rights,
rights of first refusal, rights of first offer, registration rights, director designation rights or similar rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.22
Certain Business Practices.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company, nor any of its respective representatives acting on their behalf has (i) used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses relating to political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees, to foreign or domestic political parties or campaigns or violated any provision of the U.S. Foreign Corrupt Practices
Act of 1977 or any other local or foreign anti-corruption or bribery Law or (iii) made any other unlawful payment. The Company, nor to
the Knowledge of the Company, any of their respective representatives acting on their behalf, has directly or indirectly, given or agreed
to give any unlawful gift or similar benefit in any material amount to any customer, supplier, governmental employee or other Person
who is or may be in a position to help or hinder the Company or assist the Company in connection with any actual or proposed transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The operations of the Company are and have been conducted at all times in compliance with money laundering statutes in all applicable
jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any Governmental Entity, and no action involving the Company with respect to any of the foregoing is pending or, to the
Knowledge of the Company, threatened.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 267 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Neither the Company nor any of its respective directors or officers, or, to the Knowledge of the Company, any other representative acting
on behalf of the Company is currently identified on the specially designated nationals or other blocked person list or otherwise currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;<b>OFAC</b>&#8221;)
or on the sanctions lists adopted by the United Nations and/or European Union, as such lists may be extended from time to time (&#8220;<b>Sanctions
List</b>&#8221;) and the Company has not in the last five (5) fiscal years, directly or indirectly, used any funds, or loaned, contributed
or otherwise made available such funds to any Subsidiary, joint venture partner or other Person, in connection with any sales or operations
in Cuba, Iran, Syria, Sudan, Myanmar or any other country sanctioned by OFAC or on the Sanctions List or for the purpose of financing
the activities of any Person currently subject to, or otherwise in violation of, any U.S. sanctions administered by OFAC or the Sanctions
List.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.23
Independent Investigation</b>. Each of Fitters Parent and the Company has conducted its own independent investigation, review and analysis
of the business, results of operations, prospects, condition (financial or otherwise) or assets of Parent, and acknowledges that it has
been provided adequate access to the personnel, properties, assets, premises, books and records, and other documents and data of Parent
for such purpose. Each of Fitters Parent and the Company acknowledges and agrees that in making its decision to enter into this Agreement
and to consummate the transactions contemplated under this Agreement, it has relied solely upon its own investigation and the express
representations and warranties of Parent set forth in this Agreement (including the related portions of Parent Disclosure Schedules)
and in any certificate delivered to the Company pursuant hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.24
No Other Representations or Warranties. </b>Each of Fitters Parent and the Company hereby acknowledges and agrees that, except for the
representations and warranties contained in this Agreement, neither Parent, Purchaser nor any other Person on behalf of Parent or Purchaser
makes any express or implied representation or warranty with respect to Parent or Purchaser, or with respect to any other information
provided to the Company, any of its shareholders or any of their respective Affiliates in connection with the transactions contemplated
by this Agreement, and (subject to the express representations and warranties of Parent and Purchaser set forth in <span style="text-decoration: underline">Article 3</span> (in
each case as qualified and limited by the Parent Disclosure Schedule)) none of the Company, or any of its representatives or shareholders,
has relied on any such information (including the accuracy or completeness thereof).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.25
Full Disclosure</b>. The representations and warranties made by each of Fitters Parent and the Company in this Agreement, including the
Company Disclosure Schedules attached hereto, and all statements set forth in the certificates delivered by each of Fitters Parent and
the Company at the Closing pursuant to this Agreement do not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make such representations, warranties or statements, in light of the circumstances under which they were made,
not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
3</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPRESENTATIONS
AND WARRANTIES OF PARENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
represents and warrants to Fitters Parent and the Company that, except as set forth in the Parent SEC Documents and the Parent Disclosure
Schedule:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.1
Organization, Standing and Corporate Power.</b> Parent is duly organized, validly existing and in good standing under the Laws of the
State of Delaware, and has the requisite corporate power and authority to own, lease and operate its properties and carry on its business
as now being conducted. Parent holds, to the extent legally required to operate its business as such business is being operated as of
the date hereof, all Permits, except for any Permits for which the failure to obtain or hold would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect on Parent. Parent is duly qualified or licensed to do business and is in
good standing in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes such qualification
or licensing necessary, other than in such jurisdictions where the failure to be so qualified or licensed or to be in good standing (individually
or in the aggregate) would not have a Material Adverse Effect with respect to Parent. Shares of common stock of Parent, par value $0.001
(&#8220;<b>Parent Common Stock</b>&#8221;), are listed on the Nasdaq under the symbol &#8220;<b>CYCC</b>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 268 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.2
Subsidiaries. </b>Except as set forth on <span style="text-decoration: underline">Schedule 3.2</span>, Parent has no Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.3
Capital Structure of Parent. </b>The authorized capital stock of Parent as of the date hereof consists of (i) 600,000,000 shares of Parent
Common Stock, of which 381,202,294 shares are issued and outstanding, and (ii) 5,000,000 shares of Preferred Stock, par value $0.001
(&#8220;<b>Parent Preferred Stock</b>&#8221;), of which 135,537 shares are issued and outstanding, and 6,834,828 shares of Parent Common
Stock or Parent Preferred Stock issuable upon the exercise of outstanding warrants, convertible notes, options or otherwise. All outstanding
shares of capital stock of Parent are duly authorized, validly issued, fully paid and nonassessable, not subject to preemptive rights,
and issued in compliance with all applicable state and federal Laws concerning the issuance of securities. Except for the Parent Common
Stock and Parent Preferred Stock, there are no outstanding bonds, debentures, notes or other indebtedness or other securities of Parent
having the right to vote (or convertible into, or exchangeable for, securities having the right to vote). Except as set forth in the
SEC Parent Documents, there are no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements or
undertakings of any kind to which Parent is a party or by which Parent is bound obligating Parent to issue, deliver or sell, or cause
to be issued, delivered or sold, additional shares of capital stock or other equity securities of Parent or obligating Parent to issue,
deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity securities of Parent or
obligating Parent to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement
or undertaking. Except as set forth in the SEC Parent Documents, there are no outstanding contractual obligations, commitments, understandings
or arrangements of Parent or any of its subsidiaries to repurchase, redeem or otherwise acquire or make any payment in respect of any
shares of capital stock of Parent or any of its subsidiaries. Except as set forth in the SEC Parent Documents, there are no agreements
or arrangements pursuant to which Parent is or could be required to register shares of Parent Common Stock or other securities under
the Securities Act or other agreements or arrangements with or among any security holders of Parent with respect to securities of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.4
Corporate Authority; Noncontravention</b>. Parent has all requisite corporate power and authority to enter into this Agreement and, subject
to receipt of the approval of its stockholders, to consummate the transactions contemplated by this Agreement. The execution and delivery
of this Agreement by Parent and the consummation by Parent of the transactions contemplated hereby have been (or at Closing will have
been) duly authorized by all necessary corporate action on the part of Parent. This Agreement has been duly executed and when delivered
by Parent, shall constitute a valid and binding obligation of Parent, enforceable against Parent in accordance with its terms, except
as such enforcement may be limited by bankruptcy, insolvency or other similar Laws affecting the enforcement of creditors&#8217; rights
generally or by general principles of equity. The execution and delivery of this Agreement do not, and the consummation of the transactions
contemplated by this Agreement and compliance with the provisions hereof will not, conflict with, or result in any breach or violation
of, or Default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration
of or &#8220;put&#8221; right with respect to any obligation or to loss of a material benefit under, or result in the creation of any
Lien upon any of the properties or Assets of Parent under, (i) the certificate of incorporation, bylaws, or other charter documents of
Parent, (ii) any loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, Permit, concession,
franchise or license applicable to Parent, its properties or Assets, or (iii) subject to the governmental filings and other matters referred
to in the following sentence, any judgment, Order, decree, statute, Law, ordinance, rule, regulation or arbitration award applicable
to Parent, its properties or Assets, other than, in the case of clauses (ii) and (iii), any such conflicts, breaches, violations, Defaults,
rights, losses or Liens that individually or in the aggregate would not have a Material Adverse Effect with respect to Parent or would
not prevent, hinder or materially delay the ability of Parent to consummate the transactions contemplated by this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 269 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.5
Government Authorization</b>. No consent, approval, Order or authorization of, or registration, declaration or filing with, or notice
to, any Governmental Entity, is required to be obtained or made by Parent in connection with the execution and delivery of this Agreement
by Parent, or the consummation by Parent of the transactions contemplated hereby, except any filings under the DGCL, Malaysian Companies
Act, Nasdaq, the Securities Act, the Exchange Act or any applicable state securities or &#8220;blue sky&#8221; laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.6
SEC Documents; Undisclosed Liabilities; Financial Statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Parent has timely filed all reports, schedules, forms, statements and other documents as required by the Securities and Exchange Commission
(the &#8220;<b>SEC</b>&#8221;) and Parent has delivered or made available to the Company all reports, schedules, forms, statements and
other documents filed with the SEC (collectively, and in each case including all exhibits and schedules thereto and documents incorporated
by reference therein, the &#8220;<b>Parent SEC Documents</b>&#8221;). As of their respective dates, the Parent SEC Documents complied
in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations
of the SEC promulgated thereunder applicable to such Parent SEC Documents. Except to the extent revised or superseded by a subsequent
filing with the SEC (a copy of which has been provided to the Company prior to the date of this Agreement), none of the Parent SEC Documents
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. The consolidated financial
statements of Parent included in such Parent SEC Documents comply as to form in all material respects with applicable accounting requirements
and the published rules and regulations of the SEC with respect thereto, have been prepared in accordance with GAAP (except, in the case
of unaudited consolidated quarterly statements, as permitted by Form 10-Q of the SEC) applied on a consistent basis during the periods
involved (except as may be indicated in the notes thereto) and fairly present the consolidated financial position of Parent and its consolidated
subsidiaries as of the dates thereof and the consolidated results of operations and changes in cash flows for the periods then ended
(subject, in the case of unaudited quarterly statements, to normal year-end audit adjustments as determined by Parent&#8217;s independent
accountants). Except as set forth in the Parent SEC Documents, at the date of the most recent financial statements of Parent included
in the Parent SEC Documents, Parent has not incurred any liabilities or monetary obligations of any nature (whether accrued, absolute,
contingent or otherwise), which, individually, or in the aggregate, could reasonably be expected to have a Material Adverse Effect on
Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Since January 1, 2025 (the &#8220;<b>Parent Balance Sheet Date</b>&#8221;), there has been no Material Adverse Effect with respect to
Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as disclosed in the Parent SEC Documents filed prior to the date hereof or as provided in this Agreement, since the Parent Balance
Sheet Date, Parent has not (i) issued, sold or otherwise disposed of, or agreed to issue, sell or otherwise dispose of, any capital stock
or any other security of Parent or (ii) granted or agreed to grant any option, warrant or other right to subscribe for or to purchase
any capital stock or any other security of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 270 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.7
Absence of Certain Changes</b>. Except as disclosed in the Parent SEC Documents filed prior to the date hereof or as set forth on <span style="text-decoration: underline">Schedule
3.7,</span> since the Parent Balance Sheet Date, Parent has conducted its business only in the ordinary course consistent with past practice
in light of its current business circumstances, and there is not and has not been any:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
event which, if it had taken place following the execution of this Agreement, would not have been permitted by <span style="text-decoration: underline">Section 5.2</span> without
prior consent of the Company;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
condition, event or occurrence which could reasonably be expected to prevent, hinder or materially delay the ability of Parent to consummate
the transactions contemplated by this Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
incurrence, assumption or guarantee by Parent of any indebtedness for borrowed money other than in the ordinary course and in amounts
and on terms consistent with past practices;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
creation or other incurrence by Parent of any Lien on any asset other than in the ordinary course consistent with past practices;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
labor dispute, other than routine, individual grievances, or, to the Knowledge of Parent, any activity or proceeding by a labor union
or representative thereof to organize any employees of Parent or any lockouts, strikes, slowdowns, work stoppages, or to the Knowledge
of Parent, or threats by or with respect to such employees to do any of the foregoing;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
payment, prepayment or discharge of any material liability other than in the ordinary course of business or any failure to pay any material
liability when due;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
material write-offs or write-downs of any Assets of Parent;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
damage, destruction or loss of any Assets of the Company having, or reasonably expected to have, a Material Adverse Effect on Parent;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
other condition, event or occurrence which individually or in the aggregate could reasonably be expected to have a Material Adverse Effect
with respect to Parent; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
agreement or commitment to do any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.8
Certain Fees.</b> No brokerage or finder&#8217;s fees or commissions are or will be payable by Parent to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other person with respect to the transactions contemplated by this
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.9
Litigation; Labor Matters; Compliance with Laws.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As of the date of this Agreement, there is no suit, action or proceeding or, to the Knowledge of Parent, investigation pending or, to
the Knowledge of Parent, threatened against or affecting Parent or to the Knowledge of Parent, any basis for any such suit, action, proceeding
or investigation in each case that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect
with respect to Parent or prevent, hinder or materially delay the ability of Parent to consummate the transactions contemplated by this
Agreement, nor is there any judgment, decree, injunction, or Order of any Governmental Entity or arbitrator outstanding against Parent
having, or which, insofar as reasonably could be foreseen by Parent, in the future could have, any such effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 271 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Parent is not a party to, or bound by, any collective bargaining agreement, Contract or other agreement or understanding with a labor
union or labor organization, nor is it, as of the date of this Agreement, the subject of any proceeding asserting that it has committed
an unfair labor practice or seeking to compel it to bargain with any labor organization as to wages or conditions of employment nor,
as of the date of this Agreement, is there any strike, work stoppage or other labor dispute involving it pending or, to its Knowledge,
threatened, in each case that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect with
respect to Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Parent is in compliance with all statutes, Laws, regulations, ordinances, rules, judgments, Orders, decrees or arbitration awards applicable
to Parent or by which Parent or any of its businesses or properties is bound, except for such non-compliance that would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect on either Parent or Purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.10
Benefit Plans</b>. Except as set forth in the SEC Parent Documents, Parent is not a party to any Benefit Plan under which Parent currently
has an obligation to provide benefits to any current or former employee, officer or director of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.11
Tax Returns and Tax Payments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Parent has timely filed with the appropriate taxing authorities all material Tax Returns required to be filed by it (taking into account
all applicable extensions). All such Tax Returns are true, correct and complete in all material respects. All material Taxes due and
owing by Parent has been paid (whether or not shown on any Tax Return and whether or not any Tax Return was required). Parent is not
currently the beneficiary of any extension of time within which to file any Tax Return or pay any Tax. No claim has ever been made in
writing or, to the Knowledge of Parent, otherwise addressed to Parent by a taxing authority in a jurisdiction where Parent does not file
Tax Returns that it is or may be subject to taxation by that jurisdiction. The unpaid Taxes of Parent did not, as of the Parent Balance
Sheet Date, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences
between book and Tax income) set forth on the face of the most recent balance sheet included in the Parent SEC Documents (rather than
in any notes thereto). Since the Parent Balance Sheet Date, Parent has not incurred any material liability for Taxes outside the ordinary
course of business consistent with past practice. As of the Closing Date, the unpaid Taxes of Parent will not materially exceed the reserve
for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set
forth on the books and records of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
No material claim for unpaid Taxes has been made or asserted in writing against Parent or become a Lien against the property of Parent,
no audit of any Tax Return of Parent is being conducted by a tax authority, and no extension of the statute of limitations on the assessment
of any Taxes has been granted by Parent and is currently in effect. Parent has withheld and paid all material Taxes required to have
been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder or other
third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 272 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.12
Environmental Matters.</b> Except for such matters as would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect on Parent, (i) Parent is in compliance with all Environmental Laws; (ii) Parent has not received any written notice regarding
any violation of any Environmental Laws, including any investigatory, remedial or corrective obligations, which, if determined adversely
to Parent, would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect; (iii) Parent holds
all Permits and authorizations required under applicable Environmental Laws and is compliance with all terms, conditions and provisions
of all such Permits and authorizations; (iv) no releases of Hazardous Materials have occurred at, from, in, to, on or under any real
property currently or formerly owned, operated or leased by Parent or any predecessor thereof and no Hazardous Materials are present
in, on, about or migrating to or from any such property; (v) Parent has not transported or arranged for the treatment, storage, handling,
disposal, or transportation of any Hazardous Material to any off-site location; (vi) Parent has no liability, absolute or contingent,
under any Environmental Law; and (vii) there are no past, pending or, to the Knowledge of Parent, threatened claims under Environmental
Laws against Parent and Parent is not aware of any facts or circumstances that could reasonably be expected to result in a liability
or claim against Parent pursuant to Environmental Laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.13
Material Contract Defaults</b>. Parent is not and has not received any written notice or has any Knowledge that any other Party is, in
Material Contract Default under any Parent Material Contract; and to the Knowledge of Parent, there has not occurred any event that with
the lapse of time or the giving of notice or both would constitute such a Material Contract Default and any Parent Material Contract.
For purposes of this Agreement, a &#8220;<b>Parent Material Contract</b>&#8221; means any Contract that is in effect as of the Closing
Date to which Parent is a party (i) with expected receipts or expenditures in excess of $100,000, (ii) requiring Parent to indemnify
any person, other than any Contract providing for indemnification of customers or other Persons pursuant to Contract entered into in
the ordinary course of business, (iii) granting exclusive rights to any party, or (iv) evidencing indebtedness for borrowed or loaned
money in excess of $100,000, including guarantees of such indebtedness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.14
Accounts Receivable</b>. All of the accounts receivable of Parent that are reflected on the most recent balance sheet included in the
Parent SEC Documents or the accounting records of Parent as of the Closing (collectively, the &#8220;<b>Parent Accounts Receivable</b>&#8221;)
represent or will represent valid obligations arising from sales actually made or services actually performed in the ordinary course
of business and are not subject to any defenses, counterclaims, or rights of set off other than those arising in the ordinary course
of business and for which adequate reserves have been established. The Parent Accounts Receivable are fully collectible to the extent
not reserved for on the balance sheet on which they are shown or on the accounting records of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.15
Properties</b>. Parent has valid land use rights for all real property that is material to its business and good, clear and marketable
title to all the tangible properties and tangible Assets reflected in the latest balance sheet included in the Parent SEC Documents as
being owned by Parent or acquired after the date thereof which are, individually or in the aggregate, material to Parent&#8217;s business
(except properties sold or otherwise disposed of since the date thereof in the ordinary course of business), free and clear of all Material
Liens. Any real property and facilities held under lease by Parent are held by it under valid, subsisting and enforceable leases of which
Parent is in compliance, except as could not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.16
Intellectual Property</b>. Parent owns or has valid rights to use the Trademarks, trade names, domain names, copyrights, patents, logos,
licenses and computer software programs (including, without limitation, the source codes thereto) that are necessary for the conduct
of its business as now being conducted. All of Parent&#8217;s licenses to use Software programs are current and have been paid for the
appropriate number of users. To the Knowledge of Parent , none of Parent&#8217;s Intellectual Property or Parent&#8217;s License Agreements
infringe upon the rights of any third party that may give rise to a cause of action or claim against Parent or its successors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.17
Board Determination and Vote Required.</b> The Board of Directors of Parent has unanimously determined that the terms of the Exchange
and transactions contemplated under this Agreement are fair to and in the best interests of Parent and its stockholders. The affirmative
vote of a majority of (a) the shares of Parent Common Stock properly cast is the only vote of the holders of any class or series of Parent&#8217;s
capital stock necessary to approve this Agreement and thereby approve the transactions contemplated under this Agreement, including the
Exchange (the &#8220;<b>Parent Stockholder Exchange Vote</b>&#8221;) and (b) if deemed necessary by Parent, the shares of Parent Common
Stock entitled to vote thereon is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve
an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split and/or increase the number of shares of
Parent Common Stock (together with the Parent Stockholder Exchange Vote, the &#8220;<b>Parent Stockholder Vote</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 273 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.18
Required Parent Share Issuance Approval.</b> Parent represents that the issuance of the Parent Common Stock will be in compliance with
the DGCL, Nasdaq, and the Certificate of Incorporation and Bylaws of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.19
Undisclosed Liabilities.</b> Parent has no liabilities or obligations of any nature (whether fixed or unfixed, secured or unsecured,
known or unknown and whether absolute, accrued, contingent, or otherwise) except for liabilities or obligations (i) reflected or reserved
against in the financial statements included in the Parent SEC Documents filed prior to the date hereof, (ii) incurred in the ordinary
course of business since the Parent Balance Sheet Date, (iii) incurred in connection with the transactions contemplated by this Agreement,
(iv) disclosed in <span style="text-decoration: underline">Schedule 3.19</span>, or (v) would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.20
Independent Investigation</b>. Parent has conducted its own independent investigation, review and analysis of the business, results of
operations, prospects, condition (financial or otherwise) or assets of the Company, and acknowledges that it has been provided adequate
access to the personnel, properties, assets, premises, books and records, and other documents and data of the Company for such purpose.
Parent acknowledges and agrees that in making its decision to enter into this Agreement and to consummate the transactions contemplated
under this Agreement, it has relied solely upon its own investigation and the express representations and warranties of Fitters Parent
and the Company set forth in this Agreement (including the related portions of Company Disclosure Schedules) and in any certificate delivered
to Parent pursuant hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.21
No Other Representations or Warranties. </b>Parent hereby acknowledges and agrees that, except for the representations and warranties
contained in this Agreement, neither the Company, nor any other Person on behalf of the Company makes any express or implied representation
or warranty with respect to the Company or with respect to any other information provided to Parent or any of its stockholders or any
of its Affiliates in connection with the transactions contemplated by this Agreement, and (subject to the express representations and
warranties of the Company set forth in <span style="text-decoration: underline">Article 2</span> (in each case as qualified and limited by the Company Disclosure Schedule) none
of Parent, or its representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.22
Full Disclosure</b>. The representations and warranties made by Parent in this Agreement, including the Parent Disclosure Schedules attached
hereto, and all statements set forth in the certificates delivered by Parent at the Closing pursuant to this Agreement, do not contain
any untrue statement of a material fact or omit to state any material fact necessary in order to make such representations, warranties
or statements, in light of the circumstances under which they were made, not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 274 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
4</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
<br/>
COVENANTS OF THE COMPANY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.1
Conduct of the Company Business</b>. From the date of this Agreement until the earlier of the Effective Time or the termination of this
Agreement in accordance with its terms, the Company shall not, unless consented to in writing by Parent (which consent shall not be unreasonably
withheld, delayed, denied, or conditioned), expressly contemplated by this Agreement, required by applicable Law, or as set forth on
<span style="text-decoration: underline">Schedule 4.1</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
engage in any transaction except in the ordinary course of business, or create or suffer to exist any material lien or other encumbrance
upon any of its assets which will not be discharged in full prior to the Effective Time;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
sell, assign or otherwise transfer any of its assets, or cancel or compromise any debts or claims relating to its assets, other than
in each case in the ordinary course of business and consistent with past practice;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
fail to use reasonable efforts to preserve intact its present business organization, keep available the services of its employees and
preserve its material relationships with customers, suppliers, licensors, licensees, distributors and others having business relationships
with it, to the end that its goodwill and ongoing business will not be materially impaired prior to the Effective Time;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
intentionally permit any Material Adverse Effect to occur with respect to the Company;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
make any material change in its accounting or bookkeeping methods, principles or practices, except as required by IFRS;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
except as required to give effect to anything in contemplation of the Closing, or effect or be a party to any merger, consolidation,
share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction
except, for the avoidance of doubt, the transactions contemplated under this Agreement; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
authorize any of, or commit or agree to take any of, the foregoing actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.2
Reserved.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.3
Satisfaction of Conditions Precedent</b>. Upon the terms and subject to the conditions set forth in this Agreement, from the date of
this Agreement until the earlier of the Effective Time or the termination of this Agreement in accordance with its terms, the Company
will use its commercially reasonable efforts to (i) satisfy or cause to be satisfied all the conditions precedent that are set forth
in <span style="text-decoration: underline">Article 7</span> and (ii) cause the Exchange and the other transactions contemplated by this Agreement to be consummated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 275 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.4
No Other Negotiations.</b> As of the date of this Agreement, Fitters Parent or the Company has not entered into any agreement or understanding
with, and is not engaging in any discussions with, any third party concerning an Alternative Acquisition (as defined below), including,
without limitation, any agreement or understanding that would require the Company to notify any third party of the terms of this Agreement.
From and after the date of this Agreement until the earlier of the Effective Time or the termination of this Agreement in accordance
with its terms, Fitters Parent and the Company shall not, directly or indirectly, (a) initiate, solicit, knowingly encourage, negotiate,
accept or discuss any transaction or series of transactions with any Person, other than Parent and its Affiliates, involving any recapitalization,
restructuring, financing, merger, consolidation, sale, license or encumbrance or other business combination transaction or extraordinary
corporate transaction of the Company which would reasonably be expected to impede, interfere with, prevent or materially delay the Exchange
(any such efforts by any such Person, including a firm proposal to make such an acquisition, to be referred to as an &#8220;<b>Alternative
Acquisition</b>&#8221;), (b) provide information with respect to the Company to any Person, other than Parent and its Affiliates, relating
to a possible Alternative Acquisition by any Person, other than Parent and its Affiliates, (c) enter into an agreement with any Person,
other than Parent and its Affiliates, providing for a possible Alternative Acquisition, or (d) make or authorize any statement, recommendation
or solicitation in support of any possible Alternative Acquisition by any Person, other than by Parent and its Affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Fitters Parent or the Company receives any unsolicited offer, inquiry or proposal to enter into discussions or negotiations relating
to an Alternative Acquisition, or that could reasonably be expected to lead to an Alternative Acquisition, or any request for nonpublic
information relating to the Company, Fitters Parent and the Company shall promptly notify Parent thereof, including the identity of the
party making any such offer, inquiry or proposal and the material terms of such offer, inquiry or proposal, as the case may be, and shall
keep Parent reasonably informed of any developments with respect to same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.5
Access.</b> From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in
accordance with its terms, the Company shall afford to Parent, and to the officers, employees, accountants, counsel, financial advisors
and other representatives of Parent, reasonable access, upon advance notice during normal business hours and in a manner as shall not
unreasonably interfere with the business or operations of the Company, to all of the Company&#8217;s properties, books, contracts, commitments,
personnel and records and, during such period, the Company shall furnish reasonably promptly to Parent, (a) a copy of each report, schedule,
and other documents filed by it during such period pursuant to the requirements of federal or state securities Laws and (b) all other
information concerning its business, properties and personnel as Parent or its representatives may reasonably request. The Company shall
not be required to provide access to or disclose information where such access or disclosure would jeopardize the protection of attorney-client
privilege or contravene any Law (it being agreed that the parties shall use their reasonable best efforts to cause such information to
be provided in a manner that would not result in such jeopardy or contravention).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.6
Notification of Certain Matters</b>. The Company shall give prompt notice to Parent of any event, change or effect between the date of
this Agreement and the Effective Time that causes or is reasonably likely to cause the failure of the any of the conditions set forth
in <span style="text-decoration: underline">Sections 7.2(a)</span>, <span style="text-decoration: underline">7.2(b)</span> or <span style="text-decoration: underline">7.2(e)</span> to be satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
5</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
<br/>
COVENANTS OF PARENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.1
Obligations of Parent</b>. Parent shall take all action necessary to perform its obligations under this Agreement and to consummate the
Exchange on the terms and conditions set forth in this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.2
Conduct of the Parent Business</b>. From the date of this Agreement until earlier of the Effective Time or the termination of this Agreement
in accordance with its terms, Parent shall not, and shall not permit Purchaser to, (w) unless consented to in writing by the Company
(which consent shall not be unreasonably withheld, delayed, denied, or conditioned), (x) expressly contemplated by this Agreement, including
in connection with the Nasdaq Reverse Split, (y) required by applicable Law, or (z) as set forth on <span style="text-decoration: underline">Schedule 5.2</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
engage in any transaction except in the ordinary course of business, or create or suffer to exist any material lien or other encumbrance
upon any of its assets which will not be discharged in full prior to the Effective Time;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 276 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
sell, assign or otherwise transfer any of its assets, or cancel or compromise any debts or claims relating to its assets, other than
in each case in the ordinary course of business and consistent with past practice;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
fail to use reasonable efforts to preserve intact its present business organizations, keep available the services of its employees and
preserve its material relationships with customers, suppliers, licensors, licensees, distributors and others having business relationships
with it, to the end that its good will and ongoing business will not be materially impaired prior to the Effective Time;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
intentionally permit any Material Adverse Effect to occur with respect to Parent;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
make any material change with respect in its accounting or bookkeeping methods, principles or practices, except as required by GAAP;
or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
authorize any of, or commit or agree to take any of, the foregoing actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.3
Access</b>. From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in
accordance with its terms, Parent shall afford to the Company, and to the officers, employees, accountants, counsel, financial advisors
and other representatives of the Company, reasonable access, upon advance notice, during normal business hours and in a manner as shall
not unreasonably interfere with the business or operations of the Company, to all of Parent&#8217;s properties, books, contracts, commitments,
personnel and records and, during such period, Parent shall reasonably furnish promptly to the Company, (a) a copy of each report, schedule,
registration statements and other documents filed by it during such period pursuant to the requirements of federal or state securities
Laws and (b) all other information concerning its business, properties and personnel as the Company or its representatives may reasonably
request. Parent shall not be required to provide access to or disclose information where such access or disclosure would not jeopardize
the protection of attorney-client privilege or contravene any Law (it being agreed that the parties shall use their reasonable best efforts
to cause such information to be provided in a manner that would not result in such jeopardy or contravention).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.4
Notification of Certain Matters</b>. Parent shall give prompt notice to the Company of any event, change or effect between the date of
this Agreement and the Effective Time that causes or is reasonably likely to cause the failure of any of the conditions set forth in
<span style="text-decoration: underline">Sections 7.3(a)</span>, <span style="text-decoration: underline">7.3(b)</span> or <span style="text-decoration: underline">7.3(e)</span> to be satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.5
Listing</b>. At or prior to the Effective Time, Parent shall use its commercially reasonable efforts to (a) maintain its listing on Nasdaq
until the Effective Time, including submitting any applicable extension requests or attending any hearings with requested by Nasdaq;
(b) prepare and submit to Nasdaq, to the extent required by the rules and regulations of Nasdaq, a notification form for the listing
of the shares of Parent Common Stock to be issued in connection with the transactions contemplated under this Agreement; and (c) prepare
and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required) and submit a copy of the amendment to Parent&#8217;s
certificate of incorporation effecting the Nasdaq Reverse Split, certified by the Secretary of State of the State of Delaware, to Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 277 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.6
Satisfaction of Conditions Precedent</b>. Upon the terms and subject to the conditions set forth in this Agreement, from the date of
this Agreement until the earlier of the Effective Time or the termination of this Agreement in accordance with its terms, Parent will
use its commercially reasonable efforts to (i) satisfy or cause to be satisfied all the conditions precedent that are set forth in <span style="text-decoration: underline">Article
7</span> and (ii) cause the Exchange and the other transactions contemplated by this Agreement to be consummated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.7
Section 16 Matters</b>. Prior to the Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of
Parent Common Stock and any options to purchase Parent Common Stock in connection with the transactions contemplated under this Agreement,
by each individual who is reasonably expected to become subject to the reporting requirements of Section 16(a) of the Exchange Act with
respect to Parent, to be exempt under Rule 16b-3 promulgated under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.8
No Other Negotiations</b>. As of the date of this Agreement, Parent has not entered into any agreement or understanding with, and is
not engaging in any discussions with, any third party concerning a Parent Alternative Acquisition (as defined below), including, without
limitation, any agreement or understanding that would require Parent to notify any third party of the terms of this Agreement. From and
after the date of this Agreement until the earlier of the Effective Time or the termination of this Agreement in accordance with its
terms, Parent shall not, directly or indirectly, (a) initiate, solicit, knowingly encourage, negotiate, accept or discuss any transaction
or series of transactions with any Person, other than the Company and its Affiliates, involving any recapitalization, restructuring,
financing, merger, consolidation, sale, license or encumbrance or other business combination transaction or extraordinary corporate transaction
of Parent which would reasonably be expected to impede, interfere with, prevent or materially delay the Exchange (any such efforts by
any such Person, including a firm proposal to make such an acquisition, to be referred to as a &#8220;<b>Parent Alternative Acquisition</b>&#8221;),
(b) provide information with respect to Parent to any Person, other than the Company and its Affiliates, relating to a possible Parent
Alternative Acquisition by any Person, other than the Company and its Affiliates, (c) enter into an agreement with any Person, other
than the Company and its Affiliates, providing for a possible Parent Alternative Acquisition, or (d) make or authorize any statement,
recommendation or solicitation in support of any possible Parent Alternative Acquisition by any Person, other than by the Company and
its Affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Parent receives any unsolicited offer, inquiry or proposal to enter into discussions or negotiations relating to a Parent Alternative
Acquisition, or that could reasonably be expected to lead to a Parent Alternative Acquisition, or any request for nonpublic information
relating to Parent, Parent shall promptly notify the Company thereof, including the identity of the party making any such offer, inquiry
or proposal and the material terms of such offer, inquiry or proposal, as the case may be, and shall keep the Company reasonably informed
of any developments with respect to same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
6</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
<br/>
COVENANTS OF PARENT AND THE COMPANY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.1
Notices of Certain Events.</b> The Company and Parent shall promptly notify the other Party of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the
transactions contemplated by this Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any notice or other communication from any Governmental Entity in connection with the transactions contemplated by this Agreement; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 278 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any actions, suits, claims, investigations or proceedings commenced or, to its Knowledge, threatened against, relating to or involving
or otherwise affecting such Party that, if pending on the date of this Agreement, would have been required to be disclosed pursuant to
<span style="text-decoration: underline">Article 2</span> or <span style="text-decoration: underline">Article 3</span> or that relate to the consummation of the transactions contemplated by this Agreement or any other
development causing a breach of any representation or warranty made by a Party hereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.2
Public Announcements; Confidentiality</b>. No Party shall have the right to issue any press release or other public statement with respect
to this Agreement or the transactions contemplated herein without the prior written consent of each other Party (not to be unreasonably
withheld, delayed, denied, or conditioned), except as required by Law. Parent, on the one hand, and the Company, on the other hand, shall,
and shall cause their respective Affiliates to, hold in confidence and not use, and shall use their respective reasonable best efforts
to cause their respective representatives to hold in confidence and not use, any and all non-public, confidential, or proprietary information,
whether written or oral, concerning the other Party, including, without limitation, any such information obtained pursuant to <span style="text-decoration: underline">Sections
4.5</span> or <span style="text-decoration: underline">5.3</span>, as applicable, except to the extent that Parent, on the one hand, or the Company, on the other hand, as the case
may be, can show that such information: (a) is generally available to and known by the public through no fault of such Party or any of
its Affiliates or their respective representatives; (b) is lawfully acquired by such Party, any of its Affiliates or their respective
representatives from sources that are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation;
or (c) is required to be disclosed by the requirements of the SEC or Nasdaq. If Parent, on the one hand, or the Company, on the other
hand, as the case may be, or any of its Affiliates or their respective representatives is compelled to disclose any information by judicial
or administrative process or by other requirements of Law, such compelled Party shall promptly notify the other Party in writing and
shall disclose only that portion of such information that such compelled Party is advised by its counsel in writing is legally required
to be disclosed, provided that such compelled Party shall use reasonable best efforts to obtain an appropriate protective order or other
reasonable assurance that confidential treatment will be accorded such information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.3
Transfer Taxes</b>. Parent and the Company shall cooperate in the preparation, execution and filing of all returns, questionnaires, applications
or other documents regarding any real property transfer or gains, sales, use, transfer, value added, stock transfer and stamp taxes,
any transfer, recording, registration and other fees, and any similar taxes which become payable in connection with the transactions
contemplated hereby that are required or permitted to be filed before the Effective Time. Parent and the Company agree that the Company
(prior to the Exchange) and the Parent (following the Exchange) will pay any real property, transfer or gains tax, stamp tax, stock transfer
tax, or other similar tax imposed on the Exchange or the surrender of the Shares pursuant to the Exchange (collectively, &#8220;<b>Transfer
Taxes</b>&#8221;), excluding any Transfer Taxes as may result from the transfer of beneficial interests in the Shares other than as a
result of the Exchange, and any penalties or interest with respect to the Transfer Taxes. The Company agrees to cooperate with Parent
in the filing of any returns with respect to the Transfer Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.4
Reasonable Efforts</b>. The parties further agree to use commercially reasonable efforts to take, or cause to be taken, all actions,
and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable
to consummate and make effective, and to satisfy all conditions to, in the most expeditious manner practicable, the Exchange and the
other transactions contemplated by this Agreement, including (i) the obtaining of all other necessary actions or nonactions, waivers,
consents, licenses, Permits, authorizations, Orders and approvals from Governmental Entities and the making of all other necessary registrations
and filings, (ii) the obtaining of all consents, approvals or waivers from third parties related to or required in connection with the
Exchange that are necessary to consummate the Exchange and the transactions contemplated by this Agreement or required to prevent a Material
Adverse Effect on the Company or Parent from occurring prior to or after the Effective Time, (iii) any notification or other document
required to be filed in connection with the Exchange under any applicable foreign Law, and (iv) the execution and delivery of any additional
instruments necessary to consummate the transactions contemplated by, and to fully carry out the purposes of, this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 279 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.5
Fees and Expenses</b>. All fees and expenses incurred by any Party in connection with this Agreement and the transactions contemplated
hereby shall be paid by the Party incurring such fees and expenses. Fees and expenses incurred by any Party in connection with the transactions
contemplated by this Agreement shall include, without limitation, out-of-pocket fees and expenses incurred for legal, financial, accounting
and other advisors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.6
Legends. </b>Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent
Common Stock to be received in the Exchange by equityholders of the Company who may be considered &#8220;affiliates&#8221; of Parent
for purposes of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate
stop transfer instructions to the Transfer Agent for Parent Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.7
Registration Statement; Proxy Statement</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As promptly as practicable after the date of this Agreement, (i) Parent shall prepare and file with the SEC a proxy statement relating
to the Parent Stockholder Meeting to be held in connection with the Exchange and changing Parent&#8217;s name to &#8220;Bio Green Med
Solution&#8221; (the &#8220;<b>Name Change</b>&#8221;) (together with any amendments thereof or supplements thereto, the &#8220;<b>Proxy
Statement</b>&#8221;) and (ii) Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement
on Form S-4 (the &#8220;<b>Form S-4</b>&#8221;), in which the Proxy Statement shall be included as a part (the Proxy Statement and the
Form S-4, collectively, the &#8220;<b>Registration Statement</b>&#8221;), in connection with the registration under the Securities Act
of the shares of Parent Common Stock to be issued by virtue of the transactions contemplated under this Agreement, including, without
limitation, the Exchange Shares. Parent shall use commercially reasonable efforts to (x) cause the Registration Statement to comply with
applicable rules and regulations promulgated by the SEC, (y) cause the Registration Statement to become effective as promptly as practicable,
and (z) respond promptly to any comments or requests of the SEC or its staff related to the Registration Statement. Parent shall take
all or any action required under any applicable federal, state, securities and other Laws in connection with the issuance of Exchange
Shares pursuant to the transactions contemplated under this Agreement. Each of the Parties shall reasonably cooperate with the other
Party and furnish all information concerning itself and their Affiliates, as applicable, to the other Parties that is required by Law
to be included in the Registration Statement as the other Parties may reasonably request in connection with such actions and the preparation
of the Registration Statement and Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included
therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the
DGCL, and (ii) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
Each of Fitters Parent and the Company covenants and agrees that the information supplied by or on behalf of the Company to Parent for
inclusion in the Registration Statement (including the Company Financial Statements) will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the
circumstances under which they were made, not misleading. Notwithstanding the foregoing, neither Party makes any covenant, representation
or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form
of proxy included therewith), if any, based on information provided by the other Party or any of its representatives regarding such other
Party or its Affiliates for inclusion therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 280 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly
as practicable after the Registration Statement is declared effective under the Securities Act. If at any time before the Effective Time,
(i) Parent, Fitters Parent or the Company (A) become aware of any event or information that, pursuant to the Securities Act or the Exchange
Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, (B) receives notice of any SEC
request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C) receives SEC
comments on the Registration Statement, or (ii) the information provided in the Registration Statement has become &#8220;stale&#8221;
and new information should be disclosed in an amendment or supplement to the Registration Statement, as the case may be, then such Party,
as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such
amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to Parent&#8217;s stockholders) or
otherwise addressing such SEC request or comments and each Party and shall use their commercially reasonable efforts to cause any such
amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1) that the Registration Statement
has become effective, (2) of the issuance of any stop order or suspension of the qualification or registration of the Parent Common Stock
issuable in connection with the transactions contemplated under this Agreement for offering or sale in any jurisdiction, or (3) any order
of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between
it or any of its representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration
Statement and all orders of the SEC relating to the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Each of Fitters Parent and the Company shall reasonably cooperate with Parent and provide, and cause its representatives to provide,
Parent and its representatives, with all true, correct and complete information regarding the Company that is required by Law to be included
in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement (collectively, the &#8220;<b>Company
Required S-4 Information</b>&#8221;). Without limiting the foregoing, the Company will use commercially reasonable efforts to cause to
be delivered to Parent a consent letter of the Company&#8217;s independent accounting firm, dated no more than two (2) Business Days
before the date on which the Registration Statement is filed with the SEC (and reasonably satisfactory in form and substance to Parent),
that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration
statements similar to the Registration Statement. The Company and its legal counsel shall be given reasonable opportunity to review and
comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and
on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. Parent may file the
Registration Statement, or any amendment or supplement thereto, without the prior consent of the Company, provided that Parent has included
the Company Required S-4 Information in the Registration Statement in substantially the same form as it was provided to Parent by the
Company pursuant to this <span style="text-decoration: underline">Section 6.7</span>; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">further</span>, that if the prior consent of the Company is not obtained
then, notwithstanding anything else herein, the Company makes no covenant or representation regarding the portion of such information
supplied by or on behalf of the Company to Parent for inclusion in such Registration Statement that the Company reasonably identifies
prior to such filing of the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 281 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
As promptly as reasonably practicable following the date of this Agreement, the Company shall furnish to Parent (i) prior to May 5, 2025,
audited financial statements for each of its fiscal years required to be included in the Registration Statement, together with the auditor&#8217;s
report thereon (the &#8220;<b>Company Audited Financial Statements</b>&#8221;), (ii) prior to May 31, 2025, unaudited interim financial
statements for the interim period completed March 31, 2025 (the &#8220;<b>Company Q1 2025 Interim Financial Statements</b>&#8221;), and
(iii) unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included
in the Registration Statement or any periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements
under the Securities Act or the Exchange Act (the &#8220;<b>Additional Company Interim Financial Statements</b>&#8221; and together with
the Company Q1 2025 Interim Financial Statements, the &#8220;<b>Company Interim Financial Statements</b>&#8221;). Each of the Company
Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion in the Registration Statement
and prepared in accordance with IFRS as applied on a consistent basis during the periods involved (except in each case as described in
the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations,
changes in shareholders&#8217; equity and cash flows of the Company as of the dates of and for the periods referred to in the Company
Audited Financial Statements or the Company Interim Financial Statements, as the case may be. The Company Audited Financial Statements
and the Company Interim Financial Statements shall be prepared under IFRS in accordance with the requirements of the PCAOB for public
companies. The Company Audited Financial Statements shall have been audited by a PCAOB qualified auditor that is independent under Rule
2-01 of Regulation S-X under the Securities Act and, with respect to the Company Interim Financial Statements, shall have been reviewed
by the Company&#8217;s auditors, as provided in AU-C-930 under the standards of the American Institute of Certified Public Accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.8
Company Shareholder Written Consent</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two (2)
Business Days thereafter, the Company shall obtain the approval by written consent from the Company&#8217;s shareholders sufficient for
the Required Company Shareholder Vote in lieu of a meeting pursuant to the Malaysian Companies Act, for purposes of adopting and approving
this Agreement and the transactions contemplated under this Agreement (the &#8220;<b>Company Shareholder Written Consents</b>&#8221;).
Under no circumstances shall the Company assert that any other approval or consent is necessary by its shareholders to approve this Agreement
and the transactions contemplated under this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company agrees that: (i) the Company Board shall recommend that the Company&#8217;s shareholders vote to adopt and approve this Agreement
and the transactions contemplated under this Agreement and shall use commercially reasonable efforts to solicit such approval within
the time set forth in <span style="text-decoration: underline">Section 6.8(a)</span> (the recommendation of the Company Board that the Company&#8217;s shareholders vote to adopt
and approve this Agreement being referred to as the &#8220;<b>Company Board Recommendation</b>&#8221;) and (ii) the Company Board Recommendation
shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation)
in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board
Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any
Alternative Acquisition shall be adopted or proposed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 282 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.9
Parent Stockholder Meeting</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common
Stock to consider and vote on proposals to (i) approve this Agreement and thereby to approve the transactions contemplated under this
Agreement, including without limitation, the Exchange and the Name Change (the &#8220;<b>Parent Stockholder Exchange Approval Matter</b>&#8221;),
(ii) amend Parent&#8217;s certificate of incorporation to, if deemed appropriate by the Parties, (A) effect a Nasdaq Reverse Split and/or
(B) increase the number of authorized shares of Parent Common Stock, and (iii) increase the number of shares available for issuance under
the existing Parent 2018 equity incentive plan by an amount directed by the Company and/or approve a new Parent equity incentive plan,
with the form of such Parent equity incentive plan and number of shares of Parent Common Stock available for issuance under such plan
to be mutually agreed upon by Parent and the Company, (clauses (i), (ii) and (iii) collectively, the &#8220;<b>Parent Stockholder Matters</b>&#8221;
and such meeting, the &#8220;<b>Parent Stockholder Meeting</b>&#8221;). The Parent Stockholder Meeting shall be held as promptly as practicable
after the date that the Registration Statement is declared effective under the Securities Act, and in any event, no later than forty-five
(45) days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited
in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Laws. Notwithstanding anything to the
contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder
Meeting is scheduled, Parent reasonably believes that (i) it will not receive proxies sufficient to obtain the Parent Stockholder Vote,
whether or not a quorum would be present or (ii) it will not have sufficient shares of Parent Common Stock represented (whether in person
or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting, Parent may postpone or adjourn,
or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting, as long as the date of the Parent Stockholder
Meeting is not postponed or adjourned more than an aggregate of thirty (30) days in connection with any postponements or adjournments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Parent agrees that (i) the Board of Directors of Parent shall recommend that the holders of Parent Common Stock vote to approve the Parent
Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in <span style="text-decoration: underline">Section
6.9(a)</span> above, and (ii) the Proxy Statement shall include a statement to the effect that the Board of Directors of Parent recommends
that Parent&#8217;s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred
to as the &#8220;<b>Parent Board Recommendation</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
7</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
<br/>
CONDITIONS TO EXCHANGE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.1
Condition to Obligation of Each Party to Effect the Exchange</b>. The respective obligations of Parent, Fitters Parent and the Company
to consummate the transactions contemplated herein are subject to the satisfaction or waiver in writing prior to the Effective Time of
the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<b>No Injunctions</b>. No temporary restraining Order, preliminary or permanent injunction issued by any court of competent jurisdiction
preventing or prohibiting the consummation of the Exchange or the other transactions contemplated herein shall be in effect; provided,
however, that each Party shall have used its commercially reasonable efforts to prevent the entry of any such Orders or injunctions and
to appeal as promptly as possible any such Orders or injunctions and to appeal as promptly as possible any such Orders or injunctions
that may be entered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<b>Stockholder Approval</b>. Parent shall have obtained the Parent Stockholder Exchange Vote and the Company shall have obtained the
Required Company Shareholder Vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<b>Notice to Bursa Malaysia.</b> Fitters Parent shall have complied with all applicable Bursa Malaysia Securities Berhad Main Market
Listing Requirements, including any required notices to Bursa Malaysia and other necessary approvals regarding the transactions contemplated
under this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<b>Effectiveness of Registration Statement</b>. The Registration Statement shall have become effective in accordance with the provisions
of the Securities Act, and shall not be subject to any stop order or proceeding (or threatened proceeding by the SEC) seeking a stop
order with respect to the Registration Statement that has not been withdrawn. Any material state securities laws applicable to the issuance
of the shares of Parent Common Stock in connection with the transactions contemplated under this Agreement shall have been complied with
and no stop order (or similar order) shall have been issued or threatened in writing in respect of thereof by any applicable state securities
commissioner or court of competent jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 283 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<b>Listing</b>. The shares of Parent Common Stock to be issued in the Exchange pursuant to this Agreement shall have been approved for
listing (subject to official notice of issuance) on Nasdaq as of the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<b>Value of Exchange Shares</b>. Parent and Fitters Parent shall agree in writing that the Exchange Shares represent mutually acceptable
consideration for the acquisition of the Shares. In the event the value of the Exchange Shares is not mutually acceptable to both Parties,
the Parties agree to negotiate in good faith an adjustment to the Exchange Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.2
Additional Conditions to Obligations of Parent</b>. The obligations of Parent to consummate the transactions contemplated herein are
also subject to the satisfaction or waiver in writing prior to the Effective Time of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<b>Representations and Warranties</b>. The representations and warranties of each of Fitters Parent and the Company contained in this
Agreement and in any certificate delivered to Parent pursuant hereto shall be true and correct as of immediately prior to the Effective
Time with the same force and effect as if made at and as of such time (except those representations and warranties that address matters
only as of a particular date, which shall be true and correct as of that date), except where the failure of such representations and
warranties to be so true and correct would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect
on the Company, and Parent shall have received a certificate to such effect signed by the President and the Chief Executive Officer of
Fitters Parent and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<b>Agreements and Covenants</b>. Each of Fitters Parent and the Company shall have performed in all material respects, or complied with
in all material respects, all agreements and covenants required by this Agreement to be performed or complied with by them prior to the
Effective Time, and Parent shall have received a certificate to such effect signed by the President and Chief Executive Officer of Fitters
Parent and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<b>Certificate of Secretary</b>. Each of Fitters Parent and the Company shall have delivered to Parent a certificate executed by the
Secretary of Fitters Parent and the Company, respectively, certifying: (i) resolutions duly adopted by the Board of Directors and shareholders
of Fitters Parent and the Company, respectively, authorizing this Agreement and the Exchange; (ii) only with respect to the Company,
the Governing Documents of the Company as in effect immediately prior to the Effective Time, including all amendments thereto; and (iii)
the incumbency of the officers of Fitters Parent and the Company, respectively, executing this Agreement and all agreements and documents
contemplated hereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<b>Consents Obtained</b>. All consents, waivers, approvals, authorizations or Orders required to be obtained, and all filings required
to be made, by the Company for the authorization, execution and delivery of this Agreement and the consummation by it of the transactions
contemplated hereby shall have been obtained and made by the Company, except for such consents, waivers, approvals, authorizations and
Orders, and such filings, which would not be reasonably likely to have a Material Adverse Effect on the Company or the Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<b>Absence of Material Adverse Effect</b>. Since the date of this Agreement, there shall not have been any Material Adverse Effect with
respect to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 284 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<b>Company Shareholder Written Consent</b>. The Company Shareholder Written Consent executed by the shareholders of the Company shall
be in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<b>Trademark License Agreement</b>. The Company and Fitters Parent shall enter into a trademark license agreement for use of the &#8220;FITTERS&#8221;
mark and logo, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.3
Additional Conditions to Obligations of the Company</b>. The obligations of Fitters Parent and the Company to consummate the transactions
contemplated herein are also subject to the satisfaction or waiver in writing prior to the Effective Time of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<b>Representations and Warranties</b>. The representations and warranties of Parent contained in this Agreement and in any certificate
delivered to the Company pursuant hereto shall be true and correct as of immediately prior to the Effective Time with the same force
and effect as if made at and as such time (except those representations and warranties that address matters only as of a particular date,
which shall be true and correct as of that date), except where the failure of such representations and warranties to be so true and correct
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on Parent, and the Company shall
have received a certificate to such effect signed by the Chief Executive Officer of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<b>Agreements and Covenants</b>. Parent shall have performed in all material respects, or complied with in all material respects, all
agreements and covenants required by this Agreement to be performed or complied with by them prior to the Effective Time, and the Company
shall have received a certificate to such effect signed by the Chief Executive Officer of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<b>Certificate of Secretary</b>. Parent shall have delivered to the Company a certificate executed by the Secretary of Parent certifying:
(i) resolutions duly adopted by the Board of Directors and stockholders of Parent authorizing this Agreement and the Exchange; (ii) the
Certificate of Incorporation and Bylaws of Parent as in effect immediately prior to the Effective Time, including all amendments thereto;
and (iii) the incumbency of the officers of Parent executing this Agreement and all agreements and documents contemplated hereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<b>Consents Obtained</b>. All consents, waivers, approvals, authorizations or Orders required to be obtained, and all filings required
to be made, by Parent for the authorization, execution and delivery of this Agreement and the consummation by it of the transactions
contemplated hereby shall have been obtained and made by Parent, except for such consents, waivers, approvals, authorizations and Orders,
and such filings, which would not be reasonably likely to have a Material Adverse Effect on Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<b>Absence of Material Adverse Effect</b>. Since the date of this Agreement, there shall not have been any Material Adverse Effect on
Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
8</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
<br/>
TERMINATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.1
Termination.</b> This Agreement may be terminated at any time prior to the Effective Time, whether before or after approval of the Exchange
by the shareholders of the Company and Parent, unless specified below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
by mutual written agreement of the Company and Parent duly authorized by the Boards of Directors of the Company and Parent;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 285 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
by either the Company or Parent, if the other Party has breached any representation, warranty, covenant or agreement of such other Party
set forth in this Agreement and such breach has resulted or is reasonably be expected to result in a Material Adverse Effect on such
other Party or would prevent or materially delay the consummation of the Exchange;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
by either the Company or Parent, if all the conditions to the obligations of such Party for Closing the Exchange shall not have been
satisfied or waived on or before the Final Date (as defined below); <span style="text-decoration: underline">provided</span> that in the event the SEC has declared effective
under the Securities Act the Registration Statement by the Final Date, then either the Company or Parent shall be entitled to extend
the Final Date for an additional sixty (60) days in order to hold the Parent Stockholder Meeting and obtain the Parent Stockholder Exchange
Vote; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that the right to terminate this Agreement pursuant to this <span style="text-decoration: underline">Section 8.1(c)</span> shall not be
available to any Party whose breach of any representation, warranty, covenant or agreement set forth in this Agreement has been the cause
of, or resulted in, such failure;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
by either the Company or Parent, if any Law, permanent injunction or other Order by any Governmental Entity which would make illegal
or otherwise restrain or prohibit the consummation of the Exchange shall have been issued, entered, or enacted and shall have become
final and nonappealable; provided, however, that the right to terminate this Agreement pursuant to this <span style="text-decoration: underline">Section 8.1(d)</span> shall not
be available to any Party whose breach of any representation, warranty, covenant or agreement set forth in this Agreement has been the
cause of, or resulted in, the issuance, entry, or enactment of any such Law or Order;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by either the Company or Parent if (i) the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have
been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Matters, and (ii) the
Parent Stockholder Exchange Approval Matter shall not have been approved at the Parent Stockholder Meeting (or at any adjournment or
postponement thereof) by the Parent Stockholder Exchange Vote; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that the right to terminate this Agreement
under this <span style="text-decoration: underline">Section 8.1(e)</span> shall not be available to Parent where the failure to obtain the Parent Stockholder Exchange Vote shall
have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent
of this Agreement; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
by Parent if the Required Company Shareholder Vote shall not have been obtained within two (2) Business Days of the Registration Statement
becoming effective in accordance with the provisions of the Securities Act; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that once the Required Company
Shareholder Vote has been obtained, Parent may not terminate this Agreement pursuant to this <span style="text-decoration: underline">Section 8.1(d)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, the &#8220;<b>Final Date</b>&#8221; shall be August 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.2
Notice of Termination</b>. Any termination of this Agreement under <span style="text-decoration: underline">Section 8.1</span> above will be effective immediately upon the delivery
of written notice of the terminating Party to the other Party hereto specifying with reasonable particularity the reason for such termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.3
Effect of Termination</b>. In the case of any termination of this Agreement as provided in this <span style="text-decoration: underline">Article 8</span>, this Agreement shall
be of no further force and effect, with no liability on the part of any Party to this Agreement (or any stockholder, director, officer,
employee, agent or representative of such Party) to any other Party hereto, except (i) with respect to <span style="text-decoration: underline">Section 6.2</span>, this <span style="text-decoration: underline">Section
8.3</span>, <span style="text-decoration: underline">Article 9</span> and <span style="text-decoration: underline">Article 10</span> (and any related definitions contained in any such Sections or Articles), which shall
remain in full force and effect and (ii) with respect to any liabilities or damages incurred or suffered by a Party, to the extent such
liabilities or damages were the result of fraud or the breach by another Party of any of its representations, warranties, covenants or
other agreements set forth in this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 286 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
9</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
<br/>
SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the representations and warranties contained in this Agreement or in any instrument delivered under this Agreement will survive the
Effective Time. This <span style="text-decoration: underline">Article 9</span> does not limit any covenant of the parties to this Agreement which, by its terms, contemplates
performance after the Effective Time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article
10</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
<br/>
GENERAL PROVISIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.1
Notices</b>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received
hereunder (a) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight
courier service, (b) upon delivery in the case of delivery by hand or (c) on the date delivered in the place of delivery if sent by email
or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding
Business Day, in each case to the intended recipient as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If to Parent:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11, Avenue 5, No. 8</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jalan
Kerinchi, Kuala Lumpur, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
+ (60) 3270 47622</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to (which shall not constitute notice):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon,
P.C.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">423
Washington Street, Suite 600</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Francisco, California 94111 U.S.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Mark Lee; Debbie Klis</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
(418) 683-5472 or (202) 935-3390</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<span style="text-decoration: underline">mark.c.lee@rimonlaw.com</span>; debbie.klis@rimonlaw.com</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If to Fitters Parent or the Company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FITTERS
Diversified Berhad</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
1, Jalan Tembaga SD 5/2</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bandar
Sri Damansara</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52200
Kuala Lumpur, Selangor, Malaysia</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Datuk Tan Chor How Christopher, Executive Director</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
+60 3-6276 7155</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<span style="text-decoration: underline">christan@fittersgroup.com</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 287 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to (which shall not constitute notice):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Messrs.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ong, Ric &amp; Partners</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advocates
&amp; Solicitors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1, Tower 11, Avenue 5, The Horizon</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
8, Jalan Kerinchi, Bangsar South</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59200
Kuala Lumpur</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Tuw Min Ric</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
(60)3 6211 3830</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<span style="text-decoration: underline">general@orplegal.com.my</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.2
Amendment</b>. This Agreement may be amended with the approval of the respective boards of directors of Fitters Parent, the Company and
Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#8217;s shareholders or before
or after obtaining the Parent Stockholder Vote); <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that after any such approval of this Agreement by a
Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further
approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of Fitters
Parent, the Company, and Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.3
Waiver</b>. Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any
other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay
on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such
power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any
other or further exercise thereof or of any other power, right, privilege or remedy. No Party shall be deemed to have waived any claim
arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power,
right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any
such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.4
Failure or Indulgence Not Waiver; Remedies Cumulative</b>. No failure or delay on the part of any Party hereto in the exercise of any
right hereunder shall impair such right or be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty
or agreement herein, nor shall any single or partial exercise of any such right preclude other or further exercise thereof or of any
other rights. Except as otherwise provided hereunder, all rights and remedies existing under this Agreement are cumulative to, and not
exclusive of, any rights or remedies otherwise available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.5
Headings</b>. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.6
Severability.</b> Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall
not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of
the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction
declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination
shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a
term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term
or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted
to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable
term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable
term or provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 288 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.7
Entire Agreement</b>. This Agreement (including the Company Disclosure Schedule and the Parent Disclosure Schedule together with the
other Transaction Documents and the exhibits and schedules attached hereto and thereto and the certificates referenced herein) constitutes
the entire agreement and supersedes all prior agreements and understandings, both oral and written, among the parties, or any of them,
with respect to the subject matter hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.8
Assignment</b>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and
their respective successors and permitted assigns; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that neither this Agreement nor any of a Party&#8217;s
rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and
any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s
prior written consent shall be void and of no effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.9
Parties In Interest.</b> This Agreement shall be binding upon and inure solely to the benefit of each Party hereto and their permitted
assigns and respective successors, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person
any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, including, without limitation, by way of
subrogation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.10
Governing Law</b>. This Agreement will be governed by, and construed and enforced in accordance with the Laws of the State of Delaware
as applied to Contracts that are executed and performed in Delaware, without regard to the principles of conflicts of Law thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.11
Counterparts</b>. This Agreement may be executed in two or more counterparts, any one of which need not contain the signatures of more
than one Party, but all such counterparts taken together will constitute one and the same Agreement. This Agreement will become effective
when each Party to this Agreement will have received counterparts signed by all of the other parties. This Agreement, to the extent a
signed version hereof or signature hereto is delivered by means of a facsimile machine or electronic mail (any such delivery, an &#8220;<b>Electronic
Delivery</b>&#8221;), shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have
the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any Party hereto,
each other Party hereto shall re-execute original forms hereof and deliver them in person to all other parties. No Party hereto shall
raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted
or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such Party forever waives
any such defense, except to the extent such defense related to lack of authenticity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.12
Attorneys&#8217; Fees</b>. If any action or proceeding relating to this Agreement, or the enforcement of any provision of this Agreement
is brought by a Party hereto against any Party hereto, the prevailing Party shall be entitled to recover reasonable attorneys&#8217;
fees, costs and disbursements (in addition to any other relief to which the prevailing Party may be entitled).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.13
Representation</b>. The parties to this Agreement, and each of them, acknowledge, agree, and represent that it: (a) has been represented
in connection with the negotiation and preparation of this Agreement by counsel of that Party&#8217;s choosing; (b) has read this Agreement
and has had it fully explained by its counsel; (c) is fully aware of the contents and legal effect of this Agreement; and (d) enters
into and signs the same by its own free will.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.14
Drafting</b>. The parties to this Agreement acknowledge that each of them have participated in the drafting and negotiation of this Agreement.
For purposes of interpreting this Agreement, each provision, paragraph, sentence and word herein shall be deemed to have been jointly
drafted by both parties. The parties intend for this Agreement to be construed and interpreted neutrally in accordance with the plain
meaning of the language contained herein, and not presumptively construed against any actual or purported drafter of any specific language
contained herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.15
Interpretation</b>. For purposes of this Agreement, references to the masculine gender shall include feminine and neuter genders and
entities. Where a reference in this Agreement is made to a Section, Exhibit or Schedule, such reference shall be to a Section of, Exhibit
to or Schedule of this Agreement unless otherwise indicated. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221;
are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221; The words &#8220;hereof,&#8221;
&#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to this Agreement
as a whole and not to any particular provision of this Agreement. References to &#8220;this Agreement&#8221; shall include the Company
Disclosure Schedule and the Parent Disclosure Schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[Remainder
of Page Intentionally Left Blank; Signature Page to Follow]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 289 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN
WITNESS WHEREOF</b>, the parties have caused this Exchange Agreement to be executed as of the date first written above by their respective
officers thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
    PHARMACEUTICALS, INC.</b>, a Delaware corporation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong Sing Ee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FITTERS
    DIVERSIFIED BERHAD</b>, a Malaysia private limited company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Tan Chor How Christopher</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FITTERS
    SDN. BHD.</b>, a Malaysia private limited company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pang
    Wei Kang</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 290; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN
DEFINITIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following terms, as used in the Agreement, have the following meanings:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Accounts
Receivable</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.14</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Additional
Company Interim Financial Statements</span>&#8221; means an unaudited interim financial statements for each interim period completed prior
to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the
Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Affiliate</span>(s)&#8221;
shall have the meaning set forth in Rule 12b-2 of the regulations promulgated under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Agreement</span>&#8221;
shall have the meaning as set forth in the Preamble.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Alternative
Acquisition</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 4.4</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Assets</span>&#8221;
of a Person shall mean all of the assets, properties, businesses and rights of such Person of every kind, nature, character and description,
whether real, personal or mixed, tangible or intangible, accrued or contingent, or otherwise relating to or utilized in such Person&#8217;s
business, directly or indirectly, in whole or in part, whether or not carried on the books and records of such Person, and whether or
not owned in the name of such Person or any Affiliate of such Person and wherever located.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Benefit
Plans</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.10</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Business
Day</span>&#8221; mans any day other than a day on which banks in the State of New York are authorized or obligated to close.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Closing</span>&#8221;
shall have the meaning as set forth in <span style="text-decoration: underline">Section 1.3</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Closing
Date</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 1.3</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Code</span>&#8221;
means the Internal Revenue Code of 1986, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company</span>&#8221;
shall have the meaning as set forth in the Preamble.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Audited Financial Statements</span>&#8221; means audited financial statements for each of its fiscal years required to be included in the
Registration Statement, together with the auditor&#8217;s report thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Balance Sheet Date</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.6(b)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Board Recommendation</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 6.8(b)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Disclosure Schedule</span>&#8221; shall have the meaning as set forth in the opening paragraph of <span style="text-decoration: underline">Article 2</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Financial Statements</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.6(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Interim Financial Statements</span>&#8221; means the Company Q1 2025 Interim Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 291; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Material Contract</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.13</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Ordinary Shares</span>&#8221; means the ordinary shares of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company-Owned
IP</span>&#8221; means all Intellectual Property owned or purported to be owned by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Q1 2025 Interim Financial Statements</span>&#8221; unaudited interim financial statements for the interim period completed March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Required S-4 Information</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.6</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Shareholder Written Consents</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.6.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Contract</span>&#8221;
means any written or oral agreement, arrangement, commitment, contract, indenture, instrument, lease, obligation, plan, restriction,
understanding or undertaking of any kind or character, or other document to which any Person is a party or by which such Person is bound
or affecting such Person&#8217;s capital stock, Assets or business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Copyrights</span>&#8221;
shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.16(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">CYCC&#8221;
</span>means the Nasdaq symbol where Shares of common stock of Parent, par value $0.001, are shown.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Default</span>&#8221;
means (i) any breach or violation of or default under any Contract, Order or Permit, (ii) any occurrence of any event that with the passage
of time or the giving of notice or both would constitute a breach or violation of or default under any Contract, Order or Permit, or
(iii) any occurrence of any event that with or without the passage of time or the giving of notice would give rise to a right to terminate
or revoke, change the current terms of, or renegotiate, or to accelerate, increase, or impose any Liability under, any Contract, Order
or Permit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">DGCL</span>&#8221;
means the Delaware General Corporation Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Effective
Time</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 1.4</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Electronic
Delivery</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 10.11</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Environmental
Laws</span>&#8221; mean any and all federal, state, local and foreign statutes, laws, judicial decisions, regulations, ordinances, rules,
judgments, orders, decrees, codes, plans, injunctions, Permits, concessions, grants, franchises, licenses, agreements and governmental
restrictions, relating to human health, the environment or to emissions, discharges or releases of pollutants, contaminants or other
Hazardous Material or wastes into the environment, including without limitation ambient air, surface water, ground water or land, or
otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of pollutants,
contaminants or other Hazardous Material or wastes or the clean-up or other remediation thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Exchange</span>&#8221;
shall have the meaning as set forth in the Recitals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Exchange
Act Documents</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.20</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Exchange
Shares</span>&#8221; shave have the meaning as set forth in <span style="text-decoration: underline">Section 1.1(b)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Final
Date</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 8.1</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 292 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Fitters
Parent</span>&#8221; means Fitters Diversified Berhad, a Malaysia private limited company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Form
S-4</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 6.7(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">GAAP</span>&#8221;
means U.S. generally accepted accounting principles in effect as of the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Governing
Documents</span>&#8221; means, with respect to any Person that is an entity, its certificate of incorporation or formation, bylaws, operating
agreement, constitution, memorandum and articles of association or similar organizational documents, in each case, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Governmental
Entity</span>&#8221; means any government or any agency, bureau, board, directorate, commission, court, department, official, political
subdivision, tribunal, or other instrumentality of any government, whether federal, state or local, domestic or foreign.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Hazardous
Material</span>&#8221; means any toxic, radioactive, corrosive or otherwise hazardous substance, including petroleum, its derivatives, by-products
and other hydrocarbons, or any substance having any constituent elements displaying any of the foregoing characteristics, which in any
event is regulated under any Environmental Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">IFRS</span>&#8221;
means international financial reporting standards in effect as of the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Intellectual
Property</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.16(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Knowledge</span>&#8221;
means the actual knowledge of the officers of a party, and knowledge that a reasonable person in such capacity should have after due
inquiry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Law</span>&#8221;
means any code, law, ordinance, regulation, reporting or licensing requirement, rule, or statute applicable to a Person or its Assets,
liabilities or business, including those promulgated, interpreted or enforced by any Regulatory Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Lien</span>&#8221;
means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect to such
asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Malaysia
Form of Transfer</span>&#8221; means a form for the transfer of securities pursuant to Form Section 105 of the Malaysian Companies Act,
in substantially the form of <span style="text-decoration: underline">Exhibit B</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Malaysian
Companies Act</span>&#8221; means the Laws of Malaysia, Act 125, Companies Act 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Marks</span>&#8221;
shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.16(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Material</span>&#8221;
and &#8220;<span style="text-decoration: underline">Materially</span>&#8221; for purposes of this Agreement shall be determined in light of the facts and circumstances of the
matter in question; provided that any specific monetary amount stated in this Agreement shall determine materiality in that instance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Material
Adverse Effect</span>&#8221; means, with respect to any Person, a material adverse effect on the condition (financial or otherwise), business,
Assets, liabilities or the results of operations of such Person and its Subsidiaries taken as a whole; provided, however, that any adverse
change, event, development or effect arising from or relating to any of the following shall not be taken into account in determining
whether there has been a Material Adverse Effect: (a) general business or economic conditions, (b) national or international political
or social conditions, including the engagement by the United States or Malaysia in hostilities, whether or not pursuant to the declaration
of a national emergency or war, or the occurrence of any military or terrorist attack upon the United States or Malaysia, respectively,
or any of its territories, possessions, or diplomatic or consular offices or upon any military installation, equipment or personnel of
the United States or Malaysia, respectively, (c) financial, banking, or securities markets (including any disruption thereof and any
decline in the price of any security or any market index), (d) changes in IFRS, (e) changes in laws, rules, regulations, orders, or other
binding directives issued by any Governmental Entity or (f) the taking of any action required by this Agreement and the other agreements
contemplated hereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 293 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Material
Contract Default</span>&#8221; means a default under any Contract which would (A) permit any other party to cancel or terminate the same
(with or without notice of passage of time) or (B) provide a basis for any other party to claim money damages in excess of $100,000 (either
individually or in the aggregate with all other such claims under that contract) or (C) give rise to a right of acceleration of any material
obligation or loss of any material benefit under any such Contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Name
Change</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 6.7(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Nasdaq</span>&#8221;
means The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Nasdaq
Reverse Split</span>&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock effected by Parent for the purpose
of maintaining compliance with Nasdaq listing standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">OFAC</span>&#8221;
also known as the Office of Foreign Assets Control of the U.S. Treasury Department.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Order</span>&#8221;
means any administrative decision or award, decree, injunction, judgment, order, quasi-judicial decision or award, ruling, or writ of
any federal, state, local or foreign or other court, arbitrator, mediator, tribunal, administrative agency or Regulatory Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent</span>&#8221;
shall have the meaning as set forth in the Preamble of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Accounts Receivable</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 3.14</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Alternative Acquisition</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 5.8</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Balance Sheet Date</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 3.6(b)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Board Recommendation</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 6.9(b)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Common Stock</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 3.1</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Disclosure Schedule</span>&#8221; shall mean the written disclosure schedule delivered prior to the execution of the Agreement by Parent
to the Company that is arranged in paragraphs corresponding to the numbered and lettered paragraphs corresponding to the numbered and
lettered paragraphs contained in the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Material Contract</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 3.13</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Preferred Stock</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 3.3</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
SEC Documents</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 3.6(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Stockholder Exchange Approval Matter</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 6.9(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Stockholder Exchange Vote</span>&#8221; means the affirmative vote of a majority of (a) the shares of Parent Common Stock properly cast
is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve this Agreement and thereby
approve the transactions contemplated under this Agreement, including the issuance of the Exchange Shares to the shareholders of the
Company pursuant to the terms of this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Stockholder Matters</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 6.9(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Stockholder Meeting</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 6.9(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Stockholder Vote</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 3.17</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 294 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Party</span>&#8221;
or &#8220;<span style="text-decoration: underline">Parties</span>&#8221; means the Company, Fitters Parent and Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Patents</span>&#8221;
shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.16(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Permit</span>&#8221;
means any federal, state, local, and foreign governmental approval, authorization, certificate, consent, easement, filing, franchise,
letter of good standing, license, notice, permit, qualification, registration or right of or from any Governmental Entity (or any extension,
modification, amendment or waiver of any of these) to which any Person is a party or that is or may be binding upon or inure to the benefit
of any Person or its securities, Assets or business, or any notice, statement, filing or other communication to be filed with or delivered
to any Governmental Entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Person</span>&#8221;
means an individual, a corporation, a partnership, an association, a trust, a limited liability company or any other entity or organization,
including a government or political subdivision or any agency or instrumentality thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Proxy
Statement</span>&#8221; means a statement relating to the Parent Stockholder Meeting to be held in connection with the Exchange (together
with any amendments thereof or supplements thereto).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Registration
Statement</span>&#8221; means the Proxy Statement and the Form S-4, collectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Required
Company Shareholder Vote</span>&#8221; means the affirmative vote (or written consent) of the holders of a majority of the capital shares
of the Company outstanding on the record date and entitled to vote thereon, voting as a single class on an as-converted basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Sanctions
List</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.22(c)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">SEC</span>&#8221;
means the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Share</span>&#8221;
or &#8220;<span style="text-decoration: underline">Shares</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 1.1(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Software</span>&#8221;
shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.16(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Subsidiary</span>&#8221;
means, with respect to any Person, (i) any corporation, limited liability company, association or other business entity of which more
than fifty percent (50%) of the total voting power of the capital shares entitled (without regard to the occurrence of any contingency)
to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such
Person or one or more of the other Subsidiaries of that Person (or a combination thereof) and (ii) any partnership (a) the sole general
partner or managing general partner of which is such Person or a Subsidiary of such Person or (b) the only general partners of which
are such Person or of one or more Subsidiaries of such Person (or any combination thereof).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Tax</span>&#8221;
or &#8220;<span style="text-decoration: underline">Taxes</span>&#8221; means all United States federal, state, provincial, local or foreign taxes and any other applicable duties,
levies, fees, charges and assessments that are in the nature of a tax, including income, gross receipts, property, sales, use, license,
excise, franchise, ad valorem, value-added, transfer, severance, stamp, occupation, premium, windfall profits, environmental (including
taxes under Section 59A of the Code), customs, capital stock, real property, personal property, alternative or add-on minimum, estimated,
social security payments, and health taxes and any deductibles relating to wages, salaries and benefits and payments to subcontractors,
together with all interest, penalties and additions imposed with respect to such amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Tax
Return</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.11(c)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Technology</span>&#8221;
shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.16(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Trade
Secrets</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 2.16(a)</span> of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Transaction
Documents</span>&#8221; means the Agreement and any other document executed and delivered pursuant hereto, together with any exhibits or
schedules to such documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Transfer
Agent</span>&#8221; shall mean Equiniti Trust Company, LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Transfer
Taxes</span>&#8221; shall have the meaning as set forth in <span style="text-decoration: underline">Section 6.3</span> of this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 295 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
B</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MALAYSIA
FORM OF TRANSFER</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 296; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
C</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">POST-CLOSING
DIRECTORS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chin Yong Shing (existing director)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
Dr. Doris Wong (new director)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 297; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_106"></span>Annex
B</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATE
OF AMENDMENT<br/>
TO THE<br/>
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>
OF<br/>
CYCLACEL PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 242 of<br/>
the General Corporation Law of the<br/>
State of Delaware</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware
(the &#8220;Corporation&#8221;), does hereby certify:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIRST</b>:
The Board of Directors of the Corporation duly adopted resolutions approving the following amendments to the Corporation&#8217;s Amended
and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;), declaring said amendments to be advisable
and providing for the consideration of such amendments at a special meeting of stockholders of the Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECOND</b>:
On _________, 2025, the special meeting of stockholders of the Corporation was duly called and held, upon notice in accordance with Section
222 of the General Corporation Law of the State of Delaware, at which meeting the necessary number of shares required by statute were
voted in favor of the amendments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIRD</b>:
Said amendments were duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOURTH</b>:
Article ONE of the Certificate of Incorporation is hereby amended in its entirety to state the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;The
name of this corporation is Bio Green Med Solution,&#160;Inc. (the &#8220;<span style="text-decoration: underline">Corporation</span>&#8221;).&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIFTH:</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
</b>Article EIGHTH of the Certificate of Incorporation is hereby amended in its entirety to state the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Any
action required by law to be taken at any meeting of stockholders of the Corporation or any action which may be taken at a meeting of
stockholders, may be taken without a meeting, without prior notice, and without a vote if a written consent thereto is signed by stockholders
holding at least a majority of the voting power of the then-outstanding shares of voting stock of the Corporation entitled to vote.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 298; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIXTH</b>:</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Article FIFTEENTH of the Certificate of Incorporation is hereby added to state the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;The
Corporation hereby expressly&#160;elects&#160;not to be governed by&#160;Section 203 of the General Corporation Law of the
State of Delaware.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEVENTH</b>:</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
The foregoing amendment to the Certificate of Incorporation shall be effective as of 12:01 am Eastern Daylight Time on _______ 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, Cyclacel Pharmaceuticals, Inc. has caused this Certificate of Amendment to the Certificate of Incorporation to be signed
by the undersigned, thereunto duly appointed, this _________, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong Sing Ee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 299; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="svv_107"></span>Annex
C</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FAIRNESS
OPINION OF STRATEGIC CAPITAL ADVISORY SDN. BHD. IN RELATION TO THE PROPOSED ACQUISITION OF THE ENTIRE EQUITY INTEREST IN FITTERS SDN
BHD AND ITS SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"><img src="annexc_001.jpg" alt="" style="width: 150px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategic
                                            Capital Advisory Sdn. Bhd.</b></span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registration
                                            No. 199901003253 (478153-U))</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investment
                                            Advisers &#8211; Corporate Finance (CMSL/A0124/2007)</b></span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Licensed
                                            by Securities Commission)</b></span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unit
                                            T05, Tower Block, Plaza Dwitasik,</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jalan
                                            Tasik Permaisuri 1, Bandar Sri Permaisuri,</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56000
                                            Kuala Lumpur</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Tel : 603 9171 9600 Our Fax : 603 9173 7600</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                                                                <img src="annexc_002.jpg" alt="" style="width: 20px"/> www.strategiccapital.my</span></p></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8
April 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL
PHARMACEUTICALS INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11, Avenue 5</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
8, Jalan Kerinchi</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bangsar
South</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59200,
Kuala Lumpur</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strictly
Private &amp; Confidential</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sirs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FAIRNESS
OPINION IN RELATION TO THE PROPOSED ACQUISITION OF THE ENTIRE EQUITY INTEREST IN FITTERS SDN BHD AND ITS SUBSIDIARIES FOR A PURCHASE
CONSIDERATION OF USD22.50 MILLION (&#8220;PROPOSED EVALUATION&#8221;)</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter (&#8220;<b>Letter</b>&#8221;) is prepared and to be included in the Form S-4 of the Securities and Exchange Commission in connection
with the proposed acquisition of the entire equity interest in Fitters Sdn Bhd and its subsidiaries (&#8220;<b>Target Co</b>&#8221;)
for the purchase consideration of USD22.50 million (&#8220;<b>Purchase Consideration</b>&#8221;) (&#8220;<b>Proposed Acquisition</b>&#8221;)
for Cyclacel Pharmaceuticals Inc&#8217;s (&#8220;<b>Company</b>&#8221;) evaluation purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTRODUCTION</b></span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
Capital Advisory Sdn Bhd (&#8220;<b>SCA</b>&#8221;) has been appointed by the Board of Directors (&#8220;<b>Board</b>&#8221;) of the
Company as an Expert to undertake the Proposed Evaluation. SCA confirms that SCA and its employees do not have any direct or indirect
financial interests in the Company or its subsidiaries and is not in a position that may affect our objectivity in performing this engagement,
therefore confirming our independence in relation to the Proposed Evaluation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of this Letter is to set out the evaluation in relation to the Proposed Evaluation and is subject to the limitations of our role
and evaluation as explained herein. Other than for this intended purpose, this Letter should not be used for any other purpose and/or
by any other persons and/or reproduced, wholly or partially, without our express written consent. Should any information and/or section
of our Letter is to be extracted, quoted and/or referenced in any document, the relevant paragraphs and/or sections of the said document
shall be reviewed and consented in writing by us prior to the release of the said document to any party for any purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BACKGROUD
                                            INFORMATION OF THE TARGET CO</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Target
Co was incorporated in Malaysia on 20 August 1982 as a private limited liability company. The Target Co is principally engaged in trading
and installation of fire safety materials and equipment. The Target Co is the holding company for Fitters (Sarawak) Sdn Bhd (&#8220;<b>FSSB</b>&#8221;),
AHT NRG Asia Sdn Bhd (&#8220;<b>AHT</b>&#8221;) and Modular Floor System (M) Sdn Bhd (&#8220;<b>MSF</b>&#8221;). FSSB is also involved
in the trading of fire safety materials and equipment whereas both AHT and MSF have ceased operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 300; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TERMS
                                            OF REFERENCE</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
basis of our opinion is the fair market value which is defined as the arms&#8217; length price at which such asset would change hands
between a willing buyer and a willing seller, neither being under any compulsion to buy or to sell, in an open and unrestricted market
and both having reasonable knowledge of relevant facts. The concept of market value means the cash equivalent price of an asset being
valued assuming the transaction took place under conditions existing at the date of valuation of the assets. The amount would not be
considered market value if it was influenced by special motivations or characteristic of a typical buyer or seller.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sources
of Information</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sources of information which we have used in our evaluation are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audited
    financial statements of the Target Co for the financial year ended 31 March (&#8220;<b>FYE</b>&#8221;) 2024;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Target Co&#8217;s management accounts for the 9-month financial period ended 31 December 2024 (&#8220;<b>9M-FPE
    2024</b>&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Letter of Intent issued by Master Pyroserve Sdn Bhd (&#8220;<b>MPSB</b>&#8221;) to the Target Co for the maintenance service under
    the Sistem Pengawasan Kebakaran Automatik (&#8220;<b>SPKA</b>&#8221;) (&#8220;<b>LOI</b>&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    financial forecast and projection of the Target Co from the FYEs 31 December 2025 to 31 December 2031 (&#8220;<b>Future Financials</b>&#8221;)
    prepared by the management of the Target Co (&#8220;<b>Management</b>&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation
    and explanation by the Management; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    publicly available information in respect of the industry that the Target Co is involved in.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assumed and relied upon, without independent verification, the validity, accuracy and completeness of information that was publicly
available or supplied or otherwise made available to us by the Management, which such information formed a substantial basis of our opinion
and we express no opinion on such documents, financials and/or other information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also relied on the Management to exercise due care to ensure that all information and documents as mentioned above and that all
relevant facts, information and representations necessary for our evaluation have been disclosed to us, that such information is accurate,
valid and there is no omission of material facts, which would make any information provided to us incomplete, misleading or inaccurate
and undertake to inform us of any material changes in the subject matters which may have an impact on our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of this Letter is based upon, amongst others, the economic, industry and other conditions prevailing as at the Date of Opinion,
as well as publicly available information and information provided to us by the Management. Such conditions may change significantly
over a relatively short period of time. It should also be highlighted that the valuation may be materially or adversely affected should
the actual results or events differ from any of the bases and assumptions upon which the relevant reports were based.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Opinion</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of our opinion is 2 April 2025 (herein also referred to as the &#8220;<b>Date of Opinion</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scope
and Limitation of Review</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCA
was not involved in the formulation or any deliberation and negotiation on the terms and conditions of any corporate exercise intended
to be undertaken by the Company. Our role as the Expert does not extend to us expressing an opinion on the commercial merits of any corporate
exercise intended to be undertaken by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 301; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assessment of the commercial merits is solely the responsibility of the Board, although we may draw upon their views in arriving at our
opinion. As such, where comments or points of consideration are included on matters, which may be commercially oriented, these are incidental
to our overall valuation and concern matters, which we may deem material for disclosure. Further, our terms of reference do not include
us rendering an expert opinion on legal, accounting and taxation issues relating to the Proposed Evaluation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
work includes holding discussions with and making enquiries from the Management regarding representations made on the Proposed Evaluation.
We rely on the Management&#8217;s oral and written representations as well as third party sources as explained in the relevant sections
of this Letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
regards to the Future Financials furnished to us by the Management, we have assumed that they have been reasonably prepared on bases
reflecting the best currently available estimates and judgement by the Management on the future financial performance of the Target Co
and of which the Management are solely responsible for the bases and assumptions and the preparation and presentation of the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we make no representations as to the accuracy or completeness of the information provided and in no event shall we, our partners, principals,
directors, shareholders, agents or employees are liable for any misrepresentations by the Management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not undertaken an independent investigation into the business of the Target Co. Our procedures and inquiries do not include any
verification work that constitutes an audit on the information that we have relied upon in preparing this Letter. Furthermore, the Future
Financials have not been audited or reviewed by a firm of accountants. Further, we have not undertaken a review on the reasonableness
of the Future Financials and we do not express any opinion on the achievability of the Future Financials. Our work involves the determination
of the discount rate to be used and undertaking a sensitivity analysis based on the information provided by the Management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
representation or warranty, whether expressed or implied, is given by SCA that the information and documents provided will remain unaltered
after the issuance of this Letter. As such, we assume no responsibility to update and revise our Letter in light of any subsequent development
after the date of this Letter that may affect our evaluation contained herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Management has, individually and collectively, accepted full responsibility for all material facts, financial and other information essential
to our evaluation have been disclosed to us and are as set out in this Letter, and for the accuracy of the information in respect of
the Proposed Evaluation (save for those in relation to our evaluation and opinion pertaining to the same) as prepared herein and confirmed
that after making all reasonable enquires and to the best of their knowledge and belief, there are no other facts omitted which would
make any statement herein incomplete, false and/or misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[the
remainder of this page has been intentionally left blank]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 302; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><img src="annexc_001.jpg" alt="" style="width: 80px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 14.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDUSTRY
                                            AND PROSPECTS OF THE MALAYSIAN ECONOMY</b></span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.3pt; text-align: justify; text-indent: -14.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
developments in the Malaysian economy as extracted from quarterly bulletin for the fourth quarter of 2024 (&#8220;<b>4Q2024</b>&#8221;)
published by Bank Negara Malaysia are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Higher
    Gross Domestic Product growth of 5.0% in the 4Q2024, driven by domestic demand. Strong investment was underpinned by the continued
    realisation of new and existing projects. The factors supporting the growth in the 4Q2024 includes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 79.05pt; text-indent: -17.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    expansion in overall investment activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continued
    growth in exports of goods and services; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustained
    household spending.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 79.05pt; text-indent: -17.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    unemployment rate declined further to 3.2% in 4Q2024 (3Q2024: 3.2%). Employment rose to 16.8 million persons in 4Q2024 (3Q2024: 16.7
    million persons) amid continued demand for labour. Labour supply remained forthcoming as the labour force participation rate remained
    at a historical high of 70.6% in 4Q2024 (3Q2024: 70.5%);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
    headline and core inflation declined to 1.8% and 1.7%, respectively. Lower inflation was observed during the quarter for mobile
    communication services and petrol (RON97) but this was offset by higher inflation for food and beverages;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
    forward, the Malaysian economy is expected to remain resilient in 2025. Growth will be driven by robust expansion in investment activity,
    resilient household spending and continued expansion in exports. Investment activities will be driven by continued progress of multi-year
    projects in both the private and public sectors, higher realisation of approved investments and the implementation of catalytic initiatives
    under the national master plans. Employment and wage growth as well as policy measures, including the upward revision of the minimum
    wage and civil servant salaries, would remain supportive of household spending. Exports are expected to be supported by the global
    tech upcycle, continued growth in non-electrical and electronics goods and higher tourist spending. The growth outlook is subject
    to downside risks if growth in major trading partners slowed amid heightened risk of trade and investment restrictions, and lower-than-expected
    commodity production. Nevertheless, growth could potentially be higher from greater spillovers from the tech upcycle, more robust
    tourism activities, and faster implementation of investment project; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    to date, both headline and core inflation averaged at 1.8%. Moving into 2025, inflation is expected to remain manageable amid easing
    global cost conditions and the absence of excessive domestic demand pressures. Global commodity prices are expected to continue to
    trend lower, contributing to moderate cost conditions in the near-term. In this environment, the overall impact of the recently announced
    domestic policy measures1 is expected to be contained.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Source:
Bank Negara Malaysia (&#8220;<b>BNM</b>&#8221;) Quarterly Bulletin 4Q2024</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fire
Protection System Market Size</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global fire protection system market size was valued at USD 68.90 billion in 2024. The market is projected to grow from USD 71.97 billion
in 2025 to USD 111.38 billion by 2032, exhibiting a compounded annual growth rate (&#8220;<b>CAGR</b>&#8221;) of 6.4% during the forecast
period. North America dominated the global market with a share of 35.63% in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
fire protection system is a comprehensive set of equipment, devices, and strategies designed to detect, control, suppress, and mitigate
fire hazards in buildings, structures, or various areas. It is an integrated network of devices and measures implemented to detect fire,
alert occupants, control smoke, suppress flames, and facilitate safe evacuation, with the ultimate goals of protecting life, minimizing
property damage, and reducing the impact of fire incidents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 303; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapid
urbanization and the development of commercial, industrial, and residential infrastructures necessitate the installation of fire protection
systems to ensure safety. The expansion of the construction industry, particularly in emerging economies, is leading to increased installations
of both active fire protection and passive fire protection systems in new buildings and structures. For instance, according to the Ceramic
World Web report, the construction sector in India increased by 13.3% in 2023 compared to 2022. Moreover, a rising number of fire cases
registered across the globe, which resulted in several injuries and deaths in recent years, creates the demand for such systems to ensure
safety in commercial and industrial premises. For instance, according to the National Safety Council, in the year 2022, around 1504,500
fire cases were registered globally, which caused 13,250 injuries and 3,790 deaths. Such a surge in the rising number of fire cases globally
drives the market growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Source:
https://www.fortunebusinessinsights.com/fire-protection-system-market-104820) </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Malaysia
Passive Fire Protection Market Sizes and Outlook</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Malaysia passive fire protection market generated a revenue of USD 45.8 million in 2023 and is expected to reach USD 56.6 million by
2030. The Malaysia market is expected to grow at a CAGR of 3.1% from 2024 to 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Source:
https://www.grandviewresearch.com/horizon/outlook/passive-fire-protection- market/malaysia</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The
Rise of electrical vehicles (&#8220;<b>EVs</b>&#8221;) and Its Fire Safety Implications for Malaysia</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
EV adoption surges in Malaysia, fire safety professionals must confront a pressing issue: Are we prepared for the fire risks posed by
this new wave of technology?</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
EVs contribute to cleaner air and reduced carbon emissions, their lithium-ion battery systems present unique fire hazards that differ
significantly from traditional vehicles. For the fire safety community, these risks must be understood and mitigated as EVs become a
central part of Malaysia&#8217;s transportation landscape.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia
is witnessing a significant shift in its automotive industry, with EV sales rapidly increasing. In the first half of 2024 alone, 10,664
EVs were sold&#8212;more than double the 4,410 units sold the previous year. EVs now represent 2.6% of all vehicle sales, reflecting
a 148% year-on-year growth. This boom in EV adoption mirrors global trends toward sustainability, but it also brings new challenges for
fire safety, especially as EV infrastructure scales up nationwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
EV numbers continue to rise, so do fire incidents linked to their lithium-ion batteries. Globally, a high-profile incident occurred in
South Korea in August 2023, where a Mercedes-Benz EV fire in an underground parking lot destroyed over 140 vehicles. The event sparked
widespread concerns and led to discussions on restricting EV access to underground parking areas due to containment and ventilation challenges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia,
too, has seen EV fire incidents. In Johor, on December 31, 2023, an electric car caught fire while charging at a showroom along Jalan
Skudai. The blaze destroyed 90% of the vehicle, 5% of the showroom structure, and 20% of the EV charging bay, according to the Larkin
Fire and Rescue Station. This incident highlights the difficulty in controlling such fires and the significant damage they can cause,
especially in enclosed spaces like garages and underground parking lots, which are commonly found in Malaysia&#8217;s urban centres.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growing EV infrastructure in Malaysia adds complexity to the fire risk landscape. As of June 25, 2024, the country has installed 2,585
EV charging units, spanning all states and federal territories except Labuan. These include 610 direct current (&#8220;<b>DC</b>&#8221;)
fast chargers and 1,975 alternating current (&#8220;<b>AC</b>&#8221;) chargers. Selangor leads with 867 chargers, followed by Kuala Lumpur
(675), Penang (277), and Johor (251). With the number of EV charging points steadily increasing&#8212; up 12.5% since the first quarter
of 2024&#8212; fire safety at these stations becomes a critical issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 304; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ministry of Investment, Trade and Industry (&#8220;<b>MITI</b>&#8221;) has projected that Malaysia will reach 10,000 public EV charging
points by 2025, a key part of the Low Carbon Mobility Blueprint 2021- 2030. However, as the EV fleet grows, ensuring these charging points
are equipped to handle potential fire hazards is essential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
the immediate threat to life, EV fires pose serious risks to infrastructure. Lithium-ion battery fires burn at higher temperatures than
conventional vehicle fires, potentially compromising the structural integrity of surrounding materials, including steel and concrete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rise of EVs in Malaysia is an important step toward sustainability, but it also presents new fire safety challenges. As more EVs hit
the roads and charging infrastructure expands, fire safety professionals must stay ahead of these developments. Adopting advanced suppression
systems, improving building designs, and promoting safe charging practices are essential steps to ensure that the benefits of EV adoption
do not come at the cost of safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia&#8217;s
evolving infrastructure must be equipped to handle the growing presence of EVs. With proactive measures in place, the fire safety community
can help mitigate the risks and ensure a safer future as we transition to cleaner, greener transportation solutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
better prepare for these challenges, fire safety professionals must also receive specialized training. Fire safety training services
are designed to help first responders, building managers, and safety personnel understand the nuances of lithium-ion battery fires and
EV-specific risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Source:
Malaysian Fire Protection Association: The Rise of EVs and Its Fire Safety Implications for Malaysia, posted on 17 February 2025</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VALUATION
                                            METHODOLOGY</b></span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing our opinion on the fairness of the Purchase Consideration, SCA has considered various methodologies, which are commonly
used for valuation, taking into consideration the Target Co&#8217;s business sustainability, subsequent income generating capabilities
as well as associated risks affecting its business. Amongst the vast variety of valuation methodologies, SCA has considered and selected
the Discounted Free Cash Flow to Firm (&#8220;<b>FCFF</b>&#8221;) to form an opinion on the fairness of the Purchase Consideration as
the underlying value of Target Co is likely to be derived from its future business operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
to the above, SCA has also considered other valuation methodologies and found that the following methodologies are not suitable in forming
an opinion on the fairness of the Purchase Consideration based on the following factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
                                            Valuation Analysis (&#8220;<b>RVA</b>&#8221;)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RVA
method seeks to compare a company&#8217;s implied trading multiple to that of comparable companies to determine the firm&#8217;s financial
worth. Based on the Target Co&#8217;s audited financial statements for the FYE 2024, the Target Co registered a profit after tax of approximately
RM357,135. As the Target Co is in the growth stage and has recently received the LOI from MPSB of which MPSB has participated in the
tender for &#8220;<i>Perkhidmatan, Merancang, Menbangun, Membekal, Memasang, Menguji, Mentauliah, Mengoperasi, Menyelenggara dan Menaiktaraf
SPKA kepada Jabatan Bomba dan Penyelamat Malaysia</i>&#8221; (&#8220;<b>SPKA Project</b>&#8221;). Management represented that the chance
of securing such contract is encouraging. Hence, we opine that the RVA method is not appropriate to be used in this Proposed Evaluation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revalued
                                            Net Asset Valuation (&#8220;<b>RNAV</b>&#8221;)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RNAV
method seeks to adjust the net asset value of a company to take into consideration the valuation of assets of a company to determine
the adjusted value of the firm&#8217;s financial value. Based on the Target Co&#8217;s audited financial statements as at 31 March 2024,
the Target Co&#8217;s property, plant and equipment attributed to approximately 2.6% of its total assets. Hence, RNAV may not accurately
reflect the potential and market value of the Target Co.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 305; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounted
FCFF Methodology</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Discounted FCFF Methodology is a commonly used investment appraisal technique to evaluate the attractiveness of an investment opportunity
which takes into consideration, amongst others, the time value of money as well as future cash flows to be derived from the business
over a specific period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounted
FCFF Methodology is a valuation method which considers both the time value of money and the projected net cash flow generated discounted
at a specified discount rate to derive at the valuation of the subject matter. It is based on discounted cash flows, involving the application
of an appropriately selected discount rate applied on the projected future cash flows to be earned by the capital contributors of a company,
i.e., equity shareholders and debt capital providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Discounted FCFF methodology entails the discounting of future cash flows to be generated from the business at a specified discount
rate to arrive at the fair value of the investment, the risk involved in generating such cash flows will also be taken into consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FCFF
is the free cash flows available to be paid to the capital contributors of the company after all expenses and reinvestment cost. The
formula used to derive the enterprise value is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Enterprise
    value =&#160;&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Present
    value of Projected FCFF based on the Future Financials</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>+</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Terminal
    value</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 25%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: middle; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vo</i></span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: middle; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>=</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FCFF
    <sub>1</sub></i></span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: middle; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>+</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 21%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FCFF
    <sub>n</sub></i></span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: middle; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>+</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FCFF
    <sub>TV</sub></i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1+DR)<sup>1</sup></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1+DR)<sup>n</sup></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(DR-g)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Where:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>V<sub>o</sub>
= Value today</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FCFF<sub>1</sub>
= Expected FCFF in year 1 FCFF<sub>TV</sub> = Terminal year FCFF</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>DR
= Discount rate derived using the weighted average cost of capital (&#8220;<b>WACC</b>&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>n
= represent time, in years into the future g = terminal year growth rate</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
projected FCFF as determined annually based on the Future Financials shall be discounted using the WACC. The WACC formula is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>WACC
= [Cost of Equity X Equity / Capital] + [Cost of Debt X Debt / Capital X (1 &#8211; Corporate Tax Rate)]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of equity takes into account a combination of risk factors associated with the industry in which the Target Co are involved in,
namely, the systematic risk, i.e., the inherent market risk such as the interest rate fluctuation, and the capital structure,
i.e., the financing risk. These risks are translated into the cost of equity which is built upon the Capital Asset Pricing Model
(&#8220;<b>CAPM</b>&#8221;). The cost of equity formula is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of equity = Risk-Free Rate + [Re-geared Beta X (Market Return &#8211; Risk-Free Rate)]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of the Discounted FCFF methodology, reference was made to valuation of public listed companies on Bursa Malaysia Securities
Berhad (&#8220;<b>Bursa Securities</b>&#8221;) and the stock exchanges in Southeast Asia which are principally engaged in the trading
of fire material and equipment and related products. Based on the above criteria, three (3) comparable companies listed on Bursa Securities,
Shenzhen Stock Exchange (&#8220;<b>SZSE</b>&#8221;) and the Stock Exchange of Thailand (&#8220;<b>SET</b>&#8221;) were selected on the
basis that the risks and structure of the industry of which Target Co is operating in are similar (&#8220;<b>Comparable Companies</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 306; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
arriving at the appropriate discount rate for the Target Co, we have applied the prevailing risk- free rate and market risk premium,
as well as adopted the betas of available Comparable Companies with relevant adjustments made taking into consideration the gearing and
the risk profile as well as other risk factors that may affect the Target Co.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
information obtained was sourced from S&amp;P Capital IQ as at the Date of Opinion unless stated otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of determining the fairness of the Purchase Consideration, the Comparable Companies&#8217; beta is adjusted (de-geared) for
its gearing ratio, and then re-geared based on the median net gearing level of the Comparable Companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is important to note that the Comparable Companies tabulated herein are by no means exhaustive and may differ from the Target Co in terms
of, inter alia, composition of business activities, scale of operations, geographical location of operations, profit track record, financial
profile, risk profile, future prospects, capital structure, marketability of their securities and other criteria. One should also note
that any comparisons made with respect to the Comparable Companies are merely to provide an indication to the implied valuation of the
Target Co and the selection of Comparable Companies and adjustments made are highly subjective and judgmental and the selected companies
may not be entirely comparable due to various factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Comparable Companies and the input parameters for CAPM at the Date of Opinion are set out as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparable
    Companies</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    activities</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unique
                                            Fire Holdings</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Berhad
    (&#8220;<b>Unique</b>&#8221;)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bursa
    Securities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engages
    in the manufacture, assembly, and distribution of active fire protection systems, equipment, and accessories for the built environment.
    The company offers filling series for fire extinguisher; fire extinguishers; fire hose reels; fire hydrant systems; sprinkler systems;
    fire detection and alarm devices; fire suppression systems; carbon dioxide fire extinguishing system; wet chemical fire suppression
    systems; fire blanket and smoke curtain; home safety kit; design fire extinguisher; unique5112 systems; wet and dry riser systems,
    and hydrant; fire hoses; and batteries, cabinets, and fire blankets, as well as home safety kits. It also provides dry chemical fire
    extinguisher refilling machines, as well as fire protection equipment services.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jade
    Bird Fire Co., Ltd (&#8220;<b>Jade</b>&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SZSE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develops,
    manufactures, and sells professional fire safety electronic products and fire safety systems in China and internationally. The company
    offers fire safety system products, including automatic fire alarm and linkage control; electricity fire safety system products,
    such as gas fire monitoring, automatic gas fire extinguishing, and gas detection and monitoring systems, as well as fire cloud platform.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harn
  Engineering Solutions Public Company Limited (&#8220;<b>Harn</b>&#8221;)<br/>
  &#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SET<br/>
  &#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Design,
  install, designs, and distributes fire protection systems and fire suppression products in Thailand. It offers sprinklers, fire hose
  cabinets, floor control valves, pump room, and fire extinguishers for fire protection and safety solutions; and compressors, unit coolers,
  controllers, inverters, condensing units, refrigerants, and fans for refrigeration, as well as cooling system controlling devices.</span></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 307; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comparable
    Company</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    Cap (RM million)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Levered
    Beta</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Debt/ Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlevered
    Beta</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unique</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jade</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,350.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.58</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.03</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harn</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">159.91</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.69</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.03</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.62</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.58</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.03</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bases
and Assumptions for Future Financials</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Future Financials have been prepared based on a set of assumptions made by the Management, which includes assumptions about future events
and outlook that may or may not necessarily occur. In particular, the Future Financials are dependent on the achievability of the specific
assumptions as set out below. We have not undertaken a review on the reasonableness of the Future Financials, and we do not express any
opinion on the achievability of the Future Financials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FCFF for each financial year in the Future Financials used to derive at the Discounted FCFF valuation are extracted from the estimate,
forecast and projections based on the Management&#8217;s best estimate, and includes the existing contracts as well as quotations provided
to its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, we wish to highlight that the Discounted FCFF valuation is based on prevailing economic, market and other conditions as at
Date of Opinion for valuation parameters, in addition to publicly available information and information provided by the Target Co. Such
conditions may change significantly over a short period of time. The resultant effect of such changes may materially and/or adversely
affect the valuation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, the Future Financials are dependent on the achievability of the specific assumptions as set out below. The results of the
Future Financials can be materially affected by economic and other circumstances. The actual results may vary considerably from the Future
Financials. The Future Financials have been prepared on the bases consistent with the historical information provided by the Management,
of which the specific key assumptions are as follows:-</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Future Financials of the Target Co as provided by the Management are set out as follows:-</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE&#160;2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE&#160;2026</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE&#160;2027</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE&#160;2028</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE&#160;2029</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE&#160;2030</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE&#160;2031</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,185</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,121</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,858</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,922</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91,121</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,776</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
    growth</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.7</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.3</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.8</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.6</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.2</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.2</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of sales</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,424</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,482</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33,481</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(46,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(67,395</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(98,329</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,511</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,761</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,639</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,377</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,726</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,446</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit margin</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenditure</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,400</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,599</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,830</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,422</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    before taxation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,798</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,912</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,141</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,813</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(179</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,631</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,227</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,579</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,114</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,933</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,195</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    after taxation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">568</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,166</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,218</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,027</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,623</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,618</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 44.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 44.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*Any
discrepancies in the table between the amount listed and totals thereof are due to rounding.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 308; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Target Co&#8217;s revenue can be further discussed in the following geographical manner:-</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE
    2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE
    2026</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE
    2027</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE
    2028</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE
    2029</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE
    2030</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FYE
    2031</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RM&#8217;000</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPKA</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,866</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,903</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,074</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FSSB</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">950</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">979</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,008</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,038</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,069</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,134</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyco</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,375</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,563</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,344</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemguard
    form</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,761</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,475</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,241</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,327</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
    apparel</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,107</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,972</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,554</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,550</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,185</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,121</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,858</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,922</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91,121</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,776</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Target Co has received the LOI from MPSB in relation to the SPKA Project, of which MPSB will
                                            award the maintenance services of the SPKA Project to the Target Co;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            revenue contribution from FSSB is expected to grow by 3.0% per annum throughout the projected
                                            period;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
                                            of Tyco&#8217;s fire product. The Management has estimated an increase of 50.0% per annum
                                            throughout the projected period due to the booming of the data centres in Malaysia, particularly
                                            in Johor Bahru;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
                                            of Chemguard form concentrates. The Management has estimated an increase of 15.0% per annum
                                            throughout the projected period to serve the oil and gas industry; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
                                            of safety apparels of which the Management has estimated an increase of 60.0% per annum throughout
                                            the projected period.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
                                            profit margin is estimated to be ranging from 20.0% to 34.2% throughout the projected period
                                            and gradually increase from approximately 61.5%.for the FYE 2025 to 64.3% for the FYE 2027.
                                            For information, the historical gross profit margin for the Target Co for the FYE 2024 and
                                            9M-FPE 2024 were 22.4% and 21.8% respectively.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Target Co&#8217;s receivables and payables turnover days are estimated to be within 45 days
                                            and 45 days respectively, based on Management&#8217;s best estimate. For information, the
                                            historical receivables turnover days for the FYE 2024 and 9M-FPE 2024 were 87 days and 117
                                            days, whereas the historical payable turnover days for the FYE 2024 and 9M-FPE 2024 were
                                            36 days and 65 days. The Management represented that it will improve its cash management
                                            system in the future to mitigate its liquidity risk.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            operating cost comprises salaries which are expected to increase by 5.0% per annum throughout
                                            the projected period. Selling and distribution expenses are expected to increase by 30.0%
                                            per annum throughout the projected period. Others comprise administrative expenses, rental,
                                            professional fees, travelling expenses and premise cost are expected to increase by 10% per
                                            annum throughout the projected period.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
                                            expense is estimated based on the Malaysia&#8217;s corporate tax rate of 24.0%.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
                                            represented that there is no capital expenditure needed for the growth of the Target Co.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no significant changes in the principal activities, key management personal, operating
                                            policies, accounting and business policies presently adopted by the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 309; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: right; margin-top: 0; margin-bottom: 0"><img src="annexc_001.jpg" alt="" style="width: 80px"/></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Future Financials have been prepared based on prevailing economic conditions and information
                                            available as at the date of its preparation and does not encompass any assessment of the
                                            potential for future changes in the economic conditions in Malaysia, Southeast Asia and globally;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no significant changes to the prevailing economic, political and market conditions
                                            in Malaysia, Southeast Asia and elsewhere that will have direct and indirect effects on the
                                            activities and performance of the Target Co and the business of the Target Co&#8217;s customers
                                            and suppliers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no material changes to the present legislation and government&#8217;s regulations
                                            and other operation regulations or restrictions affecting the Target Co&#8217;s activities
                                            or the market in which it operates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no significant changes in the credit period granted or received by the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            statutory income tax rate and other relevant duty and tax rate for the Target Co will remain
                                            at their respective existing rates with no significant changes in the bases of taxation and
                                            there will be no significant changes in the structure which would adversely affect the cash
                                            flows of the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no material adverse effect from service disruptions, equipment or network breakdown
                                            or other similar occurrences, wars, epidemic, terrorist attacks and other natural risks,
                                            both domestic and foreign, which will adversely affect the operations, income and expenditure
                                            of the Target Co;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            rate of inflation will not fluctuate significantly from their projected levels;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.65pt; text-align: justify; text-indent: -28.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            exchange rate between RM and the various currencies in which the Target Co derives its income/expenses
                                            in will not fluctuate significantly from their projected levels;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            than the estimation made by the Management, there will be no substantial impairment to the
                                            carrying value of the Target Co&#8217;s investment, property, plant and equipment and other
                                            assets;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no significant changes in wages, supplies, administration, overhead expenses and
                                            other costs other than those forecasted and projected;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no termination of any significant agreements or contracts from which the legal rights
                                            accruing to the Target Co, in respect of the principal activities are derived; Such agreements
                                            or contracts are assumed to be renewed based on current terms upon expiry;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be adequate supply of manpower and other relevant resources to the Target Co for its
                                            business activities; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            will be no major legal proceedings against the Target Co which will adversely affect the
                                            activities or performance of the Target Co or give rise to any contingent liability which
                                            will materially affect the financial position or business of the Target Co.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 310; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
of the Fairness of the Purchase Considerations</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fairness of the Purchase Consideration, and based on the Discounted FCFF Methodology using the Future Financials as provided
by the Management and the inputs from the Comparable Companies, the following were noted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">WACC Inputs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Median Net Debt/Equity Ratio of Comparable Companies</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">13.36</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free Rate <sup>[1]</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.76</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market return <sup>[2]</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.54</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-geared Beta <sup>[3]</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Illiquidity Premium <sup>[4]</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of equity derived using CAPM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.39</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of debt <sup>[5]</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">WACC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.30</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enterprise Value (&#8220;<b>EV</b>&#8221;) of the Target Co @ RM</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RM97.42 million</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">EV of the Target Co @ USD</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD21.88 million</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[1]</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based
                                            on the risk-free rate for Malaysia as extracted from http://www.bnm.gov.my. This risk-free
                                            rate is based on the yield of ten (10) years Malaysian Government Securities as at Date of
                                            Opinion.</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[2]</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based
                                            on the historical average market return for Malaysia as extracted from Bloomberg. The historical
                                            average market return is based on the average return of FTSE Bursa Malaysia Top 100 Index
                                            for the past ten (10) years extracted on the Date of Opinion.</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[3]</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Re-geared
                                            beta is arrived at based on the net debt/equity ratio of Comparable Companies.</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[4]</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
                                                                                                                                                                                                               illiquidity premium of 4.0% had been applied to derive the discount rate using CAPM to account for the lack of marketability and
                                                                                                                                                                                                               unsystematic risk as extracted from <span style="text-decoration: underline">http://people.stern.nyu.edu/adamodar/pdfiles/country/illiquidity.pdf</span>.</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[5]</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based
                                            on the lending rate as extracted from Bank Negara Malaysia.</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[6]</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based
                                            on the exchange rate extracted from Bank Negara Malaysia as of the Date of Opinion of USD1.00:
                                            RM4.4530</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminal
value is mainly computed via one of the three (3) approaches, which is (a) liquidation value (b) multiple approach or (c) stable growth
approach. For the purpose of this valuation, we have used the stable growth model to compute the terminal value as this usually applies
to companies that are growing but on a moderate pace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terminal value is computed based on the FCFF for the FYE 2031 at a terminal growth rate of nil, taking into consideration the risk of
external factors that may directly or indirectly affect the business of the Target Co. The terminal value computed of approximately RM58.03
million represent 59.6% of the Target Co&#8217;s EV of approximately RM97.42 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terminal value of the Target Co adopted in the Discounted FCFF Methodology is computed based on the parameters as stated below:-</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 40%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt"><i>Terminal
    Value</i></span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.5pt"><i>=</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 27%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FCFF<sub>n</sub>
    X <span style="letter-spacing: -0.2pt">(1+g)</span></i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt"><i>WACC-</i></span><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.5pt">g</span></i></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Where;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>n
= represent time, last year of the Future Financials WACC =Discount rate derived using WACC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>g
= terminal growth rate</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EV of the Target Co is then adjusted for the cash and bank balances and borrowings, surplus of assets and liabilities of the Target Co
to arrive the equity value in the Target Co as shown in the table below:-</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Equity Value of the Target Co</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>RM&#8217;million</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>USD&#8217; million</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">EV of the Target Co</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">97.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline">Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Amount due to holding company <sup>[1]</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.31</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add: Cash and cash equivalents <sup>[1]</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Value of 100% equity interest in the Target Co</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">99.66</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22.38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27.8pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[1]</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Based
                                            on the management accounts for the 9M-FPE 2024.</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 50.85pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 311; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="annexc_001.jpg" alt="" style="width: 80px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the underlying assumptions of the Future Financials, we have performed a sensitivity analysis on three key parameters, namely the
discount rate, terminal value and FCFF as these assumptions have significant impact on the implied valuation of the Target Co. We have
stress tested the Future Financials by varying the values adopted in the discount rate, terminal value and FCFF on a 0.5% and 3.0% upward
and downward variance respectively on the midpoint of the valuation to arrive at a reasonable range of equity valuation of the Target
Co.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
variance parameters for the discount rate, terminal value and FCFF are selected after considering the followings:-</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">World
                                            Bank had projected that Malaysia&#8217;s GDP to grow by 4.3% in 2024;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headline
                                            and core inflation are projected to remain moderate between 2% &#8210; 3.5% and 2.0% &#8210;
3.0%, respectively. (<i>Source: Economic and Financial Developments in Malaysia in the First Quarter of 2024: Bank Negara Malaysia</i>);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            average annual real GDP growth for Malaysia from year 2014 to 2023 is 4.1% as extracted from
the World Bank. Malaysia&#8217;s GDP growth for 2021, 2022 and 2023 were 3.3%, 8.7% and 3.7%
respectively; and</span>
</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            average annual inflation rate for Malaysia from year 2014 to 2023 is 2.0% as extracted from
                                            World Bank. Malaysia&#8217;s inflation rate for 2021, 2022 and 2023 were 2.5%, 3.4% and 2.5%,
                                            respectively.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the above, we are of the opinion that the 0.5% and 3.0% upward and downward variance adopted for the discount rate, terminal value
and FCFF is reasonable to take into consideration the range of possible fluctuations in the business to not only take into consideration
the potential upsides but also the downturn due to unforeseen circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of the sensitivity test is as shown below:-</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Intrinsic value</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><b>Sensitivity test</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Low range of value</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>High range of value</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left"><b><span style="text-decoration: underline">Parameters</span></b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>RM million</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>RM million</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Movement in discount rate used (&#177;0.5%)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">95.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">104.64</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Movement in terminal value (&#177;3.0%) and discount rate (&#177;0.5%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Movement in FCFF (&#177;3.0%) and discount rate (&#177;0.5%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107.71</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Premise
on the above, the fair value of entire equity interest of the Target Co ranges from RM92.27 million to RM107.71 million, this shall translate
to USD20.72 million to USD24.19 million using the exchange rate of USD1.00: RM4.453 as at the Date of Opinion. The Purchase Consideration
falls within the ranges of values derived using the Discounted FCFF methodology, hence it is <span style="text-decoration: underline">FAIR</span> from a financial point of view
to the holders of the shares.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
                                            FACTOR</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Proposed
Acquisition Risk</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the Proposed Acquisition is expected to contribute positively to the future earnings of the Company, there can be no assurance that the
anticipated benefits from the Proposed Acquisition will be realised or that the Company will be able to generate sufficient returns from
the earnings of the Target Co to offset the associated cost of acquisition incurred. In addition, any decline in economic conditions
and/or change in government policies may affect the potential benefits to be derived from the Proposed Acquisition and the duration required
for the Company to recoup its investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevertheless,
the management of the Company and the Board have exercised due care in considering the potential risks and benefits associated with the
Proposed Acquisition and believes that the Proposed Acquisition will be earnings accretive to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 312; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right"><img src="annexc_001.jpg" alt="" style="width: 80px"/></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Achievability
of the Future Financials</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
set out in Section 5 of this Letter, the Future Financials are prepared based on various bases and assumptions which are deemed reasonable
and realistic by the Management, but nevertheless subject to certain uncertainties and contingencies which are often outside the Target
Co&#8217;s control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the Target Co and MPSB will be able to secure the SPKA Project, will not face potential delays and/or cancellation
of purchase orders as well as crystallisation of its existing order and projects currently being pursued which will result in the Future
Financials not being met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contractual
risk</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
the Company decides to obtain any representations, warranties, undertakings, covenants and indemnities, to be set out in the eventual
share sale agreement (&#8220;<b>SSA</b>&#8221;), in favour of the Company, the Target Co may be subject to claims in accordance with
the terms and conditions of the SSA if the pre-completion or post-completion obligations under the SSA are not fulfilled and/or in the
event of any breach of any representations, warranties, undertakings and/or covenants given by the Target Co.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this regard, the Company will endeavour to ensure compliance with its obligations under the SSA in order to minimise the risk of any
breach of the representations, warranties, undertakings and/or covenants given.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Goodwill
and Impairment Risk</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to recognise goodwill arising from the Proposed Acquisition, the amount of which will depend on the Purchase Consideration
vis-&#224;-vis the fair value of the Target Co&#8217;s identifiable assets and liabilities acquired as at the completion date of the
Proposed Acquisition. Any subsequent fair value adjustments allocated to the identifiable assets acquired and liabilities assumed, and
the effects of amortisation of the fair value adjustments, if any, may materially affect the Company&#8217;s financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the goodwill, will be subjected to periodic impairment testing and any downward adjustment to the goodwill may materially and adversely
affect the financial position and results of the Company. Nevertheless, the Company will continuously monitor the financial performance
of the Target Co to ensure that the goodwill is supported by the operations of the relevant cash generating units at all times.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dependency
on key personnel of the Target Co</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuing success of the Target Co&#8217;s business is to a certain extent dependent on the experience and competencies of the Management
who are responsible for the Target Co&#8217;s strategic directions as well as the day-to-day operational and business activities. Any
unexpected departure of the Management without a suitable and timely replacement could adversely affect the Target Co&#8217;s business
operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Political,
economic and regulatory risks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
changes in political, economic and regulatory conditions in the United States of America and Malaysia could materially affect the financials
and prospects of the Company. Political, economic and regulatory uncertainties include, amongst others, risks of war, changes in political
state, changes in economic conditions, changes in governmental policies such as changes to labour laws, introduction of new rules or
regulations, interest rates, tariff rates, fiscal and monetary policies and method of taxation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 313; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: right; margin-top: 0; margin-bottom: 0"><img src="annexc_001.jpg" alt="" style="width: 80px"/></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIMITATION</b></span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.3pt; text-align: justify; text-indent: -14.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
should be noted that the valuation in itself is highly dependent on, amongst others, the composition of business activities, scale of
business operations, risk profile, assets base, accounting and tax policies, track record, future prospects, competitive environment,
financial positions and that such business may have fundamentally different profitability objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the Discounted FCFF Methodology to a certain extent places reliance on the Future Financials, which is the net result of forecasting
a range of variables for significant periods of time, most of which cannot be forecast and projected with a high degree of precision.
We have not undertaken a review on the reasonableness of the Future Financials and we do not express any opinion on the achievability
of the Future Financials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation In itself is highly dependent on, amongst others, the achievability of the Future Financials as well as the materialization
of the bases and assumptions used therein. Key variables such as economic growth, demand, competition and regulatory policies are beyond
the control of the Target Co. The Future Financials are also typically very sensitive to small changes in key variables and changes in
environmental and economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, relatively small changes in key variables can have a significant impact on the output of the abovementioned valuation model. It
should also be noted that the valuation may be materially or adversely affected should the actual results or events differ from any of
the bases and assumptions upon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONCLUSION</b></span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.3pt; text-align: justify; text-indent: -14.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
should be recognised that the valuation of any entity is always subject to a great deal of uncertainty and involves a high degree of
subjectivity and element of judgement. Because of the susceptibility of valuations to inputs of the model applied, valuations can change
quite quickly in response to market changes or changes in the surrounding circumstances, including the market outlook (whether in general
or relating to the industry itself).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing our opinion on the fairness of the Purchase Consideration, SCA has considered various valuation methodologies, which are
commonly used for valuation, taking into consideration the Target Co&#8217;s future earnings generating capabilities, projected future
cash flows and its sustainability as well as various business considerations and risk factors affecting its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sole valuation methodology considered and selected by SCA to evaluate the fairness of the Purchase Consideration is based on the Discounted
FCFF Methodology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the Discounted FCFF Methodology to a certain extend places reliance on the Future Financials, which is the net result of forecasting
a range of variables for significant periods of time, most of which cannot be forecast and projected with a high degree of precision.
We have not undertaken a review on the reasonableness of the Future Financials and we do not express any opinion on the achievability
of the Future Financials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
variables such as economic growth, demand, competition and regulatory policies are beyond the control of the Target Co. The Future Financials
are also typically very sensitive to small changes in key variables and changes in environmental and economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, relatively small changes in key variables can have a significant impact on the output of the abovementioned valuation model. As
a result, the range of values that can be produced by a particular valuation model can be quite wide using combinations of assumptions
which individually may appear reasonable. A degree of professional judgement is required to establish the range of values in any valuation
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 314; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="annexc_001.jpg" alt="" style="width: 80px"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Premise
on the above, the fair value of entire equity interest of the Target Co ranges from RM92.27 million to RM107.71 million, this shall translate
to USD20.72 million to USD24.19 million using the exchange rate of USD1.00: RM4.453 as at the Date of Opinion. The Purchase Consideration
falls within the ranges of values derived using the Discounted FCFF methodology, hence it is <span style="text-decoration: underline">FAIR</span> from a financial point of view
to the holders of the shares.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESTRICTIONS</span></td></tr>
</table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
for the purpose stated herein, this Letter cannot be relied upon by any party other than the Company for its intended purposes only.
Accordingly, we are not responsible or liable for any form of losses however occasioned to any third party as a result of the circulation,
publication, reproduction or use of, or reliance on this Letter, in whole or in part. We are not required to give testimony or to be
in attendance in court with reference to the opinion herein provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
SCA nor any of its members or employees undertakes responsibilities arising in any way whatsoever to any person in respect of this Letter,
including any error or omission therein, however caused, as a result of the unauthorised circulation, publication, reproduction or use
of this Letter, or any part hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
faithfully</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
and on behalf of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STRATEGIC
CAPITAL ADVISORY SDN BHD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="border-bottom: Black 1pt solid; width: 49%; text-align: left"><img src="annexc_003.jpg" alt="" style="width: 60px"/></td><td style="padding-bottom: 1pt; text-align: left; width: 2%"/><td style="border-bottom: Black 1pt solid; text-align: left; width: 49%"><img src="annexc_004.jpg" alt="" style="width: 120px"/></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><b>NG WOON LIT</b></td><td style="text-align: left">&#160;</td><td style="text-align: left"><b>TAN DAI LIANG</b></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">Director</td><td style="text-align: left">&#160;</td><td style="text-align: left">Director</td></tr>
     </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"></p>

<!-- Field: Page; Sequence: 315 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
20. <i>Indemnification of Directors and Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registrant&#8217;s amended and restated certificate of incorporation contains provisions that eliminate, to the maximum extent permitted
by the General Corporation Law of the State of Delaware, the personal liability of the Registrant&#8217;s directors and executive officers
for monetary damages for breach of their fiduciary duties as directors or officers. The Registrant&#8217;s amended and restated certificate
of incorporation and amended and restated bylaws provide that the Registrant must indemnify its directors and executive officers and
may indemnify its employees and other agents to the fullest extent permitted by the General Corporation Law of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
145 and 102(b)(7) of the General Corporation Law of the State of Delaware provide that a corporation may indemnify any person made a
party to an action by reason of the fact that he or she was a director, executive officer, employee or agent of the corporation or is
or was serving at the request of a corporation against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by him or her in connection with such action if he or she acted in good faith and in a
manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of an action by or
in right of the corporation, no indemnification may generally be made in respect of any claim as to which such person is adjudged to
be liable to the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registrant has entered into indemnification agreements with its directors and executive officers, in addition to the indemnification
provided for in its amended and restated certificate of incorporation and amended and restated bylaws, and intends to enter into indemnification
agreements with any new directors and executive officers in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registrant has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer of the Registrant
against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain
exclusions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
21. <i>Exhibits and Financial Statement Schedules</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Exhibit Index</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
list of exhibits filed with this registration statement on Form S-4 is set forth on the Exhibit Index and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements filed with this registration statement on Form S-4 are set forth on the Financial Statement Index and is incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
22. <i>Undertakings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The undersigned registrant hereby undertakes as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration
statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such
reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons
who may be deemed underwriters, in addition to the information called for by the other Items of the applicable form.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 316; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That every prospectus (i) that is filed pursuant to paragraph (a)(1) immediately preceding, or (ii) that purports to meet the requirements
of Section 10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed
as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes
of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To respond to requests for information that is incorporated by reference into this proxy statement/prospectus pursuant to Item 4, 10(b),
11, or 13 of this Form S-4, within one business day of receipt of such request, and to send the incorporated documents by first class
mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration
statement through the date of responding to the request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein,
that was not the subject of and included in the registration statement when it became effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 317; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Incorporated
    by Reference</span></b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
                                            </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000164117225008836/ex2-1.htm" style="-sec-extract: exhibit">Exchange Agreement dated May 6, 2025 by and among Cyclacel Pharmaceuticals, Inc., FITTERS Diversified Berhad and FITTERS Sdn. Bhd.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625001770/cyclacel_ex2-1.htm" style="-sec-extract: exhibit">Agreement for the Sale and Purchase of Certain Assets dated March 10, 2025 by and between Cyclacel Pharmaceuticals, Inc., Cyclacel Limited, and with its liquidators</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    14 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">2.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000164117225017906/ex2-1.htm" style="-sec-extract: exhibit">Amendment No. 1 to Exchange Agreement dated July 7, 2025 by and among Cyclacel Pharmaceuticals, Inc., FITTERS Diversified Berhad and FITTERS Sdn. Bhd.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">000-50626</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><p style="margin: 0">2.1</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><p style="margin: 0">July
                                            7, 2025</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2013</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    27, 2016</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/tm2015825d1_ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    14, 2020</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924005261/tm243656d1_ex3-4.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-282555</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    19, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924005261/tm243656d1_ex3-5.htm" style="-sec-extract: exhibit">Certificate of Correction to the Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-282555</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    19, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000164117225008988/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation, effective May 12, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    7, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920058082/tm2018924d1_ex3-01.htm" style="-sec-extract: exhibit">Second Amended and Restated Bylaws of Cyclacel Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    7, 2020</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923115233/tm2330094d1_ex3-1.htm" style="-sec-extract: exhibit">Amendment No. 1 to the Second Amended and Restated Bylaws of Cyclacel Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    7, 2023</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm" style="-sec-extract: exhibit">Certificate of Designation of 6% Convertible Exchangeable Preferred Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    5, 2004</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm" style="-sec-extract: exhibit">Certificate of Designation of Series A Preferred Stock (previously filed as Exhibit 3.5 to the Registrant&#8217;s Registration Statement on Form S-1</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-218305</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    7, 2023</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920138563/tm2039082d1_ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    22, 2020</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 318; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex3-2.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series D Preferred Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625000905/cyclacel_ex3-2.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock filed with the Secretary of State of the State of Delaware on February 10, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    12, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625000905/cyclacel_ex3-4.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock filed with the Secretary of State of the State of Delaware on February 6, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    12, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625000905/cyclacel_ex3-5.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. filed with the Secretary of State of the State of Delaware on February 10, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    12, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000164117225008988/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation, effective May 12, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    7, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm" style="-sec-extract: exhibit">Specimen of common stock Certificate (previously filed as Exhibit 4.1 to Registrant&#8217;s Registration Statement on Form S-1</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-109653</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2004</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm" style="-sec-extract: exhibit">Specimen of Preferred Stock Certificate of Designation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-119585</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    21, 2004</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm" style="-sec-extract: exhibit">Form of Warrant to purchase shares of Cyclacel Pharmaceuticals, Inc. common stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    1, 2011</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated as of December 14, 2012, by and between the Company and Aspire Capital Fund, LLC</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    17, 2012</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated November 14, 2013, by and between the Company and Aspire Capital Fund, LLC</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    14, 2013</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm" style="-sec-extract: exhibit">Form of Warrant to purchase shares of Cyclacel Pharmaceuticals, Inc.&#8217;s common stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-218305</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    17, 2017</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920051033/tm2016791d1_ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    24, 2020</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920051033/tm2016791d1_ex4-2.htm" style="-sec-extract: exhibit">Form of Common Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    24, 2020</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920138563/tm2039082d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    22, 2020</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Common Stock Purchase Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    26, 2023</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 319; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
26, 2023</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000155837025004331/cycc-20241231xex4d12.htm" style="-sec-extract: exhibit">Description of Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/tm2413298d1_ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/tm2413298d1_ex4-2.htm" style="-sec-extract: exhibit">Form of Series A Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/tm2413298d1_ex4-3.htm" style="-sec-extract: exhibit">Form of Series B Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/tm2413298d1_ex4-4.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924119469/tm2428551d1_ex4-1.htm" style="-sec-extract: exhibit">Form of Series C Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924119469/tm2428551d1_ex4-2.htm" style="-sec-extract: exhibit">Form of Series D Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924119469/tm2428551d1_ex4-3.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Legal Opinion of Rimon P.C.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"/>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm" style="-sec-extract: exhibit">Amended and Restated 2006 Equity Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    24, 2012</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm" style="-sec-extract: exhibit">2015 Equity Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    22, 2015</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/tm2318711d1_ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated 2018 Equity Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    14, 2023</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/tv506501_ex10-1.htm" style="-sec-extract: exhibit">Clinical Collaboration Agreement by and between Cyclacel Pharmaceuticals, Inc. and the University of Texas M.D. Anderson Cancer Center dated as of August 21, 2018</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2018</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000155837020013741/cycc-20200930ex1017c6286.htm" style="-sec-extract: exhibit">Cyclacel Pharmaceuticals, Inc. 2020 Inducement Equity Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    12, 2020</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000155837020013741/cycc-20200930ex1028db6db.htm" style="-sec-extract: exhibit">Form of Stock Option Grant Notice and Stock Option Agreement under the Cyclacel Pharmaceuticals, Inc. 2020 Inducement Equity Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    12, 2020</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000155837023019369/cycc-20221231xex10d16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement for directors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    29, 2023</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-1.htm" style="-sec-extract: exhibit">Placement Agency Agreement by and between Cyclacel Pharmaceuticals, Inc. and Ladenburg Thalmann &amp; Co. Inc., dated December 21, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    26, 2023</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-2.htm" style="-sec-extract: exhibit">Securities Purchase Agreement by and between Cyclacel Pharmaceuticals, Inc. and the Purchasers, dated December 21, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    26, 2023</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 320; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-3.htm" style="-sec-extract: exhibit">Securities Purchase Agreement by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis and Paul McBarron, dated December 21, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    26, 2023</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/tm2413298d1_ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of April 30, 2024, between the Company and the purchaser named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/tm2413298d1_ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated as of April 30, 2024, between the Company and the purchaser named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924119469/tm2428551d1_ex10-1.htm" style="-sec-extract: exhibit">Warrant Exercise and Reload Agreement, dated November 13, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2024</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of January 2, 2025, by and between the Company and David Lazar</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex10-2.htm" style="-sec-extract: exhibit">Form of Director Settlement Agreement and Release</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex10-3.htm" style="-sec-extract: exhibit">Settlement and Release Agreement, dated as of January 2, 2025, by and between the Company and Spiro Rombotis</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex10-4.htm" style="-sec-extract: exhibit">Settlement and Release Agreement, dated as of January 2, 2025, by and between the Company and Paul McBarron</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex10-5.htm" style="-sec-extract: exhibit">Warrant Exchange Agreement, dated as of January 2, 2025, by and between the holder and the Company</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000110465925002198/tm252869d1_ex10-1.htm" style="-sec-extract: exhibit">Addendum to Securities Purchase Agreement, dated as of January 9, 2025, by and between the Company and David Lazar</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    9, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625000765/cyclacel_ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of February 4, 2025, between the Company and David Lazar</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625000765/cyclacel_ex10-2.htm" style="-sec-extract: exhibit">Amendment Agreement, dated as of February 4, 2025, between the Company and Armistice Capital Master Fund Ltd.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625000765/cyclacel_ex10-3.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of February 5, 2025, between the Company and Helena Special Opportunities 1 Ltd.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625001180/cyclacel_10-1.htm" style="-sec-extract: exhibit">Lock-Up Addendum, dated February 20, 2025, by and between the Company and David Lazar</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    24, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625001180/cyclacel_10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement dated February 11, 2025 by and between David Elliot Lazar and Doris Wong Sing Ee</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    24, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625001253/cyclacel_ex10-2.htm" style="-sec-extract: exhibit">Assignment and Assumption Agreement dated February 26, 2025 by and between David Elliot Lazar and Doris Wong Sing Ee</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    24, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625001253/cyclacel_ex10-3.htm" style="-sec-extract: exhibit">Settlement and Release Agreement dated February 26, 2025 by and between Dr. Samuel Barker and the Company</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    24, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000182912625001770/cyclacel_ex10-1.htm" style="-sec-extract: exhibit">Assignment of Patent Rights Agreement dated March 10, 2025 by and between Cyclacel Pharmaceuticals, Inc., Cyclacel Limited, and with the liquidators of Cyclacel Limited</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    14, 2025</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28&#8224;*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-28.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officer and Director Services Agreement dated April 22, 2025 between Cyclacel Pharmaceuticals, Inc. and Datuk Dr. Doris Wong</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29&#8224;*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-29.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officer and Director Services Agreement dated April 22, 2025 between Cyclacel Pharmaceuticals, Inc. and Kiu Cu Seng</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30&#8224;*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-30.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Services Agreement dated April 22, 2025 between Cyclacel Pharmaceuticals, Inc. and Inigo Angel Laurduraj</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31&#8224;*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-31.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Services Agreement dated April 22, 2025 between Cyclacel Pharmaceuticals, Inc. and Chong Kwang Fock</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32&#8224;*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-32.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Services Agreement dated April 22, 2025 between Cyclacel Pharmaceuticals, Inc. and Dr. Satis Waran Nair Krishnan</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm" style="-sec-extract: exhibit">Subsidiaries of Cyclacel Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-50626</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    26, 2014</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Bush &amp; Associates CPA LLC</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">23.2*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex23-2.htm">Consent of RSM US LLP</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">23.3*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex23-3.htm">Consent of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP Centurion &amp; Partners PLT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Rimon, P.C. (included in Exhibit 5.1)</span></a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#DS_001">Power of Attorney</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Form of Cyclacel Pharmaceuticals, Inc. Proxy Card.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#svv_106"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed form of Certificate of Amendment of Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. (included as Annex B to the proxy statement/prospectus).</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex99-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Inigo Angel Laurduraj to serve as a director of Cyclacel Pharmaceuticals, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex99-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Chong Kwang Fock to serve as a director of Cyclacel Pharmaceuticals, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex99-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Dr. Satis Waran Nair Krishnan to serve as a director of Cyclacel Pharmaceuticals, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex107.htm">Filing Fee Table</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or compensatory plan or arrangement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">**</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Previously filed</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 321; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="DS_001"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized in Kuala Lumpur, Malaysia, on the 23 day of July 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cyclacel
    Pharmaceuticals, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
Dr. Doris Wong</span></i></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Executive Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Datuk Dr. Doris Wong and Mr. Kiu Cu Seng, and each of them, his or her true and lawful attorneys-in-fact and agent, with full power of substitution, for him or her
in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and any
registration statement relating to the offering covered by this registration statement and filed pursuant to Rule 462(b) under the Securities
Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and agents, or his substitutes or substitute, may lawfully do or cause to be
done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated opposite his/her name.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, this registration statement has been signed by the following persons on behalf of the Registrant
in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: left; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ <i>Datuk Dr. Doris Wong</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Chief
    Executive Officer and Executive Director</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><i>(Principal Executive Officer)</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">July <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,
    2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">/s/
    <i>Kiu Cu Seng</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Chief Financial Officer, Executive Director and Secretary</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiu
    Cu Seng</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Principal
Financial Officer and Principal Accounting Officer</i>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">July <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,
    2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ <i>Inigo Angel Laurduraj</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">July <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,
    2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ <i>Chong Kwang Fock</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chong
    Kwang Fock</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">July <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,
    2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ <i>Dr. Satis Waran Nair Krishnan</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">July <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,
    2025</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 322; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
23, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
10, Tower 11</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avenue
5, The Horizon</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bangsar
South City, No. 8, Jalan Kerinchi</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59200,
Kuala Lumpur, Malaysia</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Registration Statement on Form S-4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have acted as legal counsel to Cyclacel Pharmaceuticals,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the offering by the Company of up to 1,118,282
shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<U>Shares</U>&rdquo;). The Shares are being issued
to the shareholders of Fitters Sdn. Bhd., a private limited company incorporated in Malaysia (the &ldquo;<U>Fitters Sdn. Bhd.</U>&rdquo;),
pursuant to that certain Exchange Agreement dated May 6, 2025, as amended on July 7, 2025 and as it may be further amended from time
to time (collectively, the &ldquo;<U>Exchange Agreement</U>&rdquo;) by and among the Company and FITTERS Diversified Berhad, a Malaysia
publicly-listed investment holding company on Bursa Securities (KL: 9318) (&ldquo;<U>Fitters Parent</U>&rdquo;), and <U>Fitters Sdn.
Bhd.</U>, a wholly-owned subsidiary of Fitters Parent. The Shares are being registered pursuant to a registration statement on Form
S-4 filed with the Securities Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) on July 23, 2025 (the&nbsp;<U>&ldquo;Registration
Statement</U>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;). This opinion is being
furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, and no opinion is expressed
herein as to any matter pertaining to the contents of the Registration Statement, other than as expressly stated herein with respect
to the issuance of the Shares. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In connection with this opinion, we have examined
originals or copies, certified or otherwise identified to our satisfaction, of (i) the Registration Statement;; (ii) the Exchange
Agreement; (iii) the Amendment and Restated Certificate of Incorporation of the Company, as currently in effect; (iv) the
Amended and Restated Bylaws of the Company, as currently in effect; and (v)&nbsp;certain resolutions of the Board of Directors of the
Company (the &ldquo;<U>Board</U>&rdquo;) relating to the Exchange Agreement. We have also examined originals or copies, certified or
otherwise identified to our satisfaction, of such records of the Company and such agreements, certificates of public officials, certificates
of officers or other representatives of the Company and others, and such other documents, certificates and records as we have deemed
necessary or appropriate as a basis for the opinion set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our examination, we have assumed and have not verified (i) the legal capacity of all natural persons; (ii) the genuineness of all signatures
(other than persons signing on behalf of the Company); (iii) the authenticity of all documents, certificates and instruments submitted
to us as originals; (iv) the conformity with the originals of all documents supplied to us as copies; (v) the accuracy and completeness
of all corporate records and documents made available to us by the Company; and (vi) that the foregoing documents, in the form submitted
to us for our review, have not been altered or amended in any respect material to our opinion stated herein. We have relied as to factual
matters upon certificates from officers of the Company and certificates and other documents from public officials and government agencies
and departments and we have assumed the accuracy and authenticity of such certificates and documents. We have also assumed that, at or
prior to the time of the issuance and delivery of any Shares, that there will not have occurred any change in law, change in the Shares,
the Exchange Agreement or the Company&rsquo;s Amended and Restated Certificate of Incorporation, or further action by the Company&rsquo;s
Board, in each case affecting the validity of the issuance of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">With respect to our opinions as to the Shares,
we have also assumed that (i) the Registration Statement, and any amendments thereto (including post-effective amendments), will have
become effective and will comply with all applicable laws; (ii) all Shares will be issued, sold and delivered in compliance
with applicable federal and state securities laws and in the manner and for the consideration stated in the Registration Statement
and the Exchange Agreement and in accordance with the resolutions adopted by the Company&rsquo;s Board; and (iii) with respect
to the Shares, there will be sufficient shares of Common Stock authorized under the Company&rsquo;s Amended and Restated Certificate
of Incorporation, as currently in effect, and not otherwise reserved for issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon,
P.C. | P: (800) 930-7271 | E: info@Rimonlaw.com | www.Rimonlaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing and subject to the assumptions, qualifications and limitations set forth herein, we are of the opinion that the Shares
have been duly authorized and, when issued in accordance with the terms of the Exchange Agreement, will be validly issued, fully paid
and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions expressed above are limited to questions arising under the law of the State of Delaware and the Delaware General Corporation
Law. We do not express any opinion as to the laws of any other jurisdiction. We express no opinions as to the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions expressed above are as of the date hereof only, and we express no opinion as to, and assume no responsibility for, the effect
of any fact or circumstance occurring, or of which we learn, subsequent to the date of this opinion letter, including, without limitation,
legislative and other changes in the law or changes in circumstances affecting any party. We assume no responsibility to update this
opinion letter for, or to advise you of, any such facts or circumstances of which we become aware, regardless of whether or not they
affect the opinions expressed in this opinion letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references
to us, if any, in the Registration Statement and any amendments thereto. In giving these consents, we do not thereby admit
that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the or the rules and regulations
of the Commission promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Rimon P.C.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon
P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> | P A G E</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>3
<FILENAME>ex10-28.htm
<DESCRIPTION>EX-10.28
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.28</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Execution
Copy</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE
OFFICER AND DIRECTOR SERVICES AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
EXECUTIVE OFFICER AND DIRECTOR SERVICES AGREEMENT (this <B><I>&ldquo;Agreement&rdquo;</I></B>), dated as of April 22, 2025, between Cyclacel
Pharmaceuticals, Inc. (the <B><I>&ldquo;Company&rdquo;</I></B>), a Delaware corporation, with an address at 1 Level 10, Tower 11, Avenue
5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 592000, and Datuk Dr. Doris Wong, Chief Executive Officer and Director of the Company
(the <B><I>&ldquo;Director&rdquo;</I></B>), with an address of c/o the Company at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi,
Kuala Lumpur, Malaysia 592000, sets forth the agreement of the parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Director Services</U>: During the term of this Agreement, the Director agrees to serve on the Board of Directors of the Company (the
<B><I>&ldquo;Board&rdquo;</I></B>) in compliance with the bylaws of the Company (<B><I>&ldquo;Bylaws&rdquo;</I></B>) and applicable law
(the <B><I>&ldquo;Services&rdquo;</I></B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Term</U>: This Agreement is effective as of the date this Agreement is executed (the <B><I>&ldquo;Effective Date&rdquo;</I></B>) and
shall remain in full force and effect until the Director earlier resigns or is removed from the Board (in each case pursuant to the provisions
of the Bylaws); and provided that the obligations of Director set forth in <U>Section 5</U> and <U>Section 7</U> shall survive the expiration
or termination of this agreement for one year following the expiration or termination (except in the case of trade secrets, in which
case such trade secrets shall continue to be subject to <U>Section 5</U> for so long as the underlying confidential information constitutes
trade secrets under applicable law). The term of this Agreement may be extended upon mutual agreement of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Compensation and Expenses</U>: Director acknowledges and agrees that she is not granted or entitled to any other benefits or compensation
from the Company for services provided under this Agreement except expressly provided for herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Cash
Compensation</U>. For all duties rendered by Director pursuant to this Agreement, both during and outside of normal working hours, including
but not limited to, making reasonable business efforts to (A) attend all required meetings of the Board or applicable committees thereof,
executive sessions of the Directors, (B) review filing reports and other corporate documents as requested by the Company, and (C) provide
comments and opinions as to business matters as requested by the Company, the Company agrees to compensate the Director as set forth
herein. Payable on a monthly basis in arrears, on the first day of the following month for any full or partial month of service, or as
soon as practicable after the first day of each month, a monthly cash retainer to the Chief Executive Officer and Executive Director
of Five Thousand Dollars (USD$5,000.00) commencing on February 26, 2025, the date of appointment as Chief Executive Officer and Executive
Director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Expenses</U>.
During the term of the Director&rsquo;s service as a director of the Company, the Company shall promptly reimburse the Director for all
expenses incurred by her in connection with attending (i) all meetings of the Board or applicable committees thereof, (ii) executive
sessions of the Board, and (iii) stockholder meetings, as a director or a member of any committee of the Board, provided that any such
expenses over $10,000.00 shall be approved by the Company, in writing in advance. In addition, the Director shall rely on the Company
to arrange any hotel accommodation in connection with any such meetings Director must attend. The amount of such expenses eligible for
reimbursement by the Company during a calendar year shall not affect such expenses eligible for reimbursement by the Company in any other
calendar year, and the reimbursement of any such eligible expenses shall be made on or before the last day of the calendar year next
following the calendar year in which the expense was incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Taxes</U>: Director shall be responsible for the payment of all taxes to the appropriate taxing authority that she may owe such authority
due to the amounts paid to the Director hereunder, as well as the preparation and submission of all reports, returns and money which
may be imposed, requested or required by such taxing authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Confidentiality</U>: Director acknowledges that Director will receive confidential and proprietary information from or on behalf of
the Company in connection with, and during the course of providing, the Services, including but not limited to: business affairs, assets,
contracts, services; technical, financial, operations, manufacturing, marketing, commercial and/or legal information; data, reports,
drawings, models, designs, prototypes, formulas, processes, software, algorithms, specifications and patent applications; marketing strategies;
customer, vendor and subcontractor information; customer lists; and other sensitive, confidential or proprietary information, in each
case, of the Company or of its affiliates, customers, vendors, contractors, employees or other third parties (collectively, <B><I>&ldquo;Confidential
Information&rdquo;</I></B>). Confidential Information shall not include information that, at the time of disclosure and as established
by documentary evidence: (a) is or becomes generally available to and known by the public other than as a result of, directly or indirectly,
any breach of this <U>Section 5</U> by Director; (b) was known by or in the possession of Director before being provided to Director;
or (c) is required to be disclosed under applicable federal, state or local law, regulation, or a valid order issued by a court or governmental
agency of competent jurisdiction. The Director shall protect and safeguard all such Confidential Information and shall not during the
term of this Agreement or thereafter, directly or indirectly, use for herself or another, or disclose to any person, firm or corporation
any Confidential Information which the Director may have acquired in the course of or incidental to her performance of the Services hereunder.
All Confidential Information and all copies thereof (whether prepared by the Director or not) which Director obtains during the term
of this Agreement, shall be returned by the Director to the Company (or, at the election of the Company, destroyed by Director) upon
termination hereof. All Confidential Information is and shall at all times remain the exclusive property of the Company (or, as applicable,
the party who supplied the information to the Company). The obligations of the Director under this <U>Section 5</U> shall survive the
termination of this Agreement in accordance with <U>Section 2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Relationship of the Parties</U>: (a) The Director, in her capacity as such, is an independent contractor (1099) of the Company, and
the Director is not authorized to act as the Company&rsquo;s legal representative. The Director hereby represents that Director is free
to enter into this Agreement and that Director is not under any restrictive covenant, court order or any other restriction concerning
Director&rsquo;s entering into this Agreement and performing her obligations hereunder. If any conflict of interest exists at the time
of the execution of this Agreement or such conflict occurs during the term hereof, the Director shall (or have given) give advance written
notice thereof to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Intellectual Property Rights.</U> The Company is and shall be the sole and exclusive owner of all right, title, and interest throughout
the world in and to all the results and proceeds of the Services, and all work product produced in the performance of the Services performed
under this Agreement (the <B><I>&ldquo;Deliverables&rdquo;</I></B>), including all patents, copyrights, trademarks, trade secrets, and
other intellectual property rights (collectively <B><I>&ldquo;Intellectual Property Rights&rdquo;</I></B>) therein. The Director agrees
that the Deliverables are hereby deemed a &ldquo;work made for hire&rdquo; as defined in 17 U.S.C. &sect; 101 for the Company. If, for
any reason, any of the Deliverables do not constitute a &ldquo;work made for hire,&rdquo; the Director hereby irrevocably assigns to
the Company, and its successors and assigns, in each case without additional consideration, all of Director&rsquo;s right, title, and
interest throughout the world in and to the Deliverables, whether made solely by Director or jointly with others, including all Intellectual
Property Rights therein, including the right to sue, counterclaim and recover for all past, present and future infringement, misappropriation
or dilution thereof, and all rights corresponding thereto throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Termination</U>: The Director shall continue her service on the Board until the earlier to occur of the expiration of the term of
this Agreement or the termination of this Agreement in connection with the resignation or removal of the Director (in each case, pursuant
to the relevant provisions of the Bylaws). Termination of this Agreement for any reason shall not affect the rights and obligations of
the parties that may have accrued prior to the effective date of termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Indemnification</U>. The Company shall indemnify, defend, and hold harmless Director, to the full extent allowed by the law of the
State of Delaware and as provided by, or granted pursuant to, any charter provision, bylaw provision, vote of stockholders or disinterested
directors or otherwise, to action in Director&rsquo;s official capacity; provided, however, that, in accordance with the DGCL and federal
securities laws, such indemnification shall not apply where Director engages in actions or omissions which involve intentional misconduct,
fraud or knowing violation of law. Reasonable expenses incurred by the Director in defending any claim, action, suit or proceeding shall
accordingly be paid by the Company in advance of the final disposition of such claim, action, suit or proceeding, but such expenses shall
not include amounts paid in settlement by the Director or the amount of judgments or fines against the Director. In the event that the
Director is determined not to be entitled to such indemnification, then all amounts advanced under this <U>Section 9</U> shall be repaid.
In addition, the Company shall use its best efforts to purchase and maintain a customary directors&rsquo; and officers&rsquo; liability
insurance policy (or policies) during the term of this Agreement and thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>No Assignment</U>: Since this Agreement requires the performance of personal services by the Director, the Director may not assign
any right or delegate any duty described in this Agreement without the Company&rsquo;s prior written approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Severability</U>: Each provision of this Agreement is severable so that if any provision hereof is declared void and unenforceable
by any court of competent jurisdiction, the remaining provisions hereof shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Entire Agreement</U>: This Agreement constitutes the entire agreement of the Parties regarding the subject matter contained herein
and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, regarding
such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Miscellaneous</U>: (a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware; and
(b) no provision of this Agreement shall be deemed waived or modified by either party unless such waiver or modification shall be in
writing and duly signed by the party against whom the waiver or modification is sought to be enforced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[remainder
of page intentionally left blank]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cyclacel
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Datuk
Dr. Doris Wong</I></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Executive Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 160pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Datuk
    Dr. Doris Wong</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <I>Datuk
                                            Dr. Doris Wong</I> </P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 160pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 160pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>4
<FILENAME>ex10-29.htm
<DESCRIPTION>EX-10.29
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.29</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Execution
Copy</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE
OFFICER AND DIRECTOR SERVICES AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
EXECUTIVE OFFICER AND DIRECTOR SERVICES AGREEMENT (this <B><I>&ldquo;Agreement&rdquo;</I></B>), dated as of April 22, 2025, between Cyclacel
Pharmaceuticals, Inc. (the <B><I>&ldquo;Company&rdquo;</I></B>), a Delaware corporation, with an address at 1 Level 10, Tower 11, Avenue
5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 592000, and Kiu Cu Seng, Chief Financial Officer, Secretary and Executive Director of
the Company (the <B><I>&ldquo;Director&rdquo;</I></B>), with an address of c/o the Company at Level 10, Tower 11, Avenue 5, No. 8, Jalan
Kerinchi, Kuala Lumpur, Malaysia 592000, sets forth the agreement of the parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Director Services</U>: During the term of this Agreement, the Director agrees to serve on the Board of Directors of the Company (the
<B><I>&ldquo;Board&rdquo;</I></B>) in compliance with the bylaws of the Company (<B><I>&ldquo;Bylaws&rdquo;</I></B>) and applicable law
(the <B><I>&ldquo;Services&rdquo;</I></B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Term</U>: This Agreement is effective as of the date this Agreement is executed (the <B><I>&ldquo;Effective Date&rdquo;</I></B>) and
shall remain in full force and effect until the Director earlier resigns or is removed from the Board (in each case pursuant to the provisions
of the Bylaws); and provided that the obligations of Director set forth in <U>Section 5</U> and <U>Section 7</U> shall survive the expiration
or termination of this agreement for one year following the expiration or termination (except in the case of trade secrets, in which
case such trade secrets shall continue to be subject to <U>Section 5</U> for so long as the underlying confidential information constitutes
trade secrets under applicable law). The term of this Agreement may be extended upon mutual agreement of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Compensation and Expenses</U>: Director acknowledges and agrees that he is not granted or entitled to any other benefits or compensation
from the Company for services provided under this Agreement except expressly provided for herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Cash
Compensation</U>. For all duties rendered by Director pursuant to this Agreement, both during and outside of normal working hours, including
but not limited to, making reasonable business efforts to (A) attend all required meetings of the Board or applicable committees thereof,
executive sessions of the Directors, (B) review filing reports and other corporate documents as requested by the Company, and (C) provide
comments and opinions as to business matters as requested by the Company, the Company agrees to compensate the Director as set forth
herein. Payable on a monthly basis in arrears, on the first day of the following month for any full or partial month of service, or as
soon as practicable after the first day of each month, a monthly cash retainer to the Chief Financial Officer, Secretary and Executive
Director of Five Hundred Dollars (USD$500.00) commencing on February 26, 2025, the date of appointment as Chief Financial Officer, Secretary
and Executive Director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Expenses</U>.
During the term of the Director&rsquo;s service as a director of the Company, the Company shall promptly reimburse the Director for all
expenses incurred by him in connection with attending (i) all meetings of the Board or applicable committees thereof, (ii) executive
sessions of the Board, and (iii) stockholder meetings, as a director or a member of any committee of the Board, provided that any such
expenses shall be approved by the Company, in writing in advance. In addition, the Director shall rely on the Company to arrange any
hotel accommodation in connection with any such meetings Director must attend. The amount of such expenses eligible for reimbursement
by the Company during a calendar year shall not affect such expenses eligible for reimbursement by the Company in any other calendar
year, and the reimbursement of any such eligible expenses shall be made on or before the last day of the calendar year next following
the calendar year in which the expense was incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Taxes</U>: Director shall be responsible for the payment of all taxes to the appropriate taxing authority that he may owe such authority
due to the amounts paid to the Director hereunder, as well as the preparation and submission of all reports, returns and money which
may be imposed, requested or required by such taxing authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Confidentiality</U>: Director acknowledges that Director will receive confidential and proprietary information from or on behalf of
the Company in connection with, and during the course of providing, the Services, including but not limited to: business affairs, assets,
contracts, services; technical, financial, operations, manufacturing, marketing, commercial and/or legal information; data, reports,
drawings, models, designs, prototypes, formulas, processes, software, algorithms, specifications and patent applications; marketing strategies;
customer, vendor and subcontractor information; customer lists; and other sensitive, confidential or proprietary information, in each
case, of the Company or of its affiliates, customers, vendors, contractors, employees or other third parties (collectively, <B><I>&ldquo;Confidential
Information&rdquo;</I></B>). Confidential Information shall not include information that, at the time of disclosure and as established
by documentary evidence: (a) is or becomes generally available to and known by the public other than as a result of, directly or indirectly,
any breach of this <U>Section 5</U> by Director; (b) was known by or in the possession of Director before being provided to Director;
or (c) is required to be disclosed under applicable federal, state or local law, regulation, or a valid order issued by a court or governmental
agency of competent jurisdiction. The Director shall protect and safeguard all such Confidential Information and shall not during the
term of this Agreement or thereafter, directly or indirectly, use for herself or another, or disclose to any person, firm or corporation
any Confidential Information which the Director may have acquired in the course of or incidental to his performance of the Services hereunder.
All Confidential Information and all copies thereof (whether prepared by the Director or not) which Director obtains during the term
of this Agreement, shall be returned by the Director to the Company (or, at the election of the Company, destroyed by Director) upon
termination hereof. All Confidential Information is and shall at all times remain the exclusive property of the Company (or, as applicable,
the party who supplied the information to the Company). The obligations of the Director under this <U>Section 5</U> shall survive the
termination of this Agreement in accordance with <U>Section 2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Relationship of the Parties</U>: (a) The Director, in his capacity as such, is an independent contractor (1099) of the Company, and
the Director is not authorized to act as the Company&rsquo;s legal representative. The Director hereby represents that Director is free
to enter into this Agreement and that Director is not under any restrictive covenant, court order or any other restriction concerning
Director&rsquo;s entering into this Agreement and performing his obligations hereunder. If any conflict of interest exists at the time
of the execution of this Agreement or such conflict occurs during the term hereof, the Director shall (or have given) give advance written
notice thereof to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Intellectual Property Rights.</U> The Company is and shall be the sole and exclusive owner of all right, title, and interest throughout
the world in and to all the results and proceeds of the Services, and all work product produced in the performance of the Services performed
under this Agreement (the <B><I>&ldquo;Deliverables&rdquo;</I></B>), including all patents, copyrights, trademarks, trade secrets, and
other intellectual property rights (collectively <B><I>&ldquo;Intellectual Property Rights&rdquo;</I></B>) therein. The Director agrees
that the Deliverables are hereby deemed a &ldquo;work made for hire&rdquo; as defined in 17 U.S.C. &sect; 101 for the Company. If, for
any reason, any of the Deliverables do not constitute a &ldquo;work made for hire,&rdquo; the Director hereby irrevocably assigns to
the Company, and its successors and assigns, in each case without additional consideration, all of Director&rsquo;s right, title, and
interest throughout the world in and to the Deliverables, whether made solely by Director or jointly with others, including all Intellectual
Property Rights therein, including the right to sue, counterclaim and recover for all past, present and future infringement, misappropriation
or dilution thereof, and all rights corresponding thereto throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Termination</U>: The Director shall continue his service on the Board until the earlier to occur of the expiration of the term of
this Agreement or the termination of this Agreement in connection with the resignation or removal of the Director (in each case, pursuant
to the relevant provisions of the Bylaws). Termination of this Agreement for any reason shall not affect the rights and obligations of
the parties that may have accrued prior to the effective date of termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Indemnification</U>. The Company shall indemnify, defend, and hold harmless Director, to the full extent allowed by the law of the
State of Delaware and as provided by, or granted pursuant to, any charter provision, bylaw provision, vote of stockholders or disinterested
directors or otherwise, to action in Director&rsquo;s official capacity; provided, however, that, in accordance with the DGCL and federal
securities laws, such indemnification shall not apply where Director engages in actions or omissions which involve intentional misconduct,
fraud or knowing violation of law. Reasonable expenses incurred by the Director in defending any claim, action, suit or proceeding shall
accordingly be paid by the Company in advance of the final disposition of such claim, action, suit or proceeding, but such expenses shall
not include amounts paid in settlement by the Director or the amount of judgments or fines against the Director. In the event that the
Director is determined not to be entitled to such indemnification, then all amounts advanced under this <U>Section 9</U> shall be repaid.
In addition, the Company shall use its best efforts to purchase and maintain a customary directors&rsquo; and officers&rsquo; liability
insurance policy (or policies) during the term of this Agreement and thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>No Assignment</U>: Since this Agreement requires the performance of personal services by the Director, the Director may not assign
any right or delegate any duty described in this Agreement without the Company&rsquo;s prior written approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Severability</U>: Each provision of this Agreement is severable so that if any provision hereof is declared void and unenforceable
by any court of competent jurisdiction, the remaining provisions hereof shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Entire Agreement</U>: This Agreement constitutes the entire agreement of the Parties regarding the subject matter contained herein
and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, regarding
such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Miscellaneous</U>: (a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware; and
(b) no provision of this Agreement shall be deemed waived or modified by either party unless such waiver or modification shall be in
writing and duly signed by the party against whom the waiver or modification is sought to be enforced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[remainder
of page intentionally left blank]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cyclacel
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <I>Datuk
                                            Dr. Doris Wong</I> </P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Executive Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kiu
    Cu Seng</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <I>Kiu
                                            Cu Seng</I> </P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 160pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>5
<FILENAME>ex10-30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.30</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Execution
Copy</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTOR
SERVICES AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS DIRECTOR SERVICES AGREEMENT
(this <B><I>&ldquo;Agreement&rdquo;</I></B>), dated as of April 22, 2025, between Cyclacel Pharmaceuticals, Inc. (the <B><I>&ldquo;Company&rdquo;</I></B>),
a Delaware corporation, with an address at 1 Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 592000, and Inigo
Angel Laurduraj (the <B><I>&ldquo;Director&rdquo;</I></B>), with an address of c/o the Company at Level 10, Tower 11, Avenue 5, No. 8,
Jalan Kerinchi, Kuala Lumpur, Malaysia 592000, sets forth the agreement of the parties hereto as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Director Services</U>: During the term of this Agreement, the Director agrees to serve on the Board of Directors of the Company (the
<B><I>&ldquo;Board&rdquo;</I></B>) in compliance with the bylaws of the Company (<B><I>&ldquo;Bylaws&rdquo;</I></B>) and applicable law
(the <B><I>&ldquo;Services&rdquo;</I></B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Term</U>: This Agreement is effective as of the date this Agreement is executed (the <B><I>&ldquo;Effective Date&rdquo;</I></B>) and
shall remain in full force and effect until the Director earlier resigns or is removed from the Board (in each case pursuant to the provisions
of the Bylaws); and provided that the obligations of Director set forth in <U>Section 5</U> and <U>Section 7</U> shall survive the expiration
or termination of this agreement for one year following the expiration or termination (except in the case of trade secrets, in which
case such trade secrets shall continue to be subject to <U>Section 5</U> for so long as the underlying confidential information constitutes
trade secrets under applicable law). The term of this Agreement may be extended upon mutual agreement of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Compensation and Expenses</U>: Director acknowledges and agrees that she is not granted or entitled to any other benefits or compensation
from the Company for services provided under this Agreement except expressly provided for herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Cash
Compensation</U>. For all duties rendered by Director pursuant to this Agreement, both during and outside of normal working hours, including
but not limited to, making reasonable business efforts to (A) attend all required meetings of the Board or applicable committees thereof,
executive sessions of the Directors, (B) review filing reports and other corporate documents as requested by the Company, and (C) provide
comments and opinions as to business matters as requested by the Company, the Company agrees to compensate the Director as set forth
herein. Payable on a monthly basis in arrears, on the first day of the following month for any full or partial month of service, or as
soon as practicable after the first day of each month, a monthly cash retainer to the Director of One Thousand Dollars (USD$1,000.00)
commencing on April 2, 2025, the date of appointment as Director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Expenses</U>.
During the term of the Director&rsquo;s service as a director of the Company, the Company shall promptly reimburse the Director for all
expenses incurred by her in connection with attending (i) all meetings of the Board or applicable committees thereof, (ii) executive
sessions of the Board, and (iii) stockholder meetings, as a director or a member of any committee of the Board, provided that any such
expenses shall be approved by the Company, in writing in advance. In addition, the Director shall rely on the Company to arrange any
hotel accommodation in connection with any such meetings Director must attend. The amount of such expenses eligible for reimbursement
by the Company during a calendar year shall not affect such expenses eligible for reimbursement by the Company in any other calendar
year, and the reimbursement of any such eligible expenses shall be made on or before the last day of the calendar year next following
the calendar year in which the expense was incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Taxes</U>: Director shall be responsible for the payment of all taxes to the appropriate taxing authority that she may owe such authority
due to the amounts paid to the Director hereunder, as well as the preparation and submission of all reports, returns and money which
may be imposed, requested or required by such taxing authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Confidentiality</U>: Director acknowledges that Director will receive confidential and proprietary information from or on behalf of
the Company in connection with, and during the course of providing, the Services, including but not limited to: business affairs, assets,
contracts, services; technical, financial, operations, manufacturing, marketing, commercial and/or legal information; data, reports,
drawings, models, designs, prototypes, formulas, processes, software, algorithms, specifications and patent applications; marketing strategies;
customer, vendor and subcontractor information; customer lists; and other sensitive, confidential or proprietary information, in each
case, of the Company or of its affiliates, customers, vendors, contractors, employees or other third parties (collectively, <B><I>&ldquo;Confidential
Information&rdquo;</I></B>). Confidential Information shall not include information that, at the time of disclosure and as established
by documentary evidence: (a) is or becomes generally available to and known by the public other than as a result of, directly or indirectly,
any breach of this <U>Section 5</U> by Director; (b) was known by or in the possession of Director before being provided to Director;
or (c) is required to be disclosed under applicable federal, state or local law, regulation, or a valid order issued by a court or governmental
agency of competent jurisdiction. The Director shall protect and safeguard all such Confidential Information and shall not during the
term of this Agreement or thereafter, directly or indirectly, use for herself or another, or disclose to any person, firm or corporation
any Confidential Information which the Director may have acquired in the course of or incidental to her performance of the Services hereunder.
All Confidential Information and all copies thereof (whether prepared by the Director or not) which Director obtains during the term
of this Agreement, shall be returned by the Director to the Company (or, at the election of the Company, destroyed by Director) upon
termination hereof. All Confidential Information is and shall at all times remain the exclusive property of the Company (or, as applicable,
the party who supplied the information to the Company). The obligations of the Director under this <U>Section 5</U> shall survive the
termination of this Agreement in accordance with <U>Section 2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Relationship of the Parties</U>: (a) The Director, in her capacity as such, is an independent contractor (1099) of the Company, and
the Director is not authorized to act as the Company&rsquo;s legal representative. The Director hereby represents that Director is free
to enter into this Agreement and that Director is not under any restrictive covenant, court order or any other restriction concerning
Director&rsquo;s entering into this Agreement and performing her obligations hereunder. If any conflict of interest exists at the time
of the execution of this Agreement or such conflict occurs during the term hereof, the Director shall (or have given) give advance written
notice thereof to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Intellectual Property Rights.</U> The Company is and shall be the sole and exclusive owner of all right, title, and interest throughout
the world in and to all the results and proceeds of the Services, and all work product produced in the performance of the Services performed
under this Agreement (the <B><I>&ldquo;Deliverables&rdquo;</I></B>), including all patents, copyrights, trademarks, trade secrets, and
other intellectual property rights (collectively <B><I>&ldquo;Intellectual Property Rights&rdquo;</I></B>) therein. The Director agrees
that the Deliverables are hereby deemed a &ldquo;work made for hire&rdquo; as defined in 17 U.S.C. &sect; 101 for the Company. If, for
any reason, any of the Deliverables do not constitute a &ldquo;work made for hire,&rdquo; the Director hereby irrevocably assigns to
the Company, and its successors and assigns, in each case without additional consideration, all of Director&rsquo;s right, title, and
interest throughout the world in and to the Deliverables, whether made solely by Director or jointly with others, including all Intellectual
Property Rights therein, including the right to sue, counterclaim and recover for all past, present and future infringement, misappropriation
or dilution thereof, and all rights corresponding thereto throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Termination</U>: The Director shall continue her service on the Board until the earlier to occur of the expiration of the term of
this Agreement or the termination of this Agreement in connection with the resignation or removal of the Director (in each case, pursuant
to the relevant provisions of the Bylaws). Termination of this Agreement for any reason shall not affect the rights and obligations of
the parties that may have accrued prior to the effective date of termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Indemnification</U>. The Company shall indemnify, defend, and hold harmless Director, to the full extent allowed by the law of the
State of Delaware and as provided by, or granted pursuant to, any charter provision, bylaw provision, vote of stockholders or disinterested
directors or otherwise, to action in Director&rsquo;s official capacity; provided, however, that, in accordance with the DGCL and federal
securities laws, such indemnification shall not apply where Director engages in actions or omissions which involve intentional misconduct,
fraud or knowing violation of law. Reasonable expenses incurred by the Director in defending any claim, action, suit or proceeding shall
accordingly be paid by the Company in advance of the final disposition of such claim, action, suit or proceeding, but such expenses shall
not include amounts paid in settlement by the Director or the amount of judgments or fines against the Director. In the event that the
Director is determined not to be entitled to such indemnification, then all amounts advanced under this <U>Section 9</U> shall be repaid.
In addition, the Company shall use its best efforts to purchase and maintain a customary directors&rsquo; and officers&rsquo; liability
insurance policy (or policies) during the term of this Agreement and thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>No Assignment</U>: Since this Agreement requires the performance of personal services by the Director, the Director may not assign
any right or delegate any duty described in this Agreement without the Company&rsquo;s prior written approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Severability</U>: Each provision of this Agreement is severable so that if any provision hereof is declared void and unenforceable
by any court of competent jurisdiction, the remaining provisions hereof shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Entire Agreement</U>: This Agreement constitutes the entire agreement of the Parties regarding the subject matter contained herein
and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, regarding
such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Miscellaneous</U>: (a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware; and
(b) no provision of this Agreement shall be deemed waived or modified by either party unless such waiver or modification shall be in
writing and duly signed by the party against whom the waiver or modification is sought to be enforced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[remainder
of page intentionally left blank]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cyclacel
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <I>Datuk
                                            Dr. Doris Wong</I> </P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Executive Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Inigo
                                            Angel Laurduraj</B></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <I>Inigo
                                            Angel Laurduraj</I> </P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 160pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>6
<FILENAME>ex10-31.htm
<DESCRIPTION>EX-10.31
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.31</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Execution
Copy</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTOR
SERVICES AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
DIRECTOR SERVICES AGREEMENT (this <B><I>&ldquo;Agreement&rdquo;</I></B>), dated as of April 22, 2025, between Cyclacel Pharmaceuticals,
Inc. (the <B><I>&ldquo;Company&rdquo;</I></B>), a Delaware corporation, with an address at 1 Level 10, Tower 11, Avenue 5, No. 8, Jalan
Kerinchi, Kuala Lumpur, Malaysia 592000, and Chong Kwang Fock, Director of the Company (the <B><I>&ldquo;Director&rdquo;</I></B>), with
an address of c/o the Company at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 592000, sets forth the agreement
of the parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Director Services</U>: During the term of this Agreement, the Director agrees to serve on the Board of Directors of the Company (the
<B><I>&ldquo;Board&rdquo;</I></B>) in compliance with the bylaws of the Company (<B><I>&ldquo;Bylaws&rdquo;</I></B>) and applicable law
(the <B><I>&ldquo;Services&rdquo;</I></B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Term</U>: This Agreement is effective as of the date this Agreement is executed (the <B><I>&ldquo;Effective Date&rdquo;</I></B>) and
shall remain in full force and effect until the Director earlier resigns or is removed from the Board (in each case pursuant to the provisions
of the Bylaws); and provided that the obligations of Director set forth in <U>Section 5</U> and <U>Section 7</U> shall survive the expiration
or termination of this agreement for one year following the expiration or termination (except in the case of trade secrets, in which
case such trade secrets shall continue to be subject to <U>Section 5</U> for so long as the underlying confidential information constitutes
trade secrets under applicable law). The term of this Agreement may be extended upon mutual agreement of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Compensation and Expenses</U>: Director acknowledges and agrees that he is not granted or entitled to any other benefits or compensation
from the Company for services provided under this Agreement except expressly provided for herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Cash
Compensation</U>. For all duties rendered by Director pursuant to this Agreement, both during and outside of normal working hours, including
but not limited to, making reasonable business efforts to (A) attend all required meetings of the Board or applicable committees thereof,
executive sessions of the Directors, (B) review filing reports and other corporate documents as requested by the Company, and (C) provide
comments and opinions as to business matters as requested by the Company, the Company agrees to compensate the Director as set forth
herein. Payable on a monthly basis in arrears, on the first day of the following month for any full or partial month of service, or as
soon as practicable after the first day of each month, a monthly cash retainer to the Director of Five Hundred Dollars (USD$500.00) commencing
on February 26, 2025, the date of appointment as Director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Expenses</U>.
During the term of the Director&rsquo;s service as a director of the Company, the Company shall promptly reimburse the Director for all
expenses incurred by him in connection with attending (i) all meetings of the Board or applicable committees thereof, (ii) executive
sessions of the Board, and (iii) stockholder meetings, as a director or a member of any committee of the Board, provided that any such
expenses shall be approved by the Company, in writing in advance. In addition, the Director shall rely on the Company to arrange any
hotel accommodation in connection with any such meetings Director must attend. The amount of such expenses eligible for reimbursement
by the Company during a calendar year shall not affect such expenses eligible for reimbursement by the Company in any other calendar
year, and the reimbursement of any such eligible expenses shall be made on or before the last day of the calendar year next following
the calendar year in which the expense was incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Taxes</U>: Director shall be responsible for the payment of all taxes to the appropriate taxing authority that he may owe such authority
due to the amounts paid to the Director hereunder, as well as the preparation and submission of all reports, returns and money which
may be imposed, requested or required by such taxing authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Confidentiality</U>: Director acknowledges that Director will receive confidential and proprietary information from or on behalf of
the Company in connection with, and during the course of providing, the Services, including but not limited to: business affairs, assets,
contracts, services; technical, financial, operations, manufacturing, marketing, commercial and/or legal information; data, reports,
drawings, models, designs, prototypes, formulas, processes, software, algorithms, specifications and patent applications; marketing strategies;
customer, vendor and subcontractor information; customer lists; and other sensitive, confidential or proprietary information, in each
case, of the Company or of its affiliates, customers, vendors, contractors, employees or other third parties (collectively, <B><I>&ldquo;Confidential
Information&rdquo;</I></B>). Confidential Information shall not include information that, at the time of disclosure and as established
by documentary evidence: (a) is or becomes generally available to and known by the public other than as a result of, directly or indirectly,
any breach of this <U>Section 5</U> by Director; (b) was known by or in the possession of Director before being provided to Director;
or (c) is required to be disclosed under applicable federal, state or local law, regulation, or a valid order issued by a court or governmental
agency of competent jurisdiction. The Director shall protect and safeguard all such Confidential Information and shall not during the
term of this Agreement or thereafter, directly or indirectly, use for herself or another, or disclose to any person, firm or corporation
any Confidential Information which the Director may have acquired in the course of or incidental to his performance of the Services hereunder.
All Confidential Information and all copies thereof (whether prepared by the Director or not) which Director obtains during the term
of this Agreement, shall be returned by the Director to the Company (or, at the election of the Company, destroyed by Director) upon
termination hereof. All Confidential Information is and shall at all times remain the exclusive property of the Company (or, as applicable,
the party who supplied the information to the Company). The obligations of the Director under this <U>Section 5</U> shall survive the
termination of this Agreement in accordance with <U>Section 2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Relationship of the Parties</U>: (a) The Director, in his capacity as such, is an independent contractor (1099) of the Company, and
the Director is not authorized to act as the Company&rsquo;s legal representative. The Director hereby represents that Director is free
to enter into this Agreement and that Director is not under any restrictive covenant, court order or any other restriction concerning
Director&rsquo;s entering into this Agreement and performing his obligations hereunder. If any conflict of interest exists at the time
of the execution of this Agreement or such conflict occurs during the term hereof, the Director shall (or have given) give advance written
notice thereof to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Intellectual Property Rights.</U> The Company is and shall be the sole and exclusive owner of all right, title, and interest throughout
the world in and to all the results and proceeds of the Services, and all work product produced in the performance of the Services performed
under this Agreement (the <B><I>&ldquo;Deliverables&rdquo;</I></B>), including all patents, copyrights, trademarks, trade secrets, and
other intellectual property rights (collectively <B><I>&ldquo;Intellectual Property Rights&rdquo;</I></B>) therein. The Director agrees
that the Deliverables are hereby deemed a &ldquo;work made for hire&rdquo; as defined in 17 U.S.C. &sect; 101 for the Company. If, for
any reason, any of the Deliverables do not constitute a &ldquo;work made for hire,&rdquo; the Director hereby irrevocably assigns to
the Company, and its successors and assigns, in each case without additional consideration, all of Director&rsquo;s right, title, and
interest throughout the world in and to the Deliverables, whether made solely by Director or jointly with others, including all Intellectual
Property Rights therein, including the right to sue, counterclaim and recover for all past, present and future infringement, misappropriation
or dilution thereof, and all rights corresponding thereto throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Termination</U>: The Director shall continue his service on the Board until the earlier to occur of the expiration of the term of
this Agreement or the termination of this Agreement in connection with the resignation or removal of the Director (in each case, pursuant
to the relevant provisions of the Bylaws). Termination of this Agreement for any reason shall not affect the rights and obligations of
the parties that may have accrued prior to the effective date of termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Indemnification</U>. The Company shall indemnify, defend, and hold harmless Director, to the full extent allowed by the law of the
State of Delaware and as provided by, or granted pursuant to, any charter provision, bylaw provision, vote of stockholders or disinterested
directors or otherwise, to action in Director&rsquo;s official capacity; provided, however, that, in accordance with the DGCL and federal
securities laws, such indemnification shall not apply where Director engages in actions or omissions which involve intentional misconduct,
fraud or knowing violation of law. Reasonable expenses incurred by the Director in defending any claim, action, suit or proceeding shall
accordingly be paid by the Company in advance of the final disposition of such claim, action, suit or proceeding, but such expenses shall
not include amounts paid in settlement by the Director or the amount of judgments or fines against the Director. In the event that the
Director is determined not to be entitled to such indemnification, then all amounts advanced under this <U>Section 9</U> shall be repaid.
In addition, the Company shall use its best efforts to purchase and maintain a customary directors&rsquo; and officers&rsquo; liability
insurance policy (or policies) during the term of this Agreement and thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>No Assignment</U>: Since this Agreement requires the performance of personal services by the Director, the Director may not assign
any right or delegate any duty described in this Agreement without the Company&rsquo;s prior written approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Severability</U>: Each provision of this Agreement is severable so that if any provision hereof is declared void and unenforceable
by any court of competent jurisdiction, the remaining provisions hereof shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Entire Agreement</U>: This Agreement constitutes the entire agreement of the Parties regarding the subject matter contained herein
and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, regarding
such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Miscellaneous</U>: (a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware; and
(b) no provision of this Agreement shall be deemed waived or modified by either party unless such waiver or modification shall be in
writing and duly signed by the party against whom the waiver or modification is sought to be enforced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[remainder
of page intentionally left blank]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cyclacel
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <I>Datuk
                                            Dr. Doris Wong</I> </P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Executive Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chong
    Kwang Fock</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chong
    Kwang Fock</I>&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 160pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>7
<FILENAME>ex10-32.htm
<DESCRIPTION>EX-10.32
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.32</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Execution
Copy</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTOR
SERVICES AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS DIRECTOR SERVICES AGREEMENT
(this <B><I>&ldquo;Agreement&rdquo;</I></B>), dated as of April 22, 2025, between Cyclacel Pharmaceuticals, Inc. (the <B><I>&ldquo;Company&rdquo;</I></B>),
a Delaware corporation, with an address at 1 Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 592000, and
Dr. Satis Waran Nair Krishnan (the <B><I>&ldquo;Director&rdquo;</I></B>), with an address of c/o the Company at Level 10, Tower
11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 592000, sets forth the agreement of the parties hereto as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Director Services</U>: During the term of this Agreement, the Director agrees to serve on the Board of Directors of the Company (the
<B><I>&ldquo;Board&rdquo;</I></B>) in compliance with the bylaws of the Company (<B><I>&ldquo;Bylaws&rdquo;</I></B>) and applicable law
(the <B><I>&ldquo;Services&rdquo;</I></B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Term</U>: This Agreement is effective as of the date this Agreement is executed (the <B><I>&ldquo;Effective Date&rdquo;</I></B>) and
shall remain in full force and effect until the Director earlier resigns or is removed from the Board (in each case pursuant to the provisions
of the Bylaws); and provided that the obligations of Director set forth in <U>Section 5</U> and <U>Section 7</U> shall survive the expiration
or termination of this agreement for one year following the expiration or termination (except in the case of trade secrets, in which
case such trade secrets shall continue to be subject to <U>Section 5</U> for so long as the underlying confidential information constitutes
trade secrets under applicable law). The term of this Agreement may be extended upon mutual agreement of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Compensation and Expenses</U>: Director acknowledges and agrees that she is not granted or entitled to any other benefits or compensation
from the Company for services provided under this Agreement except expressly provided for herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) <U>Cash Compensation</U>.
For all duties rendered by Director pursuant to this Agreement, both during and outside of normal working hours, including but not limited
to, making reasonable business efforts to (A) attend all required meetings of the Board or applicable committees thereof, executive sessions
of the Directors, (B) review filing reports and other corporate documents as requested by the Company, and (C) provide comments and opinions
as to business matters as requested by the Company, the Company agrees to compensate the Director as set forth herein. Payable on a monthly
basis in arrears, on the first day of the following month for any full or partial month of service, or as soon as practicable after the
first day of each month, a monthly cash retainer to the Director of One Thousand Dollars (USD$1,000.00) commencing on April 2,
2025, the date of appointment as Director.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Expenses</U>.
During the term of the Director&rsquo;s service as a director of the Company, the Company shall promptly reimburse the Director for all
expenses incurred by her in connection with attending (i) all meetings of the Board or applicable committees thereof, (ii) executive
sessions of the Board, and (iii) stockholder meetings, as a director or a member of any committee of the Board, provided that any such
expenses shall be approved by the Company, in writing in advance. In addition, the Director shall rely on the Company to arrange any
hotel accommodation in connection with any such meetings Director must attend. The amount of such expenses eligible for reimbursement
by the Company during a calendar year shall not affect such expenses eligible for reimbursement by the Company in any other calendar
year, and the reimbursement of any such eligible expenses shall be made on or before the last day of the calendar year next following
the calendar year in which the expense was incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Taxes</U>: Director shall be responsible for the payment of all taxes to the appropriate taxing authority that she may owe such authority
due to the amounts paid to the Director hereunder, as well as the preparation and submission of all reports, returns and money which
may be imposed, requested or required by such taxing authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Confidentiality</U>: Director acknowledges that Director will receive confidential and proprietary information from or on behalf of
the Company in connection with, and during the course of providing, the Services, including but not limited to: business affairs, assets,
contracts, services; technical, financial, operations, manufacturing, marketing, commercial and/or legal information; data, reports,
drawings, models, designs, prototypes, formulas, processes, software, algorithms, specifications and patent applications; marketing strategies;
customer, vendor and subcontractor information; customer lists; and other sensitive, confidential or proprietary information, in each
case, of the Company or of its affiliates, customers, vendors, contractors, employees or other third parties (collectively, <B><I>&ldquo;Confidential
Information&rdquo;</I></B>). Confidential Information shall not include information that, at the time of disclosure and as established
by documentary evidence: (a) is or becomes generally available to and known by the public other than as a result of, directly or indirectly,
any breach of this <U>Section 5</U> by Director; (b) was known by or in the possession of Director before being provided to Director;
or (c) is required to be disclosed under applicable federal, state or local law, regulation, or a valid order issued by a court or governmental
agency of competent jurisdiction. The Director shall protect and safeguard all such Confidential Information and shall not during the
term of this Agreement or thereafter, directly or indirectly, use for herself or another, or disclose to any person, firm or corporation
any Confidential Information which the Director may have acquired in the course of or incidental to her performance of the Services hereunder.
All Confidential Information and all copies thereof (whether prepared by the Director or not) which Director obtains during the term
of this Agreement, shall be returned by the Director to the Company (or, at the election of the Company, destroyed by Director) upon
termination hereof. All Confidential Information is and shall at all times remain the exclusive property of the Company (or, as applicable,
the party who supplied the information to the Company). The obligations of the Director under this <U>Section 5</U> shall survive the
termination of this Agreement in accordance with <U>Section 2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Relationship of the Parties</U>: (a) The Director, in her capacity as such, is an independent contractor (1099) of the Company, and
the Director is not authorized to act as the Company&rsquo;s legal representative. The Director hereby represents that Director is free
to enter into this Agreement and that Director is not under any restrictive covenant, court order or any other restriction concerning
Director&rsquo;s entering into this Agreement and performing her obligations hereunder. If any conflict of interest exists at the time
of the execution of this Agreement or such conflict occurs during the term hereof, the Director shall (or have given) give advance written
notice thereof to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Intellectual Property Rights.</U> The Company is and shall be the sole and exclusive owner of all right, title, and interest throughout
the world in and to all the results and proceeds of the Services, and all work product produced in the performance of the Services performed
under this Agreement (the <B><I>&ldquo;Deliverables&rdquo;</I></B>), including all patents, copyrights, trademarks, trade secrets, and
other intellectual property rights (collectively <B><I>&ldquo;Intellectual Property Rights&rdquo;</I></B>) therein. The Director agrees
that the Deliverables are hereby deemed a &ldquo;work made for hire&rdquo; as defined in 17 U.S.C. &sect; 101 for the Company. If, for
any reason, any of the Deliverables do not constitute a &ldquo;work made for hire,&rdquo; the Director hereby irrevocably assigns to
the Company, and its successors and assigns, in each case without additional consideration, all of Director&rsquo;s right, title, and
interest throughout the world in and to the Deliverables, whether made solely by Director or jointly with others, including all Intellectual
Property Rights therein, including the right to sue, counterclaim and recover for all past, present and future infringement, misappropriation
or dilution thereof, and all rights corresponding thereto throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Termination</U>: The Director shall continue her service on the Board until the earlier to occur of the expiration of the term of
this Agreement or the termination of this Agreement in connection with the resignation or removal of the Director (in each case, pursuant
to the relevant provisions of the Bylaws). Termination of this Agreement for any reason shall not affect the rights and obligations of
the parties that may have accrued prior to the effective date of termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Indemnification</U>. The Company shall indemnify, defend, and hold harmless Director, to the full extent allowed by the law of the
State of Delaware and as provided by, or granted pursuant to, any charter provision, bylaw provision, vote of stockholders or disinterested
directors or otherwise, to action in Director&rsquo;s official capacity; provided, however, that, in accordance with the DGCL and federal
securities laws, such indemnification shall not apply where Director engages in actions or omissions which involve intentional misconduct,
fraud or knowing violation of law. Reasonable expenses incurred by the Director in defending any claim, action, suit or proceeding shall
accordingly be paid by the Company in advance of the final disposition of such claim, action, suit or proceeding, but such expenses shall
not include amounts paid in settlement by the Director or the amount of judgments or fines against the Director. In the event that the
Director is determined not to be entitled to such indemnification, then all amounts advanced under this <U>Section 9</U> shall be repaid.
In addition, the Company shall use its best efforts to purchase and maintain a customary directors&rsquo; and officers&rsquo; liability
insurance policy (or policies) during the term of this Agreement and thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>No Assignment</U>: Since this Agreement requires the performance of personal services by the Director, the Director may not assign
any right or delegate any duty described in this Agreement without the Company&rsquo;s prior written approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Severability</U>: Each provision of this Agreement is severable so that if any provision hereof is declared void and unenforceable
by any court of competent jurisdiction, the remaining provisions hereof shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Entire Agreement</U>: This Agreement constitutes the entire agreement of the Parties regarding the subject matter contained herein
and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, regarding
such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Miscellaneous</U>: (a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware; and
(b) no provision of this Agreement shall be deemed waived or modified by either party unless such waiver or modification shall be in
writing and duly signed by the party against whom the waiver or modification is sought to be enforced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[remainder
of page intentionally left blank]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cyclacel
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <I>Datuk
                                            Dr. Doris Wong</I> </P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Datuk
    Dr. Doris Wong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Executive Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"> <B>Dr. Satis Waran Nair
    Krishnan</B> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; word-break: break-all"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <I>Dr.
                                            Satis Waran Nair Krishnan</I> </P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 160pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_001.jpg" ALT=""></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
Whom It May Concern:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the use in the Registration Statement of Cyclacel Pharmaceuticals, Inc. on Form S-4 of our Report of Independent Registered
Public Accounting Firm, dated April 2, 2025, except for Note 1, as to which the date is July 23, 2025, on the consolidated balance sheet
of Cyclacel Pharmaceuticals, Inc. as of December 31, 2024, and the related consolidated statements of operations, changes in stockholders&rsquo;
equity and cash flows for the year then ended.</FONT> </P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the references to us under the headings &ldquo;Experts&rdquo; in such Registration Statement.</FONT> </P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT> </P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bush
&amp; Associates CPA LLC (PCAOB 6797)</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Henderson,
Nevada</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
23, 2025</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>9
<FILENAME>ex23-2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use in this Registration Statement on Form S-4 of Cyclacel Pharmaceuticals, Inc. of our report dated March 21, 2024,
relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing in the Prospectus, which
is part of this Registration Statement.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 1 to the financial statements, the 2023 consolidated financial statements have been restated to apply the reverse
stock splits effective May 12, 2025 and July 7, 2025. We have not audited the adjustments to the 2023 consolidated financial
statements to retrospectively adjust for these reverse stock splits, as described in Note 1.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in such Prospectus.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
RSM US LLP</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
23, 2025</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>10
<FILENAME>ex23-3.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.3</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation of our report dated June 13, 2025 in the Registration Statement on Form S-4, under the Securities
Act of 1933 with respect to the consolidated balance sheets of Fitters Sdn. Bhd. and its subsidiaries (collectively the &ldquo;Company&rdquo;)
as of March 31, 2025 and 2024 and the related consolidated statements of operations and comprehensive income, consolidated statement
of stockholders&rsquo; equity, and consolidated statement of cash flows for the years ended March 31, 2025 and 2024, and the related
notes included herein.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the references to us under the headings &ldquo;Experts&rdquo; in such Registration Statements. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    JP CENTURION &amp; PARTNERS PLT</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kuala
    Lumpur, Malaysia</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    23, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>11
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>12
<FILENAME>ex99-3.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
to be Named as a Director</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. is filing a Registration Statement on Form S-4 (the &ldquo;Registration Statement&rdquo;) with the Securities and
Exchange Commission under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). In connection therewith, I hereby
consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements
thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent
to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Inigo Angel Laurduraj</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inigo
    Angel Laurduraj</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    23,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>13
<FILENAME>ex99-4.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
to be Named as a Director</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. is filing a Registration Statement on Form S-4 (the &ldquo;Registration Statement&rdquo;) with the Securities and
Exchange Commission under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). In connection therewith, I hereby
consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements
thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent
to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Chong Kwang Fock</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chong
    Kwang Fock </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    23,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>14
<FILENAME>ex99-5.htm
<DESCRIPTION>EX-99.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
to be Named as a Director</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. is filing a Registration Statement on Form S-4 (the &ldquo;Registration Statement&rdquo;) with the Securities and
Exchange Commission under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). In connection therewith, I hereby
consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements
thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent
to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Dr. Satis Waran Nair Krishnan</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Satis Waran Nair Krishnan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> July 23, 2025</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>15
<FILENAME>ex107.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:CYCC="http://cyclacel.com/20250723">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_028_FFD%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_CYCC_cyclacel.com_20250723 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20250723_20250723 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001130166 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000003" name="dei:EntityCentralIndexKey">0001130166</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-07-23" id="xdx2ixbrl0009" name="ffd:FeeExhibitTp">EX-FILING FEES</ix:nonNumeric>
  <ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="From2025-07-232025-07-23_1" id="xdx2ixbrl0016" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-07-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>1</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_effd--FeeExhibitTp_dxL_c20250723__20250723_zSXnU2rH8Y6f" title="::XDX::EX-FILING FEES"><span style="-sec-ix-hidden: xdx2ixbrl0009">Exhibit 107</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Calculation
of Filing Fee Tables</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form
<span id="xdx_905_effd--SubmissnTp_c20250723__20250723_zcBdqZHEeqW1"><span id="xdx_90D_effd--FormTp_c20250723__20250723_zKistpS6JX6f"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000010" name="ffd:SubmissnTp"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000011" name="ffd:FormTp">S-4</ix:nonNumeric></ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20250723__20250723_zWioTWoqXQvg"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000012" name="dei:EntityRegistrantName">Cyclacel
Pharmaceuticals, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
1: Newly Registered and Carry Forward Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_101_zw8BuEuxY4Mb" summary="xdx: Document - Offerings" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td id="xdx_480_effd--OfferingSctyTp_z1JGc0frUxU6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Security Type</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td id="xdx_487_effd--OfferingSctyTitl_z6E3ntDJrfsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Security Class Title</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fee Calculation or Carry Forward Rule</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_48F_effd--AmtSctiesRegd_pid_zhMkCJe04Ydl" style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Amount
Registered<sup></sup></b></p>

</td>
    <td>&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_486_effd--MaxOfferingPricPerScty_pid_zMeNgcgwQ2B3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Proposed Maximum Offering Price Per Unit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48E_effd--MaxAggtOfferingPric_pid_zPzfB83RMgg8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Maximum Aggregate Offering Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_489_effd--FeeRate_pid_zFxVvOu1h2g2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fee Rate</b><sup>(3)</sup></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48A_effd--FeeAmt_pid_zZMMve99AN71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount of Registration Fee</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48D_effd--CfwdFormTp_zGYYEXrmoLC1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carry Forward Form Type</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_482_effd--CfwdPrrFileNb_zGgpco7090y8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carry Forward File Number</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_489_effd--CfwdPrrFctvDt_zXmt0QZzMqua" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carry Forward Initial Effective Date</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48A_effd--CfwdPrevslyPdFee_zZtjitRNye33" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="43" style="font-weight: bold; text-align: center">Newly Registered Securities</td></tr>
  <tr id="xdx_412_20250723__20250723__ffd--OfferingAxis__1_z8uOVYdFjIy3" style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 4%; text-align: justify"><ix:nonNumeric contextRef="From2025-07-232025-07-23_1" id="Fact000013" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 4%; text-align: justify"><ix:nonNumeric contextRef="From2025-07-232025-07-23_1" id="Fact000014" name="ffd:OfferingSctyTitl">Class A common stock, par value $0.00001 per share</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td id="xdx_984_effd--FeesOthrRuleFlg_dbT_c20250723__20250723__ffd--OfferingAxis__1_z2B73FkSW8ye" style="width: 4%; text-align: justify"><ix:nonNumeric contextRef="From2025-07-232025-07-23_1" format="ixt:booleantrue" id="Fact000024" name="ffd:FeesOthrRuleFlg">Other</ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 4%"><p style="margin: 0"><ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2025-07-232025-07-23_1" id="Fact000015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,118,282</ix:nonFraction></p></td>
    <td style="width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0016">&#8212;</span></span><p style="margin: 0"></p></td><td style="width: 1%; text-align: left">(2)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="text-align: right; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2025-07-232025-07-23_1" id="Fact000017" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">2,578,304</ix:nonFraction><sup></sup></span></p></td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><ix:nonFraction name="ffd:FeeRate" contextRef="From2025-07-232025-07-23_1" id="Fact000018" format="ixt:numdotdecimal" decimals="INF" unitRef="Ratio">0.00015310</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ffd:FeeAmt" contextRef="From2025-07-232025-07-23_1" id="Fact000019" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">394.74</ix:nonFraction></span></p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="width: 4%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fees Previously Paid</td><td>&#160;</td>
    <td style="text-align: right">&#8212;</td><td>&#160;</td>
    <td style="text-align: right">&#8212;</td><td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">&#8212;</p></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="43" style="font-weight: bold; text-align: center">Carry Forward Securities</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Carry Forward Securities</td><td>&#160;</td>
    <td style="text-align: right">&#8212;</td><td>&#160;</td>
    <td style="text-align: right">&#8212;</td><td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">&#8212;</p></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: justify">Total Offering Amounts:</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_effd--TtlOfferingAmt_c20250723__20250723_z40RnbtszgB9" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="AsOf2025-07-23" id="Fact000025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,578,304</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_effd--TtlFeeAmt_pid_c20250723__20250723_zbFvnzBCAiXb" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="AsOf2025-07-23" id="Fact000026" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">394.74</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="9" style="text-align: justify">Total <span id="xdx_90E_effd--PrevslyPdFlg_dbF_c20250723__20250723__ffd--OfferingAxis__1_zov2JFzC4zdj"><ix:nonNumeric contextRef="From2025-07-232025-07-23_1" format="ixt:booleanfalse" id="Fact000027" name="ffd:PrevslyPdFlg">Fees Previously Paid</ix:nonNumeric></span>:</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_effd--TtlPrevslyPdAmt_c20250723__20250723_zFVOxxsBTh8" style="text-align: right"><ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="AsOf2025-07-23" id="Fact000028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="9" style="text-align: justify">Total Fee Offsets:</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_effd--TtlOffsetAmt_c20250723__20250723_zNl4t6eNOUNj" style="text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="AsOf2025-07-23" id="Fact000029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="9" style="text-align: justify">Net Fee Due:</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$&#160;</td><td id="xdx_982_effd--NetFeeAmt_pid_c20250723__20250723_zMRwBTLgo07c" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="AsOf2025-07-23" id="Fact000030" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">394.74</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offering
Note</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>
<span id="xdx_90D_effd--OfferingNote_c20250723__20250723__ffd--OfferingAxis__1_gIFON-REIQAM_z2MJERhgAMEh"><ix:nonNumeric contextRef="From2025-07-232025-07-23_1" continuedAt="ConU000033-01" escape="true" id="Fact000033" name="ffd:OfferingNote">Represents the maximum number of shares of Common Stock, par value $0.001 per share (&#8220;Cyclacel Common Stock&#8221;),
of Cyclacel Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;), issuable to securityholders of Fitters Sdn. Bhd. (&#8220;Fitters&#8221;)
pursuant to the Exchange and related transactions contemplated by the Exchange Agreement, dated as of May 6, 2025, as amended on July
7, 2025, by and among the Registrant, FITTERS Diversified Berhad and Fitters.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup>
<span id="xdx_C00_gIFON-REIQAM_zbLiDoLFqAT8"><ix:continuation continuedAt="ConU000033-02" id="ConU000033-01">Estimated solely for the purpose of calculating the registration fee under Rule 457(f)(2)
under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). As Fitters is a private company, there is no market
for its securities, therefore, the proposed maximum aggregate offering price per share was calculated based on the book value as of July
10, 2025 of the Fitters Ordinary Shares that will be exchanged in the Transaction, which amount equals $2,578,304.</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><sup>3
</sup> <span><span><span id="xdx_C05_gIFON-REIQAM_zbuqVrKaM0V5"><ix:continuation id="ConU000033-02">The registration fee is determined in accordance with Section 6(b) of the
Securities Act and calculated by multiplying the estimated aggregate offering price of securities to be registered by 0.00015310.</ix:continuation></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.15pt; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLMbqLA3HSriFBlDfC0uk+LWjLRO/ST/0m5DDBdCcu9JhJiILW10jQyXVZ5BgU1bK4eQY4WM5oo+ke72Cfie401bx8q4YfyBKXkGPTMPI+X3Q7LTFssE5GLqFc9AzhIZwfIggt5PyVS6ROO0qkGZEk5MLWt0it/jhUK9yFDzHj6dka0mk0AUytH+QCyjGI7UqSfx3UKWpSKYDBWILdOj9an1y6HpSVjX2Ph3dqT/Cr7CTUpM -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>forms-4_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_001.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #5 Z@# 2(  A$! Q$!_\0
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MVW_?E?\ "C^QM/\ ^?&V_P"_*_X4 <+_ ,+!MO\ GLO_ 'T*/^%@VW_/9?\
MOH5W7]C:?_SXVW_?E?\ "C^QM/\ ^?&V_P"_*_X4 <+_ ,+!MO\ GLO_ 'T*
M/^%@VW_/9?\ OH5W7]C:?_SXVW_?E?\ "C^QM/\ ^?&V_P"_*_X4 <+_ ,+!
MMO\ GLO_ 'T*/^%@VW_/9?\ OH5W7]C:?_SXVW_?E?\ "C^QM/\ ^?&V_P"_
M*_X4 <+_ ,+!MO\ GLO_ 'T*/^%@VW_/9?\ OH5W7]C:?_SXVW_?E?\ "C^Q
MM/\ ^?&V_P"_*_X4 <+_ ,+!MO\ GLO_ 'T*/^%@VW_/9?\ OH5W7]C:?_SX
MVW_?E?\ "C^QM/\ ^?&V_P"_*_X4 <+_ ,+!MO\ GLO_ 'T*/^%@VW_/9?\
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MKE9!;1PB1X4V'&!L&:C,MFG'D#(Z_NQ1_K%#_GW^/_ #^SW_ #'7?\)_;_\
M/5?SH_X3^W_YZK^=<D9;0$9A4 G;S&*>?LK1/*(D\M3R=@I/B.G_ ,^_Q_X
M?V>_YCJO^$_M_P#GJ/SH_P"$_M_^>J_G7'^;9C'[C/I^['IF@3V>W/DJ!Q_R
MS'>H?$M-?\NG]_\ P!_V<_YCL/\ A/[?_GJOYT?\)_;_ //5?SKE$%LRN5B0
MA.IV"JQN[ *&,2 'I\@YIKB2#_Y=/[_^ )Y>U]H[3_A/[?\ YZK^='_"?V__
M #U7\Z\4^)_QV^'_ ,(-,^V>*-7M;$L"8K1$$ES-CLD8Y/U.![U\H1?M_P"K
M?$+XBV>F>%-%M-"\/B0!I;^)9KFX&X#YOX4&">!D^]=<,Z<Z;JJB^5=;_P#
M'3RYU:BI1GJS]&O^$_M_^>H_.C_A/[?_ )ZK^=<6=0TH!B!%C) .T<TPZQI0
MZF$>N5%"SIO_ )</^OD1]1_OG;_\)_;_ //5?SH_X3^W_P">J_G7)V%U8:AC
M[,(I?=4''UI[-9HS P*2IP2(QUJ'GT8NTJ37S_X ?47_ #'4_P#"?V__ #U7
M\Z/^$_M_^>J_G7*J]H2,0#/ '[L4@:TD*JL2$L<8\L4O[?A_S[_'_@"^HO\
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M(_6+_A.$]3^5'_"<)ZG\J_)W_A)=9_Z#.I?^!DG_ ,51_P )+K/_ $&=2_\
M R7_ .*H_MV/_/O\?^ '_$(\1_T&Q_\  '_\D?K%_P )PGJ?RH_X3A/4_E7Y
M30^(M9P/^)QJ)_[?)/\ XJKT.OZP?^8OJ'_@7)_\56<N((1_Y=O[_P#@&4O"
M>O'_ )C%_P" /_Y(_4O_ (3F/U-'_"<Q_P!XU^846O:L<?\ $VO_ /P*D_QJ
MY%K>J_\ 05O_ /P*D_QK!\2TU_RZ?W_\ YY>%M>/_,8O_ '_ /)'Z8_\)S'_
M 'C1_P )S'_>-?FQ'K.J?]!2^_\  E_\:MQZOJ9_YB=[_P"!+_XU@^*J:_Y<
MO[_^ 8/PRK+_ )BU_P" /_Y(_1S_ (3F/^\:/^$YC_O&OSK35M2_Z"5[_P"!
M+_XUO^$=,UKQ7JR6L.HWJ0K\TTWVA\1I^?4]J=+BA5ZD:5.@W)Z)7_X!Q8GP
M^>#HRKU\9&,8J[?*_P#Y(^\SX]A!P9 #]:/^$]@_YZ#\Z\+L[=;&UBMXF?RX
ME"+O<L2!ZD]34VYO[Q_.ON4G;4_(I63:CJCV[_A/8/\ GH/SI1X[B;H^?I7B
M&YO[Q_.O%_C)?WEOXIA6"\N($^RH=L4S*,Y;L#7F9ECEEV']O*/-JE;;<]_(
MLHEGF,6#C/D=F[VOMY71]K?\)[#DCS!D=1FA?'D+#Y9 ?I7SSX U_P"'.N_"
M;PWIGBSQG>:)J^GS7$L@M)W25]TA*^8VT[@%QCGC-3_'#7/A=XHT?6];T7QS
M?'7Q9JEII]E<216[NH 'R! .>2>>M<*SFDZ/MER[)VYU?:[7JMO,]I<*5_K?
MU67/\3CS>RDXZ2LG>]K-:WOHNY] _P#"<Q_WC5FU\8),X )/X5^9,NMZK_T%
M+[_P*D_QJK)K^L(?EU?4%^EW(/\ V:O+7$]-_P#+I_?_ , ^VCX75W_S%K_P
M!_\ R1^LNG:B+D#UHKR#]FC5)KSX6>%C/-)/*;)-\DKEF8Y/))Y)HK[&E/VE
M.,^Z3^\_&<70>%Q%3#MWY).-^]FU?\#L=6;_ (J[1Q_T]+_6O0J\[U;_ )&_
M1_\ KZ7^M>B5H<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >?EO^*\U0?[4?_H"UO:X<:>W^[7/M_R/NJ?[T?\ Z+6M_7?^0>WT
MH \IAM6G^T,&QO=E/X&K,]J\[QLH5@JD?,:X+Q'X@U'3M9N8+:[>*$'<$4#&
M3U[5F#Q?K '&H2?D/\*_)LP:6,J_XG^9]%1JI4HJW1'IT=I)T8@<Y^4Y_AQ3
M1I[(>&'W=N<=OI7FO_"7:OG_ (_Y/R'^% \7:Q_S_P OY#_"N%V-?;1['IT]
MJTMJD2\[<?>/7%,%G)E@=JA@1P>F3G^E>9_\);JXQ_I\GY#_  I#XPU?.3?R
M?DO^%)2B'MH]CTV33V+;MPSNWXIS6S?998MV6<D^W->8OXMUE2 U]*#Z8'^%
M,/B_62Q'V^3\A_A4.41JK'L>F):2(1\JJ/0'VQ2/IQ8D;N,#]!BO-/\ A+]8
MS_R$)>GHO^%(?&.L _\ '_)^2_X5DY1'[:/8ZOXBPRQ>"-8V,1*Z*5*G'0CT
MK\U?"7[5?BZXO)I]:UG38[;3;J*26QB18)KJ,2+NCC)SDD9S[ FOO+5_$>I:
MEIEW;W%V\D3Q/E"!@X!([5^4]KX4N)=<G2&VCN-1D(GC0D,/+9=V>> <9KZ_
M)JD:>'=1[)O\D95(NO:,.I;^(6H+\5O'^HZWI5C-86EW*TG^FR[O+RQ.-Q)S
M@$# K4^$VBSV7CEK:V</<) YAD4<%^-IY]\=:[C2?A'(^E1:E>ZS"&5?,%I;
MC)Z9PQ/'X ?C1\-].CLO'<-R",F)@1W[ 4\7C?:4JD4U:S/H<'ELZ%6G5DM>
M9'TAX8\(_M$7EVL>N>+;[3O,_P"?6ULI21[=JC^*TOQ&^'?@S5-3F^(GB:>2
MPCW2(VG6:!.0 =PR>I'K7U%:ZG&]A;73$ QL QKR3]IR."Z^&7B]Y(Q-$]N@
MV@]<D8_(X-?C64^)F<XK'TL)6IT^6<E%NTKZR2T]^VS.R624;3;;7*F^FZ^1
MZ3^S9?7NN_"+PMK&HW3WE[=V,<TT[@!I79>6..]>C/:R"5V 7YFW D^V,5XK
M\*;^]T#X%_"]+.=K=)O#\$C!0,,<D9YK>;Q=K /-_)^2_P"%?J^8-+$R3\OR
M1\A[51T9Z;]D=E4D@$;??H,4R*R\HI\V0K;O>O-1XOU<''V^0\^B_P"%(WC#
M6 6_T]_^^5_PK@O$2K1['J%U;-*X=0" A7DXP?6JUW"ZPJS8&)5/!SU(%>:'
MQKK?_01?_OE?\*O:%XFU/4=7MK:YNVEA9LE"JC..1T%=.!G%XJE_B7YBJS3I
MR]#Z.\/'_B7I_NU@W3?\5KI _P"FQ_\ 0&K=\/?\@]/I6#<_\CMI'_78_P#H
M#5^J'SYZ'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5Y[:M_Q6NKC_IL/_0%KT*O/+;_ )';5_\ KL/_ $!: -[Q"?\ B7M_NTGP
M[.?"\/\ UUE_]#:CQ%_QX-]*/AU_R*T'_767_P!&-0!TU%%% !1110 4444
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M6>YG;:D:#J2:-M6-)MV1?HKB/AO\9_!WQ;M[J7PIKEOJWV4@3QH&22//0E6
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M5Q_QNO=+O?ACKCZ?:R6[+#NE+MD'YEQ@=N<UM/.+73YRAY=%%<9\41Y/P?\
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M#]YRGX UVM)BFG9W0'!^&]%\3/JEQJ6M:W(L5O,5BL8856$H%&XCN5)!QGG
MSWJ9/$'A'Q'J6GZD=01K\*([9?,*2(&;D8']X@9'? ]*[25=\;J#@L",UQH\
M$ZK%=07$>KVZS1+L\UK%"[+UP3GU]J;;;N E[XL\+7T6D75^RO%*\C6TTRY"
MLG7=Z'G@'O70:)XBTC7 \>F74-R(@"PB& H-<9J6K:?930K+XQTRSND9HWB,
M4>6=6V-^[SP=Q4=.H':N;^)_CC5?ADWAVQ&H1:KXE\1:I%IVE:3:6J1/<_.#
M)([CE(XXPSN0.P'>HNAV9YU_P4E4-\#=,!4$#6X6Z=#Y<N#7Y@7'7VK],?\
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M%%%?7'S 4444 %%%% 'GK?\ (^ZI_O1_^BUK?UW_ )![?2L!O^1]U3_>C_\
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MP?\ D%J_$%?#=]XJ,MC8V[W,K1;F2,@$#CGGZU^YGQ0B\_X<>*HO[^DW:_\
MD%Z_#-;VYL)A-:RM%*BY#KUQCFO!S#2K39^D<,)RP.)CYK?S3.8\0:/<>%O$
MGARVNXG@DMXXPR/@D8F9NH^M?T):=,+C3[653E7B5A^(!K^>?QG>2W%UI%U*
MYDD\ABS'J<2-7]!?A.;S_"VCR9SOLH6S]4%>CA7S0O\ UN?&9C#V=:4;;/\
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M_P!"J?0O^0>OTJ#XD_\ (N+_ -?,7_H53Z%_R#U^E 'SI^V;_P DEUWZP_\
MHY*_/>OT(_;-_P"22Z[]8?\ T<E?GO7Q6=_[Q'_#^K/ZK\*?^1+6_P"OLO\
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MVFG?ZF7_ *ZO_.K5?D^817UNK_B?YGTU"E%THMKHC@Q\-YHV!6^C5@>#L/\
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M@'_@HIX'O-!\.KJ[W43V>JZ]%)'$@(?(MY 0_;@GCZU]_5\I_P#!2+0#JGP
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M%PAO]&NX=K=20%?'U^7]*SA14;--_>_QUU.93;EK;[C]< ,@"N$M?^1VU?\
MZ[#_ - 6N[7M]:X2V_Y';5_^NP_] 6NB1NS=\1?\>#?2CX=?\BM!_P!=9?\
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M9E^5AT/7BO: <U^0_P"S)X>G;QWX??P?%J2>/[=V=;2^U5?[.E@0[F2-BGF
M[-V$8A<CK7ZK^!+K7+S01)K]M]EOO.D58SMW&(-A&;:2 Q'. >]>C2JPK1YZ
M;31\/C<#B<OJ^QQ4'"5KV:L5_B3_ ,BXO_7S%_Z%4^A?\@]?I4'Q)_Y%Q?\
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MHSP]:^L/AC!GAKYM_:#/E^-H!_TY)_Z$U?3US%C-?+W[2#>7X\MQ_P!.,?\
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M[,IS\._#O_7JO\S12?LQ\_#GP[_UZK_,T5^[X3_=J?\ A7Y(_C#-O^1CB?\
M'/\ ]*9Z%JW_ "-^C_\ 7TO]:]$KSO5O^1OT?_KZ7^M>B5UGE!1110 4444
M%8GC'P?I/CSP_=:)K=FE]IMTH$D3]B#D,IZA@>016W2'D&DTI*S#8_)WQEI,
M&D>,M<TJ&&:.'3KN6!</YR! QQENO3%4_#-HFHW4T5O.6\F-I7^4X"KR?QKN
M/BCH-N/B?XX@BFDC2"ZE;#J),9)XR03BN7^&]E]CN-6992WEV\CY6,*3^./>
MORNI-1<EV/IJ5*,U%MGV;^QQX,TV3P?)XMFTT+K$]Q+!%<2MN9801]T$?)GO
MZXKZ1%>3?LNV\5O\']*\K^-Y&=N[-NY)KUJOT; 14<-3LMTF?/UG^\EZG!?%
M+XIP?#RVMH(=/N-7UJ^W+96$ QYC#^\W\(_6OBWXI^,_B'\3M3TS4)[&1(EF
MEM(DTVTZE3F5(Y &,A7L>@YK[[USPWI_B*UE@O8 _F1/!YJ_+(B.,,%8<KGV
MK-L/ FDZ5JNGWEI#Y"Z=:&RM+:/B*%"<D@?WCT)KCQF#K8J5G/W--/NW[]?P
M/0PN+I8:%U"\]=7J?GW\/YOB-H/BBPUO3(9[^8^;'IDMQ:>8LK*I#@*P&Y@N
M[H<YS7V!\&_V@W^(%SI^F:MHLVF:C=1,8[F'YK6=T^^H)Y0C'W3S776GPHTZ
MW\+66B27-PZV=\;^"Z0A)8Y/,+\$=N2OTKI=)\+:5HEW>W5C8PVLU[-]HN#&
MN \F,%L=B1UQU[U.$P-;#-<L[1ZK?U_X?_(TQ.-I8B+4X)RZ/;\O\OS->BBB
MO=/%"BBB@ HHHH \];_D?=4_WH__ $6M;^N_\@]OI6 W_(^ZI_O1_P#HM:W]
M=_Y![?2@#S73O]3+_P!=7_G5JJNG?ZF7_KJ_\ZM5^4YA_O=7_$_S/J\/_!AZ
M(#TIC&GTWIGBO.;.@:#QCO3HV"R GH"#^M-' _PIZ_=(  W>M2-K01D3)(F3
M\C43Q[,$,&!)&14C(<\*?>E6,/$HW*A#$D,?I0W<7P]2&-#*X&0O4Y-(T2#I
M,OY&K2P>42QD0_*> ?:JFWCT]JAZ%1?,]&<C\8)0GPW\0D'<!8.N?7Y37XR_
M#^<PZY(PX*S9_  U^R'QID\KX6^)#TQ:L/SK\:/"$,MKKMTLZ&-^) &[JP)!
M_(U]'@/>P=7^NQKA_=Q-'U/99A%>6Z-<1I*Z?,A<9*MUR/0UR_@"<)\2S)D?
M-N&/^!"M@W0,:J",<_CQ7)>"IMOQ,V_]-"/_ !Y:\_#Q?L*R_NL^YS&<7BL,
M_P"\C],[+3WN_",SJ,RQW0(_&N'^/%V\?[.WC2U)(V6^[Z?,M>H^",/:7]JP
M_P"6JG!_*O+/VBH_(^!_Q")XVVJ@?C.@K^9\KGS9I1IOI5@U\Y1/6S"K^YQ$
M)=-5\T>D?L=2D_LY^"D))*66W_Q]J]KR1BO#/V+I/,_9_P##"GG9;@?^/-7N
MH&[D<5_3F.=\1+Y?DC\G2T&[NE2#I3,<T\=*X&-"U5U/_CV'_71/_0A5JJNI
M_P#'L/\ KHG_ *$*[,#_ +U2_P 2_,QK_P *7HSTCP]_R#T^E8-S_P CMI'_
M %V/_H#5O>'O^0>GTK!N?^1VTC_KL?\ T!J_6#Y,]#KY\_;SO8;3]F#Q4DT8
MD^T/;0)G^%C.A!_0U]!U\*?\%,/CSH-AX2M_AG9W3S^)Y;RVOKJT2%B$@"N4
M^;H26VG R<"NC#3C3KPG+9-/\3.HFX22['C>N^$H]0_X)V>'=15A*;;Q5/,2
M#S&'>2(C\POYU]0?\$T]<2__ &=6TPS0O/I6KW,)AC.6C1]LB[OJ6;%>3?!O
MP)XE\:_L :IX:M-&0++#=ZA'/>Y1I)5F,@" \@_)@'I5[_@FEXTT'PM\,?%A
MNO.CU"]UD,BJF?/40H%"+U^4YSGU%=E:I&K0V][F?W/7\[F%.+C-6VL??5?
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M/_(N+_U\Q?\ H53Z%_R#U^E>R?GI\Z?MF_\ ))==^L/_ *.2OSWK]"/VS?\
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MTH \UT[_ %,O_75_YU:JKIW^IE_ZZO\ SJU7Y3F'^]U?\3_,^KP_\&'H@IC
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M_"EZ,](\/?\ (/3Z5@W/_([:1_UV/_H#5O>'O^0>GTK!N?\ D=M(_P"NQ_\
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M^L/_ *.2OSWK]"/VS?\ DDNN_6'_ -')7Y[U\5G?^\1_P_JS^J_"G_D2UO\
MK[+_ -(@'I]:^S/ W[5G@O4-2TO2+G3M3L3<-';"ZE5&C5SA06P<@9[U\9U9
MTWC4['_KXB_]#%>;A<95PC?L^MKGW7$/#6 XCIQ6-3O!2Y6G:U[7]=EN?JIJ
M7AORHSE.17YY?M&0);?'/7(W0O&LUON0#EAL3(_$5^I&OQ1"WR ,D5^87[33
M-%^T'KS1E5=9[9E+_=!")@GVS7U&=?[O'_$OR9_/_A5_R.:W_7J7_I4#ZZNE
ML_"OA#4?^$4^'?B_P99&PDWFRTRS8E2A.69Y&?'KWKY)^ OQ1TOX8ZCJ=SJ=
MI<WD=W!'&BVNW(*L22<_6OK#6]1NH=,O_$RVO@2+4[B*XVZBGC"=XGG\H^9L
MC*[&(#9V>XK\_+=\(N/2O%Q]66'JTZE)ZJ]M-/NLC]!X8RVCFV"QF%QD;QFX
M<SYKR;3;UES2;LTM6[[Z(_1WX0>.]"^,.C7EYHT=Q"]E(L5Q;W*@.A(RIX)!
M!YY]JPOVB-(%G\+M?DQC;&G_ *,6N0_X)WE99/':M]W;:'!_[:UZC^U0J)\(
M?$I7'$2?^C%KW85YXK+)U*F[C+]4?C^-RNAD_%U/!8:_)&I2M?5Z\KW^9\__
M  /U/Q9X?^&'B?6-!:SU"SBOXHSH5QI;7K7LVP'@C[@"\Y]JA_:7CN#XMT35
M+FVTVWGU735NY)-.M)+;S7\QE8RH_P V\$8SW %>7>#/B?XI\ QW,?AW7;O2
M([E@TR6[#:Y'0D$'G%,\3>-]<\<:DNH:_JEQJUZL8B6:X;)5 20HQP!DG\Z_
M.:N(A+"*AK?3TT;U6OGM;];_ +[#)Z\,VECGR<KOJM)-.*5GHEHU>[;?X6^E
M/V$WW>,/%(_Z<(O_ $8:^RZ^+?V#),^,O%?_ &#XO_1AK[0+@"OO>'5;+X+S
M?YL_G[CQ6SZJO*/_ *2B.X/%9-R>#6A<29S65<OUKZ4_/3-NN]?''[6#[?B5
M;#_J'1_^A/7V)=-7QC^UM)CXFVH_ZAL7_H;U\MQ*KX!^J/TCP^5\[2_N2_0]
M$^%GAWP-XM^&7P^FUKQ/I.BW^AZA->36L[0[[H><2(Y=Q!VD =<\&KOCOPUX
M!\*>$OBMJ^D^,-(U.\\06S-!ID+PC[.0Q(6(*Q)Z]@.E?'LCJ>PS5:1U!S@#
M\*^+IYC%4E#V*NE:]W?X>6_;8_:WPO5GB76^MR47+FY;1M;G]I:^]N;KO\M!
MTLE4I9*=++5267K7G0@?HL('Z&?LMG/PR\,_]>:?S-%-_98.?A?X7/K9I_,T
M5^RX;^!3_P *_(_A[./^1EB?^OD__2F>D:L/^*NT?_KZ7^M>AUPFJ6Q;Q1I3
MXX6Y4_SKNZZ3R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH \^(_XKW5/]Z/_ -%K6]KH_P")>W^[62;<_P#":ZE)C@LG_H"UMZS'
MNL6'M0!YAIW^IE_ZZO\ SJU45O$81*I&/WC&I:_*<P_WNK_B?YGU>'_@P]$!
MJ)C@]*EHQ7GLZ45R<=J"<\XJ<J*0)BD4,#9QQ36X(XJ; II3-0T"&%N,FDR1
MU'6G[<"FXR.M0]!B=!C'%>=_&_X'>&/CSX,F\/>);8L!F2SOX@!/92XXDC;^
M:GAAP:]%VX^M*Z T0J2IR4XNS1G)*2LS\2/C7\!O%7[.WC@Z-K<9>%R9+#5(
M5/D7L8/WE/9AQE3R#^=9G@&Y:Y^(-C.3\SS1DA?]]<U^S'Q2^%/AOXQ>$+OP
MYXGL5O+";YHY%XEMY,<2QM_"P_7H>*_,#QO^S7XB_9[^,^EV&IHU_H=Y<K_9
MNL(N([A0Z_*W]V0#JOXC(K["CF$,51E&II.S^9C1A*G6@HO2Z/US$LF?O-^=
M#EI$*.2RD8*MR"/0BE QD'UI0*^6T1JM2"VM(;./RX((H(QT2) BC\ *GR3C
MC%!XI:5V.PWN.*=1BBJO<+6"JNI?\>P_ZZ)_Z$*M5%<Q&:-5'7>O\Z[<#_O5
M+_$OS,*_\*7HST/P]_R#T_W:P;H8\;:1_P!=C_Z U='H412Q4'TK$N;8GQ?I
M;XX68_\ H+5^L'R9W=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDAY$1\M3NV]"<#C/ //-?8<05%1P?M&MG?\ !G\H>%U14LVKU&KVI2?_ )-
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M_P#G_7_P'3_"N\^P1^@H^P1^@H X/^U/%?\ S_K_ . Z?X4?VIXK_P"?]?\
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M%?\ S_K_ . Z?X4?VIXK_P"?]?\ P'3_  KO/L$?H*/L$?H* .#_ +4\5_\
M/^O_ (#I_A1_:GBO_G_7_P !T_PKO/L$?H*/L$?H* .#_M3Q7_S_ *_^ Z?X
M4?VIXK_Y_P!?_ =/\*[S[!'Z"C[!'Z"@#@_[4\5_\_Z_^ Z?X4?VIXK_ .?]
M?_ =/\*[S[!'Z"C[!'Z"@#@_[4\5_P#/^O\ X#I_A1_:?BO_ )_U_P# =/\
M"N\^P1^@H^P1^@H XRUU'Q,SCS+U6'_7!/\ "M_2K&1IGN)SNFD.6;&,GI6L
MMBB]%J=(@HZ4 5;VU\V$K7,7)U?3H_)L+@0Q DA3&K=3D]17:%014$EJKGD4
M < VI^*\\7ZX_P"O=/\ "F_VIXK_ .?]?_ =/\*[TZ?'_=%)]@C]!0!P?]J>
M*_\ G_7_ ,!T_P */[4\5_\ /^O_ (#I_A7>?8(_04?8(_04 <'_ &IXK_Y_
MU_\  =/\*/[4\5_\_P"O_@.G^%=Y]@C]!1]@C]!0!P?]J>*_^?\ 7_P'3_"C
M^U/%?_/^O_@.G^%=Y]@C]!1]@C]!0!P?]J>*_P#G_7_P'3_"C^U/%?\ S_K_
M . Z?X5WGV"/T%'V"/T% '!_VIXK_P"?]?\ P'3_  H_M3Q7_P _Z_\ @.G^
M%=Y]@C]!1]@C]!0!P?\ :GBO_G_7_P !T_PH_M3Q7_S_ *_^ Z?X5WGV"/T%
M'V"/T% '!_VIXK_Y_P!?_ =/\*/[4\5_\_Z_^ Z?X5WGV"/T%'V"/T% '!_V
MIXK_ .?]?_ =/\*/[4\5_P#/^O\ X#I_A7>?8(_04?8(_04 <'_:GBO_ )_U
M_P# =/\ "G+J?BHGF_7'_7NG^%=U]@C]!2C3X_[M '+VO]JZE&(K^<31Y#8$
M:KR/H*Z>TMA%"%J6.U5.@J<# H X#XF_#K3/B'X=O-%U>W:XT^ZV^;&DC1D[
M6##YEY'(%>#7/[%_@)7/EZ3= ?\ 7]+_ /%5]:R1!^U0&Q1NJUA4H4JKYJD$
MWYH]?!YQF67TW2P>(G3BW>T9-*^U[)[Z(^2O^&,? W_0*N?_  -E_P :5/V-
M/!$;JZZ7<AE(8?Z;+U'XU]9?8(_04?8(_05E]3PW_/M?<CN_UFSQ_P#,;5_\
M&2_S/$_^%;OZM7)WW[,OA[4O%'_"13V<[:OO5_.6X<#(&!\H..E?3'V"/T%'
MV"/T%;5:-.O'DJQ4EV:NCQ\+C<3@9.>%J2@VK-Q;3:?1VZ>1\WVW[.>AV>M7
M6K0V<J:A=($EF\Y_F QCC.!T%<Z_[&G@B1V=M+N2S$L3]MEY)Z]Z^LOL$?H*
M/L$?H*Y(9;@J;O"C%;+2*V6W3IT/3AQ#G%-WABZBV6DY;+;KT/F_P?\ LYZ)
MX":[.B6LUJ;H*)=\[R;MN<?>)QU-:NO?!NU\3:1<Z9J,<DUE< +(BN4) (/4
M<CD5[W]@C]!1]@C]!7;&G",/9Q2Y>W0\RKCL57Q'UNK5E*K=/F;;E=;.^]U9
M6[6/EV[_ &4?"U]!9PS6-R8[2+R80MW*NU<YP<'GGUI9_P!E/PM<:?:V,EC<
MM;6S,\2_:I,@MUYSD]*^H?L$?H*/L$?H*XO[.P2M^YCIK\*_R\ST_P#6'.-/
M]LJ::_'+_/S/G_X??!*R^%M[>7?AN*2RGNXUAF:21I=R@Y PV<<UV_E>(?\
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MTF"RE>[1E^\#$%W@CN,<56U?POK/A_6VT;5-(OM-UA65&T^[MGBN S8V@QL
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M'[='C'7/A_\ LG?$7Q#X;U2XT76["RBDM;^T;;+$QN(E)4]L@D?C7N]?-_\
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M&1Q0![3_ ,-V_M!?]%;\3?\ @9_]:C_ANW]H+_HK?B;_ ,#/_K5X110![O\
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MH6VDW$ENR#.6$BH5P,')SCBC8-STC_ANW]H+_HK?B;_P,_\ K4?\-V_M!?\
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M:YJES-:B]BALM.FF>2W+%1,H522A((W#C(QF@#U/_ANW]H+_ **WXF_\#/\
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M$I?^3W_!/_7KJ7_I%-5$G[W5\W_\%&/^3*?BI_V#XO\ TIAKZ0KYO_X*,?\
M)E/Q4_[!\7_I3#0!_//1110 4444 ?=OPU^(GB#4O ?A#1?!/B2_\"?$;X<^
M'[V6[^'.N6,B:5XCM]LUS<7)&0KRO;R9:.9<,L:E6Q76:)\#/%'@3]BOQ1X3
ME\*7,.G>(/!LGCK6-=,(V+?)<P2V5D#G(\NUCD=AC[TY]*^7H/VTOB'#X;AT
MQH?#TU\MA%I$WB&71H3JUU8)@"TENL;VB**(V&<E!M)Q7(G]H7QE)\4_$OQ
MFN[>Y\0^(;>^M;\S0!H7ANH7AEC5.BJ(W*J!]W:N.E$]>9+JOQU_6S\FM- A
MHXM]+?I_P5YIGT;\:?$6F>"/@Q\)_"]I\3?&'A7Q18>!K6YA\,Z':-]@NYKR
M66Z#RW"W*%6=9U!_=-@ =<\+^W!XQTGPWXLUCP[H?Q5\9V^NZ%9:;H,GA&WM
M7ATF,6]K##*%G6ZYY1FQY(RQ(]Z^6O&'Q:U[QSXXTWQ5JOV5]1T^"QM;>*.
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M"+IK;2K?1H-9/A^+^TH;>%%2()<9W!@J@9^M>+T?:=MKO\6);*^]E^04444
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M26,=C%X6F\'QJMJ-R6$UR;B7!S_K'<D%^I4XI+1:;VLOQ:^Z5ON'HY:[7O\
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M0>"/_!#;?_$4 ?S;45_23_PQ[\#/^B0>"/\ P0VW_P 11_PQ[\#/^B0>"/\
MP0VW_P 10!_-M17])/\ PQ[\#/\ HD'@C_P0VW_Q%'_#'OP,_P"B0>"/_!#;
M?_$4 ?S;45_23_PQ[\#/^B0>"/\ P0VW_P 11_PQ[\#/^B0>"/\ P0VW_P 1
M0!_-M17])/\ PQ[\#/\ HD'@C_P0VW_Q%'_#'OP,_P"B0>"/_!#;?_$4 ?S;
M45_23_PQ[\#/^B0>"/\ P0VW_P 11_PQ[\#/^B0>"/\ P0VW_P 10!_-M17]
M)/\ PQ[\#/\ HD'@C_P0VW_Q%'_#'OP,_P"B0>"/_!#;?_$4 ?S;45_23_PQ
M[\#/^B0>"/\ P0VW_P 11_PQ[\#/^B0>"/\ P0VW_P 10!_-M17])/\ PQ[\
M#/\ HD'@C_P0VW_Q%'_#'OP,_P"B0>"/_!#;?_$4 ?S;45_23_PQ[\#/^B0>
M"/\ P0VW_P 11_PQ[\#/^B0>"/\ P0VW_P 10!YO_P $P/\ DQWX;_[M_P#^
ME]Q7U/6/X3\'Z'X"T"UT+PWI%EH.BVN[R-/TZ!8((MS%FVHH &68DX'4FMB@
M#\)_^"NG_)YNK_\ 8(L/_15?%]?TS>-/V>?A?\1]<?6O%7P]\,^(]7=%C:^U
M32H;B9E4852[J3@#H*PO^&/?@9_T2#P1_P""&V_^(H _FVHK^DG_ (8]^!G_
M $2#P1_X(;;_ .(H_P"&/?@9_P!$@\$?^"&V_P#B* /YMJ*_I)_X8]^!G_1(
M/!'_ ((;;_XBC_ACWX&?]$@\$?\ @AMO_B* /YMJ*_I)_P"&/?@9_P!$@\$?
M^"&V_P#B*/\ ACWX&?\ 1(/!'_@AMO\ XB@#^;:BOZ2?^&/?@9_T2#P1_P""
M&V_^(H_X8]^!G_1(/!'_ ((;;_XB@#^;:BOZ2?\ ACWX&?\ 1(/!'_@AMO\
MXBC_ (8]^!G_ $2#P1_X(;;_ .(H _FVHK^DG_ACWX&?]$@\$?\ @AMO_B*/
M^&/?@9_T2#P1_P""&V_^(H _FVHK^DG_ (8]^!G_ $2#P1_X(;;_ .(H_P"&
M/?@9_P!$@\$?^"&V_P#B* /YMJ*_I)_X8]^!G_1(/!'_ ((;;_XBC_ACWX&?
M]$@\$?\ @AMO_B* /YMJ*_I)_P"&/?@9_P!$@\$?^"&V_P#B*/\ ACWX&?\
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M!X(_\$-M_P#$4 ?S;45_23_PQ[\#/^B0>"/_  0VW_Q%'_#'OP,_Z)!X(_\
M!#;?_$4 ?S;45_23_P ,>_ S_HD'@C_P0VW_ ,11_P ,>_ S_HD'@C_P0VW_
M ,10!_-M17])/_#'OP,_Z)!X(_\ !#;?_$4?\,>_ S_HD'@C_P $-M_\10!_
M-M17])/_  Q[\#/^B0>"/_!#;?\ Q%'_  Q[\#/^B0>"/_!#;?\ Q% '\VU%
M?TD_\,>_ S_HD'@C_P $-M_\11_PQ[\#/^B0>"/_  0VW_Q% '\VU%?TD_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>forms-4_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_002.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #5 Z@# 2(  A$! Q$!_\0
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M]C'0;[6WU+5-?O\ 49+OQA_PF.IHT,:"^GC4K:P-@?+'#GC'+<YZ\>Z>*?\
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M/P8USP'J/[._B18_B'=:W!;#1/#NMR:C%?VS$^8)X_,<8SM'..&/ID>_^/\
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M\/OC-I?PT\,_#F?QGJ5_H2ZE9I:Z@(7\PEAM?>NU8U"9+EL\]#4OC#]K+7=
MUGPSX(T[P"NJ?%34M+74]1T*35XK>STE.XENF!!.0<!1SQZC+_K\_P#(/Z_+
M_,^DZ*\3^!7[2#_%/Q9XC\%>(O#C>$?'.@1QW%UIR7J7MO- ^-LT,Z !ER0"
M" 1D?ASW[=FG_$+4?@W#'X!75)8UU&)M<@T%RFH2Z?@^8L!'.<XR%YQ[9I-V
M2?<:U=CZ+#JQ(!!(ZX/2G5^>_A;PA\#_ !U>Z(GP.^(-]\*?BE:7,;^3K<]V
MMS= 'YX;BVGD"REO12>_!!KZA^)OQE\<>'/%]GX1\%?#._\ &>KM9B[N]6NI
M_P"SM(@[;/M#*P:0\G8.1D>^*M8FY[/6%;^//#-WXED\.P>(=*F\01J7?2H[
MV-KI5'4F(-N '?BO#O!7[3GB3XG>%/B'IND^!TTWXF>#IUM+[0+[55%L2V?W
MD=TJ$$ *Y'R]AZYKP3]@2_L_ GPEUWXE^)_"&BV^C6?]H7MSX[><3:K-*) '
M@,93<%(R 0_S$#CYJ2W=]DK_ -?UY#>RMO>Q^A-%?(4G[<OBBP\)P?$'4?A.
M]I\,92DG]H+K]O)J<=NSA!.UF!G;R#MW9P1]:Y'X_P#QB^)X_:=^$:^%;2-]
M#U$33Z+90Z^\%MX@A:)'W72A,1;=WR@A\^U-*[2[Z";LFS[KHKQ#P/\ M$7V
MK?M ^)OA5XG\/P>']1T[3(=6L+R*],R7T+!?,P"BX*%L<$_=;IBK7[-GQ]N_
MVA;'Q7K,6@)I/AO3M7ETS2KW[297U!(S\TI7: @Y7 !/4\\4EKMZ_C;\Q[?U
MY7_(]C:1$/S,%^IQ0KJXRI##U!KX)_;U/AD_M-?!E/&MO=7OA-K.\_M&ULTF
M>25-PP D/SGYMOW>:YOX?WG@N/\ :T^'5A\ Y-;\*Z<ZS2^)+'6IKJUM;RV&
M,+%!=-ODD^]]T''RD8VDT0]ZWFVON"7NW\DG]Y^CE%?.OQ"_:KU*U^*6J?#S
MX<^#HO&GB'1H$GU:YO\ 5HM-LK/=C;'YC@EY"". ./P.&^&_VU?#ES\+?'GB
MGQ-H]WX;U;P//]CUK0_.2X<3L<1+#*N%D61N W'?/'-*ZM<=M;'T92;@& R,
MGD"OCWQG^VG\2_A_\+&^(&O_  0;3O#UX(6T^9O$$3NJR$;/M,8CW1[E/! /
M) (&:W_$OB[P_?\ [:'PEM[OPM+-XCU'PQ/=VVM+JTR):1E9&:(VP&R3."-Q
M(/S=.!56UM\OP;_0ENRO_6Z7ZGU)17RIX?\ VN/B#\0-;\?:-X)^$8\07OA3
M5YM/EN)-<CMK=XT9@IRZ;C*VTG8H( QEJT++]NGP\_[-%Q\6KOP]J%N]MJ!T
M>;0UD5I!>[@HC\T@*$Y!WD# [9XJ4[J_I^)5K.W]:'TW17S]X._:"^(;^,/#
MFE>-/A)<Z5I/B$[;/7O#NI#6+6V;&0+HQQ@1 Y'SY*_4 D?0-58FX4444AA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\P?L/?"+Q-\*(?BC_PDN@G0WU;Q//>6.YHF\ZV.=C#8QPO)P#C&
M3Q7T_10M&WY6_%/] >JM_77_ #/DJV\#_$[]F_XW?$7Q/X1\$K\2_"7CBYCU
M&2VM-2AL[VPNANW*1+A60[FY!]/0YI>"/V8?''BGPS\=/$7C%;'P_P",?B9;
M-;6^DV\_GPZ=$L;+$LDBC#,21DKG &>IP/L*BILN7E\K?(=VG==[_,_/SQ9X
M.^/'B?\ 9&;X,GX/BVN],LK>SDU<Z[;,EVD,JLOV>,')8[1G>5 &X]<"O3I/
M@[XS/[2OP"\2#0I?[#\.^$VT_5;SSHMMK<&!E\LC=N8Y(&5!'O7UK16B?O<W
M6]_P:_4AJZY?*WXI_H%%%%24?*WCCX3_ !#^#_[0VL_%OX9Z':^---\2VD=M
MK_AF:\6TN/,CP%F@D?Y2<*.#W+>N15MOAG\3/VC/CCX+\;?$/PQ!\/O!_@N1
M[S3-":_CO+V\NSC#RM'\B*"BG&<_+CN2/K.BB/NV\M@>M_/<^:?@+\+?%7A+
M]J;XY^*-7T>2RT#7Y;1M,O6EC9;D(I#856+#'^T!7F6B_LF>+O'/@']HSPQK
M%J?#<_BGQ0VJZ%>7$B/',$??&[!&8A20 <@$9SCBON.BDTFDNRM^*?Z%*33;
M\[_A;]3\_P#PQ^S[JTEAI7A[4/V3O":Z]%Y4-]XDO=9B_LR500))@B$REF7)
M"XZGTXK['U7X%_#K7M2&I:IX$\.:CJ6V-3=W>EPRS$(H5,NRECM"J!SP *[F
MBJN19'SYX]N_CI\//BKJ.N>']+M_B?\ #N_MU5/#2W-O87NF2@ ,8W=0)58Y
M.&8GD], GA?A'\&O&_B7]J@?%_5O ]C\)]&@TI[!M&M[R*>ZU21L_O)_)^08
MR#SS\B=>37U[126EGV_4;UT/C7X1?!3QUX4\<?&SP+K_ (4E;P=\0;V_NXO%
MUI?0F.WCECD55,)/F%SO Z8!![<U4\%Z?\?_ (3?!5_@Y9_"^S\0W-M:W&F:
M;XN@UJ"*P,$A;;++$_[P,H<_+CG _'[5HI6TY>EDONV'?6_G?[]S\Y_C?\)=
M4_9^\"_LL^#]/:VUWQ#I?B5I%$LAAM[B[=ED*;\95-S;0V.G)':O7-:\%?%+
M]H[X[_#C6?%/@-?ASX1\"7KZDS76J0WEQ?W/R[5C\HX"91>3CC/L*^@/B3\%
M?#'Q7UCPEJ?B"&YEN_"^H#4]--O<-$%F&.7 ^\/E'!KO*N[OS/>]_P %_E^1
M'+967:WXO_,*S_$-M)>:!J4$*>9-+;2HBCNQ0@#\ZT**AKF31:=G<^;_ -@S
MX4^(?A7^S]:Z#XRT/^R-:34KN9K:=HY&".^5.Y"PY'O4?[47PL\4>.?B]\!-
M6\/:,^H:7X=\0-=ZI/')&BVL.8L,0S D?*W"@GBOI2BK;O)2[6_ FVC7>_XG
MS1\&?A;XK\-?MA_&CQ?J>CR6GAK7;:R33=0:6,K<,BJ' 4,6&,'[P%>5?$+]
MEC5/"'QT\:>+I/A'IGQM\*>*9Q?);27L=M?Z7<G.]5\TA61B2>.>%Z8Y^[**
MBUK>2L4W=MOJ>*?LO?#B3P)X>UJZN/AIH/PON-3NPZ:5HUW]ID:!5Q&;AP-O
MF#+<(2,&N&_:K^"FN_%7XZ? Z_M_#2>(?"ND7]PVN^?Y301PN8L>9&Y^<':>
M #TKZDHIO5I]A+1-=SD_"OPD\#^!KQKSPYX/T'0;MA@W&FZ;#!(1Z;D4&O&/
M!_PO\4Z;^W9X[\<W.D21>$]0\-VUE:ZF98RDLR^3N0*&W#&UN2 .*^DZ*.J?
M;_*PFKIK^M'<^3;WP!\2OV?_ -H/QWX]\&>#U^(_A?QLL,UWIUMJ$5G>V-U&
M,9'FX5T.6/!SS[<ZWP$^"GC:;X@?$_XH>/;.T\.Z_P",[=+"TT&VN!<"QMD3
M:IED7AG.%SM]#ZX'TY12MI;RM\BKZW7J?#OP0_9Z\?W?[,_C;X"^,/##^&49
M+B2Q\4K?17%M=2O,)(PL:'> "H)) X[9KE_"_P"SMKNF>'K#POJ?[*?A35O%
M%O&EM+XJN-9B73+@# ,\B@F7++DE0,[CVZ5^A5%5?6[\OP%_7WGRAXQ^$OCK
MX.?M 6OQ5^'OA.U\8Z3>>'H= U/PU;7R6D]LL001M;O+A64!$&#@X!]>.[^'
MT'QA^(EGX[NO'UEIOA'1M6LGLM"\,QNES<VFZ,JTMQ<)PQ)(^5>G/M7NE%2]
M59^?XC3LTUY?@?"_PX^%?Q3TG]C'QW\'-6^'T]EJ]EI]Q%IM_'J5O+%JLDLS
M/MC ;*;01RY .16SK?[.WQ"L_A[^S]XN\-Z9;3^._AU91Q7?AO4+E8ENHVC5
M98EE&55QM.#G!SUX&?L^BJ;=[]=/PO\ YBLK6Z:_C;_(^2;OP1\3OVD?C9\.
M?$OBWP2OPT\)>![J34DM[O4H;R]O[H[=J@1954&U>2?[WMCI/V6OA?XI\!_%
MWX\ZOK^CR:;IWB'Q"MYI<[RQL+J'][\X"L2/O#A@#S7TE126FWG^-O\ (3UW
M\OPO_F?-_P"Q%\,/%/PN\*^/;7Q5I$FCW&H^*[W4+5))8W,MN^W9(-C' .#P
M<'VKI_CC;?&31_%GAWQ/\-)K+Q!HEFKQ:QX,O7BMC>@YVRQ7#*2KC/W20/E7
MKR*]IHH>MO*WX*P^_G?\7<^*?%'PQ^(_[17QI^'7B:Y^%MO\)+?POJ2ZA?:[
M=:E;SW]XJD'R$$')4[<98X^8_0\S\'_&GC;P3^TS^T?=^$? )\?0OK<2W5K;
M:I%9W$+?/L*B7Y74_-G!R,#KFOORN#\"?!7PQ\.?&?C'Q3HL-S'JWBRY2[U-
MYKAI$:1=V-BGA!\QX%$='Y6?WNW^0I:KST_"_P#F?,?A7]C[QCXY^#/QG'C*
M6S\.>-?B3J2ZJEE;R>=#IS1.9(4=ESG+$AMN< CJ>*Y3PQ^SWK TK3/#FH_L
MG^$Y/$,0BM[SQ+>:S%_9DR@@/-L0F4LRY.T#[Q_"OT#HH6CT\OP&]=_/\3Y2
M\7_#'Q]\&/VC;_XJ> O"4/CK1-<T2#2-1T"WOH[.ZM&A"+&\+285DQ&@QG/7
MV-'C+P]\<?BU\"_B]'XJT:QTV77+ V_AKP;92Q2W-N.,F>YR$9VXXS@8-?5M
M%)JZY7Y_B-.S37E^!\3_ !&^"7Q2O/@5\#M+L-&N=8TWPY:PIXK\$6^K"PFU
M +&@$?G*P5@I#@KNP=V>>V;\(O@5XLT+]K+P;XXMO@]%\-_!R:3=6LUK::G#
M=O#*R.!)<8;AF)  3<  ,G.:^ZJ*OF]YR[MO[R+>ZH^5ON/A[P5\!/'^F?!;
M]IK1;KPW-#JGBK5;VXT6W,\)-Y&X.QE(?"Y_VB*Z#4_A+\0;;]G'X3>'Y?AY
MX>\=6.DV$4'B/P=KGEK=DA  UK<%MB2*<CKSD8/6OL&BH2LK>GX&E[N_K^)\
M@_LR?"#QWX3^-%]KUEX;U/X7_"]].,#>$=5U[^TS<7>>)HT#N(0!_M9//KQH
M_LK_  _^(/P6^*WQ'\/ZUX.:;PSXAURYUNV\56]_"8%5ON1F'/F;C].#GV-?
M5M%5U3\K?C<CI;SO^@V2))5VNBNOHPR*A^P6O_/M#_WP*L44AB*H10J@*HX
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M?A;_ "/G/]E_X7'PQXBUSQ _P5T+X203VT=K9I;7RW6HS+NW2";R\QJF50@
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M)#K/_0'OO^_)H_X2'6?^@/??]^30!W6\>U&\>U<+_P )#K/_ $![[_OR:/\
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M^31_PD.L_P#0'OO^_)H [K>/:C>/:N%_X2'6?^@/??\ ?DT?\)#K/_0'OO\
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M *%703?\>!^E &7X#N&GO]:!.0KQX_)J["N)^'G_ "$==_WXOY-7;4 %%%%
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M)_Z[Q?\ H8H O^')#):(3Z45'X9_X\T^E% %K6O^/5_I7/\ PX^]K7_7RO\
MZ"*Z#6O^/5_I7/\ PX^]K7_7RO\ Z"* .THHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **Y+XC^/K;X>Z']OG@>[E=O+AMXS@NV">3V  Y-?-NO\ [4?C
M.Y622TCL-)@;(18XO-?_ +Z;(S^%>-C<VPN DH56^;LE_2.[#X*MB5>"T\SZ
M_HKXRTW]I[QO;QJTEW;7I7!9+FV7GVR@6OH[X0?% ?$S1IYI;,6-_:E4N(D?
M?&=PR&4]<?45.#SC"XZI[*FVI=FBL1@:V&7--:>1W]%%%>V>>%%%% !1110
M4444 <'XR_Y&_3/^O=O_ $*M^;_CP/TK \9?\C?IG_7NW_H5;\W_ !X'Z4 8
MWP\_Y".N_P"_%_)J[:N)^'G_ "$==_WXOY-7;4 %%%% !1110 4444 %%%%
M!1110 44A.* ?8T +129HS0 M%%% !1110 4444 %%%% !1110 5Q7Q%_P"/
MK1/^NLG_ *"*[6N*^(O_ !]:)_UUD_\ 010!L6__ "#Q_NUS_A'_ )'74/\
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M]JK?O$58@ Q'7!)(!]J_.#4_&$WCS6=4U_Q7J%_JFN:@/.-V2&+R'L<]$ X
M'0<5VWP6\3>(_A[XHMO&7A/4FL9]-N8HY QP)XW;!C=1PR$9R#TX(YKS/;?O
M>:Q]PLM;P3HJ>N^WX'[C;OK7YF_M#?M,>$X/VO+;4;C1)-5M_"M];V@O;<QR
M1RA>9,@R8;:S'#<8(.0<"O2_^"E7[07B/P%X.\*>$= N'TH^*H99K^^MW*RB
M! N84(Y4,7Y(YP,=Z_.!ETI--MQ#-/)>,&\Z-X@$'/&UL\Y]Q5XFK;W;;:GF
M99E4<7#VE9V3T7^9_0#974=]:Q7,+B2&9%D1U.0RD9!!'7@U/7Y]?\$V?C+X
MLG\3:M\+M;NC?Z3I^F+J.GF9]\EHI91Y0;NA#@@'[N..M?H(*[(2YXW/#Q6'
M>%JNDW>PM%%%:'*%%%% !1110 4444 %<M\2/^19/_7>+_T,5U-<M\2/^19/
M_7>+_P!#% %OPS_QY1_2BCPS_P >4?THH M:U_QZO]*Y_P"''WM:_P"OE?\
MT$5T&M?\>K_2N?\ AQ][6O\ KY7_ -!% ':4444 %%%% !1110 445@^+/&N
MD^"[1;G5;M;=7R(XP,O(1U"CO42G&"YI.R&HN3LEJ;U%?.OB']KO3K6[-M86
MD<>0-LEVYY/^Z.GYUSFI?M4^(%;_ $"UMKT%21]G,;8?LI!.>>.1FO+EFN%C
MM*YZ"R_$M7Y3ZLS2U\M:+^T3XVO@K75E;V61N)E1"H_V<*2<^_%=IHO[2 BD
M6+6],V=OM%J3M/.,[3T_.B.:X26\K>I7]FXKI"Y[C16+X9\7Z9XNLVN--N1,
MJD!U(PR'MD=JV2<5ZL91FN:+NCSI1<7RR6IXM^TW((]&T3@D>?,<#K_JC7R-
M/<I<O)$@2+:<[CGC\L']*^E?VM?$/[O0M,L)+:XNTDEEN89'/[I"F%+*.N3_
M  ]Z^;)%NX[V1CXDD194P;6VMHXD3\PS'\37YIG<(U,;*5]DOR/I\OFX4+)%
MV58X=*039 [L"<'_ +ZX-?0W[)\\;7VNK #Y)MK<C*XY!<$<<?K7SI&NJBV.
MSQ!<Q1C!\MTC9&]B"M>X?LR^(TTKQ?/8:A=VJ&^LPD#+'Y1>0/D(0"5)P3@\
M>E89/%4L="3>FOXHO'3E.A)'U312+TI:_5#Y,**** "BBB@ HHHH X/QE_R-
M^F?]>[?^A5OS?\>!^E8'C+_D;],_Z]V_]"K?F_X\#]* ,;X>?\A'7?\ ?B_D
MU=M7$_#S_D(Z[_OQ?R:NVH **** "BBB@ HHHH *@N[ZWT^W>XNIX[>!!EI9
M6"JH]R:P_'7C:T\"Z(]]<J9I6.R"V0_-*_H/0=R>U?+/BOQ=K'CB_:?5;MF0
M-F.U3(AB'H%[GW/-4E<B4N4]W\0_M!>']+E:'3HY]9E!QO@&R(?\"/7\!7&W
MOQW\2:@1]DMK73D/HAD;\SQ^E>56R",<*6QW'%:MFK-MXQ[FM.5&3FV=DWCK
MQ-J$FZ76;E%_NQ$(/T%68=:U61@9-1NWSZS-_C7/V4)([@=,>M;-DA. 5(]"
M>].R)N;MIJM_& PO;H'U,S'^M;-EXIU>,_\ ']*WLX#?SKG8(Y%C;#$>G&:O
MVP(7EN?I3L%V=C8^.+\#]ZD4X'4[2A-;=EXTL[DA9E>U8\9?E<_45P4"OLQQ
MQ^%2;V _NG/<=:3@F6I,]7CF250R,'4\AE.13NM>;V&JW.F.'@D.WJR'E6_"
MNXT?6(M7M?,C^5UX=#U4UDXV-5*YHT445)04444 %%%% !7%?$7_ (^M$_ZZ
MR?\ H(KM:XKXB_\ 'UHG_763_P!!% &Q;_\ (/'^[7/^$?\ D==0_P"O7_V<
M5T%O_P @\?[M<_X1_P"1UU#_ *]?_9Q0!WM%%% !1110 4444 %(QXI:0]/:
M@#YZ^,7[7VC_  L\:W/A.+36U#6+:..2;SKE844.NY<<$MQ7D6L?\%!/%5M>
MM%I_@"WO8@,K(ER6!'X'/Z5[-^T[X3^"UIH4GBSXGZ'97EPJ"WMYH]RWMRW\
M,4>PAG//?@>PK\I_&WACQ1X;\07,<5[I>G6UR6N+.TC9IC'"QRD;.#U (!SW
M!KYW&3Q5.;<:B2_+UT/T+),'EN+A!5*,I3^5I-;V]^+=MW9:=3[NLO\ @H1X
MJEO8X[GP';6\#D+YLLYC /OEC7IOPU_;9T?QEXTTKPOJFF+IVHZG.MO:O:W:
MSJTA!P"N 0.#SS7Y3Z;X:\6>(M9CTQ-4L%N';;\R,%SC/+'I7Z=_L>67P4U+
MR3X?\*:9H7Q%TR()?0SL9[D.%PTL,CDY1N3\N",X(%9X2IB:LU>JFO3?\#HS
MS+\OP,&HX>496\M.EW[\G:^FUKZ'UJ!GJ*=35(/0YKE/B7\4O#?PC\+W&O>*
M-2CT^PBX0'F29^R1IU9CZ#\<5]*VHJ[/SB$)5)*$%=O9(Z6]U"VTVTENKNXB
MM;6)2\DTSA$11U+,> /K7X]_M7^-%^(GQ]\4ZU;7'VS31,MK:75KA4FAC4*I
MP>O?YNXQ74?'S]KWQ?\ &CQ ALXCI?A>TEWVFB>;M\X@_+)<, 0SC@@8*CWZ
MUXQ>:C<7>JOJ^HL)KB67SI8OX6)Z]./TKY3,<=3KQ4*;Z_U\C]?X<X>Q.78C
MZQBH?9OTT;>WK;730B@MD&D32EKG>Q4)MM8G0COELY'X"KW@"X%G\0/#C2,W
M%]"V)(UACX<?><#('TH@T.ZNK%+@:FHN67>8+@&,,,Y 5^5Z= <5O2^,=-B\
M165O?>'AINF0" F'88Y"Z$$RDY;[_<@XYXXKRZ<?^7ETDCZS'8B\986--RE-
M/5:))+;7=]NY^SULRRQ)(I5@R@AE.01CM[5-7&?"CXCZ%\3?!UGJ^A2+]FV+
M');%@7MG '[ML>W0]",$5V=??1:DKH_G.4)4Y.$E9H****HD**** "BBB@#C
M?B3_ *G2?^OO_P!D:M2Q_P"0>/I67\2?]3I/_7W_ .R-6I8_\@\?2@#G_#G_
M "/DO_7J_P#Z$M=]7 ^'/^1\E_Z]7_\ 0EKOJ "BBB@ HHHH **** "BBB@
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M &Q;_P#(/'^[7/\ A'_D==0_Z]?_ &<5T%O_ ,@\?[M<_P"$?^1UU#_KU_\
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MHH *XKXB_P#'UHG_ %UD_P#017:UQ7Q%_P"/K1/^NLG_ *"* -BW_P"0>/\
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M  X^]K7_ %\K_P"@BN@UK_CU?Z5S_P ./O:U_P!?*_\ H(H [2BBB@ HHHH
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MGX>?\A'7?]^+^35VU !1110 4444 %%%% !1110 4444 )C-%+10 4F,TM%
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M_P M"ZN9))1\N?E "KGOS7W;733BXQ29Y6*J*K6E*.P4445H<@4444 %%%%
M!1110 5RWQ(_Y%D_]=XO_0Q74URWQ(_Y%D_]=XO_ $,4 6_#/_'E']**/#/_
M !Y1_2B@"WK(S;/]*P/ATA5M9SWN%_\ 01747L'G1LOJ*YNWDN/#AN?L]H+G
MSGWG+[<<8]#0!UU%<8_C755/&BH?^W@__$TW_A-]6_Z B?\ @0?_ (F@#M:*
MXK_A-]6_Z B?^!!_^)H_X3?5O^@(G_@0?_B: .UHKBO^$WU;_H")_P"!!_\
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MG_@0?_B:/^$WU;_H")_X$'_XF@#M:*XK_A-]6_Z B?\ @0?_ (FC_A-]6_Z
MB?\ @0?_ (F@#M:*XK_A-]6_Z B?^!!_^)H_X3?5O^@(G_@0?_B: .UHKBO^
M$WU;_H")_P"!!_\ B:/^$WU;_H")_P"!!_\ B: .UHKBO^$WU;_H")_X$'_X
MFC_A-]6_Z B?^!!_^)H [6BN*_X3?5O^@(G_ ($'_P")H_X3?5O^@(G_ ($'
M_P")H [6BN*_X3?5O^@(G_@0?_B:/^$WU;_H")_X$'_XF@#M:*XK_A-]6_Z
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M/_Q-'_";ZM_T!$_\"#_\30!VM%<5_P )OJW_ $!$_P# @_\ Q-'_  F^K?\
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M%Q:BU\++</>120Q^8Y>VFBCE\O9\PE"E#@C.1BCI</(^GO\ A\Y\9O\ H5_
MW_@ON?\ Y(H_X?.?&;_H5_ W_@ON?_DBODJW_9T^*%WXLN/#$'@#Q#-X@M[1
M;^73DTZ0RI;,0%F(Q_JR6 W],]Z@E^ ?Q(@T;3]6E\#:_'INH7$5K:W3Z?($
MFEE?9$JG'\;<+_>/3- 'UY_P^<^,W_0K^!O_  7W/_R11_P^<^,W_0K^!O\
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M3O(]LU*=QO3<^J_^'SGQF_Z%?P-_X+[G_P"2*/\ A\Y\9O\ H5_ W_@ON?\
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M_P D4?\ #YSXS?\ 0K^!O_!?<_\ R17P-10!]\_\/G/C-_T*_@;_ ,%]S_\
M)%'_  ^<^,W_ $*_@;_P7W/_ ,D5\#44 ??/_#YSXS?]"OX&_P#!?<__ "11
M_P /G/C-_P!"OX&_\%]S_P#)%? U% 'WS_P^<^,W_0K^!O\ P7W/_P D4?\
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M18:/?6OB-==A\/KIEY83Q@7#*[2B24KLB\I5#,K$-M;(! -/K;^M[?F'2_\
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MRM=8L9M2M'O].CG1[FUCE\IIH@P+H'P=I(R-V#C.<&NL_P"%$_$K_HGGBO\
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MH?B-[32]&T+QHEI)8^$Y9;B+S+J+4"YE*QCS JJD*E7._..?G?\ X43\2O\
MHGGBO_P27/\ \11_PHGXE?\ 1//%?_@DN?\ XBE&T;)_U_7X=!RUU7]?U^/4
M^M/%7[5GPO\ "GQP\=ZQ:+XE\30>(O%NGS:JLT%NMM;Z9IMVLT<-KMF/G%V@
MA"N_EA8P1@EC7 _"O]K[0O!\MGJ6N6&K:EKC^-K_ ,:7\\:QN)9OL,D6GH"S
M@G9<32.Q., C;D\5X3_PHGXE?]$\\5_^"2Y_^(H_X43\2O\ HGGBO_P27/\
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M$\\5_P#@DN?_ (BC_A1/Q*_Z)YXK_P#!)<__ !%)*UK=/^!_D@?O7OU_X/\
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MZ2%-&ATZPDMA*8I$D=IQ+]B4)\B!1([?,<5\J_\ "B?B5_T3SQ7_ ."2Y_\
MB*/^%$_$K_HGGBO_ ,$ES_\ $57,^;F7]65E^OWLBRY>5_UK=_C;[CV']IK]
MJ#3?BSIOB"U\.7NHBW\2ZX-:U.TO?#VFV&"@?R5>> M+<R(99%\QB@*G[N3Q
M;^&G[1'P\^'_ ()CTXKXMU/3)=*D@U+X>ZI%;7NB7NHM$T?VI)W?S+=2Q63$
M<7F H ),8(\3_P"%$_$K_HGGBO\ \$ES_P#$4?\ "B?B5_T3SQ7_ ."2Y_\
MB*SY4DTNO^5OR+NVTSV74_VIM!AN_%LNCVVLP+)\.+'P%H!?8C0!5MUNY)=K
MG:K[+G&W)/FC('.-#4OVF? GBSP7J?@34D\2Z+X=N/#OAS1X=6TVV@GO =.6
M1IXI(FF16AEFGD<8D!!CB)4]!X5_PHGXE?\ 1//%?_@DN?\ XBC_ (43\2O^
MB>>*_P#P27/_ ,15/WM_ZU;_ #;$M-OZV_\ D4?5NG_M^^%;:VUC2U\/:U9:
M3X@N5T[4;N"2-M3MM)M]*CL+*6WN-ZXO 1))(<!6#;,X8FN+E_:YT6T^%/AS
M2]%>_P!$\2:!X8N/#-O%%X=TV>*7S6E$DXO92TT*RQS/YD2H?F)(< \>#?\
M"B?B5_T3SQ7_ ."2Y_\ B*/^%$_$K_HGGBO_ ,$ES_\ $4/WKWZ_Y6_5_?Z
MO=M;I_P_^1W?PK^(_P /M.^ _BCP%XKNO$FF7>N:]8ZG<7>AZ?!=":UMHI0D
M'[R>/8QDF9MV& VKP:]3T[]L_P )ZGH'B+PK?:'=>'/#+?V1:Z-Y>D66O2)8
M6$4L:VUQ'=%$9W:5I_-7[LC-A2#7SC_PHGXE?]$\\5_^"2Y_^(H_X43\2O\
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M$/AK6-"BGTVT6)]3L);=9")7R%+J,D9'2IBE%)(IMR=V?JO7YS?\%MO^2%>
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MQ_:Z\!VTEC8RZ/KDNB0_\(?ISQ&&$N=-TK=/>)CS,%YKHAE!XVC)(/%?.O\
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MDP:IK=EK<>KZ!:PW<C^1%-&;>6*66(;<3%U8/PPY!%<A_P *)^)7_1//%?\
MX)+G_P"(H_X43\2O^B>>*_\ P27/_P 13[^?_#_GJ+MY?U_P#VKX@_M3>%/&
M?@[4_#5IH^L:7I5WJ>@62P[XW9=!TNV>)(F<,NZ>221I6& @;'/%=G-^V]X1
MO/BEH?B*?2]<6QB\9Z]XJO-L4)F0W%LMKIOEKYF':!(T9@Q7G(!.<U\Q?\*)
M^)7_ $3SQ7_X)+G_ .(H_P"%$_$K_HGGBO\ \$ES_P#$4/7?^MO\D_4-E9?U
MO_G8XV\\K[9/Y$DDL'F-Y<DJA79<\%@"0"1U&3]34-=Q_P *)^)7_1//%?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>forms-4_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "2 -L# 2(  A$! Q$!_\0
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M)10.P4444 %(:6B@!#10?K12& R32E@>JY[=:3/O^5+CWH$T(2O]S]:1AAF
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MK=P1SV\HVO%(N585TT:\J>G0SE&Y\ER.SH@8_=X_"O<_@]DZ1J7'_+:/_P!
MKDO''PNN-'\S4M$62YT\?,\/WI(!_P"S+[]1W]:Z_P"$ ']B:@1CF:/_ - K
MHKSC*"<2H7M*_D>C<TM+17$,3DGDYI:**06"CO113N%@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH #2445+&)0.U%%9@!H[T45:$!X(Q2K;P6P"6\,<2
C'G;&H49_"BBFA=1>U%%%,H**** "BBBF(**** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>forms-4_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "9 + # 2(  A$! Q$!_\0
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MT'H*\W'8WZNDH_$ST,%@_K$FY?"CHI/&C[_W5F-O^TW-7K#Q9:W+B.X0P,>
M2<K7$5<TS39M3NQ#'PHY=_[HKQJ688J4TD[WZ'KU<!AHP;:M;J=[J.FVVK69
MAF'O'(O5#Z@UY]JVH?V-(//!&L6\V8R@PI3U_P!UJ]'@2&TCAM%;&%P@)Y(%
M<9\2=-5["WU)%^>)O+<CNIZ?K7U,7=:GS+WT.QTV_BU/3H+R$_)*@;'H>XJ#
M7_\ D 7W_7%JYCX:7QETRZLF.?(DW+]&_P#KBNGU_P#Y %]_UQ:F(O0?\>\?
M^X/Y53UNS>_T2]M8SB22%@A_VL<?K5R#_CWC_P!P?RHFEC@A>65PD:#+,QP
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MM<U_5-.9((#8R-&8&8B?@X#$'@J1R"*U-?\ ^/*#_KZA_P#0Q5/2M MQJ_\
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M07,B$N^YV0"10H'RGMGGKZ4 ;E)FLI;JZ.F76&+S02&,.%^\ 1SCUP?TK/\
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)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>forms-4_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "2 +8# 2(  A$! Q$!_\0
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MCGCO?#Q>-YHF,MF5/"GNF3[5GZ#*DOVG1KKA+H80M_RSE'0_TJE/J5Y+J@U
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MVD6FRW *PBV=/NDX/I0!M3:I80$>;<QKP&!/3!Z'--EETV[G2WF,$TH(94<
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M1110 4444 %%%% !1110!'%$D*;(U"KUQ4E%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>forms-4_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_006.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #3 Z@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]/=9U#['
MS9Z5\'_%7_@HO+X%^(/B'PS'X,EO/[)O9+/[4-2""7:<;MOEG&?3)K[;\9,5
ML9,'M7XO?M!VIE^.?CMSR3J\Y_\ 'J^FR'!4,=6G"O&Z2ONUU\CY_.<95P5*
M,Z3LVSZ6_P"'G-T>G@B7Z?VH/_C5'_#SBZ_Z$B7_ ,&8_P#C5?%?V,XR?RI1
M9X/3-?:_V!E__/O\9?YGR/\ ;V,_G_!?Y'VG_P /.+KG_BB)?_!F/_C5+_P\
MWN@,GP3*/^XF/_C=?%?V,\\<THL^.G(H_L#+_P#GW^,O\Q?V]C/Y_P %_D?:
M9_X*;70_YDF7_P &@_\ C5!_X*;7?_0D2G_N)C_XW7Q<+/CIS]*7[%QTH_L#
M+_\ GW^,O\Q?V]C/Y_P7^1]H#_@IM='_ )DF7/\ V$Q_\;H_X>;71&?^$)E_
M\&8_^-U\8_8\]J!99R<?I1_8.7_\^_QE_F+^W\9_/^"_R/L\?\%-;O\ Z$F7
M_P &8_\ C=*/^"F=V?\ F29?_!F/_C5?&'V/_9_2E^Q]?ESGTI?V#EW_ #[_
M !E_F3_;^,_G_!?Y'V=_P\TN_P#H29?_  9C_P"-4G_#S6Z_Z$F7_P &8_\
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M_@S'_P ;I#_P4SNP<?\ "$R_^#,?_&Z^,A9$C@9H-B=W(P:/[ R[_GW^,O\
M,'G^-3LY_@O\C[-/_!3.[_Z$F4_]Q,?_ !NC_AYI=XS_ ,(3+_X,Q_\ &Z^,
M38GTI#9G\*/[ R[_ )]_C+_,/[?QG\_X+_(^SO\ AYK=\_\ %$R_^#,?_&J/
M^'FMWC_D29?_  9C_P"-U\7FS/IUH^R<GCFC^P,N_P"??XR_S'_;^,_G_!?Y
M'V@?^"FMV/\ F29?_!F/_C=!_P""FMV/^9)E_P#!F/\ XW7Q<+3';BE^QX(X
MH_L#+O\ GW^,O\P_M_&?S_@O\C[0_P"'FMWS_P 43+Q_U%!_\:H'_!36Z/\
MS),O_@S'_P :KXO^QGC(P?6E^Q>V:/[ R[_GW^,O\P_M_&?S_@O\C[/_ .'F
MMU_T),O_ (,Q_P#&Z3_AYM=?]"3+_P"#,?\ QJOC#[#CDC/%'V'*XQSZT?V!
MEW_/O\9?YA_;^,_G_!?Y'VA_P\UNLX_X0F7/_83'_P :J6#_ (*=W$;Y;P-*
MPSVU0?\ QJOBO[%CM1]BPO(H_L#+O^??XR_S#^W\9_/^"_R/VD^ 'Q@_X7#\
M.]$\4?86TS^THWD^R-+YICVR,F-V!G[N>G>O3=0O?(MRV<8%?,'[#>4^!/A%
M.@$,O'_;>2OH[7V_XE[_ .[7Y;BH1I8BI3ALI-+Y,_2<--U*$)RW:3^]'R#\
M>_V[9/A'\1]0\*KX4EU-;2.&0WJWXB#>8@; 78>F<=>:\Y3_ (*5EY"I\)RQ
M\\9U$?\ QNO%OVS%CD^/.OEI$\T):%8R,EOW*]?4>U?.VKP^6]W/%NCEW,3!
MC!3+?RKX[$8S$2J3ITI<KBWT6J^:/4C3BHIM7/OX?\%%V>YDC3PR[1+TE^WC
MYCCT">M3+_P4,N&CC?\ X1:0ACAL7V=OI_RSK\\-+U22.<"0G#8R5Z'C-=UH
MNJKY@=\J@.6*]>G<>E>+4S#,(-+VOX+_ "-XTZ4OLGVI+_P4+O88I';PD_RD
M  :B.<YY_P!7[4EU_P %#+NU;!\)N5W*I;^T0,9_[9U\@RY-NX+;@S*0A'8Y
MYW?YZTKG$SJWF1DR  -E=P'Z&OI\'BJF(HJ4M_P?H9.E%/8^QX?^"@<TC$'P
MQ,HS@$7H(/\ XY5FV_;QOKDKM\+MM.?F&H#C_P <KX^1HY&&R,Q,&!P""OX>
ME6[69[=DVG*@;R.X![_A6>.K8JA27L7>7FEV94*=-O5'V7H_[:6H:SJD%A#X
M=D^T3L$C N]V2?HE=;H_[1^JZG%J,\]E::;:Z?<"VGDNK_'S<E]N$((4#U&<
MBOE7P3M\,>'-;\7M;7!OHHUL;5USM660XW<=..XKWSX4>+E\+?!\Z?'9^6S[
M=1O=2U!$%NDSG]T &4[V8 8'3OG%>1A,9C>6V)J>]:^R^2>B\^QT.A2LK1_$
MZ_4?VCM9TS2->O)=(4RZ6D<L<"7JO]LC?!#1LH(Z$$@\C.*WOAE\6O%?Q$MK
M5YO#TV@27EO]IM!>S?NYD'7]YMPI'7![<UXGX7\(CXG>,-5NIO$5[IEW=*ZI
M>RZ<'A$S]#,58H%P..F"."*^D_AEXHA\ :?I_A;QKIG]CW%F([6WUE)C)8WC
MQJ$5U;K&S#&588YZUZ&%QE6LU*<FH^BL_6VW];F%6C&%TE=GH-CX4URYM8I)
MM4CMY6&6C$6_;^(;FK'_  AFK_\ 0;C_ / <_P#Q57O%_CC2_!'A:;7;N59+
M&(JH,1SN);  Q_GBO)-&_:AFGF9;G08-0A+';+H]^C2;<\9BDVG./0FOHN9+
M1LXE"4E=(]-_X0S5_P#H-1_^ Y_^*H_X0S5_^@U'_P" Y_\ BJR=+_:%\$WS
M+'=ZC+HDQX\O5K=[?G_>(V_K7>:;K-AK, GT^]M[Z$\^9;2K(OY@FJ33V(::
MW.9_X0S5_P#H-1_^ Y_^*H_X0S5_^@U'_P" Y_\ BJ[('-+3$<9_PAFK_P#0
M:C_\!S_\51_PAFK_ /0:C_\  <__ !5=G10!QG_"&:O_ -!J/_P'/_Q5'_"&
M:O\ ]!J/_P !S_\ %5V=% '&?\(9J_\ T&H__ <__%4?\(9J_P#T&H__  '/
M_P 579T4 <9_PAFK_P#0:C_\!S_\51_PAFK_ /0:C_\  <__ !5=G10!QG_"
M&:O_ -!J/_P'/_Q5'_"&:O\ ]!J/_P !S_\ %5V=% '&?\(9J_\ T&H__ <_
M_%4?\(9J_P#T&H__  '/_P 579T4 <9_PAFK_P#0:C_\!S_\51_PAFK_ /0:
MC_\  <__ !5=G10!QG_"&:O_ -!J/_P'/_Q5'_"&:O\ ]!J/_P !S_\ %5V=
M% '&?\(9J_\ T&H__ <__%4?\(9J_P#T&D_\!S_\579T4 <A%X/U5&RVL(W_
M &P/_P 54L-Y)IFJ?8)IA,X17+!<=<]L^U=57 ZTY'CUAGC[/'_-J .PN+OR
M[<MGM7/VT=UXB2X>WO%MA%)Y9!3=DX!]1ZUHZBW^@'Z5E_#EBUKJF?\ G[/_
M * M #6\':L3QK48_P"V!_\ BJ3_ (0W5_\ H-1_^ Y_^*KL:Q_%VN67ASPY
MJ&H:C))%911'S'A&7&?E&T>N2,4 ?-OQ*^-?B;X>:S)8+HJ:MLN#!N@O &QU
MWE0K87&.ISDX]:N/\:KM/#Z:H[0P*X)$=Q.(]V#@ $\GH>W&*^:-<^P:[\2K
M1?#OBB=ELP9)=,FF*M.0V=S!3M QM'4YYR:U/'%_I-Q<R)J&R)XEC5+C3YS,
M\F!\P<,-H.>X/MCC-.6BBNIFF[L]A?\ :><L$@MS</WV287\"1D_E3?^&G+R
M.:*.?3_L?FG"O<W C7&<9Y'3@UX1H&I2^2T.@:4Q*##W,J^=*<?-R2, _0#M
MS6E?RW^I7-YI^J1"XN;&TEO4^T0F0@8Q@%AG#' P,@]::C=BYK;GOGP6^/5_
M\9-;U*RBM1I%K9QF07LLWF))AL = !GKUK8U3XI:U9:X=/M[*2[B#[#= E4Z
M\D<'BO.?V9M/AN?"GB"]\4F.UNC.([* G:1&%S\JCD L<<^E48?#6NMXHE:;
M5=072 [% ;B/)7;QV]:VA%<S3MIW9C4G)17+?7LCV/3O'VLZG<7D*((3 =JO
M*6"OQUSC@5+:^+_%$EW';RZ:X9\XFMI!+%P"3D\%>!W KBM+\.S,H,6N7,4F
M> XCD[^V#Z]ZZ+3;CQ!X?AU*^N9K6ZL[*SEFDN$#;PFW!_=G)W8)Q@GFB45;
M1?<Q1J2OJ_O1GZC\9]8L<SQVD=YIJPRW#WL%QN58T4L3C&23C''YUZ!\/=2U
M7Q\+PI=K8BV6)CE"^[>N1W&,8KYA33+B">?4O#VHQWVCM;L3:(0K23&2-<XZ
M A"Y.,$XY%?5W[/EOL\/ZM-ACOO3&';^)510/YTIQBEH:TY2DKR.B_X0S5_^
M@U'_ . Y_P#BJ/\ A#-7_P"@U'_X#G_XJNSIDK;(G;T!-8&YX%JWCN_TF35?
M,E+Q:?)Y;.B%B_&>%7)/X9JA!\4+^YO;"V0-'+=H9$2X'E,5&.5!Z]1D$@BN
M0\4Z@#I'B6?>J>9?.F\W'V7& H_UO\)]AU_&J.@R!_$>GPP.6BBM_P!X8!]H
MBW<$>8C?/NQT8<$9K>$$U=F,YM2LC<\2_'V_\-^(8])>R:=WG6$3)*&498CG
M;G!&,[>M2>/?CQ=^!;NUAWVNL"=G7=8S.WEE0#A@4R#S^7->(?$&Y\WXLZ5"
MWR,U_ -CQ>2^-Q(P%^7'IGYNF>]:G[46IW2^(]!6_>]C.V8H-5NXV.W.!L>#
MJN<\'D'(Z5NJ47**MN9N<DF[GN<OQ6U--!L]1^SO&;AE&R=E1 "0,A\G<>>@
M&>W6GZ;\4;_4=7N[)9(0+>(2'#MYIR">8RH(''7->:3A(O"FCQP#R;T2)N$5
MB1*HW _<8[4X_C_X%6GX9>Z37]5:6XO9;8Q($$\D;PAMK9VRK\Q/L>!^-9NG
M%1;L4IMR2/>?!EIJOC#0XM234X[99#CR_*+XX'?(SUK=_P"$,U?_ *#4?_@.
M?_BJH_ Z42^ [4@Y^8@Y/.<#\OH*]!KF>YT'SI\7?B-JOPJU_3],8)J/VR(2
MB<N854;RI&,-S@9]^GO7FOA;]KR/QG\3[3P9I-G+<,_FBZU,OBWMBJ,P'3YL
ME=N> ">IK3_;CL[6X\1:#]LN'MK5[%O-DC;:RJLH;(ST]Z\7^&'BV?4/BG%H
M^D>&QHOA.*^=M8OTM^9CD[\MV&2".6;Z=*UY5RW\C)RL['T9!\7]56)9=0AA
MTR$@EI)[D?+Z<8I$^.^FYVR:[9AAU$<RM_6OG6P\':7HGCJTU/6O%%M=7<,[
M^58NQO)Y=RL,').#T. .,5Z-IVJZ?:W3RV]KJTS.P7*V;*O7@#Y1ZXJW"#V_
M!,P4YI:_BU^A[!H7Q/M-?:1;;6XY"B[B(4$I'..0K$@>^*YJ'XU:TLNKB\T[
M[+#81><DRSB3SUWA>% R#@[L'WJWX!\5PP:JT2Z%>M<O RXFMFC?8""?F*8.
M,#C->4W^D/9?$WQ'=7NH@6,J7$PL7;:\$Y^:,'&1R>,@_P 5865VCH4FTF>U
MV7C/Q;J6F?VA9:;#?6X7,D-O=;KF(Y/WHMN<$8((SUZ4WPW\58=;G:SO-471
M+\-M$=Y$?+SZ%P?E/U KSWP/;)K-LLJ^)(-!\3B0M#;2R%4="!M'FC@/G.1R
M.E:^O:I<66JPQ?$#PD;JXV^5#K=JH2X"GTD'R2#OAJQNS0]$\5^(M8\,"+:P
MU!Y$614A95W*202K%L$#'KWJUX$U75?&UU<V[23:7-"@<K<09[X[-CZ$9!KD
MI;+2;3PI;Q:!J-S/:@R-)<W)Q<09PV6W#:,8/"C&*Z3X-7TZ:\L:^(H;^REC
M;,38#,PZ*,<$C).1COQ6BUC?J1=\UNAWO_"&:O\ ]!J/_P !S_\ %4?\(9J_
M_0:C_P# <_\ Q5=G106<9_PAFK_]!J/_ ,!S_P#%4Y/!VK*03K*'_M@?_BJ[
M&B@#E5DGT2_@M;BX%PTJ%PP7;T./7WHJKXL8CQ7I@[>0_P#Z$** )_&G_'C)
M]*_'[XZ:8T_QF\:.%SNU6;^=?L#XT_X\9/I7Y9_%S3%F^*?BQ]O)U&4_K7UO
M#E7V5>;\OU1\EQ'2=:A!)]?T9XD-)D_N&E&D/S\AKT :0I'W:4:0.PK[[ZXC
M\_\ J,NYY_\ V/)_<-.&C2?W#7H T@?W>:<-(&.E+ZZ@^H2[GG_]C28^Y3ET
M:3(^3KUKT(:.,?=I?[)7^[^8I?74'U!OJ>?_ -B2#^&C^Q9/[M=^=+7TI?[-
M4?PBI^N"_L]]S@/[#D_NTHT20]4&:[W^SD]!1_9Z]QQ1]=#ZAYG!C1)<XV?C
M1_8DN?NUWHL$STI1IRGMFE]=0GE_F<%_8<A/*4HT.7^[7?C3EST%/&EJ<<4?
M71?4/,\\_L*3'W0*7^PI3QM%>B'203TQ0ND#TH^NC_L_S/._["EY^2C^PI?[
MN:]&_LD?W?R% T<=<4?70_L_S/.?[#ES]VC^PI/[H%>C?V0.NVD_LA?2G]=#
M^S_,\Z70Y&[8(I5T.7'W1UKT4:.I/04BZ,,<*.IH^NC_ +/\SSP:#*.U']A2
M#W^M>B?V./[HH;1P 3LSCTJ7C#:&#<5RWNNS/.CH;'@C:?\ :%)_PCTQC9]N
M$!P3[_Y!KZ/TKX WMEJNDZG=>)_"D=@H$TUE?3;]P*Y"E20.IYSZ5NVWAB&U
MTK6)+CQ3X)T]$O8XH=4:VC%F,(S&'EL-(-P)P>@KYVOQ+&G)QIKF\SZFAPO"
MI%3JRY;]#Y0ET"2,*3M ;)'/7%">'99+X6:F,W)(&P-D@GU_.OJ74X-,TKPA
MI,%UXU\.:?J5W T\*201;]3#3'8T*ELA7VA1C/-:UW<>'HOB'I^DVOCG2VU>
MUG#7GAN&&,SQJD8,C.>J[ NX_4URRXGJ?9IG5#A7#?:JL^2(/"5Y<&01PNVQ
M68X0G@=<<4V;PM>VL1DEM98H\X\R2-E7/IDBOJC0_'7@6ZO]9U2T^*,&I:-8
M6(%Y>1Q!(]/WR!58$+R6^8=^M4?$'Q9^#VM);PWWQ*>Z2WE,JI]F:92V.<J8
MR.A^HH7%%2^M+3^O(F?"N'Y=*VO]>9\OG19.NT4X:'+CA:]G\3^%[/4[B;6O
M#UX->\/W/[U;ZWAVB+_8D4 ;",CJ!FN=&BA3]VOIZ&9PKTU4CU/D\1E$L/4=
M.5]#SS^PI#_#0="EYPM>A_V..NWG-._L=1_#71]=.;^S_,\Z_L*4?PC'TH_L
M*0Y^7CZ5Z-_9"]A0-(4#@?I1]=#^S_,^Z?V+83;_  9\,1G@K#)_Z.>OH77_
M /D'M_NUX3^R7%Y'PPT&,?PQN/\ R(U>[:__ ,@]O]VOR+&/FQ-5]Y/\V?L&
M#CRX:E'M%?DC\B_VR]@_:%\0,S!E$5GN7."A\I2#7CM_:IJ2M=VY*AF."W56
M/K[&O9?VR(\?M!>)> 5EMK59%]<0KBO*GECL+NXMC@H=I#;<*,C/(_&OSS,,
M+B/;2KP77\.Y]#1<>5)F1<Z1%/-'-Y8MY J[XTZ$A< CZ]:T-/TB?3KM8V19
M&W8*YZ@K_2K%^JL(BJ^6&B0@9S^M;##_ (G$AZA0Q_\ ':]2."A6A&556EUL
M9[-V(([E8[&V@DD1)#+M4%@-P '(_.IK"&&SENQ';"-97)=,NHSG.0N<#Z@5
M2O;&VOK*".[LHKN(2M@R1;@IP._;\ZUX6C9!&+<)LB(4HY& !P,'->A1I0HQ
M5."T0FWJR6, EBJE00&VYS@X)Q6WIMLLEZ,C<NT9'MWK)C3DX/4@9].!_C7H
MWPL\/MK?B:U0!/)#J\IDP (UP6ZULPC=L]>MO!\]]X?\(>!K&9TO-?NPTK.A
MVQQD!M^WOMQU]JG\-Z4GBOP/:V^OZH%NY+N:>&]CC9E5Q*(1(X')"I'@9& Q
MZUZK^SAI'_"8?'O6]8?,EEX9M/L5LY4 %W/48XZ%L8]J[?\ :Q\,VVB>!Y?%
M.GZ=)>7UOY=L=+@(CANE:4-F3:-WR_.P (!)YS7'6H<])SEMU7D:.KRU.5'@
M7B?PG>:7-;E[*[C>\N9;F" ,2?LT."[2E65E4G:=O8YKZ9^&FHZ;\3K&2QU:
MWL;]8[2)X"CF3RP5YVE@&QG/\L\5PWP4T"ZU?PQ8^&]>>1;V[TUI6>^W/=0M
M([,$W'JNT@$9SG [5['X0^&D?AFXT202W236%L8&6&;-M(,8P5/S>XYXYKFP
M>%<*CJ0^&6Z?]?H@K55R\KW1XS^TEK2_"/PWI>FW,-]KFDZA>-(EO; 7$T01
M>K1OP5R1]TYS7@5CX^^'7B*X6!=0BTZ]8[1!>))8R@^F'#+G\16[_P %!_%%
MKJ7Q-T?1))M+;^S;+>(;^:6!M\AR2DJ<*<  @^U>!>$+;4-2UO2+0QZM]DEN
MXD&9H-5M -P_B/S(/?M7K22C=+8SIW:5SZ*U3P]=VFD74+:UJ$.FLA2>(HLK
M*AX.WDKGZXKSNS^'^HZ).+CPAXX2"4'*I,\EE)_WT/E-?06OQN89#;QS>=L.
M&M8U:3&1T#<'Z5PUU)8O.4OK=9OE+.7TN:&= .I(3@CU(K.,Y+8UE"+T9F:7
M\<_CY\/X5-P)=?LE_CFA2\4C_?0[J[SPI_P4,0.L'BCPHT3CY7ET^;!4]\QO
MS^M<;I-EH]_()=!UQHW)R/L-XC_^.,4;^=>5^+_@=XP;5+N_$]KJKW,AE8LQ
M@D8GV< $_0UT1J-[LYITDM4C[N\*_M<_##Q7L5?$ TN=O^66I1-"<^F[E?UK
MU?2M<T[7;<3Z;?VU_"1D26TJR#\P:_(#5/">N^'_ /D(Z/>6BC^-HB4_[Z&1
M6M\/H/$VH:A*?"][/;WMNOF'R+KR&Z\ '(R?:MN:VK.?DN['Z[9%+7YU:1^T
MA\:/AVRIJDEU?0+_  ZK:B4$?[XP?UKU/PE^W_#($C\0^&2K<!IM.G_]D?\
MQIJ28G!H^PJ*\E\+?M2_#GQ4$5-<&FS-_P LM1C,)S_O<K^M>G:=J]CJ\(FL
M;RWO8B,A[>57'Y@U1!<HHHH **** "BBB@ HHHH **** "BBB@ KS_7/^1_;
M_KWC_FU>@5Y_KG_(_M_U[Q_S:@#H=2_X\#]*S/AQ_P >FJ_]?9_] 6M/4O\
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M?O2>L?D;)\LKF59^)K+0O@MXXU;Q7I^H^*;*6ZL;#[#>:_:R.P):3Y9K5-J
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MCNX]A^H(KR?4[51:SIG+). 0B 8QN[CM]/QKUCXS^(/[3TBWB_X2)=57S$S
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M\^!3!ZE/5[?=I?B-5"+(;2*0&"3YSMF7J#P.OXUS'@J0PZ@R$%2&.?-4#'U
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MT7Y'Y.?M?1Y^/WB _P#3"U_]%+7DLMO.]I9&.%Y@8V'R8)&&/;K7K_[76/\
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M5\SS3NWY[=,?C7WAX+N/,\"^&Q&SFU_LVV\I7ZA/*7;GWQBOSE\>;S^S/\/
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M4368U%YEE4LL#2&-25Z\,#[]Z\!JH]7J>\G%'U WQ"\7QX']F:]GIA+E6_\
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MXTU80!@_W%4GD]"32207+D_Q&OAX@N+6]@MM>T=X%L ]]81V_F0K_JT!V94
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M.0!^-%8_[ &OV?B"'Q5+9V4UEY5U;QS+.26,GE'(Y]./SHK['+HN&$A%KO\
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MK2NQI(MVUKYI(>18_KS5A[&&(@>>&'M6:">.:>"?6LW>^YHG%="TRJK_ "9
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MPZ,UA9LW/C/JP\+_  QT/1+*6?[=JMD\;1DD;X5BYRAZ99E'K7Z#_!CP9#X
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M#8.._45H]8F=+W9:GDW[0GA^>T\67%XO@2+7-/GB25[VVCF282#Y7#/&2,\
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MD#%)TVI'P.!CK]3G\*G\2VVFI*WVBXD@W/N1;9Q*F,=N/H/;WKDA(8]V$WQ
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MN'H.O>OH'X-&_&AZN-3&LBY-^W_(>2".YV[%QQ!\FWT[^M>56>AWT%L>&_\
M!11E;P;X*;Y>+ZX&&)'_ "S7\Z\]\=-$/VI/AZX,)EVZ/N^8A_\ 5KCCH:]"
M_P""B3!/!/@T_-_Q_P XR &_Y9C\J\Y\<3.O[2WP^SYNPQ:,?]6-G^K7//6N
MO#O]VOF<.*5JK?G$C^&$<;_'CXF1@0;GTS6E(C9F/4]1_A7*> &A;]G3XH*1
M:A%OM+.-SF,<D<GK77_#V9T_:#^(H+7 SI^LA0T:J.A(VD=?;-<G\/I9!\ O
MBCEK@S?:=,8;HT$A^8Y(7H:Z?^ <"T_\FZE;Q:8O^&7?!'$!7^U=0 \PG /7
MY>]?HQ\*$)^$W@H@C']C6G '_3):_.WQ'*)?V6/">#,)/[9U $(%++_O#L*_
M0SX8:OIVD_!WP3-J.H6U@G]BVCEKF4( OE@9.3T]ZX,4THKU9ZF!^)^B/+/C
ME%H!\<@ZDW@E;DVL?_(>\)WNHW6.<?OH1M*^B]17AFM0^$VUF[VCX:R9?C_B
M5ZI:_P#D''[OZ5Z?\3?VKO"S^)W31==\>O:1*86?PYJL=E9NX[HCQL22>K=,
M= :^</&?Q$\;^.4NX-0\6W5U:2RAQ:W$XF=B#E=[X#,PXR:\YXZC26LOZ^XZ
M*J39](>!K?3U\*V8LI-#C@^<@:,)8K?[QR0)L/GU/2MBQ$&K1&6QNH+V)25+
MVT@D (Z@D&OB/5/#[ZA;+='6YY[Y#^]C<%LCT'.?2FZ')JFFZPLVF:BT-Q!.
MICDR80P ZL#G./3FNF&9QY;K;U.1P/N0:>Y.-O-9>J^(-#T&"2?4-6L[=(SM
M9?-#.#Z;5R<_A7D^D?M2WD*+::GIUM<3HC>;>0LT3'^Z44\=/4C)]*^<_&4N
MJ:IK]Q=V\:"UEF8^:'4!P3G+A2<$^E;/,H225-Z^8U2[G[3_ ++^HV>K> -'
MO-/N$NK.6-C'-']UAO8<?B#7M>O_ /(/;_=KY?\ ^"?!F/[.'@@W""*;[/-N
M0# '^D2U]0:__P @]O\ =JU)R7,^IV+1)'Y;_M5:2LWQK\37"L_FR6MNF"OR
M<1J>O;I7@-O<RG7WM+<K):F$+*2I!W9S@?3%>J_MG:IJ-I^T!KL=M&QC,-MM
MQT<^2I(-?/5IKNHW=U,R2F(%QYCLN%'H,]SQ7P]>MBXUJD7+W4VU]^ATJ3LC
MT6V@DNK2WD>5!9)=-%Y1;+2RX!&!Z#^?TKZ>\ >';2P\%V%[JZ:A;6JDSM=@
M^;;D!L%77L.G;^=>._!9&U36M,TEM%&H1DR.+210GF-LP6+<C('?UKW7]H34
MX_!'PU\/Z%96[65O?ZA#$Z!BPC1#YKJ6[Y( J::I8M2Q556M?2W3UWZ=SMII
M-<QZA_P3M\$R74'B?QS>XDF:YGTFUDVXR@F+N1Z<A!^%?:@%> ?L:-9Z1\);
M#0[6W$,T+2W5PQ8EF>5R^X\=]V..PKWU)4D+!75BIP0#G%?8865.5&+I?#8\
M^H[S;'T445UF0AK\G/VHO$/_  F'Q*UH2Z,-;T[4M6:!PNPM$J$*K<\@<=L5
M^I_BG5TT#PUJNINP5;.UEG)/^RI/]*_(;5+V'6/&UEY>HR0WRF2:>V,@*RDY
M8'&.,9K*;U1O3V;^11US5OB?X;U.X.FIKMCX?V@P+'9M-:LH&,A2I7GUK&TW
MXF:I?:S9VNLZ#X=U-9')+W.D+!,"!URFPY]Z?#X-^+'AZ]O+R&V\3V,3R%TE
MTV5Y(R">OR,1C%:OAWXC^/UUN.VUS4IKZV$+2!-8TZ-G!X')=,_K7G2>YZ$5
ML?27[.,EG?Z+KE[9Z3;:06NDA<6LCLLA5,YPQ.,;NQKT+7#?JEX=/57G58U^
M<9&.2>M<Q\![HZEX!%\UK9VC7%W*=MC"(D8 A0Q XSQUKHO$%OJ%Q#<_V;.8
M)EF7+#N G3]:B.YK4=H,YH>*M:M8V2]\.12Q9)+!=N?7D%OY5R7Q.N$OM"\/
M0:[8W^FQ[I6M7T;4E1SGJ&5EPV!TZUU0N?&EA$=Y@F3G&5#CKCI@']:XGXQ^
M5'9>&(O%FFZ1X@W)+-:+-%)$T!^7?@J<>G6M6WI?\3DI6Y96M\M#@KG0]-V_
MN?$^I6I[#6]&CG7\7CVFFVVD:S;2AM*U[PW>'/ MM1GT^3\G!&?QJAJ&G>%]
M;EA.FQ:IX>EB;+C0-8$BO[-')GC\JU9](T.<@1>(M9LT/;5=-BN /^!* :=T
M/5=_S*/C&X\7II$;ZQ8RW,"EUB-U=17L6[;GB1,D ].?2N ^*EUJ0T7P9/;Z
M5#J%K+HY652"2CK,PX&1QS7:Z]X??3M-\^QU[2]3_>;6&GQ20S $?>,;$YP>
MXZ5R?Q&L;VZ\#^")HM6;3KN-;NW;SW">:0ZM\W(YY]*?6Y7V3EO!0>9@HF^Q
M.2'F?;O\OGA0,C)QGC->TG0].9D>'Q&T62#_ ,371BI SV>%O3OBO"O#2G,D
M%Y,T@7)FFC;!<GH%(_G7L%CK/@^<1J=-2TF*+EM-UR2!SD=2KD@GG/XU4]2(
MWL=;#'K5O=);Z/XDL+^U?&3#JYA(Y/6.88]._>K?AI/$>A_$K199=)%E/<2_
M9AK/]GPR1$.OW6EB/S ^C=^E<TVFZ)>+NBU77[53_P _5E!?1C_@2X8U4.EM
M82P3Z?XFTBX1)D>6%4N+&X*;ANV@DJ3C/&146'L[_H>Y?$6[M[;3+^T\4>'D
MD98W9]6L,Q[0!D/TRN._/8UPWP<\0VZC1[JVN$NH(I0OVN$YCF&<$[NYQUKU
M"[M-5DAW>%M8@U:P=%=X+F=;CR\CD9.3CV->'>#[=]#UG7=(6QDTQK>Z,\MG
M,P)C>3G,8!.$)&<>]:0U5C-VC/3]3Z)^,6BV^L^"=4CN+(:E&L#3"V,A3>T?
MSKAEY!P#7PQJ\7P^OKR036?B#1Y&P_F6\L-Y$,_[+!&_6OT#@NUU+P[9W>-P
M,22$X].&_K7Q_P#$VR\9:9?RMJ'A2SURSBF>(3W.C+)E,G:?,B 8#'O62T.N
M2N?=?[!WC+3O$7P*M-)T_59-6&@3O9>;-;F!UC)WH&0D] V,@XXKZ-K\Z_\
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MC+H5GHL=Y(UWY-BA,5ON).W.2#GJ6ZDUQNG2W-_J<%O%;&ZEG*Q11*,L[=%
M'<G_  KWS_A6?@*U\5^*- C\1:]H/AVUA.=:2[2YBU6,31;4$8C49P9#C)P0
M#S@@\YH'PITW3]9M+E]?&G/')?*\T5RL_E-'*BVDL3!/F!5RY..=C8VU2E2=
M_>7WCU/)?&'AC7M$OY[75M-N=-D7!\FX3!' (_0@UBNI7="ZY4;6&>#TKV;6
M? [:V=-O-9\17MUJ<N5U.268.D0"R;=G'*EE&,9X;G&17DEWI-_#=S1C3FE9
M&,0>-<K)AL;AZ@XZUNI1MH]!ZGZ"_P#!*"!XM-^(#.X<OJ%H>.W[IZ*7_@E
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M-(\!DLF7'<YP/SJ;E6OM^#/9M /A7Q/X8T,_;7T6_P#LJQ?;! T"2E< _,0
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M^!?V2O$-IK5KJ.JW]G9/9O'-#+'/+=L&4Y'"Q@'!P<$XKZ]@N)8[*-+BVO\
M4+Q4 >X@M?LP<^O48KVL!A*^';=:;E?III]QO4Q-6I'ED_P/);[X QBRNK2*
M[2.REE$B6EO L2Q ;<*HW8 ^4=J\_P#%G['VE^*+>WAF35P+>0R(T+A02<9!
M(+<$#TKZ),_B RL4E^R0'[JWEU&<#WSG^57%OK*. _VGJ5K-<$];%<<>F5')
MKV)4XRLY(X[Z-'R/)^PYH$J[3#J:.6!P=2=>,YQS"1S4Z_L)^'U1C]FU*4D_
M<.N$ ?\ DM7TSJ6H7DLD8T%M8D.<-YBEXR/8,#6GH=KXEFF3^TK6W2USEWN
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MK6:UN649\N> 1D_\"6N/_P"$VC3)GL1MS@F&=@?R.:VCAU!6BS&/*KW1P?[
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MNNJ/R*U;PCH&D7WE,;6^17!4F4[3CC&"*YS4O^$7MKUD'AZ*=F<\/+QGUQG
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MM]/IR:^9_LK$QQ4\1&HK.^FO5G;"NHJS1^9_Q0\+7'P\O4AL?$<5X9F&^:+
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M;MD,T,C1L%QSC! _2E^(?A[Q+X>NM./AZXU.6T-J&F!N1)M?V$A]/0U]<1?
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M->I?$W1;;5/#-\EW#+/ (&D*0,%D)3YQM)! /!KV>P_9Q\,Z7%!'9Z)9VL<
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M'EA?KJ2#^2U"TQQR(%]0VKM_2N@/PCMS_!^M ^$ENO1 *.4+G,R7-N /-.F
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MQ';VLTGED$LOF,RKT9E /&:=KNR\_P .GZ>HKZ7?E^)\_P#]N:E_T$+K_O\
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M_P"_S?XU2HH N_VYJ7_00NO^_P W^-']N:E_T$+K_O\ -_C5*B@"[_;FI?\
M00NO^_S?XT?VYJ7_ $$+K_O\W^-4J* +O]N:E_T$+K_O\W^-+_;NI?\ 00N_
M^_[?XU1HH _7O_@B1>7%[\/_ (H-<3RSLNJ68!E<MC]U)TS14/\ P0__ .2>
M_%+_ +"EG_Z*DHH _3.OYR/VX_\ D[[XN?\ 8Q77_H=?T;U^??QG_P""0^@?
M&/XK>*O'%S\2-3TV?7]0EOWLX],CD6$N<[0QD&0/7% 'XMT5^N/_  X]\,_]
M%6U;_P %$7_QVD_X<?>&?^BK:M_X*(O_ ([0!^1]%?KA_P ./O#/_15M6_\
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M_@HB_P#CM 'Y'T5^N'_#C[PS_P!%6U;_ ,%$7_QVC_AQ]X9_Z*MJW_@HB_\
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MVU6WU_Q5?:G!JL5I!>QRE0)X[4N;9#@#B,R.0!Z_2OTQ_P"''WAG_HJVK?\
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M&V)57N><9K K]</^''WAG_HJVK?^"B+_ ..T?\./O#/_ $5;5O\ P41?_':
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,:** )%))HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>forms-4_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_007.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #Y Z@# 2(  A$! Q$!_\0
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M1DX5K%P<_45^>L%G%<QCH9,8QTKU<'@HXF#DY6LSDK5G2=DC]&_^&@O"^?\
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MJ\DQ>W#-$MWY?VFXW(,N %XC R < 8) ->6> _%FL:%?:WXG^WR0>7:2:AJ
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MY).^RW.CO_C'K^H:--%9:5'H>J?VDMJL]Y&9EBM /FN2IVJS$C 12<;LGI7
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MI5'3@<J:^?G-R;9[JBHQ44=!=WLMCX8U-(]-BCBEL7EDU#Q))NOY@%^58%Z
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MZ\67']IZT,[=/D<.D?IYY7AV'_/)3M'\;,1MI?$GC6ZUFY8R2M(S84(O/ X
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M-2<>A\YSVE%6WZF?J3VSW27GB#0IM*OH\%-5T]F/ED="LJ8=?Q%>H^!OC_\
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MVE?A>OA2X\2)XPM6TRW"^:@C<W",QVJA@QO#$\ 8Y-=49J:T,HRN[--'IP'
M&"Q[FEC8JYP,\=*\HOOC] OBSPMHUIX6U5[77IDC74[R2*%+<.#C?&&+AB>
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M8WVHNCS%RHRV]A@# ' '6O.? \OB>'Q+XJCTN;3;2Q34B]SJ4XCW"0Y^Z[Y
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M.V9991,HQ(>^ Q5L]C'WK/T;Q,FJV,MOIC-IPC'V:[U2:+;>W31!@41<_NP
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M?BT(X=2MG7,C?O(RL?S$=",_K73_ ,NSR*#Y<<UW;.&\6L6O[=R2P>V_K_\
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M]0LM/M;"SM=.G5I%LK9=L<,BXRSN#AF*D9=LG@X/:MOX2^'OM"OKYBDF@A0
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M>2R_G7YZ?"?X_>)/AC)>Z-I&I0:;::O*GFO=H&5"JL&=0Q 5BK !BRC*+D@
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M\LO)L[C[#>1[I%8"5%=Q_K$^<<,3Z&NCT[Q%J/B^XN]8O6^VEID26:*/"!D
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MN%NK*-?F')*@Q]0<@')]J^E=7_9*^+FDW UOQ5K^F:\(K2?38$%[YDR-=,%
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M:TSQ5K4D=Q/=6,4;@PED4Q.@Z#)R03SGIZ5O3ZUX>ADL+=+R.W^R,'C9'(4
M#OGK7FG_  L33 Q'V:XSZA!_\549^(&FD'-M<\]O+7G_ ,>H5BFM=C]&OV=I
MXKKP5HLT$RW$,D 9)5Z.,GD450_98NX[[X7^%[B)2D4MFC*K#! R?2BNI$F'
M^W!*T'[/WQ D5BC)I4C!@2"""O.1R*_%635_.WS22,Q!+!@F7!)ZD]<GW)K]
MT_VC;"SU7P-KMGJ%H-0L9[=HY[0D#SD.,KDD8S]17Y@_$CX?:/X+AN5L_"^F
M:=973_9UDN+A[G8&8$E#@%2 >@S\J]1CE.E[03:1\O7VI2I&3LD61R.3R,8X
MS[U/IUE$8#)<&1)B?NYQD>O/2M+Q7I=K9^))=.TJ:;4(5;;'<1Q%1,V"Q(4_
M-L'/J>_M4>D^%-0O=*NKJ:\A@2(*RDL7:56; V#'('4DX !]>*\ZI2EL;P+"
M:G'81QLJ+Y:,-H'.XX[@]?\ Z]>O?#;P[/;R:=XGN(8'LW1DACD(CDD<AU,@
M4]50]6XY QT./-X?#NBZ19O+J%Q/<7L4<=S!810%$GB?^(R9)4=".,G/2N^\
M+W,;Z([VZFY:RM)9K6WD0,6!@D&=P ).6VG(Y !K%45'5G0JKA-N+WT^\]^T
M;QW:ZWX"NO#FFV,ZZRE@B^3!,I=G(4[P 0_?)(!P3@UWGQ(\-WMK\,+[0[&:
M"'4O[/BB7[2\:1RR[$S&7DRHW'(R?PKX>TK79=.UBSO+X1(L;;C#.&VR_)DM
MN0@@XQR"#GFM3Q)\7+OQ7(\5W):.GF-<F(;@A=@54'G^[M'T4>]0ZC70Y7 R
M-(GTN^M]8O=;U#4(9;6%;:!K8%U><,=J%@0!& A  #<'CIQ@?\)I+/IJV$MQ
M(D98$Y;_ %8 (P.W/Y\"JFH:A!>W"7=W)( R!LR_/@=,$= ,8'%>D_ 'PGX:
M\2^-)+W5$BM-)L;26YN4;,D84*!EF_AR3P3GKT[TO=GJE8I)G/VFL"S?4+1%
MD6U:U9DMY6)B5F52LFU&(R1T#< L#QBK"#6-3L-%DM_M,"V,A@:X*C%N[-YF
MY=B[P "#NP3SUQQ72)X9\/W/B0/9:,8?#]Q>,3>%6F,<8GX*]E3#(NX\<Y)Z
M5ZYXR^&/P:\-&)]5\6P:8GEL9(9;R*XFE+?,IP@++MZ!0!D9]:>B=C7D;U1Y
M?XBO8K"2RTJ!XKK3KV &[GN6BE@DE9&#D$J &*./FQN!'!!->M>#@&\/>)KK
M39ULM5U)5BM&^WK:!3&L2-*D?"KF,JOED\!206.37CWASQU\+)K%-.U#P[<:
MWX@>=T6YTRXDAMS&$(5R\IWY(R2 O4+QQ5'Q+^T[<032V6B^$] TB*$"-9'4
MW$N ,#)<@9_X#5MMNQGR76Y]SZ'\0]*TK1XM&NM1M&D32(FDU=M1A9)KDIAX
M<!BX<'JQX/8UB_"+QSX?\,^'GM=9\16+:HT[.&%RTY9=JCACG."#W-?GK??&
M'7]5;,]U"W/W00JCZ 8%=9!XBOKBU\.QR3 &32Y[N3:>I-PZK^BBAN:38O91
M[GU9?_$CP[X<^.-WXEU'7++^P9[ QK#!!(]P\Y\M QR@P!M;//<<59^(OQ'T
M;XI)9Q:/K%B='@4RR226EPUTL^TC: %V[,,,]\^U?![>/]3M=0,KW4,X23.R
M[Q*K8;."#V/<>E=M\,_C2W@K6;#4;6U5)H"$NU@?]W<QY.<H> V"1D?EGFGS
M3M=F;IK8^T-6^./A;0/[3N5BU 6R6ENI/V;'W=X[GN3Q7A'PX_:%T[0-9OXI
M+66>RN9!^\)^=<$Y(YP.O2LGXZ?$BU^*WV*/PIJ$5]I<TEJ;I(\K*),R!59"
M-WREOH"0>]>,_$#R/"'B!;,O%:RK"DF1DYY.#GWQ3YI]"7339]7^--=\*_%3
M4-+FM/%EGIZVF28KJ-E:3+ XY( ^[[]:[Y;I+BU#6\BRC9P\3AL''J*^!],\
M7VNJ7<-L]S"[RN$4;#EB>!VKL[8:AI4X:PO)[60'(:*0CFMXS:W0W170]0TF
MTTFVTK4Y],U2"_;R)1+Y.200'SDD\X((^M?+MW>6\(!#2 MU QQ^M>S-#X@;
M3[D0W[IYD;@QPQHF_(.1P!U_K7"Z9X3O'^TM>VTD14*$691WSG')]J3?,=F'
M<:47J97A:R@:(WLD8G<ON3S%&<#_ !KZN^-WPNT6P^$7AGQ)X?M8TMHXHI)2
MB@[HIQR3_NR8'_ C7S#;ZC9V^(V;[.PS^[=<$ =^.,5]M?LVFW^-'P U3PJS
MK<R6J2:<&)Y5)07@;GL&/_CM9M:$U)ROS/8^+1I&F%N;9?P9A_6M+3S;Z?'Y
M=M&$7.>.3GZ]:JWLB66IS:?<$1WL$C0S1,,%)%)#*?0@@_E4"ZG9!AFZB&<#
ME@*BP.4VK-LW9;LWD+1/(_EMP0KD?R-;?@3X<R>,M6:"WEN5A@C,DA$S$>@'
MYURZ1$MC'/I7U9^S7X531_AQJGB6\B(AE>20R$=(HE))S^="2ZF:JSIKW6SQ
M;QQ\)KKPC96UZ+J\,$DGE.1*1M)&5_/!%96C>(-5T")TL=4O[8.07:.[D4N1
MTS@\XKZ6\.J_[0?P<UQ3;16^K*LNV*W!VI,@\R'&23EL!?Q-?)+I*W(9N1G&
M>E*R3&Z]2HK2DW\SI]0\7Z_J5N\,NNZIAAMW?;'R/H236 T4L<;9O[E1R3(T
MG(/<DG^M5Q%<,,*6_ T6WPZO_%^I6]JUU*!/(L:AW/EJ2< D#K34;Z6"%24'
MI*Q[)^S/X?U#QKXGO5M=?OTL;2US/+;7KKYC%L(A*GL23BN3^+,'Q$USQSK-
MAX?F\1:CH=K=&R1H#-,CR( '!?GN>F>*^G_V9_AM9?"SPAKX@N#=AKV1!=-&
M$,GE#!. 3@;MP'/:MF..RL8BEI:Q6T;.TK)$H56=CEF..I)Y)[UZ-##J;:>E
MCDJ8GEFY;^I\K^$?V=O&>J6Q&L:C%H,9"%8W07$IP>X4X4_4U[Q\*OA?I_P_
MUFT:VN;N^O)IHDFGN6'S .",(HPO/U^M=3-=1C.%'TS7(3^$-2U3QGI-W::]
M<6T!U&VFGM" $<+(O *X;H,8)^OI7J1H0HKFA&[.>IC*]?W93LNW0_1CP5_Q
MX)]*Y[XQC/A/6!ZV4_\ Z+:NB\%G-BIK ^+J&7PUJ<8QE[651GIDH17$=9^$
M_ANRNX=&N)+.,2!8 XDV8D.1MV@^A)^O%>K^&+2]\(>&+U](O+262 1I<6T$
M^ZY\L#YRJ?\ /,\Y89/&>U;O@#X<7OAN*[,T5L]Y.B"(I,DD2+&  V[)!.2>
MG0UQ-[X2OE\8ZO>V[C3[>UE$<<RMN\\*H!51T.0>>Q'UKBK8NG6FXIZ+\3*=
M:,G9=#)M_%%QJNN7%W>[))KF2.4IYFY0J_=#=_3)Z\5!XZT!DO;.W+,J@23$
MN5929&!!W<;LX.:]%\/>#H()B^H10^1-.L\=K:Y<(X/"<C)YYQG&/7BNHU."
M-VES#9S6DHCM%MT4Q* ,[B3UW'@XX')]*YI8Z%.;=-:K_ACGE6M=K<\>^'FO
M'2VN["Y#);W"CED!5-IP=V>HQ^?%='%XG>Y\3VMJ&6WAL,33)''M7(PV#QGG
MY1TZBM+4O"$FG3M+IS/%$CL(9'9<.VY?EZ8)()[Y.!BJ4VC66FVU[-"D\USJ
M*DR^;R\9!(0%AZ@\''(ZUSRJTZDG52U?YF<6E[Q3G\0"7Q%>:O+<R126S!1;
MJH ?=@CKT)_'K7<>&O$S>&M6EO+!58B)HBIY0*W+*,YPP8+^7'6N57P?'IFG
M1W-Y*+DRR!EC+_?=1F-@/P[]<?2L[[:^B""SBC\Y[NZ*S.>D:R#(SGT 'ZU$
M9)I>S>J_K_,:?WGVYX_\;:]\1_AAX?UNWN;+6'OFCANO#Y@FE$$T88-* &*8
MRN>0/OBO./$QTZTU'P-9^)9I[]DM)[@:?IL<:K9S%B!& I 3@;CGDDUF7VMZ
M;J7@+1=.O-;MAJ%JS+)J<%U-=M<18P(V1!L.T]\CH!5R[U&[C\<:+;>&-$B6
M&WT2&*1KZUP^[))E";L#>>?FR< 5[%/2*-YMRE=F/XG\9>&)?'\<2^"+^>[M
M[**..6]U'RH"N21D)&KEO;=Z5J^$_$TL4FK(OA>UGE\R13J%PSL,8Z*HV]/<
MFLR_F^+$WC75G^SM8:9$$ OK;28K=V0)DYF\L9 Z<&D\$0^*G\+WUTNMRV6E
MR&9X8A*L.Y<'DG@MSDY)--3]Z/S(<=B'QY_PLK4)?#!TF2/1;^.TW3):)%;H
M+=F[EV&>5/S;L^]1'P]>2^7)XD\7Z=YI(XN=4-PV<] L0;^=<;\3?"^BW>I>
M'K;7_&UG!)!")EO;F2:X>4DX9%:,/DC'(++U%:>C_P#""Z9)$L&J:KK#[E -
MGI:6ZYSP=\CN?TK=-;NPVGRI(Z'X9)X/%K?37UQ>MJKW,PDAMX/E4[@$)8LH
MZ8]>M7_%OC/3K#PK;'0/"MF]U]ICCE;6XX[B-OFP2B= VX9Y9OI6;\+O%FF6
MEC<68\,+>7RSRB2^GN&4$,W4*B9X!'5A6SXD\6_$#4O!UHOA>Q;1[E;F-=VD
M6LC3R1[]IW-\S8(P> /K6EWR]>OYF4E[]_,Z#P)%XZ\8B6))I=+ME@\Q([6W
M%C"QR!M!15#<<XW5POCSPIJNG?%;PUIHU.2"_G1Q]KLIA+)&"3D95CSC.<G/
M-=CX7\#>(]4NS=>+=1OK1/)++-K]PRHSY' $K<<9[5POQ3\+Z=#XX\+Z?%JE
MK?65S(5EGL9P$B^8;EW8 ''X<TI;-?\ #A"_-N]CT34/A5:S>#]9'B'7<W<M
MA-Y)U#48HB)=IVG!<G\SCFO%_#GA;1]'T^!=2\3:0TP0;]ER;IB>/^>2,/\
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MJ1HKF>QZF"P=3&R<8-*Q;BUOQRB+MLM*&!_MY'XYJ(WOCF1"KPZ:I+9RN_\
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M6K'3L:7_ ,)5?0Q;8%63PW&UN0!_#)&Z#9P>1GJ*^+[B\\0Z!#IBP.EAJ<<
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MY0DK?\LTZ -NR1GTSS7SE/%8NA"6&C)\CZ*_WVZ?(Z70C[7F<;ON,N=<6_\
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MFD0H\VU0I*[T4G<S,<XJM>^)XXKW6[%+O^V;AT\BW:UD+0PRORKHB]2,CH6
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M@\MZ5=U"UM)M1BN))"YDV2J2X^9RF0PP>Q!_2KLU)>9IRL[O3;RPAB7-H^"
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MB_L-_$0=;K1?^_\ )_\ &ZYG3EV.Y5Z7<\"C.>YJ9$X&>@]:]Z_X8>^(>?\
MCYT4?2>3_P"-U(/V(OB$,_Z3HV?^N\G_ ,;J'2GV+]O2_F/!@./09Z"I,!CR
MV?\ >%>[I^Q+\05_Y>=&_P"_\G_QNI!^Q5\01G-QHY_[;R?_ !NH=&;Z%?6*
M7\QX$;*W=<-#"PZ\QC!]ZL1IY))3*,>IC=E)_(U[O_PQ5\0,Y^TZ0#[3R?\
MQ%/'[%WQ '_+SHY_[;2?_$5F\//L3[:@]VCP5X[EC_Q_7BKC 7S X'I]Y32-
M9!K1K8BUG4]7NK-6<_\  @1_*O?A^QAX_P#^?C2/^_TG_P 13O\ AC+Q]_S\
MZ3UZ^=)_\14NA4?0A_5'K='A.HZ/HTZE4LK:Z4CYC/!Y+DX[["1@'IZCK65)
MX6T5HXHCI,D:AF?]Q=?*&/?! R:^BA^QEX^ '^DZ2?K-)_\ $4']C+Q_VN-(
M!/I/)_\ $5'U6?\ *#>&_F/ -'\':18W'VBW_M!'\OR0TC!L _>'![_UHM_!
ML&G1111ZM+!;Q+-&D-PK!3OX)Z$<#@<5[^/V,?'P(/VG21Z_OY/_ (BI5_8Y
M^(*<"ZTD#VFD_P#B*S>$J?RLA_5WISK[D?.\G@W4H5M1:>(;:3[.79$\P+@G
MH HP,# QQ63J7A#QPUA;^=>B1H\_NH)<[R6SEB/O8R>![5]0-^QY\07&&N=(
M/KF5SG_R'47_  QCXZSGS-&#9R")I%_DE-86IV9DXT>DE^)\Q6/A3Q%IS7%T
MZZG,EM*QAM99?,$@*@<Y&=N<G.?IZTR6\\16L$SSZ,6E$JHBB/*LG.X_GCG'
M:OJZW_8]\;IM(U*&U?\ B,5T[J?P*TZX_9%^(L;,]OK>FRLV,F16R?8Y0T?5
M:SU_0RE[/O\ C_P#Y:TWQ]J\4MU:QV,$*6TS;3+$X41@<)\O?(Y;WK6\#>,+
MVYGU:;6+I5A-R5M6.!%Y?7Y>,GKC)QTZ5]%G]DKXDK"%%UH,S\_ZXR ?HGK3
M;O\ 8]\:W^G^3<6N@M(#D+'<S(N?7A*?U>OV,9<EK)_D>>>'?B)I>@3W-R+V
M)I/* 15.<C>N[_QW-:^O?M!Z;8)J<EK]IN8V*):[$PJ@8\QF[@\DCL>*[[2/
MV,I[6VB6]T*SN)BO[TIJLP5F^A3&*O:9^Q?96V%ET4QH<%E34F<'V&8^._2L
M9X/$R=U8QBH_:9\CK\3+M_'NN^(-"U+4]$U'50#,]F^PR1@<*3@@?ZL'''/0
M]JT],^)_C"6XOGCGU:_O74Q2-<SNP ,>5*C/WE)Z$=_6OL^U_9:T/24>6S\)
MVT]TW>XNFVGZ\8_2M)OAEXOTA-F@^'?#MEQP[2,"#]1'S3^I5WNW_7W&LI4V
M[ZOU/CJ.?XL^)M'06NA7DTP.%C%L40C(&=S8YZDDG&2:U;7]F_XBZG>3ZA-+
M8:&]RNR874P8+G!W#&<'CK]:^C]3^&7QNU D+J&AVZ'_ )YRR _^BZXS5/V8
M_C!JLA:?7+"7)Y#7<H'_ *+K6.7O=ID<R6R1Q_A+X3#P'97"^(OB!IMW%NW[
M8U+E#Z;B1U_&O*/C"++5_%4+V%ZMW!#91P"6)3M)5G_H1^=>S3_L6?$F5]WV
MK1">NYIY2?\ T71:_L,^/;NY07FJ:/:0_P <D9EE/_?.U<_G7H4Z#ALC!MO4
M^6I+ I]V7./?%568C(+,#GUP*^U+?]C'4M ?]QIFF^+9!T?6KE[6'_OW$C.?
MQ>J-_P#LF^/[ZTO+4>%_A[;17"E5:V2XCDA/8H^"01^O>MU&78G7J?&S&4\!
MV_ U&\EP.DQ_$"OI5_V!?B:<[;W0AG_IYE_^-U"W[ /Q08\WV@%?>XE_^-UL
MHDV9\V&[NE/^L/MCBHFUF]A'RW-P@_V'(KZ8'_!/WXED@F[T'\+F7_XW4;?\
M$^/B80<7F@C_ +>9?_C=4HHAQD?,I\2WZJRF_NRN>5,A(_G6M\.-6,_Q+\((
MQW,=9LQR,?\ +=*]\D_X)W_$V3I>Z!GWN9?_ (W6YX _X)U_$G2O''A[5KG4
M/#_V73]2MKN95N92[)'*KL!^ZY. <5LDD9.$GT/TY\'(5M #6#\5XR_A_4%4
MX)MY #TQ\AKLM"L?L\. ,=^:SO&6B'5=.N(,9\R-D_,$?UJ#M/RJ\"P^)M=U
M&?5+J\T6)EMH+/[-]OW&VB (4G (R26[]NW2NX^)]O;:=%H$N@W<6L7-S?W,
MNH?V*GVF>)2 ( J';N^1,D9P"<<UZ_<?LDVR6$=M=V<4K([2%%FD,9<@@$ ]
M^3D^YK$N?V0+-G!AT^%20<L)64]NX'L/R%>6O:75Z?XV_1GG^WJN7-[-I_?^
MJ/)OA9X$M_A[\5=.\7W45QXDOX&:ZAL[.,-<"18R4#0J0 WF&+))XYZFN5T;
MPGXICG^TZAX>U6WO-V^2.5HY06;'0ANASP*]KD_8>L)=S&SC61B22+B;)Y[G
M//4_I4,7[#L47173]XTF$O)0,G[I_P" \8].U>I1KJGS)T;I]WK]ZBG]QQU)
M8F7+RW37:/Z<]CC)='AO]&N(7\&ZC'/)9W%ME;>-D$[E N/GR1_K6(Z@XX/-
M.D\+07/A?^S8?#=SI\_]HPWC.5 8F-6"Q!B<8!&3W);IQFNQC_8FEB@@B2:X
M"1DN%&HS867G]X..6Y/S=:<G[%5S&UDBW=U]GCD,[Q-J,QQ*01O''+<]36:5
M)N_LW_X%_P#:FGUC&I6M_P"2?_;GF>F?"WQ9I.GM?67A2_GN;R2)2\=DVQL<
MYWYP>0!UY..*YK4?AG\0K3PU9Z?'X,N[G46GD>1P!A6RJ_,3*#G@]N!@5]PS
M>%O&\7@"7PI::G#]A>W2V$EQ$9)50$;@6.=V5&.?4_6N-F^#_CA@BF[TZZV(
M(P\T3*^!TRPY;ZGGWKU(X7 N5I5&E\__ )'<\QX_..5.-!-^:?\ F?,VB^%/
MBU9::=-M?#MO8V^Y7_?QJ29%4#=N\WIZ#^=>A6_@;XCZ]IQ@\0ZUX?BM'9&:
MWBT9[AACT.Y1G.>YKUK3OA-XYTVY6>)]'613PS1._'N#Q78G_A<QLOLJ^(-+
MMX0GE@6]@J$+VYVUU2PN7*RA5;];K_VUF=/&YP[^UH)>BO\ ^W(^:M6\&Z[I
M=U+I]AITMS8Q(K?:$LE@21F'(4 ]NG]:I7-EXFME+S6=\ @.7VD[1SG!S7N4
MGPB\<W-RUQ<W]E<3.VYBZ,03]*2^^#/C"_A>-K^TC# C$<1&*J>'P"5H57_7
MR*ACLVO[^'5OF?(>I:+>:UXANFO])BGLP/-M)[K1H99$?[P5MPR.<C(.1U%=
M9;Z5X8T6VMKG3_#3V[B)ENXM)T\133SA1^\ =-IRQ(WMSP>E>U2_LU^,G=F7
M5+=2V-Q)?)Q^%4Y/V7O&AC=%U2S"-G*@R '/6O)G3PR^W)_(]6.,QVMJ*5_7
M_,\<\/Z/J.N3WBV-]<: RSN\::SI*M%)'D!<R(V0Y7G[N 0><52O?#GQ"TZ>
M2!1INH8@VB6"TBF@8[N@#$8)'L,5[;:_LQ>.;+_5W^GM@?Q239/Z59/[/7Q%
M4?+=Z63Z^=,/Z5Y\I\LFHQ;7]>AVTZE244YQLSP^*'XEVMQYEK#;0.LNY7AT
MRU5A_=((P>.I]:K:S?\ QQU2RN=+O8(]:TLS+-$MQ+"HWA3E]I&0<MC'L/K7
MO*?L_?$E22;O2_;$\O\ \33F^ OQ,*8%UIF?^OB7_P")K.4G)?#)>C?^9IS/
ML?.=A;?&+2)#]GTA(3CR%:*\BP(.N.<\AA^IK2L8_BMKMXZZS:1VFW/DW3PV
M]TW3A1D?)]<\U[N?@'\3RN/MFEK[^?(?_9*8W[/WQ/).-0TP>WF/_P#$5G&\
M6FHR^_\ X(^>75/\#R(^'_'UCI\=O;ZHB10Q#R\:?;,R' Q'SRX!'<G&>M5K
MWP)XUU2*9)-8C5-JO&4M($VG^)  XZ_Y)KV63]G_ .*3+A=1TL#WD;_XBHQ^
MSY\5<G_B9:5C_?;_ .-UI&;BK>S?]?,N=5S=W$^:!X6^(>GW"/#H%U+Y+'9N
M>VD1N>I4M@YQWJE/X)^)=_>&:7P[;7*@D0_:+B%5B5]V\!!@ Y;/L>G  KZE
M_P"&>_BG@#^T=*(_WF_^-TA_9\^*G;4=*&>O[QO_ (W42;:MRR^__@D<\NS_
M  /E:Z^'/Q+O!:1GPM$1;E@A_M!"N,@Y.&SDXR/2H+;X6_$#>;B]\+.UT&.X
MQS*4D&"-Q.[C()SC\J^KV_9Z^*C9 U+2UYZAV_\ C=/'[/GQ24C&IZ< !T\U
MA_[3IPE*$N91E?\ KS'SRZI_@?'S>$OB##I%S-/X7E6-S&^Z"3: O0J=PP0?
MEZ^E9=U8>)[4![S0[.VG:UV.[SCJ#T/8< <5]J']GSXJ&9)?[4TQI$;<K.[$
MKZ$?NZR?$7[*WQ%\6W23ZS>Z9J$B(8P9)GX4\D ;/6DFUTG]_P#P2>>>VOW(
M^/+#QW9^<HO#:P3M,I"8R5^7EBW0D], =J</'^D&ZG<3V\L5O$KVZ*O*8.2"
M?SX'8BOJZ+]BSQ5%"(!;Z"(0.% /7_OW3O\ AB_Q6C.\<&@(S+M)"D9'I_JZ
MA3KK;F^:3'[6?\I\VZ7X@TS6VN$L@MU"T2RR-$G!/(Q_O<ULV+3:C+9&VTZX
MN)YQY9$,!=D&,<XZ#([U[U;?L9^,+,GR5T2)<D@1LZ@9Z\;.:O6W[*OQ'L3B
MUO=,ME.<F&=T)^N$KMCB:BC:4&W\A^TE_*>::-\)/$&I02QSZ>FE6^\F-KLK
M['<%7)ZCVZUWVD?!O2X9A-J%Y/>2L,.L*B)#WQGDGGWK9C_9H^*"#']M6J_2
M\E_^)J0?LY?%5/N:W:C/7_2Y?_B*EXFJ_L,.=_RLZ/0?#?A_2(3%:Z/91H>3
MOA#DGW+9KI[)-.5]WV*U!]?(3/\ *O-V_9Y^+B@>7X@ME(_Z>Y!_[)3Q\ /C
M#&28_$D ;.1_IDH_]DJ/:S?V&'._Y6>O6\&G219CL[-?80(/Z5[G\-TVZ?%Q
MCY17R!IWP&^-RMBW\76\9;J7NW(_+RC7VSX,T:33=-MHI?FE6-5=AW8 9/YY
MK:G-RW31<7?H1^,TW63 5^87B]#_ ,)7KJC.XWL_/_;1J_5'7K#[5;E<9KX<
M\5_LK>,+CQ%JE[%/IODW%U+-&#*^0K.6&?DZX-364FERE'S<-.)F)8D@]*C.
MD(<R9)YX%>\O^RQXQ9L^9IWXRO\ _$4P?LK>,P,>=IYP?^>K_P#Q%<JIS[ >
M('3$>/H &ZYI(])2,K@X4<?+S7NJ?LL^,%7F73P?:1__ (FD_P"&6?&(S^]T
M]B>YE?\ ^)H=.?1&ET>+16JQ6^\#)''(YJI-IZR1*2,;N<>M>[K^R[XP\O:S
MZ<3Z^:__ ,32+^RYXP*A6?3@!TQ*_P#\14^SGV"Z/!GM%W[0"?0>E,GLMT>%
M!'/;UKW<_LJ^,0Q83:=]#(__ ,169>?L=^,;ZXEE:\M8=VT 0W4J@ >VVG[.
M?8+H\9AT=I(F5\@],D5;&E( I#$ +@\<FO9--_9&\8Z>TN;VUG5P !+<2-M^
MF5K4'[+WBPX#/8' QGS'_P#B:;A/HBTX]3P.:S$-MO&<$^G6F6ECYR.0O'7@
M8[5[U/\ LL^+I(M@?3QUSB5QD?\ ?%+9_LL^+;:,*9; X[^:^?\ T&I=.I;8
MOFBCP:UTV!KJ F(,P8\GJ*U;?2534'E1/O#D <5[.O[+/BH3"3S;'(Z*)&Q_
MZ#5Z+]FSQ7%GYK$Y[^8__P 33=.?8TC*%]6>1&WCB0G: 3U..M59;*)_G #C
MZ=:]K_X9P\5,&WM9-D=#(W_Q-8B_LD>*" 6U1U; R%NWQGO_  U'LI[V->>G
M?<\P@M%<EECVCMQBIEM%.=R\$#CWKUO3/V:?%^G6[1&XMKCYB0\TS,V/3.RI
MW_9R\7,V=]CC'_/1L_\ H-#IU-[#52G;<\:BLAY^Y,DGDCL/I1<VAV$'YCW)
MKV6/]G#Q8C$E[(DG_GHW_P 33)/V:_%CYP]CST_>-_\ $TW3G?8%.EW/'((%
M63!4#TYS2W$7SJ,#!]>U>OM^S!XJN()V;4HK.Y" 0>0 RLV>=^Y.F/2A/V:?
M%RJ@>:QE8=7#,N3]-M+V,]["]I"VYX\L.V1AG&>*LVH6.X1).54'G&#TKUI_
MV:_%C C=89[,)&!_]!K&3]D[QMG<VM*&R3D3L>O;[E+V,WTL0ZD>AP#%8Y06
MY![$53N[42[MH )&*]9T[]E_QE9J\<][:W:9RIEE8L..GW*MO^S3XJ92 UB#
MGKYC?_$T_93707/%]3P?5/#L4T<)4.DRG(D0X-2Q:1%]M^U-$@GD^\X7G\*]
MQF_9J\7M$51[#=C +2/_ /$TR+]F?Q<H7<]AD>DK_P#Q%/DJ;6,FXWN>1KI<
M!B.V,;AUR*L6\$3C!4 #IQ7K:?LW>+!G+V/(P?WC?_$TY?V</%BQA UB,=Q(
MW_Q-+V=3L%XGD<MDLD2;>H)ZBG16Q6,\9 [@5ZX/V<?%>,%[+_OXW_Q--_X9
MQ\78QYECM'0>8W'_ ([5<E3L%XGE3QX16QA151(>0QY].*]@;]G+Q<R %K$L
M.F96_P#B:B'[-WC'/+Z?CT\Q_P#XFFH5.QDVFSR5UVCAL&LWQ>AF\*ZI']XM
M;.!GZ5[8_P"S5XM?'[RQ'J/,?_XFH[O]E?QAJUA=6BS:<GGQL@9I7X)&/[E7
M&$^9774SG9Q/?_V1,O\ !OP6Y_BTR$_I177_ +//P[OOAS\,/"_A_4GBDO\
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M^+O_  4Q?_'J_%2B@#]J_P#A[;^SU_SZ^+O_  4Q?_'J/^'MO[/7_/KXN_\
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M^+O_  4Q?_'J/^'MO[/7_/KXN_\ !3%_\>K\5** /VK_ .'MO[/7_/KXN_\
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MX ?)%>O^-_VL/B1\1/!FI^&-<U2PN-.U7[*=2EATBUANK][8 0O/<)&))64
M#+,20.:\@I]6);*^X4444 %%%% !1110 4444 %>@_L[?\G _#+_ +&?3/\
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ME$T%Q+'+/\L,2@/(T2;G^\0,9P2*):I\OG;]/Z[=[((Z6OY7_7^N_:Y/\?\
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MH  VJ#P.].\ _M$^._AK:VUMHFK1I#:Z[%XEMTN[2*X$&HQJRB=/,4[25;#
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M_P#@9:?_ !ZC_AW!^TC_ -$LU'_P,M/_ (]7]"M% '\]7_#N#]I'_HEFH_\
M@9:?_'J/^'<'[2/_ $2S4?\ P,M/_CU?T*T4 ?SU?\.X/VD?^B6:C_X&6G_Q
MZC_AW!^TC_T2S4?_  ,M/_CU?T*T4 ?SU?\ #N#]I'_HEFH_^!EI_P#'J/\
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MM% '\]7_  [@_:1_Z)9J/_@9:?\ QZC_ (=P?M(_]$LU'_P,M/\ X]7]"M%
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M[@_:1_Z)9J/_ (&6G_QZOZ /"=I-8>%M&M;A#%<064,<B$Y*L$ (X]Q6K10
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MI'_HEFH_^!EI_P#'J/\ AW!^TC_T2S4?_ RT_P#CU?T*T4 ?SU?\.X/VD?\
MHEFH_P#@9:?_ !ZC_AW!^TC_ -$LU'_P,M/_ (]7]"M% '\]7_#N#]I'_HEF
MH_\ @9:?_'J/^'<'[2/_ $2S4?\ P,M/_CU?T*T4 ?SU?\.X/VD?^B6:C_X&
M6G_QZC_AW!^TC_T2S4?_  ,M/_CU?T*T4 ?SU?\ #N#]I'_HEFH_^!EI_P#'
MJ/\ AW!^TC_T2S4?_ RT_P#CU?T*T4 ?SU?\.X/VD?\ HEFH_P#@9:?_ !ZC
M_AW!^TC_ -$LU'_P,M/_ (]7]"M% '\]7_#N#]I'_HEFH_\ @9:?_'J/^'<'
M[2/_ $2S4?\ P,M/_CU?T*T4 ?SU?\.X/VD?^B6:C_X&6G_QZC_AW!^TC_T2
MS4?_  ,M/_CU?T*T4 ?SU?\ #N#]I'_HEFH_^!EI_P#'J/\ AW!^TC_T2S4?
M_ RT_P#CU?T*T4 ?SU?\.X/VD?\ HEFH_P#@9:?_ !ZC_AW!^TC_ -$LU'_P
M,M/_ (]7]"M% '\]7_#N#]I'_HEFH_\ @9:?_'J/^'<'[2/_ $2S4?\ P,M/
M_CU?T*T4 ?SU?\.X/VD?^B6:C_X&6G_QZC_AW!^TC_T2S4?_  ,M/_CU?T*T
M4 ?SU?\ #N#]I'_HEFH_^!EI_P#'J/\ AW!^TC_T2S4?_ RT_P#CU?T*T4 ?
MSU?\.X/VD?\ HEFH_P#@9:?_ !ZC_AW!^TC_ -$LU'_P,M/_ (]7]"M% 'D/
K[(G@W6OAY^S-\./#7B*P?2]<TS2(K:\LY&5FBD&<J2I(/X$T5Z]10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>forms-4_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_008.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #I Z@# 2(  A$! Q$!_\0
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M;_GHOYT?\)/;?\]%_.O#[=Y9 ,RN3_O&K:Q' S))_P!]FH^HU%U17U^EV?\
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M]%_.C_A)[;_GHOYU5_X0#1/^?:7_ ,")/\:/^$ T3_GVE_\  B3_ !H M?\
M"3VW_/1?SH_X2>V_YZ+^=5?^$ T3_GVE_P# B3_&C_A -$_Y]I?_  (D_P :
M +7_  D]M_ST7\Z/^$GMO^>B_G7G_P 3/#4/A^SANM-:YAW95E!9XUQSN+'.
M"<@ 5Y/:Z]J-S!=1B[?[2G0C^'/^'%7&#EL*Y],?\)/;?\]%_.C_ (2>V_YZ
M+^=?(^N_%C4=(TJR,5E'').A1KZ_N"%$BL5;" @9X!ZD<CBH]-\>:N--,M[?
MRNT3^7)+%#A"3R,,0 1@]1D4.+0KH^O/^$GMO^>B_G1_PD]M_P ]%_.OD"?Q
MUXDFN&ALWD9D?!RH.Y?4$X'_ .NM.T\3ZV$3S+YIY6.1$I53@'."2,#(S24;
MA<^K/^$GMO\ GHOYT?\ "3VW_/1?SKP!=7N+\,]C;WDL)R1(B,%7(!'SR%5X
M.1WR*QO$-YXGDM_^)9+!;R;BV%N!,Y4<$8 V\'W)K1TFNHE*_0^F/^$GMO\
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M@8=Z/I29S03B@!>:812TE #32$\4M)G\ZDDB(&:4+@?-BE/7BF,U(!N?FR,
M5(KAA]*@SBE#T!<E=%/3@]Z@<"G%O>HW-(97E056;%6I.155^#BDQ;$;+GI4
M#Q\GFI]PIC$&@6CW*SJ/>J[G/UJTX#9'KZ5!(,4$E9^<U XJTZ_G4#KW/:@$
M5B,&L[5'Q=6 SR93Q^%:;\=:Q-3L;8ZO87ODH;P'R!.1\PC^]M^F0#^ IK<T
M1Z?IQ_T ?[M>9^,"6UE /1J]+T[_ (\!_NUYSXE0/KR@_P!QOZ5U4?XD?4PQ
M'\*7H<]EL]*<#FK+0 $BD^S^@/-?0\R/FN5E<E?[N:C"J3R*TX]/W#GK2FPQ
MU!H]HA\K,O[.A/3K3UM ","KWV(#UIK0F/IUIN2%RLK"U&<;>:D6R'H*E 85
M-'S4N3&HE.735<9P!]*JG32C9YQ6T ?0TNS/!'YU*GW'RF,MD&[4/9<<<5OQ
M6"38XV_2I#H[]AFG[0/9-G+-8-GAJC>S;&"/RKJQHLA/W2*G/A_<O()-+VR0
M>RD<.ULR]C3?)SQ783:$!G )JHVAOG[G>K55,7LY(RK.U(4&M);1B <5;ATM
MEP2I'XU.8"@Y!%9RJ:Z%JF94EJ<Y-5W@Y/%;11&X+8I/L4;<@BA5.Y+AJ8#0
MYX Q3&LR370/81@<$56:RP3Q5J::%R,R%M=ASBI1P!\N:U4L"X.<_A3O[&)7
M(SBA30^1F*\>\GBLC6M=T[P[+&E[))O=3(5BC+E(P0-[8^ZN2!D]2<#)KJY=
M.:,\=O7BO*[K5]-EU_4=:O[Z/^RDN(%M;906ENY54>6P7(W(&8E1T+-N/1:;
MFD;4J+E>ZV.\US6K+PGHTVHWJRO'&4CC@A3?+/*[!4BC7^)V8@ ?T%16_P 0
M=#*ZG-+,;73].O(]/DU"7BW>X8A3&C=]CD(S= QQG@UY1XEUWQ+XYEBETB*Y
M@B0;8KVPM6NFL8'W*]XL0(9I9 K1Q8^XNZ0XW+4^IV&K>(-)G\&:YX-72/AZ
M+2.&UDMY(DO;B6-T8%H9),11GYOOEF)&2<FLY:LV6'Y8WE^9[9/K.D6UY':3
MZI90W<DC0I#).H<NJ&1EQGJ$!?']WFI+#4M-U2:2*SOK>Y>/8?W3A@P9!(I4
M]&!5E.5R.17@%SX7\(^';G69H]*NG?4Y))KIKCQ'80R-YEO)!(BAG) *RN<Y
MSG'.!BND^%?ACP3I^L^%9-*;5-.ET&%[:S\^ZMI;>=6MTA*-)$S _*BG'RY8
M?A6;<ETT-/9TTGK^1[5]C! XH^QBM18BPR5POJ:<84QV_.H<K&2BF9!LL]J/
ML1K;6T!44&VQVI>T'[-&)]B-(;!3U K<^SCT-'V4>E'M&+V:.9O]/$=E.X'W
M4)KO?!QSI\?TKFM9M]NE7AQTB:ND\'?\@Z/Z5P8F7-)'I86*C%V,OQDW^F67
M_7Q'_P"ABO03U->>^,O^/VR_Z^8__0Q7H1ZFN,[A*JZK>2:?IEW=0P?:I8(F
ME6#>$\P@9VY/ SZU:KS7XZ:DL/AZVT]]-N+L7,GF)<1R;(XG0@@/W.03QTX/
MI36H'@7CG61Y%Y+#:B WDK;8EE+E-Y);YNO&33]J:%X<M+7SX;=BN]_M:G82
M.00HY;^+GIQZU@(5USQC;6_E/'%:#>ZG)&3Z#OVK2\8ZND)E#ZC9P0%A$S/&
M)IUC'1@HXSM[<=>:W7<EEO0]+N)/#MYJ":,^ISWC?9?*U.<6MN\+<NT2?+A1
MA!N+<Y..E$'A6>2:WMI?!F@11S.$\ZQO_,D0 ;B>)6Q\JGDC%4-?M[*;5]*T
MR30=<\2&QM1.Q\TK+.L@W$N4#;<$@8[8QWK4\/Z=IUG<7=U%X8U#P_/;0[!]
MJG9_WCGC[P!'RAL#!S2; T]1N$\]FCMHX[= 2@)!VKV&.3P*ATZ[NY;>:31M
M8&LW%G"9;[P[J"O'!<VK_P"L$0; )7DYV\\&LNYNED#&VAGNI68#R=KNO7/(
M&WCCUQ5V^=&GL;77]#_LS5XO]-T77-/C6.*6/K) Q0XSUX).,TD]+AU+FFQP
M6CK';KLL[9-L88\QA1T-9OQ$F>V\-:=;(L_[XAY7M[#[8A')Q)'U.&9E]LC\
M+FF#S89 Z^6\KB-U]03SCWQDUE_$&&;5/%EM%';O<?9U&9[/4_LLBD]'"?Q*
MR@'']31$9Z'I=FVC?!ZVMH(V66Y5=J6U@$QO<?-'V7CD@].:PO$,Q;7I43?Y
M<*B/,9!7CCE>M=GXNM/(M/"^E/ R(+F-VCGN/E/EIG=& >2"<XKS*>\%[K]Y
M,##(QE(S&VV08['M38SU3X-?O?$3^5)F..%C(L&H#;D]!);$9!YR&'!!YZ"O
M::\L^#4 >[OYG9VECA2/;<:>(I4!.<"?_EHAZ@?6O4ZREN 4445(!1110 44
M44 %%%% '.?$#3_[1\+7:XN7:/$BQ6HRTC#H".Z\Y/TKY@1_L>OM%\HCD)0M
MZDU]>W4'VFUFA$KPF1"GF1_>7(QD>]?'GC=(M-UGS8C*\44A$6]2KL W#,#T
MSQ6L&)E.9=+L+S4/[3LI]3:%EN;6**(/)"K (VTM\JJ2!V)&,T:O\1KOQ;/!
M'/IMGI-B!LA,LV^25U &#G )P.BJ.:MZW8'4KZUBV%[;4HGLYFC.)$C=<[E/
M;# $D^@'>O/%\*Z#IFBQ6U_XEC_M"UU%;V :3 ;HG:-NUF.U1D=<$]?:M9-V
MM<S:5[V.@N]8M(XX7,[SH[>6!$,*#WY/UJG9:[+J4R)9(MM)#+\^3O8XY Y'
M?G\JMQ:-:F&14L6N$+"4B=B5#>HZ8 !IQU&WTZ5(WN;>UD9256(?.?7.WKT/
M6L2CNK75/MUFYO;J62,.0KW$Z1IY<@&5!8Y8HR@\#(J[I]ZT$D5Q;V\ETRN)
M&%K;22C)&) '("X8 '-<9X=\<?V)'9W<L<%IIQNOLUS<7:)YB+(,1.C=AO[=
M\UUOA[QHWBJW%Y ]Q=M$VV>&.-W"R(WES(.!]>G>NV$G)&,DD]3RCQDFLZAJ
MDTD\=Q\TI2/[4?F7)^5<#./H*Y?5O"6HV=D]S<S( CK')#"#)*F[H2H'3/%?
M0GB_Q#9^'-# GTZ.[GD9[9HKJ0*2HY5R%.<?ETZUXEK/CJYDDGEC;R-_WULU
M*EO09')_$UA)1CNS5-O8XWQ=I.B^ ]1N!J .L7(M?MEFM[*T*# # ^4OS$]@
M&(Y!&:^</B!XQDUB[\R9-ZR'  R"5_A&"<(!TQ7K'Q4=;F Z@\-Y9W)0H7A<
M+(RGKD'(YZ9-> ZG>3HRW<EN8UP$03KCS4/1A^1YKQ<3>4U'H<TE>5F>B:3?
M?#ZS\('0]7M-6;7[]$:75K...06Q#%@H4M\P^ZO4=SCTZ[P_JMAX4\K6O#&G
M*EO.@:.*\C$MRK;%CF&YEVLNUF*@=U XQD^;^";+6-7F@M[.W:Y,9\^2WC;;
MNC[DGL  >O\ 6O7KTPZ597,Z20VC6TB211:<KRPI@,0&VYP3A@2,#G&:[8O3
M;1&ZL?HE\#[:"Q\)Z/;6LSW%K#:0QQ3. &D0( K''&2.:*9\"I1/X/T241B$
M/9PL(QT3* X_"BK-CH_!AP=5'_3R/_0173JU<KX0;:VJ_P#7R/\ T$5TB-FE
M<S>Y;5JEW#%5%;%2HV]@N<$G%%Q'Q]\:OVQ_&GPR^+7B/PWI^EV%[IVGS(D#
M2VY+D&-6.2&&>6-=3\)/VX=*\1Z#<R>+;86.L1W&U;:PC(40E1M9M[8SNW#
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MN[G+,2H))]Z*M?"FS&G:=;V@WD6ZB(&0Y;"\<^_%%<;T9HA^@-MEU+_KN/\
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M#8&C&YL.<L3@CYAV[5)I/C;PVS*/(\!1V?F?O&M+NX8AL9!&8ADT[6?&?@R
MI+;Q^"&N7# _;KJ9 R$8)!$9)ST.:+N]PY-+%#5-22\\*Z?)'MC$.I6Z861>
M"'89^0<9ZYY]JZ;PGX]T*WU2YTHQ-->33H%N$WN,\9.YSN/N0![BETFYT9-$
M2]MM-\(0IU#6\LX@!!Z[]@]>N*W-+T>6XMX]2TO0O#DC7 !-Q#<3+N(R,AMN
M2.E*X[;'7^$%T.Y^(WAR_P!1NW6&RE6X@CMF&^0EV5<[LY7=CI@XS[5]@Z;J
M5O?:PJ0S)(T,S1N%/W6'4?AFOAU=$OXM2@G;2=%B@M29(9O-E>2)@=P9<@!3
MU[\5ZU^S/\5+3Q;\6]2T!-2?4[ZVL3>7$@D$L2G?&F Q&[///S8]LU+-J7NR
M]3[QT[_CP'^[7-Z0@?QZ@/\ S[R_^RUTFG?\> _W:YS1AGQ\G_7O+_[+0=IV
MSQ*HZ4S:<\=*GV$TOE,3VH,[(A#,O7FG&7(/RU)Y9[XI=@/;% 6*D\L4,32R
MNL,48+/([850.I)[ 5^3OQ>":MXTUMX->EN8)M3N#!!%<*ZA3,3PRCY@1ALY
M/6OU-\?1*W@;Q&& V_V;<YS_ -<FK\GO%?BO1KGPNFGZ5:8O[.!GAN&MVVI)
ML&5CSW)SGC'/6MH)O8TA!2WZ'NEU^U1\,]%#2:-/X@OKC8%F_L^RV#>% ($D
MF#R?K7EOAWQ)_P +$^..M>)[.QN[&QNK:"..*^E#S#RT"98C@DXS7A7@F;4+
MRR8P6<"@.P8NI?<?4\C&*]W^!T4MEK]TM_=0O(L !!"H ,\=/45T)D3OU/4M
M/^.FJVNFZIJTFFV<WANV<VUHTKLLUS,,@$#.-H;J/0&L/X6> M>^(-Y+XMOM
M<N;*^,@EM94) ZY&5_NGH%&!BLV^^'8U+7;+3;O7[%/#,,A:WM=X60*QW%#C
MJ3G[V<X[5]%:5JV@^';..TMYRR[0ZB"!FRN, C X'!P*RJ.QZ$JL8P2I;O?T
M[&'\0;[Q?/9RVWAVVEL[Z)$<7EOY;B9"#O3#CY-K <^XKQ#4O#^NR7ME<>(?
M%?DPN=UVEYK$<9)!.%V(XSQC P:]6^+^@V/B'2);F]\1+INGW#*(O[34A+=U
M!!V #/.0<'N.M>$V]GX0L9=)D_M)KFY5RGD6VG/^_;<>=QQU]C6$#A+GA+PS
MX3L]=N[G4O$.FZB\N[9#");B1 ,'D[,=CW[UJ^-=2\(W=G$D-KJR0'<%DM+1
M%W'_ (&P]:Q="U'PO;ZM=+!!JVHW7EDSQ"%(HU7<,X);=UP.E;NM^)M+EM].
MNY/"LTEDOF%89K\)\PQDY1#^5:;:B?8DLO%=A8>'/$<UAX86>[@M+4S1ZY)Y
MMO/$754&R/:0V<-]X@]*QI?'7C";2;.>PT[1[%6>7$>FZ(C%?N\@R;R#R/RK
MIH_'NIP:;XD.@Z)8:1J%O9V\R30(UW).K.@5,..P(.<=17$:CJ7Q6U?2H]4M
MI]7CU*>YD2:WL[40%0-HR4"<$Y-0D^@V[&YXH_X65>:M86NGZOKUVC*C7!M"
M(@FY02"$48Z_ABF6'PMU^?QUYVHR74F@P2;Y);R_.,8/)4MZXZBJ7C/P#XWO
M-6LK73)=5N8GA1[L2W;HF\JIZ%ASUZ4NG_".9?B;'J=[<:<NAVTVZ5+F_C:7
M&TC.TL3U/2KLNP_0DT/X<Z=9^+O[5N]8T&TTZ28O%'+>1L[ 9'0=#^-:'B^U
M\$Z5X-TY-;74]:LYP8TO] =%MFD0L=JLW/&[GITXK#T3P%HME\0HM>E\4^';
M73S.S?9$G#S'@@ HJ\'OS72Z_<^!-#^$.G:#KG]I>(]%^VW-Y%JOAT".%I6S
MNC!<_P .>>*S;LQJ[.,UOQUHMEX*M6O?"%Q>VD=RRPR3W@56D!Y/'/4=,FO-
MRV\M(> 22!T _&O3]9\<^&T\#6<-YX0U.\L1=2B!C>)%F7G<3CG'7@9KRF9P
MW.-BYR!V KNHN]SV\N^T64E#,H&0,C[M><>#]?U#0)]7DTX1_:9];6W_ '@R
M-K$@YKT!&Y!! 7(( .*\_P#!?B6Y\.7.LSVT44TDVM1VX$W3#D@X]ZTJJT3;
M,/X1]O\ PC^,6N>%+#^P=,T2'Q-=Q1M)=O;MY%NCLV06E8$G XPJ]LY[5UNN
M_%_QV\#!- T#39MF5E=YYW3GKC**3STQ@US?P2^+OAGP!81Z=KVE+'K<D<DL
MWV2(W$S'=\B[$!(^7NQ KJM8^-GA+5?,)\*ZS<)U FLTC)&<\;I.,'L?2O'=
M[NY\U))O:YAV0\6^(/#WB36+G5(8KNTL\V]I;6,21LQSDD,"1T]:^<?&]AJE
MO<SA_$-P\WF%3&]P@)^63(V^@P/SKZ&E\>3WGA[Q)J&E>'9[?2+.U,EZDMS&
MCR#+;1L"E?7%?//Q'\3W]QJTURFBVL#&0_+).6(SO[A%]#713<5U9S.+OI37
MX'+R:)>N\C2:E*<N%S]I'.74=C[UEMHEP;"622^D'R,0?/'/S*/7WJ^FMZTX
M\X0VZ(T@X#O@$NO]<?K6-/J6J212 1PD+'_$SGN#_/'Y5I>+>[*2E_(OP.F\
M9^$;FP.GQP:UJ$RO"@!ED60C&0%&5Z #@5S]A<^)/!UH;^UDBU:VAF;S;0QL
MLK;@-S?*<'&T=N.U:?B7Q!KVHQZ?&;*S1[*VB@S#(W[S&3O;(/S'/-5?#OC.
M71=,:36K.YM;(W0=;V(*\0/.Y7[@'KQZ5A&^CBS=+O&Q]3?!R_N=3/@J\:*6
MP:6_C>6UF'S?,XPI]#G!K]!;[6+.W\\_:8Y98P3Y$,BM*Q'\*KG);T'K7YO?
M#VZMO%5MX<%O*9])O[KRY2A*,T;G;\IZ@\GD5]5VO[+?PJ\.2W<DGA#3]L[*
M5DO\EXB%P2LK'=D]22<YIU)-/8U4%):LW?$'[1%]HNAW&M0_#/Q3)I-LADEN
M;W[/:87. 0C2%N<CL.M<3X*_;0;Q-KMG:ZGX0A\.:9=RK''?7FO0Y0%L;I%*
M +@<_>KSKXR>#OAMX-VZK-XTDUGP];*8KKP>WC#:Y&>#;YE^9E/_ "S?@]B#
M7B5U^T%\$-%F@?0_@U#?>2&W?VS>I*)E(Q\WRR,,'GCO6$9R>Z-O94TD[GWQ
MXI_:#^&DB3Z!!XZT.\UJ\_T2"QL[M9Y7E;A5PF<9/<\>]=EX._Y!T?TK\_?
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M^\WPJO' ))U;8 .>PX%:TM_FA2V(/!\OVFQ\./(A23[8?E;L=DG>M+P#,O\
M8^M," !?W.[)SSO^O^%8/@F0N?#,30@.LT\C.V<X P.,=?F..>_>MKX?28T#
M66V;,7]UTXS\YYYKGKRO49I!:'#>'+@P_%_Q)P!ON84RQQD$=OF']?I7H.J(
MNH>&]3MY5'E2VVQAGJ"C9Y#?Y]Z\Y\-N[_&#Q-^\4?Z9".7(R /N]1GZ<CVK
MTB=M^C7Q)) @'W<G^!O<U@:6/2OAO$EKX+TFW5B1'"JC)))&!ZDDUJ>(SC29
M>WS)_P"A"N7T"-SX+M8DDD@+VQ7>IPR_=Z'UKB]0^)&C>!O".BW?B764T_\
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MR9(9X[C:,^@^7GZUH7'Q/\#I'/"GA+2'5HSY;P6A51)Z.#V&.QK1A\8?#_\
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M)#*[QI%%#!'N9>6D+#'8#IQ7*^%M#B\4V&H:>UY?Z)=6T*M$!$I%S'N  ;<
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M*_AURYOV@U5XH[R1/M"*0/*8!>5 Z[L'-?46D7QFTS3%:TMU+6".V,Y'[O.
M/PKS'1_A/;Z;H>LVR>//"M[>W44R1NEVT/\ K) V/G08X%>E:4=,MS%'#KFG
M.J6JVX\J\498)MZGW[U:T,O>YF5(/$6R"*1[*)2SE1D[1V[GZUT<NL1Z59WN
MJ/N$-K;RW#I V'VHK,=K'H<+P?6L"'2F#Q1Q3Q3^4Y9FBF5P.1U8GV[5K7^E
MW^K^'=;L;'RCJ%QI\\5N+P?N2[(0 Y/5>>>*IV+1SL7[2VDR:1;Z@I\81QS6
MEG>!/MD;$+<.41>3RPQD^W2K*?&%/%,D>GZ7K7B&WU"Y>XA@2\6)E)A&7)('
M ]*\]E^#'CH:?9V[^'_#]TJ0Z7 [6DOEC$+$R8PX^5<_*._O4OPQ\&>*M ^(
MGA^XU_PE!I>G6XU)Y=0%V66$R9V#'F,#NP.HXSVHN1S2OJ9OC/XSZWX)UFST
M_4==>*Z:+?;YL(Y=J[B, [21SDXK*/QXUNZ@MY(M>TRXCF?$0N=-@/S[=W\4
M?!VUQ?[5FGOXB^+_ (=D"7<5O!HWVAQ:*3&6WR, >.N,'@UXW)9S#P)X<@AU
M)]/FOM2E0%8=K8"1Q@'OGG.>O-%A.9]%77QY\76VJ?94A\.7=TZ;F+:1;,VS
M=C)(3UKU!?B=XBT?X;V6I7%OH5Q<WFJ"*.U?3XXX@!$Y)55Q\WOZ5\N?"NW@
MO->UJ0RM(T+"#+ DG]X<=3[=J]D^/BWMO\'_  C_ &6JEEOKV0AMP+%;7"XV
M@G[S4TKNUQJ5U=GVA\'KI[_0["ZEC2*6>))7CB&$4D D*/09XHK+_9T,K?#K
MPN9QB<Z;;&0<_>\I<]>>OK17.S4_/C_@I1?6\/Q>\-6]Q LH;2&923@@_:&%
M?*T6K6%^8[5(3 %8>=*K#('4[3C@]J^G?^"FIC_X7!X80Q@S/I#")V8J,_:'
MR,^XKY:T[38[7=+/')!]I;?F3. W3;ZC\:X91]]W>C.&KNS5\$:DGA[Q+J*R
MZ/::[;,JS6T]^C?NCT) Z'CC!],UV<'Q<:TNG33=*TF%OXHH+&)=Q]=Q&:YZ
MU\.33H%5&8J>=KY_K4B^ KXPR7!MV<?P\^];K32YS<TNAG:SJ<6IZI<W_E)%
M/+RBQQHFPYSGY5 S[U;N/'FIWKVXF<FRB4(T;/N##()XQ@YQ3+[PW<6DETC6
MS;H<%LYX%0?V!>+>P1-;LHD 8$@[>M:7&G*YTVJ>-Y;K2HS936^^,C]W<PJO
M'/3J/:N5N/$%]=7#M'Y-LK.' A.Q5./;_/)K7UOPC):V*R+ 'D+ < ],_6L9
MM"NH+IP( 2A&<#U -"=@ES/<RW:Y=;BWFC1UEE$I)8C! .,$?4U +>XAEREM
M$5)R3N)/7WZ58=I(C,SC:(WV'V/./Y5$)Y))@J<KWJM07,C8TWQ!KEC$EK9W
M45M&7+$-G!)[DFNHTKQMKEJ=TEU973Q$Y^;VQR0/>N2L]-O+N,2QQF1=Q!./
M2NFT?PK=73 -&J%B1DC/:LF.\C.U'QAK=RBH\T:A&#.N 1( <X) X''UI-1\
M=:E+"L=K%!;KP&*^G8  # IVI>&+NV2-F"E6=02%Z#/6DU/P7<+ K1.&P<D*
M!R*:?<5I]1VD_$74+65DEMS.!DJ\TC#8Q.21MQUS6+J=U8ZIJ-S?7.FQ_:)F
M+@0,0A8GK@G\?QK9T[P1*\Q:60*I!7! Z@]*P-52'3M3NK-R28F*@@=Q57[%
M6D27GB&ZU._G:=[M[)P!]G$I48  P!T'2MK3?&T>FV[0VUHULI V[BI+$ CY
MR!D]N<]JHW7A:6UDDG,@^S[%?!(!Y4'^M:>D:'8:A9O(+F,-@97<,J>>*EE+
MF6Q K^&;N9;F>QDDN^&E<L3N(QR,=.E5+RS\.7""2*&Y@N5QL:097;S@$9],
M5)<ZI8V5U]G%N7*;59PO7@9JA=Z[:A3'':#YQNW;?NC)H]X;O8W;?Q-9:58.
MMC]IM+G<,,NUU=   N3@@^]5;'Q9(MZ\KW=S"S #<I&,YR3@>O'-3V#Z7?63
MQ/)%!(Y#!G],#C\Q4%I!IJ7<@^U1",# 8GN#0KC7-H7=1CT.^OEGO SRR_-)
M/%%DNW')RWI4]_KNB3:M:7MS;7=_<6C(T<VY8AA1A5*C@@8JI<W<;7H6!XG5
M> VX'/O3K[7+.#5[9(4CF13&9W"Y'^T,T:]RI.^Q5@OM&FBN4DTV6,S3>8YA
MN#\RY) Z<=><<5:LM(\/WUG<R165SN#C?'+<N ?3:>PYJ&U6X:"[DM[$E))B
M\3;.VX\?E6E:Z+XAN=*N+FWL))+<2 ?*@.#]/QI-2Z,S3=]2$:M80V2PBR<Q
MPIY8BRVTKSD$CKD]^327GC""?04T@Z:4TU63_14_U?!XX SQ[U0CUFYCM(TD
MM'\TH6.$X;&>:Z>QTB_U_P 'R216:I=+AO,X  SU-.S[FDKRM9G%ZSJS,MFM
MO$+5+5QLPPR >N.*SK]XM7=!="Z\Q7(+QRJ58=N2/85TGB?1+NTT^U:>)69'
M!=E(.?3.*PM?AN#:VQC@> ,W4J1GCFJ1G:SU.<FM8A,WEK<8&<;F4G]!_2M"
MUL;>9%;%X&*\A90,_P#CO2DTW2+O5-12WBWL[N%((YYKHK+P/<S-L)8.(W.W
M/(P#38,PSIL%QN,KWS$G)/GJ<^AY'6H!I=J+@C;=MT/$X!!_*NK?P.99A&8W
M3> 0>W YKF+'0'U._D@MR)6VLX /50 320UHB*>QMH]RK%,47H6N,XI\-A8F
MV:4QSI(J@AA>;>_7%=2OP[DDT8.X6.Y60;LG^$YK7\#^ +*_LKQ[F!)Y8;DP
MY;M@ T DSB],NI[*>X6UN[F#?&S%5NV.\XX)Y_\ KU]5?\$Z+J>\^-NMR74T
MDLPT,CYVS@?:(NE>6ZCHFF>$+62[73(YO,(^50,C/I7I_P#P3IN[BZ^/OBAI
MH_*C.D,R(1]T&XCP*%J;05I:GZQ:=_QX#_=KG=$_Y']/^O>3^:UT6G?\> _W
M:\,^.OQHD^ MF/%,6E+K,IF6R6V>8Q*/,.2Q8*>@4\8[TV['6?0VJ7\>F:==
M7<H<Q6\3S/Y:%VVJ,G"CDG Z#K7P?\=/VR!X[;2'\!7NLZ.NES&ZDCOD6UM=
M39>)+>1]P.5&1M#88MZ@5Y%\9/VW_&/Q3EF2TF_X170PYC6QL+AV=H\[EDE<
M!27R,<8 XX.:\3N]1TS7=*M;_P 3^+Y8;A4(@TRTLGD,8#$)O8@(J'KP"3U/
M7-<,L2[M<NVO5W76R0VKVU$UKXB:QJ-_<75U>L\09E1-[2;$))$88G=M'IFN
MWTWXW^(? MOH4>D>*+Q$TE7""PN'C0+)N:11G[XRRXW#@J>*\-U2YTZ"^C^P
M7LMXY),C31!4([8.<MQZ@4Z6ZEEC>Y 4P$;@6)!8>I [9KKBVTG;?OH8V:/?
M/!7[4GBSP;?6%S-K%WJ=M;W37B027<BF1VP65SDD*0,8';/<U]6>'_%=WXX\
M*>"/$M])_I>H6\UY*S$L,F0<'N0!@<]<5^8#:U+<W6P1I$&.">>!TZU^DGP,
MN=-MO@!X)GU!G+6&D!G$1SA7D;'YX%6X26Y<2MK6NV/V[Q$GVN>.VAU.VE/V
MA;I]P\H!A&%.>2#@2Y&.<9JGXJU-_%#:LD-G=)<?V9J5M<;5.V2=VB96&#P3
M& 2/7.*Z+Q#\4] T-0XT;4;V:YDSY-L4#,0.6)8@< =ZO> _&.@>+],N]3AC
MD\/O/J#V[6^H2QJ\D^T?=P2&XQ@"MO:/8OE;6QSMYKPTG7;LV6@R/-IF66.U
M#HMZS6<<<;S2*VY2H\Q?E'3;P#S5W6=9SKNGSKX:U>YU&TWW4-K:%3%&MPJE
MP_4G!5L8YY&:Z*U\06;:)=ZO!9W<MJ7:9I3M0M@[<\G@  ?E6H-?L/[1MH%@
M/F74JV^_>!V/)]>G2H51S3LMA64;-G$?&;6O%>C^$=8FT.98[J.+[19V]I9!
MY4?<!MRX8MP?3@UXCX,;XF7-_P"&EN=9UFQLW7?J4%Q$BC=YQ#)_J\K\O/&*
M^LX;J5M8U 6]S,]K;V^&CVYCCESV..I&>,FL?4?$9M;G32UO!(+J]BMFWP@$
MA\\@]C41J1BDK ^Y\TZ=HWC"+7]<E.HZ_P#8HX)&L\22+^\R-@51TS\W;H!6
MK-X?\9-X7TQ_MWB"766N3]HE-S(T@3<,;B"/EQGBOI&34Y;*\TE(M,AN5N[U
M[6YD0A?LZ ,5?'?D 'ZUAWNK'7-%OKN:VAE-FUZ(HU4JK-$Q5-V#D_F*Z=^A
MDW97N>.>+?AKXJ\2^%?%&GVT6IZG/=Z;"EFEY=%D:XWJ6*[FPI"@Y)QWKQK_
M (9>\=V?@O2=+NM.A36H;N2:Z+2QN&C(CV_-W/#=*^W?AS &T:666-#,ET8E
MF0;0Z;0>@8CJ3R*X_1?B!K=SXC\<6\U^S6VE07;01>7&/+9)&"%3C)^4?Q9Y
MJ%>[%[1-)KJ<M8_#V:.YAQIA9$M88P1&2598PIXQZYK3ET*#PS*EW?6_V.R-
MP=LLL3=#T'3@\5Z-?>,?[*"W$VZ9&L4N1''@,6P2V,]21C"BN3T'X@:K?^*P
MAU,/;-<^5+:93Y-R2.H  S@1[ <\[\\]15=+E\NNYY;X5_9XUC5/C%_PF8FA
MO;&WD<1PPNS85@<#[NT_>/0GK6CXT^ VG:O\+(/A]>^)$TJ]M=4FO;J86[3
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MC2&BA3RD6<R@201V\VS <896+?3@CJ:H6'C!+342-+BB7]URGERL9#C@\GC
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M'U J_H>V&WF^VVEYJDRR'8]U"-ZC&?R-!:>EC OO$MG?Q6R7%M&2A#NI?(8
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M<6ICGDTK5(92$E@(V+@\_)P#GGCI@UV>EV-EXI33XY=5E;RIQ,X@C_=\?=R
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MC_6?,.""<XQV%?'>O:C'XBOM0BU:XELKFW<6]M=Q#(DQ_!(IQN3 //7ZUL>
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M84GOS_.OIO1/@Y:6FI^9>2SSVXA1O]:-K29.Y<;<@8 YSW-;=O\ "O0DE7=
M6C#$\L22"V<'\.*=S'D9\A'3+R3>G]K:RZX'*Q*.?ICI57[))<3.ROXE9TX
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M62_GCN=-=A%="--C1L<;9 1SC.!BEUU*2E;<TT\77R:O>1:G<W=D0"JOYY>
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M!VDC&#^->C^*_%'P^U/0;.\AT77-8M+*S6W >[") 4R!OVI]TY)P#QG%<O\
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M26(@D+Y1#<J3QEAT':H=!^*&K_"VUMYHI-5TJ\AC:.TL-5TX0_:;<\[B1C:
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M0KM!X#9(^M>A:OX&\$^&190W_P 1K:"XO(DGMIDTYFC"%N78[\[5.,J/F(/
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M)K:9EC$2R><[$[5PH."?3T^N*35QJ+2N=KX+U,V6CZKH<ERL;IB8V\R$,&!
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M6.>YC56A9<B,GE9#MSGY2"<?0]*WO"VGQ:59Z@]NRV#G:HFN(V(ERV"%XPN
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M'DGBO%M.G\3Z=IK7UQ+/?>%H;F"UNX]/F2$J"F$(?IN*@+DCM@UM^"/",_Q
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M0X9+B6#S-1L;9[&[ QM=&AASM(S]W!&.1S46A5?+"W-Z@IV-?PM\//\ A.M
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MZ]C=8GET2N>Y^#/@/I.E:WHVKBW2VN;.Z695,$D!R&X^_P ]<X'0U]O>#O\
MD')]*_-KX4?MG>/]5\8^'O"/C/2EEN-6O(K1;R)5MY$#, 2\14;A[KC\:_27
MP=_R#T^E=M&BZ*:;.:M4=5IM6."_:%8+\.O%#'H-*NR?^_+U^-_P\\6RW%P(
M/L?V2TN;?RC-*Y5W.,J5&.<'MUK]D_V@(A/\/_$D1.T/IMTF?3,+#M7X_:5\
M''L[".[O+YIXU W^2,;1CJ<\U4Z<9R4GNCC<5)IOH;NH2W M8XP\;R[E80"0
M#H<Y*_\ US[BDL_%41O7A:PABN'^1P(0 H/S$CC*Y/ICBO2O"(\*6>BVFG74
M_P#8:6KJEQ,D"G[6#DJ#(,MR0HR>#]*PV\ R:CKW]N0E[G1H6$MW+(V7:+'(
M4J,< Y(_V<&L*D8UK:W9#]_X64](T_3--5YQI<4<BDE;D*0T;'EL$'OGFM1/
M$&CPLT<D4)<H3YK2L2"!D<$D'(_E5VZ\'77]K7UM;A(=)D0*MV[AH6Z$;LC@
M[3G"^F*HW.G:/8,L<-M'J$\8V&ZG7<./[B=/TKP,3"$&U+5_D>=62C\3)F>Z
M:T\VSD?4K'=RD0)*@C/![_UK*N[!+.2WDN;::,SO@!T8,PZ@ D?+GC/'0'ZU
MLW7C&&R6*W57BE*$J@& ".Y], ]*R[/5Y[S409VW'JO'(SU)KSJ<JK3ER'&I
M2W2-I;RUT^X2>>V/G;B8QY1\N,X&2% P?J<U%%XRTF)R9Y5NF3=_RR4;>?NX
MQ^..GK5+_A*(H;E+.&5//S\P7.U5YVCGJ3[?C5/5=0T>1G:6&-Y?XO*498],
M@GW%:T_:3DE4BTO((RE>TCLK3XG17DR6MO\ :;EI3MCBC7RU/IGMQ[5].?#6
M34V\'V;LL41=F\Q=^_:P.#]/I7QWIFH17%J(K1)+>&,E_+"\[CW!')/2OI'X
M,V^H:OH[ZC)=P63VTRLEE<JXD(9._."1CH1CG/%?2X&DJ;:2/6P]DV>P,6@T
MT^?:/+*5.S@;2#D$#UKY4^,G[,EMXFU>35+*X.F&1]\L$9!\SVQGMZ<5]$:I
M?3RJY:[GS%T3<0%XYQ7.0:6^K&1F;>V[Y=V23[X]J]:<5)69WNW4^1_#_BSQ
MU\']=:#PZUXUE:C!N(XP3-Q\Q93ZX Z9QWK[._9]_::L_BC826NL6SZ'JT '
MRSJ529>A;I\O/;W%86L_#@WEO)?VT6+J,9EB48$R@<D?[7\ZP+34[708AL\J
M)A_M8)STQ[UG2G+!OF4O=ZI[?\ \S%8"AB&YST?<^K+F*%X1(75("N_S&.$Q
MWY]*R[*[LM35C9W$%PJ-M+1L#COV]J^+O'OQNGUF*PT2QUM_LMN2@MK>$M$9
M"2<&0<!AGD8S^=:7P8^(^HZ#K%U?2W" JQ@>SN_E4KC<&.#C#$@8/(]*ZXYT
MG-14=/7\CYBME45)VD?9T-L8LEVV]L9S6G8V$UPJLB%D)P&/ S7F]C\6/#SV
MT-Q<7R1W'DA3&S84R#[^#R  .,D\\UZGX;\7*]HAMGCNX@ 00N,9YXKKQF(K
M2I?[$XN?GM;Y-:_-$8/#THSMB+J/E_7Z$=Y836X'FJRCL>U<5XDTT7H9"<2,
MI56ZXR",_K7H6K:Z]^FV1 B9YV=3Z<^E<S>QH9%*C.>]=& GB'3OBDE+RVM^
M/YLSS"E1;M0=UYGR]J&@WWAJ<P:A;-:+$I F=?W$Q_O"3ISQP<$5G!+B.*0Q
M&.2 KDJKAE'TYSW[<5]4MM,#H4+J3AEX.?0$&N'\0^#-'<2R'3[>.1AG,,03
M)_X#BLI9>Y?PI?>>M3SZ,(KV\/FO\CPP1II\<UI=CR+@,-H#K(ISD'&.2*D@
M\.0WMJ9(F2;8<$YR%!Y(8=C6QK_@65)Y9;1Y,[=BF&;Y@N<X^<=,]LUBV[W^
M@W*2R_:$D08,DULPWCT9H]P(^M9/+\9%ZQNO)G73S[+ZG_+RWJG_ ,,8?BCX
M9->Z=-]EFQ."&2+<</CM_GO1\&M0C^$?P_\ B_XSO[N&W\0"P&GZ592OB8?(
M0NU>IS(X/ _@YKJ/^$CBN^%DB>0MG9#.H(_ D'\Q4>LQ:1JVGJFK:3.".DK1
M]/\ @0_.N:I0J0?OQ:]4>K2Q6'Q"_=5%+T:9\,V6@7.AZ9"'LHIKEI/*DF6W
MVLPW?QC'SKD=>N>M=IH&N>)O#7BW3]9\&VDMQK$#I+;0%06E5L*8B% 9CG."
M,YW8->^Z/^SM%\0];N(/"5W-,S M<)+&WE1 _P 3L  /; R>P-?8GP"_9X\/
M?">SM]3,;:WXH:/Y]5NH=C0Y'*PQG[@/<GYCWQTKR534'[[UO?0TA1O\>IYY
MX%_9P\(:#JUOX\\;)'H<VH1)?1>%=39$ALKLKNE\Q@<-S@^7T!R>>E=?\4/V
M@_!VE>%KV-KK3?$5]'&C)8@K=6LCL?DC# C#, 2/[H&2 !SP?[5'Q&\,:QK7
M]AWGG:E:V:M%>3VLF!;S%21 @Y#S'C(Q\HY)'%?-6GVUK;;1;Z9;6UJ!((K-
M(RXAS@':YY9CCYF/7Z8KSZU=\SNM/S/<HT'-+74JZOK=_P"+;N^\1:HJ02%@
MKK" JQ1KDK$@7DHIX/<GKFMW_A-])\'>'K._EL+F>]O(Y,(BLOSLIP0<< @=
MP2,@5#%%ITFD2&*(1S"<1 QJQ(.1A67H.XS]*YCQ1IUQ^]OK8EHXSMELY2S&
M5.[*"#@CT[UY%2/,UH>A5H*<%'L<Y+\2CXLFCL[TNUU%<B:18WW1LN?OOA<D
M!0,G(Z\"M;7O%5I?:@9=,MBT$=KO-Q-,D4,2CJ5)^8L<@X..*X?Q.OF7MI-I
M6EI:W#AHVDGMO+$P/"^8>,Y_D!71:G\#_$[^'KVX_LV?3K>\5&&DLOF*Q(4'
M+9)4EC\L?)PN21Q655TJ=G-VOT_K_ANYYM2G&,K=#T7X4^+KGQ7IDD$:3:A!
M9$%KT8V ]!Y@'WCQ@%@>!UKNWVHK,XYY /KQTKC/ACX$F^&VDKI,4!MFN9#<
MR$2A^,;, CL0 0.VXUV=P_[ML*0!Q@>M?6970ITZ;J07Q6?KH>-.W,VC[,^"
M9SX8THXQFVBX_P" BBE^"N/^$:TO P/L\?![?***[7N:'BGQGDV>*8QZQ?\
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M?V?_ /HL'@[_ ,'$7^-?SUT4 ?T*?\-.?L_?]%@\'?\ @WB_QIK?M,_L^/\
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M\7/!8/MJT7^-?SW44 ?T)']IC]GLG)^+O@PGU_M:+_&C_AIC]GP_\U>\&?\
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MOY[** /Z$O\ AIG]GS_HKW@W_P &\7^-+_PTS^SY_P!%>\&_^#>+_&OY[**
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MR\SG*G>W[J/AL@;>G)SH6_[0WQ"M=;\/:O%XDF34M 6]73;CR(2;?[6\KW)
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M_P##:T\1^(="TK6_%=_?^%O%FC^%M2,J6R1ZA<7KO')%:$ E7C>-CE\AE4\
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MU=WB\P@D S&*&5$R0 7R2 ":\1;XZ>.6G:;^WI!*?#H\)[A!$,:7M"?9A\G
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M "-7[344 ?BS_P .5OC1_P!#3X(_\#+O_P"1J/\ ARM\:/\ H:?!'_@9=_\
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M(_\  R[_ /D:C_ARM\:/^AI\$?\ @9=__(U?M-10!^+/_#E;XT?]#3X(_P#
MR[_^1J/^'*WQH_Z&GP1_X&7?_P C5^TU% 'XL_\ #E;XT?\ 0T^"/_ R[_\
MD:C_ (<K?&C_ *&GP1_X&7?_ ,C5^TU% 'XL_P##E;XT?]#3X(_\#+O_ .1J
M/^'*WQH_Z&GP1_X&7?\ \C5^TU% 'XL_\.5OC1_T-/@C_P #+O\ ^1J/^'*W
MQH_Z&GP1_P"!EW_\C5^TU% 'XL_\.5OC1_T-/@C_ ,#+O_Y&H_X<K?&C_H:?
M!'_@9=__ "-7[344 ?BS_P .5OC1_P!#3X(_\#+O_P"1J/\ ARM\:/\ H:?!
M'_@9=_\ R-7[344 ?BS_ ,.5OC1_T-/@C_P,N_\ Y&H_X<K?&C_H:?!'_@9=
M_P#R-7[344 ?BS_PY6^-'_0T^"/_  ,N_P#Y&H_X<K?&C_H:?!'_ (&7?_R-
M7[344 ?BS_PY6^-'_0T^"/\ P,N__D:OJG_@GC^P#X^_9*^*7B+Q)XLUGP]J
M-CJ.C-IT4>D3SR2+(9XI,L)(D&W$9Z$G)'%??M% !7SE^WK^SCXC_:D^!2^"
MO"]]IFGZF-5M[[SM5DD2'9&L@(RB.<_.,<>M?1M% 'XL_P##E;XT?]#3X(_\
M#+O_ .1J/^'*WQH_Z&GP1_X&7?\ \C5^TU% 'XL_\.5OC1_T-/@C_P #+O\
M^1J/^'*WQH_Z&GP1_P"!EW_\C5^TU% 'XL_\.5OC1_T-/@C_ ,#+O_Y&H_X<
MK?&C_H:?!'_@9=__ "-7[344 ?BS_P .5OC1_P!#3X(_\#+O_P"1J/\ ARM\
M:/\ H:?!'_@9=_\ R-7[344 ?BS_ ,.5OC1_T-/@C_P,N_\ Y&H_X<K?&C_H
M:?!'_@9=_P#R-7[344 ?BS_PY6^-'_0T^"/_  ,N_P#Y&H_X<K?&C_H:?!'_
M (&7?_R-7[344 ?BS_PY6^-'_0T^"/\ P,N__D:C_ARM\:/^AI\$?^!EW_\
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M^"/_  ,N_P#Y&H_X<K?&C_H:?!'_ (&7?_R-7[344 ?BS_PY6^-'_0T^"/\
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M ?BS_P .5OC1_P!#3X(_\#+O_P"1J/\ ARM\:/\ H:?!'_@9=_\ R-7[344
M?BS_ ,.5OC1_T-/@C_P,N_\ Y&H_X<K?&C_H:?!'_@9=_P#R-7[344 ?BS_P
MY6^-'_0T^"/_  ,N_P#Y&H_X<K?&C_H:?!'_ (&7?_R-7[344 ?BS_PY6^-'
M_0T^"/\ P,N__D:C_ARM\:/^AI\$?^!EW_\ (U?M-10!^+/_  Y6^-'_ $-/
M@C_P,N__ )&H_P"'*WQH_P"AI\$?^!EW_P#(U?M-10!^+/\ PY6^-'_0T^"/
M_ R[_P#D:C_ARM\:/^AI\$?^!EW_ /(U?M-10!R?PE\*7?@/X5>#/#-_)#-?
>:+HMEIUQ);DF-Y(8$C8J2 =I*G&0#CM17644 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>forms-4_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_009.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #Y Z@# 2(  A$! Q$!_\0
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M&/$__/Q9?]_'_P#B:/\ A&/$_P#S\6/_ '\?_P")KOJ* .!_X1CQ/_S\6/\
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M6/\ W\?_ .)H_P"$8\3_ //Q8_\ ?Q__ (FN^HH X'_A&/$__/Q8_P#?Q_\
MXFC_ (1CQ/\ \_%C_P!_'_\ B:[ZB@#@?^$8\3_\_%C_ -_'_P#B:/\ A&/$
M_P#S\6/_ '\?_P")KOJ* .!_X1CQ/_S\6/\ W\?_ .)H_P"$8\3_ //Q8_\
M?Q__ (FN^HH X'_A&/$__/Q8_P#?Q_\ XFC_ (1CQ/\ \_%C_P!_'_\ B:[Z
MB@#@?^$8\3_\_%C_ -_'_P#B:/\ A&/$_P#S\6/_ '\?_P")KOJ* .!_X1CQ
M/_S\6/\ W\?_ .)H_P"$8\3_ //Q8_\ ?Q__ (FN^HH X'_A&/$__/Q8_P#?
MQ_\ XFC_ (1CQ/\ \_%C_P!_'_\ B:[ZB@#@?^$8\3_\_%C_ -_'_P#B:/\
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M6/\ W\?_ .)H_P"$8\3_ //Q8_\ ?Q__ (FN^HH X'_A&/$__/Q8_P#?Q_\
MXFC_ (1CQ/\ \_%C_P!_'_\ B:[ZB@#@?^$8\3_\_%C_ -_'_P#B:/\ A&/$
M_P#S\6/_ '\?_P")KOJ* .!_X1CQ/_S\6/\ W\?_ .)H_P"$8\3_ //Q8_\
M?Q__ (FN^HH X'_A&/$__/Q8_P#?Q_\ XFC_ (1CQ/\ \_%C_P!_'_\ B:[Z
MB@#@?^$8\3_\_%C_ -_'_P#B:/\ A&/$_P#S\6/_ '\?_P")KOJ* .!_X1CQ
M/_S\6/\ W\?_ .)H_P"$8\3_ //Q8_\ ?Q__ (FN^HH X'_A&/$__/Q8_P#?
MQ_\ XFC_ (1CQ/\ \_%C_P!_'_\ B:[ZB@#@?^$8\3_\_%C_ -_'_P#B:/\
MA&/$_P#S\6/_ '\?_P")KOJ* .!_X1CQ/_S\6/\ W\?_ .)H_P"$8\3_ //Q
M8_\ ?Q__ (FN^HH X'_A&/$__/Q8_P#?Q_\ XFC_ (1CQ/\ \_%C_P!_'_\
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M]C_"E'Q.\7G_ )F*_P#^_@_PHY@/H7_A&/$__/Q8_P#?Q_\ XFC_ (1CQ/\
M\_%C_P!_'_\ B:^?!\3?%Q/_ ",5]_WV/\*?+\3_ !3:PO-<^)[FVA12[233
MJB@#J<FBXSZ _P"$8\3_ //Q8_\ ?Q__ (FC_A&/$_\ S\6/_?Q__B:^1C^V
M)IPN_LR^/;^>7.T&&"1U8^S!,&NTT?XR:WKJ2FP\675RT1 EB#[9(B>@9" 5
M_$56O8#Z%_X1CQ/_ ,_%C_W\?_XFC_A&/$__ #\6/_?Q_P#XFO"A\2/%>?\
MD/WW_?8_PI__  L?Q5_T'[W_ +['^%*X6/<O^$8\3_\ /Q8_]_'_ /B:/^$8
M\3_\_%C_ -_'_P#B:\/'Q&\5?]!Z]S_OC_"GK\1?%..=>O?^^Q_A2Y@L>V_\
M(QXG_P"?BQ_[^/\ _$T?\(QXG_Y^+'_OX_\ \37B@^(GBG</^)]>?3>/\*D7
MXB>)_P#H.WG_ 'V/\*+A8]G_ .$8\3_\_%C_ -_'_P#B:/\ A&/$_P#S\6/_
M '\?_P")KS;P/XW\07_B_1[>YUBZF@EN KQNP(88/!XKZ'IIW$<#_P (QXG_
M .?BQ_[^/_\ $T?\(QXG_P"?BQ_[^/\ _$UWU%,#@?\ A&/$_P#S\6/_ '\?
M_P")H_X1CQ/_ ,_%C_W\?_XFN^HH X'_ (1CQ/\ \_%C_P!_'_\ B:/^$8\3
M_P#/Q8_]_'_^)KOJ* .!_P"$8\3_ //Q8_\ ?Q__ (FC_A&/$_\ S\6/_?Q_
M_B:[ZB@#@?\ A&/$_P#S\6/_ '\?_P")H_X1CQ/_ ,_%C_W\?_XFN^HH X'_
M (1CQ/\ \_%C_P!_'_\ B:/^$8\3_P#/Q8_]_'_^)KOJ* .!_P"$8\3_ //Q
M8_\ ?Q__ (FC_A&/$_\ S\6/_?Q__B:[ZB@#@?\ A&/$_P#S\6/_ '\?_P")
MH_X1CQ/_ ,_%C_W\?_XFN^HH X'_ (1CQ/\ \_%C_P!_'_\ B:4>&?$P_P"7
MBR_[^/\ _$UWM% '&BUU71(#<7TMNT8(4^4S$\G'<"BKWQ!<Q^&I6'_/6+_T
M,44 86F?\E!MO^N,O\A7H->?:9_R4&V_ZXR_R%>@T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4AZ&EI#T- 'G7P^_P"//\3_ #JUX]_Y!<W^Z?Y55^'W_'G^
M)_G5KQ[_ ,@N;_=/\J .NT7_ ) MA_U[Q_\ H(JYFJFB?\@6P_Z]X_\ T$5:
MH 4$FER:0'%!:@ W4;J:3BJ=]JUMIZEKB5(5_O.0 *YZM>G0CSU'9>8%[=Q0
M&)KYH^-/[8R_#3QOIOA'PYX-U3Q]KMW:M?O!I]S' $MU8JQ4O]]A@_**O^#O
MVX?AEK?DV?B+59_A[KC\-I7BJ%K1U/M(P"'\&K*GC*%6W)-.X'T1DT;C7,Z-
M\2O"GB&UCN--\3Z1J,#_ '9;:^C=3]"#6O\ VWIY4L+^UVXSN\Y<?SKLO<"^
M211NKS_QI\>/AYX @=_$/C;1-**+N\N:]0R$?[* EF/L!7FGP8_:\L_C'XB\
M7K9^'=0T[PSHUXEC::I=@J]X^P.Y\H@,F,C /8@UPXG&T,)3=2M)12ZM@?1>
M31NK,TK7K+5XE>TN%F![*:T=PK7#XFGB8*I2DFNZ ?SZ49/I2;O:C=72F %L
M=:-PR:1SD"D'WC3 DHHKX0N/CK\5)O&5_IUMXEQ MQ+#'OAA"KAFQ\VP\@8K
MGKUZ>&INK5=HK5OL@/N^BOB2Z^)'QDV!8/%< . "[119_+RZ\#^(7_!0CQE\
M/_$0T4^+9-7N+>Z-K?26L$""V;OPR#<1STP,C&:\7!<09=F4W3P=53:U=K@_
M=W/U7I,U^>'@/]JKQ)\3+:.70?BY;2R,P5K6:TABN%)_A\MD!S],UZ+?_$?X
MENL:6OC22 )N)DDM869P>F?DP,>U>=B>+\HP4W3Q%1QDNCC)?H"3>Q]E4M?%
M'_"P?BP#SX\)'M8P_P#Q-2+\0OBIC_D>92>Y-C#C_P!!KA?'F0+_ )?_ (/_
M "'RR['VG29K\MYOVT?BY%^T,/ALOB(RP?:!"]^+>'<!Y>\G;L[=.M?0\7CG
MXD-"S'QU<@D84FQ@QGO_  UWXWBW*<N]G]8J-<\5):-W3V$KO8^PJ*^.-1\<
M_%&RMEF'CDLN#@?98"6QZ_+UYK5\*_$+X@7Z7$=UXHGFNE^Z@BMT"_\ CO/Y
MUC3XSR6K'FC6T_PO_(3=G8^LJ*^6%\<_$%$>&;Q.5NB?D<01,GX@+4B>/_B#
M:X2\UUG+<(R1)$?8D,AK2'&.235UB%]S_P AV?8^HZ*^0;_XY:_X>UF.QU;Q
MO:VMS<.J6MI-+!'),Q[ %,GG/2NINOB7XMO+:=O[9>RE+LT?D+&ZLF!@#*<'
M/K7=_K)E*BI2Q$4GM=V_,-7L?2M%?&6I_&+XD:7+"TVLW"0F9(^5@);)]DK[
M,%>QA,;A\?3]KA9J<>Z=U^ "UP7BS_D=K'_KT'_H;5WM<%XL_P"1VL?^O0?^
MAM7<!T-Q_P >)^E8OP\_Y"&N_P"_%_)JVKC_ (\3]*Q?AY_R$==_WXOY-0!Y
M1^TRN?%ND?\ 7B?_ $8:\B6.O8?VE%W>*])_Z\C_ .C#7DZ(!UK-[C(Q%FD\
MK'K5I4'6G>7G-(14\NE"5.8\&C;WZ4P*UU=VVDV%W?WD@BM;2)IY78X 51DU
M\:Q^%?$?QBUFZUO7IWC^TR;D5BV$C[*JYP!C'%>Z_M07E]:^!+&*UGEBM;B[
M$5TL?21< JK>VZN5T7XB>#_#<XLKW7M/@F1 NQW)P?3('6IE-Q>AK"*EN;'@
M3X"V]V?LL5SME?I*5RR'U&*/'V@>(?!WQ:TCQ!:W9O4M8(+:Y R&DC0;2".,
MY7^E=/IOC;1]#N["^N]1%E9.P(N=P  ZY/:JFH>,-%\>ZE=RV'B"RUA@>#;S
M*Q'X5HZ[=.RW+]C'F.[\$_$#2/B%9W4^F&2*:UE,5S9W  FA.>-P'8]B*Z5<
M?C7S_P# \"T^,7BN.'*QRV>)5'0LK(5/UY->_*06I+57,MG8F&.M/ _*HUY%
M2B@0H6G*,FD)P#0.!ZT =)\/#_Q7.A?]?2_R-?4=?+7P[/\ Q76A?]?2_P C
M7U+5(3"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F/B+_
M ,BO+_UVB_\ 0Q11\1?^17E_Z[1?^ABB@#%TS_DH-M_UQE_D*]!KS[3/^2@V
MW_7&7^0KT&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\&:?#,8S)LBB*R;,9Z1\_I7ZCF7".59IR/$1?N1459M62V(55K8\.\2?MI^
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MQN2/TIV8+78]HHKY[F_;U^"UN<2>*]O_ &[/_A5<_P#!0+X(#KXM_P#)9_\
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MZ\UZ>"R^KCG+V;24>YR8C%4\-;GZGZJ45Y_\"/BA'\8?AAHWB=46&XN$,=U
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M.D_8H\%V7@KXS^$GM8KNXDN3>"2<J7C4>5@*& QQU/ID9K]-%;@#%?D=X?\
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MN\R@*6/^R,U]5> _C#=^#](L-.F"2VL(""-^"N6[$?6OD"/QIK5\ 'O#$OI
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MWGZ_?"75GUWX8>%+^0Y>?3+=F/J=@!_E765Y1^RSJ1U3X!^#96Y:.T,!_P"
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M\OWDM;;^;N<C/D3]M+X=OJ&BV?C"U^_8#[+=KDDM$S?*P '9CR?0UZO^RO\
M$:/XF?"VUCG&W4]'VV%QA0 P51L8#T*X_$&NV\1^'K?Q7H&I:1>+OM;V![>0
M'^ZPQG_/I7RC^S?;S?"75/B<M_<QVATLQ6BR:A+]GMY'W/Y1=N0-W'/. U?H
M>3T(<490\KJSY:E%IQ>_NO\ IK[C..A]M(P7C R.M2B7S$('!]!7QUHO[8NL
MZ#JR:5XITFVG<7YM);RTE, A'RALQ-EB%)^]P&'(Q7N7PL^.&E?%4:NVCQW2
M1Z9=?9Y'N8P%EZE73!.5(&>>>E>9B/#O,J>M*I&2^:_1FQW9'G.Z!MCANB<U
MY;^T/XS;P/\ "O795F$%S=1-:6[X ;S'XX&>N-W->OQ7D,Y5WLK=OFRRC<F[
M\CQ7G/Q]T#5?B7;V,=AX&T:Y.G RVDDNH[$68G W1;1O  !^9N<FN_*.$<93
MQM-XN-H1=WUO;6QR\KN>>?L*>#I])^'^IZY/&@&KW0:!P?F,<8*\_5MV*^J]
M-3%Q&S0M,@/S*,\_B*A\+:IIVG:/8Z9/X?L+:"WC6-5M(O("''S$8XY//Y5N
M2?Z;?/%IUQ)!8H,IY\_R)C@_,.,9Z&OB>(X5<;F%7%R3]Z5DK--=%NK;(ZX:
M#XX?)D =-P(SAVQP1QS4\:11QOYD"NP.,%BKCT/TJ:_\.WND#,RI*@ 8R0/O
M7FJ<.)G5%QN8X&YL#\S7P56E5P\^6I"S\T>@I' _%*9(;?2=^XC[>@&T#.>W
M/:OT K\[_B]=11W.C0%MV+R-L@<9W8Z>GO7Z'U_5OAU%QR*"?>7YG.W>3%K@
MO%G_ ".UC_UZ#_T-J[VN"\6?\CM8_P#7H/\ T-J_4!'0W'_'B?I6+\//^0CK
MO^_%_)JVKC_CQ/TK%^'G_(1UW_?B_DU 'C_[438\6Z/_ ->)_P#1AK\Z/VX?
M&,5SJ?AOPM$Y,EG&VH7(#<!I/EC4CUVJQ_X%7Z*_M1\^,M%7UL3_ .C#7X_?
M''Q,/&'Q6\4:I',)H9+QHH''3RH\1ICVPOZU[.44O:8ES?V4<N)E:%NYY]#8
MC4=>TRWR +B[AA+'H-S@<_G7Z,_M,W=W8Z-X>M5N"UE%<.@C;.%(0 ']*_-M
MM0;3=0L[P=;>>.;V)5PW]*_1S]HZ2VU?P7X?OEE<":Y61, $8:+/7\J^.XK;
M6?Y?);7G]]D<<-'$X7X*W<I^*>B9((_>]/\ KFU?3MW8O>72#?L4#D8S7R]\
M"K"1OBAI1MY#*T:2O@C('R'G]:^DI]4EL,AY%6Z4G+3?=)_SVK\GX\US."7\
MB_-F.(?O'3PSO81!(^(R.F*K38N%5)%\P."K1G^('@@_@:Y*#Q)K&MW&RV6)
MH4/4J0OX5T]GJMHC>9<9\V$;MH; )'-?G2BTU8Y#R?\ 8Z\*:=X#\'>.(M.7
M?#+XHO+:*[(P\L,)"(#[*2XKV6>\:.Y,N<D# KRC]FR[<_!#1KMN&U&[O[]B
M1]XR7<IS^6*]#EN"5R>3SBO0S>I*MF%64W=\UONT_0J3U-JUUF6[.)&^;L<]
MJ\X_:;N6N? 6G;L;4OU/_CC5T%O?&.YR#@9[UR7[1S"7X:6\F[&V^BR0,]01
M7;P\E'-\,_[R+IM\R/#?"MUY7C3P^8Y 6%]"=H3/\8]ZR/\ @I1<A_%_@- #
MA=.NG'U:51_2KWP]L8+SXB>&UGNV6(WL>1VSGCCZXKG?^"CLP;QUX)A+ABFE
MRCT./.ZU^ZU7?BC!^4)G;+XT<9^QWXD72/'\VGRN%35+9H!D_P#+1?G7^1%?
M9MK-M?K7YU_"'64\/^.]"U%_]3;7]NS8&,*7VG]#7Z&,?)N&7.<'%?>9M#EJ
M0GW7Y'5AGHT>F_!^?=\2O#(S_P OB_R-?;E?"WP;;/Q.\+X_Y_5_D:^Z:\5'
M8PI*6BF(\&_:-B:+4])N4RK>2R!AVP<U\U:YX:TC5)&>YM&BE)R9+9]N3[CI
M7T;^UUJ$N@Z#H>J)'YT4=PT4D73<"..>QKYVM]?T[68PUK=QR,1DQ[@&7VQ7
MX?Q3A<9AL=+%4U[DNJ_4]'!9GC,NJ<^%J.+\F><ZW\*I=K/I^IPR^D4Z[&_/
MI7!:MX \2P,P73S<?[4+!A_.O>KJ,\^HK*ND.?ZU\C#-*JTDKGZ!A?$3-:*4
M:BC/U7^1\YWGA?Q%#]_1+X?2$G^594NCZXK?-H]\/^W=_P#"OI9I)8_NR,/H
M:C-]<@\3,/QKMCFRMK ]N/B;B/MT%][/FH:3K1/&D7Q_[=W_ ,*N6_AOQ%*?
MET2^.?\ I@P_I7T.;VY/'G/^=/6YG)_UK_G3>;1Z0*?B;B/LT%][/$=.\#^)
MYF7_ (DURGO(H7^9KM="^%>L7)#7<]K8KW+R;F'X"N^CW2$;F+?6M*VBVC@8
MKEGFL_LQ1Y>(\2,SJ*U.$8_B9>C_  UTBP7_ $J\FU!^PB'E+_4UWNBQ1:?;
M+;6<*VUN.=B\\]\D]:R8 L:%G(11U9C@5GZIX]LM,Q#9LE[=,<;4?*I[D_TJ
M:'U[,JBI44W?M^I\+F/$69YGIB:S<>W3[C[:^!B>7\.K$XX:20_^/FO0:\W_
M &=&FE^#7AJ:X?S)YHGD=\8R3(U>DU_1F H/#86G1EO%)'SX4445Z ',?$7_
M )%>7_KM%_Z&**/B+_R*\O\ UVB_]#%% &+IG_)0;;_KC+_(5Z#7GVF?\E!M
MO^N,O\A7H- "$9KYV_:2^$&C6/P^^)WBV.6[$]WX>N();%&'D%OE828QG.47
MOZU]%5R'Q?\ #K>+OA9XNT5/]9?:5<P)_O&-MOZXIPA!UJ=2:^%IKR&Y2491
M3W1^'LRB.-F(R%&33+2?[1!%(?XE#<4^_5EM90PPZH0R^AQ_C7;^/_ UOX5\
M._#W4K*(I9:[X<M[W+#DSJSQS_\ CZY_&OU>KB+8I4>\6_Z^5SYN,?=YO,/@
M)J6C:5XL*>*[^[T71M3AN434+6/SBLNW]TFWG"EQSQ^/<?L3\'=(30_A5X2L
MDLQI_EZ7;E[96+;':,,PR?\ :)K\@/V7OAA%\;/B[HO@75;FYM=&N7FNYGM0
M/-"QJ7*J3T!( )[9K]J+"RBTVQM[2$%88(UB0$Y(51@<_05^1NFU5E4E%)OM
MU]3ZJ52#IQA3;LK;][:V_0L4445H8'R7_P %";&-_!_A2](_>17TL0/LT>?Y
MJ*^'O"GAL>-/''AW0"2!J%V(<KZ\X_45]Z?\% =,>X^%&D:@OW;/55#?1XW4
M?J!7RU^QUX5B\5?M&^'1.28M*BFU @#(+HI"Y_X$X/X5\KB:7/C[=['Z[E.(
M=+AR<T_AYO\ ,\-NHS#=X=<,.&'H1P:_4K]C-8U_9[\.%/XFN&/U\UJ_/#XT
M^$/^$,^*7B31&P!;:A,L9_V&;<GZ,*_03]B,R_\ #/.A><I7]]<;"?XE\P\_
MGFJRY<N(<7NDU^*#BF:JY9"K':4HO[XO_,]YJ.:%+B%XI$5XW!5E89!!X(-2
M45]0?D1YI#\)-,\$?#CQ/H6@QS-#??:+J.&64@HS#*QJXP0HP .20.]?!?B'
M]J/X:M;M!=^';[4' (:&^UFXD3([$#KS7Z<7PS93_P#7-OY&OP#\5+B^O$QG
M]_)WZ?.:^;S'(\)F4X2JW7+HN5M?D>YA,XK8+F=N9MWU<E^31]@7OQN\#^#=
M(T7[3X4OK&+5+%-3M(O[<G$,D+E@'0+T!96X//'-+\+'\-_M4>/W\,:3H.D:
M7BUDN#<7DD]Q*JJ0"RN3][YA\O0C->9_M$^&I8/@E^SYK(BQ#<>%#9F0+U9)
M2^#^$G\Z9^P#KCZ!^TUX58.5CO'FL)!V/F1-@?F!7)A^&<%AJOM8N;?G.7^9
MUUN(:]>'(X+7SD_P<FOO1^P.C:5;:'I5GIUG"EO:6D*0111C"HJC  %73TI%
MZ4$U]@E8^;>KNQ$^]4&KZ5;:YI=WI]Y&)K2ZB:&6-NC(PP1^1J=>'%2TFKZ,
M5[.Z/F#XH_!K3OAI\ 4\-1ZI=WVEPZPMQ"\X59(@Y.(P5'(R3R>>:^:KZQTC
M3+FV\S6)HSM,,0>3!Y/W1QWR:^Z/V@?#U[XC^'5S#91)*;:9;R7>X7"1@L<9
MZFO@OXIW*G38408F#B53CE<'.:_)N(Z<XYE3IQNHN*].I^I</8F<L#-N5W=M
M_-+?U.;UNS2W+*<R@M\N <GT^E>Q?LE? 'PW\3;O5]4\0?:9I--9/(MK:7RX
ME+[B2W&6;CZ>M<QXH+_V))MAW/(%9<?F>M>X?L1>&M5@&J^(4:,Z/=AK*6-V
M(D$T95E8#&",,PZUVY-F-?,<1351+W=[6ULMW\SCS+ T,#A*DJ4FN;;7SV7R
M/I_PKX:MO"6@VNDV;RO:VP(C,Q!;!).. !CGTK86FKT-/'2OTYGYRP..]<_X
M[\'V7Q \'ZQX<U$NMEJ=L]M*T9PRAA]X>X.#^%=!G%-(R*AI25F$6TTT?FE^
MTE\+-?\ V2?@SHUOH_BDW4]_XDF<S1VZJ#$;8*JLK!@&&P\CKFOCK5/B?JTV
MDZ!I?DV\7]EMNMYT&69_->7<P.1]YSQC' K]%/\ @JEJMK;_  D\)V,B*UY<
MZV986)QL5(6WG_QY1^-?E[#9W&N:S965DAEN)ITBAC!QN9B ![<FN>.%HQGS
MJ"OWZ[6U[Z-K7N95ZTYR=V=_??'CQK<(#+>V,Q7N^E6Q/Y^77Z9?\$ZM-NKC
MX%_\)1?ZBE]>Z]>2.T45K' ELL1,80; -Q/+$GUQ7Y)W<91Y8VX9&*G'(R#@
M\U^M?_!-?5FU#]F&PMVP?L&IW=N"!U&Y7_\ 9S11P>&HRYJ=.*?DD@A4G)V<
MG8^JQTIZ#[QZ<4Q:='_%]*[&:L\_^'W_ !Y_B?YU:\>_\@N;_=/\JJ_#[_CS
M_$_SJUX]_P"07-_NG^502=;I#;-#L#C/^CQ]/]T5\$>.O@/XAU;Q_P")[Z*Y
ML8[2\U.>=&>0[@K/W&*^]M).-#L3_P!.\?\ Z"*\&U8_\3K4../M,G_H5?E7
M'G$F,X=PU*M@VKR=M2)P4UJ?/%I^SUK00)_:5@N!VW''XXJ_%^S]J>W:VJVO
M/<(U>YLGS97D&I-O3/%?A$_$[B!N_M%]R"-"%CPM/V=-420%M9M%4]]C8K0C
M_9VU/RN-8LVYSPC5[-( \)7DXHM;CRODY K!^)G$,E_$7W(KV,$[GC<7[/FH
M[LOJ]NI'81M39_@)=IECK$/X1L:]W5E=,ALU7\H.I((.36:\2L_V]I^"'[.)
M\::E\&8[3]J/P!;WUZUU;W=E>JQA!4\1,1U^E>_Q_!+0HBZF2] #=1*/\*Y[
MQ6F?VHOAV=A/EZ=J#;@.A\LUZTBRF242?*N<"O8S[C#-HT\+5A6<7*%WZW9"
MII['"/\ !K05<,K7;X]9?_K5I:?\(?#B9=K*65F."7D_I77(=@ %6#<!1\A.
M3US7P57B_.9[UV6J2.)OOA+X<DEXL/+*@[&,AP#CJ1W&:8GP7\(OIVZY6<ZH
ML0#R03E87<_W01FNT,S>8&SDT32"0Y[U]%E?B#FV P\\/S<W-U?0KV1Y=<_!
M31VB81SWL)'&6<-C]*SV^!7VA?\ 1]6(QVEB/->M,A\M^,DU#;,5F7J/3-9T
M./L]H?#7N1*F<;\&?A+?:'\7M"U":[MIK:S\QRJ9#9*$?UK[$B7!8>E>/_#^
MW5O%<<H/.QOY5[!",9K^F.!LYQ.=Y9]9Q<DY7L5:RL2U^<?@1@L>ML0>=6O.
M/^VS5^CE?F[X*9OLNK(#DG5KPD_]MFKS_$=_\),5_>7Z@MSJ9;^9;>2'("$[
MB,=Q[U%I;""]$TTJ6Q6(RJTC;<]ACWZX^E,G8%6/H.M94CKYOL#WK^=J#Y6I
M/H34-"+4WU"VALXK6)YY7 615)FD/8$Y]^P%7?$-\GF0:?"%6"RC$;;<_/)_
M$3[Y)K$Y^W+=8#,)!(57Y0><D<=/PJNZR&XEEZ;V+;<\#)KM]HN1I/5_D<LB
MU;N!(1P..@KC]4T;1-<U#7]-N;2&[%V$6_@D3(D7;A<_0=/2NCAE*39"Y/M7
M'^!6.HZAXAU)P1)/>&/;_="]*_0^ L-*>8SK)Z1C^;)1P3?LA?#V]MPNS5(-
M\921UN?WDGS[\L64G(^[_NC'O7HGP\^&UI\.H=5BLYC+'?WAN0FP(L*A%1(U
M ]%0<]SDUU,3HX^\".02#GI4-UK-EIA5;JY2#(!4OP.2!UZ=2!7[XVWH:(V8
M2<58A8[NO-48)58 H0R^H.15N)L<FG:R"VIHQ2X&<\5,)MRD'!%44;IBIT8G
M':LY4X35I*Y2-/3-8N=,N(IK>9HS&VX)D[3ST(]*N7&M->SR3-!%$S'.V($*
MOX<UC)R1Z5GZU8ZI<LDFFWQM@J'*!5.YMP(//;&<CC/%?.XGAO*<7%QJT(Z]
MM/R-$[&%\1_#VL>(]5TB6PCBEAAF4NK2!6SO7GGKQ7Z.YS7Y^Z%_;PU&%=3:
MVEMV9&#1)L=#\O!&2,D[CP2!Q7Z!U[N4Y=0RO#K"X96@MNN^I2"N"\6?\CM8
M_P#7H/\ T-J[VN"\6?\ ([6/_7H/_0VKVQG0W'_'B?I6+\//^0CKO^_%_)JV
MKC_CQ/TK%^'G_(1UW_?B_DU 'B/[6LFWQ7I*;BA?377>.JY=AD5^0OQ3^%VM
M_#?7IK>_C-U:2,6AU"U4M'(#SSW5O4']:_6_]L&7R_&&B?\ 8//_ *,:OD_Q
M!X5N_%$5W)%Y4D9X9)6&&!Z#!KHP^85,#)NFD[[H?U>-?XG:Q^>&IQ^;;R*&
MWC'45]S:QXC?Q;^S!\.]70Y81PQ2=_G1&B;GURE>(?%#X':CHZW=T-&C"HI9
MF@E!&/P->T>&M"TN']D^S@LKEH;>W:"X16+,3)(P,A!/0;F?CM7S.>XN.+Q&
M$Q"BTXU$O_ KK_(XZE!T;7=RA\%=9DL?B! 8\+/);RQHS/@ E<Y_2OHC2_/U
MB7R7V3.7YD!W#ZU\Y?!GP_;W7Q-T19]4,-N6D,C; ?EV-GM7UU:7^@^%M.9K
M+2Q,=I$=P7(WC/!*^M?EO':Y,Q@UNXK\V>?B$N8AUV]M?!FD[(@LDSC!(4#!
MQ7BNO66K^)(+R?\ M.6RC$3L54$$C!..M=CJFJC6=0SJ"N\:G<D<0X_.HM90
MW/A379-/MO+6&PGE9L'("QL3_*OB<*_93CW;1QIV9/\  V+[!\#/ $/0#1X7
MQUY;+$_K7:QS$J<@,A_,?C7$^"I&T3X8>#H%!/D:):;D'7F)3_6NNTG5[2ZL
M09(9H^Q#G.?RK/'>]B:LU_-+\V#W(Y=OGY!)/YURWQY)F^%<F1C9=0,0>W)'
M]:ZEE43+(FX0D\;A7'_'A))?A?J7V:19,2Q/N(^Z-X'?KUKOR25LTPS_ +T?
MS+I_$CPKP/>)#\0?#@CACEE%['R2<#GT[UQO_!0>Z:\^+'ATLVX#1@P..!F9
M^GY5UWP@TJ:^^)^@Q7>IM% )&D"H!DL%) R!GMZUSG[8FFV_BGX[Z?8[3=&R
MTJ"&0F<Q(,L[X.%+=".AK]TK5XT^)*#DOAIR_%V/24'.I9'SMX-L[K5]8M=-
MLHVFN[N:..)5!)W;AS@<X'4^PK]("Q$@4L&8  L.YQR:\:^$7P1T7P5=6VOQ
MO'_:$D&%CME;RT# 9&^1F<^_0>U>N)+\_6OL\;BUB5!1V1V4:3@VWU/3/@N^
M?BAX6_Z_D_D:^[Z^"/@I)GXJ>%1ZWR?R-?>]<$=C=A1115B/$OVN](DU3X1S
MO"ADEMKF*4(HR2,X/Z5^>5VH:3>K%2.C*<$?B*_1S]HJXF30;*%21!)(=X]Q
MTS7QYXL^'%GK$XN+20:?-C#!$'EM[D>M?$9CGU# 8WZKBX^XTK,A[GF=OXYU
MNQPOVK[3&/X)D!_7K3YOB[<0C]_I,<GO%*0?U%0ZWX*UC2)'#VC7$0_Y:VXW
M CZ=17'7X".4D^1L?=?@U*RS(\S7/",7?L[ CK3\:+('$ND72>ZNI%,'QGT)
MCAX+F,_[0%>=W,0)X-9=Q9KD_+7-+@_+9?#=?,L]9;XT>'AG"SD^@6HS\;=(
M'^JT^[F/MM%>1?806X'3VJW;V@!P!0N#,N6[?W@>L1?&J&0_N=%ESV,LP'\A
M4[_%35;D?Z/;6]I[C+G]:\UMHUCP20 />NDTG3KJ_ %I:S7/O$A8?G73'AW)
ML&N:I%?-DLUKS6]2UK:+Z\DG4?P?=7\AQ6GX=L)-0U&"UMHFDD=N%09('<_0
M5JZ%\+M0O0)+V=-/4_P8WO\ X"O4O"WANQ\.6\<=M&&F_BN' \Q\^I]/:O.Q
M?$679='V. BG+;161'4^SO@W9Q:;\,_#]G#*)DM[?RR_J03FNUKSKX%O(_@G
MY^<7,@ ].!7HM??X2<JM"$Y[M(U"BBBNL#F/B+_R*\O_ %VB_P#0Q11\1?\
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MG)8ZDHQUMH_5_P# /TCAFDG@ZLV^NOR2_P SU']I3P*GAC6H;BS/DV>KP_:
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M+!S5;$OFDON*44CZM^ RG_A7UNY/,EQ*W_CV/Z5Z+7!_!&/R_AQIG^T9&_\
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M;Y?/3\+GP[^V+\;/''A_X\ZD+6_-I;7%A:3+IMQ!%,D.8\<!U.,XS^->I?\
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MI39X]\4%F;XX?"6.,Y<:E<2MGG""WDR/RKV2.0RC.".?XNM>1^/9Q_PT-\+
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M6VF(&0X!ZDJ0 ?2OSAX2JWI!_<:J9+(,*I ZBJL[X7K@U,C-C:R28Z<K5/4
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MN(]0MC(X+D[,^7\XZ'G:!ZFO5[7P_(VEVUQJME:7$[PI-<2119C\W'J">A)
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M\A'7?]^+^34 ?-G[;38\>>'Q_P!0P_\ HUJ^;W;K7T;^V\<>/O#P_P"H8?\
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M_=M?O6_0RUSDG_!+3X.W#,SKK;$_WM5NCC_R+7V/MHVUVJC3CM%?<,^/+/\
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M\_\ Q- '=45PO_"<ZS_T!H?^_P"?_B:/^$YUG_H#0_\ ?\__ !- '=45PO\
MPG.L_P#0&A_[_G_XFC_A.=9_Z T/_?\ /_Q- '=45PO_  G.L_\ 0&A_[_G_
M .)H_P"$YUG_ * T/_?\_P#Q- '=45PO_"<ZS_T!H?\ O^?_ (FC_A.=9_Z
MT/\ W_/_ ,30!W5%<+_PG.L_] :'_O\ G_XFC_A.=9_Z T/_ '_/_P 30!W5
M%<+_ ,)SK/\ T!H?^_Y_^)H_X3G6?^@-#_W_ #_\30!W5%<+_P )SK/_ $!H
M?^_Y_P#B:/\ A.=9_P"@-#_W_/\ \30!W5%<+_PG.L_] :'_ +_G_P")H_X3
MG6?^@-#_ -_S_P#$T =U17"_\)SK/_0&A_[_ )_^)H_X3G6?^@-#_P!_S_\
M$T =U17"_P#"<ZS_ - :'_O^?_B:/^$YUG_H#0_]_P __$T =U17"_\ "<ZS
M_P! :'_O^?\ XFC_ (3G6?\ H#0_]_S_ /$T =U17"_\)SK/_0&A_P"_Y_\
MB:/^$YUG_H#0_P#?\_\ Q- '=45PO_"<ZS_T!H?^_P"?_B:/^$YUG_H#0_\
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M1_PG.L_] :'_ +_G_P")H [JBN%_X3G6?^@-#_W_ #_\31_PG.L_] :'_O\
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M] :'_O\ G_XF@#NJ*X7_ (3G6?\ H#0_]_S_ /$T?\)SK/\ T!H?^_Y_^)H
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M'4;2:UN? F@SVTR&.2*2R0JZGJ",<BK?_"<ZS_T!H?\ O^?_ (FC_A.=9_Z
MT/\ W_/_ ,319 <?_P ,5_ ?_HDGA(?32XO\*D7]C+X%KT^$_A,?]PN/_"NL
M_P"$YUG_ * T/_?\_P#Q-'_"<ZS_ - :'_O^?_B:M2E'9V%9,Y7_ (8V^!O_
M $2CPI_X+(_\*;_PQG\#/^B4>%/_  5Q_P"%=9_PG.L_] :'_O\ G_XFC_A.
M=9_Z T/_ '_/_P 35^UJ?S/[Q<L>QR/_  Q=\"<Y_P"%2^$L_P#8+B_PI&_8
MM^!#'GX2^$C_ -PJ+_"NO_X3G6?^@-#_ -_S_P#$T?\ "<ZS_P! :'_O^?\
MXFH<Y/=CLCC_ /ABOX#YS_PJ3PC_ ."J+_"GQ_L8? J)E9/A-X35E(8$:7%P
M?7I76_\ "<ZS_P! :'_O^?\ XFC_ (3G6?\ H#0_]_S_ /$TKO:X61E0_LP?
M"2W_ -7\.O#J?[NGQC^E6D_9T^&$?W/ >@K]+%/\*M_\)SK/_0&A_P"_Y_\
MB:/^$YUG_H#0_P#?\_\ Q-39#(!^SY\-%Z>!M#'_ &Y)_A3A\ ?AN.G@G1!_
MVYI_A4O_  G.L_\ 0&A_[_G_ .)H_P"$YUG_ * T/_?\_P#Q-%D!/I7P8\"Z
M'J5MJ&G^$])L[VV<20W$-JJO&P[@@<&NSKA?^$YUG_H#0_\ ?\__ !-'_"<Z
MS_T!H?\ O^?_ (FF!W5%<+_PG.L_] :'_O\ G_XFC_A.=9_Z T/_ '_/_P 3
M0!W5)7#?\)SK/_0&A_[_ )_^)H_X3G6?^@-#_P!_S_\ $T =U17"_P#"<ZS_
M - :'_O^?_B:/^$YUG_H#0_]_P __$T =U25PW_"<ZS_ - :'_O^?_B:/^$Y
MUG_H#0_]_P __$T =U2$5PW_  G.L_\ 0&A_[_G_ .)H_P"$YUG_ * T/_?\
M_P#Q- '=4A&:X;_A.=9_Z T/_?\ /_Q-'_"<ZS_T!H?^_P"?_B: .YQ1BN&_
MX3G6?^@-#_W_ #_\31_PG.L_] :'_O\ G_XF@#N<48KAO^$YUG_H#0_]_P _
M_$T?\)SK/_0&A_[_ )_^)H [FEKA?^$YUG_H#0_]_P __$TH\<ZR3_R!X?\
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M8JAD-T+&4Q!1R6+;<8&.M 'Z7?\ #[BV_P"B+K_X4?\ ]S4?\/N+;_HBZ_\
MA1__ '-7YDW_ (2US2].CU"]T;4+2PEQLNI[5TB?/(PQ&#GZU#/X?U2UTJ'4
MYM-NXM-F;;%>/ RPR'GA7(P3P>A[4 ?IY_P^XMO^B+K_ .%'_P#<U'_#[BV_
MZ(NO_A1__<U?EI10!^I?_#[BV_Z(NO\ X4?_ -S4?\/N+;_HBZ_^%'_]S5^6
ME% 'ZE_\/N+;_HBZ_P#A1_\ W-1_P^XMO^B+K_X4?_W-7Y:5+9V<^H7<-K:P
M27-S.XCBAA0N\CDX"JHY)). !0!^HW_#[BV_Z(NO_A1__<U'_#[BV_Z(NO\
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M +FH_P"'W%M_T1=?_"C_ /N:ORYN[.?3[F6VNH)+:XB;;)#,A1T/H0>0:BH
M_4O_ (?<6W_1%U_\*/\ ^YJ/^'W%M_T1=?\ PH__ +FK\M** /U+_P"'W%M_
MT1=?_"C_ /N:C_A]Q;?]$77_ ,*/_P"YJ_,+0]!U/Q-J<6FZ/I]UJNH3!C':
M64+32N%4LQ"J"3A5)/H 3VJC0!^I?_#[BV_Z(NO_ (4?_P!S4?\ #[BV_P"B
M+K_X4?\ ]S5^6E% 'ZE_\/N+;_HBZ_\ A1__ '-1_P /N+;_ *(NO_A1_P#W
M-7Y:44 ?J7_P^XMO^B,#_P */_[FI\?_  6Z@# #X, 9XX\1_P#W-7Y8TZ/_
M %B_44 ?U/63B>TAE"[?,17V^F1FIF0-UJOI7_(+L_\ KBG_ *"*M4 ?F!X\
M_P""RT'@WQOXA\/GX0B\_LG4;BP^T?\ "0;/-\J5DW;?LYQG;G&3C/6L'_A]
MQ;?]$8'_ (4?_P!S5^=GQU_Y+=\0O^QBU'_TIDKAZ /U+_X?<6W_ $1=?_"C
M_P#N:C_A]Q;?]$77_P */_[FK\M** /U+_X?<6W_ $1=?_"C_P#N:C_A]Q;?
M]$77_P */_[FK\M** /U+_X?<6W_ $1=?_"C_P#N:C_A]Q;?]$77_P */_[F
MK\M** /U+_X?<6W_ $1=?_"C_P#N:C_A]Q;?]$77_P */_[FK\M** /U+_X?
M<6W_ $1=?_"C_P#N:C_A]Q;?]$77_P */_[FK\M** /U+_X?<6W_ $1=?_"C
M_P#N:C_A]Q;?]$77_P */_[FK\M*N:3HNHZ]=&VTRPNM1N0I<PVD+2OM'4X4
M$X]Z /T__P"'W%M_T1=?_"C_ /N:C_A]Q;?]$77_ ,*/_P"YJ_+P:;=FSENQ
M:SFUB<123^6=B.>BEL8!X/%']G7?]GB^^RS?83)Y/VGRSY>_&=N[INQSCK0!
M^H?_  ^XMO\ HBZ_^%'_ /<U'_#[BV_Z(NO_ (4?_P!S5^8=MX?U2]TRXU*W
MTV[GTZW.)KN*!FBB/HS@8'4=3WJA0!^I?_#[BV_Z(NO_ (4?_P!S4?\ #[BV
M_P"B+K_X4?\ ]S5^9VJ>"?$.B:!IFNZCH6I6&BZIN%AJ-S:21V]WM^]Y4C *
M^.^TG%8M 'ZE_P##[BV_Z(NO_A1__<U'_#[BV_Z(NO\ X4?_ -S5^6E7&T74
M%U)-.-A<C4'*JMH86\UBP!4!,9Y!&..<T ?I_P#\/N+;_HBZ_P#A1_\ W-1_
MP^XMO^B+K_X4?_W-7Y:NC1NR.I1U."K#!!]#24 ?J7_P^XMO^B+K_P"%'_\
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M:_X?<V__ $1@?^%'_P#<U'_#[BV_Z(NO_A1__<U?EI10!^I?_#[BV_Z(NO\
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M^7X:CPX=1AN9?[0&L_:?+\J%Y<;/(7.=F.O&:*^$/^"4/_)[G@W_ *\]1_\
M2.6B@#]&/^"NW_)FFJ_]ABP_]&&OPJK]U?\ @KM_R9IJO_88L/\ T8:_"J@
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M+]13:='_ *Q?J* /ZG-*_P"079_]<4_]!%6JJZ5_R"[/_KBG_H(JU0!_,?\
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M'))/4FDI)65AMW;;"BBBF(**** "BBB@ HHHH **** "OV6_X(F?\F_>./\
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MK((YKCELGESDX 'PQ;?%#QC9>#9O"-OXKUN#PK,Q:31(]0E6R<DY),(;8<D
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MC_Y&H_X<R_'?_H+>"O\ P9W'_P C5^V]% 'XD?\ #F7X[_\ 06\%?^#.X_\
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M,@8J>BB@#\;/B7_P2&^-OB_XC^*]=L=4\'+9:IJUW?0+-J-PKB.29G4,!;D
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M "-1_P .9?CO_P!!;P5_X,[C_P"1J_;>B@#\2/\ AS+\=_\ H+>"O_!G<?\
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DXIU#PQ<:+807<4L>FWTTLY,MN\:X5H5!^9AGGI17Z>T4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>forms-4_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_010.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &: F4# 2(  A$! Q$!_\0
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MRDF'AEUM$EN'@,LL9RH=<K^-?4GP<CO/$?P\C1IF@?4KV1=D:X C0 $?H:\
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MBC&YW/IZ?4UL^)/$$^O7\M]<.<L3M#'H*\TN1-XWUA+2-R-+MGW,1QYK_P"
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MX\3>$K]_*CU>VMYRL]G(OS*.Q!Z^M<IK?P'@O%:YT.=;5PNXVDYP1Z@&NM\
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M3D\$]Z6SM)POGW$+RJ.F!U-6XIVN[L?:8O*MT&2!V%2+<TM*\/3ZCY,LJ-Y
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MKJ"V\B!(PLC ;V Y/YYKN+*YCD1&B=7C(^4J<BOEK]H77%D\=6<*_O#:QH2
M?NG.37L_@KQOI4]K#;17$8;8K[0W0L Q'YFOR;,^%\1ALFP^?.3DZKO)6VO=
MI_.Q^:4\6J^(GANL3U2&ZV=#4W]H*$.3GVKGX[S?'N!R#T.:@EO77('0]_2O
M*P^>NBN6*Z&_U;F>I=FU>;29':)R8&^\N>E))K*W"!PV\'WK*:Y$JD/R#P<U
MRVJ:E+X=G,H!DMFYP.U<4<RQ=>#H1E97NEV\D=BP\-VM3I[NX#OD#J:RM5GD
M:%DAD,<V.#4%MK4&IVT=S;R!XW&0:I7NID/@XXYS7GPIS52\EJCOC!<I>L'>
MWLE68CS.^.]59]26*3D[?>L6YUXG(R,_6LN^U?<!D]37?'#2G)REU-59*R.T
M&HI/'O4_,/O#^M55UD178C)X-<=::ZUM<*>J]",]15^_C-_$H@F:-20RNO7Z
M5?U10=I;,>MM#G?B5HD=G=M?0C$5SRX _BKRCX=Z@='\5WJJ2-LNX8.*]VU6
MW.M:/-:2X\S'RMZ&OG.V+V'CF]B8%6#;6!]:^TRB3K8:K1D]4O\ ACZ_+JZK
M4?9RW6GR/K>]OF\5^%<0';>6O[YH44?Z3QQGUQ7!Z3J^I:5X<U!-6VV*W,V2
MQ_UD_H@'916-X?\ &5QI$VGR^857>(R<]5-;7Q-T*+3OLFKW5S+/87))$:\[
M6QD@'MQFOT/*<QJ/+*SE!2JJT6WU3T3_ $9^<9QE"P^/HQG)JG=RBEW6K7ZK
M_@'.12Z;<Q37B1^5I$;!I3T:\E'W4'^R#UKD)=>MO"WCM=0V-+J=\1Y\*'B%
M.W'K2Z]XSCL=&2]: +'RNGV([MV8_3K6;X/T@S&;6-2)EF?YVDEK2OFM;!2]
MM%VY5RI=S!82C5IN,E>^K9]#:/KMGK-LN[ ..HZBNAANYH8 COY\'42*<.E?
M'VL?%*^M?%'FZ-,4MX#M('W7KVOX=?%^R\5*MM,197X S&S?*_T-?H^ Q4L?
MAH3Q,>6;6W;YGQ>)P_U>H_9.\2G^T&LZRZ%KKR?;+6VF\F1QPP4G(!_(UZ-X
M1L+?Q7;PRZ)K+_9O(_>VSMAHP1R0:Y#XLZ8VJ>"=5A"E7\OS%QT)'.?YUY[\
M$?$RZEH[V\MP]G?0_NQ(IP&QV->HY.A%5*NK6E^MCE7[UVCIY'U#X36**Z70
MH',<2Y7,ASN]2:LZW\)X[:^%[9YMKE>1)#P&^M>0>%O&^I:'JC32G[;$3@L3
MD_G7O'A'XGZ?KD"Q/( 3P4<\BO/Q=9QJ*45[MC6FFTT]S@M>TK4;>SA>6U^T
MS[BLHA';L<5RU]IV\/+$3A>J8Z&OHN^T>"]A,D#!U(X*]17":AX2DLXKWRH!
M.S*7"]R?:L8J%5J4&=$:DH:,\5E1GC (VL*?:6%Q?R"&!&<]>.E;K:9;7,GF
MW1>Q<9+PR#D8KEO''Q2L_#^FR66CQ;KDX3*=?Q-93KQIM1ZGNT,#4KP=5Z1.
MGL5TOP[:3WVHW"RK;C<T?\(_QKO= \')XXBTW4;VV\_1)!O #80CWQVKRSX'
M:#>^+M:A3Q C?9'4R,)5^4K7M_CKQS8>#-%%A8!8;>-=D44? _*O=R[!/$VK
M3/'S+'PPR>'I+U?4Y3Q3X$\%S+JMMI\-KI]_=+Y<MN,!90. 1[UY3\#?V2M(
MLO%M[XHUZX6,Z?.RVL#H-I7KNR3[UEZH=1U[5)-0DF<2,Q*JO:M[P_#JVKR_
MV4M\\]TY&;<2GY5[LW/Z5OBJ^&P=>T%S75M/S/(P\JF)I^\^6Q[5X2D_X2GQ
MS9W%@HM/#VESMY)48^U3E2"3Z@#-?0ME]Q?I7B?A%+71+[1K)Q'&68QVT(X/
M"DM(?<XQ],U[99?<7Z5Z.6U?:PF^SV[:+3]3+%1Y9+T+=%%%>P<8C?=-8NL_
MZMOI6TWW36+K/^K;Z4 >->.OO2?C7YH?M@22'XO+&J C^SH>>^=\E?I?XZ^]
M)^-?G1^UC=647Q+$8M_-U!K&+#D\*NYZ[<)_%.'&*](\1T/PCY]M<71*E8E+
M,2>_I7H_P8^"WB3XS7-WIWA32HKV[M@'FDEG6((F>HSU-<%J>MWLVF6^EV-I
MP6&]E'WVK[;_ ."8>G3Z9XZ\31W3CS?LBDH.W2O8D[0D^R9XT(KFC%+JOQ/B
M;XH^#];\)>-M4\-:C&UK<V,OE3*3GD>A[UVW@3]F#QQXE^&VI>,='TJ"[TVS
M$C2R33JC(%&6.T\FOJ'_ (*5_#:#3=0L_B%I<*20W:_9[F5!D"1> 372_L=Z
MA=:M^Q/X\FN&+S,MX 3_ +G%<4<1)X9U5NOS.J>'C'$JF]GMZ'YP&Z2TC6XO
M&".5RB+R369%=R74IEC4[>@'>ND\&?#+5?'OB"UTRUMWN+VY?9%$G)//Z5]>
M:%_P38^(&FZ9#J6^Q,Z .+-G!?Z=<9KLG4C35Y,XX4ZE5VBCXDG\/W9>-I5>
M)I/F"GKBKQT0:;'_ *0K;R,J#7??$2VO_#?C*[TK4;*6RU=)%@*S+C8<XX]J
M]4\0?L$?$^W_ + DMY+?6)-9*[! W$*D9W,3P!BE[2/*I-Z,KV+4FDM5N?,%
MIIOVF[6,G:.I;/ K8U'6C9VZ:5I\JE#_ *R1!R?;-?0?Q,_8D^(?P6\.B_O+
M&'6(IV$>ZQ.\HQZ CK6[X<_X)X?$23PC_P )+?6MM$SP^?\ V>''G 8R!C/7
M%1[:FXWYM#54*EU%1U9\I&V+A 5VYXW5;O1;:;&BA?,;J2>PKJGT25?%"Z8]
MHR7,,IA%MMRSOG[N/6O?++_@G3\3O&.BR:ZUO9Z?)*H>*QEF ?;V[X%$Y1C'
MF>PHTY.7+%:GRO)XFFEMH[>) %SP O05?T:WDU%_*D7KR<\5W:_"2;P?XI;P
MUKL?]EZ]+.MJGVKB.,LV-Y/<5ZI\8/V2M:^!7@RTU_5Y8=1L[B14:XL6SMST
MS[&LW4BDI-[[%JE-MIK5'@6HVLSW+PVR*]F@"L(^Y KU?X.?L\6?B?2Y?&7C
M?5T\,^&DD,=OL0M-,5X.Q!U%=+H_[)/B^7X3GQ\NIZ?HVASQ&Y(NW(<1YXP/
M<5[7\,]2OE\?V/A_2Y+!%T_PA:S63ZD@-MYDB[VD8'CEF/-1.:2<5NO\F_T-
M84[M-[/_ #2_4\=\:_ ?PUXCT*?7/AQXMD\0G3$,MYIFH0F&X$?]]$/4"OEN
M\NKN::2WA+0QN^& X/6OO;XMZ[J/A_XH?"VTU."P;Q=*TB:C>:/!Y=K<V\I
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MIL=>LYM2 3IEX@2?QZ_C7D5ER4.?I.*^]6_-'KTI>TK.#WA)_<[_ ),^/_\
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M/7BO$/VF/CAH'Q?^(=QXDT?2WT^TEA\IH),?O&S]\X]JM^$_V<?$/CSXWS^
M[VSN[",WDKW-R(R%2/)VL#C'>N<_:A^ ,'[/?C^#P]%K*ZP9(?.)4$&(9P W
M'6DE32IOK;04G4;J+I?4\TM];M;$QB" RA6W,9.WM5MO$L>I3?OH74GC*'@5
MR\TNY@BC'J?6M/3H&"?*1N)YS6ZUT.='5^&-'?6-:T^WC?:9IE3(;G!-?9?C
M2RO-.U!] L5_TE(8;2S7& D8C7+_ )D_C7QIX CDL/%MA= %WBG5MH[\U^DV
MIZ!!XELK'Q1:H?M<=N(V0]=OH?<&ORGB?-?[/SC!TZSM3J1G&_:5XV^^UCZK
M+</SX>I-+5-?J>>0>!K#PCX"32-.0>8'$TTA^](^<LQ/>N-\)IYGB^9\=%DZ
M_2O0-2U(LVW.&<%17,^$= FM-3N[N8K]U@JCN37YWQM44.12>\7^+/U_@QJ.
M%Q/=M'D7P_\ #GVKXU:Y?H,W$%A<- WH^T@?SKM/V1X;^W\7>(&OF;>^8VWG
MG=FO"/BKXBUKP#XL@U_3)GMS!=%)D'1TST/U%?3OP?\ &7A]?##>*8"J^8!-
M,%ZY Y%?4_5(YKPU4PB^*46EZK;]#Q\YG*&9WEHE;[C9^('PCMM1\50^*(4=
ML2@S*O0L.Y%=QX5/V-ISTR!BM;2-?M);B*1B)=*U.)9%],,,@_K4FNZ/#HMR
M%@),+*"K&OYAQ.*J5:,,/6;NE;7RZ?(N"BJCLM]17U-ASG KE?$=JEU+]HB.
MU^A(J[+<AE//%9LDS;MIY4US4*?LY<R.QJYF"YECC568LPZDU6FE<OG/6M*Z
MM3(A*<,/UJLMH40MW[UZL91W'&+(%4\YYJTENMW 8'XSRI]*B@4X ;&:M(A4
M@CK1)]CIC&YC+#)#/Y4HVD<<]ZLQ6Q4D,-P/K6W<VBWD23 ?.G7WJ(0Y3IG%
M#K\R-HQ,R"R0RDA,'-:]K$B$$\$"BUC&_!X-7HK02$J,Y-<U6I?1FT8]4:NE
M?O !GCJ*C\4:>M]H>I6Y'^MB(_2I]/M3;%!UV#K5G4R)+.;'=#_*O)YW&LI1
M?46S/E_POHL>FR.P 9PQ!-=K.[S2JG\)09KSOP]<R1:IJN]CL\YL9^IJ;7/B
M0(F33=.0W.H/\N4Y"CW-?J-?#5J]:T=7^1]S2G'D3>AZG#XB?36M8[;+[<!4
M'/-=;X]U*"]\(7<<\>V::V9FC<=#MK@/A/)'I2R2ZG*D]T1N\QSPGTKJ/$7V
M37;>:5+@3@@JRJ>QZU\Q5IPI8V&GPM/F74\C'4H5WR1A:R>O>Y\WP8ADB1\$
M'IBO:OA%X/&I7 U&[CQ;1_ZI6'WSZUP^G?#XR>-O[/;+64>)!(>Z'H/K7TAH
M5FAMX[2RBQ#"@ 8<!0/6OZ6AC*6)HQJ47I)7^1^'5,-4HU94ZBU1HNP5@H/7
MC KE?''P<G^(%SHEY]HCTS^S[CSVN)>"4'4 ?7%:VH^-]#\([9Y9EOKI<_*O
MW5Q_.O*?$GQ*U_QKK+RH7L])3.78;5QC@"N26.I89NS]Y=#L67U)14ZONQ9Z
MMXT^+NE^!=,>UT6%+J]5=CW'5B<8R*\#O/%FJ>.;PQW-TX@0;YR&^6)?<^OM
M7%W&MWOBG7FTO1I"HS_I%XYRL2]R36S8V,OB"ZC\->'?^/-7'VBZ8<RGNS&N
M.=2K7I*=?W4]EU9U1K4\+/EPW;5LUX[B]\6W*Z)X7B:UL\[-T8^:4]V)%>B>
M'?V=++PCIDVHWI35-?*YBC/.Q^Q]Z[/X>>'=+^'Z(4 #",*TF,DMZBM?5O&6
MDZ2LEP]PK/U+R$<5Z^!H3A3<JLM7LNB_S/"Q%;GGHK^?<XGP_P#"2>>"2\\4
M21'SFWO\O[T@=$![#CI7H'PQUJVMM9OM,++'X=MD#K.[Y,3#L/7/I7@?Q%^/
M\^H3/;:63MY7S?7Z5G?#VV\6^,Q#I6GL8XKB;>\S@\9ZFNNK5I4GS2C=LB,)
MU-+V2/KU[F;XEW$L,!:S\.6I_>,.#,1Z^U>?WGA[4?$'Q#LH8WD@L;12NY#B
M-AC@UN^,=:D\#>%;7P]I5P&O&*+<2]?J36[H]W#X<\+RZG?X+,N\ANYZ@5M[
M65^:;V3OV1QM7?+#8S/B'XDT_P"%GA';;D)*8MD:G[WU^I//XU\A:C\4KH&.
M*_LX9+.:X>26Y<8(!/0UZ=<ZW/\ %#Q+=ZSJ4A;1;%V*;NDC ]1[5YGXRTN'
M6KF\W61M[&[RT61@$#C(_*OAZ[GF-;VCC^ZLTEY=_5[GN0@J=.U_>/4_@!)#
M8_%[P[)IEPLUE?EP<'D+L8X_,"OOVR^XOTK\LOV2M1N?#WQ\\.^'[X,0\\GV
M=_;RG./TK]3;+[B_2OTCAFG*E@G3E+F:>_R1\]F,N>JG:VA;HHHKZT\L1ONF
ML76?]6WTK:;[IK%UG_5M]* /&O'7WI/QK\R_VS=4FMOBG]GACR7T^$E\=MTE
M?IIXZ^])^-? /[0WA"SU_P"+9N-2D,5C%I\7S#C)W/QFNW":5#BQB<J5D?,_
MA/PU=:Y>1HMLTHQEW'11W-?2W[,W[4WA?]F+Q)K*ZOIMY=Q7,/DHMFJE@??)
M%>1^,/&]CX=TEM'\,P[))?EEN(SE@/3->2SVX>1GNI'EF;DENM>Q;G33V9X3
M?LK<FZ-[XH>+;#QQ\1?$6O6\<D,-_>RW4*R?> 9BPSCOS7W!\*/V[])'[. \
M!:_INI76K1:=)8?;8D4Q;.0A))SP,=J^"(]&MUA1F.7<\5U"ZM=V>FM:V,&T
M;=K/MJ9THRI>R>P4JDXU75>_^9V?PA^,FK? KQ^NN>&,RONV3(Y^69.ZFON>
M;_@I=X2M-*@N+SPQ./$C19^55*(?=LYQ7YLP0W^FVR HIEN/FRW.*2XTFYM.
M9G$DLHRWJ!14I1JI*70VIU9TKN)W'QU^..J?&;QVWB#6+AIF653! GW8D!S@
M"OHOX^_M)>&/V@?@UX?\-6^GZAI<VFM'(TMXBA7VKCY<$U\;0Z,LUQ$%;8[$
M8)Z"O1&LX;%;>P$[:C?LH"JOW$J)4H<D:=M$[KU+A5GSRJ-ZM69]$_!O]K7P
MO\(O@-?> +[3[^]U2[BE426RJ8UWYP"21ZUQ_P"RO\?/"_[/OB6?5M6TZ^N9
M;B,Q[+10<9/'4BO!X=*DM]9DCO%VJ#NW&NIL[;39%,]Z-Y5\Q0*/O*.YHY8W
ME/J]&4I2<5#HG='IGQ+^/=G)\8'\>>%/.M;N:=;D&1,,  !L;Z\U]+>&/^"D
M'A[4- 2YU_PE=MJELHQ)&B,F<=02<BO@[QMX]L5N+.VTVP6,1@F0J/O>U<AJ
MWB;4]<,L,2BTM0 2@X)K-THN"IM:+8MUY*;G?5[GL?QG_::N_P!H'XS:-J&O
MVTR^%M.N5VV%K@OY6X;@.<$D"O>/C]^TAIGQS^&6G^&/#5K>Z!I%LRF=+D*K
M2A.BC!/' KX2LF%J2^_8RCAAW-:5]XQEBTU;6.X=4Q@G-3["#BH+9._S%'$2
M4I5&]6K'V_H_[9GA'6?@?_PK/QEHVHZA<I:&T-S;!63:!A&R6'(&*^*Y=-MK
M"[EAMD:YACR$DZ\9XS[XKF](>?4)7BA9L'AFSU%=''JMQH-K+%' A4KC<QZ'
MUIQII3<UNQ>T<H*#V1SNJ0^:^U@(XE)S64EN9)@D W?6I+K4GFW[@9'<]:V=
M N+?3D$DUH[R$8W=A5[F22N>[_LB?%FS_9M\>GQ5X@L+N[LYK5H%CM "V6^I
M%2^)?B./$OQRO/B+H<3V2?:Q>0_:^&CP<\XS7B^N^*V\1S6MFL'D11N!CNU:
M7BK4)K&U,./+@"A=BGCI2:O-3ZI6_4V4K0<%L]3[VO/^"G>@7/AJ%$\+SWWB
M=8L!MBF 2>N<YQFO./B-^V'9?&;]GZ7PKXBL+T^*)99)#=1*H@4[V*CKG 4@
M=.U?%:^(?LD-O]E@"-']Z0CK5;5O$=U=Q[4W01L.%'?UKFE1AKH=$:\U;4^Y
M_A+^WMH_PL^#.B>"M.TZ]F\06#Y>9E4P.NXEAG.>GM74>*/^"I/AZ'PK?VWA
MWPK=6OB22,IYSHBPAL8+9!R?RK\\M @D$RLRN2X(! [=Z74C81%XE$@<_P 9
M'?TIU*49MN6[)IU9024>AZO^SQ\;HOA_\>[;XB>)HKG4-KR2SK;X,C%@1QDC
MUJ[^T1\5+/X]_&6\\1:-9W5EI]PJ@?:  R_7!->,64*Q1;4E\PL#GV%=+I5\
M-,TQV7(8CTZFFX)\K7V=A*;7-_>W/J[X)_M9>&O@5\%-6\&ZII]_=:C>>;L>
MW52@W=,Y(KPOX*_M':Y\$?%Z:[I,?VB.21FNK=S@21D]/J*\KOY9I[K?,Q=Y
M.?FIZ6:E2Q4[ /F'2J27,YK=Z"YGRJ'1'Z(ZG_P5*\)+HLUSIOA"\3Q"R;=\
MJ($W8_O!LD5\#?$[XA:O\5?$^I>*M<D,E[>2<@#A1V ^E8VEVJZA<?+%B$')
M9CTKH;]-'N=/%O\ :DMV7G'7)K!4XQ?,MS9U)27*V<=8Z7/J4FV #=UYXK9L
MM*N %WPLQ4X9AT%%I;(L<\BSJ8XQP5."Y]JG77)4A$$;&!&&&4'.:>O<22/3
M_@5X:36O&=NY3=%;?O7)]NE?8>C?$3_A"KJTCU$XT>^)3G^#G&?QKY\_9CT=
M?[*N[S'_ !\.(E8>@ZUZQ\3M-D\1M9:):QAFC7S6*]5'I7\J<<8U8_/W0F_<
MIJWII=OUN_P/WKAS+8/*8PFOXEV_T-/QY:#1M8MV1_,LYW$D$J]&4U8M52)-
MR<*6[UP=GXFG%J_A_57VV<#JUO<R#F%QV)]#781:C'>VXCC8-Y8'S*>#]*^>
MSG&UL?AL/&OK.%TWT:TL_7OYGL9#@IX&M6H2V=FCP7X\^$EN;/4RZ;XI5+@@
M?=8=ZY;]C[44UFT\1>$;EQ(&.45CT!X.*^@?$L8DG5FC65,$E'&0P[BO)UT&
MT\*>+(O$7AW24L+J&51*(6.+@,<%<'ZU]QPKG4:,%AJR>MK/HGMJ:\095/$6
MQ-*UXK7S1],:7%;:-IMCX8R1/;0C[,S?Q*.U=MIFHKKFA?99_P#CY@& 3U([
M5P'@;Q1I.NW2WNILEO/9JX82'#(1P:W+/5+2ZF:\TNX6> L02A_G7QO'/#<L
M+5>84%[DW=_W9?Y2_,^2PE6-3]V]UL078,.X=P>E5UD4@#IFI->O(X%W,RJS
MG(4GDUC6]YYLN.W6OSNG!RAS,]Q4W:YNH@) -,EM=K$=C4MF!(BD<^]79;;S
M4(QR*P<N5C43$^QX'-*.& /05<6/<=K#:0>AIDML48N!D5KSWT9M!$MJ0K8_
MA/%#V@@N-G1#RI/>GI'OB7)"G.:T6MEN[;:?O+R#[USN?*S=+J4XM-#7$<F2
M O7'>M..-4^Z*9:1XC7U'6K2+\V!UKEJ3;=F;:):$L29C],U!>.(M/N"Q^ZC
M<_A5Q1P!FJ'C$C1O#=Y>2D"+R6)8]N*BA3G6G:"OM^9S\ROJ?&^L7EWJ$]W:
MZ4#$LDK>9<L, #/:NG^$OP]MK^_>VMY-Q0;KFX)R?SKSK5?'4VKZDNG:-;/<
M&1]O[E<LQSVQ7L7P_P!'\0^%/!VJ&UTJY&JWDJKM*'** 3G]:_H?#X"K4BH3
M7+%_CZO]#TZ^8TJ--N#O)?UH>GR?#7PWIB?Z1?!CC+(TVTXK6T3X5Z((QJ.F
MRSB&8;=@?>K'^E>5^$O"7B?6+]8KK0)Y+B;)N+J^)$<2^WO7H$WCBP^$FGMI
M.FM+/>OP9). 3_L@U[4L!A:4?WU-<ECY/^T<96;A"=Y7^7](UX] LM"+W6O+
M_9T:.1''N!>51T/L*Q?&'Q6>^L)-+\)VFT8VEU'ZDUPWCI-<OM-_X2'Q),T-
MHHW16^[EL]*Z3X0QVQ\(7.OWDL*VRN2P7^''1<^M2W)QBL+%0AZ?IT1PU7&@
MY3KOGGWZ$>D^ 8/#_A>3Q%XLD\ZXY,%H#C<Q[FO$OB'\3;W5+B33]/'[V7"!
M(U^6)>>..]=IXU\6ZW\1+N6VL(Y9A(QC@0<I$G'S&NC^&OP=TSPH!>:BHO=2
M;G=(/E4T\-A:=2HW):7^]_Y'AUL36JJ]1Z=/(\;TN9M"\/G188FM[B3,EY)W
M(]#7M?P.U;PXNE-;6+K#?8W2&0\O]*\,^)WBVWN_B+JVGZ5 9H[A?+EFCZ1G
MH36 +Z30F-Q9R.I3Y5V'!->C&ZQ,I5O^W3GLIPT/MG6+'^UM+GA6?R&=<HZG
MI[U\N^(XK\ZE+!?:NEQ&'*AU8G.#CI6EX6^-FOS:D'M[5KF*-<-$W( QBJ_A
MCP9?^+/%/GS%?M5[<D_9D7A03UK:M6J23CAM9>1@HQCK/8[GX*_"FP\0WTU[
M>L[:=9KYDTCC"D]E'UKWS2+BT\/P6EU8P2":>8PQ)!& D* =2:X?QG=KX2T.
MR\(Z',$N'P9VC&2S=R?I6IX*GUD6O]B/NNVE(9)Q_ 1U)K7!T&H<U9\TOU\O
M);&.(J/:"LC<\-> I]9\<7.L:C?->V$;>9M?A2PYP?85PW[07Q1:\E_L*P?$
M9X(7LO>NV^*_Q M?AQX6_LV"0?:"F'PWS,?3\:^7O#MG?>.]=N9C<JEVX+JL
MA^]_LBO+S+$^VJK!4G_B_P OEU-L+2Y(^UG\CU;PX\'BVSTS0]*A>WL(45KM
MB,?49KTO4/!6G^*?[.TO8L4%NP(E(P%4=1FO//A3K=OHL&HZ=J,8L;R,ECO^
M4L!73>)_C7I1^'O]DZ1"5OYW83SOU R>0?I7K82A&K4_>.T8Z^HJLG&/N[LS
M_#&B>'[[]IKPO=:- 88M/N'5'S]\^2ZG\*^[++[B_2OSY_9_DFN/C)X?P-ZK
M*[,1S@>6_)_2OT&LON+]*^ZRR,(4Y*FK*^R]$>%B[\ZOV+=%%%>N<(C?=-8N
ML_ZMOI6TWW36+K/^K;Z4 >->.OO2?C7YP_M@:U=#XBP:9 Y1#9QN2.^6?_"O
MT>\=?>D_&OS0_:_OY;3XQP+!&LDIL(=N[M\TE=N$_B?(XL8[4OF>4W%]!X>T
M_P O[,);M^2[CI6!:R1WLK-/$#CG<*K:K-J<]U)+<'S@>IQP*32_.G;R]IP3
M]U1S7N6/GW.\K6-ZRM%OK],%5B09]A6K)KS06[!40P1_*"!C=5631KW3;))!
M"Z0RCDE3FGW>B*+:+S)]J'#%.](U2:V,Z[U[^T+J-P#%@<@]*C,[W,[B)S/(
MQQD=JW-#\'W/B*_=+6-EMD'S/L)P*U;[0M-\-._V-_,E5=N&'+-WI7&HR>K*
M,-K=:2UN'2,R2#(!Y*_6K(OM1#K;6$&+V8_-.%RWX>E?<7[%GPP\,>-O@/XG
MU?7-"M+[58O.$5S<)N=,(<8-?)7B+6(/#FKW-M;HL[AR&,*991GH*Q<TZCI]
M4E^)T1A^Z52]KMK[CC[O2[NQOOL]Y?"XE!&43DGZUL:_X@LM.TMXA,DE[,=@
MV 91>E>>>(-?>XU*XG1G2=CPJ]O:L&.6_ENTW1N79ACS%//-7RW,'4Y=CNK:
M:$O-+]A,LA4;".0OO6/?)+;+)),OER2G"*>,U]<_$?\ 9YTWX,?LFZ=XS??J
M?B/6)8GWA2%@0@D*!_6N7_9-^)7PGM]'\6CXIVUM<ZC+&HTX3VC2;#M;.,#C
MG%8N=E-1UY?S-.3X.9VYOR/FB;2C!;'S6&XX/6I+?0X[W9&F'8G YS3_ !%<
MVTVN71L\RP/,QC4= N>*T=)LVMXC/+"ZQ?Q,%/ ]JTB^97L2TD^4670+;3+;
MRX3_ *5CDJW -<[J$@MHY(WE\Z1C@X.<5H:A?)?3R_9U,$1^[N/.*K0VMO$B
MRW"N8R<^85.#4C]#.L[+Y-^TX!'S$5U"Z3?26N["Q0V_S,[>I'%0ZAJ<(L%>
M"W$*;_E##TK!U'Q#>W4;PAW"2D%E!X/I4E*R1,K%)"Y;,A;Y7I+D37,FUV:1
MR1]XUH^'] U#4O+5+9V0?Q,AP/>NPTS0-,TJXWS'SYURP0^H]:5RDCA_)BBN
M$BG 15Y9:IIY-Q?NVW*;L(G8"K=U<M.[RO""9G+#Z9J""&2:Y"10G<3_  \X
MI;ZAMH7]4N[BSVF)E0 $?N^U82W5PQVR)YBDY^8<UOZIHTJF1W8Q1184@GJ<
M<UCLV9PT>77H.*329>J-31+6,W(:=O*B')!')]JV[F[MY-1:2-%V@82,G@'U
MKGK.Z?<H5 )-W)--^U-+J&3S@_PT-!<U[7191<O+>R +DXW'&*R];U-;BX-M
M;9$2MC(/WC3_ !#JJ.4BBWAR!OW'.3533HK>V/GW()QR$!ZUE?6Q9'(TMM'L
M$I0'G:#59GDD/)W>]67?S9'G=0H8_(GI2)$2>",GG%$HJ0+00%Q\N_('85HV
M5H[,K-SGGFJ4*YE8=3TS78:+8B26TCD!8R.JJ .N363Y8)R[&\%*344?<_[/
M'AC3M!\!:3=/;CRY;07+AOX21DUVW@GPN^N_VEXF526FE:..(C[L:\<5G6%G
M_8WP]BAC79BWCMPOIA0#7K/@FR&D>$M-MU 7]UN;\3FOSC,.'\MSS"24H6=3
M7F7Q7>M[_H?;T,SQF7SLIWM[MNEET/)];\):5ONVN+>/_2 !)N'\J\QNK>3P
M5=I I,EK(3L8]QZ5[W\9])MWTU+N.9;67>OR@X#&O(?B!8F\\,J6PMW;@2K[
MCI7\^8_A_'Y!65+%/FI3=D^GEZ,_9<BS3#X]1E%^]LUU7^:,;59Q?V:R1XW#
MTKS+QIIES)=:?J,$KI%;W"/<11^@8<XKI=&UH7<&S< _]TU=N;0S(9$ W8^9
M2.#[&JP=667UXR[,^SQ&&]M3=/N8.O7TEKX\O(XV*6M_;!T(Z$FM+PGXKN_#
M-PKQDM"&S+%GJ.]>3_$WQ=>Z7KT2W,9B@BQ]GD7LO]T_2NN\.Z]!KT45U"ZL
ML@R5[@]Q7[GB9X;,\*E)7A4CJOZZH_!94:F%KSI2TE%GT-XDT^+QAX>MM0TZ
M3=-&/,A93U'=34/AJV2_L5=6RX^5AW!'45RGPNUYM%U Z9+(6T^Y.8LG_52>
MGT/]*[R+2KK2?%"W-E$)-/N\BYBSCRW[./KTK^;,UP%7*:T\#4>B]Z#[KM_7
M7U/K\-75>E?J789&MBL:KDCJ:W(!\H;&,CI4?V90WW>IJ4H1CKBOCJDE/8WY
M2&YM4\P2X&#P:@="'V@;E-72 Z%">#4%EG<R-]Y324G;7H5L4CITC3!BQ"CM
M6Q;C8H7%/\D'!S4HB P>]9SJ<RLSH35@6  DJ.M2Q0KN+$4\(4C)'6D28!2&
MQDUR7;V,VW;0<Q55XQZ\5S'Q3N;6\\"ZC;WTSPP-'CY.K>U;9G_?!.Q->;?$
M^*Z\2>(K?0XD9+>.W-P\SG$;G.-N?6OK.&L-6Q.94Z-%7OJUZ:G#BJM.A3=2
MJ]$<%\-O%'A71=*<Z7X>C@U"$[/.V[F/ODUNZE\0?%\UE))9Z3+' S;!,RG:
M3@FNVTW2?!O@_P +2_:D@6Y7#20Q#+*,=2?>O-'^)5W\4M5N?#>A1?8-$1U!
MN0.1@X))]>:_K/+>'*U9PJXJ;]Z[22Z+=W/S_$<1^QC.%!+3=O>[.A^''Q \
M=Z_<K#;6A,;'8]T1^[0#J2<5ZC+X3T/XBB*UU:^CGN2?EN+>,##>QKG;74[#
MP=:#2= O"US; +-Y:_(2>#D]SUKJ]$\4L/$6EV T8VD2$S3S,N-J@9.3ZFO0
MQN0>SHK$<_N2;M==OTUT.+"YU[2JZ+A::6MO/]?(\/\ C_\ #CQ-'<VWAJPN
MY=2L;B0*DH'^J0?PFI3IT=GX=T[X?Z.[&.U.Z\F4\,Q.6)KLOB9X[CM+O5+J
MW;S9B#Y:DX*L37 ?"37;8Z]JEE,S'5&42R!UY.?0^E?#RC*494J&R=W_ %^1
MZF(E[2<?:/9)'H>G:+:Z';I#;Q)&JJ 2HY;ZUSWQ&\;Q^#_"M]?N?WNPQPH.
MK.1QBNFN;H88'MU/I7R5^T#\13KWB6VT?3I25CD$6Y3P&)P371AZ:YE?9&=6
M=HF9I=HF@>';G4;@^9K6K,7<GDQIG-8T6JJSJOWR. H]:3Q%JHM;D6L<KA(4
M" YZUU'PN\.PZK*-8NH2+>V;(WKQ*W85RSA+%U6UUV.?FY$>C^%+ ^#_  N
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M2,7<GH;,95XPP[TXN!R:Q]-NR\(&<D<58,QD8J>*QE3:;3-HZJY>:\"\=<U
M907SZTS/;'/K3<;#F3@#D&A12V&TD9?BG6H?#>CWFK3, EM&6Y[GM7B7A'Q)
MJ?CWP;K$NI7;Z?#]L,T%](=N$8 LH/?%/_:9^(EO"EMX8@F_TBXPTD:]QV!K
M@=8BUB7P5 NH745K9V-KF&TC<#=R2,CU/6OV3A7!+!87ZW634IM6]/\ @L^7
MS&I[>?L8]!/%GBBXN?#EU8:?.]] UV(5O@3Y\F5Y)'<#'ZU>\ Z_>^$E736M
MX8[,IB1XU_>DGJQ[YKF_A7XPLTT2:WFAC:_>020ROT08((J34_'%GHFKNPA6
M]U!AG<K<*>V?7Z5^W8/BS&X"M##)<ZBMNR\OU/D,1P]A<7AI5]FW\V^_^1[-
MJ'CC2/AMI-K!80G6-?NB/LUI]]F<]&?U-=IHGBS6].\/RKKY5-6N\O(IZ0J>
M<5YU\&]*M=-%WXGU&W^TZ]*,6BS+D1Y_B&>E;/BO73&D8N1Y]Q-]]2>OM]*\
MKB'B:>,:ITGJULMDNOR7XLVR[*X8"/-5U?XM]/F9#6%QXH&I3M)D$[8Y5_A7
ML?J>OXU>^%'@2;1-6U"]OKI;R5H1'',1AMHSUK-\,:KO$MN&"/(V6+-M7V_3
M%=);ZN=#,LLLT3P[3OV2CI7SL,TP="U",]7:_GV_KN>M5RS&23J2A8Q?C'XU
M3P?X7N&24"[N04A //N:^.M&G?5O&D$DGSE"TSL>>0.M=5\7?'4WBS7YB)2U
MK!F.%2<\9KGOA5I-QK?B.:&W0O-(HB'MDC)_*OH)Z0G*';3YG@.3;29UGA7P
M)>_$+7IBH,-A$2TUP>@ [#WKT7X:17.LI%X>MD)D2<Q1JH[YQDUT5W<6/AVP
MB\.Z8!&T0S+(O!D;ODUTWP_\.K\.=&U#Q-=GR[V]+&UC(Y4'^*O0PT(X:@ZD
MM_Z_,QG><^5'3>,YX?!>BVOA;3+DB0C_ $F5/XI#UR?K5+X;/)K@71\8N87V
M2,O=<_>JEHQ:\A=[]?.O+D[@S#)YZ"N\T_3;#X6Z!<ZO* FH72$D$_<7%52G
M!0G4J^K?Z?H%2+348E;XQ>/;?P9X;31+!U7^%R."[^E?->J:5J>FW\=U? J;
M@>8DJMD?@:M^.[S5?%5R=:N8G_L]I"D3$_K^-6=$\71-I;:=JT7VRW53Y+'[
MT;=J^>A&6.Q#Q%5-?R^2Z([%:E!0C\SW?P1':Z/X5MI8&#>:@=G/5F/J:N_$
MCQ6/ WAAM)@F4ZM?KNN)$/*(?X:\3N[OQ#I?A.U657CTJ5LQ2 ^G;-<[>ZW<
MZE*6N9Y+B0\;I&+'\S7TN%A]6YG;WGL_(Y*G[RVNB-;1-(N/$FK+"IX8\M_=
M'K3=?TM= U:>V23SQ$>)!]*Z2QG3P1X;\]F4W]VH*^J@BLGP7H-WXXU]48L+
M5#ON)3Z44HNK*_3^M1R?*M3W7]F*QN]8\2:/J.J(/+MIC]C=_OD[&!_#%?<U
ME]Q?I7R%\,;J*S^(/AVRA CMQ(T<2+QTC;G]*^O;+[B_2OKL#1A1IN,.YXN(
MJ.I)-ENBBBO1.41ONFL76?\ 5M]*VF^Z:Q=9_P!6WTH \:\=?>D_&OSS_:RL
MXYO'4#RS-M^RH/+';EN:_0SQU]Z3\:_,C]L_5[R'XL)9Q2%83I\+X]]\E=N$
M_B'%C&E2NSC+B[BL]*>+3BUN)5\K)^\^>OX5]-_L.^'/A)KDEYIGCJS@?Q S
M$VUU>2?NV![ 'H:^*VURZCV^<I=@NU1Z5/%?7+;3'YGF#Y@ZD@K7LRCS1<>Y
MXJJ+F32U1^O?P[_9;\!_!7QG+XU_X2AS!$3+%%/.HCC'7KWKY=_:$_:GLK7]
MHBQ\5^&94GT_3IHXYYU&3-&O# ?K7S3X-\/ZKK.D3ZGKWB"]&DP#)CDN6(?V
MP37FOC#Q!%?ZS,]I'Y-DAQ%&O''J:Y:=*2J*4I7L=-6O'V;2C:Y^N_BCX?\
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MX9T2XUU;.*Q@1IFAD4/%(@(VD'VKS3_@G?I&G^$K;XR:5;7JSQ6S>2DCL/F
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M<3B<.[4Y-+[S[ C_ &T["2T$B:!,KD$X,HXQ5#P;^UMK'Q$\0OI-E:PZ9$<
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M.Z"*YFM&.'B;T]J^M+;Q78^'O ZZC"X\Z]B\P2'^%2.E?"&F7,"740FDV;F
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M2(2,LI91Z\]JQ(-06WE"R:>P8 # -?04Z-"M%>Y?YGRD<97IRLI'8:KJ,M_
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M]H[P#*Q)N(;J5D(/3-O(#7Z^V7W%^E?EQ^R=X"D@^.?A._W[1:L\DHQT9HG
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M\B1W3[/SKR#_ ()S>*+WQ5\;-:NKJ0A?LQ6.'LH!->7?!O\ :WUSX3_!>_\
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M97OP<_86UC0[]?LU^MG)/,@ZHS$'%>5_\$NG4^'OB4Z3--D(2S=<[7KP>_\
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MQ Z6TEN2AGD79Y<8X0?XUQH'V=5V@LQZUKI*L-@7F1?,D;&2,G%5XC]JN"5
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M*>%"C&*:FKI([&6(,,]1T)J"9I;Z4\83T]*3*6UAUC82ZC=$PDGN<=JVK?\
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M:/Q2TC_F9J+JSMT6Y4U2--<OX-&M"3;0MOF9>A]!7J4 7PSH:6Z?\?<P /\
ML)Z5@?#KP@N@6,MW><^2=TC-U>3L*NWEV]U=23.2S.?N]@*_.,3B'0A[:.[N
MHW_\FE^B_P" >O1I^UE9[+^K%<H$);D[N<=JD#!E(!VD^E-$_P"]6-D(!&<]
MJ4H<DC\!7R3N]SVTA'8D[3@<56:3:^WO4F]@2",X[FF1*DKDD8;TK1*VK-%H
M>K_LRP"[^-?AI>R-.Y/T@D(_7%?HM9_<7Z5\'_L>:&U[\4;B^,8:.QL78/\
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MK79Q+A17],Y;@U@,'3PR^RM?7=_C<_.\36=>M*IW)****](Y@J.5<BI*0C-
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MQ?>:0Z$PHY:"7^_&>GZ5Z'^S]\/M1^%^KZ=?PPD%&Q<!?XU/##\B:]2^.7Q
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MPC\6 @CD\-2A<\D7,'_Q=6+CP?\ %%"GE>')F Z_Z3#_ /%U//#NAJG/>S.
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M8_*C_A!C_P \Q^5>[_\ ".Q_W!^5'_".Q_W!^5 'A'_"#'_GF/RH_P"$&/\
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M'Y4?\(['_<'Y4 >$?\(,?^>8_*C_ (08_P#/,?E7N_\ PCL?]P?E1_PCL?\
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GE#VJ2B@"/RA2^6*?10 T*!3J** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>forms-4_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_011.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &C JT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **:6 J-IPO>@":DR*IO>JO<52FU^TA)#7$88=5W<_E32;T0KV-G
M(HR*X^S^(^BZBTZVEX+EH'*2B-&.QAV/%4-.^+FBZGK%]ID/VH75G@R^9;LJ
M\],,>#6OL:G\K)YX]SO\BC(KBW^)&G1W;0/'=+M7>93 WEX_WNE/;XB::J;P
M9FCQG>L9(Q]:/8U?Y6'/'N=CD49%>9)\>?"TL+S17<LT:,49HX6(!'45G6/[
M2W@[41<&">\(@?RY-UHXP?Q%/ZO5_E8O:05]=CU[(HR*\9M?VHO!EW?W-HCZ
MB)+< N[V,@0Y]&QS5RT_:-\*7MR88GOLA=Q=K-POYT>PJO[+&YQ6[/6LBC(K
M@;'XMZ+J*JT!N70_Q^0VW\ZE@^*NB743R03R3HC;6:.,L ?2G]7J[<K^X7M8
M6O<[G(HR*\I@_:(\(W-S>6\=S<O-:-LF46S_ "G\JI6_[3W@RYU&>R26_$\*
M!WW64@7!]#CFE["K_*P]I!:7/8\BC(KR&+]I7PC-J*V:O?F1D,F_[&^P >K=
M,^U2C]HSPF98T5[YMYQN6T<J/J>U/ZO6_D?W![2'<]9R*,BO*XOVA/"DYQ'-
M=OSM)6V8@&DA_:'\)7$\D,=S</)']]5MV.WZT_JU;^1_<+VM/^9'JN11D5Y1
M%^T7X0GOI+..ZN&N8TWM&+=LA?6FK^T;X1;5%T\7%V;ID,@7[*^-HZG.*7U>
MM_(_N#VL.YZSD49%>/WG[2_A"RU2RL';4&GO&*1E+&1D! S\S8P/QJ6^_:-\
M*V$UM&PU&5IY1$##9.X4GNQ X'O1]7K?R/[A^TAW/6\BC(KS ?'KPRS[%ENF
M;.TA;=CCZU(OQU\,/=26ZW,S31@%T6%B5!Z9H^KUOY']PO;4_P"9'I>11D5Y
MC8_'KPKJ6N2:/!=ROJ,<?G-#Y+ [,XS4MQ\;] M_$5CHK+?->7B,\;):.8P%
MZ[GQ@?C1]7J_RO[@]K#^9'I.11D5Q-Q\3=+MYTB*W+EL_,D#%5QZGM58?%_0
M7#[)Y9-AVMLB)VGT/O1]7JO[+#VM/^9'?Y%&17DR_M'>#WN+R!+FY>6T8+,B
MVSY0D9 /'I52']I_P7/-=1I-?9MMOF$V4@'/3!QS1]7K?R/[@]K3_F1[)D49
M%>+Q?M3>"YKR:W5]2W11B1I#8R!,$XX;')]JD@_:@\&W%Q-$CZC^Y179S8R!
M,$X&#CDTOJ]7^5_<'M:?\R/9,BC(KQ5?VJ?!+2W2>9J*BW*AW-C(%);.,''/
M2J*_MB?#PP23&[U!(D=D+M82 97KV[4G1J+>+*4XO9GO&11D5X+_ ,-E?#<V
MT4RZC>,DHR@6SDR1],5(O[8/P]>YMX%N[]I9\;5%C)QD9YXXK/E:Z&JC)JZ1
M[MD49%>1VO[2G@R\:18KRX9H\;A]F;C/2D?]I/P?';R3&>\,2'&X6KG=]/6J
M]G/>PN5['KN11D5XW/\ M0>"[:V@GFGOHDFV; UFX/SXVY&.^:M_\-&^$!=1
MVYN+I9G&X*;9^GK0J<WLB6[;GK.11D5Y)'^TCX.ENWMENKDRI]X?9G^7W/Y5
M#'^TWX,EW[+B\8("686CX&"!CZ\TW2FMT":D[(]AR*,BO#;W]KGP'I]HUS/-
MJ2PARF[[!(<D8SCCW%21?M9^ Y;L6PNKY9CU1[)P1]>*R.CV%6U^5GMV11D5
MX<O[6_@-HYY!<:AY<)56?[#)C)STXYZ&JQ_;'^'JP0RM<:FJRXV Z?)DY.!Q
MBG:Y+I5%O%GO611D5X!/^VA\.+:Y,$MYJ"2C)*FPDR,<'/%1)^VW\,'2X<:G
M>!8!ELV4G//0<<T68*E-[(^A,BC(KYPN_P!NWX6V5G%=2WVIB*7.W&G2DGG'
M3%6?$?[;WPR\*:-IVJ:C>ZC%9Z@@>W9=/D8L"<= .*?*WJ'LIW2MN?0V11D5
M\_:/^VK\-==U2ST^TO=0:XNSMC#6$@&?<XXKO#\:= 7J]S_X#M5PI5*BO"+9
MC4:HNU31^9Z+D49%>;GXW>'1_'=?^ [55U+X_P#A?2=/N+VXDO!!!&9'V6KL
M< 9. !S6GU:M_(_N,O;4_P"9'J611D5\@R_\%0_@9#(R/J^KAE.T_P#$HFZ_
ME4'_  ]/^ __ $&-8_\ !//_ (5'L:B^RS3FCW/L7(HR*^.1_P %4?@,1G^V
M-8_\$\_^%.7_ (*G? =B0-7U@XZ_\2>?_"E[*I_*PYH]S[$R*,BOCMO^"IOP
M(7&=7UC)Z#^QYO\ "IH_^"H?P,E<*NK:P3C/_((F_P *?L:G\K%SQ[GU]D49
M%?(0_P""H/P,)PNK:PYQGY=(F/\ 2M&'_@I'\%YU++JFJX'/.ES#^E/V%5_9
M8<\>Y]69%&17R=)_P4K^"D18-JNJ@@9_Y!4W^%47_P""HOP*CD*'6-7R#CC2
M)L?RH]A5_E8>TCW/K_(HR*^.O^'J'P&SC^V-8S_V!YO\*1O^"J/P&7KJ^L_^
M">?_  I>QJ?RL.>/<^QLBC(KXX_X>I_ 7_H,:S_X)Y_\*/\ AZI\!?\ H,:S
M_P"":?\ PI>RJ?RL?/'N?8^:6OE/3/\ @IO^SMJ$JQGQX]H[8P+G1K]!^+>0
M0,>YKUWP/^TM\+/B/L'AOXA>&]6F=@HMH=2B$^2VT9B+!QD\#(Y[5+IS6Z#F
M3ZGI]%1K*&[T\$&H*%HHHH **** "BBB@ HHHH ***1C@4 !.*AEG"#)-0W-
MVL0))Q7*>(?%,6FVLT\A)2-2Q" L3CT ZTTKZ(#?N]6CA4DN !ZUR%YX[CNM
M:@T6PD1M3N58P^8#LX[G'4#V_.L7PK:77Q3M+36':[TRQ#%X[.;Y#(1T,B]3
MZXZ"O1+9K'1+2PEU..SLKY_W*L ,ECV5NO.*[/9*GI/678PYW/X=%W,[2_#.
MH/ (=>N_MLTV_<;-#'$@[+C)/3U)JSX5^'VC>"[)[;3;9FCDE:1C.^\Y8Y/)
M[4OB#QC!X/M;5]2\VY-S/Y2-:PDA<GC(YP!ZUS7B7Q;/X/TV[GT82ZY=SSB7
M[//,/D#$9 ] !VJXPJU%[NB?W,ESIQWU.@N-&TU(;^'P^FFVFI&4/,1&#\V1
MG<!W(K/U'4/#FN7U]X:$GV;5/(W2/"FUE![AL8KSW7?$T<4.K?\ ".26EGXK
MO(Q*Z2'/S>K>U8:_$-8KBRT/5)/(\2W]LP^T6\9VY Y(:N^&%=M9/_@_Y'(Z
M_-JD>NS3Z3:W%IX9NK":ZMIK8AKYL;#@8(9AW-4WBT_07TNRT?3X+G1ANCGE
M,V3& ., ]:\L?QAJ'A.#3-"NDO-:^T%HY+T+]P>K'MUK,_M.Y\':']B\,6YU
M$-<EY5N9LE=Q^;D_RK>.&U^)_P"?F9RJ-JUCL_$]EX<O8O*\,"P@%O<@WD8
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M?[9OPLTN5?)OYKCR5*H(H6P1^5<IXA_;W\&V\4D=EI%[.C\GY0N3ZU\'QR1
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MQP2*<;W$R_I#A;^$.3MW"OMO_@F5:D?M%"10?+$3'_QTU\-VLA613GH:^_\
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M]:1(C)T%7H=-9@"5//:LTJE4IN,"FKOGK3E:0'(S70:?H0N ,DCUXZ"N@L/
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MR9! Y([5T&E:7<0*"AR&('/3/K6-XNLGM+G=G))^8BM7M=DK>Q%)=F6T.6R
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M+&0RD_6OT)_9:@^T_$WP5>8'SDMGZPO7F9C!M1:'2:YD?I+9_P"K6K=5+/\
MU:U;KPCV1&^Z:Q=8_P!4?I6TWW36+K'^J/TH \:\<]'_ ,^E?D3^VY%YG[06
MJ\#_ (]+;_T6*_7;QST?_/I7Y _MOW/E_M$ZLIZ?9+7_ -%BO1P'\7Y'/7^$
M\<A6.)"I49/0GM4HVHIR0Y-9AO(U /WOK3KC45PFP8<#K7T=TD>=8O/>011D
M1L#GCD=Z@BOW$GRDD9SBLJ2YD#DLH()S]:ECE+!B  V.!4\]V.QLM=3W(* =
M>]2QW,]M$$ZIWR>:QTN)8RK G&,&IAND!8MM'4DGBG<5CI_#7AR_\4:C;6.G
M0>=>74@CB0'DDUN?$;X7>(?AAKZ:7KL*P731^8A0[D9?8UZ-\$8[+X.?##7/
MBMJZ@W6UK+1(I.1),1RP'MSS[5;\,:_=_M-_!F^L=6?S/&_AC=>02-_K+FV.
M2R^^*_-<5Q56HYI:$5]4IR5.<NO.^J_NP=E+U?8[X87FI.77^OS/$[) 94$D
MX(/:I[GR6F:*&4E@>!C@BJ:F*)3F-MZ'HW!S5VVE24J1;C(&<YK]/OV/.+#%
M8A'&R,[DY'8&F2)(X5]FU <$D\8JD]ZS.3,NP _*!5P6\KH27$B,,A*+C166
M.1'884PYS]14[QI<*3D(H'&SO3&8JFR48'0%>HJ:*V15#N?D4<$4TP]"H8]H
M4.[;#Z57N)(H904!"$<@=S4]R8U!4M\IYZ\BH+AXPT)5?EZ!O6G<5AFZ26-G
M3/RGIFILL^U9F).."33VG505BVYP"X%-<@W,:O&?F&012N!7AA+2LK!<KT)J
MK-&L3N 5.>U:P1I'D58P2>E4-4WQ,RRA5<@*%XI] ,:53$V8R"?05&ET2&+$
MH.@&._O526Y\B1P""V<<'-9\ERSL=S<'UKFE.QHE<NW$IW\#<3Z54\\J.!@@
M]ZA-P5;*.3@=:K2RDG)SFN>52R-(Q+)G&3O.2><BH&GR<#KGK46\$8IA?FN:
M51FJ@2-)GJ,4PN14>XTTL>>:P<S11'EOUIK-D4PGCFD)K%R9HD*6I-U)147*
ML&:**0]*AMC$S1DT[O1BIL W/O1DT[;3@A-4HMA<9R#1]:D,9&*/+QFJ]FQ7
M1'@TAX[U+LS]:4QY%'(%R'%'>I3'Q32E)P87&9-')IQ3 I"#GFIY;#N)VI0*
M.<4N*:0!R#2TE+CI5@.'3GI4D4@Z,,K4/:@'BK4K$-7)9(<C<G(].]0U+%*R
M.I!Z58$*7K?*524]N@-4X<_P[BYN7<I44^2%HG*N,$4W%8V:-+DL#[)5;T.:
M^J?$?BAM6_9P#[LD*D3?A7RF@P:]K\/:D-4^"&M6 .Z2V82!?09KMH=CCK+5
M,\7F;)IJ@YZ4YCD#UI4&?<UD]9&^R)T 5/\ :S4ZL5D5N,YJ.V0NVW@9]3BI
M7PI! &X_C7;%6C<YY;EJ)@H<ECGU':KUG* ZJF2<=ZR(IOWASR#UK8TY&+ +
ML+] #W%=%-ZF4M#KM&=I(D(.UAC//0"NRCB@>%$EEWH" <#!'O7 V$CPN@90
MK;L$ =>*Z2.5H8EDD9O*(Y8'I7;%Z&#->]M[25U\IP2$/'\LUF(D.FV!PGER
M!?F9CU;TJO=7)M/+ECC+1,?E8'!S56VMS?22W%P[K$3D%N0:U6I-B"Q>YU&<
M AVB#84&M>TVZ0LY,05V4A5]16;>ZW;Z=:JL!"E1ALGYCSQ7*ZEXIGGPHDPG
M0C/-#FH;A9O0Z67Q&;:U>(.H;<#R.0:P=7\4R2L092!C!]ZY>YU!G<_-N]ZI
M2W+/SG)]ZX:F+ML;QHWU9;NM0:Y8Y)!)J@S$YIC,3G^=-))KRIUG+<[(P2V'
M;R*4-S[5'FESS6',S2QJ:=J+V,JLAP0<AJ],\,>)5U)EBNF\R208$A[5Y$&Q
M6GHVH-:W*.&(VUZ%"NXNS.2I235SU?6X"GEO'(-RCD,<G%?H)^QW>+>^*?!$
M@*DX_AZ?ZIJ_.?\ M%-4T_?$NTJ,/@Y-?>W["]X&\5>!X0V<;O\ T6];8M)P
M;..*:E'U/U%L_P#5K5NJEG_JUJW7RI[PC?=-8NL?ZH_2MIONFL76/]4?I0!X
MUXYZ/_GTK\=/V[B%_:)U8@X/V2U_]%BOV+\<]'_SZ5^1O[?&@;?C)/J08$2V
M\$94=1A.]=6&FHU$N^@.E*I"3C]E7?I>WZGS+%=$_(.<]ZM1DMC<#BH9+,6\
M8<$DYZ"K%KM=?F))/:O?C?9GF.W0FVKL!X+9Y%"2[)/O?E2R0*RC8>>XJ$A(
MR,JQQUK78C<ML,-DOD$=S78?"GP+/\2?&NF>'K0%FN9,RN.0D8Y9CZ  5Q:7
M$.-ICR.W/-?3'@__ (L%\ +_ ,4BU=O&/BE#;:9$J$RPV_\ %(.X!!-?-<0Y
MG/+L'RX?6M4?)!?WGU](J\GZ&U&G[2>NR.8_:$UQOBQ\3-$^%_@E/,T'0@+*
M%(>$DD7/F2$#C\:P)/%+_LX_&'PXVFW)N/[/B6#41_!/&S?.A]1C-<#\&_&\
M_P .OB9I?B6_BN6MDD)N&53EE;(SGOS69\3=6U;Q?XRU'5;N.>43RDQ,82HV
M9XP,5\/0RJ=+EP,TGAU!IM[RE*_,W^?JSZ>&)I4\'.G%?O)-:]HK73YGO_[0
MG@6V\/\ B>S\2Z*%E\-^(HA>V;(,JI8 M'^!->7V[[&#2DQ9/"@]:]6_9TU8
M?&+X6ZO\+M8<C5+%&O= FF^\&7)>,9^@XKQC4([C3[JXLIHC#=Q2&.1&ZHP.
M"*^LX7QTY4IY9BI7JT+*_P#-!_!+[M'YIGS6)I\LN>.S-=);=E<-*-P' ZU/
M!>K\X1B=JXR*P8<0HH=U+9ZU>COGBE/E)M.,?*.M?=:7.(T]L:R#YS.C#)XI
MUW:)(H6$O@G)!;M5.*6:*4LJ,<C^+H*?'?@IY4N/,<\%3CBJTV"[%-AY^?E#
M;1U8U7FA)MHRL0(1L'TK1,2-NV;P&'.T]*S[;]Q'('R0K=Z%V&RY;VBLP.Q5
MSQN%2RV_R\ON<<<#H*B%U+' 62-2F>#GK4%[JTOV10(PA)Y*]3331&I));[\
MD2,.Y91BN:UJY'()\QN[,>:M7$DZ0,PD;'8>M<UJ1;^+=YG<'M64Y61<5J5)
MW\OL*IM(6/-*[ C&<5%D<UYE239U109P<9IA//7-(6&::3@BN=LV2%9@1P<&
MF$XH)HR/2L6[EH0\TF*4BEQ4V&-QUI,>E.HVTK#N-(YHQ3L4H%%@N1XXI57B
MI M*%)/%4HW$Y$>SG%/6.I5A)/K5B&W)QQS[UM&E<S<[%81$@8&/ZU*L!W8Q
MU].]7_LN%7+?7'2D*%6)4=/05T*E8Q<[E1H"5P!3##UR !Z5< Z _G3F3D'L
M>,U7LQ*3,_RQGCI3C&..U:,]L$8A8\J,<YSVJN8C&N"!\W/TI>SL/GN52@'I
M49CP,FK;+@]AGL:291G@# '-9RB4I%-U&.*C(QUJSY>[I3/*P>36,H&JD0$#
M%&,GI4I3#=<@4W;\WIFL^6Q5QG>DR<T]ADYI-I:E8=Q"*0>E."G%)@^GXTK#
MN'X4Y25Q@TW:>]&/SIB-"">*[417/RG^&0=1]:KW%G);-AU(!Z'L:A(KH-#O
MK6ZB6QU!<QD_)(/O)6\4JCY9;F4O<U1@[?:O1_A=J2)8Z[82<I<64F ?4#-<
MCK7A^72F61<RVLG*3 <&IO#5TUI>L5R R,IQ[BMJ47"=F9S?-&Z,%QAS]:=$
M@)]_:G2+F4CMDU=L[1HMCM&3GD9]*F%-N1<I60SR]F"%QTXIK+YC\-[U;O)#
M=2_<"GC(6H#'C;M!/X=JZ6NABGU&JVU\$8!Z#%:UF^V<+N*C;R1506;%UV!F
MW<#(K8LM->+:LQ5,@8XZUO3@[F<FC7T^-)P&EW, 3DJ<$>AK2_M%9DA@M8Q+
M)C!'I573M',X*Q[B?3UQ71Z?I-MI=NMR"3.#E5]*[4K(P9133Y5C6YO>(QG;
M&W3CK7-^)O$@D3[/&?+V<8C/%/\ %_B6YDE\K=M<97Y3VKAYY6D8MG)]:QJU
M>161I"'-JR2XOI),DL2/4FJ9E).2U-<$]\BFX->/.I)L[8Q20K/[\5&6I=N3
MSTI2N.U8.[-%9"8X-(>>E+C%'?I4M#&XQ1BGXYI0N3TQ3Y0N-'(J:!BK#M2"
M/C.*<@P<8ZUK&+6I#=T=5X4U ++);O@K+WS7WW^Q-JZ0_&/P3IZ$ ;W7 [_N
M7-?GEH<9.HVZ9PI<#.:^Q_V)=6;_ (:G\!6ROF,W4J]?2WEJL3-JDD<L8IS3
M/VML_P#5K5NJEG_JUJW7AGJ"-]TUBZQ_JC]*VF^Z:Q=8_P!4?I0!XUXYZ/\
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M4\\T32*XRB9W9R 370HI$-LHO$%&WRQMQ]3]:88T>$EE^8'!V\5+,I6/.
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M"I![@U^.8:M5P.(IXB.DHM27YHZ6E)6/PPDWV=TT<F1(C%6'3!'6K"7:%LL
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M4C^[\U16UX89%8'D'->BJUI)LY>2ZLCV>\L@\@=8Q(H3(P,G%5X)C""[VRX
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M$:P/GS6[A2[ 8^@/ JKIRI<Z?=Q?,9%PZ8/ '>HM0&",G) IV@7#1:DD23)
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M\J?#:2RMA48_A76H/L8.2+VDQ*V[?C!XYKJI/@9XFO?#*^(M(L9-1TUB=WD
ML\?U KFXK&:' VG\J_0+]A_6[(_#Z\M;^2*(6Y+L)"!\O7-;5(-P22,%/E=S
M\WIUFM)FBF1HI%."C@@@TBRR#IFOHC]KWQSX0\>_$'_BEM*AMH[,&.>]1=OV
MA\G)P.,>]>)6VG!CV*]:B&&J7LV:NM&U[&.J3N3M!J0274&#\P YXKH;>P+
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M0>N*^Z?^"=OPT5]"U+Q?=PYE>?R(,CJ@ )Q^-?*\29K'+,FK56_>MRKU>B_
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M.0?%]]_WU7?A^%L5Q)EV%Q.'G&G&,7&SOTE+43FH-IG[$)]GLH@B[(8U[ @
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M8(S5U;901N("]<U4N#M.5K64+*[(4KO01!A6YX]*17).%Z^E)!(&!![U[O\
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MZU8$BY9-N<\ FA"I4;LCCIVK7E)NR&"++9<X7H:EM[=#*1C<!W/>IY9%\L[
M"IQV[U'YS*^\=#VJN5(5VR6"$+-C:"#P*6.$C.S/!((J>%$(5GD"8^[[U'),
M("I5MP/(;W[YK105B;DR1QS.%)8949Q4O[IRBPG QC#>M4?-DW A<%NAIIWO
M(=K9..>,5HDD(O3A%#*N6?)!QSS4)D?[-L(48Q]320*WEY&3SSCN:F\D9*G
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MK*[,1$0#[5G2^$9?^>1_*O&KUWL=M.F<#*2346RN]_X0Z0_\L3^5'_"&R?\
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M^E6],^+UC<RJ$LU6)-A,I'+$>E=Y_P (6W]T_E1_PA;?W3^58+"VZE_VZ_\
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M0A IX0"@"C#8*G:K:0A:DQBEH 0#%+110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>forms-4_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "7 LD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3[:W8]3'&%-7Z;9-@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BL[5=<L='C#74N&;[L:C+-]!6:NN:U<C?;:&4C/1KB3:?RJ7-
M+0Z(8>I./-:R[MV_,Z.BN;;7]6M!OO=$<Q#J]N^_'X5K:9J]EJ\'FV<P<#[R
M]"O7J/PH4D]!3P]2$>9K3NM5^!>HHHJC **** "BBB@ HHHH **** "BBB@
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M-)_O?B ?QK-L++6!J+W5]9VNH:@"2"US\L0ST5<<8.??FM#4?$^KZ684GTF
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MWL8OE$S!0J\<*5-8R=U=[?F>K0IJG45*+]][O^7T\_/H=)'<V4482.:%4'
M88%0WJ:=J=LUK</#(C_PEA]?Z54B\+:.D2JUA&2!UYKFGTFQU'Q;%:V-NL5O
M:Y:5T)Y)!&/S%.4I):HQHTJ4Y.49-6UO9?YFA:7=WX6NDL=0=IM/=@L-P>2I
M)Z'\2:ZV-UEC5T8,K#(([BHKNS@OK5[:XC#QN""#[C%<M'/=>$+GR;@O/I#D
M[).K0^Q]@,"CX/032Q2O'2?;OZ>?EU.PHID4J31B2-@R-T(/!I]:G!L%%%%
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M[:F[&<=\>M54\(V_V.6VEE#*Z+&'$:APH/'(%7WT.![S[27??Y318SQAA@T
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>forms-4_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "M 2X# 2(  A$! Q$!_\0
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M@CL;"-QE3/-T!Q_".:^:OB1X[UNY\)V/@W5-3?5-)GL(HY[:\P\;JI^7(]<
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MLG_7:+_T,5TMI_QZQ?[HKFOB9_R*LG_7:+_T,5TMI_QZQ?[HH YGXE?\B_\
M]M8__0Q75K]T?2N4^)7_ "+_ /VUC_\ 0Q75K]T?2@!:1E#J58!E(P0>A%+1
M0!^9W[6EC%\,?%NOPV\"6HN9"\*QKM4(W/'YU\-^);EM2N2^0&&6/O7Z*_\
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M5D_Z[1?^ABNEM/\ CUB_W10!S/Q*_P"1?_[:Q_\ H8KJU^Z/I7*?$K_D7_\
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M@"BBB@ HHHH *BGMX[E"DB!U(P01FI:* /FG]HG]CG3OB;ITVI>$Y8?#OBM
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M2EIW%<****D04444 %%%% '*?$S_ )%63_KM%_Z&*Z6T_P"/6+_=%<U\3/\
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M]B@">BH/MMO_ ,]XO^^Q1]MM_P#GO%_WV* )Z*@^VV__ #WB_P"^Q1]MM_\
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M_P#BZ/\ AYGXK_Z$S1/_  (N/_BZ^-:* /LK_AYGXK_Z$S1/_ BX_P#BZ/\
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M]I,<ZW*6T[,%$B@@-\I!Z$_G7D7_  [G_9V_Z)EIO_?R7_XN@#^>FBOZ%O\
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M%?T+?\.Y_P!G;_HF6F_]_)?_ (NC_AW/^SM_T3+3?^_DO_Q= '\]-%?T+?\
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D?!?X5>+K'Q/X6\"V.D:Y9%C;WD3R%HRP*G&6(Z$BO;Z /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>forms-4_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "S 2T# 2(  A$! Q$!_\0
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M#:/J<Y[;U^6,>_SL/RKSOX@>+-:\3WUPYNC+<2*%FOYSSM4 !5 [  "OK?\
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MZ9X8T1'FU+4[A+:%(QGECC/T Y/L*_7[X7^ [3X8?#[0?"UDQ>#2[5(/,/\
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M%6,OO7YI!&JY.TH-?UY'U#17+'5K[3Y$\UF>,N%*NOJ?6NIZUQ-6.@P/'O\
MR)FL?]>[5>\/?\@>U_W!5'Q[_P B9K'_ %[M5[P]_P @>U_W!2 Q-*_Y*!J?
M_7FG_H9KK*Y/2O\ DH&I_P#7FG_H9KK* "BBB@#&U/PAI&JO>RS:?;&YO8?L
M]Q<>4N^6/! 5SC+ 9/!]:_!3QK\*-9TWXB?$KP)8:/=WM_IE_)/!;VUNSL4C
M=L[5';RSGH>E?T"5\&_M[?'[6/V4/BCX?\4^&M"T;4[KQ+ICVETVHQ'>I@?*
ME77!&1)@@GG ]*Y:E*45*I0BG-V\KV[DM'R7\+OA=JO[*7P;U#XZ^)-(,?BJ
M3&G^%M,OXB/LTLH*F[E4]"%W;5.*^-_$>JZEXHUN]UC6+R74-4O96FN+JY?<
M\KDY))-?8'BK_@J9\1O$UL]G>^$O!EUISE6:SO;![F,D<@D.V,@].*X:Y_X*
M$>+U;?!X!^'5M(.0Z^'4)'YM7G4(8^E*56K24IRZ\UK+HEHS/5:V/F-;*2=]
MD49E;T0;C7K?Q8L=3T[2/AC9:I'+#/!X;218)D*,B/+(5R#ZC!KO]-_X*(^-
M;;4!=7?@KP'>L,<Q:+]G?_OI&S7;Z=^UKX&_:"\>^%5^(?P<M+S4$O(+*VO-
M,U21<*\BC;(CC#IDYV_6M)3QTJT)3H+EC?:2;VMLU$GWG)-K8_3']@?PZ?#?
M[)?P^@92KW%F]XP.?^6DC..OL17T#4%A8V^F64%G:01VMK!&L44,*A4C4# 5
M0.  .U3UZ^YT!5?4)?(L+F0=4B9OR!JQ5#7W$>A:BY8J%MI#N7J/E/--;D3=
MHMGYB^+)/MNKSW&W:97?_P!"//ZUSMS;,\?RC+"M&]O3<MN/9F.?4DU1>XVD
MC%?H*5DD?Q?5G*=5S74R)].FG7$D?/9AVKT/]FFYNO!WQF\$^(UGQ;74DVG7
M*_P^7(=G\P#^%<-?W;+"S;MB@<XJ+X1>/I8-3BTR4+MAO1- YZK\P)'Y\UY^
M+5X<I]IPU4E#$^VETM;[S]>J*BM)A<6L,H.0Z*P([Y&:EKXT_IY:A7SO\=O"
M/BUO&,6J:7;OJ6E7"*CHG)A(X(QZ=Z^B*1E##!&1[UYF89?1S*C["O>U[Z'I
MY?CZN75O;4DF[6U/GCP5\+[W4YXY;R)H8^I##GZ5[AI>CVOAS3V,49"Q(6(4
M9)P/YU;U#4;+0[5KBZECMH5_B;C/L!WKROQ=\9"R21:>3:6_3SF_UC?0=J\J
MOC,MX=PZI74>R6K?F_\ -G?&GCL\K^T:OY]%Y+_@'46WB[Q5J<-O>:?X9M;K
M3[E=\<AU%4=5[;@5Z^PK1M]"U36M0MKS7I8(X+9_,@TZT)9-_9Y&.-Q'8  #
MKS7GOP=^)ZW^L'0)FS"ZE[=C_"PY*_CUKVJMLIQ=/-L+'$*3?=.VC7HEIU0L
MRI5,NKNA[-1?1J[;3]6]>FEAJR([,JL"R\, >1]:=7E?COX%S>)_$=SK^A>.
M?$?@W5;E467^S+A6MY"HP&:%P5)Q7GNO^#_VFO!B-+X9\=>&?'5NG*VFOZ9]
MDN''IYD1VY_ 5]9"C"I:U1)^=U^-K?B?,2J.#UBVO+^KGT)K'AO2?$+6QU33
M+343:R>;!]J@63RG_O+N!P:T54(H50%4#  Z"O@CQA^WY\9/@I="+XE_ B>V
MM 0IU#2[EV@?GJ'VLOX;J^I_!WQKM_'^A17^FVDL&8E>17C?<K$9*+N5<X]>
ME.KAZM)+FU7D[K\!TZD)N\=_N/4:CDGCB4EW 'UK@YM2O;Q@_F3%<="1Q^5,
M6>ZD&'9P/<US\IL=K)K%N@)W9'KTJ*?4Y#;B2*,;6Z-NS7)+ \P^;!]R:UX(
M?L]BL:,68_YQ3Y4@);L^> TG..@[9KH8L^4F>N!7.V,$\M[Y$L;+Y9R<CC'U
MKI>E2P,#Q[_R)FL?]>[5>\/?\@>U_P!P51\>_P#(F:Q_U[M5[P]_R![7_<%2
M!B:5_P E U/_ *\T_P#0S765R>E?\E U/_KS3_T,UUE !1110 5^8W_!:73I
M#:?#.^5L &]A ]\1FOTYK\VO^"SLB+X4^&Z$C<;N[.,\XV1UI3^)"9\;_#KP
M?\.OB+!(-&\*7^I7$*Q)/'+((@K[1DJ3(=V3U&._:M2]^'.B:0FEW.G>%K?1
M)9Y=B3WC(\DAV,7B"LY&>.I' SWQ7RW;ZW?Z46%EJ%S9@G)^S3-'D^O!ID_B
M#5+QD:;4KV9D8NI>X=BK'J1D\'WJVGW'='OV@^"-*\86*:C-X=CU&RD'E0/%
MY<1C,;,'P0R@J< AOK[5UGPA^'W@O3OC;\/HHS<Z==3:Y9JD3R!XW=9P7R<D
M#& ,$]Z^3X]9U&WA6&*_NHH5R%B29E4 ]< ''-=Y\%_&$NB?%7PCJ]ZDFI_9
M-9M)C#(Q+2?OE) /J?YTXK4+H_I*HID4@EB1P" P#8/44^N< K"\=SRVW@G7
MI8 #,EC,5!]=AK=KG/B,,^ O$ Z9L9A_XX:N'Q(Y\3I0G;L_R/R_(Y8'L:JN
M<-5Z>%HIG0]F(JG,I7)K] /XO7Q-&#XCN-EHR#C/>N T#4CIWB*VN$)&V4=/
MK79>)WVV\OKC@UQ6B01-=P*F)IF?ESPHYKSJSO(^WRI<E)M;G[5_#^_.J>!M
M NVY::QA8G.?X!705YE^S1J[ZY\"O!][(H5I+/&%.0 &8#]!7IM?(35I-'],
MX>7/1A+NE^04445!T'@/[2KZY9WFG7NGQ/<V2(4DC49V'/WJ\DL=)U;Q*Z^3
M!+)NZC! 'U-?:-Y807\92>-9%/9AFJMMX>L+3_56Z)[*,5\K7X;P&*Q<L973
MDWTOH?24,_Q>&PRPU&RMUMJ>,_"WX57VDZA%?7#^6ZCA4'3\:]V1=J 9S@4)
M&L8PJA1[4ZOI*5&G0@J=**BET1X-6M4KS<ZLFV^K"BBBMC$BN;:&]MY(+B))
MX)!M>.50RL/0@\&L;5]$M;>R9[2S2.0;5_<KMPH] *WJ*:=@.!4[!R-OUIC2
MG) [UWKP1R?>C5OJ,T@MH0>(D'_ 15\X'&6RK(P'FD9[8K?TW2-LD<TK,53E
M$?U]:U1!&""(T!'0A14E2Y7 ****D# \>_\ (F:Q_P!>[5>\/?\ ('M?]P51
M\>_\B9K'_7NU7O#W_('M?]P4 8FE?\E U/\ Z\T_]#-=97)Z5_R4#4_^O-/_
M $,UUE !1110 5XY\?\ ]E#P%^TK)I<GC."_E?34=+=K*Z\G:&()R,$9X%>Q
MT4TVM4!\3WW_  2+^!ETK^7+XHMG8</'J:_+^<=93?\ !';X,N<MK?BUCGJ;
M^/\ ^-U]VT4^9@? >I_\$:/A%=1 6GB;Q79R9^\UQ%(/R\L5;\ ?\$B?AUX'
M\8Z7K4GBC6-8MK"ZCNEL;F*-=[(P8 NO.,@=J^\:*.9H! ,# X%+114@%8GC
M> W/@[6XE ):SE&"?]DUMU'<P)=6\L,@S'(I1AZ@C!IIV:9G4CSP<>Z/RRU.
M/%_<ANOF-G\ZR;SY(N*]5^,OPB\1> ?$]\TVESRZ5+*SV]["ADC9<\9(Z'V-
M>3WUPNW!.".QK] A.-2"E%W/XVQ>#KX+%3HUXM--[HXKQ@6^S.J<NYVY]*R=
M%B2'4K:!1RJ.>/7::V-?D5\@ ,W\*CDDUTGPI_9Y^(OQ+UZSETCP_=06+MA]
M2O8S%;HIZG<W7CL,UYU>2BVY,^SRJC5Q$8TZ46WY'Z.?LE1/#^SKX(1U*L+,
MY!_ZZ-7KM87@;PO'X*\'Z/H44GFII]LD'F?WB!R?SS6[7R4WS2;1_2.&INE0
MA3ENDE]R"BBBH.D**** "BBB@ HHHH **** "BBB@ HHHH **** ,#Q[_P B
M9K'_ %[M5[P]_P @>U_W!5'Q[_R)FL?]>[5>\/?\@>U_W!0!SEMJ%KIWCW47
MNKF&V5K1 IF<*#\YZ9KH?^$GT?\ Z"ME_P"!"_XU\B_\%%/VD+3]F'2O!^J2
M>"[3QA)KEQ<6Y6ZO&MO($:HV051LYW^W2OB'_AZG8_\ 1$]*_P#!W+_\:H _
M9C_A)]'_ .@K9?\ @0O^-'_"3Z/_ -!6R_\  A?\:_&?_AZG8_\ 1$]*_P#!
MW+_\:H_X>IV/_1$]*_\ !W+_ /&J /V8_P"$GT?_ *"ME_X$+_C1_P )/H__
M $%;+_P(7_&OQG_X>IV/_1$]*_\ !W+_ /&J/^'J=C_T1/2O_!W+_P#&J /V
M8_X2?1_^@K9?^!"_XT?\)/H__05LO_ A?\:_&?\ X>IV/_1$]*_\'<O_ ,:H
M_P"'J=C_ -$3TK_P=R__ !J@#]F/^$GT?_H*V7_@0O\ C1_PD^C_ /05LO\
MP(7_ !K\9_\ AZG8_P#1$]*_\'<O_P :H_X>IV/_ $1/2O\ P=R__&J /V8_
MX2?1_P#H*V7_ ($+_C1_PD^C_P#05LO_  (7_&OQG_X>IV/_ $1/2O\ P=R_
M_&J/^'J=C_T1/2O_  =R_P#QJ@#]F/\ A)]'_P"@K9?^!"_XT?\ "3Z/_P!!
M6R_\"%_QK\9_^'J=C_T1/2O_  =R_P#QJC_AZG8_]$3TK_P=R_\ QJ@#]EV\
M2Z,ZE6U.R(/4&=.?UKFM5\+_  ZUQMU_I_AZY;GYG2'//7FOR-_X>IV/_1$]
M*_\ !W+_ /&J/^'J=C_T1/2O_!W+_P#&JI2<=F95*5.JK5(I^JN?KAI7A/X;
MZ')YEAIOAVVDP!O2.'=QTYKIU\2Z,H &J60 X $Z?XU^-'_#U.Q_Z(GI7_@[
ME_\ C5.3_@JC8R.JCX*:5DG'_(;E_P#C5)MO=CA3A35H127EH?LM_P )/H__
M $%;+_P(7_&C_A)]'_Z"ME_X$+_C7Y:?M*_MX:;^S]\;_%/P_A^%&G:W'HDL
M48OY=5DA:;?#'+DH(R!CS,=>U>9?\/4['_HB>E?^#N7_ .-4C0_9C_A)]'_Z
M"ME_X$+_ (T?\)/H_P#T%;+_ ,"%_P :_&?_ (>IV/\ T1/2O_!W+_\ &J/^
M'J=C_P!$3TK_ ,'<O_QJ@#]F/^$GT?\ Z"ME_P"!"_XT?\)/H_\ T%;+_P "
M%_QK\9_^'J=C_P!$3TK_ ,'<O_QJC_AZG8_]$3TK_P '<O\ \:H _9C_ (2?
M1_\ H*V7_@0O^-'_  D^C_\ 05LO_ A?\:_&?_AZG8_]$3TK_P '<O\ \:H_
MX>IV/_1$]*_\'<O_ ,:H _9C_A)]'_Z"ME_X$+_C1_PD^C_]!6R_\"%_QK\M
M?@#^W=IOQN\2Z]I,GPHT[2!I>@7^MB6/59)3(;:/>(R#&,!NF>WI7F/_  ]3
ML?\ HB>E?^#N7_XU0!^S'_"3Z/\ ]!6R_P# A?\ &C_A)]'_ .@K9?\ @0O^
M-?C/_P /4['_ *(GI7_@[E_^-4?\/4['_HB>E?\ @[E_^-4 ?LQ_PD^C_P#0
M5LO_  (7_&C_ (2?1_\ H*V7_@0O^-?C/_P]3L?^B)Z5_P"#N7_XU1_P]3L?
M^B)Z5_X.Y?\ XU0!^S'_  D^C_\ 05LO_ A?\:/^$GT?_H*V7_@0O^-?C/\
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M_!=#_P#$T44 '_"M?"'_ $*NB?\ @NA_^)H_X5KX0_Z%71/_  70_P#Q-%%
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MR'@J2%Y![BJ__"M?"'_0JZ)_X+H?_B:** #_ (5KX0_Z%71/_!=#_P#$T?\
M"M?"'_0JZ)_X+H?_ (FBB@ _X5KX0_Z%71/_  70_P#Q-'_"M?"'_0JZ)_X+
MH?\ XFBB@ _X5KX0_P"A5T3_ ,%T/_Q-'_"M?"'_ $*NB?\ @NA_^)HHH /^
M%:^$/^A5T3_P70__ !-'_"M?"'_0JZ)_X+H?_B:** +&G^!O#>D7D=W8^']+
9LKJ/.R>WLHXW7(P<,%!'!(_&MRBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>forms-4_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "V 6P# 2(  A$! Q$!_\0
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MMX3_ .1MU_\ W(?_ &:NQKCO"?\ R-NO_P"Y#_[-78T %%%% !1110 4444
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M[A7N85MPLSYC&I*I==3D?B?_ ,BVG_7U#_Z&*Z:Q_P"/2+_=KF?B?_R+:?\
M7U#_ .ABNFL?^/2+_=KL//.6\)_\C;K_ /N0_P#LU=C7'>$_^1MU_P#W(?\
MV:NQH *AN+E;=>>6/11WHNKE;2%I&YQP!ZFL:6Z#C<3ECU- $ES.UP<OT_N]
MA5<Q!NU0M<<]:?%=(/O&@3'.F!Z5EZE*\<9*1A\#IWJW=:C&H^4YK O]3.>M
M4(ST\40V=T#YC6TH[UV_AWQA!JKI;R2)YS?=8'[U><Z@;.^;-Q &;^^IP:32
MXK:PNXKBW>6-T;<N<'F@29[915#1=435K%)E^_T<>AJ_4EA1110 4R65(8R[
ML%4=2:<3@9/ KE];U,W3E4/[E>GO[TP#4_$,T[&.US''_>/4UCN))&R]Q@GN
M!FH9)".]5I+C%,DMF-Q]V]<'W&10+F]@.5D2?'I\K526;/>GB0YIB-ZP\6SP
MX6="ZCJ#U'XUUEK<)=V\<T9RCC(S7G:7!9<-S]:VM!UM[29()3FW;@?[)I-%
M'7T445(PKX0_X*_?$"3PW^SWI'AR";RY-?U:-95#<M%$-Q&.X)*_E7W?7XZ?
M\%A/B.?$'QV\/>$XYMUKH-@DDD:G($LK;B?KM %5'<#R#]D/3['6?B]J]O=(
M'*:9--&A'5B4#?IFOJ";X<:1K-U#?&V26ZM5,22$?,B'JN?3VKX?_95\;KX9
M^/FA74[A+>^=[&7<> ) 5'ZXK]#+>SDTR]N2O1B>*\?'RE"KS)[GU&5JG.DX
MS6QC6-@4L)[*-=L;OLPO'/3 KSG5?AYI+Z3_ &;J<(N(;.[^TP<E=LHX#C'?
M'&:]#OO$-MIEU@W:K.'W?*XPC9XI4\+S>)]0&[)$AWL1WSS7FPG+[+LSUY48
M77M%H> _M=^'+&S^%WA'6E&+K[5- "QR60QY//UP?QK],?V _'D/C_\ 90\!
MW4<HDGL;/^SIQGE7B.W!_P" [?SK\Q?V_->M=/U#PIX+@E4#2[-KNY4?PO*1
MM!]]J@_C7OG_  1M^+RRWOC/X>32,(VC35K)6/<'9* /?*G\*^FHI^Q7-N?&
M8QQ=>7)L?J)1115'&%<S\2KRVTSP'KE]=QF2"UM7G*KU.T9&/RKIJS_$.B6_
MB30M0TJZ&ZVO('@D'LP(J9*Z:1<&E)-GYO7_ ,7M9\1:O%!-;Q1VSR#$ 3HI
M]_7%4]823[1+C[N>E8VMPV'P^^-TVCZWJ]G$VF%K:5'F4%2!\A()_B!4UU>J
MZII5^=]G>07$9/WHI W\J\#EE9\Q]ESPNN0Y>STU[JY"@=>M<;X]\>^&?"&L
M-87VH[;U "T*1LQ'XXQ7;:CJ)M>(" WK7E7C;7K^^O&BFT/3]1C4$$W:Y8#'
M;C/Y412;LR9R<5=,]'\"267B6&"]T^XCN().00>?Q'6OH#P=:QV$2,Q ;TK\
MU=?\17MBFESZ%X:NO#EU*[,SI<,, 'J%)XKZC^%GQ!\4ZW\,O$-Y:WJWOB#3
M;96MUN1E<9 +-CK@9-*<%!Z,4*GM%J?:-AXZTSPFT&HW]TL:0.IV*<R/S]U5
MZDGTKZ0AE$T22*"%=0P!&#S7Y_?L7>%9M2\>QZYX\O-)OM0N2YM/.G+22SCE
M?+1N. "< 5^@E>OAE:%[GS^.:=1*QR/Q/_Y%M/\ KZA_]#%=-8_\>D7^[7,_
M$_\ Y%M/^OJ'_P!#%=-8_P#'I%_NUUGFG+>$_P#D;=?_ -R'_P!FKL:X[PG_
M ,C;K_\ N0_^S5UMQ.+:!Y6Z*,T 8NMW.^Y$8/RQC]36/-<XXJ2YN5O))7B;
MS/F);'8^E95Q+@GM6EM +/VD>M5Y[W8.M9TMZ$%9&I:N%4\U(%^\U=5SSBL:
MXU4.3\U<_?ZQDGFLPZL"QYID'4_: YSFIXIN17.6U]O[UIP3YQ0-'I/P_P!3
M\N]:W8_),O&?45Z%7C7A>Z,.IVSCLX_G7LM2R@HHHI 9VLW)B@\M3AGZ_2N3
MU2YAT^QN;RYD$5M;QM+*[=%5023^ %='J1\RX<]A\HKP3]L+Q.GAGX)ZS;I>
MBSO-14P1<X+*!E_H,8R?>J1#=CR:7_@HA\,)M>ETX)K$,0<I'>O:_NY/<#.0
M/J*]L\+^.=,\:Z/;:KI%W'?:?<KNCFC.01_0^U?BGK$MQ"XD=U,RRYRIY'K_
M $K[._X)[?%E2NL^$+CS?+:X:[LI'^XW \Q1[YP:TL9J39]_17.:MQONQ6)!
M<*5'-:%O(V1\IJ+%HTP.*<K8-,@<-@'@TDQV-04=_H%Z;W3TW'+I\I]_2M*N
M2\'77[^6+LZ[A^%=;4%!7\[G[:?C;_A._P!ISXAZLLPGB.KR0Q,N<>7'\@'/
MT-?T!_$'Q(G@_P "^(-<=MBZ?83W.[T*H2/U K^:#Q7K$WB'Q%J>IW#%Y[RY
MDN'8]V=BQ_G5Q H0W,MC>17%NYBEB<21NO52#D&OT1_9_P#VDM%^,&C0:7K$
M\-AXHCC$4]M*^T76!C?&>^>XZBOSJ)W(/:FQ326\J2Q.T4B'<KH<%3Z@UA7H
M1KQLSKPV)EAI<T3]6]?^%>D74/G;63+9PAY^F:9XB^)OA;]G7P@^I:Q<!7"$
MV6F"3=/<-V50><9[]!7Y]:3^U+\3M(TI=.A\43R6Z+M5KB-)9%'^\P)_.O/=
M?\1ZKXLU.34=9U"XU.^D^]/<R%V^G/0>U>?1P,HRO-Z'KXC-G5ARQO\ ,U/B
M7\1-6^*GC?5_$NKOF[U"<RF,'Y8UZ*@]@,"O:OV#?B6?A/\ M7>![YYO)LKJ
M8:;=$G \N8;3GZ$BOG.WC,EQ&@[L!5ZWU2;2O$*7]JVR:VN%DB8=F4Y'\J]E
M*VA\ZVV[L_J#HKSW]GSXC1?%KX*>#?%L3!CJ>FQ2R<YQ(!M?_P >!KT*L@"B
MBB@#\H_^"M?[+.N/XOA^+OAO2)+W29;18-<:U&6MW3A9F _A*X!/J!7YKQZE
M?V.!!?W,(ZCRYF7^1K]&?^"EG[9L_CGQZ/A#X1OS'X=TV;_B=74#\7DZC_59
M!Y13U'<CVK\YKYEN)KAE &V0X Z$5LE>.H7L:%K\1/%.GX^S^(-0C YQYY/\
MZEN?BEXNO<>=XAO9,=,R=*YD]::16;A%[HT]I-;-F_/X_P#$ETX>?6KR9UX!
MDDW$5T/A+XY>.O",\ITGQ)=V1G0Q2%,'<IX(Z5Y_G%201F211[T>SAV0*K-;
M2?WGW+_P3I&L^,OVJO"-W=3W&K&R6XN97F8N(D\MANQT'+#\Z_:ZOS[_ ."1
MGPA'A[X=^(/'%U;H;C5)EL;28C+>5'R^/0%S_P".U^@E5.R=ET,[MZLY'XG_
M /(MI_U]0_\ H8KIK'_CTB_W:YGXG_\ (MI_U]0_^ABNFL?^/2+_ ':S Y;P
MG_R-NO\ ^Y#_ .S5TVH6S74:J&8)GYE7J:YGPG_R-NO_ .Y#_P"S5V- '(W%
MF+)2MD=A.2RM]YCZUSVH2/:6[L8&<J#A1G)KJ/B:8X_ &ORO<BQV64K"[\P1
MF'Y3\P?^''K7BVM?M<_ [P';6FF:M\0+:>_AAC622V,ERS-M'S$JK#FJW ZO
M5-1B>S"0Z9*U\X"QKN(&X]S]*R=2M6T&T:ZU6U\PDA8XM^ Q[DD5POB;]N3X
M1Z?H;7OASQ;8>(;]#N_LV4M;RNF#NVLRXW#T.,UG:;^WC\'?$MPFG:_<2:3-
MD8-W$)H.1G(E0E:JS[$W-^]\4Z%*"LVCRQ?[4$_]#6'J/V=8UN["9IK4G#*X
MP\9]#_C7J&E:7X \?:5'JFB/9ZGI\V1'=6<I*,1U (/:KNG^!]'T61VM;; <
M<J[;@?SI"/)K"_W@<UT=E<;@.:[V30M.<\V4(^B"H?[!L5/RVZ#Z"@9GZ'-M
MG1^H4@G'M7N-O()H(Y!T901GZ5Y3;:;;P_<C"FO0?#VK+>6ZP/A)HUQ@?Q#U
M%)E&S1THJ.:(31E"Q4'N*D#F/$<EQ;V4]S;OET((7'7FOE;]M3PGX@^)FH^$
MM"T1GMX;JWD2ZD )#!G *$ 'IC/.!Q7USJ6E*EJVR5S*V$C5CP6/ S[50@^'
MUFB,TUQ-+<28,LV0"Q_H/052=B6KGYK:[_P3NUC7Y8DN?%^G:<(5)>."S9BV
M]LDCGC' _"J_[-?[,6N?"'XXWL]\&NM,LX98HKH#;%(&(V%><Y(SD8XQ7W)\
M1?'7PL\"7+V>M^+5MM34<10MYTL?NRJ#Q[&IOA9KOP\^*)ECT36(=2NXERXM
MYL-CU*$!E/L1^=-33T*E0J0BIRBTGUZ&; LD)R#D=@.U6(9;C/?\37IDOPYT
M:")Y'DFBC0%F=I<!0.I)/:OB3XL_MX_#OP?XEN-,\-:?K/B5;*1HWN+>9(H)
M7'!PS DK[@<TT[F3TW/JBQGD( D(&.C9R:OR+O&=^:\ ^ ?[9OPJ^,NI1Z'>
M3:AX-\02G$,&J2H89CZ)(!C/L<5]/2>"Q#- $O2\,ORAM@)SC([\CK2>A2V,
M[0;W^S[Q)3\P&01Z@UW]K=1WD0DB;</U%<[#X'C0Y:\D/^ZH%:MEH:6+AHYY
M>.H)'/Z5+*1\[?\ !1_Q[_P@7[)'C*1) EQJ:QZ9&.Y,K@''X U^!4N2Q]:_
M6K_@L]\0_L7@KP1X+B?YKV[DU&=01RD8VID?5B?PK\DY&R3Q5K88BG%(P H(
MXIS=,TP(QUIP/--'WJ<1@TD!;T]A'=*YQE 6 ]P,U45B6))Y)S5[2D#WB!EW
M G&*HR+Y<KKZ,138C]J/^"0GQ)/BG]GB_P##,\FZX\/:@R1@GGR9!N7'L#NK
M[MK\>?\ @C=X]_LCXP^(O#,DH6/5M.\Q$8XR\;9X]\$U^PU1+<85\W_M]?M$
MS_LX_L_:GJ^FJ3KVJ/\ V;I[#_ED[J=TA_W5!Q[XKZ0KXI_X*Q^%(]?_ &;(
MM1:Z@C;1M12[-M+(%:=2I0A >202#@=LT1U8'XFQ:C-=:M)?7,K2SRLTDDKG
M)9CDDD_6JT,^V4D]#G-->4,Q(0)G^$=*BJKV ?G<::1@TG(IQ^:A.X" 9XJ[
M9KMN(N/XA_.H+=,L35^*U+@G'&*M(#^AS]CWX>2?#']G#P1HMQ&D=X;%;JY$
M;!E,DOSDY'7@BO9J\N_9>\0#Q1^SQ\/-2\V*9I=%M@S0GY<J@4C]*]1K%ZL#
MD?B?_P BVG_7U#_Z&*Z:Q_X](O\ =KF?B?\ \BVG_7U#_P"ABNFL?^/2+_=I
M <MX3_Y&W7_]R'_V:NQKCO"?_(VZ_P#[D/\ [-78T <7\:? Y^)?PD\7^%58
M+)J^EW%HC$=&9"%_7%?S^:GIVH:3//97,;175FS6DP*\H\9*LA]",5_1O7SW
M\;OV&OAA\;KNYU*[TV70=>G;?)J>D/Y32-W,B?=<GU(S[UK"?+HR)1N?B)J<
M45OJ,+6=Q)- R*S#!^5L<C-:>A>&]:^(GB6ST3PYIMUJ^J79V0V-LA=W([@=
M@.Y/ K];--_X)A_![1=,F\^+6=9O%A?:]U?LJE]O!VI@=>U? _[#<MQX)_;$
M\%I+F(O?7.F-DX.65T(./<5?-%N_4VA[9TITX*\=&]-K:7OT6I^IO[(?PAU7
MX._L\>%_"7B6.V;5K>-Y;F&(!DB9W+;,_P 1&<$UZ=>>#[&XRT)>T<]XS\OY
M&MVBL+F9Q<W@B^5OW5W!(OK(A!_2O ?VF?VC=)_9;O-!@\1Z;<:I_;$<SQ-I
MY'R>65SN#>NX5]95^4W_  5L\0M>_%_P[I!(\JPT3S%!Y^>65\G\E6FGKJ;4
MJ7M6XIVLF_N3?Z'WY\,KV;XG^ M"\66$'V.RU>V6ZBAN3^\13TW8[UVUCX7N
M[>97:YC3:<@H"37F7[$'B5_%7[+7@"\;3Y=.6.P%LBRL"9%C)3S![,0:]TI/
M<Q6P@Z4M%%(9@>.=6M/#WAF[UB_N$M+/3MMW--(<*BH022?3%?"/[=7[9^OZ
M#(?#G@>\%CI[QYEU*(_O+D$?P'LOOU-?=GQ"M[2[\#:]#?0I<VDEG*DL4@RK
M@J>#7Y-_M<^&!J_BQ8;1;<"*VB3;+.D0!([;B*I=RJ<%5J*FY**?5[+[CY1;
MQ3'J^N->ZO<7#7+?,)#.W+?C_*O7?A?\5K[POJW]LZ9JQT?5;>,BVOPQ&&!R
MJO\ WE)&,'UKYU\76KZ;J=Q:N$#1.4(C<.H^A'!K<MUD/@BTU&)_WR;XW4'[
MP4\Y_,42@IV[HZ,/C*F!E.$7S0E=-?9DN_KU3W3/U3^/G[6+^/?V,M-U;3I#
MINL^()3INI11'!A:,9G4=P&XQ[-7Y83^-[V'5_(T](D0-C]XFX'ZUZ38^+;K
M5OAOJ=EYSO:*$NTCS\JRE-KD>^ *\/L) NKDMUW'K]::>BL85:2A.<7JEMY]
MG]VIZ7J\HNM,M=8MT%K=Q/ME$7 5QR"OUK](_P!B#]K'4O'DG@WX>ZE#_:6H
MI+,YO)9#OCMTMV(/OAN.>QK\UC+GPC?GL9$'XXKZF_X)9V<=_P#M,R2SY62R
MT2=X%QPVXJK']:*CM8K"Q4X5(OM=>J:_2_JS]?***BNKF.SMI9Y6"11(7=CV
M &2:@R/Q/_X*V>.1XG_:=;2HW)AT33H;7;Z.V7;_ -"%?#[?>KUS]J7X@R_%
M+X\>,?$LCF1;R_E,1_Z9*Q5!_P!\@5Y(PR>*V .HI<;EI#^=*N>12 CQAJD/
M./2D<884 XI(#1T/_C[#?W1FL^=A)<2MZL3^M7M+;RS.^/NQFLX<^]4^@CZ7
M_P""=_B'_A&_VK/!%RS;8WNO(;G (<%>?S%?O_7\V7[/_B!O"WQ/T/5%;:UK
M<QS!LXQM8'^E?T@Z/?IJND65ZA#)<P),"#V90?ZU$NC&>2_M<?M#1_LP_!+5
MO'!T[^UKJ&2.UM;0MM5YI#A2Q_NCDG%?@_\ '+]H7QC^T%XKFUKQ9J,NH7+N
M6A@#L(+=>RQIT 'YU^K/_!23QW'XU^$.M>"+2UBG1G$WF/R_F1?,"OICD5^+
M8F,88!=K8VGU'M40G&5TC2=.4$G+J,W;P5/4=*CQS0."*<S ]!5^IF-ZTY.?
MK2<GM3D5\_+Q0MP-6SM%1 S<GTJS+(D2@D\YPJCN:SK=93C+D#VJ6=&DO8%'
MW4P:UOH!^X7[%WQ4TO0/V<? ]EI%J9],BLP&,DF91+N)D![?>)KZH\->+-/\
M4VQELY/G7[\+\,GUK\V/V+K+4=+_ &;](NY<K%=7=S+ #_SSW\5](_"+Q9<G
MQU96\<C;V;:RJ>&'H:\%XF5.LX2U5SW7@X5*"J1T=CZ!^)__ "+:?]?4/_H8
MKIK'_CTB_P!VN9^)_P#R+:?]?4/_ *&*Z:Q_X](O]VO6/".6\)_\C;K_ /N0
M_P#LU=C7'>$_^1MU_P#W(?\ V:NQH **** "OQ7^($9^"G[<LJ*IA;3O&4=[
M&1D Q3R*X_27]*_:BORO_P""IGPJO]"^,6@>.]/@/V?5[5(6E PJW4!RH)]2
MN#_P&FE%OWGMJ=>&K5J;E3HJ[FN6UK[M;>=TK'ZG@A@".0:6N$^!7C^V^*'P
M@\)>)K5PZW^GQ/)SDK(%"N#[A@:[ND<@5^3?Q'T2W_:W_P""@4_A^X47>BQ:
MC]@E,1QBRM5/FX8=-Q5N?5J_0[]I[XQP? SX,:_XE:0#4!$;73H\\R74@*QX
M^GWOHM?*W_!+;X-75M8^)?BIK2&2[U>1K&PED'+H'W3RC/\ >?"Y_P!DTM&]
MSTL,YT*-3$<MTTX)OHVM;>:5_2Z/N3P5X-TCX>>%-+\-Z#:"QT?381!;6X8M
ML0=LGD]36W113/-"BBB@#F_B0DDG@+7EB ,GV20J#]*_*GX[^-KSPUX_OI[=
M+!YI;1%V:@ 5 4\E<]"*_72\M4OK2:WE&8Y4*,/8C!K\B?V]/A/J'A#Q21=6
MK-;L#Y$P'RR)V.?7UK2!E/N?#GCB].I:U?7@6,"6=G/D_<Y/\/M4_A6[=]*:
MU;[NYR >@R*9J,91BC*"O]TBNG^%O@'5?&^H&#3+">[?S!&B01EBS'L *LE)
MR]U;G>?"/P+K&I^#?$@\DW-EIUK')-)$,B,2,0N?RKR?4O .M1:WBUM6E!;@
MCI7[2_L7?LI#X5?"S6X?&%C%-J?B@*+RPE&X0VZKA(F_VN2Q]"?:O._B5_P3
M.DO]5GN?!'C!-,LY266RU. R&+/99%.2/J,UC!JRN>ECW'ZQ-49.45:*N[Z*
MR7RTT\C\TM4TJ73=$L=&&);Z:3=($Y^8]OPK]'/^":WPJETK6=3\2RVBQQVE
M@+!+@I@M(Q#, >^-OZBK7PQ_X)?PZ)J\>I^+/%"ZG.#DK:Q$8'L6Z?E7VWX.
M\':3X#\/VVC:+:+9V$ ^5%ZL>[$]R?6G)W9C!JG2<>LK7\DM?Q=ON-NO&_VO
M_B%!\,OV<_&^LS7(MI&L7M(&)P3)*-@ ]\$G\*]DKXI_X*Q^!-;\6?LUIJ>D
MRR&VT._2[O[9,_O(6&S<?]TD'\326YD?BGJ\[WEY+</DM(Q8\5G'K6W;SB..
M.1U5T!PRFMS5/ _VH--:A8,HKJKN I!%;6N!Q'L: ,<5/>6,^GSM#<1F.1>Q
MJ(#<"*0#'&1D=J0<"AC\O7WIR#+BIZ@7K-?+BGR3DQ\^U9\:E\  DGTJXC%+
M:8]VXKL?"NC0VL<<SKF1DR-Z]>>=I]<5:5P,;PU!/977G,AC!0[2W'?%?T(_
MLE?$:S^)_P"S]X.U:UE\R2*QCL[E2P+)+&H1@?K@'Z&OY][Z7SM7>&#+;F$:
MCN?8^]?O3^P[\&)_@G^SWH.F:@&76=1']IWR$_ZN211A!Z84*/KFE.UK"/EO
M]I#1=0T_XEZWHU^IXE-Q:NPXDB?D?X?A7YG_ !H^'MQX*\57<T<1.F7,A>*1
M1PA/5#Z<U_0)\</@5I7QDTB,2/\ 8=;M0?LE^HR5_P!AO53^E?FW\=_V;/%O
M@FZNXM?T)[[2IB1]HB7S(7]PPZ?CS7E>]AYN2U3/9YH8JFHMVDC\W, C^M)R
MIQ7JOC_X*W&BR2W6C))<6?5K5A^]B^G]X?K7F,L6UPK JZ\,"*[XRC45XL\N
M=.5-VDB$2$5+%-DX--:, XI?(&,J>1VJ]3,T+>4*P[CUKJ?A]X#U7XF>,=+\
M.:+;O<:CJ,RQ*$&=B9^9SZ!1DD^U9'@3P3KOC[7K?1] TV?4]0G8*L4*Y"^[
M'HH'J:_5C]DO]EO3O@'H#ZA?M'J/C&_C"W5VHRMNG7R8_;U/>LJU=4H^9U4*
M$JTO(]9TSP%#X/\ AWH_AG18"T&F6L=K!&@R7(&"?Q.3^->I? CX)S^$)GU[
M6P#J<J_NK?KY(/<^]=I\.?"*6%G'J5T@:ZE&8PP_U:_XFNYKSZ&&U]K/<[,3
MBW9T:>QR/Q/_ .1;3_KZA_\ 0Q736/\ QZ1?[M<S\3_^1;3_ *^H?_0Q736/
M_'I%_NUZ1Y)RWA/_ )&W7_\ <A_]FKL:X[PG_P C;K_^Y#_[-78T %%%% !7
MGGQW^#&D?'CX=7_A;5F-N9")K6\1<O;3KRD@]?0CN":]#HHW+A.5.2G!V:U3
M/A[]E_\ X63^R9K&J^ _'_AV\O\ P').UQI_B/286N+>V=N6W!<LJ/UQCY3G
MUKZ!UW]JKP'I%K(]I<:CK=V.$LM.TV>25V[#E0!GU)KV"DVJ&W8&[UQS0]M"
M_:*4W.JKMZ]OT/@GQM\&?BU^VU\1-+O?&.F2?#WX8Z:^ZWT^XDS=RJ?O/L_Y
MZ,.-QX4=,U]Q>%?"^F>"?#FG:#HMHECI6GP+;V]O&,!$48'_ .NM6BC0=2M.
MI&--OW8WLNBON%%%%!@%%%% !7'?%#X2^&/C#X<DT7Q/IRWMJV2D@.V2(^JM
MV-=C10!\%ZC_ ,$CO ^H:Z;G_A,-5BTXON-HMNF_&>F_/ZXKZP^$'P \"_ S
M08-+\(Z%!8K&N&NG&^>4]V9SSD^V!7HE%-MLE)(****104444 %9_B#0;#Q3
MH=_H^JVR7FFWT#V]Q;R#*R(PP0?P-:%% '\^G[8_[-EY^R]\:[_09!))X;OR
M;O2KLC/F6['[I/\ >0_*?P/>O-_#.L31WEM;F<?*=JB3I[?Y-?NI^VG^R_IW
M[4/P?OM&,<<7B2P5KK1[TCYDF _U9/\ =?H?P/:OP0O-*O\ PWKEYH^IP-I^
MJZ?,]O<0S##JZD@J<^A%;1D!U_B[2;.ZM S!I+C!WS.<A0/0].:\M!P^!SFN
MFU?Q+=7]D+<S$PKP4'1JYN1NI]:<F@(I1M8BG1' ;Z8IC,2Q/<U-!]T\9)J
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MA:/  8?O'4;L8(Y7=6-I?[6_B_0_%-YKVG6NG6EW<ZGI^HO&D3>6%LH'A@@
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MHHH /^'//P%_ZF/_ ,&7_P!C1_PYY^ O_4Q_^#+_ .QHHH /^'//P%_ZF/\
M\&7_ -C1_P .>?@+_P!3'_X,O_L:** #_ASS\!?^IC_\&7_V-'_#GGX"_P#4
MQ_\ @R_^QHHH /\ ASS\!?\ J8__  9?_8T?\.>?@+_U,?\ X,O_ +&BB@ _
MX<\_ 7_J8_\ P9?_ &-'_#GGX"_]3'_X,O\ [&BB@#5\*?\ !)SX(>#O%&CZ
@_8?V_P#;M*O(;ZW\S4-R^9$X=<C;R,J.*^SZ** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>forms-4_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_016.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *R Z@# 2(  A$! Q$!_\0
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M:@_OC\Z/[:@_OC\ZQ/\ A7-K_P!!&_\ ^^T_^)H_X5S:_P#01O\ _OM/_B:
M-O\ MJ#^^/SH_MJ#^^/SK$_X5S:_]!&__P"^T_\ B:/^%<VO_01O_P#OM/\
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M_P#$T ;?]M0?WQ^=']M0?WQ^=8G_  KFU_Z"-_\ ]]I_\31_PKFU_P"@C?\
M_?:?_$T ;?\ ;4']\?G1_;4']\?G6)_PKFU_Z"-__P!]I_\ $T?\*YM?^@C?
M_P#?:?\ Q- &W_;4']\?G1_;4']\?G6)_P *YM?^@C?_ /?:?_$T?\*YM?\
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MG>020(,(O)R-HX!'(I&_9<\(SO*UU]LOO.C*2B[NI91(QC,?F,"V#($)4/U
MZ5['16/^I61IN2I2N_\ IY5_^3\E]R']9J]_P1X?'^R#X!C0Q_87>W,<4;6\
MDCO&WE1F-&(+<L%8\GG//6F_\,?^ HWADAMKBUN$5E:X@N)$EFW!@QD;=ER0
M[ D\X->Y45LN$<H7V)_^#:O_ ,F+V]3O^"_R,3PAX7M_!WAVQT:UFGGMK-/+
MC>YD,C[1T!8\G XK;HHKZNA0AAJ4:-)6C%)+=Z+1:O7[S!MMW84445N(****
M "BBB@ HHHH \]T)B?$NL?\ 7W)_Z%6OXJ8C3Y/I6/H7_(S:Q_U]R_\ H5:_
MBO\ Y![_ $H O>!3GPEIA_Z9_P!36]6!X#_Y%'3/^N7]36_0 4444 %%1S3)
M;Q/)(P2-!N9F. !7'3?$*5YG%K8;X!]V65]N[WQB@#M:*X_3OB)!+?16M] ;
M)I2 DA;*[NP/I784 %(3BEI",B@#YI\<_M9ZAX2\=ZQX>C\-M=K9Z@EBMRLO
MRH&,0\R8;?D4^;\IR<[&Z8J*?]K+5EL;:^M?#?VZVFM+N4Q0.SSBXAF$2VX0
M(<M(S(1[$G'%7/'OCSXG:9XVUVTT?X71ZUHD%["T%\T;YN+8*/.'WN9"Y.TX
MP%7D$D5G7WQ4^)0O[(6'P7F$(+"X\YI$20-@1R!]A*+SDKM+C:<@=:_+\7DN
M?U:LIT*Z2YF_XU79]+*.G?31;:G;&I22U7X(AF_:\UV.YT[_ (I01VEZ;11-
M/*R-"TPDW+(I3@H8F!Y[CUI[_MD7D7@ZQUZ7PEJ$?VK4_P"S39&,F:+$9D,C
M#'1@,(!][(Z=*ZG5O$'C.U^'\%\/"$3:_<:JMN]JNFSW(M+<EB7:-2IDP H#
M!L9;)Q@BLB?Q;\2M-EC^W^$(0TMU#&(;/1+BX6*)8%DN&:1)3D[F*1\89@<X
M'-<LLAXCDH_[0M'K^^JZKM\/7N5[6CV_!'*)^W-?2!<>#YUW%1O:7Y!O&0Y.
MS[B=)&_@;C!KKM5_:7\2V%G9:A!X1:\L)='_ +8E1)MMPB"14=%4KAF&\,.1
MD ]ZZ'X6>(/%/BCQ):6?B+PLFFZ=)I4M[).VEW%N4F:X*Q0,TA*A_* 9U&?F
M/!(KUS_A'=//_+LE35R'B64HNC722O>]:J[_ /DJM8%5H]5^"/F_0_VL_$NI
M^)M*TJ]\$RZ5!?ZE+IZ7\\V8@8P=Y'R@DY&!V.>M+XL_:UUKPYX,\4ZQ'X;$
M]]HNJKIB6F]F28%N)-Z*?X020 2.AYKZ./AO36 S:1G'(R.E+_PCNG 8^RIB
MIED/$SJ1G]822M=*M5UM*[U<6_>7NOMN@]K1MM^"/#(/VH9;OQ)X?TNWT>ZG
MAU?1FUA+Q8&"@!21$%(!+?*<YQC*^M<MJW[:.HZ5I,-ZOA&XOQ-#'.#9/YD<
M6]9F\N1MHVR+Y6"N#@MUKZ<_X1[3\Y^S)GUYI/\ A'--(Q]DCQ]*BCP]Q-3D
MG4Q7,M/^7U375M[0ZII?*_4;JT7M'\$?+U[^VOJEE-/;?\(7>75Q&D4RR6QW
M0/"T6]W#[?X6*IMZDL#6G/\ MB7%K#!-+X=N&22^-M-# K2SVD*\/<3H$^1,
ME,<\A@:^CE\-Z:J[1:1A?0# I?\ A'=.Y_T5,GKQUKIGD7$,OAKV_P"X]7_Y
M#YD^UI=OP1\]^(/VL[K1_#_A[5K?15U"/5;>2=K>.7$J,A4&%!M.^3+?=X^Z
M:QU_;+URZU>UTZQ\"7VH7,TG,5N^YUB$7F,Y.W:#U&TD'CGJ*^FU\-Z8A&VS
MB7'(P,8I?^$=TX'BU0?05G3R#B2G!QEB%)ZV;K5>K;5THK9672]ANK1;V_!'
MS+:_MIW#/:O=^&Y8;.9&D:X@D,Q7]T)%BV!=QER=C#&%88SR*H0_MS7G]L16
M-UX-OK#_ $:&6X>X#(;:1Y-K(ZE<X4<EN*^J?^$<T[.?LL?KTI#X;TTYS:1G
M(P<CK6RR+B"[O6Z?\_ZOW_!_6GG=>UI=OP7^9X!8_M4WU]X>_M5='B2.376T
M6,R3;8XP"X$\S[?D0[..#DLH[UEVG[8NI7<)F7PE<F)IDMT$;;F2:1G2**4;
M?D=F3GJ%5E)-?28\-:8H(%G$ >H P#2_\([I_P#SZISS7,L@XE7-_M*=WI^^
MJZ+33X?Q'[6C_+^"/F"S_;3U)[NR6[\)7$-I-%<R2W$1,GD/&\B)&1MY=S'P
M/]H5K^'_ -K_ /MB[TRUN]'ETBYNKBVMIH;T&-[9Y4E+;@5!PC1;.V2ZU]#C
MPUIHSBSB&3DX'4TC>&=,<DM91,?4KDUK5R#B&HFHXCENM+5ZFGGK!^GR7G<5
M6DNGX(\F\:_'N\\(^'=0U5=)N;C[%/'"\<\#0!PS;2R$@[P!DX4$GM7GDG[:
MNH0>8TO@O45A,ACMY@#LD( +ECM^0*&4DD?=W'^'%?3Q\.Z>>MLA^N:/^$>T
M_P#Y]DKDP?#O%%"FX8C%^TE??VU1:66FD.Z?WV\RI5J#>D;?)?YGS3I?[9=Q
MJUQ8VT6B*ES<ZC!8GS)"J!)(C(9@2H)0$% >YJ_X@_:VO-"UB]T\>'I9Y;*\
M:UN3NV^4HE1%DQMRV\,655R2%-?0I\,Z6>ME">W*T[_A'=._Y]4_*NF60<1^
MT4HXGW>WMJF^G7D]?G]Q/M:-MOP1P_P&^*UQ\8O P\07&G_V6S7$D(M2VYT"
MG'S<#!]J]*JM9Z=;V",EO$L*L=Q"#&3ZU9K],P%*M0PT*>(=YK?5RZ]W9OU:
M..33=T%>>>%V)UC4_P#K[E_]#->AUYWX7_Y#&J?]?<W_ *&:] @U?%S$:?)]
M*UO!ISX5TH_].Z?RK(\7_P#(/D^E:W@O_D5-)_Z]T_E0!M4444 %%%% !111
M0 44UI%12S,%4=R<5E77BO3;1BK7'F,#C;&"W;--)O8#7HKD+CXC6T97R[.>
M0'')PI&1G)!]!U^HJ$?$N)!F:QDB'5MTB\<9.>>PQGZU7)+L*Z.UHKD[?XEZ
M,X/VB5K1@.1*/;)''H",_6N@L=7LM37-K=13^R-D_E4M-;A<N4444AA1110
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M45SW@KQK9>.M-GOK!)4@BG,'[Y<%OE5P<>ZNO';D5T- !1110 4444 %%%%
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ME]_UWD_]#-% &[XL_P"/*3Z5)\/_ /D4=/\ H_\ Z,:H_%G_ !Y2?2I/A_\
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MX=\%VUYJ,Y\?S:--#>7 N@EZD3[BP>2/GYL*6'W>F:!'20Q?%+8\4ESH3%%
M$F&#R<$9X&%YYZ'I2V-[\28-::UOH-*DM%T^29;R($1FX^7;&V3D ?-R!R,&
MN<M_#_@ZV$WV?XB/:RR0NKN;Z)2GS<N0> V7 Y[$<5-H'P]\,^(H'M-*\=:A
MJ$;1Y>"*]5O,&]79V Y;)(&>G- &O+8?%6ZN(IAJ6BVJC!:"*,O&Q'N1NP?3
M/?VJ]J\GQ!A\0Q-9_P!EG29)]I$K8,<>$.3ZDXD''J..]6M2^%XOM2:^A\0:
MO92EBP6&?Y0>. #_  \=.]5K+X/6MK?6-S)KNKWOV4NPCNKC>KNR;"YSWQ0
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M7!Y_G5[Q+K&N:;K?AVVTOPZ-9L+RZ:+4;W[6D/\ 9T00D2[&&9,L NU<'G-
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MB[WAB#;E&,Y.1QQZUU%4K+1M/TV1WL[&VM7?AF@A5"WU(%7: "BBB@ HHHH
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MC5'XL_X\I/I4GP__ .11T_Z/_P"C&H Z&HYY/*@D?KM4G'X5)377>C*>A&*
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M*** "BBB@ HHHH \]\#?\?E]_P!=Y/\ T,T4>!O^/R^_Z[R?^AFB@#=\6?\
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M/[1M3G_28>#@_O!Q0!8HJ*WN8;I-\,J3)_>C8,/TJ6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \\T+_D9M8_Z^Y?_ $*M?Q7_ ,@]_I61H7_(S:Q_
MU]R_^A5K^*_^0>_TH N^ _\ D4=,_P"N7]33?'5X;30)54[9)W6)3Z$FG> _
M^11TS_KE_4U>U_2$UW2I[)VV>8/E?&2K#D&@#G?#U_-_:<,3/YJE2I!'3CK^
ME5=6O3>^);R,9,<*+&OIGJ:L:-HNJ:?=2SZI*C6]LF^$Q@ # Y7/4@]>>161
MI8+^9.QR9F,A;Z\XH&BW-9":)E(Y88!]*M6^H^58+;/Q*B8P#R3526[900F
M!W-5;A;RVL5OBR&.5Q&FY<G/K0,MP^9+S(^WGA4ZCZFJ^K.5@RH)[9I+:63
MS(68\DGO5:\N6N=0LK.'!9YE#9[C/- ,[#Q'-'"EBI0O,/F4[B  !SGUIOA<
MK>7MY=.A25"(E /R[<9SBJ'CL:@TMNEC;K*[87<X8JJY^8\=3CH*GM&E\)^%
MM8UB>WEEFA@DN?LRG+,L:$A1_M''ZT$GCWC*V^-<_B2Y&D7-PE@M_>E9(6B6
M-K=H\6FU#'N&QOO_ #$L>1QQ65/X>^.Z>')T@\2W+ZZ;2*!)7@06_FCSA)*%
M\O(R# 0"3T:NU_9U_P"$M\<:%IOQ*\2>-)M1CU^R^TV_AO3X8DTZPC<Y1 =I
MD>5 -K,S==W%<5^S?\4_%'QX\>ZMXBU*^\3Z/I%C<W5O::+'I<<.CF..0Q 2
M7)!>:?(W$ J%Z8.* -2_MOC=%%J%I8Z@TSS1/!8ZE-$JI:$R?ZZ6'86E;9@*
M PP<YS4&I:=\:3J=O=VNH:B8)9&>XM(C"!#FV0 (7CY43>8<'G!6O3;CXQ7=
MKJD]F_@7Q-LBD*?:4M Z. S+N7:22"%S]"*G;XMS20H]MX.\1SL%WR(UD8R@
MW$8^;[QZ' ['V- 'G6G?\+DA\;?#V_O \^B6FF?9O$=FCX$MR3\TRC9EV VX
MP0/O>V:TVG_&J6UOY8-5N+?4)%NX+47,:/#$'G4PS.J1\LD7F *#C.S/>O1S
M\9)Q9QS'P1XF$CW"P"$V8!*D F0<_<&?KGM5L_%:1GLQ#X2\03BXCD<D6FWR
MMI/RODC!..![B@#QK4+;]H2997COD(EN4D$-NJ1-"@*AE#M&05(!?!&>2N>A
MJQJ,'[0-W?B6+4[2VM_MS7(B@MND'E[%@.Y.<L!)N[;BO:O5;?XP3W-[96P\
M$^)XS<,BF22QVI$&;;N8YQ@=3[5Z-0!X/\)(/B[#XGT8>+IY)=(6TG6[CE:-
MB)3M\L[TC4NV0_H K <D5[Q110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7G?A?_ )#&J?\ 7W-_Z&:]$KSOPO\ \AC5/^ON;_T,T :GB_\
MY!\GTK6\&?\ (IZ5_P!>Z?RK)\7_ /(/D^E:W@O_ )%32?\ KW3^5 '!^*H7
MTWXGV5QSY5U&RD$<<J!Z>H]:U9+>!B63,3>B' JI\9[&1+;3-3A=8Y;>8+EB
M!GG<.OT(_&H+74%O+>.XB8-%*@=?QKJCK%,SV9>-P\2E0=PZ<UCZII27YXE5
M<CKGI5R:7<A X..U<?K]KJ#A_L[.#U^4UJD(;J7AA(E.V12.IQ7(ZG8/%+N9
MA@'@=ZI:E'KRYW22(J<8!Q7):KJ&I0,?,D<D<5IL1:YORVGF2<M@9X()%/AL
M P7<^%!YP:X%]?OXR )2,<8HC\1W[$_O2/\ 9[&I<@Y6>CP111$A[C8V><GK
M6K9S0*0#=*".Q8"O+HM?O)2#NY[Y'6M2*^>?&Y=PSZ47N/EL>LVTUNRX^T*Q
M/^T*T(Y@O1P0?>O(H,EL!2I]C6G;7-U&?EE=1[&IL!Z0]\%!R<BJCW9Y*OGG
MIFN174+I5R9-WL:?'J\L9RP!^AHL%SI7OG)^;<*8+@YRH/UK,A\0(X 8%3WR
M*TH;JWE"D$+]*8B>)Y)" HR3T->4>.[J;6O%]I)&[&WL+V&T5U#XWYRWW1V/
M7/%>B^(-8CTC2GDAD$EW*PAMH\XW2-P/RZ_A7G_AGPG/K'V;3'!ENO[;R[LG
M)(!))PWKW_2G>VH/:Q]$?L_^#_[#TO6-5F#&ZU.]D<LS,?D!P,;N0/ZUZS5+
M1=,CT?2K6RB "01A>/7O^M7:X)/F=S=*RL-D<1QL[':JC)/H*^/?!^K?$_\
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M"YU.;46T2T>^F+&2=T)9B0 >I] !1J,SW^-O@983*/$ME(H:1!Y3%R6CSO
M!)QM.<>E;?A+QMHGCJQGO=!U*'4[2&9K>26'.%D4 E>?J*QYO@OX%G217\*Z
M7\\CS%EMPK;W!#L&'()!(.*Z#P]X5TCPI;SP:1I\&GQ3RF:58$V[W( W'U.
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M2".G'//85>O?"4MM,CIX3N[A5C"S*->* %L;F()P0,GGKD4 >ZB52VW(W$9
MSR12AP21D$CJ/2O"F\,W45I$A\(7LDT#Y@*ZZ#D,1N!;CY, '&*=K6@7-Y=_
MVA)X5O99&_>W%M!JK"4/QM4;3@IUX/3\: /<S(H!)8 #U-&X5X;8^%GGMK>X
M?PMJ%F/-D9[)]=SRJ9CSSQN8[<=NXJA-HETT%RDW@S6IIHY-SO\ VV/GWD,<
M8_NENPQP:-0/H'<-V.,^F>:0RJN<D<#)YZ"O!9_!UVRRH?"%\?W/R2_\))M!
MZ?*2,'/UR*[&U^'FC>)+2.[UB.[L+V0%7MA?GA1P.AY& #^- 'I0D5AD'(]1
M31/&SNH=2R?>4$97Z^E< OPL\.VU[9O:WUY:/ PF\M+YB)$'&TY)^7/I44?P
MB\&VEX)!+<+<R#RW8W[[ILC W<\GCB@#T?-+7+>&/A_8^%-7O+ZRN+QEN8EC
M-M/.9(TP22PSSDYKJ:8!1110 4444 >>:%_R,VL?]?<O_H5:_BO_ )![_2LC
M0O\ D9M8_P"ON7_T*M?Q7_R#W^E %WP'_P BCIG_ %R_J:WZP/ ?_(HZ9_UR
M_J:WZ ,;Q?<FU\/7; X9E" _4XKD;=%@CV+]S)-=#XZ8-800Y&7E!VGN!7,S
M3I# %!&1VZT#0,/MT\5O&V9)FVCTK=\<PIIWAB!4&%BE0#^51>!M)\R:74I0
M6;_5IN[>IJ[\18O-\+S#^(2(1CN=U '+VS@QJW?%'ANW:Z\8QN5PL:EJCAVI
M$H)8L!T%:/@:+/B6Z<,[8AR<C&#F@;/0J1E# @C(/:EJM?:G9Z7&LEY=0VB,
M=H:>0("?09H).(\%? _PQ\.O$]_K/AM;_28[[>TVD07TG]G>8[!FD6V)*(Y(
MZJ!U/K2Z7\$?#.@?$"Y\7Z0-0TC4+QVEO;2QOI(K*\D(P9);<'8S_P"U@'O7
M4CQ;H9_YC%A_X$I_C5\-%?6NZ.020RKQ)&V001U!% $V:,UR*_#'2EM%MQ=:
MEL#*V?MKY)7_ #SZU-J/P\TW4DA66XOT\I!&&BNF0D#N<=:0'449S7)CX;:8
MK1G[5J++&"%4W;8Y)/U/6EG^&^GW$B.;W5$VILVQWKJ#[G'4TP.KHS[5R:_#
M?3UCE3[=JQ$B*A)OY,C;SD'/!/<]ZC@^&6GQ ;]1UB?!S^\OWZ<\8&..?T%
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MR!7VEQC'';I6;E=-!U/JRBN8\)_$;0_&2A;&Z"W6,M:3#;*OKQW^HKIC7(=
MM%>=P_$O6I)TC_X1*[</--"'23A-A.TOE> P!Y[<>M/@^)NHS7]Q _AB]MH(
MD=OM$P8+\J!N1MS@DX&,DT >@T5YI;?%36KF<QCPA= A-P'F'G@\ [,=L_1E
M[Y T;_XC:A!?36]OX2U:58HY&\Z5!&C.K<*#SD, 2#[ =Z5P.ZHKSS6?B;J>
MFZC<6]OX<FOHXI?*\Z-G [<GY.@SR1GVS3T^(NMRV"W,?A*[8JTWG1L^&54
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M(UBFD@995VL&0X/X5I4@&.E+3 **** "BBB@#SS0O^1FUC_K[E_]"K7\5_\
M(/?Z5D:%_P C-K'_ %]R_P#H5:_BO_D'O]* +O@/_D4=,_ZY?U-;]8'@/_D4
M=,_ZY?U-;] 'G_CV4R>(+%58_NHB2!V)/^%<[=$AOE8@DXR*M:O=&[\3:C+N
M)4-L3\!55@'N(D)P6<+T]:"D>F>%[0V6AVT;<L1N.?>J'CR11I$<9ZO,N!ZX
MYKHH8Q%$B+T4 "N+\?2F34M/@YV*C2'^0_K02<ZD2R39<$(!D\UTWPY19([^
MY"[5EEROTKE]0W+;F-.#)QGT%=UX)M!:Z0,=&;(_*@IG0UR/C6.!-=\*7%W'
M&UFE\\3M*H*JTD+JF<^K$#ZD5UU8/BW4]-MK6&PU&UFODU!FA2V@A,C.0I8\
M#I@#.?:@D^9O%+>$?CW\5_&WAC_A*$TZX\%!9IK2P&0JK]\R(<+NW$C*D].:
M^C_A[I;V/P^T2RG1HV6R1&3[K %>GL<&OG^#P9\%O@MX_G\27NGWFFZ]J+,T
MGGVS>?=%VW$S;<M(-P!!88R.<FOIC2=;L]:T:VU6UD)LKB(3([J5.TC.2#TI
M <6? END26W]F:BT'FH2XU-SC'\77/?D=ZTM2\!V&HP2*]M=LT"B*(1WKQF5
M1C!)!XJ^GQ#\-2Q>8FLVC1\?,'SC/3\ZD;QWX>2#SSJUL(L[2^_@'G@^G0TP
M,"3PM$]LULVD:D4"[-XOADC=NX.?6H1X+MK7_1X]*UAXW"$D:D=H()('WNQ-
M=*GCSP])&'76+,J3@#S!G.,].M$WCSP]!=FUEU:VCN _EF-FP0V<8H P)_"-
MM=2B232-2W2*L9"WV @7@'@^@S4-WX0@N9'/]CZNGS[RT6I%-S>OWJZ-?B#X
M;8@#6K+).,&4#!]_3\:</'OAPDC^V[#*C<09UX'K_.E:P&+:^$(0LLPM=5AE
MP5\I]1;#Y&">"1G'>H+3X?65](YDM]7L2^096U)MPXXX#'U_2NDD\<>'X96B
M?6K%)$&65IU! QGU]*A'Q#\,XR->T[&<?\?"]?3K3 B_X5]IHCN5%QJ"FX55
MD9;QP3C'(YX)P,D=:KW7PQTR[6W5K[5D$*LHV7\@W G/S'//)K5A\::%.8Q'
MJUHYD7>F)1\PYR1Z]#^51#Q[X=+%?[;L=P;85,ZY#>AI 4T^&^EQQ2(MSJ6'
M()8WTA88ST.?<U&?AAI1A$7VO5!&"6(%_)DGCJ<Y[5I-XY\/I'O.LV03YADS
M#^$X;\C2)X]\..$*ZW8D. 5/GKALG''KUI@9TGPNTB2"* W&IB*/E56_D&/U
MJ^O@FP325T_SKQH4?S$=[EVD5O4,3FEN/'OARUE,<VM64;@D$-,!C'6DN?'_
M (<M(X))=;LDCG)6-S,,,1UY_K0!%:^ =.M(M@N-0E)+'?+>.S?, #W]!TJF
M?A9I&'*W.IH[C!D6_DSTQW/:M3_A._#WE/)_;5EY<>-S><,+DX&?QIL7CWP[
M.[)'K=B[+U43#(I 2Z5X3LM(U6?487N'NIH4@=I9V92J@ ':>,\=?K6U6 WC
M[PXI(_MNQR!NP)@>/6G'QWX=6(2_VW8>67\O=]H7!;@XZ]>1Q3 W:*Y]?B!X
M;:,/_;=B%(SEI@/YU)_PF_A_RVD_MFQV J"WGK@$YP.O?!_*@#<HK C\?>')
MSB+6[&4C.0DZMTZ]/2EA\=^';AT6+6K&1F!("3J20!DGB@#>HK!3QYX=E953
M6K%F9M@7SESN]/K[4Z+QOH$T"S1ZO:2PM)Y(DCD#+OQG!(Z<4 ;E>=^%_P#D
M,:I_U]S?^AFNNL?%FC:G=);6>J6MU<.6"QPRAB2H!8<>@(KD?"__ "&-4_Z^
MYO\ T,T :GB__D'R?2M;P7_R*FD_]>Z?RK)\7_\ (/D^E:W@O_D5-)_Z]T_E
M0!KM#&[H[(K.GW6(Y'TJMJ.CV6KQ>7>6L5RGI(@./I5RB@#P#XK_  2NK6,:
MSX::9YK5&<0B3]XN$P .#O'3*FO,M*\7+]I_LS4G6VU-"ZLO(1]I )!(XZCY
M3S7V97GWQ&^"VA?$2WD:9&L-092HNK?C.2#\R]&Z#K71"K;21FX]CPJZN4<'
M(X'<BN:OOWS8 ^4?F:Z#Q1\)?&WP^AN9+2%=9TQ"\FU&:0A=XV@<;EPI/'/W
M:XB/Q5:&22*^AETZ:-G5A("R?*0#\P'J1U ZBNN+4EH1JCEKG^W_ #<66K:1
M>)O),-["\3A<GNI[#CIVKR_QK\.[WQ-XAGU&6)H;B:-8)3&^8PN0N%+(1M/7
MUKVC4=,L)]5_M:UB-[-(JPRM#MG4C/'R9RN,G)&/?-8]GX7.F2:B@NKC4S*[
M21Q7D3;H<]D/W<#TP.E)QN-,X+P39:SX&M_L=O$]WIP8[([F21V0>JX7 Y[=
M,5UTMOJMPMM>7WB6+2[<!6:"RA'[P]3DOD\X/ %6I;2[*!=@0DX^6.,X/;@G
MTZ_2EC6: 2PR)')'YH99!M5@,\*%5>1C/6IY1W-^RU6"\D*1;OE4.)"I"D'T
M)J^LA8X!Q]:XR[\W1KTS:5X>O-1NK@ F0RA8\'CGMQZ8[UTTFHVVG1(][/':
M,P!\J1OFSZ8ZT[ :<<^1M857U?5X]&MFED62X(QB*(;FYZ9]![FL2[UZXO'$
M5@HM("=K7<FTR+\VW<$)Z!L YY&1Q7<?#/X ZYXR9)KBQ?3[&49GO=00&256
M7;+$?F);D!E/05+:CN!QNG>'=9\>ZFD$<#3W>^2.WM$B?9:W$;*REF&,AA_$
M>/2OHWPC^S=+_P ?&O:B4_TA[B.VM&;*B10'1F)(//I7J7@3X<Z/\/M/^SZ;
M //<*)KM@/,F(  )/T%=37-*HWL4H]6>3V/[,'@*RE5S875P! ;8I/=NRLA.
M<'GKGOUKM[CP!X?N-'BTQM+@6SA7;&JKAD^C=:Z&BLKME61R/@OX9Z1X(GN9
M[-9)KF<_ZZ<@LB?W1Z#^===12,<#IGVI#"EKYG\7Z3^T)IOC*ZU_P;>QZK:2
MRR#_ (1SQ'/;16,407Y3"\*>:6)QC>V!@YZ\17FO?M6174(M/#'@FXM3*SGS
MKQHY!%QA7(8@/U^Z&'(YH ^G:Q/%6L7^AZ<MSIVE2ZQ-Y@#6T+A7V8)+#/!(
MQT[YKE/A7/\ %&XN[T?$*V\/6MO';6XMCH;R,99R"9BV\_*JDJH'?!/>O130
M!YK)\1_%"V@F'@VX$NY0;=F;<H..<A<'/. .F.<5HR>,?$[0K)'X3D0H6,D<
MDX+;0JD;<<$DL1C_ &36K<:#K4MX\D>N,EN6)6+RN@SG&0:U-6T^YOX(DMKU
M[)E;<SQC);@\?3.#^%(#AK7XF^)9HI-_@+4DFC."HE7:W.."1^/YU);_ !2U
M2\L[F>V\(WTSVET;:X@1QO7"@DCC!P3T_P#U5T T7Q$+@M_;R&$GE#;#./8]
MC3X-'UY(Y%DUP2$QE4(MP,-V8^N*!'.:=\1?$U[:2W#^!KZ#,H2*)Y@'*X)+
M-D<=L5$?BIKS7#QIX"U<JCE=[, -H.-W3_&NLLM+UR*Z@>ZUE+B!/OQK;A"Y
M^N:WL9H \WUCXM7VCR:<LGA'4V6[AC??V21S_JNG+?YXJ.+XJ>(9;=I3X!U6
M/+*J!W&3D>F,X%>F8HQ3&>>ZC\3M5M=1:SL_!^I:B5F6!IHCMC!*@DDD=!GG
M_'BHX_B7X@-I;2/X'U$RO)Y<D:R#]WPIW9(Y7)(_#M7HV*,4@*&@ZC+J^DVU
MY/:2V$LR;FMIOOQGT-:%)BEI@>>^!O\ C\OO^N\G_H9HH\#?\?E]_P!=Y/\
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M847CYY9Q'_PCFN)E@N]K0!><<_>Z#/Z4Z\\=FQNYH)- UEECD\M9HK7>DG.
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MMX=:XURYU2YN%N5O$D:(HQCP-ZJA.U0Q"@YY_&O4KZ26&RN)($$LZ1LT<;'
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M[I_*LGQ?_P @^3Z5K>"_^14TG_KW3^5 &U1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'GO@;_C\OO^N\G_ *&:*/ W_'Y??]=Y/_0S10!O^*D+6<@'I3_
M2E/"=@#P0'_]#:M#4[,743*?2L 7>JZ-:I:V=O;O''G!D#9Y)/8^] '7T5PY
M\3>)1TL[+_OE_P#XJD_X2;Q+_P ^5E_WR_\ \50!W-%<-_PDWB7_ )\K+_OE
M_P#XJC_A)O$O_/E9?]\O_P#%4 =S17#?\)-XE_Y\K+_OE_\ XJC_ (2;Q+_S
MY67_ 'R__P 50!W-%<-_PDWB7_GRLO\ OE__ (JC_A)O$O\ SY67_?+_ /Q5
M '<UE^)/#6G>+=*ET[5+9;FUDP=K#E6'1E/8@]ZYK_A)O$O_ #Y67_?+_P#Q
M5'_"3>)?^?*R_P"^7_\ BJ -7P?X!TKP6+A[*%6O+DCS[HQHC.!T&$ 4 >@
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M[4 5? Z[/">F@\8C_J:W:Y#[;JVCVL=K:6]N\<0PID#9_0U6/B;Q+GBSLO\
MOE__ (J@#N**X;_A)O$O_/E9?]\O_P#%4?\ "3>)?^?*R_[Y?_XJ@#N:*X;_
M (2;Q+_SY67_ 'R__P 51_PDWB7_ )\K+_OE_P#XJ@#N:*X;_A)O$O\ SY67
M_?+_ /Q5'_"3>)?^?*R_[Y?_ .*H [FL#QEX=N/$.EJ+"\_LW5K9_/LKPH'$
M4F"/F4_>4@D$>AK%_P"$F\2_\^5E_P!\O_\ %4?\)-XE_P"?*R_[Y?\ ^*H
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M_GRLO^^7_P#BJ/\ A)O$O_/E9?\ ?+__ !5 '<T5PW_"3>)?^?*R_P"^7_\
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M^5E_WR__ ,50!W-%<-_PDWB7_GRLO^^7_P#BJ/\ A)O$O_/E9?\ ?+__ !5
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M?]%=\$?^#^U_^+H_X:S^!7_17?!'_@_M?_BZ_F[HH _I%'[6OP*'_-7? _\
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M_@_M?_BZ_F[HH _I$_X:S^!7_17?!'_@_M?_ (NC_AK/X%?]%=\$?^#^U_\
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M>LN;\O=OO9JW5M6;5KV__9MMZ^];:][]$>W:+^R7\--+\;^$O 6HKKWB>_\
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M9Z&J6@ZYX@\=_MA_$M_".L1>"O![ZG>:AKFHPV<!AT_2K:1MT@5D*J=HVHH
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M@_Z*SIG_ ()9/_CU?JU_;4']\?G1_;4']\?G0!^4O_#COQ!_T5G3/_!+)_\
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M (]1_P .._$'_16=,_\ !+)_\>K]6O[:@_OC\Z/[:@_OC\Z /RE_X<=^(/\
MHK.F?^"63_X]1_PX[\0?]%9TS_P2R?\ QZOU:_MJ#^^/SH_MJ#^^/SH _*7_
M (<=^(/^BLZ9_P""63_X]1_PX[\0?]%9TS_P2R?_ !ZOU:_MJ#^^/SH_MJ#^
M^/SH _*7_AQWX@_Z*SIG_@ED_P#CU?J+\+/!TGP[^&/A'PK-=+?2Z%H]GICW
M2(469H84C+A23@';G&3C-;":M"YP''YU;BG609!S0!+7YF_';_@D)KGQB^,G
MC+QO#\2]/TR'7]3GU!+.327D:$2,2%+"49(]<"OTO>0(.:JR:G%&>6 _&@#\
MG_\ AQWX@_Z*SIG_ ()9/_CU'_#COQ!_T5G3/_!+)_\ 'J_5O^VH/[X_.D_M
MJ#^^/SH _*7_ (<=^(/^BLZ9_P""63_X]1_PX[\0?]%9TS_P2R?_ !ZOU:_M
MJ#^^/SH_MJ#^^/SH _*7_AQWX@_Z*SIG_@ED_P#CU'_#COQ!_P!%9TS_ ,$L
MG_QZOU:_MJ#^^/SH_MJ#^^/SH _*7_AQWX@_Z*SIG_@ED_\ CU'_  X[\0?]
M%9TS_P $LG_QZOU:_MJ#^^/SH_MJ#^^/SH _*7_AQWX@_P"BLZ9_X)9/_CU'
M_#COQ!_T5G3/_!+)_P#'J_5K^VH/[X_.C^VH/[X_.@#\I?\ AQWX@_Z*SIG_
M ()9/_CU'_#COQ!_T5G3/_!+)_\ 'J_5K^VH/[X_.C^VH/[X_.@#\I?^''?B
M#_HK.F?^"63_ ./4?\.._$'_ $5G3/\ P2R?_'J_5K^VH/[X_.C^VH/[X_.@
M#\I?^''?B#_HK.F?^"63_P"/4?\ #COQ!_T5G3/_  2R?_'J_5K^VH/[X_.C
M^VH/[X_.@#\I?^''?B#_ **SIG_@ED_^/4?\.._$'_16=,_\$LG_ ,>K]6O[
M:@_OC\Z/[:@_OC\Z /RE_P"''?B#_HK.F?\ @ED_^/4?\.._$'_16=,_\$LG
M_P >K]6O[:@_OC\Z/[:@_OC\Z /RE_X<=^(/^BLZ9_X)9/\ X]1_PX[\0?\
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M:3_A7-G_ -!'4/\ OXO_ ,376T4 <E_PKFS_ .@CJ'_?Q?\ XFC_ (5S9_\
M01U#_OXO_P 376T4 <E_PKFS_P"@CJ'_ '\7_P")H_X5S9_]!'4/^_B__$UU
MM% ')?\ "N;/_H(ZA_W\7_XFC_A7-G_T$=0_[^+_ /$UUM% ')?\*YL_^@CJ
M'_?Q?_B:/^%<V?\ T$=0_P"_B_\ Q-=;10!R7_"N;/\ Z".H?]_%_P#B:/\
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M_"N;/_H(ZA_W\7_XFNMHH Y+_A7-G_T$=0_[^+_\31_PKFS_ .@CJ'_?Q?\
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M^A1]HB_YZ)_WT*/K%'^=?>@L^QRW_"N;/_H(ZA_W\7_XFC_A7-G_ -!'4/\
MOXO_ ,374_:(O^>B?]]"C[1%_P ]$_[Z%'UBC_.OO06?8Y;_ (5S9_\ 01U#
M_OXO_P 31_PKFS_Z".H?]_%_^)KJ?M$7_/1/^^A1]HB_YZ)_WT*/K%'^=?>@
ML^QRW_"N;/\ Z".H?]_%_P#B:/\ A7-G_P!!'4/^_B__ !-=3]HB_P">B?\
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M*S20:Z_E^0\4HB?&]2X5R"%)7< <'K7-B:RPU&=9[13?W#2N[%G_ (5S9_\
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M>"068<$YP& _"B7'3C_S#K_P9_\ :?>'U7S_  />/^%<V?\ T$=0_P"_B_\
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M9;5/+:XFF+[2L40;<Z*H9C(!M&TCK4HT_4+:2XF'PBL7MX8@(K>&2(3,P)
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M] &#X6\1W7B 78N]%N]'DMW5-MS@B3(SE2."!TK>HHH **** "BBB@ HHHH
M**** //? W_'Y??]=Y/_ $,T4>!O^/R^_P"N\G_H9HH W?%G_'E)]*D^'_\
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M&074XESF),[3_>/?\JF<I)E74,OH166OB&P8X^U(,>IQ3CK=B^-MU'@_[0H
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MDY.\YYR<#FNJ\)>'W\,:%!I\E_<:G)'DM<W399B3DX]!Z#M0!L4444 %%%%
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MS8WUM%>65S&T,UO.@>.5&&&5E/!!!((-0/H6GOHZZ3]CB735B6!;5%VQK&H
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M\[\+_P#(8U3_ *^YO_0S7HE>=^%_^0QJG_7W-_Z&: -3Q?\ \@^3Z5K>"_\
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MIPL&T]K%X5#R2!MRNIWX()Z<=Z]3TN62]L8;B6"6TDE0.T$V-\9(^ZV.XJK
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M%L[YART<[!I1DQ'JPSD8-0_!&+XYZEK+ZW\3;SPSINC75J3#X:TBW=KBTE+
MKYD['#87(('<UZM/XIT6VNWM9M7L(KI)%A:%[E ZNWW5*DYR>PZF@#SZS_9T
M\/Z?XUC\66^I:K%KB6"Z;YXEC*M J; K*4PV%[G///4G-"3]E?P?/H,&BSSZ
MC<:9"(PMO)*F#Y;2/&3A!]UI7('09''%>IV_B+2KI5:#4[.96;8#'<(P+9QC
M@]<@C'J*;<>)]&M;N.UGU:QAN9&9$ADN45V9?O *3DD=Q0!Y)%^R-X+MYXYH
M+G58)%E\YVCFC7S6^?._Y/FSYC9]>/2H&_8W\ E0%_M&,JLJJRS(60RC$K E
M#AGQDGUKV6T\0:7?Q"6VU*TN8RI8/%.K @=3D'IP:9:>)M'U $VNJV-R _EG
MR;E'^?.-O!Z^U ''^ /@AH7PZUZ;6-.N+ZXOIK7[([W4BMO7>9"S$*"S%F)R
M<]3C%>AU077]+>>2%=2M&FC)5XQ.NY2" 01GC!('XBFMXBTI(!,VIV:PDD"0
MW";20<'G/:@#1HJO9:A:ZE$TEI<PW4:NT;/#(' 8'!4D=P>HJQ0 4444 %%%
M% 'GFA?\C-K'_7W+_P"A5K^*_P#D'O\ 2LC0O^1FUC_K[E_]"K7\5_\ (/?Z
M4 7? ?\ R*.F?]<OZFM^L#P'_P BCIG_ %R_J:WZ /#OVPX;A_A-#+!!+,L&
MIP2S-$N[RX\."Q] "1S[U\BVNI-=6+1A]RGTZ@>U?I//!'<PO%+&DL3@JZ.,
MJP/4$=Z\YN/V<_AY<2M(OAN"W=B2?(=T'/L#BOCLYR.IF-55J4DG:VI[6!Q\
M<-%PFM#XET]H%M%1(RORX.X=:R[F,Z;,5.# YRK$9"GT^E?<$?[,/@*)B5L+
MG;G(0W3[1["K1_9O\ .FR31/-7T>=S_6OG8<,8U2;<HV?F_\CTWFU!]'_7S/
M@BYU&.R1R&"KU ;@#U&:]Q_8%D:\\6^-KI89%@-O BRE"$8[VS@]#7TCI/[/
MOP\T6Y2XM_"UC),ARK7*F8#\')%=Y:6-MI\*PVMO%;0KTCA0(H^@%?297D<\
M%55:I)-KL>9B\?&O#DBB;%+117UYXHAX%>&?M#ZIOO["Q7_EC"TK?5C@?R->
MYGI7RK\1]8/B#Q?J]P&+1B;R$SV5.*^"XSQ2H9;['K.27R6K_)'MY12Y\1S_
M ,J.-B_=:=D]VK,>1%G&3\S?K6GJ*M%8;2,!1G->9>(?&$6E>)=!MI&D)NYF
MA5(T+EF(P!@5^-86A/$-J&KU/NN=17,ST:+)+,6).:N^=B.LRVEW0H:LN_[D
MUS2C<MJYZ%^SG=?\7/O$Z;].<?DZFOI[^*ODO]GR8Q_%VV!.!+:3+^@/]*^J
M=6^T_P!EWGV(@7GD/Y!89 DVG;G\<5^[\(O_ (3$NS9\%G"MBGZ(-9T>S\0Z
M1>Z7J-NMU87L+V]Q ^=LD; JRG'8@D54N/"NFW'AE?#X@,.E) ELD,3%=D:
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M3)FT[Q],+"[CLGAOX]1#R9MDZ#(V;7DPSX&2,@^M 'U)':00JBI#&BH,*%0
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M35+FY2[GEANG02NJ%!D9QC:Q&!CK7IHMHA.9A$@F(VF3:-Q'IFI*5@/)+?\
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MI\!/!VA^+M-&M>-M&AU?^T[B]M=.NIHHC)-<A5=/*R-P.T!5QQGBN@M_V/\
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M*** "BBB@ J.YD:*WE=$,CJI94'\1 X%244 ><6/C_Q;/#$TO@R96DCWY$I
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M?2M;P7_R*FD_]>Z?RH VJ2EHH 3%?G=XVN"WQ<\89[ZI-C_OJOT1-?GAXYB
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MREEXETVZCU32+B0X47,>=JD]@P)&>W%=YS')_!7]@GX>^ H--UWQ592>-OB
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M7]Q_P(_SJYQZ_A5M7%<S+U1OZ]:S9TP.G)K4OURA]16/(V[G)XK:GL#/MO\
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MO86,.FVD5K;ILAB4(BY)P![FK% 'GO@;_C\OO^N\G_H9HH\#?\?E]_UWD_\
M0S10!N^+/^/*3Z5)\/\ _D4=/^C_ /HQJC\6?\>4GTJ3X?\ _(HZ?]'_ /1C
M4 =#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GFA?\C-K'_7W+_Z%6OXK
M_P"0>_TK(T+_ )&;6/\ K[E_]"K7\5_\@]_I0!=\!_\ (HZ9_P!<OZFM^L#P
M'_R*.F?]<OZFM^@ HHHH **** "BBB@ HHI"0H))P!U- 'Q#^U3KE]XE^)MU
M':-FQTB-+4[6Y+_>?CZG'X5Y/%J#-;GJ3CFNZ\27ZZKXUUS4%4JMU=RO@_Q+
MN.#7):MH[6LCSVREHV^\@_A]_I7X/B\6L3BJDI=6[?>?HE"E[.C&*Z(^R_V4
M[;R/@QI<G_/>>>;\W(_I7K]>9?LU*H^!GA J/O69<^Y+MFO3:_:\#'DPM*/]
MU?D?!XAWK3?FSY;_ &K/WGC/3(N[:>2OL0YKP6*YV2Q_*,?Q9KW#]K.Y$/CS
M13_$+'_V<UX9<@)<2!2"C?,OTK\<SM?\*5:_5_HC[?+_ /=(?UU/;/V8D$GQ
M,8@ ".RD8 ?4"OJG6=-36='OM/D.([J"2!CZ!E*G^=?*_P"R%*;GQYK.5R(M
M-QN]"9$_^O7UI7Z)PQ!PRY7ZMGS&:ROB7Z(^4=3^!,?[5?P3T?PEK_BO6_#(
M\.!]'U+2M,*(KWL!""2;()=-@5U7(!#@UXOXA_X)5_#_ $WQQX>T>U\6>(4M
M-528G?Y+-$845FP=HSNR>W'O7V1XS\&:[X=\52^-_!")=:E/&D6KZ!/+Y4.J
M1KPKHW2.X09"L>&'RMC@CC%^*'@J/QM_PD>IZYXBCURUW06_@J\LF-U;SR*J
MOY4*H7?<%&"&:,9)R,U]8>.>>>$/V2]"_8QT?Q+XN\*^,O$5R\\,D$>B7<D3
M6]Y)(NRWA*!1F3S67#C!ZC&*^D_ASX,F\$_"G0/#(D4W=AI<=HTAY7S1'AC]
M-V:YK0O"FN?$?Q38>*O&=C_9.FZ7(9M$\-LXD>.3&!=71!*F4 D*@R$R3DMT
M]3E)6-R.H!QB@#@;'PEXKB6V:XU>TED2)5EW6Z$,X(RW"CY2HQM_(U>A\.^(
M4LI1)>637C&/;+#"$"8)WD94YR,<>W6MOPUK"ZE9"&6^M;S48%7[4+5P0A89
M7(!.,CFN*TOQ-XPF69HYM"U.W6X=3,+@(RC< $X. RC.<YR10!HZ=X,UN/5X
M[V_N=.O2J",J;=<E &(3.WIN*GCT-26'AKQ#';W"WDVG3RM"45H8E0%_,8[C
ME#_ 57O]W/>J$GB7QQ"8S]DT)XRV6=KS "\8[]35XZ[XJGTZ=H(]':Z9R(,3
M\;0AR6YP2&'8].: &VO@C5[J_@EUB\L;V*!XWC"VJ!E*L=W\/0@XQVS5:#PC
MXNLXPL>J:7*Q8OYDMD@9/G8[1A<$!=H!QG@FI(=6\76FL6D;3Z5>:6=BSW$\
MJHX  +L O!;KQP/Y&!=:\<6X)B?0=3C<NZ,TWELBECL5L$@C&WYAUR>.* )X
MO#'BXRP//?:-(ZC]ZPL@ QW Y P2.-PZ]P:AU;P]XRD:Q%LVB7%RAGE:\N+8
M*(V)_=@  G[I.2.M,E\1^.8RD)AT$SD/(Y%SM C"9!4%O4\D\ <U<A\3^*(R
MRW4&C1F5?]&(NL[V#*&'7G )].WK0!4;PSX[9V(U#0%( \MOL&2..1]">_I5
MR]LO'=GI]FMA/I4MP78W7R;!RXP4XQPN<YY-2B;QW:Z?$4M].O;EHF>02OY>
MR0MPB[>"H'<\\>M3Z7<^-)+>0:E::=#(%&TVK%B3N7/4_P!W>?RH STT[XCM
M"ZOJNBI(R8#)"YVMN.3R/[N!TZU:U>P\>27#?V=J6E1P?,5\^)BPZ[1Q^&:O
M6\_BM;VP66WLFLVMU-U(&Q(LN6W;1G!&-F/?/UK0\.'6/(E75_*:0%=CQ@ G
MCYL@<=: .<U2Q^( OFELM3TMK5V51 T!!C&%RVX]<'><>XQ3I=/^()1 FJZ.
M&WC<3;MPF>>/7'%=S10!B^&+;7+6U=-<O+:]G!&R6VB,>1CG*].OIVKE?"__
M "&-4_Z^YO\ T,UZ)7G?A?\ Y#&J?]?<W_H9H U/%_\ R#Y/I6MX+_Y%32?^
MO=/Y5D^+_P#D'R?2M;P7_P BII/_ %[I_*@#:HHHH 2OSF\<Q&#XP>+XB,;=
M2GP#Z;LU^C->&_%W]FBW\=>(V\1:/>1Z=JLJ[;F*528IR!@-QR&_G7SF>8*K
MC,,HT5=I['JY=B(4*K<]$SYBA.Y0/:D:/,B]<5Z??_LZ>-=+R4L8+Y0/O6TZ
MG]#@USUU\,/%EK*JR>'=1!!YQ 6_45^45<NQ=)^]2DODSZR.)HRVFOO.4LTQ
M#C_;/\ZLF,A36];_  \\3HI'_"/:D/F/_+LU78OAIXKNR4B\.Z@6/K"0/UK/
MZIB'HJ;^YE>VI_S+[S@[I0T9!K"G5D#C@'UKW'2OV;O&>L-^_MK?3(C_ !7,
MP)_[Y7)KOO#O[(.DPNLNOZM<:@1R8+4>4A]B>2?TKV,)DF/K_P#+NR\]#DJX
M_#T_M7]#M?V;%V_!CPY_N2'_ ,B-7I]9V@:!8>&-(MM+TRV6TL;9=D4*9PHS
MGO6C7Z]AZ;HT84WT21\75DISE)=6%>4_'.0:?JOPVU64A;2S\3P+,YZ()8I8
ME)]MSK^=>K5SGQ#\$V?Q%\&ZIX>O7>&*]BVK/%]^"0'*2+_M*P5A]*Z#,^3_
M -K>V_:C^(?B!] ^&6EKX<\'^8;<ZC;ZC%%>79QS(S9S%'V ')[U\4:1^R-^
MTK)X]NK&T&I0>)($CFN+@Z]AEC9G".S[^5)1O7Z<U^KOPH^(]UJ+R^#_ !88
M[+QYI,82XA;Y5U&(<+=P9^\C]2!RK9![55^'<&MZS\5?%7B;4O#UWX>M)-/M
M=-CCO71FEDBDF9W0J3E,.N&.,YZ<4K#N>$_!/Q%\>/ 7PI\60?&_1K:;2[/1
M[LVFO"ZB:[38C 13*OW@QQM8<YZU],_"G2I]#^$'A6PND*7%MHUO'(G0AA"N
M17"^*-13X^^+H/"FD@W/@C1KQ+G7M33F"]GC;='8Q-T<!PK2$<# 7J37MO"+
MTX Z"F(^?].TK0KS3@J^'M4@MI;=GD6._;8&4/P_R##MUSC!)]L5K:?H&A7%
MR\#:9KEHMF'99;R=U)P$<\D9VMNQ_P !/%>O:3JUOK=A'>6I9H)"0"ZE3D$@
MY!Z<@U@R?%#PW;ZOJ6FW6H"RN;"5(9OM*E%+,NY0K'AN#GB@#S+4XK&]@>W@
MT[7+5)+N.]E=)RXD*)@("1PIX/'L<=JGG\(^'+'4OLFSQ&\T<4<AF:Z<*QD8
M*R;L=4#*2/0UZ1)\4/"L)Q)KEFG&<F3C&<9ST'XU8M/B#X<OI;:.WUFTE>Y.
MV$+)]\X)P/P!- 'ETNDZ)X;GU:TM-/UN[6:,VKSPWC.548;Y25^7! SUZCKG
MBA>>$K71(;1+RV\1ZB+R>?<;>](=(D DW,NWG[VW&1G;WKU&]^+'ABPBN)9-
M0#6\&T/-&A9-S;B%!'?",?H*DO\ XI>&M/AM9WU))K:XG:V%Q;J9(T=5#$.1
M]W (Y- 'G2W7AFW$]D=/\4D7+INN61B<H' &[L!SGMR*ATZS\.6ECJ:&R\62
MPR1"UE5W=V*@H!@Y]E.1V)]Z]*D^+'@^&,2/XAL0I)&1)GIC/'MD<^]2?\+/
M\+&XD@&MVGFQ &1=^-F<XS^1XH \KO;3PEHOB&_MV_X26Y_TA;?R;8LR+)MW
MM\P.=IR!S@ CBH)I_!DD3326?C"5'5@T9$F%"E3S[G/\Z];G^(/A;3M+DU5=
M2M3;2ESYD')F9!R!CJ>GYBG7GQ*\-::)OMNKV]G)!M$T4S8>(D'"L/7@_E0!
MS=M\3-%\&Z?I>G-9ZN?.B62(31EV =R-K.3C<.3CTJ9/C=I4B%ETK6'.W<JK
M9-D\XQSWKH8?&OAW6D)MKVWU(Q2+\L(\PJW.#CL?E;\C4\'C?1+B\M+1=0C6
M[NHDFAMWRKNC@E2 ?7!XH P=2^+NGZ7<"&73=4+D@92U9EY"$C(]-X_$'THO
M_B[IMA%9ROIFJO%<P1W'F+:';$KD@;\G@C'/ID5T^B^([+7U8VC.=HR1(A4X
MR1G!]U(_"M-E#J58!E(P01D$4 <"OQFTMK99QI>L&-D#@BR8Y!&>WM5O1?BE
M8:YJ%M:Q:9JL/VA@J2SVC(G.[!)[#Y#^8KLU4(H50%4#  & !2T %%%% 'GO
M@;_C\OO^N\G_ *&:*/ W_'Y??]=Y/_0S10!N^+/^/*3Z5)\/_P#D4=/^C_\
MHQJ;XJ0M9R8]*?X#4IX3L%(P0'_]#:@#H**** "BBB@ HHHH **** "BBB@
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MY>Y?<+BWCC9H]HV.<=\Y![UZ/10!QEGX<)U5K6XT/3AI.\M&@MDPF4&\_BP
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M;?\ Q= '8_\ "2^)O^?2Q_[Y?_XJC_A)?$W_ #Z6/_?+_P#Q5<=_PU[\!?\
MHK_@C_P>VW_Q='_#7OP%_P"BO^"/_![;?_%T =C_ ,)+XF_Y]+'_ +Y?_P"*
MH_X27Q-_SZ6/_?+_ /Q5<=_PU[\!?^BO^"/_  >VW_Q='_#7OP%_Z*_X(_\
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M 7_HK_@C_P 'MM_\70!V/_"2^)O^?2Q_[Y?_ .*H_P"$E\3?\^EC_P!\O_\
M%5QW_#7OP%_Z*_X(_P#![;?_ !='_#7OP%_Z*_X(_P#![;?_ != '8_\)+XF
M_P"?2Q_[Y?\ ^*H_X27Q-_SZ6/\ WR__ ,57'?\ #7OP%_Z*_P""/_![;?\
MQ='_  U[\!?^BO\ @C_P>VW_ ,70!V/_  DOB;_GTL?^^7_^*H_X27Q-_P ^
MEC_WR_\ \57'?\->_ 7_ **_X(_\'MM_\71_PU[\!?\ HK_@C_P>VW_Q= '8
M_P#"2^)?^?2Q_P"^7_\ BJGMO$'B"1L26MF!_LJ__P 57#_\->_ 7_HK_@C_
M ,'MM_\ %TH_:^^ PZ?%_P $?^#VV_\ BZ /1]*TQEGEN)%"R2N9&"],FKVI
M6 N8"OK3] UO3/$VBV.KZ/?6^IZ5?0K<6M[:2"2*>)AE71APRD$$$5?(!ZT
M<C]MU?1[6.VM(+9XHQA3(&S^AJL?$GB7/%I8_P#?+_\ Q58?B?\ :9^#W@[7
MKW1-?^)GA/1]8LG\NYL;[5X(IH6P#M=&8$'!'!K*_P"&O?@+_P!%?\$?^#VV
M_P#BZ .Q_P"$E\3?\^EC_P!\O_\ %4?\)+XF_P"?2Q_[Y?\ ^*KCO^&O?@+_
M -%?\$?^#VV_^+H_X:]^ O\ T5_P1_X/;;_XN@#L?^$E\3?\^EC_ -\O_P#%
M4?\ "2^)O^?2Q_[Y?_XJN._X:]^ O_17_!'_ (/;;_XNC_AKWX"_]%?\$?\
M@]MO_BZ .Q_X27Q-_P ^EC_WR_\ \51_PDOB;_GTL?\ OE__ (JN._X:]^ O
M_17_  1_X/;;_P"+H_X:]^ O_17_  1_X/;;_P"+H ['_A)?$W_/I8_]\O\
M_%4?\)+XF_Y]+'_OE_\ XJN._P"&O?@+_P!%?\$?^#VV_P#BZ/\ AKWX"_\
M17_!'_@]MO\ XN@#L?\ A)?$W_/I8_\ ?+__ !5'_"2^)O\ GTL?^^7_ /BJ
MX[_AKWX"_P#17_!'_@]MO_BZ/^&O?@+_ -%?\$?^#VV_^+H ['_A)?$W_/I8
M_P#?+_\ Q5'_  DOB;_GTL?^^7_^*KCO^&O?@+_T5_P1_P"#VV_^+H_X:]^
MO_17_!'_ (/;;_XN@#L?^$E\3?\ /I8_]\O_ /%4?\)+XF_Y]+'_ +Y?_P"*
MKCO^&O?@+_T5_P $?^#VV_\ BZ/^&O?@+_T5_P $?^#VV_\ BZ .Q_X27Q-_
MSZ6/_?+_ /Q5'_"2^)O^?2Q_[Y?_ .*KCO\ AKWX"_\ 17_!'_@]MO\ XNC_
M (:]^ O_ $5_P1_X/;;_ .+H ['_ (27Q-_SZ6/_ 'R__P 51_PDOB;_ )]+
M'_OE_P#XJN._X:]^ O\ T5_P1_X/;;_XNC_AKWX"_P#17_!'_@]MO_BZ .Q_
MX27Q-_SZ6/\ WR__ ,51_P )+XF_Y]+'_OE__BJX[_AKWX"_]%?\$?\ @]MO
M_BZ/^&O?@+_T5_P1_P"#VV_^+H ['_A)?$W_ #Z6/_?+_P#Q5'_"2^)O^?2Q
M_P"^7_\ BJX[_AKWX"_]%?\ !'_@]MO_ (NC_AKWX"_]%?\ !'_@]MO_ (N@
M#L?^$E\3?\^EC_WR_P#\51_PDOB;_GTL?^^7_P#BJX[_ (:]^ O_ $5_P1_X
M/;;_ .+H_P"&O?@+_P!%?\$?^#VV_P#BZ .Q_P"$E\3?\^EC_P!\O_\ %4?\
M)+XF_P"?2Q_[Y?\ ^*KCO^&O?@+_ -%?\$?^#VV_^+H_X:]^ O\ T5_P1_X/
M;;_XN@#L?^$E\3?\^EC_ -\O_P#%4?\ "2^)O^?2Q_[Y?_XJN._X:]^ O_17
M_!'_ (/;;_XNC_AKWX"_]%?\$?\ @]MO_BZ .Q_X27Q-_P ^EC_WR_\ \51_
MPDOB;_GTL?\ OE__ (JN._X:]^ O_17_  1_X/;;_P"+H_X:]^ O_17_  1_
MX/;;_P"+H ['_A)?$W_/I8_]\O\ _%4?\)+XF_Y]+'_OE_\ XJN._P"&O?@+
M_P!%?\$?^#VV_P#BZ/\ AKWX"_\ 17_!'_@]MO\ XN@#L?\ A)?$W_/I8_\
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M8='@33M'AN?B!XPN+SQ+I4K(GG,EG<VMOL#GD(5DE8]@$8UT_P 0_A3X#O\
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M?P=\677A;XAZOXQT3P[/:Z!;!TN+N'24UA]"AG?:DD8EVQB4?<1Y,<DXYK[
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M]/\ _!')_P#'Z /S!HK]/O\ AQUKG_16]/\ _!')_P#'Z/\ AQUKG_16]/\
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MQ>,-:2[TQ[J2SG%[)O@:Y.;DJ<YS+D[_ .]WS7Z%_P##CK7/^BMZ?_X(Y/\
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M..M<_P"BMZ?_ .".3_X_0!^8-%?I]_PXZUS_ **WI_\ X(Y/_C]'_#CK7/\
MHK>G_P#@CD_^/T ?F#17Z??\..M<_P"BMZ?_ .".3_X_1_PXZUS_ **WI_\
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MZ7XLUO0[FZN=.UG4-/N+H$7$MK=/&\P)R0Y4@MD\\TFE^*M:T.VN[;3M7O\
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M7_\ P!@_QH _(*BOU]_X<A>"?^BEZ_\ ^ ,'^-'_  Y"\$_]%+U__P  8/\
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MQ;>3O;,$=(27.XJ6"C$>"2!_+UIOB;+$[<TO_!=1^72(>QG_ $T?17]MP?\
M/1?SH_MN#_GHOYUX-X>^+WPZ\5:I#IFE^(-1N=2E=(A:#(D5VC,H5OW?!" D
M^F.:P++]I'X77D#3OK.LVMNH0&2?:/G8 A H4L6Y'0&B'$V63E*$9RNK-KV=
M2^NVG+?6SL'L9K7]4?3']MP?\]%_.C^VX/\ GHOYU\\6WQO^']SX>_MH:AK4
M=DETMG<>9M5K:1U8QF0%1A7VX4C()8"JEU^T'\.K33OM+ZAK?GJRK)9;H_/C
MRQ49&,'E3P"3[41XFRN;<8U&VG;X)[_^ _U==T'L9KI^1])?VW!_ST7\Z/[;
M@_YZ+^=?,UU^TA\-+629AJ6MW%I&L;?:K?;(K;W9  H7=D%2",9%:/B+XY_#
M[P]I-OJ7]H:UJ-K+??V<6LRA,4P0NRMN"X*@<@9(/&,U4N),LC*,7-WEM[D_
M_D='Y,7L9]OQ1]$?VW!_ST7\Z/[;@_YZ+^=?.\7QZ^%LTYCC\47KJ)C;F17!
M E'5" F1@<YQC'.:OW/Q9\"Z?KNIZ1J&IZKIMW8S+ 1=2(HF8KN!C !)7_:(
M /;.*R?%.5*7(YRO:]O9U+VNEMR^:OV'["?;\4>\_P!MP?\ /0?G3TU>%^CC
M\Z\K^%6K^&/C!HMWJFAW^L?9K:X-K)]HPGSA0QQ\N&&&'(R*[Z#P':0,"M]?
M-_O2+_\ $U])0KT\3356GL^Z:_!V9BTT[,Z&*X649!S4M<GHVH8U"[M0Q98)
MFC!8\G!Q75(<K70(=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^*R192?2G^ #GP
MC8'V?_T-JC\6?\>4GTJ3X?\ _(HZ?]'_ /1C4 =#112'B@!:HZSK%MH6G3WM
MV_EP0KECW/L/>N>\=?$&U\)6^R(Q7.H$C%L6((![G'2O%O&OQ"U3Q= UK=SK
M:61! AMT/WL<$]SBOD<VXCPN7*5*,N:KT6]GY_U<VA3<M>AV]Q\<;RZ=FT[2
M%-O_  M*26/O@5!!\>;JUOK5-0T^!8)I A*$JZ_0'KZUQNC:K86&AV\7FR*(
M(U3:$;<<=\8S5+4[F'6'BD(5Q"28MX^8$\9^M?%8G-<7AJ:Q'U[FD]>5*-O^
M CI5.+TL?4<,R7$22QL&1U#*PZ$'I4E?-_A;Q[KOA6W-O#=FYM5)V07(WA<]
M@>N*]5^'_P 2H_%!>UOQ!9ZD#A(D8XD'J,]_:OMLMXEP.8.%)/EF^C[^OY'-
M.E*.IW=%)FEKZTQ"BBB@ HHHH *R?%EQ;V?A?5I[NW^UVL5I*\MOMW>:H4DI
MCG.>F/>M:BIE%3BXR6C#8^+-"^+_ ,/+T6D&K?!N[TZV-LL!6'28YMET7/G6
MJKY:@JNW.1]\\*#BM*'X[>#-9N-0M]+^&NH75P,'39+C3TCBE7?$@:5BOR?O
M<<*&($8+8P*^P,#TI"JD@D X]J^8EPODLOBPL7]_^9O[>I_,?,WQ5\9:#X5U
MBWTJ#X?1>)[B/3/[9C@VQEFGFE,2QQ?(P+OABS>F,]:XB'XY^$[5K9=,^$-U
M 9;/$+2V7V=2LTCA8@?)Z/&FXCH6=5QU-?:'EID':,C@''2EQ4_ZJ9'R\GU6
M-NU@]O4_F/CS3?CSX4\2IJ-QJ/PVDMH=/T=KG_3(E>4V0EC22W">5G<@)9HA
MD#RP.370>+?%6C65AITDGPJ^TI'IES=2KJ4"1):VB%1#&K-&1^]+)\O0'(ZB
MOJ(HN02HR.^*4J#U -*/">1QMRX2"MY![>K_ #'QGX=^)GA[Q/JVIVVF_!>&
MY6&]LK$R^1'&9I9AY88[X1\J$X)/(3<<=C]+6GP=\)VR,R:#I]O)+"()1%:Q
M@,@Q^[/R\J,#@\<"NV"@9P!R<TM6^%LEDK/"Q_'_ ##V]3^8XN]^$'A349KJ
M:YTBUEN+I#'-.T">:Z[2N"^,]"1UZ57M_@=X)M888H_#NG!(EC5-UI&Q&Q=J
M<E<DA> 3SBN\HH7"V2QCRQPT4@]O4_F./T_X3>%])N//L=(M+*?.?-MK>.-\
M[=O4*#]WCZ<5C>*/V=_ /C+3%T_5_#MG<VBNDBHL2QE2GW<% ",5Z3154^&,
MFI5%6IX:*DNJO?3;6X.O4:LV<<OPD\+)8O9#2+4VD@17@:!"CA.4W CYMI&1
MGH:AF^#'@ZYDE>;0-.E>7_6,]G$Q?DGDE>>23^)KMZ*S7"F21;:PL4WY?UV0
M>WJ?S'$+\&/!RQ&(:!IPC*A"GV.+:5'08V].3Q[TME\&_"=A9R6D.D6_V:2>
M6Y:)XE=3+)GS&P0>6R0?;BNVHIOA;)6K/"Q#V]3^8X>V^"O@RR4K;^'M-@4D
ML1%91*"2,$\+U(J2Z^#OA&^N'N+G0[&XG>19FEFM8W=I%^ZY)7)8=CU%=I13
M_P!5LE<N;ZM&_?7_ ##V]3^8QO#GA'2O"<,\6E64%C',X>18(EC#,  "=H&3
M@ ?A6S117T&&PU'"4HT*$>6*V2Z&+;D[L\]T)C_PDVL?]?DG_H5=]#]P5P&@
M_P#(S:Q_U^2_^A5W\/W!]*Z1$E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^A5W\/W!]*X#0?\ D9M8_P"OR7_T*N_A^X/I0!)1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '->+/^/*3Z5)\/_P#D4=/^C_\ HQJC\6?\>4GTJ3X?_P#(HZ?]'_\
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MJKK(PVL(]P*_-R4)P1R#UR, $6@>,-<OM<%M>> YK&U"CR[HA1L8(Q8=.Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?X9OO$?A'2OL$R03073'<[E1RA Z>]?).D> _B#I=I(ANY))&F#;H;[(V]\
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M0 4444 >>:#_ ,C-K'_7Y+_Z%7?P_<'TK@-!_P"1FUC_ *_)?_0J[^'[@^E
M$E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_&B14\$3!C]Z:,#\\_TKP$,2< 9'O7T'\6O#]_XC\-1V^GQ&>5)UE,8."0
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M@_\ (S:Q_P!?DO\ Z%7?P_<'TH DHHHH **** "BBB@ HHHH **** "BBB@
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MT+!V#,P7&>G3&/QZUZO'H6G0HRQV%M$K8W".)5S@Y'0>O-/31K"-H66RMU,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '.>*D+64F/2G^ U*>$[!2,$!_\ T-JT-2L_M416L 76K:/:
MI;6<-NT4>=OF*V>23V/O0!U]%<.?$?B;M:V/_?#_ /Q5'_"1^)O^?2Q_[X?_
M .*H [BBN'_X2/Q-_P ^EC_WP_\ \51_PD?B;_GTL?\ OA__ (J@#N**X?\
MX2/Q-_SZ6/\ WP__ ,51_P )'XF_Y]+'_OA__BJ .XHKA_\ A(_$W_/I8_\
M?#__ !5'_"1^)O\ GTL?^^'_ /BJ .XHKA_^$C\3?\^EC_WP_P#\51_PD?B;
M_GTL?^^'_P#BJ .XHKA_^$C\3?\ /I8_]\/_ /%4?\)'XF_Y]+'_ +X?_P"*
MH [BBN'_ .$C\3?\^EC_ -\/_P#%4?\ "1^)O^?2Q_[X?_XJ@#N**X?_ (2/
MQ-_SZ6/_ 'P__P 51_PD?B;_ )]+'_OA_P#XJ@#N**X?_A(_$W_/I8_]\/\
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M)<2W$BA9)7,C!>F36^HP* '4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A ->7>+OV
ME_A!X$\17F@^)/B3X6T/6K,JMSI^H:K##/"64, R,V1E64\]B*]2K^?+_@I9
M_P GO_%'_KYM/_2&WH _:'_AL+X"?]%>\%?^#NW_ /BJ/^&PO@)_T5[P5_X.
M[?\ ^*K^<.B@#^CS_AL+X"?]%>\%?^#NW_\ BJ/^&PO@)_T5[P5_X.[?_P"*
MK^<.B@#^CS_AL+X"?]%>\%?^#NW_ /BJ/^&PO@)_T5[P5_X.[?\ ^*K^<.B@
M#^CS_AL+X"?]%>\%?^#NW_\ BJ/^&PO@)_T5[P5_X.[?_P"*K^<.B@#^CS_A
ML+X"?]%>\%?^#NW_ /BJ/^&PO@)_T5[P5_X.[?\ ^*K^<.B@#^CS_AL+X"?]
M%>\%?^#NW_\ BJ/^&PO@)_T5[P5_X.[?_P"*K^<.B@#^CS_AL+X"?]%>\%?^
M#NW_ /BJ/^&PO@)_T5[P5_X.[?\ ^*K^<.B@#^CS_AL+X"?]%>\%?^#NW_\
MBJ/^&PO@)_T5[P5_X.[?_P"*K^<.B@#^CS_AL+X"?]%>\%?^#NW_ /BJ/^&P
MO@)_T5[P5_X.[?\ ^*K^<.B@#^CS_AL+X"?]%>\%?^#NW_\ BJ/^&PO@)_T5
M[P5_X.[?_P"*K^<.B@#^CS_AL+X"?]%>\%?^#NW_ /BJ/^&PO@)_T5[P5_X.
M[?\ ^*K^<.B@#^CS_AL+X"?]%>\%?^#NW_\ BJ/^&PO@)_T5[P5_X.[?_P"*
MK^<.B@#^CS_AL+X"?]%>\%?^#NW_ /BJ/^&PO@)_T5[P5_X.[?\ ^*K^<.B@
M#^CS_AL+X"?]%>\%?^#NW_\ BJ/^&PO@)_T5[P5_X.[?_P"*K^<.B@#^CS_A
ML+X"?]%>\%?^#NW_ /BJ/^&PO@)_T5[P5_X.[?\ ^*K^<.B@#^CS_AL+X"?]
M%>\%?^#NW_\ BJ/^&PO@)_T5[P5_X.[?_P"*K^<.B@#^CS_AL+X"?]%>\%?^
M#NW_ /BJ/^&PO@)_T5[P5_X.[?\ ^*K^<.B@#^CS_AL+X"?]%>\%?^#NW_\
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M:"U:0YD,:$X4L1DXZU+6B2Z6_P#2KO[[17R:V9I=W;[W_*R^YMOMK<_3#5?
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MK70-%MXDL=(T:SC"QV-E&-L460/F;'+.>68D]Z\_HHH2LK#;N%%%%,04444
M%%%% !1110!_2'^QE_R:9\'_ /L5=._])TKV6O&OV,O^33/@_P#]BKIW_I.E
M>RT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?SY?\%+/^3W_BC_ -?-I_Z0V]%%
M 'S)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '](?[&7_)IGP?_P"Q5T[_
M -)TKV6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>forms-4_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_017.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #@ Z@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7\V34445Z1\^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(,\?C7YMPBRDG#"\BE]5#<'W%,N;N%+:4JZCDJ/I6?\ 9='5O\R]-C])(O\
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M%",<GITKS9-:N89(E2\)!0D_*,!B>E>DS,&!#88=P1D&LZ6PLI$*_9H,$=U
MKU,+6]C?3<^(SO+Y8]P:E;E+5OO?X%ZO(6RK:C$ !]#7[0_L8 #]EKX; =M)
M3_T(U^-E[:):?!#5A'\D?]JH HZ<+7[,?L<J$_9?^&P'_0(C/ZFO5P$N:%1_
MWCX#-X.FZ<'T2_4]EHHHKT3YT**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *0\BEHH J2('NF'J@_G7#?'7PE<>-OA'XL\/6FMV_AVXU.Q
M>U&IW;8BA#8#;CD<$9'XUW3G;=MS_P LQ_.OE[]N_P"'4'C'PGH'B'Q+K]W9
M_#OPM<F_U[1-.MY);C558JB1KL(P02>3G&<]J:$]KF/XT_9O^(?Q,L-(FOO$
M'@4Z=I>G)9:<]K!<>5;1*R'>AWXRPC52>FT8'6N*MOV"_&UUI-I;S^)_">JV
ML<C31.]O<8&[.[!4X(;(S_NBO!?"DWB"V_8%\17!U6>/P7>>/+6/[+;W+23V
M.E>>HG20KS&#@$CCN>]=7\/OVC6^$OP?^(OA?P#K3^3JGB>\3PA?:B7E32M(
M5%,]^Y;GRDYVYZN0!6EFM#*Z>K/5++]A[XC0/=-9>,?#D<PG)BN;<3AX(R&5
MH%'("D.P)^]SUK'\3?L6>,-&CEEFUO0'W0"-DWW9W.!M27D_>53@ ?+CM7N?
M[%WQ"^&-W\+;CP_X'U'4IF\.H+C6)]>MY(+NXDE4NUVX?DK)AF!Z <5SOB?]
MM;X?^(O#?AV^L[/6[@^(KZZTZT@6W1)$E@*[MX=A@,K*R_W@10FV[,4HJUT>
M<?"GX4ZK\-HM0&MZG;ZI//&L5H;7=BWA#%F3YO5CFNN:)I+^WC7A3(!GKWKS
M:Z_:U\*742R)INL.DUVUA'NBB!><9ROW_EX'?%>DA]E[:N,*99$_=GJIZXJ[
M6,HM=#[,LABT@'_3-?Y5$BYN[D_[G\C4MF/]$@_ZYK_*F1_\?5Q_P#^5<YV'
MR7^U)^UAXW^'7Q-3P#\._"EGKNIVFC2Z_JM[JJN+>*W0%BBD8&[:I)R>X KG
MY?V]M=\2_"OX3ZGX(\#6.I^,_';7L?\ 9M[<F*VMC: F8A@,L#CY?UJ3]MWQ
MUH'Q#U36/@W'XHU7P1XEL=&F\027J(D=GJ4"PL1:O(6#$,>P[KWKRSX/?#@_
M'O\ 9'^&/C[3]>M/A)K'PX.HVR:BEGYEHUMM*SR,A(^8C)SGEL^M7;2YGUL?
M1)_;2T@?LJZ)\5AH?FZ[K3#3M.\,0D-+=:D9#&+=#C)7<"2<<+S7H/B[XRO\
M&O@1%X\^)VF16.J0P0F^TW1%\_;/(P ABW8+D9Y^AK\VY/!NM:'\$?!/Q"LM
M0U/P_P"'HM>L_#7@NXNL1SV]G<3-]JU5U(PDLQ)V'^%<<U]4_LP>%;'X_P#P
M_P#&GA3XFZK=^/=#\">-;JWTW4M1NC_I44:?(TSJ0) N]CSTX-2-7>Z+OQ2_
M:Z\%67B#5["+3]6O3I.FPZI<SVL4/EF"6)94906!/##.!@'O7'Z7^T?X>\6>
M+-&T"RT?5UN]6@6Y@,@A\M8F) D)#G/W3PN37(>)4\/Z5HOB#PSX:^&@U2UU
M2WFT[4KBZU8O(UO:.5MEMYSG:K1*I.#ALA1G!KKOA1;:;XIB'CF]\,6?A[Q1
M) -,>PAG64V4$1(C7:.$=@2V1U!]ZW3ZV.62:/6_ L:KXWTQLEE\]0!G@'-?
M4PZFOE?P)AO&NEJ>TZ$8^O>OJCO64C>GLROJ'_'E<?\ 7)OY&OQ>U$EKRZ.X
M+^_E  YS\Y[5^T&HG%E<9Z>4W\C7XC7WB?36U*Y"741!GEZL,J=[?I7UO#LE
M&56[[?J8XB+E:R,6'5KBVUYOM2;+>3Y$QT7GL:Z) /G?:=PZ)5!=4TF=RQF@
M!)P,D$ U*NM684H+B,$?WV_E7V4'RW3E<Y9IRM:-C+UK6)],O;=<*\9;)"G!
M]Q6Q9ZK'>0H8D9=N2%;'\ZJSG3[]-LQBDQ\V0>5]\]ZLVZVL/$1C"9Z9XSZT
MH\W.WS:%22Y%>.IDZQXE%C%*@B\N96X<$$'GFM&QU."\B1XV9U*Y)'(_^L:9
M?Z?I^IY64QJYZ$?>/T]:JZ?X?ALY3Y4Y<>@XR/<5'[V,[WNBK4W#LRUJ6NVN
MG0AGE+2%@<%3CD\Y^@J]!/;W*AXG5XR.,?G5*YT:WNXA',.G/ID4^ST^VLXE
M!8X.,D<'\:T3J*6NQ#5-Q5MQUYJ\%I<1HS ,[!1EN_H:G-_#<+CST(.<C(P:
MRM8T"'5"K+*JE>@8_E^-6+6R-O L)G$A/+8'\/I7F8S'?4:=3$5?ABOO\O5G
MM97E<\VQ5+!X?XYNWIW;\DKOY$T8:2;S!\J@_*V>6_&K:6GFIA47N3GU]:B1
M0<#@^N*O6BDH.Y(P :_ \PS+$9E6=6O+T71']IY)D&"X?PL:&$CKUD_BD^[?
MZ;(K"W,9R!SG^$\UT?A[4;7S!::JFZW<@?:_XX3_ %7U]*R"NQCMZC^*ESE-
M[8/;VKRD[,]ZI!58N,CMK_PT=+D>&;3X;A-FW>Z;B <?.C=^._I6Y:_#.Y\4
M>'X]+@\+-?VEQ-GSK2%O,=2,^66';O4'PP\6VUU:R^%O$-W]GT^0%[&[DY^R
M3 $CG^ZWW<>]?67[+GQ=\'>'?"LVD:EXIL[2[\\O'!=CR@!T^5CQ^%>KA*:G
M--2Y?T9^9\18W&9?A:D?8.HTUI:34HNZOHG\T?'OC[X-I\.?#MK<)X/U7PZH
MN#&9;F1FA?<,XP?XN.M-F^&ZQO$TMYJEK;2('$DMFQV9 .1QR!SBOL']N+Q?
MH.O?!2W73]8LK^3^U;=E6VN%=N,YX!S7OOAC6M"NO"VC>=>Z9)_H<.5DEC.#
ML'J:]!X?VE=WG=JSUU_K8^)AQ37P.34IQPW+SSG%J+:LDHO2Z;6^G:Q^<&F?
M#_0;S1M2T2[\503Z3?,)4@FMGAEM;OHEPF>!V5AW!IO@WX;ZC-!#X9A\+Z%/
M/:2SK?7/V>1RK,I =Y<$ G@C\*_0;Q/>_#'4+K[#K#:!<2>2TY#+&=B*0"Q(
MZ<D5YUX^U_PMIDMIH.C7>DZ-8ZU?K/?JS?/<':" PSE<[1@]#7NUL1B\3*/M
M)IV[(_.%7RW#0G*.%FG+^:6GK>R;ZGYY7O[._BG3K.YM)_#LWEKD*2F=P[L/
M:N7'P:U"UM# ]I=6I)*'<K  =R>.E?L3+X9\,26)=M'A\V10N0,@G''>N;U'
MPYX%\00/I6H?V1=7)?R#8^:JSJP7HHSD,!S7LQS3$PMS*+M?R]%IV/$A/"56
MTJ<EM>SYK6W=GU?K9'XZ2_#'[/ 5>\D0JS)OC&"3V(!' J9OAUI1T_R/])^U
M;U8WCO\ -M[KMZ8KZ.^*WA1/A[\2-;T*7;JMK93?)YY*L\;#<H/OCC-85_I^
ME:AI\5U:8,(.V2"<?O8<^X^\OH>U?%XO-\94JODERI=-.GR/Z(RCAK)(X.E4
MJT?:\ZOS>]JGJM.;1VTOHK_<?-_B?P%::'HRWL5W<SS,X1(GC!4X^\21TP*X
MYQA <]<<GN:^M-1\,:1K.F#3WTR9$.X2/;3D2/N[<]!CTK!N/V6;:YLS-8:5
MXDMB5)65K<S1+Z'[HR*]C!YM&<%'$MN7I_DCY#/N%_8XAU,M@HTVMG))W^<G
M>_R['AUEKVJ64ABAN"\2+@12+E0,5S]O,+>\MY\!]EPLA&<9.<X%?0%S\&KG
MPM8R--"UW#CRWF^SO&5/7YE897^5> PVX>_2([2IN0@XXQFOMIU55I4ITY\R
M_(_*G1GAZU6C5@XR7=6[GHMMX_TZ12;J*:V?J!MWK]*F76M"OH'=9(HYCRJM
M@$9JI>^!K=II98IO*WK@(.<'I69/X-N5,">6CKT<[>_UKZ'GKQ5I),^?4:,M
MG8I>)M,L5G003+(K#>"I!&ZLGQ3ID>G6NC;1S+;M*P/J6XQ3]4T&ZM5),:J
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M;X%M_6_?S-*STX7D%PX<+Y2>803R><8%:?A"\LO#^OQWE_/<P6T<4@+V3 3
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MG\$[34WFMO\ A)K2UTS3Y!&603F'<JN?X<[2 ?6MUW/-D[I(][F.%S7Y\_\
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M3GLB%\II/,.!SG%>B_&QU::UVX"^:R_0"N'T3P[_ &M ;EIA' A(9<?,?:O
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M/2@"M,F9P>P0\_C6%X\.LKX(UX>'(EFUXZ?.+"-W"JUQY9$8)/3YL<UNN?\
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MX@TGP[-H5OXSOX_"]TXFFTJWE9;:5^H8IG'6M]+=K.,)O"J./G'W3V!^OK7
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M<+VRV>/PKMPWQF55>ZBCXRN%ATZXN$/[V+YL^F",_6NFT(AX[9PAC5T5U/\
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MX>TL@8'V6/C_ ("*GL^DO_71^OUJ#PSD^'M+R<G[+%D_\!%6;,\2CMYK?SK
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MQ%NGMI3D%7"D#L,&J?B+0_[)ADDBTUF P TFYP?R[UW>EQ06-ND1$L:*, L
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MY;J2]!>XGEF)ZB20D?3'2FQB*+"J.<\ ]_\ ZU>Q0X>3UKU/DCY''>(\[..
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MU*K.2V;844451B%%%% !1110 4444 %%%% !2'I2T4 5)O\ CX7G'R'^8IX
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M]N/_ ,$J=0< _P#"P[8'';2V_P#CE0O_ ,$IM3(3'Q&M?E.>=+;_ ..5Y-7
M9=4UY;/RT/KL)QMFV$T6(<EVDN;\7K^)\?6OB31[_(2_CC<]4E^4UIO;?:(]
MZ%94[,A! KZHF_X)-:A-S_PL2SW9R3_91_\ CE,3_@D[K$'^H^)L-O\ ]<].
M<?\ M2O(JY/1WI5;>J/M<)XG22Y<713\XMK\'?\ ,^56@1'!*G/J13P FX#
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MT/QC\9?\2OXXZU)@*$FDPLC;>2#CFN=UCQ-%<W.TH R?+D-D'GKFOTX\#?\
M!,[2?$OC2_\ %GQ3O#J+7<AEBT"QD*QQYZ>;+U8CT7 KB]>_X([6]SJ=S)I'
MQ#>UL7D9HH+FP#-&A.0N0><=,TO9W2N=?MM3\\KO5%O].G^SH798R[@<D*#@
ML?85G37\S:0EUYZ@1R>3A3STSS7Z#S_\$;]3CMI_L_Q-@$S(5 ;3R%8]@V&Z
M5Y)\5O\ @F_XT^#O@BTFU#6[#5H+R_6*2:P@D*61/ >7(SLQDDCITK"I2^T>
MK@\6_>IWM=.WJ?(G]IWSOQ<G&.NX4U]5O5.#<D_B*^OF_8'^'487_B_=DK$
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M]IHPLI[PW-PZEW5'"#Y0<IR'^]U"USH^,.I>'X-,O-:CM[Y-7MS/;6-A&1-
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M\7Z4^FZUIMOJM@[!VMKM Z%AR"1[5!X<\$:)X227^QM)LM+,A^?[+ L9;V)
MR16_11I>X^9I<J>@S;T]:7;3J*!"!<# HQ2T4 -*^@ICPH_WD#?45+10)I/<
MQ/$&E2SZ>196\+7"L&"O\H;VS7&W4&M1*P/AZXD8<?N9XR/U->F'D4A0'M2U
M[DN$7T/)H+6[02)>V36$K<^1(X8E3WX.*R-9\.I<1F/(\O'=FR/UKUK5/#4.
MISK,9I(7 VG8 =P_$54?P19NN#--]<C_  I\L6M4<\J3OH?%_P ?/#=O;>%K
MZ%)%BB56(&YFR<<U^;-_=V^B:]XITR9]@NXE\L!3DN!D<#MS7[?>,_V<M'\:
MVK6USJ^HVT#$EUM_+!;VR5)%-^'/[*7PO^%TDMQHWA.REU*4?O=2U!!<W$GK
MEGSC\,5RSH^T7*]/^'/1I5/917<_&GP5J=G-X0TR&*\^U7EN")L'/DD_=7Z\
M9J75M5@MD_?3.F6Q\HS@^X'2OUV^+7[''@7XH^';?1[6)O!<$=V;V27PY;P0
M2S2$8RS%#7E&J?\ !+CX>ZQ,\USXJ\3&>7'G2));J92!C<V(NM>5/+6ZKDGH
MSZ"EFRA14;:GYQV^K^']#2XFUN:]U%3$1 FERI\DQ'R%V/4>H'-=9\1/A#J_
M@?PSX8UN\UC1]8L->W;(-'NC-Y955+)(X& P#=/6ON71O^"37PFT^^@EO=9\
M2ZM9QR>8UE<74:1R'T)1 <?0U]/+\"O "^%K+PV/".D?V%9<VUC]E79$<8+#
MC.X]SU-="R^"B^YRO-*CEKL?ASX_N+ :N]WHFEC1X+"TC39*Y9I&]6]R>?I7
MT#^RK\)O%/QXOXH]%\!:'HNDV42276O^(H+BX2Z;.&V+D*3WP.,5^G%M^SA\
M,;6]^V)X'T9KKY?WLML')QT^]GI7H%K806-LEO;0QVT"#"10H$51[ <"NFEA
M5!)2U9S5L;*3_=Z'ANO_ +'OPGU+3I+F_P#"%BEY%9>6\]B&@!*IRZHIX.>1
MWK\S_BUXDT6W\-:5#!K&M75K"TD<6FW,K"-UCE(9)#G/.,9ZX-?M0T>X 9Q7
M%W?P1\ W]^+VY\':+/=!S)YLEDA.XG)/3KGFM*E)SE%KH<]*OR1DI7=S\T?A
M9\6?V@O$-S+=?"WX:V'AVS,2JIT[2"%\H=%,LIRWK7W;^S.?CC>Z=<7?Q=;2
M(HY(U-K:VD>VZ1\\^81\N,=J]RBMH[>-(XD6*-!A40!5 ]@*E5=HQ6OLHWN8
M.;DK#%49_P :=MI<<YI:T2L9VL)M%(5R<TZBF P)@T['KS2T4 -51Z4M+10
MF*9+"LR,CJ'4\%2,@U)10!0_L:QS_P >%L0/6%?\*:^@Z<W73K0_6!3_ $K1
MHHLA\S74RCX;TF3AM+LC];9/\*BE\'Z%-]_0]-?W:TC/]*UA$!+O_BQC\*DI
M60^:7<K6UE#:1K'!#'!$O2.- JC\!4ZJ *=13)W$P*6BB@ HHHH 3&:,"EHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>forms-4_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_018.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #_ Z@# 2(  A$! Q$!_\0
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M6Y-E-;'T*LW*'+9-QMK)+6T4]GW/OBBBBOKC\("BBB@ HHHH **** "BBB@
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M-V;E!QCC-0O'[5I-&2,GD]S_ )[57>,U\6I'[[">B,UXLFOIG]@Y=OCK5_\
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M+>)XC\0SP'Q-JN8=&TB60*8(OX1@]">K$TXIL#L_"_CS4-5\3W.BZKHO]DW
MMUNX2)Q+F,G&'P/E;VKM5;(^E<AX(\+3Z%'<ZCJER+W7=0;S+NZX50/X8T]%
M4<>];UKKEC=W<MI;WUO/<QC=)%'(K,@]P.E*6^@&EFEKSSQY\6]/\')!%9*W
MB+6KQQ%9Z1ISAY)&Z$L1]U1W)Z5V=IJ2FUM3>M%9W<J*6MVE!*N1RH]<=*&F
MDG8"\Y('%<K\2_'=G\./ ^L>(]0YM[" R;1U9NP_$XKJCP#7SQ^W8SI^SOK
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M)%_#%<0Y1206)VC/7%=+\)Y6'C_3%$A"2!\@\]JUJ1:I2L>)7KR>[NF?4O\
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M>MG5?CAC"Z!X; '3_23_ (US?CSQ/\:-+\+:C+?^&]&EL6@=9GLI#)(B$8)
MR.E.;_A"B ?^%RZL/?[>.?\ QVK,WQ,\%>!O"&NP)X[N?%=S>0.L4-S-YT@8
MJ0 N ,#FOTR3]I2DW7:T?VXO;R2U/S"BG&K#V>%C-W6GLYI[]^8^+VC"K@'(
M'?UXZU4D'/K5T_< QCC)JJXP37Y4G>3/Z6IJR2*<HX]*^A/V*!CQSJ7TC_\
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M]5I;>;Q+IJRPR[9(;5KNY6"0=5+QQLI8>QK-U']FN^4J!XHL-AR"98=0&?\
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M@2==UC"?_'!6_77'9'G2W844450@HHHH **** "BBB@ HHHH **** "BBB@
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MD2EF)+<# KTBY^,^EPW-Q MK<YC^[)(NU)/H:XWQ)\0KG6+.X>XC6-(E,L4
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M!K(M[@9VV=TW[J0^GM7(^*OBQXK\'K86OCS2_P#A%]3E8Q:?JMNPEBN''\+
M=J]=\/Z?)J_B!1$AN+A_F3)X0>IKC]8L8/B;^T]I>F)#INK:+X(LV>[CU"X"
M%[Q^0T2_QD5326YU\_*>G_#3Q=XBU7P['=ZEIRW=W#& L$,2VL)[^8S-V]\5
MX_\ $CQT/B?XE\3RVUQ =-\.VJ6\0MFW1&Z8?O K?Q8%7?'_ ,7=&O\ Q?K/
M@37;>XL;N.'S)+U6$,GD'N!G!P.U?./QE_:!\-:;::%X4^$]J]GX?T[?)?7=
MTF9;^X;@LQ] .E88A<]*4$:X:2HU54D>@?\ !--6;]K.1F_Y];BOV,QSFOQU
M_P""7\GVO]IP3GDM83-^=?L4*BFN6*3,:[O4;ON-?I44I!P#]WTJ20X&:\?_
M &F?C*GPA^'UQ-:3*/$%\IATZ-AD;^['V%.<U"+DS*G!U9J$=V0?M(?$'P;X
M$\(FX\0Z5I_B34'<1VFEW(0LSGUSRH'<UX+X/^,/P0U]-4TKQ1X$T+POK$=L
M\D),*O!-\IP%<#(8GL:^)O&OBC5-?N[Q];NK[4;V<DRRQ$S3LYY_=@=JG_9T
M^!OQ.^(OC&0>'=-GED12TM]K:,EO .V[<.6^E>(L15KW<(^B/T"6487+W"-6
MNW!ZN2=K/R74[;X,:=<:M\:?!%M8;K:1]8\Z-5_@B#$X^FVOU[!Q+^-?*7[,
M_P"QG=_"SQ8/&?C+6(=8\1J&6VM[)"MO;[NK<]6KZO"\BNS 4)8>GRU-SS^*
M<VH9MC(2P_P05K]R2BBBO2/C0HHHH **** "BBB@ J-_O&I*BDX:@3/._CZ"
MWPLU?_=K\T/A>IC^-,6>YGZ?[M?IC\>D>3X7ZN$ZA*_,SX=.R?&BUV@,SR2H
M /\ =YKP,?\ QZ9^S<%Q;RK'M/[+T^3/U)^%XS\.O###I_9\0Z_[(KYH_;Z\
M*7>NP>&95\-6/BC2I&DANK6[M589&-K&8;7C(&<$.*]QTJ#Q=>?!OPY%X-OM
M)T[4WTZ(+<ZO \T:?+UVJ1G\:^._C9^PC\>_B[-)=^+?C5I>K6B%I#:/'/;V
MT2XR<1+\G [G\Z]V<'4C93Y?-'Y)EV+C@JT:TJ2J)?9EL[JQ\6_%WPCX!\)Q
M0ZAX7\430^(1+^^\.VTWVQ+4>HO(]NU@?X3DCUJSX;_:J^*]AX1UG3XKM=;T
MZXBC@N]5O]+%W,BK]P/<[><>CEJU_%G@#PS\&];.G6>@+XWN[6T6XNM3\0R+
M':18."8+>-QYJ>Y+9]*V=4^*'C[3;N\D@$6BVFBV<%TFGNZ6 DAF^X+>UX#A
MO3:3ZU=2I:*C&+GYGL87+(UZDZM6M'"KI'5_<K[>=SRWPS?Z;\4/$R?\+)\?
M7NEVGEDQW<D)N4=NR+_!"OOM('I7UW^RSX"AM?B_X13PMX/LO[(,_FRZV775
M7N(D'S,T^"D><C"HJU\Q^/\ 7](UJZNQXB\$VVAZO^Z+75J)+&^?>1\WV8#R
MY#@_W1FO?_@]^P=XRO-2L];^'GQ>CT&0C[1;F:QN["\ (!PZ8"MCV)!IU%[:
M*M-PMT,Z3>5NJJE&%?F32F[NWFO/U/U8>08;)QSC@\#FOB3]M8[3XF8]#J.G
MC_R"U>]?!3P?\9/!X6S^('CG0?&]JJX2XATY[>[7ZL#M;\1FO ?VVY59O$:H
MX(.J6"$_W2(6SFN/&_P6@X:5\UH/S-[]B/4+>XNS:/8V]O=10Y2Z1/GE7T))
M_E7V6.E?%/["EG#/XAU":1-TL-L-C$],U]K"N3+OX!V\4?\ (TJ"K]VB@=**
M]4^4/$?VR/\ DB.N_P#7M)_(5^7@Z"OU#_;(_P"2(Z[_ ->TG\A7Y>#H*^-S
MS^-#T_5G]0^$W_(LQ/\ U\_]MB%%%'6OF^I^Y)VU/J+X"? KPQXN\#:=KNI:
M:]]=RL^XR2-Y9 8C[HKZ&T'X?:?X?MA#INFP:?'C&((@N?J>I_&OSPTWQIK^
MC6R6VGZYJ%E;)]V*"Y=$'T .*]=_9R^,WB^V^+/AW2KK7+S4],U*Z6VGM;V4
MRKANXSD@CJ,&OJ<'F%"*C3]GKW/YZXIX-SG&K$8OZYS4US24+RM;5]VM$?8<
MOAG"#"8QTXZ5S/BW0C#H.J'!R+64_P#CAKWF[T!40X XK@/'VFK'X;UDXZ6<
M_P#Z :^LF]'Y+]#^><-?ZQ3;?VEU7='Y8*P6$'L!TZ^U?HA\'M7^(B?"OPY'
M/X?T>ST1+.-;>_BU"19GCQPS*L3G./:OSN0X@7L,=,9_&OOGX;?#Z9/ACX3N
MK$^-_$B75BLLLFC^(4MX+=CQY2H6&,>U?$93_$?I^I_5'B/[.6$P\9)7<GNO
M+O=)?,S_ -IK51/\*K]/^$CUN[F+Q;[%[$O:'YN\S0H1^=?,OP<\*V7C3QS8
MZ5?K)+:R*Q*Q.5)P/45]&?M#>"7L/@WJVI7L_B[0YK>:%8K/7M;6[BO,GD!0
MQ''O7R!I>J7FD7*7-E<RV=ROW987*,/Q'-8YERPQ,9S5TC#@[#SQ615\/AJG
M+.4FE+31V76*_P _4^[_  O\%/#F@%7LM$A$H/\ KI5+O^;5VG_",G ^3H,=
M.E? -I\3?%MM*)(O$^K(P^8-]K<X/XGG\17Z"_LV:]>_$GX1Z5K&JO\ :-1R
M\,TV "Y4\$XXZ8KZ#+\PP^(J>SI0Y7:Y^2\6<*9EE-&.,QN(]JI/EUO>]O,R
M[OP[M'*=*^8OVBX#8^,+),'/V4']:^Y=7T=8PWRU\5?M;1BV\?Z<O3_0@?KS
MTK//TOJ4GZ&'AZKYY%K^5_H,^ EO\-+FWU7_ (3J>%+Q74V:W,LJ1,O?=L!_
M6O=K?3?AT?#MU)X8A\!2ZP&!MQ>7,K1&/N6W8.[TKQ']G?XH>%_ ^C^([+7+
MM]*O[\H8=22Q6ZVH.J;2#CO^==K\.?''PG^&4FHS6?B^_P!5@OF:6YLKS1@1
M,<' #%<H.>@KY[ SIPH4U+DU3O>UU^/Z'VO$&'Q-3&UYP571KE2YG"6U[6C:
M*^;OW1\_:I(4UB^#>4&\]_EMSF,?,<[?;TJ32)<ZK8#_ *>(O_0Q6=JM[;W6
MKWT]I'Y-K+.[PQXQM0DD#^52:/*/[6L.?^7B+_T,5\0H+V^G1_J?K-2F_J;3
M5O=_0_5>P_Y!]K_US7^561W^M5M+_P"0;:_]<E_D*L'J:_=X?"EZ'\63^*7J
M./-59NE668!<9YJI,U604YAQ5&:KDS52F;K0!3E[UQ?Q3./AWXE/_4/E_P#0
M:[.9L@UQ7Q78#X<>*/\ L'R_^@URXG6A+T9W9>O]LI?XD?!GG<"O??A0GCVR
M^"&LZUX8\1KIUA932R-8Q68DGE8==K]L_2OG7SOEKU3X6_M)Z_\ "/P])I&E
MZ;I][;O,TQ:[W[LGJ.#BOQS*ZE*CB&ZTW%6:T_X&OXG]59[@L5B\#"E@Z<9R
M4DVI<MK+U[G4Z#I7Q2\6>!]5\;MXNU>UETUBOV202++(0 ?E& ".?2NG^%>N
M?%#Q_P"!/%-SJ'BF>RM;*%T>VU+3@[3H8R2 QVX],\USY_;H\8+E1H.B ?23
MG]:SM:_;8\7:SI-YI\NBZ/'%<Q/"[1B3< PQQS7TM+%8.FU*->;LFFG?5]]S
MXVKE&=XN,D\#2C>2<6G"\4FM$K:^IX")AY:^N,=:@>7.:9O"J%'0<5 \AQ7R
M2AJ['[5"#LKCGDR37TI^PJV?'6K?[L7\GKYB>7%?3'[![;O'6K_[L7\GKZ+)
M%;'4_G^3/B^.8VX<Q7_;O_I<3[WI#T-+36.%-?J9_(96E3./3-?EW^WW 8_C
M]J+ ??M(F_2OU%E)91BOS,_X*%0&+XXLV.'T^,YKR,T3>'7J?<<'SMF-N\7^
MA\EW@PF,]\U! 1'.A)\L@$DFIKCE#QG'>J+-AVR,D^M?-01^JU[-V(;Z4S3R
M/C..*M^ 9&'B[3U4D.2P&/I69.2"WH:M^"6,?C'22NY29< UV-7IL^8Q,>6Z
M1P_B1##K=^K\$7#Y_.H(92$SUP#@5:\<!HO%&K*<96X;/YUSOVTQH<9Y&!7O
MT/X<5Y'YMBOC9^Y/_!/>8W'[)O@EOO$1R#\G-?1PY/0_C7\\_A;]JCXI^ _#
M=MX=\/>-]3T;1+<GR;.U8!8\]><9J*[_ &G_ (L:D6-Q\0_$$W)S_IC ?I7>
ME(\>5G)NY_0[O'/(_.@2 X^8'Z&OYS_^%U_$"XY'C;Q"S'G_ )"$G^-=GHGC
MOQE=Z;;7@\7ZWYI!.3JLH/U(S770PU3$.T=T<TZD8?$?O[N.<8/UQ3&D '((
MSQDBOP6;X\?%'0 7M?&FMKM/RXU)VS^=='H/[<'QTTVXM8X_&&I)&TB!FND$
MH"[AN)R/3-9UJ3P[M.2N=%*$ZNM.+:\D?H;_ ,%,M0FTW]G)9XF;RUU6 2Q*
MV-Z\\'VK\STU]M5CCER2A& K'@8K[O\ VS_C+X1^*_[+6GV>B>)]/\0ZD;NU
M-Y;PR#SMP'SDIU'-? LD"VB[$C$:?P@5\OF,J4Y=V?I_"RQ=&GJ[1N^EF;=C
MK4^E:A!>6[J)XB&4N@8 _0]:AUC7KC5;VYNIV03S/O<(@49]@.@K-AD!N$,N
M3$N-P4X)'L:9JES%)<.;:-HX,X5';)'U->%&"/T&>):A:Y#=WKJ2-V3CK7.:
MEJDZK@8S]:U+V0M;S/D*RKE0#7&W&J&X4!DX)QP:]O"45+5(^#SC'^PLI2=V
M2+?SR7&2YW=P#Q7[Z_L]7'VOX'^!922^=)@Y)Y^Z*_G]8B.8[5(XZYK]ZOV4
M9S<_LZ?#]]Q;_B5QC)^E>U2@H2T/SK%5'6BI-WU/7@P-+D4Q4]Z7&._YUUGE
MCNU0,2&;/2IR>*^>/VP_CC<?"+P(+;2;I(M>U-Q%$W5H8_XGQZXZ5A6JJC!U
M'T.W!X2ICL1##T]Y/?HO-^2/3O'OQ)\'>"-*N;SQ)J5C'#;#+Q2;9)/H$Y->
M.^.?C-\)/B!\*/%IT.[T>ZO%L9-D$D")+N(XV@C.:_-OQCXMU#6-1NYV2>(2
M1[C>W$C.N[U9CQDFF_"SX?\ B_XGZB3X&\,7OB-[=O\ 2[N/Y+=6'8.>"?:O
M$6+Q.)C)0A:Y]X\FRW+JM&52NY>\FY+2*MT%L_$$WAF_T[482OVBV.^,2 D$
MXZ&OHKP#XQ\1>*O"5KK!TVR/F[@520JQ(-?-7Q8\!>+?!WBZ?0_$]HEAJR0"
MYD@M7#[$/3<1P*^A?@M#KB?#/2%L[BR:%@Q$=Q&00,^HK; T)T::C-69S<4Y
MC0S#'.K0?-%*U_0ZI]7U<)NGT"5ESQY4JG'TK:T?Q/,%THOHM\JK>L=H4'G;
MTK%.H^(;2%!+IEK<HN>8)\$\=@:U?#_B:^*Z>)-"O1MO2P*L#D[>E>S!*Y\)
M+:Z-W3?%!%QXB']DWZEILX\OI\O>N,\7^(Y9_@_J\ TJ^6)[1QYI4!5Y-=EI
M_B*=;_Q'_P 2N^5FE!P "0=O0UQ7B+Q!</\ "/5[?^R;T(UK*#,V-HY-=,F8
MPMV/ADO((#GS#%V-85Q):V>K_:G)64K@@'@C_&M>[F3[,(@LI;;C);C\JQ9M
M+FO)XI-ZJL9S@#O4QW.M;&I#?VUW&IC.]ASD_P /TK)U^PMM0MV._9<(#M8G
M[WL:L6.E_8K@R!BP;)(QWJO+HX9W9Y&9\G'MFJ:N(Q?#-PMM?'">8'7#8YP:
MZJ4Q/&OE2+U&5/4<UEIIZV[//$OE2-P<<"IX94ZE0K _>HMH5$^HO%6H7Z^"
MO#K7%ND< MU5&SNST[5]N:"63P=8( 6_T*)P%')^4<8KX-\6ZSJ%KX$T*>>*
M'R4M3Y>"26(%>X?"S]LCP-<>!M(M-7GO-(U2W@56:>$F.3'& PZ?C648N[L8
MUEL?0FG.TFX)&4P/N,.17F_Q/UYYO$=GHEG')=ZK+$1%;P(6(S_$<=![FHY?
MVQ_A!9V<AB\51?:3T3R6R&]_45P3_M0?"O1H]0DM/&4D6LZH?]+U.*U+SA.T
M<0Q\HK=+R,HQ?->QZ1<:A8?"+PK/;I.FH>*IK=F, (W!L=?8"OBKQ[\4[#P7
M8VOB#0YK.[UZY61&G=-T@E8_,_X'@&NA\=_'/PO?(-)\'Z/K#Q7K,NI>(-5<
M_:9D/4)G[H-?+/Q1U#1[CQ,R:':7.F:?#&%6WNI?,;=W93V!KCQ&'E4E"3;2
M1Z6'KQHTZD91YN8S]<\1:OXKU:YU&_N+B_OIV+2SNQ+?GZ>U8\4AD<-GVK5\
M.W<]GHNI3Q*';(#!SV/7%<^LP9V<87+?=%1&3=^;H56I0A&G).\I;GW7_P $
MJHFG_:$#XQY6GS9-?L,)0>Q%?C/_ ,$H=8>+]I*2T,J)')ITIVN<%S[5]U^+
MOVEO%G@7XQ_%7P=JD=BT6F:&NN>')=F&=,?.K_WL&M[6W."7O/0^I[RX6&VE
MF;.R-2Y'L!DU^8?[8'[4T7QU\/PZ'X:T6;3+W3+]V6]GE4[PIP0/K6_:?MO?
M%#48$SJ6D3+-""T<=@3]X<_AS7RKK/PU&L:U=7D6J:C:K=RM<3+#$=H8G)V^
M@SVKGKPJ3C[AZN7?5J=1O%P<EY.QJ_LX>/KKX-_&+3?%WBK3SK-A )#)'&ZE
MP67J >.*_7KX,?$[0_C'\/-.\6^'K=K33[\$K#)&%=2#@@XK\??#>DVO@<:E
M<ZEI]MXUM)8@BVFK0.GED'(*,I')]Z^I/@/_ ,%$O#WA'2XM!U?2-+\-Z%:1
M;;=--MI%$3#^';W.>]8TE*BOWLEJ=6/C1Q.N%A+W>[OH?HT&^4'%57URPB)#
MW42L.H+BO@SQ!_P4"\%>(G6.;Q#=Q+<$KY,$;Q10K_>D8#)/L*SI/VHO@S%'
M%]H\:.TIZFVTZ9\?5F/-=O/3M\2/!="NG\#^YGZ&QW<4J*R.KJPR"IZT_P P
M8Z'\J_.RY_:L\!Z7;B;0OB!=28&1;O:S+GZ<8KHO!G_!1;PQH !U?5[C5K K
M_J6M'%Q&?8XYK7D[$<KO;J?>:MN&:6OEKPM_P4;^#GB+5;:QEU*^T4W!P+G4
MK-XX$;L&?&!7TOI>K6NLV,%Y8W,-Y9SH)(KB!PZ.IZ$$=:R3OJ@<7'=%ZBDS
MB@')IDBT444 %12?>J6HI.IH$]C@?CGEOACK &<[*_-7X/;4_:1\-[ONG5%#
M@C(8$]"/3%?IU\4X8KKP)JT,K;5EA*@XS@]J_,#X9DV7[17AT-PRZNB8.>?F
MQFOG\P=J],_9N!ZBEEN.IK^5_DS]')_A'J^D7#KX4\>ZMX9TYG+C33;07EO$
M2<D)YB[D7_9!Q7G/B#XB:EH'Q O_  3=_&RV37;339-5N+.Y\*1R*MLB[G)=
M6"DXR=O7VIOQ]_:%\??"SXE6.E^'?!__  DFCS6(N@JVEQ)+<R;B&1)$&Q-@
M&3NKY?O?&RZHWBCQ]XF^ SRZ[%;KJ=W-'J5[;7EW;SEH"(@P*M@8R..,G%>\
MI::GY J3:/8K[XV>$]>T'3?$%_\ $SPSJ6GR2FVLKO4?A^SG<%WE8_FXP.:O
MZK\7?"NIW6G7U]\4O!.L3"&*>*]/@EK@V<3-MC>20.?(7(P-Q'2O./B;X/\
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M]E8_0&2>1QR_7WKYQ_:"O4L/B1HEQ.OF0QQ(S*!G(W5X@-8OQ_R_W9_[;O\
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M7H=^9>PA"I2Q<;\NQRNE>#KO3+66SC\37T>D3',UG!*RPR>[(#@BNFM-,-C
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M.#D]:W(I-%BD\Q'LED_OAAG-8<PMK[Q"D5W%%=0RQ QB1<X':M$^&M'E3/\
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MC\)Z-J4$J2Q7%M&^^-@RD[1GFNF%<O\ #OPK:>#?!NBZ/96\=K;6EK&@AB&
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M/B$/A-JG@KP9*\E[J$\^H)=_9"_E0R-S"?, "D^I%>,K\ /V@5ED$T.O:5)
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M>-U#*R,"".#Q5MJ8R@D4#1^"OCPR6WQ"\?6C<PVFKS"- ,!1N/ ]J]Y\,?\
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M /[T#W'\-?8_\(KY5_8@LM A\//+9FXDUUHR;S<^8T!/"@>M?5(.<^GI7V&
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M20?M!?%&$+M_XF3'/UKV#3OVF-5O?@UX*\'Z;X'O-1D\+WD5Z;^)'=)=C$X
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M'6EOY*?#;1MA.[#QEL?F:]:=2=3XF?,.;L?AY\#OB;=?!WXE:#XQL4%P=-N
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MF@*=Q-9*FXJT9'7/$JK+GJ03;W>I^<#_ +'WPF!W?\,\>-5SU"7^?_9JB?\
M8^^$$GW_ -G[QY&/]B\S_6OTD(;UI"=O5J?+/^87M:'6DOO9^:DG[&_P8<MO
M^!GQ&AQ_<N<_UKG_ !-^R)\-H].:/PE\%?'T'B*0A;:ZOISY,#?WV'<#TK]3
M-IQU/YT8;UI2A-JSD.->C!\T:2OZL_-7X0_\$LM'\8:1X@U'Q_'J.@7MW*%T
MN"VN 985 ^:60=,L>B]A78^"O^"0OP[T;58[GQ#XCU;Q':1MN^Q#; C^S$<X
MK[Y"#=GO3E %:I))(Y9S<Y.3.<\"> ?#_P -/#5KH'AG2+?1M(MEVQ6MLN%'
MN?4^YKHD&!BG44R! H'08I:** "BBB@!I/-)BGT4 -"C'2G444 %%%% !4,@
M&\]CZU-4+C,AZ4:]!.W4X'XXZG'H_P ,->NI+C[*$MSY<H)!5^Q!%?F!%K>H
M:[\8?#^I:A=&\N9M3@WW'REF7.!G'6OTT_:)LYKSX.>)HK>W6[E^S$B)^C?6
MOQ]\5W%EIM[:W6A_;]#U6W<.\3.0BR _>0_6N:K@(8NTG.S70WP/&-7A?$SA
M+#>TISBUS+HV?KWXQL]+L([.6\\+Z1J5I*-LUQ=,D4BMU P5Y'OFJ.G2^&Y_
M#]U96?AEKFT8,9+'3YTDQGKCYQ@?2OSO\,?M4?'.TL(&@\;Z7K\;+O\ L&KI
M!,P[8(8 _K79:5^V-\6[.[N6G\!^"[F[MHP96\@PEU8XXVR8)/M75]3J6M=,
M^;CQ)@JFK;39]GZ%;^%_#]U)>Z?X(UR"[E4XP"S 8YV@O[567PKX0UV+5;TZ
M;XDM1>;FN(W:7]X>"0%!.#D"ODG4?VJ_&TJN-4^ NFW6<$O;W-R%'?JI.WZ4
M67[7GB+34>ZM_@+! 92KLSW]UDD<@@$9[]14/"U5I8ZX\08%*_/^#/I__A'?
M >JQFSN/"NOW$;*S.;P.NP8R?F+@GIBH9_"_@&T:*S;P1+Y40^U02WMZ$4-V
MVY?.?SKY:_X;!\50B2.T^ VG1RW99C)/+=.TA/4Y/)_.J</[7GQ.N+DQZ7\)
M/"]M- _E))-#)*4<#/&^08K/ZI5?8K_6'!=)/[C[(\*ZWX:U_P 3+IX\+:7;
M3S!I3*TD4\FX=,\$_K7@?[?]LD%SX+CBC2WB42#"*%7GVXKPSQI^V/\ '/1Y
M(HI+C0O#3W +(-&L8#(!Z%OF(KSWQ?XYU'XD6MIJOC/Q]J/B#4%'RZ<X(V>P
MQQ^E1_9DY_%)(UPG'&&RK$1Q$:<JC5]/D?;7["7C*#4-4GT'SXIIK>T9P(SR
M!GO7VD,*,5^?7_!.S3XI/'FK7UEI;V%@MCM\V5\LY)K]!2,@=L5I"E3HKV<)
M71O1S2OG">,Q%+V3D_A[+H.7[M% Z45KL:GBW[8<1D^!WB%@,[+60G\A7Y;C
MH*_9GQGX.T_QWH-SH^JPK<Z?<H8YX'!VR*>H."#7CTW[%'PTD/[O0+2,>@$G
M_P 77@YCE]3&5(S@TK*VI^P\$\9X'AG!U</BJ<Y.<N9<JC:UDNLEV/S'HK],
M?^&(OAS_ - >U_[YD_\ BZ/^&(OAQ_T![7_OF3_XNO)_L2O_ #+\?\C]%_XB
MQE'_ #XJ_=#_ .3/S.HK],?^&(OAQ_T![7_OF3_XNC_AB+X<?] >U_[YD_\
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$YC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>forms-4_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_019.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #5 Z<# 2(  A$! Q$!_\0
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M/^A>U'_P'-+_ ,*\\4_]"]J/_?@U]HXHQ1_Q#W!_\_Y?<@_USQ7_ #ZC^/\
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M[XH/3P]J)'_7 T?\*\\4_P#0O:C_ -^#7VD!17M?\0]P?_/^7W(\O_7/%?\
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M+]7T/EFP\.ZKJF#9Z9>7(/>*!B/SQ6A_PKSQ1_T+VH_]^#7V@L:QJ%0!5'0
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M_P ^H_C_ )GQ;_PKSQ1_T+VH_P#@.:/^%>>*/^A>U'_P'-?:6*,4?\0]P?\
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MB#_R.VM?]?+5^4^(*_V.C_B_0_0>#?\ >JG^']3GZ***_"C]<"BBB@ HHHH
M*]"^ H!^)-ID9Q$]>>UZ'\!/^2D6O_7)Z^@X?_Y&F'_Q(\7.O^1=6]&?5H'6
MGTUNAI1TK^JC^? -?D+_ ,%&?VUOC+\._P!HG4_!GA#Q?/X;T33XXC%%IT,:
MR2,R@DN[*2>3TX%?KTW2OP8_X*A?\GH>(?\ =MO_ $!:8'TU\+/@O^W;\3/"
M%AXBD^,2^';6_B6>WM]1O 9FC89!98X6"_0G-=?_ ,,L?MS?]'!:?_X$R?\
MR/7W-\#/^2.>#/\ L%6__H KN: /S@_X98_;F_Z."T__ ,"9/_D>C_AEC]N;
M_HX+3_\ P)D_^1Z_1^B@#\X/^&6/VYO^C@M/_P# F3_Y'H_X98_;F_Z."T__
M ,"9/_D>OT?HH _. _LL_MS8_P"3@M/_ / F3_Y'KY?_ &C_ (J_MC?LI>);
M'3O&?Q-U)DO%,MG>V4\4UO. >1S&"#[,!7[?U^47_!;G_C^^'/\ N3T ?9O[
M ?QK\3_'W]G+1_%'B^>&ZULSRVTMQ#$(_-"' 8J.,^N*^D*^,_\ @DS_ ,FA
M:1_U_P!S_P"A"OLR@!"*\6_::C7_ (1_3'*C<)^#^%>T]Q7C'[37_(M:=_U\
M#^5?*\3K_A(K^A[V1?\ (RH^I\Z4445_+Q^_A1110 4444 %(_W3]*6D?[C?
M2FMP>Q]G?#=0O@?1L  ?9UZ5TU<U\./^1'T?_KW6NEK^O,!_NM+_  K\C^:\
M5_'J>K_,***P?''C?0_ASX5U'Q'XCU&'2]&T^(S7%U.V%51_,GL*[CF-ZBOD
M#]FG]IO7_P!LWXC:_JF@>=X9^%OAN588E4 7NK3G.#(W\$> 3M7D\9-?7H.*
M '45P_Q5^-G@;X):$VK^-_$VG^'K, E!=2@22^T<8^9S] :_-[]HC_@LU)+]
MITGX/:!Y2\H/$&NIEO\ >BMP>/JY_P" T ?I9\4/B+H7PQ\&:GK>OZ[8>'[:
M"!S'<ZA,L:EPOR@9^\<XX&:\I_8>^.=[\>_@A:^(-9URQUG71=SQ7!LPB&-
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M'YMH []A0![Y#_P5P_:)BB1#K6B2%5 WOH\6YO<^]/\ ^'NG[1'_ $%]"_\
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MEO?^/.?_ '&_E6=3X)>A4=T?#NJ_\A6]_P"N[_\ H1JK5K5?^0K>_P#7=_\
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MUXY_P4/_ ."@WPQ_:)^&T/@OP7H=WJ]P+E+C^W=3M1!]F"GD1 G?EN^<#ZT
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MQS'Y_06<]T&,,$DP49;RT+8^N*6RM)+^[AMXMOFRL$7>X1<GU)P!]37Z??\
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MR,BOHZB@#\[O^'*/PK_Z'3Q7^=O_ /&Z/^'*/PK_ .AU\5_G;_\ QNOT1HH
M^._@A_P34\*_ CQSH?B72/&_B35&T=W>UT[5O)FM8RXPQ5-HV,0?O+@U]>7@
MQ9W'^XW\JL57OR%LK@DX'EM_*LZGP2]"H[H^'M6_Y"M[_P!=W_\ 0C56K.J$
M-JEZ0<@SO_Z$:K5_(&(_C3]7^9_2M#^%'T7Y!1117.;!1110 4444 >Q?LS_
M /(S:E_UP'\Z^CEKYP_9H8#Q1J*D@$P# _&OH\C@^]?TAP9_R)Z?JS\.XH_Y
M&<_1?D-N;F.TMY)Y6V11J7=CT50,DU\WZG_P4=_9VTG4+BRN/B1:+/ [12!;
M.Y8*P.",B/UJ_P#&_P"'GQ^NO'*^)OA3\1M%L-/6V6&3PIXBT\R6DK@\N)5R
MRD].,5\<_M%_LR_$/XQ>==^-/V:;!?%##GQ1\-O$,$33-ZR6\P ?\?FYZU]V
M?)GB_P#P4+_X*'S?'ZYE\#_#^\GM?A_"W^DW>#')JCCU!P1&.P/7O7P63FOH
MF\_X)^_'_P"WRQVGPI\1-!O(C:=(E;;VR0Y7/XUU?A3_ ():?M%>)W02>#8-
M#C;K)JNHP1A?J%9C^E 'R77Z2?L6?M _"'P_^QOXL^&/CGQ]%X0U;6[B= SV
M4UP8D<+A\(N#TZ9%7?#G_!$;Q7=>')IM;^(^E:?KA7,-K9V4D\"GT>0E3^2U
MXI\0O^"4/[0'@F>3^SM!L/%UH#\D^C7R98>Z2[&% %<?LR_LS]_VIH/_  E;
MG_XJC_AF3]F?_HZ>#_PE;G_XJN!;]@']H=6(_P"%3Z_D''$:$?GNKIO"O_!,
M?]HOQ3.L?_" OHZ$X,NJWT$*CW(WD_I0!L?\,R?LS_\ 1T\'_A*W/_Q5'_#,
MG[,__1T\'_A*W/\ \57N/@C_ ((D^+-0TF2;Q7\0M+T?4&3,5KIMH]TJM_MN
MQ3CZ"O-?'W_!'SXY>%YY3H3:%XNM%^Z]G>_9Y6'NDH7'X,: .8_X9E_9G_Z.
MG@_\)6Y_^*KZ-_9/^)GPG_93U;R=*_:M@UWPI.^;GP_?>&KH0D_WHVR?+;W
MP>XKX^O_ /@GE^T5ILS1R?"O6)<'&ZW>&53^*N:]9_9Y_8:^*_AC71J?B+]G
MF[\7WT;!K2V\0:O#8Z;&?[TR EY?]W(% '[2^ _'N@?$SPM8^(_#&IQ:QHEZ
MN^WO( 0L@]L@']*WA7RW\'/AM^T9?>+=&U?X@^+?#'@[PGIVX1^"/!MEF)UQ
MA4DF;H!Z+D5]2!L4 ?/?[3__ "%=%_ZYM7B5>V?M/$'5=%&>?+;BO$Z_F7B[
M_D<UOE^2/W;AK_D5TOG^84445\<?3A1110 4444P'P?\?$/^^O\ .ON+1/\
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MKN@Z=XGTB[TK5[&WU+3;N,Q3VEU&)(Y5/4,IX-?(G_"T/%W_ $,5_P#]_/\
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MO^ABO_\ OY_]:C_B(.!_Y\S_  _S#_4W&?\ /R/X_P"1]ET$U\:?\+0\7?\
M0Q7_ /W\_P#K4R7XD^*YE*OXAU CVF(_E2?B#@K:49_A_F"X-Q?_ #]C^/\
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M?ZFXS_GY'\?\C[+S1FOC3_A:/B__ *&*_P#^_G_UJ7_A:/B[_H8K_P#[^_\
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M?0X,?5G1PM2I2^))V-'7OC/XB\)>&!XEUGX=7</A]8DGFNK358)GBC;&&,>
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M1110 4444 9_B#7['PMHE]J^ISBVL+.)III2,[5'H.YKSK0OB]XI\8:$-?\
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M/>,_^@!<?]])_C7V%25W_P#$/\N_Y^3^]?Y')_KCCOY(_<_\SX^_X4]XS_Z
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M#_+O^?D_O7^1Y7^N.._DC]S_ ,SX^_X4]XS_ .@!<?\ ?:?XT?\ "GO&?_0
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M:^GO%7Q*\)>!3&/$?B?1]!:3[BZE?16Y;Z!V&:YW_AH[X4_]%*\*?^#FW_\
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MT>_T>0I?V5Q9OZ3Q%/YU]S;:KWVG6VI6[074$=S"PP8Y4# _G7+B/#[#./\
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MO^]5/\/ZG/T445^$GZX%%%% !1110 5Z'\!/^2D6O_7)J\\KT/X"?\E(M?\
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MHK\"/%7CW]LOX8P2ZMX@U7XFZ-:VQW2W=Y]H\F/W8D%0/KQ7?_ O_@KM\6?
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MPZ4 ?//[3W&JZ+_US:O$Z]M_:?\ ^0KHO_7-J\2K^9N+O^1S6^7Y(_=>&?\
MD5TOG^84445\:?4!1110 4444 /@'^D1=\NO\Z^XM# &CV0Q_P L5_E7P[!_
MQ\0_[Z_SK[BT3_D$6?\ UQ3^0K]E\/=\1\C\PXTWH_/]"[BBEI/2OV8_,3^=
MK]OG5[[5OVM?B*;V[FNS!J+0Q><Y;RT &%7/0#TKY]KW?]NC_D[3XF?]A:3^
M0KQ+3=*O=9O8K/3[2>^O)CMCM[:-I)'/H%4$DT 5:*[_ /X9[^*)Q_Q;GQ7S
MS_R!;G_XBE_X9[^*/_1.?%?_ ();G_XB@#S^BO0/^&>_BC_T3GQ7_P""6Y_^
M(H_X9[^*/_1.?%?_ ();G_XB@#S^BO0/^&>_BC_T3GQ7_P""6Y_^(I&_9\^*
M"J2?ASXK  R3_8MS_P#$4 <!7U9_P3%U*[L/VO\ PDEM<RVZ3B6.58W*B1<=
M& ZBOEF]L;G3;N6UO+>6UN8F*20SH4=&[@J>0:^GO^":'_)X7@O_ 'I/Y4 ?
MT"4444 8OC( ^%=5! /^C/\ RKXF[GZG^=?;/C'_ )%;5O\ KW?^5?$HZGZF
MOQ+Q"_BT/1GZEP7\%;U0M%%%?D)^EB-]TU]8_ C_ ))OI_U:ODYONFOK+X$?
M\DVT_P"K5^F\!?\ (QG_ (7^:/@^,?\ <H?XOT-[XB>/M)^%_@K5_%6NR31:
M1I<#7%PUO"TLFT?W57DFOS9^(7_!73Q?\1M7?PW\!_AO=W]]*=D5]J$#74YY
MX9;>+A?^!,?I7ZC2PQW$+12QK)&XVLCC(8>A!ZUEZ'X/T'PPTK:-HFG:2TO,
MAL;2.$O]=H&:_?C\>/R"\8?LR_'3XO62>+?VG?B]:?#7PLYWBUUN^4R8SDK%
M9QD(#[=?:N-'Q@_93_9MVI\/O 5[\9_%4'3Q!XO/E6"R _>2#'(^JCZU]!_\
M%N%']A_#DXY$UQ@_@M?&7[%/@WPMKOBC5=6\2/X<E_LY$-O9^)](U#4+:1B3
M\VRT[C'\?% $7Q5_;F^.'QWB?2AK=QHV@XV)H/A6 VENB=E(C^9A]2:\+?P/
MXGE=G;P_J[LQR6-E*23Z_=K]DO#_ .T%>>$[9+?1/$GPLT>W086*P\!:W"H'
MT5!6S_PUMXL_Z*#\/O\ PC-?_P * /Q2_P"$#\2_]"[JW_@#+_\ $T?\('XE
M_P"A=U;_ , 9?_B:_:W_ (:V\6?]%!^'W_A&:_\ X4?\-;>+/^B@_#[_ ,(S
M7_\ "@#\4O\ A _$O_0NZM_X R__ !-=Q\./BI\7?@!>C4?"FK^(_"@!RR*D
MBV[_ ._&XV-^(K]=?^&MO%G_ $4'X??^$9K_ /A4%U^U5XEOHC%<^.OAS<1'
M@I+X*UY@?P*T ?#-G^WWX,^,ELFG?M"_"#1O&#D;#XF\/H+'4X\_Q'! 8CKP
MP'M6UX>_95^&GQ0U1-:_9C^.S:)XFSYD'AGQ+.VGZ@I[)',N"WY,/>O0?VFM
M)\'?%?P+K%YJ-S\-+;6K:!IH=0T'P9K5A>,PYV^85"'/^V"*^*OV/QN_:=^&
M^>?^)Q#_ #H ^V+7]L3]K?\ 8\NDT_XN^#9O&'A^)M@U"]BR64=UO(05/_ P
M37V[^R7^W-X*_:V@O;?0=/U31M;L(UEN["_BW(@/=95^5OQP?:OHJYLX+^T>
MWN88[BWD7:\4J!E8>A!X-4=#\*Z+X8BDBT;2+#2(Y#N=+&V2$,?4A0,T :A^
MZ?I7Q;\0?^1WUK_KY:OM(]#7Q;\0?^1WUK_KY:ORKQ!_W.C_ (OT/T#@W_>J
MG^']3GZ***_"3]>"BBB@04444 %>A_ 3_DI%K_UR>O/*]#^ G_)2+7_KD]?0
M\/\ _(TP_P#B1XF=_P#(NK>C/J[M7EO[0'[-/@;]IKPO;:%XYLKFZM+:;SX)
M+.Y:"2)\8R".#^(->I&E'2OZJ/Y]/!?@S^PU\%O@0\=QX:\%V<VIH>-3U;_3
M+D?1GR%_X"!7Y2_\%0/BYXTU']I/Q/X2N/%&IOX8L?+6WTA;ADMD!0$_NUP#
M^.:_=0G%?BA_P4 _9^O_ !K^U+XNU:+QGX&TF.=H]MKJWB*&VN%P@^]&W*T
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MT8@G'Z.#7Z!ZQHUAX@TVXT[4[.WU"PN$,<UK=1B2.13U#*>"*^2/B+_P2E^
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M[,?F1_.?^W1_R=I\3/\ L+2?R%>A?\$L%#?MB>&<J#BVN",C./E%>>_MT?\
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MGET#0])E6%XK*$27,SD9X+?*HQWP?I7VM_PY2^%/_0Y>*_\ OJW_ /C=8/\
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MJ -EF8*<$=C0!^+]%?37_#M?]H__ *)G>?\ @;:__':/^':_[1__ $3.\_\
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MU'2;]=T5_:1;1,/7D G\:Z7M4=I:06%M';VT,=O;Q*$CBB0*B*.@ ' %2$T
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MC>__ !=>8_\ "5ZY_P!!G4/_  )?_&C_ (2O7/\ H,ZA_P"!+_XT?\1#P_\
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MC_A*]<_Z#.H?^!+_ .-'_$0\/_T#R^]?Y!_J77_Y_+[F?;U%?$/_  E>N?\
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M/]2Z_P#S^7W,^WJ*^(?^$KUS_H,ZA_X$O_C1_P )9KG_ $&=0_\  E_\:/\
MB(>'_P"@>7WH/]2Z_P#S^7W,^WJ*^(?^$KUS_H,ZA_X$O_C1_P )7KG_ $&;
M_P#\"7_QI?\ $0\/_P! \OO7^0_]2Z__ #^7W,^VIKB.W0O+(D2#JSL !^=<
M!XP^-GAWPO%(D5TNJ7PX6"U.X _[3=!7RQ=:E>7W_'S>7%Q[2RLW\S58 #H,
M5Y>,\0*]2#CA**B^[=_PLCOPO!M*$E+$U>9=DK?B;'BWQ5?>,M;FU*_8>8_"
MQK]V->P%8]%%?E5:M4Q%256J[R>K9^A4J4*$%3IJT5L@HHHK$U"BBB@ HHHH
M *]D^%GQT'AVSBTG7EDDLD^6*[C&YHQZ,.X]Z\;HKU\LS3%936]OA96?5=&N
MS/-Q^7X?,J7LL0KKH^J]#[;T7Q7I'B"%9=.U&VNU(Z1R#</J.HK7S7P<C-$X
M9&9&'\2D@_G6C%XEUB!=L>K7R+Z"X?\ QK]/H>(:Y;5\/KY/_-'P-7@N7-^Z
MKZ>:_P F>[_M7_LPZ/\ M7?#!O"&KZI=Z,8[A;NUO;50YCE4$#<I^\O/3(^M
M?!&@?\$0-137HCK/Q1M6T97RXL=+87#+GH-S[0??FOH/_A*]<_Z#-_\ ^!+_
M .-'_"6:Y_T&=0_\"7_QKJ_XB'A_^@>7WHP_U+K_ //Y?<S[ \"^$+/P!X.T
M;PWI[RO8Z5:1VD+S-EV5% !8^O%;U?$'_"6:Y_T&;_\ \"7_ ,:7_A*]<_Z#
M.H?^!+_XT?\ $0\/_P! \OO0?ZEU_P#G\ON9]O45\0_\)7KG_09U#_P)?_&C
M_A*]<_Z#-_\ ^!+_ .-'_$0\/_T#R^]?Y!_J77_Y_+[F?;U>>_'KX,:5^T!\
M+-:\#:S=7-E8ZF@4W-H1YD3 Y5@#P<'MWKYC_P"$KUS_ *#.H?\ @2_^-)_P
ME>M_]!F__P# E_\ &C_B(>'_ .@>7WK_ "'_ *EU_P#G\ON9\\O_ ,$/]6_M
MO"_%2R_L??\ >.DO]HV_3S-N?QK](O@)\%-'_9^^%NB^!]$N+B\LM-C*_:;H
MCS)6)RS$#@9)Z#I7S)_PE>N?]!G4/_ E_P#&D_X2O6_^@S?_ /@2_P#C1_Q$
M/#_] \OO7^0O]2Z__/Y?<S[=;I6+KGC+1?#4+2:EJ=M:@<[6<%S]%')KXYF\
M2:O<+MEU6^D7T:X<_P!:SF)=RS$LW]YCDUR5_$/W?]GP^OF_T2_4Z*/!;YKU
MJVGDO\V>L_%7XV-XNMWTK1XWM]-)_>SR</-[ =A7DU%%?EV8YEB<UKNOBI7?
MX+T/O\#@*&7451PZLOQ?J%%%%>6>@%%%% !1110!Q?Q7^*5A\*- @O[JUFU&
M\O)UM;*PMR ]Q*W1<G@#U-8E]XK^*FEZ+)K$O@K0[R&./S7TNRU.5KP+U(4F
M/8S8["LS]I3P!K?B_1_#NJ>'[0ZE?Z#J"7K6"L \\8^\$SQN]JQO'WB>V\;Z
M=<7.E:/\18/%)MC'!I]HEQ8PQRXX+MQ'P>^3FON,OP6&JX:C*,(R<F^=N[Y=
M=%92CRIK7F/F<7B:\*U52DTDERI6U[[IW?D>JV'Q TM_!5MXFU?S/#-E(@:6
M/6!Y$D#?W6![Y].M0:%\6O!WB75(M,TWQ#:7&H2KNBM6W1R2#U4.!N_"O%K>
M\^(NF_LY^'/MGAV?Q%XC^WD:@NL6OVRXM8MW$HB;[[#M69XFT_7-9^*WPY\1
M)!XP\0Z9IDY%Y>ZAI0MTMR1@".%5# >^"/>MXY#A9NKS3M9S2M)->[LMGOYR
M3?2Y#S2O%0M'=1O=.^N_7IZ,^@-=^*7A#PQJ<^G:MXDT[3]0A4/):SRXD /3
MY>I_"FZI\5O"&C0V4E[X@M(!>Q^;;)\S22I_>" %L>^*\ZT?P9?2?M8ZYXCN
MM%D;2CIB);:A- #'OP,A6/0T>.];\2:?\9-K:9>Z-X>%D!%XBT/1!?WL[GK%
MOPWEC\*X:>58.=6%*,FWR*3]Y+7LO=;O][\NIT2QV(C"51Q2][E6C?S>J7Y'
MJOACQMH'C2TFN="U>UU.&$[96A?F(^C@X*_B*PY?CAX AN)X7\6:<I@8I+)O
M8Q(PZ@R8VY_&O%/A?X3\113_ !>T^[L=;T^Z\00F33]2UB'9YJXZR2+\JGVX
MIOA[QE9^&OV8+_PS?^&-3DO;6RG@F2&Q\RTD?G]Y]H'[LCOG.:[WP_AO:RC"
M4IKFBDDU=*2NVW9WL].GG8Y?[6K<B<THZ2>J>Z>V_7?J?1$?CCP]+X9'B)=:
MLCH)&X:B90(2/9CUJCX>^*OA#Q7J2Z=I7B"TN[]UWI;?-'(Z^JAP-P^E?-4?
M@#Q%XL_95^'?]D6MW*=/OEOKFRM0#,T(;[R*W#$=@:[1= ?QI\3/!E_%#XVU
MPZ5(97O];@2PAL5QTQY2F0]MHXJ99#@80J-UFW%S6ZTY=KZ=?5>5QQS3%2E"
MU-6:B^NM][>GH_,^BZ*5CDDTE? GU04444 %%%% !1110 4444 %%%% %75;
MW^S=*O;P)YAMX7EV9QNP,XKR+X;?%WQW\5/"R:_HWA'0H[*25XDCNM7D20E3
M@](B!^=>K^(H9+GPYJL,2&262UD1$7DL2IP!7@7[.7B2\^&7PQ@T/7?"/BM-
M1BN99&2WTAY%(+$C#9Q7U678:E4P%6JJ:G54HI)M[-.^B:^\\/&5IPQ5.#FX
MP:;;7?2W1GI/PW^,,7CGQ#K/AK4-(G\.^*=(/^DZ?-(LJ,O9XY!]Y?PK1U3X
MS>!]&OKBRN_$]BES;'$Z1EI!"?1RH(7\37"?#KP-K^O?$OQIX_U739O#(U>R
M-AIUE<N/M*KM(\R0*2%YQQFL?X*7\_P;\#:MX7\2>%==DU474\C36.F/=1:B
MKD[2)$!!SG^+%>A5RO 5*E25%MM*'N1DMW\5F[W47Z^IQT\=BXQC&HK)\WO-
M/9?#=*VK_I'M\OB_0XO#A\0-JUH=#">8=064-#M]=PK-TKXI>$-<NI+?3O$5
MC?RQ0F=_L[EU6,#)8L!CI[UX1HOPN\3Z/^RWXTTJ?2+B+4]6N)+JST6/YY84
M9LA-HZ'OBO7O"_AV;2O@-:Z1'IWV2]&C&)K1(@C^:4/! _BS7'7RS 4$[57)
M\_(K-+2RU>COVTT\SII8W%56KPY?=YG=/?MT++_'3X?) DW_  ENG/ W_+:-
MF>-?]Y@"%_$BGWOQM\!:<X$_BO3E7C]ZCL\0STS(H*C\37GGPS\&ZKI/[(]Y
MH%QI$UIK4MA=(;!X<2L[$[05[DU%;>"]7A_8W;PXFCSIK3:7L.FK#B4R;NA7
MUKJEE>61FX\\M*G)\4=5_-\.W]7,%CL:XI\JUAS;/?\ EW_KL>H>-?'@\,V>
MB75F^F7$&I7*0I)>7ODHRMT,9 .]O05S/B/]HWPKX9^)UGX,NI?WDT;/+?[B
M([=A_ RXR2?:N \>>"=?O_A/\);"WT>[FO-.O;9[N!(R7@5<9+#L!6_\3],U
M/2_VD?!_BM=%U'4M#MK&2":XTZU-P8W(P RCFMZ&69?RQC4?,[5-I6;<?A[[
M]/U,JN-QCDW!<JO#=7T>_;;K^AZEXC^(OACPE]D&KZY:6+W:[[>)V+22KZJB
M@L1^%3>%_'7A[QJD[:%K%KJ9MSB9(7^>+_>0X8?B*\BN=/O_  /^T/J'C;4-
M"U+5M"U;3UAM;ZQM&N);%QU1HU^9<^PJ7P5HFI^*OVC-2\=VVCW^B>'%TTV9
MDU&W-M)>RXZB,_-@>I%<4LHPBHN?._@YN:ZY>;^2UKW^?RL=*S#$.IR\J^*U
MK.]OYK[6^7S/0F^,O@5;EK8>*]->Y6;R#!'*7D$F<;2H!(YK=\/^*M'\5K<M
MHVI6^I"VD\F?R&R8G_NL.QKR7]F/P5>^%F\;W.J:,^G7=YK$DD4UQ"%>6+)P
M0>I6L?XMW%_\"?'4_BCPY9F[A\7Q_8)=/A(!%[TCE5?3DYQZ4/*<'6Q4L#AI
MOG233;7*WHVM%II?KT!8_$4\/'%5HKEOJDG==%U_0]RTGQ7H^O:A?V.FZE;W
MUYI[^7=PP-N,#?W6]#[5JUP_P=^'*_#7P7!93-YVKW;&\U*Y/WI;A^6R?;.*
M[BOFL93H4J\J>'DY16EWU[OT['M8>=2=*,JJLWT[!1117$= 5Q7Q9^*5A\)O
M#<6IW5K-J-S<S+:V=C;D!YY3T7)X ]Z[6O'OVEO 6M>,/#_A_4O#]F=3U'0=
M12_^P*X5IT&,A<\$^U>OE-+#U\;3IXIV@]];>BOTNS@Q]2M2PTYT%[R^9<U;
MQS\3O#N@G7+WP1I%]:(JR2Z9IFI227R(?[H,>UV'H*[-_B!HECX2L_$6KW:^
M'["Y16QJG[ET8_P%3SN]A7"^(_C?J=UX;>/PGX/\1S^+I$5(+._TF2*&"3N9
M)&PNT>QKGOB_X1\6ZK<?#/Q1J.EGQ!+H=P)]9TO3$#\D#YHXR?FV_P!*]^.7
MT\1.$,3"-&[>TM6DKI6;:U>BE^9Y3Q<Z493HRE4LENM%=]TE\T>IZ!\5?"'B
MC4ET[3/$%I<:@R[DM6W12./55< M^%.UOXH>$O#>J3:9JGB&RLM2B4.]F[DS
M!3T(0 D_A7DOQ32]^-/C7P&OAS0=8MAI&H"]N]6U*P>S2WB'5 7P6)]!Q6QH
MWA75(_VM-<\02Z7.-)?2XXH=1>+]V7!Y"MZU#RG!0C[2I)Q?(Y.+E'F33LE>
MW5:[7+6.Q,I<L(I^\ES6=K-;VOT];'I7A7X@>&_' N?[ UFUU1K8XGCA8AXC
M_M*P!'XBL75?C=X(TQM0A_X26PEO+-&WQ([%5<#[C. 54]N37 ^%O!FMCX[?
M%&^.GW%E9:IIJP6E_(FV.23:1\K=ZQOA/=W/P_\ @WJG@C5_!FNOKX%S&T$&
MFM+#>L^=KB8?)@^I-;+)\#=SA)S7N>ZI1NE)7;;MJH[:)>=C)YAB;*,HJ/Q:
MM.UULDK]?F>K_#'XIVWCWX<1>+K^.WT2T8R>9YDX,<:J<;BYQP:DL/C9X#U*
M[@MK?Q38-+<-LA+ED24^BNRA3^!KPVV^%7BG6/V1[3P[#I%Q:ZU;WGVI](G^
M226-7R8\'CD=JW_BQJ\OQ,^$-KX-T3P9KW]M3?9XDM[O2WMX;)DQN8RMA0!C
ML>:WGDV JUY<DGRN;C[LE:$5M)WO=?->IE',<5"E'FCKRIZIWDWT5K6_K0^B
M:Y/XF?$"'X=>'5OC;'4+^XF6VL;!&PUS,QX4'L/4UN^'-/ETKP_I=C<R^;<6
MUM'%+)G.Y@N":\U\.Z3>_$;XK7?BG5K.>UT/P^QM-%M;J,H99?X[C:?R!]J^
M9P>&H^UJ5*SO3IZOIS=DO7\$>W7K5/9PA35IS_#N_D>I6#W,MC;/=PK!=O&K
M2PQMN".1RH/?%<GJOQG\#:'?7-G>^)K**XMCMG5=T@A/H[*I"_B:[/)VL1RP
M!(&<9-?+\-]XOUG1?&&F:II&O>&]0N9)X[;0_#6B)';W8((622Z*D-GN<BNO
M*LOH9A*<JSY8JVB=MWZ-V7W=V<^/Q=3"1BJ:NW?I?;YK?^D?0=_XZ\.:7X=A
MU^[UNQ@T.;'EZ@TP\EL],-658?&7P-J>I6^GVWBC3Y+NX.V!"[*LQ]$9@%;\
M#7S3XOL+S1/V+-*T?5-*O+'4=/OHXKBSO(#&Q;S"<+GA@0>HXKM_BO/<?%KX
M9^'/"/A_PGK<6K>;;/YMWIK6\%@J8+/YI^7ITVDYKVUP_A5\4I.+G*/,G%**
M6TGIK]Z/,>;5W\,5?E3M9W;?1=CV_P 3?$3PSX-N8;;6M:MK"ZF&Z.W8EY77
MU"*"V/?%3^&O&^@>,K*>[T/5[74[>W)$S0-S$1U#*<%?Q%>0^*]2\4:'\4[*
MUFL+W2]#@TR.)?$VAZ*+^^N)  #'YA#&,?A6=\!=&UG0_%_Q)75-*UZ#^UR9
M[*[U:VPUPFW@LZ_*&_V>#7,\CPRPCK>T]ZR:U33N[/2W1:[MKJC;^TZWMU3Y
M-+M;.ZTOW_1'JR?&KP%*T2Q^+=,F,A( AD,AXZY"@D?C6+\/OV@_#'Q#\3ZQ
MH=G*+>YL9_)A:1B1=\?>3C@?6LG]DWPA>>#?AH]OJND-I.I2W\TDJSPA)74M
M\I/<C'2J/P@MM1\)?%3XA0:IH>J6\>L7PEL[P69:V=0O4R#@?C2EE^70>*HP
MO)TTN5\RUUU:27^?R*6+QC5"I*R4]U9Z:=7?_([ZZ^-/@2S:X23Q38%[>0Q3
M)$S2-$PZA@H)&/>FS_&WP%!:QW)\5Z=+!(N\/;NTP"^K; =OXXKBOV:O"FJ>
M&;;Q_P#VII4VG27NLS2PFXBVF:,@X(]157]F[P?JOA?X6^+K/4=(FTV]N[V\
M>.&:'8\JL#M(]0>U%7+,LH^U]^3Y'!?%'7FWM[KV^?R"GC<94Y/=2YE+H]+?
M/K\CU^V\7:'>^'O[>@U>SET389/[068>2%'4[JQM%^+_ (+\1:G#I^G>)+*X
MO9^88260S?[FX -^&:^>+?X3>+M3_91;0+?2[NTU>#5C>/IKJ$FEB$A)V@\$
MXY /6MW5?#\OCO5O!4$=KXZUZ;3KN*=EUBWCT^WTX*!DE_*&[IC:IYKHCD6
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MJ.%]QA<=5;T-1:3XQT+7M/O+_3M7M+NRLW:.YN4D'EPLOW@Q/3%>(_"J>_\
MA=XX^(T>L^'=<=]5U)KJQ:QT]YX[A".,.ORC_@1%<OX6^&/B[6OV<_'^B)I%
MWI6M:CJ<MS!87@\IYDW9VYZ<BM)9#A8RES5K1O!)MK52^)_+_AR%FE=J-J=Y
M6E=:]-OO/>++XV> M1O(;6W\5:>\LS^7$Q9ECD;^ZKD!2?H:AF^)\D7QJA\
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>P22/K29HHH$&3C&>**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>forms-4_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_020.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #S Z@# 2(  A$! Q$!_\0
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M9K=XU+%%<;&8 .,,.5R,Y'4&O&/A^_CIOB9\2!H+^'#X?7Q.OVD:A]H-V/\
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M%5E%::_X2\0>);+S&M4AO+6YO(-O+F, EUQCG'3O6G;_ !#\$:O'J&HP>)=
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M,IM)""I!"$["1D=N,BJ6H^"]$GLKS0/#.H0^"]4VK-))X>AM8[J*-F/)1HV
M5R&Y*]02#D9KS_2IH-1\6W_Q#\.>'Y)/#7A?0[K2=*M](@"S:V^Y'80H, Q(
M80D9Z,S.1Q@GGO@7\3[Q?B9_PC^K>&/$$&O>(K!M:U74K_1;BW$=R'"+ K/P
MMO'&!&I[L,]6-"2DTNMO\[?@K_@&J3?;_@?J[?B>Y6/PX\-V?@_3_"\FCVFH
M:)8QI'%:ZA"MPIV]&8.""Q.26ZDDFH_%>N^"_#$5M!XEU#0=)BO(S8P1:K-#
M"LR-@&%0Y&X' ^4<=.*S]6\=>)[#7Y;&U^&^M:G8K($75(-0T](G4XRX1[A9
M,#)X*YXZ5F?&&\TRTMS86>A66N^-=?M9-+L+::)69HCG>\K8)6WCW;F/0\ 9
M9A4MMZ[W!66CTL=-=:KX.^&6GVD=S=Z'X4L;AU@MEEDALXI7Q\J("5!..@%4
M[_XI?#[PMKDNC7OBWPWI&L2RJ9+"XU*W@N'D?&TE"P8LV5QQDY%>9^#/"6E^
M%?B-=>&_$\UOJ-MH_@G3[+3Y]2 *RVR&9+U_FXY*P[_;;GBN @N;Y?@1\//%
M+W6E:QHOA2X%QJ.@763/>IYNRP DW962.-HY%C=3O;9G! -:\JOO=7_"[7Z?
M?ITN)7VZ_K9/]?ZN?35UK7A+0M>TO1[F_P!&T_6I_,>PL)9HHKB3<27,49(8
MY.<[1SSFL3Q#XZ^%_@OQ?+/KGB#PEH?BDPJDDFH7EK;WOE'[H)8A]I[9XKQ[
MQ1%IDOP[^/EQK@MSXBCU.?R7D_UZ8AC.F;#]X<[-F/XBV.<UK>%-,\=7_P 7
M_'<FEW?ANV(BT?\ M!-8TR:YE:7[&-VQDFC"CKU!YJ4KI/T_%?U<MK=>OX-'
MT"L5K>/;WBI#.X0F&X #$*P&=K>AP.G7BGO:027$=PT,;3Q@JDI4%E!QD ]0
M#@9^E2*,*!Q^%+4D&?+X>TJ?68=8DTRSDU:&,Q17[VZ&>-#G*K)C<!R> >],
M;PQHSW&H7#:38M/J*"*\E-LA:Y0# 60XRX XPV:TZ*!F4OA31$T$Z&NC:>NB
ME-ATT6J?9BN<X\O&W&><8IUSX8T:\TZUT^XTFQGL+5D>WM9+9&BA9/N%%(PI
M7MCIVK3HH S-0\,Z/JVEOIE]I-C>Z:[;VL[BV22%FSNR4(QG/.<=:MQV%K#+
M')';0I)%'Y,;J@!1./E![#@<=.!5BB@"&UM(+&!8;:&.WA4DB.) JC)R>!ZD
MD_C7-:E\.K :5J%MX=<>"[V^D$LVI:%:6\<[,#DEM\;*Q.2,LIZGO75T4#N<
MUI?PY\/:9X,LO"K:9;ZAHEK&(Q;:A&MP)"#DNX8$,Q8EB2.22:TO^$9T<SZ=
M-_9-CYVG*4LI/LR;K52,$1''R#'&%QQ6G13O=W)MT,V#PUI%KJUUJD.E646I
MW2".XO4MT6:91T5W RPX'!/:K$>EV4*VJQVD"+:#%N%B4"$8QA./EXXX[5:H
MI#*ZZ=:+!/"MK"(9RS31B,;9"WWBP[Y[YZTXV=NUH;0P1FU*>5Y!0;-F,;=O
M3&.,5-10!E:AX4T35KBSN+[1]/O)[-2MM+<6J2- ",$(2,J"..*MG2[(_:,V
MD!^T((YOW2_O5 P%;CD $C!]:M44 56TNR>:.9K2 RQ1-"DAB7<D9QE <<*<
M#(Z<"J5GX/T'3]&GTBUT33K;2KC=YUC#:1I!)N^]NC VG/?(YK7HH Q])\):
M3H6I7-]86:6LT\$-JRQ?+&L46[RT1!PH&]N !UJEI7P_TC2X?$%L8!>:?K=X
M]]<V%VB20"1U42 *1RK%=Q#9Y8_2NEHH I66B:=IVE)I=I86MKIJ(8ELX852
M%4/50@&,<GC%4K?P3X>L]"GT2WT+3+?1IPPET^&SC6WDSUW1@;3GW%;5%#UW
M#8R/"7A+1_ OAVQT+0=/@TS2K*)8H+:W0*J@#';J3W)Y)Y-:5M:06<9CMX8X
M$+,Y6-0H+$Y)P.Y)))]ZEHIMMN[ I)HFG1@A=/M5!1X\"%1\KG<Z].C'DCN>
MM#:)IS%";"U)18U4F%?E"'<@'' 4\CT/2KM%(#/;P[I3ZVFLMIEFVKI%Y*Z@
M;=/M"Q_W!)C=M]LXJ4:59+ D(L[<0I)YRQB)=JR;MV\#'#;B3GKDYJW10!R.
MD?##1=+TZSM76:^:VU2761/<2?.]V[NQD;: #@R, ,8  ]*ZZBBCR#K<****
M "BBB@"KJ>F6FM:;=:?J%M%>V-U$T,]M.@>.6-AAE93P002"#7,>$?@[X&\
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M 5+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTGXWWVI6/@S4)/# @T_Q#?OI<D@U%6DM+A7F7&S8/,3]R3N!'WAQ0M;6Z_\
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MBU^:-&BBBM3A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV73M4LY;#4H=<TMY;]#(MLMT66P\[<6$JQ _,<@;U&XXS7@G_#V./_HF3_\
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M_P#)M7PW_P"P+!_Z#7XDU^VW[)?_ ";5\-_^P+!_Z#7T>1_QI^GZGXIXI_\
M(OP_^/\ ]M9ZU1117V1_-04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!AZC<:8GBW1H;BW=]4DAN#:S ?*B#9Y@//?*=CT[5N5AZCI5M<>
M+=&OY+U8KJVAN$BM3C,P?9N(YS\NT=!_%6Y0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%9WB&PO=4T+4+/3M0.DW\\#Q07PB
M$IMW(P'"$@,1UP32>PUN<X?B9!)-XLEMK&2XTKPY YN-0$@"2W"*7D@0=R@
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M7_\ 2:"OM*OT3+O]UI^A_&/&/_(_Q?\ B_1!1117HGQH4444 %%%% !1110
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MH;ZX./H:ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\W)2CS>];NUT2[!1117J'P84444 %%%% !1110 4444 %%%% !7P-_P5A_Y
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M"+(J',F6W.!U)S[#H_PG\(Z#+;2V.AV\,]O*\T=PQ9Y0[H8V8NQ+-\C%>2<
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MH*^TJ_1,N_W6GZ'\8\8_\C_%_P"+]$%%%%>B?&A1110 4444 %%%% !1110
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M?$#XQ>-/%MGXQ\23ZY:V6GQ301RPQ($<R8)^1 >GK7YL5]S?\$IO^2@^.O\
ML%P?^C37HY?B*T\5",IMKU?8^-XQRC+L/D6)JT<-",DE9J$4U[RZI'Z54445
M]V?R:%%%% !1110 4444 %%%% !1110 4444 ?D?_P %'_\ DZ'5/^P=9_\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<M\5?^27^,/^P/>?\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEOBK_R2_P 8?]@>\_\
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MOA[_ -?LG_HB2OVAK[/)/X$O7]$?S)XH_P#(UH_]>U_Z5(****^B/QH****
M"BBB@ HHHH **** "BBB@ KX&_X*P_\ (!^&_P#U]7W_ *!#7WS7P-_P5A_Y
M /PW_P"OJ^_] AKR\T_W.?R_-'WG O\ R46%]9?^D2/SHHHHK\^/[$"BBB@
MHHHH _3[_@E?_P D4\4_]C"__I-!7VE7Q;_P2O\ ^2*>*?\ L87_ /2:"OM*
MOT3+O]UI^A_&/&/_ "/\7_B_1!1117HGQH4444 %%%% !1110 4444 %%%%
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MN=I3Y/,SV_N8S6[6%J6AM>>+M%U07$:+90W$9A(^9_,V<CZ;>?K6[0 4444
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M_P"%6Z* *G]IQ?W)_P#OP_\ A3H]0CE=4"3 GC+0N!^9%6:* "BBB@ HHHH
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MR%)Z]J\T\0?%.36O#FD>#_$%];>&M8U+3$FU^[N1Y0M87&&CC4_\M9!GC/R
MDGG ,<E[H.D_%'7_ #/&5UX3TY]*TP61M9842YC"2@$&6-]V!@<$=>:;5F_7
M_,2V^7^7]?<>\V-V+^S@N5CEA65 XCGC*2+D=&4\@^QJ>JFDWEOJ&F6MS:W0
MO;:6-6CN00?-7'#9''/7BK=#T8+8****0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#"U)=+/B[13<-(-6$%S]D5<[2GR>9GM_<QFMVL3
M4- DO?%6CZL)E2.QAN(FB*Y+F39@@]L;#^=;= !1110 4444 %%%% !1110
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>forms-4_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_021.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #K Z<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7V%"G!TH^ZMET/>IPCR+3H>K_P##6?QL_P"BK^+?_!I)1_PUG\;/^BK^+?\
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M?_':/^'O?PU_Z$WQ7_WQ;?\ QVMOJ=?^0T]A5_E/N[9_M-^=&S_:;\Z^$?\
MA[W\-?\ H3?%?_?%M_\ ':/^'OGPU_Z$WQ7_ -\6W_QVCZG7_D#V%7^4^[MG
M^TWYT;/]IOSKR[]G+]H?P_\ M,> '\5^';._L+2*[>QE@U&-5D25%5B!M8@C
M#KR#WKU.N647!N,MS!IQ=F-V?[3?G1L_VF_.G56U/_D&W?)'[I^AQV-2(<T\
M"L5-PH8=07&12?:8/^?A/^^Q7\ZWC#5+ZZ\7:W+/?W<TK7T^7DN'9C^\;J2:
MR/MES_S]7'_?YO\ &O=65_W_ ,/^">E]3_O']('VF#_GX3_OL4?:8/\ GX3_
M +[%?S?_ &RY_P"?JX_[_-_C1]LN?^?JX_[_ #?XT_[+_O\ X?\ !']2_O?@
M?T@?:8/^?A/^^Q4B;9%#(^Y3T*G(-?S=_;+G_GZN/^_S?XU^L_\ P27OKF\^
M ^O"YNI[D1:RZ1B:5GV+L'"Y/ ]A7+B,#["GS\U_D8U<-[*/-<^W]G^TWYT;
M/]IOSIU%>6<0W9_M-^=?F!^T3_P4G^*WPU^.'C/PEH5CX<CTO0]0>QA-U:22
MR2!0/G9O,')STQ7Z@U^"7[8O_)UGQ6_[#TW\EKU,OIPJ3DIJ^AVX6$9R:DCV
MC_AZY\;?^?7PI_X+I?\ X]1_P]<^-O\ SZ^%/_!=+_\ 'J^-J*]WZK0_D1Z7
ML:?\I]D_\/7/C;_SZ^%/_!=+_P#'J/\ AZY\;?\ GU\*?^"Z7_X]7QM11]5H
M?R(/8T_Y3]L/V"?VD_%'[3?PUUW6?%=KI]MJ&EZH;!7TU&C25?*23<59C@_/
MC@]J^G-G^TWYU\&?\$@/^2,>.?\ L8__ &UAK[UKYC%14*THQ6AXU:*C4:0W
M9_M-^=&S_:/YTZBN4Q/P>_;8_P"3K?B7_P!A5_Y"O$J]M_;8_P"3KOB7_P!A
M5_Y"O$J^UH_PX^B/HJ?P+T"BBBMBPK]3O^"0(S\,/'?)'_$WBZ?]<J_+&OU/
M_P""/_\ R3#QW_V%XO\ T57G8_\ W=_(Y<5_"9]^[/\ :;\Z-G^TWYTZBOE3
MQ!NS_:/YU^%O[>'_ "=Y\3/^OZ+_ -)XJ_=2OPK_ &\/^3O/B9_U_1?^D\5>
MOEG\67I^J._!_&_0\%HHHKZ0]8**** /T]_X(ZC/@WXG\D?\32SZ?]<6K]#]
MG^TWYU^>'_!'3_D3?B?_ -A.S_\ 1+5^B-?)8W_>)?UT/#Q'\5C=G^TWYT;/
M]IOSIU%<)S'X:_M_?\G<>/O^N\7_ *+6OGNOH3]O[_D[CQ]_UWB_]%+7SW7V
ME#^%'T1]#3^"/H%%%%;F@5]V?\$BAGXU>,/^P*G_ *-KX3K[M_X)%?\ ):O&
M'_8%3_T;7'C/X$S#$?PI'ZO[/]IOSHV?[3?G3J*^0/!&[/\ :;\Z_$C_ (*-
M_P#)X7C;_KE9?^DR5^W-?B-_P4;_ .3P_&W_ %RLO_29*];+?XS]/U1W8/\
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MFT>[_KY'9]4I]V?M3_P\P_9^_P"AMN__  477_QN@_\ !3']GX#_ )&V\/\
MW"+K_P"-U^*U%']FT>[_ *^0?5*?=G]&7@CQMHOQ&\*:9XE\.WR:EHNI0B>U
MND4J)$/?! (Y!ZBMRO!_V%/^31/A;_V"%_\ 0VKWBOG:D5&;BNC/)DK2:"L_
MQ#>2Z=H&IW<! F@MI94+#(#*A(R/J*T*R/%__(IZU_UY3_\ HMJA;B6Y^,NI
M_P#!1W]H%M3O3'XU@MX_/<+%'I-J50!B !F,G\S5;_AXW^T)_P!#U%_X*+3_
M .-U\Y7_ /R$+S_KO)_Z&:@K[+ZO1_D7W(]_V5/^5'TI_P /&_VA/^AZB_\
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M[:_!+]L7_DZSXK?]AZ;^2U[.6?Q)>AWX/XWZ'CU%%%?1'K!1110!^K/_  2
M_P"2,>.?^QC_ /;6&OO6O@K_ () ?\D8\<_]C'_[:PU]ZU\AC/X\CPL1_%D%
M%%%<9SGX/?ML?\G7?$O_ +"K_P A7B5>V_ML?\G7?$O_ +"K_P A7B5?:T?X
M<?1'T5/X%Z!1116Q85^I_P#P1_\ ^28>._\ L+Q?^BJ_+"OU/_X(_P#_ "3#
MQW_V%XO_ $57G8__ '=_(Y<5_"9]_P!%%%?*GB!7X5_MX?\ )WGQ,_Z_HO\
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M]*8**^7S'^/\D>+BOXI^M]-WK_>'YTZDQ7F'(?,W_!1_;)^QYXY!PV&LO?\
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MY-#^%O\ V"%_]#:O=\5\56_B2]6?.S^-^HF]?[P_.LGQ<ZGPIK6&!_T*?O\
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MR_Q2_P"29^+/^P3=?^B6KJ*Y?XI?\DS\6?\ 8)NO_1+5$?B1*W1_.SW/U/\
M.BCN?J?YT5]R?2!1110 DGW&^AK]Y?V+_P#DUGX;?]@I/_0FK\&I/N-]#7[R
M_L7_ /)K/PV_[!2?^A-7CYG_  X^IP8SX4>U4445\X>28WC3_D3M=_Z\)_\
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M_0\%HHHKZ0]8**** /T]_P"".G_(F_$__L)V?_HEJ_1&OSN_X(Z?\B;\3_\
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MXV?\D:\>_P#8 O\ _P!)Y*_GAM?^/:'_ '!_*OZ'?C66_P"%->/<@ ?V!?\
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M^A^6_NC\Z^2QO^\2_KH>'B/XK'44W+?W1^=&6_NC\ZX3F/PW_;^_Y.X\??\
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MCZ*G\"] HHHK8L*_4_\ X(__ /),/'?_ &%XO_15?EA7ZG_\$?\ _DF'CO\
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M_):O&'_8%3_T;7'C/X$S#$?PI'ZPT445\@>"%?B-_P %&_\ D\/QM_URLO\
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M/(\+$?Q9!1117&<Y^#W[;'_)UWQ+_P"PJ_\ (5XE7MO[;'_)UWQ+_P"PJ_\
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M17VA] %%%% #9?\ 5/\ 0U^_O[+JY_9U^'7)'_$DMNA_V!7X!2_ZI_H:_?\
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M_P#R$+S_ *[R?^AFH*GO_P#D(7G_ %WD_P#0S4%?<GT@4444P"OV!_X)2_\
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ML_?\D+^'O_8 L?\ T0E=_7P\_B9\W+XF-\Q?[P_.OG7_ (*#,&_9&\?X(/\
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M5\?B_P"//U/!K_Q)#?,7^\/SJMJ3J=.N@"#^Z?\ ]!-6ZK:G_P @V[_ZY/\
MR-<J,#^<[Q3_ ,C1K7_7]/\ ^C&K+K4\4_\ (T:U_P!?T_\ Z,:LNON5L?2K
M8****8!7ZS?\$CV"_ ?Q'DX_XGC_ /H"U^3-?K/_ ,$CO^2$>(_^PV__ * M
M>;F'\!_(Y,5_"/N7S%_O#\Z/,7^\/SIU%?+'BC?,7^\/SK\%/VQ?^3K/BM_V
M'IOY+7[VU^"7[8O_ "=9\5O^P]-_):]G+/XDO0[\'\;]#QZBBBOHCU@HHHH
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MC:^$Z^[?^"17_):O&'_8%3_T;7'C/X$S#$?PI'ZO^8O]X?G1YB_WA^=.HKY
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M_$EZ'?@_C?H>/4445]$>L%%%% 'ZL_\ !(#_ )(QXY_[&/\ ]M8:^]:^"O\
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M\9_ F88C^%(_6&BBBOD#P0K\1O\ @HW_ ,GA^-O^N5E_Z3)7[<U^(W_!1O\
MY/#\;?\ 7*R_])DKULM_C/T_5'=@_P"(_0^:J***^E/7"BBB@#[?_P""1_\
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M/_@UD_\ D>ODY.\FT>)+5LZ.OG3_ (*#_P#)HWC_ /Z]D_\ 1BU[1]O\5_\
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M^AX\*?\ ?NY_^(H_X=!?$K_H>/"G_?NY_P#B*/KN'_F_,/K%+^8]K_X) ?\
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M-N#G%=-X:^)$.M>*;KPU?Z7>:'KUO;)>?9+HQNLL#$J'1XV93@@@CJ"*\?\
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MC!>/,0';(!Z,"/:@#H+3]H[0KR)X8M-U";6/[2728M/@$4GGW!4MB.8/Y3*
M/F;=\O<5KVWQCMIFUFR;P_K!\0:4T2SZ-!"DTS"3[CHRL4*'NQ88[UY;X7C'
MBGX8:E>:EF:ZT&ZCN-+EC8PFTD X,>S&.IXZ'N*@\0:3!/\ "#4=<:2Z76-9
MOHH[^^CNY4EG1.%0L&!"#^Z, ]Q0!Z?9?'*TN-5U?29?#^K'6=-MUN9+&P6.
M]9PS;0H:)V4/GJK$8'/3FKOASXNVVL^-O^$3O-(O-+UHVIO!&TD-PB(#@B1H
MG;RV_P!EL9[9KY]TO6+Z3P+XETJ.[FL[!88PL5BYMB,N <-'M.2."<\UV/[.
M^JW4'BIM)BD$6G"W9_L\:*JLP_B.!DGW.30!](4444 %%%% &!XL\43>&H[0
M6VBZCK=Q<R&-([%%VQX&2TLCLJQK[DUP\'[1F@RV-XS:?J!U&WU./1TL(!',
M;BZD4LJ12JYC88!+'<-N#G!K#_:@5KBS\/P-+.+?SWD:!)G2.0@<;U! <>S
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M3[XQ\Q]SFO2=*^%'A+0_C%!J>GZ)!:7L&C!(GB9PJ#S2.%SM''M0!ZI1110
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5#5@ZAE.5(R#10 %  & . !10!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>forms-4_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #7 G # 2(  A$! Q$!_\0
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M)\3:XOAOP_=:HUM)=-"%"01_>E=F"JH^I(JWI>H1:MI-GJ, (BNH4F0-U 8
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M126F^;>I4Y^7WK<\(>'?%F@WL2WLFBR66PQRF%I?,QODD&W(QG,F.>PKO**
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M1E9>F5.1QQ5.^T73-2M8K6]L+>X@A(,<<B A"!@8';CBK%I:Q65NL$(Q&I)
M^I)/\Z&QO4FHHHI""BBB@ K*UZ_&G6L$[2,D8FW2%>I549R/QVUJU0U6Q-_%
M!'L#JLP+J3C*$%6_1C0!C0^*;F[T>.XL[.&>[:1UV;W2-E1=Q*LR ], <=?;
MFM'4]1FC\)W&I6_[J?[(9DR VP[<_C6=J^@7?]E".UN=0O;G[@D>Y1'4$,"<
ME<8PV#QG !'/-3V?A:*"VOK62XG>&\@2%AYA)7&[.W/3[W'TJ97M9&M+E4DY
MO:WSU_R,T^--0^T3VR:*'F>5HK'_ $@ 7!60HY/'R8QGOFLO2_%TVG:1;27.
M^=[NZB@D:>Z&]2T4?**1SRW(^ISS73W/@_3[J/:9[N-PSLDD4NUT9I/,)4@<
M'.1]":K'P#I!BMXQ+>*('#KME'S8" *W'(_=J?J*RY9W/1C5P?+9K\'V]?Z]
M- M-2U)FN]#9UBN;2P4_;7<-(TNP?,(R/F4$]>F01531K[6;G6;:.ZU=C#>Z
M0MQ%&;5 JRD*"0P^\0<L0?[PKH#H5LVMS:J\UR\TD)A6-I,QQJ<9*+V)P,_2
ML\>"[ 2*YO-2(CB2*)?M)"Q!=O*@="VT9_I3Y97N9*K1LUM==KZVU_'_ (!A
MVFO:W;:<)+N]FN626:WDD-HJ,KAL+E!_%MVL ."&-;NI>)IK6_LH;.P^U6\J
MPO/.90GE++($0@8^;G.1VQ4]MX6M+:Q%M]JO96W.[3S2[Y&=@!O)(Y8  "L_
M6O#=Q=ZSHK6D(%M;&,3S&X*G9&X=59 ,/R./0DFBTDON*Y\/4J:K37R6VG_
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M<J$)7'!R1NSZ'CBM8Z+4XL1*$ZCE35DR&S\37LUW$EQIT4$.?+F;S\E9"9
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MJ;/2[.Q15@C;Y4\O+R,[%<D\EB2>2>33++1M/T[/V:WVY# [G9N#C(Y)XX
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M;*RA791\H  .#R/E7@\< ]10(YZ#4]6A%M"UQ:RWLEL9GNGM]NY$9SLP&[@
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M&LFGLVDN]0MED,R*"D$CS##,W4 < 8]*M3QVS6^CE$0S22?Z5D#+?OX]V_\
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M]21Q3Y;*UGB>*6VB>-V#LK(""PQ@D>HP/R%%T(RO#MW<7*R?:+LW/F11W&2
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M!I;:<&61G(&V+'F;<+Z9Y]!5R#PA:+?2RSO-+$T:KM>8GS3A@7D]6^8X/O\
M2KI\.VS6+6S7-ZSL%S<&<^;E22#N]?F(^E)C,$>*]2BC25H$G%S,7@B@MI7<
M0A4)4[0</\XPQPOK71Z'?SZCIYFN3")MY#1Q!@8O]A@>0PSS59?"]C'L\J:[
MB",A4).1@!0I7Z,%&1WQ5O3]'ATZ626.>YEDDSO::4N6]/R  'L*;L+4T***
M*0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+(;:ZMHXI+58WCF#C,D<GF1G*$$*<L&P<],5#:> KFSA@AAGMHXXI(7"KOP
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M"QD=0Q+&5N@Q&64=L >N*UCX9^TR7\ES':([,39M$I/E$YR^#T9N-P7@X]Z
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MNC3:J8KI+6/D%XB&D7C#*.X.>*Y^^\.R6^ISR@PJ][-'%"\,+&1EW[F\QN@
MCWJ.V,=SBM*'PR[)=//'9I.TA^S>4I*PID$XS]TMC) XS0@+DGB6UC\[-K>D
MPX)"PYR.C$<\A3PWI44?B>UEUO[$HD$(C<B5HR%<KW5NA'##ZBLG4?!37/\
M:(AMM)_TF5G$DL!+R;]Q/F8Z[2P*_09Q3+W0KZUA2V:YC:(E;>S$43,_S2!V
M+GH/E##/3'N<4(3.@G\1V-O<P0R+<9EA68N(CMC5L[=Y[9(P/>JDWC"T2W66
M*QU"<LB,J)!RQ8C"C)^]M(;'H:;JFE7NH:Q)!"\4=B]M$LV]#GY7=AL(XZX!
M![&DN- U%G*PSVOE($GCWAL^>J! #C^#"Y]>:0RY)XFLHWDC\FZ:19 BHD))
MD'.64=U&&R?]D^V:\?BF%XOM#VUX@RZ):_9\RR%7*[EP>F 3] :IVOA:YTVZ
MDN["+2X;GSRZRB(AI5?.[S".206X]<<]>)GT'4TE6Y@GM//MWD-OO#;65V).
M['?#-T]!0-6-.TU^ROM2DL8/-+(N1*8R(W.%8A6[D!E/XUJ9XK"L_#QM98 T
MB201%P59?O*T:I@_]\G\ZFM/"V@6%TEU::-8P3QG*21P*K+QC@@4W811LO%\
M5S<P":SN[:*>(,/-AP8CO9<N0< ': /K5[_A(K7^SC>""[)$GE" 0GS2V,C"
M^FWYOI5)?#ES)836EQ/%M<+$IC!SY:RLV3GN5;'IFF6?AVYT[1X8;&'2[6\@
MG,J+#$4B?Y2F6 YW%3GZX'2DQ]20^*TATRWGDL;N>62WAF @BR)-Y4$)D\D;
M@2/2M!-<MC:WD\D5Q#]E;:\<D>';T*CN&[>M8"^$+V.[CN%ELFFALTB29HVW
MNZA/E)[1YCS@?WCZ<V-/\+W5K9:FC-9QSW4D<J-"APSH<AY,\DL0,T]!%X^*
MK!8Y9)(;N,11>8P> @YR 4 [N,C(]Z8GBNW=I0-/U#$<2N/W/+.6*^6!G[X*
MG(]C52#PO/\ ;[J\GBTS[5=!7>YCB/FA\KN0,?X,+QW/M2:EX6N+T7"$6-Q%
M))YXBN4)4N)&958?W=KG/<$"D!H7'B2V_L^ZN[82.EM)$C-Y1(?>5X7U.&'X
MD4T^*]/&-T=T/W>YLPGY7_YY'TD.#\OM2G1)XM$GL[22WAE,J2Q;8\1IM*';
MM[#Y<?C6:WA?4G+$W-J#),+]\!N+I3D ?],^GOQ[T]!:E^;Q=80F)3;WSO(@
M;8EN258E@(V]'+*PQZBMJVN([NUBN(3F.5 ZG'8C-8UKHERC++--$96ECFE"
M [=P9V8+GM\^!]*U=.MFLM.M[9F#-$@4D=#2&6:*** *NHV,6I63VLK.JL58
M,APRE6# C\0*YC[?I.L:_H>H6"*NJ---#-\NV5(HU82QR>P<IP>Y!'6NQKE-
M9\#P7VJ/J^DZC<Z+JLJ^7-=6BJ?-3.2&5@03P.>O H S+HO=^.=1T%8RWVN:
MUO+@D?*MLB=S_M.@7'IFN^K*T3P_9Z%'*8&FGNIR&N+NX??+,1TW-Z#L!@#L
M*U: "LN;7K*&X:V9I/."N=H3/W653^KK6I6!<>'7GUPZA]I 3SHY!'MZ!5(8
M9]VVG_@- %-O%;PVP'E2W,QE4!HH?E"DJ!NY^4ME@/<4[2_$@6QB?4([B2]E
MB,K*ML(R@PN$/S$9)=0.>2W;FFIX7OX"J07EN(I6C:XW1DL?+(*A>>,\YS[8
MJ:X\+-<6<T$DD$H>)%"2Q[D++Y9&X=U)CY'H:8G>YI:;K<&J3O';P7 5$!>1
MT 56[QDY^\,C(Z>]4+CQ3;V;W$!@N[J:%9'S'" N07*IDG[QV,!].<9%,LM%
MO]/U&UF@33X( BQRQ6D)C4@\ME<XP"/E/7DU++X=EE%R/M*@33>9]T\#Y^/_
M !\?E28Q\OBJT@&)+2]$FU,1B,%F=L?NQ@_?&Y<]N>O6HKCQ1&]I+/:6]VWE
M('R800[%<^5UX;IGTJ&V\+RQZJU_+'IHGD:*:6>.#]Z7&W<H<\[/EX'7GVIJ
M^%[SSVS<6RQ!2 41@TA)/W^<'&< ]:&'0FM_$BIHMG<WDDR3;&>X!ML-\N=P
M*ACM/'')Z5-_PEED%@+VUZC2.(W5H>8"6"KYG/ )(QUZU0CT674&U()*T:&5
M(T,D3+RL95B >H+'.>AQ4>K:?>6^K@6TN?[1N8S(/L[O\B,K?>'RJ<!LEL<'
MCFJTN'0T[KQ+%!K'V01R^5$DC2R>7\KE0ORH<\L"P&/?ZU')XQLD946SOY)"
MHRD<()5SG$9YQO\ E;V^7KTS#?\ A>YO[FYC>XMC82"1TB>(L3(^TG=V*@KT
M[ACZ58L/#SV@@(%G!L>.1H;6+9&I"N"%'IE_TI:#8Z3Q/96RL$L[Q^4\E(80
M3.'!8%!GIP<YQ3V\0Q2ZM96=LDKI,<M-Y?R']TSA0?[V-IZ=#6;H_A*?3=3^
MU/+:$!57?'$1)+@-R[=R-V!Z "K=CH%]97UD?M<!LX-LCKL.]Y!#Y1P<X"]#
MZ]:-!(K:?XP1=.\_4K>\20AI"/LP&S+'9'PQRQ7D>HYXZ5:N-<GAU\Q2I/!9
M16PE?=;A@[%7;&X-D$!#QCUYJ!O#%V2D/VJ'[,&CF8;#N,J<#'.-N/QR*TM0
MTB2]N))5F50Z;<$9_@D7_P!J#\J3\@7F%CXAM+YI ([B )%YN9DV@J/O8Y/*
MY&?J*2+Q%:O:^?)!<VXPC%)8P& 8L%/!/7:35?3?#PT_4;^X6&P_TA3MF%O^
M^8MRP=NZY' _PK-;PWJD5H,7%JJ'YYX8D<@!"Q1(LG@?,>O3M0P-&/QA82+"
M1;WH,I)*F'F./Y?WC<\)AU.>O/3@TY_%NGQQ+,\5TL3;CO,> ,$@9Y_B((7U
MQVK)AT/67DM_-N8/,N+9H;EO*8*(OW:C'I)@$\\<GTJW-X4+75O<+!IEQ)';
M^26N[;S&7:6*[#V!W$'VZ4"1>;Q#$QPT-W:",1M,\T(VIG!\LX/#8(/<8/>F
M0>*+%IK>V%G>0O*<,C0X\C+8!?GC)(QU^\/?&>GA.]E"QW-S;K$8@KF$/N8[
ML[3N/*J.%)YJ[#H5ZYFGO+F W4YB,GE(0@V.",9.>54?B33 MR>(;6+49[-H
M;D>3&SF;8/+8J 2@.<[L,#C%5QXIA-RB?V??+;LLK_:6C4)B/'/WLX.<#CK5
M'5M)N9?$=M*"BI-,A AB?+JN"YE/W1P, \$YQSBEE\+WER+J.:6R6"Y,J/$D
M;% C $,%)QN+*-PZ$9[TAEE_&-DC*@LM0>4J,QI""R.<XC/.-QVM[<=>1F[:
MZW9W\3W$<,WD)(B).\8"N6.W*\YP"<'.*J:;X?>SCA^6RM]KI(T-G#Y<2D!\
MA1[[NM06OAJ\CT_4K5[FWC^T0B.$PHP 8 XD8$XW9(SCK@4"U+G_  E6GM!!
M-$MQ*LP##9'DJN6!8^@7:2?J/6JTOBN%5FGC@N'AV8B18LN[!G#,!GE0$)_
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M@GE<@'W/>HM4T234)Y)%F1 P08*Y^Z)!_P"U!^55H_"\:7FKOY=DB7Z.!/'
M!<9?E@S]P#T'^%,0R/Q?$$G>6SO RR,!"8@KQ@(I&\$]V; QGJ/>K"^*[7RD
M:6TO(Y'A601F,9WL 1%P?OD$''3GK6?_ ,(I=W6I)J&I?V9<7+L1(3;;O*7
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>forms-4_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_023.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "8 NX# 2(  A$! Q$!_\0
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M=W6CZQI6KZ;<A+S3-;\/Z]8W^CZSI=Y\]K?6\D;,XVN_R;_P4'_X*??L^?\
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M%6J:=X]MK"SU*YUG1+#3-1N=0LX]-N;J-M+FAU*..W9VCN=Z2%T7G-7X*_\
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MQS+!\'_"47BF-M.UHSM;PQ6%I++K,\T,5N\]Y);V4EK;(T?G2*&./8?V0O\
M@KY^R7^VC\-OC1XT^%FH^,M'\6_L]>"]9\=?%?X/^//#[>&?B7H.@Z-IFHZA
M+?VVE3RFVU*QDN-+N])-W#*@M-:5;'4XK226V$[C)./-&2<7&<N9-./)3?+4
MES)VY823C.5[0::DT[HMMQ=M4W*$+6UYJB4H1MO>::<%:\DTXIIW/U5+QD??
M7MCD'E@=O'?.#CZ'N*>.@YSQC-?!O[!7[=_PT_X*!_LR6G[4GPH\+^-_#/A&
M]UKQ;H2^&_&EE:6GBB/4O")B:^)MM.N;JUD.H136[VZ!RZSO)$ZB576OR/\
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M'U;6=(2>[M[^+3-+.K::MGJ<VFV+3M$CMR^[:UM+=K>NOWCZ7Z=^GWGVD9$
MW9+ X^[DC) ([X&58-VR.:1)8W"D,!N) !ZYS@C'KGCZ^]<+X\O[BQ\%^-+^
MPN_LVI6?A#Q/J=@Z.AG@N+31;J6VN527@?9Y1:S'S8W2.65%D"JR*?QJU/\
MX*)_%+X)_LK_ +,_BR_T;PM\4O'OB?\ 9VN_C'XTU+QMKOB.#Q5XMM?#,.H7
MFMZ7X8\*?#KP=XCU/_A(KVRTZXG'B/Q#:Z#X&TZ588)-3>;[2L<0?.Y1T:YG
M%;-73M;S]-[HEMKITOUV[[;>>UM3]S3.N< 9Y '(YW'"X_WCP/?CK4H=> 2
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MV064@C)"E5)'(S@LHX[D>M?C_P#M4?\ !17QY^RAK.D>'_$O@'X?^*+GPAX
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MO51YU4C%]YPE":_\#CSORFGU)****LH*HR,JN0S*I!D?YF4?*58Y&3R.#GN
M"3@<U>KYZ_:?T#X\^)?@5\3]&_9A\;^$OAS\?[WP^3\+/&/CW1CX@\&Z/XFM
M-1TZ\1O$.D+',;S3+_3[2[TN<B%YK4WXN898'A603-.2Y>\J=WV2JTI/OT4N
MG3R9$TW%V5])Z+SI58K\9)=W?34_G)_8LRO_  <&?\%@]P8!O@G9*AVM\Q_L
M7X6L-N!SN12R$9#X(0L58#\A?^"=W[:WQB^#O[*/[<?[)?P;_P""?G[0_P"U
MYXM_:&^+7QOL-*\:_#_P7J_B+X1^%;_QEH=QX,DTOQU<67AR^DBU'0[!;C7#
MI4][:0WL;Z;9-?:49Y-1B_HS_P""8G_!-O\ :J^"/QX_:U_;._;>^(GPW\2_
MM)?M4^'8?"6HZ%\+(+M?"/AC2XC:M->B>>"!8_M)T70K:PTNV-]Y%K9R7-[?
MSZC=R._T)_P2'_X)Z?$7_@G-\)?CC\/?B+\0O!GQ#U#XJ?'_ ,7?%[2[GP5;
M:W9:=HNC:_:V<%GINI#7+2RN)M6C%B)-0FM[<PD,IC9TC#&4[PI4N63C'))T
M&[-)8CZ]7JQA=IISC3DI*-FI)ZO:Y-/V]9[QGF?M4UJG26 PU-37]USC*',M
MFFK7,_\ X(=?L6_%;]A;_@GQ\//@Y\<H8-*^+.N^,?'_ ,6?&'@^WU2PU^'X
M>W7Q!UE9=(\%?VOI5U?:3J6HZ3X>T[3O[>NM(U"]TI/$E[K$5E?:S:1QZM=_
MF)K-I8?%#_@Z3TK2_BE':ZEIWPF_9IM]6^#NF:O&LFG6>N6WAV6\COM-MIHY
M(GU..YU'4KP78=&BN(PD< FBCN4_JV4;N0 =N\$@L5+GCYF8;VV8!&005VD9
M!45^&G_!3C_@E-\4/VE_C?\ ![]MK]C?XU:5\!OVS?@C9II.E:[KUE=7?A;Q
MWH5@US<:?I6LR6D=S]FNK);V_P!)9;S3-1TK5=*U.YLKY+0B.=-?:\^)I59K
MFC%55.R6_P!4=.#MKIS)12=VY)A3IVI*FI<CE3A'F;MRN-2JVF^[4D_*Z/V1
M\?:1H]]X9U[6+W3["XU/2?"'C--+U>ZM+674=*BU+0KF#4(=/OGAEN;".[@C
MC6[6WN(6NHX 9DGCC++_  T_\$//%'_!971?V5;_ $_]@7X3?LC^.OV?&^/G
MB";QAK/QP\0SZ/X]M/&=QI_@J'QG8V=C:^(=->;3+/P['I5QI%]<6Q6_NI)?
M(+C[0%_H<_9*^"W_  6?U[XM6WC;]OK]I?\ 9]M_A#HOP]^)'A2/X(_ ?P6U
MDOCOQ7XOTFVT_P .^+/&GB&\M[^=+#PD@U"]L-/TK5=.\Z^ND#V+Q82OSC_9
M>_X(\?\ !:W]BCX8:C\'_P!F+_@HY^S5\,_ 5_XFU;Q==:*_PFN/%;3^*M7M
M-/L+G5Y-1\8_#O7]3A,]EH^GI)I\5U]FBEB:2)MA%9T8J&)C5E*"C_9]"$5.
M]H26+E4E2DNDXP4IRC>RC=KJ75FOJ"HQA*56.+G)\JUE%X+D51/JI3]R]V^9
M6M>U_4?^"J/P_P! ^+W_  5Z_P""3/PG^*6E6NI^%_BI\*?C]\/_ !_HZ2(+
M2:P\5^!_%VG:S%8S7$4Z0W-I=R1WNAW>^2:"[T^UGMT=HPU?B7\>_BC\0_@7
M_P $TOV\O^".O[0FIR7?Q-_8:_:'^!&O_ [5+V">&;XB?LR>)?C;X7U32YM$
M%TB-<Z;X<37=(\6:6IGDEM/"GCNQ\/BWM8?"UXEO_5'\3_\ @GK\>OBY^V+_
M ,$U?VM/&'QB^'^L:I^QUX'\2:/\9U71=7TS5?BCXM\0^&]2TZ^USP7::?8Q
M:+I=A=:K?R7D]KJ5OIAA@5OLVT!86^;?^"R?_!#_ %3_ (*0?$SX7?'+X+_$
M;P'\(OBOX<T!OAU\3+CQMI.L2Z)\0O UCJ<.M^$[F1O#=I/>2>*_!]]=ZOIE
ML=4CN;#5- UC^SKMX/[(TMX7348U<-'G4*6)S",<3-I\E&-.I*K0Q$W9\L*,
MGS*5F[5%9-NQ$9SA*I/E<IPP]#V36_-4A[*K".JNX*[FM+)KU/JS_@H[&O\
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MDZ=2*5^]Y*WKL<I\"PJ?\$??AG,,13G_ ()ZZ([&Y*)(8V^!-NV^5HPV1L;
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M9-O:Z3UDW;X=8ONU%UDD_P#KY2A%;N\DEO8]_P#AY^Q#\)_!>@?$70/&NO\
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MU$+'E8BG6_MY6'Q!\4Z/\'/!'P\US6K^?6/B'JNI>,O@IX%^,MS\ _BM\>?
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MOBS4K6R,C65MJ'B'P_8:M>V]F96:7[+!<W<L$ E9Y?*C3>[L=Q]+# YQV_\
MKU3YDU?WFV^9]GOT\]/S)NKVZBT444P"BBB@ IK@E2 <'C'YBG5!/*8T<@$D
M*#V[MC'/MGGM[=:3=DVK:+JTE\VVDEW;:7=H%NMOGM\_(\-_:-\62^ _@/\
M&3Q=;W/V6[T'X;^+;RSN_P#GUNSH]]!9W '7=!=3Q2(N1EU'(&37BG_!/'P9
M;>$/V0O@G;V\0CN-?\.W'C+5)""KW.H^*M1O-6EEE7G+QPM:6J,22UO;H<@L
M0+_[<OB[P?I?[,WQAT#Q+XGT/P[J?BSP!XATGPW::K?P6USK6K26@FL['3[9
MG\ZYFO9H_L\#QH8DG=4FDB)7'D?[&G[7?P"/P7^#7PYU?XF^&-%\?:'X&\/^
M']7\.:K=KI,]MJNFVLMI/9B2_6VM7E5HPP6*5R[9C0&3"'\KQN>9+0\6,)A\
MQSC*L-4H<&5Z&#P^*S++Z%7#X_&9[[.O%4ZV+IU(5L9@\#1BH.,)RIJ/,DI0
M4_V7*N'.(,=X&8[&9/D>=XZEBO$_!5<RG@,IS/%\V495P;CWEU>HL-@:KJ83
M"9EB,SI5J\8UJ-'&TU&I4IU$D_TQ  Z=_P# #^0%5K@@^6ISG?N_*.3'/U'2
MH+?4H+J-)H/WL4H#0RQO'+'-&0&66-XGD5HV!&Q\[6R-I/9)IED8!200N\9Q
MRNUP>A)4_/T.#P3@XK].G.%2A4G3DJD)47.,X/GA*$XODG&<>:$H26L9QE*$
MHM24G%J3_&9Q:;@U[T*D8S2UY)1J4W*,^6_(X_:4N5IWBTI)Q7YN>#(F3_@I
MS\67.,2? 'PJR@$DX%]$G.0,<H>A/KGM7Z*:EIUOJMK-8WEM:WME<PR07EI=
MVZ74%U:SJ4GMY+>0&*6.6/=&Z2 H58EE900?ST\)C'_!37XGG^]^SQX4?VYU
M1NO.<\=!QCO7Z.(K-+@8PH^;+$9!) & #NY4]2N >#G-?G7A_353#<7TY).$
MO$;CN,HNW)4B\XPG-2J7A44J55.5*K%PDITIU(.+4F?J'BI.2S#@"<95(27A
M/X<SA.A.=.I&V28Q1J0J4IPJ4VIQBU4A.,X-<\6G%-?$EQ_P3N_9*O\ 7G\1
M7/PCT^.[N;G[;<Z7:ZEJEKX?EN?,$[2/HEO<IIJJ\V7%ND4<*%W$:H&=6^P_
M#/AG1O"FD6N@^'=(TO1-&TV-(=/TK2K*.PL;1% 4K%;0@1@\<L?G8@ER6R:W
MUA8#DCC)"YWX)Y^\5#8'84X9C)!Y!.1VQZCIZCU.>O&:^NRSAC(,FJUJV39%
MD^3U<6D\6\JP.&P<:L^9S:DJ&%I.=-2DY+WJ:YM73>Q\=F_%7%/$='"8?B#B
M+/\ .:&6ITLOP^:YSF694<+24%",:4,7CL5!N,$DJDX^TZ<U]7(H(&"23GJ3
MG/3\AG( ]O?%.J/S/;]?_K4]3N&<8YQ7NI-65G9+?2WY[OT/"LUJ+1113$%>
M!?M-?%AO@3^SW\;_ (R0V:7]Y\,_AMXP\8:;93%OLUYK>BZ/<WFAVMX4#-#9
MW.J?8HKR4!DCLC)/-M6,K7OM>>?$OPKX7^(?@/QY\/O'%K;W7@OQQX/\2^#_
M !=:W5REK!<>%_$.D7.C^(#)<RXBMEBTJ[OGEE9@(T$4K2QN@")M+<3:32ZM
MV7F]S\F/V]/VOKW]DB7]F_X8WGQRN]$\<>%?"\GQL^)6J3>&?%?B6Z^,N@?#
MM])T+5? .H_\(OX8\2)X=@^(^MZQ?ZA!/JS:3;6^GZ!>0V5T5LY/*POCQXO^
M,_QI_:V_X1[X1W'[8'B7X1S? OX(>,=/F_9?^-WPC^$N@>#Q\1_$/B0W?BCQ
MG:_$3Q!I&H>)Y9-%MK'4U@\+IK$\.FZ=<VHM'N+F-7^RO@A\7_V2-8L_B+XC
M\-_'?X7_ !8\=>%_AQX2\-?M!_$:QU=#J&N>&?AK8:EI^G^(/$NDRZI?Z=IV
M@QC7=8GU.XT&/^Q;W4M=OI6N@?L\4?O?PH^#7P<^'MO8^)/A7X3TS1DU7P/X
M1\)V&K:7?:Y?'4?A_H,^IZUX/TJ&74]6U)Y=(L)/$&J3Z>IWR)::D]J9!:",
MPCBW9IV2W[_+^OO%SQYG&_O+=:Z:2?;M"7W6W:3_ #]\9^-_C'9?'?XC?%?3
MOC)\1].\/_!7]LW]FS]DK1?@4J::WP_\9^ ?BCX+_9XU'QGXA\3:;)IDM]K'
MQ$UG6?CIK?B;1/$PO(9]+T3P_P"%TLX8;._OIKS*^$?BOX\:MX[^'GBZX_:"
M\;J/VM+;]K'1)_"GB6S\.ZQX(^"%_P#!_7]6TSP#XB^'/A]K*&UL)O#VFZ<3
MXAM]0U&ZL?$-XQO=35F"K7WIK/[*'[/?B/X\:1^TOKGPGTB_^-VAPV4%EXQ:
MY\116\EWH=G?Z9X>U_6/!UKJT?@?7O&7AO2]1O-)\)>//$/AK5?&7A?1;C^R
M/#VNPZ7%&6X31?V,?V.M<U;XU^,_#WPO\-:G>_'C2O&7@7XLW^C>*O&=UINJ
MZ?KD[Z;\1/#^@6%GXI&C?#N7Q+?1NGCQ?AQIWA>[\1ZTDU_XD>\U+=< C)2;
M26JWZ7^^VUNG?N[#O?\ #\4I+>W22?E>SLTTOGKX5Z)\6?$?@+X]>%-!_:;^
M,>I_";7/$/P_T;X*?'/Q5J?A=OC!\1?$<$6H7'QJT7X)^*?%%AHN@VGACQP]
MIIW@_P"%'BH6MW::=J4_BKQ)X*NKS1+31-6/RA=?'?\ :Q\7?";X,? [1I_C
M2_Q@U#XA_M,>'OB)9VWQ$^'7P\^-?@&V^"MM#XM\$> /B%\9?[#\;^!_$FNZ
M;X-\3^"]8U[Q-X)T34+7XEI)9:>UW#:W7B#6$_2;PI_P3X_9+\&?#;QY\(-'
M^&WB.[^&WQ!3PJFN>&_&'QI^/'Q M=.E\"RO<>#-5\!:GX^^)?B/5OA;KWA3
M518WWAG6_A;?^#/$'AO7M-TC7]/U2+4M'TJ>RZ;6_P!B+]EKQ%\)_#7P+U;X
M/6#?#WPGK4_B7PM96GB'QWI7BJP\17C7<VL^))OB5I?BC3_B7?\ B7Q;'>W\
M?COQ!J7BRXU?QK!J.HZ?XRN?$%K?W2W0VDFG%R=TEHM&Z==+=I[RCJO+6ZT3
M5]GT^=M7^46]GHMM5?\ +CXB_M7?'#Q7JGA3Q=X.\8?&2S^%/P)^"/P(^,WQ
M*^)7AC4_ '@A)T\;:_J=IXQ\0>/OAGJOAS6X?C#<1V&@WUAJ'PXT?6/!VDVU
MA'?^(/#FNW6OOINGK^L?@GQUK=O^U%\;/@YJNK3ZMHD?PR^#?QU\#SS+&W_"
M/6'CZ_\ B/\ #;Q3X,5V;='HL&M_".Q\::.UR9Y?[0\9Z]8Q7"VFG6-JO,:A
M^SE^R!\=M6\$>+)?ASX&\87?P!U.;X?^%I/#UWJVE:1X<O/ 6IQRCX=>(-"\
M.ZEI.A>+=%\&^(X8M4TWP=XYTWQ-X=\/^)$3Q#INFV>LH+E.Q^&EAX NOCG^
MTGXETGXCZ-XV^*#:O\+O 7C[0M,OK>:]^#OAKPYX(D\2_#[X;ZOIGVJ^EM9+
M\?$+Q7\4#>WD=C_;4_Q"N(8[6*WTNRDFF37+*+TDIRNG>]GR-:_)Z]+,:36^
M]W^G^:^]'R1\0OCK\2=8TSQ%XQ\+>+=6T2R@_;M^&'[/.C:)I42A8/!OA_5-
M.L?%MO<HT4PEF\8W^JWK:E(VTKI]EIL,,L3B02?3/Q8\:>+]&_:W_9'\$:/K
M6HZ=X2\;^&OVFK[QEHEJJFQUZ?PAX<^'=QX6N=1C"--)_8UWK%[+9,KQQ++>
M20R!I)H4I/&W[(/PD^)6F?%GP1\2M*O/%/PQ^+7CC0?BA=^#;34_%?@N_P!
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M_P#V;]&^+OC/X'^%-2^%GBOXJZ]XC^&E[I6@_$3QMJ/A_P 2:)X;TWPGX?\
M$&I6U]/I.E:.NJ/KVO)I=A)?7T+6UO<7B:;YAD^5_P!K7]I36/@7^S9\*?AE
M_P -B:*OQ7^(WQ1\4_#N']IW2?!M[XAN- L?@K'KGC+Q&WBCPS\-M%\:JFMS
M:KX<\'_!3Q[?P:!-:Q7GCZ]O38:?J<]K;#[;\0?L)?LR^*_A)X0^"?B?X>ZO
MXA\#_#_4K_5_ ]UJWQ5^,ES\1O"6IZM<7,^KWV@?&B?Q_<?&;3+G4UN[BTOV
MM?'Z"]TJ4Z-< Z4/LA]4^'W[/7P@^%%UX3NOAO\ #CPOX,;P)\/KOX7^#X=
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M#T?"S2?'FLWVJ:E=3ZKK$_@H+8:PUVTD>KW<4&H7J/<Q*Q^R""3G_9P/7/\
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M(MN_C>;Q&WPL\/7^GO8^&-+T#P9HN@HUQX5\/R6GDOP.\,?!CQAK/[)'@O\
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MKQ9X<^%=Z=(\7#PW9F!5N9[+Q UMX=DDGEM[6VU2\B^VW%M9I-=1:=E^V?\
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MROI?M?3OH*23BTTY)III-1;35FE)Z)M:)O1.SZ'F'Q$^&?@GXI^%[_P;X_\
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M7Q_X?<2SH9]3E@9<V"EFF%XBP^,I9['+7"DL.\?CJF,^J*>!AF52A+D?XB_
MCXNZW^SQ^T/\2_$$TNM_M)>$O"OAFP^&%SXY\/7=H^K)X1LI[:[T"YM(+N<3
M:RNE0 Z=<^0]P8Q&2US+(H=OTLT7_@I3^RA>623WGB_6_#TB9C;3]:\,:E%<
M6S8VF!VMTN8]P<.I8N-S*2P YK3OO^";G[)<MQY]C\/]4T-G+EVT/Q=XEM S
MMR\I4:BRDC"@+@(  H7YG6NE\-_\$]OV2?#=TFH1_"NTUJZAVN6\3ZKJNNQ^
M:"<RM;7]W);R.Y 9M\>WA2B@DY\WAC@[QPX1PKRO)<TX">6U\SS3,*N'SO\
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M5H\W@_7+;Q#X,\0:;'J^@ZE<3:+9RR?MPL"A@Q9F(&.<#DXW-\H RV!G
M"@  4AMT..2#M"DC )' ;)QDAL D'(# .N&Y,M2M-)*T^;KWIRBO3WFK_?L"
M25[+<_*SPG^P[\:;/P)\&_#?C/XV6_BG5?"7BOXUOXVFUV_\9^*EL_AE\=?
M-YX$U/P?X&\8^)9KGQAK&I^"XIO[1\-ZW\17U"]O)KJ>WU:ZF6""0>%^%?\
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M\)9J?BG1-;_:BUQ_$>HP_&7XOV&J1Z?HVA:['H?AFS\.>#)8+$2O96-O&O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>forms-4_024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-4_024.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $. KP# 2(  A$! Q$!_\0
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M[\)?#GAOQA\!_C%XS\2PZ-^SW^T9\6/@'I^JZ[XIT+]IGP1I.JZMXC7X:?\
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M **** "BBB@ J-NA_P"!?^ABI*C;H?\ @7_H8J*GP_/]&/I+T?Y,^)/V!_\
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MT ?HXLBL,@@C"D$'((89!!'!!'(()!&".M/R/KQG'?!Z5^,\?_!3GX*_LS?
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M_:2_X**^%?VV?VA/!/ASX4? +XT_ [PI\)+U_ R^%+7P?X7^)GPQT'Q3=?\
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M52_^7G_7I_G4*CU^7ZGQ!\!/^3R_V]?^O[]F'_U35S7W)7PW\!/^3R_V]?\
MK^_9A_\ 5-7-?<E=6*_C0_[ \M_]5V&,H;/_ !2_]*84445SEA1110 4444
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MVLO@SIWQN_8<_P""S6CZEX]L/@_X$^%GP_\ B/X1^,/[27C/X?\ Q&\1^$/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&7_YN:^W**\SVZ_Z \M_\-]'_P"6GH\K_GG_ .!,^(_[*_X*)?\ 0Z?L=_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUE_T%/V>?_!3\1?_ )/H\K]K+_H*?L\_^"GXB_\ R?3_ +.7_0RR+_PY5O\
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MV<O^AED7_ARK?_.P/KD_^A?FG_A)+_YJ/H[SE_SG_"CSE_SG_"OG'ROVLO\
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M ,%/Q%_^3Z/[.7_0RR+_ ,.5;_YV!]<G_P!"_-/_  DE_P#-1]'><O\ G/\
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M:CZ.\Y?\Y_PH\Y?\Y_PKYQ\K]K+_ *"G[//_ (*?B+_\GT>5^UE_T%/V>?\
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MZ#_"CRD]/T'^%24467G_ .!2_P#D@LNQ'Y2>GZ#_  H\I/3]!_A4E%%EY_\
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M8K:*3XD>$_$\'AGX>_#OQW9Q_#N*+P#::;:^/;O4D@$ECI<'FV7G_P"!2_\
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M;"UTK][)M+R9Q9?I#%):)9CF"26B25:BDDELDF[>K"BBBO,.\**** "BBB@
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M]QJ.MZ_JFI:OJ%PS2WE[.^&KTZD!4="H^F!1D>H_,4 +129'J/S%&1ZC\Q0
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M_B&'[)X@\!ZWKUSXC-W=26 MX=+MK:XMKJ#7#(=+U&RO;"ZLYI8)DD?]-00
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MO+_HV7]G#_Q*SQM_]#)1_P + _;R_P"C9?V</_$K/&W_ -#)7V=L/O\ D/\
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MP<L"#\W!!5@0>05(."#2!XR,APPS@E<,H.YE(+!BHPRLK<_*PPV"1D^L0_Z
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M_P#H9*/^%@?MY?\ 1LO[.'_B5GC;_P"ADK[-*XQG/)QT'4_\"I" .YZ$Y R
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MO_@2_P#D#XZ_X6!^WE_T;+^SA_XE9XV_^ADH_P"%@?MY?]&R_LX?^)6>-O\
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M_P!#)7V(&4.5* ,1D GELD@X&<G&!R.!@=BM3_*, GG!XXSA<9.-V<#*Y)
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MUI+V!S^\NC:3;Z)H^E:+9_\ 'KH^EV.E69( (@L+2*SA)50%!\J&/A0%'(
MQ0!JTC=#]#_*EI&Z'Z'^5-;KU7YH:W7JOS1%)S^!S^ "D_H*^*OV:?\ DY;_
M (*(?]E]^#/_ *QM^SG7VL_\7T?_ - %?%7[-7_)R_\ P41_[+]\&O\ UC;]
MG.JPOP8O_L&C_P"K!$3WI_XO_;9GVU1114%!1110 5&W0_\  O\ T,5)4;=#
M_P "_P#0Q45/A^?Z,?27H_R9\2?L#_\ )$?'7_9Z?_!2C_UXS^U77V_7Q!^P
M/_R1'QU_V>G_ ,%*/_7C/[5=?;];UO\ >,5_V%5?_2,,9T_@7^*04445F61R
M_<(R5). 00&!/ VD@@$],\8!)SQ@_A!_P6/^/7[5_AGP_#'^Q9J5R->_8DM?
MA_\ M]_M/:7I=I)J%W\1?A%X,\=MIVD?LS11V<\=S:7_ ,5?"ND_%SXFWDD(
ME?\ LWX):9X=U9;+2OB-;7S?NAK,U_;Z7J$^E646IZI#8WDVFZ9->+IT6I7\
M5O)):6$FH/#=1V,=W.L<$EX]K=+;(YG-M.(S$_XY? ']@R/XU6/Q]^*__!1C
M]C?X)7W[17Q1^)/BW51-I7Q;O/C#I&O?#6728])^'?@2+Q#)X.\ 2^'='\&^
M$[2R\$G3;[2-1AN;B+4/$ NMFKG3;4 \X_X++^*? '[0?_!%GXV?M:?"KQCX
MTL9M!_9UMOVB?V??B1\+OB;X]^&^N:%?ZW9:%J.DZS'J?@#Q%H9U6,Z5?26&
MI:-KD>HZ;)%+>VLMM!,[SQ_G!_P4J^+O[$=Q_P $U_@+\+_V=?V@?B)I_P 5
M?"WQ3_9>\-^%=1\'?&_]IG2/B8]O\7_BAX$T+XN)JGQ#N_$%CK?BN3Q/H.LZ
MV+V;Q7K5^MMYS7&E"QN(K.).LTO]A#_@K)H__!*[]IG_ ()96W[.7[/-WX-^
M(LWQ(\(?LZ?$+4?VP[ZZ7X._!;QUX[_X2/P_X$\::./@7%?^([SX?Z2]WI^@
MZAH-Q#:ZN9[*PN]/TJTLI9KC[T_X* _ /_@H!^UG_P $\/@]\!O W[._P>T#
MXZIXU^!_BWXBZ-XE_:8W> _!1^ 7C7PIXVLHM)\4V'PGN+[QNGCJY\++8VR-
MX?\ #Y\/K>+?WK7LMFMM< 'S]_P5Y_8=^$G[.7[ /[7'[0WP[\3?'73OB?I=
MI\&H/A7KT7[2W[1\7_"I/"6CWWPI^'5KX-\)6-Q\7+O2WM]3-MXG\0>(-8NM
M//B#Q+K_ (ZUNXUF\N7BT^XM_P!@OV8/V-_A9^SMKVH?$?X27WQ T33_ (E_
M"GP/HOB_P+XB^*?Q6^)'AIM?\/W-YK&G^-/#MC\2O'/C&W\+Z[>6OB'5-)\2
M/I%M"WB&VL_#LEU,DVD227OR[_P5"^"_[8G[9?\ P3HUWX!?"GX&_#73?C?\
M:K;P?8^/- \7_'M=.\%?"5?#?BG1/%UY-;^-M.^&E]=_$=;AM$_L>T33O#7A
M<LU_]NGDM/L3V<OZ7_!.Y^(%W\*OA\_Q3\$Z3\-_B!'X6TBV\5>"-#\9I\0]
M'\/:O9645K/9Z7XRCT3PT-=LE,(:._;0M-:9'4/:1ON) /YO_P!H%/V@/^"<
M7[>_[0G[9'[-%W\4_BK^R!\/?"GPBU/]N?\ 9!N_'7Q"^)U]:> OB8_BK5O$
MW[3'[/.D^./%/B0^%?$_PDO-*CUSQ+\.O"/]D:%K/@I]72TL["VM_MFC_6P^
M O[*?[6/[5_Q<^-'ASQ#\0?'WPU^,O["7@+XQ>#];\!_M*?'SPWX$U^?Q]XB
M\<Z<WQ!\(Z!X0^)>E>'/#_B*]T3P[H-D-8T72-.OM*FTZ.-+>UU..^:7[(^%
M/A?]J"V_;C_:.\9>/_@'\/-"_9U^*'@KP-X5\,?$.T^.5OXM\9:E<_#>+6[*
M'^WOA*WPVTJST[2/&5GXAG_<P^--8O=*.F21W<5TNHQI8?*/P,_X)Q?$S]@#
MXE_MK>,OV4+'0_BC\$/C'\.-$3]F_P#97\9?$2Z^'ND?!'QUK?BKQOXD^*7@
M;PWXON/#?BVU\*?!;5==\41^,_#^FV&FZA<>';^^UW1--T9K)-/N' /YX/V9
M_BP/%'[%_P#P3?TW]A;XT?M ^-_^"R7BCXF>&_$WQ T?3OC%\<?'.CZU\$-
M^.GBOP_\6_$?[4'AKXA>+-1^%U]\'K'P/)8:==ZX-.75O[;AT2VT:_CD%U&?
MZ'OCA\6/&G[8'_!5:/\ X)K:3\0?&?PL_9[_ &>OV8],_:D_:9?X9>)]7\$?
M$'XZ^*?'?BRS\(_#+X(OXX\.W>E>*O"/PJT[2+V[\9^.+GP7J.GZ_P",+H:9
MX4O=3TK2DD_M'XL^#'_!+3]N3PQ^P/\ LJ^';'0?A#\ ?^"CW_!-KQ!K-_\
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M'@K0X/A'XD\>7FA:L/"EJ?B#XA@MK+[*WB"ZT>[U*QM&^.O'W[!/[0/[,/\
MP4K^"_[6'_!-W]F7X(:;\'!\"?$OP3_:R\+ZQ\=]1^&%Q\8M'U[Q%9>(/!-W
MH7AQO 7CBRT[Q=\'-1TM-8L/$^M74K>)=(UFX\%Q6NBV<;:PO3_#K]D']K(_
MMF^!OVPYOV</@/\ LS?$/P-I'QL;X^ZO\!/V@-9U+PI^WOI^O^#=7T;X3^#/
M&_P\N/AKX<T?PMK6G>)U\*^,KWXH^+1XB\1>$;[2[[2='G\0Z3J9-H ;_P"S
M/^VKHNF?LC? O7/V5/V)KKPMX@_:!_:H_:$^%/AGX.W/Q FT_P"'7P\\7^%O
MB3\5[_XI_%/XS?%[1?"WCX>#/"^K:AX,\1:])/HGA3Q?(VMZ_IV@:+::C;R"
M=/N[]@S]L&P_;?\ @++\7[?P2/AUKWAWXI?%SX*>/O!]MXJTSQ]HNB_$+X)^
M/=6^'WBQ?"7CS1['2M,\<>#-0U/19-4\+^)HM,TMM6T:_M+F73;"X$UE#^+W
MPE_82_X*8^&?V;/V5OA+XJ^&7P+;PU\*_P!LSXY_%G]HS]G&S_:;\0P>"?VB
M/@]\:O$_C3XA>#UO/B+IWP<^W07/P2\>^,(-1O?A[JOA>YT3XC-X;L+Y]3L5
MF71[+]-O^"6?[,?QV_9+^%?Q\^&GQM\/?!W1(?$_[7W[2/QL^&[?!KQ-KNM:
M#=^!_C1\2]<^(=C;3:+K/A;PV?!R:!%K%MX>L= M9=:VPZ>\\D\ DBAH _41
M.57KT_B.3]2>^>M.ID>=B9.3M';';T[4^@!&Z'Z'^51'_6-_NC_T%JE;H?H?
MY5$?]8W^Z/\ T%JSG]K_  +_ -.P%_-_A9\6?L;'.M?MD8_Z/3^*0_+P9\-
M?U%?;-?$O[&G_(9_;(_[/4^*G_J'?#6OMJNO$_QZG_<+_P!,4#.E\'_;T_\
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M'I]B >T^'?\ @J9\0M(U7]H[P)\:/V5;'P3\7O@-^QU;_MK:?\/? 'Q]\/\
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M/ G@6Q\(77PY\672_$VX\<Z\VM^-ED0>#8[S5].U*]U?3?$_!_\ P31_;I\
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MD$U[?Z9XD2>+3[?]C_\ @D;^T?\ %G]I#]D[7-6^.GBQ_B-\4?@Y^TM^T_\
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M%3]J2T^&W[)'PI\2_";P9X2\7_$3X)ZC\.?B=X.URVT72OAK8^-]%^''P?\
M 6J>+=<^"_A#0XK#1O%=U:^"]3TS6[J^TZ\E^)-L?^$NN?7?V[?V!I_VZ[7X
M5:+K'[3OQL^"'A7X3_$?P3\8](\+_"KP[\"]6L-=^+'PTUL^(/A]XQ\37GQ4
M^$GQ%U&_M/#]_ME_X16&ZLO"^L3P6DNL:3>SVZL:?A/]I_XHW?\ P4_^-?['
MOB*U\"V_P?\ A]^QC\)OVE?"6NZ?9ZM:^+$U?Q]\6/B#\.=8TWQ3JMY>S:.]
MEIT/P[O-2A2SL+!(X-6@$AE:TN)U]KT_]NK]BK5O"WQ+\=:7^U]^R]J7@GX-
MRV4'Q=\9:?\ 'GX6W7AGX5W&JZ@NF:3!\1]=M_%4VG^#7U._DBL-,.O7.G)?
M71>W@S,(HG[(4_9JWM:E76Z=2--22Z1O3C%2TU;:3;OHD[+Y_%UZ6)Q%2O1P
M.&RVE/E<<%A*^,KX>C:*35.IC9SKVDTY-.5F_>=YRJ-_-L/_  32@\8?'OX-
M?M'_ +37[6'[0G[4_CK]G"Z\4:U^S[X>^(.D_ OP'\+?A9XZ\5:/+H5Q\3(O
MA[\%?A%\-[3QIX[TNPFDMO#^J>/+WQ)9Z()FGT_3H+M8;F/YJU7_ ((@6&N_
M GXH?L]:K^WI^U9>>"?B[^T^O[8'BZZ/@;]D*WUQOCE)XYTSXFW^LZ?-8_LW
M6FFZ?X?OOB!HFC>)I_#%MI*:5!-IT>D6:6WAN[U'1KS]-U_;3_8_G\(?#3X@
M0_M6_LX3^ _C3XP@^'WP;\;P_&OX;2>%/BQX[N+Q]/@\#?#CQ&OB==&\<>+[
MJ[5K*#P]X<O+_4WNL)';O(NP=)X3_:?_ &;OB%XV\:?#+P!^T'\$?&GQ+^'Q
MU+_A.? 7A+XH>"/$?C/P5_91B&I3>+/"^F:]+K&@)I,DL2:K_:UO:):EXXIY
M8)94C-G,? GC7_@D)\-O$WBK]J+7_"O[2W[3OPF\,_MO>!I?#/[6OPP^&^L_
M">P\ ?%_QS<^#8_ VJ_'*QTK7OA9K]W\,OBMXFT6*%_&5]\,M0\+>'/&$\$)
M\1>%[^+[3!<_77P2_9.3X%^)_ASJ/A[X_P#[0?B;P'\,/V9?"O[-6A?!GQMX
MN\.:U\,M0C\(ZQ#J%C\:M;L;?PEI^O7GQJN-)L[3P=<^($U^W\.R>%HYK<^$
MSJ=PFJV^;\.OVD/!GPY_9>\"?&+]JO\ :M_95O;74/[3L];_ &AO"/C#P[\.
M?V>O%6HMXGUNTTF/P=J_BSQMKFDI+;:59V^BZA!_PEM_)=^(-,UEK86H+6-I
M!^T+^UCH/P8^#GAG]KC0?$'@SXD_LN:;)H>I_%KQ;X-U>U\10:5\*/%.HV.D
M'XX>"?$?A^75=,\4Z#X!NKFVUCQ/HUIYT>I>"!XBUC2]0DUC1++2=1 /M>,8
M0=LC.,DC\.  /0*JKZ**?52PN;>]M(+RTN;>\M;N**ZMKJTGBN;6XM[B-)K>
M>WN(1Y4\$\$D<T,L9*21R*Z,RD,;= !1110 4C=#]#_*EI&Z'Z'^5-;KU7YH
M:W7JOS1&_P#%]'_] %?%7[-7_)R__!1'_LOWP:_]8V_9SK[5?^+Z/_Z *^*O
MV:O^3E_^"B/_ &7[X-?^L;?LYU6%^#%_]@L/_5@B)[TO\3_])F?;5%%%04%%
M%% !4;=#_P "_P#0Q4E1MT/_  +_ -#%14^'Y_HQ])>C_)GQ)^P/_P D1\=?
M]GI_\%*/_7C/[5=?;]?$'[ __)$?'7_9Z?\ P4H_]>,_M5U]OUO6_P!XQ7_8
M55_](PQG3^!?XI!1116984444 03-M#8!+;&(P">G/ !&3GMQZ @FOF;]JGP
M,WQ3^!?Q(^&MSX=\6^)M!\=Z/+X9\4Z9\//$MGX+^(Q\,ZK-"FJ7?@7Q'J!^
MP6'BFRB19=.GN+W29XV\VYT_5K#4K6TDD^GF16^\,C&,'H1[CO7R5\;_ -H&
MT\%_%WX-?LV>#+6+6/C5\=XO%FN:/!=,LFC>!OAKX"M;6Y\<_$WQ/#N2>>RT
M^YU#1_#OA_1[8[]?\2:U9VDEQ8V=O>7D+>L)1C*5*4K?O(*,I=+NSLKKI=]%
MKVNA*-+$T:\Z-+$TZ4HRGA*U3%T:5=1=W"=; U:&*I<Z]V-6E/VV%E_M6%;Q
M"47^=,O[*?QO\2^+/@YJ?QV'[37[1?@?]F_XB>%?B+\(_A!\0OBK\!E\"Z1\
M6?#.C)9?"OQ]XI\=>#O@[X2^+GQIT_P-;7MUJVOZU\3O$%[?:%X[EO+S_A$_
MB.]AIVII\^>(/^"7>IZQX"^-?P'\.V'[9OP]_9E^./Q4TOX_R_LU>%?CS\"[
M?X=_#?XI^&/BCX>^+_C.\\ >*-<^#WB?XH>%=!\;^-/#\OB;P9X"N?&'BSX?
M^*->O;J?6M'^%EU+:7^G_97A'_@HQXPT;_@JMXP_X)K_ !R^'G@_PWHNO_"?
M2OB5^SG\:/"E_P")FTWXB>(DT^36_$GPI\66>N6BZ7HGC_3_  M9:QXLL-/T
M74]1COM!TN6X0I))'$(O^"EW_!17XD_LC_%?]C3]G?\ 9^^%O@CXH?&K]K?X
MX^$/A5=:K\3M<\2>'OAC\)?#GC637-)\+:_XOU#PI9ZEKD^K^,=>T3Q#%X1T
M.PMYFU?3/ ?C^:62V72(WD\_ZIB-5_:F/ZVM#+[1[)<^$E)Q5Y:3E)_#=NQ]
M++/\HE)2_P!1^&HZ).$<?Q0J;ZMNF\SG'1I;SO4C*,*LO]FP\W\I>,/^">_Q
MF\51?MY07_CO]LRW\*_\%!= L/#_ .T/H>GW_P"Q/J>H+X O_!L7PNTG3OAT
M=4_9\:]L_&]O\,I+OP/X\L-1UDMI>GW%QXV\/^-_$'Q CLKN/]!OV+_V=OBA
M\)+SP#%XV^*/[24FC?!']G?PA^S5H_PZ\<^-/A%J_P (_&47AG4?MNE?%>VT
M+X:_"KP')=^/-#\,VFB^ 8?&TR^%!KVCV-PMUX%L]0@GU.[^H9_VC_V>- ^)
MWASX >,_CW\"-)_:'\2:;ILMK\&IOBEX1TSXB:]>7-F)G/ASX>:MK@\:W^G7
M!@GN-.\C2[RY:QA,DK!8Y9#\U? ;]J[Q[XR_;7_X*+_ 'XHR?#K0OAC^R+9_
MLVZYX(\3:?\ ;-&NU\/?&+X;^(_'FNWGQ"U;6]2FL8)M#&D1Q_;K>.PTE;)9
M)SY8$A&U/#SIR3GBZ^)5M56I82.MH_R4TW[W,]UOHEI;EQN<8#%82>&P_"^4
M935DTXXS+\RX@JUTDY7@Z68XG$X1J4)2A*7L5-^U?O*6%PE4C_;)_P""?.J_
MMA?%G]G[XLO^UQ\=_@C)^S'XPC^)GPH\'?#+PI^SYK7A73_BU#I>N:"WC_7O
M^%I?![X@ZUXBNSX<\0ZEH\'A_4-9;PQ9K)%JECI-OK<*:B,GP[_P36MV^/FC
M?M6?&?\ :J_:!_:*_:/^'OPV\>?#7]GSQ]\1](^ ^A^&/V;HOB38/IGC'QI\
M,/A3\-/A'X#^'UYX\URP%K8:KX@\?:-XV:^TNPMM+DM/L2O#)]'V_P"W3^Q/
M>?#+Q7\9[3]K[]F"Y^$'@/7=/\+^-OBE%\>OA>_P\\&>)]6>!=-\/>*_&J>)
MW\/^'M9U(W5I_9^EZQ>6=]=^?"8(95FCKI(/VM/V6[C2_@UK,/[27P(ETG]H
MB_.D? +5(OBUX$FTOXXZFC0YT[X17D>O+#\2=0W3Q(MMX1;5)9!*KB#8Z;ND
M\$_+O3?^")EAIGP*_9W_ &>X/V\?VK7\ ?LN?M*Z3^UA\)7N?!G[)<NNZ5\7
M- \9>(/B#HE[K.H2_LYD:[HNG>-?%GBS7QH^H6LL-[)KTEAJ3WNCV.F:?9=K
M\1?^"+OP<\:Z#^UI\,] _:._:G^$_P"SS^VCXJU/XD?%S]G/X;^)_AM;_#G2
M?BYXC\1:1XG\7?$?X::CXK^&7BSQ[\/Y?&NM:4=2\4^#M'\8#P'J5_J,]TWA
MN)K;3HK+[VT[]JC]G_XF:7\6-(^"G[3/[/'BGQO\,_#WB>7Q,^D?$_P1XWL_
MA?JNEVU[:KK'Q*T;PWXE;4=&T;0-6C":Y%?S:9Q:7.GO=6=P5FK#TG]ISX4?
M!G]GGX+_ !#_ &LOVJ/V7M#O/&'@[PG#J'QF3QWX4^%WP3^)OC*\T.UN]5UG
MX6W/C+QE?02>'-;G:75="L(O$>L7$>E7%NSWTH^>@#N_AI\";SX=_$OQ?X^'
MQM^-?C?1/$W@#X7> =*^%GCSQ-HNL_#KP(?AG8:G97/B_P ':=9^&]-U>S\:
M?$0ZA;WOQ#U2^UR_M-7N]+TTVFFZ=#;PP1?0B#"]\DDG)!.3ZD <^N<D=,\"
MOC7X]?M1Z=\ !\&OBQK.I>&_$'[,WQ1\8^!OA7XB^(&E7R7)\ ^(OBQJ5GHG
MP?\ B1#J]B;[2O$7PO\ %WC#5M"\$:]=&YM9= N?%/A[Q;8W^IZ$-7@M?L>'
M?AP^W<&Y*$%2< GD'<6'1BR1Y/*H%Q0!-1110 4444 (W0_0_P JB/\ K&_W
M1_Z"U2MT/T/\JB/^L;_='_H+5G/[7^!?^G8"_F_PL^*_V-/^0S^V1_V>I\5/
M_4.^&M?;5?$O[&G_ "&?VR/^SU/BI_ZAWPUK[:KKQ/\ 'J?]PO\ TQ0,Z7P?
M]O3_ /2YA1116!J%%%% 'Q3\'_\ D]7]M;_L3?V3O_4=^+%?:*]5^A_FU?%W
MP?\ ^3U?VUO^Q-_9._\ 4=^+%?:*]5^A_FU:8[^-+_KUEO\ ZB4#*G_#?_7Z
MI_Z=F2T445F:A6;K.F6.M:1J>C:I:I?:9J]A=Z7J-E*2(KRPU&WDL[RUE*O&
M1'<6TTL3D,"JN6'( K2I&4,,'/4'@X((Z<T ?C7X)_8 ^(+?L9>)/^":<_QG
M^+/P1^&/@R^\1^&O!_QJ^$VC?##Q%K7Q-_9H\8CQA_9GPPOKSXL^"?B58>#?
M$_AQ_%%MI?B6_P!,T?2O%X?PGI&K^#_$5MH^KW;'Z@L?V _A+<_'[X$?M:?$
M7Q!XF^)W[3_[/_P7\8?!;PY\9=>TOP!H-_XBTCQG/!<:AXJ\4>%O!7A#PYX0
MF\2Z5%!<6^@R:5HVD:5I%KJ6KQ6>DJ-1G+?>7EIG./?KU/&&QTW#'![9/K7S
M/^U/^TCX<_9B\!>&_$5]H][XO\<?$SXE^!_@C\%OAUIU[;Z??_$GXR_$S4SI
M'@[PP=3NP]MHNA6D4>J>+O''B.2"^D\-> /"WBC7K/1_$&I:=9:!J8!\1_ K
M]@_XF_L,7?[5GQ1^%'[2?QY_:;^+G[6WBF]\>>(/#WQE\,? 73_!<?Q\U30]
M/\)Z9\4KZZ^&'PI^&>I>&/"NA:/I&CP:MX:L=67P_)X?T2*ST71UUN>.YF^L
M/V0?V8]"_8E_9.^$?[,GPYD&OP?"?P9>VDFK:C(NGOXT^('B/4];\:^/_%FH
MR+9S6^G77CKXB>(/$WB6\+64UM;3ZVRPQB-75/C#]K+_ (*+?%3]AO\ :N_8
MH^#GQD\'>!/%OP$_:AUF^\!>-OCCX>_X2?1M<^$GQ NYK#3O"ESK^@O'?^'(
M/ >O^)]7L?#=MK%SJL-]%)+;?:HC<7&7]@_X*L_MYW?_  3G_9*\5_M >&_A
M[#\6?B/'J6G>'OAY\-KF^GTO3]:O+NX2?7-7\1:K:&2;2?"?A+P[:ZGXEU[5
M4!-IIEJL9MVN&7<U;WKWUBTFMTWL_D"=I0E;F49QDX724XQ=W";<9/DEM.,5
M%SC>'/",Y2/C;Q#^Q+\7_$/PM\2_L[V^N?MO6G[*_P 1AXZ;X@? 74/C9^SU
MK%QXT\#>,]2O[WXF?#I_BQXA^%&H_&'X:6^O2W]SI_@KX=_#_P"*>A>$=6\,
M7<5G-XY\ VU_XIMM-ZK5?V/?&&G?M':9^TM\$_A[^T7^S!XBN?AEX0^!GQ0\
M%? CXO\ P@;X?_&KX9>$-,;1?@UHWBOPY\2?AQKM]X>U?P!HIBT36_B!\/\
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M91 LDL4<DBQ; \D:.P+*I#D\,>&HE9(_#^@QHVF)HK*FCV"*VC1 "/265;4
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M7+L^KIHVGKJ;L]LMDY>_6U%TQ>S1+1R926ME6 YB4(.$^)GA;QG'\+_&5A\
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MZPOM-AU'V?\ 9^\7>!]1_P"#9K]NWP_IOB?2?%B^"/ __!0CP/JUO9:*=/\
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M?LYU]JEA@C&>",DY/(QSQZ?X5\5?LU?\G+_\%$/^R_?!K]/V-OV<_P#$=?\
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MV_:X_P""+OCV]M9I_AMX5_;W\1>'O%TYP^GZ?XN^)7[-_P 7/"/PEO+^)F5
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MB\?^@;"?^"\3_P#-P6E_/^"/BS_A._\ @H-_T:_^QE_XGC\<?_I<5'_"=_\
M!0;_ *-?_8R_\3Q^./\ ]+BK[3HHYH_] V$_\%XG_P";@M+^?\$?%G_"=_\
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M)X_''_Z7%7VG13YH_P#0-A/_  7B?_FX+2_G_!'Q9_PG?_!0;_HU_P#8R_\
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M^+/^$[_X*#?]&O\ [&7_ (GC\<?Z?\$XJ/\ A._^"@W_ $:_^QE_XGC\<?\
MZ7%7VG14WC_T#83_ ,%XG_YN*M+^?\$?%G_"=_\ !0;_ *-?_8R_\3Q^./\
M]+BH_P"$[_X*#?\ 1K_[&7_B>/QQ_P#I<5?:=%/FC_T#83_P7B?_ )N%:7\_
MX(^+/^$[_P""@W_1K_[&7_B>/QQ_^EQ4?\)W_P %!O\ HU_]C+_Q/'XX_P#T
MN*OM.BCFC_T#83_P7B?_ )N"TOY_P1\6?\)W_P %!O\ HU_]C+_Q/'XX_P#T
MN*C_ (3O_@H-_P!&O_L9?^)X_''_ .EQ5]IT4<T?^@;"?^"\3_\ -P6E_/\
M@CXL_P"$[_X*#?\ 1K_[&7_B>/QQ_P#I<5'_  G?_!0;_HU_]C+_ ,3Q^./_
M -+BK[3HHYH_] V$_P#!>)_^;@M+^?\ !'Q9_P )W_P4&_Z-?_8R_P#$\?CC
M_P#2XJ/^$[_X*#?]&O\ [&7_ (GC\<?_ *7%7VG11>/_ $#83_P7B?\ YN"T
MOY_P1\6?\)W_ ,%!O^C7_P!C+_Q/'XX__2XJ/^$[_P""@W_1K_[&7_B>/QQ_
M^EQ5]IT4<T?^@;"?^"\3_P#-P6E_/^"/BS_A._\ @H-_T:_^QE_XGC\<?_I<
M5'_"=_\ !0?_ *-?_8R_\3Q^./T_Z1Q>@ _"OM.BB\?^@;"?^"\3_P#-P6E_
M/^"/BS_A._\ @H-_T:_^QE_XGC\<?_I<5'_"=_\ !0;_ *-?_8R_\3Q^./\
M]+BK[3HHYH_] V$_\%XG_P";@M+^?\$?%G_"=_\ !0;_ *-?_8R_\3Q^./\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>aud_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aud_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  C .,# 2(  A$! Q$!_\0
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MYH ZVD) QD]:XW29I?#/B>ZT">[GN=.>S-]:/.Y=X0IVO&6/)'((S[UE>%=
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M7TW1EE,OV.!8C)_>(ZG\\T 0:%X3L-"FDNEDN;S4)1MDO;R4R2L.N,G@#/8
M5@^/-E]K.CZ/JUREIX<G+2W;L2!<.A&V!FZ*IZG/7&*[NHYH(KB%HIXDEC88
M9'4,#]0: *BZKI$%NA74+*.!5 4B9 H'MSC%<1XV\9VVI^';W3?"FKRS:N\9
M,?\ 9]N;@D9P5W#A<_WL\5TT?@;PK$X=/#VFAAT_T=?7/I6W;VMO9Q"*V@BA
MC48"1H% _ 4 >8>$_ /B'0O!,.=>E@U (9WLY8(Y( _4JXQN8^ISFLKP;X>O
M/%/A[0M4TC5(M.6,W:ZA)% ?-:65_G,;'CIP#VKV@@$$$9!ZU';6MO9VZ6]K
M#'#"GW8XU"J/H!0!P.GZ7XYMT/AV+4#!9VC.8M:G"S2S1_\ +./:>XZ,Q].*
MU5\/:OKT%A'XJFM72SF+RV]J#Y5X1C8S@\@#D[>1FNNHH \^A\(^+="6671/
M$44D4=R\EMI<\ 6#RF8L8RP^8'DX(Z>E=VT*75KY5W#&X=<21L-R^XYZU-10
M!7L;&TTRSCL[&WCM[:(82*-<*HZ\"L77/!UEKOB/1-;FEECN=)D9X]F,2 C[
MI]L\UT5% %#5=$TS6X%@U.QANHU.5$BYVGV/45@:E\,?"&IV"6<FCQ0QKG#6
MY,;'/7)')Z#KGI7744 >9C2=<37O#FB7NGO>6FEW#O'J6Q3$]MY;*%D!Z.,@
M>AQFNNN_!/A>^WFXT#3V+_>(@52?Q&*WJ* .1E^&GAJ3<8H+NW;(:,P7DJ>4
MP&,I\V :1_".M1JXLO&FJQ@+B-9TCEVGMDE<D?C77T4 <I;VWCJ:XMTN]1T>
MWMXF!EDMX'=YP.HPQPF?;-8/Q%LM7N/&'A V;W#:=+>JEW'&"5&U@ZL?3H>:
M])HH PO%OA^?Q/H4FEQ:E+8)*P$KQH&+IW7GIGUJKI/@BPT;QA?^(K6:82WL
M"Q20-@H",?,.X)P*Z>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>annexc_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 annexc_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #) .$# 2(  A$! Q$!_\0
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M "BBB@ HHHH *JWVI66F0B:_NX+6(L%#SR!%)/;)/6K59NNZ'8>(]%N=(U*
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MQXG'VW5M)U+59&DD2-[.&XF)7@MOV9/!Y7('7'M7T$&##*E6XXP: '444G-
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M_#WPEHMSX%\+W]]HUF^H0VT<T<[0*)%/WE.<9]#7B6@^'-?^-?C6YUB^(MK
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M*!\V!_$"#TK$\=_!/4O#.G7.I:)>/J&EQC?/$X"S1J/XB!PP'/(P1SQUK@_
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MO''B7Q/9QVFM:M->6\<GFHCJH ;!&> .Q-5?#_B;6?"UY)=Z+?R6<\D?ENR
M'<N0<$$$=0*^K_\ A3GP_P#^A<B_[_R__%U&WP6^'[,3_8"C/87,N/\ T*@#
MYY7XR^/E)_XG\ASZPQ__ !-2#XU>/@ /[<SCUMX__B:]\/P/\ EB?[(D&>PN
MI/\ &H#\!_ 1.?[/NAST%V_^- 'AX^./C]2#_;$9QZVL7_Q-2#XZ^/AUU2 _
M6TC_ /B:]H_X4%X%_P"?>^_\"C1_PH+P+_S[WW_@4: /&!\=_'H_YB-L?^W2
M/_"NK^'/Q=\7^)/'VDZ1J-W;O:7+N)%2V520$9NH''(KN_\ A0/@;_GWOO\
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M>69M@WE<YVYZXSSB@#QKQQX"L;_Q#X0@U40-=WD\\VK7T($/FA(U8G))PHP
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J5'^]$A $49_W4"\>I-=138_]6GT%.H **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>annexc_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 annexc_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < !<# 2(  A$! Q$!_\0
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581C;&I/)Z;F/&YCTP% *ZRB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>annexc_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 annexc_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ #P# 2(  A$! Q$!_\0
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,@$]>%_6NBHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>annexc_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 annexc_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A +8# 2(  A$! Q$!_\0
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M2#I2<"D M-8<@^E+1D4KBW'4444QA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>?\ Q'0Z9?\ AKQ/&,'3=06&<_\ 3&;Y&)]@<&O0*XGX@^!;
MSQE9^79:[<:<S1^3-$?G@E3<&^9/[P(X8<T =J"",CD&EJ*"+R+>.-GW%$"E
MCWP.M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, KP# 2(  A$! Q$!_\0
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M+8&Z@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\GHJ#>WH?_'?\:-[>A_\=_QHNNZ_KY![W9?>3T5!O;T/_CO^-&]O0_\ CO\
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MA_A1_:$O_/*+_O\ #_"OY[/^%8_M&_\ 21_]NK_PH/V;O_H:*/\ A6/[1O\
MTD?_ &ZO_"@_9N_^AHH_UPP7_0NQ_P#X587_ ##_ (EQXB_Z+GAO_P ,?$9_
M0G_:$O\ SRB_[_#_  H_M"7_ )Y1?]_A_A7\]G_"L?VC?^DC_P"W5_X4'[-W
M_P!#11_PK']HW_I(_P#MU?\ A0?LW?\ T-%'^N&"_P"A=C__  JPO^8?\2X\
M1?\ 1<\-_P#ACXC/Z$_[0E_YY1?]_A_A1_:$O_/*+_O\/\*_GL_X5C^T;_TD
M?_;J_P#"@_9N_P#H:*/^%8_M&_\ 21_]NK_PH/V;O_H:*/\ 7#!?]"['_P#A
M5A?\P_XEQXB_Z+GAO_PQ\1G]"?\ :$O_ #RB_P"_P_PH_M"7_GE%_P!_A_A7
M\]G_  K']HW_ *2/_MU?^%!^S=_]#11_PK']HW_I(_\ MU?^%!^S=_\ 0T4?
MZX8+_H78_P#\*L+_ )A_Q+CQ%_T7/#?_ (8^(S^A/^T)?^>47_?X?X4?VA+_
M ,\HO^_P_P *_GL_X5C^T;_TD?\ VZO_  H/V;O_ *&BC_A6/[1O_21_]NK_
M ,*#]F[_ .AHH_UPP7_0NQ__ (587_,/^)<>(O\ HN>&_P#PQ\1G]"?]H2_\
M\HO^_P /\*/[0E_YY1?]_A_A7\]G_"L?VC?^DC_[=7_A0?LW?_0T4?\ "L?V
MC?\ I(_^W5_X4'[-W_T-%'^N&"_Z%V/_ /"K"_YA_P 2X\1?]%SPW_X8^(S^
MA/\ M"7_ )Y1?]_A_A1_:$O_ #RB_P"_P_PK^>S_ (5C^T;_ -)'_P!NK_PH
M/V;O_H:*/^%8_M&_])'_ -NK_P *#]F[_P"AHH_UPP7_ $+L?_X587_,/^)<
M>(O^BYX;_P##'Q&?T)_VA+_SRB_[_#_"C^T)?^>47_?X?X5_/9_PK']HW_I(
M_P#MU?\ A0?LW?\ T-%'_"L?VC?^DC_[=7_A0?LW?_0T4?ZX8+_H78__ ,*L
M+_F'_$N/$7_1<\-_^&/B,_H3_M"7_GE%_P!_A_A1_:$O_/*+_O\ #_"OY[/^
M%8_M&_\ 21_]NK_PH/V;O_H:*/\ A6/[1O\ TD?_ &ZO_"@_9N_^AHH_UPP7
M_0NQ_P#X587_ ##_ (EQXB_Z+GAO_P ,?$9_0G_:$O\ SRB_[_#_  H_M"7_
M )Y1?]_A_A7\]G_"L?VC?^DC_P"W5_X4'[-W_P!#11_PK']HW_I(_P#MU?\
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MGL_X5C^T;_TD?_;J_P#"@_9N_P#H:*/^%8_M&_\ 21_]NK_PH/V;O_H:*/\
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/DY.=5.#6FJM=NUK*]__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R ,@# 2(  A$! Q$!_\0
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M3[0PB:2*-'1?.;861%D8B-?,. KLP0;@Q(7F@"6BOB/]FG]LJZ_:6^)7QU\
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M^.?QC_9]^"$\MJ5^U);?$?XU>!='NI+,R*\8N8;,7,\.]'0-$"\;)N!^9/\
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MC]PVF%_L#08&WR#;F';\FS;Q7WQ13,SPCXH?LP_L^_&O3=#T3XM?"/P3\0M
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H 0\# 2(  A$! Q$!_\0
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M74H;4+>&[D\RXM;>[9(9&]2M;:^#='36]+U:*&2*?2[<VUJB.0BQD8P1WX-
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> !SCBBBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0) R # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&OVC=6\<1Z@B-M6[L/"LUS'./-BA25AL_,/Q;\.?V/OBUXEU/P7X=TCXA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'+WQ!;>)+&S;3]2OM)MM.UC2+N^!^SE?ETOVNC^]#(/0@_C2U_%;_P $Z_\
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M<G)).,<L23P..I/IQUR<D@#J*** "BBB@ HHHH **** "BBB@ HHHH ****
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MX/T#7= D:2SUNX:'[1\>?\&EW[!&B_LX:CI7PH\;_&7PS^U5X4\,7?B/P?\
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MTN[:6.>WFDB=6.Y0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1!96%G<WES)%;02RI_&'<?"7_@H-_P %,?V3O^"F'QO^'/\ P3UTSXB>'/\
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M5IMG!%:V-C:6]K!&D,,:( ?Q[^-OV\_#?Q?\8?\ !L__ ,%B/C-J.F:1\"]
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MQI>I>([30/#=WI>N0W&EW^B0!+:\O?F?X7_\$?=>^._COP[^T;_P6$^--O\
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M]L]6T;6-.GO-(UG2KRTU/2KZ\L;F&XD^-?V2/^#8W]L+]B+]H'P'^TO^S_\
M\%(?A-HGQ-^'\FK1Z>=?_9)\0>(?#6M:-XBTB\T'Q%X:\3:'-^T#;'4=$UO2
M+ZYM;@6E[INJV$_V;5=$U72M9L;'4+>U^V!_P;,?MC_MS_'_ ,9_M*?M!_\
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M_%C5_$/@ZSF\"?!_QW+V?AB\'B74_P!N./\ :"_9S^.MSX2^/4OAW3+G1XO
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M+5?!8LAXEN]7T+5_,UR+PSJ5BVG7/VQ0(**** "BBB@ HHHH **** "BBB@
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MO-0\_P""-QX,34=0L/AMX+BO?AQ\)O$5C)JWA!/"?AC6/AL+/4- \$6Z:O\
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M7]GGQ%X"^*NN?$'PC\9/&D>D?$GXS^)/C-\9_"6NZ/\ #[4=)\9S7_P%\!?
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MBJPNO$7/:+;_ /!*2SNO"_[07A;P[X+T:_L/%_Q%^,WA_P <>$_!_P 5] U
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ME_;(O=8@T3Q7XST;1_CO\>=#U"VUY/CE^T#H.E?&3Q)=:?\ $+4O'/B/QEZ
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M&'Q#\(Z+JU_XF\%>)-*TSXD^(/\ P6)^%7P?\(7_ (B^-'[-W[27P4UY-*^
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M?V@?B5X/\;R3KXGT.%_V<K;P9_P5C^._[>,NKWD4<TQU/QYXG^%'QXTY)E\
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MTM+']H'1OC1JBVNL>/M?%^NNQ^(].OH[773H^C?>%% @HHHH **** "BBB@
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M#6M7FG7_ ,*O">E^)T^)_C/3_$/C$>+K6;PHGAVTUGQ'\4? D7B*]U#0M/\
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M]<T>ZM[62#4[*2?Y6M/A7^S?\'/B;\//&<_B?XB>*/&VJ_$[QW\3? ]AX?\
MA</B/KNGZ]\3_#_CZ^^)Z:I=_"SX.ZMX\\,^ /%^I?&>Y\?ZQ'XRUO3=!TSQ
M#%X*L]-U/2_#6D:9X6'F6C_"?]C+3++7=;3Q[\1+W1?V5/!FMW'CT^+OAJ-7
M\.Z[\+O /@SX1_"KX@:?;6'B3X)RZ3\4_#VW]C'PQ_PD>K?!>WU?7+#Q5:ZS
MIVC:QIFG^+=#\/.#T\_P/MVQ_:H_9TU#PY\,/%]M\9?A^WA?XS3>*X?ACKS^
M(;*'2O%P\">'O$WBOQI<V%Y.\45O8>$]!\'>)+SQ)J.HFSL=#ETX:?JEQ::G
M>6%E==#=?'[X(VF@^!_%)^*_@"Y\+_$OQY:_##P!XETSQ3H^K>'O%WQ"O;K6
MK&W\'Z%K>EW5YIE_KS7_ (=UVP>PBNC+%J&DW]A*$O;=X!\CW.F_LY_%CPM\
M(/V;)OC+\6K'4M?G_:,N? >EZYX.G\%>.-4TSPYX*\4_"_XB?#WQ3:^.OA!I
ML'A[4? O@K]H33-;\$:'XJTCP[\2/&GA_1=!^(MK<?$7P;I7Q!U/5^N\/+\#
MM6^!?B[X]:9\:_B!K_@W0OBCXV^._CKXX+H.GC7-=U;X S7WPO\ &YMO"EC\
M,;/1M6\%:?X-^%%U\.-*?P+\.FF\:>$-(L?'/@K7/$?BGQ!8?$?6@1[_ &G[
M27[.U_I]MJUC\>_@M>Z5>>%X_&]IJ=I\4O ]SI]UX+FU[3_"T7B^WO8==>VF
M\+R^)]6TKPY'X@CE;27U[4]/T=;LZC>VUM+)<_M&?L]V>G'6+OX[_!JUTD:1
MHFOG5+GXH>"(-.&A>)=2AT;PYK1O9=<6V&D:_J]S;Z5HFI&7['JNI7$-C833
MW4L<3?)?A3]G3X 7VK_#?Q"WQF^+]G_PA_AOP7KG@'X;_%&YTKP+JGA[PC\"
M+WX1://J5K\.OB+\-_#'Q!\)^#+K5?@OX>U3Q;':Z=X?\-:CJGC#Q1XIM8[<
M^)_#E_I5SP9\-?V5[_XDZEXK\(?M'0:KJ&A?$FVU/7?"6C^/?A.- O\ XC_'
M'XDV'[3?@&+Q/%I7AJWU?Q9K&H1>(A9?!235]7U+4]/^'/BSQ/I?@V^FNO$F
MO:E, ?06K?M:_LX:/IEMXBE^-'PQO_!\VI6V@W/C/1/B#X*UWP]I?B34/%OP
MM\$Z5H&IOI.OWFIV]W?:]\9OAXESJ$>FS>'_  S8^(M*U'QIK/AJSUOP[-K/
MH?B'XQ_"+PBVL)XL^*?PY\+2>'9Q:^($\1^-_#.B/H5TS>!U%MK"ZGJ=J=,G
M+?$WX; 0WH@D)^(7@;"_\5;H']H?(^C?LM_L\6D/@/PCX9^-6NV^O:%X4\*>
M#/A\-/\ &7PQO->:;X3I^SCK>B:SIVD-X3GM-:UO09OV5O &MZK9?V5<Z!)!
M?>,DU#01I.H:9;:%Q:>%OAA\2OVL_C3XO3Q7\2/ /C+P+JG@#0/"6JZ9\,/'
M>AZ5X(\?^'O"FI/\6?B$WB[XN_!2U^$.O:G\:/AC+\.?AIX@TFQU?XGZ%+\+
MO@Q\/OB)X'UWPUXJU+^T_#8!]Q77QQ^"MCH+^*K[XO\ POL_"\<VGVTGB2[\
M?^%+;0$N-6\,:3XVTJ!M8GU9-.6;4_!FOZ%XOT^(W/F7OA?6]'\06PETG4[&
M\GT-4^+GPIT/3KW6-:^)OP^TC2=-OCIFHZIJGC/PYI^G6&I#P6/B0=/O;V[U
M*&VM;W_A7;+X]^RSRQS_ /"%LOBG9_8;"_/Q7H_[.7[-NE:=IFJVO[2&KW/@
M;X=ZI\*/BKJUC<>.O@M+X6/B'PKH'A#X:^&/B#XMUB/P/'?V%GXRTWX0Q:'<
M6=EK>@^"=0U*+Q:GAS1=-O(K9-$]B^+G[/'PC\>?%*P\7^*?B#XB\(^/O%_A
MSPGX1\%Z1IGB;PGIB3^(/A+\2]!^/F@^-/"GAG7]!U1?$?C[P[K_ ('\/WFI
MOJ%OXBT6?P=X?32=8\.3:/\ ;3, =7/^UE^SG%K-QHT/QD^&EVVF>%]+\>>(
M=6B\?^"[;P[X<^'VM>&OBGXKT[QUJ/B#4]?T_2;WPZ^D?!KQ_>7[>';K7-4T
M/2M&F\5:]IFE^"X+WQ+9]/\ \-#_   _XHW_ (OE\'S_ ,+&U*;1OA[CXE^"
MS_PGFKV_B>#P3<:5X,_XG7_%4ZE!XSNK;PC-8Z']ONHO%%Q!X?>(:M-'9M\6
M^-/V:/V88OAYXG\<Z_\ &[X@ZYX)U$>+O _BG6?"=[X)\9R^(?'_ ,7_ !#^
MT_X&UE[#2/!'PSUW4-1^(_B+QY^V[\2-&TOP9X4TE[-_%K> =!TWP85TW4-(
MU^SXY^#'A6^\6^'_ !3X3^*5KX!\-7VL?"GX\_&L?$7Q=HO@_P 2P^!_"'[4
M?B3]JKX?6?B/X1^,/@_%XH\/Z6?B!XD^)'A'3]4O_B!\&M9\.C6[Z#QM9_$3
M6/!<6@  ^RX?C]\&1KJ>$]4^)_PZT#QC/-XN%EX-UCXA^ T\4ZAI_@G5O'&D
MZ]K=CHMCXEO[N?2K)OAMXZN[Y]BWFA0^$?%-IXFL]#UCPKXGTO1\.W_:H_9K
MN=>D\,Q?'CX2G5TM? 5W#&_CWPU'9:@OQ1O/&-A\/K72-7DU%-(UG5O%EUX
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MX=LO"VM>'8M8O+C6N-\(? 3]GKQ5\)/#3>!?C9\0M#\*^#;*X\/^%?B5X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\06-I%*D&G6E[X7_ +(DWPJB_:4U'PUXZTS3?'?[0'_"92VOC^P\*^)]0O\
MPM>>(_%_Q=\=:#?:SX1^('Q/^(/PY\6S^"O$/Q>UB33(M,\'>!['6=,LXM&\
M4V>MZ=]@ATGAOAK^P%H'P_UB[\2OXD\)WGB2'Q'\)=>\(:II7PWU&PF^'</@
M/XT>./BUX[T;P/J'B7XC>-_$^A:;\7K7Q_XA\*>)H+3Q+'!!;:MKD]U;ZWHN
MK?\ "+68!^AM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>&_M(?##
MQ'\9/@]XC^'OA7Q(OA?6-5U;P+JGVJ9+*2PUS2?"/C_POXQ\1> M:&IZ'XJT
MI/#GQ-\/:!JGPX\2S:OX/\;:/;Z!XJU*?5_ WC738[KPMJ_N5(2!U/?'XT ?
MEYIG["'Q"T_QIX:\00?%75]/TBPO_">HQ1:;XHT8^,/ >K^%?A3\$?!,/B70
M?&6H_!B^E\5ZEJU[\*]0\,>,=.TK3/@Y8^.?AE?:?X;U::R\/WGBSP7K_3V/
M[$S7DO@Z;6? ?P(T&\M/"OPY\%>/]6\)0Z_<:CXMT?X9?'GP1\7K[[1J.K^'
MX_%6N:/\:X]+\3R_$?PAXT\8^(XH-6GM;3Q1XD^,-OX@\0ZO'^CM1K+$TDD*
MRQM-$J/+$KJ9(DE+^6TB [D638^QF #['VD[3@ _+74_V!?'7B'PYJGA_6O'
M7AI'73[>V34[2Z\:/<_$'X@:/\(_VFO!%E^TE\0X([W3;*W^,WB+Q7\</ 'B
MK61I]KK%QHNJ_!?PYXDTWQSJ>H:;\--*^%7TK\*_@'XL\ ?%OQ!XY\1R>"_'
M]EKVH?$G4-"\3:S<ZVOCOX56?BWXN_%#Q];>$?!%O=Z;JND7'AC7M$\=Z#9>
M)9;:_P#"6MVFK^%YX+V^\=>%'\":!\-/KFH([JVEFGMXKB"2XM3&+J".6-YK
M8S)YD(GB5B\)EC_>1B15+I\ZY7F@#\V=1_8G^)<LEJL?Q'\/ZS%8WGC+POX'
MO-;?Q?%J_P "_ *7'PSTWX(^+_AQ<1:AJ%MX@^+OP>\'_#[7[.UU+Q';:;+K
M?B?XJ^+=;;Q;8Z+/XW\+?%;'U/\ 8 UJ^T?QUX:TS5_ ?A#PQJ&J_$O6/ /A
MWPM:Z[I.A^&M>\4:Y^VUXA\(>+QH^B0Z#IVF^)/#>K?M/?#W5DFT^"ZGTWQ'
M\(]/\5:/JD>NZ?X2N] _43(]1V[^IP/S/ ]3P*6@#\\_A)\#?B1I/QL^/&K7
M^BIH6@ZYH?QFTJV^)%W=WD.N_$K7?BQ\7M=\?>$9M2TY?$NMS3VWP7\$3Z7\
M.O#^JNL"IX.M_"UGHFJ6\8U#X3_!3FM;_8C\?Q^#]+L_#'BWP?+XZ>#XG2^)
M]>\1IJ.H>'_%'BC7OBWX;\:?!SQ3X]\+:[H?C'1_BSHGP/\ "4'C#0]!^&_C
M*PMK)+_Q-<:C\/\ Q=\*?%::3\0/#_Z6O+%&T222QQO/(88%=U5II5BEG,<2
ML09)!##-,40,PBBDD(V1L1)0!^<VC?L6^(/"5Y\2=<\*/\.M-UFZ^)VC_$CX
M<0V']M^'+"YE3]KWQ?\ M5>-K+Q/_8^E/!X7U3XC:5XAT+X*^(/$^EZ7XVOQ
MH7@ZQ\47EMK6G:E-\.;+-@_8M\9W7A34_#WCZT^#/Q<UN>^_9Y\9:9XU\96N
MM2:CIE[\#O$/P(\2:K\#=.L/$/A_QY>:1\'_ !UXI^$/B7X@PZ_9^)9I/"_C
M#XEZI=W7PM\7:Q9ZIXM\4?I71D<\CCK[?6@#\RT_8@^(MU?^$8-<\?>'M6MM
M(U?X*ZIXI\:27OC)?''B[P3\/?AY\,OA]XM_9WOD>XE9/A)XDU_P5XA^.L%U
M#XFAMIOB=XFBBOOA_'J\7B7XC>+O7?%'[)=QXJ^&_P ._ $WB/1=*G^&7Q@^
M-GQ"\ ^(K7P_:ZC>_##2O&NA?M">'/@ZGPSL]5AN++PUKOP-TSXL>"(O!@LD
ML]*T*V^']MI>@)IVG0Z9%;?:P(/0@_0@^X_,<TM 'YHVG[#WBF_MM4_M?4?
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MBEM?%7Q4;Q;_ $Y44!?R7^?K_P "Q_-EX2_8M^ =MX^^+OPG^-?[)WQ'^/\
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M&GTJPU*ZL_&/PC&J^";G3+K3/"GQ:O= ^)FL^']:]^,?[4OBCP/^R9XM\#^
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MXF_M0^&F_9Q\;:-H$NI^,M4_9T^+5SXZ\'^#_A/\>_'/PL\5_&6[U3]G*_\
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ME_&OXE#PY\._CSXF\66R>'[3X<-X(^)^E>%6VWCS]H;5_@S\?_%_]H_$N_\
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M/_#_ (5\.^)?%?AO1=:\0?#GX?>/? 7A/PUJLM_=^-/&7@7PII/QA^.+W_\
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M1?T#HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#_BAI6BQW_C?1-&TKQ3?TW]N_P +^'] U34M>_9J^.&DZIX6^&?C'Q=XSM?
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M^*?PRT'_ (1S25\2W%Q8MK'C#X=Z3X,L-8T][6TL[OXS_!>#6KO1[+QC?RZ
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M\2^']>O="-[XB^)9\"ZIX!^'VL"^U$?$C7O'G@32]'U"]T/QS::F>#@_:P^
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M:#%;7OB7A-2_;,^$?B+3QXB^&7P4UG5/B1?>'_A%I]A;^(/!7P\CU;5?A/\
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M\0^*40:WK=UH]L^J3S1ZKX-U^*_L[X*+C1]7A\1?#KX>^)H-;T633]8A\3>
M_!GB**^36O"^B7UB ?"$6L_LXZ9\:/"'AR?]CE/"WC'X5^)/B?X/^"?PJT3P
M)\ KN?Q+XO?1OV-_C!K7COPA%HWC.+P%X'\5>&;.\\-ZK::KJGB#2]1L]#^'
MNMZ]_;VEW5AINC7?4-\:OV0+A?$7BV#]EHW=G-I>I>#M4\6'X-_".U.MZU\2
MO"NG_''QY\)]6FU+Q!8ZUIWVKP]\;?%_C[XP:WXVL]"^#FD32?&'4OB!X^M;
MZV\1O>?9=[^SY\%]1EU"YOOAYH%U?:F;&6[U2:*X;6!>Z9;?#BUTW5[36/M
MU33M?T^/X/\ PJELO$6GW=KKUM>?#KP9J,.HI?\ AW2[FVMQ_ KX/VNCP>']
M+^'GACP_HUG=:?>Z;8>%=/3PG%HMYI'@;2OAEH]WH#^&CI4WA^YT?X>:%HW@
MG29M%EL)-,\,Z98Z18M!9VT42@&?/\(_@/\ %7PIH-WXA^$'PJ\8>'-6@O\
MQ;I=CXB\&> ?&&EI<?$"[E\6>(=4M9([?7_#]U=^*-8U6[UW7M8T:^OK3Q)J
MU]=ZU)J6JR7K7\_2V?PA^$VG^(;WQ=8?##X>67BO4YM#N-1\3VO@OPW;^(=0
MG\,6.GZ9X:FO=:BTU-2NI?#VF:1I6G:%)/<R-I%AI>G6>GFWMK&UBBZ+PQX2
M\,^"M*AT+PCH6F>&M"M(K"VL=$T6UBT_1],LM*TG3M"TO3M)TNV6.PTG2],T
M;2=-TO3=+TVWM=.L+&RM[>TMH8T"UT5 'DOCCX#_  :^(]UK^J>,_AIX/UCQ
M%XE\$Z]\.=5\9KHMKIGQ!/@GQ+H^JZ#K7A[3?B'I"6'CC0[.\TG7-7M$?0_$
M&FW-D-0N9K">VN)#-6SXJ^$OPK\=^)?"/C3QO\-/ 'C+QA\/VO6\!>*_%7@[
MP[XA\2>!VU'5/#>N:BW@_7-7TZ\U/PR^H:WX-\(:Q?/HEU8M=ZKX4\-:A<&2
M[T'2IK3T&B@#PZZ_9B_9KOO*-[^SU\#KPP^+-<\>PFZ^$W@&X,7CKQ/;:?9>
M)?&D?FZ _E^+/$-GI&E6FN>(TQK&K6VF:?!?WEQ%96R1=7H_P>^$GA[6];\2
MZ!\+?AUHGB/Q-K]KXK\2>(-(\$^&M-UOQ#XILIM:N+/Q+KNJV>F0W^K^(+2X
M\2>(I[76M0N+C4H)M?UN6*Y1]5OVN/1J* .%U?X7_#7Q -4&O_#[P3K8US5[
M[7]:&K^%M#U,:OKNI>!9?A=J.M:H+VQG&H:MJ'PQGF^'%]J-V)KR[\ S2^#;
MB:3PY(^FM@1? 3X%P:>NDP?!?X3PZ4GAKQQX,32XOAUX0CTY/!_Q.O\ P_JG
MQ*\*+8IHZVJ^&OB%J?A/PKJ7CG0A$-+\6W_ACP]>:_:ZA<:)IDEKZS10!Y3X
MH^"_P_\ %7ACP1X%N=#L-*\!>!/&WP_\>Z5X'T'2- TWPQ/K'PJ\2V'CSX<6
MTNGKI$QTK3O!WQ'T#PC\0M'7PO-X?OD\2^#="AN=0N?#DVO:!K>7JW[-O[.N
MO6GB2PUSX"?!?6K#QCKEQXG\7V.K?"WP/J-GXJ\2W2^(4NO$7B2UO-"F@UW7
M;A/%OBM)M7U2.ZU"5/$_B)7N&76]3%U[510!YKXR^$G@'QSX*U'X>:UX=TQ/
M!VL>)-/\5:UH%GIFEQ:3K>JVOCRR^(^IC6M*FL;C3-6M/%GBFTFN_&=O?V4X
M\3IJVM?VF\T^J75PU.Y^!'P.O?#;^#+SX-?"F[\'RVNDV,GA2Y^'GA"X\-26
M.@:CJ^L:%9OH4NCOI;6FBZOX@U[5=)MS:F'3=2UO5[ZS2&YU.]EG]6HH \0\
M6_LZ_"#Q@OA6&\\$>&=,M?"OCCPMX_AMM#\+>$]/_M36?!7C/PS\3?#-MJ-\
M=!FU:UT[3OBKX#^&_P 3)$\/:AH5_J7BWX;^$&U74+[1+34M%U3KO%GPE^%7
MCW4HM9\=?#/X?>--7@T'6_"L&J^+/!GASQ'J4/A?Q-97.F^(_#<5]K&FWEU'
MH'B#3KV]L-;T=)5T[5;*\NK6_MKB"XF1_0:* /)YO@-\#)_#<_@Z?X,?">;P
MA<SVEU<^%9?AUX0D\-W%SI^KZMXAL;B?0WT=M,EGLM?U[7=<M)7M6DMM8UK5
MM3A9+W4;R>;HF^&GPY:T\+V#> ?!9L? ^FZ;H_@NS_X1;0Q:>$-(T75O"NOZ
M/I?ABW%B(= T[2==\">!];TRQTI+2UL-8\&>$]3M(H;[PYH\]GVU% '&7_PX
M^'FJ:)8>&M3\">#=1\.:4=4.E^'[[PSHMWHFFG7-$USPUK9L-)GLI+"S_MCP
MYXG\2^']5^SV\?\ :&A^(M>TF[\ZPUC4;>YQ]+^#'P?T/7=1\4Z+\*?AOH_B
M?6-;E\2ZOXCTKP/X9T[7M5\1SP^,;>?Q!J6L6>F0ZC?:W/;_ !$^(,$VJW5S
M+?RP>._&<,EPT?BC7%OO2Z* /-?#OP9^$'A#Q3+XY\)_"KX;^%_&UQH47A:X
M\8>'/ WAC0_%,_AB"R\,Z;!X<G\0:9I=KJTN@PZ=X+\&V$6CR7;:='9^$O#%
MLELL.@:2EH6_P8^#]G=1WMI\*?AM:WD-SXLO8;NV\#>&(+F&\\>_$*U^+GCJ
MZBGBTM98[CQI\5[&Q^)_BR9&63Q%\1+.U\;:PUYXEMX=33TJB@#RVY^!WP4O
M=3U#6KSX0?"Z\UG5M%\1^&]5U>Z\ >%+C5-3\/>,-4\3:YXNT'4=0FTE[N]T
M;Q3K?C7QEK'B32[F:6QUS5?%OB?4-4@NKO7]5FNW>-?A!X)\<^$T\#:CIL&G
M>$9?&ND>.]9\/Z/IN@P:7XGU;3/'4'Q)O+?Q#9WFCWT%Y8^)_&=N-<\7/!':
M:KX@NY[][S5"VI:BUUZA10!Y3>? CX'Z@/&8O_@U\*;X?$:]T?4OB$+SX>>$
M;D>.]1\/:Y+XGT#4/&?G:/)_PE%[H?B2>;Q#H]UK8OI],UR675K*2"_D>X.K
M?_"3X5:IH_@KP]J?PS^'^I:!\-9](NOASH=_X-\.7FC^ +GP_I[:1H-QX)TR
MYTZ2R\*SZ)I+-I>D3:%!82:;IQ-C9M!:_NJ]!HH \K\.? OX)>#O[+_X1#X/
M?"WPK_8ES<WNBCPW\/\ PGH8TB\O(O#,%W=Z6-,TBU&GW5U!X*\&0W-Q:>3-
M/%X1\+QRNZ>'])6TNGX/?"0^+-1\>_\ "KOAU_PG.L3V=SJWC0>"?#0\6ZI<
MZ=<^&[S3[C4?$8TP:Q>SV%YX-\'W=E+<WLLEK=>%/#5Q T<V@Z6]KZ/10!YA
MIGP2^#.B^(]!\8Z/\)/AEI/B[PKH]CX=\,>*M,\!^%K#Q)X<\/Z9H\WAW3="
MT'7;72HM4TC1=/\ #US<:#9:5I]U;V%IHD\VDP6\=A+);MH+\*/A<FHZMJ\?
MPW\!QZMK^N:;XGUW5(_"'A^/4=;\2Z-J>AZWH_B'5[Y-/6ZU+7-)UKPQX:UC
M3-6O99[^PU7P[H6I6MQ%>Z/IT]MW]% 'ENB_ WX*>&[>*T\._"#X7Z#:037M
MQ!::+X \*:7:PSZEJ/A75]2GBMK'28(8YM0U;P+X'U2^E1!)>:CX,\)7UPTE
MSX;T:6RU?%WPK^&'C^/5(?'?PX\!^-8=<M- L-;A\6^$?#_B.'6+'PIJ&KZM
MX6L]5BUC3[R/4;7PUJNOZ]J?A^WO%FBT74-;UB\TU+:XU.]DG[VB@#RS6?@9
M\$_$=GJNG>(?@[\+->T_73HYUNQUKX?>$M4L]8/A[3K+1] .JVU]I$\.H?V'
MI.FZ=I>C_:TF_LS3K"RL;+R+6U@BCTK;X2_"NSUBW\0VGPT\ 6NO6?C*+XBV
MFMV_@[P]#JUK\08/AE_PI2#QW;:C'IRWD'C*#X-?\6CA\3Q3+K<7PP_XH&.^
M7PI_Q*:]!HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M17_Q,TK3?B!XC\0>*/%7B&UTZVO_  Q]I_$S]F;P#\5_B)I/Q \3W.NQ_9?
M7BOP'K?A[2+V#2=/\60Z_H/BSPGX>US6=6M+-/%=MJ_PZ\)_%'XW:'X-BT/Q
M!I&E)_PN;Q9JVN:=K&N:-X(U+POY#KO[#6A>)Q->Z]\7/B-=^);R2-;WQ+IM
MEX%\*7/D:/'\#KOP==Z;IG@SPGX=T;2?$/ASQ1^SA\*?%T^LP6,EOK%\GB_P
MXVDV'@+4O!WA'P  >:_%G]GSX-67@+7OC^OC#QM\:/%WQ!T:?P3I'C*+6- U
M*P^*%S^TWI?@[]GO[%J5I\)?#G@_P]J?@?X@:3!\ M)\2VOAJWT3P[]E^!?P
MO\?6D^A^,=&\5>./$G?Z%?\ [+WB?X(?L\:9X;_:5L?#L7PR/PJF^$OQ+E\9
M>!_#_P 2[7QGXN^$/B#P_P"&9?$?A?XG:%J&F2_$+XI?"OQ9XW;4?!OQ"^'D
M^O7/]O:YX@L/#^E>+-#T_6=$]KUK]FCX>>*?@KIGP-\5:?I^N^$(O&O@WX@^
M(K/4-&T[5M/\8^*/#'QDT7XZZM=>(M*\3Q^(X=53QMX^TFXU'Q1<:Q-JVM7\
MFKZEJ5QK-QKTIU@^<^,OV)OA_P")[+Q'I^C^(=<\#6GBS0/B[X"URU\+Z5X/
MBL7^%WQO\/?#+POXY\"Z9IM]X<O-/TJ.#2/A%X%A\(ZQ#;27?AH:-%9>3J6B
M/+H[@'F%O^SU^Q8GB7XF/K7Q=T+Q)J?Q;\>:E\+O&VBZU\4? -C?ZEXN\0:/
M\?\ PHGP>NKWPY:^'_&&J>,4TK]HOXG:1I]MXCUK6OBXT47ARSF\07<7A:QM
MQV]AX?\ @+JG@;XB^!K;]HZZ^)^L_M >*/#GC7Q)XEL_B5\&;CQKX@O(;GX9
M? >SU33M"T'2/#OPUU+P/;77P_\ "O@WQ5X*?P'J_@SQW<IXF\#^*O"?CBY\
M8:OX3UO;O?V-/#FHWOP^;4?'GBO4M#^&4/CCPMX8\,WD5A!I5Y\)?B+XE\ ^
M*_$?PQ\9C1$T5_'5I:ZC\-O"UAHOB7Q-]NUNZT;3R_CYOB!XJU#7?%>L9WA_
M]B?0M"U+PM>CXE>+ULO"]YX0N8M"TBPT+0]%O-,\ ?%;1OBQX$\!2V,-G<Q1
M?"OX>:QI-S9_"SP$@:T^$EGXG\9:=\,;_P )^&?$^I>&9 #S-?A9^PM:?#$0
MGX_^![3X<OXM\6^'QXDLOC#\+M!\/Q>.?%WPZ^,NG:YX=TK4-!AT?PQH.O0>
M$?C_ .,O%&D^%_#MMI3>'84\*ZGHNE:?H.BV]G<?2UQ\'?A[X%^&&N6/Q ^(
MOB&[\.6WQ-\/?'OQC\1OB)X@\*:-=KXE\#^/_"OQ0LM3UW5K#0/"_A'1/#=M
MK?@K1+>ZL;31M(TVST"*?3;-[!#!-;?,?Q0_8*O9OAU8>!_@_P"*7T^_NOV=
MK_\ 9,U77O%&L:-IUIIGP>UWX>>$OA]KFI1>&[;X3>,K#Q3K]RG@/P9KLFC1
MW'@&&XET2;1=/\5>'M.U:XDMOL3QA\*]:^)7PXN_!?CGQB4UI/B/I7Q"\/\
MBCPMH6FV#:%-\/\ XU6/Q=^#]A)I&NKX@T_56\*1>&O!?A[Q1>3QV[^+SI6K
MZK:1>&+G6+>/20#XQTGX&_L0V%]/\/['XA>']+LO%'BOPQK>B/8WOPB\)V7C
M6#XH>#?BAX7TGX+Z!\0_#W@S0M=^*D&J?#?XZ^)8X-#U+Q5XT^*?AGPW\6/
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MXS^!-=NK#6/#>J06OA";3Y=7\/\ B3PSJ^DWGB?@-?\ @?\ L-_$>?P?%/\
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M_P#&H\.2?$[X:V_A3XFZG\/_ (E_&3XL:]XOMX7L[[5]>\&^ O$GQ6^)$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$./]H+XM^)/#GP\^*Q^%OP*O;'2/V<=.\=_%_P")GA1T^$6J?#F'5+OX!_\
M"&Z3%\0/VK_$<WP T73]0^'4>LZ7XQ^&L'BBT\<W_@[QLVE6H!^G%%?'&AZE
M\<[7XTZ9\%O&GQ;TS4['6/V43K3^)_!WPYT3PQXKT[XJ^'-=\+>$/%'Q(M;C
MQ!J/CCPO=C7[_P 17&M>'_"-WX,3PWX7%G:V&I6OBV*:9T^--5_:9^.VC?#;
M5O&^C_&F.\\+3? W]M;]L'X3^*OB#X5^&MQJGCKX4_LS7GP2\.?"2U\4:AX.
M\.>$/#.J?!;XR6OC+7?C3X@UKPGX2\"_$C3O /Q#^%OAK2?'.AZMH6OZSXC
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M<^!UOX-F^%/['OQO_:UD\2SZ[%KEK\%O%?P"\+S^!8]*CTI].N?$+?'7XO\
MPFM[V+Q$VH7D6F+X;GUN:W?1KXZI%8)+8-=_4E% 'Y5_\-^_M??](:_VZO\
MP['_  3X_P#HR:^U?#WQ?^(VL_L\7GQDU/\ 9K^*GA;XEVW@[Q9XDA_9AUGQ
M!\)+GXM7FN>'WUE=&\"Q>(M"^(FK_!U/$'C-=-L)-#O9/B2/#EHNNZ>-=UK2
MG@U%;/W^B@#\J_\ AOW]K[_I#7^W5_X=C_@GQ_\ 1DU]3?LR_M _&'XY2>.4
M^*W[&?QU_9(7PK'X9?P^WQJ\6_L_>*/^%@G7#XB&K+X;_P"%$_&+XMK8_P#"
M)_V-IAU@^*'T)KK_ (2;2_[&74A;ZH;'ZNHH _-KX@?MM?M2>$/'7C'PIX;_
M ."4?[9/Q-\/>&_$VMZ'H?Q&\)?$S]A[3O"_CK2=+U"XL[#Q;X>L/&G[5?A?
MQ=9:-K]M#'J>FVOB7PYH>N06ES%'J>E6-XLMM'+\.?VUOVH?&GCWP?X2\3_\
M$J?VQ?A7X=\1^(=+T?6_B3XR^)?[$6I>%? VF7URD%WXG\0:?X'_ &J/%GB^
M\TG2(6:[O;;PYX;UO6)88V2QTZ[G*1-^D%% 'R;^TS^T)\8_@==^#;?X4_L6
M_'C]K:+Q+;Z_-KMU\%O%W[//A>+P')I$FCIIMOXB7X[?&7X2O>R>)$U&^DTL
M^&1KJVZZ'?C5CIYGT[[9\N_\-^_M??\ 2&O]NK_P['_!/C_Z,FOU4HH ^?\
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M4Y(?$/@Q_P %%O@%\</ GCKXPZ!H'QY\%_ 3P1\*K[XY0?M _&+X _%+X/\
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M2>(-)\0Z#I>J2S)\4U\*WL5E)97.K7=K<36L_P"7>G_$/XJZ'XK\-^,O"_\
MP1=_X*/>#M6\(:I\2-1\.6OA+]J3]CGP_P"'M(MOB]XB^&_C#XD^&['PKI_[
M=D7ANU\'>+/%OPI\(>)K[PC;Z7'X?M=:'B&\TNPL&\7^*EUCJ/C!^T%K6BZW
M\/\ 0? W[1NG>,OV=-8_:RT;P-I'Q>\=_M#1?!3POJQF_8S_ &L_B!XV^!]I
M^TIX-\'Z_JGC'PS\./&OPX^%GC:V\96Z>*=?OO'6M>(OA3XJ\97\OP_\0:%I
M?L7CCQOKO@3QA^T=HGA7XC_&G7_$OC?XH?"3X%_![2](\8^(/'M]X1L?B_\
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MTP:-XEC^'J:[J%IX=O\ P5#+X4O?$#?%3PI]$_';XF?$'X@?"3]@C4?@;?\
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MJ&L_M">%O$_ASP7XGTZ_USPA/\%H8+GXI^!H]2\4^+!:P?JS0 4444 %%%%
M!^./R_J#117\^W[2W_!PA\%?AK^T)XY_99_90_97_:K_ ."A_P 9/A+=7EA\
M8++]E;X>:CXR\*_#W5=+U&[T?6] O=7T2P\2>(M8UGP]K%G-I&O7>C>#;KP9
MINM17GAV3QDWB?1]=T/2P:3>B_-+\6TOQ/Z":*_F7_XB /VJ?^D!G_!5S_PP
M_P 6/_G+T?\ $0!^U3_T@,_X*N?^&'^+'_SEZ!\DO+_P*/\ \D?TT45_,O\
M\1 '[5/_ $@,_P""KG_AA_BQ_P#.7H_XB /VJ?\ I 9_P5<_\,/\6/\ YR]
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M,O\ \1 '[5/_ $@,_P""KG_AA_BQ_P#.7H_XB /VJ?\ I 9_P5<_\,/\6/\
MYR] <DO+_P "C_\ )']-%%?S+_\ $0!^U3_T@,_X*N?^&'^+'_SEZ/\ B( _
M:I_Z0&?\%7/_  P_Q8_^<O0')+R_\"C_ /)']-%%?S+_ /$0!^U3_P!(#/\
M@JY_X8?XL?\ SEZ/^(@#]JG_ *0&?\%7/_##_%C_ .<O0')+R_\  H__ "1_
M3117\R__ !$ ?M4_](#/^"KG_AA_BQ_\Y>C_ (B /VJ?^D!G_!5S_P ,/\6/
M_G+T!R2\O_ H_P#R1_3117\R_P#Q$ ?M4_\ 2 S_ (*N?^&'^+'_ ,Y>C_B(
M _:I_P"D!G_!5S_PP_Q8_P#G+T!R2\O_  */_P D?TT45_,O_P 1 '[5/_2
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M?_.7H_XB /VJ?^D!G_!5S_PP_P 6/_G+T!R2\O\ P*/_ ,D?TT45_,O_ ,1
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M1/&7A;P?/KME:74G@R;Q4VG:PFF_N10)IK1JP4444""BBB@#RCX\^(-7\)?
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M]1UW5=2DO;[PG\,?#MYXFE36(H=1URXU:\TR#1K*ZM=.L=W2?^"<'[!^C3^
M+RT_90^"D^I?"K6I?$/PVUG5_!>G>(-?\#ZS-J^AZ^U[X9U_7EU+6M)9-9\,
M>&]0MX;2^CM[6XT#1FMH85TVS6'T_P"&?[)'[,'P8U[XC>*/A)\ ?A-\-_$/
MQ?;47^*6L>"_ ^@^';_Q^^KZMJ^NZJ_BR?3+*W;6FU'6M?US5KUK[SC=:CJ^
MHWDQ:>\GDD T[=O^#]_Z'X/_ +*?_!6S]N_QAX#_ &.?B?\ &_\ 9_M_&_PZ
M_:@^(OP"T70=<^#O[-'Q5^%GC;Q_9_%#_@GM^U3^U/\ %WP5\(/AC\7?C7KN
MK>--+^ ?Q1^%'PATRR_:9@U&Q^%7QK^&WBKQK<_#SPK=2>%%\7ZAE_%K_@NI
M\3/AC^RI^S?\9+W1O@MH7Q1\=?&;]NGQW\6/AQ\0K'6?"VK7'['W[#7[57Q+
M^"GB?X?_  [\/?\ "Q9KS3OVO/B)H=M\,_#_ ($L=8U?Q-X5U+QMIWQ8U.U\
M-:CIOAU=%L?Z*=+^"'P>T31O@SX=TCX9>"=,T+]G5-.3X#Z18^'=,MM/^$":
M1\/-<^$NEI\.[6*W6+PHNG_#'Q-XA\ V@TA;40>$]:U+0XPMA>30/A^"?V:?
MV>OAMJNLZ[X!^"?PP\(:SXA\.ZQX1US4_#_@K0--OM6\*^(OB'X[^+?B'PY?
MW%O8I)<Z)KWQ/^)_Q#\?ZUIDK-9ZKXM\9^(==OX;C4-2N)V NNJ^Y_UZW/Q6
MO_\ @J5^TIJG_!2'Q-^S[\.?^%+^*OV:8_B98^$/"FKWGP>^(-F=<\!7O_!,
M;2?VWSXXT+]J*#XV'X>>)?B:/&NKZ=%H?[/>E_ ZX\1>+_@K/K'C:W\5^']*
M\(^)O&&E_-_P4_X+:_M<_%#P)^P+H%WX0_9Z_P"%Y_$#XT_LXK^W&^D>%_&Z
M^#/!GP"_:Q^)'[&5O^SN?A;H,WQ0O-:\,_$#XL?"+]N;P-XBT36_%6O^-?#L
M?B7X(?':SCT.X.@MH^F_T&Z+^Q=^R3X=T[1-)T+]F_X,Z3IWAKQ'\/?%_AZT
ML?A]X;MX]#\4_";X56_P+^&7B'23'8!]/U?P)\%;2W^$OA:_M6BN-'^&\?\
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M#Y \2_\ !0WX\V>E_%--)MOA#;ZUX6_X+._!_P#X)V>'3?\ A;Q+J$,/P?\
MB+>? >/4M8U?2X/B'IMUJ?Q.LM+^)^NZW9ZG:WVD:"=.MM+N9O";VL%S=7?C
M_@C]O?\ ;J\*:Q#/\6O&'[./Q-T*Q_X*FW'_  3[U/1OAC^S-\2/AUXFU+PI
MX-^%WCKXB^*_'F@RZS^U5\4H)/%_BV;2-"T;PMX8?3Y;'0IK>]:[O_$;ZQ;Q
MZ1^N]Y^Q?^R=J'QVMOVF[W]GGX3W/Q^M+S3-4A^*LO@W2&\6'7]$\-'P5HGB
MR>\\CRKKQMHO@DCP3I'C>Z@E\7:7X-2+PI8:U;^'X8M.3LA^SC\ TN(KI?@Y
M\.%N8?C3/^T;%<+X0T031_'RYTNXT6X^,:R?8]P^)$VD7=SIDGB_/]MO93R6
MS7AA=D(%_)>G3:W_  ?4_(73?V^/VEO!7_!-K2_^"C/Q=^,'[+R7'[47PD^!
M.K?LU_!Z#X=:[X4^&_P5^*_[4>L>%=!^$.E?$[XLZI\:K[7?BAX1^&I\?:3J
M_P"T1J-AHGP_NWT;P+\1?%?AF+P'HVGC2+'T']BG_@I;XV_:M\4?L%:"D7PM
MO5^-?[/G[>&I_M)W'@FWU2]LM(_:#_8H^+O[*OP8U!_AE>/XKU4:)\+/&FL?
M%SQOXV\-67B;_A*-<U;P#KOPNU&#Q JO=7NN_=/@O]@G]B_X<^.H?B5X#_9C
M^#7A'QE:>,G^(NEZIH/@G2-.MM \?RV'BO3+GQOX8T2W@30?"WBN^L_'/C-=
M1\0>'=,TS5=1G\4Z]>7]U<WFJ7EQ+-X\_8._8M^*/B)O%WQ$_99^!'C3Q._C
M?Q#\2SK_ (B^&?A74]5_X6%XNT7X=^'?%7C47MQIKSCQ/XFT/X2?##2]?UH.
M+_6+3P#X4BU">X&B6/D@:?U^7ZW_  /F/]@G]J;X^?%/XU_M._!#]KJXTWX=
M_'[X>ZJOBWPY^SE9?!K5_!^E>&?@/J/Q'^)OA/X;_%KX>_'67XB^.?#_ .TI
MX%^)/AWP_P"&HM6\0:=IG@77_ OQ(T7QCHOB;P5X7CUG0O#FC_-_[=?_  4:
M_:Y^ O[1OQ*^"G[/'PW^$_Q,U+PEJ?\ P3O;P5X(\4Z?XCL_$OQ';]I?4OV\
MKSXI_#^P\46GC#3M%T;Q?XGTO]E;P5X6^$'B#4=&/A_PIXK\3ZEJ'C2S\0:+
M<Q_V+^AL7_!/#]C*RUQ?$FC? 3P7X>UR;XT_#[]H'6M4\/PWNDWWBKXG?";7
MO$'B_P"&&H^++RTNTNO$6@?#[QUXGU;X@>#O!6I33>#_  ]X\F7Q=I6B6NMJ
M]W)[AK_[/GP,\4^.5^)OB7X2?#W7?B&NJ_#?7%\:ZMX4T>_\3+K/P>E\<3?"
MK5%UBYM9+U;_ .'<WQ,^(4G@ZZ$PF\/OXT\2G37MSK%[YP&E_+_@?YGXG? '
M_@I5^T3^WE\7=&^#?[-/Q)^!'PW\*>.-1_;(^*O@K]H'6/@SXN^(Z:]\ /@)
MXY_9R\$_"KPKX5\"7_Q?\#P7'Q3U^;X]+XA^+FO:]>0VWA+0]%M/#MM\.]*\
M1>)?[8\+?T#:;'J$6GV$6JW=I?ZI%96L>IWUC8RZ997FH)!&MY=V>FSW^J3:
M=:W%P))K>QFU/49;2%T@DO[MXS<2?)GBW_@G[^Q'XY\,Q>#_ !-^RQ\$+W0+
M7XA>-OBQIUK:> -"T:ZT?XE_$J0R?$;QSH6K:):Z=K&@>)O'P9H/&FJZ-?V-
MUXILV:QUR2^LF:W/OOP[^$OPP^$=MXGL_A?X \)> +;QKXKNO'7C"'PEH6GZ
M$GBCQI?Z1HF@7WBS7_[/@@.K>([S1/#>@:7=ZQ?&>_N;'1M-MYKAX[2$( [=
M-/+_ ()Z'1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#^6__@Z.T+1O"?P<_P"">'[2F@:;:Z;\;OA!_P %
M'O@CH_P^^(=L@A\0^'M&UKPQ\0_B%JFD6E\@\T:?>>-/A+\._$4D#;E34?"]
MA+'M4W,<_P#4A7\PO_!UA_R93^QW_P!I+OV?O_53?M$5_3U06_@AZS_-!111
M00%%%% 'A_[3?_)MO[0G_9#_ (L?^H%K]?D'_P &QO\ RA'_ &-O^PE^TY_Z
MUW\>:_7S]IO_ )-M_:$_[(?\6/\ U M?K\@_^#8W_E"/^QM_V$OVG/\ UKOX
M\T%?9?\ B7Y,_>RBBB@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?R>?\'AW_*.#
M]G7_ +/U^'__ *S-^UC7]8=?R>?\'AW_ "C@_9U_[/U^'_\ ZS-^UC073^./
MK^C/ZPZ***"#^87_ (.L/^3*?V._^TEW[/W_ *J;]HBOZ>J_F%_X.L/^3*?V
M._\ M)=^S]_ZJ;]HBOZ>J"W\$/6?YH****" HHHH \/_ &F_^3;?VA/^R'_%
MC_U M?K\@_\ @V-_Y0C_ +&W_82_:<_]:[^/-?KY^TW_ ,FV_M"?]D/^+'_J
M!:_7Y!_\&QO_ "A'_8V_["7[3G_K7?QYH*^R_P#$OR9^]E%%%!(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHH("BBB@#P_]IO_ )-M_:$_[(?\6/\ U M?K\@_^#8W_E"/^QM_V$OVG/\
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MS+V'_!5+]O+Q)\'-2^/>K:1^SI\#/AC:^&/^"7FE^)M<\;?!;XM:YIWP2O\
M]N_X??LT_$GXX_'CXE:_>_&WPAI]]\+?V:K+QQ\2O"5CX>6T\+0QZOXF\*^)
MOBCX^\/^'_A1XJMOB)Z_\!_VN?VB_AQ_P2%\._M%?\))IWBSXD>(_P!LGXX^
M%/%7QL^+?A/XGZWX ^$?P4^(?_!4CXL_#?5OVA_$OPZ\4^.=!^**?!7X'? _
M5XO&7AOP5KGQ&T2/P7\-O#WAVU\3^,M'\$^&=8URT_H*I,<8_J?YYS^M K^2
M]?Z^]G\[?[,/QA_:K_:Y_;M_8>^('Q%\>^";SX-^ ?@U_P %0]4TN;X<?#SX
MO>$OA5^T7_PJ#]I+X'?L^?"O]J'P>L7[1.H>%4MOB_\ #'XDZ%XC^$,'CK0/
MC!X9\*^&-+^/FJ_#S4_'ND?'OX=?$;X*>0^ ?CA\<Y?VRO$.C_"[XX_M.>.O
MVB/^'N7Q#^&/CO\ 9WU/5/B'\0/@)H__  3OMM1TF/QAXO\ &'A?Q-9:A\.O
M@3X=^'_AB74_$/P?^(OA74_!.O\ C7XD6VB?#JVE\<66NWN@VO\ 4%C XY^I
M)_4Y-'?J/IW_ )_TH'?RZ6_X?1W_  ]>_P#+AX%_X*2?M[:#^RMHGQ$T+P9\
M-=(\%?#3]CW_ ()2^+?$0\5>"?C-\2_&VC^)OVWIO#UC\:?B=XO^+/[0W[6W
MAYM2\"?LO^%-)\5>(-6F^,'Q*DU75KS7M-\5?'GX^^ _"7@+QEXL\5^R^"?^
M"B?[8WQ;N_!7@";XK_LH? GQIX]_9*^(GQ4^!NO'X9#XY67[:OQ6@^+/[4/P
MZ\-Z#^SAJ'P^_:LU/X1R>)/A[\,_A)\%_CC\1_@_X'^*O[16NC4/CE9Z-IGB
MG4/A_P"#KOQ=XH_HKHQ]>F.I_P Y]^M 7\E]W_!/Y=?V9_\ @JM^UMXDM/V.
M/#>O?%#]GSXF:OXW\!_\$Y;$>%;+X+>,YOC!^VG)^TW\1K[P+^UG\2?A;K_A
MOXV'PEX U#]@CP_8:M-^TA9VO@+QOI?ASQ_\)/BCJ7Q1T/X!>&/B9\-_#'@7
MU;X/?\%*/VV9X?\ @ESXB^/FL?LVPVG[>TFD:UXH^%WP=^$?B"T^.OA%_&]W
M\)?#G@OPWI7P>^)_[45IX^O/A%X52[^*7C3X]?M#>#=-^*NK_""77? 47BKX
M/Z-\-O!'BGX@>-OZ,RH/7/\ WTW^-&![_F?\:!'X/_ME?M^?MH_!#XE?M@MX
M#\/?"BW^!W[/'BK]C;X<Z=K^K?"G6]9\3Z)!^T[J7@F]^(WQU\;>-?&/[17P
M9^$"> O@CX=@\6Z5]FUK5OA]X.LM8\=>'O&OQ5^)O@OP/\)_%$7C_P ET[_@
MJ9^U[_9<FI:_;_LXP^-M'_8!^(G[2_P4^"/@[P]_PL+6?^"DWQBT*]_;#L+#
MP;^RQ\1_AY^T?X[\%:='X-\)_ SX&_%[Q_\ ";X:S?M0^/?[)^-\_A[0O&.H
M:+I/A_Q[XH_HZ(R/_KD?J.:-H]_^^F_QH'?R1_,9J/\ P5(_;GUK3O$GASX'
M>.OV3?CWHNE>*?B^OAK]L7P1^S5\8[OX,_$C1_AY^P3K/[5VH>"O!_PXT_\
M::U$0>-_ _Q:T%/@]XRUH?%[Q+I-G%XNT[P?J&A:;\7_ (?>-='U+:B_X*3_
M /!1_4M$A\'6VB_L^:3\0]7^)EW;_P#"?S_LV_&G5O">A?#S5_\ @DPG_!0K
M2="LO (_:$T6^U+Q5X=^+<5U\#I_&NH^/;?1]<TVXM)9? VD^+K*?3-3_I9
M Z9_$D_S)I<8_P#UD_SH"_DOQ_S/Y:?$G_!7#]OKPC\,M*U#QKH/[/W@W4_$
M7Q ^!L]_\;-6^%C>"O@]\+/"GQP_8(L/VI_#WP\\:0?M ?MB_ OP-;ZE'\9+
MW_A4S?%;Q5^T%X$LM8TG3KWPIH_P[C^+_B?P=IK_ $I'_P %"/\ @H2GCE/$
M%Q\)?@QJOA*W^+4'P$_X9T\$^ _'_BGXDZ[X]U'_ ((JVO\ P4I74M _:&L/
MBM<^"O$-@G[1MG-^SCX7;1?@P-)\1>'=>28ZG)XK@TZYF_H"(SZ_F1_*B@+^
M2^[_ ()_'?X2_P""I7[5WAWPK^T=^U;8_M!? CXFZ3JUW_P3]L]:N](\$>*M
M+\%_V?XI_9J_:3^(7Q3^$W[%W[._QR_:S^'F@?%#]J[2?BQH_A3P+XR^%/A?
MXW67C?QK8>#O'/A6'P=+^T!X5@\%:9^U_P"W+^V+^U!^SO\ 'W]G7X2?"'P/
M\//%>A_MAZ;9_"WX*:UXF\ _$76[WP/^TGIOQD^%<GC.Y^)YT'QOX8LM0^&>
MF_LB^*?C;\?K+PS O@?Q*MS^R_X\T>?QO<7/B_P[I&F_K!@>_P"9_P :\FU_
MX&?"_P 5?%SP%\<_$OAR?7/B7\+=(\0Z/\.=6U/Q%XHN]$\%CQ79W>E>(-=\
M/>!IM:;P'IWC?4M!U'5O"TOQ#@\,KX\C\':YK_@ZW\1P^%]>UC2+X"ZOMIV/
MY[?%?_!7#]L_PMJ'QVU2ST+X!>))OAGI_P"U/XE^)GP/M_A#\4)?B)^PUX._
M9Y_;)^%/P;^'>N_M)^(=*^-5R/&]E^T1^S5XF^(7QW\,7^G^$/A/;O9^%?\
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MOBI\<O 'Q;^&>DZKX?\ AYJMBOA[X3[?%WPF_97T6P^('A7P<ESY7AB2^O\
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M(/'6I:=;^#;K5O#G@G0];\:ZUX9L]=N/$VF^#-&U?Q9=:1%X>TR^U*#C;_\
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M@J;QS#K/AK5/&&GB[T+3_$WA?Q-X+-W+X[TB;PLWU@#D ^HS0 4444 %%%%
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M$Y_A?I/C/0_')\>?$'4=7\.1^ [726U&U^'$]Y'I?@+XL?LU_&'2M!O/%)\
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M\ >'V^'L'@_7_CQ\6=(\':C\.9_#6I?\(MXVU*'QI<>-?%>F>$O&'AG[THH
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M/PKX$MM0TF\^(_Q!\=3:E>>$;V34O&_C;7@T=IX&M/!_@;PC]:44 ?,OB?\
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M;5K(Z9>^&O%*^$DM=/\ $7AV\\0:-)27]AWP=#KUC>6GQ)^)-MX1T'Q)XO\
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MH:1H)/A.ZTKPE!#XY\,ZA9K<:KH/Q!M[/4H=0GTRU32F\[T;_@GC\*M$\/\
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M?Q#=>'?"-IXW^)>OZ=X0T74/$/B#5=.\,6FDVNK:[K&I17>I7/U110 4444
M?#?[9W[-WQA^-&J_LU?%K]GCXA?#?P#\=/V5?B_XC^*'@>#XR^"/$OC[X3>-
M+#QW\%_BA\"/&GA3QAI?@KQIX \8:3./#'Q2O?$?ACQ+H?B"X_LSQ)X?T^SU
M7P_K6D:G>I;^>_!7]G+]L77?VI/!?[3W[9'Q._9IUF_^#OP1^-'P5^%/@?\
M9H^&/Q1\'65Q%^T#XS^!/C'X@^+/'WB/XH?%/QW<:A/I8_9X\$Z1X0\/Z!H>
MD0VZZSXHU36-9U%WTG3[#])J* _KT"BBB@!#G!QUQQSC]0"1]<&OPAM/V#_^
M"G'A_P#8^3_@GCX7_:/_ &'(_P!FO3_V>W_9"T'XH:Y^SG\=+_X]V'P)_P"%
M?M\(M/\ $E_H5C^T1IOPVU;XMZ1\/'B<SH=-\&ZSXPLUU>?1=.T>\ET"W_=^
MB@:=NW_#',>"?">F^ O!GA'P-HTMY/I'@OPQH/A/2I]1EAGU";3?#FE6FCV$
MM_/;V]I!->R6MG$]U+!:VT+SM(T<$2%8UZ>BB@1_,+_P=8?\F4_L=_\ :2[]
MG[_U4W[1%?T]5_,+_P '6'_)E/['?_:2[]G[_P!5-^T17]/5!;^"'K/\T%%%
M%! 4444 >'_M-_\ )MO[0G_9#_BQ_P"H%K]?D'_P;&_\H1_V-O\ L)?M.?\
MK7?QYK]?/VF_^3;?VA/^R'_%C_U M?K\@_\ @V-_Y0C_ +&W_82_:<_]:[^/
M-!7V7_B7Y,_>RBBB@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH _F%_X.L/\ DRG]CO\ [27?L_?^JF_:(K^GJOYA?^#K
M#_DRG]CO_M)=^S]_ZJ;]HBOZ>J"W\$/6?YH****" HHHH \/_:;_ .3;?VA/
M^R'_ !8_]0+7Z_(/_@V-_P"4(_[&W_82_:<_]:[^/-?KY^TW_P FV_M"?]D/
M^+'_ *@6OU^0?_!L;_RA'_8V_P"PE^TY_P"M=_'F@K[+_P 2_)G[V445#<3)
M;037$@E:."*29U@@GNIV2)"[+#;6T<US<RL%(C@MX99YG*QPQO(RJ0DFHKR[
MX7?&3P%\8[;Q5<>![KQ(9O _B:'P?XNTCQ?X!\??#3Q+X?\ $5SX4\,>.+73
M]3\*?$GPSX3\2V_VOPGXS\,ZW:W3:4;*XMM5BCBN&NK>\@MO4: "BL;Q!KEG
MX:T74M>O[;6+NSTNU>[N+;P_X?USQ3K4T:%04TWP]X:T_5=>U>Y.1LL]+TZ\
MNY "4A8*2/-?A-\>_A?\;/"_A7QAX#UG6/[%\=:<-:\$)XU\%>-_A=KOC#0#
MHNA>(1XB\->$_B=X=\(>*]9\.C2?$NBW+ZY8Z+-I<3WGV26Z2\@N;>$ ]CHK
M#;Q-X;34[[16\0:(NLZ9;Z;=ZEI#:M8+J>GVNLW#V>D7-]8&X%U:6^JW<<EK
MILUQ%''?7,;P6K2RHRBG#XW\%W-OH5W;^+_"\]IXHDM(?#-U#K^DRV_B*;4(
M[N:PBT*9+MH]7DO8K"^EM(]/>X:YCLKMX0ZVTQ0 ZBBN<7Q?X2>>TM4\4>'7
MNM0U3^P[&V76],:>]UK^R$U_^R+2$71DN=4_L%TUO^SX5>[_ +(==2\G[&PF
M,DWBOPO;6L-]<>)- @LKE-"EM[R;6-.BM9X_%-Z-,\,20W#W*Q2IXCU'_0-!
M='9=7O?]$T\W$^(Z -^BO%OB+^T%\*?AAXBT7P7XE\4V#>._$%SX!72_ FG7
M5E=>+IM(^(OQ<\%?!+1/%3:*]U!<Q^%;3QYX]T*SU;5R"MO:)J<]I#?3:=/;
M5Z1;>+?"M[%X<GL_$WAZ[@\8(\GA*:VUK3IXO%*)IT^L._AR2*Y=-;1-(M;G
M5';3#=!=.MY[XD6T4DJ@'0T5D)K^@R:R_AV/6])?Q"EK/?R:$FI6;:REC:G3
MEN;Q]+$QO5M+<ZQI GN# (8CJFG"1U-];>;QUU\8OA39ZMX!T*X^(W@M=7^*
MFI^(M%^&]A'XCTJ>X\;ZKX1M+R]\4V/AE8+F4:M<>'H+&Z&L):F3^S[B,6=U
MY=W+#!( >D45RR>.?!4EGI>H1>,/"TEAKFHG2-%OD\0:2UGK&K+JJ:"VF:7<
MK=F'4-177)(]&:RM'FN1JKIIWE?;&6$\?X=^.?PF\71:E>^%_'7AS7M$T.[^
M)6F>)/$NFZK8S^&_#&L_"+Q%IGA7Q_H?B;63<+::)JV@ZQJD<<UGJ#0F2TM[
MK48G:P2&XG /6:*\NLOB]X0U*Y^(]OIS:AJ"_#"PT+4]<N["VAOK/4K+Q'X8
MB\7:5-X;FM+J;^V$N-(FB8,BP+).Z) TT;+,>J'C;P891 /%WA@S-XG;P4(1
MK^E&4^,DM9+]_"0C^U[SXF2RBDO&T$ ZJMK&]P;00HS@ Z>BN;O?&/A'3;*/
M4M0\5>&[#3Y8M&GBO[W7-,M;*2#Q'<26?AZ:.ZGNHX'BUZ[BEM=&D60IJEQ%
M)!8F>5&478/$&@W.KW&@6VMZ1<:]:V8U&ZT2#4K.75[;3VNYK!;ZXTV.=KR&
MS:^M[BR%U)"L!NX)K</YT3HH!KT5S.E>-/!VNKHSZ)XL\,ZROB.VU:]\/-I6
MO:7J"Z[9Z#<P66N7>C&TNIAJEMHUY=VMIJT]B9XM.N;F""\>&6:-&X_XI_&O
MX:?!OP+\3?B%X[\5Z3INA?"'P/J/Q#\=P1:CI\FL:1X9L;#4;^"Y?2I+N&X$
M^M?V5>6/AZ&?R!K>IQ_V?8/+<$H #U:BN0T?QMH>HZ1X0U*_NK/PY=^-=/TN
M\T;0=9UOPU-JTMSJFDMK*Z/!/H.N:WH6MZE:VD-XT\OA;6O$&D7*6%Y>:3JN
MIZ9&E_)?@\6^%;J+PY-:^)O#]Q#XP!;PE+!K.FS1^*573YM68^')([EDUL+I
M5O/J;'3#= :?!->'_1HWE4 Z"BN=@\7^$[FZTZQM_%'AVXO=8N+JUTFS@UO3
M);K5+JQTV+6;RVTZWCN6FO;BTT>>#5KJ&V262WTV:*^E5+61)6\FUK]IOX):
M)XM'@F;Q[X?NM=L?B6/A-XO@L]6THQ?#GQA+\&?%'QYLX/B#+<WUJ/#6GZA\
M//"E[>6.H7 EBN-2O-.TU%\TZ@^G@'O=%8LGB3P[%JMSH4NOZ+%K=EID>M7F
MCR:K8IJMIH\UPUI#JUSIS3B[@TR:Z1[:._EA2U>X1H4E:12HP-8^(WA/2/!S
M^/8+K5/%7AD2VD,-U\-_#7B;XIWU^][J\.AHVEZ%\-](\5:[JL%MJ4VS5+O3
MM-NK71;6WO\ 4]9GL-+TW4;RU .YHKYFL/VPOV>M4N_ %G8^-M3F;XEZ%\./
M$7AN[/P^^)<&DZ?8?%[Q%JO@WX8VWC_6Y_!\6C_"?7?''CC0M8\!>'_"_P 4
M[[P;XEOO'VFW?@9=('BN(Z.=CP!^U#\$?BE-H=MX$\5:EKD_B;6SHV@12^"?
M'FB/K-N_@:7XC6?C#3%\0^&=).H?"_6/"4<=YX=^+=GY_P ,/$NI7NF>'?#_
M (MU/Q)JFGZ3<@6/H&BLR]UK1].O=)TW4-6TRQU'7KBXM-#L+R_M;6]UFZL[
M.?4;NVTJUGFCGU&XM=/MKB^N(;..:6"SMY[J55@BDD7Y_P##/[6?P-\1>!=4
M^)L_C;1/#7P^LOC7J?P"TKQAXBU_PM%H?BOXA:=\15^$T-KX=NM(U[6&:SUG
MXABX\/Z&-9CT;5K^&U;Q'_9,7A2[TO7M0 /I.BO+O _QC\ >/?"&H>-=,UVR
MTW1]$35)O$::_?Z7IE[X5MM)N=1@N+OQ3!]OGCT"TEM],N=5MKC49X8I=',6
MHEDA9MG6ZGXLT+1KB"+4[V*RLYO#VO\ BB76KF6&WT&PT3PV=(.J7NHZQ-+'
M9V,,<.LV]W'+/(L+6=O?7+2I%:2-0!TE%<[9>+_">I77V'3O%'AV_O?LND7W
MV.RUK3;JZ^Q>(8;FXT"\^SP74DOV77(+.[GT>YV>3J<-K<263SI#(RVTU_09
M+^STN/6M)DU/4;;4[S3].34;-[^_L]$NK6QUFZL[-9C<75MI%]?65GJ<\$<D
M5A=7EK;W3137$2. :]%>:>#?BYX&\=_\+%G\/:Q;7&D?#'Q-#X7\0^(VN].;
MPU<7,WP]\%?$M]3TC6[>]N+*]T2U\.^.](BO=2DDMH[;5+35[1T,5B+F;J(/
M&/A&ZFT"WMO%/ARXN/%=DFI>%H(-<TR:;Q+ITMC-JD=_H$4=TTFL64FF6UQJ
M*76G+<P/8P37:R&WBDD4 Z.BO-_#_P 5?!_BGXB^-?AEH5\VI:_X!\+>#/%7
MB*[LWL[O18+?QMXH^*7@^QTB*_M;N=CXATC7?A#XMMO$>DSV]O+I).EI(\L]
MU/!9]9I_B?PUJ]I#?Z5XAT/4[&X&JF"]T_5K"]M)AH5VVGZV8KFVN)89!HU^
MCV.JE'8:?>(UM=^3,I0 &Y17F&C?&KX0^(9_$=MHGQ-\"ZE/X1\;_P#"M/$B
M6WBG1G&D?$'^RK76_P#A"[IS>",>)1I=Y#=-I$;/>*!<1-$)[*\BMY_!?QA^
M%/Q%T#P?XI\"_$;P7XKT#X@Z%<>)O!&IZ+XDTJ\@\4Z!9*C:AJNB+'=&:^M=
M+,BQ:N\,3-I-QNMM26UN$>)0#TBBN=B\8>$I[2;4(/%'AV:PM]<A\,7%]%K>
MF26<'B6YU&UT>W\/37*730Q:Y/JU]9:7#I+NM_+J-Y:V4=NUS<11/P7PX^.7
MP]^)G@+P%\1=+U1M T/XE:-X(UGPC;>,7L?#VKZHOQ!\(^&O&?AW3;>RGOI4
MN]8FTSQ7I5I/8:?<7KKJWVFP@>X>$/( >OT5C6OB+P_?:OJ/A^SUS1[O7M'$
M;:MHEMJ=E/J^EB:WL[R$ZCIL4[WED);34=/NHC<PQ"2WOK.=,Q74#/P0^-7P
MX?QQH_@*+Q)I<^IZ_I.KZGI&I0:GI,N@7UYHGB6V\)ZAX9M]334")_%D>MSS
M6PT""&6\SI^II((Y[&:  'JU%<T?&?@]6U5&\5^&@^A7YTK6T.NZ6&T;5!8'
M53INJJ;K.GWXTL'4C9W8AN!8 WAC^SCS*:_C7P;'O\SQ;X83R_$T/@N3?KVE
M+L\8W'D^1X2?==C;XFG^T0>3H38U23SX=EHWF)N .GHK U;Q9X6T"9[?7?$O
MA_19X]&U;Q%)!JVLZ=ILR>'] 2&37==>.\N8771M%CN;=]6U-E%EIJ3PM>3P
MK*A/A>@?M6?"76_@S\*?CE+<>([#PG\;CHZ_"W1;'P[??$#QWXTF\0Z5J_B3
M1K3P]X+^$G_"P]9US4)_!N@ZUXZU33=$AU*^\)>"]%\0:_XUM_#=KX6\5#0P
M#Z3HKF/#WC#P_P")],T[5=-NKJWCU1X8+?3M?TK5_"GB*WO9]+77(]+U7PIX
MHL='\3:'K0T9TU671-:TBPU>#3F6]FLH[9A*>'T_X[_"W4_$GB/P]:^+M$-M
MX9\(_#[QG>^+'UG11X*N]-^)?B[XE^!_#=GIGB5=2>QO-6'B7X4^*--U"Q!C
M-O<OI=M#+<W=W-;VH!Z_17-:EXR\(:-<ZI9ZQXK\-Z3=Z'H?_"3ZU:ZEKNEV
M-SI'AHS3VX\0ZI!=744NGZ&9[:YA_M:[6&P\ZWGB^T%XI%7&\+_$CPYXMUGX
MIZ)IS7=O<?"#QI8^!/%MSJ,4-K8G6+_X9?#[XL17&FW(N)1<Z5'X5^)?AT3W
MLZVC1ZE%JEJ8#!9QW=T =]17+6/CGP5JBZ<VF>,/"VHKJ^AW/B?26L?$&DW:
MZIX:LI8(;WQ#IQM[N07NAVDUU:Q7.K6QEL();F".6X1IHPTMMXQ\(WD@BM/%
M7ARZE-MK]XL=OKFF3R&S\*ZG'HOBBZ"173,;;PWK,L6DZ_.!Y6CZG)'8:B]O
M=.L1 .DHKG=*\7^$M=G2UT/Q1X<UFYDTYM7CM]*UO3-1G?24U"ZTA]42&TN9
MI&TY-5L;W2VO54VRZA9W5D91<V\T201>./!4UEH.IP^,/"TNF^*9K:U\,:A'
MX@TF2R\1W-[*(+*WT&[6[:#6)[N8B&UBT^2XDN)2(XE=R!0!U-%>>_$3XL_#
M+X2>'M=\5?$WQYX4\#:!X9\,:UXSUS4?$FMV&EI8>%?#OV8:WKKP7$RW4VGZ
M;)>V-M<S6T$V+R_L+)%:[OK2";J+#Q)X=U6\DT_2]>T74K^+3--UN6QL-4L;
MR\CT;6?M']CZO);6\\DR:9JOV2[_ +-OV06E]]EN/LLLODR;0#:HKR[PO\8_
MA_XS\4:UX5\.:]8ZI/I&G^%-0AU:SO\ 3+KP_P"((_&,'BVZTR#PQJMI?W$6
MN75O;>"/$4^I0VJ9M8K&616F2&[-MTT'C;PS+<K97.K6>EWT^OW7AFPL-8NK
M;3+W5M7M?[1;[/H]K=31SZG]IAT?5KJR^R)*]U:Z9J$\2&.RN3$ =7165=Z]
MH=AJFD:'?ZSI5EK7B :@V@Z/=ZC9VVJ:VNDP1W6JMI&GS3)=ZD-,MI8KC4#9
MPS"R@DCFN?+C=6.5%XZ\$3V&A:I#XQ\*S:9XIN(+3PSJ,7B'2)+#Q'=W5S'9
M6UKH5XEX;?5[BXO)8K2"'3Y+B2:YEC@C5I75" =517.'QAX24>(BWBGPXH\(
M6WVWQ83K>F >&+/[/<W?VOQ$3<@:);?9;.\N?/U+[-%]GM+F;?Y<$K)S7C[X
MP?"KX6>%[_QK\1?B%X/\&^%M.\+Z_P"-;G6M>U[3[&U?PIX6TV/6/$.O60DG
M\[4].TC3)H+R\FTV*[\N&YM2 S75NL@!Z117'V'CSPEJ(M7CUS38(M3UF+0=
M GO+ZRMH/%-_<:)#XCM5\+327&SQ!%>:+*VI6;Z8;@W5G;7=U"KVUO)*-.W\
M4>&;N76H+7Q%H5S/X:2*7Q%#;ZOI\TN@1SV\MU!)K4<=PSZ4DUK#-<Q/?"!9
M+>*69"8XW8 &[17-:_XMT+PYHVOZW?7L<T'AO3I=2U*TL'BN]2V+:27EM:6]
MBDHFFU#4XX_+TJS^6749Y(HK8.TBY\KT_P#:7^"VL?$&T^&^B^.="UG6I6^)
M=AJ-_IVJZ5/H/A[Q/\*/%_PC\"^*? OB#4C?)_9WCA_$WQL\"Z=I/AQH)+K4
M)KF]@5HKJ*UMKT ]YHKQCXD?M _"GX5ZYI/A+Q5XJT]?'&NV6DZOH_@2PNK*
MY\8:AX?U7XA>"_A@?$MOHDMW;S_V!IWBWQ_X<M-1U%V1$@EOIK5;MM-O(HO1
MK3Q;X5O[?P_=V/B;P_>6OBUWC\*W-KK.FW%OXFDCL;K5)$\/S0W+QZRZ:98W
MNHNFG-<LMA9W5VP%O;S2( =#17A5Q^T?\*[+XHZS\']0O/&>E>,/#NAVWB?7
M;S5_A3\4])^'^D>&[V+6WL-?O_BWJ7@VU^%5OI-_/X;US3K*\?QF(KG6-/DT
M:(MJ<MM:S^G7'C;P9:'7ENO%WABV/A8@>)Q<:_I4)\.%M-EUD#7A)=J=()T>
M"?50-0^SYTV&6^'^BQO*H!T]%<S=^-?!MA)/%?>+?#-E+;>'7\7W,5WKVE6T
MEOX2CD$,GBB=)KM&B\.I,?*?6Y NF+(1&UR&XKG?'7Q@^%?PS\*7?CCQ_P#$
M/P?X3\)6?A?7O&KZ[K.OZ=:V5QX3\+Z,?$/B'7].)G,NJZ=I.B :I>3:7'>>
M79R0S8*SP[P#TBBN+L?B'X-OXH[I/$&E6]C>:[I/AS1-2O-1L;;3?%.J:]H.
ME^)=$B\*7TER+;Q$NKZ5JUO-IC:7)<-?M%=BT69+=W.[8>(-!U6_U32M,UO2
M-1U30VMEUO3;#4K*\O\ 1VO?M'V-=4L[>:2XT]KO[)=?9A=QPF?[-<>5O\F3
M: :]%%% !129'_U\<<>_3CZTM !1110 44F1G&><9Q[=,TM !1110 4'ZD?E
M_4&BD)QV)^@S0)NW]?\  8M%%% S^87_ (.L/^3*?V._^TEW[/W_ *J;]HBO
MZ>J_F%_X.L/^3*?V._\ M)=^S]_ZJ;]HBOZ>J"W\$/6?YH****" HHHH \/_
M &F_^3;?VA/^R'_%C_U M?K\@_\ @V-_Y0C_ +&W_82_:<_]:[^/-?KY^TW_
M ,FV_M"?]D/^+'_J!:_7Y!_\&QO_ "A'_8V_["7[3G_K7?QYH*^R_P#$OR9^
M]E9^K#56TK4QH3Z?'K9T^\&C2:M'<3:4FJFVD_L]]3BLY8;N73UN_)-[':S0
MW+VPE6"6.4HZZ%%!)\K_ +./PJ^*WPI\+-9^.;WP!K_COQC\1-0\>?&OQ_I=
MUXCO=3^)FLZKX(BTB]\3Q0W^EZ0GA^_L=7T+P3X/\&^%)'UK0_ _P3\)Z!X$
MTW5+Z3P]I5VOU1110 UF559F8*J@EF) 50!DEB>  .23P "3@5^:'A+]@[Q!
MX>L/@UI#>/?!6IV'@GPY^Q1;^(/&3^";X?$K3]0_8QNX]2T[0?AEXF;7Y8M#
M^&WQ7F-[9ZQX<OK:2?P?I_C7XX^1=^,'^-TR^ /MCX]> ;OXJ_ _XP_#+3Y&
MAU'X@_##QWX,TZ5=9UCPZ$U'Q+X8U/1[!I==\/S6^M:5;B[NX?M-[IDJW<%O
MYK1!R-C?%/PR^%W[2&G_ !H^'NNWFF?&3PUX,T_Q-X0U7;XR^/H\6>"O"_P
MTW]E&R\!:C\#_&7P\M/B9XP@\9?'4?M.0ZE\1;CQ^NG^+5F\-W^G^(I_VDM?
M_LL_!>4 YG]I+]B[XK?$CQAX]^(J>)O"7CM]<O+'PQX5\(:]X4U+5-*@\#^-
M?BI^REJ^L:'XP\'_ /"<>$O GB'PGX$LO@/J/B/Q?-=VM]\1/C!I&H:7X7_X
M3'P9IO@;0](UK&\2?L-?$;Q9\2OBC]J@^$VBZ/\ &WX<>.['Q5XHTWP/--:?
M"/5/B5\0/".JZG%^S](^OVNK:%XWT>U^'FF?$W5_$FIZ39:?XW_:/\2S?M O
M%X8NM!'PRUGTOXB?#/\ :$U#Q=\8[B#2/CCK\VJ_$;P1XBT'Q#X%_:&G\"^"
M_$?[/>F^(/A'<^)O@UX!\)CXL^%_^%4_&QK+1/%YD\8_\(=86_C33K/7;)_C
M_P##T?%672O!7F^@?LT_M2ZQJ\6J>-/'7QSL=+M)O@E9>#M%T[]IOQSI5UX;
M^&4G[6_[3WB3X@>$?'0\+^/HK+QI\3O#W[('C?X&?#3QW\0=9U/Q_P"(]<\3
M>$8]4\ ?%#Q/XR\.6WQ(NP#KM?\ V%8O#W@JYL['Q?\ #+PYH]Y\()_ 7C_Q
M3JO@%O[1^%ILOBGK?QK\0_'/X":A;:W8P^ /BSJ^LZD-8U[Q'JJ:BTGQ%^'O
MP ^,%S>W5S\"D\$_$'G=5_X)Y_\ "7^'K>]M?'_@_P ::'_PDGB^P\">&;_0
MM6T/P5:_LH^)OAGXX^'?PI^"-GJ7AS6I]1@3X.^&_BGX^A\)>*8K>_M]9\%?
M$/XG?#]]&T6/X@0^,/"?F&@_"[]J/Q)K'Q<\"@?''6/$7A#Q[H'@O1/&>O\
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M$^"VK:[XB_9/\3?!CX>:OX2TK3V\8?';0?B-X3^)&F? G6+O4-,\,^"_#O\
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MO$6BS:CXO;Q]>>&/%<WAO5)[_P""GBWP9\"?@#\,?%'PRDL? MCX@L_T/HH
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M$&K:W%<:[\&[;Q!\3=3\2^'/A3<'P/I_P_OM5^)R^%;Y="^)NF^%_AO^E5%
M'YJ>.OV'/&'CS5/BKK5WXM^'EG>?'31=6\,^)I+[PCJGB/5_@Q::^GPYU*^\
M9?L^>))=3T:70/B+:ZYX(%RNN:AI-M%JOB/PI^SU\1)DTV[^ @\&_$/V;X9_
MLGZ9\/?'NA>+XY/"+6"Z!^UYI'C?0]*\)P:;#XYN/VF?VB_"_P =]*NM;(GD
M@U./P>+/QOI-Y%J\&H-JFI>/==U6TDTY-2U>VU#[%HH _(&X_P""8/B&Y\%:
MYX6N?C%I5[J'BKX/?$_X:>,/$5[X4UFXO/&&J>'_ (1^//V;/V/?$&M07/BR
MZM_*^%GP&^)_BUOC):HLMS\5/B_8^$?'_AV]\ 66D7GA_4_8/B!^PC/\0M;^
M+USJ^M> IM,\:?#K]M+P7X--_P"#)-3O]"U3]K_2/@9;W/B35HKF[^R/?>#[
MKX:>,=(NI=+>"Z\4>%O%EC9R3Z1+;ZNFJ_H]10!\=?M(_LOW?Q[\3^"-1EU'
MP@OA[3/!'B'P%XWT;Q-X=FUL^)=$UOXQ_LX_%>2U*F=;.^TBZM?@7K/A'5O#
M^KP26M[!X[&K"[1-#O-%\1^2ZW^P:=4^+=OX\G\1:+J?A"?QW=^)Y/ I7Q-X
M5C\'X^/GA[]H^R\0^ ]0\+:O;I9^)-3^)&A1:YX^L9[.ULO'7BK1/AMXTO=6
ML+GP%J>A^._T?HH ^0OC/^RXGQA\=:IXDU;5?#MQX>U:V_93AO/#&O>'#K=M
M._[-_P"TV_[0=R]PLUXEG<#Q#&+;1M,66T9='U2UBU:<7\(%FOD"_L/^*=<^
M.VF?%_X@>/O"?BZTT;XDZWXN32+OPMK<AUK1(/BQKOQ0^%5E-H=QXF?X>^%=
M2^#]EJ^F^#M#O_"W@N#7/%.MZ!J?QB\:^*M;\:>-YM-\+?HY10!^9>G_ +$/
MQ,\'":U^&/Q'\&>!])E\.:/H?B+3--\.ZC]G^(6D>&_C+X.\:>%O"$274M_#
M\#[?PK\(/#WBKX%Z#X]^$D,/B6TT?QWX<\3_ -DMK7P ^$(L,[0O^"?GB?P_
M\/\ XL_"]/&_PXUC1OC9\"O'?P5U?QAJ?@3Q1=^-/A;:ZX?C\?#,?P^O?$7C
MWQ;K/B'P#HT7QKMH+?P+XJ\7VNKZ7?:;X[\03^/_ !/?_$^:W\)_J+10.[M;
M]%^>Y^8OQ6_83\:_%2^^*&O7?BCX5:=J_P :?!GQ@\!>);/4? ^K>)[3X?6/
MQQ^$7[+?P\\0>*? &J2ZOHUS?>(?!>J_LY3ZEHEG?Z;H</BFT\1: ]]JOA>Y
M\'-%K_O'PD_95MOA5\3]!^(FG:CX;B%G_P -L3>(+/1O#2Z3>>([[]J_]J/P
MG^T5HM[J%_#<G[5<>!XM&U_1-1FO8;F76=6\27FM6+:3%->65U]A44""BBB@
M#\$?V<OV"_V-OVV/B?\ M[_&#]KS]G#X5_M)_$W1?V]OC9\*]"\9?&?PW;^/
MM7\._#3X<^'?AUH_@?X?^&F\0M?6WAOP=X;LGN&L/#FAV]AI+:E?ZMKEU:W&
MN:UJ^I7WV#_P2+FO%_88\'Z!<:IK6JZ;\//CQ^VW\(?!HU_7-8\2:AH?PS^"
MW[</[1GPD^%'@V/6_$%]JFMWNE> _AIX*\)^"M .IZC?7EOH.@:;:RW4Y@\Q
MG^*_^";HE^)?Q4^(OP3_ &W?VW/V5+'XS^.KCXI>/_AG\"/$G[.-_P##34/B
M;J>BZ)H7B7QUIFE_'C]F?XW>(O#NJ>+;7P[I%WXCTK0/%&G>$[O68;O7+7PY
M9:MK&M7FH_7/[-W[/G@']EKX,>#?@;\-)?$M[X7\(?\ "0WTNN>-?$%YXK\;
M>+_%GC;Q7KOC_P"(?C[QKXDO@DNM>,OB'\0?%/B?QOXKU"&WL+"?7_$&HMI>
MF:5IOV33K4&W=?=9=%I9V[?*U^I[C1110(_)K_@I-\/?!OQU^./_  3+_9P^
M+NA6OCWX#_&/]J;XNCXM_"?7'N)/!7Q,M/AS^Q5^TQ\1_!&D^.]&MYH(?%/A
M_P /^/\ PYX=\8VWAO63=^'[CQ'X?T+5K_3;N\T73);7A/AW^R?^SE^Q3_P4
M]_9G\(_LD_"'PA^SQX-^.G[%7[<^K_&'P3\*;.;PGX(^(NN_!GXQ_L!P_"OQ
M+XH\&Z?<)X9U#Q7X$M/BY\2]-\.^*VTI?$=CI'C;7]%75&TF_DLJ^^/VIOV3
M_"O[4VE?#9M0^(WQ9^"WQ"^#'Q ;XF_"'XT_ W6_"VA?$[X=^*[SP?XK^'>O
MR:1)XZ\&_$3P+K.C>*_ 'CCQ7X1\2>'?&7@;Q/HE_INKF\BL;;7--T;5M-\W
M^ G["&G?!WXS1?M ?$']I[]J?]K+XK:-\-O%'PD\ ^(/VE/$WPBNK'X7>!/'
MWB7P9XM^(NF^!O"WP/\ @M\#_"46I?$#7/AM\.IO$OB;Q+H?B7Q.;'P1HFCZ
M/K&D:0^K6.I@7T2[7OYN^CMML[?(^\**** "OY6/!7_!.[]B;Q9_P0\T/]M3
MQ-^SE\/]>_;"\2_\$PX_VJ]<_:GU>'5]0_:'U#]I'6OV9&^,>H?&Y_C+=ZI+
M\0X?B,WQ.N9?%]CXEM_$,-_I%^MK;Z0]AIMC8V5O_5..@_IT_"OQ]_X<^>&[
M7X83_L\Z)^WM_P %#O#O[*;>%;SX8V?[+VE_$K]GZX^'&C_ ^]M)M%;X%:3X
MXUS]F;6/VBK7X<6G@Z=_ 6E3M\<)?'VC^#DMM,TKQS9SV=G>VX-.WWK\'M\S
M]+/@3K>K>)O@?\&_$FO7TVJ:[X@^%/P\UO6M2N!&+C4=6U7PCI%_J-].(DBB
M$UW>7$UQ((XXXP\C;$1<*/5JR]$T72O#>BZ1X=T*PM]+T/0=+L-%T;3+1/+M
M-.TK2[2*QTZPMH\G9;V=G!#;PID[8XU&>*U*!'\PO_!UA_R93^QW_P!I+OV?
MO_53?M$5_3U7\PO_  =8?\F4_L=_]I+OV?O_ %4W[1%?T]4%OX(>L_S04444
M$!1110!X?^TW_P FV_M"?]D/^+'_ *@6OU^0?_!L;_RA'_8V_P"PE^TY_P"M
M=_'FOU\_:;_Y-M_:$_[(?\6/_4"U^OR#_P"#8W_E"/\ L;?]A+]IS_UKOX\T
M%?9?^)?DS][****"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "DP..!QTXZ?3T[4M% !1110 4444 %%%% !1110 4444
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M",QB<*-/ DT=L\T2W$\<TL-NTB"::*W,2SR11%@\D<+3P+,ZJ5C,T0<J9$R
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M_P"#K#_DRG]CO_M)=^S]_P"JF_:(K^GJ@M_!#UG^:"BBB@@**** /#_VF_\
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M?A3\$-.^$_ASX.:KIGQ0U'Q)X,\5^)-/^)?QO\62_$BZN_#'P^\-^%^:\?\
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M_;_Q(U;7_@E\+_B_8:OH!UGP?J7Q!UO0-+^#.B:1X_\ #.MW<7P\T#P+J9\
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M (@^'7[77QAM-+T&\UE/"/C/PMH5_P#L^:9XLN[W[1%\1/&&I?M0?M>_&/\
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M^8WQ9_:VT[_A /B9X!_9OMO#/P8\ >"O#?Q%^*_@/Q#\#;?0?@P=8\-?$O\
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M1X'\1^$3?6GPKC\6#PWHG[-EKHGB&\NXO$)\9+;3V_CE?%-I;2RVEQY]X?\
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M6M3T#6O!%EKT=EJ.GHNIQSWFG/+HM]J+X"3^%/VM/"_BSQE9?#'Q)\)/B5X
M\>:KX,T7XH/X3\;0_#B_FA\$Z]H'BC7_  EXAO[WP7X]\9:*EUJ-]\.O&OA-
M])_M"76M%\6>"M0:\M$\)WW@[Q;XG]Z\)?"#X:> KFYG\$>#M(\(VMWX1\)^
M!)=!\.1RZ/X07PKX%T^XT;PCI=MX)L98?"%D="T*>/PY9W]GH<&I_P#",Z=H
MGAJ:\ET'P_HFG:?Y='^QS^S9#H$/AB+X7Z?'HUOJ%A>VT*:YXK6\M;/2O"^K
M>!=+\*6FKC7AK%K\.--\">(-?\"6'PMM[^/X;VG@?7M:\'V_A6/PWJM_IEP
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M5?\ A^71_$7B36=2TMK2XO[AG /&O"W[9O@'Q)J]AHEA\(/B9IOAVQ\1> _
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MAF^MOMNC^)A\2+G5+SQW%J]G=-+%=6_BFXUO5GU:U8"VG6_N(EA2)]@XZ_\
MV<_@IK&A2>&O$/@#2O%NBW.HZAK&IV?C6YU3QJ_B'5M7^$%[\ ];U/Q5>^++
M_6;_ ,67^O\ P?U/4_ GB&[\2W6JS>(-*U+4)M9>^U*\N+Z0 \ \;_M4:OXE
M_9_G^)/P9L-#T#Q<?VB/@)^S],?B1I%E\2/!]A-\5_VBO@W\)?$6N6%U\+?B
M5IWAWXAZ1%X.^)TFO^'K[PA\3TM+/Q L'A_Q@NE^*?#?C+P-IGGMO^U'\:]1
M^)/BG]G>-?A=I7Q7^&&H?&;5_'OQ4L_A=\1?B%X2U[PE\(/AK^R3\1?/\!_L
M_P#A7XA6GQ+N/&?BC1/VRO &A1>';?XF^*+K3M2\&>*8])/C"3Q#X9TI/L[7
M/@7\.?$WPW3X3^([;Q;K_@^+6_#?B6)M:^)OQ-U3QA#XA\'>-='^(GA+78/B
M5?>,)_B3!JWAGQGX>T/7-!U"'Q8EUI4VDV%K92PV%M%:+FW'[-GP2F\+^'_"
M-KX$M="T_P *:WK/BCPUJOA+5_$7@SQMH7BOQ.^H2>+_ !=I?Q'\)ZQHOQ!L
M_%WCA]7UEO'WBJ'Q.OB#QXVN:Z?&&I:W_;>J_; #PWX1?%SQU^T+JEI=?"SQ
M#\)K7X4>#_#WP2_X2_Q!XJ^"_C^#Q/\ &%?B'\/?"'Q@NYO /@'5_B/X+U+X
M'^"(/ ?C/0;+PK=^/U^*NO0^.]6\8^&?$'A+2YOA'=R?$;WGX _$#5?BG\-K
M7QIX@L=(L=6F\:_%;06@T>WN(+%;;P/\4_&G@'3+F-+V[OKD7=YI'ARRN-1D
M-TR2W]Q=M;QVUJ\-I#7L?V;?@MH][X"U+P]X-/A._P#AKX:\'>"?"UWX*\1^
M*_!,[>!_A[=SW_@?P-XID\)Z[HS?$#P1X5O[S4[_ $/P?X_/B?PW87VM^(;R
M#3%N/$6N2:A?\%_ 7X:_#[4;C4?"5KXOTT3^+=4\<KH\_P 4/BAK'A2Q\2ZY
M_P )PVLW>C>#-;\9:CX2T&QU:Y^(OBS4=2T+1=%T_0+_ %BYTG6KK2YM6\*^
M%+W1 #UM[2TDE,TEM;R3-;R6C2R0QM*UK*P>6V,C*7:WE=5>2$DQNRAF4D T
MY;>W4*JP0JJI"BJL2 *ENQ>W0 +@+ Y+PJ.(F)9 I.:FHH JK8V2);QI9VJ1
MV<IFM(UMXE2UF994::W4(%AE*7$Z&2(*Q6:52V)'!>UM;,AC:W@:,I'&4:*,
MH8X26AC*%2I2)B6C4C;&22H!)-3T4 1M#$TJ3-%&TT2R)%*44RQI+L\U4D(W
M(LGEQ^8JD!_+3<#M7#&M;9D\MK>!HPL*A&BC*;;9_,MUVE2H6"3YX1C$3_-&
M%;FIZ* &%$.P%$Q&08^!\A"E04X^4A6905P0I('!(J,VMJ8_*-M;F+[0+KRS
M#&8_M2W(O%N=A7;]H6\ NA-CS!<@3AO- :IZ* .+\5?#[PEXVD\,-XETV?4(
M/"'B?2/&>C:<FKZUI^BR>)/#S--X=U#7="TW4+/1O%:>&]26T\0^'=/\56.L
MZ9H/BW2/#OC#2;*S\4^&?#^L:9UP@A&XB&(%R"Q$: L5E>92QQR5FDDF!.2)
M7>0?.[$S44 >9>!?A!X&^'6L^)O$?ARW\1W'B+QA:Z'I_B'7_%WCSQW\0=;O
M=*\,W/B"\\.Z)#JOC[Q)XEOM-T'1+WQ9XGOM-T/2Y[+2;>_\0:SJ"V9OM3O+
MB;T46EJ$:,6UN$:2:9D$,81IKGS/M$K*%P9)_.E\YR"TOFR;RV]LV** .0U#
MP'X3U;QMX<^(FHZ0MUXO\)^&/%O@[P_JDEYJ BL/#WCG7? /B7Q/9'24NUT6
M[FO]<^%_@74+?4[[3[G5=)DT/R]'O=/@U/6(M0ZL11*P98XU8>9A@BAAYS!Y
M<$ $>:ZJ\G]]E#-D@$244 0Q006Z1QP0Q0I'%%;QI#&D:1P0@K#"BHJJD40)
M$<:@)&"0JJ":400AI7$,0><*)V$:!I@J[%$I S(%3Y%#E@%^4<<5+10!5BLK
M.W\H06EM"((8K>$0P11^3;VZR+!!$$1=D,*RRK#$F$C660(JAV!>EM;1@K';
MP(I,[%4BC5=UU*T]TQ 4 FYF9I9SC,TK-))N9B:GHH BDAAE18Y8HY(T>&14
MDC5T62WE2>WD56!4/!-''-"X ,4L:2(5= 1R7A;P#X7\&ZGXVUK0;2_CU;XB
M>)_^$O\ %M_J>NZ]K]SJ&LIHND>';9;1]>U/4QH>BZ?HVAZ;9:7X9T$:9X;T
MOR[FZL-)M[W4M3N;SLJ* *ZVEJ@VI;6ZK]H>[(6&-1]J=VD>YP% ^T/(S.\W
M^L9V9BQ8DTC65F\)MWM+9[=I_M30-!$T)N?M7V[[08BA0S_;?],\XKYGVK_2
M-WF_/5FB@"$6]NKK(((1(@PCB) Z#]YPK!=RC][+T('[R3^^V4-K:L4+6T!,
M<$MK&3#&2EM.8C/;H2ORP3&" RQ+B.0PQ%U/EIB>B@"(0PB5YQ#$)W6-'F$:
M^:Z0^;Y2-(!O98O/G\M22$\Z7:!YCY2"VM[9$BMK>&WBBABMXHX(DB2." ,(
M8$2-55(80S"*-0$C#,$503F:B@ HHHH ^"/C)_P3 _8/^/OQ(\2?%[XH_L\Z
M!K'Q)\8C3&\8>*]!\4?$'P!?^+;O1],MM$TS5O$\7P]\7>%;'Q!K]GH=CINA
MQ^(M7M;S73HFDZ-I$FHOIVCZ9;6GUQ\+OA7\./@E\/?"'PF^$/@CPS\./AIX
M!T2T\.>#? _A#2;31/#GAS1;)2(+'3--LHXX(5+O+<7,I5KB]O)[B^O)I[RX
MGGD[^B@ HHHH \)_:%_9E^ O[5W@6V^&W[0_PP\-?%/P=I_B/2?&6BZ?X@AN
MHKWPSXPT.*^M=*\6^$?$&E76G^(O"'BBSL-5UC2(_$/AC5M)U=M"UO7-!EO'
MT?6]5L;WS3]G/]@3]C_]DSQ3XB\<_ #X'>&O GCGQ5H%MX3UOQQ/J7BCQAXS
MF\)VVHC6%\)V?BOQUKOB;7](\+7&L)!K&H>'-'U&PT75-8LM-U34K&[O],T^
MXMOL&B@=W:UW;M?3[@HHHH$%?F7??\$;O^"9&I:U?:Q>_L@_#B2WU3Q!=^)=
M0\'IJ'C2#X6WNHZAK$FOZE:W/P>M_%,7PJF\/:GJ\UQ>ZGX2?P:?"NI/<W<=
M]HL\%U<12_II10 B@* J@!0,     =  .@ X  P ,4M%% '\PO\ P=8?\F4_
ML=_]I+OV?O\ U4W[1%?T]5_,+_P=8?\ )E/['?\ VDN_9^_]5-^T17]/5!;^
M"'K/\T%%%%! 4444 >'_ +3?_)MO[0G_ &0_XL?^H%K]?D'_ ,&QO_*$?]C;
M_L)?M.?^M=_'FOU\_:;_ .3;?VA/^R'_ !8_]0+7Z_(/_@V-_P"4(_[&W_82
M_:<_]:[^/-!7V7_B7Y,_>RBBB@D**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M".X,JV\DT()DBCG,$X@=U59O)E\LMY;XGH **** "BBB@ HHHH **C,T(F2
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M@KXY:CI_Q";PQK.M?"SQ/XNCO/#&@>( 1R/P,TWXSZCX*_;AU;X?>)OBQ?\
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MM[<Z6NF^*SKHT?4_T\HH$?B[//\ MI_!?P=XN'PIL_B%KEEXW^*7[:?C6_\
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MOQ-3Q'\&]4\=>/?VF-,\9^)_"/P[^$5S$OPKT#P9-^T#X&\7H/\ A._UWHH
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M=^&/A.J?'K]LCPIX ^)>IG2/CSXYU72/AS^U_P"%? _B'2/V=-6N;CQ_\?\
M3O!G[/OB;]F;7?!_PO;X%^#?&GPW\ :C>7WQPT#2=/\ BK#XQ\":/XITG5/#
M7CO]H'XH6H^'GBS6?V*HH _$#XB_ 7XS:7!\6?'&B6WQ1\;>)8;+_@I]X[\.
M^&?$?P<^#'B_0/$?CK6?#^G>#?@=#J.DS_ R35O%9UOPKYWA_P"'RZAJUYKG
MB?PJMWX&.JZ[\/;W4/"5UZE\3_'7[8!7Q%K'@GPOXY\:_';P;\9/VHYO!?PE
M\5?!/1H/@;X<\,^&_@%^V5;?LHZ_X(^,=S\.K7S;KXP'3OV?A\2_$FG_ !W\
M1:EHOB?XE>(_AOJ4'PSL]>UGX::9^MM% 'X^CQG^WC=^ M6\3:1XT^(U\?"'
MPB_:J^)_@C3X/@HS^,/B5XR^'>F_LXZC\#_A7\8H?B3^RI\ ]5>Z\8^*-3^/
M6D0Z!\*/@U\)?$'BSP!<^'[/P]XUE\;>"M;\8ZE[Y\/9_CUX,_9M^.&H'Q)\
M:?&/Q1^'7[2OQ[\;VNG>/?!=EJ7B_P 7_"OPQ^TGKOQ*TKX4_"Y4\"Z'IOBG
MP_\ %?\ 9]BL?!OPYU[0;;Q+%X1U;QTOA[P]K.E7G@6T\)^$/T&HH _+/2?&
M_P"V9?\ B;PM9Z[J'Q;T#Q;XNU_X1ZIH?@+3OA#X/O/A-8?"GXI:B_B'XUW'
MQ!^+S?#/5;'PI\4OV:O#?B'QQX2\ ^'M7\:^%/\ A--5^"OP>U37/#'Q*U+X
MO>*-!U7PWX+>,/V\K'P_\"_ VI>+_BSX=@T3]F7P-!KOC/XO_!3X@_$'6=9\
M>Z=\*OB);?%76?B#HGAC]E_^T?$GQ#\"?$O1[*#PCH=_\>_A'-\6-)\,^$;S
M3E^*-]\5K;Q!XE_;ZB@=_3[D?!_ASQ3\9?%_[/GP*\1ZWX/\=GQ\?C/:6GBV
MT^('@_0]?\7Q>'O#OC[QEH:>-Y-//P:^$2Z#I6MZ/I>D^*/">O7'P=^%_B[2
M/"FM:))K_A_P_P")I-7MJT?V9I?VD-2TK5?"/QG\:_$;4+[7OV;/V>/B#%\2
M=>^'_P /_!_B#PA\9_B9IWQ4T7XO^"O"EAI7P^TKP4L'PWNO!7@;Q5IOA3QK
MX;\;^)/#.K>-KBV\::QXE\/:GX>T;3?M^B@1^%?PQU/]M_X?> _V8/@)\%O!
M7Q.\*/X2_9Q\(>#]4D^(7@7PMIO@1_%L'['WQ!^)NB>)]8CTG]F_2?#'A&ST
M_P#:&L?AM\ _%=EJ'QXTCQX;F/Q8MY\"-+AU+0/C1K?O=C\6_P!L/7_$7@KQ
M-=:?\8O"F@?$)_A7X\^$O@"#X%V(L]5\/?$/]HKQQ:>.OAM^TS?:CX%\0>(?
M@)JGPE_95M?@GXDU)O$'B7X;^)M+^)OC;XNPZ;-\:;WPC8_"_P &_JS10._I
M]R_R/@33M>_:6TC]B7X/>*O$/B+XFZI\<?%&D_ /7_C7K=G\*_"=U\4?A[IW
MCC6?!%Y\;H?!/P;T7P'_ &=<:I\/-'U3Q/9:'X6U;PGXT\5Z)IUA+>:AI_Q3
M\5:+'X?\4<W^R[X:^,_B?XZZC\7_ (S2_$*62U^"5WX(\"W/C'X>^"O"D6K^
M$(OVE_C[#X(\6:S GP]T7QAX,^*WC[X(>'_@KX[^*O@C3M4\!:=;:_XCCM_%
M'PA\'76C>&_"/@O]'Z*!!1110!^$_P"RK^VY^QU^R5\2O^"@/PF_:H_:C^ ?
M[-?Q-N_^"@WQQ\?Z=X$^/?Q6\%_"'Q/J_@+X@^&/AEXA\$>.="TGQ_K'A^YU
M_P &>*M(N%NM&\5:(FH:!>30W^G+J U32]4LK/ZD_P""04C7_P"PGX/\3P6]
M_'H7Q$^/G[<?Q:\$7VH:9J.D'Q+\,_C#^W3^TC\4OA9XYTVSU:TL=0;P[\0/
MAQXO\+>-_"U]/:PC5?#7B#2M5@4V]Y$S?I@\44G^LCCDXQ\Z*W'I\P/'MTJ2
M@;=[^=K_ "5@HHHH$?DW_P %'?B#X&^"/[0/_!+KX\_&#Q9H'PT^"7PQ_:K^
M,5O\2?BUXVU.T\._#SX>#X@?L0_M.^ _!5UXY\6ZG+;Z+X2TOQ)XUUO1?">F
MZSK]YI^D2^(M9TC1WOH[_5M/M[GD/"/[47[.'[7O_!4K]EW7/V5?CG\*OVC_
M  ]\%_V(/V[K;XM>)_@CXY\/?$[PI\.=0^+OQI_X)_)\,-&\8>*/!]_J_A_0
M_$/CM/A5\2+OPSX<O=1BU[5=-\$^(]5MM.?3-+N;M/V2*JP(*@@@J00""IZ@
M@]0>X/![TU8T3[B1HN=WRJ%^;&W=P ,[?ESUQQTH!NZ2[)I?-M_FQ]%%% !7
M\LW@+_@H'^P_X:_X(+:)^RYXC_:P^ WA_P#:?\+_ /!*]_V;?$'[-&N?$CPY
MI'[16D_M!>&_V7YOA!K/P4N_@7J-[;?%5?BC:_$VPNO!4/@A/"3^(-0UM(H-
M+L;V*ZM)I_ZF:9Y4>\R>6F\G)?8N\G;LR6QDG: O7[HV].*!IV^]/[G<\J^
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M4:*U@AMXWGN;EHX(DA1KB\N);N[G9(U53-=7<\US<RD;Y[B:6>5GED=VFHH
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M'_J!:_7Y!_\ !L;_ ,H1_P!C;_L)?M.?^M=_'F@K[+_Q+\F?O911102%%%%
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MW=G*X^&S>'?A#X7G^)OCGQOH'PYEU7]H7]JSXC#PP^G:K#8::EMX<^%7Q&^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!_,+_P=8?\ )E/['?\ VDN_9^_]5-^T17]/5?S"_P#!UA_R93^QW_VD
MN_9^_P#53?M$5_3U06_@AZS_ #04444$!1110!X?^TW_ ,FV_M"?]D/^+'_J
M!:_7Y!_\&QO_ "A'_8V_["7[3G_K7?QYK]?/VF_^3;?VA/\ LA_Q8_\ 4"U^
MOR#_ .#8W_E"/^QM_P!A+]IS_P!:[^/-!7V7_B7Y,_>RBBB@D**** "BBB@
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M1>+M:L4\)?%_79+[X:VOACQA\9?'T/BG2O%/PW /UD+  DG '4D$?SHR/?\
M(_X5\/\ [&'[)][^S=X<UJX\:CX?>(OB=JWAGX(>$)?''A+1;JRN&\-_"O\
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MQ\1>';[5/#VJ:7JEY^'_ (3_ & =1^-%A^T#XS?X/?!WX,:3X_\ #W[4VD_
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M?X^>/_ASI^M:AJ_B+1?BTOQR_;?^!'[:GA[3/&EM=^ -=\.^"_#\6D?"J_\
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MFTW4;62>RNXHKFTE=H+B..5&4?F+\-/^"?'B?P9!X$N]9\,_L]ZMJ7PRUO\
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MXD\*Z#X"N/A'X:TKPUH7BW0;[3;CP> ?>5%%% !1110 4444 %%%% !1110
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MK7X&^&=0^+7@>[^)-I<>+?B5\.?"/ARP^(.O7?BOQ/H/B[QL+6^^*,OPJO\
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MS7=/GT2_\6W7E^'/$6E>)+#0O%FH:)I_B7]6J*!'Y?\ @#X.?M'_  \^!WQ
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M+M>OX?$GQFM_&FH:%<:9\0_$7Q-T/X<>*/"%O9:SX0U_08]/\&_-'Q(\(_\
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M7OCQ_P"(L_M._P#SH:/^&C?A]_T+WQX_\19_:=_^=#7O%% '@_\ PT;\/O\
MH7OCQ_XBS^T[_P#.AH_X:-^'W_0O?'C_ ,19_:=_^=#7O%% '@__  T;\/O^
MA>^/'_B+/[3O_P Z&C_AHWX??]"]\>/_ !%G]IW_ .=#7O%% '@__#1OP^_Z
M%[X\?^(L_M.__.AH_P"&C?A]_P!"]\>/_$6?VG?_ )T->\44 >#_ /#1OP^_
MZ%[X\?\ B+/[3O\ \Z&C_AHWX??]"]\>/_$6?VG?_G0U[Q10!X/_ ,-&_#[_
M *%[X\?^(L_M._\ SH:/^&C?A]_T+WQX_P#$6?VG?_G0U[Q10!X/_P -&_#[
M_H7OCQ_XBS^T[_\ .AH_X:-^'W_0O?'C_P 19_:=_P#G0U[Q10!X/_PT;\/O
M^A>^/'_B+/[3O_SH:/\ AHWX??\ 0O?'C_Q%G]IW_P"=#7O%% '@_P#PT;\/
MO^A>^/'_ (BS^T[_ /.AH_X:-^'W_0O?'C_Q%G]IW_YT->\44 >#_P##1OP^
M_P"A>^/'_B+/[3O_ ,Z&C_AHWX??]"]\>/\ Q%G]IW_YT->\44 >#_\ #1OP
M^_Z%[X\?^(L_M.__ #H:SM5_:D^%FB6?V_5M*^.5C9F\TS3Q//\ LM?M/!&O
MM9U.ST;2K50OP?9FFOM4U"RLH$526FN(P<*21]$UXE^T+_R34?\ 91?@G_ZN
MKX?4 5/^&C?A]_T+WQX_\19_:=_^=#1_PT;\/O\ H7OCQ_XBS^T[_P#.AKWB
MB@#P?_AHWX??]"]\>/\ Q%G]IW_YT-'_  T;\/O^A>^/'_B+/[3O_P Z&O>*
M* /!_P#AHWX??]"]\>/_ !%G]IW_ .=#5G2?VA?AQK'B;PKX1CM?BCI.M^-=
M5OM#\,CQ;\!OCKX'TG4M6T[PQXA\8W=@?$GC/X<:#X<L;A?#?A;7]1A34=6M
M/M?]GM969GU"XM+2X]OKP?XO?\E!_98_[+QXA_\ 68OVC: />**** "BBB@
MHHHH **** "BBB@ HHHH **** "N)\=_$+PQ\.-,L-5\4/KA@U;6+;0-*LO#
M7A#Q?X[UW4]7NK6]OH[/3_#/@;0O$?B*],=AINH:A=S6VERV]C86-W?7LMO:
MV\LR]M7B?Q=_Y&3X ?\ 9;(O_54_%:@"G_PT;\/O^A>^/'_B+/[3O_SH:/\
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M_P"&C?A]_P!"]\>/_$6?VG?_ )T->\44 >#_ /#1OP^_Z%[X\?\ B+/[3O\
M\Z&C_AHWX??]"]\>/_$6?VG?_G0U[Q10!X/_ ,-&_#[_ *%[X\?^(L_M._\
MSH:/^&C?A]_T+WQX_P#$6?VG?_G0U[Q10!X/_P -&_#[_H7OCQ_XBS^T[_\
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M?>@HHHH"Z[K[T%%%% 77=?>@HHHH"Z[K[T%%%% 77=?>@HHHH"Z[K[T%%%%
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MVB*_IZH+?P0]9_F@HHHH("BBB@#P_P#:;_Y-M_:$_P"R'_%C_P!0+7Z_(/\
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M=?3VEQ#9:@=<T.[%C=20NEO>&TEOTBNQ:S,DYMI'2.<)Y+LJN6 2?SX^&?\
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MKX1^&FD,/'/Q23QOI'ACQ;X9\'17UQ:>%-8U[2-9\/Z?Z1JW_!-3X7:/H_Q
MURY_X*8_\%V)+'X9_&CP)\#_ !0\/_!0WQD1;Z[X\U?X6Z7!XK22988(_ 7A
MFW^+.B:]XPUV_FL;S1O#VB>*=2CTB]_LRTAU']%;#]FSP)>?$6\^*/CKX^^
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M (6!X#_Z';PC_P"%)HW_ ,FT?\+ \!_]#MX1_P#"DT;_ .3: .NHKD?^%@>
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M(_\ E%1_PY,T'_I*/_P6M_\ %C?Q(_\ E%7[!_\ "P/ ?_0[>$?_  I-&_\
MDVC_ (6!X#_Z';PC_P"%)HW_ ,FT!S/O^$?_ )$_'S_AR9H/_24?_@M;_P"+
M&_B1_P#**C_AR9H/_24?_@M;_P"+&_B1_P#**OV#_P"%@> _^AV\(_\ A2:-
M_P#)M'_"P/ ?_0[>$?\ PI-&_P#DV@.9]_PC_P#(GX^?\.3-!_Z2C_\ !:W_
M ,6-_$C_ .45'_#DS0?^DH__  6M_P#%C?Q(_P#E%7[!_P#"P/ ?_0[>$?\
MPI-&_P#DVC_A8'@/_H=O"/\ X4FC?_)M <S[_A'_ .1/Q\_X<F:#_P!)1_\
M@M;_ .+&_B1_\HJ\<^.?_!)7X??!_P $V'Q%\0_\%$O^"Y'CZ;2_'_PR\)>%
M= \+?\%#M;NO%DGC?XQ^/_#WP-\)OX<N?&[^$O#ND7,^J_$V'3-6U>]\3Z(E
MIX8U#7E:ZGBEEL+S]YO^%@> _P#H=O"/_A2:-_\ )M>-_'C2O!WQD^'L?@[3
M?BUX)\):MIWQ"^#7Q+T/7KRXTGQ+I]KX@^"GQB\!_&;P_:ZKH$/B;PY<:KHN
MK:WX!T_1];M+/Q!HE^^DW]ZVGZK8WJ6]Q&!S2[_A'_Y$_%?PS_P3L^!VIZ?J
MC^-?^"JW_!;/X+^)/#WC]?A?XF\$?%S_ (*5Z]H6OZ#XYN- \(^+M+T5M4T*
MX\3>!O$*:SX1^(/@'Q#I^K>#/&'B;1!'XPTG0K_4K'Q=#JWAW3'>&?\ @GY^
MRUXHM[">V_X+/_\ !7O1Y=7^)OQ$^$&B:?XI_P""FWCGPOJVN^/?A=\1X_A-
MXMT;1=,US2;*[U3R/'M[H/A_3KJRBFMM3U#Q?X*LK.62_P#%V@6E]]]_$7]D
M;P+\2['Q/'X@_:NO9=2^*3_$^Y^,Q.I>&U\+>+M4^(W@OX3> M,U?PSX#LM>
ML/#'A;4OA1X2^#GAWPC\*+KQ#:_$&?P_X9\2_$?4-6D\0_%#QG/\4+'5U#]E
M/X5W_BFUUVZ^./A?5=$7Q?\ &V[UGP9KFH7Q\.>*_AS\??C/9_'_ ,8^"_%5
MEX7^*7A&UUW7-!^(DWBFQ\$^(M1M;CP=#X \21^'?'?PL^('B+0-,\:T!S/3
M7UTC_P#(GSM_PY,T'_I*/_P6M_\ %C?Q(_\ E%1_PY,T'_I*/_P6M_\ %C?Q
M(_\ E%7[!_\ "P/ ?_0[>$?_  I-&_\ DVC_ (6!X#_Z';PC_P"%)HW_ ,FT
M!S/O^$?_ )$_'S_AR9H/_24?_@M;_P"+&_B1_P#**OJG]D?_ ()X>&_V2/'W
MB/XC6_[5?[=/[2>MZ]X/F\%6=I^U]^TQXA^/^C^#]*O-:TG7=5N/ UCXBTFT
MD\+ZGKMWH.BQ:[=6-T$U:UTC3(KR"5K"TD@^VO\ A8'@/_H=O"/_ (4FC?\
MR;1_PL#P'_T.WA'_ ,*31O\ Y-H$Y2>C?X)?E%'745R/_"P/ ?\ T.WA'_PI
M-&_^3:/^%@> _P#H=O"/_A2:-_\ )M CKJ*Y'_A8'@/_ *';PC_X4FC?_)M'
M_"P/ ?\ T.WA'_PI-&_^3: .NHKD?^%@> _^AV\(_P#A2:-_\FT?\+ \!_\
M0[>$?_"DT;_Y-H ZZBN1_P"%@> _^AV\(_\ A2:-_P#)M'_"P/ ?_0[>$?\
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MO_,_G"_XA3/^"-W_ $1[XJ_^'U^(/_RQH_XA3/\ @C=_T1[XJ_\ A]?B#_\
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M?_#Z_$'_ .6-'_$*9_P1N_Z(]\5?_#Z_$'_Y8U_1[10'-+^:7WO_ #/YPO\
MB%,_X(W?]$>^*O\ X?7X@_\ RQH_XA3/^"-W_1'OBK_X?7X@_P#RQK^CVB@.
M:7\TOO?^9_.%_P 0IG_!&[_HCWQ5_P##Z_$'_P"6-'_$*9_P1N_Z(]\5?_#Z
M_$'_ .6-?T>T4!S2_FE][_S/YPO^(4S_ ((W?]$>^*O_ (?7X@__ "QH_P"(
M4S_@C=_T1[XJ_P#A]?B#_P#+&OZ/:* YI?S2^]_YG\X7_$*9_P $;O\ HCWQ
M5_\ #Z_$'_Y8T?\ $*9_P1N_Z(]\5?\ P^OQ!_\ EC7]'M% <TOYI?>_\S^<
M+_B%,_X(W?\ 1'OBK_X?7X@__+&C_B%,_P""-W_1'OBK_P"'U^(/_P L:_H]
MHH#FE_-+[W_F?SA?\0IG_!&[_HCWQ5_\/K\0?_EC1_Q"F?\ !&[_ *(]\5?_
M  ^OQ!_^6-?T>T4!S2_FE][_ ,S^<+_B%,_X(W?]$>^*O_A]?B#_ /+&C_B%
M,_X(W?\ 1'OBK_X?7X@__+&OZ/:* YI?S2^]_P"9_.%_Q"F?\$;O^B/?%7_P
M^OQ!_P#EC1_Q"F?\$;O^B/?%7_P^OQ!_^6-?T>T4!S2_FE][_P S^<+_ (A3
M/^"-W_1'OBK_ .'U^(/_ ,L:/^(4S_@C=_T1[XJ_^'U^(/\ \L:_H]HH#FE_
M-+[W_F?SA?\ $*9_P1N_Z(]\5?\ P^OQ!_\ EC1_Q"F?\$;O^B/?%7_P^OQ!
M_P#EC7]'M% <TOYI?>_\S^<+_B%,_P""-W_1'OBK_P"'U^(/_P L:/\ B%,_
MX(W?]$>^*O\ X?7X@_\ RQK^CVB@.:7\TOO?^9_.%_Q"F?\ !&[_ *(]\5?_
M  ^OQ!_^6-'_ !"F?\$;O^B/?%7_ ,/K\0?_ )8U_1[10'-+^:7WO_,_G"_X
MA3/^"-W_ $1[XJ_^'U^(/_RQH_XA3/\ @C=_T1[XJ_\ A]?B#_\ +&OZ/:*
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M]_YG\X7_ !"F?\$;O^B/?%7_ ,/K\0?_ )8T?\0IG_!&[_HCWQ5_\/K\0?\
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M6-?T>T4!S2_FE][_ ,S^<+_B%,_X(W?]$>^*O_A]?B#_ /+&C_B%,_X(W?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0) R # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\;3>$M:UK3O FKWNCZ-XSO="U37=%M+_ *GP!_P48_8L^)_Q>\2? ?P5\=]
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M%?!:>'?B#\(M/^(-GKGQ@\,?#K_A/-.DAO\ 0;#X9W7C:[GU<:1]UV7_  4
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MT<4VNMM;7"3<HJ%WRQY[):?'&4)ZJSUC.5NS=UJC^2'XF?LF?M._LL_MO_\
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M-_:!\&?';]F;]H3XK^)_@#K7B32O^"CW[<O_  4-_:0\#>%+[QG=^#O!^O\
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MP5^K3;NY,:J2C*,TTI)146U=6A)U%IM?F=Y/1M.S>I^<_P"UC\!_VD?VRO\
M@F;^T#^SGXMT7X+_  K_ &E_CY^S_P#$'X9SZ5I'Q.\;^/O@OX8\6>)K'4M$
MT>ZD^)-U\(?"7C?4=%DL6T_4M9EC^$WVW2=0N;[1K&+Q);:?;^(-6^%O&/\
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MB3?^//#FF>.?#GV/5OB'X;DU9M3T37?NBV_;]\4VVL_MZ>$_$O@3P[I'B/\
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MX1GQU:>-/B7%\'?B_<?"I==^&>LGPUXY\)>%OB3!X&E\&_$#QEH'BQ9_!/\
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MC9>ZPWASPUXI\%:IK6H7G_"G(O#5E;#Q1I5O:OK[ZE.UU]A2PNO(?@K_ ,%
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M5I\8M \0_%35? _B[X@Z)XUT7PUXV\!:SXP\6ZUX5U'Q[XO\46>L_8?[;?[
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M9+#3OAMJ5C%%J,C/VT_^"2G_  4C_:4^'WQ:^!>G?&'X7^(?A=XS_9=_9O\
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M]"TC2-/U7P]K%WJW$?%_]OWP'X=\#7_B#P.WB[2/$?@OXN_L@:!\0O!WQ2^
M_P ;_!WCJW^&?[3OQ_T7X4:%KGA?X:^*/"/A/Q[XKU7QW:6WC?0/AI;>%=$\
M1:M??$G0;GP7)X:O_&6E:CX.*CRKWDW;VL*DKV7OPC3I1<N\+5865W'FDI)7
MDKR[M*&K4:4XI)NSC4E4G-)7UG>G-7LFDE&]KV_+OXS_ /!)7]L;QIX _;J_
M8M\'>)?V;V_9$_;^_;IG_;)\9_M!>(?%_P 1-+_:8^#^E>,OB-\*OBC\2OAW
MX;^#&F_"36/ 'C_Q5IWB/X<V6E?"'XBZG\<O"*>'_#<,4FLZ'#J.D:##%Z;X
MZ_X)D?M<>)?^"E%I_P %2M'US]F.Q^,'@;X[^%/A]X!^#=_J/B-OAIXB_8)T
M;X7>/?AMXE\4^/\ QS9? Z#QM:?MP:[=_%#Q5XC\(Z]I^EZ_X1^'/A.PTKX'
MR>/O&W@+4-8O3^C][^V1HGB_Q[^SEX9^$LUR8O&/[6GBC]G#XY^&_B+\/?'O
M@/X@>!+G1OV+?V@/VF;#3#X6\;6'A#6]"UC4;KP1\+=>TOQ!=Z/K?AGQ-\/O
M$4]]X:EU"VUS2_$-CZO\'OVMO@;\=];M/#_PY\1>(KR[UKP==?$?P1>^)/AO
M\2/ F@_%;X:6&JZ3H>H?$KX.>(O'/A/P[H/Q:\ V.J>(/#"W?BOX?:CXATB'
M2/&OPY\5FY/@[XI?#/Q%XNU3E%PL]8IR3MT]FJ3=U96=->S>NL'):M\\1M\L
MD_AFI1=M+WG[RMW=2,9V::YX0=K7C+^?[_@F!\"/#?Q3_P""H7[7/QA^%/CC
MPW\5_P!@W]DKXR?'+XB?LB>(_#,6L7OA*P_:C_X*$>$_A?XA_:N\,>$?$4*6
M_A#4H/@(_@WQUX<AT30(;RW\&1?M,:QI4FI#4[K5] \._H;^WW_P35\4?MN?
MM V'BC4]=\#Z9\&-6_X)_?MG?LB>+X-2O-:D\?6'C;]HO4?A+JGP_P#&WA;1
M8O"]_P"';O3_  -JGPZD\0W%]J/B;3=4T_7;;09M,T;5%6XFM?T1\>_M&_#/
MX8^-?#G@;QM_PG^BW/BG6_!/A;2_%K?"/XJWOPLA\5?$KQ%#X/\ A[X9U3XN
MZ?X,NOAII&M^,/%=Q:>&=*L]2\56WE>)-5\->']4?3M9\9^#+'Q!RO[+W[4O
MA;]J3PQXS\3^&O"/Q,\(1>"_B9\2/AY<VGQ$^%?Q;^'$VI)X#^(/B_P-:ZSI
M9^)_P\\ G59=73PG)J>L:'HD6L7_ ("U"\_X1'Q?+8>)[*[L$R<5:FG=>QI2
MM)=E3GAYRORIMI5^6-^:5.-/#6;="+'S-RG*Z]^4$XZ-)<U.I"*5[)2>'<I6
MLIN=>\4JLD?C!^SK_P $EOVR_AS\1OV&_CU\2?C'\#=2_:)\ >.?^"GWQM_;
M+^*?A^^\9:]:^(OCI^VK\/\ PI\-_@WXE^#?@_6OAKX>L/%WASX9^$OA[\/?
M#GB/0_&]_P##:*UT?PC;6^@0ZU!="SM-7]CK_@FC^W=X)_:4_9X^/7[47Q#\
M%^(]1^&G[+W[1?P(^+WBR?\ ;3_:_P#VJO&?Q.^)_P 8?^%0S3?&_P !^#/C
MIX"\&_"+X ^%O$^J?#W4[F\^!?P<\/\ @K2?"5C%X?.I^+OB:RZ%HWPS_9GP
MY^US^SWXLOOV;=-T+Q^]U>?M>?#_ %?XG?L\Q7'A+QUI@^('A#0_!V@_$#4K
MEY-5\,V4/@_6HO!OB.QU^W\(>.Y/#'C"_M++Q(FGZ#=7/@_Q;#HG)ZA^WG^R
MCI7PG^+OQQU+XIR6/PM^!FK:-I'Q)\4W'@+XF1C3&\2_\(Y_PB^L^']&;P;_
M ,)!X^\'^*_^$KT0>$_'?P_TGQ1X*\4&6_70-?U$Z)K@T[234FTTGS0K4W&U
MHJ$XU:%:,8QLHVCB*E.3BUR.45[KA%Q$Y+9N\I4YWM><I1E&5.[:DW>5&-E9
MW<7:]W%_ACX:_P""2/[;NC_L^_\ !-C1/$*?!O6OBM_P3<\*_'S]GZ/P9\*?
MVY_VQ/V7]*_:#^!GQ9\)_#FUT?XDZ?\ M+_ CX6>$?BY\!_BAH?BWX7Z E_\
M(AX-^*OPX\7>%KC4/[<\>6-W-I>E>'?M/]EK_@F'XH^!/[2O[%OQBMO!/P3^
M''PW_9L_9:_:_P#ACJGPR\-?&3XW?'S7_#7Q@_:>_:(\,_&:?Q!X(^*/QQ\&
M6GCCX@Z9<:>/B!#XP\>>-M6\)>)KG6?&%[I^B^#;;PQ>FRT[]4+S]H7X0Z=\
M9]._9]O?%4]O\5]6TG3-8T[09/#'B[^R;J+6=.\?:UIFE1^.%T$^ QXJO-!^
M%WCWQ)%X*D\3+XP_X1CPY=>)GT-=!N+#4;OG/ W[67[/_P 2] ^&?BCP/X_7
M7]!^,?Q1\<?!GX;:A;^&/&EJ/$_Q#^'6E?%'7_%.DP07_ARTNM/TN#P]\&OB
M%XET;Q?J\.G^#?%GAG2M*\1^$]?US0_%_@V_\0-RE*47*3E)2E4B]+MM2I3:
M44DXMU))IIJ,Y:<KT2V4K:1LHRWLE_%BG?1-1IMQL^9P4K\RU/Q0MO\ @FE_
MP4#^'W@'X:>!OA]\3/ 6K^!;/]KC_@H-\=/C3\(/!'[8G[4W[&MO\2]#_:B^
M+>H^/?V=/$%S^T-^SM\)F^.%OJ/P+M==\1WWC?X1:)-X:\'>.]8UJ.&X\9ZQ
M!X=TBXEYO]FS_@C7^T+\)/A_^SOX,^+47[,GQPT;X0?\$\O^"AG[(7Q"^'M]
M\1_C#X<\'_&'Q/\ M5?M!:5\3_ .FW7B8?"?6/%WAGX<:QX+T@Z+\3?%*0ZS
MX\\#ZWJDS^$=%^(K:9!X@O\ ]J/&7[</[.'@3QSXW^'OB'Q7XLBUGX7>+O!'
M@GXKZOIWPD^+NM>!?A1K7Q&T+P7XE\&W'Q*^(^C^!K[P#X,\.:MH?Q"\*:G<
M>,-:\1VOA/P_8WFIW_B?6M$L/"_BNZT.#5?VZ?V;-*U3Q]I$GB?QMJ%[\-/'
M%G\+?$RZ!\%OC5XBBG^*^HZY;:%9_"CPC<:'\/K^#X@_$V1KRV\07'@;P!)X
ME\1Z;X"GA^).K6%A\/YX/$LJBVHQC&SC&,%'W4WRTJ/L(7E]I*G-J[NVVK/1
M<KLVY[WG*4Y[ZRJ576;5K<K<TVK6T35K*Y\\?\$NOV6_VGOV5_A]\8_"?[0'
MC>WE\$^(?B=8ZQ^S=\!+;X_?%3]K*+]F3X1V'@;PQH(^&MK^TI\;O WPZ^)W
MCO2YO$6FZIJ&@^&M5\,#1?A[H<>G:/H>LZM]KU"6'XN\4?\ !)O]H_5_@I^U
MGHFD^._@I:?%[Q5_P66/_!53]FBSUK5O'>L_"7Q!IO@[Q!\(?$?@/X4?M&BW
M\$:7XAT2'Q'+X#U_3?%\'@?3?'=GX9>Z\.Z]HNI>*IK.YTE/UOTC]M+]G#4X
MM,;4?'MWX)N+[Q=X^^'^HV/Q-\%>//AC=^#/'?PQ^&DWQI\8^$/B0OCWPSX>
MA^&NMVWP9M[CXQ>'X/',V@0>//A%'_PM/X?W'BGX?RP>))9M,_;*_9ZU;P!K
MWQ,L_%GBA?"_A?QM\'?AMKT%_P#"7XPZ3XQT[Q]\?]"^#'B3X2^$9?AQJO@*
MR^(KZ]XJTG]H/X1R/IT/A66?P]>^*;C1_%"Z)K'A?Q?8:!,K:2;5XJ#OJW:,
MJ=2+;;E*4I2IPDY2YY5-7)2;;0KI-+:;>EM&W&I%QC:R2Y9U$U&RBK6Y;)O\
M7OBU_P $J?VNOVI-8_:P^-7QF7]ESP#\2OVJ/CI_P33U>Z^!/A7QY\1/B)\*
M_#/P)_8/^*47C_Q*/&OQ8U7X)>!]6^*7Q7^)=AX@\:Z%I^FR?!;PWX6T#1[+
MPYX:F\4WNG:IJFH:9^V'[8/P1U7]I;]DC]J']G30];L?#6M_'[]G/XV_!/2/
M$>JV]Q=:9X?U3XJ_#3Q+X%L-;U*UM,W=U8:5=Z[#?WD%KFXFMH'C@_>E:R]>
M_;3_ &9_#OA+P/XYO_B6+GPQ\3/A+I7QN^'VH:#X0\?>*I?&?P]\2^)/A9X-
M\$W'AW3?"WA;6=6U3Q=\2_&'QI^&GA+X2?#.UL9/B;\7/$_B-_#_ ,-/"'BK
M5M$\16FD^3?$_P#X*+_!7X?> +GQI8^'/C/XEU71?CG\$/@;XQ^'=O\  #]H
M&V^(_@G5OC1X[\ ^&+'7O$7@:T^$NL^+;71$\.^-W\2>"M4_L/\ X1WXO:[I
M*_#3X<>(]8\=:K::8@X:3IV:3DTXI.ZGRNC)*]W>/))23<N6:ES6LHIQ<G.%
M9.\H\CA+[-X.G5AHVH_8ATC>-D[WN_B[]F;]@+]J_P ._M"_ /X^?':Q_9T\
M/R?"?_@DIK__  3WUGP[\./BC\0OB3<7_P 3;;XM?#K7?#GQ T:^\5? GX:Q
MVG@;Q-X'\"W=[X@M[DR^(O"VNZTGA2TL_&>F6T_BRX^+?"7_  10_:B^%/AK
M]BO6["\^'GQD\6_![_@GMX>_81^._P +O"_[>?[;'[!_AF]F\)?%'6OB#X>^
M(O@7X[?LR?#^]\:_$7PIJ"^-_%VB>.?A;\4_A=INDWUC8^'-;T.X76[ VDO]
M!,O[7?P+A^)W_"II->\51^(H?&'A[X<ZGKLGPO\ BA%\,] ^)7BWPS8>+_"O
MPV\3?%R3P</ACX;\?>(M%U;14TSPIK?BRQU9_$'B3P?X+GMX/&OCGP3X=\1=
M-\6/VBOAE\&M:\(^%O%4OC36?&7CNS\3ZMX5\#?#;X9?$?XL^-=4\/>"/[#'
MC3Q6_A?X9^%O%6KZ9X0\*S^*/"VFZSXKUFVT[P_!XA\5^$/"4.HW'B[QAX5T
M+6:E)N56<I/GKU)3FY6]Z<JN)K345LDZN*Q$G&*M:>BY80:4;I1A%64()123
MNHQA3A%M[MQC3I)-M--)R?,VCR30_@GXV^$'["_@K]GGX+?"WX#ZKXI^'WP%
M\ _"+P[\%_B=X\^)NK_L[7&EZ%X;T'PEXA^&VI_$#Q#X4^)'Q1U?X<1>&(-:
M\-^'=7\5>#?%&O:EID>D+XHT2X6?4K=?YBOVC?\ @G)\=/V3OV;?V@?%$WA7
M]FOX#:7^UY_P5 _X)@^*/@I^QE\"M7^(?Q9_95_9PU?PM\:_!OAO6_%6HC7_
M  /\'O[6F^+/B35],O\ XM>%_ 7PR\%>&;?POX&T/1O#EVUFUA8^'OZE[S]M
M/]GNP\=MX N_$/C"*^MOB!X-^$FL>*V^$7Q='PN\-?%?XB1>'CX&^&7BKXN?
M\(-_PK3PSXX\37_BWPOX:L]!USQ387-GXZ\3>%OASK!TWXA>+_"?A?7.6G_X
M*!_LRIK$FAV>M?$[6+R;XE?$CX+^'+G0OV?/C]K&C>/OC+\'_%?BGP;\4/A1
M\-O$5A\,Y] ^('CKP3K'@3QY=Z[HWA+4M5$/A?X>?$WQS%<2^"OA5\3/$'A%
M6DFI)MOGI-MJ]U2Q&'Q#A=O[;P\8M^\TI.23UYDFHKELN7EG>-[:5*5>BI/M
MRJO*2LHW:<6U%V/Q@^,__!(3]LC]I[QW^T_^U-\3-:_9]^%'Q^^)G[4O[!?Q
MN^%_P0^$GQY_:#L/AY)X2_88\#_%/X=?V)X]_:[\ ?"_X*?'CPGXU^*^D?'#
MQWJ.C?$/X9_"2WU[X63>$_AK+8)K-Q'J-GI/?6?_  2]_:6\)2_L_P#[2/PA
M^&/P*\#_ +2OP(_;1\;_ +3NM?!#XM?MT_M@?M9^ OCSX=^)/[,&@?LT>,+W
MX@_M8?'CX4ZY\4_#_P >=.\+Z3 GP\UW2O@_KO@+PC!X7\(6=W:ZVR:GJ0_?
M;X8?%'P3\8_!6D_$'X?:I=:MX9UFXURPADU'0O$/A;6M.UGPMX@U7PEXK\-^
M)?"OBS2M#\5>$O%OA+Q7H6M^%?%OA+Q3HNC^)/"_B71M5T#7=+L-5TZ[M(>_
M/O[>O6A1Y=$N7WHS25U9Q25UJ_BM[Z=U*[=DWI3G)JS=TXU(/1:QGI*-TEHK
M6BUK%*REOS?@Q\8_V%?^"A/C_P :?MN_'WX8_$/X-? 3XU?M4_LX?L%?#?0;
M'P)\9_BBMSX5\0_L]_$OXB>*?VB/!%K\9;?X%:+XC\&Z!\1? 'CW4/A_\//C
M5X7\#7_CK1;R^O/%"^!?"FI6.F7"?-W@_P#X(]?M?GQ-\3_%_B+7?@QX>_X6
M3_P4+_X)D?MAV/AC6_VJ_P!JS]J3Q-X4^'W[&6H:4_Q0\$:_\>_VAOAQJ/Q4
M^)_C?4-/T.P3X=:IX@N;'P_??;&\.F/X8^$?#>@:;7]//OZ^_P#G]*0?0\^O
M;]:(KD5HZ).,DM[.%:&(CO=V]K33M?9R6\I,3]Z_-9W33=K/6DZ+U6G\-\M[
M7NDU:R/SX_;K_9.\>_M1>+OV#M8\'WW@2WT/]F?]MGP=^T5\4--\<WNL6K>(
MOAKHWP=^-OPVUSP_X5LM+\,>)++6?$U]>_$[2I(M'\0R^'M!O-)MM6%WKUO,
MEM:7GXY_!O\ X(<?M2?#7P_X'T_Q%\9/A+X[UGX1_P#!1_\ 8%\<?"O5=4\6
M?$';H?\ P3*_X)U^(?$E]\"?A;,DOPSEDA^/UOIOQ!\?3:EX6MS<?#Z[U:^L
M#)\56B1KF'^I3J/3^8I  , ?A_G\:3BG'EZ<TI]+\TY49RDGT;]A3BFMH.<5
MI4FQ-OJ[^[&-K?9BJJ2WVO7G)]Y*G)O]U!'\Y_P?_P""17Q4^'?[2?G^/_"7
MA#XW_ W0_P!O;Q[^W#\,?BOKG_!0[]O?P+J_PYO/%GQ)U?XR^'-+E_8!T#3]
M3_92\5_%KP-XY\4:_P"'S\2T\>>'/#WQ&\*WEYXB\<>#W\1:OX@T'7E_X)X?
M\$B_BK^R'\1/V:]"^)_A/P1\4/!G['FM?%R?X-_M'R_\%!/V[_$6NRZ-XV\/
M?%'P/X;OO#7_  3X\8://^RI\&O'.I^!/&\/A?XHW/A?XBZ]X2:VNM>U/P?H
MKZIK"OH7]%_U_P#K&EIQ7+&,8V48QC&*MHHQC&,?.\(0A%.^JC[UVV5*4I<_
M-)MSDYR=VFY2YN9Z-:3<IN4?A;DVE<_G1_9._P""7'[7OP6T;_@FW\-/'^I?
ML[3^"?\ @G1^UW^U)\5+7QUX5^)?Q(U7Q3\:/A)\>_"G[2D6@:@W@#5/@?H6
ME?#_ .(6@:_\;] T[6O",GQ$\6^'KBPT;7M8T_QP9%TK2-2VOV6/^"47[1/P
M2^!W_!'CX:^*?$GP*E\1?\$_/VB_VE_B_P#&VY\*>)_'-WHWB3P_\:M+_:7L
MM&MOA9?:A\+] U'7?$ N_C1X<O\ Q-'XKTWP+9PW%CKTEGJFL2V]A+J7]"E'
M?_\ 5Q_7G'Z4HP4596MS*6VMU&$;MWUNJ4.:UDWK9-L;G)RJ2;NZJDJG9N:J
M)M+:/\6I;>S:MLD?Q _L@:7XKT[]H?\ X))_\$XOAQ\8/V7?VF/#'_!//]KK
M]HKQ7J&O_L[Z!\6+CXP>$/A%X5\%_'S0[OQO^U[H_B?P1X;\&?LP:[9^*?%V
MG^!4\'1>)/'W_"\O'?B?1->\/^)+'_A&X4\;_P!A7[.$/[0,/P:\)1_M2:7\
M$-%^.@G\4GQKIG[.-[XUU#X-6T#^,?$3^$?^$1O/B)I&@^,)IY_ [^&KCQ0=
M6TJTC3QE-X@BTSS](2PN)O<\<=2._&./;IC%&,$G/&.G8?X_6FD^5*3N^:4I
M/3WIS]ES2T2M?V,-[WUV%)J4FTDE9)+=J*E6DE>]FKUY].BL[:"T4450@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGZ/X0:TG[4>I?'@
MZKIA\/WOP$T+X2QZ($N_[936-*^(?B#QC-JK2F,67]F2V6KP6D<:R_:?M<,K
M.@A*.?H&BI<4VGU5VOG&47^$FEV;3Z"MHUT>_P#X%&7YQ7Y=3\HM9_X)S^(_
M&/[(W[.?[*_B/XBZ'H]M\-/^"?7Q/_8F^(/BWP[I=_>33:C\3/V<O _P+G\<
M>"-+O_L,<UEHUUX;U+7;;3=:N=-FN;::QM7>"0W!C^AOV5?@+XH^&NL>,_&/
MQ*^%7PJ\&?$37/#_ (6\*2^,_A]\?_CC\=[SQEH^B7OB+5[W[=_PN_P;X:U/
MX<:(NNZU<:SHG@G1M9\=6]G/K.K"_P#%.HW,,5]>_:]'^?\ /Z52=DTGIS3E
MKNI5'%RUT=GRQ5KM6NK:B:3WU^'?6_(I6OO?XFV]7=)II[_EG\<?V O&GQ.^
M!?[3?A/PUXX\(>&_C/X]^-/Q?^-?P#\=:EINLZCX?\':A\3?A:OPEUCPAX^T
MZW:WNM2\->/OA[JOCKX<^.VTV._NM&T'QG_PF'@Y8?'_ (5\*:MI65X__8G^
M/=YX*_:Q^ _@?7?A!=?"+]NCP[HVC?%OQ]XLU7Q7IGQ'^"]QJ'[+OPI_9"^)
M<_PZ\ Z9X)UWPG\8(=;^%WPA\/\ B#P+%XR\;_#$^#O'NIZS/XB_X3_PM_9_
MANT_6'I122Y8<B^%J":>JDJ</9Q4MKKEUDM%*2YGK>[2V?6+G*+V<95&I2::
MV?,E9N_+LC\[/&'[*WQ8UWQG^T!9:?>_#N+X>_&']KC]B[]KO2O$]YXC\3CQ
MGH^J_LX^(/V-++QM\,-0\#1>"9]%FT[6/"'[)T^M^%OB#!\16N[GQ)XZB\,Z
MOX"TG2_#;^+M<\\U3]C7X]:K^SIXQ_8QNKWX1M\(?#^JQ^,?@3\;U\:?$6R^
M(L.K^!/CIH/QX^"'@CXJ_!C1?!NBP7FC>&+_ $32O WQ)^)/@G]IG0O%_P 1
M--T&Z\9:!X=^''B'QF;#P7^JH]>>>Q.<?Y_/UH)QGN1VI**7WWN[-M\ZJ)M]
M6I)./1))--7N-+=I/HK[)*'L[*S5DZ?NR_NO2S2:^3OV6O@G=?"NQ\<:_P")
M_A)\/?A9X^\::EHMEK#^!?CU\6/VCW\1>&/"NFR?\(L^N?$7XQ?#[X:>)X)]
M)U+Q!XNM[#PO9^'9=%TBRNCJ-MJMS=ZW?6>G?G1K?_!-GX]WFC>'O!OAN\^
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MO6_$_B?]G?P9X\_9Y^$?CSP%\(_&O@YO&WBG2_'GQ5^(7AWPO\/C\?\ QIX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6/0;![+XE037'B?_ (22"^U>X6ZT<B'2/[#:*_R^HVA'V910._DO36WSUO\
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MMGY2^+?VO?\ @IQH_BSQ7H_A7_@D'J7C+POH_B?Q#I/AGQBG[>7[-.@IXO\
M#FFZQ>V6@^*TT#4[0ZIH*^)-)@L];70]3)U'2!?C3KXFZMI2>[^!/[3G_!0/
MX@?%GPAX/^-G_!,/4/V??A?K3ZZOBKXQ3?MD? +XI1>"TT_POKFK:([^ ?!E
MM'XG\0_\)#XDL-&\)*FE.#I3Z^NN7N=-TR\S^C]% K_W8^OO7_\ 2N7\#X2_
M:=_: _;5^%'CW1_#O[.'_!/R]_:O\#WOA"PUK5?B+;_M3?!GX(IHWBNXUK7[
M&^\%MX4^(EO+K>H-I^D:=H>N?\)#:/\ V5=KXB&FPJ+O2;TM\X/^V?\ \%6%
M1V7_ ((O:H[*K%4_X>$_LMKO8 D+N-GA=QP-QX&<G@5^OE% 7_NQ?F^:_P"#
M2_ ^<_C%\3/C[X*^!-M\0?A-^S-/\;/C5+:^#);C]GZ'XP^ _AW/:W6N7.F1
M>+[/_A:7BN)_!D__  @]O=:C<O<1QB+Q(-*,.D[9+VW(^$?^&S?^"JW_ $A@
MU3_Q8/\ LN?_ "'7Z]44!?R3];_HT?-O[,/Q/_:"^*W@'6?$7[2/[,-Q^R?X
MWL?&5]HFD?#RX^,O@'XWR:YX2M]%\/7UEXV'BOX=11Z)IRZAK&I:]H0\.72M
MJMJ?#1U.=OLFKV(7X53]L_\ X*KLJLW_  1=U1&*@LG_  \)_9:;:Q'*[Q9[
M6P>,@8..*_7RB@/DO36R]-;_ 'MGY[_LZ_M'_MW?$KXG6/A3X^?\$W;[]F?X
M<7&CZS>WGQ6G_:X^!OQ?BT_5K*&)](T3_A"/ =M'XBNFUR9Y(%U&%Q::;Y)E
MN\JZ M_:(_:0_;P^&WQ/U'PI\!/^";=]^TM\-[;2=%O+#XKP?M=? SX0Q:GJ
ME];-+J^CCP/X[MI/$5F=#N0MJ;^=VM=2WB>T C4BOT*HH'?6]EZ:V_._XGY"
M_P##9W_!53@-_P $8-4 ) )/_!0C]EL  D D_P"ADG ). ,G&!R17W/^U#\4
M/V@_A/X#T+Q#^S=^R_/^UCXVU#QG8Z)K/P]M_C-X ^!S^'_"-QH'B34;WQP?
M%7Q&BFT755T_7-,\/>'3X;LU75KH^*%U:!OL6BWZM])T4"O?HEZ7_5L_(7_A
MLW_@JK_TA@U3_P 6#_LN?_(=?=_PB^)GQ]\9_ 6Y^(7Q4_9FG^#'QNBL/&UQ
M;_L\S?&+P'\09KJ]T*ZU:'P=I_\ PM;PM$O@N#_A.[:STN[2[DB,/AD:P(-7
M#2Z?<Y^BZ*!WOT2]+_JV?D&G[9__  5795+?\$7M41RJET_X>$_LMML8@$J6
M6SP=IR,C@XR.*^D/V8?V@/VT_BMX[UGP]^TA_P $_KW]E#P58^$KO6=(^(5Q
M^U+\&?C<FN>*8=9T2QM?!H\*_#NWCUK36O-(O]9UP>(+MCI=N-!.FRC[7J=F
M1]V44"OY17FKW_%M?@?F]\=?VG?^"@O@#XM>,O!WP6_X)@W_ .T#\+=$FT%/
M"7QBA_;)^ 7PNB\;Q:AX5T'5];F7P!XSMI/$_AS_ (1[Q/J&M^$&CU9F;5&\
M/'7K(_V;JMDJ\1X._:Z_X*;:UXP\(Z+XK_X)#:EX)\)ZSXJ\.:1XI\:-^W?^
MS5XB3P9X9U/6K&Q\0>+W\/:59C5?$"^%](GO-<;0=+(U+618'3; B[NH2/U8
MHH'?RCZ^]?\ .U_D?)_[5'Q@_:>^$>F^#;K]F?\ 8^NOVN=2UO4=6MO%NDVW
MQ[^&?P);P1I]G:6LVE:FU[\289K;Q(-9NI;JS%GI.VXT\V?VBZS%<18^-?\
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MF*&:2'_@BUJD\R12/% /^"A7[+,7G2(A*1>8]GLC\Q@$WM\J;MS< U^P%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^OW]I_\ ];$_:!H+7\.7^*/Y2/WGHHHH("BBB@ HHHH **** "BBB@ HHHH
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MN9(F]+WTLW%]+25KQ?:2NM-]5IJKI:J+6JDKQ:U4EWBU=->:;7F>Z\\_I_\
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MG^<0HHHH("BBB@#P_P#:;_Y-M_:$_P"R'_%C_P!0+7Z_(C_@V1_Y0A_L7?\
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MG@[XR^/?!OB:X>PN?^$;K]1?C#_P5S_8"^ 5Q\-+;XN?%_QEX-NOBU\$-/\
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MR7[0'_!1[]D#]F?XH:=\$?B7\1?%.J?&?4/"$OQ!?X2?!KX)_'7]H[XDZ'X
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M^TC?3>"I?!OC7X+>-[WPPT=K:MXEBOKCP[HFIW-I;V+PW,VF:I:B[^KO@_\
MM;? C]E[_@LU_P %7)OCEXC\5^";3]I&P_X)G:5\$]1B^$?QA\6:3XYO]!^
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M5']N'X:_&OP/H/\ P7F\"?M.ZOXF_:'_ &LO&7[ _P"SAXG_ &?_ -H?PO\
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M?XQ:E\1/A!XHT;4_BWX%\)^ -(7X+CXB0^ ?%$'AFWU'PGX>T;4M4TV\ATB
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M_P#UL3]H&@M?PY?XH_E(_>>BBB@@**** "BBB@ HHHH **** "BBB@ HHHH
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MXZ_\%<OV'OV=/V1?@;^V]\2/B+K\?P"_:+3PR_PIU?PQX#\5>+?$^M?\)/\
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M?"^2%*=H[0IQP\(IQ2LI\U)7DU=JI:2O&$U_,M\ ?@%\??@!\ _^"5'[3OQ
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MBBB@ HHHH **** "BBB@#^8O_@ZJ_P"3+/V.?^TF7[//_JJ?VAZ_ITK^8O\
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MJ:E%I2_&#0M7UE;:?X>WEW9ZU%_9FN&X2W.E707[=\??MI?!CX;_ !@_9?\
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M^*M:\,_M.>'?'7P;\?\ P/\ AK\1_P!G7Q;^S=\2?!O[1^@^)?VD=:G\/_!
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MOHW:#4^;527*TU>\7\S?L8?"WXF^$O\ @JC_ ,%G_B1XI\ >,?#?P\^+FO\
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M9%_;L^!O[0_QLU^W.N_\%&_A!\.Y_ 'C/PY^S_\ $7XQ>(YX]'OO'7P'\/\
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M)UY58RT:J12T@Y0E^,__  7*^$7Q.^,?[&O@O0/A7X ^,/Q&UOP[^US^R?\
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M-E>[DXMQ:;;DHP]FDW;W?9RI6NDG>TY2;W<F];62_CM_;X_90_;6_;@\%_\
M!5O]L33_ -CWXI?!4_%W]A[X"_L<?LS_ +.'B*7P+K?[1GQS7P/^T=I?QD\9
M_&+XC>"?AIXN\:Z#X)U+2Y;R?P9X-\/ZEXLU/Q/?>#]$FU/4++0[.'3X]4L?
MMW_\$\_VK/B?^T!_P5^_:%\%> ?COX\\-6?QW_X)O?%3P3^R9'J<FF?L[_\
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MH[;/1V>AN8Z9YQ_G/IGT_&EKX]U+]OS]C.QUCX)Z)9_M,_ SQ+<?M"?$6_\
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MXY\-KJ]O:6E_-I4FN^%=1U?38]0BLM0T^[FM#.;F&TO[.Y>'RKF!I/DG4/\
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MQ/I7PZ\"_P#"%^+] ^'_ ,#O$NC+XU\42^%M/^,6N:9XE\=]QXR_98\>6O\
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MVW;W$U)WM=<SE=S;J2E)W=]YR2MLYRA&24=W:48V6G+S67NN/+\L?L^_"_\
M:1_9]C^ WC76?V:O''Q,U;X5_LE>'?V+-=\)Z!X]^ R^,-(UKX4:YH6I:?\
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M.^JOS)12W3>]WRKWHP3DD]4FY0NXNW1V_F2?-=1NOAO]F/\ 9D^//[,OB/\
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ML-?&7X.";QOIC>./&OPO_8W^%G[!=A'X7U#Q[XCTCQ!:6GQ N-<_9Q^)6D^
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M\-/CMX-^.'PI\1?#S]G;XE?L^^&=<\/^'=3_ &T?VV/C/X4_X2ZT^/U[X?\
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MU_$1/B_!XHT/7?A>/B]\3-$L[SQ[-XC^"S:UK&G>$X_IS5OV7/&.F?\ !/\
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M7Q'^ ?Q"M=5T+7/C%KEC>ZWX/NO@1J-[:0_"WX"K\5/B#\4]:\6_$GP[X/\
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MH>_\7>&/BW/\0_B1_P $XOB_^SL;_P"/_P 8O@UK/B+QK^T9XJA>99M$\/\
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MF=1Q=N;E/AKPU^S]^T%IWB']G'X3WOP+TJX\-_ ']N[XW?M.:_\ M ZAXQ\
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MNW%RBO=L]8N,DU&*:7+2?162Z.R/%_%O[._Q2^(_PO\ ^"A6KV_PQ3P9X_\
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MOQE\2^&KOPI\-?&7C+Q#X5T;XFZ[9:OX;^'6K:[XDTZZL;?[KLIGN+.UN)
M\UO#,X4%0'DC5V 4Y( )P 22.AY&:JTDFI7TE9\V]VY-1:LOA;GT5KN^K8VX
MMQ=DG9J-EHDN52MVO:":O=VC=:%JBBB@9_,7_P '57_)EG['/_:3+]GG_P!5
M3^T/7].E?S%_\'57_)EG['/_ &DR_9Y_]53^T/7].E!;^"'K/\XA11100%%%
M% 'A_P"TW_R;;^T)_P!D/^+'_J!:_7Y$?\&R/_*$/]B[_K]_:?\ _6Q/V@:_
M7?\ :;_Y-M_:$_[(?\6/_4"U^OR(_P"#9'_E"'^Q=_U^_M/_ /K8G[0-!:_A
MR_Q1_*1^\]%%%!!Y7\;?"=GX[^$_Q \%W_@'2?BC8^)_"^I:->?#_6M?E\)V
M/BJTOHC!/I0\4P6MY<>';YXV>;2M:MHX+K3=5ALKJUO]+N8XM4L_R@\2_L-_
MM8?%/1K*;Q9XJ\.)_P (G\(_VK?!OP>\.?%;XF^(_BAXK\-6?C7XW?L+_&3]
MGCX6_&GXHVO@K^UOBAX>EO/V8?'>@?%SQO>?\);XZT7P7XI\->%;_P 3_M#^
M*]/\1?%KQ7^MOQ9^).E?"#X;>-?B;KNF^)M9TCP1X=U#Q#?:9X.\)^*/&_B6
M^BL8?,%KI7A?P7HOB+Q+J<LKE!*VFZ+??8+8S:C>K#I]G=W,'S/I7_!0+]GV
M3X>_#;QSK[?%?1KWXB_"V/XO-X%TW]GC]HSQCX]\$^!TN9=-N_%'Q#\%^$_A
M)JGC#X?>#9M9L]8L/"OCCQ[X<\*>%_B%:Z%K&N^!K_7=$TZ]O;:%9.4D]E!.
M]G%:NHG9M7;]C)N3NE",XWBG.ZLVHK5IRERI7:DW%4VFM;Z54K65W..\E&WR
M)\9?V2OVG?V@_BGX]^/^O> _ GP_OX-)_8AM_ ?PNT']HWXD>$?&OC8?LX^/
MOVRM0^*VF>,/C?\ "+PKX5USX;G4?#?[5#ZK\$CX-U/Q+!/XH\)Z7=?$*^\,
MZ9XM\2^'?#7Z _LP?"/3/A/X*\53V_@'Q+\._$/Q)\>W_P 0O&FE>-OCW\1?
MVC_%FI:Y'X>\+> =(U?Q#\1_B5XA\4ZJNI2^ _ /@W39/#>BZYJ7AC0%TR*W
MTN^U&62]U&\]-\0?&'X9^&?!7ACXD:IXQTF3P'XSUSX6^'?"GBW1GF\2:#X@
MU/XU^,_"GP_^%C:5J/AR'5;>\TOQEXM\<>%-,TS7X7;0(H-:MM7O]3M-%2XU
M&'S'QK^U]\ ? 7B#6?".L^+=?U;QIH/CQ?AIJ/@3P!\,/BM\5O'I\9+\,_"7
MQCO=/T[P-\+O!/C#Q;K5AHWPS\?>!_%GB3Q%HVCZCX:\+6GB[PW:>(]8TK5-
M8L+&=I)<T5&UY-R7O)\SY7)--WN^1-JR^&]KJ5AOF4=;JRY6M?=3:5GJN5.3
MM+HY-7U2?R#X)_9D_:&T_0?@C^SKKOAGX<6'PI^!W[3$WQL;X\Z?XXOKWQEX
MS\$>%_B1XP^*7PZTO3/ K>$+6]TSXR>,-:U31?"_Q_UG5O$">%+_ ,.7OQ!U
MWPOK7B+4O'">&?#?VG^S+\,/$_PC^%;^#O%T^DW&LO\ $_X^^, ^BWMW?V(T
MGXF_'SXF_$SPVIN;RQTZ8WT7AOQ?I$.K0?9!%::K%>VEM<WUO!%>W/DFG?M\
M_!'7_C5\%?A'X6B\>>)-.^-WP>^+GQ>T;XEZ;\+/BR? /AFV^$/B_P"'?@OQ
M!X6\<>))? 2>'_!'B32M9\9:]I7Q%TWQIK7AK4?@IXK\(0>!/BWIWA3QEXZ\
M%:/JWK'P6_:I^!_[0-]?:9\+O$NOZE?6?AG0_&]K!XH^&GQ1^&?_  D_@3Q-
M=7]GH'C_ , R?$[P9X/B^)'P_P!7N-.F6Q\=> '\2^$YTN-+F76/)UK1Y+Y)
M<JY5>W)%[7?+"T$]=5_#46]+J-[MN4F-N7-S)KWI-[JTG*<I7UW<JDWW7-;W
M5RQ/EOP[^S;\85^+7A.;6M!\'1^!?AC^WS\2/VI])\62^+7U*Z\7>!/BM^SA
M^T7X%&GZ?X7'AP77A_QKX$^(WQ4\,V%UI^HW[Z1J>@VMYXLT;Q)]NB7PTG,>
M*?V-_'^K>,_&WB+Q#X/\!?$_P-KWCO\ :S\27WPXN?&VL>&+SQ7X7^.'@OX0
M^'O#6BQ:U%X:,?AWQ M_X)U^^N=2M;ZV?P_?C0M5TK7%U&22]TC[<\>_M'_"
MSX8>-O#?@'QU<^.=!U3Q9J_@OP]HOB23X/?&&_\ A4/$7Q%\1CP=X&\-ZQ\;
M=+\"7WP;\,^)/%?BZ?3?"NB:!XE\>:1J][XC\1>$M#BLCJ?C'PM:ZQS'[-'[
M4?A+]I_2/'VK^$?"?Q.\*Q> /B/XT^'E]#\2/A/\5OAD^IR^$?%.O>&$U72'
M^)O@7P3'JOV^3P_=76I:5HS:K?\ @Z6:VT;Q>-)UN3[ KBW[K6\())V>L8>R
MI7]YI73C33LE>3YK/22=FU)?9=D[Z:RE4J))WOJW-NVJ5EMHV_LG>#?C1X&^
M&NJZ%\:-7U"^F'CGQ1<_#+1/$7CR[^+'CKP-\'[A[/\ X0?P/\1?BU?Z5I%_
M\3/&.A*FI&Z\4ZL/$.OPZ5=Z/X;\4?$GXQ>)_#^L_&#QW\0^'OV7/VKQH7A'
MX/W/ASX+^"= \ ?ME_M1_M8Z%\;-'\8ZOXAEFTWXD_&#]I+XN?!O0XOAD?!V
M@7]O\0SXG^+_ (9L/C:LWBEO">M>!;#QC-H?BW4-?\=R>&?"'=^,?^"DOA6Q
M\6>*]!T3POXX\-:9\)?VQ_AU^S'\2=6^(7P/^.NFMXHTWQ]\%K/XD6%U\)+&
M\\'>&K[Q9XZU;Q;KNB>"/"?A'PO:^/O$'B:.;P]XDT+POK/AWXL_"[5]9^EY
M?VU/V>8O!NA^-1XC\<74'B/Q]KOPMTGP5IWP0^.>I_&B7X@^&+'4]8\1>%KK
M]G[3_AO<_'32]1T;P[I-UXPU#^U?AU96]OX&FTOQT\P\'ZWHVMZ@G&^K<HMQ
M4+I\LM8TZD)IK7G]^,XMK63;E#2P:Q:]Q/FO-<T7*-I>TA*&ON\O+&491OI"
M*M)7U_.30_V'/VHO$FJZ#XG\9(+37X/ 7P&T'QOJOQ._:R^+WQ_UCQ=\2OAQ
M^UA^SY\;_BEXU\.V/B#PS9_#OX:^"O%FA_#+Q5=^"M!^%G@CX66.K:G-HVG>
M)?AG\.M(M?#F@^#O;?AS^S;^T7^SO\1C\7?"/@_X=_%Z]\0:U^V[I/B#P7<?
M$:\\&W_AW0OCK^W'\5?VH?@MXE\)>(=6\$ZAIJQ7?ASXB0Z%^T!H4]M;W]K>
MZ/X6O_!DWCIO!<.F>)/NC5?CKH-Y^SQX@_:*^$^C:[\;M"MOA5XC^*7@CPIX
M T^[F\8_$M=%\,ZCXATWP7X9T*_MK;5(/&WB*[L%\,67AW5;"SUC3_$UR-%U
M;3K/4K:ZLXO!?AE^U7!IOP*L/VD?CM\8OV>/$GPE^(%]\.;#X9^*?V:=-^(W
MCW0)_$OQ&\41> M(^'&EZM;3>*=<^+NOZA\1-6\/^ ?"&K^&_!/@C6_%GBF\
M?1;GX8>&->DM]%+TDTK)-6DE&-HWJ2FE&*C[MY.M.,8QN[.*3;4.8UMK'F7P
M-6NWRJ,FF[IIQ]E&3;:=XR;3]_E\#^&_P<^-O[&&G:'\3;CP);_&VQ\(?LB?
M%*'XE^&O@_J.J3Z]IWQ3T;QO\0_VC8O /P8^']UX:?7?'7@_Q3K_ (RU3X3?
M"?3M/CLO%>C6>C^$;>[\*7PU6>/2/O3XF6?QU\9_LV^/[#X9:AX;^$7[2WBK
MX)^*[/P!J=[J<'B[P?\ ##XX:WX$U&W\*WUWK-[X+U2U\3^'?!?CVYL)Y]4O
M/AWJ5MK.G::UY<>"+V&X?0)?/T_;>_9P?PO)XI3Q-XZ:6+XIR?!*7P"/@7\>
MC\;4^*T7@F'XG/X);]GP?#,_'0:NOPKN;;XM?\D[-HWPDN;;XI)='P!<1>(Y
M+,O[:O[.KQ^ _P"Q/%7C#QS>_$?PJOC;0-!^%WP9^-GQ:\6:7X5;5Y_#HUOX
M@^#_ (9_#OQ9XI^$UJOB>PUKPG*OQ4T?P;/#XO\ #'C'PG-#'XB\%^+-,T8Y
M7:,;.T8J*5MDFFE?LU9:W5E%*2O*X]^9*UVV_P"5M6C:VB5FFG:UV[6T2/@_
MP7^Q'\;G^)GCOXC7&E3^$M$\6ZO_ ,$W+[3M ^*W[4GQ@_:4^(@_X9)_:7^.
M'Q=^,&HZQXO^($7B2S\,Q:YH'Q(T:#X=^ O ^J3^#Y[ZROM8U";PAJ/B35=)
MT3[P^!/P+\0^"OV5M&^ WC?5HM.UX^$_&OA;6-:\$ZK<NVG+XLU7Q'/'J'A_
M5;W3M/N$U&PL=:@GMKF73H_L^I0?*DL<:R29,W[7GPT\#_#K4/B'\0O$GB/Q
M3X;LOB'^T?X8O?%WP=_9Q_:,\;>&_"ME\!OC)XX^'GB32_'$7@CPA\2[OPK?
M_#R/PVWA7Q;XQ\1W>@^$O'?B;PKXP\:^ K>S\%O#I^C=?\$OC#K/Q/\ B!^T
M]H-Y_P (S-X;^$'QF\'> _ FI>'H[EI-9\*^)?V8_P!GSXU/JFM:@^K:G8:Q
M?R>)/BQX@@T_4=&M]'TQO#-OH%N;"YU"VOM:U691C.-6$DY1J4Y1FM;."3C*
M-TURWC)J-G%M*7*[Q]TE-Q=.>J]G.+A)+53DVHRUO=J<5=M73LVI7U^+/#'[
M-/[2WBKPO^S/\./B'X,^#_PYTO\ 9)^#_CKPC9^+O ?C;4M4L_BUX^U/X :[
M^SKX/L/!_AD^#=-O?A]\%+OPSXOUKQ_XOTCQ-J-WXC\.^//#GP_\*:%I?C31
M- E^(-[^BGP3\':O\//@S\)? /B"2QN-=\#_  R\!^$-:ETN>:[TV75_#7A;
M2]'U*33KFZM;*XN;*2\LYFM+BXL[2:: QR2VMN[-$OSA^S/^UIJ_QK^*_P"T
MS\*_&?@W2_!-]\&_B1XDL?AUJ6GZS=:G9_$3X3:'XN\4_#&X\3WKZA9:9_9G
MC30/B3\.O&EIXT\,:4-8T[PYX4U_X2Z]<ZT)_'T6G67E/P$_X*1>#OB%X3^(
M/C'XI>&M3\&VB?M W/PW^!?AOX:^$_BG\<OB)\5_A?KOP#^$O[2WPT^(A^&G
MPT\ >(OB%I^K:W\(?BUH7BGQOHEIX6OM,^&[31Z/X@UP7H$EQ5W-2DVY>TM7
MDVM9.I.I>;6EI5*E2HY1BEM)J*C!N,\J5HJ*C[/]U&,;^ZN6&BO*4G%1A&TG
M)VT7,^97N_LZ_LV_%_P7XZ^ .L^/]#\(:;IG[/OAK]M'X<1ZA9^*F\17OBVS
M^-'Q:^"WC3X8>/O#UJ?#]B^BIJ/A3PAXLTSQ?HFK7%GJWA76&&CZ?<^+-&O_
M .W9/EJX_P""=7Q'T[Q'XMU7QAX)N/C/X4^+_P %]7^!_B_P)\/?VR?V@?V7
M[+0;.P_:6_; ^+>@7/BO_A6-SX9TWXG^!?'?@/\ :LN/#_C!]1MI_%7PHU7P
M0MEX)\+?$K2_B'K&H>#?T6U7]NC]EW2;;PAJ$GQ)N]2T;QE\/O"7Q9@\2^&O
MA[\3_%_A'P=\+?'>IZAI'A'XC_&'Q?X4\&:SX7^ _@37;[1/%"6GBWXV:O\
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M=#\1O%D'@[X5_%GXIP?#KX>76H:QI>G_ ! ^+.H?"SP1XRT_X1>!M5O/#7C
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M('L?'44OBUKA L7A\BQ\$2KJFB?Z=;,]XXLAO\/C[';[E^/'[>7P]\"ZC9>
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MDK_'NN?LB_M)1_"7]J/]F/2O#WPNU7P3^V-;>%[+6_C7)X\U72]=^#>F:_\
MLW_!K]G'XOSZCX/D\&76H^/O&'@72/AC=^+?V<=3TG6M-TW7YKGPE\/?'0^%
M&D^ (O'7B_W9_P!EGXB#X8:KX0BE\%QZ[J7_  4%T7]J)KA=3OX[63X>:?\
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M>/O&WPYAU^Z\;^"OAE\9_$?@K2?@_P#$_P 9>'+'PCXWU/4/"OP^\=>)=?\
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M3+K2]-U675?!]WJ!\4>%O$>G:=YM;?M6:_HGQT_:I\"_%+X?:=\/?A9^SO\
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M\-/&WAOQ[K'B+PQ\4/#OQ+O?!>L?!'Q'X2;PY\6].\):YXJ\)66K:5C_ ,%
M?V2KWPWK_C.3XI7>B>#O#_A;2_'R^+?%WPV^*_@KPQXN^'&K^)],\(6/Q1^%
M?B#QAX'T/2?C+\*CKGB#PL+OXG_":\\:^ =,TCQIX%\3:EXBM/#7CGPEJVLN
M,U&HY05GS6C'62C*,H.*C=W;CSTXIM7DG&W,Y,CEDXJ-I-^[+;XMW>RNK2Y)
M-JUDDULFCG/@YX,_:"^ .O?%GX>:9\-/!/Q"^'GBWXQ_'GXX> _BH?BBWA;6
M&;XRZYXM^,<O@?XJ^&;SP;JNI6.K:!\5?%$_PN\*^(/"4OC/2$^#=CX7\1ZE
M%IFOZ!<>";_[8T*XUF[T/1KKQ%IMAHWB&YTG3[C7=(TK5I=?TS2M8FM(9-3T
M[3M<N-*T*XUJPLKUI[:SU:?0]&FU&WBCO)=*TZ28VD/R)I__  4#_9:U#6QX
M;/BWXAZ5KUOXO\)>!?$FE>)OV>/VC?"%[\.O$GQ!O] TOX>P?%^'Q5\)]';X
M,:9\1=0\3Z/;?#WQ'\5QX,\-^.WEOF\)ZOK":/K#6'&_L^_MY?#_ .(>IW7@
M+XBZL="^)=Y^U#^UA^S[X:ET;X7?%NR^%6HZA\$?V@?C?X%\!>#9?C#?Z'K7
MPD3XN:S\)?ACI/B37?!TOQ(M/$.M^(9-8GT'PAH]M=6'ANP+/ET2LN57ZV::
MCHVULEVNE%ZN]V]]K7<F_-[N3NV]^RLMFDK''_LA?LQ_&#X7Q_L6/\3-$\%:
M1?\ [+'[#WC']CWQ%=:+XGD\2S^)-=@U;]E2TT3QIX/N#X=TN6+P3XSL/@)K
MNO7%EK;:+XBTHR^%K+5-"FOFO3H_R3-^P7^V')\"?A7\ ];U+3?$MM\.OV9O
MV/OA;X&N?#G[4'Q>^%'P<^&^O?!3PGX2TGX[:=XJ^%GP_P##OAY_CQJ/CK7/
M#WVWX?:Y\4+;Q9X,U+06TWPWK7@GX56GA_Q#-\8/TIM?V]?V4KBQ\<ZS/\4+
MC1O#7P]^'7C[XP:OXR\4?#SXH^$/ >O?"3X6ZCI^E_$7XI?#+Q[XI\%:/X-^
M,GPY\%W.L^'I?$/CCX1ZYXW\,:=IWBKP?K$VJ+I'B_PS?:M]%_#_ ,>Z'\2O
M"6D^-?#MGXNL=%UI]12RM_'7P^\??"WQ.ATS5;W1[AM1\"_$[PWX1\;Z-%/=
MZ?//I<^L^'K"'6M(EL-?T9[_ $+5--U*[2LIQJ1MS4W&2T3C=SCB(MK5-N<5
M.*:TBW9<LKLM+E?,M)/6\;;4YTN5/MR5'S13M*7*Y*Z2/$/@CX#^(7@+XO\
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M4HHHJAG\Q?\ P=5?\F6?L<_]I,OV>?\ U5/[0]?TZ5_,7_P=5?\ )EG['/\
MVDR_9Y_]53^T/7].E!;^"'K/\XA11100%%%% 'A_[3?_ ";;^T)_V0_XL?\
MJ!:_7Y$?\&R/_*$/]B[_ *_?VG__ %L3]H&OUW_:;_Y-M_:$_P"R'_%C_P!0
M+7Z_(C_@V1_Y0A_L7?\ 7[^T_P#^MB?M T%K^'+_ !1_*1^\]%%%!!ROCKPU
M_P )IX*\8>#_ +8=._X2OPOK_AO^T1;B[-A_;NE7>EF]%J9K<7)M1=>?]G-Q
M )O+\LS1;MZ_FS\-/@+^VI\(+KPS\2O"7A3]ES6_B?XC_9-^!'[,OQ.\&>(O
MC9\5++P'X*U7]F/Q-\;]3^&_Q&\">/=-_9NN/$_Q)TWQC8?'?Q#<>-?AUXA\
M"?"M_#UYH6D6/ASQ[J:ZAJ^MS?HM\2/B3X.^$GA#4O'OC_57T+PCHUSHEMK&
MMC3-8U:#25\0:]IOANQO]2@T/3M4O+'1+;4]7LI->\07-M%H?A;15O\ Q-XF
MU'2/#>D:MJUEY;KG[6/P"\.:W^T1X=UCQV;;6/V4? 'A_P")WQ\M(?"WC6__
M .$&\'^*/#/B3QAH=W%<:=X;N[7QAJUWX;\*:OJLOA3P)/XH\66$$V@)J.AV
M=QXM\)PZW%DKZOW[)VN]4I)6MLVJK7G>/5*ZTMK:RWNDTKN*:N^\HQO:ST[-
MG$Z+^R%H.E_L)>&/V&[CQAJMSHOA?]ESPM^S78_$NUTO3]-\2V<GA#X8Z9\/
M=!^)VBZ6DMUI^A^+=%U#2=/\;>'H[2X>+0/$5AI\FGW2&QMYQ\[^$/V5/VDO
MAG>_ CX^:&?@A\0_VGM"T']J&S_:#\*^(?&?C?X>?"GQ;JO[8OQ!^#_Q@\>O
M\//BI8_#'XG_ ! M=.^"?B?X%?#CX6?" >,OAGJ%SXA^"6BP:5XC'AO7=.T:
MYL/KFS_:V^ -_J/P)TBV\=,VK?M)ZOX]T'X/:7/X4\<VFI:_K/PMTC6-8^(F
MF^(+"[\,0W7PXO/!HT+4="U^#XF1>#VL/&IT[X?RX\<ZWHWAW4.8U+]NC]E_
M1_ WQT^(VJ_$>ZL?"?[-NI:KI'Q>NI?A_P#$]M4T2^TGQSXI^&4B^&_#,?@I
M_$_Q+M=3^(O@GQ=X$\+ZE\+]'\9:9XR\7>'-8\/>$KS6]5L9K93F7OM/1WE*
MR25HJ+;6BM&U6G%I7@XRHK3]V%GHG=ZNUU=WESP>K3=W*-6S5FY1JO5J:C\B
M_P##!?Q<FT[P'I.LZU\.M8L?'?PR_P""E_PZ_:1ETOQ/XE\)77@D_P#!27X\
M> _VA_$.L? S/P_\56WQ ;X0ZYX5U/X?Z/9>-X/A5+X\T^_LOB/J^I^'=<CU
M/P?J7MG['W[,WCWX4ZVOBKXT^"?"A^(OAGX;6?PR\/\ Q1T/]L+]J[]I*7Q)
MI.IZAHVH>/CIGP[_ &E-%6T^ 6@^*=7\#>!O$I\)^$O'?Q,N#-:VGA[5O%NK
M0^#].U_Q#]0:]\?OA;X:N_B;8:EX@O+B\^#_ ,(= ^._C^WT'PMXO\4SZ=\+
M?%3?$M/#?B'1H/#'A_5Y?&=]K<GP?^(D>G^$_!2>(?&,[:%;@>'P?$/AD:QQ
M/C3]I3X;V'BWX;^"- ^*?A>R\0^,KOX8^(H()/ OC;XA:;XF\ _%&]\5Z7X)
M@TKQ'X0O])\.>#-4^(M_X0\2?\(1XI\3ZIJFERVGA#Q5>IX6UJQTZ]O=,?,K
MK9MI05TD[<THQ@D[6U<TEW=16E+F2&URMWT2G-VVY;*<Y.VCBTH.3^&RINZ5
MF_CWX\?L<_M&?%WX[Z]XGG\1^$/$'PZE_:3_ &,?C7\.==\4_'SXZ:-+\'OA
MW^SA\3/V=_B/X_\ @[H/[+GASPE/\#_%FO\ CGQ)\)_BCXOTWXZ:]XTL?&MQ
MJ/QATKPAXDT>X\*?"7P>\OV!^SC\-/B3\*+_ .-_ASQ=8^")O!/B'XV_$;XJ
M?#+Q1X=\6Z[JGBC6]-^+WBO6OB!XBTKQWX*U/P)H.D^!K[P;KFMR>&]%D\/>
M//B3;^,M*M1XEOW\%7<__",1>'3_ /!2OX$:GJ'[-K_#_0/C3\0O!_[27Q=O
M_A7X:\?:'^SU^T6/#-NEC\$O'_Q>D\3:7=+\'KJ/Q)9P7O@ZQ\&:K8Q3:7)H
MES<^.]?U&ZBTOX-_$Q-"^H]+_:&^$>MQ> Y=-\4272?$WXP?$SX">"B/#WBN
M$:S\6/@\/B^_Q&\+DSZ'%_9D7AY?@+\5V3Q'K/\ 9WA36QX6C'AW7=6_X2+P
MM_;8HWL];)22TMI)TY-VLMW"#T5OF[)NZM&6G9/O'F3^:]Z]WT;LK-OY2O?V
M7/C'??M ?$#Q=*WPQ3X8:]^V;\(?VLO#VJ_\)7XHF\=RVWA']DWP%^S?XK\#
M:SX)?X?1^'=.NK76?AW8^+_"_B>R^(FJIK-CK\^EZEH'AF[T"*^UWS+XQ?L*
M?%C7_C3XM^/?@G5-!U_7-1^.GC7Q9IW@$_M#_M"?LOQ:S\*OB5^S1^RC\)/$
M-IJ7QD_9]TK4/''AOQSX?^)'[,&B^*=)TI_#7C_P!XD\%WM_HFL6&E>*-2T;
MQ3X&]M^*7[:>AP^&M1MOAE8^+M$^(VB_$+]ERPG\-_&7X-?%KX8RZQ\.?CA^
MTY\/?@GK?BCPMIWQ!\/^!+CQ&++3];\26$K:5<7>H>!_$,WA*_\ &FAV.G>)
M_"T'B;)^.'[=WA3PU\)]9^(WPMC\37FG>$OVB_V9?A1KGBWQ-\&?BVG@7Q-X
M:^(?[:/PL_9K^*__  J[6'T#1[7XFZ[9Z=XB\9Z=X&D\"7GB,^(/$<7A[7O"
MNE>./#FI:4NNBNW9;KEMLVTX0M;1M**I0BM':RBK:))M\W=\MDNB2E*+36FK
M<Y-ZNZ]Y:*S^F?A+\.[WX/? ?2/!?@?P)X4\->+-)\.^(-<B\#2_%3Q[XZ\(
M_P#"S_%=[J_C/Q';ZI\:O&7A.?XD^*M-U_XAZYJM_KGQ*U_P++XMU8:C>^);
MOPBVI3G1:_+7XT?L^_M":$?'?QQN/AU^S]\+/B!\9/VE/^";DT?P9^$'C#QS
M\3_AMXJ\??!O]J^T\3>*/CC\5O']]\%/@Y?0^._B=X3\3>%?A3X@\::7\$]7
M\2^!O!/PD\(>+?$?BGXMV7A_P/\ #SX;_I7X?_:L^%_BCP?XV\6Z!I7Q=U2;
MX<^.;7X:>,_ ]O\  OXQ?\+0T'QOJ'A_PSXLTO2-0^'$G@E/%EO8ZEX6\:>$
M_$=MXKETU/!<>AZ_9:I?>([*SCO9;3CI/V\?V7C)X @/CC6S<_$?1O'OB32;
M.;X8_%2TO/#'A?X3>,X_A[\9?%'Q9AU#P3:CX'^&_@MXVE3PI\8=8^,;^!K/
MX:>(I(-!\7/I6L7MA87<^ZW&UE;D:5FERIJ=M+))QI[[*,=;<JLU%M2BH\UU
M*+]WF:>L6[+6Z<WLDVY63]]J7R!X\_8C_:*^(GCV7]I77$^'.G_&>]^+5UJU
M[\%O /[47[27P>^'Z?!R?X(^&OA)%X>A_:B^$/@#P1\5[CXC+XM\+V?Q8N->
MO/@<_@Z^\.WLOP,O?!\]WI.B?':U]1^&G[-'QS_9S^(5O\2/@/\ #3X#W5C\
M3_@_X&\!_&?X4^.?VBOC*\G@CQQX1^,W[0WQOUCXA^"_C_K?P(^)OC[XZWGQ
M$\7_ +4WQ1U#QLGQ/\%?#O5;WQ%IVF>++?68KOQ3XETZ#2^+O_!0KX?Z7\++
MGQG\,Y/%VF^(/#_Q4_8AL_$'AKXK? GXV>!_%%_\'/VH?VM?AE\#[CQ3X.^'
MWB[PGX/\;>+]0\1>%M:\<Z?X'M/#&E:WKMEX_LM'T?5?"UUK4UKX6U;VQ?VV
MO@(?#L^N->_$.+6(?BXOP#C^&DWP;^+47QCO?C'+\/X/BS;^ ]/^$S^#/^$Y
MOKV7X4W4/Q2EUVWT9_".F_#-;[XAZQXBTWP;I&LZUI]*T+62BG=);+1J+5DU
M>\G?7F?.Y-<KYD)WD[N[:MK97U5TO_ 8VNK+E5G?XCX6\<_L&?M-ZCH'B'P5
MI'BOP'XM\$^,=6_;POX?"^J_'KX__!CPA\.?$7[57[5WQG^.'A+XGZQX.^$7
MA2XA_:9U73/ ?Q-\,>&];^&OQ)UWP%H7@C7? VLGX<^-B/B3KOB+3?N#]E+]
MG_Q=\![?XM0^*M4\/:I)\0?%OPH\0Z6?#]QJ$Z65KX#_ &3?V=/@'JUOJ#:A
MI>D@3W7BKX.^(=7TXVL,D4GA[4M%FN!9ZE)?:;8<'>?MQ_#J[\=^ ]?TSQGH
MVC_L\I^S]^VI\5_C'XG\;^&?%W@;Q5\-]:_9/\=_L\^&?$-GXNT3QA9^'/$O
M@!?!MC\0/B)+XXT#Q7X0AUD_V?HFHVQM+&$-J_.V?_!03X=M\8O'VEZ_/XQ\
M%?#'P#\"OA5\0-3T?QW\!_CAX)^,LOBWXP_%_6_AC\-[#1?ACXC\'Z?\1O%T
M?Q.U*#2?"?P[\,>%/A_J_B;Q!\2&U3X?VT$GC[2-:\'Z0)M7BKN[G?577+&<
MI72_E4GRZ.3O&S<5%)2;:LUHI4GI_,VE"UTY7O%-JZ5[MI2=Y>??$']@'XC>
M+/#VI6>A^.O"7AGQ!XN_:"_::C^(>LVY\1O>Z_\ L4_MB>+K>^^/'PDT'4[:
M"RN/"GQ4U'2= ^'WB?PKXNM;>[M/#OQ ^'/A_P O4)=#O=6,_/\ Q+_8#^+-
MU\=_&O[0'@._\-:S?:M\8O'^K:+\-K;]HK]H?]E2UN_@_P#$W]F[]B?X5ZK:
MWOQ>_9VT>^\8Z#XS\*?$7]CG1=;T?PM-X5\=?#CQ#X(URYL]2CT?Q:FA:YX2
M^O)?VZ_V=H3X:T^76/'X\8^*O'>O_"[3?A='\%_C'<_%NV^(WA71_#7BCQ'X
M0UOX:V?@2X\5^'K[3/!'B_PY\2UU'7-.L/#^K?"/5K/XPZ#K&K?"R9/&!Q3_
M ,%"OV9)=7AT33=9^)FO7VK>-OB#\+_!DF@? 'X\:MI?Q+^*WPE\1ZYX7^)_
MPP^&&N6WPX.B>/O&_@#4_#/BN[\5:5X<U"]ATKPUX%^*/C.:\/A#X.?%[7/
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M_"Z:'+KNL>G^(/V^/V9/#WA?1?&4OBSQAJWA_4_ VL_$[7+KPQ\'?C'XFO\
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M?LZ:IXY_9D_9I^)WPC^"B^'?'OQ&G\._'[XO>.+'X;V=M\8?BVE]\)-)U/\
M9RT,Q_":&SG^'7@F7]I2?2=/^+OB[9XV\07?P\\/S^-<;X[_ +)7Q^\92?M?
M?"SX=M\')?@9_P % ;&R@^.WB[QGXP\:Z)\5/@]?:_\  OP/^R[\6-0^&'@O
M1/AUXE\*_%<>(O@?\-_!K^ K3Q7X_P#A.O@;XC6FKZYKLWC_ ,.ZK;^&]+^M
M]0_:J^#F@^-]6\">,=1\7?#RZTK2O'&L?\)9\3?AI\1OAS\+M5L?AI8'6?'T
MFA?%;QKX6T/X>:O_ ,(WX=6Y\5$VGB-TU_P=I7B7QAX2;Q!X8\&^,M6T#Y*\
M1?\ !0;PUK?Q7\">&O _B+4/AOX(UCX ^.?BYXEU7XX?LT_'[1/$=I(WQS_9
M.^''P@U33? /B&+X5^+K[PQ\0=*^+OQ*T43P6<D_AWQ1;Z-J?BN/2E\'^(O"
MVK6G*<KV<Y2E.3:2=Y2DZLYR5DG*52S?NW<FHJ*6BF_LXI)*$81@K1T48PBW
M!:2;4813DM>5*/-)VC<?=_LF_'YM0F^!EC+\'H?V4KK]LO2OVRE^(#>+?&*?
M'K3+^V_:>TW]MW6OA&GPO7X<3?#_ %:SUW]IFPU"-OBG<?%^PN-/^#OB2X\*
MQ_"ZY\6Z';>,M4^D_P!IO]GS7OVC[OX.^$;OQCJG@[X3>#_B+:_%GXB#PGKV
MH:#XZ\5^)OAY#_:?P6\/Z5=VNGRVMAH?AWXGW&C_ !CU+6FU&VU.S\5?"?P%
MI=EI>JZ;KNO7&DSVW[9'P'N?'\'P]BUSQ5YUU\2-1^#-IX^?X9?$M/@K>?%_
M1IK[3]7^&-I\<G\)#X37/B[3O$FFZE\/Y[6+Q@UBWQ=T_4/@G#J$GQAT[4/
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MKHWBW3='\4Z?=Z3J<_A_5KNPU2UT[4S87D\<%W-IUZD1D9C"YQCPGP!^W?\
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M <FNV\$GA836%MK+^(](W_V;M \??"JUTG]FV^TC7]=^%W[._P"S[^SC\/\
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M_9E;X,?#?P[X_P#'7Q-^&^O?\,\?%KX@_%?Q%_PM3XD:I\(/A9K^D+\7M/\
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M#Q?\8/$'C/Q5X/TGQ!KGP\^+/BWXQ_#C0?BWI_Q0@\'?$S3].O-<^)_AR_\
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M4K]MW]F?X#?\%+?A-\3?%OP'N_VI?V ?B?\ L"VGA_\ :<T_X:7V@?"/XE?
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MWDXI)2<N519ZQDYZ<>O^ _\ U4G?J".^3R/\/<=NU?RLQ?\ !:[]H_QMJ/\
MP2H\:?#FS^&K?"#XG_ ']DGXN_\ !135-0\+:A)_PC-[^UK^T[X&_8MT>Q\
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M_P!IV6GW=_[LO_!1;XW:]_P5<_:"_9&U_P#;7^"7[/O@/X2?M*_LT_#/X8?
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MQ0\$:+>:M_Q+==TBZM?BG\$_$[6-_JUMX6^(7POFO[II#XBT^%_N#PE^T/\
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M/V@:"U_#E_BC^4C]YZ***"!K#(QUZ>G_ .H5^//B'_@DKINN_L&_MR_L//\
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MB)IW@'_@F]XC_8&U#]I[Q1XS\2>-OV@O@]^T%XU_:(UKX<64>N:_K7P5\??
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M,^'O&NB^.OV9?'NO17NF_L_?'CX-77CG2;;X@^%O ?AW2?"/ASP?JWA_X@>
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M]WX+U#Q)X1TV]TV;7[VSU"^6;46AFBL'LYK.>.]D>'SVR_8*^-GB[XM?L/\
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MW?X2?\%JOVC/ 'PU_;O^,NJ?%?X8_P#!0']GG]E']BOP3\99/C9X6_9_U_\
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M49S@_<C$E2;C&<=812K0DHI>Y-1ASJ\5+DE*G3I24D^:<J<9J7/*1]A>.?\
M@FG^TY^TG^S5\:_V3?VV_P#@H#<_M ?"CXE?#[PSX;\&Z[X%_9A\'? 3XN^#
MO'_@/XA>$OB9X"^+OBKQOHGQ(\8Z#XZ\3>'_ !-X)T&:[T?1/ OPW\,ZU&MX
MUSIL%Q<I/!Z)^S?_ ,$^OC1X._:MM?VS?VOOVPI_VL?C/X/^ FH?LY_"6T\+
M_ ;PO^SE\.O O@CQ/XGT#Q=X^\4:GX0T;QO\2;SQ3\3O&NK>%/#Z:AXCM_$7
MAKPU8:=%J.FZ7X)MK:?25T+X:_:-_;__ &[_ -G+]H?X\_\ !/Z#1],^)/[3
M?[57CSP3J_\ P2:^+,GPWDM/AS#\)OB+/-I_QT_X79%X=LI]$%Q^P!I?A[Q1
M\1?$E[/+JFO?$WPCJ'@2_P!8\.V%MKYC7[\_X*=?&;]HW]D/_@G9\2OVA?@I
MXDC\9?%?]F[1/AG\2?'%[K/A'P]=#XF_#?P1XR\(O^T$]YH45O;Z-X;O=:^%
MR^./$L%SH%O91Z#J-G!#I9L;) 82[DH2;23FE&3<4E*?[FI)V5XN"JSIUYI7
M4>:*<TDHIQ:O"W-S)M15GS+W91Y;VM&<J473C>SE#F:CJY<5!_P2JTN']DS_
M (*6?LKO\;-1EL_^"C'QX_:U^-VI>-CX"M4N/A*_[5%II5I=^&;#05\6F+QG
M#X*&F![;5KC5_#4NOF=EEL-)$89^(^)7_!,/]IKX]?L4?&C]B_\ :!_;[L?B
M)H?CB']F6'X2^-]%_9-\&> KWX.#]G?XM^&?BG>/?Z'I'Q2O(_B:WCX^!_!V
M@S#6-7T%?#*Z3=ZG:KJK:M<6,?SPW_!4WXQ^'_\ @JKXU\$^)/$G@R]_X)N6
M=C\5O@EX>U[2?#UI/K=I^T#\%_V)/A'^W[XR\87WC9'%[<:&?A)XJ\:^';71
M)Y(K 7WAN\GD5;A+*:7Y;\!_\%0O^"A5M\,KS7/BCXP\!1>,-6_X-T_VH/\
M@JSI%EIWPY\/VEMH/QM7XL:IK?P!:>% [7.A^"_@WXA\&^&->\*W^;;7M7TN
MZU;7(O[5N;M%3?*W.3:FW"4]5[2+H^VITE))OEG"&%DTDU4C!P<HISTM*<W"
M*Y9.4DJ;:34WB/8.3C)QLXMUZ<9_8<N9+FY7?]-&_P""<_[1?A#Q%\;/VQ]2
M_:JUG]J[_@HQ#^R[\4/@1^R1XJ^)7@CX>?!G]GC]G^_\66<NL:/>>%/A+X,\
M.^*K6SU#5O'MKH=_X^\;^+]1^(?B37?"FF1^$(TAT4/8W/ZL_"70?'GA?X5_
M#7PS\4O&Q^)GQ-\/> O!VB?$7XD'1]'\.GX@>.M)\/Z;8^+?&W]@>'=+T3P_
MH8\4Z_;ZAKG]C:%H^DZ/I@OOL.FZ;8V<,-M'^17[2O[;7[0'PU_X);_L9_M2
M>$]>T*T^,?QHU[_@F[I_CW6+KPQI=_I%_;?M*>//@UH/Q66P\/W*/I^EG5K#
MQIKT>F&U4-HK3POI[1/;1,O[8;@$7G.70$;CD!G49)R6R!W)!/4\DFJ<7#GB
M[?NZLJ+6BM.GSRFE;2TI2E*<KMSFDVW9(Q4E)0;;7/#VL=-7!RC2BY.UURVY
M80NE&+;2NVS\#_!?_!!OP!X,^$'_  45^#MK^T%XGNM%_;;U:SE^$TY\!:?;
MP_L@>%O!_P >/C!^TQ\)_!OP^T__ (2V<^+=,^'7QM^-'B3QO!<W-[X3GUF^
MM[<RI83E+FW^A?AU_P $H_#_ ,.?!G_!,WPEI_QFU?49_P#@GA\3OB)\8-5U
MR^\$V0OOV@?'_P 6_!'Q3T/XDZ]K,47B@1^!+CQ/XZ^+OBCXB7!MW\7&*YE.
MCGS1*=5C_(+_ ()-?\%:/VU/VH_CQ^P_X+^(G[0GPM^-</[2N@_M0:I^T-\&
M]0_9EU+X!ZS^SYX=^"T?C*#P!XS^$/QRN?$NB>#_ -H?5O&6NZ1X-L?%/@/P
M%X<\;ZUX,T7Q%KFIZ_;:%8:'?^(M$^E/^"%W[?G[0O[==E\//&/QT_;8@^(O
MCG7O@SX[\=>.?V6])_80\5?"?PQX4?1OB-I?@G2_$VB_M7O;6WP[\;O91WFC
M7,OA#PS=7NH7LGB>_B:W5?!NMRVA'512TC%49QCK[KH*4:=DKI<OM91<HMPD
MV_:2FXIK:K"4754[22G5ISMLYUVX5;M**O-8>_OKF24?9\KJ-2]M^'?_  1V
M_:$\"_LK?&C]ARY_X*"V^N_LI_%KX;?M8^!;7X?']DKP=IGBGPKJG[4NJ_$K
MQ7=^)Q\1X?BO<Z[KH\%>./B;K&OVNC7$%C#KME;V^@37VE66R:#]&/V,/V??
MVE?V=O"^I>"_CQ^UEI/[3?AC2O"_PZ\)?"C3M._9Y\*_ N?X=Z3X)T[6M)U4
M7]]X=\:>+YO&TWBBPF\+1^9J0T[^Q)/#$\MJ+HZ]=+:> ?%']KOXC_L_?\%1
M_AE\"_B]XJ\,Z9^R-^TQ^Q]\7/'7PDU/4=-TZQU?PI^T;^S!K-CXP^,>B7WB
M&VCANY_"FK?L_>)(?'<*:U+<O97W@S73I8%G]L%I^<'PL_X*"_\ !07]I3PQ
M_P $\?A'X)\6>!_@?\7O^"G%U^UK^UC#\6/&/PHTCQG<_LM_L*_#37+36_@-
MX/\  OPZ.KZ#X;^)/Q5^)/@7Q7\,Y%\;^/-1UG3_  _:Z[XDU'5/#'B61M%N
M]-B+2C%0C:,E",4TE=4G5HQ5I:ITX4*EI/:C!N,FK1:E)S<I2LWS5*LIM)-R
MJ)5JLDTDWSSG'G2T]K**:3M(^D?VE?\ @BQXM_:1^+?[;>I7G[;'BKX=_LV?
M\%!_%/P.UO\ :3^ WA#X$?#K4?%^M:+\$OAG\/\ X;6/ASPM\</&NM>)[CPD
M=>@\"1ZO=:SIOPZ:^TZXOT@M%D^PFYO?<XO^"=?[1?@7]M[]I#]K?X!?MOVG
MPI\*_M5>-/V<?$OQ=^#&N?LR>%_B>^I:/^SW\+/"/PE@\.Z5\2]?^)FG:MI,
MGB[P[H&MRW>NV_APWFE77B&&1+?49=%CFO\ YR\#?&'_ (*(>(/CG^U9_P $
MZO%'[7'P]\/?&_\ 9R\(?!/]IWX7_MC:-^RYX6UV\^,O[.?Q-L/B-H?B3X=?
M%'X#W/Q!TSP%X/\ B5X.^)/AJ&PLO'?@K7;#2_%_A>VLK]? _A>\DU%+KX9L
M?^"@G_!1+PM_P29_9G_;[^(_[9'@I-:_;#^-O['_ (.BN=,_8_\ #NI6_P"S
M-\/_ (B?$?QGX1^,VN6/A;POKVMZW\>]3FT&?0]<T#0+30] \0?:O![Z-X?M
M;[4?%92U<6DERZ12HJ+6BDJM2I0HQU6L54I5H6E[L%2FW>+BYNTI>[S1ES.I
M%QLKIPHPQ,VK123E25.IS1]Z4I1C=232_J6^,_PF\'_'KX0?%3X'?$*SDU'P
M%\8_ASXW^%WC6QBD$<UWX4\?^&M2\*^(+:&8JPAGETG5KI()0KF*5DE )05^
M6G[.O_!&/X0_#+_@GG\=?^"?_P >?BGXV_:5TW]IN]U[4?C9\9]6TZT\%^/?
M$&J2>%?!/@3X>:OH%K-J?CBTT'5?A)X/^%WPRM?!<FHWGB/3EUSP=;:UJ.EW
M4&H7VDR?(WC+]K_]KJ_^%'[ 'A_X$?MZ:7\1O$G[8/[>/C#X"ZS^TEXM_8'O
M?@Y<^'O FB?!/XD>+3X8M_V<_BEJ/AG5I[O2/&/P],B^,+B_T<ZW8ZRPLGN+
M.QB>\^Z/V$?VK/VG-=_:B_:^_8*_;%D^%GC/XO?LO:'\&/B7X%^/GP:\+ZW\
M.O"WQO\ @M\;=/\ $D.C:EXD^%>M^*O'\OP\^(GA'Q'X-U;3/$=IIWC74M!U
MF/4[5M"L;6TT=]8\0NR?.EK=3A)6:YE15&K)JZC9P5>G)M<LG%:-PA9)IQY=
M;M<E6-MX^TE5HPD[QMK.C.%O>49:RBI2;?.^!_\ @F1\>/%'Q6_9J\;_ +;G
M[>'B/]L#P-^QQXJ@^)/P ^&<'P$\'_!5-3^,.C^']8\)>#/C)^T-XLTCQGXW
MOOC'\0O >@:_JLWAF]\.Z;\)]&C\47,GB74=#U&2YU*QO_J7X4?L66OPK_:Y
M_;M_:MB^(EUK=U^V]X>_9G\/WG@>7PU;Z=;?#9/V</AWXU\ 6]W9^($UN[F\
M5MXP7QD^JSPSZ1H(T1[!;*.34DN3<P^7ZC+_ ,%,!^W3+'8P^ #^PG_PMSX>
M"*;S/ P\:_\ "HV_9/\ BT_Q%:4RW'_"7#4U_:Q7X2Q6 BB&I_\ ",OJ/V%6
M\.#4GC_%;]G[_@L/\;=.^'W[8G[2/QI_:M3XG:E^S'H'[='BB#]B/1_V*/%?
M@3P_JNE_ 7XD^+? ?PG6;]M2STV;P 9M1:V\%76OZ;I@U3Q! FN:C!/I%Y?:
M%J4"YS]G)5(SV=&M.<5NX5'"G5;<;-RJ2<87LNC3C%)JH<ZM*&EJE"G!JR7/
MS^TI))KDC&$H<]W976JDY)2_1K]G3_@D]^T3\%/V-/'W[!'B_P#;[MOB?^S1
MK_['OQA_95\#^&(_V4/"'@?Q+X#O?BEH%UX<T_XEW7C*P^*FMZOXOE\):?K/
MB5%\'WITNTUUM7MVN-;L9-+ADFW_ ( ?\$C/$_A'QA^R'XB_:E_;)^('[4_A
M?]@C0=%TO]D_X-V?PH^'GP.^#O@?Q#X=\ P_#+0?B5XVT/PU)XI\8?%;XC^&
MO"%K;VOA'7/%?CLZ9X4U&75M6T70K6\US4GG^=O$7[1O_!33]C+P;^Q=^UC^
MT[^T+\&?VA?AA^TW\;/V=?A#^T=^SCX7_9_TWX4Z=^SW#^U->66C^'_$G[.W
MQ2TCQOXC\:^,4^#GC36=!T/6-*^+-OXRF^*'A1M8U2QNO 6KS6<VF_&W@7_@
MK;^V[XA_;L\1_ SP9^T!\)?BMXT7_@K;\9_V0-*_81U#]F;5++Q,W[&?PO\
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M[XK>%?!WQ(\7:1)X;\/>.67X>BZL=2\9Z?=:=K&JZM:17=G;"UTNW[SX&?\
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MP!\2O%O@CX?_ +,_BK]D[6_"?C#Q)I]IX^\7>(-,_95^('@?QYIFG^)!#?\
M@[33JOC>7P5':ZIJFE6^FZ1H-QJDMQH?A>+2[*RT&/\ 3X#  ] ![^G]*P_$
MUMK]YX>UVU\*:KINA^*+G1=6M_#>M:UI4^OZ1I&OS6,\6CZIJN@VNJZ'<ZWI
MNGZ@UO=W^DP:WH]QJ-M%+9Q:II\DZW</XR?L3?'O]KR#_@I#^TY^Q/\ %O\
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MX6?#GQ%:1[K?6$URVA,<[BZM?#/^"@W_  5C^-7PMUO_ ()9_'3]CY=$\?\
M[-'[1OP8_:%_:Z^//@;4O#EAJ'CKQU^S#\&/!G[//Q.\6MX"O9;J.?P]\3?
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MIOQ9^Q-^WAXF_9"^'/[9GB^]^)_[0/PO?X#^#OC+-I/QB\1Z#I/A;X@?%_\
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M_P '57_)EG['/_:3+]GG_P!53^T/7].E!;^"'K/\XA11100%%%% 'A_[3?\
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M (*0:+^R)^UK\3OA7^U1X^_:"\#^!/\ @GQ^SQ\=D_:R\=?L@?#CX577[/\
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M\_;(\)_MM:/^VQ:>$?#R^//A[\1_ANT7AOX6?#[PKX/N]0N],OO@/X"^#/\
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M1_P43\?>-_!'@6^_9:U'X ZJ_P"S;\!_#VH_!6Z_96\::'XN\(O!%H%A9_\
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MI_%?P3I_Q!\3:IXHC\!:GX\TSPU=:M;:#+J%I=6N@V=D?KG_ ()=_M"_&/\
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MAH/[#WAZS\,?LU_''Q?\.]'UC]JKQI^T)\7+6#POI/B-?B[\/-?O?'<_A?\
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M#VEVK>]:E>,7)-I7248ZR_IM^*O[(VC_ !1_;!_9-_:]NO&NK:/K?[*?@O\
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M%LC/<W7V/2='LH=/TZU-S>37%W<&WLX(H3/=7$US-L\R>:21F<[$9)!SS@D
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MM/TV_P# ,87X(:]J5YJVL_%1IG\ O)/\=-3U*_O=0O\ 7IS)X+O-0O;N_NO
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M'PBD;0M"\&^'_"?A:?PG\-/"EQ:Z/9"\U235?$4LNM/[Q\3_ -B?P[\9[?\
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M5^S+KW[>'C;]OS43XON/'OQ0^ OB3X _%7X37-UX<O\ X'_$C1?%VAZ!X/\
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M3_$OAWPO\1M>CB\7ZOX*U7Q#KGAC0/$CWUWX(TWPQ;:QK-I?_9%'Y?\ ZO\
M"ERIQG%_#.+A);)Q:IQ:T2LK4Z<8I6Y(PBH*"NFKMM/JFG\U*<TWNVW.I4DV
MVW*4I.?,[6^7/V+?V4/ O[#O[+OP=_90^&OB'Q=XL\#?!;PW<^%_#?B'Q]<Z
M+=^+]3L+G7-6U[S-<N?#NB>'-&FN8I]7GMXWL=%L$^S0P>9&\XEFD\/\2?\
M!-'X&^)?^"BW@;_@I9-XE^)&G?&#P-\.+?P'%\/M,U;P]!\(/$FL:=X:^+/@
M71OB?XGT*7PS/XFU#XC:%\/OC1XW\"Z3JL'BRSTRS\-7RV<6D++-J,]_^B='
M2K>LE-N\TY-2>]Y1<).]OM0;@^\7;LTDE&+C&ZBTHM)M)I2YTGW][WM>NO5W
M_%[P!_P0V_97^&G[+/[;?[)GAKQ[\;O^$'_;FU._/CSQ+J6N^";SQE\._!A2
M6/PM\,/A7=+X"@T/2/ 7@!+[75\'Z;X@T+Q+?6/_  D6K?:M1O/,@,/J]_\
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MVMHOWD(PGHDOBA&*?^%-6:N%W9+6R<&EV=.I[2#_ .W:GOKSWNG8_*KX4_\
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M,O#_ ,:_A5X)^.7[./Q\\-^ =/\ !6AV?Q$\2^+IO%GA_P *^!O'+Z5X[N]
M\2Z1'XQU#2M!UCPY;:=^SW_!(3XJ_$O]L#X:?$#]OSXI_'&Z\4W_ .T;XPUO
M2O W[+WA/7M4_P"%5?L3^ OAUK6H^&=/^"&K:#J&F>']7\0?M)K-9KK/[0_Q
M"\7:+8FY\4W-OH/PST+P[\/;*#4?&=:OFWM#D<V]+>UI4ZE-6>MY>TL[>ZG%
MR<K3IQG$DXJ#>JGSJ#333=*K.E46^G+RN5VO>ORQNXRY?V(I/IW]<_R_IQC]
M*_+#_@KZG[9;?LIZ/-^Q<GQ8NM;L_CA\*;[]H/3OV=M1\(Z7^TWJO[)]EJ>H
MW'QMTW]FF_\ &ZG0+;XUW%A'HP\+LTB:I+9KK%OH8FU>6SM+G\V_A9^V%H7B
M;Q?_ ,$@/#_[+/[2_P"USXW^&OC3]M;]L#X/?M&^&/VI]=\02?M$:9XM^'_[
M-/Q5^(6K_L\?M":9XDT;2?$!USX0>+$\/#2M"UEM6N+6W@T*Z7Q#X@CEM]4N
M$Y)6?>I3IZ7=O:.:4W:]HQ<&KV?-*\5:2M)M-1<]THU)-+HJ<>:S;LE*2=XQ
M;5U[UW%.W].8S^';UY]L?EZ?R >V"/J,5_'/\(_VN/$7B_\ 9)_9[_X*R_MM
M_M5?\%,X=+_:5^*'BKQ5X>\!?L+3Z!I7[(O[*7@CPG^T3I_PI^'/P7^+.AP:
M%#I_B0^--8U'1?!6M^*?BG/XC\1>+]4N?$>@:<VE:OH+^(-6]T\0?MN?M0_
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M:BU&<(PC%2Y6IUH*25I<O]OU'U_QZ?U_R*_DLO/$?[9OB3X3?\%M/VU_A_\
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MT2[T35-0L+WQ3>2G=R7\OM.[<O95%"7*EJTKJ<GKRQ:;33;BGHYKK3E&,O\
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MEM\4E'_"::KX?UI?!F-$L_$.JS?9_P 6= _::_X)K^(O^":WQMT_]OC]HO\
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MDC2<'"4X74N2K5I7C=W=%5.:26CLY4IP2TESQDG;D9_<2._7KW_STHK^,_\
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M32;ERZ7LVM;IJTI1>G\\(J:WY5-*5I*27ZY\# _+\*/4Y[<^WO@]#CM_/O\
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MQK<Q7<NG6NCI?^9_ #_@H+^V=8_LZ_\ !,+X$?&OX[^-K[]H+QM^VS_P2?\
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M6GTS\1O^":?[+7Q9\-_MQ^$OB#H'B;Q'H'_!0;4_!NN?'O3[SQ#A+?Q!\._
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M=_:L_9$^#?[8W[-/C?\ 9,^+5AK-A\'?'MCX/TS5],\ ZG%X0U2RT[P+XO\
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M5.2EUDG"<H6;:46TDE:WYP_$;_@E;^R/\6/@E^UU^S_X[T'Q?KGP^_;4^/\
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MAIHVHVVORVW@U[,Z5XU\-Q>+-2\)Q6PM]1\>6W@[X@^*?!-KXGN+II[?PEJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!_,7_P=5?\F6?L<_\ :3+]GG_U5/[0]?TZ5_,7_P '57_)
MEG['/_:3+]GG_P!53^T/7].E!;^"'K/\XA11100%%%% 'A_[3?\ R;;^T)_V
M0_XL?^H%K]?D1_P;(_\ *$/]B[_K]_:?_P#6Q/V@:_7?]IO_ )-M_:$_[(?\
M6/\ U M?K\B/^#9'_E"'^Q=_U^_M/_\ K8G[0-!:_AR_Q1_*1^\]%%%! 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_,7
M_P '57_)EG['/_:3+]GG_P!53^T/7].E?S%_\'57_)EG['/_ &DR_9Y_]53^
MT/7].E!;^"'K/\XA11100%%%% 'A_P"TW_R;;^T)_P!D/^+'_J!:_7Y$?\&R
M/_*$/]B[_K]_:?\ _6Q/V@:_7?\ :;_Y-M_:$_[(?\6/_4"U^OR(_P"#9'_E
M"'^Q=_U^_M/_ /K8G[0-!:_AR_Q1_*1^\]%%%! 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!_,7_P=5?\F6?L<_\ :3+]
MGG_U5/[0]?TZ5_,7_P '57_)EG['/_:3+]GG_P!53^T/7].E!;^"'K/\XA11
M100%%%% 'A_[3?\ R;;^T)_V0_XL?^H%K]?D1_P;(_\ *$/]B[_K]_:?_P#6
MQ/V@:_7?]IO_ )-M_:$_[(?\6/\ U M?K\B/^#9'_E"'^Q=_U^_M/_\ K8G[
M0-!:_AR_Q1_*1^\]%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!_,7_P '57_)EG['/_:3+]GG_P!53^T/7].E?S%_
M\'57_)EG['/_ &DR_9Y_]53^T/7].E!;^"'K/\XA11100%%%% 'A_P"TW_R;
M;^T)_P!D/^+'_J!:_7Y$?\&R/_*$/]B[_K]_:?\ _6Q/V@:_7?\ :;_Y-M_:
M$_[(?\6/_4"U^OR(_P"#9'_E"'^Q=_U^_M/_ /K8G[0-!:_AR_Q1_*1^\]%%
M%! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2IN &[/![YX_S]!VYHW 9&0"!G&>0"<#U[\=#@\<U_+W\:/@EHW_  3JNO\
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M6P\">,/C1X@\&Z1/KB7=Y(=;TC0['7].N[V^O])U2POKRYN)>A_9L_X)2?\
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M:7=W;J_=5WW=H15^T8?RQLE>+33::5D[M-+WG9-:J[G-OHW*3WD^;XR\'?\
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M_P!*_P#DN@#IZ*YC_A-O!G_0W>&/_!_I7_R71_PFW@S_ *&[PQ_X/]*_^2Z
M.GHKF/\ A-O!G_0W>&/_  ?Z5_\ )='_  FW@S_H;O#'_@_TK_Y+H Z>BN8_
MX3;P9_T-WAC_ ,'^E?\ R71_PFW@S_H;O#'_ (/]*_\ DN@#IZ*YC_A-O!G_
M $-WAC_P?Z5_\ET?\)MX,_Z&[PQ_X/\ 2O\ Y+H Z>BN8_X3;P9_T-WAC_P?
MZ5_\ET?\)MX,_P"AN\,?^#_2O_DN@#IZ*YC_ (3;P9_T-WAC_P '^E?_ "71
M_P )MX,_Z&[PQ_X/]*_^2Z .GHKF/^$V\&?]#=X8_P#!_I7_ ,ET?\)MX,_Z
M&[PQ_P"#_2O_ )+H Z>BN8_X3;P9_P!#=X8_\'^E?_)='_";>#/^AN\,?^#_
M $K_ .2Z .GHKF/^$V\&?]#=X8_\'^E?_)='_";>#/\ H;O#'_@_TK_Y+H Z
M>BN8_P"$V\&?]#=X8_\ !_I7_P ET?\ ";>#/^AN\,?^#_2O_DN@#IZ*YC_A
M-O!G_0W>&/\ P?Z5_P#)='_";>#/^AN\,?\ @_TK_P"2Z .GHKF/^$V\&?\
M0W>&/_!_I7_R71_PFW@S_H;O#'_@_P!*_P#DN@#IZ*YC_A-O!G_0W>&/_!_I
M7_R71_PFW@S_ *&[PQ_X/]*_^2Z .GHKF/\ A-O!G_0W>&/_  ?Z5_\ )='_
M  FW@S_H;O#'_@_TK_Y+H Z>BN8_X3;P9_T-WAC_ ,'^E?\ R71_PFW@S_H;
MO#'_ (/]*_\ DN@#IZ*YC_A-O!G_ $-WAC_P?Z5_\ET?\)MX,_Z&[PQ_X/\
M2O\ Y+H Z>BN8_X3;P9_T-WAC_P?Z5_\ET?\)MX,_P"AN\,?^#_2O_DN@#IZ
M*YC_ (3;P9_T-WAC_P '^E?_ "71_P )MX,_Z&[PQ_X/]*_^2Z .GHKF/^$V
M\&?]#=X8_P#!_I7_ ,ET?\)MX,_Z&[PQ_P"#_2O_ )+H Z>BN8_X3;P9_P!#
M=X8_\'^E?_)='_";>#/^AN\,?^#_ $K_ .2Z .GHKF/^$V\&?]#=X8_\'^E?
M_)='_";>#/\ H;O#'_@_TK_Y+H Z>BN8_P"$V\&?]#=X8_\ !_I7_P ET?\
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M0UN+K^L7G'7GU/\ ^O\ K06_@@NMYO5-:-JS^=F+11100%%%% !7Y0_MH_\
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M\2O_ )<T?\0J7_!&O_HBGQ._\/O\2O\ Y<U_1M10'-+^:7WO_,_G)_XA4O\
M@C7_ -$4^)W_ (??XE?_ "YH_P"(5+_@C7_T13XG?^'W^)7_ ,N:_HVHH#FE
M_-+[W_F?SD_\0J7_  1K_P"B*?$[_P /O\2O_ES1_P 0J7_!&O\ Z(I\3O\
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M+_@C7_T13XG?^'W^)7_RYK^C:B@.:7\TOO?^9_.3_P 0J7_!&O\ Z(I\3O\
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MI\3O_#[_ !*_^7-'_$*E_P $:_\ HBGQ._\ #[_$K_Y<U_1M10'-+^:7WO\
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MN:/^(5+_ ((U_P#1%/B=_P"'W^)7_P N:_HVHH#FE_-+[W_F?FY^Q!_P2/\
M^"?O_!.W4=7\1_LK_L_:/X/\>:_IC:+J_P 2_$GB#Q7\1?B)-HLDZ7-UHFE>
M*/'FM^(+OPCH6I36]C+K>@>"5\-:'K]QI6D7FNZ=J-]I=E=0_I'110)MMW;;
M?=MM_B%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>50
<FILENAME>cycc-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeOKbP9z5Z8qekhvWBybSka3yUtohI2gijfvHl2UXYC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:CYCC="http://cyclacel.com/20250331" elementFormDefault="qualified" targetNamespace="http://cyclacel.com/20250331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cyclacel.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
          <link:definition>00000005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
          <link:definition>00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical" id="StatementsOfStockholdersEquityDeficitParenthetical">
          <link:definition>00000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/CompanyOverview" id="CompanyOverview">
          <link:definition>999009 - Disclosure - Company Overview</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/SignificantContracts" id="SignificantContracts">
          <link:definition>999011 - Disclosure - Significant Contracts</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
          <link:definition>999012 - Disclosure - Cash and Cash Equivalents</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities" id="FairValueOfFinancialAssetsAndLiabilities">
          <link:definition>999013 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
          <link:definition>999014 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/Non-currentAssets" id="Non-currentAssets">
          <link:definition>999015 - Disclosure - Non-Current Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999016 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilities" id="AccruedAndOtherLiabilities">
          <link:definition>999017 - Disclosure - Accrued and Other Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999018 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999019 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StockBasedCompensation" id="StockBasedCompensation">
          <link:definition>999020 - Disclosure - Stock Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/EmployeeBenefitPlans" id="EmployeeBenefitPlans">
          <link:definition>999021 - Disclosure - Employee Benefit Plans</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/Taxes" id="Taxes">
          <link:definition>999022 - Disclosure - Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
          <link:definition>999023 - Disclosure - Net Loss per Common Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/GeographicAndSegmentInformation" id="GeographicAndSegmentInformation">
          <link:definition>999024 - Disclosure - Geographic and Segment Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/Revenue" id="Revenue">
          <link:definition>999025 - Disclosure - Revenue</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/Leases" id="Leases">
          <link:definition>999026 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999027 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999028 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
          <link:definition>999029 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" id="FairValueOfFinancialAssetsAndLiabilitiesTables">
          <link:definition>999030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
          <link:definition>999031 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999032 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables" id="AccruedAndOtherLiabilitiesTables">
          <link:definition>999033 - Disclosure - Accrued and Other Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999034 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999035 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
          <link:definition>999036 - Disclosure - Stock Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/TaxesTables" id="TaxesTables">
          <link:definition>999037 - Disclosure - Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
          <link:definition>999038 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/GeographicAndSegmentInformationTables" id="GeographicAndSegmentInformationTables">
          <link:definition>999039 - Disclosure - Geographic and Segment Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999040 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" id="OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative">
          <link:definition>999041 - Disclosure - Organization of the Company and Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/CompanyOverviewDetailsNarrative" id="CompanyOverviewDetailsNarrative">
          <link:definition>999042 - Disclosure - Company Overview (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/SignificantContractsDetailsNarrative" id="SignificantContractsDetailsNarrative">
          <link:definition>999044 - Disclosure - Significant Contracts (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails" id="SummaryOfCashAndCashEquivalentsDetails">
          <link:definition>999045 - Disclosure - Summary of Cash and Cash Equivalents (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:definition>999046 - Disclosure - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:definition>999047 - Disclosure - Schedule of prepaid expenses and other current assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/Non-currentAssetsDetailsNarrative" id="Non-currentAssetsDetailsNarrative">
          <link:definition>999048 - Disclosure - Non-Current Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999049 - Disclosure - Schedule of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
          <link:definition>999050 - Disclosure - Schedule of Accrued and Other Current Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative" id="AccruedAndOtherLiabilitiesDetailsNarrative">
          <link:definition>999051 - Disclosure - Accrued and Other Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" id="ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails">
          <link:definition>999052 - Disclosure - Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999053 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" id="ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails">
          <link:definition>999054 - Disclosure - Schedule of Fair Value of Instruments Issued in Offering (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" id="ScheduleOfFairValueOfWarrantsValuationAssumptionDetails">
          <link:definition>999055 - Disclosure - Schedule of Fair value of Warrants Valuation Assumption (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999056 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails" id="ScheduleOfStockBasedCompensationExpenseDetails">
          <link:definition>999057 - Disclosure - Schedule of Stock Based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails" id="ScheduleOfShareOptionActivityDetails">
          <link:definition>999058 - Disclosure - Schedule of Share Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" id="ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails">
          <link:definition>999059 - Disclosure - Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" id="ScheduleOfRestrictedStockUnitsActivityDetails">
          <link:definition>999060 - Disclosure - Schedule of Restricted Stock Units Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/StockBasedCompensationDetailsNarrative" id="StockBasedCompensationDetailsNarrative">
          <link:definition>999061 - Disclosure - Stock Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative" id="EmployeeBenefitPlansDetailsNarrative">
          <link:definition>999062 - Disclosure - Employee Benefit Plans (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" id="ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails">
          <link:definition>999063 - Disclosure - Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" id="ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails">
          <link:definition>999064 - Disclosure - Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" id="ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails">
          <link:definition>999065 - Disclosure - Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" id="ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails">
          <link:definition>999066 - Disclosure - Schedule of Significant Components of the Entity's Deferred Tax Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/TaxesDetailsNarrative" id="TaxesDetailsNarrative">
          <link:definition>999067 - Disclosure - Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" id="ScheduleOfBasicAndDilutedNetLossPerShareDetails">
          <link:definition>999068 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails">
          <link:definition>999069 - Disclosure - Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfGeographicInformationDetails" id="ScheduleOfGeographicInformationDetails">
          <link:definition>999070 - Disclosure - Schedule of Geographic Information (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails" id="ScheduleOfSummaryOfConsolidatedNetLossDetails">
          <link:definition>999071 - Disclosure - Schedule of Summary of Consolidated Net Loss (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" id="ScheduleOfEarningsPerShareBasicAndDilutedDetails">
          <link:definition>999072 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure">
          <link:definition>999073 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/RevenueDetailsNarrative" id="RevenueDetailsNarrative">
          <link:definition>999074 - Disclosure - Revenue (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails" id="ScheduleOfRemainingLeasePaymentsDetails">
          <link:definition>999075 - Disclosure - Schedule of Remaining Lease Payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999076 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cyclacel.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999077 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="CYCC_SixPercentConvertibleExchangeablePreferredStockMember" name="SixPercentConvertibleExchangeablePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ClinicalTrialSupplyMember" name="ClinicalTrialSupplyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" name="JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" name="FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_HelenaSpecialOpportunitiesOneLtdMember" name="HelenaSpecialOpportunitiesOneLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesCAndDConvertiblePreferredStockMember" name="SeriesCAndDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CyclacelLimitedUnitedKingdomMember" name="CyclacelLimitedUnitedKingdomMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_AssetsOfCyclacelLimitedMember" name="AssetsOfCyclacelLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesEConvertiblePreferredStockMember" name="SeriesEConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" name="MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_RombotisSettlementAgreementMember" name="RombotisSettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_McBarronSettlementAgreementMember" name="McBarronSettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_MdAndersonMember" name="MdAndersonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ClinicalCollaborationAgreementMember" name="ClinicalCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_OfficeEquipmentAndFurnitureMember" name="OfficeEquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_UnitedKingdomSubsidiaryCompanyMember" name="UnitedKingdomSubsidiaryCompanyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_BerkeleyHeightsFacilityMember" name="BerkeleyHeightsFacilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" name="CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DundeeScotlandMember" name="DundeeScotlandMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_November2024WarrantExerciseAndReloadAgreementMember" name="November2024WarrantExerciseAndReloadAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesDWarrantsMember" name="SeriesDWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" name="AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PreFundedWarrantsAndCommonWarrantsMember" name="PreFundedWarrantsAndCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_RothCapitalPartnersLlcMember" name="RothCapitalPartnersLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_LadenburgThalmannCo.IncMember" name="LadenburgThalmannCo.IncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" name="DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember" name="ChiefFinancialOfficerAndChiefOperatingOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_InsiderPrivatePlacementMember" name="InsiderPrivatePlacementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CantorFitzgeraldCoMember" name="CantorFitzgeraldCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_August2021ControlledEquityOfferingSalesAgreementMember" name="August2021ControlledEquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" name="NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_AprilTwoThousandTwentyFourWarrantsMember" name="AprilTwoThousandTwentyFourWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_April2024WarrantsMember" name="April2024WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SeriesBWarrantMember" name="SeriesBWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_December2023PrivatePlacementMember" name="December2023PrivatePlacementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember" name="DecemberTwoThousandTwentyThreePrivatePlacementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_December2023PlacementAgencyAgreementMember" name="December2023PlacementAgencyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DecemberTwoThousandTwentyWarrantMember" name="DecemberTwoThousandTwentyWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_AprilTwoThousandTwentyWarrantsMember" name="AprilTwoThousandTwentyWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_EquityIncentivePlan2018Member" name="EquityIncentivePlan2018Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember" name="InducementEquityIncentivePlanTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember" name="OptionsVestingOnThirdAnniversaryOfGrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_Plan401KMember" name="Plan401KMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SingleReportableSegmentMember" name="SingleReportableSegmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SixPercentConvertibleExchangeablePreferredMember" name="SixPercentConvertibleExchangeablePreferredMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_KualaLumpurFacilityMember" name="KualaLumpurFacilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_FittersDiversifiedBerhadMember" name="FittersDiversifiedBerhadMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" name="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" name="IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" name="IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock" name="IncreaseInCarryingAmountOfRedeemableCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ReclassificationOfRedeemableCommonStockShares" name="ReclassificationOfRedeemableCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" name="StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" name="StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" name="StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" name="StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" name="StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" name="StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" name="StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" name="StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" name="StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" name="StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" name="StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" name="StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" name="StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise" name="StockIssuedDuringPeriodValueIssueOnWarrantExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise" name="StockIssuedDuringPeriodSharesIssueOnWarrantExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" name="StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment" name="StockIssuedDuringPeriodValueTranslationAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" name="ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_AccrualOfPreferredStockDividends" name="AccrualOfPreferredStockDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DisclosureSignificantContractsAbstract" name="DisclosureSignificantContractsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SignificantContractsDisclosureTextBlock" name="SignificantContractsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" name="DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DisclosureNoncurrentAssetsAbstract" name="DisclosureNoncurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_NonCurrentAssetsTextBlock" name="NonCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_OtherIncomePolicyTextBlock" name="OtherIncomePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ClinicalTrialAccountingPolicyTextBlock" name="ClinicalTrialAccountingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" name="ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" name="StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CommonStockValueAgreedToBeIssued" name="CommonStockValueAgreedToBeIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue" name="SharePurchaseAgreementIncrementExerciseLotOneValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue" name="SharePurchaseAgreementIncrementExerciseLotTwoValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PercentageOfOutstandingCommonStock" name="PercentageOfOutstandingCommonStock" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_SettlementPaymentSettlementAgreement" name="SettlementPaymentSettlementAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_FutureOneTimeSettlementPaymentSettlementAgreement" name="FutureOneTimeSettlementPaymentSettlementAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CashFinancialServicesCompensationSchemeInsuredAmount" name="CashFinancialServicesCompensationSchemeInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_TermOfAgreement" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ConductClinicalStudies" name="ConductClinicalStudies" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_LicenseAgreementPaymentEarned" name="LicenseAgreementPaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" name="PrepaymentsAndValueAddedTaxReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_OtherCurrentLiabilities" name="OtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_AccruedResearchAndDevelopmentCostCurrent" name="AccruedResearchAndDevelopmentCostCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_LesseeOperatingLeaseTermOfContractExtension" name="LesseeOperatingLeaseTermOfContractExtension" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser" name="PercentageOfOutstandingCommonStockAtElectionOfPurchaser" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CashPlacementFeePercentage" name="CashPlacementFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ManagementFeePercentageToAggregateGrossProceeds" name="ManagementFeePercentageToAggregateGrossProceeds" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CompensationPercentageToAggregateGrossProceeds" name="CompensationPercentageToAggregateGrossProceeds" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_AggregateProceedsFromSaleOfStock" name="AggregateProceedsFromSaleOfStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ReclassificationOfCommonStockShares" name="ReclassificationOfCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived" name="ReclassificationOfCommonStockSharesNoProceedsReceived" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ReclassificationOfCommonStockValue" name="ReclassificationOfCommonStockValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ClassOfWarrantOrRightsExercisable" name="ClassOfWarrantOrRightsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ConvertiblePreferredStockConversionPercentage" name="ConvertiblePreferredStockConversionPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ConvertiblePreferredStockConversionPricePerShare" name="ConvertiblePreferredStockConversionPricePerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_CommonStockClosingPriceThreshold" name="CommonStockClosingPriceThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" name="PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" name="PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PreferredStockConversionObligationNumberOfTradingDays" name="PreferredStockConversionObligationNumberOfTradingDays" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" name="PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" name="DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" name="DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" name="DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" name="DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" name="IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount" name="EffectiveIncomeTaxRateReconciliationOtherItemsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DeferredTaxAssetsLeaseRightOfUseAsset" name="DeferredTaxAssetsLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability" name="DeferredTaxAssetsLeaseRightOfUseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" name="PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>51
<FILENAME>cycc-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Cover" roleURI="http://cyclacel.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#BalanceSheets" roleURI="http://cyclacel.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#BalanceSheetsParenthetical" roleURI="http://cyclacel.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfOperations" roleURI="http://cyclacel.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfComprehensiveLoss" roleURI="http://cyclacel.com/role/StatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfStockholdersEquityDeficit" roleURI="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfStockholdersEquityDeficitParenthetical" roleURI="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfCashFlows" roleURI="http://cyclacel.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CompanyOverview" roleURI="http://cyclacel.com/role/CompanyOverview" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SignificantContracts" roleURI="http://cyclacel.com/role/SignificantContracts" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CashAndCashEquivalents" roleURI="http://cyclacel.com/role/CashAndCashEquivalents" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#FairValueOfFinancialAssetsAndLiabilities" roleURI="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Non-currentAssets" roleURI="http://cyclacel.com/role/Non-currentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PropertyAndEquipment" roleURI="http://cyclacel.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilities" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingencies" roleURI="http://cyclacel.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquity" roleURI="http://cyclacel.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensation" roleURI="http://cyclacel.com/role/StockBasedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#EmployeeBenefitPlans" roleURI="http://cyclacel.com/role/EmployeeBenefitPlans" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Taxes" roleURI="http://cyclacel.com/role/Taxes" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#NetLossPerCommonShare" roleURI="http://cyclacel.com/role/NetLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#GeographicAndSegmentInformation" roleURI="http://cyclacel.com/role/GeographicAndSegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Revenue" roleURI="http://cyclacel.com/role/Revenue" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Leases" roleURI="http://cyclacel.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SubsequentEvents" roleURI="http://cyclacel.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CashAndCashEquivalentsTables" roleURI="http://cyclacel.com/role/CashAndCashEquivalentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#FairValueOfFinancialAssetsAndLiabilitiesTables" roleURI="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PropertyAndEquipmentTables" roleURI="http://cyclacel.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilitiesTables" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingenciesTables" roleURI="http://cyclacel.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquityTables" roleURI="http://cyclacel.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensationTables" roleURI="http://cyclacel.com/role/StockBasedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#TaxesTables" roleURI="http://cyclacel.com/role/TaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#NetLossPerCommonShareTables" roleURI="http://cyclacel.com/role/NetLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#GeographicAndSegmentInformationTables" roleURI="http://cyclacel.com/role/GeographicAndSegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#LeasesTables" roleURI="http://cyclacel.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" roleURI="http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CompanyOverviewDetailsNarrative" roleURI="http://cyclacel.com/role/CompanyOverviewDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SignificantContractsDetailsNarrative" roleURI="http://cyclacel.com/role/SignificantContractsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfCashAndCashEquivalentsDetails" roleURI="http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Non-currentAssetsDetailsNarrative" roleURI="http://cyclacel.com/role/Non-currentAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilitiesDetailsNarrative" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" roleURI="http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" roleURI="http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" roleURI="http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cyclacel.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfShareOptionActivityDetails" roleURI="http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" roleURI="http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" roleURI="http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensationDetailsNarrative" roleURI="http://cyclacel.com/role/StockBasedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#EmployeeBenefitPlansDetailsNarrative" roleURI="http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" roleURI="http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" roleURI="http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" roleURI="http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" roleURI="http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#TaxesDetailsNarrative" roleURI="http://cyclacel.com/role/TaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" roleURI="http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfGeographicInformationDetails" roleURI="http://cyclacel.com/role/ScheduleOfGeographicInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfSummaryOfConsolidatedNetLossDetails" roleURI="http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfEarningsPerShareBasicAndDilutedDetails" roleURI="http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" roleURI="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#RevenueDetailsNarrative" roleURI="http://cyclacel.com/role/RevenueDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfRemainingLeasePaymentsDetails" roleURI="http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#LeasesDetailsNarrative" roleURI="http://cyclacel.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SubsequentEventsDetailsNarrative" roleURI="http://cyclacel.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_CYCCOtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_CYCCOtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" xlink:label="loc_CYCCProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CYCCProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CompanyOverview" xlink:title="999009 - Disclosure - Company Overview" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SignificantContracts" xlink:title="999011 - Disclosure - Significant Contracts" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashAndCashEquivalents" xlink:title="999012 - Disclosure - Cash and Cash Equivalents" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:title="999013 - Disclosure - Fair Value of Financial Assets and Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999014 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Non-currentAssets" xlink:title="999015 - Disclosure - Non-Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PropertyAndEquipment" xlink:title="999016 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilities" xlink:title="999017 - Disclosure - Accrued and Other Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensation" xlink:title="999020 - Disclosure - Stock Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/EmployeeBenefitPlans" xlink:title="999021 - Disclosure - Employee Benefit Plans" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Taxes" xlink:title="999022 - Disclosure - Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/NetLossPerCommonShare" xlink:title="999023 - Disclosure - Net Loss per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/GeographicAndSegmentInformation" xlink:title="999024 - Disclosure - Geographic and Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Revenue" xlink:title="999025 - Disclosure - Revenue" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Leases" xlink:title="999026 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashAndCashEquivalentsTables" xlink:title="999029 - Disclosure - Cash and Cash Equivalents (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:title="999030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999031 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables" xlink:title="999033 - Disclosure - Accrued and Other Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingenciesTables" xlink:title="999034 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensationTables" xlink:title="999036 - Disclosure - Stock Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/TaxesTables" xlink:title="999037 - Disclosure - Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/NetLossPerCommonShareTables" xlink:title="999038 - Disclosure - Net Loss per Common Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/GeographicAndSegmentInformationTables" xlink:title="999039 - Disclosure - Geographic and Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/LeasesTables" xlink:title="999040 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" xlink:title="999041 - Disclosure - Organization of the Company and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CompanyOverviewDetailsNarrative" xlink:title="999042 - Disclosure - Company Overview (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SignificantContractsDetailsNarrative" xlink:title="999044 - Disclosure - Significant Contracts (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails" xlink:title="999045 - Disclosure - Summary of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999046 - Disclosure - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999047 - Disclosure - Schedule of prepaid expenses and other current assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="loc_us-gaapDeferredIncomeTaxesAndOtherTaxReceivableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" xlink:label="loc_CYCCPrepaymentsAndValueAddedTaxReceivableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_CYCCPrepaymentsAndValueAddedTaxReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Non-currentAssetsDetailsNarrative" xlink:title="999048 - Disclosure - Non-Current Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999049 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:title="999050 - Disclosure - Schedule of Accrued and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="loc_CYCCAccruedResearchAndDevelopmentCostsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CYCCAccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherCurrentLiabilities" xlink:label="loc_CYCCOtherCurrentLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CYCCOtherCurrentLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative" xlink:title="999051 - Disclosure - Accrued and Other Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" xlink:title="999052 - Disclosure - Schedule of the Company&apos;s Contractual Obligations and Commitments Relating to its Facilities Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999053 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" xlink:title="999054 - Disclosure - Schedule of Fair Value of Instruments Issued in Offering (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" xlink:title="999055 - Disclosure - Schedule of Fair value of Warrants Valuation Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquityDetailsNarrative" xlink:title="999056 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="999057 - Disclosure - Schedule of Stock Based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails" xlink:title="999058 - Disclosure - Schedule of Share Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" xlink:title="999059 - Disclosure - Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="999060 - Disclosure - Schedule of Restricted Stock Units Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensationDetailsNarrative" xlink:title="999061 - Disclosure - Stock Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="999062 - Disclosure - Employee Benefit Plans (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" xlink:title="999063 - Disclosure - Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" xlink:title="999064 - Disclosure - Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" xlink:title="999065 - Disclosure - Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" xlink:title="999066 - Disclosure - Schedule of Significant Components of the Entity&apos;s Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:label="loc_CYCCDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CYCCDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" xlink:label="loc_CYCCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CYCCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:label="loc_CYCCDeferredTaxAssetsLeaseRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CYCCDeferredTaxAssetsLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsLeaseRightOfUseLiability" xlink:label="loc_CYCCDeferredTaxAssetsLeaseRightOfUseLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CYCCDeferredTaxAssetsLeaseRightOfUseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/TaxesDetailsNarrative" xlink:title="999067 - Disclosure - Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999068 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="999069 - Disclosure - Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfGeographicInformationDetails" xlink:title="999070 - Disclosure - Schedule of Geographic Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails" xlink:title="999071 - Disclosure - Schedule of Summary of Consolidated Net Loss (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:title="999072 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" xlink:title="999073 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" xlink:label="loc_CYCCPrepaymentsAndValueAddedTaxReceivableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_CYCCPrepaymentsAndValueAddedTaxReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/RevenueDetailsNarrative" xlink:title="999074 - Disclosure - Revenue (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails" xlink:title="999075 - Disclosure - Schedule of Remaining Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="loc_CYCCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_CYCCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/LeasesDetailsNarrative" xlink:title="999076 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SubsequentEventsDetailsNarrative" xlink:title="999077 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>52
<FILENAME>cycc-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Cover" roleURI="http://cyclacel.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#BalanceSheets" roleURI="http://cyclacel.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#BalanceSheetsParenthetical" roleURI="http://cyclacel.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfOperations" roleURI="http://cyclacel.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfComprehensiveLoss" roleURI="http://cyclacel.com/role/StatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfStockholdersEquityDeficit" roleURI="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfStockholdersEquityDeficitParenthetical" roleURI="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfCashFlows" roleURI="http://cyclacel.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CompanyOverview" roleURI="http://cyclacel.com/role/CompanyOverview" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SignificantContracts" roleURI="http://cyclacel.com/role/SignificantContracts" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CashAndCashEquivalents" roleURI="http://cyclacel.com/role/CashAndCashEquivalents" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#FairValueOfFinancialAssetsAndLiabilities" roleURI="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Non-currentAssets" roleURI="http://cyclacel.com/role/Non-currentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PropertyAndEquipment" roleURI="http://cyclacel.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilities" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingencies" roleURI="http://cyclacel.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquity" roleURI="http://cyclacel.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensation" roleURI="http://cyclacel.com/role/StockBasedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#EmployeeBenefitPlans" roleURI="http://cyclacel.com/role/EmployeeBenefitPlans" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Taxes" roleURI="http://cyclacel.com/role/Taxes" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#NetLossPerCommonShare" roleURI="http://cyclacel.com/role/NetLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#GeographicAndSegmentInformation" roleURI="http://cyclacel.com/role/GeographicAndSegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Revenue" roleURI="http://cyclacel.com/role/Revenue" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Leases" roleURI="http://cyclacel.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SubsequentEvents" roleURI="http://cyclacel.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CashAndCashEquivalentsTables" roleURI="http://cyclacel.com/role/CashAndCashEquivalentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#FairValueOfFinancialAssetsAndLiabilitiesTables" roleURI="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PropertyAndEquipmentTables" roleURI="http://cyclacel.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilitiesTables" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingenciesTables" roleURI="http://cyclacel.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquityTables" roleURI="http://cyclacel.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensationTables" roleURI="http://cyclacel.com/role/StockBasedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#TaxesTables" roleURI="http://cyclacel.com/role/TaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#NetLossPerCommonShareTables" roleURI="http://cyclacel.com/role/NetLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#GeographicAndSegmentInformationTables" roleURI="http://cyclacel.com/role/GeographicAndSegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#LeasesTables" roleURI="http://cyclacel.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" roleURI="http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CompanyOverviewDetailsNarrative" roleURI="http://cyclacel.com/role/CompanyOverviewDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SignificantContractsDetailsNarrative" roleURI="http://cyclacel.com/role/SignificantContractsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfCashAndCashEquivalentsDetails" roleURI="http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Non-currentAssetsDetailsNarrative" roleURI="http://cyclacel.com/role/Non-currentAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilitiesDetailsNarrative" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" roleURI="http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" roleURI="http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" roleURI="http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cyclacel.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfShareOptionActivityDetails" roleURI="http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" roleURI="http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" roleURI="http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensationDetailsNarrative" roleURI="http://cyclacel.com/role/StockBasedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#EmployeeBenefitPlansDetailsNarrative" roleURI="http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" roleURI="http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" roleURI="http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" roleURI="http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" roleURI="http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#TaxesDetailsNarrative" roleURI="http://cyclacel.com/role/TaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" roleURI="http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfGeographicInformationDetails" roleURI="http://cyclacel.com/role/ScheduleOfGeographicInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfSummaryOfConsolidatedNetLossDetails" roleURI="http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfEarningsPerShareBasicAndDilutedDetails" roleURI="http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" roleURI="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#RevenueDetailsNarrative" roleURI="http://cyclacel.com/role/RevenueDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfRemainingLeasePaymentsDetails" roleURI="http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#LeasesDetailsNarrative" roleURI="http://cyclacel.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SubsequentEventsDetailsNarrative" roleURI="http://cyclacel.com/role/SubsequentEventsDetailsNarrative" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SixPercentConvertibleExchangeablePreferredStockMember" xlink:label="loc_CYCCSixPercentConvertibleExchangeablePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSixPercentConvertibleExchangeablePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_190" xlink:to="loc_us-gaapAssetsCurrentAbstract_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_190" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_190" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_190" xlink:to="loc_us-gaapAssetsCurrent_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_190" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_190" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_190" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_190" xlink:to="loc_us-gaapAssets_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_190" xlink:to="loc_us-gaapLiabilitiesAbstract_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_190" xlink:to="loc_us-gaapAccountsPayableCurrent_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_190" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_190" xlink:to="loc_us-gaapLiabilitiesCurrent_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_190" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_190" xlink:to="loc_us-gaapLiabilities_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_190" xlink:to="loc_us-gaapPreferredStockValue_190" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_190" xlink:to="loc_us-gaapCommonStockValue_190" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_190" xlink:to="loc_us-gaapAdditionalPaidInCapital_190" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_190" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_190" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_190" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_190" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_190" xlink:to="loc_us-gaapStockholdersEquity_190" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_190" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_190" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SixPercentConvertibleExchangeablePreferredStockMember" xlink:label="loc_CYCCSixPercentConvertibleExchangeablePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSixPercentConvertibleExchangeablePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_170" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClinicalTrialSupplyMember" xlink:label="loc_CYCCClinicalTrialSupplyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_CYCCClinicalTrialSupplyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_90" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapOperatingExpenses_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapInterestIncomeExpenseNet_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapNonoperatingIncomeExpense_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareAbstract_90" xlink:to="loc_us-gaapEarningsPerShareDiluted_90" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:label="loc_CYCCIssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCIssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:label="loc_CYCCIssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCIssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock" xlink:label="loc_CYCCIncreaseInCarryingAmountOfRedeemableCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCIncreaseInCarryingAmountOfRedeemableCommonStock_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfRedeemableCommonStockShares" xlink:label="loc_CYCCReclassificationOfRedeemableCommonStockShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCReclassificationOfRedeemableCommonStockShares_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_CYCCOtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCOtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" xlink:label="loc_CYCCStockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_CYCCStockIssuedDuringPeriodValueWarrantsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueWarrantsExercised_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesStockWarrantsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesStockWarrantsExercised_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:label="loc_CYCCStockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" xlink:label="loc_CYCCStockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" xlink:label="loc_CYCCStockIssuedDuringPeriodValueSeriesCPreferredStockConversions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueSeriesCPreferredStockConversions_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesSeriesCPreferredStockConversions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesSeriesCPreferredStockConversions_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:label="loc_CYCCStockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" xlink:label="loc_CYCCStockIssuedDuringPeriodValueSeriesDPreferredStockConversions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueSeriesDPreferredStockConversions_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesSeriesDPreferredStockConversions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesSeriesDPreferredStockConversions_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:label="loc_CYCCStockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise" xlink:label="loc_CYCCStockIssuedDuringPeriodValueIssueOnWarrantExercise_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueIssueOnWarrantExercise_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesIssueOnWarrantExercise_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesIssueOnWarrantExercise_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" xlink:label="loc_CYCCStockIssuedDuringPeriodValueDeconsolidationOfSubsidiary_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueDeconsolidationOfSubsidiary_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueTranslationAdjustment" xlink:label="loc_CYCCStockIssuedDuringPeriodValueTranslationAdjustment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueTranslationAdjustment_70" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CompanyOverview" xlink:title="999009 - Disclosure - Company Overview" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SignificantContracts" xlink:title="999011 - Disclosure - Significant Contracts" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashAndCashEquivalents" xlink:title="999012 - Disclosure - Cash and Cash Equivalents" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:title="999013 - Disclosure - Fair Value of Financial Assets and Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999014 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Non-currentAssets" xlink:title="999015 - Disclosure - Non-Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PropertyAndEquipment" xlink:title="999016 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilities" xlink:title="999017 - Disclosure - Accrued and Other Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensation" xlink:title="999020 - Disclosure - Stock Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/EmployeeBenefitPlans" xlink:title="999021 - Disclosure - Employee Benefit Plans" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Taxes" xlink:title="999022 - Disclosure - Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/NetLossPerCommonShare" xlink:title="999023 - Disclosure - Net Loss per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/GeographicAndSegmentInformation" xlink:title="999024 - Disclosure - Geographic and Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Revenue" xlink:title="999025 - Disclosure - Revenue" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Leases" xlink:title="999026 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashAndCashEquivalentsTables" xlink:title="999029 - Disclosure - Cash and Cash Equivalents (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:title="999030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999031 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables" xlink:title="999033 - Disclosure - Accrued and Other Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingenciesTables" xlink:title="999034 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="loc_CYCCInsiderPrivatePlacementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCInsiderPrivatePlacementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" xlink:label="loc_CYCCScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensationTables" xlink:title="999036 - Disclosure - Stock Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/TaxesTables" xlink:title="999037 - Disclosure - Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/NetLossPerCommonShareTables" xlink:title="999038 - Disclosure - Net Loss per Common Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/GeographicAndSegmentInformationTables" xlink:title="999039 - Disclosure - Geographic and Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/LeasesTables" xlink:title="999040 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" xlink:title="999041 - Disclosure - Organization of the Company and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesCConvertiblePreferredStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesCConvertiblePreferredStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesDConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesDConvertiblePreferredStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesDConvertiblePreferredStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCAndDConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesCAndDConvertiblePreferredStockMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesCAndDConvertiblePreferredStockMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesEConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesEConvertiblePreferredStockMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesEConvertiblePreferredStockMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCJanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCJanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCFebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCFebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCMarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCMarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_210" xlink:type="arc" order="213" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_HelenaSpecialOpportunitiesOneLtdMember" xlink:label="loc_CYCCHelenaSpecialOpportunitiesOneLtdMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCHelenaSpecialOpportunitiesOneLtdMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CyclacelLimitedUnitedKingdomMember" xlink:label="loc_CYCCCyclacelLimitedUnitedKingdomMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCCyclacelLimitedUnitedKingdomMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AssetsOfCyclacelLimitedMember" xlink:label="loc_CYCCAssetsOfCyclacelLimitedMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_CYCCAssetsOfCyclacelLimitedMember_200" xlink:type="arc" order="203" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_RombotisSettlementAgreementMember" xlink:label="loc_CYCCRombotisSettlementAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CYCCRombotisSettlementAgreementMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_McBarronSettlementAgreementMember" xlink:label="loc_CYCCMcBarronSettlementAgreementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CYCCMcBarronSettlementAgreementMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_290" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" xlink:label="loc_CYCCStockholderSEquityIncreaseFromDeConsolidationOfSubsidiary_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCStockholderSEquityIncreaseFromDeConsolidationOfSubsidiary_290" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockValueAgreedToBeIssued" xlink:label="loc_CYCCCommonStockValueAgreedToBeIssued_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCCommonStockValueAgreedToBeIssued_290" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_290" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue" xlink:label="loc_CYCCSharePurchaseAgreementIncrementExerciseLotOneValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCSharePurchaseAgreementIncrementExerciseLotOneValue_290" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue" xlink:label="loc_CYCCSharePurchaseAgreementIncrementExerciseLotTwoValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCSharePurchaseAgreementIncrementExerciseLotTwoValue_290" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_290" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_290" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_290" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfOutstandingCommonStock" xlink:label="loc_CYCCPercentageOfOutstandingCommonStock_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCPercentageOfOutstandingCommonStock_290" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_290" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred_290" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SettlementPaymentSettlementAgreement" xlink:label="loc_CYCCSettlementPaymentSettlementAgreement_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCSettlementPaymentSettlementAgreement_290" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FutureOneTimeSettlementPaymentSettlementAgreement" xlink:label="loc_CYCCFutureOneTimeSettlementPaymentSettlementAgreement_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCFutureOneTimeSettlementPaymentSettlementAgreement_290" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CompanyOverviewDetailsNarrative" xlink:title="999042 - Disclosure - Company Overview (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:label="loc_CYCCCashFinancialServicesCompensationSchemeInsuredAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CYCCCashFinancialServicesCompensationSchemeInsuredAmount_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="loc_us-gaapNumberOfCountriesInWhichEntityOperates_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfCountriesInWhichEntityOperates_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligation_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaapReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernWithinOneYear_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernWithinOneYear_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTax_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_130" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SignificantContractsDetailsNarrative" xlink:title="999044 - Disclosure - Significant Contracts (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_MdAndersonMember" xlink:label="loc_CYCCMdAndersonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCMdAndersonMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClinicalCollaborationAgreementMember" xlink:label="loc_CYCCClinicalCollaborationAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CYCCClinicalCollaborationAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_TermOfAgreement" xlink:label="loc_CYCCTermOfAgreement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_CYCCTermOfAgreement_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConductClinicalStudies" xlink:label="loc_CYCCConductClinicalStudies_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_CYCCConductClinicalStudies_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LicenseAgreementPaymentEarned" xlink:label="loc_CYCCLicenseAgreementPaymentEarned_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_CYCCLicenseAgreementPaymentEarned_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails" xlink:title="999045 - Disclosure - Summary of Cash and Cash Equivalents (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999046 - Disclosure - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999047 - Disclosure - Schedule of prepaid expenses and other current assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Non-currentAssetsDetailsNarrative" xlink:title="999048 - Disclosure - Non-Current Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999049 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OfficeEquipmentAndFurnitureMember" xlink:label="loc_CYCCOfficeEquipmentAndFurnitureMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CYCCOfficeEquipmentAndFurnitureMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:title="999050 - Disclosure - Schedule of Accrued and Other Current Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative" xlink:title="999051 - Disclosure - Accrued and Other Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_UnitedKingdomSubsidiaryCompanyMember" xlink:label="loc_CYCCUnitedKingdomSubsidiaryCompanyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CYCCUnitedKingdomSubsidiaryCompanyMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" xlink:title="999052 - Disclosure - Schedule of the Company&apos;s Contractual Obligations and Commitments Relating to its Facilities Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999053 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapProductLiabilityContingencyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_BerkeleyHeightsFacilityMember" xlink:label="loc_CYCCBerkeleyHeightsFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCBerkeleyHeightsFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" xlink:label="loc_CYCCCorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCCorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DundeeScotlandMember" xlink:label="loc_CYCCDundeeScotlandMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCDundeeScotlandMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LesseeOperatingLeaseTermOfContractExtension" xlink:label="loc_CYCCLesseeOperatingLeaseTermOfContractExtension_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_CYCCLesseeOperatingLeaseTermOfContractExtension_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" xlink:title="999054 - Disclosure - Schedule of Fair Value of Instruments Issued in Offering (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsMember" xlink:label="loc_CYCCPreFundedWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CYCCPreFundedWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CYCCCommonStockWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="loc_CYCCInsiderPrivatePlacementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCInsiderPrivatePlacementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:label="loc_CYCCStockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" xlink:title="999055 - Disclosure - Schedule of Fair value of Warrants Valuation Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsMember" xlink:label="loc_CYCCPreFundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPreFundedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCCommonStockWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PlacementAgentWarrantsMember" xlink:label="loc_CYCCPlacementAgentWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPlacementAgentWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="loc_CYCCInsiderPrivatePlacementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCInsiderPrivatePlacementMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_550" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquityDetailsNarrative" xlink:title="999056 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_November2024WarrantExerciseAndReloadAgreementMember" xlink:label="loc_CYCCNovember2024WarrantExerciseAndReloadAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCNovember2024WarrantExerciseAndReloadAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCAprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCAprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCDecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="loc_CYCCInsiderPrivatePlacementMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCInsiderPrivatePlacementMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_August2021ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_CYCCAugust2021ControlledEquityOfferingSalesAgreementMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCAugust2021ControlledEquityOfferingSalesAgreementMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" xlink:label="loc_CYCCNovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCNovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyFourWarrantsMember" xlink:label="loc_CYCCAprilTwoThousandTwentyFourWarrantsMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCAprilTwoThousandTwentyFourWarrantsMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_April2024WarrantsMember" xlink:label="loc_CYCCApril2024WarrantsMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCApril2024WarrantsMember_470" xlink:type="arc" order="472" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_December2023PrivatePlacementMember" xlink:label="loc_CYCCDecember2023PrivatePlacementMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecember2023PrivatePlacementMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember" xlink:label="loc_CYCCDecemberTwoThousandTwentyThreePrivatePlacementMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecemberTwoThousandTwentyThreePrivatePlacementMember_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_December2023PlacementAgencyAgreementMember" xlink:label="loc_CYCCDecember2023PlacementAgencyAgreementMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecember2023PlacementAgencyAgreementMember_560" xlink:type="arc" order="561" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyWarrantMember" xlink:label="loc_CYCCDecemberTwoThousandTwentyWarrantMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecemberTwoThousandTwentyWarrantMember_580" xlink:type="arc" order="581" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyWarrantsMember" xlink:label="loc_CYCCAprilTwoThousandTwentyWarrantsMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCAprilTwoThousandTwentyWarrantsMember_610" xlink:type="arc" order="611" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesBWarrantsMember" xlink:label="loc_CYCCSeriesBWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesBWarrantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCWarrantsMember" xlink:label="loc_CYCCSeriesCWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesCWarrantsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesDWarrantsMember" xlink:label="loc_CYCCSeriesDWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesDWarrantsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsMember" xlink:label="loc_CYCCPreFundedWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPreFundedWarrantsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesAWarrantsMember" xlink:label="loc_CYCCSeriesAWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesAWarrantsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsAndCommonWarrantsMember" xlink:label="loc_CYCCPreFundedWarrantsAndCommonWarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPreFundedWarrantsAndCommonWarrantsMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCCommonStockWarrantsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PlacementAgentWarrantsMember" xlink:label="loc_CYCCPlacementAgentWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPlacementAgentWarrantsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesBWarrantMember" xlink:label="loc_CYCCSeriesBWarrantMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesBWarrantMember_520" xlink:type="arc" order="522" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_550" xlink:type="arc" order="552" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_RothCapitalPartnersLlcMember" xlink:label="loc_CYCCRothCapitalPartnersLlcMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCRothCapitalPartnersLlcMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LadenburgThalmannCo.IncMember" xlink:label="loc_CYCCLadenburgThalmannCo.IncMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCLadenburgThalmannCo.IncMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CantorFitzgeraldCoMember" xlink:label="loc_CYCCCantorFitzgeraldCoMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCCantorFitzgeraldCoMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_590" xlink:type="arc" order="592" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_660" xlink:type="arc" order="661" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_710" xlink:type="arc" order="711" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_1010" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_1010" xlink:type="arc" order="1011" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_1030" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_1030" xlink:type="arc" order="1031" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_1040" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_1040" xlink:type="arc" order="1041" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesCConvertiblePreferredStockMember_1050" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesCConvertiblePreferredStockMember_1050" xlink:type="arc" order="1051" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesDConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesDConvertiblePreferredStockMember_1060" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesDConvertiblePreferredStockMember_1060" xlink:type="arc" order="1061" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember" xlink:label="loc_CYCCChiefFinancialOfficerAndChiefOperatingOfficerMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CYCCChiefFinancialOfficerAndChiefOperatingOfficerMember_280" xlink:type="arc" order="283" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" xlink:label="loc_CYCCClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_1170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_1170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_1170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfOutstandingCommonStock" xlink:label="loc_CYCCPercentageOfOutstandingCommonStock_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPercentageOfOutstandingCommonStock_1170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser" xlink:label="loc_CYCCPercentageOfOutstandingCommonStockAtElectionOfPurchaser_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPercentageOfOutstandingCommonStockAtElectionOfPurchaser_1170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_1170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CashPlacementFeePercentage" xlink:label="loc_CYCCCashPlacementFeePercentage_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCCashPlacementFeePercentage_1170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ManagementFeePercentageToAggregateGrossProceeds" xlink:label="loc_CYCCManagementFeePercentageToAggregateGrossProceeds_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCManagementFeePercentageToAggregateGrossProceeds_1170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CompensationPercentageToAggregateGrossProceeds" xlink:label="loc_CYCCCompensationPercentageToAggregateGrossProceeds_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCCompensationPercentageToAggregateGrossProceeds_1170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_1170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_1170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_1170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AggregateProceedsFromSaleOfStock" xlink:label="loc_CYCCAggregateProceedsFromSaleOfStock_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCAggregateProceedsFromSaleOfStock_1170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProfessionalFees_1170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_1170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_1170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockShares" xlink:label="loc_CYCCReclassificationOfCommonStockShares_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCReclassificationOfCommonStockShares_1170" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived" xlink:label="loc_CYCCReclassificationOfCommonStockSharesNoProceedsReceived_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCReclassificationOfCommonStockSharesNoProceedsReceived_1170" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockValue" xlink:label="loc_CYCCReclassificationOfCommonStockValue_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCReclassificationOfCommonStockValue_1170" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_CYCCProceedsFromIssuanceOfCommonStockGross_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCProceedsFromIssuanceOfCommonStockGross_1170" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightsExercisable" xlink:label="loc_CYCCClassOfWarrantOrRightsExercisable_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCClassOfWarrantOrRightsExercisable_1170" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightExercised" xlink:label="loc_CYCCClassOfWarrantOrRightExercised_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCClassOfWarrantOrRightExercised_1170" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_1170" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_1170" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_1170" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_1170" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_1170" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_1170" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConvertiblePreferredStockConversionPercentage" xlink:label="loc_CYCCConvertiblePreferredStockConversionPercentage_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCConvertiblePreferredStockConversionPercentage_1170" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_1170" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_1170" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_1170" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_1170" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_1170" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="loc_us-gaapPreferredStockAmountOfPreferredDividendsInArrears_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockAmountOfPreferredDividendsInArrears_1170" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:label="loc_us-gaapPreferredStockPerShareAmountsOfPreferredDividendsInArrears_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockPerShareAmountsOfPreferredDividendsInArrears_1170" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConvertiblePreferredStockConversionPricePerShare" xlink:label="loc_CYCCConvertiblePreferredStockConversionPricePerShare_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCConvertiblePreferredStockConversionPricePerShare_1170" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_1170" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockClosingPriceThreshold" xlink:label="loc_CYCCCommonStockClosingPriceThreshold_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCCommonStockClosingPriceThreshold_1170" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="loc_CYCCPreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_1170" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="loc_CYCCPreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_1170" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationNumberOfTradingDays" xlink:label="loc_CYCCPreferredStockConversionObligationNumberOfTradingDays_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPreferredStockConversionObligationNumberOfTradingDays_1170" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:label="loc_CYCCPreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_1170" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" xlink:label="loc_CYCCDirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCDirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_1170" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare_1170" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_1170" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaapPreferredStockDividendsPerShareDeclared_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendsPerShareDeclared_1170" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_1170" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_1170" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1170" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_1170" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaapDebtInstrumentRedemptionPricePercentage_1170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionPricePercentage_1170" xlink:type="arc" order="53" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="999057 - Disclosure - Schedule of Stock Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails" xlink:title="999058 - Disclosure - Schedule of Share Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_90" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" xlink:title="999059 - Disclosure - Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="999060 - Disclosure - Schedule of Restricted Stock Units Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_CYCCShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensationDetailsNarrative" xlink:title="999061 - Disclosure - Stock Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_EquityIncentivePlan2018Member" xlink:label="loc_CYCCEquityIncentivePlan2018Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CYCCEquityIncentivePlan2018Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember" xlink:label="loc_CYCCInducementEquityIncentivePlanTwoThousandTwentyMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CYCCInducementEquityIncentivePlanTwoThousandTwentyMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember" xlink:label="loc_CYCCOptionsVestingOnThirdAnniversaryOfGrantMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_CYCCOptionsVestingOnThirdAnniversaryOfGrantMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_340" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_340" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_340" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_340" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_340" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_340" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_340" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_340" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_340" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_340" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_340" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_340" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_340" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_340" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_340" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_340" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_340" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="999062 - Disclosure - Employee Benefit Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaapRetirementPlanTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRetirementPlanTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaapRetirementPlanTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRetirementPlanTypeAxis" xlink:to="loc_us-gaapRetirementPlanTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaapRetirementPlanTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRetirementPlanTypeAxis" xlink:to="loc_us-gaapRetirementPlanTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_Plan401KMember" xlink:label="loc_CYCCPlan401KMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRetirementPlanTypeDomain" xlink:to="loc_CYCCPlan401KMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:label="loc_CYCCDefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_CYCCDefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:label="loc_CYCCDefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_CYCCDefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:label="loc_CYCCDefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_CYCCDefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" xlink:title="999063 - Disclosure - Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" xlink:title="999064 - Disclosure - Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" xlink:title="999065 - Disclosure - Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" xlink:title="999066 - Disclosure - Schedule of Significant Components of the Entity&apos;s Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/TaxesDetailsNarrative" xlink:title="999067 - Disclosure - Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaapOperatingLossCarryforwardsValuationAllowance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsValuationAllowance_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:label="loc_CYCCPercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CYCCPercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_110" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999068 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="999069 - Disclosure - Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CYCCCommonStockWarrantsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_150" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfGeographicInformationDetails" xlink:title="999070 - Disclosure - Schedule of Geographic Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="loc_countryGB_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryGB_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails" xlink:title="999071 - Disclosure - Schedule of Summary of Consolidated Net Loss (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SingleReportableSegmentMember" xlink:label="loc_CYCCSingleReportableSegmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CYCCSingleReportableSegmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_30" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_30" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_30" xlink:to="loc_us-gaapOperatingExpenses_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:title="999072 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SixPercentConvertibleExchangeablePreferredMember" xlink:label="loc_CYCCSixPercentConvertibleExchangeablePreferredMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CYCCSixPercentConvertibleExchangeablePreferredMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CYCCCommonStockWarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" xlink:title="999073 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/RevenueDetailsNarrative" xlink:title="999074 - Disclosure - Revenue (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails" xlink:title="999075 - Disclosure - Schedule of Remaining Lease Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/LeasesDetailsNarrative" xlink:title="999076 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DundeeScotlandMember" xlink:label="loc_CYCCDundeeScotlandMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCDundeeScotlandMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_KualaLumpurFacilityMember" xlink:label="loc_CYCCKualaLumpurFacilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCKualaLumpurFacilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SubsequentEventsDetailsNarrative" xlink:title="999077 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FittersDiversifiedBerhadMember" xlink:label="loc_CYCCFittersDiversifiedBerhadMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_CYCCFittersDiversifiedBerhadMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_110" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>53
<FILENAME>cycc-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SixPercentConvertibleExchangeablePreferredStockMember" xlink:label="CYCC_SixPercentConvertibleExchangeablePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SixPercentConvertibleExchangeablePreferredStockMember" xlink:to="CYCC_SixPercentConvertibleExchangeablePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SixPercentConvertibleExchangeablePreferredStockMember_lbl" xml:lang="en-US">6% Convertible Exchangeable Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xml:lang="en-US">Series E Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClinicalTrialSupplyMember" xlink:label="CYCC_ClinicalTrialSupplyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClinicalTrialSupplyMember" xlink:to="CYCC_ClinicalTrialSupplyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ClinicalTrialSupplyMember_lbl" xml:lang="en-US">Clinical Trial Supply [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:to="CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">February 2025 Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:to="CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">February Two Thousand Twenty Five Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_HelenaSpecialOpportunitiesOneLtdMember" xlink:label="CYCC_HelenaSpecialOpportunitiesOneLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_HelenaSpecialOpportunitiesOneLtdMember" xlink:to="CYCC_HelenaSpecialOpportunitiesOneLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_HelenaSpecialOpportunitiesOneLtdMember_lbl" xml:lang="en-US">Helena Special Opportunities One Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCConvertiblePreferredStockMember" xlink:label="CYCC_SeriesCConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesCConvertiblePreferredStockMember" xlink:to="CYCC_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesDConvertiblePreferredStockMember" xlink:label="CYCC_SeriesDConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesDConvertiblePreferredStockMember" xlink:to="CYCC_SeriesDConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCAndDConvertiblePreferredStockMember" xlink:label="CYCC_SeriesCAndDConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesCAndDConvertiblePreferredStockMember" xlink:to="CYCC_SeriesCAndDConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesCAndDConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series C And D Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CyclacelLimitedUnitedKingdomMember" xlink:label="CYCC_CyclacelLimitedUnitedKingdomMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CyclacelLimitedUnitedKingdomMember" xlink:to="CYCC_CyclacelLimitedUnitedKingdomMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CyclacelLimitedUnitedKingdomMember_lbl" xml:lang="en-US">Cyclacel Limited United Kingdom [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AssetsOfCyclacelLimitedMember" xlink:label="CYCC_AssetsOfCyclacelLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AssetsOfCyclacelLimitedMember" xlink:to="CYCC_AssetsOfCyclacelLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_AssetsOfCyclacelLimitedMember_lbl" xml:lang="en-US">Assets Of Cyclacel Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesEConvertiblePreferredStockMember" xlink:label="CYCC_SeriesEConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesEConvertiblePreferredStockMember" xlink:to="CYCC_SeriesEConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesEConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:to="CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">March 2025 Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_RombotisSettlementAgreementMember" xlink:label="CYCC_RombotisSettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_RombotisSettlementAgreementMember" xlink:to="CYCC_RombotisSettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_RombotisSettlementAgreementMember_lbl" xml:lang="en-US">Rombotis Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_McBarronSettlementAgreementMember" xlink:label="CYCC_McBarronSettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_McBarronSettlementAgreementMember" xlink:to="CYCC_McBarronSettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_McBarronSettlementAgreementMember_lbl" xml:lang="en-US">Mc Barron Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_MdAndersonMember" xlink:label="CYCC_MdAndersonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_MdAndersonMember" xlink:to="CYCC_MdAndersonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_MdAndersonMember_lbl" xml:lang="en-US">Md Anderson [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClinicalCollaborationAgreementMember" xlink:label="CYCC_ClinicalCollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClinicalCollaborationAgreementMember" xlink:to="CYCC_ClinicalCollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ClinicalCollaborationAgreementMember_lbl" xml:lang="en-US">Clinical Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OfficeEquipmentAndFurnitureMember" xlink:label="CYCC_OfficeEquipmentAndFurnitureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OfficeEquipmentAndFurnitureMember" xlink:to="CYCC_OfficeEquipmentAndFurnitureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_OfficeEquipmentAndFurnitureMember_lbl" xml:lang="en-US">Office Equipment snd Furniture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_UnitedKingdomSubsidiaryCompanyMember" xlink:label="CYCC_UnitedKingdomSubsidiaryCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_UnitedKingdomSubsidiaryCompanyMember" xlink:to="CYCC_UnitedKingdomSubsidiaryCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_UnitedKingdomSubsidiaryCompanyMember_lbl" xml:lang="en-US">United Kingdom Subsidiary Company [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_BerkeleyHeightsFacilityMember" xlink:label="CYCC_BerkeleyHeightsFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_BerkeleyHeightsFacilityMember" xlink:to="CYCC_BerkeleyHeightsFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_BerkeleyHeightsFacilityMember_lbl" xml:lang="en-US">Berkeley Heights Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" xlink:label="CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" xlink:to="CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_lbl" xml:lang="en-US">Corporate Headquarters. Tower 11 Kuala Lumpur Malaysia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DundeeScotlandMember" xlink:label="CYCC_DundeeScotlandMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DundeeScotlandMember" xlink:to="CYCC_DundeeScotlandMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DundeeScotlandMember_lbl" xml:lang="en-US">Dundee facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_November2024WarrantExerciseAndReloadAgreementMember" xlink:label="CYCC_November2024WarrantExerciseAndReloadAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_November2024WarrantExerciseAndReloadAgreementMember" xlink:to="CYCC_November2024WarrantExerciseAndReloadAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_November2024WarrantExerciseAndReloadAgreementMember_lbl" xml:lang="en-US">November 2024 Warrant Exercise And Reload Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesBWarrantsMember" xlink:label="CYCC_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesBWarrantsMember" xlink:to="CYCC_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCWarrantsMember" xlink:label="CYCC_SeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesCWarrantsMember" xlink:to="CYCC_SeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesDWarrantsMember" xlink:label="CYCC_SeriesDWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesDWarrantsMember" xlink:to="CYCC_SeriesDWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesDWarrantsMember_lbl" xml:lang="en-US">Series D Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:label="CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:to="CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">April 2024 Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsMember" xlink:label="CYCC_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreFundedWarrantsMember" xlink:to="CYCC_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PreFundedWarrantsMember_lbl" xml:lang="en-US">PreFunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesAWarrantsMember" xlink:label="CYCC_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesAWarrantsMember" xlink:to="CYCC_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsAndCommonWarrantsMember" xlink:label="CYCC_PreFundedWarrantsAndCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreFundedWarrantsAndCommonWarrantsMember" xlink:to="CYCC_PreFundedWarrantsAndCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PreFundedWarrantsAndCommonWarrantsMember_lbl" xml:lang="en-US">PreFunded Warrants And Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="CYCC_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CommonStockWarrantsMember" xlink:to="CYCC_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PlacementAgentWarrantsMember" xlink:label="CYCC_PlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PlacementAgentWarrantsMember" xlink:to="CYCC_PlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_RothCapitalPartnersLlcMember" xlink:label="CYCC_RothCapitalPartnersLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_RothCapitalPartnersLlcMember" xlink:to="CYCC_RothCapitalPartnersLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_RothCapitalPartnersLlcMember_lbl" xml:lang="en-US">Roth Capital Partners Llc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LadenburgThalmannCo.IncMember" xlink:label="CYCC_LadenburgThalmannCo.IncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_LadenburgThalmannCo.IncMember" xlink:to="CYCC_LadenburgThalmannCo.IncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_LadenburgThalmannCo.IncMember_lbl" xml:lang="en-US">Ladenburg Thalmann Co .Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" xlink:label="CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" xlink:to="CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">December 2023 Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember" xlink:label="CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember" xlink:to="CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer And Chief Operating Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="CYCC_InsiderPrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_InsiderPrivatePlacementMember" xlink:to="CYCC_InsiderPrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_InsiderPrivatePlacementMember_lbl" xml:lang="en-US">Insider Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CantorFitzgeraldCoMember" xlink:label="CYCC_CantorFitzgeraldCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CantorFitzgeraldCoMember" xlink:to="CYCC_CantorFitzgeraldCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CantorFitzgeraldCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_August2021ControlledEquityOfferingSalesAgreementMember" xlink:label="CYCC_August2021ControlledEquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_August2021ControlledEquityOfferingSalesAgreementMember" xlink:to="CYCC_August2021ControlledEquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_August2021ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">August 2021 Controlled Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" xlink:label="CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" xlink:to="CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_lbl" xml:lang="en-US">November Two Thousand Twenty Four Warrant Exercise And Reload Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyFourWarrantsMember" xlink:label="CYCC_AprilTwoThousandTwentyFourWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AprilTwoThousandTwentyFourWarrantsMember" xlink:to="CYCC_AprilTwoThousandTwentyFourWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_AprilTwoThousandTwentyFourWarrantsMember_lbl" xml:lang="en-US">April 2024 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_April2024WarrantsMember" xlink:label="CYCC_April2024WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_April2024WarrantsMember" xlink:to="CYCC_April2024WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_April2024WarrantsMember_lbl" xml:lang="en-US">April 2024 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesBWarrantMember" xlink:label="CYCC_SeriesBWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesBWarrantMember" xlink:to="CYCC_SeriesBWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SeriesBWarrantMember_lbl" xml:lang="en-US">Series B Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_December2023PrivatePlacementMember" xlink:label="CYCC_December2023PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_December2023PrivatePlacementMember" xlink:to="CYCC_December2023PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_December2023PrivatePlacementMember_lbl" xml:lang="en-US">December 2023 Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember" xlink:label="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember" xlink:to="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember_lbl" xml:lang="en-US">December 2023 Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_December2023PlacementAgencyAgreementMember" xlink:label="CYCC_December2023PlacementAgencyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_December2023PlacementAgencyAgreementMember" xlink:to="CYCC_December2023PlacementAgencyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_December2023PlacementAgencyAgreementMember_lbl" xml:lang="en-US">December 2023 Placement Agency Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyWarrantMember" xlink:label="CYCC_DecemberTwoThousandTwentyWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DecemberTwoThousandTwentyWarrantMember" xlink:to="CYCC_DecemberTwoThousandTwentyWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DecemberTwoThousandTwentyWarrantMember_lbl" xml:lang="en-US">December 2020 Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyWarrantsMember" xlink:label="CYCC_AprilTwoThousandTwentyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AprilTwoThousandTwentyWarrantsMember" xlink:to="CYCC_AprilTwoThousandTwentyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_AprilTwoThousandTwentyWarrantsMember_lbl" xml:lang="en-US">April 2020 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_EquityIncentivePlan2018Member" xlink:label="CYCC_EquityIncentivePlan2018Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_EquityIncentivePlan2018Member" xlink:to="CYCC_EquityIncentivePlan2018Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_EquityIncentivePlan2018Member_lbl" xml:lang="en-US">2018 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember" xlink:label="CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember" xlink:to="CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember_lbl" xml:lang="en-US">2020 Inducement Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember" xlink:label="CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember" xlink:to="CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember_lbl" xml:lang="en-US">Options Vesting On Third Anniversary Of Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_Plan401KMember" xlink:label="CYCC_Plan401KMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_Plan401KMember" xlink:to="CYCC_Plan401KMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_Plan401KMember_lbl" xml:lang="en-US">Plan 401K [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_GB_lbl" xml:lang="en-US">UNITED KINGDOM</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SingleReportableSegmentMember" xlink:label="CYCC_SingleReportableSegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SingleReportableSegmentMember" xlink:to="CYCC_SingleReportableSegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SingleReportableSegmentMember_lbl" xml:lang="en-US">Single Reportable Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SixPercentConvertibleExchangeablePreferredMember" xlink:label="CYCC_SixPercentConvertibleExchangeablePreferredMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SixPercentConvertibleExchangeablePreferredMember" xlink:to="CYCC_SixPercentConvertibleExchangeablePreferredMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SixPercentConvertibleExchangeablePreferredMember_lbl" xml:lang="en-US">Six Percent Convertible Exchangeable Preferred [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_KualaLumpurFacilityMember" xlink:label="CYCC_KualaLumpurFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_KualaLumpurFacilityMember" xlink:to="CYCC_KualaLumpurFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_KualaLumpurFacilityMember_lbl" xml:lang="en-US">Kuala Lumpur facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FittersDiversifiedBerhadMember" xlink:label="CYCC_FittersDiversifiedBerhadMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_FittersDiversifiedBerhadMember" xlink:to="CYCC_FittersDiversifiedBerhadMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_FittersDiversifiedBerhadMember_lbl" xml:lang="en-US">FITTERS Diversified Berhad [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use lease asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Non-current deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 250,000,000 shares authorized at March 31, 2025 and 100,000,000 shares authorized at December&#160;31,&#160;2024; 863,902 shares issued and outstanding at March&#160;31,&#160;2025 and 36,913 shares issued and outstanding at December&#160;31,&#160;2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gains (losses)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xml:lang="en-US">Gain on deconsolidation of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Dividend on convertible exchangeable preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss applicable to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Basic and diluted earnings per common share:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:to="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_lbl" xml:lang="en-US">Unrealized foreign exchange loss on intercompany loans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:label="CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:to="CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_lbl" xml:lang="en-US">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:label="CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:to="CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_lbl" xml:lang="en-US">Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct Offering, net of expenses, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Series B Preferred stock conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Series B Preferred stock conversions, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock" xlink:label="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock" xlink:to="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock_lbl" xml:lang="en-US">Reclassification of redeemable common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfRedeemableCommonStockShares" xlink:label="CYCC_ReclassificationOfRedeemableCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReclassificationOfRedeemableCommonStockShares" xlink:to="CYCC_ReclassificationOfRedeemableCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ReclassificationOfRedeemableCommonStockShares_lbl" xml:lang="en-US">Reclassification of redeemable common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl" xml:lang="en-US">Preferred stock dividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:to="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_2_lbl" xml:lang="en-US">Unrealized foreign exchange on intercompany loans</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Loss for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" xlink:label="CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" xlink:to="CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred_lbl" xml:lang="en-US">Conversion of series 6% Convertible Exchangeable Preferred</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" xlink:label="CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" xlink:to="CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred_lbl" xml:lang="en-US">Conversion of series 6% Convertible Exchangeable Preferred, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="CYCC_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="CYCC_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Warrant Exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Warrant Exercises, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:label="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:to="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_lbl" xml:lang="en-US">Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:label="CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:to="CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_lbl" xml:lang="en-US">Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses_lbl" xml:lang="en-US">Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issue of Series C preferred stock in Securities Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issue of Series C preferred stock in Securities Purchase Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" xlink:label="CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" xlink:to="CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions_lbl" xml:lang="en-US">Series C Preferred stock conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" xlink:label="CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" xlink:to="CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions_lbl" xml:lang="en-US">Series C Preferred stock conversions, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_lbl" xml:lang="en-US">Issue of Series D preferred stock in Securities Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:to="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_lbl" xml:lang="en-US">Issue of Series D preferred stock in Securities Purchase Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" xlink:label="CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" xlink:to="CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions_lbl" xml:lang="en-US">Series D Preferred stock conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" xlink:label="CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" xlink:to="CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions_lbl" xml:lang="en-US">Series D Preferred stock conversions, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_lbl" xml:lang="en-US">Issue of Series D preferred stock in Securities Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:to="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_lbl" xml:lang="en-US">Issue of Series D preferred stock in Securities Purchase Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise_lbl" xml:lang="en-US">Warrant Exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise" xlink:to="CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise_lbl" xml:lang="en-US">Warrant Exercise, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issue of common stock on Securities Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issue of common stock on Securities Purchase Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" xlink:label="CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" xlink:to="CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary_lbl" xml:lang="en-US">Deconsolidation of Subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueTranslationAdjustment" xlink:label="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment" xlink:to="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment_lbl" xml:lang="en-US">Translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Changes in lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accounts payable, accrued and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs from issuing common stock and pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" xlink:label="CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" xlink:to="CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from the exercise of stock options and warrants, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Payment of preferred stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used) in financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Cash received during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xml:lang="en-US">Research &amp; development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxesPaidNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Noncash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AccrualOfPreferredStockDividends" xlink:label="CYCC_AccrualOfPreferredStockDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AccrualOfPreferredStockDividends" xlink:to="CYCC_AccrualOfPreferredStockDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_AccrualOfPreferredStockDividends_lbl" xml:lang="en-US">Accrual of preferred stock dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Company Overview</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureSignificantContractsAbstract" xlink:label="CYCC_DisclosureSignificantContractsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DisclosureSignificantContractsAbstract" xlink:to="CYCC_DisclosureSignificantContractsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DisclosureSignificantContractsAbstract_lbl" xml:lang="en-US">Significant Contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SignificantContractsDisclosureTextBlock" xlink:label="CYCC_SignificantContractsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SignificantContractsDisclosureTextBlock" xlink:to="CYCC_SignificantContractsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_SignificantContractsDisclosureTextBlock_lbl" xml:lang="en-US">Significant Contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureNoncurrentAssetsAbstract" xlink:label="CYCC_DisclosureNoncurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DisclosureNoncurrentAssetsAbstract" xlink:to="CYCC_DisclosureNoncurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DisclosureNoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_NonCurrentAssetsTextBlock" xlink:label="CYCC_NonCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_NonCurrentAssetsTextBlock" xlink:to="CYCC_NonCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_NonCurrentAssetsTextBlock_lbl" xml:lang="en-US">Non-Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued and Other Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Geographic and Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureLeasesAbstract" xlink:label="CYCC_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DisclosureLeasesAbstract" xlink:to="CYCC_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency and Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherIncomePolicyTextBlock" xlink:label="CYCC_OtherIncomePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OtherIncomePolicyTextBlock" xlink:to="CYCC_OtherIncomePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_OtherIncomePolicyTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClinicalTrialAccountingPolicyTextBlock" xlink:label="CYCC_ClinicalTrialAccountingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClinicalTrialAccountingPolicyTextBlock" xlink:to="CYCC_ClinicalTrialAccountingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ClinicalTrialAccountingPolicyTextBlock_lbl" xml:lang="en-US">Clinical Trial Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PatentCostsPolicyTextBlock" xlink:label="CYCC_PatentCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PatentCostsPolicyTextBlock" xlink:to="CYCC_PatentCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_GoingConcernPolicyTextBlock" xlink:label="CYCC_GoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_GoingConcernPolicyTextBlock" xlink:to="CYCC_GoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Newly Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Summary of Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured on a Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued and Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" xlink:label="CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" xlink:to="CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Instruments Issued in Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair value of Warrants Valuation Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of (Loss) Income Before Taxes from Continuing Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Benefit (Provision) for Income Taxes from Continuing Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Significant Components of the Entity's Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive shares excluded from computation of diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Geographic Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Summary of Consolidated Net Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2_lbl" xml:lang="en-US">Schedule of Remaining Lease Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" xlink:label="CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" xlink:to="CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary_lbl" xml:lang="en-US">[custom:StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockValueAgreedToBeIssued" xlink:label="CYCC_CommonStockValueAgreedToBeIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CommonStockValueAgreedToBeIssued" xlink:to="CYCC_CommonStockValueAgreedToBeIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CommonStockValueAgreedToBeIssued_lbl" xml:lang="en-US">[custom:CommonStockValueAgreedToBeIssued]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue" xlink:label="CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue" xlink:to="CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue_lbl" xml:lang="en-US">[custom:SharePurchaseAgreementIncrementExerciseLotOneValue]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue" xlink:label="CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue" xlink:to="CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue_lbl" xml:lang="en-US">[custom:SharePurchaseAgreementIncrementExerciseLotTwoValue]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfOutstandingCommonStock" xlink:label="CYCC_PercentageOfOutstandingCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PercentageOfOutstandingCommonStock" xlink:to="CYCC_PercentageOfOutstandingCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PercentageOfOutstandingCommonStock_lbl" xml:lang="en-US">[custom:PercentageOfOutstandingCommonStock]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SettlementPaymentSettlementAgreement" xlink:label="CYCC_SettlementPaymentSettlementAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SettlementPaymentSettlementAgreement" xlink:to="CYCC_SettlementPaymentSettlementAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SettlementPaymentSettlementAgreement_lbl" xml:lang="en-US">[custom:SettlementPaymentSettlementAgreement]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FutureOneTimeSettlementPaymentSettlementAgreement" xlink:label="CYCC_FutureOneTimeSettlementPaymentSettlementAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_FutureOneTimeSettlementPaymentSettlementAgreement" xlink:to="CYCC_FutureOneTimeSettlementPaymentSettlementAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_FutureOneTimeSettlementPaymentSettlementAgreement_lbl" xml:lang="en-US">[custom:FutureOneTimeSettlementPaymentSettlementAgreement-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_2_lbl" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:label="CYCC_CashFinancialServicesCompensationSchemeInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:to="CYCC_CashFinancialServicesCompensationSchemeInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CashFinancialServicesCompensationSchemeInsuredAmount_lbl" xml:lang="en-US">[custom:CashFinancialServicesCompensationSchemeInsuredAmount-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="us-gaap_NumberOfCountriesInWhichEntityOperates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates_lbl" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xml:lang="en-US">Substantial Doubt about Going Concern, within One Year [true false]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_TermOfAgreement" xlink:label="CYCC_TermOfAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_TermOfAgreement" xlink:to="CYCC_TermOfAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_TermOfAgreement_lbl" xml:lang="en-US">[custom:TermOfAgreement]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConductClinicalStudies" xlink:label="CYCC_ConductClinicalStudies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ConductClinicalStudies" xlink:to="CYCC_ConductClinicalStudies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ConductClinicalStudies_lbl" xml:lang="en-US">[custom:ConductClinicalStudies]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LicenseAgreementPaymentEarned" xlink:label="CYCC_LicenseAgreementPaymentEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_LicenseAgreementPaymentEarned" xlink:to="CYCC_LicenseAgreementPaymentEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_LicenseAgreementPaymentEarned_lbl" xml:lang="en-US">[custom:LicenseAgreementPaymentEarned-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Total cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_lbl" xml:lang="en-US">Research and development tax credit receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" xlink:label="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" xlink:to="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent_lbl" xml:lang="en-US">Prepayments and VAT receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_2_lbl" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Office equipment and furniture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="CYCC_AccruedResearchAndDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="CYCC_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_AccruedResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherCurrentLiabilities" xlink:label="CYCC_OtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OtherCurrentLiabilities" xlink:to="CYCC_OtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">&#160;Accrued and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AccruedResearchAndDevelopmentCostCurrent" xlink:label="CYCC_AccruedResearchAndDevelopmentCostCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AccruedResearchAndDevelopmentCostCurrent" xlink:to="CYCC_AccruedResearchAndDevelopmentCostCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_AccruedResearchAndDevelopmentCostCurrent_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued and other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyTable" xlink:to="us-gaap_ProductLiabilityContingencyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyTable_lbl" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="us-gaap_ProductLiabilityContingencyLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_ProductLiabilityContingencyLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyLineItems_lbl" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LesseeOperatingLeaseTermOfContractExtension" xlink:label="CYCC_LesseeOperatingLeaseTermOfContractExtension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_LesseeOperatingLeaseTermOfContractExtension" xlink:to="CYCC_LesseeOperatingLeaseTermOfContractExtension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_LesseeOperatingLeaseTermOfContractExtension_lbl" xml:lang="en-US">[custom:LesseeOperatingLeaseTermOfContractExtension]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:to="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_2_lbl" xml:lang="en-US">Net Proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and rights outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" xlink:label="CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" xlink:to="CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">[custom:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PercentageOfOutstandingCommonStock" xlink:to="CYCC_PercentageOfOutstandingCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_PercentageOfOutstandingCommonStock_2_lbl" xml:lang="en-US">Percentage of outstanding common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser" xlink:label="CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser" xlink:to="CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser_lbl" xml:lang="en-US">Outstanding common stock at election of purchaser</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CashPlacementFeePercentage" xlink:label="CYCC_CashPlacementFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CashPlacementFeePercentage" xlink:to="CYCC_CashPlacementFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CashPlacementFeePercentage_lbl" xml:lang="en-US">Cash placement fee, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ManagementFeePercentageToAggregateGrossProceeds" xlink:label="CYCC_ManagementFeePercentageToAggregateGrossProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ManagementFeePercentageToAggregateGrossProceeds" xlink:to="CYCC_ManagementFeePercentageToAggregateGrossProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ManagementFeePercentageToAggregateGrossProceeds_lbl" xml:lang="en-US">[custom:ManagementFeePercentageToAggregateGrossProceeds-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CompensationPercentageToAggregateGrossProceeds" xlink:label="CYCC_CompensationPercentageToAggregateGrossProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CompensationPercentageToAggregateGrossProceeds" xlink:to="CYCC_CompensationPercentageToAggregateGrossProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CompensationPercentageToAggregateGrossProceeds_lbl" xml:lang="en-US">[custom:CompensationPercentageToAggregateGrossProceeds-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Share issue price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AggregateProceedsFromSaleOfStock" xlink:label="CYCC_AggregateProceedsFromSaleOfStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AggregateProceedsFromSaleOfStock" xlink:to="CYCC_AggregateProceedsFromSaleOfStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_AggregateProceedsFromSaleOfStock_lbl" xml:lang="en-US">[custom:AggregateProceedsFromSaleOfStock-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of share sold</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockShares" xlink:label="CYCC_ReclassificationOfCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReclassificationOfCommonStockShares" xlink:to="CYCC_ReclassificationOfCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ReclassificationOfCommonStockShares_lbl" xml:lang="en-US">[custom:ReclassificationOfCommonStockShares]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived" xlink:label="CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived" xlink:to="CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived_lbl" xml:lang="en-US">[custom:ReclassificationOfCommonStockSharesNoProceedsReceived]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockValue" xlink:label="CYCC_ReclassificationOfCommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReclassificationOfCommonStockValue" xlink:to="CYCC_ReclassificationOfCommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ReclassificationOfCommonStockValue_lbl" xml:lang="en-US">[custom:ReclassificationOfCommonStockValue]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ProceedsFromIssuanceOfCommonStockGross" xlink:label="CYCC_ProceedsFromIssuanceOfCommonStockGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ProceedsFromIssuanceOfCommonStockGross" xlink:to="CYCC_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US">[custom:ProceedsFromIssuanceOfCommonStockGross]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightsExercisable" xlink:label="CYCC_ClassOfWarrantOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClassOfWarrantOrRightsExercisable" xlink:to="CYCC_ClassOfWarrantOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ClassOfWarrantOrRightsExercisable_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightExercised" xlink:label="CYCC_ClassOfWarrantOrRightExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClassOfWarrantOrRightExercised" xlink:to="CYCC_ClassOfWarrantOrRightExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Conversion of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price of convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConvertiblePreferredStockConversionPercentage" xlink:label="CYCC_ConvertiblePreferredStockConversionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ConvertiblePreferredStockConversionPercentage" xlink:to="CYCC_ConvertiblePreferredStockConversionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ConvertiblePreferredStockConversionPercentage_lbl" xml:lang="en-US">Conversion percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_2_lbl" xml:lang="en-US">Preferred stock, dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Liquidation preference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_lbl" xml:lang="en-US">Preferred Stock, Amount of Preferred Dividends in Arrears</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:label="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:to="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_lbl" xml:lang="en-US">Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConvertiblePreferredStockConversionPricePerShare" xlink:label="CYCC_ConvertiblePreferredStockConversionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ConvertiblePreferredStockConversionPricePerShare" xlink:to="CYCC_ConvertiblePreferredStockConversionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ConvertiblePreferredStockConversionPricePerShare_lbl" xml:lang="en-US">[custom:ConvertiblePreferredStockConversionPricePerShare]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockClosingPriceThreshold" xlink:label="CYCC_CommonStockClosingPriceThreshold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CommonStockClosingPriceThreshold" xlink:to="CYCC_CommonStockClosingPriceThreshold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_CommonStockClosingPriceThreshold_lbl" xml:lang="en-US">[custom:CommonStockClosingPriceThreshold-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:to="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_lbl" xml:lang="en-US">[custom:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_lbl" xml:lang="en-US">[custom:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationNumberOfTradingDays" xlink:label="CYCC_PreferredStockConversionObligationNumberOfTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreferredStockConversionObligationNumberOfTradingDays" xlink:to="CYCC_PreferredStockConversionObligationNumberOfTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PreferredStockConversionObligationNumberOfTradingDays_lbl" xml:lang="en-US">[custom:PreferredStockConversionObligationNumberOfTradingDays]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:label="CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:to="CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_lbl" xml:lang="en-US">[custom:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" xlink:label="CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" xlink:to="CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_lbl" xml:lang="en-US">[custom:DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Redemption price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt instrument, term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Conversion of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Conversion price percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregrate Intrinsic Value, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options Outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options Outstanding, Cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled/forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregrate Intrinsic Value, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Options Outstanding, Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregrate Intrinsic Value, Vested and Exerciseable</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Restricted Stock Units, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Restricted Stock Units, Grant Date Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted Stock Units, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Value per share, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Restricted Stock Units, Cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Value per share, Cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Restricted Stock Units, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Restricted Stock Units, Grant Date Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_lbl" xml:lang="en-US">Restricted Stock Units, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Value per share, Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted Stock Units, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Value per share, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Value per share, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Value per share, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:label="CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:to="CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_lbl" xml:lang="en-US">[custom:DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:label="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:to="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_lbl" xml:lang="en-US">[custom:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge]</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:label="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:to="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_lbl" xml:lang="en-US">[custom:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss from continuing operations before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current - domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Current - foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current - total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred - domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax expense computed at statutory federal tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Additional research and development tax relief</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Loss surrendered to generate R&amp;D credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Other foreign items</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xlink:label="CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xlink:to="CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_lbl" xml:lang="en-US">Disallowed expenses and non-taxable income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Foreign items, including change in tax rates, and other</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount" xlink:label="CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount" xlink:to="CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount_lbl" xml:lang="en-US">Other items</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current - total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss and tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:label="CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:to="CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_lbl" xml:lang="en-US">Depreciation, amortization and impairment of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" xlink:label="CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" xlink:to="CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:label="CYCC_DeferredTaxAssetsLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:to="CYCC_DeferredTaxAssetsLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DeferredTaxAssetsLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsLeaseRightOfUseLiability" xlink:label="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability" xlink:to="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:label="CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:to="CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_lbl" xml:lang="en-US">[custom:PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US">Numerator:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss attributable to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US">Denominator:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total shares excluded from calculation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3_lbl" xml:lang="en-US">Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_3_lbl" xml:lang="en-US">Long Lived Assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_5_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" xlink:to="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent_2_lbl" xml:lang="en-US">Prepayments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DisclosureLeasesAbstract" xlink:to="CYCC_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CYCC_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Remaining Lease Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Total future minimum lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2_lbl" xml:lang="en-US">Number of common shares issued upon conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:to="CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_doc" xml:lang="en-US">Represents the percentage of employees' deferral for which the employer contributes a matching contribution to the defined contribution plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SixPercentConvertibleExchangeablePreferredStockMember" xlink:to="CYCC_SixPercentConvertibleExchangeablePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SixPercentConvertibleExchangeablePreferredStockMember_doc" xml:lang="en-US">6% Convertible Exchangeable Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:to="CYCC_CashFinancialServicesCompensationSchemeInsuredAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CashFinancialServicesCompensationSchemeInsuredAmount_doc" xml:lang="en-US">Cash financial services compensation scheme insured amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OtherIncomePolicyTextBlock" xlink:to="CYCC_OtherIncomePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_OtherIncomePolicyTextBlock_doc" xml:lang="en-US">Other Income [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClinicalTrialAccountingPolicyTextBlock" xlink:to="CYCC_ClinicalTrialAccountingPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ClinicalTrialAccountingPolicyTextBlock_doc" xml:lang="en-US">Clinical Trial Accounting [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PatentCostsPolicyTextBlock" xlink:to="CYCC_PatentCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PatentCostsPolicyTextBlock_doc" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently Issued Accounting Pronouncements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SignificantContractsDisclosureTextBlock" xlink:to="CYCC_SignificantContractsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SignificantContractsDisclosureTextBlock_doc" xml:lang="en-US">Significant Contracts Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_MdAndersonMember" xlink:to="CYCC_MdAndersonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_MdAndersonMember_doc" xml:lang="en-US">Md Anderson [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ConductClinicalStudies" xlink:to="CYCC_ConductClinicalStudies_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ConductClinicalStudies_doc" xml:lang="en-US">Conduct clinical studies.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClinicalCollaborationAgreementMember" xlink:to="CYCC_ClinicalCollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ClinicalCollaborationAgreementMember_doc" xml:lang="en-US">Clinical Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OfficeEquipmentAndFurnitureMember" xlink:to="CYCC_OfficeEquipmentAndFurnitureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_OfficeEquipmentAndFurnitureMember_doc" xml:lang="en-US">Office Equipment snd Furniture [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="CYCC_AccruedResearchAndDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_AccruedResearchAndDevelopmentCostsCurrent_doc" xml:lang="en-US">Accrued research and development costs current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_UnitedKingdomSubsidiaryCompanyMember" xlink:to="CYCC_UnitedKingdomSubsidiaryCompanyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_UnitedKingdomSubsidiaryCompanyMember_doc" xml:lang="en-US">United Kingdom Subsidiary Company [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_TermOfAgreement" xlink:to="CYCC_TermOfAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_TermOfAgreement_doc" xml:lang="en-US">Term of agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_LicenseAgreementPaymentEarned" xlink:to="CYCC_LicenseAgreementPaymentEarned_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_LicenseAgreementPaymentEarned_doc" xml:lang="en-US">License agreement payment earned.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock_doc" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" xlink:to="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent_doc" xml:lang="en-US">Prepayments and value added tax receivable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_NonCurrentAssetsTextBlock" xlink:to="CYCC_NonCurrentAssetsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_NonCurrentAssetsTextBlock_doc" xml:lang="en-US">Non Current Assets [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options grants in period weighted average grant date cumulative fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment orginal award equity instruments other than options forfeited in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_doc" xml:lang="en-US">The number of additional equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_doc" xml:lang="en-US">The number of unvested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Per share or unit weighted-average fair value of unvested award under share-based payment arrangement. Excludes share and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, grants during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, unvested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:to="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_doc" xml:lang="en-US">Other comprehensive income unrealized foreign exchange on intercompany loans net of tax.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:to="CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_doc" xml:lang="en-US">Issue of common stock preferred stock pre funded warrants and warrants on equity financing net of expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:to="CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses_doc" xml:lang="en-US">Issue of common stock preferred stock shares pre funded warrants and warrants on equity financing net of expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser" xlink:to="CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser_doc" xml:lang="en-US">Percentage of outstanding common stock at election of purchaser.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClassOfWarrantOrRightExercised" xlink:to="CYCC_ClassOfWarrantOrRightExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ClassOfWarrantOrRightExercised_doc" xml:lang="en-US">Class of warrant or right exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClassOfWarrantOrRightsExercisable" xlink:to="CYCC_ClassOfWarrantOrRightsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ClassOfWarrantOrRightsExercisable_doc" xml:lang="en-US">Class of warrant or rights exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:to="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_doc" xml:lang="en-US">Stock issued during period value upon conversion of pre funded warrants in offering issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock" xlink:to="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock_doc" xml:lang="en-US">Increase in carrying amount of redeemable common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" xlink:to="CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred_doc" xml:lang="en-US">Stock issued during period shares conversion of convertible exchangeable preferred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" xlink:to="CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred_doc" xml:lang="en-US">Stock issued during period value conversion of convertible exchangeable preferred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="CYCC_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Stock issued during period value warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares stock warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:to="CYCC_DeferredTaxAssetsLeaseRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DeferredTaxAssetsLeaseRightOfUseAsset_doc" xml:lang="en-US">Deferred tax assets lease right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReclassificationOfRedeemableCommonStockShares" xlink:to="CYCC_ReclassificationOfRedeemableCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ReclassificationOfRedeemableCommonStockShares_doc" xml:lang="en-US">Reclassification of redeemable common stock shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" xlink:to="CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts_doc" xml:lang="en-US">Proceeds from exercise of stock options and warrant exercises net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AccrualOfPreferredStockDividends" xlink:to="CYCC_AccrualOfPreferredStockDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_AccrualOfPreferredStockDividends_doc" xml:lang="en-US">Accrual of preferred stock dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" xlink:to="CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary_doc" xml:lang="en-US">Stockholder equity increase from de consolidation of subsidiary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:to="CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_doc" xml:lang="en-US">Percentage of tax rate adopted in respect of deferred tax assets measurement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability" xlink:to="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability_doc" xml:lang="en-US">Deferred tax assets lease right of use liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" xlink:to="CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_doc" xml:lang="en-US">Deferred tax assets tax deferred expense compensation and benefits research and development credits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount" xlink:to="CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount_doc" xml:lang="en-US">Effective income tax rate reconciliation other items amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xlink:to="CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_doc" xml:lang="en-US">Income tax reconciliation nondeductible expense and tax exempt income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CommonStockValueAgreedToBeIssued" xlink:to="CYCC_CommonStockValueAgreedToBeIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CommonStockValueAgreedToBeIssued_doc" xml:lang="en-US">Common stock value agreed to be issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue" xlink:to="CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue_doc" xml:lang="en-US">Share purchase agreement increment exercise lot one value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PercentageOfOutstandingCommonStock" xlink:to="CYCC_PercentageOfOutstandingCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PercentageOfOutstandingCommonStock_doc" xml:lang="en-US">Percentage of outstanding common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:to="CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">February Two Thousand Twenty Five Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SettlementPaymentSettlementAgreement" xlink:to="CYCC_SettlementPaymentSettlementAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SettlementPaymentSettlementAgreement_doc" xml:lang="en-US">Settlement payment settlement agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_FutureOneTimeSettlementPaymentSettlementAgreement" xlink:to="CYCC_FutureOneTimeSettlementPaymentSettlementAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_FutureOneTimeSettlementPaymentSettlementAgreement_doc" xml:lang="en-US">Future one time settlement payment settlement agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_LesseeOperatingLeaseTermOfContractExtension" xlink:to="CYCC_LesseeOperatingLeaseTermOfContractExtension_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_LesseeOperatingLeaseTermOfContractExtension_doc" xml:lang="en-US">Lessee operating lease term of contract extension.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_doc" xml:lang="en-US">Lessee operating lease liability payments due after year two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" xlink:to="CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_doc" xml:lang="en-US">Class of warrant or right reduced exercise price of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CashPlacementFeePercentage" xlink:to="CYCC_CashPlacementFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CashPlacementFeePercentage_doc" xml:lang="en-US">Cash placement fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ManagementFeePercentageToAggregateGrossProceeds" xlink:to="CYCC_ManagementFeePercentageToAggregateGrossProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ManagementFeePercentageToAggregateGrossProceeds_doc" xml:lang="en-US">Management fee percentage to aggregate gross proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CompensationPercentageToAggregateGrossProceeds" xlink:to="CYCC_CompensationPercentageToAggregateGrossProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CompensationPercentageToAggregateGrossProceeds_doc" xml:lang="en-US">Compensation percentage to aggregate gross proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" xlink:to="CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_doc" xml:lang="en-US">Schedule Of Instruments Issued In Offering And Their Classification Under Shareholders Equity [Table Text Block ]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AggregateProceedsFromSaleOfStock" xlink:to="CYCC_AggregateProceedsFromSaleOfStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_AggregateProceedsFromSaleOfStock_doc" xml:lang="en-US">Aggregate proceeds from sale of stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:to="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_doc" xml:lang="en-US">Defined contribution plan employee statutorily prescribed annual contribution limit after attaining specified age.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:to="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_doc" xml:lang="en-US">Defined contribution plan employee statutorily prescribed annual contribution limit before attaining specified age.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses_doc" xml:lang="en-US">Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" xlink:to="CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions_doc" xml:lang="en-US">Stock issued during period value series C preferred stock conversions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" xlink:to="CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions_doc" xml:lang="en-US">Stock issued during period shares series C preferred stock conversions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_doc" xml:lang="en-US">Stock issued during period value issue of series d preferred stock in securities purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:to="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement_doc" xml:lang="en-US">Stock issued during period shares issue of series d preferred stock in securities purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" xlink:to="CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions_doc" xml:lang="en-US">Stock issued during period value series D preferred stock conversions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" xlink:to="CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions_doc" xml:lang="en-US">Stock issued during period shares series D preferred stock conversions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_doc" xml:lang="en-US">Stock issued during period value issue of series D preferred stock in securities purchase agreement one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:to="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_doc" xml:lang="en-US">Stock issued during period shares issue of series D preferred stock in securities purchase agreement one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise_doc" xml:lang="en-US">Stock issued during period value issue on warrant exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise" xlink:to="CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise_doc" xml:lang="en-US">Stock issued during period shares issue on warrant exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" xlink:to="CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary_doc" xml:lang="en-US">Stock issued during period value deconsolidation of subsidiary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue" xlink:to="CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue_doc" xml:lang="en-US">Share purchase agreement increment exercise lot two value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ConvertiblePreferredStockConversionPercentage" xlink:to="CYCC_ConvertiblePreferredStockConversionPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ConvertiblePreferredStockConversionPercentage_doc" xml:lang="en-US">Convertible preferred stock conversion percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_GoingConcernPolicyTextBlock" xlink:to="CYCC_GoingConcernPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_GoingConcernPolicyTextBlock_doc" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:to="CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_doc" xml:lang="en-US">Stock issued during period shares upon conversion of pre funded warrants in offering issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:to="CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_doc" xml:lang="en-US">Deferred tax assets tax deferred expense reserves and accruals depreciation amortization and impairment losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReclassificationOfCommonStockShares" xlink:to="CYCC_ReclassificationOfCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ReclassificationOfCommonStockShares_doc" xml:lang="en-US">Reclassification of common stock shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReclassificationOfCommonStockValue" xlink:to="CYCC_ReclassificationOfCommonStockValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ReclassificationOfCommonStockValue_doc" xml:lang="en-US">Reclassification of common stock value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ConvertiblePreferredStockConversionPricePerShare" xlink:to="CYCC_ConvertiblePreferredStockConversionPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ConvertiblePreferredStockConversionPricePerShare_doc" xml:lang="en-US">Convertible preferred stock conversion price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:to="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_doc" xml:lang="en-US">Preferred stock conversion obligation common stock closing sales price as percentage of conversion price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_doc" xml:lang="en-US">Preferred stock conversion obligation common stock closing sales price number of trading days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreferredStockConversionObligationNumberOfTradingDays" xlink:to="CYCC_PreferredStockConversionObligationNumberOfTradingDays_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PreferredStockConversionObligationNumberOfTradingDays_doc" xml:lang="en-US">Preferred stock conversion obligation number of trading days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:to="CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_doc" xml:lang="en-US">Preferred stock conversion obligation thirty day trading period ending within number of trading days prior to notice of automatic conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" xlink:to="CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_doc" xml:lang="en-US">Director election trigger number of quarterly periods with no dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived" xlink:to="CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived_doc" xml:lang="en-US">Reclassification of common stock shares no proceeds received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ProceedsFromIssuanceOfCommonStockGross" xlink:to="CYCC_ProceedsFromIssuanceOfCommonStockGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ProceedsFromIssuanceOfCommonStockGross_doc" xml:lang="en-US">Proceeds from issuance of common stock gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment" xlink:to="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment_doc" xml:lang="en-US">Translation adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AccruedResearchAndDevelopmentCostCurrent" xlink:to="CYCC_AccruedResearchAndDevelopmentCostCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_AccruedResearchAndDevelopmentCostCurrent_doc" xml:lang="en-US">Accrued research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OtherCurrentLiabilities" xlink:to="CYCC_OtherCurrentLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_OtherCurrentLiabilities_doc" xml:lang="en-US">Other current liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CommonStockClosingPriceThreshold" xlink:to="CYCC_CommonStockClosingPriceThreshold_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CommonStockClosingPriceThreshold_doc" xml:lang="en-US">Common stock closing price threshold.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ClinicalTrialSupplyMember" xlink:to="CYCC_ClinicalTrialSupplyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ClinicalTrialSupplyMember_doc" xml:lang="en-US">Clinical Trial Supply [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:to="CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">February 2025 Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_HelenaSpecialOpportunitiesOneLtdMember" xlink:to="CYCC_HelenaSpecialOpportunitiesOneLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_HelenaSpecialOpportunitiesOneLtdMember_doc" xml:lang="en-US">Helena Special Opportunities One Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesCConvertiblePreferredStockMember" xlink:to="CYCC_SeriesCConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesCConvertiblePreferredStockMember_doc" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesDConvertiblePreferredStockMember" xlink:to="CYCC_SeriesDConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesDConvertiblePreferredStockMember_doc" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesCAndDConvertiblePreferredStockMember" xlink:to="CYCC_SeriesCAndDConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesCAndDConvertiblePreferredStockMember_doc" xml:lang="en-US">Series C And D Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CyclacelLimitedUnitedKingdomMember" xlink:to="CYCC_CyclacelLimitedUnitedKingdomMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CyclacelLimitedUnitedKingdomMember_doc" xml:lang="en-US">Cyclacel Limited United Kingdom [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AssetsOfCyclacelLimitedMember" xlink:to="CYCC_AssetsOfCyclacelLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_AssetsOfCyclacelLimitedMember_doc" xml:lang="en-US">Assets Of Cyclacel Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesEConvertiblePreferredStockMember" xlink:to="CYCC_SeriesEConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesEConvertiblePreferredStockMember_doc" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:to="CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">March 2025 Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_RombotisSettlementAgreementMember" xlink:to="CYCC_RombotisSettlementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_RombotisSettlementAgreementMember_doc" xml:lang="en-US">Rombotis Settlement Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_McBarronSettlementAgreementMember" xlink:to="CYCC_McBarronSettlementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_McBarronSettlementAgreementMember_doc" xml:lang="en-US">Mc Barron Settlement Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_BerkeleyHeightsFacilityMember" xlink:to="CYCC_BerkeleyHeightsFacilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_BerkeleyHeightsFacilityMember_doc" xml:lang="en-US">Berkeley Heights Facility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DundeeScotlandMember" xlink:to="CYCC_DundeeScotlandMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DundeeScotlandMember_doc" xml:lang="en-US">Dundee facility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_November2024WarrantExerciseAndReloadAgreementMember" xlink:to="CYCC_November2024WarrantExerciseAndReloadAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_November2024WarrantExerciseAndReloadAgreementMember_doc" xml:lang="en-US">November 2024 Warrant Exercise And Reload Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesBWarrantsMember" xlink:to="CYCC_SeriesBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesBWarrantsMember_doc" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesCWarrantsMember" xlink:to="CYCC_SeriesCWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesCWarrantsMember_doc" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesDWarrantsMember" xlink:to="CYCC_SeriesDWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesDWarrantsMember_doc" xml:lang="en-US">Series D Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:to="CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">April 2024 Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreFundedWarrantsMember" xlink:to="CYCC_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PreFundedWarrantsMember_doc" xml:lang="en-US">PreFunded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesAWarrantsMember" xlink:to="CYCC_SeriesAWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesAWarrantsMember_doc" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PreFundedWarrantsAndCommonWarrantsMember" xlink:to="CYCC_PreFundedWarrantsAndCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PreFundedWarrantsAndCommonWarrantsMember_doc" xml:lang="en-US">PreFunded Warrants And Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CommonStockWarrantsMember" xlink:to="CYCC_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_PlacementAgentWarrantsMember" xlink:to="CYCC_PlacementAgentWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_PlacementAgentWarrantsMember_doc" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_RothCapitalPartnersLlcMember" xlink:to="CYCC_RothCapitalPartnersLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_RothCapitalPartnersLlcMember_doc" xml:lang="en-US">Roth Capital Partners Llc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_LadenburgThalmannCo.IncMember" xlink:to="CYCC_LadenburgThalmannCo.IncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_LadenburgThalmannCo.IncMember_doc" xml:lang="en-US">Ladenburg Thalmann Co .Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" xlink:to="CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">December 2023 Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember" xlink:to="CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember_doc" xml:lang="en-US">Chief Financial Officer And Chief Operating Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_InsiderPrivatePlacementMember" xlink:to="CYCC_InsiderPrivatePlacementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_InsiderPrivatePlacementMember_doc" xml:lang="en-US">Insider Private Placement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CantorFitzgeraldCoMember" xlink:to="CYCC_CantorFitzgeraldCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CantorFitzgeraldCoMember_doc" xml:lang="en-US">Cantor Fitzgerald Co [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_August2021ControlledEquityOfferingSalesAgreementMember" xlink:to="CYCC_August2021ControlledEquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_August2021ControlledEquityOfferingSalesAgreementMember_doc" xml:lang="en-US">August 2021 Controlled Equity Offering Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" xlink:to="CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_doc" xml:lang="en-US">November Two Thousand Twenty Four Warrant Exercise And Reload Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AprilTwoThousandTwentyFourWarrantsMember" xlink:to="CYCC_AprilTwoThousandTwentyFourWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_AprilTwoThousandTwentyFourWarrantsMember_doc" xml:lang="en-US">April 2024 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_April2024WarrantsMember" xlink:to="CYCC_April2024WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_April2024WarrantsMember_doc" xml:lang="en-US">April 2024 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SeriesBWarrantMember" xlink:to="CYCC_SeriesBWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SeriesBWarrantMember_doc" xml:lang="en-US">Series B Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_December2023PrivatePlacementMember" xlink:to="CYCC_December2023PrivatePlacementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_December2023PrivatePlacementMember_doc" xml:lang="en-US">December 2023 Private Placement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember" xlink:to="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember_doc" xml:lang="en-US">December 2023 Private Placement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_December2023PlacementAgencyAgreementMember" xlink:to="CYCC_December2023PlacementAgencyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_December2023PlacementAgencyAgreementMember_doc" xml:lang="en-US">December 2023 Placement Agency Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DecemberTwoThousandTwentyWarrantMember" xlink:to="CYCC_DecemberTwoThousandTwentyWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_DecemberTwoThousandTwentyWarrantMember_doc" xml:lang="en-US">December 2020 Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AprilTwoThousandTwentyWarrantsMember" xlink:to="CYCC_AprilTwoThousandTwentyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_AprilTwoThousandTwentyWarrantsMember_doc" xml:lang="en-US">April 2020 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_EquityIncentivePlan2018Member" xlink:to="CYCC_EquityIncentivePlan2018Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_EquityIncentivePlan2018Member_doc" xml:lang="en-US">2018 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember" xlink:to="CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember_doc" xml:lang="en-US">2020 Inducement Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember" xlink:to="CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember_doc" xml:lang="en-US">Options Vesting On Third Anniversary Of Grant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_Plan401KMember" xlink:to="CYCC_Plan401KMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_Plan401KMember_doc" xml:lang="en-US">Plan 401K [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SingleReportableSegmentMember" xlink:to="CYCC_SingleReportableSegmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SingleReportableSegmentMember_doc" xml:lang="en-US">Single Reportable Segment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SixPercentConvertibleExchangeablePreferredMember" xlink:to="CYCC_SixPercentConvertibleExchangeablePreferredMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_SixPercentConvertibleExchangeablePreferredMember_doc" xml:lang="en-US">Six Percent Convertible Exchangeable Preferred [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_KualaLumpurFacilityMember" xlink:to="CYCC_KualaLumpurFacilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_KualaLumpurFacilityMember_doc" xml:lang="en-US">Kuala Lumpur facility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_FittersDiversifiedBerhadMember" xlink:to="CYCC_FittersDiversifiedBerhadMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_FittersDiversifiedBerhadMember_doc" xml:lang="en-US">FITTERS Diversified Berhad [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" xlink:to="CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_doc" xml:lang="en-US">Corporate Headquarters. Tower 11 Kuala Lumpur Malaysia [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding weighted average exercise price 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by stock based payment award equity instruments other than options nonvested weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_April2024WarrantsMember" xlink:to="CYCC_April2024WarrantsMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_April2024WarrantsMember_3_lbl" xml:lang="en-US">April 2024 Warrants [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember" xlink:to="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember_3_lbl" xml:lang="en-US">December 2023 Private Placement [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock" xlink:to="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock_3_lbl" xml:lang="en-US">IncreaseInCarryingAmountOfRedeemableCommonStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:to="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:to="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment" xlink:to="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_StockIssuedDuringPeriodValueTranslationAdjustment_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueTranslationAdjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_2_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_SignificantContractsDisclosureTextBlock" xlink:to="CYCC_SignificantContractsDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_SignificantContractsDisclosureTextBlock_3_lbl" xml:lang="en-US">Significant Contracts Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_2_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_AccruedResearchAndDevelopmentCostCurrent" xlink:to="CYCC_AccruedResearchAndDevelopmentCostCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_AccruedResearchAndDevelopmentCostCurrent_3_lbl" xml:lang="en-US">AccruedResearchAndDevelopmentCostCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability" xlink:to="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CYCC_DeferredTaxAssetsLeaseRightOfUseLiability_3_lbl" xml:lang="en-US">DeferredTaxAssetsLeaseRightOfUseLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_2_lbl" xml:lang="en-US">Prepaid Expense, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>54
<FILENAME>cycc-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Cover" roleURI="http://cyclacel.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#BalanceSheets" roleURI="http://cyclacel.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#BalanceSheetsParenthetical" roleURI="http://cyclacel.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfOperations" roleURI="http://cyclacel.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfComprehensiveLoss" roleURI="http://cyclacel.com/role/StatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfStockholdersEquityDeficit" roleURI="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfStockholdersEquityDeficitParenthetical" roleURI="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StatementsOfCashFlows" roleURI="http://cyclacel.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CompanyOverview" roleURI="http://cyclacel.com/role/CompanyOverview" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SignificantContracts" roleURI="http://cyclacel.com/role/SignificantContracts" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CashAndCashEquivalents" roleURI="http://cyclacel.com/role/CashAndCashEquivalents" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#FairValueOfFinancialAssetsAndLiabilities" roleURI="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Non-currentAssets" roleURI="http://cyclacel.com/role/Non-currentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PropertyAndEquipment" roleURI="http://cyclacel.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilities" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingencies" roleURI="http://cyclacel.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquity" roleURI="http://cyclacel.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensation" roleURI="http://cyclacel.com/role/StockBasedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#EmployeeBenefitPlans" roleURI="http://cyclacel.com/role/EmployeeBenefitPlans" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Taxes" roleURI="http://cyclacel.com/role/Taxes" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#NetLossPerCommonShare" roleURI="http://cyclacel.com/role/NetLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#GeographicAndSegmentInformation" roleURI="http://cyclacel.com/role/GeographicAndSegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Revenue" roleURI="http://cyclacel.com/role/Revenue" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Leases" roleURI="http://cyclacel.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SubsequentEvents" roleURI="http://cyclacel.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CashAndCashEquivalentsTables" roleURI="http://cyclacel.com/role/CashAndCashEquivalentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#FairValueOfFinancialAssetsAndLiabilitiesTables" roleURI="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#PropertyAndEquipmentTables" roleURI="http://cyclacel.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilitiesTables" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingenciesTables" roleURI="http://cyclacel.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquityTables" roleURI="http://cyclacel.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensationTables" roleURI="http://cyclacel.com/role/StockBasedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#TaxesTables" roleURI="http://cyclacel.com/role/TaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#NetLossPerCommonShareTables" roleURI="http://cyclacel.com/role/NetLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#GeographicAndSegmentInformationTables" roleURI="http://cyclacel.com/role/GeographicAndSegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#LeasesTables" roleURI="http://cyclacel.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" roleURI="http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CompanyOverviewDetailsNarrative" roleURI="http://cyclacel.com/role/CompanyOverviewDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SignificantContractsDetailsNarrative" roleURI="http://cyclacel.com/role/SignificantContractsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SummaryOfCashAndCashEquivalentsDetails" roleURI="http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#Non-currentAssetsDetailsNarrative" roleURI="http://cyclacel.com/role/Non-currentAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#AccruedAndOtherLiabilitiesDetailsNarrative" roleURI="http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" roleURI="http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" roleURI="http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" roleURI="http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cyclacel.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfShareOptionActivityDetails" roleURI="http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" roleURI="http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" roleURI="http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#StockBasedCompensationDetailsNarrative" roleURI="http://cyclacel.com/role/StockBasedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#EmployeeBenefitPlansDetailsNarrative" roleURI="http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" roleURI="http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" roleURI="http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" roleURI="http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" roleURI="http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#TaxesDetailsNarrative" roleURI="http://cyclacel.com/role/TaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" roleURI="http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfGeographicInformationDetails" roleURI="http://cyclacel.com/role/ScheduleOfGeographicInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfSummaryOfConsolidatedNetLossDetails" roleURI="http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfEarningsPerShareBasicAndDilutedDetails" roleURI="http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" roleURI="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#RevenueDetailsNarrative" roleURI="http://cyclacel.com/role/RevenueDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#ScheduleOfRemainingLeasePaymentsDetails" roleURI="http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#LeasesDetailsNarrative" roleURI="http://cyclacel.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cycc-20250331.xsd#SubsequentEventsDetailsNarrative" roleURI="http://cyclacel.com/role/SubsequentEventsDetailsNarrative" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SixPercentConvertibleExchangeablePreferredStockMember" xlink:label="loc_CYCCSixPercentConvertibleExchangeablePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSixPercentConvertibleExchangeablePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SixPercentConvertibleExchangeablePreferredStockMember" xlink:label="loc_CYCCSixPercentConvertibleExchangeablePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSixPercentConvertibleExchangeablePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClinicalTrialSupplyMember" xlink:label="loc_CYCCClinicalTrialSupplyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_CYCCClinicalTrialSupplyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_CYCCOtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_CYCCOtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:label="loc_CYCCIssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCIssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:label="loc_CYCCIssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCIssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock" xlink:label="loc_CYCCIncreaseInCarryingAmountOfRedeemableCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCIncreaseInCarryingAmountOfRedeemableCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfRedeemableCommonStockShares" xlink:label="loc_CYCCReclassificationOfRedeemableCommonStockShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCReclassificationOfRedeemableCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_CYCCOtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCOtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" xlink:label="loc_CYCCStockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_CYCCStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:label="loc_CYCCStockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" xlink:label="loc_CYCCStockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions" xlink:label="loc_CYCCStockIssuedDuringPeriodValueSeriesCPreferredStockConversions" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueSeriesCPreferredStockConversions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesSeriesCPreferredStockConversions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:label="loc_CYCCStockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions" xlink:label="loc_CYCCStockIssuedDuringPeriodValueSeriesDPreferredStockConversions" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueSeriesDPreferredStockConversions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesSeriesDPreferredStockConversions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:label="loc_CYCCStockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise" xlink:label="loc_CYCCStockIssuedDuringPeriodValueIssueOnWarrantExercise" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueIssueOnWarrantExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise" xlink:label="loc_CYCCStockIssuedDuringPeriodSharesIssueOnWarrantExercise" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodSharesIssueOnWarrantExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" xlink:label="loc_CYCCStockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueDeconsolidationOfSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueTranslationAdjustment" xlink:label="loc_CYCCStockIssuedDuringPeriodValueTranslationAdjustment" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueTranslationAdjustment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" xlink:label="loc_CYCCProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CYCCProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaapProceedsFromInterestReceived" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapProceedsFromInterestReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaapProceedsFromIncomeTaxRefunds" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapProceedsFromIncomeTaxRefunds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="loc_us-gaapIncomeTaxesPaidNetAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxesPaidNetAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxesPaidNetAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AccrualOfPreferredStockDividends" xlink:label="loc_CYCCAccrualOfPreferredStockDividends" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CYCCAccrualOfPreferredStockDividends" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CompanyOverview" xlink:title="999009 - Disclosure - Company Overview">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SignificantContracts" xlink:title="999011 - Disclosure - Significant Contracts">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureSignificantContractsAbstract" xlink:label="loc_CYCCDisclosureSignificantContractsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SignificantContractsDisclosureTextBlock" xlink:label="loc_CYCCSignificantContractsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureSignificantContractsAbstract" xlink:to="loc_CYCCSignificantContractsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashAndCashEquivalents" xlink:title="999012 - Disclosure - Cash and Cash Equivalents">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:title="999013 - Disclosure - Fair Value of Financial Assets and Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999014 - Disclosure - Prepaid Expenses and Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_CYCCPrepaidExpensesAndOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_CYCCPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Non-currentAssets" xlink:title="999015 - Disclosure - Non-Current Assets">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureNoncurrentAssetsAbstract" xlink:label="loc_CYCCDisclosureNoncurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_NonCurrentAssetsTextBlock" xlink:label="loc_CYCCNonCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureNoncurrentAssetsAbstract" xlink:to="loc_CYCCNonCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PropertyAndEquipment" xlink:title="999016 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilities" xlink:title="999017 - Disclosure - Accrued and Other Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensation" xlink:title="999020 - Disclosure - Stock Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/EmployeeBenefitPlans" xlink:title="999021 - Disclosure - Employee Benefit Plans">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Taxes" xlink:title="999022 - Disclosure - Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/NetLossPerCommonShare" xlink:title="999023 - Disclosure - Net Loss per Common Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/GeographicAndSegmentInformation" xlink:title="999024 - Disclosure - Geographic and Segment Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Revenue" xlink:title="999025 - Disclosure - Revenue">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Leases" xlink:title="999026 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureLeasesAbstract" xlink:label="loc_CYCCDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherIncomePolicyTextBlock" xlink:label="loc_CYCCOtherIncomePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CYCCOtherIncomePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClinicalTrialAccountingPolicyTextBlock" xlink:label="loc_CYCCClinicalTrialAccountingPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CYCCClinicalTrialAccountingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PatentCostsPolicyTextBlock" xlink:label="loc_CYCCPatentCostsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CYCCPatentCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_CYCCRecentlyIssuedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CYCCRecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_GoingConcernPolicyTextBlock" xlink:label="loc_CYCCGoingConcernPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CYCCGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashAndCashEquivalentsTables" xlink:title="999029 - Disclosure - Cash and Cash Equivalents (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:title="999030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999031 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables" xlink:title="999033 - Disclosure - Accrued and Other Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingenciesTables" xlink:title="999034 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="loc_CYCCInsiderPrivatePlacementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCInsiderPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" xlink:label="loc_CYCCScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensationTables" xlink:title="999036 - Disclosure - Stock Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/TaxesTables" xlink:title="999037 - Disclosure - Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/NetLossPerCommonShareTables" xlink:title="999038 - Disclosure - Net Loss per Common Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/GeographicAndSegmentInformationTables" xlink:title="999039 - Disclosure - Geographic and Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/LeasesTables" xlink:title="999040 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureLeasesAbstract" xlink:label="loc_CYCCDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative" xlink:title="999041 - Disclosure - Organization of the Company and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesCConvertiblePreferredStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesCConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesDConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesDConvertiblePreferredStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesDConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCAndDConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesCAndDConvertiblePreferredStockMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesCAndDConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesEConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesEConvertiblePreferredStockMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesEConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCJanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCJanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCFebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCFebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCMarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCMarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtCounterpartyNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_HelenaSpecialOpportunitiesOneLtdMember" xlink:label="loc_CYCCHelenaSpecialOpportunitiesOneLtdMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCHelenaSpecialOpportunitiesOneLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CyclacelLimitedUnitedKingdomMember" xlink:label="loc_CYCCCyclacelLimitedUnitedKingdomMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCCyclacelLimitedUnitedKingdomMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AssetsOfCyclacelLimitedMember" xlink:label="loc_CYCCAssetsOfCyclacelLimitedMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_CYCCAssetsOfCyclacelLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_RombotisSettlementAgreementMember" xlink:label="loc_CYCCRombotisSettlementAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CYCCRombotisSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_McBarronSettlementAgreementMember" xlink:label="loc_CYCCMcBarronSettlementAgreementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CYCCMcBarronSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" xlink:label="loc_CYCCStockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCStockholderSEquityIncreaseFromDeConsolidationOfSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockValueAgreedToBeIssued" xlink:label="loc_CYCCCommonStockValueAgreedToBeIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCCommonStockValueAgreedToBeIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue" xlink:label="loc_CYCCSharePurchaseAgreementIncrementExerciseLotOneValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCSharePurchaseAgreementIncrementExerciseLotOneValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue" xlink:label="loc_CYCCSharePurchaseAgreementIncrementExerciseLotTwoValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCSharePurchaseAgreementIncrementExerciseLotTwoValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfOutstandingCommonStock" xlink:label="loc_CYCCPercentageOfOutstandingCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCPercentageOfOutstandingCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SettlementPaymentSettlementAgreement" xlink:label="loc_CYCCSettlementPaymentSettlementAgreement" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCSettlementPaymentSettlementAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FutureOneTimeSettlementPaymentSettlementAgreement" xlink:label="loc_CYCCFutureOneTimeSettlementPaymentSettlementAgreement" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CYCCFutureOneTimeSettlementPaymentSettlementAgreement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CompanyOverviewDetailsNarrative" xlink:title="999042 - Disclosure - Company Overview (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:label="loc_CYCCCashFinancialServicesCompensationSchemeInsuredAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CYCCCashFinancialServicesCompensationSchemeInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="loc_us-gaapNumberOfCountriesInWhichEntityOperates" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfCountriesInWhichEntityOperates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaapReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernWithinOneYear" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernWithinOneYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTax" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SignificantContractsDetailsNarrative" xlink:title="999044 - Disclosure - Significant Contracts (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureSignificantContractsAbstract" xlink:label="loc_CYCCDisclosureSignificantContractsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureSignificantContractsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_MdAndersonMember" xlink:label="loc_CYCCMdAndersonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCMdAndersonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClinicalCollaborationAgreementMember" xlink:label="loc_CYCCClinicalCollaborationAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CYCCClinicalCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_TermOfAgreement" xlink:label="loc_CYCCTermOfAgreement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_CYCCTermOfAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConductClinicalStudies" xlink:label="loc_CYCCConductClinicalStudies" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_CYCCConductClinicalStudies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LicenseAgreementPaymentEarned" xlink:label="loc_CYCCLicenseAgreementPaymentEarned" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_CYCCLicenseAgreementPaymentEarned" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails" xlink:title="999045 - Disclosure - Summary of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999046 - Disclosure - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999047 - Disclosure - Schedule of prepaid expenses and other current assets (Details)">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="loc_us-gaapDeferredIncomeTaxesAndOtherTaxReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" xlink:label="loc_CYCCPrepaymentsAndValueAddedTaxReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_CYCCPrepaymentsAndValueAddedTaxReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Non-currentAssetsDetailsNarrative" xlink:title="999048 - Disclosure - Non-Current Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureNoncurrentAssetsAbstract" xlink:label="loc_CYCCDisclosureNoncurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureNoncurrentAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999049 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OfficeEquipmentAndFurnitureMember" xlink:label="loc_CYCCOfficeEquipmentAndFurnitureMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CYCCOfficeEquipmentAndFurnitureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:title="999050 - Disclosure - Schedule of Accrued and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="loc_CYCCAccruedResearchAndDevelopmentCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CYCCAccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OtherCurrentLiabilities" xlink:label="loc_CYCCOtherCurrentLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CYCCOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AccruedResearchAndDevelopmentCostCurrent" xlink:label="loc_CYCCAccruedResearchAndDevelopmentCostCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CYCCAccruedResearchAndDevelopmentCostCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative" xlink:title="999051 - Disclosure - Accrued and Other Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_UnitedKingdomSubsidiaryCompanyMember" xlink:label="loc_CYCCUnitedKingdomSubsidiaryCompanyMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CYCCUnitedKingdomSubsidiaryCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails" xlink:title="999052 - Disclosure - Schedule of the Company&apos;s Contractual Obligations and Commitments Relating to its Facilities Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="loc_CYCCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CYCCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999053 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapProductLiabilityContingencyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapProductLiabilityContingencyLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_BerkeleyHeightsFacilityMember" xlink:label="loc_CYCCBerkeleyHeightsFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCBerkeleyHeightsFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" xlink:label="loc_CYCCCorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCCorporateHeadquarters.Tower11KualaLumpurMalaysiaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DundeeScotlandMember" xlink:label="loc_CYCCDundeeScotlandMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCDundeeScotlandMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LesseeOperatingLeaseTermOfContractExtension" xlink:label="loc_CYCCLesseeOperatingLeaseTermOfContractExtension" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_CYCCLesseeOperatingLeaseTermOfContractExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails" xlink:title="999054 - Disclosure - Schedule of Fair Value of Instruments Issued in Offering (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsMember" xlink:label="loc_CYCCPreFundedWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CYCCPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CYCCCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="loc_CYCCInsiderPrivatePlacementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCInsiderPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:label="loc_CYCCStockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CYCCStockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails" xlink:title="999055 - Disclosure - Schedule of Fair value of Warrants Valuation Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsMember" xlink:label="loc_CYCCPreFundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PlacementAgentWarrantsMember" xlink:label="loc_CYCCPlacementAgentWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="loc_CYCCInsiderPrivatePlacementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCInsiderPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquityDetailsNarrative" xlink:title="999056 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_November2024WarrantExerciseAndReloadAgreementMember" xlink:label="loc_CYCCNovember2024WarrantExerciseAndReloadAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCNovember2024WarrantExerciseAndReloadAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCAprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCAprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" xlink:label="loc_CYCCDecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InsiderPrivatePlacementMember" xlink:label="loc_CYCCInsiderPrivatePlacementMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCInsiderPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_August2021ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_CYCCAugust2021ControlledEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCAugust2021ControlledEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" xlink:label="loc_CYCCNovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCNovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyFourWarrantsMember" xlink:label="loc_CYCCAprilTwoThousandTwentyFourWarrantsMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCAprilTwoThousandTwentyFourWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_April2024WarrantsMember" xlink:label="loc_CYCCApril2024WarrantsMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCApril2024WarrantsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_December2023PrivatePlacementMember" xlink:label="loc_CYCCDecember2023PrivatePlacementMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecember2023PrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember" xlink:label="loc_CYCCDecemberTwoThousandTwentyThreePrivatePlacementMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecemberTwoThousandTwentyThreePrivatePlacementMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_December2023PlacementAgencyAgreementMember" xlink:label="loc_CYCCDecember2023PlacementAgencyAgreementMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecember2023PlacementAgencyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DecemberTwoThousandTwentyWarrantMember" xlink:label="loc_CYCCDecemberTwoThousandTwentyWarrantMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCDecemberTwoThousandTwentyWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AprilTwoThousandTwentyWarrantsMember" xlink:label="loc_CYCCAprilTwoThousandTwentyWarrantsMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CYCCAprilTwoThousandTwentyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesBWarrantsMember" xlink:label="loc_CYCCSeriesBWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCWarrantsMember" xlink:label="loc_CYCCSeriesCWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesDWarrantsMember" xlink:label="loc_CYCCSeriesDWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesDWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsMember" xlink:label="loc_CYCCPreFundedWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesAWarrantsMember" xlink:label="loc_CYCCSeriesAWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreFundedWarrantsAndCommonWarrantsMember" xlink:label="loc_CYCCPreFundedWarrantsAndCommonWarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPreFundedWarrantsAndCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PlacementAgentWarrantsMember" xlink:label="loc_CYCCPlacementAgentWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesBWarrantMember" xlink:label="loc_CYCCSeriesBWarrantMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CYCCSeriesBWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtCounterpartyNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_RothCapitalPartnersLlcMember" xlink:label="loc_CYCCRothCapitalPartnersLlcMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCRothCapitalPartnersLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LadenburgThalmannCo.IncMember" xlink:label="loc_CYCCLadenburgThalmannCo.IncMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCLadenburgThalmannCo.IncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CantorFitzgeraldCoMember" xlink:label="loc_CYCCCantorFitzgeraldCoMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CYCCCantorFitzgeraldCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="1020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="1040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="1050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesCConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesCConvertiblePreferredStockMember" />
      <link:presentationArc order="1060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesCConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SeriesDConvertiblePreferredStockMember" xlink:label="loc_CYCCSeriesDConvertiblePreferredStockMember" />
      <link:presentationArc order="1070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CYCCSeriesDConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember" xlink:label="loc_CYCCChiefFinancialOfficerAndChiefOperatingOfficerMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CYCCChiefFinancialOfficerAndChiefOperatingOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" xlink:label="loc_CYCCClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfOutstandingCommonStock" xlink:label="loc_CYCCPercentageOfOutstandingCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPercentageOfOutstandingCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser" xlink:label="loc_CYCCPercentageOfOutstandingCommonStockAtElectionOfPurchaser" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPercentageOfOutstandingCommonStockAtElectionOfPurchaser" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CashPlacementFeePercentage" xlink:label="loc_CYCCCashPlacementFeePercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCCashPlacementFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ManagementFeePercentageToAggregateGrossProceeds" xlink:label="loc_CYCCManagementFeePercentageToAggregateGrossProceeds" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCManagementFeePercentageToAggregateGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CompensationPercentageToAggregateGrossProceeds" xlink:label="loc_CYCCCompensationPercentageToAggregateGrossProceeds" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCCompensationPercentageToAggregateGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_AggregateProceedsFromSaleOfStock" xlink:label="loc_CYCCAggregateProceedsFromSaleOfStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCAggregateProceedsFromSaleOfStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockShares" xlink:label="loc_CYCCReclassificationOfCommonStockShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCReclassificationOfCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived" xlink:label="loc_CYCCReclassificationOfCommonStockSharesNoProceedsReceived" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCReclassificationOfCommonStockSharesNoProceedsReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ReclassificationOfCommonStockValue" xlink:label="loc_CYCCReclassificationOfCommonStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCReclassificationOfCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_CYCCProceedsFromIssuanceOfCommonStockGross" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightsExercisable" xlink:label="loc_CYCCClassOfWarrantOrRightsExercisable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCClassOfWarrantOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ClassOfWarrantOrRightExercised" xlink:label="loc_CYCCClassOfWarrantOrRightExercised" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCClassOfWarrantOrRightExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConvertiblePreferredStockConversionPercentage" xlink:label="loc_CYCCConvertiblePreferredStockConversionPercentage" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCConvertiblePreferredStockConversionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="loc_us-gaapPreferredStockAmountOfPreferredDividendsInArrears" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockAmountOfPreferredDividendsInArrears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:label="loc_us-gaapPreferredStockPerShareAmountsOfPreferredDividendsInArrears" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ConvertiblePreferredStockConversionPricePerShare" xlink:label="loc_CYCCConvertiblePreferredStockConversionPricePerShare" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCConvertiblePreferredStockConversionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockClosingPriceThreshold" xlink:label="loc_CYCCCommonStockClosingPriceThreshold" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCCommonStockClosingPriceThreshold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="loc_CYCCPreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="loc_CYCCPreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationNumberOfTradingDays" xlink:label="loc_CYCCPreferredStockConversionObligationNumberOfTradingDays" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPreferredStockConversionObligationNumberOfTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:label="loc_CYCCPreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCPreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" xlink:label="loc_CYCCDirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CYCCDirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaapPreferredStockDividendsPerShareDeclared" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendsPerShareDeclared" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaapDebtInstrumentRedemptionPricePercentage" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionPricePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="999057 - Disclosure - Schedule of Stock Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails" xlink:title="999058 - Disclosure - Schedule of Share Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails" xlink:title="999059 - Disclosure - Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="999060 - Disclosure - Schedule of Restricted Stock Units Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_CYCCShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_CYCCShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensationDetailsNarrative" xlink:title="999061 - Disclosure - Stock Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_EquityIncentivePlan2018Member" xlink:label="loc_CYCCEquityIncentivePlan2018Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CYCCEquityIncentivePlan2018Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember" xlink:label="loc_CYCCInducementEquityIncentivePlanTwoThousandTwentyMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CYCCInducementEquityIncentivePlanTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember" xlink:label="loc_CYCCOptionsVestingOnThirdAnniversaryOfGrantMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_CYCCOptionsVestingOnThirdAnniversaryOfGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" xlink:label="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CYCCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="999062 - Disclosure - Employee Benefit Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaapRetirementPlanTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRetirementPlanTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaapRetirementPlanTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanTypeAxis" xlink:to="loc_us-gaapRetirementPlanTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_Plan401KMember" xlink:label="loc_CYCCPlan401KMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanTypeDomain" xlink:to="loc_CYCCPlan401KMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:label="loc_CYCCDefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_CYCCDefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:label="loc_CYCCDefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_CYCCDefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:label="loc_CYCCDefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_CYCCDefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails" xlink:title="999063 - Disclosure - Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails" xlink:title="999064 - Disclosure - Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails" xlink:title="999065 - Disclosure - Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xlink:label="loc_CYCCIncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CYCCIncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount" xlink:label="loc_CYCCEffectiveIncomeTaxRateReconciliationOtherItemsAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CYCCEffectiveIncomeTaxRateReconciliationOtherItemsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails" xlink:title="999066 - Disclosure - Schedule of Significant Components of the Entity&apos;s Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:label="loc_CYCCDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CYCCDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" xlink:label="loc_CYCCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CYCCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:label="loc_CYCCDeferredTaxAssetsLeaseRightOfUseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CYCCDeferredTaxAssetsLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DeferredTaxAssetsLeaseRightOfUseLiability" xlink:label="loc_CYCCDeferredTaxAssetsLeaseRightOfUseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CYCCDeferredTaxAssetsLeaseRightOfUseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/TaxesDetailsNarrative" xlink:title="999067 - Disclosure - Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaapOperatingLossCarryforwardsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:label="loc_CYCCPercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CYCCPercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999068 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="999069 - Disclosure - Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CYCCCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfGeographicInformationDetails" xlink:title="999070 - Disclosure - Schedule of Geographic Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="loc_countryGB" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryGB" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails" xlink:title="999071 - Disclosure - Schedule of Summary of Consolidated Net Loss (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SingleReportableSegmentMember" xlink:label="loc_CYCCSingleReportableSegmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CYCCSingleReportableSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:title="999072 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_SixPercentConvertibleExchangeablePreferredMember" xlink:label="loc_CYCCSixPercentConvertibleExchangeablePreferredMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CYCCSixPercentConvertibleExchangeablePreferredMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_CommonStockWarrantsMember" xlink:label="loc_CYCCCommonStockWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CYCCCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure" xlink:title="999073 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent" xlink:label="loc_CYCCPrepaymentsAndValueAddedTaxReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_CYCCPrepaymentsAndValueAddedTaxReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/RevenueDetailsNarrative" xlink:title="999074 - Disclosure - Revenue (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails" xlink:title="999075 - Disclosure - Schedule of Remaining Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureLeasesAbstract" xlink:label="loc_CYCCDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="loc_CYCCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureLeasesAbstract" xlink:to="loc_CYCCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/LeasesDetailsNarrative" xlink:title="999076 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DisclosureLeasesAbstract" xlink:label="loc_CYCCDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CYCCDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_DundeeScotlandMember" xlink:label="loc_CYCCDundeeScotlandMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCDundeeScotlandMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_KualaLumpurFacilityMember" xlink:label="loc_CYCCKualaLumpurFacilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CYCCKualaLumpurFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SubsequentEventsDetailsNarrative" xlink:title="999077 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cycc-20250331.xsd#CYCC_FittersDiversifiedBerhadMember" xlink:label="loc_CYCCFittersDiversifiedBerhadMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_CYCCFittersDiversifiedBerhadMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CYCLACEL
PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001130166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">93-2403210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Level
10, Tower 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Avenue 5, The Horizon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Bangsar
South City, No. 8, Jalan Kerinchi<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Kuala Lumpur<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">59200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">517-7330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Level
10, Tower 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Avenue 5, The Horizon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Bangsar
South City, No. 8, Jalan Kerinchi<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Kuala Lumpur<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">MY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">59200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">517-7330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Datuk
Dr. Doris Wong<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,450<span></span>
</td>
<td class="nump">$ 3,137<span></span>
</td>
<td class="nump">$ 3,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,714<span></span>
</td>
<td class="nump">3,674<span></span>
</td>
<td class="nump">7,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease asset</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Non-current deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,734<span></span>
</td>
<td class="nump">4,094<span></span>
</td>
<td class="nump">8,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">4,599<span></span>
</td>
<td class="nump">3,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">4,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">6,268<span></span>
</td>
<td class="nump">8,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">672<span></span>
</td>
<td class="nump">6,268<span></span>
</td>
<td class="nump">8,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 250,000,000 shares authorized at March 31, 2025 and 100,000,000 shares authorized at December&#160;31,&#160;2024; 863,902 shares issued and outstanding at March&#160;31,&#160;2025 and 36,913 shares issued and outstanding at December&#160;31,&#160;2024</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">443,521<span></span>
</td>
<td class="nump">438,211<span></span>
</td>
<td class="nump">429,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(891)<span></span>
</td>
<td class="num">(908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(440,461)<span></span>
</td>
<td class="num">(439,494)<span></span>
</td>
<td class="num">(428,282)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">3,062<span></span>
</td>
<td class="num">(2,174)<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">3,734<span></span>
</td>
<td class="nump">4,094<span></span>
</td>
<td class="nump">8,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CYCC_SixPercentConvertibleExchangeablePreferredStockMember', window );">6% Convertible Exchangeable Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CYCC_SixPercentConvertibleExchangeablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CYCC_SixPercentConvertibleExchangeablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">36,913<span></span>
</td>
<td class="nump">4,412<span></span>
</td>
<td class="nump">863,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CYCC_SixPercentConvertibleExchangeablePreferredStockMember', window );">6% Convertible Exchangeable Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">135,273<span></span>
</td>
<td class="nump">335,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">335,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock, Liquidation Preference, Value</a></td>
<td class="nump">$ 1,697,676<span></span>
</td>
<td class="nump">$ 4,006,512<span></span>
</td>
<td class="nump">$ 1,717,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CYCC_SixPercentConvertibleExchangeablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CYCC_SixPercentConvertibleExchangeablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">822,000<span></span>
</td>
<td class="nump">2,802,000<span></span>
</td>
<td class="nump">6,655,000<span></span>
</td>
<td class="nump">19,155,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,214,000<span></span>
</td>
<td class="nump">1,582,000<span></span>
</td>
<td class="nump">5,392,000<span></span>
</td>
<td class="nump">6,718,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,036,000<span></span>
</td>
<td class="nump">4,384,000<span></span>
</td>
<td class="nump">12,047,000<span></span>
</td>
<td class="nump">25,873,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,036,000)<span></span>
</td>
<td class="num">(4,355,000)<span></span>
</td>
<td class="num">(12,004,000)<span></span>
</td>
<td class="num">(25,453,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses)</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(54,000)<span></span>
</td>
<td class="num">(414,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="nump">4,947,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">4,955,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="num">(98,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(81,000)<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="num">(11,994,000)<span></span>
</td>
<td class="num">(25,551,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,354,000<span></span>
</td>
<td class="nump">782,000<span></span>
</td>
<td class="nump">2,996,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(81,000)<span></span>
</td>
<td class="num">(2,946,000)<span></span>
</td>
<td class="num">(11,212,000)<span></span>
</td>
<td class="num">(22,555,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on convertible exchangeable preferred shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(201,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common shareholders</a></td>
<td class="num">$ (81,000)<span></span>
</td>
<td class="num">$ (2,946,000)<span></span>
</td>
<td class="num">$ (11,212,000)<span></span>
</td>
<td class="num">$ (22,756,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (545.33)<span></span>
</td>
<td class="num">$ (502.46)<span></span>
</td>
<td class="num">$ (6,419.07)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=CYCC_ClinicalTrialSupplyMember', window );">Clinical Trial Supply [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=CYCC_ClinicalTrialSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=CYCC_ClinicalTrialSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81)<span></span>
</td>
<td class="num">$ (2,946)<span></span>
</td>
<td class="num">$ (11,212)<span></span>
</td>
<td class="num">$ (22,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="nump">3,272<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">2,916<span></span>
</td>
<td class="num">(12,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax', window );">Unrealized foreign exchange loss on intercompany loans</a></td>
<td class="num">(2,380)<span></span>
</td>
<td class="num">(2,130)<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
<td class="nump">12,550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="nump">$ 811<span></span>
</td>
<td class="num">$ (2,936)<span></span>
</td>
<td class="num">$ (11,195)<span></span>
</td>
<td class="num">$ (22,147)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income unrealized foreign exchange on intercompany loans net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 422,982<span></span>
</td>
<td class="num">$ (1,316)<span></span>
</td>
<td class="num">$ (405,727)<span></span>
</td>
<td class="nump">$ 15,939<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">573,282<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses', window );">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses', window );">Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct Offering, net of expenses, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series B Preferred stock conversions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series B Preferred stock conversions, shares</a></td>
<td class="num">(118,745)<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock', window );">Reclassification of redeemable common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,494<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ReclassificationOfRedeemableCommonStockShares', window );">Reclassification of redeemable common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,473<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Preferred stock dividends</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax', window );">Unrealized foreign exchange on intercompany loans</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,550<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,142)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22,555)<span></span>
</td>
<td class="num">(22,555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">429,797<span></span>
</td>
<td class="num">(908)<span></span>
</td>
<td class="num">(428,282)<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">454,537<span></span>
</td>
<td class="nump">4,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series B Preferred stock conversions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series B Preferred stock conversions, shares</a></td>
<td class="num">(119,000)<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax', window );">Unrealized foreign exchange on intercompany loans</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,130)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,946)<span></span>
</td>
<td class="num">(2,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances at Mar. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">429,920<span></span>
</td>
<td class="num">(898)<span></span>
</td>
<td class="num">(431,228)<span></span>
</td>
<td class="num">(2,206)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">335,537<span></span>
</td>
<td class="nump">5,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">429,797<span></span>
</td>
<td class="num">(908)<span></span>
</td>
<td class="num">(428,282)<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">454,537<span></span>
</td>
<td class="nump">4,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses', window );">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,209<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses', window );">Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct Offering, net of expenses, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series B Preferred stock conversions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series B Preferred stock conversions, shares</a></td>
<td class="num">(119,000)<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax', window );">Unrealized foreign exchange on intercompany loans</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,212)<span></span>
</td>
<td class="num">(11,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred', window );">Conversion of series 6% Convertible Exchangeable Preferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred', window );">Conversion of series 6% Convertible Exchangeable Preferred, shares</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrant Exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Warrant Exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,290,213<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">438,211<span></span>
</td>
<td class="num">(891)<span></span>
</td>
<td class="num">(439,494)<span></span>
</td>
<td class="num">(2,174)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">135,537<span></span>
</td>
<td class="nump">36,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,666<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax', window );">Unrealized foreign exchange on intercompany loans</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,380)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,290,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses', window );">Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(248)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issue of Series C preferred stock in Securities Purchase Agreement</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issue of Series C preferred stock in Securities Purchase Agreement, shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions', window );">Series C Preferred stock conversions</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions', window );">Series C Preferred stock conversions, shares</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="nump">11,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement', window );">Issue of Series D preferred stock in Securities Purchase Agreement</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,892<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement', window );">Issue of Series D preferred stock in Securities Purchase Agreement, shares</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions', window );">Series D Preferred stock conversions</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions', window );">Series D Preferred stock conversions, shares</a></td>
<td class="num">(1,745,262)<span></span>
</td>
<td class="nump">799,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne', window );">Issue of Series D preferred stock in Securities Purchase Agreement</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne', window );">Issue of Series D preferred stock in Securities Purchase Agreement, shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise', window );">Warrant Exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise', window );">Warrant Exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue of common stock on Securities Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of common stock on Securities Purchase Agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary', window );">Deconsolidation of Subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="num">(886)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueTranslationAdjustment', window );">Translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,385<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,385<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances at Mar. 31, 2025</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 443,521<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (440,461)<span></span>
</td>
<td class="nump">$ 3,062<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">1,490,275<span></span>
</td>
<td class="nump">863,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in carrying amount of redeemable common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of common stock preferred stock pre funded warrants and warrants on equity financing net of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of common stock preferred stock shares pre funded warrants and warrants on equity financing net of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income unrealized foreign exchange on intercompany loans net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ReclassificationOfRedeemableCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of redeemable common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ReclassificationOfRedeemableCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of convertible exchangeable preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issue of series d preferred stock in securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issue of series D preferred stock in securities purchase agreement one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issue on warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares series C preferred stock conversions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares series D preferred stock conversions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares upon conversion of pre funded warrants in offering issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of convertible exchangeable preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value deconsolidation of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issue of series d preferred stock in securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issue of series D preferred stock in securities purchase agreement one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issue on warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value series C preferred stock conversions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value series D preferred stock conversions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value upon conversion of pre funded warrants in offering issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81)<span></span>
</td>
<td class="num">$ (2,946)<span></span>
</td>
<td class="num">$ (11,212)<span></span>
</td>
<td class="num">$ (22,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Changes in lease liability</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">2,020<span></span>
</td>
<td class="nump">4,472<span></span>
</td>
<td class="nump">4,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable, accrued and other current liabilities</a></td>
<td class="num">(5,499)<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="num">(1,811)<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,247)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="num">(7,990)<span></span>
</td>
<td class="num">(16,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net</a></td>
<td class="nump">3,894<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,209<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs from issuing common stock and pre-funded warrants</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts', window );">Proceeds from the exercise of stock options and warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payment of preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used) in financing activities</a></td>
<td class="nump">3,646<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="nump">7,822<span></span>
</td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">313<span></span>
</td>
<td class="num">(580)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="num">(14,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">18,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">2,798<span></span>
</td>
<td class="nump">3,137<span></span>
</td>
<td class="nump">3,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash received during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Research &amp; development tax credits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,925<span></span>
</td>
<td class="nump">3,715<span></span>
</td>
<td class="nump">4,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNetAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_AccrualOfPreferredStockDividends', window );">Accrual of preferred stock dividends</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_AccrualOfPreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual of preferred stock dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_AccrualOfPreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options and warrant exercises net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax refund received from tax jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Overview<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Company Overview</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z4QVIQpJaImf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_825_z7y7QvXuEHO7">Company Overview</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company developing
innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis control biology. Cyclacel is a pioneer
company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology
into medicines that can overcome resistance and ultimately increase a patient&#8217;s overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2025, the Company&#8217;s wholly owned United Kingdom subsidiary Cyclacel Limited entered into a creditors voluntary liquidation.
Upon the commencement of the liquidation of the Cyclacel Limited, the Company lost operational and strategic control over the Cyclacel
Limited and the financial results of Cyclacel Limited have been deconsolidated from Company as of January 24, 2025. The deconsolidation
of the subsidiary resulted in a gain on deconsolidation of approximately $<span id="xdx_900_eus-gaap--DeconsolidationGainOrLossAmount_pn5n6_c20250124__20250124_zjpz5YHCYdUc">5.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million shown as other income within the income statement for
the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 31, 2025, substantially all efforts of the Company to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_znfds40WrRDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
Organization of the Company and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82C_z9TCUACedVif" style="display: none">Company
Overview</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
Pharmaceuticals, Inc. (&#8220;Cyclacel&#8221; or &#8220;the Company&#8221;) is a clinical-stage biopharmaceutical company developing
innovative cancer medicines based on cell cycle and mitosis control biology. Cyclacel is a pioneer company in the field of cancer cell
cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome
resistance and ultimately increase a patient&#8217;s overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, substantially all efforts of the Company to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited
to, the fact that drug candidates developed by the Company typically will require approvals or clearances from the U.S. Food and Drug
Administration, the European Medicines Agency or other similar regulatory agencies in other countries prior to commercial sales. There
can be no assurance that the Company&#8217;s drug candidates will receive any of the required approvals or clearances. If any of the
Company&#8217;s drug candidates are denied approval or clearance or such approval is delayed, or if the Company is unable to obtain the
necessary financing to complete development and approval, there will be a material adverse impact on the Company&#8217;s financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
December 31, 2024, the Company has funded all of its operations and capital expenditures with proceeds from the issuance of public equity
securities, private placements of securities, government grants, research and development tax credits, interest on investments, royalty
income, product revenue and licensing revenue. The Company has incurred recurring losses since its inception, including net losses of
$<span id="xdx_901_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_z7CYLlOgcdd8">11.2</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zk9yXx1P6kE">22.6</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company had an accumulated deficit of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zRTcx8aPX5F6">439.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company expects to continue to generate operating
losses for the foreseeable future due to, among other things, costs related to the clinical development of its drug candidate, its preclinical
programs and its administrative organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going
Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Accounting Standard Codification (ASC) 205-40, <i>Presentation of Financial Statements-Going Concern</i>, management
is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial
doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have
not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,
management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company&#8217;s
ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern for one year after the date that these financial statements are issued. In
performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40,
the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered
probable at this time because these plans are not entirely within the Company&#8217;s control nor have they been approved by the Board
of Directors as of the date of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s current operating plan, it is anticipated that cash and cash equivalents of $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zdm8vsc8Mgnc">3.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of December 31, 2024 will allow it to meet liquidity
requirements into the second quarter of 2025. The Company continues to work to raise additional capital, however, as of the date of these
financial statements there is no guarantee that the Company will be able to raise additional funds to extend operations beyond the second
quarter of 2025. The Company&#8217;s history of losses, negative cash flows from operations, liquid resources currently on hand, and
dependence on the ability to obtain additional financing to fund its operations, about which there can be no certainty, have resulted
in the assessment that there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at
least twelve months from the issuance date of these financial statements. While the Company has plans in place to mitigate this risk,
which primarily consist of raising additional capital through a combination of public or private equity or debt financings or by entering
into partnership agreements for further development of our drug candidates, there is no guarantee that it will be successful in these
mitigation efforts. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates
realization of assets and the satisfaction of liabilities in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America, or GAAP and include the financial statements of Cyclacel Pharmaceuticals, Inc. and all of the Company&#8217;s
wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20231218__20231218_zE0NtuWg5gx">15:1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse stock split of the Company&#8217;s common stock on
December 18, 2023 (the &#8220;Reverse Stock Split&#8221;). All share and per share information has been adjusted to give effect to the
Reverse Stock Split for all periods presented, unless otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company held a special meeting of stockholders (the &#8220;Special Meeting&#8221;) on February 6, 2025 at which, among other matters,
the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to effect
a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20250206__20250206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5x4FQ6t8Hd1">reverse
stock split at a ratio not less than 1:4 and not more than 1:16</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&#8220;2025 Reverse Stock Split&#8221;) such ratio and the implementation and timing of such Reverse Stock Split to be determined in
the discretion of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). The 2025 Reverse Stock Split is expected to be implemented
by the Board in or around May 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd7x1WMim2fg">All references to issued and outstanding shares
all periods reflect: the 1-for-16 reverse stock split effective May 12, 2025, and the 1-for-15 reverse stock split effective July 7,
2025. As a result, all share numbers for all periods, including the number of shares underlying warrants, options, and other convertible
securities, and all exercise prices applicable to such warrants, options and convertible securities have been adjusted retrospectively
to give effect to the 1-for-16 and 1-for-15 reverse stock splits</span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zJwWmGnpsfP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_828_zTZG0jPxPjta">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z5SC1TKoNBg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86B_zkCZdtJqw1A2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated balance sheet as of March 31, 2025, the consolidated statements of operations, comprehensive loss, and stockholders&#8217;
equity (deficit) for the three months ended March 31, 2025 and 2024 and the consolidated statements of cash flows for the three months
ended March 31, 2025 and 2024, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance
sheet as of December 31, 2024 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K
for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 2, 2025.
The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States
(&#8220;GAAP&#8221;) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they
do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete
set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary
to present fairly the consolidated balance sheet as of March 31, 2025, and the results of operations, comprehensive loss, and changes
in stockholders&#8217; equity (deficit) for the three months ended March 31, 2025, and cash flows for the three months ended March 31,
2025, have been made. The interim results for three months ended March 31, 2025 are not necessarily indicative of the results to be expected
for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2024 that are included
in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on April 2, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_z3jJ9Fw35e6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_860_zXCLHemlLPI" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Accounting Standard Codification (ASC) 205-40, <i>Presentation of Financial Statements-Going Concern</i>, management
is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial
doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have
not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,
management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company&#8217;s
ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern for one year after the date that these financial statements are issued. In
performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40,
the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered
probable at this time because these plans are not entirely within the Company&#8217;s control nor have they been approved by the Board
of Directors as of the date of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s current operating plan, it is anticipated that cash and cash equivalents of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zymioRMWspyf">3.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of March 31, 2025, will allow it to meet its liquidity
requirements into the second quarter of 2025. The Company&#8217;s history of losses, negative cash flows from operations, liquidity resources
currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources
are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company&#8217;s
ability to <span id="xdx_90F_eus-gaap--SubstantialDoubtAboutGoingConcernWithinOneYear_pn5n6_dbTp_c20250101__20250331_zOlc6k16dxaj">continue</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a going concern for a period of at least twelve months from
the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist
of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will
be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations,
delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, Nasdaq notified the Company that it has regained compliance with the equity requirement in Listing Rule 5550(b)(1)
(the &#8220;Equity Rule&#8221;), as required by the Nasdaq Hearing Panel&#8217;s decision dated October 22, 2024. Following the Company&#8217;s
regaining compliance with the Equity Rule, the Company will be subject to a Mandatory Panel Monitor for a period of one year from February
25, 2025 pursuant to Listing Rule 5815(d)(4)(B).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets
and the satisfaction of liabilities in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9NhsWiwFzV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86F_zNiNRgXykyMj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Newly
Adopted Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2025, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740): Improvements
to Income Tax Disclosures&#8221;. This standard requires all entities to include specified captions when reconciling the statutory income
tax rate to the effective tax rate, on both a percentage and absolute dollar basis, in the annual financial statements. ASU 2023-09 also
requires entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and
foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts
from, exceed a defined threshold. The company does not anticipate the adoption of ASU 2023-09 will require significant adjustments to
the presentation of that information in the Company&#8217;s annual financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zxj2fc1u1Yq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_867_z8XQNyu0LXFb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2024-03, &#8220;<i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKMAUBis1ymd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86B_zSjmyuNmHdNa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts
payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zbBtUWjxgeO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86A_zKuGX21dU0w7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
Income (Loss)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). <span id="xdx_90E_eus-gaap--OtherComprehensiveIncomeLossTax_do_c20250101__20250331_zKmQocSIJAh8">No</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">taxes were recorded on items of other comprehensive income
(loss). There were <span id="xdx_90F_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20250101__20250331_zmEZIzVWNKMf">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reclassifications out of other comprehensive income (loss)
during the three months ended March 31, 2024. However, upon deconsolidation of the Company&#8217;s formerly wholly-owned subsidiary on
January 24, 2025, $<span id="xdx_901_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_pn5n6_do_c20250124_zKO3BurNZ4G5">0.9</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of accumulated comprehensive income (loss) was reclassified
into earnings as part of the gain on deconsolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z9r0BdZUBTpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86D_ztLasLFOULI3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency and Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied
to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
January 24, 2025, the assets and liabilities of the Company&#8217;s international subsidiary were translated from its functional currency
into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used
to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation
adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign
exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable
future and that are of a long-term-investment nature, were recorded in other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zvYatxd84zDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_860_zSNBLpn78rl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease contracts in accordance with ASC 842. As of March 31, 2025, the Company&#8217;s outstanding leases are classified
as operating leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#8217;s obligation to make lease payments under the lease. As the Company&#8217;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing
versus bullet), and the Company&#8217;s credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect
the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In
assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease payments due in any optional period;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
    for failure to exercise (or not exercise) the option;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    factors, such as the availability of similar assets and current rental rates for such assets;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature of the underlying leased asset and its importance to the Company&#8217;s operations; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    remaining useful lives of any related leasehold improvements.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized
in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded
as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and
the right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z0Y03lbdDMUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_864_znXMbcaOvK78" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company enters into contracts with customers, the Company recognizes revenue using the five step-model provided in ASC 606, <i>Revenue
from Contracts with Customers </i>(&#8220;ASC 606&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract with a customer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when, or as, the Company satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines
the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then
applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the
Company considers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    achievement of a development milestone is highly susceptible to factors outside the entity&#8217;s influence, such as milestones
    involving the judgment or actions of third parties, including regulatory bodies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    the Company can reasonably predict that a milestone will be achieved based on previous experience; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    complexity and inherent uncertainty underlying the achievement of the milestone.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The
best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions,
entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment
due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part
satisfied) performance obligations. Once the right to receive consideration is unconditional, that amount is presented as a receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
revenue received from organizations that are not the Company&#8217;s customers, such as charitable foundations or government agencies,
is presented as a reduction against the related research and development expenses.</span></p>

<p id="xdx_851_zISaSAnOQu58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zkPOm8snEPCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_824_zBrTlNiBQtY1">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zf22ZbzN9hBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_860_zORo9d23eFii" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and
the reported expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals and stock-based
compensation expense. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various
other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates.
Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the
Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zTsyEQTmcUjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zzBt6yywtCb9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency and Currency Translation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities of the Company&#8217;s international subsidiary are translated from its functional currency into United States
dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the
statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising
on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses
arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable future and that
are of a long-term-investment nature, are recorded in other comprehensive loss. As discussed in the subsequent events note, the foreign
subsidiary will be liquidated. Upon loss of control of the foreign subsidiary, the accumulated translation adjustments currently recorded
in other comprehensive income within equity will be reversed and recorded as part of the gain/loss from deconsolidation of the subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhPazvbBRD2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_868_zg5mNVQtEq1k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and Cash Equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds, to maintain sufficient
liquidity to meet Cyclacel&#8217;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial
institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is
exposed to any significant credit risk on cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash and cash equivalents balance at December 31, 2024 was $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z8mXOaPoUwya">3.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and it maintains its cash accounts in several entities
both within the United States and the United Kingdom. The cash balances for amounts held in the United States are insured by the Federal
Deposit Insurance Corporation, or FDIC up to $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20241231__srt--RangeAxis__srt--MaximumMember_ztFkYdx0KeVa">250,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per account. The Company has cash balances exceeding the balance
insured by the FDIC that totaled approximately $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zRYaqA6cTC64">2.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million at December 31, 2024. The cash balances for amounts
held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme, or FSCS up to &#163;<span id="xdx_907_ecustom--CashFinancialServicesCompensationSchemeInsuredAmount_iI_uGBP_c20241231__srt--RangeAxis__srt--MaximumMember_z8induwTekb5">85,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per account. The Company does not have cash balances exceeding
the balance insured by the FSCS at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8XV9i7HEWC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zJXr7MejXSGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and Equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of
the related assets, which are generally three <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zKERt8IxurR8" style="display: none">3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zS7NMRj7zts8">five
years</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Amortization of leasehold
improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life
of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are
removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss.
Expenditures for maintenance and repairs are charged to operating expenses as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zSYMxV5D0yt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zqSOuNl91Gt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets
by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment,
if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrUHKJjdqFV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86B_zqNibifhTxSh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy,
of which the first two are considered observable and the last is considered unobservable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1&#8201;&#8212;&#8201;Quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2&#8201;&#8212;&#8201;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that
are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3&#8201;&#8212;&#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining
the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values
due to the short-term nature of these assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZSdFDq0EjRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_z0RohBEsyXM9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is managed and operated as <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zTSW8xTZfz6a">one</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business which is focused on using cell cycle, transcriptional
regulation and mitosis control biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire
business is managed by a single management team that reports to the Chief Executive Officer. Historically, the Company has not operated
separate lines of business with respect to any of its products or product candidates and the Company did not prepare discrete financial
information with respect to separate products or product candidates or by location through December 31, 2024. Accordingly, the Company
has viewed its business historically as <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zWLd0JQd0Sx3">one</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reportable operating segment with development operations in
<span id="xdx_909_eus-gaap--NumberOfCountriesInWhichEntityOperates_iI_dc_uInteger_c20241231_zEdDnnew2oul">two</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">geographic
areas, namely the United States and the United Kingdom. With the commencement of the liquidation of the Subsidiary, the Company will
no longer be considered to have control over the Subsidiary and the financial results of the Subsidiary will be deconsolidated from those
of the Company commencing with its first quarter 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zyfbuT5pdDSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zr7bBrD150F5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, <i>Revenue from Contracts with Customers</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not generated any revenues from product sales to date. However, the Company recognized $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zdRogL4upoDl">43,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenue for the year ended December 31, 2024. This revenue
relates to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center
(&#8220;CSMC&#8221;). There was $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230101__20231231_zJpEFhhMydod">420,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenues recognized for the comparative period in 2023.
All revenues from this customer are recognized at the point in time that the related clinical supply are transferred to CSMC and CSMC
obtains control over the goods. The arrangements with CSMC comprise a single performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not recognized any other sources of revenue during the years ended December 31 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invoices CSMC following the transfer of the clinical supply and provides CSMC with typical payment terms. The Company has collected
all amounts due from CSMC. As of December 31, 2024, December 31, 2023, and January, 1, 2023, the Company has not recognized any accounts
receivable from CSMC, credit loss allowances, contract assets, contract liabilities, or warranty provisions. There were <span id="xdx_905_eus-gaap--RevenueRemainingPerformanceObligation_iI_do_c20241231_zyystFxOLx5">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining performance obligations outstanding as of December
31, 2024; however, CSMC may place additional orders for clinical supply in 2025 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84D_ecustom--OtherIncomePolicyTextBlock_z48CGyEtEVP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_864_zpPxy3yffl8d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part
of the Company&#8217;s ongoing operations and activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIW8polrH7g2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_869_zhV5KtObiUm7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs associated with the development of the Company&#8217;s product candidates, including
upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials,
costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development
are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84F_ecustom--ClinicalTrialAccountingPolicyTextBlock_zz39pDabBkt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86D_zboMqvkHKNq2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial Accounting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
management and monitoring of the Company&#8217;s clinical trials are performed with the assistance of contract research organizations,
or CROs or clinical research associates, or CRAs in accordance with the Company&#8217;s standard operating procedures. Typically, CROs
and CRAs bill monthly for services performed, and others bill based upon milestones achieved. The Company accrues unbilled clinical trial
expenses based on estimates of the level of services performed each period. Clinical trial costs related to patient enrollment are accrued
as patients are entered into and progress through the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zghWh5wi7XVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_861_zGXaAhljvi39" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zaElcefeAcl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zBP3UW2DZHD" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease contracts in accordance with ASC 842. As of December 31, 2024 and 2023, all of the Company&#8217;s leases
are classified as operating leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#8217;s obligation to make lease payments under the lease. As the Company&#8217;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how a loan would be repaid (e.g.,
amortizing versus bullet), and the Company&#8217;s credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of
exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether
it is reasonably certain that the Company will exercise an option, the Company considers factors such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease payments due in any optional period;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
    for failure to exercise (or not exercise) the option;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    factors, such as the availability of similar assets and current rental rates for such assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature of the underlying leased asset and its importance to the Company&#8217;s operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    remaining useful lives of any related leasehold improvements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term and is reported as a component
of general and administrative expense. Variable lease payments, if any, are recognized in the period when the obligation to make those
payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed
lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw7hrtGvrsh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86C_zqnZce9J5QU" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date
of the grant and recognizes compensation expense of those awards over the requisite service period, which for the Company is the period
between the grant date and the date the award vests or becomes exercisable. Many awards granted by the Company vest ratably over three<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z2zvqtVyXwXj" style="display: none">3</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zJTSjJa78iD3">four
years</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. However, certain awards granted to members
of the Company&#8217;s Board of Directors vest in their entirety on the one<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_z8fUbfdTSME4" style="display: none">1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only
service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain years,
the Company will grant share-based payment awards to employees that are dependent upon the fulfillment of certain clinical and financial
conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes compensation
expense when the award is probable of vesting (See Note 12&#8201;&#8212;&#8201;Stock-Based Compensation).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expenses in its statement of operations in the same manner in which the award recipient&#8217;s
payroll costs are classified. The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of restricted stock and restricted stock units is determined based on the number of shares granted and the quoted price of
the Company&#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated
using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#8217;s share price, expected
term of the award, interest rates, and dividend yields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on its historical volatility as an input to the option pricing model as management believes that this rate will be representative
of future volatility over the expected term of the options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average risk-free interest rate represents the interest rate for treasury constant maturities published by the Federal Reserve
Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel
interpolates a discount rate based on the two Federal Reserve securities closest to the expected term of the employee option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected dividend yield is zero, as the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends
on common stock in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z54Xjh3qPW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86C_zqR9Wghh5rvd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based
on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year
in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred
tax assets to the amounts expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the
amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained
upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not-to be sustained, the tax position
is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized
is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes
includes the effects of any resulting tax reserves for unrecognized tax benefits that are considered appropriate as well as the related
net interest and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records research and development tax credits within income taxes. Credit is taken in the accounting period for research and development
tax credits, when claimed from H.M. Revenue &amp; Customs, or HMRC, the United Kingdom&#8217;s taxation and customs authority, in respect
of qualifying research and development costs incurred in the same accounting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zg7mEvChTDKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zfnnR38qNFEf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss Per Common Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221;. Basic and diluted net loss
per common share was determined by dividing the net loss applicable to common stockholders by the weighted average number of common shares
outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common
stockholders is the same as basic net loss per share attributable to common stockholders since potentially dilutive common shares are
not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders
for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z1D5SLfGoCwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86F_zHxZvlU9nSie" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Comprehensive
Income (Loss)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported to arrive at comprehensive income (loss). There were <span id="xdx_905_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20230101__20231231_zgku0Qy7OIg9">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reclassifications out of other comprehensive income (loss)
during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_z4CYFimM2Iy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_866_zzVz1m4j8wpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2024-03, &#8220;<i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;. This standard will require
all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage
and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received)
disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions
for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods
beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation
of that information.</span></p>

<p id="xdx_85E_zSxsf6fBNRa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosureSignificantContractsAbstract', window );"><strong>Significant Contracts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_SignificantContractsDisclosureTextBlock', window );">Significant Contracts</a></td>
<td class="text"><p id="xdx_80B_ecustom--SignificantContractsDisclosureTextBlock_zG5SVzWD8z2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82A_zrJx7x7nmhb8">Significant Contracts</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution,
Licensing and Research Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into licensing and similar agreements with academic and research organizations. Under the terms of these agreements,
the Company has received licenses to technology and patent applications. The Company may be required to pay royalties on future sales
of products employing the technology or falling under claims of patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
a 2003 license agreement, the Company licensed certain patent rights for sapacitabine. The Company will not be pursuing further development
of sapacitabine and the license agreement was terminated effective as of March 23, 2023 for commercial reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three<span id="xdx_902_ecustom--TermOfAgreement_dtY_c20210901__20210930__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zJN1Y8Vra9Z6" style="display: none">3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
term of the Clinical Collaboration Agreement, or CCA with The University of Texas MD Anderson Cancer Center, or MD Anderson ended in
September 2021, in accordance with its terms. The main objective of the CCA was to clinically evaluate the safety and efficacy of three
Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic
syndromes and other advanced leukemias. Under the terms of the CCA, MD Anderson conducted <span id="xdx_907_ecustom--ConductClinicalStudies_dc_uInteger_c20210901__20210930__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zX8BqBaVQNI5">four</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical studies and under the risk-sharing agreement MD Anderson
assumed the patient costs for all studies and Cyclacel, who is the sponsor, provided investigational drugs and other limited support.
The agreement provided that the Company would make certain payments to MD Anderson upon first commercial sale in specific indications
studied in the alliance. There were <span id="xdx_909_ecustom--LicenseAgreementPaymentEarned_iI_do_c20231231__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zXvQVl3uVxs4">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such payments earned in 2024 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosureSignificantContractsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosureSignificantContractsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_SignificantContractsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Contracts Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_SignificantContractsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_808_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zYZBZ7Fszs8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82B_zbwIypBARO7e">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zKGCPiHTH0vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash and cash equivalents at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zSET5jeIuAFb" style="display: none">Summary
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zCrSHJ6cUOUa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z3X01H23zeu9" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Cash_iI_pn3n3_maCACEAzyS5_zOQ4QyfcCAj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">93</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,303</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_maCACEAzyS5_ztNzonajCXL9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtCACEAzyS5_ztcDYgnqRxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,378</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zlpBK3rZKgqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents are made up entirely of money market funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zeQ0gULVRKzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_825_zPqp0YORJTqh">Fair Value of Financial Assets and Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zQMBDnQxiAIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zfWV7hPOTay2" style="display: none">Schedule
of Financial Assets and Liabilities Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwX5DJUCfoAc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    1</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgjTt48bL3B6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    2</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zfavjkQ0qZS8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    3</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z03y08eOqvN3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">Fair Value Measurements</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">as of December 31, 2024 Using:</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 1</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 2</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 3</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zoNhzn6SrTel" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,044</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,044</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zI3MZ1GRH2td" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,044</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVw0fayAHRdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zljm8svDHA5a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxVo90jidCB1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCFgvYNLB1Nd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">as of December 31, 2023 Using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zz6uWUGiipWl" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zs7yLDFJFqs1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AB_z4BNglRLtnA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_80A_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_za2ce6ncCEFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_820_zeGrSPn69j39">Prepaid Expenses and Other Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_898_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zaAfOm0GuBpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zrrHepcxb5El" style="display: none">Schedule
of Prepaid Expenses and Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250331_zfFI1ZvlaPic" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20241231_zETxqZSOI6q3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPECzxNf_zZhhBXB2luka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Prepayments</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">237</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPECzxNf_zhNtmZdVkIt9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">194</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseCurrent_iTI_pn3n3_mtPECzxNf_zon8974OLUTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">264</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">537</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AD_z9IxNttGV2P8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zJiNGqNYU9Ca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
Prepaid Expenses and Other Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_829_zPuB703Js7B" style="display: none">Prepaid
Expenses and Other Current Assets</span></span></p>

<p id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zQgaOlf1dqf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of prepaid expenses and other current assets at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B3_zoCIaaOCdeBb" style="display: none">Schedule
of prepaid expenses and other current assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_z7lf3DnBHndi" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zKUsKElCmOml" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxesAndOtherTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zNaZJS6qlveb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development tax credit receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,933</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zfR5pVGM24T6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepayments and VAT receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">792</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQOL_zcBXTXszRPd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">341</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQOL_z5PJ3bmEwOj2" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other assets</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,066</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zulAoQBuRbql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosureNoncurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_NonCurrentAssetsTextBlock', window );">Non-Current Assets</a></td>
<td class="text"><p id="xdx_80A_ecustom--NonCurrentAssetsTextBlock_z5UduPuSn50f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_828_zNbPBkrz68y9">Non-Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_907_eus-gaap--DepositsAssetsNoncurrent_iI_dxL_c20250331_zzx61uyaNAXh" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1882">0</span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-current
assets as of March 31, 2025 and $<span id="xdx_908_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20241231_zZBshIPL6pF6">0.4</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of December 31, 2024. The balance at December 31,
2024 primarily comprised of deposits held by a contract research organization in relation to the Company&#8217;s clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_805_ecustom--NonCurrentAssetsTextBlock_zeJZXRYmhcki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_825_zKmxr92m22H">Non-Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at December 31, 2024, the Company had non-current assets of $<span id="xdx_90A_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20241231_zm2zxTjof2Z6">0.4</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which comprised clinical trial deposits held by a
contract research organization in relation to the Company&#8217;s Phase 1/2 clinical trials. As at December 31, 2023, the Company had
non-current assets of $<span id="xdx_901_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20231231_zblFozQVrCq">1.3</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million,
which was wholly attributable to clinical trial deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosureNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosureNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_NonCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Current Assets [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_NonCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRAliyO6pFj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_82F_zUSzh6bAoghk">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5FwiODQbG4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zA2wcsohQTJ3" style="display: none">Schedule
of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_zwww3daVkxr1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zApi9l4rFhx3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><b>Lives in</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zDPi9ChoS2B7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Leasehold improvements</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVSyesfIk2Xj">2</span>
    to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z60zWO360104">5</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zP0tiNECtJP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment and furniture</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zwbT4afEWMY2">3</span>
    to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_ztazAMISFTch">5</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">423</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_maPPAENzWpG_zblZiY2R2G18" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">429</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzWpG_zWafk7wLbO2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: accumulated depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(424</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzWpG_zSnlF9zZX9a9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zL4k8x7IAF6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and Other Liabilities</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zvOj8T2jVOqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82F_znSHTrXHVLJl">Accrued and Other Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_ztbudYMeSXQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
and other current liabilities consisted of the following (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zi8hNVrt2Rpc" style="display: none">Schedule
of Accrued and Other Current Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250331_zZRyuple1Nz1" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_z6ahcDahe2xj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCostCurrent_iI_pn3n3_zLff99MwH0ji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1889">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,300</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_zBMIXPiwxp6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued legal and professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">532</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_zP40xWtPhJ6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other current liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">284</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_zl7SdYb7Ozl6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued and other current
    liabilities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">549</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,671</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_zqtmuHxKFHN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80F_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zHc4nHN70Xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
Accrued and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_822_zzyIFd8uN2gb" style="display: none">Accrued
and Other Liabilities</span></span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaF3qBcqwcx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
and other current liabilities consisted of the following at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zbG35D6tYoFb" style="display: none">Schedule
of Accrued and Other Current Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zaNSbn7pGCEe" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zWyxteIAyah1" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_pn3n3_maALCzjWX_zxdCwQ5F9Xhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,299</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,668</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzjWX_zYEd45USEZVb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">570</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--OtherCurrentLiabilities_iI_pn3n3_maALCzjWX_zNaqeuRnK0Oj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">380</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzjWX_zdKU4QmktAa4" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,669</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,618</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zkwCvpwKGGCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at December 31, 2024, the Company had accounts payables of $<span id="xdx_902_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20241231_z0nvYC2wo6Ba">4.6</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, of which $<span id="xdx_90C_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--UnitedKingdomSubsidiaryCompanyMember_zdj93MkE06j5">4.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million related to the UK subsidiary. As at December 31, 2023,
the Company had accounts payables of $<span id="xdx_901_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20231231_zQFCi6UqWH2b">3.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, of which $<span id="xdx_909_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--UnitedKingdomSubsidiaryCompanyMember_zONXGAeXRTO">3.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million related to the UK subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAEWNduzmAte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_821_zNIoIndDsXm1">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to <i>Note 3&#8201;&#8212;&#8201;Significant Contracts</i> for further discussion of certain of the Company&#8217;s commitments
and contingencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, the Company extended the lease for its corporate headquarters facility in Berkeley Heights, New Jersey for a further <span id="xdx_90A_ecustom--LesseeOperatingLeaseTermOfContractExtension_dc_c20220401__20220430__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_z9dGR3SGzIS8">three
years</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, expiring in July 2025. In December 2024,
the Company terminated this lease, effective as of January 31, 2025. Effective March 1, 2025, the Company entered into a <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20241231__srt--StatementGeographicalAxis__custom--CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_zxR258m07qDb">two
year</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lease agreement for our corporate headquarters
at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia, which we believe will be adequate to accommodate
our business needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and December 31, 2023, the Company recognized operating lease expenses of $<span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zmXNvBr5nk46">82,830</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zeMeGg0KHhKi">74,218</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively, including $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zbWfZnQMwJb6">9,104</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20230101__20231231__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zs9wSo2B9ce4">10,851</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively relating to a short term lease for offices in
Dundee, Scotland. The remaining lease term as of December 31, 2024 is <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dc_c20241231__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_zzfOXMvQYFUl">one
month</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the Berkeley Heights facility and no
remaining lease term for Dundee, Scotland. The discount rate used by the Company in determining the lease liability was <span id="xdx_901_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20241231__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_zzSwAo6pIW29">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z440AH7tNQMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s future contractual obligations and commitments relating to its facilities lease as at December
31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BC_zB11ngH9qKE2" style="display: none">Schedule
of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zrvqNs2ZDnBg" style="text-align: center; font-weight: bold">Operating Lease</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Obligation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zYSfO3aFolH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zwF0630Vo0yb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_zFHUvGgprMR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0708">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zXdwuRZhI9kd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z3kbC3utV7Md" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z148Y2pkKCnc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zMqrRRcp51j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs4GUMLb48n9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82F_zBtRPV7o9WC9">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Common
Stock Equity Offerings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Securities Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2024, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor (the &#8220;Purchaser&#8221;) for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of (i)
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_zmVqw0jjT8y3">604</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock, (ii) pre-funded
warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zuymfjDHeJk1">20,100</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Pre-Funded Warrants&#8221;),
(iii) series A warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zxgh8A3yNQFg">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series A Warrants&#8221;),
and (iv) series B warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z4wlJtWOymT8">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series B Warrants&#8221;
and together with the Series A Warrants, the &#8220;Common Warrants&#8221;). The purchase price of each share of common stock and associated
Common Warrants was $386.40 and the purchase price of each Pre-Funded Warrant and associated Common Warrants was $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsAndCommonWarrantsMember_zni0dunyKQna">386.376</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants are exercisable immediately upon issuance at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zFt1UcVulfog">326.40</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Series A Warrants will expire five and one-half
years<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zeyPH0DhQ0uj" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance and the Series B Warrants will expire
<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_z3Y1WYKLO0k1">eighteen
months</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance. The Pre-Funded
Warrants are exercisable immediately upon issuance at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zgo6sIDf7gT8">0.024</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and may be exercised at any time until the Pre-Funded
Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its affiliates) may not exercise any
portion of such warrants to the extent that the holder would own more than <span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zp7eFIdS9X19">4.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
(or, at the election of the holder <span id="xdx_907_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zhBWHyy6vAGb">9.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)
of the Company&#8217;s outstanding common stock immediately after exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Private Placement, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
dated as of April 30, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) registering the resale of the securities issued in the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Placement closed on May 2, 2024. The gross proceeds to the Company from the Private Placement were approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240502__20240502_zfXWsPjyzQxg">8.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, before deducting placement agent fees and estimated
offering expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the Company&#8217;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of April 29, 2024, between the Company and Wainwright (as amended, the
&#8220;Engagement Letter&#8221;). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to <span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20240429_zBrA9gHcwGs">7.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds of the Private Placement and (ii) a management fee of <span id="xdx_90E_ecustom--ManagementFeePercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240429_zByJDqWP4oP5">1.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued
to Wainwright or its designees warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zmhBLE2axGt8">1,242</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price equal to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zKb8wEowljf">124.512</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Placement Agent Warrants are exercisable immediately
upon issuance and have a term of exercise equal to five and a half years<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zuD3aEBuYzLa" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company was required to compensate Roth Capital Partners, LLC, pursuant to a tail provision contained
in an engagement letter entered into on March 14, 2024, in an amount equal to <span id="xdx_902_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240314__srt--CounterpartyNameAxis__custom--RothCapitalPartnersLlcMember_z5vZ5JiKyDN9">7.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate proceeds of the Private Placement plus the reimbursement of certain expenses. The Company was also required to compensate
Ladenburg Thalmann &amp; Co. Inc, pursuant to a tail provision contained in an engagement letter entered into on October 30, 2023, in
an amount equal to <span id="xdx_907_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20231030__srt--CounterpartyNameAxis__custom--LadenburgThalmannCo.IncMember_zPS9NG1TTRLf">8.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate proceeds of the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the instruments issued in the Private Placement have been classified and recorded as part of shareholders&#8217; equity (deficit).
The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective
instruments as follows:</span></p>

<p id="xdx_897_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_zA78XcnVP3d9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zoHcCeHWglHg" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250101__20250331_zGjcrW70H7G8" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Allocated
    Amount</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuojg1Le9Ry5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%"><span style="font-family: Times New Roman, Times, Serif">Common shares</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72,108</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSSPmw9N1rvj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prefunded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,398,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYpsat2GSfXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,819,274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zs3KLuTxpE01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,290,213</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AD_zyL72AZbeih7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fair value of the Placement Agent Warrants was $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zO9gzZVzzPmj" title="Warrants exercise price">609,179</span>. These have been accounted for as a direct cost of the Private Placement,
resulting in no net effect to overall shareholders&#8217; equity (deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zTUa68Prla6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zxPcTvzLnbz2" style="display: none">Schedule of Fair value of Warrants Valuation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded
    Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Placement
    Agent Warrants</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKuoTFVcMyZ1" title="Warrants and rights outstanding">100</span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zDnR00CKxMGj" title="Warrants and rights outstanding">103</span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zzNklfHgkJNh" title="Warrants and rights outstanding">121</span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0huGRbp6ax3" title="Warrants and rights outstanding">103</span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0cu2bRSDefd" title="Warrants and rights outstanding">1</span> year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 7pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zENaCO5e8ZGh" title="Contractual term">1.5</span> </span><span style="font-family: Times New Roman, Times, Serif">1&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">- 5&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">years <span style="display: none; font-size: 7pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zO0bmRuNgBzl" title="Contractual term">5.5</span></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">5&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">years <span style="display: none; font-size: 7pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPcIKiW6chD8">5.5</span></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztL9uwwXw2Z9" title="Warrants and rights outstanding">5.51</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z6AfpudEkteh" title="Warrants and rights outstanding">4.57</span>% - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zWqD4S4fITBk" title="Warrants and rights outstanding">5.51</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zF6xSJIXdgW8" title="Warrants and rights outstanding">4.57</span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxxy4WOQ6Ip" title="Warrants and rights outstanding">0</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zb3qu8Q9Wg4e" title="Warrants and rights outstanding">0</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcVi1mljH135" title="Warrants and rights outstanding">0</span>%</span></td></tr>
  </table>

<p id="xdx_8A5_zIYAZP4KnbVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the common shares was determined using the closing price of the Company&#8217;s common stock as of May 2, 2024, which is
the date that the Private Placement closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2023 Registered Direct Offering Securities Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with
certain institutional investors (&#8220;Purchasers&#8221;). Pursuant to the Securities Purchase Agreement, the Company agreed to
sell in a registered direct offering (&#8220;Registered Direct Offering&#8221;) <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z7KSS8HvQImj">702</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
(&#8220;Shares&#8221;) of the Company&#8217;s common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXgX3pF9BFr5">0.001</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par
value per share (&#8220;Common Stock&#8221;), and pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z9GBVwRk7evk">915</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock. The Pre-Funded Warrants have an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zmbSw9wXVz5a">0.24 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share and can be exercised at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each
Share is being sold at an offering price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI7XvSgnZLP9">795.60</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
each Pre-Funded Warrant is being sold at an offering price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zPmArmRugOCe">795.36</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(equal
to the purchase price per Share minus the exercise price of the Pre-Funded Warrant). The Pre-Funded Warrants have been included in
the calculation of basic and diluted loss per share for all periods outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the &#8220;Offerings&#8221;),
the Company also agreed to issue to the Purchasers unregistered warrants (&#8220;Common Warrants&#8221;) to purchase up to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zcGGNLguUNC7">1,617</span>
shares of Common Stock. Each Common Warrant has an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zj0bFuWECwe3">765.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, is exercisable immediately following their original
issuance and will expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zlPI0n1FE893">seven
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the original issuance date. The closing
of the offering occurred on December 26, 2023, and the net proceeds to the Company were approximately $<span id="xdx_907_ecustom--AggregateProceedsFromSaleOfStock_iI_pn5n6_c20231226__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zbokclLNzJ2g">1.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and other offering
expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, in a separate concurrent insider private placement (the &#8220;Insider Private Placement&#8221;), the Company also
entered into a Securities Purchase Agreement with certain of its executive officers (the &#8220;Insider Securities Purchase Agreement&#8221;)
pursuant to which the Company agreed to sell in a private placement (i) <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJ5yYlv0H2Ec">25</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock and warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zFknP8RvmKu">25</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Spiro Rombotis, the Company&#8217;s Chief Executive Officer, and (ii) <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember_zrbeLsRQlMMe">8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock and warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zhPBpDu4Boik">8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Paul McBarron, the Company&#8217;s Executive Vice President-Finance, Chief Financial Officer
and Chief Operating Officer. Each such share of Common Stock and accompanying warrant was sold at a purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zafyPJ2aQeXa">795.60</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was the same purchase price for the Shares sold in the Registered Direct Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg
Thalmann &amp; Co. Inc. (the &#8220;Placement Agent&#8221;) acted as the exclusive placement agent for the Offerings, pursuant to a placement
agency agreement (the &#8220;Placement Agency Agreement&#8221;), dated December 21, 2023, by and between the Company and the Placement
Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Placement Agency Agreement, the Company paid the Placement Agent a cash placement fee equal to <span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zzaZoE0raod1" title="Cash placement fee, percentage">8.0</span>% of the aggregate gross proceeds
raised in the Offerings from sales arranged for by the Placement Agent. Subject to certain conditions, the Company also agreed to reimburse
all reasonable travel and other out-of-pocket expenses of the Placement Agent in connection with the Offerings, including but not limited
to legal fees, up to a maximum of $<span id="xdx_90A_eus-gaap--ProfessionalFees_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zuCzCsxkXyD1" title="Professional fees">85,000</span>. In addition, the Placement Agent also received warrants that have substantially the same terms
as the Warrants issued in the concurrent private placement to the Purchasers in the Offerings to purchase that number of shares of Common
Stock equal to <span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zhiD8vh866p5" title="Percentage of outstanding common stock">6.0</span>% of the aggregate number of shares of Common Stock and Prefunded Warrants sold in the Offerings, or an aggregate of
<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zL0ufWmxoJl9" title="Warrants outstanding">99</span> shares of Common Stock, at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zRZ2qm2L5R0j" title="Warrant exercise price">994.50</span> per share (the &#8220;Placement Agent Warrants&#8221;). The Placement
Agent Warrants will be exercisable immediately following the date of issuance and will expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zgX4pa6bSZx4" title="Warrant outstanding Term">five years</span> from issuance. The Placement
Agency Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The
Company has agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and
liabilities arising from breaches of representations and warranties contained in the Placement Agency Agreement, or to contribute to
payments that the Placement Agent may be required to make in respect of those liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the instruments issued in the Offerings and the Insider Private Placement have been classified and recorded as part of shareholders&#8217;
equity (deficit). The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying
values of the respective instruments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"></p><p id="xdx_89C_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zZ8211qrMUHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zRuUJ2cLdkP8" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPyX9aCkusHa" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Allocated
    Amount</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjgcPPPJlqXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%"><span style="font-family: Times New Roman, Times, Serif">Common Shares</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">258,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zlthtXzj474i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">321,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGaGssgFOYu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Regular Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">470,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zbraQ6ny1bE9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,049,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_z7Nfb6onCP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fair value of the Placement Agent Warrants was $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_znWVI7GjaHId" title="Warrants exercise price">47,000</span>. These have been accounted for as a direct cost of the Offerings and
Inside Private Placement, resulting in no net effect to overall shareholders&#8217; equity (deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIfFlUzMp4s4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zOuAHdkHrU5l" style="display: none">Schedule of Fair value of Warrants Valuation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded
    Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Regular Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Placement
    Agent Warrants</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zxKTq7hZhrd2" title="Warrants and rights outstanding">134</span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zFEVlJ8CHIyc" title="Warrants and rights outstanding">96</span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zpB6jZiLkPt7" title="Warrants and rights outstanding">99</span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual/ expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAkLJTwKcqFl" title="Warrants and rights outstanding">1</span> month</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zs4ti35RRENe" title="Contractual term">7</span> years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zc3OwhDykApd" title="Contractual term">5</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zJ5dZf57aYed" title="Warrants and rights outstanding">5.53</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zfYtLFqlCxH9" title="Warrants and rights outstanding">3.91</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPGIqLtKCXz1" title="Warrants and rights outstanding">3.89</span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zP2XHomOv7Xj" title="Warrants and rights outstanding">0</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zGU7TLCKdSU4" title="Warrants and rights outstanding">0</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zSfRb5M2gZ3e" title="Warrants and rights outstanding">0</span>%</span></td></tr>
  </table>

<p id="xdx_8A4_zSGN6mLcGGn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the common shares was determined using the closing price of the Company&#8217;s common stock as of December 26, 2023, which
is the date that the Offerings and the Insider Private Placement closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>November
2024 Warrants (As Amended)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, warrants to purchase a total of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zkcMv1Hg4Pzj" title="Warrants to purchase shares">77,526</span> shares of common stock issued pursuant to a securities purchase agreement
in a November 2024 financing transaction (the &#8220;November 2024 Warrant Exercise and Reload Agreement&#8221;) and as amended in a
January 2, 2025 Warrant Exchange Agreement, remained outstanding. A total of <span id="xdx_904_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_ziWMN0bG94Y1" title="Exercisable warrants">82,816</span> warrants were issued in pursuant to the November
2024 Warrant Exercise and Reload Agreement. This consisted of i) series C warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zUvaaA4Bzeyb" title="Warrants to purchase shares">41,408</span> shares of common stock,
exercisable immediately from the date of issuance for a period of five and a half years<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_zK1HsjILzh9a" style="display: none" title="Warrant outstanding Term">5.5</span> after the date of issuance, at an exercise price
of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zKj2kuaJpwWf" title="Warrant exercise price">99.60</span> per warrant share, ii) series D warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zO2cbLs6sHJk" title="Warrants to purchase shares">41,408</span> shares of common stock, exercisable immediately from the
date of issuance for a period of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zJCntURLdsp7" title="Warrant term">eighteen months</span> after the date of issuance, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zet3ZEStQ8il" title="Warrant exercise price">99.60</span> per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_pid_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zd2eb2Y4cayb" title="Warrants exercised">5,289</span> of these warrants were exercised during the three months ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, warrants to purchase a total of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zX6nfLCSawN9">31,934</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in an April 2024 financing transaction (the &#8220;April 2024 Securities Purchase Agreement&#8221;) remained outstanding. A
total of <span id="xdx_908_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zR2Zh0SwJdKg">62,750</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were issued in pursuant to the April 2024 Securities
Purchase Agreement. This consisted of i) pre-funded warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zeboZxC2BIsc">20,100</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of common stock, exercisable immediately from the date of issuance,
and with no expiry date, at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zHitqqljdRM6">0.24</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, ii) series A warrants to purchase up to
<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zWlbvYD8z0P9">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zPpXhQ9L5Zce" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zRlUHfrKaXyd">326.40</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, iii) series B warrants to purchase up to
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zuQAmXLNEec2">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zJWatDmblluh">eighteen
months</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zsqKtwHR50Bh">326.40</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share. A further <span id="xdx_90E_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zts2BaHIU36j">1,242</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of five and a half years<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zUKwuRMeFo6l" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxpGjAhPERKk">124.512</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercised_pid_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_z7Q8K41fr22e" title="Warrants exercised">9,988</span> Series B warrants were exercised during the three months ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2023 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, warrants to purchase a total of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zHgpj8Ogb3ol" title="Warrants to purchase shares">1,750</span> shares of common stock issued pursuant to a securities purchase agreement
in a December 2023 financing transaction remained outstanding. A total of <span id="xdx_901_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zNIZl9MpeXn7" title="Warrants exerciseable">1,651</span> warrants, including <span id="xdx_90C_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreePrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zYetQAMjqvn3" title="Warrants exerciseable">33</span> warrants issued in a concurrent
private placement, are exercisable immediately from the date of issuance for a period of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zftguHdWf4H3" title="Warrant term">seven years</span> after the date of issuance, at an
exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zmYARZA6K7Zc" title="Warrant exercise price">765.60</span> per warrant share. A further <span id="xdx_906_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPxWoeO6a9c3" title="Warrants exercisable">99</span> warrants issued in a concurrent placement agency agreement, are exercisable
immediately from the date of issuance for a period of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_z8V30rblwKr5" title="Warrant term">five years</span> after the date of issuance, at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zqSJ6PU1vsJg" title="Warrant exercise price">994.50</span> per warrant
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zRANP317UFZb" title="Warrants exercised"><span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zpV4ybVDiICk" title="Warrants exercised">no</span></span> exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2020 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zYUBqq4swWmd" title="Warrants to purchase shares">186</span> shares of common stock issued pursuant to a securities purchase agreement in a December
2020 financing transaction remained outstanding (the &#8220;December 2020 Securities Purchase Agreement&#8221;). Each warrant shall be
exercisable beginning on the 12-month anniversary of the date of issuance for a period of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zX8zGeFh6K3i" title="Warrant term">five years</span> after the date of issuance, at an
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zPYRsqvitn9j" title="Warrant exercise price">14,868</span> per warrant share. The exercise price of the warrants will be subject to adjustment in the event of any stock
dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the warrants. The
warrants may be exercised on a &#8220;cashless&#8221; basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zupY5LG7oIA1" title="Warrants exercised"><span id="xdx_904_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zr5RfpDPtfk5" title="Warrants exercised">no</span></span> exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2020 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zS3hgIxDurTj" title="Warrant outstanding">497</span> warrants issued pursuant to a securities purchase agreement in connection with an April 2020 equity financing
remained outstanding, each with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_z0kzxT9mVZG1" title="Warrant exercise price">18,000.00</span>. The common warrants are immediately exercisable and will expire on the fifth
anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject
to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company&#8217;s
common stock. The common warrants were issued separately from the common stock and were eligible for transfer immediately after issuance.
A common warrant to purchase one share of common stock was issued for every share of common stock purchased in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise
notice accompanied by payment in full for the number of shares of the Company&#8217;s common stock purchased upon such exercise (except
in the case of a cashless exercise). <span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zwoDOH4r2sX8" title="Debt description">A holder (together with its affiliates) may not exercise any portion of the common warrant to the
extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least
61 days prior notice from the holder to the Company, the holder may increase the amount of ownership of outstanding stock after exercising
the holder&#8217;s common warrants up to 9.99% of the number of shares of the Company&#8217;s common stock outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants.</span> No fractional
shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, the Company
will round down to the next whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zvGypY5H1Vq8" title="Warrants exercised"><span id="xdx_902_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_znF2EDkHduS8" title="Warrants exercised">no</span></span> exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Preferred
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
E Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zpYmcvRxdd22" title="Number of share sold">1,000,000</span> shares of the Company&#8217;s Series E Preferred Stock were issued pursuant to a March 2025 Securities Purchase Agreement
with certain accredited investors. The Company received proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zORkeXYmqnYi" title="Gross proceeds">1.0</span> million, net of issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series E Preferred Stock is convertible into </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zPE19G3De40c">0.45833</span>
shares of the Company&#8217;s common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zFYuxC1XNDC8">0.001</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (&#8220;Common Stock&#8221;). In no event will the
Series E Preferred Stock be convertible into Common Stock in a manner that would result in each Investor or their transferees or their
affiliates holding more than the lower of (i) the maximum percentage of the number of shares of Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series E Preferred Stock that can be issued
to the holder without requiring a vote of the stockholders of the Company under the rules and regulations of The Nasdaq Capital Market
(&#8220;Nasdaq&#8221;); and (ii) <span id="xdx_900_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zJc8SRYs2dQa">4.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the number of shares of Common Stock outstanding immediately before the original issue date (the &#8220;Series E Ownership Limitation&#8221;),
prior to the date that the Company&#8217;s stockholders approve the issuance of shares of Common Stock to the Investors upon conversion
of the Series E Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, the Company filed a certificate of designations (the &#8220;Series E Certificate of Designations&#8221;) with
the Secretary of State of Delaware designating the rights, preferences and limitations of the shares of the Series E Preferred Stock
on March 21, 2025. The Series E Certificate of Designations provides, in particular, that the Series E Preferred Stock will vote together
with the Common Stock on an as-converted basis, subject to the Series E Ownership Limitation, subject further to adjustments for any
stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series E Preferred Stock will be entitled to participate in any dividends made on shares of Common Stock (on an as-converted
basis) if and when such dividends are declared. Upon any liquidation or sale of the Company or all or substantially all of its assets,
the holders of the Series E Preferred Stock will be entitled to receive pari passu with the other holders of preferred stock, prior to
and in preference to any distribution to holders of Common Stock, an amount equal to $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zSkwpv9KbYka" title="Share price">1.00</span> per share, the stated value of the Series
E Preferred Stock, then held by them plus any accrued but unpaid dividends. Thereafter, the remaining assets of the Company will be distributed
to the holders of Common Stock until such holders receive a return of their capital originally contributed, and thereafter, any remaining
assets will be distributed to all holders of Common Stock and preferred stock pro rata based on the number of shares held on an as-converted
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z1tjIWXFGAW3" title="Preferred stock shares issued">1,000,000</span> shares of the Series E Preferred Stock remain issued and outstanding. The <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zjgMHtKDXS6g" title="Preferred stock shares outstanding">1,000,000</span> shares of Series E Preferred
Stock issued and outstanding at March 31, 2025, are convertible into <span id="xdx_908_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zbG7ge5i7Wz" title="Conversion of shares">458,333</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
C and Series D Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zb4CxxZfbd95" title="Number of share sold">1,000,000</span> shares of the Company&#8217;s Series C Preferred Stock and <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zutCw4YoU4Nf" title="Number of share sold">2,100,000</span> shares of the Company&#8217;s Series D Preferred
Stock were issued pursuant to a January 2025 Securities Purchase Agreement with David E. Lazar, pursuant to which he agreed to purchase
from the Company <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zQU0TJCDrbA2" title="Number of share sold">1,000,000</span> shares of Series C Convertible Preferred Stock (the &#8220;Series C Preferred Stock&#8221;) and <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z0cVsNfTWDH6" title="Number of share sold">2,100,000</span>
shares of Series D Convertible Preferred Stock (the &#8220;Series D Preferred Stock&#8221; and, together with the Series C Preferred
Stock, the &#8220;Preferred Stock&#8221;) of the Company at a purchase price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zLNqQfQwzW1f" title="Share price">1.00</span> per share for aggregate gross proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_ziSnJURRTme8" title="Gross proceeds">3.1</span>
million, subject to the terms and conditions of the Purchase Agreement. The proceeds of the transaction were used to repay and settle
outstanding liabilities of the Company and for other general corporate and operating purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt">Each share of
Series C Preferred Stock is convertible into <span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7ysKNX5ZqXg" title="Conversion of shares">0.011</span>
shares of the Company&#8217;s common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250331_zYU2fJn9LU1j" title="Common stock par value">0.001</span>
per share (&#8220;Common Stock&#8221;), and each share of Series D Preferred Stock is convertible into <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z722kWYFLCmf" title="Conversion of shares">0.45833</span>
shares of Common Stock. In no event will the Series C Preferred Stock be convertible into Common Stock in a manner that would result
in Mr. Lazar or his transferees or their affiliates holding more than the lower of (i) the maximum percentage of the number of
shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
conversion of the Preferred Stock that can be issued to the holder without requiring a vote of the stockholders of the Company under
the rules and regulations of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;); and (ii) <span id="xdx_90A_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zVLbTH6plbRc" title="Outstanding common stock at election of purchaser">5</span>%
of the number of shares of Common Stock outstanding immediately before the original issue date (the &#8220;Series C Ownership
Limitation&#8221;), prior to the date that the Company&#8217;s stockholders approve the issuance of shares of Common Stock to Mr.
Lazar upon conversion of the Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, prior to a Fundamental Transaction (as defined below), in no event will the Series D Preferred Stock be convertible into Common
Stock in a manner that would result in Mr. Lazar or his transferees or their affiliates holding more than the lower of (i) the maximum
percentage of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon conversion of the Preferred Stock that can be issued to the Holder without requiring a vote of the stockholders of
the Company under the rules and regulations of Nasdaq; and, (ii) <span id="xdx_904_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zk70bDflPDbl" title="Outstanding common stock at election of purchaser">49.99</span>% of the number of shares of the Common Stock outstanding immediately
before the original issue date (the &#8220;Series D Ownership Limitation&#8221;). The term &#8220;Fundamental Transaction,&#8221; means
when (i) the Company effects any merger of the Company with or into another entity and the Company is not the surviving entity, (ii)
any tender offer or exchange offer (whether by the Company or by another individual or entity, and approved by the Company) is completed
pursuant to which holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash
or property and the holders of at least 50% of the Common Stock accept such offer, or (iii) the Company effects any reclassification
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock). The certificate
of designations for each of the Series C Preferred Stock and Series D Preferred Stock further provide that even following a vote of the
stockholders of the Company in accordance with the rules and regulations of the trading market on which the Common Stock trades on such
date and applicable securities laws to approve the removal of the Series C Ownership Limitation, the Company shall not affect any conversion
of the Preferred Stock, and a holder of the Preferred Stock shall not have the right to convert any portion of the Preferred Stock, to
the extent that, after giving effect to the conversion, such holder (together with any other shares of Common Stock otherwise held by
such holder(s) or their affiliates) would beneficially own the number of shares of Common Stock, which would be in excess of any statutory
threshold pursuant to which the acquisition of such shares would trigger a compulsory offer requirement under applicable federal or state
tender offer rules for the holder and its affiliates to make a tender offer for all the shares of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2025, all of the Series C preferred shares were converted in conjunction with the Purchase Agreement. As of March 31, 2025
there were no remaining shares of the Series C Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2025, <span id="xdx_90F_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250224__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zMCO5G34RGRb" title="Conversion of shares">1,745,262</span> of the Series D preferred shares were converted in conjunction with the Purchase Agreement. As of March
31, 2025, <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zN3mCOEZFIu2" title="Preferred stock shares issued">354,738</span> shares of the Series D Preferred Stock remain issued and outstanding. The <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zCH8jksCD2B9" title="Preferred stock shares outstanding">354,738</span> shares of Series D Preferred Stock
issued and outstanding at March 31, 2025, are convertible into <span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z6hjriCr2rc8" title="Conversion of shares">162,588</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLsRIdlcPqab" title="Number of share sold">237,745</span> shares of the Company&#8217;s Series B Preferred Stock were issued pursuant to a December 2020 Securities Purchase Agreement.
Each share of Series B Preferred Stock was initially convertible into one third (1/3) share of common stock (the &#8220;Conversion Shares&#8221;),
subject to adjustment in accordance with the Certificate of Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPu9HnRo13u2" title="Number of shares converted">119,000</span> shares of Series B Preferred Stock were converted, at the option of the holder, into <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zeyl6WJF2ak7">165</span>
shares of common stock. As of March 31, 2025, there were <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_do_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkj3mD0PFwli" title="Conversion of shares">no</span> remaining shares of the Series&#160;B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOOlbNWOJTJ3" title="Number of share sold">8,872</span> shares of the Company&#8217;s Series A Preferred Stock were issued in a July 2017 Underwritten Public Offering. Each share
of Series A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined
by dividing $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqBCZjQGWjf3" title="Stock value">1,000</span> by the initial conversion price of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsTURdQmFgKa" title="Conversion price of convertible preferred stock">144,000.00</span> per share, subject to a <span id="xdx_90D_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAESJnthatX" title="Outstanding common stock at election of purchaser">4.99</span>% blocker provision, or, upon election by a
holder prior to the issuance of shares of Series A Preferred Stock, <span id="xdx_90B_ecustom--ConvertiblePreferredStockConversionPercentage_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3PoyIUtBKNe" title="Conversion percentage">9.99</span>%, and is subject to adjustment for stock splits, stock dividends,
distributions, subdivisions and combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 and December 31, 2024, <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4mei2YiKrAd" title="Preferred stock shares issued">264</span> shares of the Series A Preferred Stock remain issued and outstanding. The <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_za8mkKWMRoOg" title="Preferred stock shares outstanding">264</span> shares of
Series A Preferred Stock issued and outstanding at March 31, 2025, are convertible into <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVmvgQBjVWUa" title="Conversion of shares">2</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock
basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends
in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted
basis. There is no restriction on the Company&#8217;s ability to repurchase shares of Series A Preferred Stock while there is an arrearage
in the payment of dividends on such shares, and there are no sinking fund provisions applicable to Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder
of the Series A Preferred Stock to convert all or part of such holder&#8217;s Series A Preferred Stock in the event that (i) the volume
weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds <span id="xdx_908_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcTrwOmPwfBg" title="Outstanding common stock at election of purchaser">300</span>% of the initial conversion
price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends
and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $<span id="xdx_908_eus-gaap--ConversionOfStockAmountConverted1_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVyAW3bRuw8i" title="Conversion of amount">500,000</span> per trading
day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information
which was provided by the Company. The right to cause each holder of Series A Preferred Stock to convert all or part of such holder&#8217;s
Series A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains
no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common
stock in the distribution of assets, to the extent legally available for distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>6%
Convertible Exchangeable Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3WdMmP29BVd" title="Preferred stock shares issued">135,273</span> shares of the Company&#8217;s <span id="xdx_907_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ze6pXP3PNsi2" title="Preferred stock, dividend rate">6</span>% Convertible Exchangeable Preferred Stock (the &#8220;<span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zjsOuoDx1f7b" title="Preferred stock, dividend rate">6</span>% Preferred
Stock&#8221;) issued and outstanding at an issue price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ztLikzfrwhWg" title="Share issue price per share">10.00</span> per share. Dividends on the <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zeKGc9t23jmk" title="Preferred stock, dividend rate">6</span>% Preferred Stock are cumulative from the
date of original issuance at the annual rate of <span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z5ldLMp0Zw1a" title="Preferred stock, dividend rate">6</span>% of the liquidation preference of the <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zCeU7ykmoW3d" title="Preferred stock, dividend rate">6</span>% Preferred Stock, payable quarterly on the
first day of February, May, August and November, commencing February 1, 2005. Any dividends must be declared by the Company&#8217;s board
of directors and must come from funds that are legally available for dividend payments. The <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zt7IYqiOti9d" title="Preferred stock, dividend rate">6</span>% Preferred Stock has a liquidation preference
of $<span id="xdx_902_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zkradnCESYi1" title="Liquidation preference">10.00</span> per share, plus accrued and unpaid dividends. As of March 31, 2024, there were no accrued and unpaid dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may automatically convert the 6% Preferred Stock into common stock if the per share closing price of the Company&#8217;s common
stock has exceeded $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zinJmwiIaa2l" title="Conversion amount">213,192,000</span>, which is <span id="xdx_90D_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zm7PD695dYbg" title="Conversion price percentage">150</span>% of the conversion price of the <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zU2NIHGoSfde" title="Preferred stock, dividend rate">6</span>% Preferred Stock, for at least 20 trading days during any
30 day trading period, ending within five trading days prior to notice of automatic conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zJGsK7OFNHo" title="Preferred stock, dividend rate">6</span>% Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may, at its option, redeem the <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z4Jwz1yauNbf" title="Preferred stock, dividend rate">6</span>% Preferred Stock in whole or in part, out of funds legally available at the redemption price
of $<span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zaxlBPAqB1C3" title="Redemption price per share">10.00</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
6% Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on
November&#160;1, 2005 (the &#8220;Exchange Date&#8221;) for the Company&#8217;s <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zFYZg4Hm6QEj" title="Preferred stock, dividend rate">6</span>% Convertible Subordinated Debentures (the &#8220;Debentures&#8221;)
at the rate of $<span id="xdx_908_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zVrdSenLYaai" title="Redemption price per share">10.00</span> principal amount of Debentures for each share of <span id="xdx_908_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z1xGOnD8mM64" title="Preferred stock, dividend rate">6</span>% Preferred Stock. The Debentures, if issued, will mature <span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zzRktYzy60nl" title="Debt instrument, term">25</span>
years after the Exchange Date and have substantially similar terms to those of the <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zY3klpZtJJWj" title="Preferred stock, dividend rate">6</span>% Preferred Stock. No such exchanges have taken place
to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zalWS0btNRB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_82F_zOaHl5fSNiFg">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has completed the following equity issuances during the periods presented in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>November
2024 Warrant Exercise and Reload Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2024, Cyclacel Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into a letter agreement (the &#8220;Warrant Exercise
and Reload Agreement&#8221;) with the holder (the &#8220;Holder&#8221;) of its issued and outstanding Series B Warrants (the &#8220;Prior
Warrants&#8221;) to purchase an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_zIthoNGmdFGf">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the Company offering the Holder the
opportunity to exercise all of its Prior Warrants for cash at a reduced exercise price equal to $<span id="xdx_90F_ecustom--ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zIw77kU1BSQj">99.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share provided the Prior Warrants were exercised in full
for cash on or before 12:30 P.M. Eastern Time on the date of the Warrant Exercise and Reload Agreement. In consideration for the exercise
of the Prior Warrants, the Holder received new unregistered Series C Warrants (the &#8220;Series C Warrants&#8221;) exercisable for up
to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MaximumMember_z2nJt8iIEQ98">41,408</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series C Warrant Shares&#8221;)
and new unregistered Series D Warrants (the &#8220;Series D Warrants&#8221; and, together with the Series C Warrants, the &#8220;New
Warrants&#8221;) exercisable for up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember__srt--RangeAxis__srt--MaximumMember_z7P5lyeVpbA3">41,408</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series D Warrant Shares&#8221;
and, together with the Series C Warrant Shares, the &#8220;New Warrant Shares&#8221;). The Series C Warrants are exercisable beginning
on the date upon which the Company receives stockholder approval of the issuance of the New Warrant Shares and the Placement Agent Warrant
Shares (as defined below) (the &#8220;Stockholder Approval Date&#8221;) for a period of five and one-half (<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zwphBe7Sx8v9">5.5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
years following the Stockholder Approval Date and the Series D Warrants are exercisable beginning on the Stockholder Approval Date for
a period of eighteen (<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zaK6EsTtSSx5">18</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
months following the Stockholder Approval Date. The New Warrants each have an exercise price of $<span id="xdx_904_ecustom--ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zwleHMtS4Yqf">99.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The shares of common stock issued upon exercise
of the Prior Warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-279157).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Securities Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2024, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor (the &#8220;Purchaser&#8221;) for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of (i)
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_zaKIA9oBY35f">604</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock, (ii) pre-funded
warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z5erFSmnQjh7">20,100</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Pre-Funded Warrants&#8221;),
(iii) series A warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_ztG73B9rt8jc">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series A Warrants&#8221;),
and (iv) series B warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zcItD1sBQpn4">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the &#8220;Series B Warrants&#8221;
and together with the Series A Warrants, the &#8220;Common Warrants&#8221;). The purchase price of each share of common stock and associated
Common Warrants was $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNXTFLy0SvWi">386.40</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the purchase price of each Pre-Funded Warrant and associated
Common Warrants was $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsAndCommonWarrantsMember_zCo8viJY06Ch">386.376</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants are exercisable immediately upon issuance at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zMYaDXFUgKg6">326.40</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Series A Warrants will expire five and one-half
years<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zUiLe2DtvpE2" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance and the Series B Warrants will expire
eighteen months from the date of issuance. The Pre-Funded Warrants are exercisable immediately upon issuance at an exercise price of
$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_znxWUrSAWMI3">0.024</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and may be exercised at any time until the Pre-Funded
Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its affiliates) may not exercise any
portion of such warrants to the extent that the holder would own more than <span id="xdx_902_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zP1rZsr56qjb">4.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
(or, at the election of the holder <span id="xdx_907_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zsnWwNxkiFPi">9.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)
of the Company&#8217;s outstanding common stock immediately after exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Private Placement, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
dated as of April 30, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) registering the resale of the securities issued in the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Placement closed on May 2, 2024. The gross proceeds to the Company from the Private Placement were approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240502__20240502_zSzPTAYzb5m8">8.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, before deducting placement agent fees and estimated
offering expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the Company&#8217;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of April 29, 2024, between the Company and Wainwright (as amended, the
&#8220;Engagement Letter&#8221;). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to <span id="xdx_902_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20240429_zD4yCmuXVAf1">7.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds of the Private Placement and (ii) a management fee of <span id="xdx_90D_ecustom--ManagementFeePercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240429_zhsfS6elTY21">1.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued
to Wainwright or its designees warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zJEJFIefpf0j">1,242</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price equal to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z2k13njyoMgh">124.512</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Placement Agent Warrants are exercisable immediately
upon issuance and have a term of exercise equal to five and a half years<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zS5z7m5Zd4J3" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company was required to compensate Roth Capital Partners, LLC, pursuant to a tail provision contained
in an engagement letter entered into on March 14, 2024, in an amount equal to <span id="xdx_90D_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240314__srt--CounterpartyNameAxis__custom--RothCapitalPartnersLlcMember_zDxCywiasD27">7.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate proceeds of the Private Placement plus the reimbursement of certain expenses. The Company was also required to compensate
Ladenburg Thalmann &amp; Co. Inc, pursuant to a tail provision contained in an engagement letter entered into on October 30, 2023, in
an amount equal to <span id="xdx_907_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20231030__srt--CounterpartyNameAxis__custom--LadenburgThalmannCo.IncMember_zclQRSY20Kw1">8.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate proceeds of the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the instruments issued in the Private Placement have been classified and recorded as part of shareholders&#8217; equity (deficit).
The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective
instruments as follows:</span></p>

<p id="xdx_893_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_z7m7v6VBOkz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_z6NUgLOQ9Vi8" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zBIhHSrSJReb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Allocated
    Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq3QwXNUjED6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Common shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">72,108</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zpODY3vap7N4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prefunded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,398,831</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWUkBjHcDr4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,819,274</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_zCzqzHT8J5V4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net proceeds</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,290,213</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z25frHlhgXC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fair value of the Placement Agent Warrants was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zKhQ2wTFXwo5">609,179</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
These have been accounted for as a direct cost of the Private Placement, resulting in no net effect to overall shareholders&#8217; equity
(deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjUMBilXRxKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BE_zH2Kn3OlToH6" style="display: none">Schedule
of Fair value of Warrants Valuation Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Pre-Funded Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Common Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Placement Agent Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zQlb4fHHvBn">100</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zfxP64rao9gd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            - <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zmZIGElcjLW2">121</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z3gwiYo35EJ6">103</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGismNVQlp66" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">year</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUPPyBSjAiy9" style="display: none">1.5</span></span>1&#189;
                                            - 5&#189; years<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zXeVsP78Db5d" style="display: none">5.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuHIcIE3sdjd" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#189;
                                            years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zn43bSaXZy6a">5.51</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zXt0T5Dj3Kec" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.57</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            - <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ztk2p9BCs8ig">5.51</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZ1tCBxmj8l3">4.57</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zSpvZGyUq6h4">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJMWTO3OuCFf">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMBjP67BlMnj">0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AE_zKTss7DXffqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the common stock was determined using the closing price of the Company&#8217;s common stock as of May 2, 2024, which is
the date that the Private Placement closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2023 Registered Direct Offering Securities Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain
institutional investors (&#8220;Purchasers&#8221;). Pursuant to the Securities Purchase Agreement, the Company agreed to sell in a registered
direct offering (&#8220;Registered Direct Offering&#8221;) <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUSvaUf0eOp7">702</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (&#8220;Shares&#8221;) of the Company&#8217;s common
stock and pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z8f25EwLQJtl">915</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. The Pre-Funded Warrants have an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z3cYy5VF96pf">0.24</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and are immediately exercisable and can be exercised
at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each Share is being sold at an offering
price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z696kwAm0G3e">795.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and each Pre-Funded Warrant is being sold at an offering price
of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zO3rfrOkVtii">795.36</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(equal to the purchase price per Share minus the exercise price
of the Pre-Funded Warrant).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the &#8220;Offerings&#8221;),
the Company also agreed to issue to the Purchasers unregistered warrants (&#8220;Common Warrants&#8221;) to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zfhbyd13R8R">1,617</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. Each Common Warrant has an exercise
price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zxyKxYf2JjZf">765.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, is exercisable immediately following their original
issuance and will expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zLBW1gBg5sD">seven
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the original issuance date. The closing
of the offering occurred on December 26, 2023, and the net proceeds to the Company were approximately $<span id="xdx_90E_ecustom--AggregateProceedsFromSaleOfStock_iI_pn5n6_c20231226__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zJHQ1MXWzG76">1.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and other offering
expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2023, in a separate concurrent insider private placement (the &#8220;Insider Private Placement&#8221;), the Company also
entered into a Securities Purchase Agreement with certain of its executive officers (the &#8220;Insider Securities Purchase Agreement&#8221;)
pursuant to which the Company agreed to sell in a private placement (i) <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDbEsQKu9cN4">25</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_z3l9jhhwa6Th">25</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Spiro Rombotis, the Company&#8217;s Chief Executive Officer, and (ii) <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember_zzfWOP4FHBU3">8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zQcDV3K7eude">8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Paul McBarron, the Company&#8217;s Executive Vice President-Finance, Chief Financial Officer
and Chief Operating Officer. Each such share of common stock and accompanying warrant was sold at a purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_z59qt1SSJDYk">795.60</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was the same purchase price for the Shares sold in the Registered Direct Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg
Thalmann &amp; Co. Inc. (the &#8220;Placement Agent&#8221;) acted as the exclusive placement agent for the Offerings, pursuant to a placement
agency agreement (the &#8220;Placement Agency Agreement&#8221;), dated December 21, 2023, by and between the Company and the Placement
Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Placement Agency Agreement, the Company paid the Placement Agent a cash placement fee equal to <span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zxyTpFX2Zh2f">8.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate gross proceeds raised in the Offerings from sales arranged for by the Placement Agent. Subject to certain conditions,
the Company also agreed to reimburse all reasonable travel and other out-of-pocket expenses of the Placement Agent in connection with
the Offerings, including but not limited to legal fees, up to a maximum of $<span id="xdx_90A_eus-gaap--ProfessionalFees_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zrNaBYwgRAFk">85,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In addition, the Placement Agent also received warrants that have substantially the same terms as the Warrants issued in the concurrent
private placement to the Purchasers in the Offerings to purchase that number of shares of common stock equal to <span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zoYkp4PnmHTl">6.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the aggregate number of shares of common stock and Prefunded Warrants sold in the Offerings, or an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zpU5LIm5eA24">99</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z9Jp8Gp4Tmda">994.50</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (the &#8220;Placement Agent Warrants&#8221;). The
Placement Agent Warrants will be exercisable immediately following the date of issuance and will expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zNfBBPfsUow9">five
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from issuance. The Placement Agency Agreement
contains customary representations, warranties and agreements by the Company and customary conditions to closing. The Company has agreed
to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and liabilities arising
from breaches of representations and warranties contained in the Placement Agency Agreement, or to contribute to payments that the Placement
Agent may be required to make in respect of those liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the instruments issued in the Offerings and the Insider Private Placement have been classified and recorded as part of shareholders&#8217;
equity. The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values
of the respective instruments as follows:</span></p>

<p id="xdx_89F_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4OcU6YuX39i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zY381SfL0bfd" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zyjBGzo64avj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Allocated
    Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHUGbPFf2sba" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Common Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">258,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSZmexFaegDa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Pre-Funded Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">321,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzNFN989B3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Regular Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">470,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zQqPN6pWrAzk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net Proceeds</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,049,000</td><td style="text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AA_zb4MaUITsIzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fair value of the Placement Agent Warrants was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zFMPYS5N4FH9">47,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
These have been accounted for as a direct cost of the Offerings and Inside Private Placement, resulting in no net effect to overall shareholders&#8217;
equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4JNxJDtzfie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zWpLB9du8iUi" style="display: none">Schedule
of Fair value of Warrants Valuation Assumption</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pre-Funded Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Regular Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Placement Agent Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zgIRxBJJrZac">134</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zymclqOdcvj7">96</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_ztxHj2RvY8S1">99</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Contractual/expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z70PhkHMtHj5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">month</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zKVZgEYRcRl8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zdZmDyp6Len2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAoG8yfczVX5">5.53</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z6gjOzFvrbt5">3.91</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zrQBxpZsYiS6">3.89</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zVXETncroDmk">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zvysFIElhW06">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIppfgQqqL54">0</span></td><td style="text-align: left">%</td></tr>
  </table>
<p id="xdx_8A8_zdarbiT7nGxh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the common shares was determined using the closing price of the Company&#8217;s common stock as of December 26, 2023, which
is the date that the Offerings and the Insider Private Placement closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>August
2021 Controlled Equity Offering Sales Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor
Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), pursuant to which the Company could issue and sell, from time to time, shares of its common
stock having an aggregate offering price of up to $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210812__20210812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_zJMdMEFhmXR9">50.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million through Cantor as the sales agent. Cantor could sell
the Company&#8217;s common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule
415(a)(4) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2022, the Company became aware that the shelf registration statement on Form S-3 (file number 333-231923) (the &#8220;Registration
Statement&#8221;) associated with this Sales Agreement had expired on June 21, 2022. Prior to becoming aware of the expiration, the Company
sold an aggregate of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zsPeJM7cseI8">552</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock at the market price, following the
expiration of the Registration Statement and through August 12, 2022, for aggregate proceeds of approximately $<span id="xdx_902_ecustom--AggregateProceedsFromSaleOfStock_iI_c20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zopApQOCgqQ5">2,721,187</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
There was no sale of shares post August 12, 2022. The sale of these shares were subject to potential rescission rights by certain shareholders.
As a result of these potential rescission rights, the Company reclassified <span id="xdx_901_ecustom--ReclassificationOfCommonStockShares_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zv03kIgeoAE2">866</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (including <span id="xdx_90B_ecustom--ReclassificationOfCommonStockSharesNoProceedsReceived_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zHuX4PF4IDH4">314</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares sold for which the Company did not receive any proceeds),
with an aggregate purchase price of $<span id="xdx_90C_ecustom--ReclassificationOfCommonStockValue_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_z0sRpDI1mmYa">4,494,496</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of its common stock outside stockholders&#8217; equity as of
December 31, 2022. These shares have been treated as issued and outstanding for financial reporting purposes. The rescission rights for
these shares lapsed and the shares were reclassified back to permanent equity as of December 31, 2023. As of December 31, 2024, there
have been no claims or demands to exercise such rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2022, the Sales Agreement was mutually terminated. A total of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220815__20220815__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_z1l7eIi8F1pk">911</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares, for gross proceeds of approximately $<span id="xdx_908_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20220815__20220815__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_zSEwHJLzhdM5">7.6</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, had been sold pursuant to the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>November
2024 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, warrants to purchase a total of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_z5ioFWcPrz2e">82,816</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in a November 2024 financing transaction (the &#8220;November 2024 Warrant Exercise and Reload Agreement&#8221;) remained outstanding.
A total of <span id="xdx_903_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zupPvhXsoch9">82,816</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were issued in pursuant to the November 2024 Warrant
Exercise and Reload Agreement. This consisted of i) series C warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zO0lcJxyhHN5">41,408</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_z0hd0si37Pki" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_z2FwheneL143">99.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, ii) series D warrants to purchase up to
<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zU3LMLXpr5Ya">41,408</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zUVO9AuNCVq1">eighteen
months</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zadW48rwEWAi">99.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_pid_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zOsFWFPc3GB8">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercises of these warrants during the years ended December
31, 2024 or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, warrants to purchase a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zoJySxMJhdyf">31,934</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in an April 2024 financing transaction (the &#8220;April 2024 Securities Purchase Agreement&#8221;) remained outstanding. A
total of <span id="xdx_905_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zZXZ2TKx37kf">62,750</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were issued in pursuant to the April 2024 Securities
Purchase Agreement. This consisted of i) pre-funded warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zEb1Z3rQ8K8d">20,100</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of common stock, exercisable immediately from the date of issuance,
and with no expiry date, at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zDZWOZonCYFa">0.24</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, ii) series A warrants to purchase up to
<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPCecdUahTjj">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zsisPXuun5yi" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zByQEcmurQsh">326.40</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share, iii) series B warrants to purchase up to
<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zcsaiDPTj29">20,704</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, exercisable immediately from the date
of issuance for a period of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zxZ3QjgQ4aRl">eighteen
months</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zN6BwN8MCAZ7">326.40</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share. A further <span id="xdx_906_ecustom--ClassOfWarrantOrRightsExercisable_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zsZi8sUXM4Z6">1,242</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of five and a half years<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zgIk9ZfIUNl" style="display: none">5.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zaZ6gP9cddB4">124.512</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercised_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zJvVogHkTsQk">20,100</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-funded warrants and <span id="xdx_901_ecustom--ClassOfWarrantOrRightExercised_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_zSuLSN8a4tU8">10,716</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B warrants were exercised during the year ended December
31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2023 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, warrants to purchase a total of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zFDZ84J9sTpg">1,750</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in a December 2023 financing transaction remained outstanding. A total of <span id="xdx_90F_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zOCDhAz0VnX6">1,651</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants, including <span id="xdx_901_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreePrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zkRorAjArK25">33</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in a concurrent private placement, are exercisable
immediately from the date of issuance for a period of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zy80jv03DSm9">seven
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zGDvXea7VShe">765.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share. A further <span id="xdx_902_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcZWXIlfGF9">99</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zkzgA2wgcZNh">five
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zHvYGsHpLMV2">994.50</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_z1pM3Xf04aQd">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercises of these warrants during the years ended December
31, 2024 or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>December
2020 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z0PZl1O7TLQa">186</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued pursuant to a securities purchase
agreement in a December 2020 financing transaction remained outstanding. Each warrant shall be exercisable beginning on the 12-month
anniversary of the date of issuance for a period of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z2hbvJdrqlgk">five
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the date of issuance, at an exercise
price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zjRA4NuhW6w2">14,868.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per warrant share. The exercise price of the warrants will
be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar
transaction, as described in the warrants. The warrants may be exercised on a &#8220;cashless&#8221; basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, <span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercised_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfzBNRAkfqy1">65</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants lapsed upon conversion of the associated Series B
Preferred Stock. There were <span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z3Rwgk9BzASg">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercises of these warrants during the year ended December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2020 Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zcg8CHGkLTfh">497</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued in connection with an April 2020 equity financing
remained outstanding, each with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zQmvWkjnxcYj">18,000.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The common warrants are immediately exercisable and will expire on the fifth anniversary of the original issuance date. The exercise
price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting the Company&#8217;s common stock. The common warrants were issued separately
from the common stock and were eligible for transfer immediately after issuance. A common warrant to purchase one share of common stock
was issued for every share of common stock purchased in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise
notice accompanied by payment in full for the number of shares of the Company&#8217;s common stock purchased upon such exercise (except
in the case of a cashless exercise). <span id="xdx_90E_eus-gaap--DebtInstrumentDescription_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zjHjUmnK3Cg9">A
holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more
than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days prior notice from the holder
to the Company, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s common warrants
up to 9.99% of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the common warrants.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, the
Company will round down to the next whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90B_ecustom--ClassOfWarrantOrRightExercised_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_z3cX5KcR4pDc">111</span> warrants were exercised during the year ended December 31, 2024. <span id="xdx_906_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zIxfkqhLW8zg">No</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were exercised during the year ended December 31,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
B Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNid3PIJiCs1">237,745</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s Series B Preferred Stock were
issued in a December 2020 Securities Purchase Agreement. Each share of Series B Preferred Stock shall initially be convertible into one
third (1/3) share of common stock (the &#8220;Conversion Shares&#8221;), subject to adjustment in accordance with the Certificate of
Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock
basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series
B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company
will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a)
alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Certificate
of Designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights
of the holders of Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, (e) pay certain
dividends or (f) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock does not have a preference
upon any liquidation, dissolution or winding-up of the Company. The Purchaser may convert shares of Series B Preferred Stock through
a conversion into shares of common stock if and solely to the extent that such conversion would not result in the Purchaser beneficially
owning in excess of <span id="xdx_90B_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbrVB1A6kuJk">9.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of then-outstanding common stock or aggregate voting power of the Company (such limitation, the &#8220;Ownership Limitation&#8221;) and
any portion in excess of such limitation will remain outstanding as Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z80ypU7lmqX3">119,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series B Preferred Stock was converted, at the option
of the holder, into <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zocqvnwoQRD6">165</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. As of December 31, 2024, there were
<span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlostzkFR6zg">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining shares of the Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
A Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYBA5ymp05Hg">8,872</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s Series A Preferred Stock were
issued in a July 2017 Underwritten Public Offering. Each share of Series A Preferred Stock is convertible at any time at the option of
the holder thereof, into a number of shares of common stock determined by dividing $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHzzSK2nIpO6">1,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by the initial conversion price of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2IYGWDYiHw4">144,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, subject to a <span id="xdx_90D_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLJFziQuW93g">4.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
blocker provision, or, upon election by a holder prior to the issuance of shares of Series A Preferred Stock, <span id="xdx_907_ecustom--ConvertiblePreferredStockConversionPercentage_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2BPEAHa2UZ2">9.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0cm0Sof4318">264</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Series A Preferred Stock remain issued and outstanding.
The <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zw6z4u0mehFa">264</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series A Preferred Stock issued and outstanding at
December 31, 2024, are convertible into <span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoedssE9uV12">2</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock
basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends
in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted
basis. There is no restriction on the Company&#8217;s ability to repurchase shares of Series A Preferred Stock while there is an arrearage
in the payment of dividends on such shares, and there are no sinking fund provisions applicable to Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder
of the Series A Preferred Stock to convert all or part of such holder&#8217;s Series A Preferred Stock in the event that (i) the volume
weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds <span id="xdx_906_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKvYphkB3ODl">300</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations,
stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $<span id="xdx_900_eus-gaap--ConversionOfStockAmountConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSkscOcyJSWf">500,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per trading day and (iii) the holder is not in possession of
any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to
cause each holder of Series A Preferred Stock to convert all or part of such holder&#8217;s Series A Preferred Stock shall be exercised
ratably among the holders of the then outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains
no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common
stock in the distribution of assets, to the extent legally available for distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6%
Convertible Exchangeable Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zmW1tAtLncpl">135,273</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z2XPeCSRRKtd">6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
Convertible Exchangeable, or Preferred Stock issued and outstanding at an issue price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zLGOPcPZlrKc">10.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. Dividends on the Preferred Stock are cumulative
from the date of original issuance at the annual rate of <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zOSxPD0ojie9">6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the liquidation preference of the Preferred Stock, and if declared, payable quarterly on the first day of February, May, August and
November, commencing February 1, 2005. Any dividends must be declared by the Company&#8217;s Board of Directors and must come from funds
that are legally available for dividend payments. The Preferred Stock has a liquidation preference of $<span id="xdx_90E_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zLKfEnzExJoh">10.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, plus accrued and unpaid dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Board of Directors considers numerous factors in determining whether to declare the quarterly dividend pursuant to the
Certificate of Designations governing the terms of the Company&#8217;s Preferred Stock, including the requisite financial analysis and
determination of a surplus. Accumulated but unpaid dividends in arrears on preferred stock were $<span id="xdx_901_eus-gaap--PreferredStockAmountOfPreferredDividendsInArrears_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zIKtoRIgiTQ7">0.3</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, or $<span id="xdx_90F_eus-gaap--PreferredStockPerShareAmountsOfPreferredDividendsInArrears_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zHVTZio9m3j">2.55</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, of preferred stock, as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Stock is convertible at the option of the holder at any time into the Company&#8217;s shares of common stock at a conversion
rate of approximately <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zOGNhn7UbHV">0.0000001</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for each share of Preferred Stock based
on a price of $<span id="xdx_90F_ecustom--ConvertiblePreferredStockConversionPricePerShare_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ztBeBzRoU1Ej">142,128,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company has reserved <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3IEihCHsAbi">6</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for issuance upon conversion of the
remaining shares of Preferred Stock outstanding at December 31, 2024. The shares of previously converted Preferred Stock have been retired,
cancelled and restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors
as shares of Preferred Stock of one or more series.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&#8217;s common stock has
exceeded $<span id="xdx_90D_ecustom--CommonStockClosingPriceThreshold_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zZTyEkWeG0jb">213,192,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which is <span id="xdx_901_ecustom--PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zH3UxVhle3bb">150</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the conversion price of the Preferred Stock, for at least <span id="xdx_90D_ecustom--PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zq3xaJ5siC7a">20</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading days during any <span id="xdx_90B_ecustom--PreferredStockConversionObligationNumberOfTradingDays_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ziudvZhBorI5">30</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-day
trading period, ending within <span id="xdx_909_ecustom--PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z7qW4QFrgAj9" style="display: none">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">five
trading days prior to notice of automatic conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock
for <span id="xdx_904_ecustom--DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_dc_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z0ty4fIsJuX9">six</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quarterly periods, holders of Preferred Stock are entitled
to nominate and elect two directors to the Company&#8217;s Board of Directors. This right accrued to the holders of Preferred Stock as
of August 2, 2010 and two directors were nominated and elected at the annual meeting held on May 24, 2011.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption price of
$<span id="xdx_904_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zQ53MohjAj38">10.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November
1, 2005, or Exchange Date for the Company&#8217;s <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zphZvKjMwR6b">6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
Convertible Subordinated Debentures, or Debentures at the rate of $<span id="xdx_908_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zK8Wfzuii8Rl">10.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">principal amount of Debentures for each share of Preferred
Stock. The Debentures, if issued, will mature <span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zkuYmJjsUAAf">25</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years after the Exchange Date and have terms substantially
similar to those of the Preferred Stock. No such exchanges have taken place as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, the company declared dividends of $<span id="xdx_90A_eus-gaap--PreferredStockDividendsPerShareDeclared_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zoIeHqACcAB8">0.15</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share quarterly on its <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zUWFr7Wm18E7">6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
Convertible Exchangeable Preferred Stock. These dividends were paid on February 1, 2024. No further dividends were declared or paid subsequent
to this.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z0M8qK40nSn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_826_zmTnXRsUqxkd">Stock Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the
Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based
awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods
when they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYtfZyMeRNhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended
March 31, 2025 and 2024 as shown in the following table (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zKQAAO8uuGuh" style="display: none">Schedule
of Stock Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250331_zpby0g2Vqtmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20240331_zxKy2IqfCBvg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March&#160;31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYy8HPBaUKN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,592</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zInBf5ZVuUYd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zu8nndUTR1i1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,666</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">203</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_zfbzK3CbrNwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2018
Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2018, the Company&#8217;s stockholders approved the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), under which Cyclacel
may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan allows for various types of award
grants, including stock options and restricted stock units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2025, the Company&#8217;s stockholders approved an amendment to the 2018 Plan to reserve an additional <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zOP6vKFv9OK1">500,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock for issuance thereunder, which number
would not be adjusted as a result of the Reverse Stock Split. As of March 31, 2025, the Company has reserved approximately <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zWr9O94r64a3">468,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock under the 2018 Plan
for future issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option awards granted under the Company&#8217;s equity incentive plans have a maximum life of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member__srt--RangeAxis__srt--MaximumMember_z1HQAHZ8ao32">10</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and generally <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20250101__20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zD8btxalzYGl">vest
over a one to four-year period from the date of grant.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2020
Inducement Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), became effective. Under the Inducement Plan,
Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder
approval). The Inducement Plan allows for the issuance of up to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20201031__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zenVrPqMNLYh">55</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock (or the equivalent
of such number). As of March 31, 2025, there were no shares issued under the Inducement Plan, leaving a remaining reserve of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zECb1czm6h26">55</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Awards Granted Outside of the 2018 Plan and Inducement Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
February 2025, the Company issued stock option awards to employees and consultants outside of the 2018 Plan and the Inducement Plan.
The shares underlying these options are not registered for resale. All of the options granted outside of the 2018 Plan and Inducement
Plan vest immediately upon grant and can be exercised beginning three months from the recipient&#8217;s Termination Date through the
expiry of the option awards, which is ten years from the grant date. The Termination Date is defined as the date on which an award recipient
ceases to be an employee, director or consultant of the Company or of an Affiliate for any reason other than the death or disability,
or termination of the recipient for cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Grants and Exercises</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpvnHevrbHue">24,818</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted during the three months ended March 31, 2025.
Of these awards, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmNdTSemosNj">1,068</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were issued under the 2018 Plan and the rest were issued outside
of the 2018 Plan and the Inducement Plan. Options granted during the three months ended March 31, 2025 had a grant date fair value ranging
between $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxMFXKlbm1q1">60.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__srt--RangeAxis__srt--MaximumMember_zB252Sjpw7Qd">72.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSywSSjd0i1b">52</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted under the 2018 Plan during the three months
ended March 31, 2024. These options had a grant date fair value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuwfH12Fjlq4">424.80</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zk3oxX36nWv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span id="xdx_8BE_zYhg4KfeWeV2" style="display: none">Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three months
    ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three months
    ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqFUkCdCtZWf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTjpv8bpNTi5">10</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwUUjiySqPj" style="font-family: Times New Roman, Times, Serif">6</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zKsRwGExvwIf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.060</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            &#8201;&#8211;&#8201;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zse7pFP0qWPl">4.250</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztCBFHieoNN" style="font-family: Times New Roman, Times, Serif">3.995</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zJNe79AcKKUc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&#8201;&#8211;&#8201;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zepvyxBHtzrc">107</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlentDg6UWHh" style="font-family: Times New Roman, Times, Serif">93</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield over expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrx1L8kJHrYh" style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaXlxtGKKdpd" style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Resulting weighted average grant date fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj7mjJsL01uf" style="font-family: Times New Roman, Times, Serif">69.60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNK8Lp6rs0V2" style="font-family: Times New Roman, Times, Serif">424.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zOU16x43Y1g3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_do_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5Hk5HSFpwW4">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock options exercised during each of the three months ended
March 31, 2025 and 2024, respectively. The Company does not expect to be able to benefit from the deduction for stock option exercises
that may occur because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Outstanding
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zQQmAYU3aYkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the share option activity and related information is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8BD_zoZ4fKD31OYc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Share Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price
    Per Share</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term&#160;(Years)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value&#160;($000)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstwfN5m9aj6" style="width: 12%; text-align: right" title="Number of Options Outstanding, Balance"><span style="font-family: Times New Roman, Times, Serif">494</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zytlelT6Ae67" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif">10,658.40</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9kHDuWSUJ9" style="font-family: Times New Roman, Times, Serif">7.20</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaEZNWTN3Ty1" style="width: 12%; text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1971">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z29rIEzredui" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif">24,818</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztxQ9q4xeaZ3" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">70.79</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zktzPgOv4HSh" style="text-align: right" title="Number of Options Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1977">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQqUjyUxUUkh" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1979">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLjl4YGhFYG1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">(53</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZfT3AMOY5Ld" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">2,238.25</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNELwZ9Cktb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Balance"><span style="font-family: Times New Roman, Times, Serif">25,259</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMdsAc4XTAV9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif">276.67</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv863YW7rCB1" style="font-family: Times New Roman, Times, Serif">9.76</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zorV9XJzvHS1" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1990">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYWebtg3xGp3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Unvested"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1PDNg7ypaj1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Unvested"><span style="font-family: Times New Roman, Times, Serif">2,094.84</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable
    at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpqjbPFISF37" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Vested and exercisable"><span style="font-family: Times New Roman, Times, Serif">25,238</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsebhVlWTaRe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable"><span style="font-family: Times New Roman, Times, Serif">275.17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zProbUO1VJKc" style="font-family: Times New Roman, Times, Serif">9.77</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlEDaTXVzfdl" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregrate Intrinsic Value, Vested and Exerciseable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl2001">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A6_zvFMNAb2hnYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxZJr4GZCzJb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units were issued during the three months
ended March 31, 2025. The Company issued <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze5Ema5bMKsf">52</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units during the three months ended March
31, 2024. These restricted stock units vested monthly over a six-month <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtM_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zT5g5dA4dah1" style="display: none">6</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">service period. These restricted stock units were valued at
$<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_iI_c20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9WPBZCBmJH7">547.20</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze3MYAgYX9Gb">71.36</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units were issued in January 2023. These units
vest on the third anniversary of their date of grant, or earlier if certain defined clinical trial related performance targets are met.
A three-year <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLLZ7NDCWYqd" style="display: none">3</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vesting assumption was applied to these restricted stock units
as satisfaction of the performance conditions is not probable at this time. Each restricted stock unit was valued at $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbOWdnDFImp7">3,240.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date. As of March 31, 2025, all but <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM4bwDq1qFh3">13</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the original awards granted have been forfeited due to the
recipient&#8217;s termination of service with the Company. In the three months ended March 31, 2025, the Company reduced stock compensation
cost, a component of selling general, and administrative expense, by approximately $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAWh4Ot3BwK4">61,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a result of forfeitures of these awards during that period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zIlyBKat9Eci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized
information for restricted stock units as of March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zlz1nvtipnN9" style="display: none">Schedule
of Restricted Stock Units Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Restricted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Grant Date</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Units</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value
    per share</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units outstanding
    at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zccoDBjfXf64" style="width: 14%; text-align: right" title="Restricted Stock Units, Balance"><span style="font-family: Times New Roman, Times, Serif">164</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAVbyDwPg9b" style="width: 14%; text-align: right" title="Weighted Average Grant Date Value per share, Balance"><span style="font-family: Times New Roman, Times, Serif">2,882.40</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJBQIK9FaNrb" style="font-family: Times New Roman, Times, Serif">8.30</span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zitdVZA2rNjd" style="text-align: right" title="Restricted Stock Units, Granted"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zylkNtvV5h7e" style="text-align: right" title="Weighted Average Grant Date Value per share, Granted"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbmenNYJpFbl" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted Stock Units, Cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">(28</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQf3PvJrKsG2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Value per share, Cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">3,300.00</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units
    outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC6Pc9nonvbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted Stock Units, Balance"><span style="font-family: Times New Roman, Times, Serif">136</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4ngbjnxOPEb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Value per share, Balance"><span style="font-family: Times New Roman, Times, Serif">2,795.37</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEq554owd7ha" style="font-family: Times New Roman, Times, Serif">8.09</span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested at March 31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAhgUkCLGvL3" style="text-align: right" title="Restricted Stock Units, unvested"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgEvQltVVBR4" style="text-align: right" title="Weighted Average Grant Date Value per share, Unvested"><span style="font-family: Times New Roman, Times, Serif">3,240.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTZDNVuDP0Oh" style="font-family: Times New Roman, Times, Serif">7.82</span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Vested at March 31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2aBmLd5Wzh" style="text-align: right" title="Restricted Stock Units, Vested"><span style="font-family: Times New Roman, Times, Serif">123</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zU0TV8voZ7ze" style="text-align: right" title="Weighted Average Grant Date Value per share, Vested"><span style="font-family: Times New Roman, Times, Serif">2,747.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlBhulV3rLeb" style="font-family: Times New Roman, Times, Serif">8.12</span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p id="xdx_8AD_zkCzJRcHThC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_znQWdRcu69i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_821_zEM0MRbmF4ef" style="display: none">Stock
Based Compensation</span></span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zXCK22xGcJEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the years ended 2024 and
2023 as shown in the following table (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zW9fimmMO287" style="display: none">Schedule
of Stock Based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z5J1LKCuPOd6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zoBc2yGOwLFk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zG7j9d9M17T4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">498</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,039</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5qIKuYJsX7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zUb79rLOxow5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,473</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zyYSPO1y2Ai9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2018
Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2018, the Company&#8217;s stockholders approved the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), under which Cyclacel
may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan replaced the 2015 Equity Incentive
Plan (the &#8220;2015 Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2018 Plan allows for various types of award grants, including stock options and restricted stock units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2024, the Company&#8217;s stockholders approved an additional <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240621__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zeFiU61TQvt">160,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that may be issued under the 2018 Plan.
On June 13, 2023, the Company&#8217;s stockholders approved an additional <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230613__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z6ms7IFo8Lij">60,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that may be issued under the 2018 Plan.
As of December 31, 2024, the Company has reserved approximately <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z9agf1Z10yx5">196,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock under the 2018 Plan
for future issuances. Stock option awards granted under the Company&#8217;s equity incentive plans have a maximum life of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member__srt--RangeAxis__srt--MaximumMember_zgbuIy9LIkuf">10</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and generally <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240101__20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z27qR6ke1CFl">vest
over a one to four-year period from the date of grant.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020
Inducement Equity Incentive Plan </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), became effective. Under the Inducement Plan,
Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder
approval). The Inducement Plan allows for the issuance of up to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20201031__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zy9d7OagRbpd">55</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock (or the equivalent
of such number). As of December 31, 2024, the reserve remains at <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zVvOaQTEFAYk">55</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Grants and Exercises</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeIIfNY9BWz4">52</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted during the year ended December 31, 2024, all
issued under the 2018 Plan. These options had a grant date fair value of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr01DMLhwYbe">424.80</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per option. There were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCLNscJVcAu1">181</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted during the year ended December 31, 2023. These
options had a grant date fair value ranging between $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zNpnvqTKb2te">1,516.80</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zpp49O0UskSl">2,635.20</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the options granted during the year ended December 31, 2024, all vested <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0KzoUypebxi">six
months</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from their date of grant. Of the options
granted during the year ended December 31, 2023, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--OptionsVestingOnThirdAnniversaryOfGrantMember_zScAeDCVQIA5">71</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">awards shall vest on the third anniversary of their date of
grant, or earlier if either of the certain performance conditions are met relating to enrollment goals for various clinical studies.
A further <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV64TXIKVcYc">36</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options granted during the year ended December 31, 2023 were
forfeited during 2024 due to the holders&#8217; termination of employment with the Company. The Company had assumed that these awards
will vest after <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dc_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--OptionsVestingOnThirdAnniversaryOfGrantMember_zZuZYVw122Q1">three
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as satisfaction of the performance conditions
is not probable at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the total remaining unrecognized compensation cost related to the non-vested stock options with service conditions
amounted to approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231_zKgpLL0nXbzc">0.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which will be amortized over the weighted-average
remaining requisite service period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_z8HmQwph5sce">1.30</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Outstanding
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zYaETrg97Iuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the share option activity and related information is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zYiLYeCPA6tk" style="display: none">Schedule
of Share Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Exercise</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Remaining</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Aggregate</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Options</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Price Per</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Contractual</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Intrinsic</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Term (Years)</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value ($000)</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%">Options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZba66nJpzr1" style="width: 10%; text-align: right" title="Number of Options Outstanding, Balance">447</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpPSaXrFwvVa" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Balance">21,049.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6ihu0t7sqTc">8.34</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKlyebtltsKg" style="width: 10%; text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4uBx3qaHJJj" style="text-align: right" title="Number of Options Outstanding, Granted">181</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG6lVgIsPxrf" style="text-align: right" title="Weighted Average Exercise Price, Granted">2,117.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjZg89pcq0ce" style="text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4rlVdRnM6O9" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0951">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zei0oYx5BAD2" style="text-align: right" title="Number of Options Outstanding, Cancelled/forfeited">(33</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAp2gYljl4z3" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited">79,737.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW6MdwH7khT8" style="text-align: right" title="Number of Options Outstanding, Balance">595</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxNXXZznHXje" style="text-align: right" title="Weighted Average Exercise Price, Balance">12,048.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmJ5D0fqqkT3">7.96</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1THMMqemkLb" style="text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0962">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTDEG35BHJkf" style="text-align: right" title="Number of Options Outstanding, Granted">52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKNNH2gjtHA2" style="text-align: right" title="Weighted Average Exercise Price, Granted">547.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z45Oa4VM7lp9" style="text-align: right" title="Number of Options Outstanding, Cancelled/forfeited">(153</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqB5l4LngxRl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited">12327.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1aMINQMRCJc" style="text-align: right" title="Number of Options Outstanding, Balance">494</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvHykPYxeNHh" style="text-align: right" title="Weighted Average Exercise Price, Balance">10,658.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgOqXuyCcwD2">7.20</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXPhzx6MQkGi" style="text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3wxdHLU6Wd4" style="text-align: right" title="Number of Options Outstanding, Unvested">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjrVZ71REUt4" style="text-align: right" title="Weighted Average Exercise Price, Unvested">2,250.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmh8LOODM46c">8.45</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTSjcDWGjEBi" style="text-align: right" title="Number of Options Outstanding, Vested and exercisable">420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7JzNxuMInj7" style="text-align: right" title="Weighted Average Exercise Price, Vested and exercisable">12,141.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwcSRTTunONf">6.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDlk1p37R0C7" style="text-align: right" title="Aggregrate Intrinsic Value, Vested and Exerciseable"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zHpzs7E0GNpb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLk6BC2Yaog5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B7_zuL5AUzeIOG2" style="display: none">Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Year ended</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Year ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdy05diIKDd6">6</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zi4hnL1Nbi65" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zWa2OUYvebgi">6</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr79fZTdLQOe">3.995</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zPj9fqVcqaJ2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.660</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            &#8201;&#8211;&#8201;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTCRQ6XLrwv5">4.160</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6AtZ7wEbaLk">93</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHPdnGuNw9Z6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&#8201;&#8211;&#8201;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zD8iL2fdMt72">92</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield over expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSyMhqwDeVMb">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDBGHpXkRUOe">0.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Resulting weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqLTmwaaiAih">424.80</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjDlkN8WLLZ5">1,591.20</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zkuTqvoTGAA" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSbXS9y0d0S9" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1005">no</span></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock options exercised during each of the years ended December
31, 2024 and 2023, respectively. The Company does not expect to be able to benefit from the deduction for stock option exercises that
may occur because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK3tmfhPqMs9">52</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units during the year ended December 31, 2024.
These restricted stock units vest monthly over a six-month<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtM_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbiwy96lLcQb" style="display: none">6</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">service period. These restricted stock units were valued at
$<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdQNw50UDo8d">547.20</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbKBK3EXdol5">71</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units were issued in January 2023 vest on
the third anniversary of their date of grant, or earlier if certain defined clinical trial related performance targets are met. A three-year<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1s54avrM6Ee" style="display: none">3</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vesting assumption was applied to these restricted stock units
as satisfaction of the performance conditions is not probable at this time. Each of these restricted stock units was valued at $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgQdUy0iVF2e">3,240.00</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date. During 2023, <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0krSL20mtli">1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of these restricted stock units were forfeited as the recipient
voluntarily terminated employment with the Company. A further <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSdTTweCTRNh">35</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units issued in June 2023 vest on the first
anniversary of the date of grant. Each of these restricted stock units were valued at $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pp2d_c20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWLOO99AkOpg">2,121.60</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the date of grant, which was equivalent to the market price
of a share of the Company&#8217;s common stock on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, an additional <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGyHbUH9o1x3">32</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of these restricted stock units have been forfeited due to
the holders&#8217; termination of employment with the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z0y5of2jRFW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized
information for restricted stock units as of December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z3I6sU64j9Ca" style="display: none">Schedule
of Restricted Stock Units Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Restricted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Remaining</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Stock Units</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Term</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 51%; text-align: left">Restricted Stock Units outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4bnpsxRNzp5" style="width: 14%; text-align: right" title="Restricted Stock Units outstanding, Beginning balance">38</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5vmvcpilDg8" style="width: 10%; text-align: right" title="Restricted Stock Units, Grant Date Value Per Share">6,768.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFYiu1O9hNg" style="text-align: right" title="Granted">107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zARNwFuag36h" style="text-align: right" title="Granted">2,870.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdkJjVayPsI5" style="text-align: right" title="Cancelled/forfeited">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRFRVJA2uDT2" style="text-align: right" title="Cancelled/forfeited">3,240.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrWRPQXoR4yd" style="text-align: right" title="Restricted Stock Units outstanding, Beginning balance">144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBGAA1hpRkl1" style="text-align: right" title="Restricted Stock Units, Grant Date Value Per Share">3,902.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPxTjzhMzzX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.96</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRomSdcQm0g8" style="text-align: right" title="Granted">52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJFqXxPzH1Ej" style="text-align: right" title="Granted">547.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkqh0qcxHcUi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.03</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAfRIpbwJTIk" style="text-align: right" title="Cancelled/forfeited">(32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD5MLF0pZK74" style="text-align: right" title="Cancelled/forfeited">3,675.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZrTIw89T5rl" style="text-align: right" title="Restricted Stock Units outstanding, Ending balance">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6AnS530vm5j" style="text-align: right" title="Restricted Stock Units, Grant Date Value Per Share">2,881.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdrTMg2j6Qw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.30</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzrxrQL9jip3" style="text-align: right" title="Unvested">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztEIEWKXLf67" style="text-align: right" title="Unvested, Weighted Average Grant Date Value Per Share">3,280.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8A61gEZ9Bf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.06</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb6xI7zGQfe6" style="text-align: right" title="Vested">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQYuj9KVPi75" style="text-align: right" title="Vested">2,747.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdKSrMuFyqBb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.39</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z6vaINvgkkf5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z4JEEJEo67V9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_82E_zqDEuSLYSI8i">Employee Benefit Plans</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pension
Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates a defined contribution group personal pension plan for all of its UK based employees. Company contributions to the plan
totaled approximately $<span id="xdx_907_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20240101__20241231_z2dd5cvF5pd7">51,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_z2Whnnugw6F">52,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>401(k)
Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
401(k) Plan provides for matching contributions by the Company in an amount equal to the lesser of <span id="xdx_907_ecustom--DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_pid_dp_uPure_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zsBo8GLJzrd4">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the employee&#8217;s deferral or <span id="xdx_901_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pid_dp_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_z9kCUlpY4w7e">6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the U.S. employee&#8217;s qualifying compensation. The 401(k) Plan is intended to qualify under Section 401(k) of the Internal Revenue
Code, so that contributions to the 401(k) Plan by employees or by the Company, and the investment earnings thereon, are not taxable to
the employees until they are withdrawn. Company matching contributions are tax deductible by the Company when made. In 2024, Company
employees could elect to reduce their current compensation by up to the statutorily prescribed annual limit of $<span id="xdx_90E_ecustom--DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_z2wXwLdjHdV">23,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if under 50 years old and $<span id="xdx_90C_ecustom--DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zFq0vlBb6pQ5">30,500</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if over 50 years old and to have those funds contributed to
the 401(k) Plan. The Company made contributions of approximately $<span id="xdx_906_eus-gaap--DefinedContributionPlanCostRecognized_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zNkj37no1lpl">40,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pp0d_c20230101__20231231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_ztTBMIszXbdc">103,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the 401(k) Plan for the years ended December 31, 2024 and
2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_z0l3rkrmF2o1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_82C_z9ds2jaJjJoa">Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zi2SGX2EgT35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Loss)
income from continuing operations before taxes is comprised of the following components for the years ended December 31, 2024 and 2023
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_ziPhwKKQ7QD9" style="display: none">Schedule
of Components of (Loss) Income Before Taxes from Continuing Operations</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z40s8ijn56Sg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_z6hypnLtSc9c" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_zpbZuNxDOIb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(806</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_zn0TTtefFfZ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,745</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztT40wwpCbvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from continuing operations before taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,994</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(25,551</td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8AA_zgXzGKTTjWei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zP6uKjErOoEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
benefit (provision) for income taxes from continuing operations consists of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zzIQKg3SheM1" style="display: none">Schedule
of Benefit (Provision) for Income Taxes from Continuing Operations</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Current&#8201;&#8201;&#8211;&#8201;&#8201;domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20240101__20241231_zHkvjHh0ciX7" style="width: 15%; text-align: right" title="Current - domestic">(21</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230101__20231231_zDspSsLfAIQe" style="width: 15%; text-align: right" title="Current - domestic">(2</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current&#8201;&#8201;&#8211;&#8201;&#8201;foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20240101__20241231_z9oZ5jhlCOdj" style="text-align: right" title="Current - foreign">803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20230101__20231231_z6Hfu5Pnc17b" style="text-align: right" title="Current - foreign">2,998</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current&#8201;&#8201;&#8211;&#8201;&#8201;total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zloeSjLyuHY7" style="text-align: right" title="Current - total">782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_z9VgN91v53Lk" style="text-align: right" title="Current - total">2,996</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred&#8201;&#8201;&#8211;&#8201;&#8201;domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20240101__20241231_zQ2kfkKvaYm5" style="text-align: right" title="Deferred  -  domestic"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20230101__20231231_zSiCUsFkQC8k" style="text-align: right" title="Deferred  -  domestic"><span style="-sec-ix-hidden: xdx2ixbrl1099">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20240101__20241231_z1GEgQ9Enx3h" style="text-align: right" title="Income tax benefit">782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20230101__20231231_zwWKMtcDwWP7" style="text-align: right" title="Income tax benefit">2,996</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z0hVNo1lu5Ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a taxable loss in each of the operating periods since incorporation. The income tax credits of $<span id="xdx_90A_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231_zKVJoKduiR1d">0.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20231231_zWcBYe3D7Oyk">3.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for the years ended December 31, 2024 and 2023, respectively,
represent UK research and development (&#8220;R&amp;D&#8221;) tax credits for expenditures in the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zIXbJHNN5g85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory
federal tax rate to loss from continuing operations before income taxes is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BD_zGLXvuCpGWSa" style="display: none">Schedule
of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory
Federal Tax Rate to Loss Before Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z8pHbjV9u6k3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zHIcFpd8tN45" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_z4J0PexTZVJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Loss from continuing operations before taxes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(11,994</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(25,551</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_z6JAAMhrd20f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax expense computed at statutory federal tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,527</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,366</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_zV1GNveNkmd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional research and development tax relief</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,409</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_zyhfrwmzo8hf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss surrendered to generate R&amp;D credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,865</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_zZ68zSJfuL25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,261</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_zdz7HvdWK7cj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other foreign items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,158</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">809</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_pn3n3_zvxQ78xJhSSe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Disallowed expenses and non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">782</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_zocg3OA9DKb3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_zkjIlTHWkJAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign items, including change in tax rates, and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationOtherItemsAmount_pn3n3_zI4jzmlThK9f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zrvdoTqNWRlb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Current - total</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(782</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,996</td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8AD_zWX1gTWRmRj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTQBA6wBlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&#8217;s deferred tax assets are shown below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zaRTNnpL4Wy7" style="display: none">Schedule
of Significant Components of the Entity's Deferred Tax Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zYKpNA6rzTgb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zXMGekTlL4Cl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzNQW_z9WHoQsvbAp2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Net operating loss and tax credit carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">59,417</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">57,074</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_iI_pn3n3_maDTAGzNQW_zgSYHJggyol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation, amortization and impairment of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzNQW_zkSqryKkSQNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_iI_pn3n3_maDTAGzNQW_zeB95xzQFgza" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseRightOfUseAsset_iI_pn3n3_maDTAGzNQW_zUcW5ieyLWNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsLeaseRightOfUseLiability_iI_pn3n3_maDTAGzNQW_zudO5YVuNRlc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzNQW_zqg5xGjm4Fmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzNQW_maDTANzSsl_z8fPaw5CXOh7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,323</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzSsl_zlMJjZXNVAXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation allowance for deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(59,820</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57,323</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzSsl_zET7nPL47GL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zJQF0WqlpXk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance has been established, as realization of such assets is uncertain. The Company&#8217;s management evaluated the positive
and negative evidence bearing upon the realizability of its deferred assets, and has determined that, at present, the Company may not
be able to recognize the benefits of the deferred tax assets under the more likely than not criteria. Accordingly, a valuation allowance
of approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20241231_zVgt0vwS60J6">59.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million has been established at December 31, 2024. The valuation
allowance increased by approximately $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zjQ2QYDP92g1">2.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
specified in the Tax Reform Act of 1986, due to ownership changes, the Company&#8217;s ability to utilize its net operating loss (&#8220;NOL&#8221;)
carryforwards may be limited. Utilization of the NOLs may be subject to a substantial annual limitation under Section 382 of the Internal
Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership
changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and
tax, respectively. The Company completed a Section 382 study and has concluded that an ownership change occurred on March 4, 2015 and
July 21, 2017. As a result of the ownership changes, the NOLs are limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company has federal NOLs of $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zjWiNCg79XT7">3.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zswJqJgLAcXf">3.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. The federal NOLs have an indefinite
life. As of December 31, 2024 and 2023, the Company has state NOLs of&#8201;$<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zcg5ohylH34">16.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ziCVmlso24De">17.3</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively, which will begin to expire in 2028.
As of December 31, 2024 and 2023, the Company had foreign NOLs of $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zJgjQM3J2bcc">230.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zcWSGz9BC0jk">220.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. The Company&#8217;s foreign NOL&#8217;s
do not expire under UK tax law however the use of these NOLs is restricted to an annual &#163;<span id="xdx_906_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn6n6_uGBP_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zET1OBwkf7Zd">5.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million allowance in each standalone company or group and above
this allowance, there will be a <span id="xdx_90A_ecustom--PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_pid_dp_uPure_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z7JNT7IuFkw1">50</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
restriction in the profits that can be covered by losses brought forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated all significant tax positions at December 31, 2024 and 2023 and concluded that there are no material uncertain tax positions.
The Company would recognize both interest and penalties related to unrecognized benefits in income tax expense. The Company has not recorded
any interest and penalties on any unrecognized tax benefits since its inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
years 2020 - 2023 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the
United Kingdom and the United States, as carryforward attributes generated in years past may still be adjusted upon examination by the
United Kingdom&#8217;s H.M. Revenue &amp; Customs, the Internal Revenue Service (&#8220;IRS&#8221;) or state tax authorities. The Company
is currently not under examination by the IRS or any other jurisdictions for any tax years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not provided a deferred tax liability on the cumulative amount of unremitted foreign earnings of international subsidiaries because
it is our intent to permanently reinvest such earnings outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an aggregate deficit in foreign earnings and therefore has not provided any deferred tax liability on its outside book-tax
basis difference in its foreign subsidiaries and because it is also our intent to permanently reinvest any earnings outside of the United
States. We would recognize this deferred tax liability if we were to experience a change in circumstances producing a change in that
intention. As a result of the repeal of Section 902 foreign tax credit under the Tax Act, future distributions would not be offset by
a foreign tax credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental
to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting
these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses
for tax years tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be
amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E
activities are broader in scope than qualified research activities that are considered under IRC Section 41 (relating to the research
tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that
the company does not have any R&amp;E expenses in the US. The company will continue to monitor this issue for future developments, but
it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zpofJ7nei8Zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_824_zRM4uZwVOCvk">Net Loss per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (&#8220;ASC 260&#8221;). Basic
and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number
of shares of common stock outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zbzAXbJny5Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months
ended March 31, 2025 and 2024, as the result would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_z43J4DXcFng7" style="display: none">Schedule
of Earnings Per Share, Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250331_zSVobvtRXP52" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20240331_zZJFVDt0iGye" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWpMgCBotake" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><p style="margin: 0">25,259</p></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">619</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuyEMv5nfs8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">136</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SixPercentConvertibleExchangeablePreferredMember_zYxhTPDB1Uue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">6% convertible exchangeable preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zmOM5NfdY59d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;A preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesDPreferredStockMember_zOhr2In2vgyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;D preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,588</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1857">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zRfDUYCbGV05" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;E preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">458,333</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zXNf4hOm0ZY4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">101,905</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,648</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zs36fcpXjAL4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total shares excluded
    from calculation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">748,224</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,456</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_z4RvWrHKJQIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zzhzGbR1nhnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
Net Loss Per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_823_zj1AqnScSNpl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Loss per Common Share</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaPgmkrAWcSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to common stockholders was calculated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zmPAJzP3Lbrl" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zApuHLCLafz8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zosuHDqHoUu3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Years ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_iB_zkye7KFpM8v1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pn3n3_zbSYFLhOBBbd" style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(11,212</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(22,555</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockDividendsIncomeStatementImpact_i01N_pn3n3_di_zWwGMIonyOHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend on convertible exchangeable preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(201</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01_pn3n3_zZDaggpx6Wfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to common shareholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(22,756</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zpuiu0OGIyBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average number of common shares used in loss per share&#8201;&#8211;&#8201;basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_z2K08zwrNZj9">22,314</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zU4gHRANFRC2">3,545</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss per share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zPueyGER5C51">(502.46</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zHsdxXBu0y1h">(6,419.07</span></td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8A9_zBdjnzCqCrA6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss
per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per
share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on
amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the
periods indicated because including them would have had an anti-dilutive effect:</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8A5qjK8ZPL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zMnLkR0Etvvg" style="display: none">Schedule
of antidilutive shares excluded from computation of diluted net loss per share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zk6Kqj4vAPUe" style="text-align: center">December 31,</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zlAdyJ4k5uG7" style="text-align: center">December 31,</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrCtIDMllqvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">494</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">595</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zR6bOlwu5J4h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zyDexCfFVXUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20231231_zrUem3V7owIj">6</span>%
    convertible exchangeable preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zRFaUHnu69b4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zCe0VYxg8vfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1222">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_ziemC2QSOQWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,648</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zVCB9AnJJVy5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total shares excluded from calculation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,554</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zP6iQB9a6Ofh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic and Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Geographic and Segment Information</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zFvFF9ZiFIz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_827_zCY0RQhiwx5l">Geographic and Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zhvSlWLPSFni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geographic
information for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zjd4R6VCOs8i" style="display: none">Schedule
of Geographic Information</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenue</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">United Kingdom</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z31mrJ5xVR5f" style="width: 15%; text-align: right" title="Revenue">43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zYpp0Btyfs8h" style="width: 15%; text-align: right" title="Revenue">420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231_zmcpsLEtp13f" style="text-align: right" title="Revenue">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231_zkaLebsGMq57" style="text-align: right" title="Revenue">420</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United States</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z93MITdRGmJg" style="text-align: right" title="Net Loss">(37</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zB8d1IKB0Y7b" style="text-align: right" title="Net Loss">(808</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z9oQ8kHoVvNf" style="text-align: right" title="Net Loss">(11,175</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zRJ0Tzg31Vwf" style="text-align: right" title="Net Loss">(21,747</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Net Loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231_z9ia6vKOwEye" style="text-align: right" title="Net Loss">(11,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231_zBLG7QHpFici" style="text-align: right" title="Net Loss">(22,555</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_z4mkAC6qKjjd" style="width: 15%; text-align: right" title="Total Assets">3,285</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_z3BUwgBWuDD3" style="width: 15%; text-align: right" title="Total Assets">2,938</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zIbAgLrDsWP9" style="text-align: right" title="Total Assets">809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zsxWshuvtgH" style="text-align: right" title="Total Assets">5,867</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20241231_zUlx5ZeC1M8j" style="text-align: right" title="Total Assets">4,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20231231_zAJ7AObNigng" style="text-align: right" title="Total Assets">8,805</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long Lived Assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">United States</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_zCpCcEUOJzub" style="text-align: right" title="Long Lived Assets, net">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_zJfAm2BtN2of" style="text-align: right" title="Long Lived Assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1269">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zSuaHLMaO2Nc" style="text-align: right" title="Long Lived Assets, net">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zKbX2ASHevdk" style="text-align: right" title="Long Lived Assets, net">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Long Lived Assets, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231_zTND4cTeXCu1" style="text-align: right" title="Long Lived Assets, net">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231_zRyQfY2EJ2Nf" style="text-align: right" title="Long Lived Assets, net">9</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zsP8HMlkbOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as a single segment engaged in the development of innovative cancer medicines based on cell cycle, transcriptional regulation
and mitosis control biology. Consistent with our operational structure, our Chief Executive Officer (CEO), as the chief operating decision
maker, makes resource allocation and business process decisions globally across our consolidated business. Managing and allocating resources
at the consolidated level enables our CEO to assess the overall level of resources available and how to best deploy these resources across
functions, and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on
a geographic or some other basis. Consistent with this decision-making process, our CEO considers consolidated net loss, which is our
single segment&#8217;s principal measure of segment profit and loss, when evaluating performance and allocating company-wide resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
expenses are amounts that are regularly provided to our CEO and included in consolidated net loss, our primary measure of our single
segment&#8217;s profit or loss. Our CEO regularly reviews reported consolidated revenues, significant expenses and consolidated net loss,
in addition to forecasted revenues, significant expenses and net loss amounts for future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zKx9LsphFx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of our consolidated net loss for the years ended December 31, 2024 and 2023 is as follows, including the significant expenses
provided to and regularly reviewed by our CEO:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B0_z7QwPwziIp66" style="display: none">Schedule
of Summary of Consolidated Net Loss</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zGDczUfPKtg" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zp3qrFRvlZzk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zWylEmRgvbF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zMpaKm9T8JXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzPoy_zyBHG2eEx5zf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,155</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pn3n3_maOEzPoy_zmCmaBoierR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,718</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEzPoy_z6BXTAH0TEac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_pn3n3_maILFCOzkrX_z5BrWNbJ2yTb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,004</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,453</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_maILFCOzkrX_z30IvRkRIle8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzkrX_maNILz14R_zBwzAszUDlab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,994</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_di_msNILz14R_zQ2xcxeqceca" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,996</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz14R_zb1OinZBvAt1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(22,555</td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8AA_zHmoeihOuKli" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p id="xdx_804_eus-gaap--RevenueFromContractWithCustomerTextBlock_zpHZwylWVeue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_820_zHz5eSwZwLtd">Revenue</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_dxL_c20250101__20250331_zoY26LBzUa2l" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1837">0</span></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue for the three months ended March 31, 2025 and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20240331_z4IUS3sB0iXe">29,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the three months ended March 31, 2024. This revenue is
related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zV3IkZxjpg3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_82E_zNdrso9qbDLh">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has an operating lease liability relating to its facilities in Kuala Lumpur, Malaysia. The Company terminated its lease
agreement for its previous headquarters in Berkely Heights, New Jersey, effective January 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2025 and 2024, the Company recognized operating lease expenses of $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20250101__20250331_zfafTDQdbiAf">1,176</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20240331_z2xbsuVlcEK5">19,039</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively, including $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20250101__20250331__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_znOi1ut4nW03">0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240101__20240331__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zMBdCNNRjAoe">3,011</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively relating to a short term lease for offices in
Dundee, Scotland. Cash payments made during the three months ended March 31, 2025 and 2024 totaled $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20250101__20250331_zi1fw9t1Hfh1">0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90E_eus-gaap--OperatingLeasePayments_c20240101__20240331_zXpJey0GUjUg">19,037</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, and were presented within cash outflows from operating activities. The remaining lease term as of March 31, 2025 is approximately
<span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331__srt--StatementGeographicalAxis__custom--KualaLumpurFacilityMember_zZcGgK6QrlAe">1.9</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years for the Kuala Lumpur facility. The discount rate used
by the Company in determining the lease liability was <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20250331_zJl1vjsFJsVh">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z7uw9TXndB96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining
lease payments for both facilities are as follows (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zVNt5lnBaftk" style="display: none">Schedule
of Remaining Lease Payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20250331_zn4xLC10bj1e" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzo6M_zxqWjMRO59ug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_pn3n3_maLOLLPzo6M_z9ML6eh0b3T1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_pn3n3_maLOLLPzo6M_z4w1j7Zt1rL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maLOLLPzo6M_zsCZr4fNrUng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1919">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzo6M_zDO9QjtMUjIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total future minimum
    lease obligation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zRRwrwyyhI1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zKLzuswfrDM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_822_zKfc4OaQw7g3">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends
on 6% Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2025, the board of directors of the Company declared a quarterly cash dividend on the Company&#8217;s <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250419__20250419__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zerVJoSVrM8b" title="Preferred stock, dividend rate">6</span>% Convertible Exchangeable
Preferred Stock scheduled for May 1, 2025. The cash dividend was paid on May 1, 2025, to Preferred Stock stockholders of record as of
the close of business on April 29, 2025. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on
a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock Conversions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2025, all of the remaining <span id="xdx_909_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250402__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXp45eGMmaEa" title="Number of common shares issued upon conversion">354,738</span> shares of the Company&#8217;s Series D Preferred Stock was converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250402__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zumQM22wlBZk" title="Number of shares converted">162,588</span> shares
of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2025, all of the <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv2zE2pslVTg" title="Number of common shares issued upon conversion">1,000,000</span> shares of the Company&#8217;s Series E Preferred Stock was converted into <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250429__20250429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBBonK5PAX64" title="Number of shares converted">45,833</span> shares of
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Amendment to Amended and Restated
Certificate of Incorporation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 25, 2025, after obtaining the
approval of the Board of Directors and the Company&#8217;s majority stockholder, the Company filed a Certificate of Amendment to its Amended
and Restated Certificate of Incorporation to increase the number of authorized shares of the Company&#8217;s common stock from two hundred
fifty million (<span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20250424_zAc9tKH6mDb8" title="Common stock, shares authorized">250,000,000</span>) to six hundred million (<span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20250425_zlbcXLeMvJT7" title="Common stock, shares authorized">600,000,000</span>). The amendment did not result in any changes to the issued and outstanding
shares of the Company&#8217;s common stock, and only affects the number of shares that may be issued by the Company in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Proposed
Business Combination of FITTERS Diversified Berhad</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2025, the Company entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; &#8220;FITTERS&#8221;), an investment
holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention
systems, &#8220;Waste-To-Resource&#8221; services and real estate development and construction. Pursuant to the Exchange Agreement, all
of the ordinary shares owned by FITTERS of FITTERS&#8217; subsidiary, Fitters Sdn. Bhd., a Malaysia-based private limited company (&#8220;Fitters
Sub&#8221;) shall be exchanged for common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250506__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8rn5pZbpNz2">0.001</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
of the Company (the &#8220;Purchaser Stock&#8221;), and Fitters Sub shall be continuing as a wholly-owned subsidiary of the Company (the
&#8220;Transaction&#8221;). As part of the Transaction, Cyclacel shall issue an amount of Purchaser Stock equal to 19.99% percent, which
percentage may be subject to adjustment, of the issued and outstanding shares of Purchaser Stock as of the closing date to FITTERS. At
the closing, it is expected that Cyclacel stockholders will own approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20250506__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FittersDiversifiedBerhadMember_zKEj4G1rxi17">80.01</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the combined company. Cyclacel expects that at the closing of the Transaction, its common shares will continue to be listed on the
Nasdaq Capital Market under a new ticker symbol and Cyclacel will be renamed Bio Green Med Solution, Inc. Among the termination rights,
both Cyclacel and FITTERS have the right to terminate the Exchange Agreement if the closing date of the Transaction has not occurred
on or before September 30, 2025. It is currently anticipated that at least one of the officers or directors of FITTERS or Fitters Sub
will be appointed to Cyclacel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction is subject to approval from Cyclacel stockholders and FITTERS shareholders. The Exchange Agreement has been unanimously approved
by the Boards of Directors of each of Cyclacel, FITTERS and Fitters Sub.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2025, the Company filed an amendment to its Certificate of Incorporation (&#8220;Certificate of Amendment&#8221;)
to implement a <span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20250507__20250507_zOr33nZ0KVag" title="Reverse stock split">one-for-sixteen</span> reverse stock split. The effective date of the Certificate of Amendment is May 12, 2025 (the &#8220;Effective
Date&#8221;). The Company&#8217;s common stock began trading on a split-adjusted basis when the market opened on the Effective Date. The
Board of Directors of the Company approved the amendment to the Company&#8217;s Certificate of Incorporation primarily to meet the share
bid price requirements of The Nasdaq Capital Market. The Company&#8217;s stockholders approved the Certificate of Amendment at a special
meeting of its stockholders held on February 6, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
reverse stock split, on the Effective Date, every sixteen shares of common stock then issued and outstanding automatically was combined
into one share of common stock, with no change in par value per share. No fractional shares were outstanding following the reverse stock
split, and any fractional shares that would have resulted from the reverse stock split have been (a) rounded up to the nearest whole
number for any shareholder who would otherwise be entitled to receive one-half or more of a fractional split-adjusted share, and (b)
rounded down to the nearest whole number for any shareholder who would otherwise be entitled to receive less than one-half of a fractional
split-adjusted share.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zf22ZbzN9hBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_860_zORo9d23eFii" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and
the reported expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals and stock-based
compensation expense. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various
other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates.
Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the
Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency and Currency Translation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z9r0BdZUBTpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86D_ztLasLFOULI3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency and Currency Translation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied
to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
January 24, 2025, the assets and liabilities of the Company&#8217;s international subsidiary were translated from its functional currency
into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used
to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation
adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign
exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable
future and that are of a long-term-investment nature, were recorded in other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zTsyEQTmcUjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zzBt6yywtCb9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency and Currency Translation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities of the Company&#8217;s international subsidiary are translated from its functional currency into United States
dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the
statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising
on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses
arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable future and that
are of a long-term-investment nature, are recorded in other comprehensive loss. As discussed in the subsequent events note, the foreign
subsidiary will be liquidated. Upon loss of control of the foreign subsidiary, the accumulated translation adjustments currently recorded
in other comprehensive income within equity will be reversed and recorded as part of the gain/loss from deconsolidation of the subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhPazvbBRD2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_868_zg5mNVQtEq1k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and Cash Equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds, to maintain sufficient
liquidity to meet Cyclacel&#8217;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial
institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is
exposed to any significant credit risk on cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash and cash equivalents balance at December 31, 2024 was $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z8mXOaPoUwya">3.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and it maintains its cash accounts in several entities
both within the United States and the United Kingdom. The cash balances for amounts held in the United States are insured by the Federal
Deposit Insurance Corporation, or FDIC up to $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20241231__srt--RangeAxis__srt--MaximumMember_ztFkYdx0KeVa">250,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per account. The Company has cash balances exceeding the balance
insured by the FDIC that totaled approximately $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zRYaqA6cTC64">2.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million at December 31, 2024. The cash balances for amounts
held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme, or FSCS up to &#163;<span id="xdx_907_ecustom--CashFinancialServicesCompensationSchemeInsuredAmount_iI_uGBP_c20241231__srt--RangeAxis__srt--MaximumMember_z8induwTekb5">85,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per account. The Company does not have cash balances exceeding
the balance insured by the FSCS at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8XV9i7HEWC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zJXr7MejXSGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and Equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of
the related assets, which are generally three <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zKERt8IxurR8" style="display: none">3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zS7NMRj7zts8">five
years</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Amortization of leasehold
improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life
of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are
removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss.
Expenditures for maintenance and repairs are charged to operating expenses as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zSYMxV5D0yt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zqSOuNl91Gt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets
by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment,
if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKMAUBis1ymd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86B_zSjmyuNmHdNa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts
payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrUHKJjdqFV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86B_zqNibifhTxSh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy,
of which the first two are considered observable and the last is considered unobservable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#9679; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1&#8201;&#8212;&#8201;Quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2&#8201;&#8212;&#8201;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that
are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3&#8201;&#8212;&#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining
the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values
due to the short-term nature of these assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZSdFDq0EjRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_z0RohBEsyXM9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is managed and operated as <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zTSW8xTZfz6a">one</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business which is focused on using cell cycle, transcriptional
regulation and mitosis control biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire
business is managed by a single management team that reports to the Chief Executive Officer. Historically, the Company has not operated
separate lines of business with respect to any of its products or product candidates and the Company did not prepare discrete financial
information with respect to separate products or product candidates or by location through December 31, 2024. Accordingly, the Company
has viewed its business historically as <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zWLd0JQd0Sx3">one</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reportable operating segment with development operations in
<span id="xdx_909_eus-gaap--NumberOfCountriesInWhichEntityOperates_iI_dc_uInteger_c20241231_zEdDnnew2oul">two</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">geographic
areas, namely the United States and the United Kingdom. With the commencement of the liquidation of the Subsidiary, the Company will
no longer be considered to have control over the Subsidiary and the financial results of the Subsidiary will be deconsolidated from those
of the Company commencing with its first quarter 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z0Y03lbdDMUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_864_znXMbcaOvK78" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company enters into contracts with customers, the Company recognizes revenue using the five step-model provided in ASC 606, <i>Revenue
from Contracts with Customers </i>(&#8220;ASC 606&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract with a customer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when, or as, the Company satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines
the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then
applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the
Company considers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    achievement of a development milestone is highly susceptible to factors outside the entity&#8217;s influence, such as milestones
    involving the judgment or actions of third parties, including regulatory bodies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
    the Company can reasonably predict that a milestone will be achieved based on previous experience; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    complexity and inherent uncertainty underlying the achievement of the milestone.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The
best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions,
entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment
due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part
satisfied) performance obligations. Once the right to receive consideration is unconditional, that amount is presented as a receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
revenue received from organizations that are not the Company&#8217;s customers, such as charitable foundations or government agencies,
is presented as a reduction against the related research and development expenses.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zyfbuT5pdDSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zr7bBrD150F5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, <i>Revenue from Contracts with Customers</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not generated any revenues from product sales to date. However, the Company recognized $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zdRogL4upoDl">43,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenue for the year ended December 31, 2024. This revenue
relates to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center
(&#8220;CSMC&#8221;). There was $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230101__20231231_zJpEFhhMydod">420,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenues recognized for the comparative period in 2023.
All revenues from this customer are recognized at the point in time that the related clinical supply are transferred to CSMC and CSMC
obtains control over the goods. The arrangements with CSMC comprise a single performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not recognized any other sources of revenue during the years ended December 31 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invoices CSMC following the transfer of the clinical supply and provides CSMC with typical payment terms. The Company has collected
all amounts due from CSMC. As of December 31, 2024, December 31, 2023, and January, 1, 2023, the Company has not recognized any accounts
receivable from CSMC, credit loss allowances, contract assets, contract liabilities, or warranty provisions. There were <span id="xdx_905_eus-gaap--RevenueRemainingPerformanceObligation_iI_do_c20241231_zyystFxOLx5">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining performance obligations outstanding as of December
31, 2024; however, CSMC may place additional orders for clinical supply in 2025 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_OtherIncomePolicyTextBlock', window );">Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_ecustom--OtherIncomePolicyTextBlock_z48CGyEtEVP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_864_zpPxy3yffl8d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part
of the Company&#8217;s ongoing operations and activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIW8polrH7g2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_869_zhV5KtObiUm7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs associated with the development of the Company&#8217;s product candidates, including
upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials,
costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development
are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClinicalTrialAccountingPolicyTextBlock', window );">Clinical Trial Accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--ClinicalTrialAccountingPolicyTextBlock_zz39pDabBkt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86D_zboMqvkHKNq2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial Accounting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
management and monitoring of the Company&#8217;s clinical trials are performed with the assistance of contract research organizations,
or CROs or clinical research associates, or CRAs in accordance with the Company&#8217;s standard operating procedures. Typically, CROs
and CRAs bill monthly for services performed, and others bill based upon milestones achieved. The Company accrues unbilled clinical trial
expenses based on estimates of the level of services performed each period. Clinical trial costs related to patient enrollment are accrued
as patients are entered into and progress through the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zghWh5wi7XVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_861_zGXaAhljvi39" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zvYatxd84zDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_860_zSNBLpn78rl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease contracts in accordance with ASC 842. As of March 31, 2025, the Company&#8217;s outstanding leases are classified
as operating leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#8217;s obligation to make lease payments under the lease. As the Company&#8217;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing
versus bullet), and the Company&#8217;s credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect
the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In
assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease payments due in any optional period;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
    for failure to exercise (or not exercise) the option;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    factors, such as the availability of similar assets and current rental rates for such assets;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature of the underlying leased asset and its importance to the Company&#8217;s operations; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    remaining useful lives of any related leasehold improvements.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized
in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded
as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and
the right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zaElcefeAcl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_867_zBP3UW2DZHD" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease contracts in accordance with ASC 842. As of December 31, 2024 and 2023, all of the Company&#8217;s leases
are classified as operating leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#8217;s obligation to make lease payments under the lease. As the Company&#8217;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how a loan would be repaid (e.g.,
amortizing versus bullet), and the Company&#8217;s credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of
exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether
it is reasonably certain that the Company will exercise an option, the Company considers factors such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease payments due in any optional period;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
    for failure to exercise (or not exercise) the option;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    factors, such as the availability of similar assets and current rental rates for such assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature of the underlying leased asset and its importance to the Company&#8217;s operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    remaining useful lives of any related leasehold improvements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term and is reported as a component
of general and administrative expense. Variable lease payments, if any, are recognized in the period when the obligation to make those
payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed
lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw7hrtGvrsh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86C_zqnZce9J5QU" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date
of the grant and recognizes compensation expense of those awards over the requisite service period, which for the Company is the period
between the grant date and the date the award vests or becomes exercisable. Many awards granted by the Company vest ratably over three<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z2zvqtVyXwXj" style="display: none">3</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zJTSjJa78iD3">four
years</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. However, certain awards granted to members
of the Company&#8217;s Board of Directors vest in their entirety on the one<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_z8fUbfdTSME4" style="display: none">1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only
service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain years,
the Company will grant share-based payment awards to employees that are dependent upon the fulfillment of certain clinical and financial
conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes compensation
expense when the award is probable of vesting (See Note 12&#8201;&#8212;&#8201;Stock-Based Compensation).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expenses in its statement of operations in the same manner in which the award recipient&#8217;s
payroll costs are classified. The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of restricted stock and restricted stock units is determined based on the number of shares granted and the quoted price of
the Company&#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated
using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#8217;s share price, expected
term of the award, interest rates, and dividend yields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on its historical volatility as an input to the option pricing model as management believes that this rate will be representative
of future volatility over the expected term of the options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average risk-free interest rate represents the interest rate for treasury constant maturities published by the Federal Reserve
Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel
interpolates a discount rate based on the two Federal Reserve securities closest to the expected term of the employee option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected dividend yield is zero, as the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends
on common stock in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z54Xjh3qPW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86C_zqR9Wghh5rvd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based
on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year
in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred
tax assets to the amounts expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the
amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained
upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not-to be sustained, the tax position
is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized
is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes
includes the effects of any resulting tax reserves for unrecognized tax benefits that are considered appropriate as well as the related
net interest and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records research and development tax credits within income taxes. Credit is taken in the accounting period for research and development
tax credits, when claimed from H.M. Revenue &amp; Customs, or HMRC, the United Kingdom&#8217;s taxation and customs authority, in respect
of qualifying research and development costs incurred in the same accounting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zg7mEvChTDKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_862_zfnnR38qNFEf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss Per Common Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221;. Basic and diluted net loss
per common share was determined by dividing the net loss applicable to common stockholders by the weighted average number of common shares
outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common
stockholders is the same as basic net loss per share attributable to common stockholders since potentially dilutive common shares are
not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders
for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zbBtUWjxgeO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86A_zKuGX21dU0w7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
Income (Loss)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). <span id="xdx_90E_eus-gaap--OtherComprehensiveIncomeLossTax_do_c20250101__20250331_zKmQocSIJAh8">No</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">taxes were recorded on items of other comprehensive income
(loss). There were <span id="xdx_90F_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20250101__20250331_zmEZIzVWNKMf">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reclassifications out of other comprehensive income (loss)
during the three months ended March 31, 2024. However, upon deconsolidation of the Company&#8217;s formerly wholly-owned subsidiary on
January 24, 2025, $<span id="xdx_901_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_pn5n6_do_c20250124_zKO3BurNZ4G5">0.9</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of accumulated comprehensive income (loss) was reclassified
into earnings as part of the gain on deconsolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z1D5SLfGoCwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86F_zHxZvlU9nSie" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Comprehensive
Income (Loss)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported to arrive at comprehensive income (loss). There were <span id="xdx_905_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20230101__20231231_zgku0Qy7OIg9">no</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reclassifications out of other comprehensive income (loss)
during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_848_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zxj2fc1u1Yq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_867_z8XQNyu0LXFb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2024-03, &#8220;<i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_z4CYFimM2Iy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_866_zzVz1m4j8wpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2024-03, &#8220;<i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB has issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;. This standard will require
all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage
and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received)
disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions
for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods
beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation
of that information.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z5SC1TKoNBg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86B_zkCZdtJqw1A2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated balance sheet as of March 31, 2025, the consolidated statements of operations, comprehensive loss, and stockholders&#8217;
equity (deficit) for the three months ended March 31, 2025 and 2024 and the consolidated statements of cash flows for the three months
ended March 31, 2025 and 2024, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance
sheet as of December 31, 2024 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K
for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 2, 2025.
The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States
(&#8220;GAAP&#8221;) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they
do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete
set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary
to present fairly the consolidated balance sheet as of March 31, 2025, and the results of operations, comprehensive loss, and changes
in stockholders&#8217; equity (deficit) for the three months ended March 31, 2025, and cash flows for the three months ended March 31,
2025, have been made. The interim results for three months ended March 31, 2025 are not necessarily indicative of the results to be expected
for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2024 that are included
in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on April 2, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_z3jJ9Fw35e6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_860_zXCLHemlLPI" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Accounting Standard Codification (ASC) 205-40, <i>Presentation of Financial Statements-Going Concern</i>, management
is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial
doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have
not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,
management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company&#8217;s
ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern for one year after the date that these financial statements are issued. In
performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40,
the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered
probable at this time because these plans are not entirely within the Company&#8217;s control nor have they been approved by the Board
of Directors as of the date of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s current operating plan, it is anticipated that cash and cash equivalents of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zymioRMWspyf">3.5</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of March 31, 2025, will allow it to meet its liquidity
requirements into the second quarter of 2025. The Company&#8217;s history of losses, negative cash flows from operations, liquidity resources
currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources
are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company&#8217;s
ability to <span id="xdx_90F_eus-gaap--SubstantialDoubtAboutGoingConcernWithinOneYear_pn5n6_dbTp_c20250101__20250331_zOlc6k16dxaj">continue</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a going concern for a period of at least twelve months from
the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist
of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will
be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations,
delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, Nasdaq notified the Company that it has regained compliance with the equity requirement in Listing Rule 5550(b)(1)
(the &#8220;Equity Rule&#8221;), as required by the Nasdaq Hearing Panel&#8217;s decision dated October 22, 2024. Following the Company&#8217;s
regaining compliance with the Equity Rule, the Company will be subject to a Mandatory Panel Monitor for a period of one year from February
25, 2025 pursuant to Listing Rule 5815(d)(4)(B).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets
and the satisfaction of liabilities in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9NhsWiwFzV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_86F_zNiNRgXykyMj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Newly
Adopted Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2025, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740): Improvements
to Income Tax Disclosures&#8221;. This standard requires all entities to include specified captions when reconciling the statutory income
tax rate to the effective tax rate, on both a percentage and absolute dollar basis, in the annual financial statements. ASU 2023-09 also
requires entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and
foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts
from, exceed a defined threshold. The company does not anticipate the adoption of ASU 2023-09 will require significant adjustments to
the presentation of that information in the Company&#8217;s annual financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ClinicalTrialAccountingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Accounting [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ClinicalTrialAccountingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_OtherIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Income [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_OtherIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Issued Accounting Pronouncements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zKGCPiHTH0vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash and cash equivalents at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zSET5jeIuAFb" style="display: none">Summary
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zCrSHJ6cUOUa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z3X01H23zeu9" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Cash_iI_pn3n3_maCACEAzyS5_zOQ4QyfcCAj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">93</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,303</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_maCACEAzyS5_ztNzonajCXL9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtCACEAzyS5_ztcDYgnqRxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,378</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zQMBDnQxiAIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zfWV7hPOTay2" style="display: none">Schedule
of Financial Assets and Liabilities Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwX5DJUCfoAc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    1</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgjTt48bL3B6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    2</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zfavjkQ0qZS8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level
    3</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z03y08eOqvN3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">Fair Value Measurements</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">as of December 31, 2024 Using:</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 1</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 2</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 3</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zoNhzn6SrTel" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,044</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,044</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zI3MZ1GRH2td" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,044</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVw0fayAHRdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zljm8svDHA5a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxVo90jidCB1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level
    3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCFgvYNLB1Nd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">as of December 31, 2023 Using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zz6uWUGiipWl" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zs7yLDFJFqs1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_898_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zaAfOm0GuBpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zrrHepcxb5El" style="display: none">Schedule
of Prepaid Expenses and Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250331_zfFI1ZvlaPic" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20241231_zETxqZSOI6q3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPECzxNf_zZhhBXB2luka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Prepayments</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">237</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPECzxNf_zhNtmZdVkIt9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">194</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseCurrent_iTI_pn3n3_mtPECzxNf_zon8974OLUTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">264</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">537</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zQgaOlf1dqf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of prepaid expenses and other current assets at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B3_zoCIaaOCdeBb" style="display: none">Schedule
of prepaid expenses and other current assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_z7lf3DnBHndi" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zKUsKElCmOml" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxesAndOtherTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zNaZJS6qlveb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development tax credit receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,933</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zfR5pVGM24T6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepayments and VAT receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">792</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQOL_zcBXTXszRPd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">341</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQOL_z5PJ3bmEwOj2" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other assets</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,066</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5FwiODQbG4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zA2wcsohQTJ3" style="display: none">Schedule
of Property and Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_zwww3daVkxr1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zApi9l4rFhx3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><b>Lives in</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zDPi9ChoS2B7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Leasehold improvements</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVSyesfIk2Xj">2</span>
    to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z60zWO360104">5</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zP0tiNECtJP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment and furniture</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zwbT4afEWMY2">3</span>
    to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_ztazAMISFTch">5</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">423</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_maPPAENzWpG_zblZiY2R2G18" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">429</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzWpG_zWafk7wLbO2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: accumulated depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(424</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzWpG_zSnlF9zZX9a9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_ztbudYMeSXQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
and other current liabilities consisted of the following (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zi8hNVrt2Rpc" style="display: none">Schedule
of Accrued and Other Current Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250331_zZRyuple1Nz1" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_z6ahcDahe2xj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCostCurrent_iI_pn3n3_zLff99MwH0ji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1889">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,300</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_zBMIXPiwxp6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued legal and professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">532</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_zP40xWtPhJ6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other current liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">284</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_zl7SdYb7Ozl6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued and other current
    liabilities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">549</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,671</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaF3qBcqwcx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
and other current liabilities consisted of the following at December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zbG35D6tYoFb" style="display: none">Schedule
of Accrued and Other Current Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zaNSbn7pGCEe" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zWyxteIAyah1" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_pn3n3_maALCzjWX_zxdCwQ5F9Xhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,299</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,668</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzjWX_zYEd45USEZVb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">570</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--OtherCurrentLiabilities_iI_pn3n3_maALCzjWX_zNaqeuRnK0Oj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">380</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzjWX_zdKU4QmktAa4" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,669</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,618</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z7uw9TXndB96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining
lease payments for both facilities are as follows (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zVNt5lnBaftk" style="display: none">Schedule
of Remaining Lease Payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20250331_zn4xLC10bj1e" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzo6M_zxqWjMRO59ug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_pn3n3_maLOLLPzo6M_z9ML6eh0b3T1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_pn3n3_maLOLLPzo6M_z4w1j7Zt1rL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maLOLLPzo6M_zsCZr4fNrUng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1919">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzo6M_zDO9QjtMUjIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total future minimum
    lease obligation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z440AH7tNQMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s future contractual obligations and commitments relating to its facilities lease as at December
31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BC_zB11ngH9qKE2" style="display: none">Schedule
of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zrvqNs2ZDnBg" style="text-align: center; font-weight: bold">Operating Lease</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Obligation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zYSfO3aFolH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zwF0630Vo0yb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_zFHUvGgprMR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0708">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zXdwuRZhI9kd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z3kbC3utV7Md" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z148Y2pkKCnc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock', window );">Schedule of Fair Value of Instruments Issued in Offering</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_zA78XcnVP3d9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zoHcCeHWglHg" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250101__20250331_zGjcrW70H7G8" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Allocated
    Amount</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuojg1Le9Ry5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%"><span style="font-family: Times New Roman, Times, Serif">Common shares</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72,108</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSSPmw9N1rvj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prefunded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,398,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYpsat2GSfXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,819,274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zs3KLuTxpE01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,290,213</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_z7m7v6VBOkz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_z6NUgLOQ9Vi8" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zBIhHSrSJReb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Allocated
    Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq3QwXNUjED6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Common shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">72,108</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zpODY3vap7N4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prefunded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,398,831</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWUkBjHcDr4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,819,274</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_zCzqzHT8J5V4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net proceeds</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,290,213</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair value of Warrants Valuation Assumption</a></td>
<td class="text"><p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zTUa68Prla6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zxPcTvzLnbz2" style="display: none">Schedule of Fair value of Warrants Valuation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded
    Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Placement
    Agent Warrants</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKuoTFVcMyZ1" title="Warrants and rights outstanding">100</span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zDnR00CKxMGj" title="Warrants and rights outstanding">103</span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zzNklfHgkJNh" title="Warrants and rights outstanding">121</span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0huGRbp6ax3" title="Warrants and rights outstanding">103</span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0cu2bRSDefd" title="Warrants and rights outstanding">1</span> year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 7pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zENaCO5e8ZGh" title="Contractual term">1.5</span> </span><span style="font-family: Times New Roman, Times, Serif">1&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">- 5&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">years <span style="display: none; font-size: 7pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zO0bmRuNgBzl" title="Contractual term">5.5</span></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">5&#189;</span>
    <span style="font-family: Times New Roman, Times, Serif">years <span style="display: none; font-size: 7pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPcIKiW6chD8">5.5</span></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztL9uwwXw2Z9" title="Warrants and rights outstanding">5.51</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z6AfpudEkteh" title="Warrants and rights outstanding">4.57</span>% - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zWqD4S4fITBk" title="Warrants and rights outstanding">5.51</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zF6xSJIXdgW8" title="Warrants and rights outstanding">4.57</span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxxy4WOQ6Ip" title="Warrants and rights outstanding">0</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zb3qu8Q9Wg4e" title="Warrants and rights outstanding">0</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcVi1mljH135" title="Warrants and rights outstanding">0</span>%</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjUMBilXRxKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BE_zH2Kn3OlToH6" style="display: none">Schedule
of Fair value of Warrants Valuation Assumption</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Pre-Funded Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Common Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Placement Agent Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zQlb4fHHvBn">100</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zfxP64rao9gd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            - <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zmZIGElcjLW2">121</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z3gwiYo35EJ6">103</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGismNVQlp66" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">year</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUPPyBSjAiy9" style="display: none">1.5</span></span>1&#189;
                                            - 5&#189; years<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zXeVsP78Db5d" style="display: none">5.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuHIcIE3sdjd" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#189;
                                            years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zn43bSaXZy6a">5.51</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zXt0T5Dj3Kec" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.57</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            - <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ztk2p9BCs8ig">5.51</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZ1tCBxmj8l3">4.57</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zSpvZGyUq6h4">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJMWTO3OuCFf">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMBjP67BlMnj">0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember', window );">Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock', window );">Schedule of Fair Value of Instruments Issued in Offering</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zZ8211qrMUHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zRuUJ2cLdkP8" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPyX9aCkusHa" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Allocated
    Amount</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjgcPPPJlqXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%"><span style="font-family: Times New Roman, Times, Serif">Common Shares</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">258,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zlthtXzj474i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">321,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGaGssgFOYu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Regular Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">470,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zbraQ6ny1bE9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,049,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4OcU6YuX39i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zY381SfL0bfd" style="display: none">Schedule
of Fair Value of Instruments Issued in Offering</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zyjBGzo64avj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Allocated
    Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHUGbPFf2sba" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Common Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">258,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSZmexFaegDa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Pre-Funded Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">321,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzNFN989B3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Regular Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">470,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zQqPN6pWrAzk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net Proceeds</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,049,000</td><td style="text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair value of Warrants Valuation Assumption</a></td>
<td class="text"><p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIfFlUzMp4s4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zOuAHdkHrU5l" style="display: none">Schedule of Fair value of Warrants Valuation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded
    Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Regular Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Placement
    Agent Warrants</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zxKTq7hZhrd2" title="Warrants and rights outstanding">134</span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zFEVlJ8CHIyc" title="Warrants and rights outstanding">96</span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zpB6jZiLkPt7" title="Warrants and rights outstanding">99</span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual/ expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAkLJTwKcqFl" title="Warrants and rights outstanding">1</span> month</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zs4ti35RRENe" title="Contractual term">7</span> years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zc3OwhDykApd" title="Contractual term">5</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zJ5dZf57aYed" title="Warrants and rights outstanding">5.53</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zfYtLFqlCxH9" title="Warrants and rights outstanding">3.91</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPGIqLtKCXz1" title="Warrants and rights outstanding">3.89</span>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zP2XHomOv7Xj" title="Warrants and rights outstanding">0</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zGU7TLCKdSU4" title="Warrants and rights outstanding">0</span>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zSfRb5M2gZ3e" title="Warrants and rights outstanding">0</span>%</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4JNxJDtzfie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zWpLB9du8iUi" style="display: none">Schedule
of Fair value of Warrants Valuation Assumption</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pre-Funded Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Regular Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Placement Agent Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zgIRxBJJrZac">134</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zymclqOdcvj7">96</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_ztxHj2RvY8S1">99</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Contractual/expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z70PhkHMtHj5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">month</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zKVZgEYRcRl8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zdZmDyp6Len2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAoG8yfczVX5">5.53</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z6gjOzFvrbt5">3.91</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zrQBxpZsYiS6">3.89</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zVXETncroDmk">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zvysFIElhW06">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIppfgQqqL54">0</span></td><td style="text-align: left">%</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Instruments Issued In Offering And Their Classification Under Shareholders Equity [Table Text Block ]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock Based Compensation Expense</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYtfZyMeRNhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended
March 31, 2025 and 2024 as shown in the following table (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zKQAAO8uuGuh" style="display: none">Schedule
of Stock Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250331_zpby0g2Vqtmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20240331_zxKy2IqfCBvg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March&#160;31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYy8HPBaUKN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,592</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zInBf5ZVuUYd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zu8nndUTR1i1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,666</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">203</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zXCK22xGcJEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the years ended 2024 and
2023 as shown in the following table (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zW9fimmMO287" style="display: none">Schedule
of Stock Based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z5J1LKCuPOd6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zoBc2yGOwLFk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zG7j9d9M17T4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">498</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,039</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5qIKuYJsX7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zUb79rLOxow5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,473</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share Option Activity</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zQQmAYU3aYkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the share option activity and related information is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8BD_zoZ4fKD31OYc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Share Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price
    Per Share</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term&#160;(Years)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value&#160;($000)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstwfN5m9aj6" style="width: 12%; text-align: right" title="Number of Options Outstanding, Balance"><span style="font-family: Times New Roman, Times, Serif">494</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zytlelT6Ae67" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif">10,658.40</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9kHDuWSUJ9" style="font-family: Times New Roman, Times, Serif">7.20</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaEZNWTN3Ty1" style="width: 12%; text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1971">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z29rIEzredui" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif">24,818</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztxQ9q4xeaZ3" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">70.79</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zktzPgOv4HSh" style="text-align: right" title="Number of Options Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1977">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQqUjyUxUUkh" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1979">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLjl4YGhFYG1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">(53</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZfT3AMOY5Ld" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">2,238.25</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNELwZ9Cktb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Balance"><span style="font-family: Times New Roman, Times, Serif">25,259</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMdsAc4XTAV9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif">276.67</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv863YW7rCB1" style="font-family: Times New Roman, Times, Serif">9.76</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zorV9XJzvHS1" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1990">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYWebtg3xGp3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Unvested"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1PDNg7ypaj1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Unvested"><span style="font-family: Times New Roman, Times, Serif">2,094.84</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable
    at March 31, 2025</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpqjbPFISF37" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Vested and exercisable"><span style="font-family: Times New Roman, Times, Serif">25,238</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsebhVlWTaRe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable"><span style="font-family: Times New Roman, Times, Serif">275.17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zProbUO1VJKc" style="font-family: Times New Roman, Times, Serif">9.77</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlEDaTXVzfdl" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregrate Intrinsic Value, Vested and Exerciseable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl2001">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zYaETrg97Iuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the share option activity and related information is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zYiLYeCPA6tk" style="display: none">Schedule
of Share Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Exercise</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Remaining</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Aggregate</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Options</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Price Per</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Contractual</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Intrinsic</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Term (Years)</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value ($000)</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%">Options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZba66nJpzr1" style="width: 10%; text-align: right" title="Number of Options Outstanding, Balance">447</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpPSaXrFwvVa" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Balance">21,049.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6ihu0t7sqTc">8.34</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKlyebtltsKg" style="width: 10%; text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4uBx3qaHJJj" style="text-align: right" title="Number of Options Outstanding, Granted">181</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG6lVgIsPxrf" style="text-align: right" title="Weighted Average Exercise Price, Granted">2,117.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjZg89pcq0ce" style="text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4rlVdRnM6O9" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0951">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zei0oYx5BAD2" style="text-align: right" title="Number of Options Outstanding, Cancelled/forfeited">(33</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAp2gYljl4z3" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited">79,737.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW6MdwH7khT8" style="text-align: right" title="Number of Options Outstanding, Balance">595</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxNXXZznHXje" style="text-align: right" title="Weighted Average Exercise Price, Balance">12,048.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmJ5D0fqqkT3">7.96</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1THMMqemkLb" style="text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0962">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTDEG35BHJkf" style="text-align: right" title="Number of Options Outstanding, Granted">52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKNNH2gjtHA2" style="text-align: right" title="Weighted Average Exercise Price, Granted">547.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z45Oa4VM7lp9" style="text-align: right" title="Number of Options Outstanding, Cancelled/forfeited">(153</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqB5l4LngxRl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited">12327.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1aMINQMRCJc" style="text-align: right" title="Number of Options Outstanding, Balance">494</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvHykPYxeNHh" style="text-align: right" title="Weighted Average Exercise Price, Balance">10,658.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgOqXuyCcwD2">7.20</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXPhzx6MQkGi" style="text-align: right" title="Aggregrate Intrinsic Value, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3wxdHLU6Wd4" style="text-align: right" title="Number of Options Outstanding, Unvested">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjrVZ71REUt4" style="text-align: right" title="Weighted Average Exercise Price, Unvested">2,250.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmh8LOODM46c">8.45</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTSjcDWGjEBi" style="text-align: right" title="Number of Options Outstanding, Vested and exercisable">420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7JzNxuMInj7" style="text-align: right" title="Weighted Average Exercise Price, Vested and exercisable">12,141.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwcSRTTunONf">6.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDlk1p37R0C7" style="text-align: right" title="Aggregrate Intrinsic Value, Vested and Exerciseable"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zk3oxX36nWv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span id="xdx_8BE_zYhg4KfeWeV2" style="display: none">Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three months
    ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three months
    ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqFUkCdCtZWf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTjpv8bpNTi5">10</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwUUjiySqPj" style="font-family: Times New Roman, Times, Serif">6</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zKsRwGExvwIf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.060</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            &#8201;&#8211;&#8201;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zse7pFP0qWPl">4.250</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztCBFHieoNN" style="font-family: Times New Roman, Times, Serif">3.995</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zJNe79AcKKUc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&#8201;&#8211;&#8201;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zepvyxBHtzrc">107</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlentDg6UWHh" style="font-family: Times New Roman, Times, Serif">93</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield over expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrx1L8kJHrYh" style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaXlxtGKKdpd" style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Resulting weighted average grant date fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj7mjJsL01uf" style="font-family: Times New Roman, Times, Serif">69.60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNK8Lp6rs0V2" style="font-family: Times New Roman, Times, Serif">424.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLk6BC2Yaog5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B7_zuL5AUzeIOG2" style="display: none">Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Year ended</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Year ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdy05diIKDd6">6</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zi4hnL1Nbi65" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span>
                                            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zWa2OUYvebgi">6</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr79fZTdLQOe">3.995</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zPj9fqVcqaJ2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.660</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            &#8201;&#8211;&#8201;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTCRQ6XLrwv5">4.160</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6AtZ7wEbaLk">93</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHPdnGuNw9Z6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&#8201;&#8211;&#8201;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zD8iL2fdMt72">92</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield over expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSyMhqwDeVMb">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDBGHpXkRUOe">0.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Resulting weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqLTmwaaiAih">424.80</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjDlkN8WLLZ5">1,591.20</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zIlyBKat9Eci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized
information for restricted stock units as of March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zlz1nvtipnN9" style="display: none">Schedule
of Restricted Stock Units Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Restricted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Grant Date</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Units</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value
    per share</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units outstanding
    at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zccoDBjfXf64" style="width: 14%; text-align: right" title="Restricted Stock Units, Balance"><span style="font-family: Times New Roman, Times, Serif">164</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAVbyDwPg9b" style="width: 14%; text-align: right" title="Weighted Average Grant Date Value per share, Balance"><span style="font-family: Times New Roman, Times, Serif">2,882.40</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJBQIK9FaNrb" style="font-family: Times New Roman, Times, Serif">8.30</span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zitdVZA2rNjd" style="text-align: right" title="Restricted Stock Units, Granted"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zylkNtvV5h7e" style="text-align: right" title="Weighted Average Grant Date Value per share, Granted"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbmenNYJpFbl" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted Stock Units, Cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">(28</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQf3PvJrKsG2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Value per share, Cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">3,300.00</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units
    outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC6Pc9nonvbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted Stock Units, Balance"><span style="font-family: Times New Roman, Times, Serif">136</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4ngbjnxOPEb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Value per share, Balance"><span style="font-family: Times New Roman, Times, Serif">2,795.37</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEq554owd7ha" style="font-family: Times New Roman, Times, Serif">8.09</span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested at March 31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAhgUkCLGvL3" style="text-align: right" title="Restricted Stock Units, unvested"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgEvQltVVBR4" style="text-align: right" title="Weighted Average Grant Date Value per share, Unvested"><span style="font-family: Times New Roman, Times, Serif">3,240.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTZDNVuDP0Oh" style="font-family: Times New Roman, Times, Serif">7.82</span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Vested at March 31, 2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2aBmLd5Wzh" style="text-align: right" title="Restricted Stock Units, Vested"><span style="font-family: Times New Roman, Times, Serif">123</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zU0TV8voZ7ze" style="text-align: right" title="Weighted Average Grant Date Value per share, Vested"><span style="font-family: Times New Roman, Times, Serif">2,747.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlBhulV3rLeb" style="font-family: Times New Roman, Times, Serif">8.12</span>
                                            <span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<span></span>
</td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z0y5of2jRFW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized
information for restricted stock units as of December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z3I6sU64j9Ca" style="display: none">Schedule
of Restricted Stock Units Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Restricted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">Remaining</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Stock Units</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Term</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 51%; text-align: left">Restricted Stock Units outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4bnpsxRNzp5" style="width: 14%; text-align: right" title="Restricted Stock Units outstanding, Beginning balance">38</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5vmvcpilDg8" style="width: 10%; text-align: right" title="Restricted Stock Units, Grant Date Value Per Share">6,768.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFYiu1O9hNg" style="text-align: right" title="Granted">107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zARNwFuag36h" style="text-align: right" title="Granted">2,870.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdkJjVayPsI5" style="text-align: right" title="Cancelled/forfeited">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRFRVJA2uDT2" style="text-align: right" title="Cancelled/forfeited">3,240.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrWRPQXoR4yd" style="text-align: right" title="Restricted Stock Units outstanding, Beginning balance">144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBGAA1hpRkl1" style="text-align: right" title="Restricted Stock Units, Grant Date Value Per Share">3,902.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPxTjzhMzzX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.96</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRomSdcQm0g8" style="text-align: right" title="Granted">52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJFqXxPzH1Ej" style="text-align: right" title="Granted">547.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkqh0qcxHcUi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.03</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAfRIpbwJTIk" style="text-align: right" title="Cancelled/forfeited">(32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD5MLF0pZK74" style="text-align: right" title="Cancelled/forfeited">3,675.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZrTIw89T5rl" style="text-align: right" title="Restricted Stock Units outstanding, Ending balance">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6AnS530vm5j" style="text-align: right" title="Restricted Stock Units, Grant Date Value Per Share">2,881.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdrTMg2j6Qw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.30</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzrxrQL9jip3" style="text-align: right" title="Unvested">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztEIEWKXLf67" style="text-align: right" title="Unvested, Weighted Average Grant Date Value Per Share">3,280.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8A61gEZ9Bf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.06</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb6xI7zGQfe6" style="text-align: right" title="Vested">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQYuj9KVPi75" style="text-align: right" title="Vested">2,747.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdKSrMuFyqBb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.39</span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of (Loss) Income Before Taxes from Continuing Operations</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zi2SGX2EgT35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Loss)
income from continuing operations before taxes is comprised of the following components for the years ended December 31, 2024 and 2023
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_ziPhwKKQ7QD9" style="display: none">Schedule
of Components of (Loss) Income Before Taxes from Continuing Operations</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z40s8ijn56Sg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_z6hypnLtSc9c" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_zpbZuNxDOIb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(806</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_zn0TTtefFfZ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,745</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztT40wwpCbvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from continuing operations before taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,994</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(25,551</td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Benefit (Provision) for Income Taxes from Continuing Operations</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zP6uKjErOoEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
benefit (provision) for income taxes from continuing operations consists of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zzIQKg3SheM1" style="display: none">Schedule
of Benefit (Provision) for Income Taxes from Continuing Operations</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Current&#8201;&#8201;&#8211;&#8201;&#8201;domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20240101__20241231_zHkvjHh0ciX7" style="width: 15%; text-align: right" title="Current - domestic">(21</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230101__20231231_zDspSsLfAIQe" style="width: 15%; text-align: right" title="Current - domestic">(2</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current&#8201;&#8201;&#8211;&#8201;&#8201;foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20240101__20241231_z9oZ5jhlCOdj" style="text-align: right" title="Current - foreign">803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20230101__20231231_z6Hfu5Pnc17b" style="text-align: right" title="Current - foreign">2,998</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current&#8201;&#8201;&#8211;&#8201;&#8201;total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zloeSjLyuHY7" style="text-align: right" title="Current - total">782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_z9VgN91v53Lk" style="text-align: right" title="Current - total">2,996</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred&#8201;&#8201;&#8211;&#8201;&#8201;domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20240101__20241231_zQ2kfkKvaYm5" style="text-align: right" title="Deferred  -  domestic"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20230101__20231231_zSiCUsFkQC8k" style="text-align: right" title="Deferred  -  domestic"><span style="-sec-ix-hidden: xdx2ixbrl1099">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20240101__20241231_z1GEgQ9Enx3h" style="text-align: right" title="Income tax benefit">782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20230101__20231231_zwWKMtcDwWP7" style="text-align: right" title="Income tax benefit">2,996</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zIXbJHNN5g85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory
federal tax rate to loss from continuing operations before income taxes is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BD_zGLXvuCpGWSa" style="display: none">Schedule
of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory
Federal Tax Rate to Loss Before Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z8pHbjV9u6k3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zHIcFpd8tN45" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_z4J0PexTZVJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Loss from continuing operations before taxes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(11,994</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(25,551</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_z6JAAMhrd20f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax expense computed at statutory federal tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,527</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,366</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_zV1GNveNkmd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional research and development tax relief</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,409</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_zyhfrwmzo8hf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss surrendered to generate R&amp;D credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,865</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_zZ68zSJfuL25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,261</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_zdz7HvdWK7cj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other foreign items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,158</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">809</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_pn3n3_zvxQ78xJhSSe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Disallowed expenses and non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">782</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_zocg3OA9DKb3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_zkjIlTHWkJAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign items, including change in tax rates, and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationOtherItemsAmount_pn3n3_zI4jzmlThK9f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zrvdoTqNWRlb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Current - total</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(782</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,996</td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of the Entity's Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTQBA6wBlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&#8217;s deferred tax assets are shown below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zaRTNnpL4Wy7" style="display: none">Schedule
of Significant Components of the Entity's Deferred Tax Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zYKpNA6rzTgb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zXMGekTlL4Cl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzNQW_z9WHoQsvbAp2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Net operating loss and tax credit carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">59,417</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">57,074</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_iI_pn3n3_maDTAGzNQW_zgSYHJggyol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation, amortization and impairment of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzNQW_zkSqryKkSQNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_iI_pn3n3_maDTAGzNQW_zeB95xzQFgza" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseRightOfUseAsset_iI_pn3n3_maDTAGzNQW_zUcW5ieyLWNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsLeaseRightOfUseLiability_iI_pn3n3_maDTAGzNQW_zudO5YVuNRlc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzNQW_zqg5xGjm4Fmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzNQW_maDTANzSsl_z8fPaw5CXOh7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,323</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzSsl_zlMJjZXNVAXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation allowance for deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(59,820</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57,323</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzSsl_zET7nPL47GL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zbzAXbJny5Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months
ended March 31, 2025 and 2024, as the result would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_z43J4DXcFng7" style="display: none">Schedule
of Earnings Per Share, Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250331_zSVobvtRXP52" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20240331_zZJFVDt0iGye" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWpMgCBotake" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><p style="margin: 0">25,259</p></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">619</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuyEMv5nfs8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock Units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">136</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SixPercentConvertibleExchangeablePreferredMember_zYxhTPDB1Uue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">6% convertible exchangeable preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zmOM5NfdY59d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;A preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesDPreferredStockMember_zOhr2In2vgyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;D preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,588</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1857">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zRfDUYCbGV05" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series&#160;E preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">458,333</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zXNf4hOm0ZY4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">101,905</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,648</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zs36fcpXjAL4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total shares excluded
    from calculation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">748,224</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,456</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaPgmkrAWcSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to common stockholders was calculated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zmPAJzP3Lbrl" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zApuHLCLafz8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zosuHDqHoUu3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Years ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_iB_zkye7KFpM8v1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pn3n3_zbSYFLhOBBbd" style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(11,212</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(22,555</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockDividendsIncomeStatementImpact_i01N_pn3n3_di_zWwGMIonyOHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend on convertible exchangeable preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(201</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01_pn3n3_zZDaggpx6Wfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to common shareholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(22,756</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zpuiu0OGIyBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average number of common shares used in loss per share&#8201;&#8211;&#8201;basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_z2K08zwrNZj9">22,314</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zU4gHRANFRC2">3,545</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss per share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zPueyGER5C51">(502.46</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zHsdxXBu0y1h">(6,419.07</span></td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive shares excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8A5qjK8ZPL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zMnLkR0Etvvg" style="display: none">Schedule
of antidilutive shares excluded from computation of diluted net loss per share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zk6Kqj4vAPUe" style="text-align: center">December 31,</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zlAdyJ4k5uG7" style="text-align: center">December 31,</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrCtIDMllqvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">494</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">595</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zR6bOlwu5J4h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zyDexCfFVXUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20231231_zrUem3V7owIj">6</span>%
    convertible exchangeable preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zRFaUHnu69b4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zCe0VYxg8vfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1222">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_ziemC2QSOQWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,648</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zVCB9AnJJVy5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total shares excluded from calculation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,554</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic and Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Geographic Information</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zhvSlWLPSFni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geographic
information for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zjd4R6VCOs8i" style="display: none">Schedule
of Geographic Information</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenue</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">United Kingdom</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z31mrJ5xVR5f" style="width: 15%; text-align: right" title="Revenue">43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zYpp0Btyfs8h" style="width: 15%; text-align: right" title="Revenue">420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231_zmcpsLEtp13f" style="text-align: right" title="Revenue">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231_zkaLebsGMq57" style="text-align: right" title="Revenue">420</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United States</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z93MITdRGmJg" style="text-align: right" title="Net Loss">(37</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zB8d1IKB0Y7b" style="text-align: right" title="Net Loss">(808</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z9oQ8kHoVvNf" style="text-align: right" title="Net Loss">(11,175</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zRJ0Tzg31Vwf" style="text-align: right" title="Net Loss">(21,747</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Net Loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231_z9ia6vKOwEye" style="text-align: right" title="Net Loss">(11,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231_zBLG7QHpFici" style="text-align: right" title="Net Loss">(22,555</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_z4mkAC6qKjjd" style="width: 15%; text-align: right" title="Total Assets">3,285</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_z3BUwgBWuDD3" style="width: 15%; text-align: right" title="Total Assets">2,938</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zIbAgLrDsWP9" style="text-align: right" title="Total Assets">809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zsxWshuvtgH" style="text-align: right" title="Total Assets">5,867</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20241231_zUlx5ZeC1M8j" style="text-align: right" title="Total Assets">4,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20231231_zAJ7AObNigng" style="text-align: right" title="Total Assets">8,805</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long Lived Assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">United States</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_zCpCcEUOJzub" style="text-align: right" title="Long Lived Assets, net">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_zJfAm2BtN2of" style="text-align: right" title="Long Lived Assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1269">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zSuaHLMaO2Nc" style="text-align: right" title="Long Lived Assets, net">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zKbX2ASHevdk" style="text-align: right" title="Long Lived Assets, net">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Long Lived Assets, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231_zTND4cTeXCu1" style="text-align: right" title="Long Lived Assets, net">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231_zRyQfY2EJ2Nf" style="text-align: right" title="Long Lived Assets, net">9</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Summary of Consolidated Net Loss</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zKx9LsphFx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of our consolidated net loss for the years ended December 31, 2024 and 2023 is as follows, including the significant expenses
provided to and regularly reviewed by our CEO:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B0_z7QwPwziIp66" style="display: none">Schedule
of Summary of Consolidated Net Loss</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zGDczUfPKtg" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zp3qrFRvlZzk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zWylEmRgvbF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 62%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zMpaKm9T8JXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzPoy_zyBHG2eEx5zf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,155</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pn3n3_maOEzPoy_zmCmaBoierR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,718</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEzPoy_z6BXTAH0TEac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_pn3n3_maILFCOzkrX_z5BrWNbJ2yTb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,004</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,453</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_maILFCOzkrX_z30IvRkRIle8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzkrX_maNILz14R_zBwzAszUDlab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,994</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_di_msNILz14R_zQ2xcxeqceca" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,996</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz14R_zb1OinZBvAt1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(22,555</td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Remaining Lease Payments</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z7uw9TXndB96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining
lease payments for both facilities are as follows (in $000s):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zVNt5lnBaftk" style="display: none">Schedule
of Remaining Lease Payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20250331_zn4xLC10bj1e" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzo6M_zxqWjMRO59ug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_pn3n3_maLOLLPzo6M_z9ML6eh0b3T1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_pn3n3_maLOLLPzo6M_z4w1j7Zt1rL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maLOLLPzo6M_zsCZr4fNrUng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1919">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzo6M_zDO9QjtMUjIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total future minimum
    lease obligation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z440AH7tNQMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s future contractual obligations and commitments relating to its facilities lease as at December
31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BC_zB11ngH9qKE2" style="display: none">Schedule
of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zrvqNs2ZDnBg" style="text-align: center; font-weight: bold">Operating Lease</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Obligation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zYSfO3aFolH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zwF0630Vo0yb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_zFHUvGgprMR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0708">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zXdwuRZhI9kd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z3kbC3utV7Md" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z148Y2pkKCnc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization of the Company and Basis of Presentation (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>May 07, 2025</div></th>
<th class="th">
<div>Apr. 29, 2025 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 19, 2025</div></th>
<th class="th">
<div>Apr. 02, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 21, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 10, 2025 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Feb. 26, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th">
<div>Feb. 05, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 04, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 29, 2025</div></th>
<th class="th">
<div>Jan. 02, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 06, 2025 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-sixteen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary', window );">[custom:StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">All references to issued and outstanding shares
all periods reflect: the 1-for-16 reverse stock split effective May 12, 2025, and the 1-for-15 reverse stock split effective July 7,
2025. As a result, all share numbers for all periods, including the number of shares underlying warrants, options, and other convertible
securities, and all exercise prices applicable to such warrants, options and convertible securities have been adjusted retrospectively
to give effect to the 1-for-16 and 1-for-15 reverse stock splits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">reverse
stock split at a ratio not less than 1:4 and not more than 1:16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Rombotis Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_SettlementPaymentSettlementAgreement', window );">[custom:SettlementPaymentSettlementAgreement] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,415.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_FutureOneTimeSettlementPaymentSettlementAgreement', window );">[custom:FutureOneTimeSettlementPaymentSettlementAgreement-0] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,415.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Mc Barron Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_SettlementPaymentSettlementAgreement', window );">[custom:SettlementPaymentSettlementAgreement] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,164.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_FutureOneTimeSettlementPaymentSettlementAgreement', window );">[custom:FutureOneTimeSettlementPaymentSettlementAgreement-0] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,164.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Cyclacel Limited United Kingdom [Member] | Assets Of Cyclacel Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset Acquisition, Consideration Transferred | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | February 2025 Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | February Two Thousand Twenty Five Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStock', window );">[custom:PercentageOfOutstandingCommonStock]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | February Two Thousand Twenty Five Securities Purchase Agreement [Member] | Helena Special Opportunities One Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Subsequent Event [Member] | February 2025 Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Subsequent Event [Member] | February Two Thousand Twenty Five Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Subsequent Event [Member] | February 2025 Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_CommonStockValueAgreedToBeIssued', window );">[custom:CommonStockValueAgreedToBeIssued] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue', window );">[custom:SharePurchaseAgreementIncrementExerciseLotOneValue] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue', window );">[custom:SharePurchaseAgreementIncrementExerciseLotTwoValue] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member] | February Two Thousand Twenty Five Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member] | Subsequent Event [Member] | February Two Thousand Twenty Five Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock [Member] | Subsequent Event [Member] | February Two Thousand Twenty Five Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesCAndDConvertiblePreferredStockMember', window );">Series C And D Convertible Preferred Stock [Member] | Subsequent Event [Member] | February Two Thousand Twenty Five Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock [Member] | Subsequent Event [Member] | March 2025 Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_CommonStockValueAgreedToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock value agreed to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_CommonStockValueAgreedToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_FutureOneTimeSettlementPaymentSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future one time settlement payment settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_FutureOneTimeSettlementPaymentSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PercentageOfOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PercentageOfOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_SettlementPaymentSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement payment settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_SettlementPaymentSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share purchase agreement increment exercise lot one value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share purchase agreement increment exercise lot two value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholder equity increase from de consolidation of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CYCC_RombotisSettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CYCC_RombotisSettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CYCC_McBarronSettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CYCC_McBarronSettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CYCC_CyclacelLimitedUnitedKingdomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CYCC_CyclacelLimitedUnitedKingdomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=CYCC_AssetsOfCyclacelLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=CYCC_AssetsOfCyclacelLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CYCC_HelenaSpecialOpportunitiesOneLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CYCC_HelenaSpecialOpportunitiesOneLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CYCC_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CYCC_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesCAndDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CYCC_SeriesCAndDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CYCC_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Overview (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 07, 2025</div></th>
<th class="th"><div>Jan. 24, 2025</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 2,946<span></span>
</td>
<td class="nump">$ 11,212<span></span>
</td>
<td class="nump">$ 22,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,494<span></span>
</td>
<td class="nump">428,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,137<span></span>
</td>
<td class="nump">$ 3,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">one-for-sixteen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Deconsolidation, Gain (Loss), Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,947<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Integer </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 24, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>GBP (&#163;) </div>
<div>Integer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">$ 3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,137,000<span></span>
</td>
<td class="nump">$ 3,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of Countries in which Entity Operates | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear', window );">Substantial Doubt about Going Concern, within One Year [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other Comprehensive Income (Loss), Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (891,000)<span></span>
</td>
<td class="num">$ (908,000)<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC Insured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_CashFinancialServicesCompensationSchemeInsuredAmount', window );">[custom:CashFinancialServicesCompensationSchemeInsuredAmount-0] | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_CashFinancialServicesCompensationSchemeInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash financial services compensation scheme insured amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_CashFinancialServicesCompensationSchemeInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -SubTopic 40<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479710/205-40-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts (Details Narrative) - Md Anderson [Member] - Clinical Collaboration Agreement [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_TermOfAgreement', window );">[custom:TermOfAgreement]</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ConductClinicalStudies', window );">[custom:ConductClinicalStudies] | Integer</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_LicenseAgreementPaymentEarned', window );">[custom:LicenseAgreementPaymentEarned-0] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ConductClinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conduct clinical studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ConductClinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_LicenseAgreementPaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_LicenseAgreementPaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CYCC_MdAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CYCC_MdAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CYCC_ClinicalCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CYCC_ClinicalCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 3,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 3,450<span></span>
</td>
<td class="nump">$ 3,137<span></span>
</td>
<td class="nump">$ 3,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 3,044<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent', window );">Research and development tax credit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent', window );">Prepayments and VAT receivable</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
<td class="nump">$ 4,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments and value added tax receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other tax receivables expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-Current Assets (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosureNoncurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits Assets, Noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosureNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosureNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(424)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CYCC_OfficeEquipmentAndFurnitureMember', window );">Office Equipment snd Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CYCC_OfficeEquipmentAndFurnitureMember', window );">Office Equipment snd Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CYCC_OfficeEquipmentAndFurnitureMember', window );">Office Equipment snd Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CYCC_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CYCC_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,299<span></span>
</td>
<td class="nump">$ 3,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and professional fees</a></td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">&#160;Accrued and other current liabilities</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">$ 4,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_AccruedResearchAndDevelopmentCostCurrent', window );">Accrued research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">$ 1,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_AccruedResearchAndDevelopmentCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_AccruedResearchAndDevelopmentCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Liabilities (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 4,599<span></span>
</td>
<td class="nump">$ 3,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CYCC_UnitedKingdomSubsidiaryCompanyMember', window );">United Kingdom Subsidiary Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CYCC_UnitedKingdomSubsidiaryCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CYCC_UnitedKingdomSubsidiaryCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease obligation</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,176<span></span>
</td>
<td class="nump">$ 19,039<span></span>
</td>
<td class="nump">$ 82,830<span></span>
</td>
<td class="nump">$ 74,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CYCC_BerkeleyHeightsFacilityMember', window );">Berkeley Heights Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_LesseeOperatingLeaseTermOfContractExtension', window );">[custom:LesseeOperatingLeaseTermOfContractExtension]</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember', window );">Corporate Headquarters. Tower 11 Kuala Lumpur Malaysia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CYCC_DundeeScotlandMember', window );">Dundee facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,011<span></span>
</td>
<td class="nump">$ 9,104<span></span>
</td>
<td class="nump">$ 10,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_LesseeOperatingLeaseTermOfContractExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease term of contract extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_LesseeOperatingLeaseTermOfContractExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CYCC_BerkeleyHeightsFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CYCC_BerkeleyHeightsFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CYCC_DundeeScotlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CYCC_DundeeScotlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Instruments Issued in Offering (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">$ 6,290,213<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="nump">$ 6,290,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember', window );">Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">1,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">72,108<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">72,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">2,398,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,398,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">3,819,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">$ 470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value upon conversion of pre funded warrants in offering issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CYCC_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CYCC_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CYCC_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CYCC_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair value of Warrants Valuation Assumption (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Measurement Input, Price Volatility [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Measurement Input, Expected Term [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">5.51<span></span>
</td>
<td class="nump">5.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">5.53<span></span>
</td>
<td class="nump">5.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember', window );">PreFunded Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Price Volatility [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Expected Term [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">3.91<span></span>
</td>
<td class="nump">3.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">4.57<span></span>
</td>
<td class="nump">4.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">5.51<span></span>
</td>
<td class="nump">5.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">4.57<span></span>
</td>
<td class="nump">4.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="nump">3.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | Insider Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 02, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 21, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 24, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 24, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 13, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 29, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th">
<div>Dec. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,894,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,209,000<span></span>
</td>
<td class="nump">$ 1,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_CashPlacementFeePercentage', window );">Cash placement fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ManagementFeePercentageToAggregateGrossProceeds', window );">[custom:ManagementFeePercentageToAggregateGrossProceeds-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser', window );">Outstanding common stock at election of purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser', window );">Outstanding common stock at election of purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price of convertible preferred stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ConvertiblePreferredStockConversionPercentage', window );">Conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Preferred Stock, Amount of Preferred Dividends in Arrears | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears', window );">Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ConvertiblePreferredStockConversionPricePerShare', window );">[custom:ConvertiblePreferredStockConversionPricePerShare] | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_CommonStockClosingPriceThreshold', window );">[custom:CommonStockClosingPriceThreshold-0] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice', window );">[custom:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays', window );">[custom:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PreferredStockConversionObligationNumberOfTradingDays', window );">[custom:PreferredStockConversionObligationNumberOfTradingDays]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion', window );">[custom:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends', window );">[custom:DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends] | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser', window );">Outstanding common stock at election of purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.45833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser', window );">Outstanding common stock at election of purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser', window );">Outstanding common stock at election of purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.45833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=CYCC_RothCapitalPartnersLlcMember', window );">Roth Capital Partners Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_CompensationPercentageToAggregateGrossProceeds', window );">[custom:CompensationPercentageToAggregateGrossProceeds-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=CYCC_LadenburgThalmannCo.IncMember', window );">Ladenburg Thalmann Co .Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_CompensationPercentageToAggregateGrossProceeds', window );">[custom:CompensationPercentageToAggregateGrossProceeds-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=CYCC_CantorFitzgeraldCoMember', window );">Cantor Fitzgerald Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ProceedsFromIssuanceOfCommonStockGross', window );">[custom:ProceedsFromIssuanceOfCommonStockGross] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrants exercise price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_November2024WarrantExerciseAndReloadAgreementMember', window );">November 2024 Warrant Exercise And Reload Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_November2024WarrantExerciseAndReloadAgreementMember', window );">November 2024 Warrant Exercise And Reload Agreement [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights', window );">[custom:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights-0] | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_November2024WarrantExerciseAndReloadAgreementMember', window );">November 2024 Warrant Exercise And Reload Agreement [Member] | Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_November2024WarrantExerciseAndReloadAgreementMember', window );">November 2024 Warrant Exercise And Reload Agreement [Member] | Series C Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_November2024WarrantExerciseAndReloadAgreementMember', window );">November 2024 Warrant Exercise And Reload Agreement [Member] | Series D Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_November2024WarrantExerciseAndReloadAgreementMember', window );">November 2024 Warrant Exercise And Reload Agreement [Member] | Series D Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember', window );">April 2024 Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember', window );">April 2024 Securities Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember', window );">April 2024 Securities Purchase Agreement [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember', window );">April 2024 Securities Purchase Agreement [Member] | PreFunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember', window );">April 2024 Securities Purchase Agreement [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember', window );">April 2024 Securities Purchase Agreement [Member] | PreFunded Warrants And Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386.376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember', window );">April 2024 Securities Purchase Agreement [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStock', window );">Percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser', window );">Outstanding common stock at election of purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_CashPlacementFeePercentage', window );">Cash placement fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Common Stock [Member] | Chief Financial Officer And Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | PreFunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_AggregateProceedsFromSaleOfStock', window );">[custom:AggregateProceedsFromSaleOfStock-0] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Common Stock Warrants [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Common Stock Warrants [Member] | Chief Financial Officer And Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember', window );">December 2023 Securities Purchase Agreement [Member] | Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfOutstandingCommonStock', window );">Percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember', window );">Insider Private Placement [Member] | Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrants exercise price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_August2021ControlledEquityOfferingSalesAgreementMember', window );">August 2021 Controlled Equity Offering Sales Agreement [Member] | Cantor Fitzgerald Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_AggregateProceedsFromSaleOfStock', window );">[custom:AggregateProceedsFromSaleOfStock-0] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,721,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ReclassificationOfCommonStockShares', window );">[custom:ReclassificationOfCommonStockShares]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived', window );">[custom:ReclassificationOfCommonStockSharesNoProceedsReceived]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ReclassificationOfCommonStockValue', window );">[custom:ReclassificationOfCommonStockValue] | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,494,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember', window );">November Two Thousand Twenty Four Warrant Exercise And Reload Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember', window );">November Two Thousand Twenty Four Warrant Exercise And Reload Agreement [Member] | Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember', window );">November Two Thousand Twenty Four Warrant Exercise And Reload Agreement [Member] | Series D Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourWarrantsMember', window );">April 2024 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourWarrantsMember', window );">April 2024 Warrants [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourWarrantsMember', window );">April 2024 Warrants [Member] | PreFunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourWarrantsMember', window );">April 2024 Warrants [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourWarrantsMember', window );">April 2024 Warrants [Member] | Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourWarrantsMember', window );">April 2024 Warrants [Member] | Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_April2024WarrantsMember', window );">April 2024 Warrants [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_April2024WarrantsMember', window );">April 2024 Warrants [Member] | Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_December2023PrivatePlacementMember', window );">December 2023 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_December2023PrivatePlacementMember', window );">December 2023 Private Placement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember', window );">December 2023 Private Placement [Member] | Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_December2023PlacementAgencyAgreementMember', window );">December 2023 Placement Agency Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyWarrantMember', window );">December 2020 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,868.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyWarrantMember', window );">December 2020 Warrant [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyWarrantsMember', window );">April 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A holder (together with its affiliates) may not exercise any portion of the common warrant to the
extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least
61 days prior notice from the holder to the Company, the holder may increase the amount of ownership of outstanding stock after exercising
the holder&#8217;s common warrants up to 9.99% of the number of shares of the Company&#8217;s common stock outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A
holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more
than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days prior notice from the holder
to the Company, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s common warrants
up to 9.99% of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the common warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_AggregateProceedsFromSaleOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds from sale of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_AggregateProceedsFromSaleOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_CashPlacementFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash placement fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_CashPlacementFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right reduced exercise price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ClassOfWarrantOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ClassOfWarrantOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_CommonStockClosingPriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock closing price threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_CommonStockClosingPriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_CompensationPercentageToAggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation percentage to aggregate gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_CompensationPercentageToAggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ConvertiblePreferredStockConversionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock conversion percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ConvertiblePreferredStockConversionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ConvertiblePreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ConvertiblePreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Director election trigger number of quarterly periods with no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ManagementFeePercentageToAggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Management fee percentage to aggregate gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ManagementFeePercentageToAggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PercentageOfOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PercentageOfOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding common stock at election of purchaser.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion obligation common stock closing sales price as percentage of conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion obligation common stock closing sales price number of trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PreferredStockConversionObligationNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion obligation number of trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PreferredStockConversionObligationNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion obligation thirty day trading period ending within number of trading days prior to notice of automatic conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ReclassificationOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ReclassificationOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of common stock shares no proceeds received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ReclassificationOfCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of common stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ReclassificationOfCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAmountOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CYCC_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CYCC_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CYCC_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CYCC_RothCapitalPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CYCC_RothCapitalPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CYCC_LadenburgThalmannCo.IncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CYCC_LadenburgThalmannCo.IncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CYCC_CantorFitzgeraldCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CYCC_CantorFitzgeraldCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_November2024WarrantExerciseAndReloadAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_November2024WarrantExerciseAndReloadAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsAndCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_PreFundedWarrantsAndCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_InsiderPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_August2021ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_August2021ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyFourWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CYCC_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_April2024WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_April2024WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_December2023PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_December2023PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_December2023PlacementAgencyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_December2023PlacementAgencyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_DecemberTwoThousandTwentyWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CYCC_AprilTwoThousandTwentyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 592<span></span>
</td>
<td class="nump">$ 1,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Share Option Activity (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Balance</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="nump">$ 10,658.14<span></span>
</td>
<td class="nump">$ 12,048.00<span></span>
</td>
<td class="nump">$ 12,048.00<span></span>
</td>
<td class="nump">$ 21,049.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">9 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregrate Intrinsic Value, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted</a></td>
<td class="nump">24,818<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 70.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547.20<span></span>
</td>
<td class="nump">$ 2,117.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options Outstanding, Cancelled/forfeited</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/forfeited</a></td>
<td class="nump">$ 2,238.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,327.88<span></span>
</td>
<td class="nump">$ 79,737.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Balance</a></td>
<td class="nump">25,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,658.14<span></span>
</td>
<td class="nump">$ 12,048.00<span></span>
</td>
<td class="nump">$ 21,049.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregrate Intrinsic Value, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Outstanding, Unvested</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Unvested</a></td>
<td class="nump">$ 2,094.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options Outstanding, Vested and exercisable</a></td>
<td class="nump">25,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">$ 275.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,141.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">9 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregrate Intrinsic Value, Vested and Exerciseable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="nump">$ 10,658.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="nump">$ 276.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,658.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding weighted average exercise price 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.995%<span></span>
</td>
<td class="nump">3.995%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue]</a></td>
<td class="nump">$ 69.60<span></span>
</td>
<td class="nump">$ 424.80<span></span>
</td>
<td class="nump">$ 424.80<span></span>
</td>
<td class="nump">$ 1,591.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">4.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">107.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grants in period weighted average grant date cumulative fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted Stock Units, Grant Date Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,768.00<span></span>
</td>
<td class="nump">$ 2,881.62<span></span>
</td>
<td class="nump">$ 3,902.40<span></span>
</td>
<td class="nump">$ 3,902.40<span></span>
</td>
<td class="nump">$ 6,768.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted Stock Units, Granted</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">71.36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Value per share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547.20<span></span>
</td>
<td class="nump">$ 2,870.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted Stock Units, Cancelled/forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Value per share, Cancelled/forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,675.17<span></span>
</td>
<td class="nump">$ 3,240.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted Stock Units, Grant Date Value Per Share</a></td>
<td class="nump">$ 2,121.60<span></span>
</td>
<td class="nump">$ 3,240.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,881.62<span></span>
</td>
<td class="nump">$ 3,902.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber', window );">Restricted Stock Units, unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Value per share, Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,240.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,280.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted Stock Units, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Value per share, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,747.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,747.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Value per share, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,882.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Value per share, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,795.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,882.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, grants during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of unvested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of unvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, unvested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by stock based payment award equity instruments other than options nonvested weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Jun. 21, 2024</div></th>
<th class="th"><div>Jun. 13, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,818<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.80<span></span>
</td>
<td class="nump">$ 424.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Options Vesting On Third Anniversary Of Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">71.36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 2,121.60<span></span>
</td>
<td class="nump">$ 3,240.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,881.62<span></span>
</td>
<td class="nump">$ 3,902.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,768.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,635.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,516.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CYCC_EquityIncentivePlan2018Member', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest
over a one to four-year period from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest
over a one to four-year period from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CYCC_EquityIncentivePlan2018Member', window );">2018 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember', window );">2020 Inducement Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of additional equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment orginal award equity instruments other than options forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CYCC_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CYCC_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=CYCC_Plan401KMember', window );">Plan 401K [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral', window );">[custom:DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral]</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge', window );">[custom:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge]</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge', window );">[custom:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge]</a></td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employee statutorily prescribed annual contribution limit after attaining specified age.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employee statutorily prescribed annual contribution limit before attaining specified age.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of employees' deferral for which the employer contributes a matching contribution to the defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=CYCC_Plan401KMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=CYCC_Plan401KMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="num">$ (806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,030)<span></span>
</td>
<td class="num">(24,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before taxes</a></td>
<td class="num">$ (81)<span></span>
</td>
<td class="num">$ (4,300)<span></span>
</td>
<td class="num">$ (11,994)<span></span>
</td>
<td class="num">$ (25,551)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current - domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current - foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current - total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred - domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,354<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">$ 2,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before taxes</a></td>
<td class="num">$ (81)<span></span>
</td>
<td class="num">$ (4,300)<span></span>
</td>
<td class="num">$ (11,994)<span></span>
</td>
<td class="num">$ (25,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense computed at statutory federal tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,527)<span></span>
</td>
<td class="num">(5,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Additional research and development tax relief</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Loss surrendered to generate R&amp;D credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,798<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other foreign items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome', window );">Disallowed expenses and non-taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Foreign items, including change in tax rates, and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount', window );">Other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Current - total</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,354)<span></span>
</td>
<td class="num">$ (782)<span></span>
</td>
<td class="num">$ (2,996)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation other items amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense and tax exempt income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Significant Components of the Entity's Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss and tax credit carryforwards</a></td>
<td class="nump">$ 59,417<span></span>
</td>
<td class="nump">$ 57,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses', window );">Depreciation, amortization and impairment of property and equipment</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DeferredTaxAssetsLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DeferredTaxAssetsLeaseRightOfUseLiability', window );">Lease liability</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">114<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">59,820<span></span>
</td>
<td class="nump">57,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(59,820)<span></span>
</td>
<td class="num">(57,323)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DeferredTaxAssetsLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DeferredTaxAssetsLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DeferredTaxAssetsLeaseRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease right of use liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DeferredTaxAssetsLeaseRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and benefits research and development credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense reserves and accruals depreciation amortization and impairment losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details Narrative)<br> $ in Thousands, &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">59,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">16,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating Loss Carryforwards, Valuation Allowance | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement', window );">[custom:PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement]</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of tax rate adopted in respect of deferred tax assets measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81)<span></span>
</td>
<td class="num">$ (2,946)<span></span>
</td>
<td class="num">$ (11,212)<span></span>
</td>
<td class="num">$ (22,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on convertible exchangeable preferred shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,212)<span></span>
</td>
<td class="num">$ (22,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,314<span></span>
</td>
<td class="nump">3,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (545.33)<span></span>
</td>
<td class="num">$ (502.46)<span></span>
</td>
<td class="num">$ (6,419.07)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">748,224<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">117,842,000<span></span>
</td>
<td class="nump">3,554,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">25,259<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="nump">494,000<span></span>
</td>
<td class="nump">595,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">101,905<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">117,182,000<span></span>
</td>
<td class="nump">2,648,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Geographic Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(81,000)<span></span>
</td>
<td class="num">$ (2,946,000)<span></span>
</td>
<td class="num">(11,212,000)<span></span>
</td>
<td class="num">(22,555,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">3,734,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,094,000<span></span>
</td>
<td class="nump">8,805,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long Lived Assets, net</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">UNITED KINGDOM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,175,000)<span></span>
</td>
<td class="num">(21,747,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809,000<span></span>
</td>
<td class="nump">5,867,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long Lived Assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
<td class="num">(808,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,285,000<span></span>
</td>
<td class="nump">2,938,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long Lived Assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Summary of Consolidated Net Loss (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">822,000<span></span>
</td>
<td class="nump">2,802,000<span></span>
</td>
<td class="nump">6,655,000<span></span>
</td>
<td class="nump">19,155,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,036,000<span></span>
</td>
<td class="nump">4,384,000<span></span>
</td>
<td class="nump">12,047,000<span></span>
</td>
<td class="nump">25,873,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,036,000)<span></span>
</td>
<td class="num">(4,355,000)<span></span>
</td>
<td class="num">(12,004,000)<span></span>
</td>
<td class="num">(25,453,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">4,955,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="num">(98,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(81,000)<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="num">(11,994,000)<span></span>
</td>
<td class="num">(25,551,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,354,000)<span></span>
</td>
<td class="num">(782,000)<span></span>
</td>
<td class="num">(2,996,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81,000)<span></span>
</td>
<td class="num">$ (2,946,000)<span></span>
</td>
<td class="num">(11,212,000)<span></span>
</td>
<td class="num">(22,555,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=CYCC_SingleReportableSegmentMember', window );">Single Reportable Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,655,000<span></span>
</td>
<td class="nump">19,155,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,392,000<span></span>
</td>
<td class="nump">6,718,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,047,000<span></span>
</td>
<td class="nump">25,873,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,004,000)<span></span>
</td>
<td class="num">(25,453,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="num">(98,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,994,000)<span></span>
</td>
<td class="num">(25,551,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(782,000)<span></span>
</td>
<td class="num">(2,996,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,212,000)<span></span>
</td>
<td class="num">$ (22,555,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CYCC_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CYCC_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Earnings Per Share, Basic and Diluted (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">748,224<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">117,842,000<span></span>
</td>
<td class="nump">3,554,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">25,259<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="nump">494,000<span></span>
</td>
<td class="nump">595,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_SixPercentConvertibleExchangeablePreferredMember', window );">Six Percent Convertible Exchangeable Preferred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">162,588<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">458,333<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">101,905<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">117,182,000<span></span>
</td>
<td class="nump">2,648,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_SixPercentConvertibleExchangeablePreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_SixPercentConvertibleExchangeablePreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CYCC_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent', window );">Prepayments</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments and value added tax receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Remaining Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2026</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2027</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease obligation</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CYCC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 1,176<span></span>
</td>
<td class="nump">$ 19,039<span></span>
</td>
<td class="nump">$ 82,830<span></span>
</td>
<td class="nump">$ 74,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">19,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CYCC_DundeeScotlandMember', window );">Dundee facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,011<span></span>
</td>
<td class="nump">$ 9,104<span></span>
</td>
<td class="nump">$ 10,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CYCC_KualaLumpurFacilityMember', window );">Kuala Lumpur facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CYCC_DundeeScotlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CYCC_DundeeScotlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CYCC_KualaLumpurFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CYCC_KualaLumpurFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>May 07, 2025</div></th>
<th class="th"><div>Apr. 29, 2025</div></th>
<th class="th"><div>Apr. 19, 2025</div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 06, 2025</div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 24, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-sixteen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CYCC_FittersDiversifiedBerhadMember', window );">FITTERS Diversified Berhad [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,588<span></span>
</td>
<td class="nump">1,745,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">All references to issued and outstanding shares
all periods reflect: the 1-for-16 reverse stock split effective May 12, 2025, and the 1-for-15 reverse stock split effective July 7,
2025. As a result, all share numbers for all periods, including the number of shares underlying warrants, options, and other convertible
securities, and all exercise prices applicable to such warrants, options and convertible securities have been adjusted retrospectively
to give effect to the 1-for-16 and 1-for-15 reverse stock splits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">reverse
stock split at a ratio not less than 1:4 and not more than 1:16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CYCC_FittersDiversifiedBerhadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CYCC_FittersDiversifiedBerhadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Jul. 23, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001130166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Cyclacel
Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Jul. 23, 2025 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Class A common stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">1,118,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 2,578,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 394.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Represents the maximum number of shares of Common Stock, par value $0.001 per share (&#8220;Cyclacel Common Stock&#8221;),
of Cyclacel Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;), issuable to securityholders of Fitters Sdn. Bhd. (&#8220;Fitters&#8221;)
pursuant to the Exchange and related transactions contemplated by the Exchange Agreement, dated as of May 6, 2025, as amended on July
7, 2025, by and among the Registrant, FITTERS Diversified Berhad and Fitters.Estimated solely for the purpose of calculating the registration fee under Rule 457(f)(2)
under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). As Fitters is a private company, there is no market
for its securities, therefore, the proposed maximum aggregate offering price per share was calculated based on the book value as of July
10, 2025 of the Fitters Ordinary Shares that will be exchanged in the Transaction, which amount equals $2,578,304.The registration fee is determined in accordance with Section 6(b) of the
Securities Act and calculated by multiplying the estimated aggregate offering price of securities to be registered by 0.00015310.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Jul. 23, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 2,578,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">394.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 394.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>418</ContextCount>
  <ElementCount>393</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - Company Overview</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CompanyOverview</Role>
      <ShortName>Company Overview</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - Significant Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SignificantContracts</Role>
      <ShortName>Significant Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Non-Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Non-currentAssets</Role>
      <ShortName>Non-Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Accrued and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/AccruedAndOtherLiabilities</Role>
      <ShortName>Accrued and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Taxes</Role>
      <ShortName>Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Geographic and Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/GeographicAndSegmentInformation</Role>
      <ShortName>Geographic and Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/CashAndCashEquivalents</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/PropertyAndEquipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Accrued and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables</Role>
      <ShortName>Accrued and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/AccruedAndOtherLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/StockholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/TaxesTables</Role>
      <ShortName>Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/Taxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/NetLossPerCommonShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Geographic and Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/GeographicAndSegmentInformationTables</Role>
      <ShortName>Geographic and Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/GeographicAndSegmentInformation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cyclacel.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Organization of the Company and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Organization of the Company and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Company Overview (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CompanyOverviewDetailsNarrative</Role>
      <ShortName>Company Overview (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/CompanyOverview</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Significant Contracts (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SignificantContractsDetailsNarrative</Role>
      <ShortName>Significant Contracts (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/SignificantContracts</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Summary of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Summary of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Schedule of prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Non-Current Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Non-currentAssetsDetailsNarrative</Role>
      <ShortName>Non-Current Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/Non-currentAssets</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Schedule of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Accrued and Other Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative</Role>
      <ShortName>Accrued and Other Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails</Role>
      <ShortName>Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Schedule of Fair Value of Instruments Issued in Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails</Role>
      <ShortName>Schedule of Fair Value of Instruments Issued in Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Fair value of Warrants Valuation Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails</Role>
      <ShortName>Schedule of Fair value of Warrants Valuation Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/StockholdersEquityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Schedule of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Schedule of Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails</Role>
      <ShortName>Schedule of Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails</Role>
      <ShortName>Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Stock Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StockBasedCompensationDetailsNarrative</Role>
      <ShortName>Stock Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/StockBasedCompensationTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Employee Benefit Plans (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative</Role>
      <ShortName>Employee Benefit Plans (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails</Role>
      <ShortName>Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails</Role>
      <ShortName>Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Schedule of Significant Components of the Entity's Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Significant Components of the Entity's Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/TaxesDetailsNarrative</Role>
      <ShortName>Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/TaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999069 - Disclosure - Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Schedule of Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfGeographicInformationDetails</Role>
      <ShortName>Schedule of Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999071 - Disclosure - Schedule of Summary of Consolidated Net Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails</Role>
      <ShortName>Schedule of Summary of Consolidated Net Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999072 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999073 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure</Role>
      <ShortName>Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999074 - Disclosure - Revenue (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/RevenueDetailsNarrative</Role>
      <ShortName>Revenue (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/Revenue</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999075 - Disclosure - Schedule of Remaining Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails</Role>
      <ShortName>Schedule of Remaining Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999076 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/LeasesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="forms-4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>999077 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cyclacel.com/role/SubsequentEvents</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ex107.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cycc-20250331.xsd</File>
    <File>cycc-20250331_cal.xml</File>
    <File>cycc-20250331_def.xml</File>
    <File>cycc-20250331_lab.xml</File>
    <File>cycc-20250331_pre.xml</File>
    <File doctype="S-4" isDefinitelyFs="true" isUsgaap="true" original="forms-4.htm">forms-4.htm</File>
    <File doctype="EX-FILING FEES" original="ex107.htm">ex107.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>annexc_001.jpg</File>
    <File>annexc_002.jpg</File>
    <File>annexc_003.jpg</File>
    <File>annexc_004.jpg</File>
    <File>aud_001.jpg</File>
    <File>forms-4_001.jpg</File>
    <File>forms-4_002.jpg</File>
    <File>forms-4_003.jpg</File>
    <File>forms-4_004.jpg</File>
    <File>forms-4_005.jpg</File>
    <File>forms-4_006.jpg</File>
    <File>forms-4_007.jpg</File>
    <File>forms-4_008.jpg</File>
    <File>forms-4_009.jpg</File>
    <File>forms-4_010.jpg</File>
    <File>forms-4_011.jpg</File>
    <File>forms-4_012.jpg</File>
    <File>forms-4_013.jpg</File>
    <File>forms-4_014.jpg</File>
    <File>forms-4_015.jpg</File>
    <File>forms-4_016.jpg</File>
    <File>forms-4_017.jpg</File>
    <File>forms-4_018.jpg</File>
    <File>forms-4_019.jpg</File>
    <File>forms-4_020.jpg</File>
    <File>forms-4_021.jpg</File>
    <File>forms-4_022.jpg</File>
    <File>forms-4_023.jpg</File>
    <File>forms-4_024.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1276">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/ffd/2024q2</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>143
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "forms-4.htm": {
   "nsprefix": "CYCC",
   "nsuri": "http://cyclacel.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "cycc-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cycc-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cycc-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cycc-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cycc-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "forms-4.htm"
     ]
    }
   },
   "keyStandard": 279,
   "keyCustom": 94,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 38,
   "memberCustom": 55,
   "hidden": {
    "total": 251,
    "http://fasb.org/us-gaap/2024": 169,
    "http://cyclacel.com/20250331": 80,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 416,
   "entityCount": 1,
   "segmentCount": 104,
   "elementCount": 639,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1276,
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://cyclacel.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cyclacel.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cyclacel.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://cyclacel.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cyclacel.com/role/StatementsOfComprehensiveLoss",
     "longName": "00000005 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
     "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical",
     "longName": "00000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://cyclacel.com/role/StatementsOfCashFlows",
     "longName": "00000008 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://cyclacel.com/role/CompanyOverview",
     "longName": "999009 - Disclosure - Company Overview",
     "shortName": "Company Overview",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cyclacel.com/role/SignificantContracts",
     "longName": "999011 - Disclosure - Significant Contracts",
     "shortName": "Significant Contracts",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "CYCC:SignificantContractsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "CYCC:SignificantContractsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cyclacel.com/role/CashAndCashEquivalents",
     "longName": "999012 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities",
     "longName": "999013 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "999014 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cyclacel.com/role/Non-currentAssets",
     "longName": "999015 - Disclosure - Non-Current Assets",
     "shortName": "Non-Current Assets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "CYCC:NonCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "CYCC:NonCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cyclacel.com/role/PropertyAndEquipment",
     "longName": "999016 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cyclacel.com/role/AccruedAndOtherLiabilities",
     "longName": "999017 - Disclosure - Accrued and Other Liabilities",
     "shortName": "Accrued and Other Liabilities",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cyclacel.com/role/CommitmentsAndContingencies",
     "longName": "999018 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cyclacel.com/role/StockholdersEquity",
     "longName": "999019 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cyclacel.com/role/StockBasedCompensation",
     "longName": "999020 - Disclosure - Stock Based Compensation",
     "shortName": "Stock Based Compensation",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cyclacel.com/role/EmployeeBenefitPlans",
     "longName": "999021 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cyclacel.com/role/Taxes",
     "longName": "999022 - Disclosure - Taxes",
     "shortName": "Taxes",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cyclacel.com/role/NetLossPerCommonShare",
     "longName": "999023 - Disclosure - Net Loss per Common Share",
     "shortName": "Net Loss per Common Share",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cyclacel.com/role/GeographicAndSegmentInformation",
     "longName": "999024 - Disclosure - Geographic and Segment Information",
     "shortName": "Geographic and Segment Information",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cyclacel.com/role/Revenue",
     "longName": "999025 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cyclacel.com/role/Leases",
     "longName": "999026 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cyclacel.com/role/SubsequentEvents",
     "longName": "999027 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999028 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cyclacel.com/role/CashAndCashEquivalentsTables",
     "longName": "999029 - Disclosure - Cash and Cash Equivalents (Tables)",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
     "longName": "999030 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "999031 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cyclacel.com/role/PropertyAndEquipmentTables",
     "longName": "999032 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables",
     "longName": "999033 - Disclosure - Accrued and Other Liabilities (Tables)",
     "shortName": "Accrued and Other Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cyclacel.com/role/CommitmentsAndContingenciesTables",
     "longName": "999034 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://cyclacel.com/role/StockholdersEquityTables",
     "longName": "999035 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cyclacel.com/role/StockBasedCompensationTables",
     "longName": "999036 - Disclosure - Stock Based Compensation (Tables)",
     "shortName": "Stock Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cyclacel.com/role/TaxesTables",
     "longName": "999037 - Disclosure - Taxes (Tables)",
     "shortName": "Taxes (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cyclacel.com/role/NetLossPerCommonShareTables",
     "longName": "999038 - Disclosure - Net Loss per Common Share (Tables)",
     "shortName": "Net Loss per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://cyclacel.com/role/GeographicAndSegmentInformationTables",
     "longName": "999039 - Disclosure - Geographic and Segment Information (Tables)",
     "shortName": "Geographic and Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cyclacel.com/role/LeasesTables",
     "longName": "999040 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
     "longName": "999041 - Disclosure - Organization of the Company and Basis of Presentation (Details Narrative)",
     "shortName": "Organization of the Company and Basis of Presentation (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-312025-01-31_us-gaap_SubsequentEventMember",
      "name": "CYCC:StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://cyclacel.com/role/CompanyOverviewDetailsNarrative",
     "longName": "999042 - Disclosure - Company Overview (Details Narrative)",
     "shortName": "Company Overview (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-242025-01-24",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://cyclacel.com/role/SignificantContractsDetailsNarrative",
     "longName": "999044 - Disclosure - Significant Contracts (Details Narrative)",
     "shortName": "Significant Contracts (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2021-09-012021-09-30_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember",
      "name": "CYCC:TermOfAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "CYCC:SignificantContractsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-09-012021-09-30_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember",
      "name": "CYCC:TermOfAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "CYCC:SignificantContractsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails",
     "longName": "999045 - Disclosure - Summary of Cash and Cash Equivalents (Details)",
     "shortName": "Summary of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "999046 - Disclosure - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "shortName": "Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "999047 - Disclosure - Schedule of prepaid expenses and other current assets (Details)",
     "shortName": "Schedule of prepaid expenses and other current assets (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://cyclacel.com/role/Non-currentAssetsDetailsNarrative",
     "longName": "999048 - Disclosure - Non-Current Assets (Details Narrative)",
     "shortName": "Non-Current Assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DepositsAssetsNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999049 - Disclosure - Schedule of Property and Equipment (Details)",
     "shortName": "Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "999050 - Disclosure - Schedule of Accrued and Other Current Liabilities (Details)",
     "shortName": "Schedule of Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CYCC:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CYCC:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative",
     "longName": "999051 - Disclosure - Accrued and Other Liabilities (Details Narrative)",
     "shortName": "Accrued and Other Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_UnitedKingdomSubsidiaryCompanyMember",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails",
     "longName": "999052 - Disclosure - Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases (Details)",
     "shortName": "Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999053 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-012022-04-30_custom_BerkeleyHeightsFacilityMember",
      "name": "CYCC:LesseeOperatingLeaseTermOfContractExtension",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
     "longName": "999054 - Disclosure - Schedule of Fair Value of Instruments Issued in Offering (Details)",
     "shortName": "Schedule of Fair Value of Instruments Issued in Offering (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember",
      "name": "CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
     "longName": "999055 - Disclosure - Schedule of Fair value of Warrants Valuation Assumption (Details)",
     "shortName": "Schedule of Fair value of Warrants Valuation Assumption (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999056 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-05-022024-05-02",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-05-022024-05-02",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails",
     "longName": "999057 - Disclosure - Schedule of Stock Based Compensation Expense (Details)",
     "shortName": "Schedule of Stock Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails",
     "longName": "999058 - Disclosure - Schedule of Share Option Activity (Details)",
     "shortName": "Schedule of Share Option Activity (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
     "longName": "999059 - Disclosure - Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
     "longName": "999060 - Disclosure - Schedule of Restricted Stock Units Activity (Details)",
     "shortName": "Schedule of Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative",
     "longName": "999061 - Disclosure - Stock Based Compensation (Details Narrative)",
     "shortName": "Stock Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative",
     "longName": "999062 - Disclosure - Employee Benefit Plans (Details Narrative)",
     "shortName": "Employee Benefit Plans (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails",
     "longName": "999063 - Disclosure - Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details)",
     "shortName": "Schedule of Components of (Loss) Income Before Taxes from Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails",
     "longName": "999064 - Disclosure - Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details)",
     "shortName": "Schedule of Benefit (Provision) for Income Taxes from Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails",
     "longName": "999065 - Disclosure - Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details)",
     "shortName": "Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails",
     "longName": "999066 - Disclosure - Schedule of Significant Components of the Entity's Deferred Tax Assets (Details)",
     "shortName": "Schedule of Significant Components of the Entity's Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://cyclacel.com/role/TaxesDetailsNarrative",
     "longName": "999067 - Disclosure - Taxes (Details Narrative)",
     "shortName": "Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "999068 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "longName": "999069 - Disclosure - Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details)",
     "shortName": "Schedule of antidilutive shares excluded from computation of diluted net loss per share (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember54207671",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails",
     "longName": "999070 - Disclosure - Schedule of Geographic Information (Details)",
     "shortName": "Schedule of Geographic Information (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_country_GB",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
     "longName": "999071 - Disclosure - Schedule of Summary of Consolidated Net Loss (Details)",
     "shortName": "Schedule of Summary of Consolidated Net Loss (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_SingleReportableSegmentMember",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "longName": "999072 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "shortName": "Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_custom_SixPercentConvertibleExchangeablePreferredMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure",
     "longName": "999073 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://cyclacel.com/role/RevenueDetailsNarrative",
     "longName": "999074 - Disclosure - Revenue (Details Narrative)",
     "shortName": "Revenue (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails",
     "longName": "999075 - Disclosure - Schedule of Remaining Lease Payments (Details)",
     "shortName": "Schedule of Remaining Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://cyclacel.com/role/LeasesDetailsNarrative",
     "longName": "999076 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://cyclacel.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999077 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-06_custom_FittersDiversifiedBerhadMember",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-4.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://cyclacel.com/role/AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued and Other Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative",
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "verboseLabel": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r837"
     ]
    },
    "CYCC_AccrualOfPreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "AccrualOfPreferredStockDividends",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual of preferred stock dividends",
        "documentation": "Accrual of preferred stock dividends."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued and other current liabilities",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued legal and professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "CYCC_AccruedResearchAndDevelopmentCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "AccruedResearchAndDevelopmentCostCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued research and development",
        "documentation": "Accrued research and development.",
        "label": "AccruedResearchAndDevelopmentCostCurrent"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued research and development",
        "documentation": "Accrued research and development costs current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r143",
      "r626"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r81",
      "r148",
      "r622",
      "r662",
      "r663"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r21",
      "r513",
      "r516",
      "r567",
      "r658",
      "r659",
      "r909",
      "r910",
      "r911",
      "r918",
      "r919",
      "r920",
      "r922"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r837",
      "r1048"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r918",
      "r919",
      "r920",
      "r922",
      "r993",
      "r1051"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred stock dividends",
        "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r104"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r417"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_AggregateProceedsFromSaleOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "AggregateProceedsFromSaleOfStock",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:AggregateProceedsFromSaleOfStock-0]",
        "documentation": "Aggregate proceeds from sale of stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation costs",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r458"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total shares excluded from calculation",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "CYCC_April2024WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "April2024WarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "April 2024 Warrants [Member]",
        "documentation": "April 2024 Warrants [Member]",
        "label": "April 2024 Warrants [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2024 Securities Purchase Agreement [Member]",
        "documentation": "April 2024 Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_AprilTwoThousandTwentyFourWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "AprilTwoThousandTwentyFourWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2024 Warrants [Member]",
        "documentation": "April 2024 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_AprilTwoThousandTwentyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "AprilTwoThousandTwentyWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2020 Warrants [Member]",
        "documentation": "April 2020 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r989"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r989"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Total Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r121",
      "r144",
      "r174",
      "r214",
      "r222",
      "r247",
      "r251",
      "r264",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r506",
      "r510",
      "r541",
      "r618",
      "r715",
      "r799",
      "r800",
      "r837",
      "r863",
      "r940",
      "r941",
      "r1006"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r151",
      "r174",
      "r264",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r506",
      "r510",
      "r541",
      "r837",
      "r940",
      "r941",
      "r1006"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r829"
     ]
    },
    "CYCC_AssetsOfCyclacelLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "AssetsOfCyclacelLimitedMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Of Cyclacel Limited [Member]",
        "documentation": "Assets Of Cyclacel Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "CYCC_August2021ControlledEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "August2021ControlledEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2021 Controlled Equity Offering Sales Agreement [Member]",
        "documentation": "August 2021 Controlled Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_BerkeleyHeightsFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "BerkeleyHeightsFacilityMember",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Berkeley Heights Facility [Member]",
        "documentation": "Berkeley Heights Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r878"
     ]
    },
    "CYCC_CantorFitzgeraldCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CantorFitzgeraldCoMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cantor Fitzgerald Co [Member]",
        "documentation": "Cantor Fitzgerald Co [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r619",
      "r688",
      "r710",
      "r837",
      "r863",
      "r904"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/CompanyOverviewDetailsNarrative",
      "http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Total cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r141",
      "r785"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/CashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r619"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Taxes",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r90",
      "r170"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r90",
      "r170"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r90"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://cyclacel.com/role/SummaryOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r1015"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_CashFinancialServicesCompensationSchemeInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CashFinancialServicesCompensationSchemeInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CashFinancialServicesCompensationSchemeInsuredAmount-0]",
        "documentation": "Cash financial services compensation scheme insured amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_CashPlacementFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CashPlacementFeePercentage",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash placement fee, percentage",
        "documentation": "Cash placement fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Uninsured Amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "CYCC_ChiefFinancialOfficerAndChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ChiefFinancialOfficerAndChiefOperatingOfficerMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer And Chief Operating Officer [Member]",
        "documentation": "Chief Financial Officer And Chief Operating Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r145",
      "r146",
      "r147",
      "r174",
      "r198",
      "r199",
      "r206",
      "r208",
      "r216",
      "r217",
      "r264",
      "r297",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r310",
      "r311",
      "r315",
      "r318",
      "r326",
      "r541",
      "r669",
      "r670",
      "r671",
      "r672",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r702",
      "r724",
      "r743",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r896",
      "r915",
      "r923"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r216",
      "r310",
      "r311",
      "r313",
      "r315",
      "r318",
      "r324",
      "r326",
      "r669",
      "r670",
      "r671",
      "r672",
      "r809",
      "r896",
      "r915"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "CYCC_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Class of warrant or right exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights-0]",
        "documentation": "Class of warrant or right reduced exercise price of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "CYCC_ClassOfWarrantOrRightsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ClassOfWarrantOrRightsExercisable",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable",
        "documentation": "Class of warrant or rights exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ClinicalCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ClinicalCollaborationAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Collaboration Agreement [Member]",
        "documentation": "Clinical Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ClinicalTrialAccountingPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ClinicalTrialAccountingPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Accounting",
        "documentation": "Clinical Trial Accounting [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ClinicalTrialSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ClinicalTrialSupplyMember",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Supply [Member]",
        "documentation": "Clinical Trial Supply [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r291",
      "r292",
      "r769",
      "r933",
      "r935"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "CYCC_CommonStockClosingPriceThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CommonStockClosingPriceThreshold",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CommonStockClosingPriceThreshold-0]",
        "documentation": "Common stock closing price threshold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r918",
      "r919",
      "r922",
      "r993",
      "r1046",
      "r1051"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r702"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r75",
      "r702",
      "r721",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 250,000,000 shares authorized at March 31, 2025 and 100,000,000 shares authorized at December\u00a031,\u00a02024; 863,902 shares issued and outstanding at March\u00a031,\u00a02025 and 36,913 shares issued and outstanding at December\u00a031,\u00a02024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r621",
      "r837"
     ]
    },
    "CYCC_CommonStockValueAgreedToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CommonStockValueAgreedToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CommonStockValueAgreedToBeIssued]",
        "documentation": "Common stock value agreed to be issued."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_CompensationPercentageToAggregateGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CompensationPercentageToAggregateGrossProceeds",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CompensationPercentageToAggregateGrossProceeds-0]",
        "documentation": "Compensation percentage to aggregate gross proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r153",
      "r155",
      "r161",
      "r613",
      "r632",
      "r633"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss)",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ConductClinicalStudies": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ConductClinicalStudies",
     "presentation": [
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ConductClinicalStudies]",
        "documentation": "Conduct clinical studies."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion amount",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "verboseLabel": "Number of shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "CYCC_ConvertiblePreferredStockConversionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ConvertiblePreferredStockConversionPercentage",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion percentage",
        "documentation": "Convertible preferred stock conversion percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ConvertiblePreferredStockConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ConvertiblePreferredStockConversionPricePerShare",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ConvertiblePreferredStockConversionPricePerShare]",
        "documentation": "Convertible preferred stock conversion price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r315",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of shares",
        "verboseLabel": "Number of common shares issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r44",
      "r74",
      "r102",
      "r321"
     ]
    },
    "CYCC_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Headquarters. Tower 11 Kuala Lumpur Malaysia [Member]",
        "documentation": "Corporate Headquarters. Tower 11 Kuala Lumpur Malaysia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r306",
      "r313",
      "r568",
      "r577",
      "r617",
      "r787",
      "r789"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current - domestic",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r917",
      "r984"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current - foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r917"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current - total",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r917"
     ]
    },
    "CYCC_CyclacelLimitedUnitedKingdomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "CyclacelLimitedUnitedKingdomMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cyclacel Limited United Kingdom [Member]",
        "documentation": "Cyclacel Limited United Kingdom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r44",
      "r64",
      "r67",
      "r111",
      "r113",
      "r554"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_December2023PlacementAgencyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "December2023PlacementAgencyAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2023 Placement Agency Agreement [Member]",
        "documentation": "December 2023 Placement Agency Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_December2023PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "December2023PrivatePlacementMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2023 Private Placement [Member]",
        "documentation": "December 2023 Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DecemberTwoThousandTwentyThreePrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DecemberTwoThousandTwentyThreePrivatePlacementMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "December 2023 Private Placement [Member]",
        "documentation": "December 2023 Private Placement [Member]",
        "label": "December 2023 Private Placement [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2023 Securities Purchase Agreement [Member]",
        "documentation": "December 2023 Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DecemberTwoThousandTwentyWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DecemberTwoThousandTwentyWarrantMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2020 Warrant [Member]",
        "documentation": "December 2020 Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeconsolidationGainOrLossAmount",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/CompanyOverviewDetailsNarrative",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on deconsolidation of subsidiary",
        "verboseLabel": "Deconsolidation, Gain (Loss), Amount",
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred - domestic",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r983",
      "r984"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndOtherTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credit receivable",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other tax receivables expected to be realized or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "CYCC_DeferredTaxAssetsLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DeferredTaxAssetsLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset",
        "documentation": "Deferred tax assets lease right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DeferredTaxAssetsLeaseRightOfUseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DeferredTaxAssetsLeaseRightOfUseLiability",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability",
        "documentation": "Deferred tax assets lease right of use liability.",
        "label": "DeferredTaxAssetsLeaseRightOfUseLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss and tax credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "CYCC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Deferred tax assets tax deferred expense compensation and benefits research and development credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "CYCC_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, amortization and impairment of property and equipment",
        "documentation": "Deferred tax assets tax deferred expense reserves and accruals depreciation amortization and impairment losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSignificantComponentsOfEntitysDeferredTaxAssetsDetails",
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance for deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge]",
        "documentation": "Defined contribution plan employee statutorily prescribed annual contribution limit after attaining specified age."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge]",
        "documentation": "Defined contribution plan employee statutorily prescribed annual contribution limit before attaining specified age."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral]",
        "documentation": "Represents the percentage of employees' deferral for which the employer contributes a matching contribution to the defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/Non-currentAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current deposits",
        "verboseLabel": "Deposits Assets, Noncurrent",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39"
     ]
    },
    "CYCC_DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends]",
        "documentation": "Director election trigger number of quarterly periods with no dividends."
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1047"
     ]
    },
    "CYCC_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Remaining Lease Payments"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DisclosureNoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DisclosureNoncurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r419",
      "r450",
      "r451",
      "r453",
      "r823"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Current Assets",
        "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_DisclosureSignificantContractsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DisclosureSignificantContractsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r877",
      "r878"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "CYCC_DundeeScotlandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "DundeeScotlandMember",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cyclacel.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dundee facility [Member]",
        "documentation": "Dundee facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted earnings per common share:",
        "verboseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r198",
      "r206",
      "r207",
      "r208",
      "r213",
      "r500",
      "r503",
      "r520",
      "r521",
      "r614",
      "r634",
      "r791"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r210"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cyclacel.com/role/NetLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r209",
      "r211",
      "r212"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469",
      "r825"
     ]
    },
    "CYCC_EffectiveIncomeTaxRateReconciliationOtherItemsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherItemsAmount",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other items",
        "documentation": "Effective income tax rate reconciliation other items amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469",
      "r825"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r135",
      "r157",
      "r158",
      "r159",
      "r179",
      "r180",
      "r181",
      "r183",
      "r188",
      "r190",
      "r192",
      "r215",
      "r265",
      "r266",
      "r284",
      "r329",
      "r487",
      "r488",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r558",
      "r567",
      "r631",
      "r658",
      "r659",
      "r660",
      "r677",
      "r743"
     ]
    },
    "CYCC_EquityIncentivePlan2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "EquityIncentivePlan2018Member",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2018 Plan [Member]",
        "documentation": "2018 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r496",
      "r898",
      "r899",
      "r900",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercise price",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r534",
      "r829"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r534",
      "r829"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair value of Warrants Valuation Assumption",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r831"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r533",
      "r534",
      "r536",
      "r572",
      "r573",
      "r574",
      "r807",
      "r808",
      "r812",
      "r813",
      "r814",
      "r829",
      "r831"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r527",
      "r829",
      "r997",
      "r999"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Assets and Liabilities",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r531",
      "r532",
      "r533",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r610",
      "r829",
      "r832"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r367",
      "r372",
      "r524",
      "r534",
      "r572",
      "r812",
      "r813",
      "r814",
      "r829"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r367",
      "r372",
      "r524",
      "r525",
      "r534",
      "r573",
      "r807",
      "r808",
      "r812",
      "r813",
      "r814",
      "r829"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r524",
      "r525",
      "r526",
      "r527",
      "r534",
      "r574",
      "r807",
      "r808",
      "r812",
      "r813",
      "r814",
      "r829",
      "r831"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r527",
      "r829",
      "r997",
      "r999"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r533",
      "r534",
      "r536",
      "r572",
      "r573",
      "r574",
      "r807",
      "r808",
      "r812",
      "r813",
      "r814",
      "r829",
      "r831"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "CYCC_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Two Thousand Twenty Five Securities Purchase Agreement [Member]",
        "documentation": "February Two Thousand Twenty Five Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_FittersDiversifiedBerhadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "FittersDiversifiedBerhadMember",
     "presentation": [
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FITTERS Diversified Berhad [Member]",
        "documentation": "FITTERS Diversified Berhad [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gains (losses)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r546",
      "r740"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency and Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "CYCC_FutureOneTimeSettlementPaymentSettlementAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "FutureOneTimeSettlementPaymentSettlementAgreement",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:FutureOneTimeSettlementPaymentSettlementAgreement-0]",
        "documentation": "Future one time settlement payment settlement agreement."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "GB",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r726"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "CYCC_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "Going Concern [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_HelenaSpecialOpportunitiesOneLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "HelenaSpecialOpportunitiesOneLtdMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Helena Special Opportunities One Ltd [Member]",
        "documentation": "Helena Special Opportunities One Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r97"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r467"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails",
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails",
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before taxes",
        "label": "Loss from continuing operations before taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r115",
      "r120",
      "r615",
      "r628",
      "r793",
      "r799",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfComponentsOfLossIncomeBeforeTaxesFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r467"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r287",
      "r288",
      "r528",
      "r530",
      "r535",
      "r655",
      "r657",
      "r727",
      "r781",
      "r830",
      "r1017"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r528",
      "r530",
      "r535",
      "r655",
      "r657",
      "r727",
      "r781",
      "r830",
      "r1017"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r468",
      "r469",
      "r475",
      "r483",
      "r825",
      "r980"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r468",
      "r469",
      "r475",
      "r483",
      "r825",
      "r980"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/Taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r463",
      "r468",
      "r472",
      "r473",
      "r474",
      "r476",
      "r482",
      "r489",
      "r491",
      "r494",
      "r495",
      "r674",
      "r825"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBenefitProvisionForIncomeTaxesFromContinuingOperationsDetails",
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails",
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit",
        "verboseLabel": "Current - total",
        "label": "Income tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r132",
      "r191",
      "r192",
      "r214",
      "r230",
      "r251",
      "r466",
      "r468",
      "r490",
      "r635",
      "r825"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r464",
      "r465",
      "r476",
      "r477",
      "r481",
      "r485",
      "r668"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r825",
      "r973"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense computed at statutory federal tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r825"
     ]
    },
    "CYCC_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disallowed expenses and non-taxable income",
        "documentation": "Income tax reconciliation nondeductible expense and tax exempt income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign items, including change in tax rates, and other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r973",
      "r975"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss surrendered to generate R&amp;D credit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r973",
      "r975"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r973",
      "r975"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional research and development tax relief",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r973",
      "r974"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfReconciliationOfBenefitProvisionForIncomeTaxesFromContinuingOperationsWithAmountComputedByApplyingStatutoryFederalTaxRateToLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other foreign items",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r973",
      "r974"
     ]
    },
    "us-gaap_IncomeTaxesPaidNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNetAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable, accrued and other current liabilities",
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r913"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "CYCC_IncreaseInCarryingAmountOfRedeemableCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "IncreaseInCarryingAmountOfRedeemableCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassification of redeemable common stock",
        "documentation": "Increase in carrying amount of redeemable common stock.",
        "label": "IncreaseInCarryingAmountOfRedeemableCommonStock"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_InducementEquityIncentivePlanTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "InducementEquityIncentivePlanTwoThousandTwentyMember",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Inducement Equity Incentive Plan [Member]",
        "documentation": "2020 Inducement Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_InsiderPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "InsiderPrivatePlacementMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Private Placement [Member]",
        "documentation": "Insider Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r927"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r167",
      "r168"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses",
        "documentation": "Issue of common stock preferred stock pre funded warrants and warrants on equity financing net of expenses."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct Offering, net of expenses, shares",
        "documentation": "Issue of common stock preferred stock shares pre funded warrants and warrants on equity financing net of expenses."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2025 Securities Purchase Agreement [Member]",
        "documentation": "February 2025 Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_KualaLumpurFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "KualaLumpurFacilityMember",
     "presentation": [
      "http://cyclacel.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kuala Lumpur facility [Member]",
        "documentation": "Kuala Lumpur facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_LadenburgThalmannCo.IncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "LadenburgThalmannCo.IncMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ladenburg Thalmann Co .Inc [Member]",
        "documentation": "Ladenburg Thalmann Co .Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r566"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cyclacel.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesTables",
      "http://cyclacel.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases",
        "verboseLabel": "Schedule of Remaining Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails",
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total future minimum lease obligation",
        "totalLabel": "Total future minimum lease obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "CYCC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails",
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Lessee operating lease liability payments due after year two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRemainingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "CYCC_LesseeOperatingLeaseTermOfContractExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "LesseeOperatingLeaseTermOfContractExtension",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:LesseeOperatingLeaseTermOfContractExtension]",
        "documentation": "Lessee operating lease term of contract extension."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://cyclacel.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r174",
      "r264",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r507",
      "r510",
      "r511",
      "r541",
      "r701",
      "r792",
      "r863",
      "r940",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r114",
      "r624",
      "r837",
      "r916",
      "r932",
      "r1000"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r140",
      "r174",
      "r264",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r507",
      "r510",
      "r511",
      "r541",
      "r837",
      "r940",
      "r1006",
      "r1007"
     ]
    },
    "CYCC_LicenseAgreementPaymentEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "LicenseAgreementPaymentEarned",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:LicenseAgreementPaymentEarned-0]",
        "documentation": "License agreement payment earned."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ManagementFeePercentageToAggregateGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ManagementFeePercentageToAggregateGrossProceeds",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ManagementFeePercentageToAggregateGrossProceeds-0]",
        "documentation": "Management fee percentage to aggregate gross proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2025 Securities Purchase Agreement [Member]",
        "documentation": "March 2025 Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r412",
      "r459",
      "r527",
      "r578",
      "r654",
      "r656",
      "r664",
      "r693",
      "r694",
      "r748",
      "r751",
      "r755",
      "r756",
      "r758",
      "r779",
      "r780",
      "r805",
      "r809",
      "r822",
      "r831",
      "r832",
      "r833",
      "r834",
      "r847",
      "r942",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "CYCC_McBarronSettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "McBarronSettlementAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mc Barron Settlement Agreement [Member]",
        "documentation": "Mc Barron Settlement Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_MdAndersonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "MdAndersonMember",
     "presentation": [
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Md Anderson [Member]",
        "documentation": "Md Anderson [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r831"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r831"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r412",
      "r459",
      "r527",
      "r578",
      "r654",
      "r656",
      "r664",
      "r693",
      "r694",
      "r748",
      "r751",
      "r755",
      "r756",
      "r758",
      "r779",
      "r780",
      "r805",
      "r809",
      "r822",
      "r831",
      "r832",
      "r833",
      "r847",
      "r942",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used) in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/CompanyOverviewDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails",
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfCashFlows",
      "http://cyclacel.com/role/StatementsOfComprehensiveLoss",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "verboseLabel": "Loss for the period",
        "negatedLabel": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r92",
      "r116",
      "r138",
      "r152",
      "r154",
      "r159",
      "r174",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r204",
      "r264",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r500",
      "r503",
      "r521",
      "r541",
      "r630",
      "r723",
      "r741",
      "r742",
      "r861",
      "r940"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss applicable to common shareholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r184",
      "r185",
      "r186",
      "r187",
      "r195",
      "r196",
      "r205",
      "r208",
      "r503"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to common shareholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r197",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r208"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Newly Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_NonCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "NonCurrentAssetsTextBlock",
     "presentation": [
      "http://cyclacel.com/role/Non-currentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Current Assets",
        "documentation": "Non Current Assets [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_November2024WarrantExerciseAndReloadAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "November2024WarrantExerciseAndReloadAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2024 Warrant Exercise And Reload Agreement [Member]",
        "documentation": "November 2024 Warrant Exercise And Reload Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November Two Thousand Twenty Four Warrant Exercise And Reload Agreement [Member]",
        "documentation": "November Two Thousand Twenty Four Warrant Exercise And Reload Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Countries in which Entity Operates",
        "documentation": "The number of countries in which the entity operates as of balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r926"
     ]
    },
    "CYCC_OfficeEquipmentAndFurnitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "OfficeEquipmentAndFurnitureMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment snd Furniture [Member]",
        "documentation": "Office Equipment snd Furniture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r793",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cyclacel.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfCompanysContractualObligationsAndCommitmentsRelatingToItsFacilitiesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r563"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use lease asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cyclacel.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r836"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "CYCC_OptionsVestingOnThirdAnniversaryOfGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "OptionsVestingOnThirdAnniversaryOfGrantMember",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Vesting On Third Anniversary Of Grant [Member]",
        "documentation": "Options Vesting On Third Anniversary Of Grant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/CompanyOverview"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Overview",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r109",
      "r665",
      "r666"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r837"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfComprehensiveLoss",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r631"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTax",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r157",
      "r160",
      "r466",
      "r492",
      "r493",
      "r547",
      "r550",
      "r552",
      "r612",
      "r631"
     ]
    },
    "CYCC_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfComprehensiveLoss",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized foreign exchange loss on intercompany loans",
        "verboseLabel": "Unrealized foreign exchange on intercompany loans",
        "documentation": "Other comprehensive income unrealized foreign exchange on intercompany loans net of tax."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_OtherIncomePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "OtherIncomePolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income",
        "documentation": "Other Income [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "CYCC_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs",
        "documentation": "Patent Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of preferred stock dividend",
        "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Costs from issuing common stock and pre-funded warrants",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r364",
      "r366",
      "r372",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r407",
      "r408",
      "r409",
      "r814"
     ]
    },
    "CYCC_PercentageOfOutstandingCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PercentageOfOutstandingCommonStock",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PercentageOfOutstandingCommonStock]",
        "verboseLabel": "Percentage of outstanding common stock",
        "documentation": "Percentage of outstanding common stock."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_PercentageOfOutstandingCommonStockAtElectionOfPurchaser": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PercentageOfOutstandingCommonStockAtElectionOfPurchaser",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding common stock at election of purchaser",
        "documentation": "Percentage of outstanding common stock at election of purchaser."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement]",
        "documentation": "Percentage of tax rate adopted in respect of deferred tax assets measurement."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants [Member]",
        "documentation": "Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_Plan401KMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "Plan401KMember",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 401K [Member]",
        "documentation": "Plan 401K [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "CYCC_PreFundedWarrantsAndCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PreFundedWarrantsAndCommonWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PreFunded Warrants And Common Warrants [Member]",
        "documentation": "PreFunded Warrants And Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PreFunded Warrants [Member]",
        "documentation": "PreFunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockAmountOfPreferredDividendsInArrears",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Amount of Preferred Dividends in Arrears",
        "documentation": "Aggregate amount of cumulative preferred dividends in arrears."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice]",
        "documentation": "Preferred stock conversion obligation common stock closing sales price as percentage of conversion price."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays]",
        "documentation": "Preferred stock conversion obligation common stock closing sales price number of trading days."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_PreferredStockConversionObligationNumberOfTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PreferredStockConversionObligationNumberOfTradingDays",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PreferredStockConversionObligationNumberOfTradingDays]",
        "documentation": "Preferred stock conversion obligation number of trading days."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion]",
        "documentation": "Preferred stock conversion obligation thirty day trading period ending within number of trading days prior to notice of automatic conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price of convertible preferred stock",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "verboseLabel": "Preferred stock, dividend rate",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r749",
      "r752",
      "r754",
      "r759"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend on convertible exchangeable preferred shares",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsPerShareDeclared",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividends Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidation preference",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r74",
      "r915",
      "r943"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference, Value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r315",
      "r328"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r857",
      "r858",
      "r859",
      "r860",
      "r1046",
      "r1051"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r310"
     ]
    },
    "us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockPerShareAmountsOfPreferredDividendsInArrears",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears",
        "documentation": "Per share amount of cumulative preferred dividends in arrears."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption price per share",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r47"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r702"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r310"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r702",
      "r721",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r620",
      "r837"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r267",
      "r268",
      "r786"
     ]
    },
    "CYCC_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets",
        "documentation": "Prepaid Expenses And Other Current Assets [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_PrepaymentsAndValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "PrepaymentsAndValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://cyclacel.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments and VAT receivable",
        "verboseLabel": "Prepayments",
        "documentation": "Prepayments and value added tax receivable current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of stock options and warrants, net of issuance costs",
        "documentation": "Proceeds from exercise of stock options and warrant exercises net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development tax credits",
        "documentation": "Amount of income tax refund received from tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r91",
      "r914",
      "r978",
      "r979"
     ]
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromInterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Interest received on loans and other debt instruments during the current period."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "CYCC_ProceedsFromIssuanceOfCommonStockGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ProceedsFromIssuanceOfCommonStockGross]",
        "documentation": "Proceeds from issuance of common stock gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net",
        "verboseLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r669"
     ]
    },
    "us-gaap_ProductLiabilityContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductLiabilityContingencyLineItems",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_ProductLiabilityContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductLiabilityContingencyTable",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Table]",
        "documentation": "Disclosure of information about product liability contingency arising from reasonably possible loss from liability related to individual product."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r936",
      "r937",
      "r938"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r579",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r783",
      "r810",
      "r846",
      "r847",
      "r848",
      "r851",
      "r852",
      "r938",
      "r939",
      "r945",
      "r1016",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "auth_ref": [
      "r255",
      "r579",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r783",
      "r810",
      "r846",
      "r847",
      "r848",
      "r851",
      "r852",
      "r938",
      "r939",
      "r945",
      "r1016",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r861",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r152",
      "r154",
      "r165",
      "r174",
      "r182",
      "r188",
      "r191",
      "r192",
      "r264",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r500",
      "r503",
      "r505",
      "r508",
      "r509",
      "r521",
      "r541",
      "r615",
      "r629",
      "r676",
      "r723",
      "r741",
      "r742",
      "r827",
      "r828",
      "r862",
      "r911",
      "r940"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r566"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r126",
      "r130",
      "r131"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office equipment and furniture",
        "totalLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r142",
      "r627"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails",
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Long Lived Assets, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r566",
      "r616",
      "r627",
      "r837"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r126",
      "r130",
      "r625"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cyclacel.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r566"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r364",
      "r412",
      "r445",
      "r446",
      "r447",
      "r459",
      "r527",
      "r575",
      "r576",
      "r578",
      "r654",
      "r656",
      "r664",
      "r693",
      "r694",
      "r748",
      "r751",
      "r755",
      "r756",
      "r758",
      "r779",
      "r780",
      "r805",
      "r809",
      "r822",
      "r831",
      "r832",
      "r833",
      "r834",
      "r847",
      "r855",
      "r934",
      "r942",
      "r997",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r364",
      "r412",
      "r445",
      "r446",
      "r447",
      "r459",
      "r527",
      "r575",
      "r576",
      "r578",
      "r654",
      "r656",
      "r664",
      "r693",
      "r694",
      "r748",
      "r751",
      "r755",
      "r756",
      "r758",
      "r779",
      "r780",
      "r805",
      "r809",
      "r822",
      "r831",
      "r832",
      "r833",
      "r834",
      "r847",
      "r855",
      "r934",
      "r942",
      "r997",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "CYCC_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Recently Issued Accounting Pronouncements [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r21",
      "r158",
      "r547",
      "r551",
      "r552",
      "r631",
      "r909"
     ]
    },
    "CYCC_ReclassificationOfCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ReclassificationOfCommonStockShares",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ReclassificationOfCommonStockShares]",
        "documentation": "Reclassification of common stock shares."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ReclassificationOfCommonStockSharesNoProceedsReceived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ReclassificationOfCommonStockSharesNoProceedsReceived",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ReclassificationOfCommonStockSharesNoProceedsReceived]",
        "documentation": "Reclassification of common stock shares no proceeds received."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ReclassificationOfCommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ReclassificationOfCommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ReclassificationOfCommonStockValue]",
        "documentation": "Reclassification of common stock value."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ReclassificationOfRedeemableCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ReclassificationOfRedeemableCommonStockShares",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of redeemable common stock, shares",
        "documentation": "Reclassification of redeemable common stock shares."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r177",
      "r178",
      "r306",
      "r313",
      "r568",
      "r577",
      "r617",
      "r788",
      "r789"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r781",
      "r799",
      "r1014"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/CompanyOverviewDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r104",
      "r623",
      "r661",
      "r663",
      "r673",
      "r703",
      "r837"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r179",
      "r180",
      "r181",
      "r183",
      "r188",
      "r190",
      "r192",
      "r265",
      "r266",
      "r284",
      "r487",
      "r488",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r512",
      "r514",
      "r515",
      "r517",
      "r519",
      "r555",
      "r558",
      "r658",
      "r660",
      "r677",
      "r1051"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r410",
      "r411",
      "r414",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r410",
      "r411",
      "r414",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/RevenueDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails",
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails",
      "http://cyclacel.com/role/StatementsOfOperations",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r214",
      "r223",
      "r224",
      "r245",
      "r251",
      "r255",
      "r257",
      "r259",
      "r338",
      "r339",
      "r579"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://cyclacel.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r782",
      "r790"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_RombotisSettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "RombotisSettlementAgreementMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rombotis Settlement Agreement [Member]",
        "documentation": "Rombotis Settlement Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_RothCapitalPartnersLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "RothCapitalPartnersLlcMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roth Capital Partners Llc [Member]",
        "documentation": "Roth Capital Partners Llc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock value",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "auth_ref": [
      "r193",
      "r413",
      "r897",
      "r921"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/AccruedAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://cyclacel.com/role/NetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of antidilutive shares excluded from computation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/CashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Benefit (Provision) for Income Taxes from Continuing Operations",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Components of the Entity's Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://cyclacel.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/NetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory Federal Tax Rate to Loss Before Income Taxes",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r825",
      "r973"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r496",
      "r898",
      "r899",
      "r900",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Liabilities Measured on a Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r995"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of (Loss) Income Before Taxes from Continuing Operations",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "CYCC_ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Instruments Issued in Offering",
        "documentation": "Schedule Of Instruments Issued In Offering And Their Classification Under Shareholders Equity [Table Text Block ]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r566"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/GeographicAndSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Geographic Information",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://cyclacel.com/role/GeographicAndSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summary of Consolidated Net Loss",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Units Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r106"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r44",
      "r45",
      "r46",
      "r49",
      "r99",
      "r101",
      "r103",
      "r104",
      "r145",
      "r146",
      "r147",
      "r216",
      "r310",
      "r311",
      "r313",
      "r315",
      "r318",
      "r324",
      "r326",
      "r669",
      "r670",
      "r671",
      "r672",
      "r809",
      "r896",
      "r915"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r214",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r259",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r283",
      "r289",
      "r290",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r796",
      "r799",
      "r800",
      "r806",
      "r850",
      "r1016",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cyclacel.com/role/LeasesDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "auth_ref": [
      "r257",
      "r258",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r690",
      "r691",
      "r692",
      "r750",
      "r753",
      "r757",
      "r760",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r784",
      "r811",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r849",
      "r855",
      "r945",
      "r1016",
      "r1018",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/GeographicAndSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic and Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r214",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r234",
      "r236",
      "r237",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r259",
      "r794",
      "r797",
      "r798",
      "r799",
      "r801",
      "r803",
      "r804"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r254",
      "r257",
      "r795",
      "r796",
      "r802"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907",
      "r944"
     ]
    },
    "CYCC_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]",
        "documentation": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/ScheduleOfAntidilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907",
      "r944"
     ]
    },
    "CYCC_SeriesBWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesBWarrantMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrant [Member]",
        "documentation": "Series B Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]",
        "documentation": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SeriesCAndDConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesCAndDConvertiblePreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C And D Convertible Preferred Stock [Member]",
        "documentation": "Series C And D Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SeriesCConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesCConvertiblePreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Convertible Preferred Stock [Member]",
        "documentation": "Series C Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907",
      "r944"
     ]
    },
    "CYCC_SeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesCWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Warrants [Member]",
        "documentation": "Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SeriesDConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesDConvertiblePreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Convertible Preferred Stock [Member]",
        "documentation": "Series D Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907",
      "r944"
     ]
    },
    "CYCC_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Warrants [Member]",
        "documentation": "Series D Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SeriesEConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SeriesEConvertiblePreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series E Convertible Preferred Stock [Member]",
        "documentation": "Series E Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesEPreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series E Preferred Stock [Member]",
        "documentation": "Series E preferred stock."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907",
      "r944"
     ]
    },
    "CYCC_SettlementPaymentSettlementAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SettlementPaymentSettlementAgreement",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:SettlementPaymentSettlementAgreement]",
        "documentation": "Settlement payment settlement agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cyclacel.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted Stock Units, Cancelled/forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions]",
        "documentation": "The number of additional equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Value per share, Cancelled/forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms]",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, grants during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units, Granted",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Value per share, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restricted Stock Units, Balance",
        "periodEndLabel": "Restricted Stock Units, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restricted Stock Units, Grant Date Value Per Share",
        "periodEndLabel": "Restricted Stock Units, Grant Date Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433"
     ]
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1-0]",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units, unvested",
        "documentation": "The number of unvested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Value per share, Unvested",
        "documentation": "Per share or unit weighted-average fair value of unvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms]",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, unvested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms]",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units, Vested",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Value per share, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Outstanding, Cancelled/forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Cancelled/forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Granted",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue]",
        "documentation": "Share based compensation arrangement by share based payment award options grants in period weighted average grant date cumulative fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregrate Intrinsic Value, Balance",
        "periodEndLabel": "Aggregrate Intrinsic Value, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Outstanding, Balance",
        "periodEndLabel": "Number of Options Outstanding, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Balance",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average exercise price 1",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm]",
        "documentation": "Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options Outstanding, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "CYCC_ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod]",
        "documentation": "Share based compensation arrangement by share based payment orginal award equity instruments other than options forfeited in period."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Value per share, Balance",
        "periodEndLabel": "Weighted Average Grant Date Value per share, Balance",
        "documentation": "Share based compensation arrangement by stock based payment award equity instruments other than options nonvested weighted average grant date fair value.",
        "label": "ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r423",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SharePurchaseAgreementIncrementExerciseLotOneValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SharePurchaseAgreementIncrementExerciseLotOneValue",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:SharePurchaseAgreementIncrementExerciseLotOneValue]",
        "documentation": "Share purchase agreement increment exercise lot one value."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SharePurchaseAgreementIncrementExerciseLotTwoValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SharePurchaseAgreementIncrementExerciseLotTwoValue",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:SharePurchaseAgreementIncrementExerciseLotTwoValue]",
        "documentation": "Share purchase agreement increment exercise lot two value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfAssumptionsUsedForFairValueOfStockOptionsGrantedUsingBlack-scholesOption-pricingModelDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregrate Intrinsic Value, Vested and Exerciseable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options Outstanding, Unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Share issue price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r171"
     ]
    },
    "CYCC_SignificantContractsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SignificantContractsDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SignificantContracts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Contracts",
        "documentation": "Significant Contracts Disclosure [Text Block]",
        "label": "Significant Contracts Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Single Reportable Segment [Member]",
        "documentation": "Single Reportable Segment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SixPercentConvertibleExchangeablePreferredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SixPercentConvertibleExchangeablePreferredMember",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Six Percent Convertible Exchangeable Preferred [Member]",
        "documentation": "Six Percent Convertible Exchangeable Preferred [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_SixPercentConvertibleExchangeablePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "SixPercentConvertibleExchangeablePreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "6% Convertible Exchangeable Preferred Stock [Member]",
        "documentation": "6% Convertible Exchangeable Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfSummaryOfConsolidatedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r137",
      "r214",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r259",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r283",
      "r286",
      "r289",
      "r290",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r796",
      "r799",
      "r800",
      "r806",
      "r850",
      "r1016",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r145",
      "r146",
      "r147",
      "r174",
      "r198",
      "r199",
      "r206",
      "r208",
      "r216",
      "r217",
      "r264",
      "r297",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r310",
      "r311",
      "r315",
      "r318",
      "r326",
      "r541",
      "r669",
      "r670",
      "r671",
      "r672",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r702",
      "r724",
      "r743",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r896",
      "r915",
      "r923"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r75",
      "r78",
      "r79",
      "r135",
      "r157",
      "r158",
      "r159",
      "r179",
      "r180",
      "r181",
      "r183",
      "r188",
      "r190",
      "r192",
      "r215",
      "r265",
      "r266",
      "r284",
      "r329",
      "r487",
      "r488",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r558",
      "r567",
      "r631",
      "r658",
      "r659",
      "r660",
      "r677",
      "r743"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://cyclacel.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cyclacel.com/role/LeasesDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r690",
      "r691",
      "r692",
      "r750",
      "r753",
      "r757",
      "r760",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r784",
      "r811",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r849",
      "r855",
      "r945",
      "r1016",
      "r1018",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative",
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/LeasesDetailsNarrative",
      "http://cyclacel.com/role/StatementsOfOperations",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r215",
      "r558",
      "r579",
      "r667",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r702",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r722",
      "r725",
      "r726",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r856"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r413",
      "r897",
      "r901",
      "r921"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative",
      "http://cyclacel.com/role/BalanceSheets",
      "http://cyclacel.com/role/BalanceSheetsParenthetical",
      "http://cyclacel.com/role/LeasesDetailsNarrative",
      "http://cyclacel.com/role/StatementsOfOperations",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r215",
      "r260",
      "r558",
      "r579",
      "r667",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r702",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r722",
      "r725",
      "r726",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r856"
     ]
    },
    "CYCC_StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of series 6% Convertible Exchangeable Preferred, shares",
        "documentation": "Stock issued during period shares conversion of convertible exchangeable preferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred stock conversions, shares",
        "verboseLabel": "Conversion of shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r44",
      "r75",
      "r78",
      "r104",
      "r308"
     ]
    },
    "CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of Series D preferred stock in Securities Purchase Agreement, shares",
        "documentation": "Stock issued during period shares issue of series d preferred stock in securities purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issue of Series D preferred stock in Securities Purchase Agreement, shares",
        "documentation": "Stock issued during period shares issue of series D preferred stock in securities purchase agreement one.",
        "label": "StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodSharesIssueOnWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesIssueOnWarrantExercise",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise, shares",
        "documentation": "Stock issued during period shares issue on warrant exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of common stock on Securities Purchase Agreement, shares",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r75",
      "r104",
      "r669",
      "r743",
      "r762"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of Series C preferred stock in Securities Purchase Agreement, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred stock conversions, shares",
        "documentation": "Stock issued during period shares series C preferred stock conversions."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred stock conversions, shares",
        "documentation": "Stock issued during period shares series D preferred stock conversions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfShareOptionActivityDetails",
      "http://cyclacel.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Exercised",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r75",
      "r104",
      "r429"
     ]
    },
    "CYCC_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercises, shares",
        "documentation": "Stock issued during period shares stock warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering, shares",
        "documentation": "Stock issued during period shares upon conversion of pre funded warrants in offering issuance."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of series 6% Convertible Exchangeable Preferred",
        "documentation": "Stock issued during period value conversion of convertible exchangeable preferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred stock conversions",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r75",
      "r78",
      "r79",
      "r104"
     ]
    },
    "CYCC_StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deconsolidation of Subsidiary",
        "documentation": "Stock issued during period value deconsolidation of subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses",
        "documentation": "Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of Series D preferred stock in Securities Purchase Agreement",
        "documentation": "Stock issued during period value issue of series d preferred stock in securities purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issue of Series D preferred stock in Securities Purchase Agreement",
        "documentation": "Stock issued during period value issue of series D preferred stock in securities purchase agreement one.",
        "label": "StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueIssueOnWarrantExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssueOnWarrantExercise",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise",
        "documentation": "Stock issued during period value issue on warrant exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of common stock on Securities Purchase Agreement",
        "verboseLabel": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r75",
      "r104",
      "r677",
      "r743",
      "r762",
      "r862"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of Series C preferred stock in Securities Purchase Agreement",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueSeriesCPreferredStockConversions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueSeriesCPreferredStockConversions",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred stock conversions",
        "documentation": "Stock issued during period value series C preferred stock conversions."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueSeriesDPreferredStockConversions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueSeriesDPreferredStockConversions",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred stock conversions",
        "documentation": "Stock issued during period value series D preferred stock conversions."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueTranslationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueTranslationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Translation adjustment",
        "documentation": "Translation adjustment.",
        "label": "StockIssuedDuringPeriodValueTranslationAdjustment"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering",
        "verboseLabel": "Net Proceeds",
        "documentation": "Stock issued during period value upon conversion of pre funded warrants in offering issuance"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercises",
        "documentation": "Stock issued during period value warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary]",
        "documentation": "Stockholder equity increase from de consolidation of subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cyclacel.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r78",
      "r79",
      "r94",
      "r704",
      "r721",
      "r744",
      "r745",
      "r837",
      "r863",
      "r916",
      "r932",
      "r1000",
      "r1051"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cyclacel.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r63",
      "r135",
      "r136",
      "r158",
      "r179",
      "r180",
      "r181",
      "r183",
      "r188",
      "r190",
      "r265",
      "r266",
      "r284",
      "r329",
      "r487",
      "r488",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r547",
      "r548",
      "r552",
      "r556",
      "r567",
      "r659",
      "r660",
      "r675",
      "r704",
      "r721",
      "r744",
      "r745",
      "r766",
      "r862",
      "r916",
      "r932",
      "r1000",
      "r1051"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r173",
      "r309",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r329",
      "r518",
      "r746",
      "r747",
      "r767"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://cyclacel.com/role/CompanyOverviewDetailsNarrative",
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "verboseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cyclacel.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r571"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/ScheduleOfFairValueOfInstrumentsIssuedInOfferingDetails",
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails",
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern, within One Year [true false]",
        "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cyclacel.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash received during the period for:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "CYCC_TermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "TermOfAgreement",
     "presentation": [
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:TermOfAgreement]",
        "documentation": "Term of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1005"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative",
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsNarrative",
      "http://cyclacel.com/role/SignificantContractsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "CYCC_UnitedKingdomSubsidiaryCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cyclacel.com/20250331",
     "localname": "UnitedKingdomSubsidiaryCompanyMember",
     "presentation": [
      "http://cyclacel.com/role/AccruedAndOtherLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom Subsidiary Company [Member]",
        "documentation": "United Kingdom Subsidiary Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cyclacel.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r124",
      "r125",
      "r127",
      "r128"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/TaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfFairValueOfWarrantsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://cyclacel.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r208"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://cyclacel.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    }
   }
  },
  "ex107.htm": {
   "dts": {
    "inline": {
     "local": [
      "ex107.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"
     ]
    }
   },
   "keyStandard": 20,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/ffd/2024q2": 2,
    "http://xbrl.sec.gov/dei/2024": 1
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2024q2": 18,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "report": {
    "R78": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "78",
     "firstAnchor": {
      "contextRef": "AsOf2025-07-23",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-07-23",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "79",
     "firstAnchor": {
      "contextRef": "From2025-07-232025-07-23_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-232025-07-23_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "80",
     "firstAnchor": {
      "contextRef": "AsOf2025-07-23",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-07-23",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee prevoiusly paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r890"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "SubTopic": "40",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479710/205-40-50-13"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>144
<FILENAME>0001641172-25-020763-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-020763-xbrl.zip
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M(R?*\\9;S!'2/[%%D-!&5^*=2QP0.<(BXTI^4Z\ZM3CR9#V4Y_W=QLVUCPI
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M3ALBX-7]T?V+WLZ<NC/6]ARJ*V.,T=$69*[SR9U;'B"S ,-QA;"[/PR0<0R
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MKRSIUX&.*S >)#E5GXGKHI=CY=,?/4F"BQPJ$VGUQV+HT94\SCA9"U?OV.&
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M7D5YTFOGB3479UV\PH+?0XI],]=;:1VQ4)&8II7VLKDV^N\GK66M!E=>PSS
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MA2MRA46NGLX>+36&=X:Z5XF#(7-M$]="Y>]D%IGYS[++3U6L,&?E9#W9@*Q
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M/Z7D07U3^),X'%#5S=:X&F&2,P=AL//A[U*^X@I]><%]S'2KV\7&8'=GPW'
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M)P\WCP0OKX21HHRB$<G@_P$&00X&&09Q9D8E!B9!1F9!QO]'&.09&!A9&<&
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MF1%297H 3;;\2UP0#O\&4$L#!!0    ( $*O]UH79'#DX0@  *<)   +
M875D7S P,2YJ<&>EU7L\T_L?!_#O;+/-QFQ6R?VR$%-AKHE%EO(C2BZ;>\KM
MR&4,.<X)95JBD:F5>TPYD=S7G!]R[2B79)I:9J?D&B6D3GXZC]_EG]\?O\OK
M\WC_]7X_WH_'\_'^X[,YOCD)R!\E'R$#(! ("-AZP.8$8 _ I:5ATE X# 9#
M(. R*)PL"HE$[<0JH'&J2NIJJDHJ*AKX/;H:6@1M%14]\]V$?49$(E%=U_*
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MDPWGG,UUHBN&(2W_WDY#^G8C?A8.8>Z *_35N0#RKQ=2AN\]+86GQ4A.;$Q
M$"^7I/ IH;X_M_>?M'%S=D_DUR@AP-/&[N(\FS&S\)S&!%_:F[S(ZO]>!82)
M\_1>L\TXSV=4+H@D.]R[ ?\KB6:#N=SD*AM]#.'9R7*P6(1+H%(?)HT87Y[C
M .A#8'2#(CQFLD/0_4"AAMK8TDTQ+3R],8]9UBN=YKQ(U/O>RQ1LY?\/H*=B
MI)7U4FV]NZ67ZIO,IQ*EO41KR=N3>LO5,G5H*^FI2U7W[<L^3U/<DIP/R&<
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M^A_]G:5PJ7464MU/S-B]OC&7;[Z^HT;'$P314W$&/I#QE4X]G"QSDB1'.GA
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MFR]"ML3\"D7^+!W/DO?E/']"B4]5PA*%6?;M"1@[L8+0K!B^C1 P99R$RVN
MR <:&310B 2*12[)G$0G>,(X'D21#AIN%]A7'S\8Y,N/7ZTV5]?1MV@ M77T
M:UF[L3)7C:U/N>O=\HS*SXGH91HF[\:-_>0B;G6=A#Q\BAXA%)XO(ETL->*F
M3%PUSMED(A<2TD]T2 4A:"DKJ>\* $:B?+2G8UE737&:K$Z!'LD=%>@Q?99
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M<;\W=]PBY/_TEDGV*RDF("_X%&,5Y)@^;EM'\(=>";94D20\E%M'XR\MHC&
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M2$D=N5N3DC[NM#B1A%.)L G2B5LK5N[.U\;6U",'-V)9:V4USH'R?)V5E0Z
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M3[V(R>QNCE":J,R_TZ$7.FX\@N)TCM+0]Z+61.WTUD4A^]K0@HZ<3!XG2[9
M4+U2$AG4LP_*V I%T!S%2?B$KG'2FL"& ?J@\R[%_A]S' 5T';WX,PO3U3EZ
M#/TP;4NO8""C=+?6V2ZC]J(Q7C*_C/"/]IJRZ:B++J9\7KR:T"7N*40_U-;#
MG2[:9)0M%AY947#"61Q2-+PX'?L^SN*4FA@W.*+X(#6A*8ZDC?+--&<X3HGG
MJRWMS?VT84O591P'['^8BC]Y$5,C)8B!GKHHN_1"PFVHR>-E&-.-)/2B<9+0
MK83.>AUZ#V$4IHI8JX^EB_H;@I9>&%P\+^F:C=@T$[I@D+.,L*4CGUN%<K5Q
M=%']#<<O_;8D-G32)T5,=^9T1=EF.K9D:YR:U)KZZ:**KA(D0T&)14M=%/76
MN&(OPI3O".P3Q7Q)H^<P11*%W?7M=KN[J]I65^^EE:)3>IH(V/9%OS=N$BI3
MU=!3%V47M!%>(71*S\"/U/Z@=K42D,W]=%%U[SVKZ5/14-LJA5)F M_099 J
M*H[OYM0>4UJIFCOJHNL+PC/B+>>A3[^:.S1C'Q#S#)"%LB))A]!%ZRUZ0G&F
M)+5U4UUS7R/ZI2@I3ME2G_7XD* _,RK4BR=5.Z?>QZPMJ]^FU6_;-MN"]]Y#
MI+CA"/N;MBC5Z6X[HDGK4IV+-J/U:=FUH1CNW;^5ITZG? P#%E^+SU ^2'_6
MGSJ9<-]^+<&6%(+]M=I?ZD1M->_5%E.G2=C=D%VF3JWB0'KM)'7RMMOKHF)"
M9EX<_HMSF#NBO9@MO%2]PV3R2#>/A(J!__D<I5X8)=\\PKSI3TK6Y5[#]^3A
M[,*'= BS5F,7%KJ.W*>'M!,?2N-HQZ/9B"TF;B5_R4C:*/?G*,@BF?'ZE2XK
M&4'!)+Y%S,]'=8%_G&TXTS23?LY5;-].C+8:N#?_;9?/1V&0/G"H6_0=Y2X8
M2#_=.Q9^ 6]%ISLQH3YJ_Z>=+BK49C3]F!1;<5(N_ID731ZB<)9'^/G)9GW.
MN461QW:W>WR5)I>>7Y"9FU*=L-,_NX$S8D>+1WVX'O:LC>_E*DY2DG%*KI*$
M*MX5-24?$=L_NFU2[8;NE;??F0SI[.Q'KD)T3<X6RXH]W)DWE:'[.^]WLNP4
M1M&/1O-IOMC9.X&@-F(/G+#C]80C//:IN#8";$F_8)P>]MBU6B;?J<@N,:DH
M,1=E3DKRA:DS"KXGS'"DQ/_Q,O&IMJ D__O+):$GF'CV%0<HZK8O]TJ)?LG=
M(KIZA3ZEA!/W/0[I6KT/\$H#]NN%Z[QN*(S49[RV"]UJX_1C0>$X3RAC_KFK
MF))$J7C$S#OWC))+@A?YCI]1-=ZD3W:VF/:;3;\$2HD3_!2RE'+ZJ>=DZ6=_
MSZGZ6#5\'#-;M'#*=2/P]S"=CQ?,><3PS>B2<;H:+Y?1BK;B.?(I)JM+1+=R
M+Z(#W7HINL<,_ASXR@P=5RI'F>AA5Z_ZNS:?T@5E)UW1B:FY2E! J=C#G=%U
M#JVQCBY+*-"QAQ7#2WA<X#R,F)YL(AO<6.JV,J@-V8/%16$-V*145GRNY.+9
MC[* FCS\0V&?0O%=:617WZSZ);()_50"/IVX%(_4P^JP]BK3]0Q'8>!M!-=M
M*5 94#\?%QZ)Z:J[!GOGX^C$BNJ85OW.YV'B1Y@YQGOS0%>GT)QAUF7-!KOV
M8>LLO)#I />YW7BK1=N@C>I0>J/"7<0*]>PKNZY;#%(VQC:U'O%5"09N$I87
M&MD5PO><CSD=@OC9 WH9A MVY8HE7A835:E?CQ+&Z2O:]%71YE7C /W3O9[L
M98"9*K8CNM[; ,5\II<+M'A@UR=;D;O=M7]:O2AJ1R'OT#]=,4[';4DK^QC5
M2?3H95':62G+[MLTTU_3-9>94-?TQRVZT7.*8FH\EI2S >57>(L1PI0U+FYN
MGXQ>LFO>/ Q _YFW+,@H"8FPOS5[Q.XX8U(76U+RFR#_YQE^>A6@D,KNS3OV
M#[:@OLL%A\)I?KH:!P$UA>G*33E$5RE:).6@D?> (C[5E#:'6[\R3RO/0E*B
MLVBY2^,&V#$IJ2VT0O'3RU7Q%Y\>ZZDJ7$3\AB15YSQOJZ3MD1XM%$18B M+
MN*A*E1+S8H1)@,BO+TY>;^BAAA8*?GV1DJR!;0/0%/^XI^./GT,U9:KUT0I7
MXWXIAV=;YB T +\-()F!HT+/>;'3-B'0T$RKT.O[O5SBD"BQB&I(W&]>NRWO
MZ4D#@;I$7NYF^R]2'3#AG$&PO#4$RVF6T.4UX7D2GI]^+0RY)F@:F_8 S[9)
MV2!Z6+NQ K'@NF-HX2E-&$9^LZ"K+:9-BM"S?%OLOS52(>F:6F4H,0$CZ#+R
M9L *4VWBN'CKM-K>-4N"SE'BDW"95HP$0,R5ED.1]B[)X-YI=L6X1;,P2?.8
MV+K8B'@):>SB. QRVL%-TRP>XSC.O.@6+3&1P%!M.1#IUTB&A/[.K-#_=^:1
M%)%HI2+WG<8#$7T3U9#TWQLV6HA'36<F+!7Q[[8>B/P;R88 ^& 6@+LYBJ(B
MN5D%@GK[@8  $ [!\-$>##Q$<D[W)W4DUET&",8V[1 >G\SB<8-(B -J)1 %
M)'8:#P2#)JHAZ7^V(?V+.%"5?=%T4)*OTBQR,)L4_&68^%Z4TW=)?P>XD<'F
M P&@F6Y7'#DY=?^)/*(,P;KQH #8IAH4OZ%3<9%!LR%-N/Y K1T'0$@VB("A
M<W#.!ZO^_2V#W<:[K1R7>".YH*0-'7YSHDJ'2)RR&N<B:6^W'(3$&T@&I6[H
MT)L3=H;8#=+H*@[0\S_12B3VG::#D'L3S:#@#1UV<\IN2,@R7.]"7[Z\[+8=
MA.@;B09E;^B$FY-V[SU?!50S^&4#)C$Y!$"702 AHAT$Q- 1-Z>0W6$A2USQ
MAI^Q^S!D=88#X58@[#@(<.0<@! 9.@=OL53\#^/K1"&KI]I\$'! =(-!,D-G
M8HBZ-^U >#-0$-Z(03!T)H:H>]L.A+<#!>&M& 1#)^,MZL[H/R?D'O\ XO1
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M]"\C[ G/ 95F@Y#V+KV@L(V>AD^]^ ^2+5-_=4.PCQ +'27K[U+A.*8TP"
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M#O_,6%2)O9A RGJQK7+.X!&&!IZ,$]#%X4!"6GM+4J&S^P J,P'Z/AS 3MV
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MR()U.^V<"<G!8M\-P35R:C30EB#_YQE^>A6@,,>&_F,#"?UA>HUF7G3!'\H
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MF!7A1CS[F!5QS(HX9D7\A;(BFHS=V[OO"B^EP=T./SM"RO[PMB9(-A=_9O2
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MW:P#V-[I(DURRMWS#6_>SV36IS3YN[&YK8KURI823+7"^=4F'N7)1160LOW
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M-I<.M[G@:?C)59)D*/B^Q''>L&HG-!SYV@\V%(@[L^:<MVM#8&&JYQP4#*)
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M5M?1[*YS=-'0@XMT'2V+6YITDL?IHUG(4[)Z@:&!,4(<*OC@ 5&OK"HL-AP
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M>X&'4&$A2'J4\* B4D\'&,Z#")./A74%5WJ@(;Q*-OB[L]-FD5K-$7/WCR!
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M0H\$$!9$>DFPP$A13>L%"^<;G#^2X>V'//M2/E7U6:6V2:C=8D.I<A\C0E)
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M"JZ;0ZL?/B[HVMPHO<ER-MZ491X_[$J^"V9UQCZ7<+\%HP_I$'61Z2F2G?K
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MSM-19@/2JW3)64SSY),>ATKV:]8%UVG=(XJ<:_IV6'.!H4VS_MRQJNY?[0T
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MKT]4\GS[D979%NL3N3#0/F%C@60:=P9S?3(+J$T%^D:UG>$VZY,CQ;65"5.
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MPM*0"@+X=.5#JY62']N<_C02'(33E7R2%;L<:X;CP\6ZAO\<G3#T@$-D@ID
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MK8T8[T@]7'=9_?U:!B)"$)."*C$5E!<KMJ0W0;DNMA3@L'#2!,,ZY9$LN&'
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MY%F(<<06KU3'@'Q/>KJ?$O<K8S(6WN35>07S%DFG6$MQ7/AHBHF#*D@V(L"
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MT; <QZ<2*6SXO2#M]HP6LORYJ_&"7;< 'O.Y7\\9F*'<=Q@R>0_IMIHJ(GG
M.$ $B;/XF4S<TXC62A:/OC9\T,.%1FM-S#A!4<6/<@BEI?NV7<6_[>*(7UQA
M?\"IX5I%PNEOF:(T18Y)(1N8N&&NZZC2>4M;K4$H,3#X\2C(*KORW]:^5ERF
M*_+O()<GDUO+\0=-"S/E0#40 A2VYIK+8^D=CZ5<%%UCMW]JI*$X194\8#BO
M;PMQ]8O# 6\GT!_RIQ@N=P$;:4!]88()6J<@,A&_;E9)7=X_#MB&$MT*M-T
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MHKSH9\;A?_H[-JNUZHK\Y;+$TC=?#7E=PM3*G"X\C1C!P-)&6R,XMNSH9RH
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M",JH71O"(ZPMS*1</F"F,4$$,PD+.)BI]93#;*T?.%VBK GF-B"3,GG F,8
M <0D'- 0IE93#K"2EJ7R#B]^8HNC*AS;P<R4V?&^CX5!@XT? TXP\+-25[#U
MPY@AC:>-!73C*@WC)&:32XEAJWH&4>^_[EO^H)0E],[<AONU\LS=,UX]S=0
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M?%/:\>Y##HP;^M"M+$V&3SV=N=45)HY_2]^2N5Y_+C#[I5'OB!G]05YEB!S
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M>@[BA.Y3W6>GV6:3I2R/[2E+(IP79W%":RRM'HHR#T+91/D >2YC_L%F=P>
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MW6BG2?>/4D55BJ@3*NJ^'9Z7NAYHM..45N?Q.EO=K6>)F5<>[MK'GN;7,0L
MG/GR7H#[(NP@^R9D)!]<FK;?(!Q.U5KZG/KU04.C:$Z8Y@GMUH:KIT=T-,OF
M2SUQYOP!3&5M>CNBVKN;XP*WEZSVDSE!!+#HB0S^<0Z$8M9J2CPX9;4S4C^H
MZA1G@)9#W-Z 908Q(/;C[X#IKI(!U+W)\EZFF?A3K"W;N]FM^%%L/%#?3W"
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M#:FGU+["5 Z$S<XC&C\6ZW6\:2FZT-H2&4 [Q+23[JKV1!(01>&U ,)_T^2
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M6Y&_37XA,:%>EM"_3_[E13G_37(31H1.+I/5.B(987\H/ORWR0]?O_4F;]X
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M3H/"-H#,@:HE5/1N'([;^<04^4.29E[T_X5KG5G:WAXJ?C>.R2J>C^WZ+%2
M>TMDT54'3:"BQCX9MW)V;.ER8BGQY$J]WP(J6^SC;AM?1Q;M7<*O;99)K'0:
M-UM!18Q];I7Q=^Q%FF<WI=*UH?9G<*@?]A)\R-&1)?HK#3-& 2]LE<>EGTAR
MS2=I"I4T]F%3R>F1I?XD"HORXF$?F+E)0_ZD5IO(V]I!Y8U]M)3S>&1A/U#"
M02?,G!=1;CP_DHJ*9NU"5[6'"A_[9*GG&1<$45B.FD+1T@L*"/8A$\K_L1<B
M7G26\?#VW<LSS_Z5+$.-5E"Q8Q\P9?P=6<SWR3/U^"N_3YO52Q+)\W-:&T*%
MC7V<5'!Y9'GOT=$NZ8,F4!ECGR-;.4-:-*X_^TLO7A!YZ$9[2ZBLL<^5*C[1
MUND%:)U>&*[3V.=+&7](8BYB[WE9M&T98[7$6SN <YX<$;Z"ZV,G6XKTJUJQ
MJ!OVCW8$)$VALL<^E2HY/;;4\R#,> ES3M+VU8+=2\L2 +2]H%A@GUBA_*/<
M3/Q*HNB?<?(I?B)>FL0D*(X0JLL):1<H(-BG6!#G*&C\*XER)C JXFBILCA*
MHRE4^MA'5B6G.*&K1:3X=I\2Y4B5PI?U@&* ?7Z%\(T4R)<17D@J?"577N:5
M%*J@D/6 0H%]NH7PC9:J0"_9)K5(U%$"!PVA@L<^\BJX1)'WT\J+HJJ@CDK>
M!PVA\L8^]BJX1)'W]8K0!5OU?J')IVQ9YN2JY"[I )4_]ED8P#4.#I]W!0**
M#$4E""VMP<4HW$! RB]6[97MPX3, (@#CTH 4+6'0H!]+M;S?&001"'AN@4F
MB.'DJR(^]+V@@& ?CJ'\XVS)M6H-RAUYKQU4]&X<@]MXQ$EERU^BT+^)$D]I
M[^\U@XK:C3-O"X<HDK[PXM]IOL[\S0--?$+XS4^ZG8. ,Q=P "@Z;IR&C:2"
MXZ<H'O;F+S 5CSK,\BSE*R:C3^FM4/:#HN3&01DB R0[*MWEW_'';1[Y2RX\
M,..9?,XNV(=^5YM5@.Y0J+"/UL82.7H\N"A7RZSO-(EC$LEOFMM;0G' /G*K
M^&P1^7]^T^"&C?Y[]=?6/^Z-9OA*P(47>4P;F 5":K<@>Z\%O)N\F6QO2L1S
M ;N'4B9E_TDY0&_%F7OIBP D3]\L/&]=: ^)LK3ZS4Z-RE_\MB6N]B#W0U*<
M[A2O#93=8;W[3XE>G,D>)3CDP8TG"8PDNS]C) P-^U9!+R@:DUT!1ZVM8Y"T
M%LM7D#_LBP6] +B,O#0M'RB5/%]PR$BSRQCA:'(QZ-,%74"IDR1]S:!LW-;6
M,1ADJG6 2!LG/9\U:'G?_-^7E[\]A9^9Y>!STI+XE;!C$-.3*FB-Z\P#+1\K
M%,1(GS?@@W4<"ZVRMD+8^ZCT8,Z"Z=MI;2,T).D4"&:EM:I.:,6AP:A!N' *
MGHLN\$@ZH14O[@:/DG5'X+GL H^D$UY]Q6[X*'EW!)^K+OA(.N%5".R&CY)W
M1_"Y[H*/I!->4;MN^"AY1\>G>-Q4[\DX; =$P18&\A/S 0;M_#DB]NJ!6:#T
M&\W!1<(MH2 1;AL"$E;1@;CTTN4T#OC_7/^1AZ]>Q/W:T^S2HY0_7?\O+\H5
MSC%@=W!M.ZM R3!(NK#D"'[[3S=7+S?O\2M'#]09^XQJ@IV!--"1 V+4#8WA
M P(ZH*&3^[HR#.X*KJ44"O*R)/,BT1)OKB5K0K/-0^3QIZX"OCRL^29\3Y23
M3-4+VY< VL(@C*//IQDCT<NJ1]4?P\4RF\T_LE6 <RB'1],-B,_PP0,F^(!8
M1P?HBJSY!55:L'2?Q+YN[9/WP/;Q@&#1,8R.2$&8;N\!2WOX< !S._L$MIF[
MT'L)HS#CKMNX.#0ODXA)..7K;K;1'Y?@(P"1'3ZVW_0<:RH4]+E5)]@(,//3
MK2UPC&4NA\PU=,KX^/3!V_ +++T5+FD/Q<B:"T(EY 3$@CN(T)RMT3M^(*#(
MND!QL>9Q,,)%S3@Z-":8] '#F@L!#@8(A;$9%/O'@XK%#<0"!W2%HFO-)=%S
MFP)+QZ5Y")J #MSE#6="G, \[&+*#V"\6WA6S-1Z'X&]OG]+J;GV:&V,?C%K
M/+T4/*/C44N$T=U!-5I"D;#FL#!&0L8M.@S3(! QY5[TX(7!;7SIK<.LM>YR
M9<[*.D!!L>AK, 1%PSL^-KZ?K_*(YXJ(>RZ>Y4K)DA=&?R4\-6E%[I(TO2?9
M;/[L?58>I,P& M_GNH-E-UFA8_Q(,H]MKL&U1V.>L%GCXXK,>:5P.:R0OE D
MK3DPC)&$2P0=O"9O)H8>'!QK7@QC<.0<C]ANUQUBNCOBX1!;\XWT<NNJI#$H
MX*BIFP]"CDN2A7YM]]_+XWP/S^.<_&5OO+^>\SHM<7;.ZSSG=9[S.L]YG>>\
M3JLPG/,ZSWF=7U1>IS5W^CFO\YS7>?IYG=8\2>>\SD'R.JTYD\YYG8/D=5J+
MHSBIO,Y]XAX\.J/"8@W$]1HS>T1U/>@-K[S_6/) S>3A&'Q%)<1IGBT3&OZY
M<^+I8&OVP\X8[8B73 ".X705OH8!B8-'QF1YLO 6X$DFZXV=/-H1,[4P'$,.
M4F]5H9E="JY:O-'H,<=LEUL="BKQF)/A0ECUP<XA[070/N..87,7_I'S2Q_^
M] &MJL$:Q9*I1L#.%>V(FUXHZ"C6PJ_,34509VS?$A@[ U&X!!O<1%1VPO8Q
M=8')6>/0L)Z[C+,NQH7%R,ZN ,$LBV,'.NR>Z9S-RTR())84J_Y.%>2P&VB2
MS">UH5!4KXCHV]*DCVB0=C@',9A/$HWTSW$+1T'!M;B%E&8UX;.?=H)G/_#J
M*D'N9\SB(/0U](DD3($U;6\Y!J%+B;<3E "3N CC*XA)I?$(.\K;FB/+7BI6
MF?3;>+ 3C'#)FO POV?*W\3.U^MHHPPX4+1'\ZNHY;8O8PT/CEBFC^25Q#FD
M,D.SY5@\_C(>71'^#>.,/^#":?LUS):7>9HQJX$RXR'*N97,"[JP_PN4J2N=
M!L.^!9!"TXI@%T&A@[S-JBYK\0&FFJ++:*X M&RC _/(),<^STM<7C']BA)1
MR*TD5S7/E-VP??YZN1].+8 4T+'ZA<2,K8@1.0U6;$_E+/$GU+5H:3MB7P&8
MX@64!#IB#;X,ECM\![\I*E)N1YSLM>5IEQ0*P+#>>#2N?@6K(P;P/HF3?<:J
M<L!:"P30=307!& QH*^9-PDEX2(NZBWY&_%Z/*./"?07=L#D6GE!YJR-\AQ@
M- CV)0(<FZ0[DXZ@>T7\[35!2>B,<E*G*UZ.3HZHMB-V[<JN* (E@H[<;9P1
M)M)LCS=EJ6MY#_1:EEW!T@D!'251S4+*G<)TT?1##^?OBAA,(.BX=8!L +2L
M>4BZHF4"U-@LT9U97;GPPCAG?.XNQXOMNFC'-FV27G]FPF)@A;%'-\*\XW4(
MN?,OB2(AHF(YTEUD6_HH>B5/L/E[!-F/7C,9U^5DNR QF:M*"4D[H&>M&&J$
ME&=S-'\NT(S)@@? 8+],PEA1^RKJ;=#K@AJ$DAYR-N)IUYX@D!Z$R]RNUDHO
MA=DHXRD2VD4ZHYZU[!BQVZ:FKUX8\9B1YZ06.EA65KKPTM!7&(:F SE0JA3J
MQNHFHQ$O$E5=NRK:6N^VE/=PH! J$&<=U^CGM4,"K\(HSU1QYM(.Z(50M;)6
M0W/ N6-!S'N%/??LAKU8YN_AL<Q[(T[$D.>8YK[;'7 S0P^W,@ME;F41?>E2
M%;R57RE,XT#\%!6B#OX[3[/RS3]-.6%;W\,.VS+3!;M2[ZM4DG!5&=$?8TJ\
MB&<7E:179:)FL7"+L#9K+][<)8QTA8+P;PS[">S(,*!.#,^X(VM+"S_Z!4+9
M"3N4S&R6 _@?=2'<NFG5K/5[6'![S\3Z 6YBU4?^#V^=I'^?%!^8_*7\!'Z9
MW&ZOMX"ZGW/,>A7*[5"E_)QQ9A431S+.N@!0*!!?UI.8+T_ :KGMW<8(2SLG
MZ%5S#\C2%<Z5-'<,$)6R'7IAVAFJ!9.Z<*>AJX#7K_2==2^E 1Y.5[^K><=U
MB+0TQ3Y3=8%#RC$Z%I)7I'2X:+IAGY*Z8 22!#Y>^I>BM-C!A\!.Q.F$HZF$
MT#$]?#-*!Z"L/7:"3A>TU+RC0],\O&WS6A\2*@2;931\R;/BXM<T'FZH\9VQ
M41HG1.T37'T$VMEYM28T3)AQY-$,]]%=>.6I[N6F\!./(36F4 "47#2(,H[B
MMG9;;6Z_0C$E-SGW4_[J4>K%HO)$]<]97.AU^4!2O! >5T7&)?^BS0\Z8XQ)
MM<2V!*Q>2ND(+W3_Z!K3_[/.&'^]]&8H\;MABA3U9:]RRO=+L02*VI?%"SDI
M X9+8OM:SA/Q6<OZ^_02"Z3[L,[8G"##HZ_X7%6"0LF'UP+PN*/)*A]&@+:V
MDMBGQ$L)=SY0NN'%<T32Y6S^2 )"5MPDKBUTLIW!=!3WL\8[L=75PAPN!EL"
M\R/Q^6,FX3STA8PE'!0Z*0'9< SLG'(8Q)T$@[XF[\*@TN=$XD44)+\P[0VX
M5X09%H*_1\(,CS3,2%FUKEB+F!2212Q&T11GM_]E["QV\+I^+!#0M4TP<7'(
MQ)2;L@LAJ8O-KLF#MQ%10I\\&M0?*+B-"RXUWH;A/H.>86_FJAA:ONA: YD>
MM9RFZ\\^X:]M'7IG^RU%H ^@9_8/NN08R-1!0^54XVWM%1J V3F68VW-/*GL
ME/.2I 2WK-D7E@. 7X' [?A_M[-Y'"@7H$OE.?H2('OMW-SKUOK$MV3W&&[X
M$=0<&)9AJXZL+EZV 7#O,OX(*A ,S#$&\D)!JPN7Z\_,E G33K.Z98P1E OH
MP!7>_!1_[(F5>J01)/YWY@UM=GU<)W%](6A<>=ZR7[(U@(?1L!&\V&<[1IK)
M',QV/H5>7:#_7.TK9XPI?1S=Z/LM<#B3D\HQC*01%@[Q:T'$+*YH4@14\"KW
M:9KX(7<Z[6(H/C(FZ2<:9AG9<@B)8W&",JCF(3H=G9&5(R=\E2R$<Z-;R$O9
M%:H0#H160N7@*F)E;&@GR/;Z0C'#=[[!)8&P'3RQ?[(CY?YRL=O2NJSC^B&A
MV"$'&PXA-Y0CW:"80L>$@NJF3\U,<EAVVVQ>4'BU3^%MO M:>\BIO_12,EU0
M(J31U1+K]BVH%KCI8!M&TAAS_DCJT?MC4/UPTWTWD*S1]OFKX?=YU9!0L-WT
M_!G)#6^?'PI3Z)A04-UTZIE);DS[_"QNBQVUMMF)SX&3S9S4A<'D/9ZK^)X;
MF+&.#?$]J)*YZ:X;3N+CT;+:Q(I+;V-U9]9YB6H.!-4+Y/"_[C+".T?T0TT]
M$A0VY SE'E)RU?<J5.Z>?!)_Z9@D6NL.!1(_?LY('JZB5VA>=_@:_:'X.9O-
M*Y$(@M%^\(PFV^CSES0,0H]N.FQXRM&@J#GL8 -("P'#UE#G#NA)QH'BYJ;C
M2R^A46<D#%NGR%;AI]_>P=4(_Q6=X7CNJ6!%\:#K&/>!K3ZUGTR QT_.;27?
M$H9.EJ!_$.)<DBSTO6C+^EX]^A\'K4<_^<O>)\_UZ<_UZ;N(5K*,G^O36\5D
MQ/7I+WG]CE*G@+7IFUW&"$>3"_2:]'62= 7IV]HZ!H-,M0Y+;;=PLGN%#:O@
M^38GRZP@O;8C=MU7N8XU*J"#1(#N:MLGKBK?\,ATD!U[?2[:A6*SA_5&?C2P
MYY/'[;)P[9U-+UW>1,DGR?N:/QF\K\E&FA1#8=O06Z:,3.>67F@Y^9R6!YIP
M10HN-A]37BEGQDYR#/]X,?4SIF+\SE//7Y>Q7)EV"B";6?X=)8:^CMHMP& +
MHQX"'\-3JWL5BWB%L]@/([)'ZW,RV!RU\S7LFN>#J8A-,- U[8HP7'AR&4-%
MKB'[K;#KE%L%)%$P[@AF[97O-$[IEO;8=<./B*-:9*.^ *O*[5Z1JNSN5CQW
M_.>[T'L)HS!KN\XNQS 8 KN,^!%UQEBPZ N#@N*RS*'>&# 9 [N8N!O*(!&M
M@]KP0,G:"X.K<HDK4\6G<?'^UC1-26LE":D(8.-A5RWO )T.>Q-!8I8+M:!#
M4]_GQ=S3!V_#W>T5S[NEL5P5E:\8]!P6NTBZ!8WJ(%;T!09^PAK"/X1?XWQ(
MIX.AX#I;J%G"M!%U"9$P>QN_DG0@;Z)R+'<JFO?V)P)DAKXHE)76>:5M_X\\
MI(0QP?0ZVSQ$7IRQ=8V'+JPE 9K5?8;!&.AER'M@E73F^@1,"[C<AE@/'"@Y
M/IBBF$ON]+:/[1MP VP?RK'<J13>>_L R Q_^Z")3TB0WC Q;*NCT2<O(K-Y
M$?2FNM37]T6O'-X#F\-+?ZBD\$$M=[8R_D17N?)@/VSOA5X'?#@@ =)Q\,V1
MNOY5:90E"[,U1Z'V=&?U]^(Q#$CETL%&1R\;WE]/!I6'<TO"]N6=1MW+XA>$
MT2Y^ UDI# 9#KT9N80$QEN4IGB!:!#B$2>A -?3!-,9<<B,^05S/Y\07E7&+
M5Q9X7.0LYOSS_\]-I5=F-+'Y\\B.3S3TF5KS/[!)L_^+6LMM.MQ5F*Z3U(M^
MH4F^9CW8SSP3+HQS$I3NO/9J3B5Q+M#F3JEW^ G'!;DYLI/V8KI($6Y>1Y2B
MJ(NW$+E<E8]-ASM%Z.%JBX/5B-=N-U9I)]?C(]2X/Y)B]U]YNV0D,RYI=E;N
MHT)GD U_A(K];JKWZ91-R-?K2 C:BRI!W\;SA*X*K/6Y,= !W'E0 *Y2AM)!
M-S/WW,UEA8]'XI/PM?7)L38G=:,7_F,"AB H// 2D3B&&P^+?/8^/Y)Y'@<J
MW[NR%_Y[ 0/BUBX2=-RVA)&4/U1^3S)0[*ZTCSO5_>%KI%X&#L!4S/N2/A4V
M!PW1R^D#I'L(1RNOH\Z>Z&7963*J':B^;ZP;@\AQY 9OM:SQ<FCLG[MXG#AH
M\:QSZS]*TIP2_<+>?V1W2O^;G;J&D*>EBI13WZ>Y%XFG(UO*+\ANMO7=T$OS
M#R;XQ(1M*5C'KD_!4P2]>#-C^]-K2#YM*2LJ4_S\\\_??OOSY,UDQ[<H3"'Z
M3+:=4%:@&5UX<?BGD,)EO5!K<0.\E=!L7N+H1;LB&OIE:*#A<5;G7L3OL'YF
MRG01*<,1AO\2<D6,0=7J8)&W!8L#Z\A3OEIY=#.;/X6+.)R'/@_C+O)\1"75
M*/3K-^R[Y>7MMX?+2SF4*"JY&VRR&VVR'0ZG8$6#+4#9"44?)(^E"B? Q(?V
M1Y[.>K .?95&<G%AYNT(ON2%B1EKK?/L;6.>U2;7KN> 1N/N:VTT*B8-[PWM
M/&C=]98OP79#49,<VAMK2IB(M6G4&@IG8$_)T>WBXA@O.[S7YM6[AGG,B[-Y
M<5#\H]X;[:3>Y 1V#E?UP_,[-*DR,ED-AD#>O&#0M7@2C"3DP!YVXX6T>!Q^
M9_D6E048)VWIX+7Y]_YP_O'!)F(T;D)NQYL4 XJ961\218VW#.\H!TQ)=2^<
M"=E&$V 2:KHA3SP(/ ?3#B0'!Z9:6<ZC+..15L47+G/*Y7)0SJ,VS;X[G&;E
M0)-J)#&QQ%B3<K!RQMDQ*2%\@$U,L\&&S2S2?UEG>!J.X8;YV06__22A#H)S
M8/[=)_$;7S?9OC^<;+S7,685]X)WFD'RCD/.%O85HYFA:._&+-#)NZ[Q6N8=
MT.ZJC$-K!8>:@O_0W$V*CF(7V77%"B-JKT6AM]  7=%"H]H),SHZF8V";,2!
M86R&3!F+RH&I)RX=25!MA)I3TX^'$[#L7K/BT ])97TPOK>7-ZJ ,Y*R$U*%
MZX-Z9X6D:^)MP6R'3;GF V;GT-_!GK]Z^ ^K5UL1M -S^S)9K<*B^"=W[8A
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M0_H(#7WQ;\LPOXT9O_EJM]PI=GI8=R"FUFH%F^_J)F)!!_'0M5Z0!YZGP.Y
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MI\=X0!"M6:@@$'OR:-?/N\MX*!X5X>97\)Q<D&+5D'EYM=V R%@S3L'(0"6
MOE36"'WPZ(R*!,I T*S?T$"=@9@=)?Q=MR0:2,/6,LB_T;AQ%M.:_^/Z,S.$
M0V;Z)-DL)H(PV?K782#L2!OXPM=92NBP/7]*AH%M-Q 0MI]&!-NAE-#72<G)
M1A#9_;!WV!T[3FJ LUZ[1,9]U&L\U,V+PM&4B#\\K:-055<0TAE\QG<&>)@X
MT*?M_A'&W,*!]H<"Z(27QDPHEG;,G4=O-I_E69IY<< 6D9H%)MDA(1V=RDY6
M;HEP,:#/I<(SD!9'23'5A2.H=!B0X*WJH*#MZE3^LOZ< !0%.FB'5_S<)<#?
M'"XJ_O+KE&(I@,>+R$> 0HCK.#%FR^[!87M'53X.U7)I)3LJ@+I"0<'WF9B(
MPE;R1)[QI[QB\ARN2 ]H.HSC5)D )4Z=A>1 Y=NR)N;LE;\R2CY!:FV^.ZRU
M6=75K 9QIXQFO0KHGN]W&@?UPI^S^4T8>S$/!=X63 ,\ CS0\#@;X3W)BA==
M^/LD<AX/FB%?G@\*Z,$&V"H0\W/ZS\7$BLF"GR!0S^F/?!K&)*C>8ICZ?K[*
MQ4.,5V0>^JIC.J0O]DV\36V RV[4*G+II4LF+?X_W'7QZD5"-MDE6[DWC&^9
M:[;:(V'=L6_S;2J*D03/;K\AW'[6CKPV]61,7L(K_C+?COM?V$HXHWQ;G*YX
M$H\<96U'[% "FP@#I3;RROU/^6KET0T[&(6+.&0[H<=.-K[/.>1W'HQ]GQ>T
M QPDWA\>),JA>5G^VN"3W>B3:GAWCAA-UO7G!E4?[ K^#S19$YIM'B*.:QSP
MI6HM0HVAY?QU([B1A*#'35KG7\<@?M%_*84-/T9KB)^VKQL0FBIM,]Q/RZBE
MAP)TV?0\O%]>P:#VYW$#L<^+G8K_$%%+<T0J AW)G]J75[LL!\J#ZB3,#][G
M<)7+,]=9FX,F: ?#0W$UA-G*"TIIDP]AK)7J?A.T8Y1>JFV\H!]WI*O6Q49?
MLA74>=SKM FGZ'5=Y:P!*KR".KL!IH'20G%TJ0*LE$A]U3Q-1VPGDX&"0H%S
M8)=ZY@?[V?PV#GB68NY%<OM5TM2-:=7#EI7P9:<LK"D<OX;9\I%$0IKI,EP_
M)]?L])MM5&6YC ?!MX^5:JC"2L<:ACU]%5+BLZ%4IM]A&\R"7!V5K@9+.\?H
M!J)3MV1'WY<:3J,O]@:,LWAS=7MY&W./=:"[#9$TQ[XV[P6TE'TG)NG'.(1#
MTVB,?4W="Q@)Z[8R6KDJ;&_(>-R7S\-]5VL2IT)>W(Y:$=U$$:FAG89RUHJ7
M8M6=5T<FF)3ECRF9Y]%=.%<FC@ Z8]\.=YZ !J)!A_$^Y[;5;+Y]=OZ)+,3U
MMB((4-X%.P.],V1:,3@#E"B<RM^]NHU_78;^LK"A"[I5.9;0_M@)Z;TAA D(
M'4\>[Q/GHA3%91*+NV9^0+K,TRQ9$7H;^U'.<YUX)@;[O^#9^RP'M]-@V/GL
MG9'N(;I1'SA*OA\)/R\7*<7SA*Y$99J7*%P(Y+1*HNN.G2_?5RU@XD&?_R(G
M[L)CZEFW^&KU_2XVNR9E]LCTDT<#\9]_D33;)I4K4@N'_0IV GYGU; A;'0-
M>B0^3TH2@7&<';X>U@+39]F24,XN)4O&<?A*BH2&RYQR41?<W)-L-M=L+4-^
M!3V5O\?J,KRTT56(U[S*F"#8^?,JR5^RZ4N29[\D(L6:+9LTYOMJ&,]B\F_B
M:9Y<-!D'O2! ]Y6DD\30@9:I)P](5DY_;4?T8@*=H03*!!T[P"K#2=8OY<8#
MH5<=Z(QM1YF-/1I_%R=?'8Q L???-6+O:P'WVY$&"[.7>)%W%+3QH0BDY[VA
MG;$CZB^3B%&>%.)K5O/V)7^NE_8&Q]X/]RWDJWP3@-MW;0LRP0_L'X"7QCK:
M5IUFR*^X%M<S]'QLE,(94G@X"0BG]IJB+<AUCS >.9?A_ CC(3KHCS!^")B*
M$9HFL?HADD8SM""1OH_WR3A&/U0IGQT:[6-8EG<SB130H_S/;VB-[@VM2]:$
MF?!136.9Q$#O-,&Z8L?5#?!2DXF,+$5V/1.Z8IJE*>C6:(7]JI*%@U$=&(E4
MK+T7$0>YGU7:\)3E0=@:Z5$\K=#>&'LZV(9$+21+R-R%/HEK=E%Y<\BK1$F?
M\=#TP8XZM8T32&0.E$+<%C9ICV<O/:%MSM3O%85,^"@3+PZ*?]3&V_I6D0J7
M2*+VM<5+=/WP@K_5-.-O42"!MT1V.W."ZI/_,D#BB[V=JBLR1NDNY]0EBWM8
M5P3MYRUE2>9%V+>$6W?!-OF@>,"<L7\7>B]A%&;,=OI /)%W,(L?B9]3_H;)
MA9>&JJWOA\;65WZ*[WW;CTV*KXE]L/:]2?7!21)/O,GVHQ/Q5>P-\L8+J5"!
M'7^ [5'="V<-V-($!+TP_.B>#FBN( ?\A!L.%@CZ!^O)@#+ OVD<@IG&L<".
MWMRY=M<X^'RSH&AWUN\8NRC;Q6;[S_\*"6527V[NR"N159,X%(BF_Q>F'AII
MV+FD[ )[R;3P.C1)UA7M,1S&,24 J;P,81C'V+5\MI3=QNL\2P5W;W47,\I.
MV"?&3IHK U$N%?338QN-[[H@]PZ]XI]EY-Z- +GW79![[TK=+%O(O7<5N8M-
MC=,;2O[(2>QOP):0O+-C.Z!],T@N"O1 AC:MWM+8Q?)I='8,;;U6 XR=!I/.
MF#CUQ6FKNN!U5]G;1:-'HJH0>U4B'?3U%_F6PSIZ0SITQGDG4DB@Q<.G"!.3
M=W%F6EH$5BNQ$[D>>:!D[87!]6>>,4ZX+(M<LB*EMY""XC;D1]5MR+H8>T+*
MP<5M2,*'G_C%^!.ON";I=_&AS;6", G.O3(;#.LYHT(ABRS 9^_SCD[V YL8
MA*U8S) LB9:O L8#8:WY?3!J70 ZBM!2%)9@:%,%*16+7Q"(LB\0-,4[XT9#
MH*WQPP%ISK0CN[5@L>!-.T';VJ)YG :?A'))H(.TSUW%'! U4&<T]]/@,!K(
M:M1F%;,RW_@MEI,R,?VG0Q.*CU)*I0HC.5I6.@]_[605R3MB64#K) T9'8*:
M'74J4T?6PPV;1@=-PWY1"V#L92 :KQ;42V<H3BP_JTXLU5CBI+(=#3LN2UHA
M1!^<!>B*72WB2WE_$8SB^1G&\S.,^!%*YR?"!G\B#"_NZ/Q$V$D\$79'O)3P
M%]5O5VN:O!:W2KJK-F4G;%=^]Z?! +*PY(N;S>>A3W;;=QS<Y#0.,V9.*G.Z
M ?V<K2TOAP/(F4VOS?EQX19>[,1YG!\7/C^#Z_@SN%A/-@__1HM+3S8/86S^
M0I.TRZ&A[#?6U^)@\G 7MF,_=N1>0>PQ/79D9_;]]@X_D-W2!.2L6;A[0JN?
M?448\7XH8&'_CHC )^9OJ]$L_%/\7BH113S88%_ #JL?HN#V($(VU[>?"WV+
MR8(3@:IQ4N[N29?["-'K]%[#JPECU#?;NS,IFP0T)\%!&$ M %-^]_;]MZJ[
MMW)@<?4FAIY4E^#U @K85W'>AA^]>12$H->+ !42E)V&]$R5(GQDN//,(/:]
M*Y[ODZR+@J:I*C*%#V#0']L8U^-0=U 9"P;=C"LI9@O+G*0I$ZH7W1"BCRS2
M]4.WP>'  3FRZ^MM7^-D'EY9:W33V6RZ:+AV97+42(/.B[8NZ/9HURDAYQ_O
M)--U9^JY,9F":<^$''AC&@I8%][V+*(^S>>NKA_ZK9GQ!(9)8M1@2[DKBZQV
M7K /^J._Y3S<ZMTJF5$?&P\.B\U3HBHR^ONWA\?%YA&Q[6C8-TCZ5 Z)_6,T
MF1(02"3F03LWKM'-)^8A'_CQE%N*&@XH!0IWSL5+MNJ13/AWMJ(@4^)_O4A>
MOPE(6,B>_6,G<O;#;W=DX477,5N#9$5'6*M&HS$(N8WN0:,2]<(M/BT--F1-
M]EL@B[5-8@V9[E-LYQ61CW&8D>"?8;P(DA5_FC<,0H]N^&N?7KQ11IS!NJ(Y
M)QH";)Z/3)AWP2W!'XU*RYT'XI-H;8_L6Y5O.DU#5L'OR208E<J65@]Q,DMB
M]A*%"_$9;EZP!JLP*TN\1.S7\>(YN>75(_S2-A7!JJJ;D7>JFQ%FZ4Y*(O[#
M6R?IW]-)C99)C9CBW84=.9.*GDF63$+V\XZD24$3]H5*C5@AR9A32V*?'Q&V
M\@"\T6 V#%;X=IH2,EL3*C 1 %0'F$WY2$AZE9-[IJK/GTCT2CXP1I8*FZ_[
MB-A/0W2!O1$!WD^<Z/L%E(%_$X\^?TKZJ\%V(.Q;H&/"?R ]6\\D :F9SC-"
MY8"*YX,Z#85]Q=0+TNYLCVPJ]Y_#^/=5QYR\XP#X8QPPQL6#L<'U9Y\UG:[X
M3QW1E@^'?;ME'7J=)-'U0$*WXO)*U@'[UFH(+#72:$'KV,<X%9> *XCWA^>R
M^N&J.&S51G3G"N)+.E8]T(0_B[G5OAV9&\W%A;ZG&[[=(::JGE?\ZPX%C0U?
ME!&:=ZY=B4!U%@[BG?7B$9K$NJW;\!>2+*BW7O(W:N5IMXKFXX1(S9.=$A Z
M2,CBD!KI_0LG7]X</U57JUYU'.2,V+FCN2#T=Q*1S7^1<+'<.G[5ES.:/F@N
M&K7\FN=V$.^6O"Z7"5WSAYK)?Q$O^"/W:$9H^O5S\HG0MV__F7N1=Y>OUCG]
MP/ZU24-/"4C7P= \+Z9(]9.6)0BO<F;-DR<_R2)F3RL!:F^*=HXR%;^*TR-Z
M)9\)7?%+K>("Z9H?IWA4O8$S4CH"=E*(@?FH\SQJI(3NA]#3;.9\.NR+?4/0
M!4L#]AQ!<9_(LCXNU)>T;8[M^N^!E5( CL'SJS!P2#!]9;]=D$?"%_JZ@KV%
M(@<9"=O+/QBH<+&AX]VV<ER5_NA'9C>9+:G[/;%=]P,OJ&UB<<#=6WOWO7JZ
M93:_C=.,YL)]=INF.7_383:?$_X6C"(DYSOE0^]L](D8GO]4^\"D^,(DC"?5
M-[!#;'@R>K;1.WL/VZ%7LBC2$),54Y E-[]>2?$8QUV2ZEYG-QO%#8=3.T[R
M&A0 QO!=ND!Z >Y=\Y'<@+6+0G<#W;X+N$OJ0J'6G.0D%C<8RLK!FFXG ZF&
M3_2*P0=DZ6H$2YJ[ 1=(%0_PD3"$70&8WP0F\5.6^+_KZOZV-,4^U"N5ZO!E
M11FGEEQE#Y3<< ==\"N_NE?552[?E6IOC7T6!XE8R8%EA_T659"<%>VQ#\A@
M26MY1C_W[A)KGCQ^=A*T:O9I>1<W%OTA]F@YC^BO:-<HNO=6[)_/3+%2=F[@
M!>DTFS6DKQL@:A7S$#$ 9W9N@&^97K%Q'VCXRE3N@;LEN,6A7-PT?; #!.$J
M5E_M0(*PM+L(6@L'S%7.72\/A(9)\>SC1[9,7R;Q*Z'\'D<\?+N__^V<0GP$
M+_:)* PFP<[.IY OT+H>UNOXV\3@9%(*:\[)BG7^8X$SXWRU+@J+2IV3WVN=
MDZ^5<[+ZP&3[A<GN$V??I-'I*_+2= O9C#[RFPV-)U+5QXU-%N1W5+&![V5L
MI0[@4]3U<P,@O=I!P'+*.]A*H?K$H>AR2C YXO]KI4UWL%!V<A@DQ8E"R9*=
MH\1Q/5'V<GSU&O0E^J/L)>":R=NZ5TJFW=6)<+I@_X&IN+(+=F"%J9X#^$=W
M"'X@'C]7<#)OXW4NGG]3[\[R'@ZO^ZK-6<X0NN^OC33=UJSJXP9".IT#X./*
M+=TA;0\T],F_$EZ*1YD6(F%-TAU[@]>KH08RI5B<6P-Y<*J?D8"'+)HBV-87
MV[W;&SZY0)S#[C%,?[^AA-S&&6%B%E&+IABJQ@!B^;.S6.H%Y!RFE?I=A:]A
M0.*@"Z:J,:#+J[4+YL$FJ%Q"=D ]L?=XX:9CZPN\[\\O\)Y?X#U&+N@7_P(O
MQKO&3K[ >XKQ/,8'>'WTSG?GZ)US] YR],Y;:P^3.!R^TWO^5&[3*3-J1=6)
M69ZEF1<'8;PXM(+E,\EL%.R*N: K[H,9U45.+F3Q<:5=)A$3:%I$)T!JM?W0
MB(FI#?,?_^.G=V]__/ND&,Z=0FWC"H#9K>@S6E#T@63+)+B-7TF:$5);<RXV
MS<95,]U[,H-^Q8V]$!1D,RSC^&$YK09 8\T"&J-WKH7EV)@,$!OVSJ5 GE,\
M:F !ZTCHS_EPXM;AY#YY%=8W!ZHTZ*X_$^J'*>%V'8D2+Y@N*-$?63J-A'W-
MV.T<TT-HE@)?IFL:1L^?DN=EDJ?,!'_^Q+Z\N4ER^D3\G(I'61YRZB\]1B((
MSEXC F']T2U8!Q"BK3IVQ!>?:1#WS+J1KA#W'A7JD+86EM8-YX&D:0EK/'?1
M^W.VUVY!S1=YFK'?OQ5UW9(H(D%A@55)1)RG%+B6=AP,BIMKZV@OV5D"M-JS
M6]?W82R??D.#0TW= GM(N1[=. )%",.[0R%T;)TUE8]-F&HF-0"5MM90$'YR
M$ 0Y]P-GIPYIE+*_O#>R5B =H0&,UB+O^YF6>IF@G!0ZP60V%!0XQ]; /G)S
M?6[6DT+\C=G9$#( %'+'S%1S&1U[SI9;0;=9>M 9"I*U,.*!YV6K;(YJ0/8P
M'CO:+#\XYD@QD0MZ6,<I9H4?X3))GT>.EZMVSB-'RR-_(C0DZ05H#92T'5E.
MLY)C6S6GQ#<O#:3<:(M=R;"3E"4<6Y7RE8&4&VU'EB>NY/@D:J!:\^Z,HO)$
M@>_40*,;;;&S#CMIM(3C8VFT>#^55[[HIN+2[M H"5>V2E/!G$S]%7OYFN<"
M+&K!.[/>'Z$""\@D-[#(35U$KBBYBN%S\C&R^^"<KGQBZ<KGQ%K+WJQ3?M3F
M&%'OH$=O\-)RSX_>?,&/WISVJS=#I=SJ .AHKUK+@C81OCM6ZB5_6I-0QF&V
MX9=]<H.UO:4C2Y!=V[6=]5K9M".:L61]&(A^2)UT,^&F$+P[O@FLTLVZ-0SG
MR<[UUV.2+2^]=9AYT0/[8DQH>A?YRC.WN@MT(QG>WVHFSN8I'"(*2QZ/.R\@
M\4M.%\]++UIY<7R9?'T;JV'0] %?2CJ' T@8MCRM;&=+Z$V8_;D@U(N"RT3M
M:)4VAYX9A]_2^XI?)P)T&VMKLY=>-D@RM;S+Z1L!>AE445G8\2^")&#8RUY;
M1T#4*69[M,L>)V,^1?[VSH%,2KDJZ0Z1G'Q7EKCB0N"A"L(&X:'L! W,M):4
M!<8%P+LC^$R[X"/I!,7'6NBY(3Y*WM'Q*9[/RT*V&YIAI.T(+0C@POH&D@$Z
M5H4^77>92Y).X%H<^" !F'<$H,LN $DZ@0&R'68(!4C)O", 774!2-()#)"U
MY#=#@)3,VXUI-M]K:N'!0^TW;[^U=C>@1\*$GR,@<M4'$7UG,"*(IIH)/X@7
M.,^\+NEL?AL'_.V%W(OD-SB2IHX<_.U>X4AXK]6>0H3LUS!;/I)(2#Q=ANOG
MY#K.>"U:Q4V.\2#X]SE*555AI6,-(P3J<AF2^?5GXN>\IN]L/@]]0E4!4<H.
M4)?/\.MA%WDW+TCUPK!UV<"_?!/&7NR'7E1^F4>8\]_/UH277(X7.GB$S[[+
M2%#<K-S4]<2M,]..F.RM <+W.:>1;13;PFV7'B\Y=;'-1"X;FF;ZF@R,7, =
M5@P9DC9J+DU;T[R-ND<2Y#X)JH)2XI&_;1L5SD+S^XR(7JG4".'>[#HRX55O
M#/"G >4S6M\3._^XTYR%"@0=.<'-;9KF)+C*><V_!W:P2H*G)1-->D\^B3\I
M[YYA_;'SFSNA:"8<S/I"=K9LS?+SUG"CU@^'G9\]W/X,%9VM!#_V=2ZX!?MV
M;>FIW0I+-E](1VA KQLH0;G"G\2=L9QFUQ$118!F\ZH:LC2/L^MHX#OV$:&N
M%!SZWOQ $Y^0(+UAHN!;#3L*DADMN"]\:_(%&-(7O?Q[E]46+A0'I_*EERZW
MJ<<WA.PT5'864G3 +K'1X:BC9=_2=OC!B]E'&E]]3J:+!24++R._T"1-*]V2
M@&$\"G9Q#G.$.@K*7F6(-8E3(:_.J)D. O8@N(-:-SFA[V\W7DC_Y44YF0;_
MG:<9U[J=I2S?VC3=T'/].FUK(%F@(U8SG8I#\#3/E@D-_]P]ZZB,I&UV0J^9
MT^W(IY<#.E8%887W0IQ"V<H@?J=PYLB[H%?6Z>; T<G 01MQNVC7+=T:SY)M
M3M\-"J$CWA484XY,-D;?G*0IDZ07,<M)L7LU6T)Q<<2?(N7#$2@D3ENQN79W
M:!]VAX+FB#O$C#G\M7'0!RRKJ]+:9G ;URIG*Y3!:!2H3KCE4.DB*4OGO4?B
M<U]Z. ]]KW#*-0PMR>X'ZHE>I,Y\ S20"!XF]TFU/;/&)'QM/0P N6D;"R_I
MWB9N<JEA("FV@"ZPE1WQ$O+M8+0G#VN%:5M<V74BA-M&=H\#[ P%QA%WB EK
M=GV/;;>Z:7FM6P]EAD0O[?=#SR(>*$BI31K'1*.Z8Y=M-[I.4!P<\6E 6'+D
M#-9*9NT*UC!P9*\G%#5'W!A@OAR![HJ\9+=QFM&<^Z"O2.K3<*T^)2FZ0,%R
MR[>AE0$Z2D7>4RJLEII-6:9#D4 5FJ7O"D7-+><&6":C=FQ(,][JA_:/ZR3>
MB4.G"X:#X67$]->.3G)#G^TU-AEUXK5U(>WJX#@S]F9!AH'B[(B[I!N3CB"\
MKY(U7=UIH[B_4MTK0$? RXSJ=]]@)B%K(2F29:1&AC:HRVP,<.B\&WAUX-#)
M25C?%Z#3;K\/%#A'7"\ CD[ ?FIC#W0RU7:$PNV(6P?*U@E@WC@93%>\8&BG
MTU*S*Q1W1]Q(<,:<7):O>$8UB8-''A6BVFE;]5O6&XJA6TXE$\F,>@+O,WH7
M_I&'01'M*OY 8KAE+.D,50"W'%4&<G%L&A>KS6R^_6VEO>DMDS<E'E7&4!D/
MA5>Q>CA\#63F&-I5V&7!03H([&9C0O%WRVG57XJ(QV!-S#'TG-@I#OF](TZI
M;DPZ,H=K-^[ERQ'%\>"1B9R^DN FH3=YEE-27=*KS&CCH:!(N^6FZBPS>RE4
M6WJB).4AGUS7GEFG=)E$TJMS;3=PJKX;\,"8L@J%;/+/7J)P(>36))"SE@HJ
MIVD]G5GO%BX?>+;W1:@"..+=LBX/AW6GBNM]IA[WZ5QY&WE4V>#?@>J)(VXQ
M2U) UHXA-: 7RHXXP7IPBHSD\S*DV8:14A)59'!<"V<MKS(8ME'-]#*AS\E]
MDHEJ--,\2U9L-%\9(P"3D35ZH!KEB$L.65I6M?(JI,1GC:MB*<\T7"P(K4C]
MW[E',T*C3<%-RAFY3[9G4HEJ]1T4JA^.>.R&8-F1<^&^FC^2@*S6&>#$W^K4
MD':'XNNRQTXC&W0D]P,=U94:V]I",7++JR;G&AV0]AN=M%*<*YZR0N'Q"(H!
MH- YXD@S9<\1/&OGA >/SJAX1*_(M]4OE*#.4!R==9/IY#+RB\NV5"9]C1M=
M/W )1J=0ATD#?=)*LN3KX>1IF2^X]>SOZG#+0>T[+A1T1SQN W%] JN X%43
MOUMO P7:$9=9"P>.S.1]2Z]IC6NCA\ #0"%SQ/]ERIX4S__\IL$N^^COU5];
M_[@W&OF<,0MN9[+MR<3?^+Q<9/2UGZR*Z?SD+TF0[QX<\E(2U,O?77_F_V2&
M8.:%T8YM_A['/[[Z^>>?O_W^Q\F;R568^E&2YI2P'ZHA)\E\(@:=B%$G]6$G
MY;B3OY0C__4K'(7>$BX2HK?TB;=%N"32+!7S\(6S\.!M.*[I](5![/F90L][
MCHNTKFZ5X7JUCI(-81L'?66J*TAMZ,8T$F2(S>:1^,DBY@7;BNU(</@LR>NN
MIIB=S[GQRM<PFG6X)=B16+T$)X[F#<-.8WENZMS@'W)#VZS.W ,E'%R$]5HF
M..IW&[,-D8A#,Y^&=R7ID@<&RU[*3E^>6BC%47LFR"F$I>\.JIERY*5!B.1-
ML++ZRJ !6+^0F% OFL;!-%B%<<CW1/[<7FDTZAXK!G;'?MH*I)('P!E)!OVX
MR(/TV.>7C-PK\DJB9,T9!:((ZHS]#%(7# VD@HY@N2.0H'W#*(F6@PCMC_R.
MH"7S\P!X,V&ZY1S@%,^$+V/JLP6'/[4I=PG\I'0)\*$FQ5B3:K"S'\!-/X!D
M)O +AN)9B_1BLVM3TC_]Y-$ ?/;O_0DWC##+Y_W>4L(_XVM9D'$ .-8/,;8;
M>C3XW&N[5>@I*?P#>\$F^X#ZB'[0[,M ^(!I]*-W=RYWG,3!0^3%]]Z*Z$[L
M=K[FAN:T:KWI_.[$/[9'8&N@\_NDPG;4G1\57;!/_C9GA,Q9*Q,<^A&S\X94
M<%,OKE($_EJP$N2?0CZX#F=3#64FZ%#I''BR+L)<,H]F^,$GPTCF5\*KUI)@
M^DJHMR![;QP?18O5!#B_3#J@W! (3T/E7_3R>C&6UR/A>Y=X1#@6!^'<BW@
M^3N-^A^;&/!S#*.<"CC0GI+E<<M8#.,T]&7O?@R_\AQ^$OLJ9 RK=3M,I[$^
M]Y#0+R)>_#8N[C)DKZ0,!$?KQ\#5+[XTY55 X_[Z*3W&MC)GR1H>D@APFLC)
MJ>GP4.*KKRJ1HN8O257OXE3RZS 64)GLY>-:4Z;.@L77B;[SH&()>U4SI .H
MB_;RCIU=V#H!ZKX>:[B^2>B<A+RN6CJ-@^O/Z[!X]6$K!7OV(>#30&VUEVKM
MJK4(ALW\R/-S<>2)Q?/AP:B/.UHIX?AE>Y(%G!3V\M9'.RF^B!4=\YKL-[@'
M]:V]#'M7];-57(-XIJ[C<2_48[DJ,]'O\VV90HAGK7?L6L%$LT=Z^65+;*>C
MRSVN!^]Y#9*4S?BJ)E_A!+)WNRO](%2+1WH_9@^CLP87TCG8NX3#^XJ=A6^\
MD$*6YR/1 -7SD5ZE'15)7-67%(_MNVE];)>"+%RC1:LY&4>G JK7([I[0Y'C
MB;@S_B6X+OPYQ&?_?$[XK\H3!<^.L.WE@%, 5=T1WO0=&<53L$6LB@O'3=*7
M+N@$.<'KQZ,@?@K3IH?A9RQ$V>ZI>-?6)1JATVFD]Z..2-DE0ZJ'2&J\[_NP
M+"J[ZIM0Y1WI/:95I$[RO J\/FA3UR$.6/#/@W-$QJ.YQQ6@&]'X7[8:&USX
MO!O15>:Q16AI/<8K #5-TWQ5NIS2XMG5REM:EHZN!X*3X"-_P^^"#??[F]1?
MLK'2XN]OUDQ&[$\?DH!$BA)2/ZM*2-6(F7!J)O.$3C@]$T$0;Y(M25E\NJ1K
M4A(V$91-"M*>"M+*-F\>"MHF@KAS2:KV<<\EJ<XEJ<XEJ<XEJ<XEJ<XEJ<XE
MJ<XEJ<XEJ<XEJ<90DBJE60U6]M,.4O;#;X^<4<G2S?Y>^[,;$\_:DKW/;*VP
MR9&QD$ZFBD#HU+&,Q[Z\VF59D6IES=((\T,8AZM\I1+G01.T8C>'XFH(LY47
ME.7B@_=9*]7])FCU6?12;>-EO!=;6\=4S4VTO>^S=(L+^.9)5PJTBI,;JMA%
M=FTL/H;I[S>4\#L\PE2 S<W,1F@._-/.FYY'#[XQA>VT%+2:@_]*(C9,%&:;
M(ZJH[..G78#O.-"=III6C]8C*.G^I\\%^/K"UE=!+5W=*VM;;;-'+O-5SF?=
MJS(C:(B+Z![TG%Z=/62!2A47[ZK^D5DG-.1S3'C8/L9AENH?;?KA6]6-^V[,
M\E9=C'I^ONE\5WZ^*S_?E9_ORL]WY>>[\O-=^?FN_'Q7WJI#;2;IX]-'P!/
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MYT+T)LSX\ZI7X2O[;S@/27!!Z-)37XWJ.J%5H "(L7F%!Q,!^CZVOXHS:L.
MQ %WX995:KR%PA<'ZXU]RZ?Q9C5S\< 2&76L=JW^T#[/(E<_O4W3G 0?UTE<
M-$P96HK#0)?!'#M6ZS2CA\!.0%%24=*AQF\I#A(H+C !7;&/)9V4 "",D4.^
M+0=3\#?-V=9'PS]WUVYM8"LZH5]MFL*L%<"I /S@T1D5+I.B#D15K04$M+PS
M]GFV.^ Z@: ;;>TG@]FGF"U,RW -L=P,AL"NLF@(I+%PT.$42K=,(B;&M*">
M9Y+3M*B]^K2.5&^A@#JCO]%D!J&!0(Z6.%_^A?_GQ4L)^\W_#U!+ P04
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M;*RX[G@<&_6IA+TF4'9W?#;CD).\LKD#/Q'X5C .3:<V)%0+RL,0U.8X^'0
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MIU].WTQH_:<36L]^[X369H;J(9-_OU !$>Z[T]\(])Z^Z;\]?_DO4$L#!!0
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MP[WKU*S;L>,P252N)R'T&/\-2WP$KD*520V%$%6F!9QJR[!TF"<&: [@A_!
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M[O%J^"8Q35SG 5'&83J@6Z)30_UK.N$;6HUJB5HMEAS6Y0 $8J').3ZF=G!
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M,@3YA;B&69[-C87#L_V>8U8L8^>0B>#/8ZQ:3. ]Z.-LB!-C'VF;1DQ.P/D
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M5["@.PF"K:.&?L\9M;H*ERPUPB\UA7)-8/[#T$(+X);#' =%HG'9Q,CDMD"
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MF>CZPN1W"7]!?R1>_FH\_7'Y_P=02P,$%     @ 0J_W6KC+^HS3%0  -WX
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M;X2*@)U,G3=9THGMV%Q#E#L(-K;$).+WOT 2!J;^Z^E31&TFSXX0GH[,,1:
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M)':$A=4]=:=\K._H')6,*!?DV"3T[Z4( ,#S%#D0YB-X7BR#NE#N.T:92)Q
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M##H/C$L0(C>M/-X=.KXT]Z/+IG8:GV"7Q_VXD*4Y2)%2*V$F3<@1\B+\]5)
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MO]^?\?C80U'KN7I&?_A=_A(\_<'X?P%02P,$%     @ 0J_W6GWY&07K%0
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M,1/!G\=8M1C!B]#'61\GQJ[3-HV8G('S!=@0,KXC_F'R+TC0O%;CS9?\I@C
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M<7T%"ORM3_(CK6.[&$P%59!$4P9T65Q"^>7?.EJ[+QQSGU%2LW)F9<74MD[
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M<!R?O&ZW.M((JV*":"85-0G[@Q2BW:V&SUK]KGU#(0M=V1T/22JY!!I:Y?F
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M)!5^691(H@+3:VK2_DII>*_6X9U['MN_Q/@B&Z7,D+.8D/_+2-1D5!4-8X9
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MUUQ-F"B4%M"3/%$[Y<25;>/+RE_G.!/7ZD_"WS;7(=7]B+E&^0-02P,$%
M  @ 0J_W6F11Y]SI P  LA$   H   !E>#(S+3,N:'1M[5AMC]I&$/Z.Q'^8
M(@6U$F#N2"(%'"1>3,+59Y#QM<K'Q5[P-K;7M[O.'?WUG;4QQU&NZ46.=*G*
M!^-=[\P^\\S;VN9'[]H>UFOF1VLTQ7_0/].;>[8U-(WB'Y\:^\?F>#']!"OO
MDVV];VQXHOIPT4T5>"RF$AQZ!RZ/2=(J)EJPHH)M&BB(HLM23M%[U281VR9]
M\&FBJ!C O]4U@)B(+4O:BJ=]P.6'B357BL?Y7&-HSA:.=XRSO2$QBW;]KVG/
MUTKV)RW -(;-9"W3@6EHA<C(\L262G$/X)@:P;9AI::8XZ%U'[(U4_7:9:_3
M,XWQ\$G#?B@GH66EG_[!I._HJX*ABDV:+)R5Y7CUVF(&<V=J+2V\H'K7^C!?
M>99K36%Y,[;G$QA-)HL;QYL['V V=Z__.XZM./O.>.Z/3"JVV2%HMT+<O]-Z
M+:2"KG?@\T0BS: XJ) "2WPN4BZ(8CP!O@&>"1 49Q0$1-$ KK*$PD6O!9?=
MRS>X/A=SZ99)M9=:*5P8:Z4XF'$1PZK]N@59$E"1KUY1/Q-,,2KKM9&O]#87
M[WH]N&,JQ,UD2OT#((V/1ZS8>TTBDO@49$BIDEINQA2&B(15D'1@' 8=($D
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MJYREGUM1?7SAWN3%496YK!()!AEX+H%Q2!%:*' 3'VNV](PE@B .@U;6.5N
M%=5IR?VST=C6;-^>?1&NX69QF)-4Y41GL4P#^G(!'/*S."V>-!M%:*Q!-8]8
M =94$4(M,60]!G=$R0Q#$Y>G+[YX^+"/OW+Z)O<);Z#^H*XJU@@_EX54R[7H
M]'B #>WXA#;-1:%J#T@SLL^8C3G3Q(*$?IA0$B?9N#!W--Y2"#LRB/U\DR34
MK=@&3KCPFH#DAL_ P8"V'.#!E)(DC<$ B0!2 !-#:>!RH]C&B2(@&)51&SS2
M8G/G.WP]H-!78"%DH=;29;8"?A(!<.K\FQNB.!,SFHELNT PESK)1/HZ8RHG
MPU!@KCQ%.R*W@1OWED V5E$.IXI@&45G@^U1?[+<5B5BN\'\G/P6YC%4$QF.
M:J:[S].[^66._^& 56D^9[\Z O[:IT1)I\1#;5Z3LU&7OK^$/@H>L-$IK5!R
MI I&U!;%M$D2.CRPDUH,Z1'T6:%]H*/TK1,2*0]5QBIB5Z;9R@QIZ7#HNEQC
M*@-,,Y,ZE,-0N956T\@";5E1R([H$;:AQC$IMZ(C0+![-EU7"3DLF4RJ9EK-
MO:5E#)4"R0HM/8^7J1$1.L"+HU=$Z6!",BS L73\*B-; C% 6]L<'?T)0W,9
M-AN6%QIDQ1BY<J2<B"VQ;QWBU@R@!G%VACK <L]Q#.N/;&R%&?ME-2A0R+ S
M.YR^USUH[8CK1LI8NR99*5,M+BVGE<2H,PY @%:"4AO:. %UFR]YK)4TI*S1
M>@8T8DFM5QH$4JVY)O_%@?*"L<]Q.^#>+E[B1!'DO<K7)3]&&KXYM@H']/5*
M14%9ZD3B2X3%HPG+--PRN55[+Y9 #DI<@.U:25*T1)B6S$"TRZ]GP-C '<9G
MR?]7@/<BDCQH!:R2\=0\T3AG6SG3^7WVMYG)5C(P-G?RO8*7&FMG6*&E(S_,
MN1"1Q"9K6U*H:9FR\[YG#9)6;S:&P#Y8=J4C>9MF? 1H.C@FO)0$N3YC(1%2
M%X#HB:LJ\"@8WU"Y6I9]:PGF&5!SQ5E4P$\X-\8BFNP"&N&5EJN,%%)>P!I3
M)]H^J$R9^C(GMM&&E84SBV"V;IV" R&L&$VS9%Q@(&FRHB9VOXHM!-WC=&X%
MPF"?P@;;="6O7Q)M&<0)K;79ARP!MSD)1Q&.MQOSYB6DE&@"'9N<H91D6E8N
MSVV5\HZJE(R)]/X-,BS+!W\2+5@N/*N!!D?/&FILSD2*PD162>.(+*<S9<^G
M (0'YJ-;]/U-MRZV^KY)X^P #3>=\X[XK[@Y%JWGAX?[XL7CP_:SHV==M%T>
M0\.C^-_<%3[0@0.A>3Z?=ZI-WQAI_B:9?EW<?[3;XI5687 L;D!F>ACX,0>G
MH0&BW787R/H75[\4R]>NYSPEH8> %)66;6>AA"-WL7/@B@ZPZN#T[/I2G%]>
M7]^<7EQ<O7_]<N]PC[_?W9R>%]_="FXVJIO+Q$"2XE,/,!)D$]K+X;\V;6YP
M6\PQ(P3P95BH,HN35=V&:L0C+HH1E:F79SNXH$MS5.GC'> O-+%!*<-4R=_;
M0T4\^E@DK,GJQ::G+-[-J@[=F[ZEKZ_,7CF9 SH:>QJ[;V$/[Q;NZ![P2MC1
MRI6P;\S%OTE<.I-<^8^C6CIJ*U###XZ?<@9%M#-AMN*)C\@#;:2W[ 7=^;6B
M^UXO(W%5@UXD.3Y?9)UE(FQ92[/!+)=3V8#>Z%1("9; +$C;'%^\CU0AS$[+
MS'.=DGDE)>*<@TB(I9](9D)\2Z0.+*6+XJB-/5,)#03SZ^0>?W-K'%!!N<R#
MRC=30@[CF;6?XMTU;!+QTCCK2[4AHUWR5C";,G7D9(!*U\6%@8*OEPVO5<2Y
MP_F2J#8;UR!'E/<',?-2)PSG4H7U+A.UHNC.3SDE_H#<PP2:$V.>IYA@^?;-
M_/D)OK%S_#\U/EGB"EU?8&BC2G]$]PM<W6G]E.TANT2<,W=Z2%D;I9M#'5+9
M UAIKRC8=,B6'6$*5''CEQXZ]?,IDBVNB7!-" ;/-1CTG$^T/Z'50R53;)1>
M[3.=++$[<#Y0?<V&WE3%H[J,*P-XC*)QGE6P'!E&2'EO*,N$W]JG!593),?L
M<2NM59E-I=Y#^Z)ZW8+=XEZ54+DS8;E)Z/)DG-168[;B)H,9Y8N+.,<6/9Z?
M"WJD/%/7GEE1F"MH, QX=(4!67;H2N.(-;Q13$  @,\+! ;>1C6&54V%=;&F
MX>_>^Q6$_E79^PO#!==Q*K;?OSW)35G$7#D?:6R%!D?(/PFQ+W+CSU1[["6;
MVY.B\EE9BXI;J1I!!C(S5Z^'=[$G>T4-ZS-3NV+1YFH=7WP05Y$8ZYFKFAI5
M+&^87[E(E3DUR  ^3.5@4"S'OLB]G0Q4HQG'MA)=O.B93^+EG'0WQ%T\*2I"
M=^Z-_;,RMM9NR+AWB?9/FH?E.\KB=HI]H>(J2\4EGR2-IWDXYE(;"\^K??>:
M[5Y'_46EP*\L)5H-J$R-M[NR;E^7V\U;3P[,0;/!-31!];?^P=76?T:VU=<0
M6R\\VKKCW\F"MOQSN#]?#SSJB9]LVGU,"Q0@?"T-0.T7NE:,/G^OFN':+T17
M5D/7BCH+1?;$8)%@^=-4#K7?$^\18ZVRW\>DO:.5RE\QBIY0=5V<BM?B\@N%
MR0<J'3Z\7QS0KY'MSY/I5\S_ U!+ P04    " !"K_=:+;76#<4!   $!@
M"@   &5X.3DM,2YH=&WM5$UOHS 4O%?J?WAK:7NJ"_10*<%!@D#;2+1%"5JI
MIY4A#G%+,&N\FZB_OG8(*?W8E7;WT![* >./>?.8&9E<IE>Q=WA +B,_U".8
MAZ23-(X\8K6CWK5VVR2X"6]AEM[&T0@M1*6&X-BU@I2O6 /7; U3L:+5<;MP
M##,F^0)IH(8F'6Y%9<&K(=C(.ZJRIG:)E;PXHMA&85KR0A^3O%@J%WHH$GC1
M9LDSKF P.'&(%7BO2_PE2\XJQ61'@Y6H-70_S8128M623ZXN8#8=CQ#;# ;8
M^6[;SLE=72#PXW2$T!NM_!//[YKNZ]!M?L$8SCDKYT-(:,%<K?N/GZS*F;8'
M,-[Y2L+)M^=5]GQGM58X$W+.Y'XM*&E^#XYVMQ$EGVNZU _B",91'"=^&$ZN
M+T;(1MOY+/''W7S'L*N6B[*D=:,[Z;Y<6/.Y6IKDV%]=,"G"#7]@;90,S;2K
M\8M)Q7-:=N)IM5SHJUFRQ181=HA>Z2<)T]!D>6I>Y@_TJ)5X0Y1,,GJ/,[80
M4G=3;Y7L^W2V;>^U$V;YR:YGU7O.6,::UHUWRNGI!\[IJ0LWM>*B:H80TT9]
MQO;/L?V?8%GF%F^O=7/[/P)02P,$%     @ 0J_W6M#3#Z2L P  #!,   H
M  !E>#DY+3,N:'1MY5AM;^)&$/Z.Q'^8(EW42C@F(5<UX+,$F/2H:(+ JG0?
M%WN!O:YW?;OK2^BO[ZQ?"@G<I:E,E5Z1P%[OO#SS[.S.8.]]^.O4;S:\]^-!
M@%>P'R^<A-.Q[[G%%6?=<MH;W@4?8!%^F([?M592F!Y<=%(#(4NHAEMZ#W.9
M$-$N'K1A015;M5 156>5GJ$/QB&<K44/%%MO3!\2HM8,AYV6?R:6.NU[[NR)
MUM_U5AESC$S18/J7=6<IC9%)^>P 1,OW;NYNPWUWSHHDC&][SSG,937[@Q;X
MT-+0'S]LV)*99N/Z^KSKN4-DTYKW_]7 (BH,535'5BW0-Q322 J-=IL-(V%)
MX98D- :B@4# %(V,5-]4N"=8P2/0/V;:L-6V3NRC;<1)1'FS,=L0E>!M9EA$
M.*I,1'0.3,.*<2;6N')SNF;:*&*8%+ PQ- $N00<W$B5P,*Y@N_-AL(9CS]E
MLG]<_$SEDS_ /3,;L.(+&F6*&8:XB8B;C?%#M"%B36$DDX1I;=4S$5/U5'H0
MH?,57%QWN^T\M]!^C&FV#^*Q>.7\'(.#2 J!F6C-HX*B%A!&#?9^N6TVHB*%
MVY!F2F<$(\5<GF><PE7W)^OX$$X;\G2W=(D\XUEN^TO,8;CXW197SHL [$S.
M!.@L37DNJ7$?65AH/=]#J\QDBD)"DR724D)92J)B.XC+'::KF4@F2R80#MZD
MUN%*<B[O+<QB6N@L20ITI4I"U9HJY F!:0G1WG:VTV5.Y,*8(N5T#DX +0YJ
M*&6?"WX7=!GC^2GW$*<K4U])_**#^G;H@HD(:>';]NEIJ0]U1?!CQ.%@.!W#
M:#R=+F:#T>3VYW>M3BL?SP9!4(U?'-4]B\W&BG;>]'$;*#PKG A3G*0: 55W
MK;P9\\+YRQU\IBH_%2NVL-JTRM;."X-_#/CMFQ-2'@:'"$MNJMHXQ*/_=[A
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M'^WO=JFW9WI'9Y4,52)X+E)3L;3'K6O)+0C,:7?M2ZSBK99]^?4G4$L#!!0
M   ( $*O]UH6I^[VLP,   43   *    97@Y.2TU+FAT;>58;6_B1A#^CL1_
MF")=U$HX)F]5 SY+@,D=/8X@L*ZZCXN]AFWM7=_NN@G]]3?KEX.$7-+T3)5>
MD<!>[^S,,\_,[@QVWOKO)VZSX;P=]3V\@ODX_MB?C%S'+JXX:Y?3SN#:^P@+
M_^-D]+H5":Z[<-))-?@LH0JF] ;F(B&\73QHPX)*%K5P(2Z=5>LTO=46B=F*
M=T&RU5KW("%RQ7#8:;E'?*G2GF//[JWZN]8J9986*2I,OVBWED)KD93/]D"T
M7.?J>NKOFK,BDK!XTWW*8"ZKV%^TP(>:!N[H=LV63#<;EY?'%XX]0#:->O=?
M=2R@7%-9LV=5@+XCEX:"*]3;;&@!2PI3DM 0B ("'I,TT$)^5^X>(((/0/\]
M4YI%FSJQ#S=!3 (:-QNS-9$)WF::!23&)6,>' -3$+&8\15&;DY73&E)-!,<
M%IIHFB"7@(,K(1-86.?PHUY3.(K#3YGH/2Q^)//)G^"&Z348\04-,LDT0]R$
MA\W&Z#98$[ZB,!1)PI0RRS,>4GE?NA^@\0A.+L_.VGENH?X0TVP7Q%WQRO@Q
M.@>!X!PST:C'!9(:0.@UF/OEIMD(BA1N0YI)E1'T%'-YGL44SL]^,8;WX;0A
M3W=#%\\SGN6ZO\8<NHO?37&-X\(!,Y,S 2I+TSB75+B/#"S4GN^A*-.9I)#0
M9(FTE%"6@LC0#,)RAZEJ)A#)DG&$@S>I,1B).!8W!F8QS566) 6Z<DE"Y8I*
MY F!*0'!SG8VTV5.Y,*8(N5T#HX#+0YJ*&6?<G[K=.GC\2'W4$PC75])_*J!
M^G;H@O$ :8DW[</34A_JBN"[B/W^8#*"X6@R6<SZP_'TS>M6IY6/9WW/J\;/
M]NJ&A7IM1#NO>K@-))X55H I3E*%@*J[5MZ,.?[\^0;^I#(_%2NVL-JTRM;.
M\;U_#/CBU0$I][U]A"4W56T<X-'_!YP@7B5B%A8ZG^7!>;TN.&/75G8!V\/3
M9X&'AH+?B,1394J8A'>2J34GW+''[J.>/C\6G0,' W_F+R4#Z_34M';=$DD=
M$:D3&^90@>.11'IAD/\_B>-A)U 7_7/WURS>P.D9%LFY"Z>=TXO_1DCMO"2Z
MWUS-#UZ[$>$/E@57C,9A%V9D17NHX%-&L3O!A3VX3DV#I[HP(4J#957<>^,/
M%:JG_JO];)X]7J/0SVT3L=LTW&\J[E:\_6[@7M>P7XJVF^V!+?1@\[3-LAW5
M6SJKN%<Q=VRDIF)IAUO;D%L0^*+2XM&_N;9YC56\US*OOSX#4$L#!!0    (
M $*O]UJ6%G4CFZX( /#N8  +    9F]R;7,M-"YH=&WLO6MWXDBR-OJ=7Z'7
M>\_>56O9+BZ^=[??@P%7,6T;#^"^S%EGU1)28C0E)%H7V_2O/Q&9*2&!N$L@
MB9S5TXU!EXR,)R(C(B,B?_Z_'T-=>B.6K9G&+_];.BW^KT0,Q50UX_67_ZUV
M:LWF__[?V\+/ P<N@TL-^Y>C@>.,;KY\>7]_/WVOG)K6ZY?2]?7UEP^\YHA=
M=/,1>5VY6"Q]^>/QH:,,R% ^T0S;D0V%^#?IFO%C_O/Q5__2GJ5KH4OQ&^\E
ME2\SCX9?U<D-P8LOOK ?0Y<ZD9>>LTL=[U+--L_*I<M%XV!7^#=\S+NVA&,&
M"LD?=^V'R>5.]/632[\XEFS8?=,:R@ZP$)]T?E(LGY0O @\YL8D2>A#\??IJ
MOBU]SM5)I>0]9X8Y84KQYYYL^S.NDJGI]MX)/\ =Y3/O0M<^>97ED7]Q7[9[
M]+'\A^F++5,G=N35])?0Y:ICG3CC$;&C!PX_?\&?\9[R2;$2H%8Q7<.QQM$D
M\!]#K[(M9W90\&7HHMJ?M9I_E3)6=%DA^JEB#O&J\V(%WH_"1F3UMB#A_WYV
M-$<GMS]_8?\M_#PDCBSA T[(7Z[V]LM1S30<8C@G7:#C2%+87[\<.>3#^4(E
M\@O<]84]\N?_<W(BW6M$5V^D#G%^DI[D(;F1/M2/GZ1FG7[X7BS7O[]T_E&N
M?ZU6G^$_.'SIY&3%FRO5[TCC]R!MWSW:5G_,68/=5"J6-KC[_/H[ 93!X.&?
MZI 8*OS?N=?EU^]]6;?)&D^Z"CRI80 3QC5XE"7K34,E'[^2\?<BZ+12I5BZ
MN%C]L9?7W_^H__$=I<V&!Y^=PK>KWWUQ!PRJ?R]]Y\J%C0Z^6N,1Y>^=@6P1
M^WOY.U6E[!DV_6Z-QR!4ZL_\4969 6WU[.OOSZY%OI\%'S*";]9X1.E[$\3A
ME5C?B]ZGM>[^>O<,=X:H@J_6>$3C>X>\(OB^GWN?V-T]4QU+MC/6R2]'?9#9
M&ZE4'#E25QO"'#V1=ZEM#F7CF'UQ#&^PM#ZJ!E5[\VY3-7NDR^,;R3 -@K]I
M'S<HYL0"W4'_T%25&*A(\"^XZLD=PG,4IB0^G#;I_W)T;YE#E+"38@G^<4SV
MF6E"387?9<4IXO\J1Y(!),)[B783$JJC6RI5/W\)O26N]YX%WQLI@D>W$QF<
M/XA["YX(*QM_&E]<;EHC8L&*9[P^$%B\'C2YI^GPBB?34%S+@A<=A89=M5M]
MU(@GI;(_5&!U64.0%D&PCR37T-BU( "@]^T;0]-!'ULN,,D;GC>8Y>-[MDB?
MP$#4CF,J/WZ3=9<L&M%WQ;4=4+D=[>.96 J,']8',.\<K:>3QH<RD(U7(L/G
M\',?R;!'K!ERKLO[(J>2"#F5?7.'W_<=Y9G8U55&#4O@OIFPT:CW!IWHN;Y;
M;=07Z9KK%4=]F<6Y+NU=N6PTZH1U2%U[TV#55NTF>.%#TG%DA^!"VQR.X.ZC
MJ#7TC*VA\Y>ETM55W(.F8QV8.E@;=@,<$6<,X]5=#!L\FQ;>4'4<2^NY#FKG
MKHGK*8P</#3P$U_1%@-C,'IM+4]Q9Q6VE$NQ*4ET7VZ:MNV25K]F#H>F0=\;
M'@7\=>^"^:'^+EO@-SMVU? _M@PV(?>:(1L*4/M$G%:_\3$BADWL2 Y6? Y.
M0W,EXLNQ25*ZB ^,8![EL4ECNBBO*HH[='60?;7E#(@%(QI99 "/TMX(TPSS
M9N0\GS/2)HZL&41MR)8!C[+GD1_[ D[)I-.@UET+]1NL%J9*5Q=FC&+H%*?(
M-TP[!'P'S=&2D?9*[/;@+DE<+M.5V.V"7=)7554-AR#KS[*F-HV:/-(<69]'
M:^S6Q$YIW5A+5<ZR3/>*NJ@2FRK>(9&S5,2F4=F"8B@61EI0,BQK##14AQA-
M;_7;1"5DB.9B0$<DH4#/8C:7$J5HN;X\B]D&2I2<S57&6<R&3:)DKJ@ASF*W
M5JKJ?US;08?1[IISUB(:KL>M.A5G'Z:>[OBU<3_)UAS0&-:;IA"F6MI$,5\-
M^I0(?SH>>3R/W:!)V2PLE^'SV&V>E$W!YG)_'KNID+*I65%7G,=N3:PR#X%P
M5.-#(;:-^C$\WB14PD4Q'\0NE_R+O2B_^"G=7, O8O>!]C,#*\KQ16SZC-HQ
M\R;[Q0#S1M?^)NJ]:1'MU?!VRUH&C;["-2/9&#^8LF'3N$Q7_DA$DF/;F]@W
MN2O(<FQA]GW3NEX4XR*V7>]]T[VB#%_&KK3GT?Q@VC:GMD;S$91Q%Q/UV$.J
MADK_TJEU,E%[20KT9>SV6"IH7R[=E[$;8*D@?#U1OXS=8TW%)*PJ]['OH\)X
M)^0F(:Y7L:NJ;8:\7,JN8O>$MQGO>L)Q%;LEN]78-[;(KY*)SB>3+K"95&0I
M(6(C"J_CM<EVO \\D]*R%O&54FSA@W01O[%(5^)+6TK7C*RV<%=*&=AOW!;S
ML:<>[Y+$I89!I1Q[2'"7]*UE2%3*&4CQ2$)+Q9?(M@^Z5]1%\>6L[9#(62KB
M#6-N0$)D^G\2FK42KS6Q)U*7:]CX$LOV2>=ZFC:^9+.]TKRQQHTO 6V?]*^H
M>>/+.ML#L;/4Q)L0LX@:SW1O?!!+T>QDU&S,:5E)TK.YO,6<Q90DD2L*54YR
MF+8$;TYRF+8Q'W*2PY2$U.<DAVEK71%?#M-N-HJW50H9RP?82OHSE@,0EP,1
M7Z;:ONE>488O8E?S.]P!WE*@+[*< K"-=%]D>=L_-E&/O<P^%9.PJMS'OK^P
M?'-[2W&]W$,NP392=KF'_(&XA"/^M+"MQKZQJ1Y_EE>"F0&;244R&X4IHO Z
M]JW"9WGL^5H*$&B19\L<$<L9/^NRX8!"1K)'PYEV4:L&\\[B+X@%\:G)]@ &
MBHGNZMWX!1S!)EB+;S#76.X&-[UML0-T5HDWLQL&JA"BVOA^+V35ZE,VMT9X
M<2"'P/N=F;H8_\)>GS73=C:L<CT[3PPRK;Y?:A &+Y##OH#EG<PO,ES.B/@#
M+YY(HN*'*=YP3N-+AZ,  9UNN;+>ZL]IF+/A[%W''KE#L4-]\";K"("JXU68
MKMY'Z5[6+'IUTQBYCOU WHA>9MIN]II'(MNN1;L$V6W<U\5 <+1JO(@O,RIA
M:BNQ4!M_5-:VB6/[@ZEKMJ*;.)X]LS7^XL#8"8V'H[$[HAO@=SHA,S&VQI_S
ME!"UL? V_JRG]4"\.[;N65IWQ]'8I;7.EW[FPW7E#X)F(?7QX \8#P%H8^N&
M]9NW7L3?C.>! %_(G!:SGH%8=\F?1+:Z[^8ZH[V,KU4EM:Y6'6JU#Z;A1N.-
M/>5^X9!?#!6$ #MZ$)45^++^'FN-.?X6E71/[FYZ3ZZ*7LTKE:F[\>02/NW5
M=]E2N0_4 OET9$-E?C.(GJTI\U7W="O%QG"DFV-" EY5M.1>Q]=49DF2(NL=
M'G3S%N<KS*]W68.X8 2$#6 'G+67L-9W:IL&FYK?B?8Z /A6WP#AK\3[_=G2
ME'5[3*P^-].)#,\[FY]8D;_Y!,2_O[5;RJ=-\=4IOXQ]?R,Z V&6\MYBD< %
M/4QY*6;2KW95/+%[=5<J%L\34'>>(79/5$)[\7-[C-?QW!&#]+7-HJ$E@&)2
M=N,&PUT6Z(+AQHX>?WR8EV,H8-%0R:%V;B#U9[/I+<4?+9@SWB<3:\!<A>>^
MTJEN$QNL1V4 9GL='0US\[ Y4!*[4;D&)90;&PX\?E\CEH$OQ7HIYASJ1K]/
M<"."3(8O.R0"]4V'#"--^-5''N]^A:=18,C,^X8/WG=\GD.+GJ%R)6-'2T -
M[M.F17JA?P)R'&^$?9<DS>-2_*F2,U1%P'_)H.)O434SJ)EMEB6LC[\%S<I#
MFC=+\:=;)'XT0JET'7]JKN%HJJ:[J-4F97:-#]P1!P,$!H9"Y#I,M_6]M!NP
M#ZEMMD#'S<]W6'""Q?E9N7AY<74Y37GXU("XS,*Y^^)+P/2='ZGW_:4S,]#X
M,X_J9&3:H)DXSA>?]10ZEFHRK!A+Q_QTL!C/HBHED'2^ZODJ?,;B/+RIE$#>
MZ1Z/U@)R]G86E<>=L.Y8Y50G,*'V=A;5YB=HE1+( ]QNKE<Y:0A&O;>SJ#8_
MU0E&O;>SJ*+GNK;2J./ODK7=7*\XZI3ANK[:J%.&ZQ5'G;(SUAHKC3IM)QZN
M..K8#;X5\H$QRS@Z@WZQ'7@6_R9A&UQHPR7,5<"C3A7G=\T9U*C]02P_N1;-
M5_A'G9?S?^[["U,664W7#$V1]:ZER7K''8WT<30KSLJQPSYFXF9/C@V,/K[.
M'1// 89BF[JF4O?MJZP9+0NALZ+;%CW.^ H%9Z*!*P2X5YG)^'VPK7W[588=
M?S9_K"&).8-.Y@RSU#0G+)U=QUL8NZ@+PLO(-(+-.&8ZTS7A2Q@QTKDTCWR&
M=VN1?5Z,MT8V!60OJVDJG<?<BC$%-&]:6P1SL;L.)SN:BY5J!X'PC+4\VT"V
MX]^)W"6)*\AQQMI+3LGL&K6,I?.LM9J,2S]EK>WD1KHH:STF(VW$\_B;2.Z]
MH\P&2K<<?Z @7;.P7"_'[^*F; HV5V?Q;]"E;&I6U'@Q]WC<:8N:#91"S ?6
M[I'<%:0_8Z=KQ66A53+<66LC&3Z+7<WOJ??,!@(=?RU**FA?+MUG63YJ*RY1
MCZ]C:JHF856YCWW_9;VV.AN(:_RM-+89\G(IB[]UZS;C74\XXF_]L=78-S;5
MXTMDWL&6QV92$7]Q5:JZ+I7.XSO]-*T4QM<Y:VG\GGY-(_)@:O( _8+SEF!Q
MJMJVJ6@H>Y.#EEX,F+IW2W,<XH?[EY^V-)LVL-8LQ==]*Z.SM'S)B:_G4$:G
M:/.5(KZ,IHQ.W8J&8_QU#8NF:GY%V59BLM,]M4UHV!C'%\6=[C%M0MMJ0+LH
M[DZ71>;&3G98=J:$+G:8R!$SS2LR=8=9&]L0N"CW*\;F;ZNM%*U^9#YQTYAL
M]CV[EC*0;5)]M0B96_:\A<J\B"\-(35$;RZF\>WCIV8R5I3?^';R5Y3?^OZ5
M<GR;P;NF>46F[O <PFT(7*B4=WC&X,8BV3*B-V*WT<LQ;UBEA.[-A36^_:PT
MS<>*@GRV:R$PIOIF)Q#VN8CO'+C=$+5<9N/;>]D-16MM'5R<[5HC;4O=YKIF
MQV';;2E=48O$M\^6 %D+C8#X=]P6#?Z)O--?D@AV7\1WHEV2I"S7=>?)U!S%
M3,=Z&BZA+;>X:=I8K\5?-9@$?:MJLYW6%ZQ$S$(=%M^Y?WM-+MU2_5WDXV#3
M;31G_&<"IFP*-E=0\1^8E[*I65&WQ9<9L=12FZI/![?7[=F:JLG6. GYCZ\?
MT XI6R[3\34,VB%9ZQE'\9TUF!2)"Y??^&KD=Y, OJV<92S??2OAR]A)TG%)
MY%7&3I+>>EF,KWW54A44F;F=A*!>Q7O"?=(T+9?&^+IU[82@-45N=Q'>.(A;
M5:[V<%+SEF)SO8<\]FVD(OZ^:MN,=SW0QY\9N-78-_8NK[-T4G-L9%\6D^E?
MD':RXV\A4R?P:H4=,;"I'W(9?_G]ED=-KS+H!#I#QW<^]IPAQR[L6YZ/O=(\
M)U&\%]>AWG.&'/N>0O!<;S^+WNK(.FGUF;;9<*CQ1Q=#0YT<I])WYYTNO0H(
MXC^,?I73N9=/7_QG+"$RI\Z7;<,P+4T!=8\_@!X(?Q&X<IV6JY?Q-8C=_&3Q
M%7A_58S7&]SZ!/0YHXQ][W>'/5ZOXFN!X6\R[.0 CXT;:%^%EI6X#N[8']$K
M]82^"NVWQG>(W?;G@%S%',:B0D[4.2<JF;:SZ&CCN6.,5V'&=ECPG/%>)]!M
M,!.'<):NXS]A8TY4:MV3*.>[\&L0EX3F2L'!N[',S13D,WKP[N83$+^AO./C
M9S<EO5S<J(82OQMH*EA^\"=.!%U&";A7-OU=UXP?-[8R($,9GBM]T+\'%KY"
M&2O*"8ZX6*F43C]LD'CVLS,>P?S9&HR<''WQ7Q-Z,GN5;;H6?Q-<A&1H-WQ.
M*'4++#AVCW\73#JL&MZ7_M=HTCI:7R.61(F <0T<9W3SY<O[^_NI39335_/M
M2ZWYZ]%M$2:P5"F6+BY^_C)]L_^R+U%OX^\:4;&?&0+ WG+JLD-N)Y1XSYG\
M-GT76.*!>Y#BR;O5X!W>U\&W>]_QJ5QQ>@/@4XGV_<ZU-0.6:+2] 3 <='N9
M]LE<DE<4K\GW_!<51O(QTC5%X^.45&V(\4#3^.4(B+EIT'%65=5"H\/F'[H
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M?P(M@SW9^DH,8LEZU5"KZE S--NQ9$=[(\@MP\Y!AF[34,PAZ3C ;'S(@ZD
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M3OPEQ>ULYP$MWRU',Q$-/>/1T#VWCTRNJ>A%UHH]=KU8E8]N[WP:<K@?MGL
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MRT5,].9>0T6>!===Z;[U\-#Z'3<:<$<!=2,_MC#7_;M+YUGS\'8<#+HZQ_W
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ML#MMMH]][+\ XZ3P+#"#P%:R6=C2]X(*=/IYD#&8I# 3\2,&KE>^ ,!\O,I
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MBE$J!Y:%?[H&D4I7_B*"";O*9\D<,1_;]8O6_$0[%E]F--$>%3:=.[B,)[K
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M<\[1IT/4GD+YL0/PPPD/XKR31X[F,"]&0=+H5MBS=/XQJR96@:DH'?LBJ5U
ML5(:<.R'=[Y,P5G_S,)XB\NRI!Q9L 2#9(5OY>"N.R3Q8V*HQ83G1_?#QN #
M00=+C*#%I<N8 S &K!**N.1<)#\8*$OT,\VQ;WV:;$4I CC."0<RYG&BM!B-
M91R'%T[WDS%[45&^CIDEQ UEMB7>0ZMU=#GU[Z&]R>]6[#L_QD;;^2<QNAI@
M()MEGA_AE8S+DE1-6RMBKJ4;FI*!66<D.W+P!V HR4937QJV8M0[QD&\+%;I
MPXH2T,MT-40AA85+*CD-D.=?ZYT<>?XM/%E>#<DQ[VI8NZ>:'#SNFC:WWV5\
MWRB<72@<</RF\USS:^;%XLFO#G[,99GG!Q A,_]9@*]X(@:OIB9LNM.PZ1^Y
M#9%;6C@7QO,3K%W%<;(QV(A9.A&#(;4ICZK 8<JHF[I3>H8>FRQ=,=4:K%:B
MNOC+A\FH*NJ0992H28JU-WI&';S<=:Z\1[D5W?2US1%V?7$#IN/%!1H6\%$-
M;$DM4T)$GNB=\FE"">LXYWC)-W$6V_)O=^QW):R)1Z*:*Z8B:TY1#.@#$UH;
MNA-G =<O@'#4LUA?@M@613/ZJO,4$?VB>Z4ZE8<E&]$8X/P6M.8RNF-_">V%
M!5MB4:AI<W)*.Z:35[[;THS^O U5S%61PN(TOZMTH;H!#VUM1"T9"_W\:0O$
MJFVYB8!3W[$ZJ11^$Q'S1-U]"'=*WG$KTDOKJ=%!U1HINEX&HX<OO<PWJF47
MEL8E/.U*M<&:2BFA.<IWL GX&S(&C:VPI4J!4L[$BN@%ZFVY2X5,%OND7;]B
M>G(XQR(B#,5@L+'66QW-7V4">O&_SO%+9_:^G4MG4%Q'VR$\07.]1+A-)*%C
M"2N>?2R_:>=W?I0EP=SV.+JK<7Z+4OB8XJBB*V^EIO$,&45W7,0D+:%ZR<&,
M<58/'F3*.T1DN4S5,F;)*C !YC[R.Q[8.(+SAJ:S]WH.^)4\S+@]=,#I[-AG
MCOUWAM=)_T"GU9WXCO4/\+R9_3&;SC*P4S[!#_,$_._A>;\+#[I(Y93:G^U_
M^)GJK^/8U YFL16,HS4?4KTRR^UA=HTD(PI/%06!=P%H, OR2$4U':X&VF]L
MK46JV>?&[;,(DBD[<$&3B+MIJ52T<%A'J(.E7U2.L$.W,"'EL?IIPH.QHP[.
M*+;D<<ET!2J!ERM0+=I/+QGC]2/U-J!P'6K4*%XYR%<4Y4PC^+!J*8H?=RR5
M&:1CV"FA6T\4%V%F*LK(AT<6*4A;LH];#_+M- 3&%"XVE_=GI9JO")Q0/V6F
M <FNX_S_XD(D9IC]$N0=I]P(\TXPX"]V1BH,D8;XIX\>\Q>0SLIX\.DLB.8<
M*,%0@?RF^H)V05@Y?\"K97_B+SG6$79LG23QSN+!5)&7OS2,;,R?( ><QH5C
M?BQ3EZGJ?I+'=V#9),6#6?*=$IH3)P]XX/A!<6&+)Z&?9C*,("\>Q8O'OI>!
MBHIE6Q%Y!ZSQ1;\K%O6 ?DQ5AQA3D%E,\'MU_:G'*44S8F[E[%7$IGAM%G-_
M.LKBA S'J5H</!S[9H0)-WT!7H+X?W&+LF/!GF8XI!K[]H/Y_CMNVX5WYR=1
M/+=_BZ-LYM@?/UXZ=+LELF<+3U.*240-F]PH#+EJ<I-.5)!'AO-DQVVRTFB2
M+9QG6 ^R<')^!:AD+*1@(KZ)%6.U'Z"1,.?@!%V\[Q,]HR;P3.""RC]F'HH3
M)@T"^&61PY]S2U?A-@W#%7BOJ@$*>E-(2[]*1*V 02L^8<%X&2<6UOEA0<C!
M.M 5FCWFY(:5!_?^I2_&!L^"+#$2M',K *,P$Q[, !X).KG3>7&%:P[_W><&
MU\?-2FVR[BE,'?AH]>L'[LSGR3J]R=3U%_@0,?D0,K=4Z,_B A]\SVRA"Y3>
MPZ,2]1Y'^6U"*1](BZWC13XJW16*SR+EW ?VC49P_,-'T:&XSGQP3OK=GF/_
M'3CI3B+'_OQON]<['0Y421G9+S_;!\/>R:%]/A@<#7J@5V1Y&9DSU#P&/)$@
M^C\!43 ! C#W@!ZA4JH.>H>6J&#%'(6OR,A_RAP%QS[H'U)==Z7NG!YP,#C$
M%&B/2FS5^TI0(3!Y& 1E(@I$-T !6#4__(K?5!;+_REE1DAHY]G3I7>H5DF6
MS(H0O*\4TQZ 'PP^'YY5-"?A4-T&R1YK-I+0L>6-KG0+U;U(?B%;E+^HTDCP
M.ME,9-@1,1:@<-[.]BRK,X\')O-X<YG'0Y-YW)(#3VSYAL\[\3#?^]L/R=W=
M_^UV^S\H(^/KMR_77]]?WOQQ;5W_\>G3Q;=_[ZKJ9_,+;;=5@FWU_,2B7H)P
M-$_\VTF >;PX<2<0 WZT=GVV3!=>;7>@[:)2ELD00+=;.-6EAU%H$![E3V=1
MG(+G9(GT#[K-'W',\A'G)KQ%YEHOC"HJ_#21LZHE7]1'.$MF2M'6#&]K8JZ\
MJK6[FZ6U/0GS5';AR\GV9T535&7^P0-YC*1B;JX?+FF1:-6W2"Q:S^;-#*E-
MXK\HT1=S//&"_ ,8!/8G?.15\4B]^R%\8XT&B/2.EF*\1;Y:56,.<HUY,^'6
MI6K<U0YW;1\J.B__??GQXO+]1^OK[Q??/L&__KBYNKSX>.W85Y\OVQJ\H/MN
M:]E]-^:@_Q[%_O^+PI:N[RUHXX3%UC6XM1/[TD_G2V[Q6[H^D6.P) .A^7KA
MZ^1GZ^"\>W9H#WNG1Z>#0;?Y-+?:R%-!)>OKA($%X/*,G,,$KV_=#F5@VF[@
MA^0Q4GM'>^1'L]*'50=Y^SZ*OY/E$]D>I]Z/8*R$T1VCY!6781MX&R=-NMA@
MWAXQ&@H9DK=KNT )=RP^\['!$#Q8&HM^&B5 !KPUB&[G= TCPF,SL%8XC_.W
MRVC&V)?MGN3[BH>K9Z@4)(SOB#0@L#*Q\0;XD*D/UHTUX2Q()RY5%\Y%C7W
M5(JL,($Q(BY>H)[JA_"D8G5DP6)D%?L7 HUHTL%"4OR2Z(H?I"K^#1HG)CN.
M*1)4-WX+OXT&<I+%=_X="]IZL+1:2M#"*H#Y$R8E'R$P4]$\[S9FU V%P_YD
M B<S@$3DP'Y^_?B/'NSOQ!_AE1*E<5 XR$ZSJ;JFG7#  8*(I&E*Z\ D,'6I
MFP "4XX02R@G//,!X<SV,$$N\0'P7HU0JC$.A9BAR,PX1OE0/$ N>6![<48M
MV3T?$_(2#"8#3,6<A] 5P"Z1B&"E,"(EB;=T/UL-1G7)B<E_-, C%AI)]'><
M@K(!EQ8^3_=W2G<KA4PNJ+[?F%*$]WP*+1'%@JGX(A%=*U*Z@X=_"J^?^O:R
M.,7F<!-_9K$X1@\7'YSD-X/B^AWE B!\G8U0[:4^Y1M13@.\D8]QT F]@W)!
M:4TCCA,H. :]16]('J-GBG#$WA@L!@^9,@Z*U3CHUWM89A#>6OER4[KS=]0'
M50X6<U5=$#8>#G ]F:AWAC>A+1@S/Q%3"F9^R@+9VL.-,S_/XP)A% V11/)$
MB"U-+A+BB4S6D-Y8,5)%6ZML"H7O$YJ"$CL<3+^BPBG9<$DL?QRY6:**-/4=
MA/>0AH&_!=N*M;=:"C=)YX>KFYOWWZZM=U?_A/]<?;AZ_\Y^^_[;[Q?OFD\[
M^#963_DV-WPZ8K?,OGYG#W_J-Y]X<-8\]-5BWW['IAC=BUO@PPS[X()5/+!K
M#OR_C5KGB_U_)UU[<'32/SVQ3WO#8?.);O7)GBL:S;![R^,)\]"2S.L(9MDH
M\-U@?A1@DS ,PM_Q)*5S ;,%Q*$B?"(X.MYF<<*P6""+?9J_=?"/CS_;YX,>
M.-D':LBE+\IFO[)8^A[]WIM#"T\[G-&1P 'N>S+/3LS-=+GX4V$WS.3XS82Z
M6((;)D+FJ8Q(BWYA<(11Z0/:P%FIZ6VL_+?>^6E75!]^<=-HQ&/KV(%?GL/_
M+9-IWPKS)QK+MBS(#F&XTH-@R6 8V&_5(%#!B)R+&D<$CW-N5#E6XL<]$_R@
M"TOL<(93$")M$MLGO-*HO%1[%Q#W]PR^1D.2NJ?F['X).1,XL@JXDY66PWQ>
M0.W:"SOVVXG7L0]P<R5"-/L.@2'!SPGZ"F#Y8Z.0'R5I-%L0"7G[!*@5DH9!
MA;LHN"N:6L!BLC$#&S6FVRFP/#UEA:HO_S\YN@#,:J8&6N&+CL;H%>"GL11>
M6(U W3VG=%N9]S&;!7/U!3MA8YY2\90B$/Z)AK5,&U19NRW=]+98FS57/<>E
MJQY]_ML!7OQAYH-]TC]LQ]5/JS7'U=BJ3D2D"O)\3DWEB$HFZ.[".73'Y]C>
M&=M%.LJ+E(T[18X_'J;DR(.8X]4M?0B=U!B+<S!/N?A<A&F^6(TOZ^EK5)/]
M17[&OJ;/J"O=*%8?+/^>J@68.T%#0_] H>+&I=&<0)!88H<Z)XN'Y8N2;4<E
M$^1E^Z6<'YKS1*3U<THB0F?:E9XMY0)@OK(GPQ,I7?+K;GG1 40CJH,3W$NC
MP"D=D::,H=^?^/K$OVN9F5C:*<I1#C';&CO<@>:D,3/V7WJ8GDPIRA3W32;V
M 3PYR3 <(3X+.G6:83 AF%N4W2TSPDNSB"0+#L7FXA*UMU7Z[SD84; QHLCM
MOW0[W6X/>2167MIQN8!+\=UK_&YNL>0K",%42KGL]T4_S(_P/_8D"SW8KB3?
M@(/>>>?\_,?#!W:BV(&:]U-"_5A?LO4.8SPZV7EJ1 F(ATAL68APFH?HJXK&
MHVCF3UR1;Z@\2/7-4[N!_0KY+,T;:D3I!!],QEC=YMA(J4P@D1^CT)3<5.0E
MOXU2GXE^R[=1Y&'C<+Q1 .YZJ'3HL)5/K5"'^9L+*L2+N*"9^L;BE8,V8*2K
MIFERGS)&D*@YY="(2)$:YK4BU41[UQZ=WJN3-8]-LN;FDC5/3++FZ[5YKI?-
M_Z6<<$SB\S$]!"N;[L7Y@A_.R^&D4UZ<%_GW]=,.].(4[T[%?6@QC[B4U'?
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M9CP7O<$_L\1C_[7E[:':(0*(2!03%P-:OHOJ*I#*_!_1>Z.X,\BO&/1S6?N
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M]GST:)*=4$,Q#;<+L+7/:]_4799RA9:R=*ME6ZNB^"+AC2\45NAM=F3#;3P
M&'VKZJ7E:GU+4?_M]X859!<VTXN(\TW-?2PYP&A5J-0+$F@R2&2367GDRH >
MAJ,355BG B[YD4W5/O?V+4<?>3;! "%^FS(,2$FH+*P_0HSIVM=X$9=(8F2A
M?A[N$03I6$BB+';%ZQ6Y=/_+< P.P_S*6(SX&LLB?T0@C4OT95S1*OJQ2_?-
M'XL_"E_=TV,)9-(4D7Q\;!GX*H ."E%F!\D;A=5%[=:!*GH^-(;(DP\FD9_
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MY4*D_*?$_L8#)M.@Z[_0CMO2-J4[^[]J]W_6@X,-;<QJP5TPU4"[TPP7*54
M%[TQ4OA\[? [''Z^H@)9SY^=\(!R8):T;5"IK5Z>MY)/QEQL";$XUD&O 16I
MOAW[<V2/8T%I:?AY?6,)18@LK2[EAE"Z275N&-92)REG.)@@"![SJKPR&=^E
M^F<MX0N[!5UT2UI*=:3 XJ@XRJC/63;#9.7(QM:VE$R4\[V^DKVEB&RU.&%&
M8#&MOF;P.MC>;B9.(I$1S:@,'GY5:F@'*(M<EM:@!6L"9(< =JNW0Z1Q/I8L
M .C8%]5<+I0US/!B[G\S7S3)SH>!K@:QHX *GP/8S1A-CY++Y)CU!F1:?^DY
MW6X7_T<"A4G=!SC-(,OG_*(D%T/GQ;1XROFOFS)_*),704*UM^43A+%F"0FD
MV<N6(L(.@0DISCFC:F7\84[_L2<@0S'W$OM S")>M\U"P9J:]Q8)^);*1WI7
MNVFH#$D!A&*8QBB*OA_![XOV#7D;^X72:H4=:B@,.I>>D2>PL=DL$*-5]6:)
MJD#WM\N/JOA:]*U>;%U!50ICO,&XE5VLLQE5$XB,2]%@IZX&,V^$TTI!;;66
M>8OE,I8LEN'P^"E5F13946P4W7&GVAQU]7!;;7;XDH:S-5/#K0>FAA<'8?E(
M?]H<<;N8(UY]OE5ZOFC2AL4@@:8L5\X99T6+6JT]X:(&%UHBU555.37-DDEK
MBQX&=62A+;LC4:-*)ZVG;<UQ@5FSA<K4&HI'F'LP0<9A?[E:#6J]H^::E"XK
M/T95V5+S4N<^T<Z!\IMO<?S+F*%B07U;L*;J,0GJ8#&+S8J]B N:L1$OITQM
MH)AZ75B#O.$/]RDS%XF:4VMB[# +>R65SGI-)8SB>?'> 7F3/#)R9;YF%O(_
ML>$KBE,)E0^Z&*6T3_T,+JNQ_#G6DN=T[(_^=XY9W([( ]<>=<]B^* 8()67
MM*UMP^M/\K6DU^VN<]ES]D@"5M>LG9J:M<W5K)V;FK77J[]%5.XR;^.N:I,N
M5YF&-7$Y^_QL2X$Y<_ZN#"]$EK3B^;( G32-I3NJ=>POO(.E!BJ8FDF*D:@$
MK\&ID@W.M7N&!=Q:4V9T/N'<LHKR^WTJQ'C4P;#^ DOGA*XMNPL'5+=T;CSW
M<O=)MVN26MG(]Z=?-_"0S4\F+%W./?<.<3O:]K.XTU[W_UV%_\E",24#%2[%
MM<%]PM+=F":XI#$8C2B#7] @P9):CE)(87@05?!U@3#1:$T]2?JLCZ*#YL-C
M'XA,#!A%I<-Q)@NP*?83SQ=/5L->Z#( :S(G_LA/BWA#2'6XVK'R*")R_20O
M">0P8'U\)#: !?;(F[UZG2:"EB/R<85-_>919*C*6P>+4G'2N6PL0NKV*_FP
MXA7D7-.D&U%(JP9?!',YMIH42S'!]I%4%$$#$3@$CE+M+,97"0V)Z'::(TAX
MS=2LE3,:M@)+F<[2@&8.S:(D\3%L^!@J-O'"!Q[R*'KRX48CX@K6C7<6KNSS
M^_K-'4P=4&CK-$(_VH;N,T>6.;*V>&1=%R'?1\GB!?5H98$XN$HW1J09Q?0-
MJ:?EG[5W%:K[GUCTKR)^LC7=HRA9]M)OV/()6TNH?G<4R92OQ[=*&YHNG,>B
M?1:6&=L'X@KED:JI[C0Z-.K)J">CGIZAGMZKL"BU-GN,1(+!]$V?"W*MVK@(
MC75#&J+N[[I"D1-"BN#L(]5"W1WNXL5M,3G(OG!3<5\FB,#+E5'Y$DLT4)D]
MCA=H>DFCW>6<W/H#LK/!5 5#GX+W^5_ '2"JWE\>V@GGWT7> KY4/DAOT?(X
M+1E)S5S+=S+O)BR1J^8B.<>+V3TVLPOQ\@AL/C'6'6^/DF+@TF.("-A]HEVD
M*Z+T"_MRED1=*L!B$M&C'9[EK@TF ,6K'1R)3B[F;@88N[D7=WF/<_W"2-]8
MRN  !S-@L?C-X<+KY)5H&3S #6RZ1!<EX9.0(9@><\R6$-ZHMD/5[29O"P@!
MS@E8/^"YFE/8G,+F%'[&*?P1U+6/581P<CY*K&\>5*28VJ"G9I:TGC[FJUX=
M/M53(%V6SZ[$9+E K-$^T Y;ZG^/!PZ<2+XX&M0Q<8C9(Y]9XK'_@@?Q!%VW
MV'3[]2BGUMP8:$-1%0;Q&O0VHMN6A5L7D7X3C0(<3ZPL/*V]<,U?:YH0ZSW:
MX:5Y8)53GO(3S09,:&!!$NFVI&BVA7<_14\\NOZ)]1.]E.Z0V^/6C9:FH"9'
M:/=/Z%7KHWP>FI/34H"T&MT?HM@"%8NM%9.%K+0<.H[J#OY0%$=-19+S-C%=
M%?1GC%<"H'&IN2-&L6&Q_XEB;,9=LK2M)0<$]G[D<3#''&-T"]1]0Q3"[]1#
M\1=:LBK=9@0LH6ASPJF3=_[X8HR;;&@ITG[ E@<7$]N(:A//5B>HQ7PT+WWT
M:;)9G8:LCAAK2:+@8KYQ]9P4,]R7[J@1MIU40\DT1ZR&6KH5*ME";V'9[9DR
MJ.T"Z3VEI%J+QR^HBR(I$%[V8*JJD&MU_M'8!DJD</W8S::8Z^<B(2)#60PL
MUN_V](HYZFDO]%MQY)L9:+NO.^WG=:??^"U6[T1P**C[#JQ;U'.CMI8:U9;-
MV(4-CJ)2FBA?#&4524P4!)O+$%@1.!ISK(<2$Y\7@D@B#BCM[3C#L??X4RSV
M7-GGZ,$*-\\2]L@G,;V^/@!8BB(^E&BLWCWV@[RW\4HCN2A6U"+&I=+:RSPP
M1B5A^K@0$5USM$*?ZL!L6Q^8#5\52NL!FBSL6D_)_8X6NRU'S8T.>QFQ^<0"
M-D]\YE2/.2T04@D?PZ\U^7D+=B6SU6-TU+WE\81Y\">0 RD1,DBD[EVI#E\S
M;2TQJ$C>R8J "MFRE9=021[E_N06N;2Q4?EBQ6R<6\H/V]N SGTT>U=GT)^9
M#/K-9=#WNB:%OK%:=,N6X$";3""N'JT_.M<=^X.T*ZY".NANV)\V]KN0T$CJ
ML^IUJ[$W-*TN=E";GT]5JTR^_*)Z6<B(RF+S"M6J0M_"<H&]:N.0TBTH3>QA
M83''+>]A@06BU]),!"W4*VCQ9+EF?JU-V%(VJR^PE0*VW JVA&&FS?!5$W:2
M+67F-QM4ZUQLJ'L->>=6V6Y+UNBYT6T(I-JW5*L7VT&4),6<0MB&.SY'ZQY+
M@!-XFXC>D1VOZNHQ^@C/PINB%,P5G$L NXP]O&5EOIP_J)7BZ(BTBAA?T4O
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M1*QE;LO^""(> 0ZZ?8;I'S]6*F0<>(KV&-L#\L2+Z'OX$!T0HXC%L+6<4:&
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MCWJXWWG41A)W;U3F20@UUR*S"*\RZ1O2'8#3(HLIIE4\K;C!="QYNQ#%F*I
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MP<.$'(P.M[XW@^-'[LT6K,XU'=]O/.&488+U)AZ8I4$TPVNH%KL!9_W^:_6
M7K?_][I7OQG8[_@*IXX<F1<7WMH?::3+5I7UP=#I#DX>UM;;/C0.CGL-(&*=
M W3K1,".G'?7IL/<?QMBFD),(ZXROM!L+#]THRFW#_B?,\Q&/G3LD+?9J#MV
MSH<+(;/7<K0/%MR)U[+RUVW2 >@78R -O=2HHP'M-UL4M-@I^W/K4;V#LR88
M46<-H*$1AERON_YVF/L-0TP#B=E!8.Z'7Z^$K08:$I1ER,=^NF5.-.46M/7P
M:,H.-<+QT& LO8X6FUZOV_ TJW^]JV]+%E4=#9]Y*N> &S_#^!G&SS#$M(28
MEU*8;UGBN^+NWP^RE'LV9W$(VCZQ9SRVP:";1J&=3%C,?VX@VPPQK2!FUXE9
MR@P@#!-X'8 R]ES(\%HY*AJO4%?5'KZW(@=/X^)?UCFNNIW%F_J-G9IK4M!=
M_X*U44C:$CL>8<9L\K[Y7Z2=0>DR> ;V9]+U;6)'69JD@$G$[)&$J,@U?!9(
MU]Z@P<D0Q&X-VVHGBF?@=+M=_%]#Z#GH.R>HEX;K9(\<N-N6IM.3KG-^^L2J
M M79KCWMI#9$Y[!S7/5FF]P?[-]@G<F^8.^XRZ<C.-]D:[#C]K8&:R*=#6Y>
M]MPN^4\?B+5M0:F HZS)GM$C=!>4YCRMZ9?3*-)5TS@B>$GCN#9N0'LH;0U4
M\OY[;>1R>RAM#1ZT-H9$<ZF581LYWQY*6X,1L&J)5M45LHW,KG'R7]+H>O "
MKMFBT@CR5\G/>E.^&H+6<OO+O=F?EI-OX-7L_6FOWGT^LEX>5'4-;O=A;]I+
M^9Z@JMQQ>!\VIE&F9^.D9]="T1L^(:J[9=1ONZET8[%8?Q7VI.\_[$WOF""S
M(+.@72]H-_.7UVL*\2+3 HLNC&TXE)YU#HFK_X:=YF8J>IN,HOUCG,&?P5]S
M]M;@S^#/X._%V;@;JWA%S<9ZKUH]9&1S'*)FO$1F/K+DF?NIS:AHIMRNG%S1
M./%X8#)'8^EM%7<-6%L&UIYSBNW"#%8-5AN/5:-8#5A; ]:V*]9F!;U?VO]1
M8\^(NO+H,^.2O[R[NW'I/1ZTS1TWV-L7[+4S'&3P9_#7+C8:_#43?^T[>QL0
M"C=9(48,7[L8&NSM"_8V$SQI/!<-_)H)OR,#/0.]%]-\YV=M@U_;8L6- Y61
MQF9*HPF%&/P9_!G\-99Q!G\&?\W96X._IH2#=POYRRA)B8YH;%,>M!'')D#=
MB*/!WU[AK^<,3EH7'#'PVQ?X&?5G\&?47R.-X;;D$?_&0Q[+-.*_TH02YDW]
MT$]2G&!P]]RB02.YS93<H3,X[[=-<@W\]@5^)\>M.S8,^/8%?,-NH[%WX*UN
MWVN UU;@G3C=\V9CKZVQX^URY1M/.(O="5%'DR;Y'0^B&?9$-J*ZIZ)Z8O(]
M#?Q,8,_@KY&,,_@S^&O.WIKCMWF!Y2=-I=DTE^0@W/"6:/P8)2818S\%]J#7
M=[K=XT:+K FK["GV^B?-CJH8X.TI\!H>23:XVU/<P6$[Z+7IL&U%$+EQ,#+R
MUTSY,]$1@S^#/X._QC+.X,_@KSE[:_#7P/#P2S/H2SKA,9'FAVXTY?8!_W/&
MPX0?.G;(35I%(Z1B\P4#S0Z8F%-CG['7OE(5 [Y] 5\[31:#OWW!7^^T=<JO
M 3'C1N108-8$D3?BXRCF=LK^-/TL]E1,#WH]Y_R\33<[!GM[@[V&%X0:W.TI
M[DP6A<'="V51] 8G+<)>VR+(C4.4$<5FBJ*)CAC\&?P9_#66<09_!G_-V5N#
MOZ8$B%^:*U>4.T&TI>Q/>\1#/O9-\D0C)&#C4GIZUNP G3DB]AA\[3PB#/X,
M_MK%1H._9N*OA8=OV\+%.S659;:QD=:]E%9S6AC\O23^>CV#/8,]H_L,_AK(
M.*/[FA=(;D2F\6<NAN8%ID_;O@HG)ACW>\UV94W"W9YBK^$A%(.[/<6=23 V
MN'NALW9PW*9BGK9%C!N'*".*S11%$Q,Q^#/X,_AK+.,,_@S^FK.W!G\F+JRQ
MYBU+?+<8?N<'6<H]F[,X],/;Q)[QV':CZ32"MTU8S'\V0MP$ 3%";/!G\-="
M-AK\&?P9_+60<09_)@OY 0;I*19D.)/%[(#]'*9^F($];4=B9EX4)O9?__>L
MW^OA>L$ UXUO(^&/IO,OS1;N@V&WWSEN4S<: [M]@%VWTQT8T.T9Z(PUTQP2
M7R/^FJ[T^J>=7INT7@,"T;L%^K\X[CGW1- 9EL!N>2G&G-A1EB8IF,1H,A])
M"_FO;#I[8VSD)NGDC0MOO_FS+\VYL<?X&SC=;A?_9R!H(/A2]HMS@K&N8</#
M!0?<.&_[B<#CWIG3';9VI,A/*1L%_%?KE]GC29ZR^-8'<O&C^?^V2/?L5ZLU
M=%J__,_1D?W!YX'WL_T5;/8W\.W_9CQTX5O]X1O[GRS(\ 'VT9&4/L^_4]2,
MHMCC\9%P4'ZVWP;@H=@](#N) M]3*\K_?H)$_$([:;L\"&;,0V?@;S]T?Z"?
M@2Y7_5Q^ _@[ 9LE0(CZUQO[WO?2"2ZM^V/-6C7/J^I/I=&L%L>%..A_='F8
M\KCT.OBLQC7%KS?VS7P&[[^(V<AWW]B?V90+GGZ.D'N]4_U;/ZFOX9\*K"N@
M__(3L+F&X3%GWX_$6)F?[1GMEV0RK$IQ.,>>AJAB]V>EA^LD(:VTSZV![\;H
M+ -"[/DF:?]E].OG*.6)E49V.N'V'R'+/!^3LK[&D?TABJ?,OHQ"#SO<>/"O
MZ<@/X1\?_)"%KL\"^RH<XX?PENF7GT:_MI8+:A.WM80M;)K5Z]B84)?8T1BV
MBR? ERUO1,N87L;-?[(D]<?S3:[A9L*M+!>9&8@,20->PDJ1<97(C'.126"7
M^!0V*[$G[([;(\Y#^"Z?L1@^ER48AT)99.Y_,S_Q<4?M*4\GD4<7M[,L3C(6
MIK84V3@+0'[Q+S&_S0(F+GP!$OC'Z_>7XDL"'O2[@LR"IEDD7R2>DV1!2L_0
MKI#E$_,%P3^ C7,,F"'9LRBT)GZ21C&>:=JC_4)#V&P,DFO?^G>X1CX><S=?
M1AJS,&$NO<NAWWSP4_AT4N+#:&Y?SETXSWE@?YTP>*[+,SI%$U!%;L?!!5CZ
MLVA%S,/-%SSW>.+&_@AH]D-\3\*!&U$:HAKLM!2'NSN"MB1$-5@'O2:@!;^Z
MN+ZTS[I#QWZ+XL&31!Y%$IH'E-YP\D;^1WZ:?CI](_]S2$#($B -P35F?FS?
MH1&)PNKR69I8'A\3LGWYPG[7L3_@Y\C8M#]QEF2QE%QZ9;_[1GZ0?NJ].>PH
M4D&(8$4QKIM-(TS&P#'5\&I,=$9\L]2>1DEJLR3AJ00YR#\)<N"#J18 -X!8
M^'LV!:)&(.G<C6Y#X!P FD092"O6@1]50JJSTP-MTP'AL-&JQ=\X.8T\0:O.
M3R;$%/%,9$?B>U+LA2B->8RJ"79D*GA !+@9_!9T"J#F.T]!K?A@-6H/R:92
MZH$H@(I&4\=^!_P$P1\'F9MF<A>%.)8?!U]5\F[5R;O<W"0/Z:>1^QW9"[3*
M'<#] BLY"("MWWDPE^H-7\>(<SF1@G- 3V#C5]-YF1?$(@L>[/F@N6CIXSB:
MTM>*YTA-J]0+?+PX(&J.A3IEK&G,CGT)7@*#1RD=!6]/W"#"74BL$#\7P)K\
MT TR3[RT]J3)SQ=<MNN"^\+0R+_WTXG]1^>Z8_]V<?%5.X\*4J/8CJ:HBLM'
M3Y*YD_JSQRC1%EHB@ T-NO!='85H(&0QV AX6Q8&\XY]0^=FS0NMQ[P0\&R'
MW 5]SF*?4.R!:*?^'5?B6&^*D*ZZC[+ TQ#+W(G/[SC^"BR LD4AQ1I>D;+O
M:&VA1E&Z"A5DHM[-A9'E140<K3HFO(/^+9.WR@Y1:LD:9RD(:IVAA6(E5@2'
M@UPF\;6.JVMO8S(AKM!AP4C8X9O_R4+B@D72CDNN-=2TQQ0VTH@'T;V1Z!<@
M7GEY_8[]'AX.DDBP^YK%[@3L(G3+B[.IQ3[4OOB!XR@ 44%IAC.?H3(-_"D(
M5SQ'.RO?OP43BQH(NRCN0LOH%A?\1GE)%:L.GB3]HY\WR;,6BF1MS'3S#\ZC
M3J,R-^@S'ECF8C=_!O4-.QN BO[AUZ\:!N#TB=S<U)PI*7;+4BS9,EJV@OXL
M_:G7&_YH7\2@LAW[=Q[<<3QW8 $ FZ/%5>@!5GC@HZ+<Z[/MX7CX&<:GRZE'
MFTS*EV\Y/?OQC2U7EL?W^YTA\N%2N C7Z"+0 ?[ORTO[6N0 ??GI6KI/?\_
M2CAU['ZW/ZQ>1\F7])>_0_&ZYDZP]E*"O@;61@:[4L3R?ZS#M/;HISWU[,?:
MN[R>,SP;..<GRU;;6[;:AXA<S#5[<@999?&KV+PNXVHX\? '-[O(Y:C^M7?>
M.3__L8+2G^TM,V!P/JP#PNZV6<CF5Q%)D.(8\JHX/F[U?UECX3574\"-SO!4
M7$N]/"#4LZJ"V"/%QI))]2 IDUS[M<?J*NT"=0TN/^81N2;*$Z(>)'^'RJ=D
M]]Q3/JEHI[!(P])SX29*P<-2=KRWQ(JWJPNO>>56#IXUEK;N%C_JP7+C^\YQ
MK^^<=1<TSY)S9RUR=Z"E]_)46H+^Q1>2VL%@B8O_P(CI'0LP?+!EA@S/!TYW
MN,-3:@4"KL([6'$4^WS;JT;E>.R<=\\:B(0+UX7OI1AR=SF@ $1_V^PX/3EQ
MSGLG30#!\G>_X]*/OV%_;IL?YT[W=-! ;'S%BP??DQ45XA9,W1R)NZ^M"\YQ
MOPN'RVFSL?(UQG!P.G<P.(V\ <6*.G6&$5G'#GFZ93[UG4'_N($ ^O;E#_L"
M@;+E]1\/G6'WO-D@P>-&Y#'L2';Z?:<[Z#<0%3<Q\S@8P_-='#8'O3,X?H_7
MX,/AR^ "#N XDU=7916KI1)LG4E.OW_FU(3-ML*FM9'RD:.?I?@PWW8,Y>#_
M9^]+F]Q&DBR_QZ^ M=6:26806V=5J6IVS%0ZJC5=AT92;]E\&@.)8!(M$&#A
MR!3[UZ^?<8 @,Z5.B4D):[O;I20)Q.'AX<?SYX_!2+N"77(D27$F24%=#*F#
MH5N;3[TT#[Y+'SR\PCW\Z<3CBI&$G[+F#$$7ZJ9__GC*!T1[#P=5;MW[]E'Z
M\/'.Q7;%E?@L8GK9<OX;*_\1H:,/^/%!%_UF1*T^.D05(-_J9?*;[=@*:Y,G
M E5+>.13T.H3!ZVTQNC?S6<.,H$GDUR_IF0Q5Z)07G=0__.)DL@?^<+#I4_?
M3J5/UUCZ]/U4^G3#T!R?MF+FP2RH:WH2% 4@X!$A-D\"B,U41G,JX-4SA&3N
M+2<)T(S9O#ZGS'*Q3(H.D:))O2!7F<H,?LW W#</[G&ZF83"XUX9NG7%8<ZS
MDO#5[<I:CN7]5U;UB /BAS^\_.%F[\.#F4>XV ^"C^Y[B$)?!5%NL,0'#4+$
M&\$'U9W&XH(AS@U<H^9,2P<(89\U14OKFRG*7F865>0,]F,6G42I KCB4NR%
M%F=XIA&0=[WXN".#5S\1>BNZMR/C9==TB>[QJ[]BY,8'7^6C2OUEM'=G]Q\5
MU5_^^G%\ ?%#KI-2(_MWJ2H^N61A50J9&E?]/[Y\#H[UL@0URT54@FX,ZV<"
M9+G4T'BDJA07^@=\T" JF)\\LNT:K!MJ[+ZBQ%34%YR('W9X&Z[-H?+_;P9"
M-+IM\L<"%1>\X,[UR]ND)BX[X=]=AYJXYETK;KR2*%HL]5I\V!F%XX@8PN\>
M/G3D>LNH- _-,]4&KS). L/_Y6_[FK]O$'N7?M"KYU;KIK$Z#O^;7[B)P(0>
MVSO[#'KA'IWV*RJ&22],>N$_BYNO&*0*F0K*/E W?".Y"'"/.+_BRB!&7(:@
M0AO^4EE7*FW?+ZQ%Z?V@UY.]XH+;X_47DT[XVG7"S70IYC=>*5R;2Z%F!Y_Y
MB]AXP/ "WNP#;3%6K/^YS?XOP\*7DXG1]Q^2K._JJU1V/0J.>,/I+?SI9ZCV
M^O[N:*64<CX[OF>Q1;&49GB"7$G7P6SD1Q1FZ4^^':^Z>@ WX?T']_;]ZM(7
M'253?&]S8'7%K#]AJ(2X+D?.XW\XJN<#-TI9W$YXI[[[]F[Z^+M+,^\W W$Q
MG/<74B?R,>BSJXKD)RL:&!6;&R AOR"GU=]\['3DQOIDH+SQF^B&(!;WZ+8]
MZW7Z=]"M!_]F$>3G@];NV9JW0>95"H/09O<YOE/>G8 O_3IV9W))ID#"YPPD
M+&Y\($'QIQ\43$ LA;(;PF7P!)$#R=(B)6*7?'/O?OKH[EWJD?EGGS5P04RQ
M@>D@'O<@YC?^($X@@4DC?)D:X4;F_6Z\/ICP -><^_LBTGQ3PN!S)0RT6^&4
M+TAN2C1@RA><RDZY+F-3OF#*%WP )<BXV-P "3EBOF#\(IK2!5.ZX*.V9DH7
M'#%=<&\*/TP!20I(_ML-=D\Q,_"(-"=]:=F79;*UV9>=&SC,+?#=Q"UPC=P"
MCT^'6V#JU/EYI\ /*_+_^Y?V_/Q_[]Z_[TA.?GWR^N_/WYI7KU\^?9X\^>U9
M\NSE_WOY[#G\Q\O?7OS^^M<G;U_^_MOISOU3\D5\CD8UPXU[X#:.@]<F[#%Q
MPH0,7P*IQ,B.8&>>$KQ 9GM LH3?LC;/_DR>9IL"V:]^Y=Z#U,*%<@?M=CVO
MRT2:/:)[/9-6C\D+U^]'DHN;TH9)SL"Q2:D?F>0WH@$1:\*B1I^'.R+.[?@(
M^>LR/DR1TB\[8L'TPQVF.%T?,LR+5G!#I3J5GXHZ^;G!OFF_PM??U&7/K2&U
MJ2+.$%^#/\2W4 *%%L,_XN=?W[COXE!]!R2^]*6?'.R1T*N8#>Q5G0?-UKC3
M*ZS4&>5Y5N WT6OA.038X#Q0FY6VY<P-4[6,+66&]-/8K6W?[AI9/7R S18K
MW2@=5,N?=2MN>I92F0FYH=(1K[%@6[16$DGMIBRZ+ZK9X=%Z SV^:F^@W2C#
M938I3?PRUK7_9EA0\AP.TDZ8>^0)5PY!P$QQ@?_O7^X/3=R/';#>R;_  7E#
MQ^*5)DE'#L65P@X[;]P7 ;F9*_$WU!F?9RD^;2Q3#L.#\60><1,ERDWT";*2
M.TR)^\8CP:UO'\Z^VV$5_?B\YR<9^C#=J[G4>P]FNV']FY1+1:+>A5W/02G)
MEKN(^_5W/_KNX>PJW-;_3E;J*L-X]/B[V<UHZ['_W6_LII-MN?NIM^7^_>]G
M#SZ0D/Y3C./AP^]GWWW&3AM7/B+4&^S3'X\']^[-'G]@$O!3C./QH\>SQY^1
MB_]CSD=T2WW"/7GXX-N1V^?S[\GWWSV:/;Z);5>&U\>#3[<&C^Y_-WO\@?KA
MD^C+]+O[=V=724W?J!OD$^X,]HSZ;G;O!IR3!^F];Q_-KL+]?Z1;Y#/LQ7>/
MOY_M9H*/<DX>?3_;[0APM;VX_FS8"?:<_LS<N(I@WASP;YF_=IL\8@>1 VME
MUG8N?)?#I_ $#,4Q1^ZFGY?%(LFJ"@[.@LA31X.7%UF;?/-P]OU='Y)++P^W
M2;!REOQD%UG?6GKNFD-P!R=2M$G;S_\I9+[+$JLX,A]&E4<X9B@*TSIP^=@#
MB9]V@#*G\.G<)O#?15=RJW7N7F>5@C9$IJQA[8IJT6 O&0,KF%O^[R\I_'<R
M@W_2&@7OW[L;B'MCDPO\__[W?V$KSS"*CKS.J[K,<>.1Y;AOHNH#)$P&::MZ
MNH_S&D814!_S=_3G& "^6-5KD35#;UK9$COI:$2\JM=%9:W&Q.$7\D';-<@#
MC1'X('_0P$^)V9A$#(:<-;GF$^:VLLN"F(WKBPH&L"HV.(46F_:$ S->Z#%P
M'HMYFK26#UYK69"=O,O(_J/XSU<-3+C8P)O>A!-VS_V/OQ;_Z::$YZW 6'S]
M'DNLA'/YK_#O=@.OZ+^H@/BG&;S@#SYE7O*ARTN*/!@1D=]1PI"&G#N*GW!Z
M[TM(40XVI];-D>L,4U\^&8BG^%<D390T%AS%G_JFS>#?9;9MBPQ>L^@;:O4&
M=VZ#Y/9!(I-NPHI *B]>OGW[_/4;TA=\0SZM<_N#>?S@WO>SJV7RDNO*Y VN
M95T"HTL06QD?LP973/=]27IK2N1]"8D\U=4T"-;7R2V4_?]Y??LK3^Q]ZJ7Y
MDA-]?QUYW+X<W]W9_B%\WAS?Z*CWI/?^O5&?4';OKY=$>F A/C V_0D&\'5D
M]*ZP$A\8F#[Z $XDAW>5B7^@#)[TTA\I;7>%1?C0Y/[UC^ F9K&O)U-WE>4_
M]NJ?'+CCDVW%AUZ*)ZV0/F,F[DM>^BGQ=@,2;WO"52X!]4ES<.#=)N3;',C#
M?6!T[+JB7A_0Z_BS5!4=+G3\?BITO+Y"Q_MW3Z?0\6,$?&S1KB#TIZE'/TNY
MXR.7G7K]\LW?S8LG3]_^_OK-5-5XG#Q:P3?=H'+, 226V<)BM5FW2C+%7MCJ
MO&CJBBXK E<L\/[J\.N;QN;%@BA[JIP_+*KSNCR'0;4PAV()*@LI0HOV'8QJ
MC:^">^IB52Q61M\YM]L:?EUT+=7&-74Y2UY6KI!?[\X:<_Y1#AV_G=$T",-Q
M,%&=)MNZAUNT[DN8-=RE2 '@NP@)UD0:']-P@\;%E#)*6&$A&*2@VWT%?X.Q
MG=>=Q8<WAW$IT9RBT8 VS VNGPZ&<VLTAJQMZT5!3<QH4P@LT(.5@A0W\**G
MVP5<5[9,7L&[U_!?/5T2+9?VP9 =&*?51R*X!;Y1)YFTT)9Z1M@;LXRJ' .3
MA$H+[_\8/@<VEB0&C7_<@,-#T=K$Y$E5];#$K\F*01L&V[.#=-[Y.UDW_2;'
MV9KY%F%!+5TO72*9'M@P_ET;_O"_X8<@22I7E$A=%F6X9&^>/YTE_^.7G.:/
MZY[LK/N.F)G+A6N6O"H1'[0??^%0%83!^(/0*SB>I["(+PH8PZ\H6B_]6T,8
M!ORBJ,SE2(SB5#/C_U$XK?IYYO 90!G?1M?>&_/Z^2]/WCY_EKS]/7G[M^?)
MV]=/?GL#5^%G+/"?7+[=3>/K4"!AH$&>OU^L"-0@:494EJ#D7&%PY,T]%7^Q
MWR!FL.]0KV5GC8W\.K@*R .3W[@7/'%?G&<M>7,AWM&YH$ZKQJWQY";N8(:P
M3BN\WX8@QJA!'O_"#QGGM<K.868)C /O/<2OE7"KP%W(8$MX@?L9OF??\-%7
MQ;O>YJ*")FD^"DRR,^$&CT05AN$,,%>8CN#<;O'NQ4U,V9##7RU!)N1>1=.,
M(EH@97B?T9<*-*QMV[G3(#;$ '2&'\L+X2*U*C^*+%ID[6HHJF1*VN%99*S2
M94?5?):C.HIN'AQ5(\0!]=5.YN(*)S/YX)-IW,D\2:$^Z1.)-XL<BB$24[@_
M])PUC$CWE.BAR+IC"@/L>O U,'B#,<%%(+K(URY>6-UW8!]6Y*(LA O#>R;!
M29TE3\"@!)D?""0>33SQV>+/OFB+D.6$1Y_&&H3>G:!(KI'/<>1L&C#CX<#!
M%"OP7#KD(2&V$?S']@[^3[("+P*6H743NW7O\>SQX_]S^Y(9'JX%R/R<>37-
M,SA1(S3TX&Z$O6CG=?WN#OS=QWH;*ZA(=8Z&Z@>46[98U$U.SW">1[;9E. &
M,:RR/H?UA+4V,JAG/S_])15ER@TLO*Y ]?ODC'SN6KPB]@L%ZT[P\%$$]W38
MCS#X-P.0OKL,=CA_Z@N6?OPR[FC1P*T(6QI+\ZC=-TM>KM<VQW@ N,+9LA.?
M-;KE;V6WDT7?$!T2"X3SO2-Y03?9OD?GD;4/C6N##B81+\(+OK\[NWOO_P0-
M54B5X=AOS6\/3U#1'GZ:X?,\B>D-\'E>9$79-]; /@F3E1TQ4C!0@J$<W7WO
M?@P+NE DECUUWW'!*5+4&[E32*0)EBU2-+D*1QS\RZ49[G;!M5 J#7FZO\J(
M%$=0LM=%%004&_SA1!?F,+H^3.P-$W\?/,$H[[<W/SB$UU_]^>-<Q@,\PP</
M]Y/3UHZ +F[$(!]_^]WC:QKE)Y9A[:%VL.@6G<S<+DJTO+D#VQJ1!.=U">JZ
MM-%,1]! 1Q+#FREW-W-4GUM73H)RA5$Y/7*3-U85R.71,')M*%955.1QY%'2
M%]V!JB7?N<S$+=CQ5MH>,W9M4MHS#,F!+LI<6P@:!M*W#S+'R1IF3>GGK,@3
M>V[!?MD)=^Z8-,1P.LGKJ8]J4FPW;DM.1+$)130.+S*&V-.=([)#ZJ^73;T^
M0!A=8$8$]4M?D7.@;O1V-.PGSR@EQ--@P]J&%&B[VX4RA/Y^B@84\>H>IS_M
MR;B#+ROC 3MRPXQ<@R (X!Y3UV,'A++@TV5-CE=6#KN]Z.HP0IOLEL+GEI_!
M%VYK[3MX$F-1-*0BJ*V,Q\,,* +"J6K,W_4-Q9XI,VP+^NW>]RGX2@5XB2"4
MC-(!%?P./Z9(=\UAZ]Q2H^7SK,0C!(];(UXEZ[H&;]MS.T@A4(:*PT;1GVL&
MC=$#<PRZ4TP(7[H=X^'!=BYP[^N@L%=L64YQPV/$#:-A'T);/Y[0UM>(MK[W
M9:.MIY/XD1%\">&">N7[R;EIB[WX#XK;HD>TMMTN6@@C0OAAO0!/;HK.'W'P
MS\&?-2/^+,?IV),.<]5CR6C<:LJ^G?,UZSB!=I+%X(%O[ )<=@*#.VE"#]O,
MD<&G*UKZ$ G1LN*<W?A]62/"Z+217%*VP)'OR"4_8D7A]#SB6KXG.%HSPF/V
M=O0Q@E-^NG,NGA[JV!*";:^ ]C7[<R,"C2=CC%#A;(T)CFIP9-4&&UGD6?)R
MY^MZ?MW7C?OZ)>>9GBLO R<GV^(O</3[)T*&&3X$](EE'KJ:\6 $QH#[K2(3
MCHCK.H=H"&7A1,_?22L/CVD="L/<^E 8Q\RZ5=V?K7S50Y9SPQL^4PRH V72
MEQT[Q.377E*YB QA,*MF>P=L'VOT490,)H>$ZA':Z8(YKEM[!L>VR<KT4C<1
M_4NLE6GM(;4OSG&#*"VJ&QJ5*"DX0>O$OR_ HX&(=A?4HPH$[]NPJ); 3\.K
MSNG\U/G<^XV?6?*W^@(;.J5@G#=8-91T8'G312A":O*:-.8&_7#G0+-O2G2Q
MEZU"ZD+1%-268;KH4HO!:OBY@#MW%LG2ZAA8S='5F=3I,4#5U=;$0LR;##*7
MP_^6]68M.\6[!W=T01)("I.:B&%&E0,IDL*(\1(,H91RNBY[AP)4X9<Y"X+F
MB(:&,"-RL;(DEGS:5ED+/T,T)9P9$:<G,MSG-* O"8GQ!81#;V6W5?<&97P@
M/6#FU>MB$9A[Z1<W^2]U3^>W#0=ED;VYX;H(]X=-71842<*/J):S##=9V*<5
M5&RKL^Q,2@W8:_M'5:#!]@;]$!(5Q^X FF%5PQQ+8GA($U$-Z!30-=8WZ",Z
MB!;"/3*)PX(6RA(W1'A? T*YV++[ 5>DW#SD.S16_$Q47VM\&\+8\1NV:6I0
M=PA8[S"(1[45?LQF=\PIVI/H1('/4FY3C>]*A0D^L.C@D3B;3=V"G=CR(B$%
M>[$I:RR-7."_,*S<PW3@ITLBEX6_T>NC02*H&K0K!\P1@UXX=0V7?%M7E75N
MV=YU'HSYBQ/?+_54+FZ;95%E%9ZX-)EGU3LX9"1*K:=%X1(>8A/58X@2E!=M
MTV\DDP$7+4E_SA\):DH"% YEA9_)@[<JU_QT@[-\?WN2G!.9UJW\MO-;89?_
M\2;Y^<F35[BG+U^\?C-MXXE,ZY:-MK',+N#+35_B;QI[UO.U0)<+1D1),TB^
MM>#2(D[<%LAE(<5'\RV=ZY]K,+&)#P-NS^<8FJ2[[(M;PB]5,I:W*7D"WI8$
M"ZBL92%].0B>X:+F>R+5GBG"59$R>XE=;SA$C_?&_%-Y[5^H4'R.RH=AE),#
MY(>#X6AEEP?B/BZ],E(,'%.J2(1J)%Q.X=:V!Z^]D48U:&+T325QV+Q?\)NC
M5DCA \30WY?GT3G5C9F#Z$[QI*.%Y]_4:VOL>[ 6"3K#/DS#4?(QM-"(1 KJ
MEBOPVS'L#.>=D*^H0)G"'U%0"IF*6D?79+C5U;)D7 $\9$WXHW[#]#R-IA%W
MGH]0M[KOI)$1_H@XD-R8IA#_,:M14<(^1JY08#8>^)TUU.*%KS>2*$6#D:00
MW/%2*33[I#"(?J18/(Z7,=ZI+3:R:LY1DV8X>CTA' ?@>0QJV<?5["BW9HMI
M $J><T:]P^1R7;E4)JOS; '*V_IX"9H%X-EE%RCL8!)V/&AFCZ+:7DQ:YW;-
M\'?..;Q0H-QHYR^CF51>/4]"L2\E>YG&V%W_G8Y@[5A+L$&Z4'+H+X<C>^9>
MA*]][D;SNX[&2];N2,(4._X\3N0?>+OY@+</2Y(/CF)J;G8C!^\SV%?I'KF7
ML"XN<<.LI*2R1X$*TTUU3)*4JVSTU;>3^$NR@"@(6W<.8NW%\BM/C(VZCI^=
MYY:*1DQ1X7V*FAUV:M$E%5R0'&UWM-FBDMU5-.0O=0P7$?V _UFL)F*.K/#J
MNZY3=&I<P3=!'&02(A7)]3V8,VN<GQ]1%T*\=YTB-5Z'6+58742U%U(EQ(0I
M'(A$.\<E+#B/R$@J>&]6;L$2^O'Z8HR?63[-$07T^N6I&R-0=NV$L\6JL.(O
M$Y<586;5N1C%98/BRS9%7G):M1;1Z-@-Z KLUMMQ1#*.[33FL,#$]NO7=\G=
M\%*9!W>G4IEK+)6Y/Y7*3"=QC.PJ;KL<1/HU7Z\*U?,99!)PSX-V[/C#\YK
M?([ZM*@X!D2_M.]!W1>M);+.(*B*V4(A#*T$W0.7?3IJR%[=K,A:_DWCB!6*
M1GG?+AVU, DJKL7PVXL)F'U<M"D2^JDQNK]:121'MGHHQ+MAL$#B24Z)FB]I
MUUE9VD;Y-K,S.PBI4DL"36/%*"A?W^L%C86J:((O)DZL8C+>")=].:.AX6)[
MF3!\#:.O:V84P9#T6&7S+IFAIQ_<H;,+DF1DFH^KA]1<K*@6YB#C*+U=Z)1"
MGM(]9(U[!KO#O.@&:X+!PJ6[Z#G;C H!G9.$XLS(4TP)1 =JHK>?%>?X#W&%
M1C;#</66KB^7'$6<QZ$]NI^*F<!2,4L<TS)S_KSU)>![Z\&FV.NQ"0\(IXZG
M>,U=$L<)#48O,9+JHH('9:[)2NN<;]5<(RDIJA\TF[KM[H1WW?BK]=R_R4&-
M_+3*9XYK5=]65_YM,@L9P\@3/7>'+ $>M6=9U[]+GC6SY!EB79,_:DS[/ 47
M;[F3@Q@D)IX%F2J=W5,8&[<T0?CKB.H>86<P6C,BB28"&"X'!@4')\ M6!1V
M_[Y<U;B8#M_1K-6G7)UD/%GT_L(G#HH7[:+N&[R_NU4!0JWI6\JS@@9>PS$A
M+G 0 MMQ?\,:CABUYO%7A/LC7ZK"IM_V8!\$5W>4$([P3GOQ4I-)>>3T"E8/
M'9(BV/E5,2^DYO<@/(!EBM3,/IEB>+XP_\('I%89;M^:-4/N^DJ>@29<]LZ2
MAQ1(I7V_L!OR4\IB3=]:%,VB7Z,UA6C_BY6MN,B.RO-\J'97JP>\.O"XL[K.
MS3*#(:5B$W$E <=@!<] 2(;<;BR!Z(*@;);#D:P;X@("=9HZ,GH$1&"Y5HN&
M,@-OJFB2N^MD/*$_8T\OM!<8+!2H?2K8#0FU)=]%'F?BCN7N@WTGMB6S/-/1
MA446JCU![TA5H@E>6!;O).?BW@6OPI@(BP4;!. 6%UA<D?==<-7LKOR@WUEQ
M@/O(L2>9/1+:5]B=*R J"*4A5=@$C8=N3L;KP0+6<SA9RCVX 95V%4Y"(R2#
M_Z9R#3HZ[$Z9*VR*)HKHLD#A>ZE*VL1..J]Q&XLW,RI)P(&RHR(LZ#-8HG3:
M'=JU7N\GJ'_W#?DDEH/-A)^L%Q$*"U-)E[07EGSZ,A [:02BSBOH852('<&R
MB@4>=I :B]!2[3,!VJ/1+H,[;FLLS881JI3J&#!^[0,F%BT+K0LDX.MTX [A
M*J\1_3Z<!!R6O]:N=AW&8/"$$][J2H\=/.^3V"F?21QTZ"=MJWS682/J;*13
M3A#=42DI6C#&BW,.S*PL=H]LZ0J>@YS35;@3<N-658?.);EG>U_ICB>,'*DB
MRZT_J.@..J.&C)4=&0=OV/?]' 3X%$O(<$:^/J2Z9;<K#L68AZV!J/U0+?Q3
M>Z> 7>'<,',?1*KL6=T5G/)VA _!!9X*M2;6?Q;$3;B2?DCN^$9A-\-A-YZ(
MZ"!R1O;P'5Y!ZQR<&-EJ7N4DJG*,>V9V=H80SV[LZ?M5,HA,G8 U0>8* Q.Q
ME0(;-VIUP 6^Z"G@#W]\H0KZ]TU12:3X30<;9<^*A5'*TB=LLVXQ2D)!$NJR
MBG9-W[;TI 998!#)?3D:<G.-I*1?ECJY5H6N6OQD7>:1=JC?N0W9:8?Z]'^>
M_O+DZ?-?DE=_>_+Z5_BO?[Q]^?3)+Y^M1?BTB>-S*/[S'Q6J2V4:Q/=I?5S+
M2/V+HK68&B)H_\(Z"+H/- K.^S6UC'[MG2[?F>IJI&MX[<FS7$Y*?RU_CQ\I
M?[RPPZ_U[0@.'9P\]U=VF?>VLS;8SAJ=\&<PFPO\]J)N-C7?D*?<A?D+,AX/
MH6[N3:B;:T3=/)A0-]-)'-Y]I.U-H.U_[YOD.4<7AI9J\J04OIQSVY[R=?DE
M7/D43(#-,L3J7F@9H L,4981B86PS%@W, LVT/&.SBG>#"9!N^S+*05TW*3^
M,_"+*?M]_^[]AT%K/^;RE'1!P:W<';%-O9#HGWV_*>N&N7$P0W%>6*:N&Y<
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M/#ZE>S!(R1\./V=CBU80"AB('[=G$,BKEHNM5L0<$63M2<3MD,B3TQ=(1.G
M>G3 $)2(=$/CFD&*"2SC_=J^W3#+_EI8,O&G:#N1ON*&">Y\#TSV'?WID ]\
MO<-+QJSZC@# -;&_]!4]C=:.JR+@>PQ)81ILOYPPCAI-(=_]T70@2V(PMC#N
M!0^K0$@-B*5:DS*&0Z(0+VQ8K)NLE-.[V]<,R[CTT:"O%)-W.4B,+!S7<>QN
MLN;5(DB+-T[]T ,S58!T$C UX=.84P=Y*;7]Y4YUAUP&*B'KC)-&40%@YNRQ
MK'W'8J1L/9<'5%,3N&IAKQ 4LO UL^1%W^!JI4QR.397E]3W+0;ZLE,TN[X(
M^^MI+4P )#>^.+(YL/@GJC1/6N,C__GXAC/D@T0;=3H>;>P!"_M<W6D0UTP.
MHSMHH)";,WP3\TTM$'9F2=0JT&9W2-[1'+B#=AWK*CAFO183$+B#BB^"_K)8
MSW0FB>D%TJA;)G1KE+^5GA]@I&O?2T\=*F;G%TXXJD#A,G'LF;*1K#</P5UJ
MAM%Q+=/[V/<92GPJFC,Z_SA7S+P7)=9*6+@I6_]40>KYNQ+3O:&Z^\H9*HY#
M1B'#OL9J<9#ENA489E^]J[#8IRRRN?!VG^!"?;[MO?[:?6E4+93F& ?I,K[#
M<SOO6'>47+^A/;;:@/XKH(X60"F1S2S@TY89W:?]/.WCNBK.N+^&Q# I1!=L
M,"GMZ.;!N,0)KM\IG^(+.(,VR4&5TN'4B$%#^'XNJ6R28KW)BH8N?K$^IETZ
M;2(?M1MS)(MLNN)?? +5LSVYA9JV-WJP@[ANA5>3J0JXBE']_X%5'O7Q8!IO
MY>\62]]*9>>(2>]^?')[,$E.K!B\JB>^/^'V7Q4;V?QW=DN<QF7!Q$G) OR>
M>BU%M_OD)N?@5M!%8%!PZ]@/3FXK)@$:4GK!]F82L$4";%N68E<03O#45FK:
MW\/[VUC*T*%>P KF>FO9S\-;0JOEI8O/B&;X5,1J-U8"/GO<<8%99;CSRVUJ
MLE(ZU>Z-\B>:#B+;GZI%J>*U;@(0$A%12 >'O8%LE\BN,HP^^H[4)IO7YW:6
M/(%?[@;Y+WQS7:F<#[E/&!'=V+,ZBHE2P$],'8Q"'FX,BNDPD$[C(Y@^=.@:
MRL4<E5/(_$8#D>]/0.1K!"(_G(#(TTG<@V9U%+Z8JL:,MV^<6Z[1S<0\;D-E
MEH[V0>!$<G^H;0"Z->\7U!<[1VR,Y*<T98\%B$11EML%\5OA"Y%#@%/E9LF9
MU"%(*4#U* 3K'[,W,R84ZAMP6U--]P_2[,EXFIUNG/%W$=" N-T^(A?OF1$F
MC.]-&OP?EIJL9 [D=J>E@M]Y46^B\B5/T54W[Z0OM0@(2%Y5GV=,W(=659,@
M,]^"N%-<_2[>),EBN\"4I]T4V,P8'BQ9VJ*KVZ(U\%80LBT!1WA8&[!-K/6F
MM9:)H6JD%NS\/O_P1)[![GN6,!<2I9G7C'#8P$BI$Y)%^W!!6 @QS;CEMBDJ
M."@K[DLC+]"G$E3(SXYL.+0K$;T(8R3:C8+Y16AF 9C!):\S'8('WF%C&:0?
MZ9OS @X3LYGY5?HKIIKNX"IA&UN%(19M>/(4!Y2\^N7O]^!EQ,Q#G#,5W_M)
MUZ^U"\K*PJ!P1K2U:Y(O- D1M/,[P3CH&&^QAATKI/L"D]V@D="P9"J570EQ
MRM+M.>[?QE+K!=@K$!);)@0O#+5@GC>(^D,#MUKP*D=#Q)7+I3/.9)D>$[['
MOB]L;</'@[!<ZS62US)VG9Q@1<N&U\?@UL/O^2[FY.YPXI2A<DBO1 >MM:5\
MA#A/"9F9B$I,R?=:J^<"1/B-3\\B- /3.O#& "0L=SERX^!ESM<CP^EL@TR8
M*([[ ',IN4UPF:.N<-/MT/6"190OZMW(00!ET2UQ/CU#B>%-V/X3 ;$ACP1?
MR8NF9Z(LPG/!=RB.[>+.!]'0YE(T='H #IV,PZ$9@$S(YQ.5XE,_@GA1!?K>
M82\/5-3('7A6HWR.@E"341#J$% 8HTH-6;Z7H$H#<&0J80M*C9,M3++D8.57
M YTZX=1.F&,#=0LB*,T#RR+\6*[YI8!LI=[F1,7DI&6<JA7,WBC=0(53H%T+
M)F)TM% I.RHZZKZ^)%I9[H''F.QYOU48K<( BB7,/;=8RB3H7^9 [*29NY+!
M4&7#.#Z8(K_X0!8I1\BJ0-E:J /71$0]0 8/ I5FL 39((:(Y_:\+HF<.0Q
M"\$5SRL-,+;NO<+C=P"Q3+L!YZ:M]V^)!D[E/@PQ\4XOU,T>M>!L^1X#IM.)
M.UJ@0^Z6-C*:HG@&*_JU6"$^[X$V0[; W(B2OSD1D[*Q;#Q:+F45*((EH7/A
M&)HHIT)^"]$7(5-YDX[U;N-[!&RY+("]DV'&!'(X;'1706<L"-G.499D"Y(Y
M-2PX<FEQN!<I:I)":4USO?W];HJO47'UKYC*<<6OW^A0!O1SN2#0M <5QS3<
MOZ(;GY5&&H&RYXNEQ/HFEN) 8SF&S7VGH;7V76AKR*=<282/#S/%8PDFL^?
M'+#04CFKI%!+Q*N)9\ '8#=W.;@T_52<>Y$:?_)@<-? 9<YAR+\7??*T!ZG
MW^.[^1DO7#Y*MB+U3S".#1T?\ 8<(XOEJ3 4L-\0S#<P"V2.4HXD+5ZE$%5Z
MZN(N.N9885/U^\36(9N:[0I[65<8=;'4XP"UE<OTM=QJV"%!^,_!:T7#N7(?
MI ',L-8QWI:KDR2@%C07C#" >[-<%N+:-A;KKDC0F;B6H4JMIQ 4TV"Z9H\P
M^*=,I$NM ;A;M04M=*;TO]SH!/'@?_8P"(JN>:U"% @=JL/4W7*[9QJ%(,8D
MH+V'B/,%^WZ!S&%$CU/#W).%L4GJS4DN@%Y5!R;C_JO\B:;91^H/K^ IFM!3
M! /\(BRXW!N((,J&"K9 $BNME,2%WW:48WB?P/%HA5<A[/'JVHL;3+<4&PQ6
MXK,PEHL&/^4MT#S"O,5%D5.MSWE6E)@/9%H&I<L6M3 Z7E2[<:2(+6>ASD;>
M3HS)$"&DEB1)E%UVV,N&ARYR%^^ B%<"1\%7(B.;UK>R>.V0#GV[BV[AW]>-
M.:3I7$/Q-!*ZU)&B<\V4%O%2Z18<@=P.59]FDJ1"%)]J.7#L9 VN(M#'<#JP
M@?JDOHY!&]$WL6VN@),PG0AZK6>!QTJE.ZOZPE7]-@4EU$5+R47DE9D*6GA%
ML]RMQ_$ME(,<Q;B$.-TZ$K2KZ+$_--1$[T,<$*Z?W;0#/>M]%!,;96<-ND]L
M;4K=#_+\Y;"VFVP;L+V3:=1F8%T5HFH+-/]099 Q&Y#$S.NJ;UUH6ZL%P>LB
MN@Y)J!JD_*\8ZA2:0*%Q*OYZ9;':/C+OJ%O"V<JY56*9MZ"K<#1S82..UW<Z
MB3<:(O1@@@A=(T3HT001FD[B3GN<?1:2?5^T7>1/2]>.L+&*6EH^9(H&;,%'
MC*H.%@791L4B%0L=[[[4F9'(GGN&3?SJ9IN:874XYS\B,S CR _;^Y7E9C1B
M(>>INVG%/=7L+ 7JUM+_1"[RH-P&'KLJE.'-\,6#_\)BR')[IWT'-F[DS7!&
M*KC?Q*Q=>)<5;R@*C),K@$L67&J$%@%_'%GUV9R0+FUNJ@;66G^4=7#!@W5
M?H(+;L3I9ZJE)^L8[N_Z GL.N5;MFJO^($."0^MX)>-JXDP.F-D' PK78F:;
M V9V'4 ]I@O]LL'+9?/)^4Y_$M&<@M-'SHJ(W[$JD"Z2>91<@AK/K?)-7=B
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MBB >73\P70K$4M'#' >AP*]H/3U%WD#'[%(/!@1BD]USY$B&$I=1<'7K=59
M(.FL:0]BP<U'?MC?LC;/_DR>"@;K5ZG:&I9;:[U*;O%A#-&3,#:X!DH[%?TB
MVR7>9V 8CTY>J,@P]A&P@&<(YL:8[&14'9>,-=I8[$KGU(Z( QD)4K,OS>='
M)2NYA1WN[]_]D3^E?]S[\;:W8MA"V2;^\WO?_=AZ839CPAP$O].$N_.YW N'
M?A.\.=?].F(ED*=[+AO\P]U[/WYS?T /[7\^+W(1>2V_B?D.W2/NS>[>Q:P$
MN\%4+T7Y"CY 3"<88%8_%.^IW&J&;GHPS+2QE7^Z+"C%9]Q7O%)PAFL0H6YK
M=[5J/@-<78S&6T$.H>$L.RC0SG9ER])H:TK9T!,5]9,^IU?'$7P[X0BN$4?P
M_80CF$YB-/@GQFGY,>H:-L'W&E]B"NE50'4$&&QE[DQ7N+[/Y')16X,N7X-<
M]K52D\CE$C58=T;<V!,'P78_K4&KJ1W"8C7OQ-<Q83]M7PVLC6H=XPJ76WG.
ME(@@1:-S/BX=,^MH_#DHVYYO/8E1:MH>G7OJ)>WCN^0Y1["-I;T(08612[M!
M2&A?,;GAB8KG29^M/ZRQ6A*8)?<>_7"/0J]H*_$9:&&+N]'3 ?_AZ!+O?<^=
M0I);*$-BT;R6![VAK[_!!ZF!JM8:)U0P F:HAO$L&X&U#&S7'=LQKB9(?J^2
M%W;>] BT0-9-YMX4W8"-RZEC\-/M I.7)5MH!8:L6QD 6,7#(1!A$YNUP<OP
MS/PB)_AU#X?LT:-'=V_-;]^Z=SM:B.?\2_R*7X LB*8P6EW'^#>;82K+O,HJ
M6[IIYW91($2$F"WSY/=%5^/*W[_/1)64@$&($X)32<GAT>)GN[G"KU_4H&.^
MO_/WE.)SN9\>UC3"Y^ZY#X42U 1_O/=(>4+=(]>V\\^()] F-(. XA.Q)%[!
M>/5'&EQ^/& >PY]HPI!WQ+C7!>M*VSY<DV"8$M7*#PS3+3"+)K%8A8*">.O2
MB;S1!4KV"^[.&%_4FG[4I[KMY4=H0]P#3\&$&7($(VZ+4-8CPN[&[*-]#NJ5
MP;U8Y1S8XXG_6E>8P]O/JDK;L_,:-Q \NO$Q^/[>HUOY[5L/;]_ZZ?:DUH\1
M9*C,KW"UW[L?4 ^'>O[;<3V?AMV*A.R6T!X'52[*"A\I5>O1HPU?(=A9**Q
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M2]Z@G(@B<S)V$7:><\V%&*-FC29<4B4 =2("?^)>"Z1GYO#I$@F2@X\O:M"
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M>S1F=_#\V[OV47HY((II1>AO&.&4CEC[<BDGJ?!.6EO_80UG\G?S*+'[P-T
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MKU< D[EQ5.WM.U)=NNL.X&\[NT,0OI>HF\HO0XT7FK$.?6CF?4=W@):UHI5
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M6F+QJRZC3(O[*VD?1OS?H"4$-9;=U"4J+BE8_;,O8 GTWN2ZUW_V3='FVN4
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MFJ&HLC9.+[WZY>\T+F%ED*1EMM/(:):\"+ 1?.\?LJT05TU%G%A59L*$DB8
M-O@*^-FRL38'7P:=8 GP43 VL*O"]B4\![^H[8J>!],D[UO6IZ^8LBSW:3&,
M(!),.U>&ZZ+B6L-U76$*38,>H26&*P+&BU0]8&2 00HR(;+4,26\YJ#SW+I:
M3C(NE^Z?%Q+-*AK#]_N%  $&408UX0-,6C @-6&H;JA#ZU@-2L;6!#QI9*TW
M+KNWD_HS\3S[RH6Z^C9L*H4\#4V0KQD(H&SIN4"1)$=%4PDJ3M*QMC1D)YI1
M,]%EZBZH>+).=$GB_*D>(]X.+J"5\;$%S9PC?K0P0RFQ$@8E 9*889^MN(20
MHD3PTR8-H[!!4BLJ'9):3ZD;"FL)I=YTT3>N"P)^P3_(1*!]'P'%=V-<S3:=
M-XF=AX@(+%<Y!=*$H#.TR=UQKC?<'2KSWIO(5JCI5CW"NC+X1I,9.68:(Y.O
M7X GARS*;+.>U^_@H;<HK%D1YLE2%+ZT^>W)##U:B&&5M>RXAJG50%BCE-H"
M!!_VOPWJ&0,J!VTA>2"E+1([@#)@4BZ&.T@?2JK\?>;R[CY=K#&(;9"&UTLJ
M&+RD9MC13)T6I5B9U)U@G/>.B_.2+RUL0PC*Z((\LF.OQ/+ABM&(5#(<9+X'
M:4++-=(4D>-JP]A5%K4TT'46 79P.A%!-TA.[.32.>.OBX 8 Q^/8#1"M+&*
M3<+["R\$,7"T6YA:*1(NELHNX_/Z3UJ^[5&]4^W@V%ZKJEG[XOU4>L9GYW61
MAY"4P<"G!B]3@Y<C$.=-#5Z0WY>9VN 8KXHY>12DWEK+R:E:XZ5,Z+-U"".U
M,-:>G V,*<'I.F-@59>8 !=+*?HHLB*+CD91M.0JA93H>3UQ#Y[\J":2RANW
M)5^YO@M5S-!<:NIM5BHLE[(C"#UH$(>I+I\4OSL/%VR<*LP.B.+[$53C@I
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MTW,W9;:P[-B#W.?2(P1#FBSFNG0Y*GRNF$9*,1WNLFC68HPR:3*5*,F'<+Y
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M,=\4?[?H]K-HLKP1$?1V]-H42=@# 0L]7ECBC!= QD=*(-FC%%-;&@#;\K(
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M,Q<;2B0-.&&S'3D_ZJ&Z2KT"_9*Y*$(B"V]AG$ZV@$_G>6V7:DG/9'[1,2O
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MJ&#H3!?LK'?[YIU3CZ?.J??8.?7YU#DUG<3Q]."M:=^S3@/>HYJ)7QHFP1;
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M(D%TKBX!_U;4A:A9+OI/Z6HCJPHU]A43H7.CJ8 H[G9DR_EPBF_WXK+ZI \
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M%'=[R)@!SI3@BQAZ?HK[<"5W]2+B!8BN4W*_6RZ&*N9 D^ !U8!K"(/*WFX
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M&8#5((D?(]"JF;H-1UHM_T0A1DK\F5OR9?Y"^&-8/?"[M%:*H0'8EN2_8EM
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MDK(_:>A<+ENQ)NCEY)\A(62<#N ^\:,81PZ.L&^TN4+/EGACR?LLMBA4#N!
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M+UJ@*Q=5MG/T?Z6ZC-%8/$RQTXQ(/147W8>I_6K$"D[H='PD/LJ#[#<M^"@
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M[TP)U V8>[GY_ET#" GR'*"J!'\'P80]T"O7#+!=,2QFH9_\HRGIV\"A$!7
M2+#"[R>-6^\^DD%! 9K<IG#%I#\F_?%OT!_+LMOU^W<L$/ ,Y)'?8=2;L$BX
M(FC7EFY?M%;C$S.*G^ .!U[*NGCG2*AV?$F7#<-J'24](]S?E:J7.$(ZZ9=)
MOTSZY0,E(Y4!X5T5S-*A::C7GL_7[@ WJ6OJVE73<9V.ZW1</\AQC3R"=SJP
MJ!?LR_26!]Q7S7%+[LH#LSAW#MHE_T&/\:B WAY8UZ,)K.L]@G5]-H%U_9O!
MNJ8+9KI@WD^]R^J=[I6X4[V-0]M%=0#8T;)A"$Z.3G?@ >M<T2XV4KK.W:M
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MRT';<.7$MM@4.Q*^V8T2,X/TA9A.F0^W1/YW5ZC9) 12J!,P ^&HC?_[I[/
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M."IQZFL/W1L7.DWE;&<V-:E%?TF.*YC BJ1?O^ZW<U"IK2)8Y:.*V;G"Q@Y
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M;2V/ Q=[^_S\)A2(;+*X,K7R7 =P\0],*3/5L/64&F[:"$8PQ+!5DA Q"H*
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MSXB'02'+7L, ^QL,3\;9U1KJ^.G@/K73!L?==F1J%V70*;(Z9()@6\.&JQ%
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MYNWA'@A7:==(#9;4*DW0/$0;@1Z"I01HZN:(KBNH#UJ6&QS+_>1<MNK-]@2
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MC!1\.XPZ3$PP#%2L1&XKJ71ZE Q$]UGZKA&NRE#B1H:7]UG:Y@ BD4:?_(G
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M)&*4B""7.?YU@PV^T%^I:H(:&&&%)R%'+6LE,,LH6H@'XQ/U%*5.YEKO)$0
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M%6Y17<_?6!80,=*+Y%L[I, P?_ ",.),L?P)U0;:I\%\IE+@.,95$[XT1?<
MNR$7M#8JI;BT=<(QM4^G7NJ>3@[$ +\PV8; <"+ ^;.' J@+]Q:#\,UHPAQ>
MP9/Y4_HMRRW: J/2'C%U4U0W!4%0O;)HT,D$=,JX(F4?W<@5=/!V-U[.Q'&O
MD)M\SXU F%U,;VB*. D<)).:#><!$R#(QD_LH!O)5#5%L"C+FWLR-1;,S=IJ
M%LZQ4)3M=4 +VC4*;O5@,DQ^@AL\^?=3YPI-0(&)(MG4&YTNG7;&=,:($\%,
M'+1*ROUYMV538_\&M1!"#30V40=TH[9,H-E&(.$4I)4U%HD.@V6[]"Q%<^D@
MG%:$Z6\5]F)9@3G/VH6[2S9L8W_R_G'V)YO,<*",YCVW)9]=8,0W/ ?RPMB(
MSO(;VSHME5<9#$WWA8KEF +$&!"M"[POS%FB3]K1!+PC6^_CUG,O%G\&=4P=
M1V@.0UJ]1OTQ?VZKD)NE[\X-Z;@\_*59=5AV7E/;P\$Z[&$#YM[)[<,%GT8_
M['#U)D]4BT:P)E=I9U=KAP^,%UA*&%@ >H<788/6JP-E;#+7,2U,@;DVN*$)
M:YGBU@I'>SIP[.F5YO<RRSI<FV5-F,)&QM*$UMR?.6[D;>WN<(G=O6# &;L[
M,';WHS'&5F-'#CQV9(W8D2./'?'8D6^9VOLTX'#7P3-#+%[C<#G89K*+W5G*
M%FNNS;3J4N7(M*I(-$C7>OC:L-<%$VA=&U@(J5W=L^,K)TAA28/L_>KPG(G'
MC2ER#EY(XZ:/#,FW*U/3M0+<\PVNR>)E@DD)!;1?TFHJ<TS^8H?5PO!OZE"4
M-HSAAZ[<&[;E1I#9,8O(Y=/!:"]"6S:U?V+PFI'4Q$9"D6/[]EEC=<7L*4EF
MZ[O0*G82FS %1+@9]A==J&Q_.Y8)AA$1\*+*T(0KL;\>&(?%!"NY;>.5!CS.
M*2A;\K"ZT%QWX>./.^-$*KU6.L;+^9"PW@8FO6TI<B47:XDA)B<HZFMK4>N;
M7\;I('PQB4.W.=7+>F1,G=-)MHXI2'A&:7B!G33G<.ZFZO-&?+FSTF80OD]U
MXN;@W)QD2U^B3320'B%."8Y9N=9^.&;84CBC:C;$'568"TFPK)A);)S,2$MI
MU,-E.'TI#9-&UH#G.5,(.@*^FL6>FES1*[B9@)$ZW^/ FOL^6.),+)#:K1HG
MK59@==VAQAF:T]"N%+?["'3OL90D4&-FN/?D.RJ_=&)TI"(9QL"YK\YLORE[
M-+P,1!\M"F6(!HMJA)$U=.B<6JB@G6M8]5Q7&G92;^VZ2F[I*ZOXM$S7%F/;
M"NS>Z2;%RF=Z01^%<2[&)<L+-F$:*@YY)Q(?C<%5JNHM+3;N]_=OK1:CW;-@
M-C1'[25ORZ;V0I8W4EHOR)X=!#]D(,#)HF?4P)*13%E<00@B0TJM*B0#<*S@
MMFI'._3](+#'6-=CVT*,VP(?QT_@M$?K(1U".^0I-[.Z#L]MLRA+&]GXM&9Y
M5EV9U3P77;0 WAD':#,SW,)M,;%)-ECS'02FD/UBEJLD/(XT+\0G/>FOW3.J
M^];A:8BZ(G)Q?Q9CA:12&L 66M!:ZOH5 5H-%GX_TN: 2PV,U[>F1%P_HIC
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M__VHIGBB?!B\K%LYT&=NN!9K@*ED#>LY"J90LG=JU["T<+<#E%B0N)&&1/.
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M3:;)AL*7DA3YDHGT>_-&V]81.VP%RDL+RW;-^H5@'(A)U!6M+!35C&&&ICV
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M2X"</(NK44E\O>"L)KJ@F-CE!-%0& 6+*KG/.-X@5.L54FJ5AC^<PJ_<BX)
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MU[MTU5Z_>/WB]<MVZY>I%+C;QQ7&ZHSMI=F.AXD:H5;H:3PM"=Q%MMY53<F
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M+ R%:-_P7)<8H AUT9)+0HBWK?G@^/AJ0+B)AA&$:4JFP9)BZZ)^I\VB1T-
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MZ6^8Z1LGON=8>&\LE[R2E/*T-QW^)KA>+ RO>2R4Y-6 ='PP0:)R23-=SZ+
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MK9RDTD&WNUN\_D:]U4^F! !OMH-+:JAPE[?.VEEN.N'V**F9G 5],,DCF6F
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MA7P+5-K2?6$#IE3(66.G(!Z=.TAX'T!F\PN=&2_4DU#Q@1D5\*4<O-,HS:3
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M+*$S$SB]N%2=!4!U5H:_,(_[2D'%,GX'P\\\',5B%%Q%Q[VD \RS4:R@";"
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MW'!P/6N#PO<SJOH,D=2J]S9C(^<7+]G1RFHT\W[%2S.6!E_,BH8^PVC>#V3
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MV.>*+A-JG+<VV ?@"(::2"2VT8[Z4B>_5:;'O>]X^DZIF;>X%D'(LR@+8M,
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M%BHGW;IT)F)JI2/E5+I&\ BF 7=1Q6X#\-A8$C/*#4U624EQ-BW.E))B52/
MQ:>SS#T%(X$-ZE3_13TQ4PLA.?&=&KHW:/4=F,Q$02Z0\F-C<!2EYG8>(?>*
MJKA@2\VLE#VGDV :,H@QQ7282$:%,.$(T@#R#,RH_Y^]-VUN&TO2A;_C5R!Z
M[D18-VB5E]JK;T7(LNQ2CQ>]DFIZ^M,-D#P4T08!-A;)O+_^S2<SSP(2E 27
MJEID86(ZRI)(X*RY/OFD0%Y2SIZN6Q6W(HP'[?X[#[G3S%MCL&J#33N(+<0L
MN^?%Z'* JTC2W@CQ>*X$0*)M7)OCU2,E4T@62^39NZ#+X'=J1QQL2")?K]FX
MI>1E'24-Q&N-&0.H99D!&=-U50BQY>:BX*YW$SWD\#3H 9D$Y"UBC2Z_EC)Y
MP05SOR6MT+ TF=3@#/N4%S>9F5X9IFW1J PM,'ZO+"J)C8]M)[=:CQ&)$SS<
MN]^[NKU3+G=3@*SAY.&\.0Q+5YM0KUW@;&VR)]G8B'A;TWN5-G>&=IL:8KHC
MW%K/2RX 2!SNL9B1YI!J%/>[<5E\<HT!R?N/,#.&1-I(J4>E:[8[Z-YI"5JT
M-"'M#C_?00"H'5VW\"[[:? C=;Q%T$98IE5US4NRQ?J=38D:HI!4R;>-CLAO
MH]O"VV2H%/E#J6\*:0E'0"#(,U7:!@/D +HFP:4A9% <V 9?:XQSFQI7><O,
M1IO26,2+T%BMR7J_0X'4/XR[;PHO*,_6"<_MV^]W.61A[SBENA@<>60[R=$
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MP[??_>#W#2B*+QG@[WRZ/I972:[5LB.&7=SW_RYLX!G7U%:)F/BL(/73GC;
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M9  &V;6+LFO FPQXDT%B#1)K=R36@#>Y V]2#8"370&<]!K$8&X.PGO7A?<
M..D&G$B(<+C3PYW>O3O])\&:M*[L%P)/^LF3=9#*>CC][='1V9 !':3&3DJ-
MQX\]<2GFWJ+C8=+1^\M#MLND3M\,I$X/2>KTW4#J]">_?7K0?D]:I6\=K5)
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M!S3YA8,F']G2[0%^O'M3NQU^S%7YEE"&C?XU#+'O]A:/':YPZH@2-LA 1]O
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M[UJ2).)&JE/KIC2#S_A8*I">/QLJD!ZT NG%4($TW+N'B]74$<*D'MVUI>]
M$,CFT$Q65)M1&6>-MN*&I5E :".0(27\EULC']%1Q38C3$AF/NZ((]F([OK+
M V(!3\JH;>@X8; E5Q%WY"JB+;F*ZL$R%4=>A6W%44>=.&I,KJF3,.*Z?5+A
M<+X<*!W]/D#IN!]0.AJ TG]:,25H0N8I<TQFN"46^[/7&$*9O-W=/9[H$0E?
ML.=)1BQ!L+)L%C%?90%!JTA];_$]#!_N0%W?BK@638"/5JBBJH50E][2TC:1
M!4V3L&;^/GIAMAJ1PRJ,Q4F83G.400'-J7+UHM%[/&U*6Y>V#L\N2H?@'M%#
M)1H#JOJG>$"4:ZIZ7#%L@!/Z F.R:4;(0"M8^9V8TRB4NO6\L?D^,"/FA2T%
M4R9A4F/,E,_K(X*3U\$!PT,0RT,!P^,O!(9'?P9@^/X#9P9\^*/2V3N##W\1
MX,-',7T"\&_ZTXGP#GQ\?_;N'R K^/OIY2_QAZ.+UT?_7_SN].*2?A>=__KN
M1'*WKP]&#!4_H[=]N#REYX8P\_<?SX$]/_K X"NE., '3E['1Q]H-K]>7ES2
M/Y@4X9>C\Y.+K>#T1R*B!@:$!P&@?[<)0'_9!J [GDOK91TIR1T4UKEA9V0:
M'R.8A)R\6"NG.=D7RZ)L.75*8;?/R[OG!V@;*#TP3KM+_F[E34C63U@2G+#2
MGK")/V'0JNGZ"7,OIH<P.8(X[AQ-2'R\(OP6@TY4,GLZ CJ[SF^G9^G?7Z4%
M*BY,3J;Z-+XH!%,XBH)/CY@E 1VMTCJV_&;C51ND1C_;;N8,54'1.!,L3 [B
M8HE@DX-NCBU--RWEV.9'/<LV6"HMS_2+9R_MMUZ_/7XWPFMF:29D9OT7.-Y8
M8'53)@H5W03&'=)*N#3&;SD1/*8$)Y<Y\@2E:L%WK<5<7TB/]HFZ^.&<TQ0^
M0K]:Q5->@_=)29;^B^="V#RBGU?Q\Q?R$X_L;PWY/L^_5T+GM;B.>!EF&CW
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M->4$Y/N<>_8\90#D7A^E_99-A 3CI=M%GX#L4 X'6@&Y/<PL2*=Z1M-NT!,
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M8<(;4_K?WTB%":2M]918?-!W6[$_)U1S8Z:ND!?..+E!Z55BHS7J'K$9;C?
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M6T"2Q+"8UHZ)LI@7.DG!\<2=9DMI.. 8OV/2THW0E GZ:\+@:<5/.?[F#<O
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M@'4V,8MZ<+K)D[5HEERYI%9$.J"E89G.1"/JJ.UOS1_CK*E(OR#)+$\%_B'
MVEKU&]![1"@ATBY> 7UFBU93F*B8;+/=Z(+3H+QHKE0*/PF:2W ^%"4/\=(D
M)0B7_N!2*'3]51J=<5J2<P&;&CS^SG9,@%J[U(R )VYJ&/EF4PWAX@C(>>.2
M*(4&E@#M)()5F179Q/-JR1.BKB=@@[!T&)AG+@9((: X;:?MIP%],C!OV+W4
M5.V7>7DL7#,]J1&,?-E$4,O7>;.U&?N<,^&!KTY!=TUM4IA*^9:%BL&*"^Z
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M,[,,,!>*:_/"ZO9X36K#,/[:?DO<7+!Z$U-+QY0T;^4K+*;#K0=8CC.I'&=
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M"7XM)?BZ03WM9QUS=)T]S].V*<P9/S[9_,#N#PU\](5#%=.TK.I Z7RNTNN
M3@RZ$L&MY+FWWD7K"'D:M-8P?F&CW)_9E"I%C;3BI#9$T!VRMD+_=VE]I89G
M:#WR\/T8/Z_9#RQ;5[1F'S@N$*U%NIE+D:7LCS?G3Z,8VRR=!*@_&O(Y;HN!
MAV5\SB@VS+_7XG?5H?* *F$V\$P'_JBYJD:.UEJ3:8.H#%Q$NU@%>JY47:X"
M]"K+/7-\#.;-CX:-KQ:8AX$I:84@3VZF*1D^26;;H'( 5V/""J$8)57*KPH
M4S0[YARW1PL30-6[]EX>1-HJ4YLVTW4W[BE(MFUJR(C;=M&( /55-EL[M9,\
M<D#R%9JSX^&'88MO]=X1[%,RKO<>W'MT/\0(W3M^=C]^4\2/]A_^M+^[^X"/
M=\?O#W<?X?</H4$""?)DTM%1VRZX3D[L/@A01YF'*"F1G4,,C8,W;<KA2RF
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M*0YK!P!:=2Z1+S9(2?0KM@_"$ J;#FUPB8<T!J$N"WF)%"#.!5L:(^NX3%V
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M-WF*XTI>:44C-)R>KTQ)6SW.4@9OI'E<I/*M\Z2R.(QE3']'RAY_%N0"EU&
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MME@V^\96)PS)BLL :>;8@__Z87_5:?^K@P4YUC]!0GR,VXFQ%XB_CF?QP=Z
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M"J)CD8)M]RKOG*+6TTDJ<0ZP<\EG"6X3^H6-G=>)^!%Y1_\FM0SZ.SKDTO1
M'<,'_P__5+?PO@:'?BV+JHJ?DS>"QKBQML.([_WZ_/1^?%X6E_4,D/##X>Z/
M@;ZB.98%'?>)_1Z-C/3 0.D@61$5\=,D_TAS/D_*Q*D:%Z?Z?S+*;!D_;4A-
MU#0'.#LRR&'\#])M+EI%"BY2+W-BU6N:TYTC+(A,IIC3VK(J^B.M;&<$T'Q7
MN#XJ\&S2=P&7-.3[3> !Y]XIQYO2O#'X.FAB=>9R(S2YF2^R@DDE(W:W)V:<
M\?-HD@?#_1^Q 3)P757_!7"!ZG+L/1P^CDD<,NA5NC4JIM8$%V*<)2,X>@5[
MG@G,^W0AGB"_CS;@T>[PX8]T"9#K"P=Z@O=',G2P,>93]1SGQ<245M?N#1__
MR&_8&SY:B>L-T.)ND=+#9^DYO.EI44SXLR.Z6DL8SD*#.(Q?%04SB"9X[V!M
M)R,KG>A#_ =>("\O#2Y>)Z:UI;.1ZYP66>ZD8!_I ]QQ>H=!W7[_+C$:V1&]
M_L&.N_3,JW#1HWF:I_-F+I\F^R"MF&QT2Q7 5M\K)WGD:T36U1@)BFZN2 JV
M-@;CIY/V!\/#'_&;0_IS$-!UB@%3H^%UG<X3:00N/20A^)4]N/*,W1^'?R=9
M^^4!+2/]$;TL+B';&!8-03\)*[49<4, >J$E?U6S*C1*U41#&,F@+J%*[?EU
M6G!%+H?Q,6L382QU4X[H/2.3FVE:>QY8^W0SGL7-8KPDRTBH:TFGI]4<8^8H
MEJ46EI!;128AG5T[E=R&&EW,+&8ZUCDM#GJ2:TP,>F*25F6S$#[>Z,2IC^XS
M+$36'.=PAY@W14<=OH'#5FRS"NOP)1;<YQU$%2I;[EBZ>.82E^O/ZO?MJAN=
M>K/_3/K OV879/OMP;N2"H)9J&>NVU&S3N,E>7X@TZ9C3(KUP]GS^.'CX9/=
M>*3FAQSC!Y*1Z%+'K)CPO4=[PR>/5KYW&$DE7KRWMS<\>.Q^2]?Y_N[!_H!T
MR"P=I:J>X?LCFT\ORQL:N6HKUO7WGAW]^NX^U/7#X8,?XTGC&+ 1$1RCTZZP
M4Z^8EB](K9)=%CVU'/XG.1-?D\Y]P\5C1^21IN.$;*4,!M;!X?#AP8_PDDNK
MP\C(?-'M[/IX19B&F1B-4S O-!OAYV#_EE;!HM8E9J'ZKLA\Y$*^-:<E.4]L
MEF66_)F4W#\T'C5IAJE5]N$-LW[B:T)=3L_6<4JP91"SN8.4DPVYQ)-D3EIZ
MP%8AW5]@)\>[X(V#67W<L(H?QN^213J)FW*4Y.F?B4LID U9)N[5F*[)"IV[
MV*1-EL!>I_$Z?U^#'!@0.P?J"&#WHA%LU40R3T)RVAE!L*LNQC97<Y9Z24GX
MR+D,U@0$J3A"&TF\=S \@/4]+HT2)I[09>*=C/!I41B^H?T_&)!E#SYO6-"5
MV 1\;PWCHXG-%,%05@L^/'?H^(&4E7##[_^\-SC<?4#_VXU)9+EK ]Y !V&<
M-/SEO8/!_N$N_?Q?).%&./L/!H_H1$Y,4L\07S%2T/@FT221-O=Z1D>']E)?
M!&,]8X9W2RO/7I/Z1&'TI2HR3?/38'PJ3K?:9N.BRM0XIOW=^_WC+]&I'A!6
M2\%EW-_"MVLJ87!FHU;3B_B<#'T;K^&R<RV.CQ\<!M$ U4CV.FZ;X,@FXQN'
M#X</W3?DJMT=1%"*?,_"?\)MRK">X=Z/<H7S+4^/X0^W[]!?2[SNMQ3SUHX/
MP_AT4YBW'9W?@5N/]@\U>3^%-B$)X LTB7&9<IK2MH2PK4[P=4VWH]N#MG'@
M6X>!2]!> S8:,NYW8=/JMO^-[9.AF?G3?[Y[^_SM.QG&74UL;\_98(=;_.WV
M#(*\[+LF,SLV-QMF@VU!Z"%2TNMY>=Z4[N)A'4*X?$@)ZW_#G'#KY5NWLC:4
M<6;,>DC5QE="]<'&_.'.X? P7M#AP5ED3<,J8?_P;Z1?$*+8^9\TGS7)73T_
MGP"&'/; D!L%ACSJ@2%?&1BBTJTS3>=TAY9C/+.<5SL/_G=W?W?XK\7Y#W&2
MU?_U@Q.RF7(>[#UZL/C#[?3#1[N+/W[XZ2\<^B]>$+]3VZ2)O\S^2V[< HQ@
MU(G;[(:CKUUYA(^P>PMQO\-"[+W [WUY;>D&W"/?[HR;#_XMFM7UHOK;3S]=
M7EX.S^%C /AE>\H-R;#_:5:4Z9]%_A. +$7Q\2<]0SOL6?@SM"/"_--<A1MN
MX_V[L,EW2%S;$8RKE2'*7_8>[T#1Q/<^G/V?U_?O& W@YNMX[\KK^.'CSNOX
MKJW+]D9\ NWV4G175_0$AP'>V:'U?S'?K2ULN0O%.;0CG-G46/K)?)'9=K$P
M@HXM%O&W%A8QQ'=NL]#>@8,'4[M,*[:9:6M:R%LDUI"#8>A7-_"4$; *EV6T
M41N0LAIH/ZJJ8IQ*2HS^_X49E4U2+LE?&C"@94AC4/K2JBG/%62U.WCX\ $J
MI>K*(?'2LJIC&L;4HO &R%8]>/PCEWSND&W#&">;N0(V2Z>#<.?^\"'7=RI$
M5EXYC%\!8=S,=Y#,&B5H&+UT*4MZ,=8'O9(Q%/*X6TG&03QJRESCQ(KXHN\Q
M=EF:5\\2I(ERA54GF7NYC]<">](.UT:2<Q1(AS&9!=/1K.H;(UC=:F?BNR $
M-"5 PKJ2U V/3S*95!IF_P/0'27DE0) VNDX ['D.%F8(1T,B.-_-[F)@?T1
M@9;JXR9'2G7&2'.N8*-3L3\X?'P8T>OI)$J>F$_'(,8T10JS#""@6B5K:H!:
M!/RI+-.Z0(J4_%=TB(Y?):,FR=G+Y0RO )\>[NW: K=Q4Y9 #]Y[_NQ^/ 5B
M@-_*/+'Y)-H;/'ET",/+E+D QMP7CN@+]K-#6E&:\'E1QIE))EIH^/CA(_>)
M02Q<M:)(_M'0.L:OFOFB*>-[#Q\=WA_$IR@R.(_O[3]Z=%\2_O]=D*M#/SC<
MNS^,?L<3.6W;S$>"SPV72/IKXQPEDY33[*P;Z%>:^VT6\=X^@''TL[$)],P*
MX%<_WJYDX(1Q9:)*F[#'(S,&;(U+.S11DU958S2>D.8IY\KIF2<.H4G2Q^@W
M3,V6]L3W7I^\/[G/$A# 2-#!VXG:99IE&L8@;;F[NQLMFA'=Q%WSY\06A"R1
MWN-:T8C9OBHNXV=).4)*M.#NZ\OX:=:0YJ1OXEM[.Q(1<4 _K0FAUTPS8P0=
MB.):33Q%O"9K0^!6] !^+$3#DVJ<9&B ;KO6M^$;0"-6\IM>Y7V'P;\I.)(<
M.5!&B!!Y;L:&3YNR+QP,6!H$Q"'GTT.:16R!(RV+)>W]DUV^AA-W%S+:DZ\\
MQ/.J67%9%L4\!)*H2#%,LP,W0^JK0,=39  4N"Q(''STHR F 6):R^V$)V5%
MJ9^7M%0(X$'KBJ:-Z!2M:&O69U";SY^M:\E8M.31LT#;,?KT\U2!A6ROG/(-
M1]SJ] !I!%MNC$(O1BXEDPL4;4U4D_DBL%8-O*^^GP#^JDEFJ9NF:0+T7O#V
M *#E$%C'O^W8HB1WX]&DH7(EX\P0=2QFJF78R$&'*M46F/=G_I;Y!2GD(D[G
MV$  %$A4%G0^+DE;VU*01&X/6,5UG-9"'G -?X(M(8:;XZ6SM&9Z%Y3_BRQN
M.J+FCP6,J<&J $U%GM$&? X %PUN*746>N>M' ] TXJ%X"KMX0C.1>2J]6CV
M97&!SUEHH>(4*UM 6<P+?@[# _T)+0'8@VKB2]#>:[R&3.K 5Z<118FY*Y"]
M4FLFX>'12"9%G!< =P.U7ZNM6/%5+M/OT''FHL@N.E:/EV;4>2<S=%[-7=F_
ML96)80R#"SP0BD%TY2(D+(N,]._ &[QVIXOY'&>>_D8B-#/9PFL,WFE&WSOL
MBL$ED("]8=K8+NV7!EHHKQA R#089$_F9(R066Z0#))?LW *R-$"]4@?HC
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M<IN#-WMVC=\A)*53[L8G[+%,,W43\VGF>KR<K]+8Y) U-U:;$VYSPFU.> U
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MWR*7Y'>@8L!BIWO^]43UD>&LAD2C,8TG@*ZE%0B' JTU?3)L-1[]^;7*1N'
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M0APH. \2JDWHW(>(IY"7\%70"<:4Y/ODZK)[(58*##FU2RH G@:(I1S[4$(
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M -9:TRFL!1G0"XV%GN%]4RY2GP;)5&32]EI?L,GL:9M'"E(Q&5D.M,=3W$#
M2 )'=/LZAXT5=TT N]X6,JZU HFC*3J4KJ2PMG"GL)O34^2H ,$IZL6M2#'Q
M5/,W3=O @<R[$>*.)"JIH\;X%:;# <M[G[6GCM.*ZLKG)U>Q%'I,T ATW0^*
MF>NVF+DGQ<P=MIBY9\;,;=V=W=WS!'$%KE(Q:/$_K%(CO)/&P#K,,.E4=F(Z
MP4U3)G)=B1<&9<8ZDNTU&)[D*J:@B2W(5C,AHW,GEL$W1)(6'KZL74\=N.$
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MW)F.@CFA-.62LE7+3E>M0:IR-A@*W+_L(]?*SKQ:800Z$QLRRBI$M*! 21J
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MOI3$TJ<?AE)Z!:)+ZW)YLY_2BLC=-(,\/#KJWG>N0TM:SX=84+35 ZSS!+(
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M!HU)<_A'1#O#!!^T&=$_&SR91A^0+\JSG7 '_HO]BG5%!^:+4::4P;>+$O[
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M:X>:(TL,6]_MA8#6<WOR).?;[B=I$]U*U(;L4W,DZDII?O(;<D&Y,YNQO6C
M"(UQ4T?FX7BN?N$SOOD>N5U+7#/^8Y2 4.3O_N[3>VC/$VQ8XX0:';M=!)35
M'9_ 1T/".0XK<EGR DR %R*[-$#%XCV($-_-5X>.>QIG>\@XVQ?[^_O/BK'=
MN$S4VA"\IT>/!O ^)U:M<_C48+7/+'H?1/3>0/36 UEM%+[7'LX-A#-N'9BY
M4=A/*.L-%(H6F-T"EK<2L"P9X,]9F.3]+)KHUNY7DBU@#ON;<)"1B="/H]YR
MX.2]\*1[,9!S O( O/'@Y/0>>..C4;'?;^"=X-51MYE#W^D$!\?W(;D?@[']
M]F'?NQY+Q_[JY%L&_LS(5WG765)$N^.H2.G!_LXD3H=ISJ0(=O7N6ZM5%VC1
M(3J>0^T]]+1G&LGIO%RM:20[Q_LK#.6Y=V9GE?5X AE]^,:8?>V2F_834W+?
M[Z[GJ+QO+,3U5=- W$\V\Y-O130W?N8[G=6L\RT#<W>.GP;,_8RWYKP:ZNX=
M5>4B?UH1Z:<]=H/X9_X@+7NQ^O82@^5/,2>R.V="+IS MQ_*S9Y_-SC9_[%7
M@&SQTY,':RZ6+L&#ZNF99O\('?7P$KSJ_-GY/TG5R7PHH*4:?%2""!K;>U!C
M _!OJ%G]SO%?^8O'AW\UY+NI[3=@?_$X2B$F<O-T BJB 4Q_4*K5XY9J]4FI
M5D^VFVIUH=9HM9M%9BPNA*FTU$#U:7=SJ5][T74:.'"C"/K+2?675>G.N!O$
M_OPOO0=UX9[_ILJM5R^<"0UG56AXDJ7#+!S3B>%)A'.D\7/$G[__YN5E+X\&
M49A-@XJ?]'TTCIAXNZ>@Q^/H/V4DO;% WV\83P_-.!\N1&$H,L,.4K^VI?-^
MQYWX'4[T30N<5]^?_;UCNZ;R^%OEL(+KN\,M(-3,XGA#G!?2%L3A^OR#7JE9
MO_4<F'H^)NV3R.]S^D?@I<P'GF9CL^[2XGP,+ 7&%J7A;1C%I(2 _VF+WK8;
MZG(OG9S7TLD]%YW<@X&0!_C!OB$E^#W@*TPRMT;8RB(+K)%L?2U%WX\A."T2
MI*7H:Q$O#4:\6"71(-#+87#ZZCY6KPW&CG0.@H.CQT$P-F;L.R?!P<DWP4<V
M /?R;8"=[\/XMA#Z\MS0BDYP=#R7WUP3V(0.]'QR?5W EX/@L#N745D']&4.
MV;<!T)?[.0JW'_W2Z<SMRH\" CGI-(W(\.F0(,>G#^98MQ$ <[):\<&:K\\?
M&P-S'!P?/;A-6XT!Z9P&G1]\"78ZW>!H_P?'P1Q_NPRT[*N;DSUZ.%/L(F".
MC@0!\VHE!,QJW8<"_SG0+VT*\1GA ATZVC-X@<[I7G<.,' /8^\!8P6.]UXM
M_)&WE.;W&V$"]?&?[!TN'2LDV;S7L\+ZJ*2[)B,V[_3O0I>=<B I^+#Z/$HJ
M9F)AS1,F3+1=[^X=>F:HLPS%/'?;87X4QFC#SG^]'.&YG;]U?>$JIC^/U#@L
M0"6D"9 A3.CR#;DPY,.Q,DW20Z3VT:O\-HP9-T22X17I'[ZAMAH(=3+W"J4Y
M2ZLQ/>*.65P<[4'9YX?2$!;UML,O#AQIXM;E[-@F:;)KE\5)1Z/%Y8O]:@<?
M"\FX1+QG1B .5A2(*MF]-H'H5%"0.<IJV0V2>"5=XEW*:WY.I9MUMU?]+5D3
M>FU=<%@XZN-:Q)PM&W)4[3K)9)Q.'4Y7^<;Q(W99_\2JA_9>6 _Y,*-+F-&Z
MP03$6T*B'";DS4<3Z=$<%CYX[>\E5%YHD2VYD(^D([0]ZSE-)+JA8YD4:/S,
M.HW[EGH/<?$#C'>'V[E?YL#0P4H4!6,/NKZ6N3DUG75^<T^1,JBI *=7JI,3
MTP31GKG:2;$*<H_VY:LJ=)_LG.XMJ'8,]M]I1(MA@'UI9A""UQ8.V&J7-0S^
MK0&ML429[=$W$O[T^V_.%@4LW;@S&(_,7XC3G.^6]"Y163Z*)L8I>=@B#""B
M,P?*6\^!FGF0]]"!HE_KWO;NT&"TN7DM<\0:*AR-EFRZ;WY6"62)/:IP,":]
MEQ=B$S;X#MJ&>W3YQE2G6S<0T,8KSOK,-RWO=.#':JAISL6@I7-W(^:W,6AS
MS00\E#?34S.X;$7UPO:0;@AN>J:7MMFQ^V3E\>5><S2 WOJPT2WSWR)NVN\'
MCMM>3L#UK&?+%K@-N.J& U1;'L'MFF>+JMYL5/4*U"PK6')+P;-+'_WG\O./
M0PL_XH%+<=S=>6*A>[HS/Q+"L6W+U0F.3NZC3&R7:X8<Y_A@6Y?KFW$S#XG8
M/"3\SZ[8$V)JOB^WP@/L(*]:=I G90<Y;=E!?N#(%W,?K1+<<K%?)X>"_3HX
M;@+[T2:$OQHS^!5CXA5@)IQ,LO2/"+WM8J:/.9Z%@[E_>11]S.%>UWOL+X\"
M Z+)%:?P_#11NP5-VO84G@?*]$=A,F2<"7>#3.,9XIB?O JBDZ-W5JUKEED8
MC<DYK, O%_\['$]^^D0+EI=9"*WJ8F!>55]<^KC]O0,7*>-)BL%]2J>%Q6QV
MYJ!8U>M\)%BVSJWBK9U;94OS!RU92TO6TI*U;%=2H25K:<X\6[*6;9ED@],*
MJQ6\MIF%?QX%!Z?;&OM]AN4Z#EYU[B-V:9=KIMHV..@^2:!\.3_.-F452-L]
MX6(]7T*AC3$\?8SV4-?G=E>*T:Y8G]O&9]<]^$]E]J H&*[>F4I=)Y0HD=EE
M);?WUND>50%.;X4?':Y4\%BK#5T0874#G@N+"SU3(.1^L^L&6 W0FLY(FA7U
MJE/GJ[RH47*K<E0'26GGS "<[P[#*,D+6S2K2ST]*8/5!9\-%;1&GY*V6G%S
MYO!%>=!*_>)!_V@1Q_C2BBK2&CWE][(T',1<U1Y'B9*4#NZZ10_T[M-3@2XF
M-#D?>CHM5LZ9I())[?^+NBL3Z@_GDT;M25_/"6'R.T^;-(&?J*+!IV4;3OP#
M23$ICMK1&_82Z>1T+!OW9TIHUM]=8$LS8-]00=/6R7Q+>J)1N9RV&F9+)*.M
M>6F3<&URJL')*0G2ODTS&A?08]HQ 2/&/0FG[TE??T\0^C&A^>_8+>!1(]Z<
M1@%S'-D-:1)P.D^AN@%= N1=[Z @5%YH/\6,\YG8YS>E,\!<$G=-XYB[8=>U
M'O,2NEKYS?.W!I!W_QR2'YPF"+2G"=]]H2%0JGI=/O=F!:>'F]).8G=#QM'@
M-?D.ZO7>?A9.8&@%ZVQ3R?Q_W.X-1W.7R(\R\YW#;YUZL]M6_,EF'=_WSGP
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MY(8""ZZY56_HAHICHX,@S!*PRP:,=^ZPS#<X9+ -80^R=X=,*R54(.E$.XZ
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MK[ SEJB)OFN#.;7*1M2!TF'76%UTB .B2LK&A.;O7I[R^=K!&<KR^=4;::S
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M77B:YNQLY\<+ 8M0]T.J>$_LZL>6G^HG)* P5%5-NUZ5YMZXDS]QJI7)N;(
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M_8[L?P^QC;.._WMR)2]E&C0A&Y.&<26C:!?6AITK P0G)]!6@5"RA%77&_R
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M$G8]7*YXR8^23,DA ]S'ES,2T?1AP/4:)>5G7\[F4;*0W,,$7J(/_TPM1VS
MOZ"*]D?"3LXC23^5.(%)ZDN$M <=A&G+:^;@5[E&_VHJ">%_9($,HE- *1/C
MCDUG+P2*3B8,?4)CB#@N2!_3+#('5D^ W882SA.C\4\PDO<*) ;Q>6] <!4'
M0:F>A+-;?@"!8@X[_FM6C,8)+Q$F!R_/\!X9!R4L/RQSS!?#3*#'!.'^(U2
M0/>QH*8)(J8^"1X:/U,NFXY1@N#1N?T!#Z\I5$35JW-L@Q'G#%:TBL.8JPUH
M8.83:F"<PWSDI8@*1@[D!B *R3%C'Q \:PX#04 BN"#U3*"G@;6!\S&\#9\&
M)5%MOQJ)SNSASUG3G/0QP2/[A'P\[9D\7 H,[,*@+G0C@) WPIV/XV"WVP_\
MMR%WG4 )M_.99.M^=_#B)_^DY'K@R_/7I_Y'D8J+5,RGF?^Q2+-"<#</_!-(
MV\G$OC5>%A$*%+R=.CYBA*('<80P,;,$>W5H.8<O&R[4&#+P4;NI$78, 8ON
MHL!;:Y0NYGFRR_CU5>8W&IN,+]#_0@C[!G +Y&0279)197_B9R1/2FZ@0"$^
M*6&@#PF2*U0?_HJ'E6?(:B'L,(J?RC%!A/C&H]I2=FKU6; A55-Y&<HKV$IX
M6Y2\FAD-!PP'/B,=_YWIQ>5K>R+$IEUL^9(CG>YT_%;Y@7PJX+D<[@BX'[@G
M#0AT9!5/^!FL$:]]/#>W%JKWQ3WWI/ANV%HXBR>1<%A?:Y/LMR@!&Q=DGB(;
M\?!0RIAE+.LK47*%,C(E2TS!@I$R&(XMP[=)PJ'S""[W(N(6(E9[.85-7('A
MZW@G$79FNIBR JD^@ZKKTO3"N')*JK,+\&B!* 9RP:D2_@2^ VJ4THXN:,V^
M'($9.>/&'U<2"!V3N$;1G5*[I9(JV X-E2S45/11'*FJF51<F94S60C3-*8+
M42-(6DZTYWT^_P\J V%.G.4AL?X%G5[];*N#RLI13M(TS+ZX [T6C?\"LJ+W
MNE3NOS+ +GF&#349W9T#N.2G0KT&YJ1>'/&QL/YNW%?8=1#TJ3?4=A#F0E8M
M_)>:R:'90]XTCWQI8YBD:GQ6WE1P<O.TH NS@@Y($\2[E"T>."N2SHTUZP"L
M[1S'&2>EX\ZO#V5_E>#FT7(J6)JA28ST@!6<$+\5F>[*5!N+"5>0?=HX^TS!
M'#I'WMK Q*>*N3R3.T#<Y+")[Q;7TID:;,88ZQ_N30Q*\0T-W!K"H5$\WASU
MFD38L%!=S*$E ZK;Y,-5JRYE#P^+O@$O$G1"9$G$8: $NQI&=N]'N%#)?05W
M*AMB,_%/DF(#0W7L2C\5RB[0GI,9O*P<&C7)%")YC(O+^_/\%8WZ^L]/.ODD
MY3I6_E@9K"M;IBHZ1<D()J<7ZT[QVMC)2+RZ RLP^U1C&NZ?*<>V0IE1QD6@
M5$/\"&P);#ELE:T]\B)!5/^>7&&O3+IB=,M:=(+-DCA$Q:XRI _FN\BY028Y
M8:-%+;X)@T68LD;,:RN#X<C'N )Y''*^ CF*ZW,4=[R(@7(CNCPR("\MS,.>
MGJ9'"AZR)8;UQ04VB,X;V [64T16)SDXE? GMB?)MZNY6E1[L5S1:T-9=F1%
M@EB'J0I7[;C[9N[&KK2ET,JEF#$!D6,5IV4U5D,?51D)5)CAF3H2P$VD2+"_
MU'C(J-FK5"Y]]@V;'>>OA(3=/X:])B]LX$]E-%<M+544'?\["76C6I50H.+^
MY-3'6,2E"ERJ+[;5K<2Z@^:I1U 5-M]4AG5ISVD_M_576X2S#A\I)F"L<W8?
M"L%ADJ:,0%X&R*Y53):O"+ZOT-I/EM)L)F6'C5@Y^8J<O'OL-Z;F5Q,Q4@[S
MCO^J;,6T?'-6;:MK;TP=:JJX6+Q*LVARME"?5;Y0G>A?S_FKM6DM1[/K>G>/
MY3 /&- ^"F=ASKL5<K-:U($H%<IBE([_%X4_RUX28>;K5NLJL(VA40\V+IL"
M@W ;<-U'C5JQ3\B'I5/-C-*LWM8N+]5]?,RSLRX#5/03H=2MJC7_E]&KDB*+
M%IY6K)0]#'_CEN[*P04S@)/D#T7\Q9\G43A:&%<!AB;IOEL*#&:<=J>73^?2
M\>;-O'D^157/JPN)$)1%RP6*2FY=Z%55RZ#<$0QE<Y 9I9"M25BZ]@6P#'LN
M@:<P-R$*_RU"X(.%1]V-=4K /"TPWF&)U9D)B9#&CF;8E8RB7?T:>Z/$,$O2
M(4CQ,9EE52L4>9<=@,L^9>-$]H!#5:O[>23BIQ0WN[Y. )YV=0*;K!/HNSJ!
M;]5K]1H>1I'5U8&;5<WI8^'XO[_++B__;_=HS]00_)\_3]Y_/OM\\OGL?UY[
M)^]?^?"+M^IG_]79^>G;#^=_?GI][I^\_/#G9__=R:<_7G_V/YV=_^%_>..?
M_GWZ]N3T]=M6$^=A]_?^;:]/>.><8WXA^4@6S@R[C;9L<FDHPFFZIV'GLJ-.
M'TR/*%*FTZ10101E>UJKBYIN:9=/4XD679Q/5<LIK];K&754+%>D<4@+I6[%
MH))<BHBL0&HQW1F8P07]JMZYBM.+*-U"1!39IN2D&>9V8T*.T7(JE1\<SZ+B
M1W054MPRQ> 3C&!BV+B8NJ58QIM69""9"%99V*'(HKS\U0"6=\,'54*)23#!
M@#E;-4J1,F$M&-**[U':H A3'W,!I2K^I 36<E;X*65A8EO"E=%!JR\>?-"R
M9F*!EDD'$RS9HB&#AM73AN\$_M0X?G&_=%"P?,E3Q3J5HAA,.ZTVS@MTZBW:
M97&^U+,,>136=BG"B%0@;6CQ)YV1LG;C4?9\>SK.Y[_6WM)/%,%W$G9="6N'
ML.DH-P3&1$/0/D7_T@R.1F$*6NAD%_&(Z[*L9_D<J$R!FF-;);EP C+) L\*
MJW?\$S@Y]=%W[?F!*)<YYLUP]B3)Q\A*(164"C[,2-7&/ 5KVC"SQEEE@4<^
M#0JFH!A0?<Y3$,E@"/\OOIHMQZ%V^+$7ZCTE[,HLY$IB$HK5,+.S_I2# W\9
M98E.Z<9HRQ+YJQL$HDS[E.9B@8(EX]2&D80[BWZD&X,N)"!2'O%\,+D<S%DT
MDRGM71<!ENG="29\2PKZL !T(FH=K27%U#+O/R(ND#&Q!J;,>U[!IE40A#+O
M$D,W:;7BD=@9- ?X=N"?+D9@<LO(?\O>072$I"HUA;N34@(.90 WG$TZN'_&
MY%>D A6X4]&\QL2[^J' S#2\N4BSXC.MRM9\KEC#0PPG%KW?YAULKZV^XHU+
MWS1[I!FJ024-F2E?=VITD!*.3IZD:-(OC[/BJY3  (I6OK E#)Y#]0BI<F-D
M"*6%I"$%-QD]@OP9_)#2.L;A9"*1C!)3!?,KS!84E<7C)E=)I-0-*GR-(O3!
M%C$H&.2<718H=?FC9T1;FEO3IM1%2PQ$"?QMY:%']:T\^-[U!U^7*7- 0%T0
M,)Z 0>(+4K=V+:V(-2_%A2@OT['*3#0H'66U%2[+290U)$KBX=E:[H%;+RH-
M5A2*ZEN.O)<<&];F0$ /+-TP4SF^J/?513=H8Z9=[3Q9D^3ZA(SD3R4)#\-8
MX5C?^?Z?G?..J6&3(F4UOE8%C^!H8>2IIM;,WZC?DQC(*2\V,/;1)1AW2:H3
M96.T)02^I$KI61!AY1R_Z(<3),03\NRV9_)6182Y^&SK<8DY*=N!F$/[\CEY
MDB65*73+R!U0Y1#M$Z#(JS8LJ6J/E4]+(>:D'DH"J\1HZ18?P4VB8A,6I%")
MXFHG2E2@(:S4=%WCEM>/@X?'H:6;V7I.7%:3KM?/B#6-2H;/,BOYRZQ$=^=2
M:A;%[;%2+44W##D18!I<G%E5;);#5XD6F;GA).U0L1B-C@I6B;*QP:H&G@];
MAZ@K&U2L-BIF!:N13?>WJKQ%6RF,&?T#(0G@)"@"*86K>B>4*>-\A2T3L;5B
M^,EE$+UF+O2HC-U4/#GWRAUJ_59X3DW%D:F#X%@YH8*C'WI5F1ZJ5,TE3US$
MOE@NV_8P,R2,6WRZ5@2';HAB]UP4>Z-1[+UG&,5^1.YN4_2V'MK>-Z'M=R?O
M3WY[_>[U^\_>FP]OWW[XZ^S];_[GWU_[&-/&?W]X0S]^_G3R_OSD]//9A_>M
MIL23B&/7=G-@=O/U5SDJ*$[(T.7*TGX5IA)+8!U:TFVTK#J9#PR9.<"5>X;<
MOB$WW/D?!?[1Z6.WTL<8DTB[ECE8JXF;6,0UGO6/4Y'.X%\%7;[P];-XU/%W
M\$T%/&59A7W0-4#]4G_@#;*PK#P;L$-7&'$"K0(K'E)&MG;D<N6G]IKC;Q4J
M4K)D8SI'ZMI&S0VRRS+V>3>T"O^FLANG8"A3?&!I*]I^(N]]'S1:CZ?<:29\
M?W*12I706Z)3";,CY>]R&*"!\H%"! LI'QR'U \-"6(.?AC7MUD?.I.8K]TE
M$QI<%T*H;Y:OZ\?()Q(2W.M$H6+!>S-"]BH'41YXE@@\&W:+6$>< JU1B"G5
MY-411$2A790ZK=E\-(Q!_0W'!?JOKZ:)SVCII8#)J,V0R!HDG(H4F,646&YQ
M$N]JW#;F*?.45U*,<[+F27R]4/IIDT>@A;[+55/F;Y<6I&TQUBW*6X^O++PC
MM"=7VIW?U5ISK/OYY48<-QG/MY@X-FG915K 1./D*A5@X*[J&:)6N4]F["9O
M"+1W*]*[H0^&VA^SZ!YNM9I1_X=K6VALCEQ-UGVCCT";_ >;)M7)Q6-2JFG]
MZU/OP?GJ<YA'2^1J:))S]R7 9C?WR5GO8&^P?E_DQ1>:R*NTX[]*X'KT_TKB
MBR9&N:G=S%W/PB;7L[]W7S/?Y"Q/IZ&<T$26S,6GSW)_A 5-X[3 9/O6<AHV
M(&\3IY7 SHK32*\\EZ.4LC(;^4[W9/HFW>J^]3ZGFSG=S.EF3C?;U$G\QBOV
M:>EF][[(^U/85C'G)F=?.BAIFY3[Y>FSYB/J</>^MOM3[!Q'WB-'7HGX@A7=
M!"ZXT^F3$Y2M9LOGPXAP5]/<SD6.][5(X;OOL8SV#[B_IV"#/2VN[#JN; -7
MGL7A14*S.XDOL A-%.FX2,4_CAO;P8T;<<4\;ES.SAKL+J5J=K][A!?:D091
MSSHZ-%E''*1N2CJJY7@]@0SW)Y2LSY9]U:KW=W=]O3CZ.UG]])=A2KTC9]QM
M'6;2[ZJ>&\G$@E:S&E50ER&9^FD245H!N8&7@PWPOF=7*HI1FF09=:A,"DPU
M&!>(%@XK3%6Z.Q6T)F%$_'4A8*7S%!/:<RQUOY11,N><D"R)1!H@#GD82XGS
M#[ U+,K0C'Z8) F#@P\E5^(&WG+?#%QQQS_'*F/L>T?5MU3O8HJTJH-BVUQY
M$8[*.D+=MB!)YPD5Y< DP@S!$A%?6J87^JQ8=6*$X/E/$@)%$5F1:FJ9,.]$
M)!99*&!_81%B3IV?@+8Q_.8_8D[[/T7(D)C7=A:/$YAF*#KX FS+!SB.JM]B
M-_!KVVPZF6 V""&)XM2L7=/GF4!LL %<#$OE?BU8RX:9(C;NB6HZJI-  MUN
M;RK+H5078MI:$R"PJ[@EX8R"YHH3,F2_2+B$$XFILZR:\G9@@/1"Q*I?8%G4
M%TK=H9#6AIV4>(/+G06^^@<K6GC_";0&P19PUJHA%Y<KE\QJ%IY0X6@1\S@5
M=@$RIAF5:' 2DH* IW0:.,0**%YU!R1$&9K<%.1LK6#J2HHHGW9:7477ZLF7
M0M2<'L,A^@A1Z1REK36=H9?G;T'TL63 K*B7,L4ZGIT_WIZ__@G_>OKAT\<7
M?D9']YU8^-PF5>A&GY@ 5J: ,A()%OL8=LODA8(CAK.4AWFAFX;-"+R;2T_C
M IL1,>("3(H0W:D#R4P27)1(%0K%1 Q3Q;B4P)4DD>ZZ)$D0AU0Z- K341&J
MS+7,W_EX^O(%U1S.AA'U5Q!1Y.>+.==*R@C(09)$G4CZF<IPRZY% <I9JG,B
M /Q%QBW"[0FI:NX+7H4W%)E4"[":'U$=.(IFA,HPW8_J<I"2X0BXA>396,X1
M_HN:0ZJ](\)Q0TZ5R28*!,6%H:@#ITD&].QVIM:?X:W7,4K_&3& ;Z W=/*@
MVN$$@2,4M(1IEML[()B0GH]P,!'=LP(D#E"?$=NS!G;SX ,&9N20WM_K6&FJ
M]FQ,S6HU84\@872%:Z5-#I:G<8$9B\0*#W+2)!& .?0W[,/XCX13+4?3.(F2
MBX55#KWS7F1C\>]/_F^?SUX@K^L[+T8&N\0K5,,;Z^1"W=57?]AD4<.\&6NM
MQ\ J^^K*\YJVNMQ=6)^9(Y-84^Y (;^U5&*U6MR2 N.]D<.4F;C;.URMP0A*
M3K7/+B6KFF-1GF18;8J_^:C5R-_2I)@C+_H[W5[OJ//'VQ<=^"O('P*B#NBL
MEI ]W=XQ=1*5\]RTLEY6K4H^8TWXU.B#6A.&8V-4JM>EUFJ?C&YW?P^G4^I1
M'@+(9Z"V_OZIHC1EP+G)\!_.@"XA#>$I[B$!P@D;.,",0+.8<Z7Y,"79RBKL
MPJ\F\%XC(W\C#2;RWI$=D+(H [(,D"SPWP-<VBL1[IZ-IJ'_1_A%?"FL594Z
M(0+$TWJDU)<3V!KCJ **4-&W1U&(6VOF3-VB:6=)MT+UB5'&E:BGW\[D.!2,
M:D.&0+W9!9; HM!0#<5@!7VUDL$UVWIN5/^7:JK>J<$2H0WXS]N/?_EO8:_>
MA A88JG"L$:$)VLV!O@756M@+ F'Q(9ZBA:,9;)D.9$QH?:DJU?27UY)CN"1
M8[I,1J!LRI2%(NTJ[L KZ\2\#\6%P-[?HW(C;>T>RU7 \L-5X5VO-\^S*H]A
M'HCF;9E,E8;.9A=-BW+6[IE%L6%OV;;$SC,7P&.2%/-*(ULTN7#K0VJM1B0Q
MF$1L2SPAD7Y#B7/?E3AOM,1Y_QF6.#NE1#-D2Z=-7D!,HE )%+;S[QW<"? G
MWA?E^K.!)2P@2KJKR/*Q7']EMW(V8K!=KVVHH@FA /X0UY(<B9X&*28+H:G!
M=<=7\[(NW4:CA16LY6Q3N@-/B@N@IH\7(%E0.2,PTG516CO>1JP=OVKM+!DC
MVB=G^MWW K-&4&0]2\4BE52UJ-?ZQ,O3=_Y)I!J\D/?M'&B+.I9E5QF$J55*
M;L?_/21T$#"1LU#U[@K)<W:!SWA50$-J,:Y[K?ZGB*51@"W%W%Y(N0BM'P+%
MSE_^[?^7F(' _@A:1XQ:S\>WG_T=QK $?OD2)U>$EGT> D^_3&!+_I:HIO!;
M)UF68-<Y1%"%$V%<A-RZ;"+IEB=GG^$CVPVHNJ(1 ]=PBE*J+80M)__-J.9X
M]IC7%1I7D7*7IEQ\+5T0UI"L#U5\QPR2BQ_!!T"#0BPP5XY[L\!Z0S:7XK?#
M&K_UCIOX3:!@"^&@G""]$> 2CZ-A*+^9H=#4PY=(ZQ0Y6WN(#JZ-N]X!EJ*:
MJ32/G,E9N)OQ\$(-K\&-C>5'\H:/[P1,@L#__SK^R;NS]\H\*U7R,-,J>8BA
ME]X>>R6\RJQX>7]_/J\OJ12<%ZD8%P3>28LZBR>I,,V9$-N5?--P_O\H1"3\
MM\5L7I@6Y2BF>7 :: B:-AABJ1:[WEAB0:Z_0W_]/8F3% XGO'M2O2UHY,KW
M5T_C%$V("U7T+L "F4? ++6/$DFZQWRC==I>3_V0.D!8_1@--T8<5I)F/P&3
M@9*.H/C?_?H^B7=?JTI?SXKJ*B*'CMYKZUR4)EBF"!+^0Z_W<T7[HK_P*A'C
M&WZFS@YP<"T= !U&)AQ(@4Q6U1 4-5I40K1X?K6"52IJNJ3^5+MX?I=5U_>9
MY3[3FX[A1DPF4U\EV8I?L-S>5<?XJ>T /VUP@'OD .<8QQT]X'?7P%#YL2C"
MM>T89M!W- 9$&H(M%/"84:=@Y8#1_5:;7-0J"KCLG.GX'P@LD8+JV,2CH 9H
M'F):%]12CS6.REYCM 'C3*I5I-0J. <W]'@8 "%U@\+#!IS@Y.SCR2GH>Q>$
MF?\[>]WH<W9,\Y-N".F5#%<B-5)O;PYTQBNW2WZ5Z2C$'F\(@CT&Q?)"DKJ$
MGE1Y50WXHN$[@DM ]ZS]1VJ(8',</)HD\2<!MJI;G<FNU$C<K3]^?WM*VJ12
MOV"#$5VU0<7EB:@Z-#)PT&117\J6PN6L]((20H>KM]_D]36SM0Z25C]J\T0=
MN*+]DEUA^O4V:)I&)^UXOZ]8%6YFCA'(:Q=G455!_RLMP[IAR5E(E_7G(OY2
M^"?#<1'YG\041)V^F.&X6'96>2<37QE/''Y8*R,JDE3*LU/TXDS"BF2#(\R_
M59$]GDUK@RY/+WDH[7@KDXN7[C/T,-,3=).]DV,*[;Y*M"_Y%#MW@N#XG=(9
M*%:0)A=@RH&D.T6.6/AODR*?!OX90BO'8+'B)_5X'GUV&EY,HX4ER5&*H,%.
MO1WAO*4AD(N]Y,C36IA6OT5>=F+*^I34T-7SOE?:"IYE*X!LZ.(A5*X&?#"H
M#D,B5Y- J==*?$YYR FZ[DS8YAW(6+@O*":CYE3>!G^Q<@R*FQA+C^+WN'#R
MPYC'6/RG"F$::2Q3L#[91\ ] O!NJ)[2-\0E_L<I? %^':O>5>J+.R=O/KY[
M8>Z5,Y5?@#>[9W\=!GL)*L^7Y$N9FU2CAU)<A$II82#C.:5J42(98G-CW(IW
M2S,3-0D=A=Q@"4-FZ $(_$]%1L%BC 7]^866C)R-&#@8/4+V4Y@WI1=@#FN&
M[^R.-$(^FEOZ+IHEK BH5LW4-G0H2<Q55E&1I#/%YVP5>6RW=?D.L#T46N)B
MR)GC:'Z->,1H3KU>4S9QFGDMQ7Q9QP;%HORK8C]JQ$5.(.ONM1R1VB%4U9J)
M+RAJ9A1N.M$B]Y2:!XIU=;PF%T4YCG:3@6@\^W#F?XAD I;VC #E[&@;^KW&
M(09=,!LRE1,^V]15W'['8%6A-.GUU!QU0/#0>$"!/X^6G!_9U)@$^HV!]0;\
MP):"UG%PC'<)IHF>YW*.3C5_)TZN^'<>9PI24L<%)PVBW\/JP@>4ZX%B1;0@
MWZOQG*F_UES/K$"6BE'0I#8%W._//.-I'5U'C\W+I6O&^B#*-_&UU+UJFPG4
MQ"L#:7 K'<?;.3D]/7FA/#K<K$^ I&2O"G[@)"5C:,G7T=MWXF!M545G/Y6F
M[$@Z']':5.1<+./C0Q.X$I31#2G9>$&Q6.)84C"F(2<7 PKP'<XHFXE_0#?+
M%]R7:#G3+J,.2&.)@7K2S<@I13GCU/5L1&'GM(A4:B 8MD4D#/0=HN;Q&D @
MH<_E'7>/?_OVM*WFQ.T#_GLNX+_1@/_ !?Q=P+]ETWZ)WD"/4#C#&+V&K*>@
M^):9B0@IBP<]4&-_"/8TJ"-47Y.@+]'D3(($'\DTU@'\A/7?(4@-#!FC>6<A
M)Y-B,YF$4:B2$[T20)178UHF9=-P#FNX^0I1?3%4+)YFB9X_=*U;U?=L9=8]
M%9XVV )5(0,&0[TF537W_;> #9DLKDL$=ZC+]Z"UF2B!@9%]J7G@<2L*VTE4
M/D_:?>\UJ61VGR7=&&]MQN;#8B#*L?)/7*H6A.5G3.U#]A-;:9[Y3:#2,!KJ
M)-@L4BULM=E7VFD7:'VS#6C>>4**77LFCW#Y?$@I3&,I[#>(Z!7REZJ'&Z1W
MZ6[C<!#^&20TV0/C<<BA.$]9)5SZ!,.6@:8HA(D)5919K]D)+2.16R/5'E!.
M #9"_'6,$"W SE^?&E?ILA4%#[&5TOEEF/[XJT?_OZ6< /*;O$&>D>(N/V#M
M(U0/IY>"65G-6?,IHKH2.!XKSM/-QRF@(XK<>C7%2K2ZQA-< _;.X/3UJ6=4
MR ?K!7D^E%,13<H^)-?H=H%74[548,3R_)'3$&X9/IVU+Y9'W?2%QNK!,!L5
MU*O0--"PQQ ZE@Q_P."")0<"CR.INM!1?\?4_,EQXY@W#*0J+U4</:#^QS/X
MYYC\RTU4\BHW]M54JL2!AFED?C9-B@A+VQ5:/T?U:Y\5<5Q@5VR*]>NX,2CJ
M\+"9/,@M%L:J,"?SREF;#X6X-JNF65Z*J%#_IH6"7+XPCE%R^5!C5FNMS3S$
MGF&@]EQU@:!M]Z]2_'/LC=C%ZA3K]81+_3:K-;4P-30J)4:WAD!X7@Y29M0Q
M-],U27Q8QH4IIJ\D(X14=V9I?U9N]:-:1DYCLZP"X]IML JF5<]KF3/"=G'(
M>3@JY-_O_ESGKU(L<C17-SVBST[HFY@+_OK4:_;?DHI&B4[49E9+74O:)O,I
MZE)6!3AI?AF(0[L@01@_M?(?:Y^PTL0\HXD%M<F=@33W][N'.^,7.X,72)Y/
M9H+^^>X?(+82VTU@RWK35259EKQ52@4-CO5KG-=:CUS2/2U=L^*7MTJ;L:LH
M7*5RGG.W=RY1Q#I(3P.3!.C0*7OXDE&&F6@3W%+T$O%B O4,I:ZALJR5XTHM
M-7T,^PG'Q@F$N1DD14I]H./=[/-!;D3'$]]F)MZ@N^50D7_99KNI)'\FI6J7
M4[$/8.Y>1?,OM?N[Q!7XMC0[T3%]?&R?55"*1N]:VSHPYO<-BU,V.'QJ4=[>
M-H?43*+*\KR[+\_=O>M81'82K#.,[J"[K,@B;K:/5OD4C)%4-Z#6L(\\[<)H
MMH_\JC&T8KJV*0%G,TU0'NST7O"^T(EEG3P3$3>(I]-6E<5*AZI)S(;.A/CN
M3O^%U?O+I\;KJH@:_X7H2U3IA2D)UTZ=+V*5G>J)#(EMJK6-]2)T%WD00*@-
M DD:[)F*KV^>1)C%I=.G.7=-.2%Y&,N6$N,9Y\*M(D/UTY' %.*SV%@DG)=<
M)53EG>"ZG/696%C:L$D)P6G4W)>Z\#]3_DK@381N6B*42;U;A8]6H61E$"6#
MF3G,HCR]^VMLIL2>WQA1I1 ,<V9EB F6]R!GVK9_>26W56W_?"TLCXTF<)TE
M=%N[QT6$[F^S[MU^O5Y)NZ,5T+RL8*6/V%NEEFEEOZ;GHZ^D4=7WOT'5]VQ5
M?WE-#0X]16NQY*I;E1N$VK?V;UE+PCO7F!",)*54:\HH#B=@#P;FQ:R Z]J*
M._M7Y!$+@45"5N[UA\U\_BG&%QI 2UA53-=L6QG#ZJRQNE4FS+)VOX+CFRT8
MVI*'MV#$)%>#7.O<66G!K%@C&3*XT$9+K6&=@3&()T5,0^*!Q1)N9('K1K'-
M)0*/6=-<N@4MO<<TEQXSZ6S?)9UM-.GLP"6=/5]?;5NG'?[ZWF1ND"0L8>]^
M*S,W'L ?TMEO94_H!UX ZMKOJZDVUV_8"O_+#9'FT@_3Z(CQ5KAO*@Z8JVIL
M8KBPDL^;5"\.;E[KLZFNW+MAY=HU<?VP8'=,B@B44 (QQ#+U)1MC"!NE J@+
M ZE$OB$\-';?=AUVJ39LKW6/7SF70$7D<0S+3$#Z*83(YO PJF)8'T4:%6HW
M"H8ZL)TJ5,'(Y>A$I[4B_1Q19SQ'O7+C(*&OKA,);TP&0RQ!B= 561F\#B^F
M5%\]DL!0<ME)U?@A0B3.IPJ.F.KS[TF':[V(NO?)?RA2L+?&'.A2F^&/(H:[
M2(H<]YMJ15G-GRGS>VSP9!2H>E1D9)<P0 #6=&K?%G +_.9*1O %A=44^S*^
M#-,DIL_!X+ Z,#_ANS/QA; G9V@NDS$![$\*6*#92HX#74:(A<-D.  #1PA3
MP><5!".V'O!3@85J&DM"U2L3.CQ9."DP\P5->AQF0A7[)ZF7R:\%/PZS$^R+
M^$M2_B6A$%&5C?&PRJ]HWX0HKN%/G$L#4YX2T=AEHOV2)!MB3'=)PYE&T^!D
MS"G(]"Q#<NQ.$/$'@44\BT@T ZJ?12^CP"-7P"'ZER9J@/$7FNB,4#!"UP15
MY9EB;M+6AX1&<ZD.8IRG<@X"01;8HH%>@J/LW&@WGYVSV*M?,I;X'L'/B/"&
M7U"FN;KF<F!R0II-C&^&>8$>2T-JEJ%C&70/WRCW21$DVYR]2@@^3RE1, Z>
M,#G+^(/SE.&K/I/G3C^&3GB5U&0\-G"W?8$[-BC/>F#'_QFP2N'#J(@GCVVC
MPBFQ,IL#?Z.5B>0+5 87+',>B1(46=/+"K]41\.GK-_!>SQ@];9NR+HHO1E4
MCTP2[ KNGVEU8.7.&I+3#X023UFGP%8Q<RO7)7<&65CIV-IGL_QPDUYTDT:H
M<\'9C<>]65#>%$-Z8&SK$":O&Q-E";W&\*'!/FB:58E:?XGL;K<D(-BT<@#"
MT2%J:\<O5[/4F;X6E_%H%4C<BPL4V;D<5P(YI<9Y*^)T_+,)$=]J,@-RTJZX
M$?;T$38 AHRE3K-7C%62C8LHR\(<O:2 #U@YCEX0D/4*",HZY)H+* /63M*N
M9T3=JEYAXW$,[Z[Q*%:0-ACS:LKUNX4W^3;Y,-?3V-N,5]FWO,IW<"1K<FQ_
MN7([CQY6C]4ZU1W5.M69?,>EBK)*K-Q5EMTBA]0;)_ 61ASM.K++2CQR.>5C
MT4'TX@9/@:4*E96B^30!^7,U3?P2!@XU1F.Y>3N_A+^&'=D)".6E[&Y@-;C#
M$X<XJ KS^D508O:,1%:+%=EQ3A-/ SEKM;O3?Z9V!R"?LDI44D%<8[\8?R<#
M4:'29&&>ZHFRI0),;#GWH\J0""'&^;,@.9.K%TX@W$D@'-=;5]YJ$UJ+W-9J
MQT]-=*](=2MMG#FV<$$QQ)<X2@VZIDNI<=,75JED94+(DEZ"FGPJ)S)-67$B
MI8EARKXNRL*@'^%G\@T5F>X-I^1"+-#G=-/4.DH*?/-6-L4I*^UKT1U9;V!+
MA^H1H\H#%U7>:%3Y\&E'E;>3Q^])\"J>V3 6PWDQ@[$7U03LS\@0&T9@N'9'
MFK:RG;MT3QX'"ZZ!A)G!$:ZBO6#T0<?KUKMO[G![>BMN3W3<L8EOZ="K;EK+
M'Q"QOZ[)&8!18%62.P9#/>6<P6%R29";=/]FRGN6ASE6MI9*^+MR$F\J8!>G
M*P>L:N&PU;$")D>QYV,K*'<67*;,-T_[5OK(^DM;3W/Y#F]A2U=9__MUK89Y
M]CMUJY>ZS$TZ&H\X3*+Q'2_YS2(@SB0M@*%[PW@4SD7D?U3N1[-QJ"V52[SE
M$M0V&Y+T'OR4P_1;O4UOX!80$2WA;RG2)[0M+9^^X2H0-OC;__ZN7S>E[I7#
MOO4.7KZ!-ZQCGV.IWZ*N2/L;_M_VTV'G^Q>_9,7\UYW>"R!$,:_;%D_A,+1\
M^H]]EC>'AIG$1<906[@D9+VGLTLMG_Z383**X++JB"D7CM^V<_I/AM\^4"V_
M8[AMG_Z38;B3B VN97P*QWE;.?TGPWF?DUQ$)9-]_X3VB$)NF_7 _6Q!LZ/W
M+TE_\M.+X4Z_NQ_T]XZ"_F#P8ME+M_ZHRGFXU_OA?@-2E--#TZSF]00^(BPA
M@$JE@+")%VZQG/X/#^MNN_4$CW^X;^[$U*5-D?.^F6,-8?V4-O^^R7F]2+W-
M1+NUF:98A[?)J1YT@VZWZ_CT6?+I9LFY?]^\2CEL_8W-MUW4=<SJF+4UU'7,
MZIBU-=1US.J8M374??;,NC';ZM"95JURIH6YP%8VM_6?;II.ILB)9JD+G40\
M_L:-WM9C?>].LOUO/B%;+[W;L+=;2;B6:!);3T?'@-O*@!N?XU:2T?&?XS_'
M?RTDG.,_QW_;L[>._QS_/3'^:Z4!XAQ#-SJ&-##.,SBX]^(5VFO;F7B:>[N5
MA'-"V3'@TV9 IY4Z_G/\Y_AO2PGG^,_QW_;LK>,_QW]/C/]::8 \C%?HKVF8
MRV\IN+M/JOP1%C0QA9%=UM;Y;T($U<>^.QLHLVO#P=W2@KJMERUMV-OMR^F\
MWT3.C>1Q.L[;0LYSZL 6T=$QH&- QX!M))QC0,> C@&? !V?(P,ZZ^-)^H*V
M)"U(58@9%/2R299+$?HV9Y K'-N*O=U*PCE]P#'@TV9 %Z)T_.?XS_'?EA+.
M\9_CO^W96\=_CO^>&/^UT@#9 K?08_/\UDUHBST\K@AL*_9V*PGG!*QCP*?-
M@$[#=/SG^,_QWY82SO&?X[_MV5O'?X[_GAC_M=( V2YHH,<FT!]7(KZ@J;U)
M1E_\TRDV7'L&!]85?SW=O77IEUM&0,=Y3@UH/QT= SH&= S81L(Y!G0,Z!CP
M"=#Q.3+@\[0^?MPV1\V6%&N=Q6,YE_#_XMRA.&_ 9>-*M+9B;[>2<"Y^X_AO
M>_;6\9_C/\=_+22CXS_'?X[_6D@XQW^._[9G;YW7L)WY.UO'5FTXCZY8Z^GN
M[582SMWUCO^V9V\=_SG^<_S70C(Z_G/\Y_BOA81S_.?X;WOVUOEZ6H3&<[]4
M>95V:&+G(@\S_R^1PG??BS#U_TC#;!K#%Y[!D7756D]W;Y]9OF2O[\JUGBKK
M.4U@B^CH&- QH&/ -A+.,:!C0,> 3X".SY$!G?GQ-/U KO[KL4^JJ_]ZNGN[
ME81S,2''?]NSMX[_'/\Y_FLA&1W_.?YS_-="PCG^<_RW/7OKW)!;XPMZ;)[?
MN@EML8/'%7UMQ=YN)>'<!>_X;WOVUO&?XS_'?RTDH^,_QW^._UI(.,=_CO^V
M9V^=@Z>= #_WG? 37B0TM9/X0D;^6U&DXR(5_[BZ+U?WU>:]=8F7VT9!QWI.
M&6@_'1T#.@9T#-A&PCD&= SH&/ )T/$Y,J S/YZ\*\B5@#WVH74E8$]W;[>2
M<"Y"Y/AO>_;6\9_C/\=_+22CXS_'?X[_6D@XQW^._[9G;YU'<AO=0H_-_ELW
MH2WV];AJL*W8VZTDG+OK'?]MS]XZ_G/\Y_BOA61T_.?XS_%?"PGG^,_QW_;L
MK?/U5'T]/^9B&,E?/>^7^>WG/!/I10CSQ4?-_U67\D^1Y>%DL<G5F'7,6S7M
MVB:T:_(/.VU''#=M-VTW[4><=L/\]%IV\V1.ZS&_X& '_>[^%D$7M3^24307
MXW$87_SW=]WOZ&=X:J1_'B;I6*;TSUNO^2H<YU-\M/O#FFOUK%A1/0($;W['
MX22C#34258W:[?0'8;Q)\NWT7M14W.NGLLFQ3Y/97,:9R,,D]D6:BOA"SF2<
M9_"#].77>2JS3([],/;_/'_565;-2L6L3<?N31)%R17PHI=/@5>3."MF,R9"
M,O'Q=Y^!%)D8X:\"_R,0(\Z1''($I,D3OXB!>W/Q1?H"7I\!F:9 QO!2^JF\
M#&$>\!D11;Z,%#GAYQ#^([_*49'C<\ED$HYDZHMX[(U5"C=]RFS'/$TN4C$+
M@/BCJ,"31#.;%/&(MRL>^V.9 8W,U_\MPGR!S\.8.(CZ1-9IJ7A\.%UTTZ;,
M+T/UL7#\W]]EEY?_MWO<-9+2/G7>IS#[XK\3L>"3]\N/P[9>9JVV'/B,>U.1
MD3P(X7R#W,,#E^(&B2Q+1J'(X7=783ZEXU8]K4D4CD(8$H_E/$71,8*?)G"J
M21#,YE&RD.KO0QF%\A)^"',?1^1CC'*V]EEOQ6=!'@L@5!R#!,FG(O?'"?PV
M3G)_E$J892D#,O[[*"FB,7"Y&*/XDE_A(RRN<'$@R%BZP(-7].!47$H:(0=R
MB<@38[@V,[@1)A.05#ZLE^GUL()%,UB[Y4#/R(&7B4C''@AO7<-#]\2;, >J
M9[ZYI.H7DA,1#VREWSM9/L324XK'J$A)V9C)V5 R0^"OA\@J^,.XB57.QW''
M?SD==_P=]//UNS^KO]!/O9]?^&&FU!=) @!$7![&A<1_9S)%?23&<;SF<7 &
M>&F)>.&+24Y"!WX3)1FRY[+*Q#(2?XDF@-:K7HF\^.*_2CO^JR3%;O9)?!'X
M20%ZSS24DU(Y\I1R%/A7TT13)%KXTR0:9V;12BL#0R*,1;KPLRG\(N-WKD*0
MN4,8?CY/PE@M>C4=K?55)%H+>//)']^-3?XSL#<;IW#])E? ]SG=SYI3X42,
MPCE=\25SV)Q?S/F0^*.5C/]32VG3M+&E(6\;[G7#_HX+W,6+]B=?%'EB3.LC
MM.?9,8!)F)&89S!!_2_S)H5&^-7O-I8'JKT %>-;S46[$EY&8O3%[\'',]#*
MQDS&NV8VFE4/#G[8L,*A!"2MIKP9M(X! M/_H(S/]V(F*]I$0XA-;;:A0@^=
M+->LI_]#R4X-GWL0FO:[FZ;IR<6-A%I_YG<AZ4-&55NZ1Y_#/%JQ2YM,&0=1
MT9Y\\=-I&-,\_@9ERS^'GRZ:=OZZ$_LMN[W)I0P.-G'ZMC,_89.S:@*$>+!3
ML$6-<\C<8(B,BLG15O[?W]LV3FLK_^N81;OU\WN=?-/9ON*SO<$[.ZQ^C.8Q
MEJ,D)>?G3QQFB<(81M5*;:G0OC:Q%*7.LI/4^-(,M<*']98]@)?R/B+10]P.
M4A=*52&PB&SLAQUQ(<%J>>'O[OI,W.&O[T#"XKN6FF%<4?IOQA=UD8IQ07;V
M)$UF_L<D6N1R-(W#$5K4?XD()K[SYQ\O//(B"?^E&$W!8D_QKZ]CH(V$->
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MG1=+[%P3HX<D ED4^:]-9[D=N!(S-)G@L:NINA:U!,)ODSH";X^*%*0GO($
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M\P'G*))^E[#6!?_^91H"$<]'4] B\__EW_V!?\^GWAN97A19PDFP[\#$_T/
M=8 M[+[ 5W:TB*L(L$]24\VTK3)"3$194B'!C"R]3!OFPP0SIN"'TLHW(09/
M&.&SYK9P0D3]+K;I5;F4,YGG$8L4H3^1E;Q@UN6]6IZ<?X?)?;1NRU+<ZNA
MXVP"7Z)ML#R5DJC8&Q!^QETVK>XHSLNDUM-ZJ2EM%L,V&5)%OY?!5R+*)AUI
M'U&V^GU/92?+\+(Z#= ;4K2V^)6)9*?2I #+&K/UT$A7.<P3%?'@3FMH<T0B
MQ"OH D,?^1*K<_XJ=AL,,TDG#D[QI8PYDUQ2JG4^I435E21]EJ*UT9JH..7O
M5Q]>>09%XR;Q(7Q'@DU)URMT* X7U5]:"@=WGF%=@IC9RW0S2'7<]/C '=Q/
M$Z,\^6*]PP*_!J/H@B4#.@S+ U\/!Y[$L/@(SNP<F!$5C#>@E@-M=O\P1C;E
M]DG0=,84^+M9;I$<O17A2O^%HIQG__9:ROGW33EO'<KYZU'N+*X)%7R2*(5;
MQ')^M7BMY+14U=<JHZF[W=!/)[*3#MX_/ [V>X/.H$L/?M\[& 2]@WWXN7Y]
MD[^&!?0\195WA$&V0+FC87A_!L=IFOGH=,>DL4F1DLQ+8KF;A^BVX8%O&->7
M(;T&.S82V=0GZI7;8 >Y*QY)KSK=>Q/;_@JQ32YY;\556".EJC59>=_:0M,Y
M9I[ 0A\\SN'VU2W4+?11%[J%B[.S@GN]9:_0DIIF'+_&?2<:';_4J_HFOR^%
M13G"%WC5)M8-[EA^@/[8X):]LQ>VJK^Q^M(+#O<'0?^@K_]Z9\]K[>M6-W@R
M3Y41P,3.$JY/X+[?M%!.?<;D/Z ]UF@OT#\Z(FH?=G\PGE74;!;^.(P*3(U6
M$4)25XH\R^$?E#+0E/G'B80KMHN\FUR3:=BDKYR'E>U67<)QZK*L-CLQOD14
M<JS] RT6O;B\A9B9@1G:F@Y&A29 (;:,=76I]JDZ1>E)B5^G#[7N4N&FN58D
M\ J3I$:6*&1[M2)SJADC<Z$KX+_O=KK=GA7ZJ<@6JV)D143)4T$9L.)&VJRS
MKPM,B:;4Z)\H\04?;;HORC@7W!E7LF$Y<$=V]WO6*SPY3X7"3&+(T@5B+HMF
M,AT>'P?'O>4/JP@*^E1HN9:8M06JIROTQXK,^/F,&A:S#%69;]H)8A:)$S93
M4X/3A"IE.MITYFH;]D78]$VNR)][U.L&QX.]58MPHGFKD]?:GGFWI*!8>FR@
M/8-41J;"S>C^X\B#T(&&%4$M=4Q4JD!3W,HHI!B)@Q,",HT^GT0471DEN]?D
M*2@GTNZUV0JH*&59F.5E4,?R<C8[(3VL1UD9C,,!(ML'K(LTF]R9@MV9Z37N
M3"OE57DU=3*DIZM"GGE6ZO61BPV'A'4@/VC4WN%5,2MDY+_M^"]%BA%1$X6C
M#)<5$4UDU;5]]Y@/JD^)CGG8)X=R#J;A3)L >&1TP&UH FX/>'%\USK.?*)%
M5"W=@!MJOXY<[=<F:[\.NJ[VR]5^K;&$>NW7P!S;5Z_/3S^=?<2:+N_#&__T
MY./9YY.W_OGG#Z=_//22VXGJ^1OC@VR06.XN^A:/C"CR:9(28-U(S,-<1+K
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MI\)2ZJ@RMRM55^>FAQFU>L0. 9',)>678W\T_F5,72)$%"D09H0)%_3A15+
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M8@PBE09 %2?Z7F1C\2_(7[Y@WF%]O:+5==V6O<KT5]*//*&('HIH#C@SE9J
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M$4 ZXX*_RFFLX]I3&S=*:;Y4O<WPO$8AV.1CP8"\8V"Q)"KT.&")(%_O@CW
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ML9"R5M>5IW-N:/%F?C-RL0MZU:?8?ND-]E /O!',Q] JRY F-!J00%T):YD
M@ P<EV>EU\=9?)ORC,_T(O2$]*%LD(X+@N3W2.'S:&G.*D2OR>#Y\+$O ?D1
M)H:GZ #DK3.<MR%I'.#$G+LE9FV'!K E:X6PYJG@KY[M1Q%D.4#E\,(;NB$R
M@IH)<AL+7=>U()!."+L7R 6H0_)Q5GSN0L> ;5HD=R"03KE;DK/J,<P;OL1;
MLK:I$XGV5GB12EP@)8-G;T,A:2&TD4MH[3;K*@QJI_%T+EG'8@W!0:JW<V0%
M"076PW#RO"N!F]V<CF8*"8-H$$@*DEF9$L$9,?"O%*N]FR%;Y@$VDK0$KR!B
MKN4W#U:A5:B66RI4<Y^/"ZIA=5^4Y<GY2_B(GBU<&@9OY69$5F3F(VFTC5G/
M655S%$[&VWZS>KR!0#0;V94X\M238;B+#'9R!8*&."K>GG6G=M#I]DVEYMN^
M6%O(BK5C+=8N9<7:?Z_CD=9E#_[K.I8N=R?JNHBCKZQ?;1LXI9DN*SFA()0X
MAWY98_J6/7_8^O,%N^F/T=$328H4U0$,-I\72D+0K!PVX\8+'&&@X1R @9!A
M/S GCB%R!6<&W#*5(P?)D8,<X2!/I2Z< R;MF=[J^G#/>?:UM=B&]6Q[[BR%
M]T.2U[5LY.Q-581\M5QP]DZ:^-AF -%YJ1<Z[ )8XS:!#"=S%B >>$NFR(S(
M&,2<+[6%0AX;P]7>!A9'T5MN5].?/2'20C""E4/*A]Z66V,NT=-,UI_)APB0
MGZCFK,B,37C%?_H_A5.\*[A59TNSYDG+>.&&U;GINVS:7H(77RV4 AC$LX=<
MJ#TP'YSF#.$7(_F!.:8<&>L(2$P&FQ,30 38*^>SUZ)0.2T5<KZ[=;9[%L]V
M@X\LMVZ["#(E,!\5/]6<[+31U6/%0F#UH>:H8-M;=;@?T"%4 FT)]1;8$Z6"
MBST:0+VT)3E/DYS;\BC=<&XOY\L+I=,R+_CL.[,.FZV#HQZ90G+TEL,F<%#8
M>%3YBM.2[56CUKE(G#37K<@<#I6C<>4Y&I)T!E?DB0TJD21"/5^OU9Q']JA\
M 0#- #W3=';@PRE&,9$72Y 8_O"EB(77>E'9Q?U,CG,AELZ>2&T >Q)H H\=
M?4&A;'H6;PV]H?P$;F'QN&YA=BZ[^)G@D<7K9SJZAO"&OZ<9X"RZ5U8I\_;Z
MW760Q:+]XUR0_=3E!S!@MAW=R6RZ_ 2#P&<O&<O<%L:R6BF?5M;["%R]'MY!
MR,7J("P[@"&] C\/MU['7H'O1OMD:"-1_<1?MJXM:!(;/\3>_)(I,P)M&5[[
M\@^+F?<119<7LA!_GZJ7KU5VU;:<6]OFO-JVL)6V;4'E@$LXZ1VP6W4,$*8F
M&3C*:E!XX81Z?%Z$WUSL*L4WT"CE:Y7::<%/JP"8O\_?P!L<;].YY;81=NSN
MDY621G*-3T[&U?,(-3HS138)%@#LW[K8)#_-YW3$KOCE!:MYU)&FCT65?4\G
MTV(NPXZYZX (+A]%$AHX"+[6PNEEOKT-=E?HN,UPXVEE;8:B,0&@0):5R0U$
M0S9VT+E!*I?+5&YDE=N'@Q]A?=L8DQ ?,]4-%C0#,X2>:=S0:)\F(R/)D9CL
MYI21D0*Y R#6TBC6UI^YK&*%RO5U  >W"]DZG285LW5/=:#()4D'-$[9R)5J
MV&)BO=(SL5;&WI=0U"5NI&B:GB?[^:'IO_%7/^#FK53,<[>]Q@L*6S?<P!:S
M&]A8;V#++_L&UH]JGC+YF;G"$O2LXE3/UBX/HXCI/N-VZLG#9.G?5\;#PWVA
M7K'O;Z]OVE?-]G6CD^OUN\TOG[J=\]9-C^M><,T?S4ZCV>JD>N.'/;L]&387
MO!/1=*1FF2)'$M@KI"(HE88\R:.*R%0S<.2:ST/("BA+6%8VI)2KXIJ!9;KB
M%6[PG*%$[=# $Z29L(J,T,3SBJG6G=MM#DU\;(2BK]S7S!YZ.RLM13'O9\\;
M@&X LF(Z:9!@SXUUC;9N  R[(I/20OIK NRC 03Q;U5[I*..+.6"E0-6+ZY)
M/^77@5IFM545KR%W8,9?&]X<Z""/]SI*]4S79+KF\+J&56"K.%Z1(+DTG)-F
M&0T*O+&>R;3#T5^7:8=,.QQ9.UA7EW97A'\7?J8:,M60J8:7K1IP<.&G&58]
M!Y*]<-JH1#JB"D<SJR@$$&A;0 3ISEVD9O&0JW(&A;F24>ZQI,8$HDAVHTG3
M,K+!#43KXA+_=SS6T9A= _/Y<JV8KU?*2Y-H5G):YM++1]YDV$J3ONN=Q3P,
MVRD7JVO0'OQFRV25A\==_)F=F\BY>,TSIS8(BV&NV)?=7*_59,-SH:(,&59W
M+$7$0*P<@/9/^\)LV#49I[D[P/5&4Q<C-2FC]EP3V]C LR&;O 93SD B2%D!
M3#2V4S3P-KR#"AM%O)*C7>J0<,JN@/NMV4:ZI_+$.R/.F; \UV>LMQ_F#SD
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M#(B*M$<O3QYM3,BR2>IB:!+ 1;8DJQ8WKF@Q*YR-&C"(^!25W"=(VC:D!]F
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M+/@JN "6Y?]6_]:\4K\,>T/T]V8 O+?%=$Q)IJM>H*[: '[O(SJ1['RLXRC
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MKI"9 62\;$VU(>1Q1"62B8^U68+G\T+:2ABS3$$F-ML;]6CW>T%&7<"!?<J
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M;+'PVF_/3K2P' .8VLS7DOC+->4^S^M>_7=QXB:<1;(/7/]YAE?0T,6!//S
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MQ[';,>QJSXL-4JE9LBLU2_L;RU WOW5_+^:3[]5XBSO6SF HQB+[3O5L,2R
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MU.S>Z;%?S;G<U'3N;6H"M^5:UV LBG3V?&L@J:UV9T@73;R"QM"4'\B\K\;
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M\[%_Z%M1'\6U/,G3C=_W_]S&[Q>7MT<WVNVEKG: UX]/+YH7K=/FF1[U@M_
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M;2_G]2B\S^N8#L*3KGMVT6E>+&Q.EM<Q?6U%_C*.Y-OZF.PU&H5&:=UNW2V
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MZ,Q,;.SP1BUFQWTTP.6C3P.T !*J$!.L9XXPZ$*RSE/H6.F= T ,#[\&EC4
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M;,(=#EU'W$-.V@UVB\Q% J?/FY3@WW;PD\KD$-JA7&E"W=-9B H74XLN&JP
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M>U+QK!7_HZXW#A'IC/C99KF^T&9^+;7F@\#&H;&1R5904^I;DS'B) ,1QEJ
MF![5.RA%YBH(D58$5Q$Q)1&I--6FHNNY(\]"B).O/Q';%M8J1^1K#@DBWPQ9
MA44E]U9OK9C3#)(-,]L<P%XSFBB604_HLUV]Q3BD0+Z->R(QYBK F,'@YW53
MT)37%-AE2-U<:R@ZIW_:/=_512_C_[\Q'/W#NQ?[2!'^Z?RZQ51 O(>\S&?
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M14R"2*^1>>6S1[WV\@B$EPKEQN+@S9H!YE:]_.EQLSQBXY5"O;Z_9&!<(^[
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MV,0,R%5T9*LLVQR!B=NE>ZB\X3E]!.EECD9L:_*(7YPO3C1KJ"TR!M$#Y\H
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M"_()YI+(Q%$[/).[3]X29#D2SG 8RPG(X7@=J7X)+A'>CFA&Y26H\*<"#\8
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MH@:];($.0(W@#>J$$T0%/6^(OL7):/F*&Y$!4.JD'$(GY9!SWE#Q&'.2-:@
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MOKI+=Q5^UQ>6#8S$<BJ$. Q&PMGU:^AJ=%#3<VD%2Z8YBK]$>T.WG/L%"K[
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M4W"'H3/"+6[,)RL0 _[73%J_.3=8O%DKE>/&]&7,GKM45Z'!1#<D.UPPIP2
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M0ZU7N;?G8(E)9!%+R#;#2*-M:PB\QS;6&\$3"SF>D.='CCIT#@I:O1VI!X=
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MX$-JMLQQ40BWUBT#Z&FB5)3*T\CY6E<!V$ G=G5BF?2!N-5O44$&J]Q6A+8
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MR:C<;WSYJ'PIA-UH*J_N,C%4OJ0NR*G;Y5:5T37)DC$K6.4P>3&2;<*Z.RO
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MC]A5WMO5JBH:)!>OC&0TQ3D*3+9>GC,%66&DJ130E5I?8XBP\IM$L06K+)V
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MJL]7_>HTLLJ2(>"A*HL3M'TCHYGC4!6TX(0$GC*9I :>_&X@&UJUZ5K>@^U
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ML3TN1&D7>BA_SRG;)%FXQD3; ]>A!*]+Z2+[64[U[@1T-@-AI SG"ND,>^C
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MS=Y8M=WJMIN-6KE7KZ4JY294-76J>UFO][J?:/N?#KA_->34?VB:AI\"'SQ
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MZ9Q3#[DFX#300>QI#^_@,039.4M1"Y47O?7>4?Z(4FSW!"&2!6_J3!F>&1J
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M1(>9X/JSWK039B2(&9YW;AZ9EM59HW[Q,!C(DV$BF_VN+M]*H\3=$_09]9<
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M40CNJXAML+,CF/V;,S:,6^9,NI )K!<P#8]GT A^3P6_C@:.#>.^.YNF@Q_
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MPA645:AC^9]4"VI>D]@M!=$ODU_]UC_VU]"OEKK&5C3__@,)[4!R%7 O9P,
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MV@PD\=839V RXJV.@:[S%8>\+#P;FH[G;?84E[LA[)H-. T(R(T&LL:A#W4
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MD!#.B3.0A' 2RL#$V@[WLI!\.(,6$F,7',,:.7]E(35(45E3)%' 9&\/N\9
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M)P"W(\+^]9FY9_C[F<1W)5DR1XQG&T9YI(_OR5UM%0MWAA\T1A"T^[SR!%\
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MU<ZX/JK_?/EE'7^[K./\,ZK/<)<@REXD,G318C-(GLRY8U<\HYS!_J.D@$4
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MPX?!5T4S>E>-73+_2]/F?Z,SOOW]M?!\]7KU;/+86&DP0#D*].8#!N=!@W/
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M5 <##L+T;AK<TM%?(0";MM47E!8653%8U50.IV/IU"YB#@XW-,<YG^11B-
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M%[\K7ZN+<'')-\ZJ"9AN*%IJQ% 34#AH;KXF@#7?<: R#\NX(<TF=)"4-LO
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MO;!?O3PD )(IVWGWK')&8<%(?]&C8^^J&#,DN$2.E>9O/5"X$:I(1];#9AB
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M0\6<]CH59$FA4P3A]1;ZW=B(0O2V81<.0Q4D^A@K2,46,3CI#BU+;'ZJX5A
MM'4-TQ)'N 8(>Q%S#=M$Y'5C_T92>(D[Q] 7O*--]9ZW;BHFK0)4ID96']LS
MPZ^(?@/&&)DE\YL^>I[Y# AYM?>]KA"I\5O:)2%?F1;RE<[X^KQB_1[>7[9?
M !H7Q.1P(CUZ2M"T!0KBZ.DSL9]6"O.+?> A F;8P0(*W*3LW*3 ;M+ FYPU
M[:Y4*W!VZPP']3G ?7;]=A<-SM]< QYPFFL<<(>\(0DYZH&09 L9XNP-#/E
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MDP#:+BF81!_ 0HX <CPI0\GL^TGG@#M5YCH#?<3B>XS#Z:>"*X\$'Z;D!-4
MJN;I'T$Q 6*F[Y=E%*E/1 $.*>=I1@<OPA8EN$UX$(Y'7G$1DN>Z(Y2UNOH*
MMV,2>30MW&+)@EF(J2PQ!;80S(YA.2G)4&GKH5^Y-,N'PQ^5Q(H,USMW<M1:
M+$2DUD)0HNU]J17SA8T*,E &42NS9(K</:_1NRV90#FT"=CUMX,DLMV8N^JM
M"/>V1'5[FZJ''7L<,01>PSP0'76C !:4ILP(H0_<1B9VD?R4; I#,69& !J\
M *K?HF)]"]LZE.'SO4".4S,0E8CW39WQJ3PZ_,&;S6-!2C1[*FFOU(TU@,W
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M7:[CPGIGB1DGG2"*]1KKEPKYXB:G>GMTX:>!":9,]MFY.>?@#EO.YX!6@%A
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M 40 5S(W]R <C688>]$2#9J3@=5%<-G[4CVHS@CZQX\%/5T=4%5/1*\T,+.
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MQL&Y+>:%->E].3GZ^?FE^+W[M=R>)9:AU\Q4+>[6Q<OYW"8AB<B5=JEE _X
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MNV,&]X*,OJ&P_R=,9Q^0O#EEV\KHU!4"\\P2MBHY!(P^)9A%4B/9T$$F+@2
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MFRK2&XXM98BJ28G38G@+ZDP !6L&N7&W\VV[T68T/K 6V-%+/0)Y*TTDR$(
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M$7/[+!8\$TD1%-PQ/4?[UNF=.,<2N3]O3K\Q#PB;!N2(%N<_DP$MR'P@ @T
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M^XKAL#!/"F1O+$U,K^)0_?7<X,_:^BA% GRE(:6UW$;<P>>X?-C0L;BY8^6
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MV746HJA;OV3L["1.ID'4T,XD LW+ZA/Q&H^E]_@74^%9FAI35SXK.+?F6GE
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M#C_91KC^^/@[GRL>F29HN]-L_6 &7;;1[?2[5^UF?=!J(E^Z4^\TVO4KMC]
MO[AN=09]MGMN^=C]9N>4/;MLGJ:YU3\8="*1%QG1V[3%FE.,><7<ROMS2;E
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M)H*DR2\8B$J090MD"OJF,-8%Q[@?,5-UR6_T.(%SB;!G:,?2S99 SP5BO(R
M@V7(P0:^0<(PTF 4 Y8G;D@#NC84W()(QQ/+Z*#O1 6]%%K<T-\!4F)LHG#=
M*I@EL*C2:5^C)HV$77;;9X)J595S!OVZ#- *53Z9@MGGO2$_2!<97YD#K:-4
M",P0RTM#209>#8#I1"\3[O W3]DNDFF>;TD8!%1\!D$&TL.4>0&S /U71.#C
M5"(TL4K43]GO(EZIP,Z,H2R-G&)D(FE3M) [0.P!Z8S%#+SMAGS4E(9U^RM=
MC)@$0#G8.V2.75+FO05!<-.H=\\L=#K<X*I9'=QC"A4$_8LS$3<QDG=3,>WI
M(<?2? 23Z;#VME9Y>]H_92?B&.0?HXLC0T.R'-VN+#S9^,C";(:V@L/IF@$"
MDZ #WADRE=3TOOKV]^$3%A0*(,U).N"D6X_$>]N.%,T8,H+%AQ3CV,"8:3:=
M!]$(;L,VT6GLRV,'>)"W_5=*F;3A6H0YSN3"D4H'+4QH"5X%Q$G0NAE NE85
M3%N"KAL:?K4P5 WH61:A%3G88@%VF&@B[I.VS!2@-/,CG/6,,1V?J&E(*Z#_
MGVAH(2Z, T;2*;JPS5]@%W/HMQII27\230!/^"/=%8;\)+NB)@P 0FG0K@TP
M')HJL^HC-%U;.]#$F:J!)' !^-GWP#R)"YQ.3@M>A?6<U1D/KXSZ.G:(#A6V
M:%I1R(F>T=F45&KBIG]+<)H^FX72X00D]0KG57:-B0S]$\Q,.%0JLA4Z%9R^
M/C.R]K!XI%<92QS@&846_Q*K61V)8P/C*H ?HA,L $!^TQ_T0$8TB<:/C?V9
ME#&9E'.*$.\20-(0*V!,%!Z0,U[**=L'4G)\V-J.^(S.1L'XD1CM90X "1CC
M!2 S8&HJ!DJY$S"-,@2:!90W46MC20?4.OK,P&T1$X4>I2#KJF,!9(BKB6?A
M[Y08.@7D0*:"@I%5E#F#5HJ1*\$6&HL F6O;1!QX7$\B<MG0_WI> ;P(SASU
M\02GO^:_^.\ _R!+XB.5YP[Q!*@OZ)0P-(DEO E&#D@6A[>9<7"2W:0&V&HC
M9/?AUD_D1^,XSC9]I>SFECE*S(A>"C4IIN12L#U@_UO"BMK"KZ%@ER D)75L
M&R.!AA.UT#0,;3HU% S;- :[R+0Y&.)=N/YL"5ADUFMWIJ]S![)%(6:;0B V
M_V6/\^]I, NK"2+@*+JF+3T)'"?9&=$9U&FQ%LTXK3V N>'? [RZ*C]2RU6D
MR%(R'@0AR\@^PX*=8CI*8+\1#&\D5)_1I8WO'!)N+!*<4A,:%+00L;T N<AU
M$PP]_9V(M#3G4G>;1?>"0825>I$:KQAP(2)4%AQ]8L(KPRB$1!"ZPD*)&UU
M":K"ME$[@(@<JDX"Z@9\ZBEC6%!PT6NTLUO_O9]OV$:K,[CMM;L=]O^$Z>P#
M>U/O#3H ^G)S-6"/L8O[+UNN\(7W?J>PA2V;=9Y;JW9)K#S9V:K-5)<N:J!
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M(NV=D';=K*\-5Q-S>PL4T#3K#2T=,3]'. 3L5\-X/\VOK.HE'U_WE$UX<.L
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MFK(!C I+)62%^(/?8C\#_"OPL0G6AP^!VXT<"TO:3EC/^CMVD"VF!4*P"A;
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M[]M!D5K]:,HZ-K9L"\<@$H_AG"8F&SNW8]EO#E"&%N\=2$!EOTM/*,#A!PY
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M)3+5<:<91"_C ;OE5YME_+8HXW>K&;^=-YCQN_44.LK)TU9GO!:6]*P8&.(
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M9>*.G[:-4_-!'@*A7BW;+V;;EM=(JL!1?@$#G3-@)>5"'^A;RSK]K[%U\H8
MVFNR0QYZPP4ZY91A]W#:C!P/DUT&.=X.6S*BB\U8#)/BM#,UA>3Q3-\Y1>14
M=?(*[4<H*&,7#=U$(@"3SYB[NH[-XTK-9)]SF:>)3=BH-,$F[,VI'NART#\#
MO3?@MP&?CD-V%0=AC'97\A5PV]$H+S4^Q"XR%)1.)ZQ:J\W3FB8^AA12/H</
M9U28YG##HOD1S/!7G*MZ&Z/4LH+9-/*/58AAD?AM7ZBFJ\*[Y;<BRZ=3LW^
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M'@&@.K,W00.=MEGK[J_2^$W3@$[EQFLC$E1N_";0O[^F(V\5_;I(@,<B)"0
MW@();&K8'&B9^0'4FO[C^)A]<H1K_\*N^"V0QT#\'0O/@H=JS>HI^X.[,2[
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M\> _$;X/F8.QJC./@^CR@+'XP2WWG/^HU<,H0)8$7)L#8P%%'?_[\/6A".Z
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M4;EN% 14K5UY1-^+G$0EZ-T&HBQU$'6JCM2;T+6KB>B%(:!WMYX *D77!MU
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M,AW2@PU>"[A9,4)F"_RRVNVT3/E*E ?"-A[X">T%>^C O5=/1!H[I^QR*MG
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MSA(U5CC8<EVL*3A Y2J/"Z;FN^Q2(7TNL@"\"F1=VS%G>WHRA'CB6U\3R>+
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MAR=$1_JY>T.W:4EY1MA<AB7O&?3OC]Z[[T"8=D(A69]@ZM3=&C>6X@:8?\U
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M^JR6;H5ULT";O7#T.7ADE8N_VX #*=6A\SKWH3B>9)XM!"JFEAZ8<6]I6F
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MQ^7J:YFGG?:\ZUY[F;2BD*AG))O]ZHFH#8:D(X3EV9,KXY^8OEDN3<^CFKH
MOYV6#9E$TQ7U-.C^H<9N?8,K8H2.R[BCY:K#6O!O#O?5'9X0WU>/W<NBP21E
M\JO&'CX*;<.A+_/=SKQU^C(C"-O765.I%2<PB6E=":#)="<>YY J*;&5XGDV
MFY+?@??\JI6. -B(OI6NC;/L$LQG;N*'%<&<"C\KIZA;*$J-8A2K1O\MHKUO
MB]A;6=08=$,?#,=S00T5Z1:2U.Q5^+YD?JF=L.3D40?5<_1Q)J:'EJ/KD5K@
MU(UM>[_FFV$,@E\EP'T&*XKL+19M3@/R;%&>J.SXE,ADZ,$OZZ99@33X$T2^
M('SRT2\__12SF&$OF)F%&* "?S#A!PC\=8QF7G.%/4K"Q>S7IK/"LD)1(T@6
MB9U,&?Y=V5Q?:KC0E^\%C=CI3R@?%UR00A<G]6_!7\6[BT)D;P]N,[U4YI4
M!:">DYJ15YZCP'"41LW4_.X'>>2KT5V>UW&;9J)_5<XF"D46LP6!QDIOJEB[
MMD56VQC@/ C4$<)T:G=-E$EH+@5#_8 "N*/308H1/$<>+MZ/6C0>/"+8H] H
M-N,.]4MZZ4!#,.Y5 ;8WRA:!@[A;;*N-Z$.K,==!'E&<8C43X%1C[&I*9RL7
M8BYE4#,MF?%V&7XWC;X(?SU;E7DQ8Y8HYOL I9#/RTK8.%PHA&)T<I>"Y#4F
MUT,[7('$<SBHV\)DJ-:K1P@&I[/?KLKMTJYJK\_4EC3Y3X<T^6W3Y(\>'O+D
M^Y<G_PY$*>^+4H(M0;6M-\#S@ =K-(+3IKOQJ 1C+S;(Q![#IN)BO_=+OTRK
M\!#7E@@?<=91EE5]>?B;TN<: .48;-4O/KQ%09:X8LR_Q'6ZNY!QW,+%)V!6
M<Z5H0>P'1FUB"%\,8>D)0;&->A;9V9\;*L2Y2EX5:*TSJ"ID8#Z\.7D9=<()
M+53"(#A&E.7UPC"H"/#W?4#=8MG7ZQ66$H#,P)^)&K-5O  ^0DQ'8DQ%K!PU
MT,$[GW:TC)-#I_I^]PZ^; <YF/SABCWZ]2QK$1*-/%'/1C9GY8,Q?:,[]M_2
MT"8K#>X;W^IA$]FO"(Q3.%%V_V0S3[&70UYFV'7U=[BDEPDR1"*4 _>BLMW;
M/TI3LC5&,7<9PD][\PH91UZNQEF:O&WP )Y>@<$/_UGE^--O5UDUSYK8@Z*>
M.,V5WUK>390!TSK'KWOR3L1V *<]9<P&'"4"&K O6A8>L2(!M7"6@IAW*IEA
M%K9F,=WE%.B(H^&2F.RU*7._0TD</'OBWL(+T%#EC+AV)H8=E!X_U\CW>O<!
MKP[$-Y7FV:5]=BJ):#'TD>JT]#CAT'>/:V!)BL-!(Y)7NI9:TXXX.9IZW%*,
ME6)OM^#'\/"%C75-'M^1,\1M!U$+::.M.+7/=TE5S%+3"B>55^'OBGE)_*WC
MNOZBS@ZUOK*4K@$@0.RAR*/L1^D\O$M.^LZ[$<V,IHJA"YUD!5+XA5P4>&T.
M-V@K(0.R0+DK8@RJ<L)TY$OEBBVP+$V/Q,@L@4F 4X=W.-CN6.FR6J"?Y07&
M"(F?5O$5C8;66>-!2TLNJ0^RZCI9C]".JM=0(#D*60BIK.',%WQ<O61YRBO.
M!^']H+F:=N0$L$[AFU &E*#W>5$T?9I"3[Z%WNVR/B04[O"$6"<^=>!(?:#C
M^:DC<7 @_^4%CE/ANRI(V/WQYI,9U7)BL&"+O..)RZC>8J!M1B7&O2J\CZMF
M H>O:(*);PR=)++ 90KP.?\M!RI#\O5R&LEBPZ@0M8>U R6>5QYF/U8R\.S4
M$\-V8RI+)H(.U>5>*7<Y3XS/$A>,6-[6.#8<, W7AIWVV1&$,\)X#T9Q)3LK
M+OQ#V*E(C>V<5S[!* 38O]H"&C6>BQ@/X3J;L1^%[U,*6G$DUBN_T0ADI^I[
M=UV7,0ZYXQUF=B1UY@JHJY )-MO<U=$9LF)D$^Z0+N WRO,MI3W(0:G>X0FQ
M4GWFWJQF,R-6;%Y^/B^VG0YRZT X=P3*#>C"2)JT$&SP>D^RY3+#'^2V#K3]
M;6C,V+$NBK@<.!@"&\<<HY8D$R.]<VW7ZH[UDM?D68OJEQS4LED588!:?289
MIRFB*] BAE..#Z3/14DI1Q\)Q:74(HGL-ZQAU<K;SBZED0)KS/J0TSPC=ERM
M?"L;L'(1P(0=>-DV- UC+['B%W<Y)58P,)MG19;_L?SU]_A8<R#YVXU=GDZ7
M(:IHN&P6X.[@94*'6^X;]^1'82V^]01I%KH_]W@*GUY__/3Z]/7[SR>?WWYX
M?^I.WK]*_G7RZ=/)^\]O7Y\F']XD'T\^P9_O]21_[#[](.4@_KY7L=$=2!&'
M+9=>Y#YD U>4?._T]<L Z?9/Z9E\3B_$O^[1(N^C8?7D^)'[P/UG)*YVJC!A
MW-R7BL5//B*:F*M<9+?!K( =OO+M:W)A#25Z=M/Q& 0(.^TE'G\<H*_O0KM#
M1[6"Q!M0S#)N)J75)QQF^?>JQ 9_H;&@()S)P/+]/Y@9*94VS10G8R8[\BTZ
M3;@G<$"H#X1E!7>4?+CLDWO+O-$/:=/@H5%3/B0KY?*8@ BV+PY5C6V?4%RZ
M='O&O599T.-:'# B/R)! EI('=(F^3W]''I)&P*4>DSF'L)YL-?VSJ6([I:E
MB+QFQUV9"0XDYF4,#RF8IU'G-6)1=;'\*-U+U 73T[7CZ*2^5AS*0 O)4N>Y
M;NGE,'^!I7<$A ,6M%DR7":@<7[(^#UO]::)09X3L7QGB.TP-<T86YNL61!"
MK@DX*UZ#HVUDJ[;<E  ZZ[=I.,)RS%P,C,KF@JD6"Z9L$'R1-4+V]U\/CQ\^
M?.2.; /'7JV5S?FEB6D)(YFJ]UF;9_\V^J&]FH_KF6VP^+\O*;UY+(_9(V5\
M?:C+SP>HRZVA+H\.4)?]@[I\'T/IL?/I_Q"['S"8;T0O!X_W= %J9S"M1/32
M/5K3_122)^ZE5#"=+ANP&\4,T2L5908CEJ9%G:]XBB_7;C<^:3U,=;M";H5E
M"L\?4D,Q_']3SR?N8%SG#+]G"^G)SX_2QP\?IX]_>:K?H<I;[G)')G.H%I2\
M!,+NGPV]B0IS&V(,I+?L8!)TOA-;!7Z4CYX\2Y\]^6G7$3Y/?W[R-/WY\<^]
M91 3Q)WR FM&JSL,)B#$:Y 2RFS;8\,I!LC8 DKUJPD]0#<9?@TL+12/>A&3
M[R&&X#@Y06[N\ C#X;5V_[&)']K*05:"@Z4(92[F]O23%5CRV+NVY3Y!U)4U
M))06& -><%F#U,.QB4VK.@#2CG'8/O";)],"-!AVTT+_C9I0-Y7F6I3'$:<2
M2N>/D]=1:G)P;RAY-;@Y0HR8"#&BW8QQ3?BNO!@S%*M->2<"% M/_!C,3/4!
MI&0QE%V&$R,\B%P*+^W9/&F;W6S$.%#BJI!B=UHA(J4T#U[WN)%?CH%0B\,8
MBT940O7\V@4([_/"EUH1A5UL4U^\B*9\J90%H0<7FN--)DSTN$J.;JDEX3P\
M"@Q^R)F)&T]H\.DR(>G&@IVKWE_']0I/K% *P8CE3]A;#&4OU90'I0' YDRY
M &G5%D[<'Q'WD!K!3U*W.#17&:Z9K#U3NN7HF\,HAW;>DAX-C-"M'6'R T?H
M-JTAU;]*]_J<V[9X,([/D<J#KU12O*"PG(B86"E);06PD1%FIO(BLDF@DVL*
M]$1*>JEJ*!!1=60WD'6@A.)P8@FV.VN3^\:<PM5KBH6DRQ$MEL-,8SAC-J&
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ME.B&V3"A8_<&P[.K!KGDVB'D1M9G6^P]Q9 M)O,BJW@[_& X>-H&%]C$.B4
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M)IKCGEO;]WM";Z=NLX4A?-=\!:PJ$2&BS9NBVBTKO(>OM/6OZA5S2JPY@9T
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MA^4X A)O9:6/?>I;].:A6%)O<,?)F]N,=Y.#W;]5>9QL,17#^0?X^4$]?;
M%Q5+J->/#0'?$C3V5(.I850U;(-*0+CG=\3]GA =K.?N77%65#F()1ZH"(&*
ME0)HQ$I<'(0,,VHF$#OCKZHIAJR+^(U&K-Z_H'<3B&C:I+B@M)R'['=H>]P
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M;M@=3/LH,"+O8B1@G_=E048\W'$2]Y>CB:UF8*?R!D;5WH$+DUL0N^UVX'=
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MVR9M3D.F66'K /#JXFZ/OM)T5C&W;%=I)(Q[&L&LZ#)M+>UU8KWN%-$GHJB
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M TNT$Q=@$%M$Y7"\_IM5.8=J"[!OAACX(7FRHRF_U/P5<)?<Q!!#!<.!;X8
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MOB"2(H.O=!(AM[J-<'2@_.:IXB:9'I$)YUU,W>(Q@1N_R,6U[B&+Y&&B.>6
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MRS$\(PZ+,?O4N;:>^$]D6=)7]OD9G&610#_L$$3?OP7W-+!9AN3\9C";/B4
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MNCPZ/PY\DT;@+TPC\$<">XX7&:$GP\DXP^J=1VT%EK]L'7L]ZG7#[D+^*C
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MK35C5QVW)^TT1Q958!ZQZ?&)(.O]BVF:9#(%16A1S.*B&B4QX?1Y\3L6E/]
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MU1OLY:\+AV.6EF;M))[A&.0D^5FF?62RL,"@54KL)>,,M3]B5LQ?GLFT+KD
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M"Z(<I\3#'MF$>/.EA'T YB'K2?K,L?L:=SOU8M 1&=  ,:QF8BZ4\1+ATRE
M,RA!X)%<YUCGY!1N$ 9?<!0D\)QS!H-TL8;6QP0*B=+I6OJ8]CK43[U#,F0F
MMB)TH\DD1L64+G,,**L:4KB34+_39F.^<.XD:#I:Y,ZH&,["@=X39KK7UF?=
M0*1BO3K:/78@@;WPKR*6/A87,%HBQTD+6/ I"0 =X@56VPWVW^U[[K8A-2]
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MEPT(_B RR (Y-^TFR*V^^RXBXPHC03D08>.CIA1ISCC+BEY&3O"<>VY+4]Q
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MC;E;!L@DMS?7Q[VC#>JC/$/?7Z5E<:67,?G#09=#V%"=:%AJ /H:K5"@QGD
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MYHQ='X?(T/!E ZR"CO5CYE57CH-X% &E8# &'!\##[Y1LS$C'LU[R,?X?L'
MQV;#E&Q:T:H_9RX(""&EO#NEK#\.<LWN5EIU:GW/XQ^9&RWA3[D-G3G2=A!.
M MP-,F)V9X@_@H%A-4$!DC]%2U?7I:O_VOW^LKCG7F"%WH)8T7X  =7$!9=
MKG.(>S F\CEWN).%@9B^%X_2+)0LR"^OJ5W7X(64;A[9YCXXSE[E)(J2\00]
MTJC(Y) "+:8"U5]]7H]6A:T$_-3GJ"<C&)4[ %;Z$)J.F#^4.7@R!H'0QIV
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MSC8-)7'EF63]B_D)"V7V@MD36-82-NVWBT?H"F%9I"LH,B?&%(("8HRF%!2
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M+7IO?&-13'TFU]!GLO/"/I/K:P6YH821!_L&PN? F>*_HWCL'?__4$L#!!0
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M-K:Z2B[@#? *,$R-!-K,C%0SC9VJW'R2Y(BDFC"+A*73C5M4V4O+F)K>'W_
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M[I>&;#!Z_@O3HDSIX<.MSV5!T)5B"#PEJJ"^*H%J.S]F-ORBDD#ESEWJO;S
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MC *7&M^ZE[\<V61%AQ1?80&7"@5CP1&7" ]&=]T9E# A2JFR&46M#E- ]9\
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M07$M,D" #-B[^ON=HM_%_\ C"HA&Z/V7/.*CLW^@=@.'A:<25^,I,:LM\O<
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ME_($$)074\TVS2:<%->KD0W^P[V5.#>3])>Z-#_/'0LV&I !@<_AW5$$"3+
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M?R\(>1%O;(3VR#MV1&9!UY+#[WB4C1:ES;W4'HQ_S0@<KA)L9/0Z[GP@\VN
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MH.D3JPWPM_L$.;L9:RL3E98L\67BV%958#NOPE7@FS*I)-OD)349</&YR%R
MW/N_Q:Y=K.&:YOA*HH!,QPK)(,,W[-+XE9A8KFNI79JOOU%Q'= 4V>&U*1%E
MO>?Y/;Q=2^W\NQ=5S\OD$W+5W4KBNLY;: =AOP!U_MZ0D@% /WY,[ONLANB'
MZ)"&(KGX-/7A]2G+D<^>I*TW3-NR'(Q YABZ4'&[SZD/Y]@%]XPCY:5OUX<)
MS*9-7D!-*9S6Y)7B6F \H-KZ-[[_6RADB$H/@0ECLM\>SG&@<VJ*)XU+5(O=
M^F3LWBT]O_?H'B]@(6C -JD5=,[/8<E.VI%P?X$(AU:$/SH?M^YC>7@G"L"M
M=NO#-5KGB1@%CM2_]TE&2(I+ Q8Z?+/1G[+MYOJ>45_I%22K7JI[+:!;Z<C
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M?N7#IQHHUUS-@DH=$5#"N_W7L)6!A,(V#WK3I!RBE:CU4?MSE/E)"6I59^2
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M"3XU+3F+__TA\7T^=)L.&[#X"27&\0A@Z/[97'Q^&"L6,O^2#=ATAQQC WX
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MN.0TKQ%%[SP:/"8FKX55(/W#M']:]K]G6,S_D67_T[#_M&L*X&%C86X>FR
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MX0KCS"*4TRJEVI3L0_L8&82O?F?[I4_I!<?C3H>'US18^+<%] X^J\[N63.
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MU$ 'YFF$3%FRUKS0E*5_&?D>I*.R9ENNV>5#*OW:P[S8F>I2<S?H4Z0P^/Y
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M0 2VA-MOMG5KF])<E?*,AYN.1^23>J14O^HG\5P\)P\O:8V!E14H%0=L72-
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M1F IQJ]60+&]4&]C@2\X>'U" ;CS^@K&*S.GW#* J$_*499 ,&([WTI+L"!
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M^!>#7M>'_^C;>PQ&%VFN7++Z]R&A^!-KSZSF0L^'^C,H>+-,6IN]/:>BWOV
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M3G2>5U/<JY%HY*FC/D%S,NL^G@HXC%^!NV8^X;91KP,CUGOB075)I+SYN)3
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MX:,.UTO9=EOIL9CKX40NY^FK5#B$_*HXU;\JSOXTF?$F!7 A-Q7Y<\B: LA
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MKD+,TB+WRR=>,@(36"MHIH61Y71O!'%;KF6O"/' TR/N\A2 +UO'W; 3QS_
MA%1FOCN4NM3@!:6+'G:T1ZH*HX_7 LD<.LVH?9$D$!4FSO\Z*JY&O)C\%KJE
MHZA/]9MF,EDP4SA.=(3,[ZF5AEJWI[K7.WFNR,/0_N 94:C<6U-+ZN9@>@]\
MNY-E='1Q-<,0-+)HY)X/,DQ 7<NJ>89O\X]^\^:ST:2BS($F =1BI+4:U_P
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M6_8QZEN5<%?*^ODD!7G>%,&H:2_(8PZ]&G0D>VT&#Y_*7F7%;4Y1@\:L-XB
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MNA? ?>W^S8#?I]574/\P(E[&9_LA7X*9E\X,^LJL"C9('VS#\DF2"$%=FY\
MDVB:J,]S7F#;G/_ /Q#Z[_RB#/T_4$L#!!0    ( $*O]UKX15\OXQ(  -,3
M   /    9F]R;7,M-%\P,#,N:G!GG5=W5%/;LSZ!8&C*30A5('00!*1)$8F
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MHJP@QP2FOENCFHT8TQ?.2X%G,5XE?O[C1VO]!2FPGD(VI#0WY&;J4#L!-^L
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M%VE!F(!\6X,/+T8%L=5\TIV]IXQR5IS:4%Z\-"#1EI$X?YPS.9C38^30T4H
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M[IR+J^/+6P-Q J0\WKG/FA#KAVBH;T8^HCH9\HJ_I!DZT^Q@+>H^TB1_O](
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MN\ K+W5.ZGAFW/4WS%3J:M"LX\C8KA&N\.L:O+Q#"9\O\T'<H9&A_=M57YD
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MXM\\+@J]4)K20+-53OFVJSD7Z.IB\@LOUU)GWJPFEN@$UTGW<!0J*4JUY*F
M6>=JH%&=A8KJ0KES3D*GDE?[3(H+X]R/,4T%TXQ5JNQHR]GO1G%$RR[K 8=;
MY\*M5$[G[T8\Q*J\8:6_\9J0-J]G8^_9]BWY]BTST@0'&S$1=?=>/J^997Q8
MDR F!F=7N#D'C%9I,HY%:]^P,#&,KQD7IZ9]6^+S2 Q']2@K8]X]2P\)2=!S
MJ;DV4"-AV]BE#BTX&_%FF. Z?.F-;:M824V^R*>@IFK#T,+>T=R^S90QK^SH
M,87/Z,'Z9+\V_Z4/;?+<N'"4+4.EJ\NNO%#:-+(QM=8XMA4_=5+7F20^],T*
M]";PB,->^@Q[66NMSUE&%4UQKON3M)M$MI*7*JW<<NSG;"^7I%/:7_^!8;6.
M^A="$)FI/T1RXX@TN2_MM8N?7VG'W!&NKUN"!::O)DVJUCCV4^9JEOVRLI(>
MCI-;S=B=]RNJZ:4_^E^D)E1;:WS:>R<E_[O?38QHZ[==M$"1=I'CL.#[I)F[
M?IJL(='O!43VH8\K9U/<-9,SC%+032U(KFXR@^5#0T_U&T^N(;!C$H_7VIGW
M5Z2*B6;:-P.'H*_ Q(?U([!0G?3 +%\)6&D9R5@R]M&/KZD@B)^P'FX%3\0(
M'+"[V>%NU4L[NSIU\OZQ^X_3RFLX ,I:8I;&.$?MKM2#T(.'[?/(4X+<6M]
MBQXYB1OEEK"U4T2_F5"UT=8J0TN1)RA1#A#4KN6$%3BR23^ORLKN4?Z<8@^'
MQ!863N2CNJA^(X=E>UB[CH.&7<6# XK,0EL=$C, /\-U)6FTG4P8%16ULQ]
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M-V'I6_.E+$(NX\S_&8'N2*?:/H=G 7V?1?XG_K__S;\%/*D&1I;@HZFFM[&
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M>JE)D891SY*1M8?YZW2A,[E9']!!?I&M6!X-.<I#M5:ED_7NH8?"%;M[$^@
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M.>[/<ZTQ7N8'U?>[*"JF/>L !!\8W5LELG^C,7T:^8:E_%S!84TZ.6O*'K
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M92:T:+M69=VDG[*KL^=S_6Y-60KNBX^EB98K9C%36T!&M#8U/)Q6.69WS/Z
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M-DVTF<#BXU]C ?OD<N0#HX198$64?B?OAUT&&"Q/SW.FP-I.X#+7@WT=8C/
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M9TGH0'LC+9)RO(Y]#U0[/)IZ2_UMJ7K_['H<)P>,Y,LE]0,?!_HK>S;)A?-
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MQEC -U]PLS%0'U5]9CG_&T,L2;L1H("9*<V<(^H&GOV$WY9XY=Y<NX=*0AO
MFBS$/.N5#C1@AA54B]>.!1AP@4\5X=\-?C),J+)[']_9PTSH)(/",]*D*,8'
MOI9IG=>K@,1^8X8;:>%<K#-+O=V7J@XYHFHKF:GX:4YB.IRE7I!WL*E]@;V0
M5EI57)MR7-OG56PKI@_A;X^\/[QW?K82-A^%F)D4])P9LR[A?@LAZ9TE[UW5
M7>TE6Q0,&!8JLXU"?Q6YVJK)[N!U-]T @7WF*D-^].)+/,<"U@M^L$".5'^.
MHR*[ZV*YA7)NLCY+G?\DH#^(-U9%XT[0K@D?\!;;:MR=EJ*ON<LF\LB!\:FL
M'#Z]*8KP&/1%J HEWB$&C322INXIV-;T^M6T&F#@P?YUJRWOYJL$W1(0]79N
MJEM6?#A@Y_"^:?QF,,S[Z@\HF@HN<$-4<OE,O_%4A"X_)^)0HI/$S_G:U$]C
MZG29 13FMH=T_,02,^Q-6:GEZ2)/W,<H>W<#D0TM]U,N)<'OFDO,FWD\O:00
MR 'XEA=T"=]J[U,...SEVTV9&DE+$EO*8_VL;SLPS6BM_HI1+=& B71XV%+8
MS%[!<.'H@X"UR7"7UQNU6L<6> #C)/' &0X"XWYH7#T\-BFH[-P++5GNLW5D
M\$]]7W^?[=Z/4[\XUY@TG=$D!O:ZV(=Q>S\#6(_VSALG'(BK,(Q)6( EM!!L
MGDR#!72E+,[9^H36T,YI4 LC[>*82^/:O>O=]U)64B]4%5,N8I;[OBF[4[$H
MI]^,*2376]<_%HT/Y*^]644QZ? SP>.V4ZKB5"F&8C_T>RSU/J2X"X)DNY^M
MU;=8YPOEG>\WJ4^]=OAH#VV)_#X()OS#&,9R-FJT<]RU:FB^,7X&H]!C$H*Z
M 8+9W' 8X7#(2+'X*\BEE[=$%2X3/97IS=F-=]$4'U5Q=/C&QP-0@NR;7C[[
MS2^FA_H#W\ K',!?R>='W0&76I#5#+ZPDQ5-_&)5G?K%?%2TUN-^^\??Z-@N
M1V:3BB1(VZ-=60B_=17QD6N%BIYH$?N_6A><-J*0K&O+SW*W?V+B\N.ZK'!+
MLH^Z"Z6X:C)YW$S!1\#;=@9\<\.I>\:7&%8@O^EM#KB*A4QJ6>SD)+#1/1'^
M '!M]!)%S.7Q2?SX%0]9BVX$JJO],KWL#G&24Z!TW/L][2D@Z=@3![:R@C]Y
MY.]LA0Q7J*[7J=-XY9B"=[E^MM#B6=&^\J>D*21J#-]2(?N#=K)S<YVS@?B'
MP@B)1UD+HZ(Z+[_$K*LW"36?/R!\P^>$?\US$%%_9/-'F?-]Z-QJJHO*$;]X
M*!MEG\I+D0WW/>T6O4=Z@CP+*P$O=VB;=&+<J</=A:L;YYU*OO7XDK%N#?&<
M/.V7Y-Q;GC'N';-=)N*N914@<<XQI.M6UV]ME,^[3.)M5_%T6VMSNRE$B]M-
M[(A]_[:3WP5K3#S?4K(6O4S0T%YQ83S4D;ZF\*HX[,("J(&*#9':^LPF8]FR
M*4@>^[BWEY-EI?W]"Z*%RKO4N6ZC[45Y^ *P&>_.?UU%\2G@RNN>LB1L,4 .
MZ%<6^74:*C/5S*SNOT_K[GW0A7H34RAA27>1[YRWU%>L;K",?L%,K-OG D?>
MB]4*>;^DXL\[W6A,BQDS(CKR.[!G/]G5L9'R<D.A%S.&%@#^-2D&_7[0JITI
MQ!4"#3G  HR06(!0!5CQI@0#M*&A=5VPT=AQF9<UL[6=B1C@J/7J-]TG,4$+
MH1*P ")CK5:XQJ+]1TI8+2_>PJ_P*$<LP':++6;RSY.4A;-6)8P$V7AU #,6
MT%=0B@48@Z\?3]?EWV[-^#L?0*1]5]Q%OO[0O^[(LJDP?'7)H"">,AB($DA$
M%/L5^L"9*6IP9*S_!=EK_/( W_K0,PA*.4/\QH?YC71S@DDUS7'?B_G!IWAJ
M.@_]UWQ=\&SWL("YYE[,O8E3XWU52ETESU("Y:FHWL669K\C_:%^N@Y1IE-Z
M:%2[Y3!CUV_4 'O3Y*/)F<OZ:&^'H2VX2<;C6^0O6F(7M$M=!GXHUPM U%"-
M>3;K*JUMOP69Y30GXM[6QS"ZSR->KH3,!JK[.#B^,5)>Q0*(;<:7RE(6SE.X
MBM_SO;BPE1RP8\Z2H_F#&C#AA*+@JU *Z\@"55/'$MLGJ&8BN1_/YV1?Z@QY
M/)+N1 2-V$8>;86)L?>=_ZG*MQKG@]1T$O>>OW(]<3P^SL5AOH:#E%(8SU,T
M4.#N%',LX/RL(#OO;;R"@"VCS/-^\LM/WV)TG($OV9S_%Q-G&155W+;[050,
MNAL$%&D$Z1@1*9$0D0X5$&&D.P=!.@9$0+I+8N@AAHXAI+L9AI 8F"$'&(;C
M^YSG/>M\W6NO_6'O__K=UW6M?=WF-X!]C4*EM4CXVTK*R^,W":;J7RF_1GX3
M5/HL,\"K(&L8;^_K-7<R2K^H!=TYK[*PPR[.O8E9)'X>-&CN&?R=/R%89I3N
MA'>_UJW87P1'\_LZ9\B+;']R"6RG1"\4?V<QLV<C%,6[4-=:>MB8O)WNO=K=
M1HK5Z1E:/,<*M59<G^*:_#@$SF/^=)[]8/18D#F#JM:'S1<MI7T7(SWQQL8I
M1$)%JC&PL'IH1(A9+=8QVTO><5((SJ\9H[(9@ZQ&\!;[GBR+Z[Q-.-LS?C_W
MP[-J5ZUZ7R _;16$D:%U.@/3E$_4+6J6YL5N-CPUNC4_CX!R^LV&^/O@$&7>
M<BC5IIS%'<G+E-"--OJ&!E>5V*%J(NM/HDH.V_D4OI<<G6F2V0'K#J+F$M4P
M<=[4R%N58ZY*(])H2[[LZ#:>V39Q):1FK.RD_J3(:5A<E]S5!X@]*;HJR#!/
MN'OP;._UN?^"'#//CX:22Q&D0<$*#PZ2JR8!=PE(?_]C?)HRIK5M@S<K?Z-#
M<?K,9<W%DITPS(!>YX@P85NJ^@69/ZA\\\J-A7K0[?23#LKRPS8W748SVS/Y
MVAX.)L4![(/#;LG/P^S]*MNM?W*-ZH+H'K0KCR+-LM%$*!8G:G^6*?^4H$%>
M=1N51UW!'?X] 6/*I.<R"-\+)/ZSY=D@+AS$OZ1E)X_D:HPUM7:Z;<5Y1 )#
MZI]":02;VQ(+C;6VC4 T&O"^Q3,S-=>8EC#UI?X:*\7PB9;?>L%%:29_?9X+
MZ"?YJ&KOO1- J4QW@6:BTKPB)&ZK+VY5I?2_[R0F;=Q#T(W\I3%?P9D<O;L!
MW&=YR6.==,AS[Y'YH*0.QTJ"PCWY;3JIOD6?2KA5$F;C,L=(_=A2WRC#!C)4
M=Z3#!DH?+\]-GNFS<Q^GS[?O'C =U@?;FVPI):E[$?%;)<EY#YR4%J'O_8-"
MZ;2$#^PZ\)7EG?SD*U3@(LBT)>6+<";7^.$K/<WS)C7><[6YJQEP3U^394RM
MLI=3F?+S^R#:ALOKRR$WBD&X#G^&%L3J+U_@;17V6JS.VV.ANE8#8)490Q0!
M67?EQ7.2BGC4M"L@TD>/,?:W^3%F/+<#(DT>5[:]TVV)H*<+-/6AN.S\BZA@
M.%_-A<[+02GWI)R_>)9?9D%M.+(2%J^AKXT_ ?CZ:UDWV%L663\UWP!"#(_-
M-<J%^@H] AF<ADKFRHD"5?L>7&^=G$!EL<3+=B8V&6B[2B.%I1+]N:6**9@]
M;<9W,T;N0XBS0 '.>'V@;B_!<:!2:"2_5,6&UF1\A+8/_>B%MC.5QHBT="%/
MAHFXH=Z;R[TS$*ZXV 0OQH(^N$U?+#8RG'3"$]?CX8B 5@30.3BG>&)U6!SC
M5,C+Y8+%!(ZM.A4?R8IT+#LO+.VW^8'YGPXEN6H2=5+T$RNH?1(X4>XH'U[+
M!+0+N^/$ O#UQ5'YS#K+HIV&I2;X[># Y7@-WN[ANZ]X?'RSY=<^]"V#^7%2
M?>Q,.(\"2SMF2*2_DL?C/R;^;]GDM"W%UC<[+C*:6&^Y$G$:KEK"]._J?+^T
M#CIFKZ#:BY-4!*V!:?X"R=$<W3#F@U(?%P^0=;5P9J%:2B:LVM;VZYHCCUM<
M6%78D&6+6X-M+=X4ZUX1D"\Q^OUYIO'G";23PX$'JU1R[%U*NLZ!^T>)6:[V
MYUVK=/8$O@FG 0?@&U.9!.J']P ORM.;K<]_6U+*@UR*=RS(6R#=LAY+#)>/
M:^<'P,<:MP%T<9*,<A'$B5EN6KAWJ&'3'EN#N(V=!3W3"&.NR=PY1DFEY5%I
M!-TD8V\7/O:BP;FI_FVEGR_WU/,R\T]J+Q:@R875"7?E(-@*",2@]HOE_8I3
M<]7/L[D&0=&:'<SRL$'U?IX/)]NM-G;HDGXI22C_\>).VM] OIUS X[;'FPF
M!P0MBX?>_H?5Y@Y?K 6>/ NF< S,:^)')!4/.:5.JQHV;S6A+CUA= O>.KT,
M\14Q978\S 'P'TEO:[[^&,*_DKRWG;MC$5OFKSONT?2#@@6GNN!C^$ 8"1EL
M?+>TM@;I#/6YF_K;V#N_2Y%UIMY!ED633/9@:V&0)"'!'Z$BE,&1^B#C6]K)
MM2U*J7V<?K9G@:U^L^S5;2G=[H:OK XV>@\:$9,2 ^\T#MP15M4820CF8,NZ
M><+#[G&2F<PD-*.73QMI&>RRF*B#/4M_;L'O4S>T5S)C&]MP*]U [!?I?:81
MWXVT#45*CCN:+B6/M\INF;W>W/_AYQ5)DQ$::*R3N_&YA2,"ILB18C19?"54
MD3F\6=3_Z\DZ/:]<DB?&4"@[M_@?##'KZ>=,AEVK=0'%70IW[_E_RN*<DF")
MF(:G^]T:4UW:$+ ^\D6=0"FQT%@1O/'ZU2J-M^I W5\)T^\]:>BZ=TO:![TL
MG_<C9N3)2;A_^!G6>'M.OA:U6.SED7)#.'\V\GQ]$-ONS+B2XU^ 4>>P2-H$
MTE>$ARL"YW^_++4ID8;K+KILU5"DJCK+G+(F[)C7;=YK*+?AV:3]]TJ0##U[
M%;[F,GCPDXQHQ@2M\K>_13N0ZOPZE@>SR;@];2Q'F/M?)PD*)E!:/"BIP<^I
M@<]FQ.=Z_JL54^?>1%L+P]E.A;?7.ZL'Z2VBL0(:CC%S)+$C\GWH<V]H(OB+
M#GU#^24AVOKU=9:=6<<WIB*]0/-O=*:[,OL^A^M;/M%=8_N;>36$U, !-L0^
MP_H5E%$DFK<Q3D5=)"^.-W4^<Q;DJLEZ=D)K((6G^3&X/JF#M=)J'_QQ1"$2
MJ,8E9AHR68)7RJOO'-#^;L, QKF]*H<T_K\XL'A="O^3@@H\NY\]TJX"_]_+
MT/6G-X"H&T /\/2*]QB:-]0>*:(\\"=I!S&U?>ML6)Z3-B_CKJQAB]OVOLQ=
M_@WBA/>Z5BN5IC$)D)GH.$1"X$0%3*E&\8-E>DL-*EM7&IKZ_'#%N_8%X(!7
M][OS8GN,[^SD:ET9[;B@-I9QU/)9(NLEZE:;_9C5,=X)V3N"WQ6] 5#ZX[LG
MX/:0E=0=Q#Y'"<>#2DL"E<,=LHV<^]J4]L\H4/(^-N"$(OS;*:=\[ +<MRV?
MOO^72.(Z&_UC;9\M;QCO>$T WS\Y2O\9DQR<,UKW6GL:]";@>"ZV&[.5C@5J
MM6<C++YZPHY$(_:]3ZX?O(O)0/M$[-P M.ZJ.8*VLOM&2ZZ>_CMI:;TS^?FF
M//\\97$DI<\[[^PWTR_DPMGUWW)#<G@,(U2.'DY;4R6(/GY9@]XX&7%6:(*Z
MXI!GL(FOA)GSR9>/7ZSXIPDB5;$+HU^C3[;@_-0Y*Z'\OY_<!@P?Q62E-P=*
M_)V8.RYS]&WO&.9B>_=Z*ON*6N'#<8H3^9(];KN2VWM9K1$O:PCSYYP6FD10
M+G27]C(D5Y)E,&^54D(VY%DT_QXSC#VC0X)O[:.A[FB-C:H0O5VOH8)=YA\0
M'%V9@##P];G3=_9'4:@^JH7N2C59U4K%(8HHD2>4^.)O#@&4/P1O .[5PZXS
MRYG//56W>_D*DB=[@*UB)=H::1.6!Y> &\#YJ 1R/"9 8$GQ:?F/15#/0;R@
MS^WKN#<4*<U(Q)1AY*/;L_5)P.6AV1-YLW&+@H#[AL6%<NV^^K28_'J_%'GM
MMXW/&XO'7R,'U4*TW\OL:*.UB:.$60L20LQ@/7O##X 4BPN@Y+3"2QUI/O+$
M$K7/-X"GNW_6-C50>^9Z#Y $D<6=&KLT\5V!@B33Y#D)(\?'>BYSRB.!<$-A
M+LL63]DJK,6X6><$G@89JRK)V\E<GZ.4N; -X6HP9*O^-KHYF78F\HWC'IZ;
M66G];UUAU:S[U0ZR :3@<_J4ZT&N*@^)U0_&[3AQ"Y8U-E/5)OC4W73R1,$@
M,I0ZYO'*[VN=%6H,_)P-M,OQ37ATS6>HH+IZZB#0^.1C 0QS QBJN@JYF!V:
M^?G#_@:0>E+WZ&'Q8#MQUPU@+?<H&Z?F_Y I(4-B>?RB<$':Z :@6!^),D8Z
M+89TY+N[RNO]W9W[>7#[!=QAQY0#\Y;</1O@=6OK,,\1S>;6QB=T R"K1DKV
MY)*MI%$,/L#>N@$PO#VIA ,Q*?GX42 =WG:/HQ^!4RXQ@42O,AY@F6+KV-RX
MI#Y_8.J_J)V$VF_AR=R<2/8+L7P4\U'#E3OJ]U:LD$;'*_4$6L$$O!*N?NO^
M+S:2]QT?_ADP(=E; BQ=>=;7O^#^[3NDJ!YF+QE=W-RUW*<6]AN RU911;N&
M![^_JC5'+;!K3#XVR[-(=?/KK<\<7APS[:KXQ[8@GS4*BFXW![8>ZAW/0>SK
ME@3$3SB=@DJ@&_XE=?O^/&;6[I=#XEM!JC!M&S:W:X$3<&>"-(8AS-J=O_A-
MO8S3Y4;]YCJ!\;)VL</?]02RX4/18WP#0+)CW1M\3<QW9H*?#IKN6)+3O(MY
MQII==_()W ))*?11+,.J]=#[]IQAO?/[HZ0$-C4Q(\\S WY9 2YG2_%F05)Q
M3UPC]C;ZQ&X U,!JPV+\)9CB:K5W!@[2C2(HO#S\9#],%?_]*/#QH@8EQ[ZX
M_Q^%816>M-D360&-BO9W+6/UT==@]8;6*2>MZZ$BTAO O)66'A$G$6#G]-"
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M70O&QNFUXR6XKV:-C[WB_O><CXFCMS^U35VW^VNQA8>YDSTK,H+)PUSI]3H
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ME;X(J+:8Q(2O443#J2KV8*HW@.XS"H4?W32[,T?V5'Q+8DQ,JFJL@1*1/E=
MW"2!7K*PM,Y$H4>*X9.N@_!PW2O2C/T^?5^ -UVVV-;7E06!C+;ZHO+F@$*X
MP3>>I)Y$%>2PRF8JX>VQ68H@Y38.L)=V"ISO1E:TCIYMM928K-R>?&1=#9LJ
M%FM,[;/0=;Y[JT3WV7+9D+Q7D85*@$/AJNG\KI=GG/^B%I$6W$64\<_$KQN
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M\U1F'+ZZTODRO4_WS!E$-Q5[KM. &VH3[?^)8.=/_QO!HCAJE4:_G4#/66X
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MO0^Q3-%Y91*WL/*^TWSV_]?3S_YO3]_BV=5S<#^D$-RX>LEB6/N_*RBW[6\
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M^9]'F1H7?R5*2O19@ENT)FH%O\+%Q3%+8E%>YL>C][YS]\:X+GZ99[#8]#H
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M*0)3D6]//+^M;6U568[C -'8&.1XS^5JS?7K]I04+B>&+,K<=(G!;74/$?M
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M/TPM-;P)^B</.[G*K]$YST[#T=Q<:[NFJ_B)>80YR'@X;OEG1:8V>B[2._*
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M^GLP2D>^BTD%WDCK3YG6_#: AIYI[I]-CE;.F++_%1Z7;?>N"+)K#US.*RH
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M^_*%MY-HZ5.& 9T"W[,R)W&4=4E@V3QB3XHJTDLT:5#0(_\%[1T2H\(>B%\
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MRT4X#5%=!3XWME=XA[8\O_HH%5[6+/GIXU=5J9&>D"28*&)OF3U06OUDW^M
M\,/-YAQ3@(["2Z+ -6;:++:U O=@ZC(7YU:JU:C?LYD:+7'.!POCKCEVE.4G
M[I);4Q!0ZKD&J.OUYN??+E62CS<#6W#M8"TA(;<<89,I3UG)GVSLU+6?./[I
M3[CB<_EQF_ V:50K7X^J!Q=]BDB(NW6&6)>[WUW.2WBEP1Z0*DNQ2%U-)5H
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M;0?K'I0Z@;5870D5/)S=/T*UAZ]X_-5X':]+F&KE[-;%M=6FT#?GH=/<8&&
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M/%"C/$^P+!VT 1"XG)IHR^'>-?53=)<)A7X0GIDX53<H2/1C<C=\[8]X[C5
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M\K/:$[SU=P2;C36G[L4'R#YLWHO#,QP(BX695;-L6$_PW:,X+!)*GNF1,45
M]ZDMF*.$HY=%,[1#C?M::44N!7Y[R[>*=@2^S+QRH.UO20\<QG*%]=R7R;+C
M;8LGQ 'J9E:^MSP:T\Y29=F2RAZHJJRSG'9.7,IM[JAO"8\I2YWW1U!*?__
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M))PO;ES.=.2@A?WEIVD.G-[9'73\>(_'5^!(02?.4*5ZB:5.&A8X=C@_1N,
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MW"&D>X-XN:-$9!Q3;KW]:O/Y&SFH9Z>#'$_J,:5.<\0_!B>J3-RCR4%JX/!
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M0D1IFZFY^^U*F;\_<@B]1KRST369])U?884@W:+ED!]OT%@<X/ZV^(O5V:#
M66:28"-$5G;)8U&O41O.3X^_F/2CFX<OW0BJUX6WH?_ <7G-B)02/V?>]OX2
M+R'*$N687^Q/LW.GADP-FM13]$%2H_E&S\Z\;!OL"#L;:M["_0*EE4$A"FN/
MA*35X5DS,8&IQZJ/1]UY^[H6D8F=W+D#4C=.'W:L:LX5=2<L27_?IN%QV>+G
M"G=R+BF)VS^"]V=92TA_259Y\/VF'!./, &M=RN#1/4G'\N*0/V=R\B/K56(
M\[".<??"T"=1JY//!\2LU@^!;V>7@57][^?!/26?AX1J3'93:9]>]/Q2=OE8
MU&26=E9I%G7F@(BWX84O20<GCG]6'M'4"=#P8KZ#<LA#$6B*2#Q,<RZ8I[]O
M<:OF0.<@9O14#)CL-._'EFS*(_)VI5\C N!923O3*^);-LP'=<U_/L"=\,7J
M]2YDW/Z\V3%XH*%9VKU3I*4U-?'.4HN3%3UF5\GGZ;#+Q7&;\]L++$.&55%Y
MS'0WV=/?/;Z?3Y)%9M_B  0'A*!F;6U@L-YC-W-Y>Q\EUSCX$,<0,^T//K+R
M=F0X]M,4XF3GW)_3BPJOJV;&/>D@R;0*)6PI(9N_\P)XA_?3:ZWBZ[)_$%OG
M%C(FSS'-TEV1M19EXJG>^XEL!)9^=NK^"P?H5NDH-*8KZ//4]N<VT#S<2)-)
M$D5-UR%(%LUOM3<#(# +K)!;[%8V#F#+!_'Q*L;# 33JJ-E^WRS _JA_3M,1
M;H'UW1Z!?F_']V9%$1.AXT%[)5^O<<5\+HX.&(/LE11\[][*@;PU['>_*BGD
M1\]X4>3\@,%ZG[C1ZDXVX0"%YQ0X@-%17% EF?%"\&EBOG,8K*G'1&5%[W8.
M5X6K0SF/Q?W0%/>K)35M3)_JU==>*\LJ]X-O9+MM^MJ<W9NI1Y@5+6YZ&?+Y
M[P5F'%;2<@-"S<KN.;3N+V@?O24_]9C*8[]ZFE.NP1#>SU8758DP6\BY2FG0
M["9Z.?,$<A\$US):9];J8\QKCK5,B*,)V^4[@*+270PE?PX&8"><( 4.D.[L
M.AP@6UT.!;+U[25A#&Z.8CUD,.M6.$U9P7 +W%DE$9CRDG%L1.G!4:*6D,T/
ML+ NM.(.^3VW6R/\'#?F'QM %HROR\R:R:O,VSA G)3?5<V-Z^;,#DKA+63S
M,V8;>*<\[!DPB_&+.X.D'+,!N.)K\ 6O/(S1C06L-=\*4=LFZY9TQP#+\> <
M+2>R7)M$F2.I(JMD0COO(8W%SW& F5+AI3#.D1]3.$!=C2IFU-,!42&$S@>^
M+TF%]T:<6UE=OHG5:NZ&V!OUG7N0\-X&;<9FM%Y$^B!I^FX(.^21:=;:!4$*
MO/([1=6>\/W"F]M1#N(G4%\(.HF?^$XKA=70,:YG64)%KOJROQ' ?&N&Z?DG
MY=F?LY]GK]X]<5^5K)TY6\4!%A2TU1&_[* S)F,KAIJHZR?%N$Z&BY4<,0(.
MA-C3Z4Z+EW67NP^G,Y1A86@"]L#D:55$X,S+5/FMZ<R<O>>@VV\U#>Y=V6Z^
M=H]HH:4B.UFA4R"7U@,0' NGG 52Q0PO.XC25D@<$.3 +F>_QGTXP\.:3F;F
MW-[/9REON2D=<KUX([.]V923"R*^SU-U8F-8-W" ]5X<@-L0R[*K'TQSG^=&
M],W=\4OSNZ>O4&:L0+9[.,"[(!U(=V,\L<_Q^M6EN$&%M\>Q=ZU9=-GV#_F5
MX]&T-^#ADF\(C&3S)^O#"Q:FF7M\$,$@L]T58E%FR_CKRF^7$$MJ:)9S4ASX
MH[TW6@53JYE\2I09UEU)-F<G$3WQ<] :Q)\Y H\]G,,KFHP\);N#$9]L>W"=
M<C8&<E9;Y),^7+0^3(2G>96OF0H@$I"&LVH(P8$[TE[LJ,(BQE_QW<VR$0 #
MVAT\8041!S8",5GG?>-HN@KHB00 .7ZPI([]0 L^OX+V)Z'==:XY/&3V"NN,
M_/9*Z];*P>C_OGEQ77O^PWF)MBPMI%&8__*.*63EVH_[H']L%"@"3+&+4]#M
M!QXX "0#8_N/#?MD/]I]&.)<%IE2O<[KWD?CMCM/&^POZK'VZ"3<VC9#RWM9
M+"\D*] R>N@IK=4&:\,=J> 1Y62(DSWXA+SE6B!&K_7E'QK"IS%'G=*":SFA
M&/IRC3R4?M=]T^G"RK(5[["NQEE:5Y$L"WRW<<+JM"BBS_.*LMU:99: J^[I
MB*+ P1;^N'<D@OH(F<H*L\9P?\D2^Q;2F&*#WNO']$1=%1X34WROD9!LD3B/
M^11+^*6PKO'TZJ$TKQ\. (8ICX(6TE.O\/F@1[\A,<!_. ]PL$'3H"C[F'^;
MHE*I*^*%@^ %[<91/%9^/RW"=VGO.'%&JSL2)SVV9UMBSU!_K22HW .N(0LZ
MK/2GR+-?%IDV-D%2%Q:5JWH4&/0]S''\:CC\3F:&Z2OI+X,#I@GY]5_T4C].
ML!V0E(Z@J\"<[.RB8>"?'!%^C7Z,HM*=> >A55C+(3?REMCJ-BJ*.%QKA:UB
M)T(<^68F;A:G#EMEZVM]K>IG$.^W[V]&/_('&:O_%(JC\8[?H_2FPE(-&PB3
M/,6/G"$)2IG?3-%YGNA:'V].R#8H+L:<,UMY 6IRT'?>*[JH;+OP^D?TY/]C
MH[*T[26:W!O2DXI$J?@KU*2N/98(32T<+2B?SBB8[IN:Z!,B?Y;$$&(K]:.O
M($;ASF*T:Q;H-G802NROO)Y#7)&S!J+<8V:$,&NL7LDY.;(T^-6%TF2K?Z:W
M?/NL.$<FT+RBP&=5$@)VN](6Q79H8*-1Z#_[8H?21NQUYMP+E/9.W6^X_ HA
M.3%F>MD+F2M_0CM+XQG?UCUM2=\CH*N!B?_:J&V6@5B'AP6#;'/N>*OKM".$
M*X-LICH>&'H;C;8)/%X_.$M28!N[NSC,PGN#/(F++4*%);$N_\AX;"6J\9>X
M7WG%+(8:!V#;R/E#(D&5\A$YW?RTH+"%[F4JV#L[*=/*W9D4_?2XL .^7-B)
M-#?O[Z9PZ-AH\V!6+1L=PN &F&<7#,#0P@\8GD^>YE#OGBU+STA)DH7OKS9,
M?IQ_*P]_EM*0I%+^BR!1Y/EWVF&E!+E!8OD7NWN7+="+JU&24KLK9^?QW\\1
M?TKMCDC4$?JQM_KJ>(B_ ATJS")@'4QJLF!D9@=QJ/5H3QXR_M@8*9[N/4(R
M.Z:XB$=^6\!4M <<)D.*F-T_724C=Q!9(7MI@A0I+399-$$=KJ&H8:^]<Z/E
MF&IO0KQ3\7/:O/'FDW/ >Y=3J05Q27][L_$'%KDL,KU*]<=;!T9B\:*Z+I>+
M"KQ%^T?+'9Y$%>-U9.0;MG6+UXPV1T79C0'Q 6GLO\H5T<+^CZ?].5>M$\][
M?4E&S C:D+,1I_Q\/*$.8/'UADBNJ!!]&X/NC?=Z6JKCSSJ8;8I.<("AJQX(
M+3>V ?P-/9X$^K,W@: YHAY1'(#T],"3C'SOOG6)(WPXA\;HISUR3IE[CH>L
MEKV*M^?%\^^#>KJR[P?S\=U-A<?W??+L<0"*PQ-I"^U4M=K)"J&XNW*N!0N&
M<QS8$HXZ'9,2AXQD2@TJ-3S6FT?Q+EE+60>SE^#LH,DK$!RJ[+Y>^:<@Y8)_
MMJH$/VM&,B[S-3<A"H-+'.;!X1Z2QL(7G#7I8OMK#?(K4JF.0G+4U1\,CN_-
MV/2!YOB54 $(2&\@1UQOJDVO#'TSK.Q46N3W?N:B*<$*(/;11@HA*]<<%<"
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M) B/"SFTH&WI&Z['EGY;U"!I+Y\J  X3IK4-YL=MSM]+26*?'? 0U72:Q>
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M134X4^&#9O/&<RP")0R_U T^)I;@!TNY(CIG<[P%SUXBE/ON2 E7>EOT^1Y
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MY6L$?U'XL^.PM(TA+16ZE=CVT@E;/(0Q]FX7#L!9?[U%O#R&04\2)2YN0MU
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MX_^L2UGM?[O$KJ.:%\F%AYO[7U!+ P04    " !"K_=:$I>!+D%- 0 F7@$
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M/=[)"13;<3APG7X(MMPO_2K:K,.TW1U'I?9]S_OE[)'(#X?P.37&C]0/E4\
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MA<.V3K'NJRL]%'U@6O;JL,WCF%+^48%1?R3-G,I\+1244:HJYXWDS%8K"^_
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M+H3/S;*]SH+E^@UMUV2N<%9_,BD]7S?O%7VO"6PS5ZD?#GZF@+A/@/O;Y">
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M&O)!2S86W4M6Z9S6XZ=H=W_=W!VB''G"_]+.2$.66;[HP+:.67C'V@E\^R4
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M^(>:V1, I832-U"/+ GIB@C[> J3T1L*S"(%EKY-KW+U5(?R59HKS$3-%"'
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MS@83!"YR)K2COKK/PKG@]-*;\S")UJ;C:6QJ[\CIPXA>'Y.ET_U&@\GLAK"
MSG]57-,]Z87$B1Q5F=277RNK#5P4GCLF^E3:S=@A>2)D_Q@?3-O?P/CRO]3S
MX2A!P[]02O5N\KH?+_WU-SP7[#_#.\HT";E:V:I:%\N1G1QXL?7&>VIDS]6
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M)'=4D#?0QUYCY?/M/X;KJVS"FR"1>WK5.74$2EZ6_U ?,>@LBWY7*?7?E5L
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M**VGVB!Y0PA7[I4GY.@^]CKUI^I_9(=-LEM/$&H>$[.:9C/]NWO-??*<K&
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M>M#.W3Y'#I'Z>>5X=A_SR4[1_&S$;:7Q)XUNM9N6,DK2,V%"+SP. ,#L.P'
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MRH69,'OCI^!JD/#&L:7&DNAZR\UKU2VOOW\)'<*V=P_ UM?#V*.3P5IJ%%*
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MGM7"*KMR!GWJ_HNHIH>JVNH/;1WIMG\T02_<9ATS]#@_4"OH:]!5*<H=UT/
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M>"3/K_AO2]:OXX1=7$+3,(DVH/G8* "3V [UB^!]#\0R^+/%[:V=1>Q2Y5+
MWSL4*"23)C!X P%Y Z8Y-=YJ-ZX\'QO#&T=P;0*0T>PASDGY0>.O%8WPX^V:
M-X8N(]48HH\M5NKN\,C.%W9+LP')+<G/.!P*M-F;7F<=X[\"W?BCXD>#+G2K
M[2[<Z9=I+J$,SC[4\(ERJ(@4G#8/)*CBNJ^(MQIVC^$-074_M"6=Q$]LYM(?
M-EW284%4[\G\*S= T>>]\;OXAL[R!H#(K%UC242A"=HW<YP<XP>.:K^+M9T?
MQQK#>'K6[DGO+1F:=$BD0(RD C>0 >O8G-7J]!Z:&WX(\+V/ACPK;6UB\\\"
MS3E6N4"/G=AN  .HX-<-IVN:/KGQ,D%QIVFQW5NR6]MJ#S$W$H6)MWRGA2"2
MF.I!)K=\5>)+/X2>$;5%L[O4(B_DJJ7"CRV8$Y)<].#P/RJMX7L+66Q@UEK4
M12W<*SJ#@E0P#=>_7K3LV"Y497Q7U.\L_#%P;(LMPZE%>-0Q3(Y;!X/&1^.:
M^79WWZLS%0"7'/XUZAK?Q5U#7OB%JWAB62QCCM8+B5%@@8,R+G&YV<\XY.!7
MDPE=KX2EH^""P;('Y@'%<6*T46?8\.*\JMNR/3]+0S:/=JO#"-R"O7(&1_*O
MJ#QXHNDCD.3OA1^OKS7R+HWB;[+9W 9;,@J^0]WM."IZ#97UGXAGC?P]H\[,
M=LFG6\N?K&IKEI&^<Q:<&_/]#Y,>',C?[Q_F:]@^!%GYOCK0N.$6>3CVB8?^
MS5X?/KGE3. D! 9OO7(4]3U!'!KW/]F+5DU?XA11;(%-OIT\NZ*Y$AY*+T &
M/O5G#XCU,=>.%D_(]O\ B1#G3U3@<D_I7P7\4 6\>:JH 8"0#\E%?>WQ,=5M
MHPW  ;+9XKX1\;SQW/B_6)U&\-.ZKF1!G!X)!.1^5;3TBCY_)?XTGY?JBO\
M#E-OB C '[MN?7D5]<>"(/M'PKT\9P8[BY3Z?OY*^2_"MPFGZLMUY18+&5*+
M+$!UZY+BOKGX37,>J?"%+E%,8-[=$(Q!8?O2>Q([T4]SLSE?NT_-?J>%?%ZP
M^SWMG)DG+NG3V!_I7-^&AM<Y'<=Z[GXW&."UB.=TJSJPC4C<0<@XS]17FNAZ
MSY,CDV=R0,$[2G'_ (]3G\5R< ^;"^ESWGPY$;KX>:>.I1[F(Y[8G?\ QKPC
MXAV!M]?8]-T0;@>C$?X5[W\.)EU#X;I,$DA O[H;)>& +!AGKZYKQGXM".'4
MK9US(W[R,K'\Q'0C/ZUT_P#+L\B@^7'-=VSAO%K%K^W<DL'MOZ__ %Z^J/ .
MI17.C^%GD4[Y8[;:QY!X6OD?6]7662R;9)MCB,;!DQ@Y'?O7TS\&=3%WX9\)
MAL9 B3!]GQ_2O=P#4JLTNQ&<Q:P]-OH_\S]!?!7_ !X)]*P_BN2- OR&V$02
M8;T^4\UN>"O^/!/I7/?&$$^%=7 ZFSGQ_P!^VI'DGYPZQ\0KKPK?VEIHEC+K
MIG08DV+')/+&J[B-N1G))SDCTKK-1T_PQJ>EV=SJ_A^&:].ZZOII?D F8KNV
MY. <XSTSM Z5X?\ "/PM!)X*TZ]U.;4%OD\U@L<Y7;#@ . W&2>@'!Z\8YWS
MK(OOB5!IEQ>:E)%?!A+:R@J#"#@)P=QQ][GT'UKPUAUAXN-/XEO+9NWH8N+B
MO0]BE\6Z5I.A:G?BQTVUN;/YI"&$P"8W1\CN!@$#IGCBJ>G^*-(T]HKQ);?4
M=<:-S)J-M;EXXU*XR<D,!CY=QSC!X'%8_@;4+#14TR>PME2PUJY,?V01Y$L>
MW8S$'(4, 1R.N#ZUBZQ8Z-X7,6FW7GZ>()9-0AFMG^XY81+#+TW1Y.2!C..H
M[XRM7CR56WT7Y/\ $B5I)7-+XG:GI"ZC9RQ)YBZGB.+=@B%QP2A7^$DJV/<U
MPH1HI2""KJ<'L0:J>)=7U"ZU>?3%M8)8)_)DL[:P FADD&0[,W\(R<=L<'H*
MV;VU?[2[,CQLYW%900RDC.#7ZOPI.4<(\/-MJ.UW?3M\CX;/</&G.%6*U>YT
M>A_$:XT>R$+HT[KP&W8X[5T.K>+X]6TH"!Y(9"GSF/:R@=^O->>3:5)##YX'
M[M<9W#G\JJFXDM87DB)+,0D43'"NQ[&O=Q=/"T:;Q,M%'<\["U\34DL.M;[?
MYES1+>>_\16MO:V?]H/)*#]ADE,*S <E2V1@8[YKVM+Y6U'3M+DFAAA<A!X?
MT4 -+U+1EQ@8ZY/S<9KR+PS)!XDU6QCU'1;R^O SJ]C8MMDD5,#>64'A21GI
M]17JS"YTZ_EFN3:>'[%8'^6S827TY6,[%)&6 S@,6;IGBOE\SQM/&TZ52EMK
M]_W_ *?/H?29;A)X656$_P"OP_7Y=3F-.O='NO &MO?3:WK\3"X/V#3P%2U5
MF(VH6ZMSU Z]Z+?2HXH] M;/P3.D$C^9%87DS>=.%7B60D=%/88JY%>ZEI'P
MI2.Z\;Z;X.G9(Q&++@IN88\S:K'<0>C'KZ5EA]%.HZ7Y^NZO<PR&1GNEA99;
MF3 R@!/W".<L0..E>!'2Q[<^OJ6OBK++;>$?$$6L:A9Z%IK&W6:STB(/=1?=
MS( IW?+QCYAWXKG?"FGZ1>V<0T#1-4\83[1B[U+=Y;<?>*)@?]],:WO&\=R_
MA_4T\+^'8XKU]1AC@NM7*.DS+&"(V5L)@+G.23D4^&SU:?38_P#A+/&-A81A
M>=/TIO-V<<@*F$_45#UD;+X4-\!3ZA;:QXD2XURS\/V9OG5K.WVK,\H505 C
MRVSHHQ@<4JVUXNC6$G@S31KUR]SF]U'6;6-DMQ\^'C,A^4@Y&6QQC%4OAS-I
MT?B/Q']ET*?5KYKN11=W#%(O*  7A<DL!SC(Z]:N^/++[1X4\.2>,[]?"]FM
MWFQ@T^S+-.=K?*=K DE<'YFP2.E-?"2_B.BTRWLI%FD\6:[+KNJ@@QVNGLLP
MB3'*[LA$.>P)XKR2Q7PP/B;K\NK27Z8N=UI80)O9U(R=S$A01P,YS7J_@O58
M;2SN8/"/AQYQO7S+[5H@\I8@[=L:;0HQG@D_C7G,%]X@TOXO^(8;30;6_P!3
MF>-YWN+<N;5L+]V,$ 9)'^%6TURLB+7O%OXA:OH<&K>&/+^'4T\H2>.RNII'
MD,K90MO"[0>V.3^-7C/XXN+-1';VGAJR?&$E*VB8]U&UF_)JUOB)9_% 6FBS
M_P!M6]@LDTD<]E-+%;>1'M!#A!M(YX_'FN3N/#FFQ*6U[Q@#*PRXM TC9^IV
M#]32E\00^'0P/%2;-0O3JV+V2(P3O;V9W+*P?;'=1YP2"2%?.. >AS60T1C8
MANJG!^M;GB&QALYX3H=W+=07$+KINIW>US;2X!,,Q'&U^H.,'Z@UB2Q[)70
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M=97D*6?[G[9!&"MJ[]%)'5VS\N>V:R<XK=F=.A.I\"*\0BM=/NM)T^"XEW2
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M>2R_G7YZ?"?X_>)/AC)>Z-I&I0:;::O*GFO=H&5"JL&=0Q 5BK !BRC*+D@
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M\LO)L[C[#>1[I%8"5%=Q_K$^<<,3Z&NCT[Q%J/B^XN]8O6^VEID26:*/"!D
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MN%NK*-?F')*@Q]0<@')]J^E=7_9*^+FDW UOQ5K^F:\(K2?38$%[YDR-=,%
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M:TSQ5K4D=Q/=6,4;@PED4Q.@Z#)R03SGIZ5O3ZUX>ADL+=+R.W^R,'C9'(4
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M_AW%-8UE?M]Z-QSE05$47.<;4X]:V/\ A*?$VH^&&U2:Z6T\0.TL?F(8Y"O
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M] T2ZU/6%MO]"_<R/!YQW2;-Q!R@R#CD 'CBOFOQ[!JOB7Q+>7>CV<UAIDC
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M.=,Q*NGSQR>8@R?LMVHQ^ D$?_?5?GY;6X@NPW\:L"&]*<=M17NMSVZ#32Y
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M6-'P'JVL7VAP_P!F6DLMQ&B!VM=.-Q,&C8F,EN0  SKV(KFOBAX6TVXLUO\
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ML,#3-/#$]=[_ ,JV]!L D"J , 8Z5T4%FF02,#'>G8YX^1PI\0^-MRG^SM.
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MUUMI\5=:L=.QI?\ PE5]#%M@59/#<;6Y '\,D;H-G!Y&>HKXON+SQ#H$.F+
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MN>!599-#@FR5-S0N)WKDFTZ,%$[;!?C2T\ 3B[_>C?AA3/MZ,:93-?01,&?
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MR&69&FIRLAVM/7T#TJK],AR_*<"AF? 9U^*T]J$X^S31*AA*B@I;TU1V](1
M')E^[XWR5BK\#GD#Z';!9Z-LEZ:4&.I+V2DLA7N.> 1:=!(YVHED4*7;)K [
M5^@KE/*XO#UFI,_IE7%/+RH*8 XT^1L'IDQ__RM_)-VZ_L4\P\,(B13UG(C>
M(\521^&5F.DHUOI).E_6>P$PCB-"'\OH^Z()TQ)8K;B2 &(PZ#Y_<8UE2](
MD[+BYY _T.0P!A+]I5BFETF;>_*LZ@L'TL"3U=*"FECL]5^"A,K!QJ&,F%M
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M?VXRC88SG&#C?NTG+?'%7'0'#T@UVY7L<H\J,KTR[(V)W_2]J7_ Y*H)"Y!
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M_EVUZX\J# 96>_P$+CECQ10@-O#(S!K&9S:P8_I_JGO%VM(!@3;L0X;3@UL
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M2RPT/Q&_A!F, ZVAU+M3AZ3UM?57$20O!X?B/AP4+2/=$.ZBWC/KS&>C5;>
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M%-N?^]1WL(R,KBE,Y@$S_[],V*;RJQ'Z.H-@45!TP](XF$A6JYO4<4N!\L0
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M*5/P)9G5XRWP,+<AP-8V\77RL:KBUB^=J &B,,7?U79"K[^G24P7-NH=&+>
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MZF[@W$=X[G !;RM2A(7GQLTW2HJ(/8[MS*C$V<I7WTEU%1$)^B,+WVRT_:P
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MR>I[GHHHF=NS=T<XKR[KXZ6/DPB,[4")=F;4#F02&(Q \8FU&18[UOC+8^H
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ML-U$E<]^^"<DDOAG2GE+-*UM&SESEBQ49R?6BI/@W$D&@:='&[2(D$:J[=6
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M4+R+  00J #/'3U%="9$[]3U+3_CIJMKINJ:M)IMG-X;MG-M:-*[+-<S#(!
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MZ(3J]\IO SC[.\#,)%_A#?)T/3KTJKDG*ZQ\9+RZT2:/0->:PG^0"6.'R]J
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MMYKE6,SMY;[^.H_N8[]/>O3/$NBVNGI+9RW%LKF25FFBF1@J%F"DX/ X/6N
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M5C1_#:TU&ZF,UH+33(V(6ZU"4&68YP2J@9"GD]L^]33Q%";>ENA=TEL:NO\
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M9XDC.,MEL*>B_I6+X*_9_P#@QX#^$/B>/4_',%IH.O)!;SW>JRJI9$4A'8(
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MI?5=/N+J-F>&7,G9G ?=C^8K2+N;4T[69[S\)KP2:(X8+$XOYAY1;+ !1Q^
MJGJLP7QC98.3Y:_+_%U/&*YFWDMM<TS4+JUO([6Z&I/<VMVS^7Y& 6X[X/3
MZDUS#>)YM2\0Q:E<*$O8;B,B(?+D+\K*/3KTJK]!*%WH>@>(M9U)Y[70[.Y2
MSN(YIY9"5W[(@F5!_O9R1Z<=ZX>#7-1%PP2ZE%S'";5"N!PQ  'IG/ZFKGBO
MQ(VG>,[2XELEBFBBV.HEW$JP((],\]ZR_#NI0MXFMIF6,1+)YSL3M7"@X)]/
M3ZXI-7&HM*YVO@O4S9:/JNAR7*QNF)C;S(0P8$!D!Z$?Q<5EZW%(\-VRQ2%"
ML8W$8&=WK65#K2+KTU[(65IG*[@Q&POQG=_L\?E6>^JW9DN;>_G-WE0(YB<Y
MY&#[@T0>A/+=W.[\*7$,&K1R[69(X\,\1R3[#TZ53UNY0:A*Z6^R:1B?WO)_
M&IO!D:7&LVJLY#R;</&Q5AQ^O?K47C&VD37I(]GFD,6RO+$<^G>L73;?O,SM
MJ=;X:UV%;NWPP5;2-C<R.,"+(!P,=>GTY%<5J.MRV6JS:BEA,X,KL%)),:G)
M^[CTY-=3HILT_LZWM[5KNZ^9Q';D C(X=V/3GU]*Y/Q+<W5C>:A$@B0"1QY@
M.3G'0>E;7\Q^AN_"_75AM=7TE6!B69;VV3>,>4_4*?J>E3*QF\3VP; 7:5_/
M@UYIJUO%X2U6SEM9HKS,>^6':"(W[KCIR.W6NQ\ >(;*X\9Z#?QJXL8[R-9[
M:4;PBY!.T'\]O?M5IV*G!M<RV'?%B4QZ5H\49^>WD#?I\IKHI9[3QAIUF9K=
M6@OK;+NGWN5Y'X$&O6/VL_ ^B6OPJG\06<,:78N[0QS0_P"K=&)'R^F0<UX'
M\-KR)=(<2W1BDL[PCRR"W[IUR"!]=U%]2W"T"SH_B,Z3I[_;A)((V\C=$H,L
MA7@!0?48Y/K67IWB-;>%)+=E2>69X_)D=FRIY"A ,$ 'D\5I:KJ$,>OWL]MC
MR"%C-R& 1&P Y P220 ..E8B:+)-+YNEVJO>2#:V7YV9'RCL#@C.3TK-:R)C
M:VIV?A-[B_L'M[B7^S[>T)40VR['E5V!#,?3' ^AK[<_8CL=6T;5EM([J'4/
M"T]F]S;.S[I[2;S$S%G^)&!8\\J5(Z$5^?L>O:RDZ7=O#!.DDK::,S Q2'KY
M:_*.%/<$CGK7W'_P3[UQ1K-YH)M+N*YMK=KB60A7MD)= 465>&;)SCJ!6R-(
M)J:/TJT[_CP'^[7Q?_P47U"+3/A-!-/'))$=9M581N$.").YX%?:&G?\> _W
M:^*?^"DL3W7P7:UCM9+N:YU6V@C2(D,&828(_ESQS45OX<CM3L[GQ!XH^/.I
M:3H>FW>FR06MJ]C''+ID<>Z-5 *D;V^8]SG/&>#Q6;#\9X_BO;26OB-[N2S:
M<[+>QA"F,L6R$8G"@9/?TXP*\;N/#VKZ*;.RN[!8Y[F-5:%ER(R>5D.W.?E(
M)Q]#TK>\+:?%I5GJ#V[+8.=JB:XC8B7+8(7C"X W'OCBO$J)QI.7.WVU-N>3
M=V>AC5-"M='CA5[F>WLB61C(N^3 &T$*. !GG/52/>N2\1^))_$;VMY]K338
MG!4F16+2DKQN YP<;=Q./RJA/XJUS3&U'2]->"6R<K-)=1@!9@,89@_4#D8Q
MU-6K2"WO])>^OY9$<_.D*@-\PR>!W4'')'? KE4(T[3J2;_'?RL-RYBC8WUJ
MB2KJL+,BH6$B#J_&,#H>G>J?BVZO]>@@VSP2Z>(UC$4L@'R*<X4]AG]>W%;W
M_$ITW1FN8KB1Y&1A(LTJ2F-6.3M4^N,<9XSTKCY;:#5!=/I.G278A&]S(A=$
M/4'.1CKT'TKHIVY^>ST_ AF[X1NM.L_/2:P>[TPLA>!;H[R5)&S=@C:3@],\
M5UNA>.9_#6G:D;:Q2SM[IA'/)+(&E:,.I";L9'*_P\\\YQ7E5OX4UZUO\R0N
M%1?.<12 C'J2,@8(Z'FNC""&2%;'4UNE9 ZO,NSRG(.XX'W@.W?^=54C=W4K
MW]?Z0N9H[:T\3KXBFAEM[&:PTR(F06XGDDWX.6(,AR,GDG@?A5KPAXCU#6]<
MFM](GDOM9F<?8[:VG\HR$'<<\;MH[8*GIR17!27QL(Y$O97NUE&)5MRP8H/O
M'H0!G\16#I&JOI^O+JMFHEM2=BK=D*ZC/ &><8[CMZ5A'#M\TE\A\Q]C?#CQ
MIK45W%I?Q9U7Q;#IUZJQ6ELEY(T$2I(V?/<;OE#)@9Y/!R1TUO%O[5WC&SC1
M-&\,/9SD/;F:TE'FK)O90P7D[2NPAB>?FXKY<L?']YK#20Z?J=S!*%\J(&Y.
MR/YLN$"@G:1D<XQGBO5? _Q-U_P?HDNGK-:SQPLK3BY:-S&0!GYROS_>QM)/
M0\"NA8WZLKRA=_UW+4.=:"6OQ8UW1/$\VHK;O=7F2$NKNPDMV8 8*X#<KQ@@
MD@UP1\;-XAUJSOO$.F:@UQ>@(XLI4M+.% Q 6.*-=S?>P=S9ZYZUZ;%\0]3N
MY9-/TZ>PU%[NY+1R&#;<@D@JJG;PIX'Z=ZW=-\47-UYD>NZ3I?V"W78T\(6&
M6)^2%.2 22&X8$Y'X5$<TCB4X.#3:Z:/_,<(M/1G%>&?$N@*T%H;V]L[:"[-
MWL,9D:0\*$##E1@#U[<5K_%33M>U;3+NYN[:^UW5+QHFM]9OC<QBU@ )V@3!
M=Q4'!(!'7G)JC)K\7A_1+B]M].LSY(8A.6F$;-_K2<849P,G&<X%9]C\5/$W
MC2XTF_749+VXLO,P;NY\T1;5!$1##( QC;R"",=*X:%6K9\])R\Y,F6IREFV
M@ZXT.C-->0W<(=O/2 [IF)PI(8XC..<#@CGK73:+)8>&+F;^TKT:S%#;/LNY
M/E,9. 6<')^3VQGCFJVI>/+75-%N&O$M;?6&.Z=+1& .#A6$@;CKTQCV-<QX
M;U^T\/:M)LT:.\NKZ&2"07<DI\Y'& 5W<$\C('7 K.,)XFWM(\J]$_Z_$6JV
M/IKX>Z/H/C#PB?/\.:@_A^R<S27%M<>7O( .U8\_.N>65C\H.1TP<_4]=\,P
MW\=[I?A^9?"\5J9K^?2K=;Z:TDR=I=F90JGITXP>2>*\6TZ?Q/IVFM?7$L]]
MX6AN8+6[CT^9(2H*80A^FXJ N2.V#6WX(\(S_$#5)[.UM[X^$;*16N=+"K/<
MR*<\2-%L(&<C(.1CO7TN$Y84U!W?K;]+%>ZWJVF?6O@_1].\1?#BVU73KDW\
MTT1G@A"Q1%VQ\L9."N5/?ID<YKG/&FGVW]A)KVN:AJNCWD$IBNV^Q:7!J6G,
M6551RZ;MG.[*_P /;D"N%\>^'-:\*Z'X5?X?3:IINF:4V^#1+F246Z/D^87#
MHS'=&\@QGJ0>HK4?Q59:;//K=CXN\12RLH*^'YE%PD;E0H.&P6 ((YX/?BNE
M*[LNI#[L]5^%>M66LZ/8Z=XHU/PO?>(9EEG@@C6VNQ) K860F--H8 X(_' Y
MK4^*CZ3X*\#:MXELO"^C:WJ.F1&>&$6*/(SE@I*X7( !)..P-?,%QK^IW.N0
M:QX<6#3_ !,K2///J]I(;<*2#Y13#+$QP<-&1TP1CFO7?AC^T!_PE,4VGZW:
MV^F:] I+)&\[0SJ%)+QD9Z#JIY].*4Z"A[W0<9IZ'@<G[53:MX@M7UC0O#MW
MX6MK+S+G2)K(0P,2RD#+* )%(&W/RY8C/-?4'@5/"_Q#\+:%XW\+^&])G7[(
MYMY$A47,"\[HE&_Y<D$8Z'/'6GW?Q(\/ZS<ZEIEAX2F\=74%D+DW6C3V\L?*
MAD52Z,-Q)QM()&,D5P/Q<^*6O?#C4-%M=)\)>*]#ADN)8/,U&QMGL;L#&UT:
M&'.TC/W<$8Y'-1:%5\L+<WJ"G8U_"WP\_P"$ZT"XU#QU\*].TW5[ R8%U')%
M,UMO9HF$:ONP4R>F25..N:P-:T7X<7>CZA=^%;;3--OD:);>UUFVU"V,\))W
M,=I! X.T G\:H^%?VDKKXF2G2]2T'Q4-=\.Q[+BXTW4;QY5)8L"PCP0,-\I8
M%L"L?X@ZEHNLR3WUIX0\<Z]XDE=5@6>:>:TG;!(22*2-7) 7);.WUYR3:@D_
M>0VY/5,Y_P")VM7WB*ST^WTFP_T&&)K;[%:N;N:,NV7>.5@S ';]S)8<]ZS/
M ?@:_P#%UK>6FE2VDVHI)Y M+CS#=1,3A3)$0"H."?RYKTGP_P#LY^"(OAWI
M?C/7]&D\/ZB8UENK?^VO)1)BWW1N4C.0!@-UR,TO@Z[\._LY^(]1US1]-\07
M/B/5X!9)>:E<#4(H%9E.YHBJB4;<@!7)'I45*-*:LE9ETXU)>\G<K_\ "@_B
M-IN@7,FFZ1%?.5,4PBOUMHY%[@B1P"!SSSS4OA_]G7Q3X@TS4+KQ#HWB*739
M;DQ*GAM+.[9WV$F4R[_N!@%.W)'7'%=_X5T73_'6FZ@OAV]^&5]>B)RK26MY
M8W]F&(W.\#RF*10-Q8;L8!P<US=]'J7P&\#VS>&O&7A6+Q/J$\0MK+PY=76H
M)?0L<![=6'E*<$E55><;>M9QP-+=:LB<YW5[H\TN/V6M8\!:1)XK\8>%UTKP
M_%(RK9:WKEN&ECR<-RV3G &!@G( ZUZY\&/B/I,U['I_@;X;WD6FR)MNGT^
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M_"K^E2>&=&T=Y$GGT^69=BAT\R1QGD;CC!&.@XJY/\$?B!XE:W&D>#]4%VX
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M.RNE%*[O?S>KMMTL%T]$;MQ\:[+QWJ4>N>396NJ6EJL%W;V*!U##.9,[516
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M\E4;;&UTR>X$@SD!BHQCCGTKA_@C\$/$/BOQS'I.O>#]5M=/GMI0TFI:5/'
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MTI949'%K%N##!!VCJ**U>YN0?%#XN?#+X8:G;:?XV\;Z#X6OKJ+[1!;:K?)
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M9_>O7@#E4H2I<U-9SXJ8$VD7(TX;*+S]B:\S&ZTP%M?=C#_I$-&EH-I=?B9
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MF;GSYC_WK9EY<]^'M]Z[N_M\.&O7J555>^^J^M6I@_N#6P3N:*BHJP!X>'C
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M+6Y8@<53GA!?>N+-@-5)M^6O!DW(]6(GC\M+Z1S,[\D.MHJ,Q3&(W1!AH?,
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M0/Q8I3<M*I5-HS*>K^S;\%NYG17/YY9H=L]>'K6"QN;:1\4A@6W0YG?R\;?
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MZ/']YAM-YVTO5I<$)R*>V>1_2OEU#0M"0CZF7X/SZ["MNL?^ PWIW%ITIC#
M]AC?-X&545F1)HJ2?J#(2GZRF.[%,UU?3CO!RKQGV<L:CT\@$.1JR\A;.A/
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MM[-95.\B25]5,L44Q4WN7-SP>2H#_P@G3\A.?-0-XOS8??3,;P,?'4^N[+E
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M'>II>_^ JG"5>L89\MF/X$/+.]1^R2"DT$!T<57<3/$?*[?3+(%WOB(2PI9
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MA7G,DV'X*+/9-3$AWA]%!D*/\EV.Q&1ZUV9A5"[0,:W4^5*N!5P#A=&)MPE
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MX6+$O[_]])J!SD9Z[@&0S!4S3H*L$)VS_.W')WP=/K(-7P>%"#X F,1OJQX
M=$T.B,WN6":AWPS_$''"O8V+V_R_2O0Q=UM:#X""Z'I[Z.EKYMD(RT2AV@?
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M+S2\Y6-8$CK$*0;:1%N?1""YP9SSUK.KME&-/:>)IJCP+K$C#_X6 W7_L ?
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M(Z825.Y<K2&0^GX/FBNFG?8_=OV=,1U#'J!($TMTS3YR4*R#ONQVV:7X-^"
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MD_24KROFF<)ZT*^=?JN[^Q!F&H]#I"Q&+!,LG_A_4OM^2>Y6(>IW< @;LNI
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M<< 8YBYR ]*8WZ60:ZPU-;(8!'%M];IR+J"+^1M_CTZ1^?L-9I SY =4B>
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MI6;/60A]D^="QJ2K:B*\JX6SLFFBR8J[.J6SV/1FR->NWJ>=[!S+2MP_3@R
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MFH>?(7<B?>3<'(HV]/5/$[8_-35X6M3$;[.T/+_X/)7OEFO]%_Z?'&\SJM[
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M"LMS8@Q1DB%;;Z)DVN:E&T=E51)U-!PG&M1K+6WLJG.D$KT_ZLOF#9-MJ0
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M3EJ"G1,UT>& MS(Q6)5L+&L?"HX-G+^" ]K2NG$ I\%V,RT!.A8'4+Q$[^(
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MW>@]V>@]/\(3\$?*_[4487UI,64W'9EMX8/&&XD+597@^J^D?&(:EM-*OUX
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M\WL9:\O!R5O7(+%I"6W[G/R.QDN32[O)R)3A(;#P![LSU<60\LC8]*D%\J:
M[@:N@RD%'R= IJ__*8G'3;E7XNT+0"7N:$NE]EPD%O#'Y?"ZJ%7"$F5WQ7GE
M/3WV'SG%J?;YZT?=Z=#61C2;WX^EU]DY.8\I! ?B4N4K?_(YFN3EQ\6?9WD=
M*66/EEAUGD=?OQTENQ:]4EL%W[E[8)V_IJ/Q;6^EFK7OUPK%?+>7-MSPK0]/
M.XFQQHD/Z$K0AU6?.*W;I1G$A:%QB6*V"%I:6J06EB;ZHY+BO3]59=X2=_F@
M@+G#Q91YO<CHTQ)DT*@Z.*JF4I0>T; 4W^] *H0]H+J D6MESV$^YDQRJ9>+
MR9'K@\^)F>YRJ->U?G)G@OQEF'2X :;.>,<RT&'IA?2>25 H/^1K![W7N/JQ
M%L<)>WX3!X-=,!/)N=I*FA(K%R1=J5]2;6DQ,7;24QP-2*VZ2&:[G.AQ))[P
MYH>HMEB<GNZ" 6$X<Z=)F\Y=F8^8S8:U"TCFK7SZ;@L^2W8=,N-F(IT08Y0P
MSKE)>V'1L/.0;L10/\.XNDS4KZ1I%H7WR\%?^TH_YH!S\ML/MR <9J$B.I.T
MF+09:Q9>X_FRCXB,C9#6*:9HL"V'<.R8V#'9V:D#QT[<_4YL#!1I#*P\Z7 F
M.IHC38 E\N4GBO#5AR;Y+CF,D?4UR@.;1VPBWOO0\]K<D@_K/=NIJ8]JC0RV
MK9>WU5D)/F0C/IBEZ(&):/J9N*KJ0 ?:H:V/7U9E+"=R"R<A8"!*2,[*T(ES
MI\!0 ,:LPX_/(R.@3U$=(?CKKC[:F'N; '/:%(=$Y$R"0JJZ^Q9<];Q9OF2F
MQFB0P5FG65EZH.ZD#8'X/=9)(05"/U^&0 H!?E0D3L:1'S^24]3B75';HH(5
M*.AREUC+.B7/*:IG)]R6^&3HVZ]:-R%*&V-BILNDL\>Y\)51<H[+1DG(!\I2
M@8+\//$QDG(3QDTB@WO5R-2.@F&K.RO[\CGY>4%*">'!:"%[IOV]%4_QA$FK
M!Z*^7&_VC1_[*1<E13RC+HJM7YKR3F+KK(5$Z%6;\0:]!W)?*;M')U3\(-0:
MJ378E-B/!&>L1WEGA)UT;[^[;O'*F=:2%+%C*X]KNKFN_'A1>*)9K*QZXS-P
M&DB1%\!%!$UNYQETM!9.3CY>7+\4T_,R9+1?B;S(0O14OMNRC#BY7C!WX*K/
M,?=\A8H:@''7@0FSN),+ZUN2J5-=4;%&;_C1B81&<5HI?\%T<NIRT:&>I?XW
MN[>'V\PYJD'M]Z7M5##-BH/YU.A\-S?JE ":1/G.0>F)<'CI=]A:])>2B2Y%
M[GPBXH:6N#@'Y4%JZ:]#A<I32;T/U"@ZC9!,,.9$+Z-?W$=X@CCD6 *CG1$W
MI&K8V+7BP2RF!7F'PR?0,&N+<U&,+T/MZ%E,@3;3&BM-ZH)'OR%"PAP7;[T7
M;=&>IM%S'FQ^&WQH9!>Z/1+\AH@L80:D5^AF>>2B0MNG-BM[*Y8D!77((!3N
M#^/(=7P!<*E.MGW_BZ:AUX"NA[1VEG=9QT$%*SK;(Q76(GF1U,,9G!3UKCK.
M3TCEW$2]B>O4,#L/EJ8 ?2I1(."#;+E1NVW;W%IM,9ODGCJZ:>2N\KX -J.M
MIXJ55LLQ>0Y4"*PSL=OD0L\_)2EZ":L@#%'[AF^'1C[CS0Y;S9>6Z8[7"Z#<
M<0/0D#)94R[N>D1> +@!/;4];PWU""!,QC_EKOF,>NN_-R3./U,W):(D[2V5
M.18T:^QEI-MG.<R26C=;3JBB_ZX*W>J-ZI1\7/82WFYG_0XKO$CJIGX#%R-#
MCAZ#QQ'O1(JJ'/1/S'-N=D22M7^']I9T-7!%8Q9U:Q=;^;->G$<H'UNKS9WV
MCQ(&(SQW;!NBB)I=) BQB F[@B?.7;>UA.FV,P1N71W"_%D2CWN3(X!51J+O
M_X B_2;$7 QS+[8_DD7!LU[S';LMA%3$F+Z]UZ:D1OM-=.W?<7'5G857U\@;
M9>0M7,7:5(5.&7A=^096N''^>GRK",Y?_0*P/%2ML&B."8E><9<^DG&W@)7<
M6+/\]#]^-'CC#A];J>%]FT&N>S:OO>A-Q05]T].<% X'HA89C,5C3ZK3$3S>
MH<6)A:ET-8P^S9Y_/RVL]]#UA>"=BH9*[&ATX#%-WV!F,"E,;5ZRV?Z2PS<M
M>0%X/L3/0PM@]K>4 D8"SL&[THR ?C= @")\J((%%UNMG&FHDH1IWJ?A./NA
M@AQ34"-7N:2U_!WDLDZ[H+ <+C=3<-$1=%(7S)7XO.L[G#0N1%>X:<A09-1=
MJ"L:-T 7SM6T\N#M![2%Q?<0',]?KNL+#1/4<1VPCG)\7!.8PY\2H%.J]QN1
MHP*_ +Y6BF>06B:/6U?61J?>!V2>3)/^B);[>HO74)=8L18P&^O332;ZS#P;
M6NR!MYPNB?LYMX$*D@TU[8G8;'MOY>Z,.L.HKZSQ BA57S[6OE$A6X2+5@]]
M-)\1K:D_COG%_Y[DB;4/_Q)HJI9X="F;Z&7D(G1NE-.7;I+ ;!LSN/M.,ZV8
MQK64CD2K?S0:,JFG)T]H#]@KII4AZD)!YB2: BW7[?&&O/%XBT)YG$VSBF_E
MO&K='&2PS%H5G(0AN#RQU]+&!!+'G3]U SLKQQ;!:Q F59Q@VMDP\LV;^IC-
M0>.F'X9;IQ+>.I9(4ZU3^Y_(M"I]-NUDOM<U,IR:2W0^10<HOFN<C3?H(+04
M^4-UA57L@3],CO;C*TV8U+M:EDN-^70X!]2T'ZL9Y=&V&3(@M=I9<5K@17CO
M&Z/^^:!1*>GWKYF?Z$%".)XY2GU.]81L:*2B&JJ@/%O=Z#UQB''T!"K7<?C2
M0$26DB\'E-PSHHO?17&YPICJ8T]ZW!$:TTHD=5\+S:BG=B<[R"*[Y' GCI+8
M;3\PN YZWA3 <L<K1'0'(ZNHI^+V.;VC%C&D2""3/L@)/WO_>I;\;BFTDBHA
MH:2>CA=AKYVOE27.Q0C)?_;N]0IL6>5JL6%Y@3@,Z2W/0&?6(-JND;/GGCU]
MY=< &W"UP]:]N>7:"\ D6C 7Z:>2!&-SU7J/(%1Y9CS#%^AZ=S>I]T-!YO'D
M;X\1WNJ7K?TI^V>'HLD>Z(*'6=?D.:4A:^(A5-!O+M8[_=NI09#SV'!)+M"_
MGJ\\ X(K[)/BV^+L7'T]JCT#*;5@F>PC-;E7]:'VMLBV&H@@_R1E"FO6\K8.
M\B*R6QA"4S_78'(%4O84,"TAMK;Y <IF-7^D68[TS U,D[TB5DC^&/(S5S35
MK-*ZH)'&MT_L2NYWDT]D[71>B]6:RFI/ZP8.Q"RETKZWSK[H]^6((Z"DP?]=
M2N[E6W)G_NO#SV]C:5>Z]_J<K5:\73F-CK23\(9MXFQ#W/I]M=P@WX;[UM1?
MXR(_S"Z36,2K-#9ZH8J?8=MZ^L^!)RG>T]FIQBUL7^4-*3Z&QF\JV+.+3[N]
MCR:1W<Z:@MBVJKJ!,>2L#NT#%>M"G&5MV@M+^EU8K'<4=F3&)H1B.[IJ^:Q]
MT\PCAA&EO*FZIW)GYC?U\/WJM]7:?(;C[-DWCH/GLCN@D;%*[QIZC).L,)=I
MJSDKF*Q:VX8Q7%G:CL0XI=)4XX-CT^U/=1?TQ[/9EE;Z!CY^Y[\3//XLC30R
M&'O5<5FN@G?X E@,%?27WO7MX/2V#RY,6R3S8GS]3<2Y'X !$L%-2++= V%Z
M^4(8H'6)SPEZEO+T@9_1&FV;D" *Q8;=M,GL>'M?G/80>E6GZ@[SVC8[O+WC
MX;Q#O.3 UH;IYWG1%F/.QIV_C#520FJ*5:K[LF%_! 89)FC.H39:(YL&+J0.
MQPUL"E2L>7R9B0SE9K10O>QK<U+76\J&J"%P#ZS_+':%VL2W*(Z8'GTX/]6[
M$V<))5=A)'?5,(Y:G8NU)G05X2(WO%]  2SY<5NSVV'-&UD$29VR^N9!U70,
MY5"S>-YSM[P \*X+^4L)^;\/VPP*7% K1H-^I5+SI\YI'SLX#V'ROT*CU_)]
MS&^]))+M$Y$FZ+PK@@\RI5CZ)@(V[HJ_&%R^BU40^WHNDVQ 'E6XJ//QI\'[
MC%!N&D'L4V"CS QC GM8K'WAKNS.]6%JFE)UYK):[&X4EF++;>,C)*7X*%1G
ME9B:?3@^_<M6P5*B3A68W.NC /_RF/-(!M#5O0/W](;UH$" %6S3[;7FC;#4
M"'(^^?,KSD\&K-?KY#C*T+L9S2 UI'\CU(?6)F)=%#^SWC%?,%5@)P#,P'!E
MHI" 2.;K&ZRNTJTIQYJ=+D=B[$S-Z*\H\>C?VU$I[F?WV_R>]P"*SSH#Q(Z$
MRK3V&R#CW[8C!MJ:I4FH^<>\*D1Z4V]^78HE1GPAFY5%'N'N7VNTUAC1]MFV
MYXK7RHE3XFK]I-F&<"B=L##%&"8_<T.KT]N%D[=5.MX^8<M%Y"8:)SRW(LZ<
MV37]1*DSL,^ALNI@TV>G]O@Y(R)(4H@9Q925/0H/DW75% F-LGDN,>4QGU04
MIZY>ZV!JA[IV2-CAF<53P="40I5'@<X. U6)VF:TW<@KE<$/G?=1E_-&4SXA
MST,0(Y=^OLU38H,A]Y6]*,A]R7LH;:LVQ#XA:>;!HIDS. "S[)GRX *6U(,O
MA[U3VF8:ZSP@!KBIE+X0*]_OPZ48:^:KCEXX!:4-QS;2X@P? /V=,BR/V#>M
M!BO.^#O6KHTBQ,?9!\!:>5 7K:!C]HZ-A%;,"Z0_F6R)(#L1^78\*1[VDQK?
MW,-^O>LGB8V&4#A:P3!#"ID9%]9XT6CHS\J<!P+#T3*%7#CC!6A_N+X^5.R2
M:L.T^(XIWS>8^KNH^2,0+OD\-.4[K(+[L><GPB*%U^["0^;L%:DVA@4%,")!
ML?'']!_UVBS>M):U^>OU^N74<6HYSO!?7S+D+A;]^<5:-F)^\ 7@>2Y1$G2%
M?[DPS'C?V#%C'^C1*+&*_# _Z3T1^JS?C=$7L8(#4=]LZ 93H\'LI^6F32_M
M:%1;YF3/^EH@DS2O7E<BM?DTU:,*K7(6[\Z8JF!3$M2TEL]<;?_XQ2(\N[.R
M5CEP55G#_ F ;6G0&>P<&^D=?N;V)+R$3*,-=J=MC,A]NTZQX'G5C0.!4?G$
M2[.G%8IG:-]3RWRK..8P<R'+C O7W3:4$[RI,-6"\D7_:#B]Q)121KV*G/=S
M)GR+X1*=4N&A?[$;]OWTH_8<=$B.>:2)!7QI+:P!;M28HP)EJ8>5-]0M[!M#
M^;/*>@:M7;#*Y*0DB3:-2)ZI;6?(-2_@/PK!'QS,E.F2%I[ U5"/(-/)<P%1
MH/WP'<=;$6F,OIFZQ43Z6'OZ#CE@F9F0^1W1G1>[M;G;=GCGK,V3R+UX%+5\
M3:LX?T9AF=%:NR7*1D"X5CN]]B1D %G@XOG,RB@FV8-HFJ$^?U,WT8Y%I>&0
M_@QLN1O_-&TH! 5W>;Q1=AL5K!/.3UEV-#TZ$N8#PQE@RQ3G."FEBK2-FUHF
MCC5^?L</6:R]_3Q=;)K8\STM$K/N$E2CW \IANR;)? LV8Z1!PFYJ3+?@$)T
MNSQYCNJ@R$Z*Q_ @SA!#UFF.]GE+FP9)(52F?6K%O0K>FY2IHS[9JE9JX1H*
MUGF[C1? C[O/-8O'N R_AB_S=\P";_C<WO7EU&V[.C)N7;M;>FQRDH];$[H;
MTE:EKDH"Y ]DIV\JYGM_-D1>*[#G99WRXU(A5V6M<1;X@6-F?#6WS"87C1/'
M075N@EZ$7+U>3UE]E"J=%X8KJ];'6*]S!1*#,3-GMS6[E-/UF=<^)T;Q%8Z<
MY!OTV3@HL*N_;^<^(',/!.<QY$$C!M^B(#Z=1#?!2V.K8U\ -<!NNVZ.16=N
MC_ [/\[-M1]0NFYW[W8U W>-1^FR\D[+^_ 8Y<;*=]"PX$I?1ON3U#F0=HKN
M-CY6 70BV)#GSU0Y2[*GKF2Y:%Y"16NJ>$VB"Q^&F\5Z7<3\XZ2=B(2LE\>/
M5FG*U:X#?H[*@/<C)[@/1>,.Q<\)#84+.C )1=T*T% HPXJ*R^D-WU:#.-9\
M*U,I]6NAV-6=5=:J(X7#Z_)RRQZ]L,B/7./)FY&6PY0\>E\NKJNN$X3) T"9
M_B)XVF\T9TON6#R#M=)ZA4>2XAQ#MG@IB6R8RQ9)B(AH%\7BL0(S9VMM2Z!8
M@<TM#D,W0OC UTNR](X4KB1;;<,;\]U/H6*&]\K=S]GD]ZF;XI2P=ZTRI>CY
MZK?,K]B<_H@G7!N43^E)$[)DJ\K.(E65'<V[:^0VE;WCC$K#AP<#MEKOMN9#
M3>=Y.>LZN8I U-S<P@U%%4-'=X/*0J83FCX@?HLK"Y$=L9@/K(IXCC9R8B ^
M"]]K>WL'8PB4GK[\*1ZE,=*CW\5P=_,<3W)+C RS$8>[0SBZ?ZJUOZ]9]T(B
M?/0@QC_>5U&%A)H#5\\A&*("DX(#;]&2_!.\I:69;*D2SA0QR@ABAN$Q?$J)
M6I9ES)8_$S?E)%529553??/=?3M\*'W4ZT;YCS4;7TNE+=S8=Q_KO]-?A#3-
MPLG;WGL>_>$)9!D(R;I#?TZXOL9.(+KT_[%-R=K50>++M$DNE43V;29ZG@!'
MOD?9Z72JO;Q.2-+(/%%*XZ!QV.?Y.Q0:0.:^2FR5$WXS1D-^EMHWAT/GD&_;
ML,H74?;W2\ A'^"Y'PU*8;V2NQV;+ZR'I1&EVU6C1*KA"\?I]OHG>AZ?*\#F
M]^1.8[[<!9 D-%TF <-$ QH8W/]2)]P+MO<4G3&.-4WC4TSE(3*IK*S, U(#
M:SW81%4C.?H?W1+%D@8B=MY_1)/@]%:@&A]S9Q[)S3:=:JO=GZYYHS9#_;F9
MRE*0VM4U1^3PE)85';VEJB3 /I2:YV1(-RT28F5-)KH4F>G7R=65R[;Z#1'8
M]KTPU2?$X,")9,-G5D2)M%(^-N]>P*1%R?,D.]PGQ9&=UN!W_##$18NGKH'*
MX#?6V$X1G\#,=((;?7-5>)^\>RQ])$*O%?D[/J%M*5D<5#0;WU3V0[?8:=](
MN=53O40MI8)QGE5]Y$3.&Z?BQQ%K XZ"$LZJYI!;/=GD>KR<8=:-@7Z86$E>
M)M.,WFA.];*#'<F2/%)J9YL%HB66[F(T:*YP@LW^/,58OTK( BU6IFY&*,U=
MNJ[-W@<<EK#%/>0MWQVH*D?1W)ZC<V:^LW''-Z=[$,,=H4I\GVS&$IVY5YBD
M9(1C7:"),7\95TJR[]!4[-ZD7[;%:6+^2W8('7M&Z_9;G@&F@F54?3> 8_&F
MB)>=T4!.,Y2_>\2<//EI=J^A5:X"9-6L.9J17NKBX:C8OA8;G9!FSGQCF77D
M$>/CO!.G8+LS%QJ1O7(4Y[=15<DVXLA2YBXB6OCS1%8T2]V /\M2I+,*:5>:
M>;7Q!> >@LZORM5<%RM)[]13AN T\\3RGBE(5WR\F<\6L;^XHM5:3SG%UIQ&
M/Y(E2;36 \Z: ,4IXC3X1")K**Z<G+?HSG+XP#!66_2-GHB4/DMR5!M*$C?W
M.2T:3>]4E-U604& #5QU;G$8H[@OJC/,E3&&M1RCHJ@B%<=]6DX;/J+$--KR
M&_5W(_\C-V&\@@/'(Q'3Q6WV6VX\B =5H]A!V\1W8FL+@Q+%G%O$/"H?EC-W
MNGIOK:A?"I1-NF]P5':U*TU4*3#)HAN75V96W'G8B*;,OF"^=ODJ/*])^135
MBLE;OWG6N6+6CR&GS"(SQ7["_KLQ]0-E-#'?D=]1:/FM(.^M8V_&PH5U7>8W
MUNPD<49KN]TX;2-Q=PYY"M.I&MJL4W4%)Z?WSLIHTTM%1P3]3KPFO"SAOUW@
M1_@IC@2QN@L%8T&/&M/9U>%S8^C$&^FM99Y\G^3O_/4&=NVV3L]UNXA_^,Y1
M=<46NALT=8Y9VZ)"IA>Z7^O@RYD.MUP_J-41/^20?I&TV_WZBJG<LEM0%OUN
M^T#&E<P_?3Z<%F*^L'XY&L-TJ'#4%RYQ$2DVDO-J>>37)>[%]K%*EB1_GWQ!
MAI8O%K,HV0K_MJ1%$#RY^PLB#M#,<+FOEO2N%8K;+*>J-E5M-?Y(?W^I>WNZ
MPWRNQV6395YC9?*5=S_X+45X]-:>GQ2?58[(C.DN96GEA<"?2GS/FJWA@9!E
MO96X=>L$>8PWI3XW%5YCO+,[H[EH[/B"H<W-J3(\2%]=XAHK\\0Q8:AC0UT2
MQ+#0]>0+V_*T<Q'OK8Q-H\5;$OBG)+VVBQE7'YJ]H64,I&BGU"GH7>1N<WOX
M5!<-EN<B1N7J-Q1_EYZ4J^[NHV0A_TM0QZ[!^'2C7*BAM<%\3ZE:Z+-#M8_.
M#(3SNSAS_52YQLKJV);@;Y4FC,<G%#^)[*4%7]J:B5;JG.<[4(>Y]5ZD><:X
MEL1)=-8WKX:3AHT!WE/N\UYMKGC1D'ZL&C?Q,@FRVP!T&,Z^/"Q*(NJ\PJ0M
M=0LE>@AI;O7#'[C"7D>F$VDFE6?Q)AC8]XNOF*$LK7G2=ZUPQ=)S05D)5X9!
MF8SYV@$>N[M.62ZJ"7780DGJKL0MFY*TK@<J7UDO3%&?4\M0MAT?Q@2OO[K.
M"O&G;ICD/9BMR) V--C>2W@!=-6Y^LDOC;N(:EU(\@VNLE7_QNJ?25T0GE^,
MM>C;H_9\F#_GWA;M($J8[#0OGLY%;JJ )+D_-C3=$U;Q:7IIEI9EKLE9@^VK
M9 $DQ0R.WQ4$>RUTCV_GM:3,8KU=1TW :RR1,M7D>_V"E=D]^X)8.'B:D;/E
M^=&"QB6SQ<-VG\;Q;6PO&X0 MQ7BM]>H@Z)4,T\J.OC50G]&71HB[>FU<33*
M ^B<</PH#&E]X]I> $CG59XJELBI5,T]/"N#^%3JYSX:48S>9 .)6ZR60]*M
M\HXG$.$5-(,2KU.C#,V@^/WP&LM:,G?*DL/ZA]'TQ#MF2A+3S-G-3)K:M"Z]
MK,5"E&SL2P$3R!FFD&%!4^5W*M*87CV*ZB+$0\(Z6S$_UIEA+@GMHN(9&/7F
MGH\.EG373%T[L2=3]$90WQXY+,F5H#*)VYVV-5X*QM#27VNHC^7IC KZY92U
M9AE+<C=.=*P7IU#D:7=Z]KJ\YT,NJZ,T#JO/!O985KE^-[@4-<-6?Q"E28)U
M<-G-']IU7_ZIQEYT[:1M_@50WS&]YP$EUE6B#HFRJ&3QKN1;.&-KY?[[-42N
M"J5/<ZC$:,L/W_0?1HSF.?,L:98(M6M5*)!SO:,=F_-X1V!0, &[YG/7<1#U
MVRJMG^G^4["8,6^[C43Y4S,J0"U)U2RH;]SU=9]OFJ.XDI6<MD.EY$UE2?<^
M1%-WL ]ZT)IX J.PT 1V8:C5K957BB7=3$#,-U0(83[#?N+R$'(L^*3T6]M*
MB%,6\2E(+4)YZK?%&X$&EIJEQNZ2X#@)Q;2N=E$_$3UB![8:.3)2\^5)0@\F
MR.>V&3NX E1K--=O:VIE,/V29'[A2[5&]424K_@H-4UXMCJZD%KI=+6/+-2P
M<*,T>2:OJB<,D-"'XIVQ'^EZ_L.0.!,S4=6'XF./LOA%,:_/*8]Z'9E_I35E
M)QTF'8[*MF[2"^#5R79"A:^ YY<T6-FN?8=B7P4.7_ZHPA(X^W7)%F3AZ@6
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M:W<S$\VAXY?'Q5&%1W(F+-.K7*!5+LQP9D](C":YG7M]HJ[E@4[RTZ1=P'
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MI@>?-L& T<1X(%;3%T42)_UNHAMYU9NS9*I?R50-!%L<F2W'WP(^+D?!R%I
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MW>X)/+*=XNF84[D'IB"&V0M+ZWN(W(B0$SM@;D9.!#*@9:.-VW[6JWN6+7!
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MEK\XBO\_E3#(^+;3[+A VT#D("O.)O;M*OW.V+%?P"7/:5\?V$^SMUWH%N#
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MU3W=HDG'3P=M;E([R?1SF^R'1#(QHOKEZ?O>AO62V)]",,7]E4[XG$M;,'Z
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M3VHN:P=6COVS4]%\(O$F@6)Z\7N]"M=+=X!T2U1VI!F7\3]\GC'QN?6+4]1
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M+9.P4@0H%?*'NIES[R/L"P=]'MPS,@;+6(_2RN)*TE?YH#+9:+RA[V7NRD_
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M9W %6;)Y<RA*A3(ON ,<?S"?VV;@5XM<CT4.\TX?"!@'V]98$%[UR-L*7ZV
MK"GJO2Q\O%E:D?]@$.@_GX0ZAILFX; *CCIC:JM*BM=?95T;VH3WI^'5Z<#J
MZAN8E)'01#$!K^Y(]@4*X[7>)+G/T8B^7;J(7E<S=)I4M/NH:$,$($]0%URN
M7X!BV'"E/NN[Y;GHO-'<EOHT543=O?!(C-QV<^2&&;P4N5)KNI6Y7.[K5K
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M\+'Q5&;VWGN[^SKA^V*IAWJZ2.7,'>!WJ@3]W]+!W(F5XJN5D@"9J9KRH#N
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MN9E,0""I^+NB=^,2Y5\6-,9$4N-",+CV?9+E;Q*#L];G[HLXSVZ/1@&=U;J
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M7U:NBRHSOY>A,^O)"#G9^V?#LBJBDIE;A"6"H]H:=*K]'-LN'3!]5=QPG>"
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M'X6PQ$>IOXMH.8;K*)W,?X-#. ?2>XYZO[7JDJ$!C^(SW_H0@*%[?Q.:QI)
M"G,Y&>3P4(]RSVCQB4)[R*V:-WEMJ1TVH3_HI*P'B'KP63W$>R*;[)1XA]+\
M.^-FJ.AC:__[&5!I)&\B MF]F1EM-_[6@/5"B*]&\;?#'<'FT 7#^(%*KM.6
MO/@WM9N$\\-Z(%0_9_'CXRK- (S/I^^!I_!7+,:><1+@R6UT%WY(:*5S6^"@
M%^MB#-1N0[(*5ZWJ4[&*1BPJ,[.+9IA45[ZFR0+O(+=H6^V(M"G^=I1Y>K]W
M$O(2PAXCGY^N\EW,! SD2A57?*KSJVO<;&95WP"1M](TP.O;&IK8+-IF/\)B
M:=@^/U[?71!-*K!/)<.;V!'!E1PYT&N=Q@<P=B>Y@3<D"I6TTO%A='CABFB7
M&GW\H:\G_X-.6S.FN?FCIN%^*%]WYR,JIY/J$&E(LM>KR.YS[.ZXX^T'#:[[
MY?]6>QV[]ZY?#/S2)Z7%BRF.P,),V?!4O)3>D>,="+5@JA40=C=-2HHPCZ*T
MB%6\H1Q]/XA7)KFLWW^=XBA3([; 0*UU2 \+B"MUEZNG="_^(!=%PS>4)F2@
M 4]VZ9_?5R!6Z(QZ,;G4ZF/A;7.Q/+= <C.]JOW!1&4C8!E:-?X_[_F'I<<L
M6N!I6R<>(HE'8G#6?W?_(N1_DJO-2NPU5LYZP-U7U?B1@%@:U>GDG;R(Q[<G
M_Y55*?Z/;>?$@'3:!KE_\$A/Q[94>]IX ^R;M54C/PF&IPX624L>.-'GW^GL
M0F/,),1\)>ZUYFQ1D*OH2COL1@V_ID!!]NO? 3O&26ZKAJ5T*>^I[>QOP9WB
M[Z8(B*<LX=CO1'E.6.'5:WC5(@7V!%^)7JDJSIS.] "SC)!BXB.O#P_&G#6=
MP<.)Y%'=J?P*>\!9T)%GI8(MP8:3HL% HYF*@N@6#,([W<P53M%OYG*CB9+-
M;$ZS."<,OI4W A9.BKY+R#=>,F;C^M.G[L6G/(=NIC8-80/  QGQ#\C,.DLN
MH:I0_<?,4@/V]@\8]"LLY8-5=7:HZK-\[6C<?]L_9*SVH]@KC5[G;-+X4 W+
M#,YKY-:=+/X6"&<_*BAQR.'OZA^%V1G[:H=*AX%VD/N$-J_/#9S]]H?_M"8O
M2*0.;YIO8K9PY=\K8O@+K6@ZYC.E#RXN[-<U-\8O?P.'S4(XAA:=P<3KH+;I
M]4]TJ2OT<)+H9="0*9OYP-/ICK!6A=2:/M F7XWH-*NS E=@/%2$IZ"&JV'Y
MG$826<Y&XL3,H( SN0L"<31;0U_.J'E-NM,[@<8\<T93A_DRG4M(I2G-]Y4Y
MN@JRZS]-]D\>DLLF/M*J_',M-D>:_T@^B^1G:2H6(*%??[MPB%:H-WE!//59
M[37P.O7D%?D%N?<<X;(ZHE7$_/:+MSJV6Y##>IIW@E=% X*3>_1#B-1I]W6F
M.W3.=JQ?)*U=!VV3NBBP?-"?% YK:>!*58B+>67K>73_=;+"OKSN+%80?41G
M9BS]3Y-]\E]5IG0S5.."1)*+-MS6XSMAWQS3,?5%UI'M1,>H*.=[6FG?I0/O
M;Y:D/S#CHK(#*U0+Y*LV/RZX+$<X@^A%%:BOJ&KE<8,ZA5^"242V/R>?9O;S
MN+[,*(']G8;*%S"IAO>IBT1 '6:XYNKLAW&:GP&O1?DL[&HH7-^5.4U-U4,4
M02F^DN6@A:2(42>5C>MREOKJ=E+QP QR#-_MTS+)=<S8EH7TT;6;B!8X4!),
M/_H#K\7P+,JAA&1$E5(KE4_W<,5&>]%PP=S'C0C\M4&?[JIX_>V.YW)?K@Q[
MJ/N@CK#7Y,6]350YQY9(MGB&G#W2;S-VCE16?C%JF_?VT@/1;'OD?,;53W>K
M=8@FV73J7D]56$J2; 7 D]35*B&MT)M4R2R:B%A8NE$^N5KO]6>(F*.S@DN]
M+<<TEKSDNZ,HV&FR;N=\57H8PVYG\TGJHBZT[>'U#-^)Q*I_UDEL>_6^SO=8
MP5/[!%RK%,K&*ZK2Z#H=8S)18Q?LOD[):D<)S9:#&PDV1?^V@3;@\#E)=,F!
M;;.,PSW',V##/S%E)?]GX? WG^6,P[/][=S1^<6]N]]<^R3Q?"T%DUN# 4OQ
M<J<ZN3;>%LOXEV2.E^'9[ 2].-\/X[<_[02ABF_6N]Z!!?:MP0!\O2[?7S*W
M9I+[6@C54V%V8#O<_2<Q%_FJ:90+\"[]H5(#RN8ZS5=08;E;N+SE9__[J8+&
MYM Q_(F?XE2D)W&O*1/DGT62X>445L&VOA,YY@<@LN5=/9GOW,T']7$@E$J>
MSJXVW S^<[+B/[1HL%$!'9AYRFLMD"\W06J&R).__>&JGS$KN0P"(A[D/*"?
MUZP7J^PB&QNW7L=*'LA7#KDS[5TLX89V/3'=9AN2^GB5R\@<5043BAI7!M@T
M>3HJF#,@($U'FP&;==DYDJ/;VA,B >@[[#PU!4,-V$NQV#;C-L*:*3,?,'O1
MK_FVLCE/T5%+1=\,ZNS\/*N +W[%,"P?R#P></$M^$TW<^Z"NM)#VBCK.9:D
M1XA"?-X;MCP#@ABXMS 60N%.1K96Y<V?N&)"6E*D3_'F776A -[29@,?9-HC
MUA2=ZGL%V]I'O(+53)!S-K%1V:50B\1J^3OCBL.-*OJ(^7B>L]C3RK]2\8'[
M?=_T>/9T=#PH7E*^GZ$"NI,F8/-L9;X4&O;5IJW0FYM.FKMC('?=;7.RNQ;<
MAP#OK?43U9I(ZX,^HKF60?5][N$AL_;U800C(FNEGE4@?1_CVO8S3$$M*H4B
M_?EG@/F-E6WAK>$,Y?V,!S!3<ZM^G*[TZE+0T!3]6L-@8#XM]7!8IZ7.]D%L
MXY#ID*"8R %;"-;<K8DNC<?80J$X#CDX[*I__?83QY.<D[%^8'$R1S#0\)Q=
M-/[<JU8)$Z0\IWO^#,#U%9B\V'F:+(:F;F_A9__P0<I%U!USRT!8Z0AYJF7I
M;CY7+ETZ^BJ)W'[NM,%SN Q?]Y,2PU0,[%FP.B09<HD)XKOK<0PM^JM>\HT!
M6.9%DVBI55JN:8YQ.-4I$ZD"KY]DZ\'&1\24@Y6ZM;LO<BU2!Z0/_@.5$NM:
M%X9 ^]W2@3FI-$V)I6*8TC- 7+6FFE9!JS#C,>R?X*.3<3RG=YV!X6'9I81,
MZ631^+8QNJB0A_G)_;>VUU(M<SJFLU;-%&+"AJ ]05HR\T&!:SD7HZ"3+W)U
M0>TS1M0-K/O.L1\<#9 84)LE<A@"#DMY9-L4X#3()@H0?HQ)9I'%5;9;G!EZ
ML"HDWN.]<_"L[UZ.)/$G19+(C5DSP_/!B@$MRT1]#Y_&W'(BQ)GUW+";(R.9
M]7W+C^29*H'C9H\IQ[Z2)0H^Y7;!3&E1-6$]3ME.A@_>&#DG&1TE4-O]I_A/
M@NX]:WBGY&[5[]I7%W7*V_A-!UD3-W?OR)XXD6O1&O(U@O#(%_ +QM*;@%[R
M[*!R3^\=^>N_-O5F1RB4.R.OK\F*>Y]@^2,Y4J0"A._::U$5(F%T.<WY$S=W
M7<D8=U>%H0&1]#&X8(78(7-FT(19NT( Q+U?=C2"JHG2 8KY*#X6N^+HZ#>I
M$M@P=LHT_331AWQZ:.\L0QLM^6;0=FAY:M;9^T0,JQNC;X"U*DM6<;!/1QQI
MC%&Z\0WYZM[@K^7\]$!!KL,JS%FX)*QM8C9QA:T: P W<M]NHM?NV4E4@8R%
M_O?FY[@8WF?@XQ*MS(]]3XQ>N/C.6SM^K_*>9G+PUL<NP,7BLW?SW6#J?/O!
MG^\[": #/ML0+X%N552 VE2.5""RU_-O71.,G<?O9C,I+>!= =;:,\#F^(=P
M[[\6[9G##BX_7K,U75,AC?[MBRJ)VNG$+I1USB;5B8G"SVN[X["R-X*[CW9?
MHFBG>Q6<Q$:BK:T]W)Q\QZK!N@6_4RLT'S>U=OO;F5 PUV;Y _9TK\^&^?39
MTTH*,.[1AM@4V+=3V>*9VLHT>]7?N):FRRB$@9N7B*G)HQY,<'[9\@TC!*SF
MTRB[,4*'^8>HQ!&R154J>%'*T;'$&R[(-[[#_S7(-]/""G%)I#ZU7L,/\AFB
M!>:C>">R\O_T@N9.EI+Y%M7Y?<-TT#?<RG4TUM@M/X19(1?_JEZGM]!242M1
M,7^QX/(2G/UU><VWK$_PU]/?YD%]0F++*F]O9)%X4UF==X9S9;SB#?\8_#;-
MFT;2J!!@_';'UB'G]/H3X!GP-SOIY\E^!_8?W4$/K]$$#_GAZ8T#UL/-^45#
M!9Z$H>VCJY=M@EUK5*]];(Z.\@,>THWSG@$_O"]L[_7T#MK*B ;0&1I%&GOM
MXCY9?J JN-.0?@:TZ,Z]1K<6*U&D3)!X84Q_="U6]\N=_E"04LLJ$7QXK.YH
M(D\G>&0;SZJX$1]R44$ +Q^W\6X[& 0TW\RL%AY$BR1>!$I)&.CLP'+^F\9$
M<T]M _$YE5V[Z2$7H2 Q>08L>K#F7W :>Z+PXL%72]A%J\F- ;P9#P2/>!'#
M&X5A"JY*E^S?9(BNH6$?=_50"0Y1R"2MYEAG<L 9#04J@2;B9OFJX>3+3=EJ
M3-$)X_XP5_>#@?O7<$R: YY,[Y_&SC?PWB'9-01-3[IB_W8O+4;T5!G+CN0>
MZRK3&Q9:)B+!AE;H!I!.@1/-:=1N::*"(7P=4LKM FHC;J4R]&6_"2K>><C@
MENG.S%G^&3X_E=C^2L6GI%S_B\MK'H7X;'Q5[SO2?@5#&B%KXDEAB%R/\RPJ
MPTW&7<(+OLX7Z;(&K) )[EJ1(?#-)?GAA*JM BFE12K],OVG@2HER].3ZO_H
M:B1550$DW'  >0;*)>N'N_]!P_IAHN7%)R8$*6# -N"BMX8B:Z!32?FL$7]H
M[ I6O$PC+1^!_/>$.>X&"NL+U(Y+S!L,PLS=0S\2OH6O<>UJ5E1L) 69X,\0
M+7OJ=,))8_:UTLS"? \TS^O<<\7>?'.V@$!E_MCB[Y$4D^MY1E!#J6%]=CI;
M3Y=%V)M_=K*3)CP[#28O#35;4E(AYK?F.A(=P&3/[L$<%N_L*8ZU#'B86UYD
M\P_/OHT@$/#^/BM0IAY+\&[:0CI<M*:09FH:X]6FF;[@CET84IB*K_!79150
M,<$'#P'6T)W14!DG&!"1)#RC1,QMS% XNK C?AQUQ'K7>WDYN@^>\3]M\T9K
MC*6/ZD^Q00JD$]^U+1F#ZL$!3F6*M,$OFT^4+3/"IMCD$I<J)3U>Y1.__F>>
M=YEO5L_'YX,CVS$%NNV0G]]RPTD?C-%FCI?.8SS:JJWDV'!6% GL;2R>VW3;
MR/296JC 8= /._HRL"4S2D\-,].?]PF'2Y>3NO8?Z[UK#,W:SIX>F]TMHXIO
M3G+'S8WU?C>@\\Z  S-[2$YF]&7M1HP.Y-SBAP@R4_C7&Q:S<G\81F$Q0X<9
M]Q<"#"Z]?CEW \=J111>G3@=$8]4G(7P9IG4O*(-9&CUQ"E]E%:A8#>3G-TT
M4:IZY169^UI1VEL;6K1 +SZSGK[Y(/H?#G0_M=5M\L-;/W?%7'*:K54.N"-[
MO!*89WP$ +A;K;./R:VOYFW)]<&H-:]O>;>UM6[?IM5\XJ,>P2-MEFT_SCT'
M-8*T&D-?J]P\M)_E7;L8R_MJGD97AD/G/3TDHROQ*?H#>>]G>*@K_6H?RLZ'
M[OD"CNKX_ (&'T;'N'T;OT5T3;O[B:8$Z$P>\SPXK2DKK<E%0GR%"N(25#*T
MW@?7U5,2B_]"/M6Z6:\\OASLH*8TW$=\-+T^LA93$/NW56(+HJ3!>&#Y/I/(
M/AH!4V-H;:!,U;@Q,QZ!(6CR.$-<MTZ3FP!3UM$I*K" 6[/0\BB\@-.JH5,^
M7E=S=H'$1PEI/T.Q:26[BXA':>3%H\3J?YB,<0(:SS#M^.FZ7KE?W9LV?<V7
M9>510@LIL4H[M8$'@;[MM=_>7) (+^.F\%F.H@8*$,B?>GKW?*.OV<:PQ@RF
M1LR\61\EE[,N-=@AL%/;O?H6DGRD%= :V:]U2?]6ATB4(<!1]3V1U:2"FU(C
MGQ.A(8N:=\&D8_.!:[; 37)Z3"Y'L\0PNG-JW;W[+A!7 '\'2--^YWNW, DF
MSR>K9'+>C%7M1#5* -B6"2ZMIJ$P_CM%_Z.!Q2:Y=ROOC[QS*CS$.4YQJD(O
MQL$V4G\II"J\=#.%R\*3"6(#O(US@?AVBLZW=$QK>)&B.\D]<R%C3O$&]%@O
M>M6]TZ.^3HZ,'("TA>ZT!CV_+T$+_9+Q,,F=U")JY&+5\Q>/!I'C6?FQR4T!
MV/MH"HU=0?QGW]<GEZHAN2*8I"^;54.7,%.ZF](#@]G63"Q<EF=U&HTQY?!#
MD\CW3FTV<R/*0BK(ZPP+8IHMN*1K.<@H7Y(W/@/>[>-LVH<Y./QX852]%HLE
ME?SFRB:PEP"=M?6'3DYK#L2F.V-+_/*&6@#C;$BC4$L DN/J?YYD]:EW=5KW
MP= WK==FB:RAL8FD?HX])UX$S[MY+5(D6H:V.OIUY(=:'97ZTW7\(OE#+;YH
M,Q%2C(,W.<%&E[_ R#(]/BIONNDF!?C0,/ +;'*(?U7IZV*PJP?YIZ9@$X>/
ME&V-%\4/[%;L[-E/YDVV&&@"]G?:A6$\Q/0;UGSW 3@G!R=:VD#"8W[X8<#4
M U1LQ#SZL1OOI\1_@#X^@S&-\*-I\,MB,D&BM2>6&)$VZJ^QYUU][\^J'$[Y
M\]*U$C/]KU3CG?; G0YC]9&JS@WHTTZRXMQ.'>T'&0&Y!B)!CCGX#!MMZMOA
M9*Z+Y,QYZ_$1W4TP^-/0%"?:47,S_$SJSGL-CM G0;&O2HX &7'HC=F<X+)+
MO\@?CO$8R.V4+Z?NTD\<C';@H$C/]^WQ>^KR,MUU,FK4Y4X&$C]$OWA5@0D6
M]P2DE!*9TI/3-ES:N]V6F) 0$_S9OKSOO8.WMT2#OO@W2F[/@#<52_6B1Y##
M+7KJWNQ7_O&)Z_ZU*M-)Z2 )CB=M"=Z1[RK!<NHB E4E%Q@E3L31!8]% 2F;
M2RN7_33NB(E]U13#NC:DX\T2ET/T&&Y@D[+5J:_IFJ0Y9?X!_S:;0F^J#U(@
M$L;;D*H+RH*?^$*IWI1GZ<14C;2^*O 3>1BEYKKZCJ@7]&3GI^&ZU[$^$3_<
MOEE<63/(W.-ZFSB?OBJJ4R63.^?HF)E8]V%/V<VX=I]B.:H5,_5EJ1MI!N9I
M55Z'^A5W1%%=8[>VHL+"(]]CJ3@^9_?QK_2L7\P4ZG51BR!*9T,,]R?!WG7C
MG.4:2B>]IW%J\I!=+)7Z5T3R._\HM]JD8*.1WST=UT.25H';^/-VR +IH^^B
M(YVG56F7H\%RJS.'G:N1\^  3L5I!Y1G1.QO+O3XVZW6&AB#NJ)2_M29K7(/
M!V?U-LV)QOQMA3^++MN;K0'7.JQ0Z)+=N<1<Z)73J5S7(JY/ED1G#X7>"[F6
MU(,(?Q6G')6DP^5ZG>",7AJ81) K(=D]I)RKX1E@[37LTWLH<EH28/$,"/:G
MF?3ELG2DFNS=Z(CZPV;SPR)^3R$/L:[R/G,Q)7FCNWZ0J/'V]G1TI2WB":T6
M1T<A 5LIA6O>D'.8@N9KQ.H3N2_5J6I7QJ[IR5*B>-7W5-MLKK-<\:(VI58J
M7YGJQ[HVRVAG/_4.HJE\A8_IW(UO6"LWW2Z&O;8?WC,.[3KYRL(_D, ;(D0?
M!6)WC278T,5KJ?5$-)O/+X23K/N.8'(CD\^ =HDGCED]<:AX(H2[>'GCBZ"M
M>.IE!>?;IYX<0H1I[M>K=-;=X;K2C#ETZ[.J@E:JISEQ!N23>%4PGY*^4Z&!
M<0;A:W'+;<"39^7D5>YCKJC.24J/,']*[KP^A=#ZN847AL)VH3?A2:J\AAO'
MK?;UQ^DR?Q5H1\HR&NP9$#ACMMPM[*-[L/%5GH7K2/.ZOQ*ZJAK$MTP-CN6#
M10ZR00=A/_ :\@.W6EL?H?:'_I^>AM,]PLB(A:2ZW16O!"E^TU2"-:[L3Q[$
MW]P("40D=PWZ.;T7=0H>/# BDMO,Z6FUI@C2+?>.R&D>=)V9B]7W:HE)=VMD
M@50<GHLRK9$<G*]7X=KL.J.<!XO^-1?<BQR9[@T!1Q'O3_;U;W[ZB16%VW%4
MFBB?R>J^Q' R-O[/A>M<.Z:Z:58;]_V6IX"1XX(MRHV0T?KD5+==*?D(_ >+
MME+]&5 GLS@=B0^F^G=N9O0B?'0(N%G[E1@K/S_F5T%Q?=_D>,\BHBD;3EZH
M6Z)FZ\+@MN6E&O$@$+#2HKXVJ!LV9S ?U51O:G"4M09D-YQCSVQFTHBXJ[TZ
M/:'P+%L=KH]Q12?HP?>?&H]*Q#_N+?2-7FG#@Z<4RC28V?I;/0.PSFH-LK.U
M"[:!B_?9X&;QY5>A'=K]U.:@@!;GS2@=)8<Y^'A*&/7<[L+8YU@F"I<=8>1O
M]\(0;Q/-=))0!X3.FCX.P3^,YN;?L@47WZ93[P%O'H!;+%)N%B7MABWXZ_P)
MB.RPN\$K[I/P25$*OXJ^ H52 ],W5&:QK'B/%\9G1)=$?SLBUA^P5^\#<'>T
MR2%Y]O"ZX(_1"OU8^6@5[DX<A#H7(_I!NF^I1+GO@<:&R^LNYPAE:Z.Z4@_Z
MO C@A%!@?I(SJZ(4SV?*UA;SK7PG([YU,<+DN,.J@-9Z@H]K#7B$-GF6 2FB
M:IB=R]1/>*";9X!2C#FNFYAH7?(!@NS%_7CB\<_8+Y=\9]+I(]%YDO0IR,.K
MV7!YB.%W<[K85/?>0O]43VCG)MD(ZA;[*NTQF^E4'=ZVVFP),>/)*./K>"QT
MNDYYK-Y],/XVZD!=S]G,'D,I [P_!>70@U-LO7B4*?S/U/6:L89"9AT__!W6
M;E3(RUI/HA:B,RND-"G!1,>?G8Z4MW"6?4/O7J4LDLVS+%E#2YN8G55R*KE=
MO,*\G^Z;_+F&]LQGNJ[65>A;5HMXG7[#A,<''?E/\9M%3"=$1<AK OMZU(0(
MKE0V*]"'3T]T[H4M3Q]H-H:EKB]Z7WK X+L8,[^<@).5[SA!C\MD1/:\JB>5
MM$G=KPNJDIIAT7/>5"Z77B+RNG$,2X^W?JP<JJPM@RC$)"'KR8\5DS@@+6IZ
M[I]Y'0UHK"YMW=E*.UZU0M7#,S$POD-'[%3+S>>] T2Q!O4YGHNSL?>S"-*'
M.10]*,%;:ZH^6:<CE_3(-A;Z59>8K* G(BZ()YOKLH*4\,\E]5H.1C07M57G
M7Q=M2XYYN<1@ZM_L&)'62O7UK.<C!:_P8 %),CZ5J%'"[U_,Z*3W5C:JR_<3
M>7\5?QD6QV8,Y];<'AMW'K=6G<1YZ%!E#IM)<$)FE2XLH%4'L7EU].ZP;I#,
MP,=>YYF479"57N?&'M/+>ARH>J? "V>'4V7#1Y3PM>(<G':UC9CBDF=EO2,2
MYK\FJ+C3#-3>I.F__\*V']U59R<(&IOLXF%QC\JW*F5,<]XP?8T& W$-_R25
M!?AHV?/J-OX:<N;^HY/K2W:CX')*8O13^NL55U_NB9!+3A,P[<0XD$^5')R,
M<BM069-[L4Q)>\W8]@7Q8B62YJ<_=GV<%%0OF7,!B'?Y.<;@?F;0VJO\.V^C
MV>/V#8U^HF6;;D+%-R.@Y>(S(&%/H$LX).<DLOT9, LOC_L:CP=7HG&0F*Z:
M+'1Y!N#4%4T>TO2F7U!P5$J2R_S.,HMRVOIT*9I>L<KYEB8<=/#T$3E8'WPQ
MI\3L>.N;2NV?S]=6+%/LJW-J._D'8U+EIQS*$(-X"7]<KI'HYHFV;O<9,-/_
M#-@H>[C/\?]M[<$9*/(,\'H&Q"V_L>WM$8:-AO/9MP:;W+YZ!FQN^?_S_FEP
M'?V@7.RK]/^T=UU!33C=/MA 6D"D"@D*2%.:()W8J H("$%*(DV:-)%>HG1!
M#-(1!*4C)2*])4# 2)>.] BAET1:@!!N_O/=.W/OS'VZK_=[."^[9W][MIWS
M.[.SLR3I?5"6N1 "U]MS\"P&P7"@!M4FB7:\($[0$D:90R.M0C$C;<:\;;V1
MS;.:=>0 ?)6*ED/#I\HK,H=;SZFD4X"]+TI.MHA'I0:\16/J20\I"6LC.8I5
MT201VB3@*+W;7-^(M>%N^!Q@A0(OMSMAE6VK-\1U$<X3+&D8 U+Y\,)#.%%)
MYZG]"_P4.68?E:?F4SSM_/AA?NN2FX<Q>-5/O"L22 Q?<T%&[ZIZT#MG+L8I
MLLK=&E=HK7IAD?F*JKS1),28;B$;9NA SDBM_4;F;O^V2IQ7,XJ4WN5<4JR3
M1KE(F4;-:SS&E7OX-UG4CZ) ##N$96;M0%RXYLXF[V>SXT?Z2>_SH77A[<UJ
M\M"@K@/'3.6=ICKWSB >K+(93S(_WU38W#.PE//81_A^[L4\ZS0O*6%89J3+
M;^<AO55^KZKN1;''RGTA\0SB4O8!*?;#5=>)U'AO%!SKZ,KK^.&U!K9!89?&
M#]14Z:-VB]T$X8URO2I)YG 6-!C(Y!SFG-NWB+W1$3+G0N-U]H\H\4^AI?V'
M9MB(%PW9"Q%W?T5;A8_/-A_\F /F-SHV#K_A)>12<ULDE/+IS[.J.R_-M J+
MST/[ER9X%F2J#CR$,V%%5:E+G)Z<(ZLMH'@_#;,1^7C?6:(PNURETF$T)T*?
M^&2<6W:@N-OAE;(@Z'P0?4R*Q\U\I^2+0B_L@<M6"5'/)F390DJ7R(KL$>4&
MIE^'#:IA,TT0R*^CLE, ^)V+#++)P'*J=$/3SPG$L/"42RRQX&&Z6_G/>%U-
ML/^PXY!CNM2HR-OMR:J:)M<FIT0&.Y&I+QOJZWMZY-]XXE\43(]]YN"0&D/N
M5>?]X_(C1<&W'PK#N)D\E1SC43EQC8UJ(XPOI[]'?=PU#[YULUE8(E4T=< X
MQ*6$.)*@![=9'L,P=BYA+#N>E,UUYNY"G-KF4[F!? ^+EKS] B&3Z;[%^F'F
M;9):]V5XCOA6]I3Z/C6=OV<OQ+M;-N5VS?G&D'Q\MJZENO+UAI)^XU@T3E-'
MTR7@_1?\E8%+ZUR^MW4S"!FZ=H-: :(3T$+__GT@_8J14Z-G)[90( UE8+@
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M)W17W==1O8?TQC7(1S4=$1=EVX^@@^ JT?:G\DQ0$FN1^Z!+76FMV%R9C&>
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M[F17C$JD19\$3W<1.+ /]B8FQC$G<T:88YCK2MUBI>*"[.U"!YM.0;W1Y-+
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M\&B_KDH!9+RBBQ($3GNEU:6\*,12*\Q-:R12C=%AAM8%K88-OBP'7"XS(..
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M-+/Y2^224X0]!0*S<G5O:KZ%JA'MW3>NQ>'*X0<.0-J7;L2*T[36*H)L9$:
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M74C[I$6=%9#OZ9U4\>6IO_KF3[)S0=:^DM978T&T4#IHM?Y9+OZ!BK)TS6G
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M%M7M3<WENH#]]?B/?S%- IFW6?7>4,EVLB*L:R]N4^H38B?W?[XRQ\T'.U.
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M0PA@M\[^L2>I\.X? D+>J,\N;R@I]G(P/%KU@%I<BA>/Q3ZO.OP$53^2YW?
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MJKN5AR1?9W(S2R2P7$U PB5MGSDL=S!65AQ+)H(FE$M#<=<67D!@^-1>P=J
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M.0QK:Y8^2H)BX)0+D<!*R!23P(3[.^#;FJH^,P8B\/I[+''AIW^WP$7L8F(
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MK8+3\04&+*:^M8,*89->N?.XQ46EN_2XJ;Q#]''V#JM$3UMQZ@Y^QL*T)I8
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M>41L>5=@KE!/WYH493B:O]*7_OV%V#:,8SEPDJK\'/2(=<PE06[?6G+=.%E
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MO:RT!AYEFL1-II>7]/P0Z<I,CXC,%@C_ZETU,L3QZ3!";<T?LCN3U&_SLV1
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M;)#Z+?-$C/'F=.BL@OV>#Y^G:.//7HY@,)Z-CY)O"33 P#:^G4(\_R9>?\Y
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M#3(]7?]5>N/9Y:A&HXBR%BR1O6I K>7/%S*MW1AY*2=E4F@A(^&+Y]27)T\
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M1/C6RJHGT:WO029Z/$?CK?"UJK\47C%!?^O1F<.(-Z<P2!;O65"5%?<43X
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MIXA.-B[469PIC65,2B57<7/)!.&68<&LLA22!JJIV1OWG!4XYCK'LR7U%94
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M]G[)F*2?SWAF=Q LL_G565:&.G'2T>WC+'<MI\%*2(<8IJ*F$!/G3"H-.>Y
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MW[^34$X%6_ZA<4+VDFSF2A=)#@OO5 L",IRU?2I!E*C-B-12&)CL"_62')T
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M9E:9F/#0M-;A&A"P)HCV1E7/83G>2UH/MS+.L1K:KPAM?3Q1>, 4BW.LVRJ
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M[AH#8VK@LE)2*J#!2Y=G@/N:Z:BS<MW-/GA. ?A #JV425O94C&+N5\I6-]
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MW/ %!=<&X ?1LWENKQ);0H,DNKP?=W%I:M3E\&C^WVLLMPO_!U!+ P04
M" !"K_=:5AT:V!X?  !2)   #P   &9O<FUS+31?,#$R+FIP9]UX=UA4W9-F
MDS.(-JF) DK..8M(DR1*CB)(:LD2!*$!!00)DB5GFM0@H8$F@V0D-4F:G&D0
M).<P_F9W9W=VOOF>F=U_9K?N\_Y5Y[GWO%7OK:IS[G[>+0'NJ8/5P  L+"S
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M\XO+?_#" N!@_0_[2UZ4?WAAX^+BX!+\@Q<6ML\_%E#BXCT4PK^OJ$M@[?Z
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MYVY!WF209B5EEFTE^W4C8U9D):^J!4C;E,X-)<)/9(HKBT:]#(_XV?1L$N\
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MXQXIUA;Z= <(LK\TLHG;,=^] X2[N(AUE)HN?GV-0\M-B(GD?CSU<6F35G-
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MV7#(UAQ=L(DCYSY-9:I-BM8@R^ _!"*4E>FNVNTK-PU^7;,YV[6S-^59S.*
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MBM923^UR"Y%GSC(&C0W12<[KLW6/:'%((M$YV'\ZT/^+H+B;^2=02P,$%
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M,:7GC#RZ2?E5+4SBRA8X7D>?(68^"94Y2?P?:/^&[%\#%O:?0O978/\+UP3
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MV/KIVA;IE7B[GS]#R/I!VLY%P[-FF4^>02B(7HY%I5H()?]F/O?NA>B[F',
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M$U;:#G!WK-7EF.;F)KH/)*??_IZ@V&+=Y9KO<6I\5;%/WHF10_PQT@3$M;&
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MD/U%XCFY1NK#E'^O23949RRZ!5_*1_;9>$WTD &+QLC!UFGVQE$O"?"Y7.F
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M5SR7GU.5+1++UI^IS*G4 KXG5THE5SAX*Y0T6X^1E-DBP/),X5(SVWLPS(>
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M^+.>Q11(FN['J()6Q/&.D-M7V\7+UP4[N05-/]>$B!N,S)>:$**CE\O;\7#
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M[1Y_;,V6NRZZW37:H*:?FF.3-9>FIB(57YHFJ[2HNI>T1'O#Y'[\:U\71T\
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M\^A8O6E<1/.[CHSSJ.:C-4C%AT= *@'X1\+.4D*&#PP4;3NNT<6-!.&4*_
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MX*P6@M #=I7=5]&&;I:VT,KFB!,0PQ^[&;>2-%L/EX*MRXC.6*G$F[VD(63
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M?$M!3NM%(S:N02G74ZGMW/L;E-;.,/;/-FNDR1_AXHH]>:9H_O78&&DOXZ^
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M=^]KE+(P]__>UU_[LNX?DOL Z6RH@0'9,3#@\2KK09GJI,P>\H<. @/\"V
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M[/-LY]I'<?9K+;N-5[S"A"LLP/#0D:LO;ZOD<Z/3:1L2M9GD/S0(>Q%<A,(
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M3(*Z$C>2^F*ZMM9LY,6"+/,LI1E"3$7P4I7RJRL$H\A-=C$ZD*S.4%6FA/-
M9T)">KP_BG%AH5QW?;PEF(26 N06U4<BN/.K-Z#&(/& ):?F1X,P),*'.^0J
M0G\\<%-1M%*.,C#Z$9Q=,7U0PSM2.J5Y3V?^I,7&6V_0((.O0:S^;YF,%H6C
M;LW)59QOT8K"YKQ>YS5>OZS'CV#=TS]PQ=-1&V1@I947>U=WH:^V.\%Z=/4?
M)1DVF*69^D2B+\H,M(Q-PXMT;C4A+@WJ.C:4_O;W&GZB31DT<3I)OY\CD9A#
M"^T8(TE21Z0 P^%VC U!BI\7QM6JP5M3B>TKJD@+>VRYN9Z$$W*M?S"^!)G
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M<NK'@#]%4[5,>N#/$F3BS4") 9(= LRV0^F3NT.MM>EE^65IW/[:,WM+M)9
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M-Q$%+=?AO+KNX/?4//$[+U2IR8-")"@(_G,@XKOJ>//0"@/*SB!_+"-%,&$
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M?\RW<.U-K,\C['-&ML:6YMCXA=+8DI%  819&2,*]Y 8W9 HA/XL4<GN!%^
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MZ7V'!4V-'$O7]7EZB5@(C,,4'\875^XTJAV'0D?O"]BB3!/)G@0A5Q2$WEO
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M>;/#J_*?!"\6PQQXI9OG>"H^3;+_;,E+;JZCCF66]+6FVA-)R!.@*V1N^P-
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MNBN1;A[A0Z]4N0;>Q?:YGRB?R_X!6%:7.&-K>(K\Q2(T9WQ\'L/'.@TNXOG
MK[DQ_?Y5[)&&;=^#6K/O*<"J+/LY9"F.DP5$3?>VGN-U"R=-CY+5H%/TJ1BC
M=O+7/L=#N<.V2,P^T=:K>NO2OMKZ,M4EORCC[KHEAH=*8]T\F._W"\'Q^I*'
MFF\5-P9R**M8+5D1'DA9B80T.YQ][7I2V;&=<Y_!W%2OZ?R)"40O6>3)RCPD
MXR2?F;YE,R9(OHI*G%K\#CD[L@/WWR9(G]B=<!C7::K -S,;UREB]6 &D3M8
M)J)T\AXT<7+N+*AV>1/\LFLXHU7;!G[;.6B3Y3X9GQS-6UY61UL9Z?WE&+&.
M-Z^+O&QPP%0??2=?<%YZ9VZB-8P&CM7:XT??<]TC= V<B;_4'_,J2,W235^7
MZ;[S1T,TAMR</\RO;"7NN?/+C_2:.9';GKB51B4>L$ W48XV\?X ;*-U]1>_
M.E 8>'/"C8N.\*Q73 X<\VQ(\SZN&E@F=2^E$0/0']$_:IN:&3=KO98IKHIN
MP_>E]>WW#&W>3GU"*7V2AIM[%2L6'Q*]D&,P[.7L->P'6LDA^BMC"KRHTXGF
MW";"9_\ ,%<OY!U>VY)VE(=B\77;;]JLZ8-&*EC<R E-3\ 1S^D\?KCP',._
M%K'5$'Z4+39/YQ]YCF7U1N(YT>P2LS3D4S5+4"AC)NGQ'X#U9F#5H_P35H9D
MH_DLKYL5KR+H=/A[S+:8>8SZ-762\;D>QTE]E?*VP^O.H'HJ_T409OW]%D?Q
M,:EZN=\RD</K+O,D'.$:MZ!C<<KYRB>G"X[0-@F7'T>^]+6U\Q79[W[7Q64=
MS !4*(4#L111!@R1]?*XP;=;:*K -NZL$UF)0% D.65H^;$?^A/=CJC4#99"
M;XO/[ZNAFOJQN%BN-'%T!5<!@*DHESK95F/ 4K48\>QE?[B8]C!CR80?A])2
M?EOW_1N;3J(VNI\&BG9>%;V8O]8R!'_%C&)V [^[ 4+NE3Q>OH^S0/D#Z[-D
M#V^S:>L2GC[.9E@PT./ZR_F4(PP@"%YWGS'/5_54H2X7]'S87D7434.L?=G%
M>^\OO<]XSH=&(B@RR];Q!BXVHL9#2?$KPCF6*K/:]X(EL)S?M1LQMN 5TU_@
M3"Z"5=K+NM!!5Y?^KI#P;"N3-7B+"5IIX[4998 ]ZPJ.YCXV: Q\66\8Q2@+
M+ +$.,5(0!<SO_)B&B*VX3@0R[;Q6Q*-33;C!S6W-+C,/2S$/K& ,+*4[*3J
M%&0Z4JL3W"6UPP&415,(TGGO-Z$. <EX[V!LWR-(/U*J$3'D35P $#/M! <+
M[. * RN,,>66[5.N[UR%92W '@QA MKXKS1SBLL].C#@A%_C#7M:#"?IQK3M
M>AKN$(61R0,EJ'=:<' @FK(7!6T7UJ3>I-YJ(Q9)1HJM:_[\5&K^*-N?L'3^
M/]")O[>C;4[571UE.HC0O238\Z0?9XM*'/*(7YX0G0 WPRQ*"!-SU\=93)WO
M;42UFUZUG:&E*,\BZ]*1O K(TQ7_9M/!$,.-%H&P)^85/WM3444B;G#;W6H<
M\,PD1JXEHO-^4ZEL7[_9L;=R<IMJ(J7_C@K&51OL)NVWB(\P>0R+K6[8P%ZY
M%A4"L2@W*)_UY5U7\2ZP>^_$ [N-0#HWQ(MF-AW^Z @Q^1;HW'T(9];@>-@:
MX:C[CXTCYNC\567&E4\Y3N[2W=KM0::)LSRHQX@1Z\14/_*3U*'F]NH!B%3R
M]X:W7O/75)$=+)&#'93S9^LI*BVU&?)6&P*Y,2+^VUJ[3"/0J#>0JI(S_/:V
M4B(G9NDUJ(@*"@E5SR2RC!VS3*%NN8O=%?K8IMCTY>[9"9:689@!OAU#W;8Q
MAM;O\-@)T^C1NJA]@:Z!]P96WKCNA=IZ31>\W1/\G;=#HU@%<MUDFK\%7EPU
ME2_FG-96I7""JS0.EZ-H>+L?DX E=*'TK5#JYY6XI6LP5; 8RJ\L\[J9[4"?
M4 9(I1ZG:JLLBGL1@2]5J"]>3:C [*=0G@AE3B"+SYE_MI=%6^%B#[>V?GX\
MG!)F3T2I*U=1-3'B5.?/C<VMQ+509SE=$-ASR[75>I"]I])*LS ?U1K [L[G
MAI,D\X2J@F+?B>J-M3M.=:M86UY.'U=WTO]MG_[L#^!8O0&NO<T8NH.7WS.]
M<<K-E#3QG(<1F_'KNHIG]@G[=M%VL)L;/YEOI*.!N'!KI'M"8.@ I:H>]((K
MZ-W[!X ONN:K%HX8#X;B[F:6>^]B4F9Z>JH!I^Q>,.&2R"[/"?3(TG&LB4,C
M^5'D6$N'RLI!V5@QLMH\[X"2J!_:X9,&-_LMV4&WZM7I(&0P$1;G6RT[UQIU
M709U+>#$%^1)@&6BVC+<^5;7R=IE6P%NU)SA,O1P8!%IM8*#,G5-DHNC?;$9
M<MV)IEV?G63#QK;<>&\\3#(@,"SJ7^&].*GQ0MRF=591>)%=Z^(8L:%Q"K'M
MW1>6I2LBOUI2/]Y$4[#C%H(HG6UK<-:^6XP Z)*E!CJ*#^]72@&\BI,4[(;6
MI,4GZ57#$./C9(]$67HR>OD_ZWP,ZR&J403NO6HY$,24WM*-3020FV156!'Q
MI_BMO(%HW&J3W3423MF4,^ ,S),IH;MN73]9 =?&(A 8_(%STTV:H4MP[?V&
MQB8_#!M"T_'X[.&;M<N2U*M)LM330?N=8L6?^CQ$3/Q!O"6%,8H3?P"KIOL;
M'\A-'PM:,1VMYG!RW;&6H&)I>W$C99GQ7</[N55(.=V+MC4_+D)@SY/#'$_T
M&1*'EPF<+C=#E0.+VWO1.PJR9S??SDXXS) ,E@RS\1V%**4!H&B ITJ\EAEY
M[&=%O(&)(PH%Q@T5:<WC0[U73ZP7I_6G&2N;!CHBF&\O9^Z_Q:.0*<G=NQQ^
MEKF([&Y("91@ZUD;$FDT]7TL'.I:GV2,>0><OE+0:PP5HUJ"JVFV==0TM9DW
MAYORS4Z817/*L;Z?4 *7%/ZOUK_X*BC9_T*]R$(G^1?H96C](U[K=\V\"#-\
M"MH\%"?Z]PK&BH>N?]=)Y@!(UG_W=K%WT1:;Y#LU2"UBUV[:*-;D>2Q1'R<F
ME3?X]:[Y;Q3K,R27]TIQ7?BX\:L50/'>T]E^!S(+N0RKZXI-\IYT]U#J+\1:
M!>*@)*DM.\:Q='UY%>W.^<*SC<+*)ZG(\8NV7GCP-VGAK#F$T54!KC+W?DJR
M1G 5\<!OQ^H2FQB*DC>!6K\HD*S@I*SPY,->81/RS"BCO8#:J1*2#Z]0AT1+
M;.IOBRP+!FH,]#]81;F%9HO[YTBDHPG$(GGC7 SV5N%M'HN1Z3Z_%3X]Y8M'
MNLY9WC#]91%O%_XN1O8HUU6LKL6PFPKS@.HUN[=A/M8'V3D.BH+VNNJ.!!:6
M8=3N!%U'M_=_ /7^7HNJ(KH_<NZCM/RVY/VB#;$(;BH/=M]\8(;1V\5)4$C@
M(_!9C3NS7 S*ZTHU$NDD=XTL/X)W_P)MD8>YE=C><7Y560W=R.O+.&E2ED))
M\3.GA3@**9)Q9]/MAM0*DD>-GZ/$-%_6&P3IGY5UM%_(#N_>T&6L?^8K'*_>
M: DZ<YJ;!9;EB<T/5_7ZB)HFB:V7X=(ROW'8'5J=D)A$O!,]$A CL88A='Y>
M8.R>/.?8+!(Q,HWQDQ"G"/6))JE4 H6NV)IWSMS( >GRT#BR:LHY90R6H3/A
M'>1+D^1.[;=E-0)/OY".L7<3E%TFQ/Q54+1S;%@2@[8[<H"2HWYE>"2(A!TN
MK2C4_,63%?2=6#S+>]8&5U]8!T4,!8"'$>*NS0651A#DX9.Z1^LJ7K3^Z.'F
M\)7?083K<>4R&Y]G4>J_7G>]^YG( ZA3M4CV1V=B^N<8197P1>=3**_RPV/&
M'\ 'WH.D_T!G_'E%_K.<3%OLGU(-RO](->1B@B+.<W!Z7P6:)6]+0D&Q\MLB
M7!Q)%@MVE_=FJ7*3=$W[F4'I1[[,1_S<[8598),9)>741.XSDL,0BLG+*E*8
M?4F)-9@RF^3$\DKZ/I\X7I<ERKYK<#Q(_\L+&8F"R\Q>UO>;0RW/C5KV'*!L
MQ>Q&\R8:9/51!XBTL73S[@O):2^PD8XZ4*B$/$@G)05#Q(R[!&5NX1 5R@LB
M,?B$CO3DI.=65JHL;)X'9(P1UG0MIN>*?TP"243LUG\S=7:K!,D[&-,E-*>E
M9A9/EA1#FU1<?AEYJ6>4,1[A-%=JZL!"X[?'=3:5YQQ45SP6(1QW7RP!U:>)
M6GS3I3*&=L6LEL]:3RRJFSH?C1]_Q+&\6N&BS2M#D>0N+Z*.K;#J13\CX9FU
MU9"1L*OH6QJC ^E,1SQ;HMB<OFI>^AGU59#7AD0D&5J@0SMP+ #=.X6K??_
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MMV28%"+AY.<YA!CE=LX64:&(JW:9G;5;G5;K"XBF1J?K=TF+1A43S"^46M>
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M(*](6(&@M6&:TXQY.+LOJ/LV5X9L&_3-%WWFR9HQB">+3_&]IK..EFD#>F[
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M!?IE1TF$Q/&OF]B?S6)>=MGGD_6J9II]/CBOILX&,9)<$ZQ#WD[I' (I2&I
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M4V<<O^MQ5D<]N0&[QQ:W7P]_:2"9M4RC2I>IX,!95BD/K.&:U9NK@AV;TW;
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MY(H<_^IE$<>2IA?$_FD3(D1+;J;D:(:$5S ;=&.9BVW;YL7[H:W$,9UDT'M
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MN]A__B83J>)311W_!6>N!C$85 ASPPJ;=HJ!X_BHG  ,7?8$<+D$(*@,0T\
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MQP_:2Y.\3EQ>O-R#)S<@ -=@:"5\HQUH+V@&E@['>\/F,J$[7@2 #K*^-$P
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M-D'$TJ!@PD,C?^X>9^Y7VA+Z;38;5!2LK\%=!;[B[@3@$4HD[4(Y.K+,8=Z
M'FG'*]5YD>XY\["]N^X5V@9J1^UZ(K16.P$@W[8OPG(B9)1:JQ@UW]FSM[A&
M]=US ^9>-5T\UR^OR90S(SQHV--EYE"G>+P%ON$D E^;/($I%38:<6ABLENL
MVM)(:S!AZ.1YW#<T51AIW.>LV/3;J^.2WQ/"^ =,9VR5:&@N>-W3OK"0Y3CK
M>CK%7</XUA* <*[@QZ.V>]"SZ_%NC3QI:_,7XB7YC]UKW,^1$U5'ZKB+4Q7T
M[(QWIW%@<&CNEAGNT7T<7R?+9GQ%P2V?^\=2R[OVB:SYRBI'[Z0#/-A*]%70
MC.WGS1&7A1%LJAN-G"ZQ>N^F:E@"^;:UQ$$2%U0MEI,<BF^600)K(5+K.ZZZ
M#P[J3A-YH4-<K4=^'=0(/%O&V(R[U'R FEFGM6Z\.BXMYJV4S3BR$ ^VOB:U
M84=2.DD?Q^RJ.,RLM^S41$PZUG BCA7\BH:%[17>::Y=G$F>.RHL]VK0>X+6
M9G!-@']I!KG4?;.Z_T6U\NYH#\TN_9E&HU+,$9I#'167_7;3VZZP>?Y$43%0
M776<1JE40_@>\[R\7[.GA14= ;B 'S"CK;^<#S;,"D9&.*F.B.9'5=CH,8P7
M%;N)(6;,4W:.GKNY+(R^S':IA*5!WPYO9TP95J\W0E$0NB03^L%#:"O,'T^+
MD4-LJMXK>^LBP^;+S1QOIWAW*4Y Q$=TV_ZI&U] FG-)ASI@%\B=HM=K5F9:
MPIN<A?7$Y+)](7X\+"*N)OJE2H66HF>]&GD_M*EH49[3].ZDJ;@;>AQ!?V(L
MVAE>\3&B<_)"^];41\H?9U;2/&Z_)2( #9$VL-;M\,:[&"W*/=.+:,7,^97B
M)+':R([G87=X71G8SIMTDE6"17WL#R,:[:[#&JXN>WW8S*R;74@&[Y;M5"[_
MX-*@F<+JX))TXL<5,<E(BKM(]-U@C2#&FJ_@ ;L9=U<[ Y:SS_6O7[U_:?Q:
M<AFF!BV$( "=#N_.SZM&$&N@1E,WD=="1$UN_C#$F#_:[7NA)+P97FZ3/YC:
MN/8:O.B.OXYI!+%%L431K@6WMYC?'8.OPK>_7XF8>295%AC9P*?4!&/U]D'U
MJ,.&L0*(7@WY$EB<55UE>6*!TS>82ZJG,%N9=BT(#<*>SW90V&F8F6;H^D(
M$E"P98Q1[OZ+6#35>N<LTVGI[0!07FHVHQ+H]1_'<Z[5TITQ9ZM_QH:(^)#7
MXSQ7717A)CR90CFJ.E_<KD;<-G,-EUFO]PESY]ZP]\U:WLS<B8:Q.(J92>E%
M ;L8<6X:P2/YN'L2_=+D1VNM!U\P99GM'O39414YG/6UXE4T IU=/(LZC]XZ
M1DSJ*#JFD",G$=="TD TBBX]@QSO0E--&)XPG("/ GN)MY\UV7N%!I4[XM?-
MQ&#J\:4[XP_5>V5[03$XP^GM):=R304#SC_,Q$,$8*.? /#.H_+Q[6JG,[8R
MHG@IX/?;4'BUUGD]7&C2[[>A8LWZA#8;3A?3;F@W?(=J/XX)?"Q9O,QX,'-:
M -1A3F/-_.HR/ER$""'R'[R$XW/MA-RZDH$ 7*Q_AM@T-/*2 ;6DT8VXT/AX
M6!_DV!6QG;U8IQ!8'Y1\!5#7U@//SU*THRO5- S0+ZH<T?*MA@_B:^T_YI[/
M0"UF3Q:9+?F'W1]6X6WKSN/L?W*/%9O\Q;W.<$ DU5QUV$4UGTU*/^3*B%WZ
MASR3CD@VW7NRJ O$@%?H+,8'7=P)([]2']P\(SB*%:=$?HGMS#814>4N<BT!
M</.Q@>-)==D\BZ4JO@*PYKVQX_42,6N1M&U4*4XONU]KC>,=I$R\A0 $REXU
MHN@E[H#2<(]+J^592]K!@K?H!?D+^4-YPND>S+Z$.L4P+IB4+""E=1IP'V4O
M8D#S12G>J@BK2C1#\;RUMPK)7D)1S&19$/@N29)1;>U7'26GV_,IR+?+RT8@
M. ?"'FI9.#'IOFT:,&F49I2J>'<[5>%[:?C#S?X9QU::\08MC8@94%235;,J
MDM+2F_=Q.RY:B&,#;V"W*+:\9;_L\.B@P'9*8*QGIPQK.SR]+U*[#%.#2!6W
MJMKZ&)U0NQ,_&,>?P2J7C9;_L*_08#>!GE^)[:&MZWP=+\YXKSU-GE$Y(?+U
MNDF*V9ERC0N^O8:,+<DR'"?F'?#M\$)^K*K'<\Z3)SWT)75UY4$&5",, XF!
MPE)N'^\,TZ."WJ+EVV>8R@<WG:$T:X8NE5$Y;'H:H?#Y]W;VWQY;W9-=G]>V
M7V_*3W+KB&*WOK2Z.^%>IU^1K#'".UIH$;HY^JD^D4ADS2EU"[@PK3PW-A03
M:T< 7+P_#V/-1/&Z:]\1*;H$H/>P?'RN!L+!O=9K=/ ,H^3@-L=QT:0H-P.C
MIUTY9B]*8YXGEFM-:UBK!.:O>C_YXMR7>+G+78NEN<3V3J9AJ-@#+51),J(R
MVOFH7H T,^/E@1AJVM3(IFRZ?K[X:MC#9'(>ZWE_[\_-^@Y7(OD085"X$Z)]
M"699V'M:O=/:5.KNP(VF17>W0IG/W7X@T=%Q.L_>9=75S4!W(JB*W>VWO:T*
MC:=2U06L^F+V>\)^#%LX!::QZ2UJ_7AUDV%L'VMTLN=E-S3]T+,!5)2/QDKW
M&^+BRHLIUV<KIH,RP?.K&]Z<\[M>Q;*QN=\%TZ[S;RY\X/FN(T^[DHY-MRP)
MUQN; 3#R\]1!$(YZ![23\5!!D?.FDUH#FOI->6YZQ'SHP ^*NOQ6=O*-D$PC
M9Z;F%[8^<.Q$!28,X<7F8#0FL#^Y(JIFS[RYSU>=Q7=URBGE>PS-82"T7FIT
M&=..#.%4AK9[EG4D2:".^4QJ*++9*S/2N$#3J_)UP4)&HKMN=5BNQL.&X(S4
MF?&&^KC"HV[<GDP/GG:VPK?EM!0P) VV<\O!U(ZKE#>6#G-'[CC1:3A)]8@+
M+GSD,CT'" J;9C]S]"C J,IC/-"*PW(EX]XN/AD_7LI2##M7VQFU5G(YSWK=
MR=L.4M&Z65+&:+>83$R/5BMNHZ8UL&91CR.M\F)(_C++]K!C\ 67%#BCZ@[7
M'O6.D&Q+;10#?G#V4KW;2[MZ.:2/N>Z[?K:N$[7F%[<_D7"XF33YR?7;5%?G
MSL!-)3UX8D\V",#\]-CKI0^VJ:EIC7:5,#7)2:-U2!WV4M8JA&D?1&.$*6X]
M?HE*"T&?WZP7SBA*8*N<5)/MWK&V^Y!'YFP91'2%)\;H6JSQ>("E1L@L)98;
M.<OA#GDT7J^9;>1>W.YIF@(W?ES8F_GE5F'Y;24600S#W+=F96E.MMM\B$VO
M@P!, @)"\[+V(!^9ZGIB,&C<DVW:X[VDJG2-?S %6Z"A-7+8*^=U.@^S9R"]
MA)BFW/L-$]H9A-\5NFBY(]POGCG#;;5H?&DG4D*V(D5+L\S-M>)XILO)<_K:
MJHN/F@5B)DQAN'MS<O#:D?7 MNPM[ /T890LM;O-2:<OX]=;:RR%O6-AB!)+
MRLSO@S?SU&S"+CX>R(][^A#E3L:J]U9/!0D+8;^!2<UKSW4O,QN1EO.ANW\N
M"Y;Z1;A#DFOYK=DS?^-IGJJGTYLXB-EXNJ8"_8.W=)KW2/[IX!C.;@8=<<N>
M(0!?28+QL9T*'&<)P$(XA@+?Q,!QK,%&1P376Q;:E"< 9S^/05Z:1;'S8=[:
MH1DZ%0*-XID96DP$%E]6RK'J"UX%EGOZU?>/;_71Z:BX7/\L_94C O#5( "M
MD5@Y J!@]>ATI<D/Q7I&81QGWX%6"E:AF*NQ!"!*;VWV8(1CEB/UVN\?@.^3
M_\Q%X[]3<TP^AGC[.A,=J1( *BDT&8X^]<ZIKJ40]!IHOM/W"@'X7)8%F8O7
MP,N8Y9O]3@RQD\.ACP;(%H6P=[?;./9TG?NQM%VGA4L. 0AFPP3B0_L^GA:C
M!B#,OF_A[\2#N JRP\[E>QP?8"@D[")DT& 8A%*]1@#8,_"L;@CJ8SY)*_QY
M"P* '#VN^)U6Z2\X?\'Y'PU'1M3=+".JST\"&@"BOHI104&:T\C3]D5OU(.^
M3%H7>["^$$UL9[H_KW*7C+E#S7643JL@X\I26A_="S^0& %XV8_A2:M #R/=
MPK!>#FBN5N5@D_J3)P:JF=*%YW[DEW_]8+6UWU1\]U]Q?E7-5:!9],/:"&WF
M@!I!D@#VR[\0<?P$O7BT^'=B4&4Z'H-=(=Y)^,D8(Y"?D<-T8;\3X^&!)\C=
M=.INLY]LH?DOCL09_DZ<<6)#O7UJ'- -R$^N5?K)D?G[X-]IH_Z!)O,O-'^A
M^5^#9O0X#%76/.0MA3&?YR#O=:X:6C&424L\5'[+\"*(+KSZB3K19(H%4O1K
M4KG@*U9?%_L;8W+13O=HQY<<.ATP/+PUZ##DM?!Z!^JV!M"C8+.1Y1':/K6K
M"R\?A"L_:=&,D7G%M]>P<$XBK]3&4='C*8@%P$+_$UK#?M=:XR^__87F+S3_
M+6@\;09JFAR/!DB$SK@[8CGFHJA?WE:O>F+MZ=(0IIY?KOP\Y/%7YKM]4T@1
MW>]:YTGE/OO=<<EO!=M_I[K%QZ$^\ S-GD"RD* G+%)7RO64[(+2*Y^;XZ%=
M#$]\;N !"52$_P$$1YESYA/&Y25DB3,',MM. !#6H'GC"0(PH/28 ,#""$#;
MN)$"\-H,561+ %:X_T[TD@"\=;(B ')L\GB\$ &X9&)'1]0%::DI(P#ID9\(
M (21 (1DX.E[H;BS+M0G&!A6S:7\,=E5 D"^U(\/D S&8<WPO%$8/3'('LT(
M:!M! -"B8X/W6!.P?,F@XW-K'(=H"";I_PE=3)TALV9]49*@HQ58ZK/-58CD
MR<!&G]X?B#C^* ><MYM! -+"C@:7E0B #.-NQN00WN4PO4S"[ \P1'X6793?
M%X7W%%I62N7 [IT*=5 ]&I\)^+X(^0G<X!^-4UO\NW8W:V'33V?E=5C*%S:9
M>7'WOR_^;)6?+X3S:?Z7V9$ _(XFZ!]H<I^BV HNG(,U.AQ^^4V8YW7BV,']
M"S:,NI_"^&G+GY8LS(W%EWG;V1GXK_ E#"2>,E#];:-/Z&\;?>:^&UXX?DQL
M*RU#_<ZYSJM+<"O#.L&1IIJXN#H31%5(C6T3_=WVIJ@;_6_*6PG (UANX1JP
M /L5Y.O$,3_KK_0'$ZR_3*=2_5/_%G[VDQ#ZA2LK0_\'Z1*=0@XL$(!?J ,M
M5S@=KI?PQW0^GX6.5J"' T60 LW3D?MIXD#"X1<RLC=I(/T/"$#C6XZ787C/
M:[B]Z\?M',MFGA2RG0)_&LPCN+]+R_AW%OH9V/5M.:L?B[\RX;_JG+%.!TGU
M6>$_8:WZ\Y&M=? .MOP9,GL_ZM]Y/(_:+6X@@9K'_[E;UGP'&;%[&B<KFO_&
MXV^&2B_;>#W[JV#1@'.=9H<0 N!#+OL/-ONAH+[&/0:?2*,_=7;NR0.SW4'0
M]B>E?^)1HO1;EN@OZ?G9)YG_$$WY#]'_=!G$<(B>4VLNQM?_1:0--1%\\BO7
M\7X);O6W"W/*!90;1MN(PLY9OFR643]//SJ>YFX2,B8*^MOFO/*BZ9%0HQ'*
MPOR[=YL*3D"4<L76E>.O3:85AQ59WTW?6T9EN=?\%K^Z58%4WC<R.8[=-!;O
M,0?/CYYJEOAO^>'+__:IX=>ZC%]"Q_2WB1, :E%E:3Z1:'#QXA$UW>=K'?N"
M]-\X54R:6-DK>D,*OHY8&6S2S4Z)%&T8_/G .YJ5'Y"56#U&UXPXV(M2@OH#
M+6MG/\=5]H301#;7WB.W;&*^Z1@^5ND_#PV75 IQ5DPV],*=@7OT8MVJ>%7#
M<A9<=[JC_:AOG'&<*O/46QK%;$70P3-Z,_?BC\4=@GWB&\PL^D;?.N1N_<H^
M9M)P=R-D40)8T.5P[%K-[@+Y,#_XY8RW&@OIC01*ENX:/"T.G30PY R* 'L5
M:3CE>D# PUD,-&IW8Z2D8A8ZTF]2_M *Z)VZ<.:F5><'<\:[@[5F,Y[K=C6G
MS(E,3->61TW'92;_-!B6VX=E0?!5K8F)J4G?(TMWP>(M!J]DC80%Q:?^%E?K
MD'X>?==#J>$, KIK<VPW/G_\K!WD$1(I^F0R&; @/6O%ND UJA')79A3+#3C
M0 !B/'$S <=5T#D?LC_U*9)%M*K#:YK8R.3%4G>/IE@$+I&_U/'N:[WO]O?.
MDI 19[ C:E1EKAV\+ZG0)P#E>W5=:<^C9%H7>![559&0RUJZ79?1%97IM5*-
MXM3L$PQ0%X3W3JQZ97=938XX4-AG#_W*\*9G. [\*@/02Y+:@ZVL+XAH&9.>
M7Y%J9B9V4JO*!K0'0)T'PU?B$A2,.C^05OG,\KCS,#QKEFAZ"B*_VJD.VJ6"
MH4ZY61\&CWH3 .*97Q0(C9"J@4;)-2>;<</X?%+HE<$B@?(3H_/*X:9E@EUF
M@4U$E6E-.W<TC=VED!$!87>E=7ASK5AX-IV-Y9WN,) ?=#^\F,Z[9$"EOF&A
M4R3]R=?@R6DX7:J:[7)8[PH>-7-:^44]5$P_ON$KT)S7T!&ZJV'+;S<$IT@>
MH6#-D(6DB/GN?^L8.WN]^5L!L]Y!3#RXA@B%Y6.!ECV(;']A?HEZAO8V$&N-
MG*TX-33]R]P"24.?W(ECHS@"H+>:(RV06HSA>/#GX>U^UM"LT^<AF]GFX5B\
M.)EB/ 5I28(MQ-9!R#;\' ]]6\K>PE,MWD%9Z1\5%2F>O86XN)!(ATU2$JLZ
M>(V%,W%*2NYJ--U^KS6[9-;BMY739->QN>,=[P6?Q'V7+3B!ROVY=.]]:\<3
M15/.)'T1/NTXNPE.DL/6&H@W4PJV6YV,Z>YAH<;Y5O2$MYPE \PQDXWRPAF/
M3T_&::^''V43 [088F* =;]@S7&\[$T6:G7"M#MS]O.AJ.^]K^/K&';DGX[O
MW3>&0IO47TRF!2JSS?,F36:E,XNM. OMNKP5$Q\[103+3DN./Z@$L0A*"^4T
M>[C8UH:I$1M5O$G3#J*YL6M.>^N*1+@@:^1Y:1T=9+56F39=K+6UC,O0YNN]
M]<4<?CX?#?N?)R4M(PS#V+0_XWCAQM#OF<4&@AK(DJ=*9H^@+*FQ,"C*NOTP
M^NFF/2ESXQ8$3D9,OW>M560,B>(-2N-QY&VL_":4ZAB42)T8[AC@P[=2JLZ-
M_Y&WZG7U,A_6N'^I1J=QE^6#3U)#.ZHOR]XB2:;MW71L6CTKY"$?1].&VN(A
MSNUT,2DOHC>1LC0;!D)V:V2JH @ 7H$-M$( CH7S0/]!)[/'9/)_Z RB6SUB
M5WCNDOK[V(DH48IUN+=U31%"9U\@%( IF/<@IGDY8SV#<0,:>[G\TFI9-AJE
M%.56&X5QUW:S7Y!F_MQR+7IH\!X'B_R)*";(Q'2\"Q-X(2;LI-Y0R5DC[<3B
M@O+M&$NU]>A;I,U-A3YF!R_1O#G%+_&W\-VCV<.V,6M&2KR*#,W-'TAC_38&
M&4![WR\DK6]!GIN=G3;N=^'-+)29*E-[9>GUYBF+,7/CD\2V-Y9!$C*>6DH;
M\G.!^4HYJGF8@"7]&;$S7IN3;YZ]\4HF2LRU#5 YR9.\H+<0)RW>LZ8!EU8S
M(@!3@H<$ &K2MQ^>-!SG"UIR2AIOV@0_1EO"PLS13:$'V!\^H8-%]PWZ.'6L
M*W.\88GTR8%^MU]YB*;.0P+@#8UE\[TZ>$ZXC6IFKWU@3P,E6YO4PYNE'Q^6
MQT"\1KP;UL?KM4YN8_3::]G],Z?ZO:RI0K\?E.K7WC])3'_!(S1CH?9F_V;O
MNHX(=,)-?J!\Q7F=TOQQH$:0FDQ&U<[<E:M)]&]OFW<Q7XUZ[35&T7JA4'X"
M][RPT.'(I:+08=Z58]S*:^)4:?<7F2?2:^+B@DC$]GO+Y<MQ.B.7G)5CRJ:
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M,5;8J@+XI2Q>1W,E;@DZ>@9=T!(%3Y>AS/4$0#_N*=6:(CH/]Y05?"*^@::
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M/^UB#=E_\/_D 577'1 /7<^ FG/_/?,HP,I_1QAE_V.4JQ*<-)H@N(KH#U/
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MTUJ06_?Q,P##"AJRO4H)?H*O/P.8_"J]O5$C>&Q /%+^5IQ9Q\0)J;C:&Y+
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M^AX#D\D9]DNH. \.VE?_NA5_U3NH;_G"0?WAG<BU5X>FERD=L.F/Z$^/]I%
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M^]_2="*8SP"*]+6K5>5'C"D)DBZ69T \HU@J?=\SX!;7]?D?M?\>I.Q!YQE
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M,7=<?_'Y<5IF*DXX3UVCVM^L^]7^-8R9NUP"F> 9$ \Q2O[@LWZ6H//3VUX
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MLS5<C?Z"6*_T'/X5!ZBE*=D<S/INS'%?DJF#- 5X<7)2'!+;>]-]./VB,6@
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M*T)7M/\.;>%?) 64@W\T7;8_6&5YTM]!X%^@_ N4?X'R?QX4[O]-4 Y<&G"
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M_B@LQ[+_W%F/;^M2TR>M&<^.;R WFC*:#80*J:@H/2H*D,&,* NZC2Z$:B+
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MHH#1QR-41JB\ED_.C'8JI[Y>RVKC7>,)*@:.GY-H3O?CKJ[_$Q,6OM-6B3B
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MR/E&UC=UF'1ZG@,>N?G'^V&NZPNJ@62#>]2ZU:-PB+;"YWF"N9LD:L9=GLK
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M">:_+1=S"&2A=Y(7=^!\>:P$][D(3JRVF:U/*4AO5HYXC^*V#@O/_0C&9,O
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MSSO.L5::&_Z.+]XJQJ7@;N6+@=H)$]A:S"$NP<''A*6FW^O>_02RGTQEA 6
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MU]LB7V]OPRC=A)ZJ&=9[28&[K:AN_%B$T0$OLWE'%-.QY$(&G7K*'F/,-5\
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MSD+^.0?Z-\>C_ZO(_?S_ 5!+ P04    " !"K_=:J4E$GE;:  !7W0  #P
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M9H.6G"39FB<NR)BS*P'@@='1 ,9N3CR>;[^/'*KV:7ILKDFNWP6]8*B:HMX
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MS=65V>?O ]2/'=T*#?\)S>]H-I+8T]76:?AUREVMNLPCQ!Z(@VZ:UH4]B?O
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M( ,I!+%EH+0.D39:3_2*A-%2J0 5^5"X6.65VH9CHU,-#)"4];O$ON^!_SQ
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M/1E6[<7&.T<_+FB??9?^#IB\9-)^/'5_7*/U:'^4X2(.[:XT7?\NY.:R7-)
M.,V1>[QV@,<QC8@YY=.2.:%*5NVC6*\<KM]WQ4*CSR!"_J3Z(PB*W^;&(G*A
M\Q\),Z*[<H6= X*^XS")S)"?JMVWE]N]8*7TRMX\X%3X=\1+#X\-PYW3@=*
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M>)&>2_GD+[[/>P"T,X[=YK09#S*M$9[M&IJ2P,9E>F_&$DT1'YW(3GXG+R7
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MHE*,[?MV=FS"SM!FICFN?ICK_=LRL3(LY@W22!OX<W6['-M%F_4]F2X:OO$
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M#X!X7_B=D_\&Z!K900LS/%AGM,L\Z8LQF= ]?.L3^TO-C*>BO6>IW&?PUWZ
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MG;E."IBT18EC!/6854\'E(>5$UO7&TREWX%:KCR,-?#*-SY-?M@4**0BD"Z
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M5M6(>!E.79PK (&(K]GW-S:=8Z)7WBRX7+ZLTI=U^%++B,4T0'=\_ZE(3N8
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MLU;Z?!6B/;R]+;1!V!=Q4,Y99=ZZMQCG@!B?;:%QO%\$1U%O=$^LO+-HY';
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MG)\:KZ02D0CL$Q#V1W+C /K+00*:)M*:"VL"/J5,^(>Z=:PGML*V-P%R.EY
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MG1%_CGL#VW/\YP=N\MQ >6D]SL"?0-A=6*%+H5>QW+1Y*RFOH5"FX[-$M.U
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MY@OKY%U++>C<-F/!^N>'8]XNCH 1CU:R1+'OAXD^6^[E,OTM5LZZ1X&+=4^
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M;!:?3A=YVKF.VY*I,^G.(8&9"$ ,G=79OY-YYHH_V6RMFV7W7G'NJAKII\N
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M+7]L "P GO?":"$&-8\9E[.MB@T<)CM71&'<_;^Y5WY=;8 G. GW?/![Y)X
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M&.PNUVON'WJQM!9I)?&&[\:&Y34%X>4NQ<_!PND-9PN5VNHO7O#Z>T!YY-(
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M\G\M4>-#/#&8"U 8]_]-X=XO_ ]02P,$%     @ 0J_W6A7OE8,=T@  #=@
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M\5 0G@"(>HH8UE_^"+CR>=H7,9C%V3/$Y?5! G#-EN7*V"-:%@^7N2\)@,,
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M(?*9K.KGJ@]BJN2=R/82;(^T%[=-I%(S&>)S![U<9]\$D9>Q?>#K2FR?,!%
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M+#4'GN[2-UMAXCI"3",BDP.:T=NF7Z8M'%S-3"OXG-X$)_52N*3&G\T+-1.
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MS-PT:&9,4Y4O7F(#M=&+K4F"[MN93CQ?^>*!57_1,S@,30 @&-LV%GL0I/Q
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M?C?KH ,]O=(D93#.TZ\3/PY/:[-\I#%#JW'^<Q]'^PW68>XR+WC;OXL,]XX
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MIYDY$+.9?!DK\QOT O(55.E4&K*R$?D,=( U3<OV3BJX'(,DG5.1]$S5133
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MG% KC($QB>^JOMW:$CL;?>1"X)NN\&.^CHN[WIFKJ6ZB6H46P>VZGR1W.B[
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M@A[$5[+L/#N[2M-,7:;])#80IA=AOC;?-5PKE?)BN\\RGJ++%R:-S5J[ 5"
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M>9S2@LN5[#$ (U(5V9.>N#-U*Z$A.UY*+YQA YE^M%=O<;Y&7^SNG-)>-MP
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M)E6KEPZJ/1EYD_M=@>_8I)N-OP%3%WOF9AQB"EZ&>$XN-^:,<Z3V*>.45UI
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M^0R]EFQG0\JH+*-I@>F-DZ>-\?U,>8RJ%["OA:H%EP6C<YCOOYA.\W0U^"J
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MH>4)_&**_6'WE<K+O-#=>=>%(C_U*>K[EYX_6)H3MQ)V)_E_]L,'%I<\2A\
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MSJRHWEKZMSC?3 T^?56ZU*1_81"W-7%X; _O:5/D9M!]$@/\;K["B8ID[;V
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M#=1OJ3".IQJ+ZVW5.M?7%I3W;OH71#I/IDQVHDR,'/%\W4J::7\Y@0]@\P^
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MXH1V]_=!_]B;7'KP^P&Z5MP**FV^89:/,I8NP;Y!)@C7]<M65'E%+N?&S *
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M[I'KMXR^:GSU_IB-QSEY<N]9WHF[U6SB%ZMIM;C8$#_A.2USG,/"R)BSQ9:
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M3-V(5OG=X-Q$VG7^C#,+#BW\H0Q0^LY5"FS@RW775FIEFZKU-]G=D7LLH$V
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M!G"PZZ-3J#FCT[Z=JW%IB@RNT VVLQC/G!-%56C.V%(\LBLOZ=0[GV5DB+"
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MQC*&V7ZG/OOS?)_O__G]7[_#>;V<8\YYO^_W?=W7?5US!O9W]BBPXZSA&4.
M@X,#> I] >Q!0!_@W+3IYS>T;8:^MVS=LF7SYBT\W-Q<6[?S;-_.R\/+R\<O
MN(./7X"?EW>'Z X!(6$1$9'M,#%Q46%Q06$1X9\WX>"$KMF\9=N6+=N$^7CY
MA/^O-_9'0& KT,.9R<FQ&]@DP,$IP,%N .  P+&%X]<&_+YQ;(+FR,6]=1L/
M+_2"DAW )@Y.SDV;.7_.&OJM/_1[8+/ %L%=JB>XA$QO<._V$#[\*"9UJ]S)
M@EJ12QUD>36[>X^W\8B*B4M([E%0W+MOO[K&$<VCQ[3T3QD8&IT^<];L\A5S
MBZN65O8W'6XY.CG?OO_ \Z&7MX]O8%!P2.B3L/!GL<_CXA->O$Q,2W^3\38S
M*SNGL*BXI+2LO**RKKZAL:FYY=/GSJ[NGMZ^[_T#1-+8^(^)R:GI&<K2\LHJ
M=8VVOO$S+@Z D^./[7^,2P"*:]/FS9R;N7_&Q;')Z^<+!#9OV:7*)7C"E/N&
MA]#NPX^V"I^,22VHW2:G=HDL8G>O@T=47IVXA_(SM%^1_7>!/?[_%=F?@?T5
MUP"PG9,#2AZG (  J#Q[<08T4W*\"?SL6L(SW=(8WNN%_M,F*2NRJXRP@(\6
M7W+?Z4EJQK)*$&]47WP^*GFPVNLF/@^F;> LO5M).SD\79ZUJ509)4*2ZB9P
MA6:=K4D;+F#DSA)@WHH&Y"I>V:2WM:[1^6('T>]\\C[JSJZB-$.S&W7.^_L9
MH'$,S+=9RIN*O)/1R>X,_!=:&4MD,1PQ9=L-DJ4[V #/<B-\1>4V@L;O,J]U
MSL*=H3\$9["!A*%HY&J;"!O02Z>Q@9<4+X92FS ;:*_.8@.$P#._KN-D.<P;
ML1B2&\9C\&:3;0RNS@,:H,3P->=*C9ZZ@=<&RB-778=6#L=],M!5B[2P(&)$
MID8TVN<]7W-?+NY53\J ;?GQ/.WJ&]DO?' *["ZXS$+>@_UMS"6QGV/"UQ-*
MX'2R,TBT]<YD!?\:D&XD;(>AA98CUMF 2@7WQF0X&\":,L!?P4W^$5PG&ZBK
MHI@P>0<P3)H&-7IOX_\X#,7]'Z$9_3P"?S] .MM%FK*!'6O<; #Q8VTG&[A&
M02[/(##K6%%$/1L0:LI(JM]XPHGO_WK3=KK/U\7U0W%R3[5"6.QZ.#U7=M5V
MJ6ED0X[OB\!0PY!P'"<G3;()%_I<&O1\XKS^A@TH27:-G?W$6@IW^53"<JRK
M8&3ATM%RJ,U=);QG<%4(\??5QZ\-X#:R_0-80D@M8Z%:I>;=SV.VF9MU"R!?
M3$HH*.W)R2:)=/7GO5RKN.4:^M6YHJ,CKVN8+RU<:;+MYMZT<."W/=]IPZ"W
M.GMPFNKQ\J#C]9R:Y,F!XN!C5YX%B0Q^#_NF3IK4O!D.IJSEEDHJI.=(6TZO
M6=B2Z[X@3B#/T:1&W8*)3^02-S;W>![8U'GA\!-_$5^TY_2A6FF!H"A1=1D1
M@',)U_->FL/JG3 ESD>E0PF?])VQ*-:D3E245M9S&/Z YF[B)"Z&PTQ@M^7!
M/DZC?ZPWTIG#P _Y1V)T\/^6F=]R,7HL_6^I[1NXFBX,-NC6LH&V=?\61)^.
M!6,#,\9R;,23<3I0QDY2T]E P 2&9I&\EPVD^D&G/M[_W[+Y"RM&/['"XDQ$
M0%A+_XDU-L#QU3\C7-7HSZH(9-YO!-NR6(@)E#54!&N_%<_::,??#Z#II?U'
M?/Y>?(NU.0DU0GWJ/Y0]TPG663.V/RMZ?F0?S[A]WKDJW;J2A;XXIAAC4WJ3
M=Q*]V][='"73_M1;+DO70(2*"*^1H/DU=AP>F:;(CWO<WQ048Y)OA&RJN4F+
M(E,7B0OOE3- O6_72JJ;5,M]X?K(+:_)^2H*H:65K_5F,W/T\/M)TD<<51S<
M+*G^_A*?.@Q$*$8]6X1-C_^V7[RP!1">LGLV<4):M:I0-D(R'O$49T$S)E_U
MKASV=+V1K'P(.WPRE.^(=NQWB_9$Q> 5'/_' N=24:H3%^)A@.I&\EO\J4\T
M%;&7EZ[,FO37SF<,KCNA+C@T'D7Q&1E&^HR7326T95-69+DH,IU<$2>Z94P\
MW.J@>@CV(V$VQ'Z6N\O\@4M]?3C8W?C>JIIQU."8CLE94X9)Q)^9@5C@W[)D
MPMJU &.!K0LG_Q]D]D]:=(+FY?/;O!C<&M3X_Y5&_J_!BC+%KO^*V+G0F[NA
M/7^R74,$B2PJ\<_^;6Z*O^86RJH@X2>[02&B4JYVQ+8CUP9;[["!X9<\\-XT
M7(6GLD*KQ:/4ZI*0!07Q?>HW0F=M]U",1S7R2B(WRD*%Z^RW_"A0W&]T+QE[
M=CVR[U'!U?WW\H*QQ>'#5FVK%0L_&-;Z0AK& OR&&R.S+([1%5,#]*V>,KT5
MB#N."YL: +_VH$>]I2A%HE^;^.Q3Y_CC/H72166G^RHT5M8"]?B]_>I,#2=Z
M-'C)>BZY&=OOLUIT>#:&8D,*?(8GSV?5^F=N',S\=JMB06I_L4+%VPV5GA4]
MR_?DA=R<Z_W3"0D[U\*YY)8;G< _\O23K1\W%61=YKC\ +AN5H!,TZ\?.FS+
MVGU^71YJ8-D>;W?A[T5>6G9G<?Q]U7]Q-^$?W'V%#?RY[IC_-EDY \G9CFG?
M6_VR;/0=''=\B1TZ>NK$S%4R1"1/_ *A2EZB/P7SO7'KJ_!F1EL4_N^0@O^#
M?FK:'GOGIT9?O6EI%Z/_YLE@W*/Q'4:F)O]/ ?2WX0+):W_V9+JQL,#_B&V$
M/S$/>4ZBJA/G^MS3>>=UA(ZYT\Z^D0./'FWFXB[(5VR";V5HDVBO6F_&>P6A
MRAZFR'$N<'-553F&=@5=>^]9@7560BLQ,/J\31[/GS5T%BZ\9@/<+,>6Y^:+
M42BXWVC40YLCRS!,XK&$-Q'?>T70)K;!YS0L3=_E[9WJV%"6[*8(CYG'5ME^
M@= U>81G;UK ;[N.11EJ'TV$"V?/7T#:\75[X(,C9Q^.^U;,TBR*XGX<?36"
M?U^O[%M6N*I357^X_L?SZCROJ<JB1M>\MU6QK64AQF&(#X*BB(P[C:,J@M\>
MI;=KB)D-69?X8S*FXB4/\&X)?B[JL??C57M>1@Y9'->=Y>UGG+!&"P7E\=98
M;,_8V2C63'A9$M21X3_YHOH/'*J#?_VL07TJ;%<)DF1'V< DHV;\QN\U"5_6
M._B+(K"_49<SXN]*Q?@_*94//Q,,_M8)WORZ_A$;./PSD6B^_Z[E_+?ZYG^2
M;G\UJO^ +#5OL8;XZ1H;;E.#U2/S5[MJE=^%'",]$X/7[Q9!Q. ^4"P'\*$/
MAM'#*=UWKE=%1@H<N([]N"K2BJS_C,+/02NKD3GZP'3L["M"35K>.!OX0O,-
MIR(B$)OMR<-O*FN";.:>3KA8:$?:]YAXS-L>0\9-^-@J[LLGTU[TK_A++B%.
M?+PEK+;?=B"P*V<&^\+40&0\^6EH*NZ=WN:]</X#AX#6(Z#6NF[--.Y=S6;P
MTY$N5A[R+5F,$>G($EM/'Z4U,S_#24S8R7=,T+:+H9(^<GL@;UP+G>0H9.+A
M>7?PDKSILX:>#0IND)-X$$?!4WTI[D'J4IBBF;52>EZM:YJ%6;FAR?7OS6-(
M/!PC'?IQ<?!@'S6!%I8S#<)T='7; M7-RBY2;-^PSETJ(V=4'7<H>NRE*LT?
MU\KP90./$U!': :X5J([OQ4!=9:26!%!5ZF?K5&/I>?MY5;4?:Z*"T=SHD[V
MH270GT$1-'>]NV:@WJ%FN:_N]MYO1T@L08_='[\&?!.6!GPVDVJ2H3M>H.D3
M7Y?5!N8X]986,HS.C&.0\10.?)E_\[:0]1C5Z>Z)@*/P<*VU>1?Z#0:BAOR#
M4*_"AU(CV^86V(("0^M>6^YME?-SXX[N"%]#TA3;YF+&$/UF]97SH4^J'#*]
M(\YW#RN4O>]"-84/G'C]1:*@+SJPY &V6',.-HH;,+OFBFP8V4L)TKSN&B)E
M<]D_?@@LX-UE:@O39 CJ+=:_^32*P>BID!DY]R)VRL.:C@FM7^2>BA-9[P;M
M\8-2M7L11#%F>M?5*+TYK?36MKXO9XQFSR6#M+W@8V5Y?>X@AH/XI=0QNFIL
MIND7(T0P@(Z8B,=+H23&V,"@UR@>,\\X06K;[DUOU)*VX-/]%E']MO25X(6/
M4X6NIE-*4TKN-*7AFI!6>!1ZFW=S_3-^F80)3G*,G#K'QBX#U'DB@:;4-\<&
MWCTWGJT&3SY]!2^=OC.#CX3ZY^=JQSI\6?-'F'CK=BVPD4_PV,2N2TJ3?N;R
M5"8I#_#G.&,Z,*SOYRY-77I#/IW:>?7[X<KD((%:$65@%R=7S0'*B@L\2B/C
MXB9F1KD(]>64"XGP!+&D[8)<7>I9-WFBQ(S&T/#Z*[)\;, WFP7OGIQ*"V?L
M9=[]0Y@KM==L"D#+#]QT%-#UF?>%?S19WR>*7_TT.W449!F^ "ERC=_PXS;6
M'5CS1[W8\VXASQ_@9M+7R7QH2.#4&H*N[I%X?C;@]-JD-GD'!<62ZE"GD50-
M,O4E/\D=?FS\89]B;-<C).Y\)YX+,9J%7/*5W<4&'@ZR@>-6U_TUR$6C^/E!
MBEJ=J.SNV#%!VL->UI[D$8)I%=>MJ) 3#M&BO"N*&GULH/X >HBP<M<*9&W^
MQ 9:5M<T/[:MRR5O9P/OK^!9 4H5*;!O,)H#9C")%<UK NGLEXAU6<R_GL ;
M3?U?O(Z3?H U])T-Q#[N8@-D!1.6$2X!"I0-A.-+-><R2-8RVDV@D*>"<>/A
M_I%^$^'>Y0 ?Z::M>E^VH E]/\08HI,L1(TT&ZC0!?R3Z!P,%PJBF=#?:D0Q
MBI@,F;56:W55;E#=RF@/Y0B/5IL-WSA9HP85V3DV\"G5&;[*!NY#GH&'?CA@
M1SC%?>"V!AL( L_=2[^+#:19%*^)C,&+^Q@15EY,%.P'4JEAEB6HM"%+-6 #
M<OOU,K\]-S4 5>#XX#_DM!RS:R7C#5A...MRUP_NB-*\6,/=\1Z .]K&=5EH
MD,=8I_SAK.K>2BM6U4>P$B)U'@9FHLJ",N.+AYKD>Y3'F#^,V!;L"1>@84Q#
MC3N*:9%]8F:E(I?!PWX\"\>B9I3&8?V9U"0H57<(3P98V2D^(Q(T:V*%N7C<
M<;'*XLFCAS7)1@$7>L8IL4C;P'# 4Z2><876/^K^V$KH-DN3<@1+G#VT[83G
M7D'C>6G[B?LK7'A-O!.&=J#[&3/S#$TWQ<?X,VR'2W8\!&.EN]X;%9#6:.>>
M=FR$/:D4JX=SW?8=P>=_]T8/;)5NOI]UKB#[+GZO!+WYZ.BMJDRJ+&W2C[(X
M&HQ[HO'Z7K-EG\$0Y9K4H2?VQ\<-)37H>)6L"3RGGB+*CI+99//P/&1A]G3K
M&* ;XEP^1<BC6[">W.\W)1 MFA#B#"'*.=E=9-MJK]3;'@()9> S4V;_#D9^
M9GLXP'KMA&M#]*NP>#J([F%8._)DX]%1,A@&%VC.36W"/ACFFEL6@J-PN@;H
M0*OA6G]7D<:JCJ$3^T.CK[XXK/6SI(4Y-'[FR@)_L=<"B R4NHD6L4NI9@.8
M8VQ@R/V'93=MS]1E+Z/ZRK3@'I7CXIN\ -A:U)5<*QPCV!V<_< &I@QS^I:X
MY&A=J^!+II(^[>(*\BG4M;[=^4-!^W'/M>>@3+,*..\&7-^XCSR])CZ-U&1]
M80-+:C/(U8^@UH:.)VZ:GY<-Q)S214Z@91KA2VK8-$8H9,_6'#_]PI/WVGP
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M_%T,;40M-T5:$J7D[G[?/[/RG( A8"\=H"E#L0EE:"S.0]<8$KE9FX9 R@#
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M0^W<"#*6:!*FITY;-"8G!-^!7^Q9'-\:GOXCRN\#EFC:'8O,9 -";& 4(WD
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M0)8V\@$$+E4T-TU_E+D695U'$%V!A>7Y".^^V6&WU_7N!5X'C-4"XF]WXEN
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M+&B!),)V;^TZWX=$^&,=*8<7KSV"SRBX!?@>-/ _+27,L4SXAQEWG-<YT?/
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MUT\IRXUXXRFY_,;&E:IE)(\EX=ITIWMQ12(TN>KMP;!IZZ>HTY0KE?.8!JT
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M%CRL;#?3^M]ZEYGU%ON;-XW5^5+#-0E79^[MNVRR/E4(BTL8*7=_! JH+X:
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MX6QUK1=_< "'+)],3^K)B36]P!A06/FQ.-Z6JDX(DQ7L=>_]7-^P8?!C3/K
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M:#O?: SJ8])LJJP?*>0)W>XM2@5$/B1IBRZ0VO-O)"+;BZ:\@<R%.,Y[I]8
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M.9A2)7T^^OZBH,\+_S'WWH"1'A<H!5E()AV('(OI$M<_^J.137?&*(VCVXM
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MXIO?]I"H>;.D3<N(7&A8<C(XK/:SS< 1CK;S5BUTE9)PQ%0:70<"@Q(2$MT
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MGF];7!QR=LXN+S$_Q%/-EL6QS,=X""G-!]E,OG5XLT^>;.<J)HFR6.,6CC\
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M;LFKN4YCA.;40HKUZ V?\L&5/+$3)1U&C+FE>\M^;#^MX\SUT78O)BZ][*[
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M!6/SGYWFTGV_5ZXG3*L@<?*LFI1X.%VOQ[8'S6825?RU#DM]U3F+8",B+W0
MY($)6Q)Q'X"<+@&VV:]]D#-G[S_OTY(PK2045348>(Y:@A\X"^[B3$;CBNX]
M"S]^SEP=V^5'$+;,YO0N2,AVT>"[6Q#TP2_ 'JD9W/8QPC:CYQJ!Y\;=X1%$
MXAKR %-2L*.7F)^18JR209$>^=]/6O\:/$'VQ/49V7V*]'MO4FBPFV"U<L*V
M8BSQ*BR$:M79BUJ>O?RSH#;--EZ\>>27,:M5])#8N24G%%G&I8FR6,%^SR73
MY-'ERZ'R]W-..;$<:4+3=DA9.#X5W9!./3E30[EL%Q?,D##@>HTX1X[MR+-Q
M3^M;/)[EGD$/\].\UPEM\:@6"C6CA-U:0[.QHWC*<1=C& ;$P9.4H$MXK8%8
M-(<8_"*MY)[^BA9L2+[TV\3\FX@%NIS10UK_7(3 (;EO"[]_(\#+3\L0=(=U
MU_]3#-W4-^]B"P=JC<A%]Y@_MC7]@!.WK543",KXEEI?OB'^_<T-T= >_DKX
MRZP=NB!%#4F"<T%M'=.MKUI])=BMI ;QYE>9#4G\=><'/)%GV;J/PB/[,(-W
MZK[P+Q<,G.=#ZS 85=8#%$I,<A9(Z-T)[]?-P@4B*QAO-[9I[0:)N#@\1P5(
MB%WZ?1#+.Q7MB) +_4-M-Z &#LUI1#,J3S*]YJX;O*XIR.Y+[],OSB6M4,-$
M"A9_J+^.F3>5C1 C*P!M&M-6!P"I2YG<KE]-"SYO)>QML=&"O>7F5*O>"G_<
M-QDLX$,,BIUG>!ATG*'5.01M?V=AWK#NW=F64ZFO'5G>FC+5^8&PF[:V05T$
MAV3/Z!X%RK?W .-Z3Y_P2];G.11U>D-R]CSXX/WIJU2QO' JY@LH($H_87?!
M23\L9>#2P(.OGTKIIJ%+./VSJ\W ]=303PX>5T 0RW%'T6JHGYSVE7J>35.
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M4K.)WUB[N7V&O^I2P^=ONN4,GDGV2Q]3=?MG&<N6Q@3FV4UD])5=U?> N<O
M(-R--1(S9+&F]HLQ=S*<5/7NMK!U4'&]Q/ ZO;T.D10-6X29S]E)(BPPF9PK
MO+&&$ECQ>A(B$<+9RG>-<'EMVK$R+5'*W.Q:8N]M&-..1= .J95ZHN011F>$
M+(-5X:K-@,QAN'^H=68)R.9=R$PU?BH1%:2864!2*+U>.D:]QMSE8H85R9_I
M=NV'G/WY/MD>I&!]:-UR$[MBJ^KW]D<QQ]=UC$.+LD_!?$#EP;;$E>CHRUOM
MUR?S#NJ%MJFM ]OL@,-\F$62FNP< WS<@%'F+E<3"'Z3$>A_Y'$D1JC>HD&+
ME>ID]J+[PQ(Y>]@<9PMI%3#]_;$L;B$P4QTA.U(TY%=XN(C#W-;L:D"N1CC)
M)OQXA\YV^#,=8?I%A9FV?#X\9&3'0-MY]@K55<.V/QQCV3VG_9XS89D5CY8$
M"GRM3J!F048L/]!I-2WK6@&R_&./J$Z#D9<B74[0^'26C(<F:6K4"&6*?*>7
M+=;93PE'4EH(TIN7/M-,!1-J;W0X;EITLC1US19WY4#U5.S=*@[/1]U+XG9.
MG@(8G9,V<":B,*)9T.?DKV9]0V8SJ35O@GWE?Q1UJB,E8*=TAVW-L3]75U3<
M0@(9IER;KZT$;PV:YTLX6*<@!?RKSQX!2*HIQ&&[."5PM>A+2V4U)!?'>!+*
MT'M5N.YCC6@VI+WFQ4+6'U5EXH;/W8_^'-ET:'")_K7,.?88>!"A7!T=(?A,
MAB[2D<TI92O65J,9L[YUHE/:++T#<7@.7'\ VOII_8M\\I3RG&EO&G6)XW7!
MW[1+'Q$W'*WMG.Z#/:0N:I@GQ&06.C%0NG60:7<QI:).\'?S%:N1G=]_7M9L
MQ]*?'14<+_LS$Z1ZN0X*@IY5:-S*+Z,$L@?@0*HY*)NUM@'NKU3H4:==0##J
M;N,#D1KJ3/]0HT)ER%<;-!62T17R>;8YV$TA/7/WALG%;$4ER)6PCXRO5BM<
M?<O@\["J$I.^H<^*RQ0T@ -=%<(2-S" V_IM1I,RD:*!GD@7 .?=%DRT)MF9
M;'Q,_@HR_;XI$;_W:C&FS8,\Q&Y)<>RI$,1W0[U#ZL53>LH!BK=-WO)\@6LD
M!_< 6D&/R['7YMI<O1FGKB5JOD..]&DFOR=_V6#A.&Q&#2<\PO$O^KF5L'@K
M<1?RZUG@ ?^EQMW5@Q#9U\2?]^&E"VSW%<3N<^5[KRI<*4Q$K$,HO7."+]F7
M2:Z&99^.J=ZC9/.AF*N5'2"G#8K [5NC-T/)(L1^ES+,AL&0?(WCM4Y"!T]J
MS9WJ9=7G/$>:TDM[TD:_%/N_!,CKX1LA5/,_5H/$9]TNC]5[-N(97%^V1+I!
M/.3+Y(J;%F.SS4OG#Y^^KL9L<'MKXM8+6PXZ,5Q=B[L'*'3N#>DN[P0NW@.B
M+\^F;X5;*P1C5AF[YJS5XE\GN#PZ,\>*[;&6!L),[=6'-H;9'LWO_SH@M/CC
M\XWV=;9.SD_E(+'22N&O_7.+'"2UK%)/8_EZFL7IT]IQTZREG(S%%QD;X-=]
MTKE#]O;$"1 5G$*_9WV>NE*MZJ@!66X.0R59NQ^GK]-7NJHF!71&;HX6+MS6
M$BYX\9J U3ZNFGZ3+$E!BIK<UO4#&W$BNP4LYDRO>J8ZQ8%T1O"!8AB=-=F"
M1HDS5,*8:$"!5\&/IUMB+#DS.:?9=>BR0P9Z#R"Y#(F?R[1BCM:";T/W9O5<
M)[X V2#@T8B,O^R&J>H1F#W;&O2PLAC9%VB):"/X/2 69+RQQ*_\HF7J4HYW
MP.QUA9F&9Q;H1_6[E+C347=?/*%H+$K6[V9<'H)3-^#-<DWKPYO;RPLYZ$9-
MWS@QRA1>FA\C*P4"9T@\KAP.-F6Q*6Q6[S ,94ONL_MH3DL=*]I%OCC^L61M
MZ>"YDB=_2;UYR]LTU6WVA,UBWD>/CU2 UT=IF]^4^Q6(BR<O)2_:X\>H9@=6
MFK2?+E15SQSK3].?U1?TMFV%>D;\QLU&R4VA5#;B@[S&>YO!7J8HQ;E+\\#X
MI3=\V2H'5L/U*ZWCPXPK.@K[)>K23<Z2B\7A?X.IT!VX5U+Y(>==*QZC-^(*
M\58T+># '&VEFB.J@5,]B=D/D-E5P\8\"^B8GG% +9N#EV\N9H1^?OPJG81X
M!F+<3W;.J%DBI83J]2]03BO!!ZG>W$?#?HXG81G=-5GRM)'P&N@\A+=T11LW
MN@K$ MM@2,[5LH.6TTS,.V8\,7&710W.-G',NC<&A4#)3=8T[?DZF>"6[4-8
MD4^+TEZG,. Q&'Y)9VMA-QS &Q(X%AS0O! H\7\V;&GX4+E9GSO.>1N/? 0V
M/\R2$S!*E_) "*02W=^UH >T]\C_);[F1LK1-1\V/WPU.";BQB=L'DQ-<4JD
M4>%\0QR-<EGEG_/PT<RGMW!^K>+S0V91+NW 8"D^A$W>BO)%>E![C_ZY;5P_
M;\GM0M 5>/?O7^MG@> N333U/8 +Z;^TMT8(S-%%N&=>W8D;96"(-I\P/)'6
MH&OT8GNV13*L2N@REX+BG*N\T%8>G'"1J%TP7T;.PJ9TR5N41&NP"&RU+FW0
M'ICE8P';A*9<*US7)?< _4O7,311CPK%:T!1'#=&O?KG@4GUX9ABOM$/@$O.
M5H4GJTCR_NS^JXZ-5I1,I4L=4X/E08"YDNR>YS5[NC T5)*KR=NLHRKQ*MW?
MH[P?:]$[17AYT LCMGAPE)Y1?%-JG/)<+:E2 **_41-C30*1LO&N(D>33A0Y
M=SDF#P>]F' @EIO]@T/">1G?:CGZG$8/C.ZJ$1PLF.S(##E$$Z.DCL=K4-((
MB2BQ-T%J4-J:Z$J.=S]XM3W$2B%A8"91NZ)FK^#W].?&Q_P0!@03%#[N1A4-
M2R1[>5:4RA%ULI!N OJINLU,24_T*=#X,W((15D(,H#[7#S?9X->!=.U0J9]
M7]:0+:K"Z:B?8&#]+?T$Q$HU=S-JR^RWPH9+Q,L:?$>Z&C3/HCPJ^N#[V98I
M;6FJ8"%VUAT3@\HBR=&$BOQOZ3H?M TKNZI./0:-MU[YN=[LAQRVG@B6(CWZ
M:Q49QU_-OIMR?Z+<QKUK;IJVS0)D8?!,>JXJ9/;!N3FC.IFP\GF;*HM1TO-2
M6_I/-/2"X%>(TP7HX&S;:AJ,B?"A))X5=14DL**CLSZ6P7,K:;7FD>!GT[@N
M<_1UV+^.8&Q:0+H.,G+.^GP]NF2*-OL=YM #=J'VNR(;^$IO;]/BMUN&OY9M
M]<V'$+Q?6)DG "]-CJ.#'E8Y7:'9VNYNG6T..-HSDSMM?E^M^PPJ'6OX5 -U
MB,D&"RVL]R:0X7OQ?5/VV2P^0OI]1<)^XH_@\YN,,[L*)*+:$@-H_@:X1[3W
MB,D)_Z6K98CUS'KLFP6:$E,]#TQ.F >?@$C*4QL@#W$^\(M)38]N;&;FBP59
M5Z8X=RVOUD?>G=2VM[+/;J'75JK+GHUY"T6\V6MS]G^[H..J]X":?G1^[+&O
MO!32>C.?TE3%N0:IV<?(47]..\,":6J%1'@(V (R+6QSO4_-?!^B*HJT8O"'
MRW-@IN)#^;?L(;#9%3:0WT-@]V&M;9U^*RE]Q^R3S=3F;'2%M7P\S)H(^+/7
MDO>5N0^C0W8LOO:'O\NOG7:X*7.Q>3_11UBH]5<)KPT$DR/RXR%R[YR_ VU5
MX2L#$:7+["RVTUD[,>V1%@ZK;(_?H!'.3];?II6MW=P#NF]1GU::@JWG=J^9
M7B _PG##@]DL1&F)8RZ8R'4=C#:*IT[?M3L1?:A^(<2[C&EN+,\P62,6Z&:T
MJ=60_Z;I]6=K#?=$69Z 3UX2W%*RF*NU$+SOP/IN2R8*2V3 X0=KMEM\G>PI
M#\LEU%#)RA+-8'#3[)^+>?)656UBG1RC^#=INDU!.MP)0JN-/ [JXQR8FRRZ
MWSWUG:UH)AIYS7/<)#3JIJJJ+4ORZ#3M8CD<-K+"0VGRMBZKI)\1].EB(KWD
M*$6]_X@V39(I\<SS?['!_N!%HP9VDMJ5/#0Z1<F5NF2 ,^;:[+^M=.Q@CXIT
M)Z6M R3"G\\#B(*PG?05*=DFW[\#-X*3AE>8&YF77M9QFWQX+D[P[@,>)D.B
M)F4)U=D8G]X@?<-S9TL2G,^A +[ 7(#4$8\+-V9V%YSQVY6;8>/+^-Z;SB+<
MG$IG\<_\$V^]:#)4C15.H^BS0R(A>*5(XU[G#>2FZZW(CAAT+3+]9"ME9(0=
M\BYKX6N>T+BB9'5<G&QHGRX6T)>?9TY+&U-36WQ67Y;*U9$FZBG&+V_M%B.L
MM,\B1L7PG32B)O$ZQDR[[,:)F)(N<V_R-J*X25M/>B*\8S-1/6SUBPINV^8D
M&1GOI.D=+),OCW4>#Q. (&22EV*B5)_-LK2>#^*ECZ;23 M<R9ELEJ]_/'X]
MH4BRN*AD_SAJE68]ANRE)[<A5FX>;CD[6NS%;6\ 9YDM=OI.8MG*0@]S-IW_
ML?YFDJ(&T4]53+NTE''.)J>")[7.OD95Y,K.6/QD-)M"?3_U-8;TP[K9,>/>
M3C1>QBT*V;YG:TH;"\/BC<G/SU*5-SB78)N^F5GDQI30@:^FE%BNKI@X&QD9
M2XQU'K@&>B>>T,VJ JAD\W0"9N28NA>)HYM$@DKW?1>]UQQON<W5^_0K T<_
M85EP<WQ-]4P;"#"ZI,#9H01''%7)FOYT1<@6;;YNBIH]6/[\+FU8L.[7@)^-
MJL'OQYA)/+/)&XETT%DRDWTS[:0<>UX1N:9O]2IT:3T<;P :IV;>>C@.B1M!
M=- ,85-G:>VD3$=>JL! &;LH":YRGH)'V@;PY%"4W#JO:WL(L=-5@*R$'[&/
MM&EW72R[+WM:(\&#L* GX@V. ^RZR],C=<[-T//Y4%K1&_!7CEM0-DA;'C$!
MZ6VO?RXUYCI2,O][2C3#Z$QT-)D%^"73[C:R9:L:1V2*WK"->_Y)>:FIVL>K
M3PU@S<1CKNPZ[J!1@,-OD50 UC7 T-6#P.G*6#IRK#/-%GN@^![ E-K_/NY:
MUO;Z$T$7UMW1[#<*C/0JH-><Z619_>#\PG%)4]S!"H7F^^IVW0QU%AVA)7HB
MGKSX=3DZ13?*RF-0\\3%/>"HG=4DA8*)F0=7*Y]?ZK#?6U3_+CAD!UK:57.H
M^)!( ?\"F)FS@B>%B'M U#%;]LNFO$5$::SN\#:HJN1.V/.RNJBVB3_ 58':
MJ>UU/YUR$/9H#9NCU]>KM\35Y_FE[G\P5"CT_B/@RGQ'MO>F C/.%6MG&WT1
M $[8KE9S6_RQ:3?V*K.?]](08SKV]CT@O*E*YQ[0*V%,2X@N9+W[>?XB:SW5
MR(HXBQV7/0EC6:W4_ZJB8#]/ IE6L,_X=,KM_<7:XX.QBH/LILH78M21]/CJ
MP\E9R\-6!O-O&<V3I:,F>P_7%3XQFKBQ(QI7^6.YS@'G>7<U<:O%UPHMYQ&8
M@QDXP'[1UJI=^^O&M(?!"UO!/)C310I>H$#)A1#^:J!@7[(8.%KP@D&_L?7)
M$%&FJ'".QF,>I<<ZO:IJ[L(\&<7K'62!O&.84.E/\O@SXI63&AM[;K9M<>*V
M0ZJ)H<8LK;S39$2JKN,7Y073(/,0!#$TCRE5EQ!HK=PVZ5T1Q IH</5H9?C$
M_9Q _1W>T[W1WVHT7'E(:H0\(I@SI%>A FC;1^*ZREKKYFHX77-A'N_)\.M#
M_*,&>#-B ,LEL';<2)2]9/+0XQR\7H/$*9=80N,>'"/SMFWAFU#?8.(IE"!G
MLO,/IPRA$D^S Y*JWF\=3R/"\<E3S<O9LY/[ T[#44*4C8P<TZ(,G+R_QA)(
M71J4GXPFAK[3VW+'Q=RF]X8U7'HP /.@UAD#<QN=3>7SE6'4;R+TIB:Y#!):
MU%I,GPL#>?.DC1P'Z,:$)Y?G3?>,S$X3?6Y-1=OQG8N,'&)V X?G.=PV5UJ3
ME;N?.E#R@ZNOL>V+)P>U?7XB938R\IT9QE:C-S3IHDWX,TQ9&N*,!X=C\/1T
MI#'>G**?@>3AS:T"B8&P-<)]VK[Z\M3>S=?@\(TMD!L'/@[?@H5G6HJ5X_HX
MGG,P)3+19Z.+?,SCQY(3&F_JJ/'O)?.3D?=1=ATA.4FOH%U+[L#J1_@YVTA2
M^'F_H$^I*ZU@I,##CBNPM!L/R',? ;"OI*=*+DI121AT-#MB89J=59SZA/0>
M!^<'?Q/@"&I#-^M>HJN#Q'RJ@)HOYAH[&'?N :I3E^6HP=K:#*>BEC1/CE']
M5)JM71DUV9TZ6>7-FD@T/@+4<)C'#,^(AJ4]*4EUH<YHON[4ORW(8+G*6X!!
M OM)G5-1,LB_GM7X'V'<EU*HS+2[ !N:WUFU=QN_Q[ZB6>=WQ:HVM$4&C>\!
MU"@_SDR_C78;UHE[0".YR11G:WKI+<U*7:I3;U*'TDXI;\F= N6=13/8JBM"
M[0\O9=7FTBJ/LLPG3KI03))*'%]P8??^7%S@HA)'GQ\A@9OLVY^OWE#I>7XF
MUB/""4YG3>"F#Z9H8G]ZA@Q\E6\:;9*FU9!F%"5"87SJ'@7\L\M3;_N!/@_C
M5.LA7HU[_K 03[.9.N!FA7Q98G']@HEA)SD2*@EU:-PK<'B--'BIC;7G6NQ\
M6/1EWGO")=^!-W=S9&#9,=?FV\>-1-ISG::I$]&<IT?\IHRKLYIV3H4/\9(B
MX9G5_/[B@P&",66HM'Q5:6=64,G\ZG[UTN)OV )[9(Y,O5Z"H^PN@\NR+U7M
M"'W*THM4%:8TNI\ ?<F_2D>2]-[KAG'<C^C,U?D>ZO;"I%5*]AB8XD]A+R!C
M21IR3JP<)%U+:U3HMC''B-_1^5E3O+30S'Q0YKD4!WA@N&\KH3ZOK,/'6T\F
M=S83O@M==(S@@_ LVG<6%ID-L%$M?G+]P,Z\U1Z%)4+%$<N6JE$EB%3U_BC_
M3>)*._E;V3/-9_*C.55O$DA)!W\)#5#3&WVC./7S<OLS%@$U4ZFN\OFI7&JJ
M4K["G 2[Y)]PR%)3\</DDZ0G7ZQ4*UUXT5S!4/*X.8)JPT:/A6: /#DS2?+8
MZ$>)<-O^;#P6O*J2]>F(Z$3,P )^$ S:&;A;);FPU%38^%S5[96_E9)2@X,0
MV$/+-N'-M!Z.4>&&-KE12T-+Y\3%[=#1=%4CF*J<3?%QSV/UX7!)6-4W@5]W
MQ>*?F1J9DSQ6!$_?$&"[2P'(G@>YS%!@&#:V<V5+94]B\NF+/F.)]6-W?*KH
MV9M+D)3[I-1Q_0Y7=Z)LDM];6WKI5<O*K@G4F5:)\[2C[;EX[O6OG::'60OB
MZC73B2RW6#,Q+:V<ZB&LX+/F<Z4PAS2^I.>F6PK%-2LM!2E,BK: E-Z_I<X.
M!@.OY\2IG5(5V7WTF9^H\?3[D2QL)T^VF7$_2L^(+7->?.WLFT'5W.;"$OM^
M(_(UI?+,"XP$+V#_:S!<-[KRXMF%9A"^%GBBC(!C:J,AT6UKW'(BK'%WV6B&
M0LZ/,"$9#ZBI!A>,?N_-CZL;H3596612T Q6_%E X'N@Z^7/E69F-/O9=, 6
M'"5)TB!E,LW-IZ/1?:+!GA^0$>?6?-)=DLWYC8;%^]80FU'V\1M0M9_TQ=Y@
MJDQ>HWALF="+]_P:*HEOOAIO/_9CIO] <29'_*I=A5ED"=IF<.A<V9SEL-BF
MLE5=X#9UC,]TC?5U!;PD6:Z:;E?+SOI[^46J_PA-K&]E#M@#DUX<IA.PM5,U
MH4B?E *'JDQ>',H8F]9D+[W)-"5?UCCO6&JO2VD.)2)(  P ,"?;#KB+?TDO
M<Q?% ?Y!1?E^1O9LCD_9 =6$U?S*RS_C;M*X22;S[]*_P)6PP@D_,I(B9=8]
M *M#?AM=>$XWE*,I_H3\D=DOM$"@?.Y;")%<15U1Z#(L9[TLE.GEM+<OW.J3
M=Y6J3RND7AID9=CW<RE]Q7?]LR+; [TIN!^TA@ D%[7#1+!'&QQ!.8*;Q<<_
MR\*&$6J.F2KL6O1@J-RV9,$YU7+(V9FP8F7478"6IC>KA/G1<5)5I'[:'L_*
M@P# _P'"1_I5 *." LY[I"E_-\F.?!0HY$AP<.:@@39L<D3-;-T\66J#$T?5
M0/1Q8P5$&:1#2)28TJG*.'[2?;)2Q=R4PT,=/DBR[<;\R&"B/SZ$K^X!VO#.
ME'>!Y6QJ_G(=N4[GA;?#?41*XVP=MLXA#7-0?C*9F(>D#D &_.:-=VS(D/3>
M2[>BHG'ZA8FM?B!M7*BO2)\9@29#"FY<'LWET<([TPLMM9G2V6>IRLFE[1A*
MPG[]PH57-\=Q4X;'<1>\^T^DS?\K<!B+Y;_F\4\4M82M&0+="4N@,OHXX\\9
M [=E&+]5>-4VT;F)ZU+M-8Q[31QX0C_PO\6-)3DZQ]MLIFXY7 4[_:<Z+JH9
M20T_&^^S7KI"/_FS/MLYZ:&-\A6J'/!:2F@/_7WFSS\G5GD/( +Q<\54-^W
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MV_@FHH3@^%X1M,% ;@CGSP7+TT?9-9_;?NW4B*5H(1#64=K_+=^,$ QKM&8
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MB7\/F%"9"#D]#(ED@L];8]\#]HKVNJXONWHC8XNJ3JMDYP(SSD!#:W?9 ?<
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M DG< VKYF&X(@]GGCL%'#T//.0-?0W?7ANR)7?@S(<KV;_+C@&4/)E *R'O
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M5--=IX*.[)GO 51J8T8HWA)KI$%?ZL$J!5R@H6!/?#$0ZE,XXDD6U+8^1),
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M4--8<:'5?C>;7XBR'5 X4^A_D(,7#_';N CD]"\#MW;JRRCQ5+4WB1@.#I(
MHI+L4N>:?;\K,FNS Z-,<?W=H%&1"M66PPQ<3 J,X+B*,A??@(Z?R_.6/8'O
M^\+$(/&L9-+KX2KB4-.I2PUWMOK.YO;4E6:MSUK5-AZJ #A0EA;0JI6M3"$L
MJ?KY9\;C#O/YP*F] F(%2V,84TSW+6/B=^"KA:[MYAHA2.OA(HVZ4LHO3H.(
MA/*2AS)8F;'A'%C39S88.\2<X\]URU&#RW;]_#TN@[R-E_1.!TY<I]^4DGEK
M3B'00P/>_[EQXF)$6V":#)0C2<4Q=/"AX./I?VOGVJ.A7/OVJ&1'I0,),16B
MG#I)A*F$L$4IYTRE$I(4<IRGLE'$B*(H(X>0-,E9,3F?TCCEG'$^RPQCS/&9
M[]:[]G[WF]IOZ_O>[UMKK_7]\:SEF?'<<S^_W_6[KM]U/_>,U<GCQ_._]TTR
MP6HN@@Z$F_UT=1H7<68"Q1%!*[>U(,G'N0B&NH0I7-(*,96*T?AZ"F%:1=.2
MDU4*,B%=PD6TY<,+H5U+[5O@ G0NZ0V:'6M>!K&6@#?CV_J-,%V8&FC&&0W2
M/BG !_NC]>YS$6(87!H])1B:42[[^E4D9_N,XSK"-+U9DY]05IZ M$OK;>EO
M=3Y%'&T5V*AT[K[X@4<U61NG*LMPI7E.T:T*KY(7]L=\L0LTRP[LI%QXJ%<=
M\"[C67'^?J;8^,^YK1?,L&?.26/SYFV1BD7)V49[FU&?CY@8[J(AUIO)1]'3
M04M%J$32^-X!&1 TE;V4ZZS+GVQ1,N?@-[("J%<HV1HX]U NPB^/BUBOQ]ZG
M7.("+*TJAT9B&V&VKWZ00R%UN1,>8E##T%$NHERQ#C7",69'L[&=1/IE]&T2
M];B;"VN*0(]!]65B!"#@R0G3N5Q$OQ/E6# J=P+:P88^0!2!:T30\(!R 'HB
M1<N"Q45Z\X!7%H=9+O V[+\.Q#9-P$X5DFH)R%E!>D"!/9N+ *F.X"+NLV[U
MN73>Z+,/=6<I"FI3BJ/3'-O"3O0TB9R;V;FL][SW$HA_CI]MR[E+&!PKE@0I
MG\0QMQIPGN$AY0JBJ-%'QU:/!C;VWGY,T&H[A[[7L]=.8%6+KDRY&;X&.1U'
M+O_>PQ)ALBI;. @^B *PF!AG<1$' XL9B^EB:!CWY3H#<XGU$9C[B!"!"67.
M5KT1'2"#.&3[K=_W+HW-L]<1X*, 3Y-G(<ZVV\5-^!#H.UR!N1L-%3934?<\
MJV ].H&"N0,HAFH<^N_\OD8([4[!NWTP?W-")MR4V3)'S[B2(1U;&^CRV:!1
MH9[XA5UQ6'?U)(__$W/! >?C7_8&DBW(7T*2Z5&":\92%5Z&[8VEW;<ZN?[I
MBQ+^(WT/TBZ_L-L<S!2W:7 #X'"X[M"9_,2\U72EQAZE0U2I!O]JJ7!O,PE"
M*7Z%%=UCY+ 1?\M8]&ZO+)W-2DWZ'1WM40H[=W94OR\14M1BP>A!5?QG%R*;
MN)-L%I"J?+=X&]UV<*Q'K$U%<=\*Q<B#LI-7$ZL4G'8NDU^1MUSQ??5)*4TG
M99TF%2R_KR'=[GS<QB9?Y:V*]4]'FY6.9*0>S"U_O'%'&C#]FVJBNGO=9;7*
M$MFRY#!_Q>Q<=8EW>[IJ9_6N5L29? G<=V[24+6ZPDL603'S522/E&$$"N)&
M])H2L@N>>F@,Q>CO&SFP5$U:R:OS%\F6YBS"7!N[QAL_P1QU>W!<9TO 7S0N
M2$ /BV@G%=6;"-+III["\7_)15!/^Q+0L0-0CZ-W%LL^@(L8U/?G(O"N[-O!
M<J^DQKXR',&9<)[ V(</!)T3+WCW$+X\AI/+ 8 ?["P&MJA]@R!G>3%6"M[+
M09E2C(7 ZVC@E)!P)]$J(5A^$CL<_S.[\6(_Y82DHS?1H6-A)KG1'O/7C"0;
M#(5F:$_F-G9[>[?I6WB'90KC0]R<U5XV65[IR[^OI"^>L")KLRO;.LBU*>_G
MV.B5=3^>#6:^$6J7G 7.2M-=I<[W%*@(]( @:VD/-!J4BGO/6?U2F56!HBA_
M8(M(;'?@,[!B9\-SU@LQ70B(H,OB JZ8;H^%C\7V37,PP*PE2.,[Q5@:D?1U
M<YRU[)I^+#OT$OCG'"XB^2@H%*84Y;L1^5N)/,\@%Y&##IG#\F"(<7O:J (C
MS>XAXB<C>L95S"ZU?P@^NO*7T:.#-_!U>/H5P3 4U409(F_HXB)"V\9<ID D
MMF52!.!W (N-E+9^CF^8JU6R>J-)I)4;YC(<3"8IEMA=JVTN;_BM,_73D-#G
M KOGJ?.H;T9J!/I00JF"@WFGX25=$*607"M?POP$,>@P#9/#"7@ HB6#8B]!
M#?K@V*I\54BFG B!+N ,K/4H4+5>^@ 7H;-DGHO@<2;0/WM>$/)S)+#9D(_@
MI$(*?&L[L,9K@1IT<Q%]^5K[P40/%G$1[ZU=8%6T%52B@4'Y'J17#!AOZ*!7
ME4=.1.5:^9H>VO2Z_-:FFMN8(WPI&9C+YMTDLH$+0TY+'?@3&R1S;UMB=+^\
ML? OM<YX\W9ZSZ[:W9-:.G?3]5;]4B-S\9E0V[O"),Q#P/7S]C,_BCT/ _D=
MH\3TA_E17(2L]@NH79T(;JNM;HY1K,H93DE'Y7JBX2./4,QY9#7 2+_6DP4/
M)D_KHAF"01P7P';& D458^OCNUPZE&&C]#X"Y]89$#NGT1G4@''S'$J(8@SK
MT"'0"DR]G'LAEU!<#3O^S/+NSCGQT-VH#:.ONZW?CD=H7W6V7SH4^H\='SY?
M=WS,22BU#E04*E*CTX4_9:NN$$Z3VL/7D1]V?69* E5D_>#GE@<4*>:P/G0/
M-2GH!:(A61@S5+P#V$)E2A#GUC2*JMUBW(L),A/A]./HT<,8@; 'V?[)BA@K
MR#OC]]TN?'EP.6G&C20(3=",.6ME, UM_?.31B"@1N1YF' >)'^=^=0JOSA]
M]@IO^ Y\GJ('ZV9#$\ 9-"4!%?9;2V_X[M3>D\AF2 :"#0PJ/GV:LT2,-5R\
M'+C?UUQ$-1^(LQ\:&EW3%AT#%1"'&(G3^T5@ P7EEP3J7>13,"S&%SKW!YNG
M "P!,M\:!X"9"9B:&L//,BA6!(.9@YL%*>+< R8YJ<&\\Q1SVVEXPK@!WC6
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M93^[[YI6K!>S=>JGMDD*?\/TKYX7N 039@S9@%[/^! Y:^;6TY'//@% >*;
M,@S<[8%DQ<UCAN@H7$_Z&1"$A6<P/%, ,JKLIZIE)"8G$@B(/CI;A5[$6@_5
M-/MJ@KQVH*A''K*TT?81T!);0@+JL09PE/<SD$P:@9H&((,^@MG[MUZ6T$#1
M0!<7:4$'<;(%]S9*GZ!@")=0SGB&"O8.>FX("6/#""(3_;.$@:KF.7LJ*8 P
MLP-(#AH)1ZX!B!K!=AQ>8+O%+4ZQ*+Z T/N -&/BZPY2DH^B.N -@63X!,TU
MX@1!@S)C?*Y(!'Z ;0(]-4$;%?J]!<6_WZ+BQ_%"Q4^DT&R)8RK:3O8N[IM>
M6J\48/A</<!I/BU\C?DAVI"RM,Q!_)BB6"?Y0]K;.FDOZQL>1!M[DG#+SSTG
M^9;=QYV^74<\CKK%E+! SP=#_>C'="7U$TVK'^0P'#CCN2#EMQ884)*T&.,A
MI$6E0/.2)<M,,*48D15(AA@PG'@G0%+A(!I4O8'O]H#HI5")!32XE$R"B_$$
MZB].TS'?$0!;6P=X!!4]C'W7BV;(O2Y^ XR$-,8-C,N@<.[\(?8XJ$0>:'0P
M*.!*(.)-E^2G=M#S%BO Z.,;K R4-KWJ'C0( 1H5&5T0I"/TAC^W8ZFR[PQO
M\-=ME[8?O/L(<^8DU837>&H_H0#%H4/D1-8QY2_&7 20^!V?A7A,_WDJ!S>'
ML$ \2$%<!'^>#N+DG\]1V?WP(!<Q#\BQ-*/QH*0LR[;+L-^X@U"E[GSO6-N-
M#?=?GKNP:YOO*%&)?OS]%Z<9.U@("H%&6@&5+O<@L:\1W$;QLJ+1VJ(J:@:M
M9BCMOH^[RZ\.BWDZ[GW0DESO03I/T"9G?7,-EGX<!F6$LT:R18'MK^4T)^2C
M7H]Q$0>TLN"M<:KPK<3YK)^Y"CNI#GTL^_$EQ>"/VXYT*7.R:ICO!:V,9?J;
MF&YR@9W]!_SO*WFMS5H[I\(4U7$[._/H[/B+%T;ME"SL&E?+RN7/ER?_4F$D
MXT;2Q8W^1;ALQQCZ_\U "__Y'/M'%M/=_O,Y14:1\JK*_'PJD=FVR6D.N625
M= NK>%41UX,=:WO9KTH(!HRV[R1U2>[Q8SGZ)Z][O\7A+_1(G9N9E%#8)*?S
MPO5X44^N&4H U:<'D.QW&2+;.P-E!>P6@.PG,>8R07_[-(^+V(3_K"Z/7$@0
M4>\_FE2"+>'B$3\^&H:\&G=C4XB[<U+9IMO2NY5ZU<J4#C'];;-T;O3.T,\,
M#HG:CE2[RFX\MS_B-SFSI/B$Z42_EW^5S4P&X[^;S;ZBL!OMZ7+[B<3U<NSJ
M]+_HT#;!*:]L.CWKM)L&UG)B: */960PEZN&IDJ(2,_A0O[2%OS++12/$"<5
M7&RJ$6^==7<O9LS\(F5B]H*WM]F/^PIMS5IKY^XWF[B(:_M<!G<H_V<1-0S+
MV(1,!]GNR U4NY?E8'X\_M)CW5\5ENMOE/".F1A-EOD0LS=9U< U9K29A2W-
M)*,J\H'N_)Y3].(<%[NP5N-FLVAX>K GB;D<VT,L)7[S7]_@2W[^6/ _. +)
MUM%PX2S5F[;OLV<#V&W@(H@96'CE%($^A"0GLH&CU,I%T??D<A$##UDI.LAV
M-R[B:= ?5PVB)^^2\>48<4Z2QJHTM'678G)1=^B60)HH6O)7_]_T%+QIPLQF
M3HK(O"P701"$A:\$S[WV/-K;VR?B\Q;WE()<\ZE?X]==*O'Q Y+6RF9<Q(D4
MVA-T-PYFH^C'_^6R:2V3M'^^( 0Y5'" ,9D&4A)@G7!SQY_/D9VNT#6(1>8B
M^LQ&X_EQ_SS5^V/P4X5R2W[T48B?_2!?T'+P[B(_3Q[($'F_/:DTK+5-)%2V
M\X*A[W(+5^S.5]Z2#^>%A>OOQF?N?;IMZGIG39;:8#O3D^EZXFHQUMD4G4:W
M7,!_!6%V O@2_P,NL)K>MUG C#7:(FD2J!'[<0)%B$*@KD(6X0)PW^3F 52*
MI;BPF>U<1._'+BXBS/S+4R'H;#/L@?R?782$2E0U-*%>[&\8Z:Q/9U=H% [4
M)G2T]GEPXM;6Z5HL#?>459G+^U-8Y7N>Z9@DB^GW5 UVO#JKT29N+KY_IN!M
MA]N/4Y1!E/[9B*MK'E8[;2+]/FYW0S[RL?#%'[N-05]MBIXVN8)3D3/=E=L9
MX/0V]7)R1$^C=?B%<*5/&T?P2S.V$2BF93V;6B2;AON]8C9&]8];&SK(!G_<
MQGKSZ^@OH4>7#=)$QVR@"N(=JU/#*<HWAUH5J1:OG.<=F0%UEV<R</Y"EGU)
MX>?M$[9+S]XZF0W<M(,D;R&EZ"'[6)FY^[NF#7)6QE-R8JW[(^2NKAX^$>!!
M6R89M!>?"#7/P&]WS>7-<:"8 QGF_<2@;*>.+?D1DUVEU5GC:RUK:>$BE9]G
M>3MYNE/4JC[LL2XDW06C"]:DZ-V07Y$C$)"3$RRM-%.PC+S\&&)99 -/I*V(
M>[\/+[DG@%QF^6DJVV(RN^LDA??3AUCK*Q6H\[_AWGU8+EK%7SQXCHLH7Z'A
MDD":D)3/:5)4*C=RL4_H/I3J3W/2C=HY>*0!%V<37A\9T!46I'K!QVMAZPBQ
M56F* Z$_%6F.!^//*I;33/1O+.GL?K-4>KOLH[5O;[:+,GM/!4?\Y?I' 7&]
MY^PQ<DZ+6=X:1Y'H$[H79]PFME^QM./C[3KW9"6EWLU]!+T!(UO26V:7T-73
M93%AE7I6^//T&LOR_5[=5&F(W_UBU>5P7'AC!D0Q+\OU\#Y=+K)^G-!Y-3;6
MPJW.OB#JJ*ZJ?B;/%MV#T@.183FKTRDNVDW41SGG0TZTN-U5#"71 G%VTF0%
M.S6%VOU2?)MGY&^3D^>#M$3I$1]94_UH@=.7=EJT.^GMUFTJVYNQ8P]/64'D
M58GJS6X5%X^ZZ1=+$A,](T^U^$K)#">ZOK(\[%P;K9?O=?9>NI0"KK1>T/;@
MUMAFEPGT3(LAD=G,IFH"4S_ %T1MCW"(/L':GQ<VWN_6_/S2U%;WE1E[G#DD
M/FG)@Q]=31W10M3858Y^.\2-S$^]O;WQE0S\H7DH_X@^SZZ(VEW5)[QI^+T4
MO@HU%?QJ!TE!"N]<7F!.J.&O^CFLM_>'!"QLSB:&&K-SPNWOL6]&>+W?5>,3
M/X82 MYJ3Z6Y[?IFG$$S[_V<*"'#1Z4&/,LM2![+^9:Y#\>:N;2QRW,94/3<
MO.2LG8?R9&^!Q5# A8/]:@/;MPZZ7=#PGW3T3DOJL1X7NY!1G]%0E!NE<NG+
M(;YZFZL=FZZW!>=I-]YN!_6E_5.//')DFH@AV:97FU99'+I.T[&9VC[C]7B*
M\^%BGM-ZDP;I(HH9-GW%0ZG,P/YM=UX9/MYWQK]+7'#$^H<_'+SH,%.]^\[2
MKL_04_JM85I2?F3M[9Z/'2-19I577]R,NXDKS76Z3X^E;*CKRPO2X=3>?67_
MT#EC\\7.-[]^5M7:>4=-H2J>+^U]$E6LQ8&>T=<8O^V%DNP%G\0SN><ZM3VN
MZ%EH/''IV?7$+D53[3EH3MH;T,>"QP7S3M=+3SO3!'Q$;<=D#@HDEHM<>[AL
M_9.K.EY1T?L>/W/4$J68.JWQO-VDJ$L[[7/R#>^SW,+\@%/(2S46+9OOK6]8
M8VQJ=I$>Z] G#IC>,^&7,FMZ(*VS3E?5^EG@^-&^SOF5Y;ZOL=/S*RJO;0<5
M&)X'%QEK0\', PX['<UR"U\E.L@^DIBD,L[OFQ(M2XI?65E[:-D^=3$2N>K.
M)/MTO,6$.O24)M[^6\/C_DM/TD8-7B^SQZL,# ^4K/-5+233D@>V^Q:=L[SB
M,M>U=JA*LTZ+8:+5>BB.+\IK>Y5&6Z*O7(O[:?/WWA<JLR3KRH:W9OI7[RY_
ML[MB"Y8NL-FLJTN3S\"C^W188;!<TK]LROKV";9X>8]")CEIC;Y'M&G-5=AF
M \V,J/$F=_?A%TL\$;C2-X(5+JM#EVB>M#E6)]/XVEHE]_KO =^IO['W>G/,
MC7+2G5QHU3L-Y2]"1NZN.[HLW]=GGG]<Z.)[=LTU2^Q!05_^F:D=IY4/M?CN
MZG_>NIG"^\1\OLFI,"-<<57.YP]'7[!T/2J?+3L3=_.V=^3AUH4?=.4B5@H:
M0N@VMMKX"@K*(+]Y'>UC\ZD6<Z*/0WQ6\U"$D\/))34*9ZX<WJT>-K<2*<+6
M=.]+7^6XK<C3?45/S\<62T-:>M!A[64AXG?$+48VOO_H:B/:ZJ:I"TG8CL<$
MT/S["$+ZPAG/,_@UM,X$\^K+6/*'W[K;^9+DN:72:4^I539S^;,^(\A&"=[8
M'&G2.#EW,6?FU!G%M;E/&Q!K3]N=)]U<+406BVECPL5H\M(4( ^V]JG=;&LR
M54P7EWID/CK=SZUU9Y>598U,5=R+#Y3L,U?,3$+##U;*WR@KEL*61S752X0E
MGI'R"U 1U\N[.*#&<[-Z'L]#69EI_,*2'FP]05A]R2HZI+Z^..F.U-EU8U,B
M3U03>2TECO)&AQ_Z(M^EP9/NX!T7O7LL;EMTA;Q0DOZ-O???IDEMT0\5LB,_
M<X8FSG,1QS4E"!DDAH2.T/&C_UM?C?\[''S<CO\"4$L#!!0    ( $*O]UK\
M@H7KQ4L  -MU   /    9F]R;7,M-%\P,C$N:G!G[+T).)1M&S<^DH0D:T5,
MA2A)FSP)TX8D))564ZDH2;8L,7<IR3K1HBA3EB3+9,\ZV9,T]HD4ANS+C'66
M>^[YKN%YG[?4\[[/^[[?\1W_XW\\JJ-<]\S<UW5>Y_G[G;_S.F]Q/W';48OV
M&A@9H/CX^%!WP2\4]S-J%XI_SAS>;_ U%_P6F"\@,'>N@+"@X+SY"X07+! 1
M%A$172BQ2'2A^$(1D44RB\0EI:2EI1>(+5XB([5$0DI:BO<A?/S@/7,%A 0$
MA*1$142E_N,O[EN4^'S4 '\\/]]*U!QQ/GYQ/FXI"HU"\0GP37^A?O_BFP/F
M.$]POI"P"'A!YB+4'#Y^_CES^7FS!E>]P7747'$!B14;=LR3-#\MN-)1:N.-
MT.?S%7>F%DD?J*4I;3KCY",D++-XR5)9Y54JJJO7;-;<HO7;5NU=N_4-#/<8
M[;4X>.BPY9&CQZS/GCMO8WOAHK.+ZU4W=P_/F[=\;_O=\0\(NW?_P</P1X\C
MHF-BXU[$OTQXE9:>D9F5_28GM[BDM*R\XEWE^[KZAL8FRJ?FE@YJ9]>W[I[>
MOG[ZZ-CXQ.04@\GBK8L/Q<_WCZ]?KDL<K&O.W+G\<P5YZ^*;X\9[@?A<@14;
MYDGL,!<\[2BY<N.-^5([0Y^G%@DI;CI DS[C5"LLH[2Y0YG.6]KTRO[:PGS^
MJY7]L;!_KJL%M8"?#VP>OS@*@^)81 >HHO[_^H<HRXG/5T]V)Q9O67]A-5&[
M9%O5;S5?Y*Z,?EI3S;]Q::<2_L&215<\RM6:[4:O3?9S$I%UL"XG#C;N("Y@
M='-1NVHW,Y(+R1=LEFT7I26F*CU7ZHK*K-]Y*U7B6^"6.*-&KY<LZ[=M8C#T
MTDL@E\;YZI?2FS5:$9_6>B%\GAIS9_N'Z"9J>]*I4_R9]3BSJF-:B  CI7 I
M_>K3]FN"=?8J6=E;6FX_EVV^>.#-?8^:9T9[BH*6;?WDM$>P '>)BRIQ@#VY
MJ.B89*AM/1=%S\5T9".Z4*UY$VGD$<3XXL9%G3^(G&,\Q5@07'!)7LJU^18=
M#LM.?N&BBC6]='[+-=*2;/5X2!%UBE=;=K6[_^#]U^21^19/1"O2O4ZV8V49
M/=3JILR7!>\9"T_*-F\>6AU]02D[M[7;46FUSND3/H2M7VZ\5;M)>'^//6L>
M4YCKV&QLL&:D^'/WQ(KPU(&5NR:O5:7+)K^_=S<NZ_H2EZ+^#>8ZN4G2P_X/
M)1PM<UCF#M3CT"WL_.1,,VE]W0>%CR7T-ZX=Q>Y]'BO^XF3S4_R'G*IESI5E
MTATD$1BBJU0H6M6-%US^.G:(+6MFZ^K^H/W JJ -OZ%;-?!>YB?=]ZV3+N*<
M3FQC,EWJX]78PUY?]5+6!!^279UY.;0;]@CO\K;3E[(D1[TQUY="_7_^#W8+
M;,Q%^=R$Y1CFG2>-BW.[DQ/DL:;0FKZUXY7G]K3E/N0GUN5 #$_L6P>6T ")
ML2H25GM^>D#357!*]M4AA5=K6?T!S,6(0CA-#O'Q'$&$7G!1PIB./HB/U*N2
MPD6U1SC0XB<NMKU#.MBRA/?DE)?$4.C'RT0'QE+V;G>5R8 :#4U( $OVL+=9
M[].QSCY*:*731KX%V_![_?<G"E2K9O@_V%IV,J:N-SJ@],.:Y/($&QN5<-W6
M149!@V'Z%O@3DH<3:7F3$Q%'27:$.WU*=7M"K4I3$W-6+!ZD+]/061!V1=<N
M7<2/5=KJ8"=7&S=TSNX3IP3Y4@_UKKC 14$4V/;[;^R8A9^'H4T&;<[,B'%2
M&F4,0=-,R0G0-1HF%CWT10OQD2%,<:!R_,R_2;Q_DR*'"GO&-MM/81['L-4A
M3 <7-5<OCC/R%@E+3GF>?\?(8;-SN:E6>9%?]YIC\"@P_+96$Q4?/>7=8WOH
M^@DM'H[I80F/CCQ]1MOH227MLGM'-/[4X#)R;9GTBL%NJI2Y_JGS.#WD<UL&
MH<Q!"%>OM[YVL\:=8TA@[)%*V>/-?5/GEW0*\.FLVU39;U=,ZDA"MD"UEG0'
M1%0I)7L2X:+NO:%/<=P"N2A]=:\I[.F=3^15V8GG:J82BG4"3?T20<@?A4'@
M1Q.I;;"LD2&L22@GL]8@ZEQ44>R#;U*'D8_H]X6=IGLF=;&(++G3AB,-R8 M
MK-O+WH8(W:23J>A24H#>ZKK\XYVZV-((+]DSK64+XZ^<;U9YG+T\RE ^'1MY
M:,H!EE!#C"V#,(/"!-:6G TN[2^-8H/4RM=$7D G;3;7]WI,%< I0D4&7%07
M#;;GHDXDD<8?JTUVD\1)[3'0J#MN"Q>5<AC+VO=@X!RI'$=XM>TU5(KSJSYH
MKN^]>L!74?6TS\;5ML_$\J#V>[*3R6[TDE+9@[G)71&7K!3"#F:$': G>D<O
MFB_X6WO4_4-HAA($/\'X0X/'PKFHO:>B"X^O/YS"$:=227?(3:S+Y,G(L7AS
MJPOOM&S8)LS:=,X+N*]A/_]5**/MJ1RFQ>'C4WW4WY?^RJ5" T["9M(2$[J(
M26Y]2OX!EF-!>HC:?/N4B%*86! 3]GY_?VGGE0=BOZUQ/&GH_X)12_1:FYY:
MER%'%DNT'=-LK4I6RJU],__K"<<\0]_*%N-1#JK%XYE8['=W,)(5+%6'.DA%
M772=PO4T>%+F !=UJ>3<@I:@;.<EM=9:YX5B'BUR6[_D=)B;]9P"R_:'F51U
MD6*M1>[W2G*#T^3/&)ML/!O2?6%XB+S:6>= I=KG.3OF;FL_A0[_[9G8Z6:D
M'N<"PN,"29N1ZZU&938,$PUA9?X3>LJ;],_(=+UY/>9^YR23<&8TP/G#T:(B
M9@XQPUHI^J'<D1 #YYO;Y_%<*89GG/J7S^8-3G_.%M[<E>KFG_&8K[3RX7+7
MWXBW'4! I1 6V#L,G_(KCEJ3$[!ZJ8QK@,!"OO(KY^;B-#.U-=>TA5J5WXU?
M#:NR"7_8>J #S;C65H)E27I9<E%>QR%Z"Z9C!!*%>DWH6 X=A%&%G4,"!=EE
M=MJ2:9:7]4^CB7-1?@6P)A?U7*L,FBK+YJ+D8Q %)HV"W&J3YJ+:9-K@JWCP
MSNV3TM!]=MX_[UA%LM%H09=P41D5U]%E./ETTNN,@*'!<S?-@P_O?B!]Y$;F
M'<6%^3>_%ICFG%L\KU/]@ZSC5>OO7.50)H8Y[\NHX3#A>87U@175.L)E)L6W
MY7<XAAI-/L+T=&!&4K$?LX,TC0>(B^V<R)#;YF1O/2MCO_.8_,NQ$>_8Y\@P
MYP34!M(DV:G#EAR 7HA0G[<9NV+\QC_>;]ARBHLBW.*B"LL@+> *.>"[1#P;
M;NLT_+P.ZNGO!*"HQ:A'JL#?/*R&#B!3[= >](6;"$X284NOM _=I3AL49/P
M3A/^PDGK07 IF)$Q*!B7#B!1>23%08]_H+B[_UJH3%K?DHC#WH&OK^3HB)T^
M\29(['4\N1H*#3ZAE8;7)&=/?A<A'C:+OA"&M'JPC] 99K 4@9I=@@U1V$1[
MZ&O=\6Z\0&S_M24FC;%AE<OWZUUU6._D7"_-NHGUP69IP$]MRAS88B;PPX)]
MA4_6F.Z]R))_<\3 Z>*>23S#LZ>\C3E!BT=$XKBHS@:HA*('<)),],703FIP
M40K$X)=$M_X,3*A">&H\'-^,H4V0@TEC QUF\&*0 52\!&Z0X@7\A( 5AMIS
ML8@N5L[<L-$66BEF;<8T^RSV267R'MUP2(M&.=GD96D7__FBK-7+2]+C#;9U
MAT;#3,J.AHB10\0NLIQY'D(I(M#VB#$5%;9R4:EX+LK^-+' KGN#^?YDU3);
M]\;H&//8?^!$#(B'% M)VK7)3X"ADAD AD];(COS]Q9D3X^D_'.DL E/Z^S%
M1\?3-+9'!ZB=*299D-KO*F(6Z+A5HNE:@?$<)V*5+,<,\"J&BZI<3V_C^%*Y
MJ-I#/=9<U)>V=]_*("$"[KO0TPY@6I3*\>9 Z7 8 AZ@XD'?A)"BN:@Z]\2I
M R1A+LI!C+F-[$^8X"Q&[I59%1Z%CWKB7HX4P0XUM&.JT85W)WP"5)^)U;<Q
M%%^2;^)41@UAD[4LB")#K.%,;W(4FF9HQI3$J7!1GTS)7-3N3-P=2J4U]%69
MXZ*C8T@_,NT+!C,\<T)E \..#4&5K>YL)*\,4'%3X37B<XS#"',;'@U1W$GC
M!RADU\G[&%_T;F]1C(_>#7VIP]TWL%>AHI6W<9KN)<C;!"XJQJY#FYV-"('P
M54XL1T\*F''D3KB3V_>5B,.KT8ELGA\&\VYK&EVXG68P8Q!X#S!;,#!;A_MG
M).<HU+?1<JCZ%T3<5 4%<3 'W4!DW>&(1;R,#F!94(15HZ_KM8$/, 0?4,((
M1\H2H/$7PJH_C:A]&T-WPJ& 7@-PV;7ZTMW+;NC;V"$KZF"UV!,7(S[&V,5=
MR!K(M<NK?*@:HQ#WZ+I:=<60#>W$=<,RC- 8%V7N#C%>90H9GST0>$VQR98(
MS'H[C0$<7-^L&,O0\N.B F(0V:IV$D<:(P2U?T4C:PAIA%'2&Z^P0<\RZ2XN
MBM:$%>"B>A,8P.OGT8"@.)C MH27ANW69\1T;'%;<5#42L&(B[IA/M@#$X<7
M&EW5M0JX73<LPCZ28G\^I/OK(;%EM>O/NNK.5_31[;_XX7IT +VMI8=JE4>[
M.>E-=PC4T=R\WD[;2WAR],1N97WEZY4610.'YN=4ZKNN65T9BS\339(4A*4B
M)WWYT;2(8SAMS7@N2@[$K-\]7 UI7/L8U/ZPGHL*IB1P(H_GPM"[0=93TUY.
M&G@;U-'5EJ'!6?B0P%#. $'N I54DFRQ+'EU#,T8)*WEO4AU\A<<I@MMD? %
MG770DFH-%>W%V!Z4PP<E+]'89AIL=W.HV'*@[>V(3+^>#F-'.Q<E?K%:KM\S
M*E*TL61GY*(\51613Y;J7FMI?5LS$X+W;HR]%]IJKB]=[NPK_1X^W+AN'./[
M=7U#DHK=\0%=V5'J5Y=RZ]#E5P\O[?3A(Q:7<I+T-$U]#C.2J>VC7D/IAT(-
MS%10R\2>I0SJ21RYU7(UM7[OS5>1^SB<:!(?IN,5LAG$IB7=#Q']!C#\IX$!
MY -A3!%*J,IA3^GCYD EA^ +O.2T4PR6JT(V^TTF,>KF01UVC/S.*-<+>Q 7
MZ+P9\ZZWZ4ERVWNU:LQYO/A%W#H.H1!MYUD]&!&2_-(VBZ)E:6'ME;;Y5/HR
MQTJB,7&E^;?+&L_?-C[U"5![P@AUU<67M$F>^+QO<FI]7_A&_<TFF:&W]NT0
M3)U[8._PVTQM;35F!Z%3HU3N\;>'9@KN3V-#JS9!EUH7A'GSUV,Z'!ALQ(\D
M"?B[OX>+"B3:L==AR0P%OX:V,72MJ#0\ A6W@?Q;C <%18T "A8;PB"U1D,U
M4U0(EC\!7-$%.E?%Y*)0K$C$FK4BFO2TB5'4^>V 80AL%OJ.B_*OYKT+^X:4
M9I#]TAT_:<^ $OHI%-F',<XO%*O=7%=X*-E_V/C!0P5EN4IE'HU^X/+4^N0=
M=4:M$RVJT?EC]V^/CLKK?;R6Z#_W,,V@[EU/]*N@>TQA9H@#8[7-(&?!* A5
M(=_2R"4IC(S$%P85KBOU# N\)3L!?&6VL6@$$&29T&]9)/J &/LFTS+!I[AD
M46R/]\(/NDL:21O8)[DHL?4< JG7/@\L4)\"W!HD$J?9&*CFLQL @D BHH4-
M:+",XT0:YB&%AC:-JZ=LALQ@G9))',@^LD:X*('%6/CR3?#W!@[A.A<5F@7B
MLW7E "\<J)E2T/G:82Z*>-?[ .$J9& UGYX52)<KCK#Q]]KF%?$P,&&G2F:N
M_AJE76USYVP5?)G\G@9]LD!,)#L<.#Z+N:A=%Z<"F"VAYI$!O>15>^MLU3"E
M6F%]+?/BW?CFV*K'/1!9</W]K2#\RV3A=W0(#O"D<#P D42W/+^LG,.H JA:
M9 C9RC2,[,-I^GS%Z!:7*=R[> AU!K4TB/"AT8'AWC8D!&[2@&6H\F+3=>P!
M%P7?TL ,Y!-82U^J#182#9F+6_%0LP5RT'LU,)4<YSFFUQ.(,0$9 GP9__,'
MG)3RML*/:N2(3;]%%0+B)V,%>E37D&=+,V#+6-+KQ>5X&2\7QA*O'9UJO9GR
MQW1WVIEEZ%]^/:PO$O2JW2;JK255$_<6S'TUU-4,@.9U(WET[UCJ>$)Q<*=4
MYJ#3F=-+ZG,-FS. [.KKNOL%Y &Q;<-:H\3NT0$$LPX: 'E.KP$I=AN),1[)
M*4<.P5]/0A7?R)RK$&<^)>\!AQ3>[^FND:&O+V69[[E#7VJ_X$ V+&&&F!!
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M5Y5TYP3:B\S;@ASAF8E@I>]1 91(18'Y6(&X[,U*>MC[( ?N 9'S;N<8D@>
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M+ V.2@#)58U&G*2!*,QG@"C UD)].H<&OA'*P@&6PNARCIA =(!:G]@1U>@
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M[-U(O@TI-A0-K=RK&EV07BMLP([O,^9QBRK_%/EG#NG"I&W%T#Y@1%Z#A"O
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MOV)IO1K^V'$==PN$T\I%T:6:,>UWT1*QP>&()%X8?HN?X+T?DP)<*7),+.D
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M8RO0:5?]J(DB ]7\I?CDDR5.1'M7S3=W#'SWK'A^J4=S'#\K"??J7N.8<.Q
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M R:]*K@_AIHUI;ZQXOU58BVHWFILD]Q([.S*BJ$49)PHR<*,#DUWE !1110
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M&<%-RY;E@H #-D@="*X#X6:G=Z)XHTI+2YE#W=ROVBXE<RSS;FY#ROEV'U-
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M#=*BSP"K8] D/=M<JPFY%7.%?].VY!L)M#]4.^82>*W:9<WF9PRBU(HY1KG
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MP32U"W/!WMQ3QIBX8PY@@EX0P$+8$S% 48H[U71EO:F\J(0]0^P*-5&['J)
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M\78]^K*]=SR!/\>@24Z3G+9DS5RG10<VCG-C:FQ.0NSYC:LF6)+P6:V;41^
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M]@L\6X0*H%P@9$^>(7U/<8ZM10P0>O8U90&@_E1<A.J(NBA_;2A>2G1DVM%
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MID(L "%&3,$2W ]FW5(K2J.F5\/<;"0R/$=$G@9K<\>@#E#BA0W&*Q)124/
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M9^F\8'#EFV:.R!6U[5=!^L&" W%]#OFRICG7[^0/S5IV(ZG,VF>R&M3S:V;
M/>8F<3#8M@ZZ9MHX@"0SORM_\2N?D*1<_$UFHJ")D]'Q2]00R^!@L8!@WU0
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MFFO(!W]@>&B9H>R@;4O1GJE\M[,B5Z_(&MV3!+ D!EF^$;--VJS"0I]I_@O
M,\R=4!#6]'SY$X,(ME6^'6&S1^7$?B#C7-_!]<'0:3-R??U7',QZI!7;XR=V
M@ YI7M?#6Y(87J9+HJ(9#5L8K*T/Q,U;3DW(V(8/EX*\R>O-C'].9..#;JY
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M<^3,R 292!BE8" H?N'DU!9"=A$MY0*;]WV$?FQ\T\\G:#&(-S(M1DCPMV\
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M+EW,5RWHM/+H?HB-=G*@?TT;QX@<_58UJU?6Y+ 3[7E-U,"83Q S>NSS^?"
M\=SNR\4^F@'#3AK$3L_I78@Z5[UYJ'"K;\8^*' 4,$#U<\2G-Q"6%,AQ7[1(
M1S %<L3OEZSN?'2/AR9@2YV']>QUE@]5.C2T3GQ/U/K:+><EU9HQ>GQ,K8=
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M%>A55N"[)ZCWB/N_2M9"-'#R'5,;B'E@$8W;1#@(E8612J9CUU/Y+3YAB*Z
MG:_["6[\YA9<NYU>6:D%*RCLUL<O[L@3YY\\R?GC=SM\%3:+]1!]+ZB7?<MW
M(:8>:2MQBRKB^*NMP@X<^"]^8ODNG8N@-T7 2F?5.C'S024^*U&F)PGHMT*D
M:G#-*9VI#(5R[A13!>1E=;)2"N)8VT/R1#<=%YL(!>@4R5%Q[P,K70^C7$2,
MP%*BQN';=E"TL$B#9B@1;&^+54R3! *% E*F3 N/$, ^,[7PDX*%UEXU@B,(
M3T0:0?GMBL>:[Q#.ULM-2;+K.935_^&W!]"0/E<KUG4) ,8FTZSF=/Q>_5%K
M1]1J=E"2,0JE@&>KLB<['Z%N)*UB(B0;42JH,,P<20.BB AU4"Y_5.JCI.S5
MQ75NJ8#( GHRS7SV*NAYOVZ4ISK-+:93_5S+OF(?T7-)BE]9-2D9#'<!/)-4
M;YLHN:Q7B*0!S0*75D^5L6FN=X5@:K$'=PY4G&T%XCJ;9-0RZ&I'['QC"=[4
MX^U0]$PWUE&_#9@2+=>#2JNPK19EU6,!H<MQKB^8Z, ]I?WA/2^Z#H3%.I_&
M?7!=>O6\<??T7L./0[,K=K7TN+E@JKF=Z<C%DI<#J&NH9#L<^091G\N#NMRO
MM LY6:3@[F"*7VWVJ6PV9@M#@2JQ'[[![3>W<BC>WO!Y\:>%E7C-P>)1KY#P
M@.DI+>>BR;;>A.)MD"7 \X)")EJ".O)BG7[0A?0MU:]?3-OD-\T_KH06+@P1
M7%Z,37$X&FY7=:9BDTLBHDM<(H,BE4LU .O^]ZH'4'Q.EA4+(3D,\<6X$4CS
M':6!E2X[\%,.0^?92<0-DE/R&']8X@Z09Q< ;C!256(PR#A0'BJ3=V ]2<E\
M$:6"U2XOJ8(:W(:8NC,V*UF4E]W!@*OU5W=$D\1;+GK)Q,_C:Z!. 25%M@7R
M)8$'G*5%"\AM>%/!?#Z??A^EYN!:)3D'XE(7$1NQ>G;- +W#73T,J4LP\U0>
MP2>'H8^^!J_%)N SJ\!(9$I(/'6,#<\U^-8O*IZOYJG6+0V$,]&_O4Q='H\T
M>F6GI[5(GWOXY;UA5!6GUW"<R2P+U!7/>RD3]+:%A-B Q_'\'OV)[[QV<_0[
MHM7G:P,WF(93,GW(C3:E/7Q/4"*8BJK S3..5(86N+X%G4LB=-^!FJ)/30T/
M3S61_\>QPGSYS4>G%+Y3/#7("$@'V,*&_X)'O,*>8?-B#9!.YH-6VD/)5<X%
MZ\9WU'MNXS&+RH\#7]M4>TJ;KY&C*#!WL9.L'Z'(P,DUPQ8T>B AR66T2QN5
MO H+[;W'VD *DG?$C)UBA^-AO(VGG@0.&5;Z0J3CP(_T2!I6SW&P;( 1>56>
M]=L4^#HZRNA.TE9R6IWQDJZ]"ZB0$7N==!>%M<Q$:5L@-_[D;;DZ2-@HY"4C
M@#.ZBA,I68; <*:\,S3&44 =KW45IHZO\8S'\><;*Z=]/MVCANX;_](=Q_>/
M\1J:TQ9\&(:>/KSRZ^6CF@B/#WMK%]$G]X?;<E=\WW>'L:]/"/(-#A69UWXO
M>6_GY1JVW>-V^L#CKI-CLB; 4Z)&FF#?)>Z"]-D%Z"RF;:@VJ6W,5VCQ#,CG
M#[> ZZ91*D2-*9ZN@W4%%,D>UP6RDB+*TMM+3A7\**D*@5=CL$W5*223J14B
MC8J_;3E[<LX*_@4[\2F1OPI;_U.;6"/\40.@9M/CQ%HA)C+]UW$I$+K"![IM
M7^0L?3X0$2E,\E_KOI?F/'4]W:S*#/$IM5( 3V+54N<\A3AEX@<>G+CF"T$+
M**>"OJ)8*55F#95T4#0MB,:2PV^ )4XK)A.ES(#SY_1/OBWLB DPX5P&'3!;
MYB\-65AGQKI\GMOEV^(P=B3DZC._F6E, V[.&K3GY^4+Z??T-D&6_$K*)ED'
M<[.43C0.)JE;HU1#_YFQHY)K26KN@0"O-;]@TQ>+0NI4+#F1<,R:EQ'MJU/6
MZ-1?M0I[3;LV.&]9]7Q_3AWZ?,CYXI9X;NU4 ]W%[O6C^LRC'N]-6PRH&ZV^
M!Y=MNMWD5U.D7:=N&T:=K?AD88FY8]I,J>;!&7O+(+@<C@&+%.NAKLP)NO+/
M8K7^'\PFS8;^$!EB(*RV\EA\E/Y]3_S.6L_:]]\.GQIM33J\?;;RHTP9SSH#
MRB<5*1EI-S117S?D$ 3\;F6:#=)N9&0&AKW I[2+M.OF6A[G%F#>M$;&F&W9
M>/'[KQ+W^=D8A-MFE8C151C]W)]L]'(A[K$H;O'WP.\]TZ+I_[-=G/'3OPHF
M<G?NT-OW)RWZB$.YU:TU!L:.S?7[>NOOS,T-9]]VKPQNJLWOJ7_D/QH2$ZPQ
M@ROFH?3;2<$\#;<)U-U5V'8'?URDR+=%D<]*QYG-K\(FAV=_+G^^^'4-)TK3
MJW.WA;._R\YKG#12JP-A>Q@?/J(T4=3".&J?26IOT-L_9+"S\NLTTF009QT2
MF'NGFZWDXU.BZN8[^NQ?L\,L\2VHN74%,]L#IAP&+5/E8C9-- ,4'T11E+FA
M#8"OWXQ/;5X"UEX7.4+YU%@@"I;UKNU*-B@:VO-H-UK/1:Q-Y)!@Y%92(D8E
MFI3*U.HCQ#^#=-IEB"')H9=CU=F.]97EW.X0Q_\]DH;1 LX'MRNDH2U&,M=D
M;R"9=DT^-H=K_/T_ OO@AU=#QC<#8[4<D*;[NW^>;Q>"CQ=JZ.H>]19%)[R[
M+@%65YX*-WXH(.\_>=I+FF_"_[23C=^>U77MCUY,5ED:B%) [R]>N_<C2!AQ
M/M_Z=CD?_>+5%^WJ<K6-CZ\<L#M?V67]HJ]KX$S%V:+CV=)],)6B5=@[^#<%
M[[<[_X1&%HE9QM_8J#/]3QL&GS9E[DE<?GUR[3$SW([7/=O7Y%T8-WKH8[/N
M!F'N1F:IR+7\HI:"P9;FKH@/<S=C5<])I"KP=1,"EL<3_MDDUX%'%1O/1&9,
M_.$;>U@^BGARYYFQ*W9[U]G[SP=SGOAD2ZY'A+RU7CA:>M6J[EM.J->MC#^X
M?X6BG$:?F/23KIW$</S^/9[0WM[._(,=%!C!Y,,:@PG,\2??-M]*>89LG,,\
M+\@KPKWD]ER]$X:-"XS<_$^ C_]HV:"F=TV%Z]RWAG^TRK(N+#M/[30^GQH8
MN [1Z[DQ@]3J3C2B+!![];:1PJ.=9SY%LH]TV7-^"DRMWFJUD0O-G(\8K+FK
M,G]NR?0N_E /,9HOM?92[ES\EGV?X2Q\^\'B:^[NWQE&UB;Y24XFY[UR35[?
M?%2T=S Q_6S0M)Z)A]O?$QN[SN\RY*-2#MS_Z1$U[3RR9Y]SJ<G9)R9>H1'I
MYW<=_*0<V4G=QNG(1P >"R,FJ[  TE8_B?Z L+FQ41SV*1];$9K'1.1-?E2K
M)3_W_5I>\/)W8&>3TPYC_X[0>T6^LZC-4) S4/X0^Q2*.=&_Z*[CGKEK8)%F
M\L%>2>?XZ6U5WI_O:3G<8D]>V7C+=T_#L,;:1P??*Q5!1A3&.1O%RQ[;,_ZY
ML^[;;?:+J6E'CUBP8&6V)GG_Y@):Z(B-4_:WI8@0!]\/KP[>V!':^[BGPD3+
MQR-JL/1;RS2V$.T^2[B-Z_3SZHBZ^3_B3H'9*NS0LSRJFV7[C\9/@8_/M/6?
M/IT1<DPSJ_/(VU:#EQ[( :KUTBWCG9<>><1F/UF4)-^"B98[[4I^.[(PLCI'
M#_Z3JT_03=G>WK?=XLW_S$OAFWI"_Y.'(P$*8G?"!=P]5 VO:Q66\<](F72R
M'94\_C>87!BX#U<3@(VU($?>><8=W[;Y\\C7:<J5M%^GM^N_V>]I,Y1!BYN[
M,]G!V@1A!(B[DCN F*U1OQR@!+(3)6X3\B3N,^975J6IIPFJ/(PL@>Z^C[38
M77^AMK)Y,L_[DOZ1;32S\+N[P\P[N.X6M)$[+;WOR:,#(F:+])&AM%"F-4ZX
MU=SG$,''*+T':P3>%;;)!+3 EY[1I-C>T!\EYP<[LF2W3 O<C;\-?[ R_IKT
MX@BRBNM>QZ0\#3@6&.7]R=-42<B6HY0D1$IC\?4@EPCQ)7P^?P?O+]D&/-NS
M4(2!Q@ RW^+>! @B.I &MD1CL(C>X;DE1#LE]7NV4_WKP6&X4OEK![OPHLA0
M<SW!#VO2&^8& D;ZR#H=]8"I#_#8I*15F(9#-)^4HJ<*<.8406TV^M@+;/%V
M"'NY(F2%],#!K;3[)6:*>SM1BQ.=NF2?N1XUZSOFYL_,K;XG=C@CYK61$S&*
M2+W1+U V'W-_L6>[-68MY-)V6[L^/[X:H^O"ER4BJ30\ZF2ROZ?W8+'_[C;/
M+:'94],Q_^859',?*SS-:#O8<+WH$8_5O2+N[-4+TA%W1U<7N(KF-L8/CY6N
MPE"$("$IXS9&5Z9/0 \P]Q-<!A@H "WJD1:BKM$T)\Z6%_#@DJ )1!I225IL
MC=@.I71P;Q1<:^"R.]R#+D)3-*CP./@W(SG>\K@<EI+Z/VG=6%@H9WR 7 0L
MLG9#EDP/WR04)8!-9&[_J.AUGQ% 3;TAL:_"ZT_(J],J)7D/.*P56*8@$5CC
ML!M[ %$A54V@$W_L3--K4%FH,^9^,8$6/U4E^X"HX3V0.80@:IF- .4$"QI[
MUAZHD)_A,]EQQO=]S+,1WE2Q'F>)K.@SW0<A L#\Y,46Y]^N0#[9X1B?ANX*
MT.P+1[UQ<*QN+^O<'J[F),T@7:5%>D,<(0I.L 2&J7&@\"28?X]HQOLY;@(6
M#1>^G%KYME N.0[([ET.$CPL(=CG=S3T->%!XHZ0<<UF4*\V&P,]7+ VY\ R
M<@I=0QNF2,Q17RIQOKUE%0;OW&L^U^_Z)^!3CQ4S%D(_)UP$$7>9CGBO(])R
MV;YITL:ZWBT25!]S$R$2]*;R;T.MH&;'3:<7?H30/N)&B-JIH6V1&,(G[W L
M+Y)W2Y*>B4;#[8+;9:@TANM$966/ZL#Q(?('38SN*@R+T"3L@?8!]LX4H9OD
MTB!REVQ 3P]*#0H#U?B<]MY,XIIZR#0,GD[8.@%_@-E.>B7!39!4L4VX1(+G
M1,O5 - V(<K]*$?@XQI(K?MJTQ"P<UAML;"- GB21RQ;*<J,.T"B"Q0FL&<E
M\[9XM554XW%="&VB ^%PW4 98$:/F.A!O_.AD)F&$-D;\J7CO<YKV(YO'Y9I
M\* #'7HZG-HQ?<S THDZ<\3)XN[RX578%<L1; =FH\0:L/2&'"_QX 0CFJ<
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MHP.6M!\MD#V?KH+?[:DJ04*XRBE**#-OV T$E3I)VY3GOMU&C7I)CKY-MK]
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MTZ)"[1P?;B5;FCVJ+>6&^/1EEEGQSB\<+5@.7S#L\Y,> XUF(\1&P0@EPCZ
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M(VA +^D9_BH;72-! [)4L2.-WJ$<TU9@X*.^R-S9O\3;@I__A%H_$LI4'UC
M643K^'L/?YVZK>]VJ^]S27BP\;BOC^UYW;KZAU'38R,2U1#'0[FV>SV\1)G-
M;RMYOC;9#6XT=#::Y]GG:"ERDSXA[H TCWY&'\7J:K:AMEDA,N8$) U\NS>3
MLX1*;;**G(I%I1.P0G_2N>QSG(4^:\2K8WIU+QAGDQMJLW;"'H@MDV1:>/M6
MV=]0F5 .>U-A@0+/3+W=P$(:<^<T/"XZ4J6A"@IZ)].%(OCB+V$_BN;,ZB%4
MVXK*/^95_:.?@EFUX8I%>Z90A9E>PLFYM4)4,JJ.U;J0P5)S< (1;2O463;@
M)NPBAX!*7;P:=J;D,K\EKH.'<#CPW.^(&:6&UR[/C'BO5CT=3A0T9^VNR9=5
M5A*<!A</+F^47,9GY2TM8.K0<_?$1PDHZ+? 4D-B";4*"BU3$.M0(;@1W(1-
M [#@,\B$X5'\Y+>L;74+]U;@'>1U\.0F7B+AHOB$Y#(8]B,1-/4!UZ>#EBX@
MIPVQ#A\[Y256[>[(DRF"9DU+QA[AV07?0VVR<4YSAZ8\_6\(/8H.!1?EY&;'
MG(GTJ^6&O'A17U3;YZA._SX0AWA+5 <TVQ?N-Y&SHN-W<(,U>5K(W?#M^.(P
MKPN7'(X)>UR.?298;AN."+7=QU;_+B/SX[6'=?7=L@X<\-%(X'T,*<:80O?$
MVI*_H!)P_X" D\[85]4C>&B;,A\M=D=TZ9GV.1@)1R3Z$0J]21;(W9#;T2%S
M@J.P0F(='1AHD=$T5_85H&7FP'^TX[;ILU$3SSG:@91$UO7N,9])C]<#LZNP
M,/K()U?ZDDZEFX[ISF+C9D]D7&7%L^0O1]^FEA6?/_SW2753?Y<Y-? +WE-@
M.1L2P?=,\U')!R;9O-KZ1N"WH+R"BD5N;P8^O2YW%:/DF*"2R,^,PQ3AUF>:
MC>_[+$%%4YVHT['68Y^H"DE/R!&Z$Z^;RSP]?"-_-L;?F,-R>TY*8UB?OE4)
MC5K..YR2O#19"AEIGO]YL)?>-,=,"1*ROE!%1"B_FN +:CY@V O6T@CA+1"N
M&AI?A1T%J:F+&NE=I U5<S>("(D3T!S,S7R#=Q'LR2[[$LS%@Y04[^X++0-6
MYOJ>+8V/S)'<\1+ 9=9%;$<X&.=+5X3L?G5-LP6?*. 8W9+@*7 _^^NWH"N?
M'[>@R!8Z^DQZ#U(I9X9P44KB%]8G%J@VRQQ5VF)?U<,2<H^RCI#*)I-]V&T(
M.'1,]!)D)S ,Y8Z7+F_NJI_+Q3902*G$>#"Z!<OGO(,_(%H.(.'!2(UA!\R$
MI];/VUS2_:<#BW&F.%67Y].VW/K4R]:,3_D%CZ:'B7%\%C=%1.N7;7X/VOI*
M2R6N0MT8P:1$C2Y*A'[4KU 3B-M_$G6A0-!^HMLOI'@[2&IWMVT;5WLS9$:C
MS_T[2/!]"K5? +_G5;SL"!KXT6\V%@5%EAU\Z_4D$#^44*DH62SSMCHTU!\2
M^9Y]KHQ4$W:*:G_RW-!\F;$U5@R0[=.9F?1(]SJ?EC"Q_01F)&ZBH5V'#)LF
M*@'MP<LH)9DN?A7&1R>&&PW7V?^OEOX7X32(2R%$"FDF)ZIQFV/VAP;L!,*3
M")8+!Y!%(GV%2EJS7ZOM9/Z<B[Q]N:!FAPXB!:7"5+Q T.LC;H6")M)DO5N-
M,I98:5P$V4%]XMO;8(.WVJR$Z']I,BM\W*QJIR&EG??@AZZ.)^A,P5;OH>_(
M#M50E8B%9"Y&=!=" [W"%T#07")=UO>WIW@CWE1$;8):C)*9*N:<=_3498PJ
MX0"_8<#AX/@:P)R<7(74(1P'<A?2)"Y/\?9L$=&4PU#' 0L=*[GLM*5NQ^LA
M492;TA)2*"*5P]PK?<U  2ZB!++K&^":W!G9*8RM LL-%R'++@T*/!J1/KX/
M+"\4-H]9\:9\RLFT4*XHK<#OD<],_W3],#GLJL$9IZV/]E9'Y.C<_OXHX^6Y
MK/PT<@L2:Q]7IV[5C[MH:G1]Z-#[ 0]7&1CG/(J.+NG>4(85?\@]F37'?5\Z
M+V_0RT@=R'G@G=X:P/.>63BUY0V ON]@S3=U&_U?AMJX+Q1YHK9_-Z.85ZHV
M9OZ_MWG6?\Z4F93E_!5W^L@G^,EO#DK\T86->+0S\*E$"%?'KXB=7J5[-H'Y
MF:/MO0+6UMXUT?%H?](F?%Q;L9XXOOW:1RNRRI2&B;I32\Z^";W&<]6161'2
MX(R<['B<U#'=%\ORG.;EIOS?339-;<_^[P@VYM Z&@.NKR#^J)_Y8]>^[+=)
MNVX>:%;\,N4=-BZZ>.YXF6_%[4OWP_;QZTO^1F^^LUT_"[9S\)-*J9'[K8!2
M(X4Y36O[3VIIHH<#!3OZTPN:&.=RASX7T1;V?K"+="Z2ECY_XE>B9/7GN[IQ
M6P\RQ-2J'X4@!=+OZ^E(JPEGP&.B_T%SFZ"N'R1=?,F[XG5 V>_W>U(F>/#@
M62Y1'.<O\\'\B7ROVQB<9Y!COOCP_<WNG=]68=<\[Y$4'>*>2[#2'*8M'GYT
M"+E3L@5*I1\+JJY[$U)LP@2NUUC="M'^GE>SP7=DI[-IS-K:_+_9V)<AI>S4
M6]*&>PX!J$N]W+5LQ&:FL9--MMA1$@&Z<])E6H2CA?&?4OD8U?'[Z5[_/?/F
MV[ZV&Y>*KJ5MM&S8,/LMP73D&5;YJ%NS'D=4#Z#2Y*=WH9728/GNRTY0I8P?
M;S-P FIX&IQ=]E4/"06#SRT:@JQK.?O&D/EA)J-^'^O1MPHW6-'.PS!PAAWE
MU[B:^?OA\_D1Z^WW=O\N-N:;W8Y/ $U-.D]?S(K!F/:"-=2"ZU":DD+J1VP[
M?(>&;W%@[M_,OC/=^IB-=Y]$A$9YSMZX3:)<B:P2)M_<X41^CS] WI^EWH4W
MI5P"HX'M2+<BH%H=S?^THUUH/$@]]M?T*BP$A&^,6!>A;GK%J.-"%0OQY S]
MZ+D(4$A;HJ21 (]5F/I4K&VZ=5&D(&:6+ CS4#;U #6>UH3J&4#N\7%6$1>Y
MO&Z]/SI.>I<W-/XR<.IYX_3WWZSIKL2JD.*=_;/6+2JR473?$E8)*[7WJBDX
M-$>_0=>_6%6]\^%&=-H)W4+\IPL.UU(R<_#+]PF!0(FH'#H9K6,YR]*"UK(+
MK.KMRE/C=*R'G@RT5=YY-BWZXVHEQ;D5)7<5G[A>GV=</?L]#;6'CUP'N0@1
MJK)6EF88*0B7%MLS7B;W!*?!\#V0$GC@W,7-2/A@N$6#^P0M=O[J-Y^+7]VM
M6YZ\>A^M^"7ZB 8=%Z*7^K)'FKNBHK2OK#7Z%9&M@T;P>U7;<AW2]^599,;Z
MF:8^(@\!O>HF=8;H^S6Q0[D[-"P8N7XENEK?H8:4MI,Y)7]L</?R4ZU^&Z9V
MO[@VOO]F84>UP?L E4.W];-N?CF9*@1O=M_\W-;7#G:YG<R).)2L"+^?O])S
MK\)A0#DY#^NI;C+>RC]&@?92.WI)(YRVX_&H.@PP@RG]FSS^+VGDS)\#I$QB
M*&3B:BCWHWQ"P/^*9D+$* BI)<H-O,3YV9MJ&W[>?!=7YJO_OR]YIUZ@2D_W
M)IM]*(F=5-HSG_%ET]&['1/+6EH.D^2X]ISO*0).T!U\*OM\R?J"PM+?#*NK
M7@_++"[^.N1UN^[$P<'$'*.-*,7.XU-":'W1B0^J*8FR'7L;VT[?]_OE=^UY
MV:&XASF-_1E^.87NQF/[Q?6=U[MN'DC+Z-82?T40]/:'-H^M/_-KXMK\YILW
MF^/"C-85P]=FJ*XQ(-#%;L2A %7I$ZL>=5PM=A4F;Y3.E<SR_(G>9.:.YN.@
M!BLB8O\QPX\98>'9'J_JOSIT)R=_+_NG2N/SUW]OD]]^/'"*M;?=<_OC*Q67
M7KTJ,@EON<WW.(\=/!?<7SXKI?G4%91YY")C'[T<W*8S")E1C'L.)NYO_[[=
M8CTS\/&5,N.!-OY@H'%7T:'A2I\65]>S;?S@/JI='8@OR'E5&]+Y@18;:[24
M&C7ZUEC_X$_' Q#X1U1Q4_%(VKO^Z(WT6C&V.3W$7.^'$I9:]S;P #?^.?>0
M'M<_;>U[I<:,5QMV)+2>UJU[FW*SM^+?28=+5P_]C*^L5\L0;NQD^OR3=")@
M?_K-@K/I<L?('7 OS\GE[$<[#',K[&Z]*3HT>%]0MOW@A]R+?07+ONXF_SPY
MEQU1</)TSE/AGA7CYR\N8ZR(')0* PWB1%>E3XE:>(UY)8PF_C<?G2FQ?EK7
MV3<P5UVG[.74F."HNNREH./^AC/TK2^\#C:Z.!-V;KQCWWK^8LM-)@HDIQ!U
M\?:=J[ M#$R\]#'?\R]\9 "8_Z!.TSN"^I.HTX^K<_>9/@C03=F!"NTFAZ<B
M3',2#CTV^'7U\<'*R.C;/HZ8[NZW_I56U3*?^,GO] P)+A)<A;U#J1%0_UV'
M-H:> 2P?@#0[!![C2YB&X.3=6@0,&Z RN(2#<WVG4 I,]8LA,>A_H)6N7S).
M?.=PD@G>WBWEQ*N6 0N+'RT)!J"[YSN$#G(=00]:FB IR3DL$[H'B,\!Y-G'
M%>WEKH)5F%XHTZ"/OC2F;8_(TB8GS=?2CG+8=L793WU#\M3P5/[DO:4PT]-Y
M;H4OK"Y:];6@%UT$G+GX,.!J.P5F3=*46(%;AH@'0E>T\>0VD<_8?6Y^:Z_"
MUZG3H40C<"%]_ =WW%=J](Y&*@\IWI/U@6L3%G1:K-RR-+BO-1)5(AO ;)>S
MTA/B6LE)B*>9C&;?DJ#Z)H9N2"Q781LU"OE*8:&KL#-#M7-_M7$GN[2+JDLN
M\VF.%M'_LU@@'*OPP?C\7(D-" @(:\A,J-M+?_,D8#2,R!KZ]TR&T=[Y:>/.
M,8*)VGD<:>%6G%%SG4O_Y#?$;!TP(,H#>SBSV1.L##O<'.(9P0[PG#,2X[Y.
MB[C#%?*2*'[D;5BLC+?L6(75F.=G6:+XAL,.3O'\C0K2?,EN;^0NT*.F<KM9
MX?%A>O7U^J$P\@.\<((]!Y_ )8J8"A#NF>QS\5]0#)4XA*G;4P=>44:TR9#0
M/<'8L0[F7M!2Q&GMU<#?8K?+'(')5&L,S-_I!>U[5LGSF;7MHI7^,- C5T2J
M/<FB(S:Q0LEIQ7N ,4ZJS%QB AD"GS@RC=ZVWOLKZ\;5I72&+4@YP5F"ZTZ+
M8O=4X% /HCR3BG7)KN!M<DS%U.N?R+^:ZXN7NSAV/8PMT[+M:=A$VZL5I-8C
MJ[ KF?K.0PS7"ED?3V7.RERG4YMUC[Y$GK-?A;UQ$2S ?7MCZ/CK_2>JOA6L
MPB[VF=.J#8?-:L%# Q]5RP2=5AXORK9->Q4LWPDZZK'7MN=]&O6\TXBCR4&Q
M4=R445-?HQO7U* D^,KELCI\P?DK90,^%G5/Y^J,:ZN&F%IUD+L8,QV;,N<D
MM+=4E9P;1"+QEB)U",7'C?0&@,B22+YE2@%G3E& 2D)MJ2+JX],L%2YBT>-J
M.#UZZIR#3N +4DC/BRF9SM!\E:1BM+>)I6<.1+92:NL+Q58$KW0T2_I"X@7T
M3PH6VNS)6I"A@[+\I";SM)\!NKGS53P]+_YKT+8#HXZ7AUV'(X;C21$"IW[K
M(E./O5?C-=O?_\B:YW-$V7S4G!&@*!Q^+72'3[ ZR>LD+L-$O:+-T"=VZ\I'
MGP:1GYYQPK2XG:-\,RFL>K'EBKT]&/ARJF'_5+Y=;I+T_O+>.X'QUQK1K#K,
M["@5JA10$JQ1&<Q-;T"75O.M#!<0Z]8TJ+&1B9@J]BB,5U].G2]0J.T/M]S)
MB6HNVM\6PA^T%#*SL$IN.0\-*Y:S2[-S&L]I5',R@OP;QVB%1;3*<-U';R)N
M3>8$9(5[^YC:>>R@8<X]B1KR+:+%_V"&2^_5TF+XN-D>T/3,L$0!C'%/:Y>7
M@;T*TX4BVQ!;9GL6_E,N_&$H8=(7>-R<X#LR.60M)9VJ3]8UFK--GK]37I<P
M?=GAUM]_U"80;:31@8GE3+0 _8!A!#0YQLBQ(@BL/ 66L=L7P1NRW0"'C=.<
M#C@(20$W^;@ZM+K37"L[3+L;+:Z#LB:96F*67GZD&N_B@;%L;_*@X )7L)9S
MN6(37X+A9Z*]GR02,$!L(AP3&#OL>@:U"<\6[62!3A][@XMUM"\W)/IJCY7H
M=U=,J84(ED^]JF\:M#X1MBAV2_]WWTYI#7/-R29RVH"@MXT'G1TFK:W%9:6"
MKL1=1^R_0EY>X*>&B0,5;/Z_5GB,;&MACZ^+!E(/S*4\J-, $0_H%I)#EY_N
MJWE3>.9E3;31H5LCSLLQ/EP+]^7_C[DW#4MJ_0*^:30SA\R<E<HI,S7+(4=.
M>=3,HU2FEA.5F5/(,35)$<IYC-+24Z94SCF0"I(3.%N9.6MJBH!F#NC>I;@3
MQ,?_\WY[K^O]_G[@(_MBK_M>:_U^%WNO>\Q2I19_(61LD?" @;S_\H] EY1%
M/]2'/UV\Q&1C#?7W"IFR]3= N^8_B, *_4[ZD9>$I"G=NFJ/GULP_WR^64=(
M63?;5C'O#<^APGV]M;Z2Q.)B[,1$'NJ^?I([;'4*"N)<AAX RY;ZVW [RTQP
MGDY,#UL9.X0<$%R2[$"*X <3V9*I.:S**K[=E']]3[FK>Q#D34A@ LF3N MU
M(XT&+*YL5Z=B1+MAP["G N.2QF8CX\[U1B^^,81IF[*B@F$HZC;<I!NBXO..
M C/W/'^V\ILC+P\);-"52-UR$U5X4U(Q+S0@VY6W/A)19C*Q5.Z*H.B[%.$G
MX-7&9!8J66A>O=T?%7NG5V+7:Q7].B2EC1LPF +(ANIU&6=2P%P8-3&PYA$E
M%UXVSA?-3VE>;0*:-I?<[&^6>D:GK%7H^J]TWR='K>37N$:_%/"?K3+[H%T=
M[L5<M]>X(%"K;3*H%:YD85V..P^!_ ,"6V*7]VY*7<XT+5$@QV(>P%D!-*YH
M )IL7+ROWY *]B;BKD>70^<,5S\,42IN=5W^I:>K1U:5@+>2:DB=W:DJ%QV]
M,>-BGD/_.P(N$4YC/,3K^]/UP=$D/V MMVEXD-QL;JYKM7+I<6^+V^G41:Y^
M2WW>?UDU4_,FHUGC<:,'-3XDKNWYWTDC8X$3KI +BT],SQ.GC-!-_$<4Y]IT
MX9<;FZH8H!6QU-&R*+-$R=)I0"E=MM=KR.?#X&HRSD'OJ6I5J8UF;K%#Q .9
M/C<U-F;"8;KH!?^\P&J[;9QA>TEV,F0$+AQQCU8K/4"8SKZ@NZ:?T'8!,*[B
M9#<-<S6H=8FN3UD#Z-4>.]OW#"_K?Q33[C$/N\1,V?3T<C5N/[]P7(=IIWBM
M7K?L[DI*W.JBK65[P9LK9P+!&!QS\@>5E,N;L*F#DD&"[6:!(2:646T73]\I
M4-@L#Q./8!&6RO@(IL"PB89)CLS*]^7TP#OKX\F=DN)8DK6JWD"C+JM7"FMM
M/7 RTRV'311HT%0-@,Z&M^X0W,FO+]BGGL]!0OI@))/W> 2O3UWOZBYM=.!C
ML-W-;AO_T U N$ G!SF6Z@4YOYUHZBF.ZUB8E[6"6VF:R)E%).L>);H.4K=@
M!F@]W2_WVDFE]:0.R82-O15L+SD/\'%L_L+4X0&<0B7T=M25[FA*J=!AZ]64
M0Q$M;AMQV9WC P;L=$R;^]?THIKG#XQ4$$N[[N;]1<BAF^/'&?OP.P+R3$&3
MY+7M?9AW$/*=)B?13X M P(;:6ADA,]JI\,=MF 2_E;[HP^IJOEK@!IQ[ED5
M&+:2F*/$#RQZEM;X?/:"7UZ_]\(SGRLNRJ3V[-K"Y) &[GX)XXL]#K7$$WWA
MQ:::TS.%JJB:E<NE]B;!Y''MR2#??E*J&;$5D0X78_BAQI0N0,[3Q/$O4"SK
M/A6,16[!XM7V$(E<0Z0,SKD6*C&*,D]'L1&)N*"@"JS$;[>$2<H6; >4W^GN
MET070[(L;PG1;DY5NYNW8(,5:96\/@NPHG&Y5+>C_G--(;6]5#G;>/'T'GM<
M3F*&\5,7E^\&+G^=UV^E']B6EQAA;YXFU+L%VQ_J!=Y_-$TX".5:'6X#4A#2
M0??[IG#>J%2"!*4WJ5[9W?%5UB5QV87CX0$6"'3!PGA2$ZC:4.SM_M.5'"55
M37J_64P(4M'A>8XB_*+UW0"K"G:%&">[TP$9']F;1)F\U>U(@[R*O'Z^I)-#
M0!&/JH;JO#F/_I,8"M_1Y,K@*@<=%:19@!&3KYB2-CUQN:!@/-@@!FW_^ZR-
M\[W@25^Y*.X/JI[V[T^K*:4] U^=7PW=G:IUOKB9[43RU;G]?M>;K_B"IQW:
MX<XQ?VV,MBG*<3NF%82&PJ'_/:#I56P'_&YF5G?&3SOZ;7.9(NXR.UI54A2;
M,-?A$"5++;P6<-YP:'7,0KMTPL,_%!EQLJ<RD#;"B_2EC;N?O;U T9^PFV:V
MGP'@+I E6U=NNQGCC0670%IK%Y@07UZ1IKIG1" *D+N8,E0B9!\6?;'5TGV<
MIZ2_,]=LY?S0ZWZJI9EEJ-/(,EO8W4VEC/#^&*[;K_H0V^#(WU:,W:HVAW\1
M'Q&"]<?,V5Z,Y$J<)#C:K*H6VT(_L@WR"18.N@G%_ZH-AF,.!ZK9 :R]/SY/
M5J[F1KGJ%/L+CU*N-UJ6>C5>&E_(L#]6@8(R^7[";H;(DM\071,7!)C$EG,%
M#][ASF1XH:YD2%F@7W^;6,"K]7^4Y=;"Q;YYC7^'R.[H>I%XGP_) KMW 2&U
M&SF%W9MSW7"3;Y45X1=7/IV9W]"9Q1P4CC#W"7:$@A'.T L.(Y$N!B!; _#*
M;02V+/ANT;UB.ZP'!6931_K11DC1Z_XA@9&:;TI;#S:J%8TAV3I;,(6 92,E
MI2CCZR<72:"=0 ;..P4@XRQ$.<S#PGZ4>!ARG^"?02-QO^:7DR.4'Q/MD=[I
M47M)9.^Q#I4:;VN11+WE8ZGM"1OC_13)*?J[VM+=7V(#O#=U":_\C+9@&8,Y
M$_Z,HZBK]93QQ;#B?>8>!/R_Q)P,ZIK5IX)>!361OHT\F !+SF/X]XZ+(*%=
MV[+^F\-E)$YT;:!B5L7/M+N.:Q(KQN9[V+H(YV'#)BOM<J,'NF3NE>]M[SJB
M]GR>^%[X63\KI<@F) ?-OR'\,HI0TMK,>0.-3IO2STX$NKE;;.^SF6%'1M+;
M;=*-DCS8FT\)_2LK\9JB;+%/64MA*HDV^>UB,/K(AQ2%<;D[LY\S[XTZ6#V9
M(VBH-GB#C-,!B"JN51?AI0>FP;MX8&;ZT./8LP*S*\'RSK&_I4143D=M1(XV
MPP]MP::+4-5:;>0X@I+0X)O I9]^%"+P</5]=_%J\_2=&5Y^;H/! D=VF?[>
M>7&T=(>R>T*F<5VX+H5^;'!J_7R,E[D++4-H7J90,>K3R:0EMJ(2Z$; :&QC
M4,E\B"-G"S9NT@:O(3Y<%NBS=[%+?4&Y%+HT%,K^FEL"_78B_CUX&]A=40BE
MC!RG>*2F^U:6!Z\Z7@^746R[=JUHP+-G?C+HC[CFA'T@#6D''E]CNJ$EZ\^,
M*C^=*/[]VN]#%^?E'S5V(I?*-Q?H0_9L_31W8KNEE@<P%0]PV"8=8DH(B1=D
M*ED6&\KRFA^P\+0PN7/#I2ZONUT<S1I3S_.(\D!?^:5?^]WC>L'HY8 Q_-BV
M8EG^H )^K8,X+R#A!7N%:"6]G3+I> 7(QV5("3E,[9'KR KQQ/K..90<B[U0
M!^I\'?&6>S^B^7ZHT:UT8C* KE ]O((.?OVPOMY]\I.-OU!+VY8)R:C3_WDV
M.&Q>MKW#BFC<=W\,-\HV'6RPC$[B.'R:ML1E_0TR.E>2Z(H0AI5,E0]+]4*V
M1]QKX6U>G#YCYUM\;6+B>V!D?*MMAN.]+%<WN$^,6/)RVB6/[A,X 9.&:)O$
M\-Y#1GQ=G(FC2!>-*2.4#"*H4.$J[M" F*6<'10JMX&()^/4@OQ>+[['G1MJ
MM"DI( 75I%X#AO/BWR11"5S+*VSG@DZ;4F:VM^O@_!W:5%ND3I.<P.0/*6R]
MTUP5_Q\'[)VWP>6";;PR8*Y%/P6^DZZT,*4T3(6$^HOUZ:0D@4MQH&)X7BJ0
MV=KO%6 EWX^+X!R\WS+39V$-GNG BT /?'@!1[,LK=O)[_YQ[[)EB$Y@B3P2
MM&N:F3HE"^UADU.]1?J$!M# N#E13& Y9/3Q)JA:KFGO/G"8=AS-Q5!M:/69
M-H/DR@JJ>*".QPM*=U )=\Z@TG_,P</D,R4BF$>M(#2;48?5F?D37L2HMW2O
M/@*:,&;>O@+B_$D4N=:R$OJ.EI '8,PR1G9^(SKQ45BW0UF.4A/&=8BJ21DL
M!-9JW_A&%3JR5<R6U_]V#.[D6_,)O(K<CO(HU=V;%0@__>1QD8>-CM/P5+HD
M:)4.FG=D3^T";#K25ZL\@ZR,!@WKJ$W6K5<":%F\\:),MH.NJJB10^XA]YK!
M-7D*+P:L$*26^64-H*D!7N[KCIC[U #=NT*6"1HUPYR)/I39$"QAD!$ET1B-
M+203&_WX>&$G0_(($-_[&.%/2LB3C^W*6I>;DLYV&<G;MU9AUMU.LY(8"O>X
M+]L[,V^&3$;K&>8&76V0W< GFXD,+]^]D:50T(.@D9;F;H+FVY'V99,4.J:[
MMV!C2DC(MU3@ 4HFNWK Q=U;0.<+PC'@NYDED,YT;C#P## +RY(%/D5'503V
M!43:T(M#E&1SRE >URV=W<^:)8\5$D),K3X65%92O4:*Q\/<.L=7_I\*W-M&
M%,%YC3+\28G;ND6"=[.5,")0%F?[HHNT*>EKMT&GG*"B-A^]&MDRUH?*HQ]&
M*6639J-7!M HKEOMT[\R+CRK1&"V?V%"-YO6CHD?SVYO$KM(B&?6=#UB!*P<
MQDY<HM,2FZ4$)\ ?->]^;MPI\V6CYQSI+W<$O0X\W;9[EKPD"&!]H""YYG^6
MR[FD[!SW(JI3+\%RSW!96<',\/" 4\_*Y#?^M>WJ07/7Z<;+"/PA'["M>2.B
MG1@G/-UO$3*=>[F211NE!&7['VL:_'$JT/U^/CI<G,HCELYGQ*H6%P7)UBIF
MD32'&FOB/XEQW!%<%O](T A*UDA7B_<("HTHPHD/PCVAJE)"D"/&9[IGI_D?
M0QIX>'-XN$#*&QML>5&A_ XH^USSS5OKT -5#OC'::\CS2WYHD;J!52D'XV$
M4EN\]:_HZFZARXZZM -/ONV._?4J9'20:#U%OS[(V.[J.M<A!S;QL;M?%R-Q
ME"0J4&*_$(BQB0IM[SZ.F"'2WD;)#[;)R1+\% OJ9X%AP[)TN".EZD/=Z,EP
M+YW+_?GT]T/ERW?(0"BON$]HA-L'$KH8XC^#MF#[: E4>.K]\:NR>4>KA[F-
MUPMQ>O1A[M%1P\E;4YWRZ*5&IY=NN8'DH#/S)/]KE>[L:]].K3HA?8,87G*D
M<Z1KR1QU&/(L=W'P<=/\PL2S4_(B D(%CNC#=_:8^H[ODB+'!.=CQH7K[C4U
M6[#DV7(24-F9#.ATDA0+,B_='HR!B%P#""$\6,*A1I\LKR]P?_\ S?4>0!IN
M9F^+T(JR<,#J*(5!V<P-1TC@I$&'Q>YIR91Q3 =C)\1LESWM;SN_7;^%Y@+-
M@;>#C?: G=>(]%?L2<.CI5C>RL7AOR-%TGKCJ*5[GNN4390Y"IZ3_VS$\[QZ
M^]S];XR-A\;&<K>IE;R8 FVOXN8[^EF<&33H!X1.)RX-L\CIHWV"$U2HBCT9
MVH&@^"4(]T[XUUN]8><&M1F;!:>BR9!DQU.(Z/QB5?P\!T?;4(E_:MP?&''_
ME&<A]QZ7?Q]+[II2ALZ%\_7Q7_$&T"('F4+:+3C*MUGPE@&11)P*@+*!_(":
M3K=L14PB!R0^#O^O\?+-* [ST**97W(8:1\6V69VGUH46 W9M;LG-+!)^W]>
MGG]9661[\>*BR\^1J?R ,I1#&=F1CK)$]@OR\*ABM3P"TGV'Z6S(RI,@MF3*
M%JPVGM2*B$.("4\$,?;1-5M*!7:@:G+^ D(LO-O1_!ST"%BQY9_;EH58-EG.
M_<]XT7^&Y 3WJ_<6QP<#:.O]BV8&-#JPV;,JES5@3P4;>/^!Y+A&%Q8CGE2S
MWI*\+;KD5.$QX)[ B?17'93X6J &R,5;R==62<070^0.QD%JCU)[J <*6^8>
M5:'53)<'UN-P]F5!Z^-6#2$EXB)_#013.VXQIJ,3>FGJ,:?^4B;F6)&<5A\D
MC]5T8D4$9OQP<C<JB0%<SB78 <6M2HQ$^(Y5K@?;K1V>Q#ALM5T;6.0N.%%5
M!-J# 2*ZX'LI8DT^78HBR59'-!-!ZU:\>H.FF!U '8V;&Z)@9'^:T9^R<[5<
M<B[495RC/X1N\KT#4%(X40#>54^,"<>(S!.4&B^7X2R>DJF;DAXU */=7#[<
M;3 L)]K#5K(0ZFH5:I':Z@56*B ]-LRPYYPN9=ZFNK9"YA31!I\D6=U6IKSK
MJVC7:WD1J\2G3N_Z/Q=H]DG\>_JTP8>C,Z$QYYQC'K3,I=1</'W%S6F!>W>D
M+/I_?]'>D+EL PN=4@=J'W'$E:X S!2*HU([77FDXD?-2)BD5$#MR\[T=V/_
MB+P(* F(C#.1=7MOGV;A)O7QOY9+\L&5YDC(%&#8 KJTUAXXJRO&L#?!.,2C
M!0/PG8#.IW[3'2E?A4S7FEUM[]V+LA157,=5SI&6.F8:4DQG=$^L6!7:J)=/
M+$PV_R8EP0\(1$"/MFQO<8@TC=J/^QO(77KOZ87%=-9+9+.]9-D_1FRR!F97
MN=[C"]\]/2YZMIF]?HG(O/UP13*5W?N(*2(\@D5<@!YP2'';OHOSF!;?Z6BY
MJK\'F]I2OY?,BA9??7YM=:1_U:%;U)!KLG2P)&'X+I=UL+E'[G@'DGSX3PW)
MR6">"!2(MBAL6K:L\4J"[6M+R\@/S,DI ]GXFGA$4U!^P%@$=PLFLMSW"ZDL
MD(2V,0,)U#X'Q5B(-H+R/%V$3AMJE"O&TEI>BB09;AOIY+C- >-?6'SOE:H\
M\:,^*>,#W^QN*A]4BO*7OE#PR\=E)=QKU\71L-1)$8^!I7"TW)6:3,<APR:G
M<;$>\TN#=U(_?WA/I^29T/)&V!8%M3\,Q$I<?K4")LV=IE]WJ%A>L*(/G5Z6
M_VK98>J<MI27NCHO]([K<MR"O=@<O?^-M6(%QQH+MV"M9M3M# L3XSJS!*.9
MD.3EQOXE+09P>W3#@@YOS&Z3JSX_:J;CY1]JG'GOKF]B[WM,S><*>1MO9"L)
M1M^/E=Z"N0X)#@&)+%(<.?R/P,&J(9S5NPO"V-6-(%BG/U":P-N1ST;,PG0)
M\&1,.;IR[</RRPN8N=J8Z^P':M^C4V\NCPFL<A_,%6_!W+,Q\KUWP[9@4<Q-
M\N!4,?/'CY &*LWK=0.O+(G?8'0_7_XGR6,)>S^1;RSLI<L,Z!DBQ7'2D#-K
M4_'75[35XL5^"Q%6K@[RP_L<5]KHS."*[A+EYZWZ&G3@B/C5B<F3[[NB, ?
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M#<7Q-4&#.Q_^:=#J_G?XM.F_RQ?!U>I717FBPU\ D_:9LS@;W-4JH_FKW:>
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MV1+9VT[:MT@_"FHMN8%=O.LY[6IM)L!$%UL_#6\(TM+@'>E^%AE?Z"HT@G1
M7V#];CE=W8GY8W_ON157M 5[C/ A$T?=",K+5O*".P S3HF=G8#P_;2Z2$,I
M^-=O%J<0_/@W6;V'?\K1C_=I"B<&< J@7)LK#]1*MM /]>,P) +%(T=^Q8;(
M ,)\L=LM5[XT)TS'=_4\P7;N._*4IA32K'(O.LOJ@G[&.5/S!-L'+?*3KZ1#
M,JFAK0_W+ER]/&=_S_GR9=< 1IE39H/K^+U^WNA;39VQCE:Y9[X:FC-+G(IQ
M!]>5633=;E9N:9Z_$_K-@@%[5E*$1R#G#K.N6$$XWP4[=_D#I0J,7J69("B8
M1$-QZ:G/@ZY@47$%-O92=EN$F='GP,C.IE+4@N)D>KLC73- MW4"W\*00N/$
MHP >YI! '23&&S&^Y; DET8K?ZHB $8:U4MZD8UL)L.QI ZA"'C;=<.[IB#0
M.._P$!>'86/U,&%<#P>P.!9GY\?"R&!O\;DCMAJ;7K*?S<SG7DEW_.=7YY/E
M\^K0AU<<E;,%'M>&T'MBGGS7/A(S86M-S/WW7<F;:\<OG?VX6]P4,^!87,']
M.COX29B3,5^)Q_OAW92";N>2_\"/XC\C=@FU!(<@G3)(CFW7X<!4@1JN@W(I
M1DTF+FAD._YT-2";2YX?,8[TBUO=9OR_/S2 M,=AN3L71A:OTT8$#Z((;#':
M$/.?)GI=54T-^6LJ$M*4X^X@TSI322D(51R<X[$%2T;4X$OY%O/U":^9,CC[
M4(VF;3^33'J/S7:K!C6K0M[\--YX_LS$S&4EQD(\WW]<@G24FC%,OI'AQ:AO
MW:,BMN/A_K3=:D<RWXL_^F_MQHY=L_(P6-'NNW-U?^IQS6O6"W&'?JW.%>\2
MT6^<O;]<0:[8@I';SK]LO"J;;'5[-,J=&8JWFQ-I)W_[S=[;!"+8M$X,#!IM
MKL<\7B,_)L#HYH+3@S@/%A?E K2;S;7"8]:9>\/3U;KZ T(]4$@,6T6RW;U]
M_$[#6\/1<67PI\E-]<Q_+F2.$N[TCDUX0,Z 4CMAGU =FW@>#*[@(&0$-T!X
MRAI1Q'\ PM@A %JC7<6B>VYM9H$G)JO3TDSE'KM'XTXV5U)NPD_2HM+NF^9D
MZ)..R$@IX[G=>S^*O%&_-^%F<>"P5 E':T?LCF\'&VAO=#,7'X<ZN87-'6ZL
M0]?.,^\;5@S7_'9FP9=RP=_6VQ9]'^H"G5DK24(%_*=QN[2[5J):#W$FY)];
M,"F!'8%-@"T@Q$XV(L'S?(\&1G]YL,  6/< ]U#IN:S4J"2C7()+HG/#2YE!
M%N4EL87YK9L]%R^TPIJSY]I)\@*9H4HK%9.42X(+D!<P0(#A C??W  E8O5B
M@[=@%"]>'EJ@7>'9KCK1[AX;D)7=SX3>?55Q<!2V4R.JX<56%^9.M@/GOEY\
M;TX+S?UV0W[OYS0?I7O:N$+8@<S'.<G!L2I.]IRAONRF")HN95GPB&E+\S*#
M[Q/X;"8()81]3(H7K6/E,5.2#L>Y 7E/@: +$)I%%L4RK!N&@RE>[LS.\964
M<#1F[@/Q0K;C<,6*(=>,X_2!]B% ?=#'SR7&COD&])FVZ]SN)'=(8"+/!42U
M]N[!9J#BW;5:].6Q6NR(>*H'.7&\. 9WE"T>T8Z2#$=);L%:97AF>8_(V)V+
M'4(#:M7@,5K.^1%*1;@A_V.Y4XYOA-P$_?QMY?=J:D>F.6H/;0U:X\_RN]ON
M/&LOF#MI*A)S3L/)]H?RTZ_[7Y6JG"L\W'U8=53@U5)G3*YVQ$1SA78__!XS
M;J ]./$K;5LP"+5-\_23V+>#S231QIO3H>\$9T&G4F!;ET^ B [SAA90WV6T
M$%A(]05J\UD-23@-%EE<),/!47I/K'-=4[WNO\L#!%_R^!E65C90W,$4Q>L(
MS(?HIW&6D+7<$LB>MSK^$Z_-@ B@'<LN,7R1&\KJ+'WW_:?<02C[;RAY^L,R
M>9+JL*]RM5<*D63$URF+NG=7#XUP$,1_SNWYQ5&X96M[#S+=,6'J!S>P_/E+
M1LKZ5/.-QIE*;OO#KMS7SWVO7"P[=ACVV%^:*IC<@JG]TF)C!(=6V/ D"B+.
MO3!^;FD.)+&='H&Q[/4N_33C[7U#;#/?]&/Y$05^8&JK/LL\F2(I>LVZTN'U
MN6GT:69;O7[LP&\N+>1G'KR:'_Z=-FJ289+_DUG=E=:H C!X_I!22,1>>I[2
MYIMI:(+CA6J-]*P7V8XD[*=0IF$$=]-OFK@C0"[[2N]KZ JSW;TH\0V$L$[Z
M<^GGD\"R68]CA6\V#4[%OI)^/1</D[H>*UVQ_FQY=WH![-HK/WFDQCTG[%EU
M*:4?"BWJOYS^??#Q,UGAD_9B(:5V?7.OR_F>HSA8Z.>'?VT[Z-D^U;@WR;$1
MFIZK+A7[;Q5-S:QWPA06/':E5:EGF&<BWVK;7(_ K*S"WJ9H/[QL(P/[?W^Z
MO!:)I=-/\_9UVN[[&AFS;T$BR(KC1/O@F\4>F?)+L<G3S) O,'#*N8A47=,(
M/OC47;M3,V[YUW>,4?&YF8.+?T5B!D>+.3[BA@UPXRG;FM@O,0%:CWJH[[&5
M=[YKUMM;9)Z,.%-V,#1$.?GDZZH[>])-#74U3W<8;EIIJS>0+C_/:OUB.![_
M9>\(6WCKR$Z'[M2['M^]E#U[8;]\GV>F?-/)D A)(UC,+4*7W-25\Q#>302$
M$T48;8Y[>D);LZ(,WT_>P+X, MU.HVP&_\FZ8EF88YPCWD%_Z9B>KV(UOB#/
M73Y2<R>IJ?RT1V<65Z4T7G',553V;YM='T_B=T%W]-.S"2J8QG/L2;_V)Y"!
MQ1X60B+P97HR8-?6LS?@!LEKVU#.6%<-WO6M&1(X&E5D\Z;R2U +]QIE9;.R
MM'V##B9O]A6%?#UE,)#MWVF9$/(XA/GF1Y'#G;RR8KM-]!!:RR]HVY^[-D;K
M,NI57V57!R:C@^L+>.#UR<" (/^7Z6O/=.N5'+I7X_4U:<FIGY01_M<R[.Z(
MIAW_NV^U[^YO/W]"3;*9/U_]Q,L[-XT+#8?%TBT5Q](.G$S3X.@]_D*DW-WQ
M> XLG+/$=B$)GH-KPO^NU^9R)\,(P&R0Q[6[;*GF9.6+L MLFQ1U%WDQ98/X
M%(U=D,_?(J5[DGWNI!R7_]_Z7S&^7VLVS5E\;/;$;./IFDI 0,6Z1YJ@.);Y
M.-?N-]P=!O%YM,UWK,VLFYLY6A\ +V8ZDBO)=\?);V:A1P9=:_NW8"Q9$IL/
MQ5ESS&-#99CC]^EPQ=W$\$+WI?JZQW,]">=X]S+PT;A;6["8GFLXZ4U:^,H8
MLIU0TUE3!NFW(62%^P2RP_B3/U&'+)2TDHBI>/.?LN.,>'(8,S:;',11"6H;
M#_O]"<,6][ SJ1V_:A#]EO7$>)B?R'NRF6(('P_E()>Z0+<NE"Q>*R#OT&:V
M4"W@_TZEC?%6HO<O6:E <VQ:_,J=>@#Q&'?GUWSF8K9;GDSJI:&*I?+53=M1
MIP^U0\MOZ?:'=KXO)_B0QYRGU[DJ8#[O&Y1@H1 .:K&7ZX"-)>P@>P![7DP_
M(3(Q'G>2+MI/64DT$S:)I_Y$3%39J73,UC&RA!QG%^-JG=K6'6/""6:M'I&O
M@%/OPX6&3,,/":Z#<^WD%/P>2!QP8&G%^E;5@"(=DFE;,.F5RB6<&DLIVOEJ
MAHJ)]?NPP3459[?1\+U\8U)!P#K-RO/K4VO]WD$\DZ0L5-T&)BJ9NX-O)VR?
M0D *',R8\SD&J(/=OP7KHLN ;G'X4_Z@?ZQGS1!=0?!/'XYKM3&E\?4%>Q\Y
MK"RBWRC<P9G703",/L/W$GXFB2'N,F.) (-])Y^-WMEU ;2+QVM!(FSXH_ _
M%KH<4@)"&K<G0J^*I9]DM6_T\Y[!\*;#XW.W:?:6Z<+,Z*B@<.4LMS-^LY*)
MS/?%K1AE80^3BFIVC.)U0%W\JY/"83.<NWZG9(I0'2ID(16@XG/OZX %+.$O
M"O XF546#J ><H_THVO;]I+>NFM2(^ 39*OA8[:?=\SE_>_4]1HH9DXHN@8F
M"O>+@R*\0(P$9,)**&61E\@BD#Y'[I%0:P%O"HP45T >=J-4%1-7 $J\.&!Q
MCK7=S^S5X4#JHB3Z07AT<8ZH)C7CEW$J#=+:@NUQ!6A<+PYB7+\57FW2I@G]
MQ$L)NYE[MV#^J(3U++QIOX7N%DS,#P6UTLT>C[)45MTG&R]O=T-D E5_KXI<
M^Q7H;9BB4S&NCSD^H5M U)C4%XH6 QN+///MNSX*-?!RH5X0P=)O-V>(V%@Q
MV.(HEL",ULJ')T32$L/C^W&ZX2R&>("B+.E -E[F?69[\35J8^-XMIM<L/J3
M#ZNDL4&>X^83^CX<8?,M(XCYT'T]SC!H)1V_'XIF,1Z;86(;'5C7Z0KZ27AE
M+RB[71L\P;-4=*T&:"D6YXJ@IYGMOT27PM(OCOXS&)Z3XQ#UARKVHMD* ^W9
MOO5+T"CHPY+C$L &MLB2?;E $Y!;RBX2W.RG>EW$I'OO L-[4^D&.*GZQZ.=
M3+$*P\W].QX41[^XK1_$'LLG_=5H4.^.-+C4-4^*@].:BCM(1%3-2C,D5/#^
M>087L9G\=K/Z"'AX-#FLNX%PP+V;W2L!^0FEQ'+-]KE&VX((VA[.XOT!W9=B
M]VT>)=VBTD4$.S:?6<@!F;PL2)O%3+52@$C3Q'$EMET7^3%*]J2^@##-=5_X
M.LAIZB=UR;YW>!UX(8QQ(,"A7M?\4MTOM:JT]G63POP,F]_$;PU"T6[ G&<)
M446(ABOCN]BT+D12*$XNE:7?HJ2?1I(R%+__FT5:^EVP $ IB+V",_V4,AUM
M*D9<CQSB9[FM".1C0[//!_I50<YS$QCN-Q]&:$&7(]!,.!;%^E'#-UHD[5L6
M:@@4H5PPGQ5<%02>:6%(WZ6*R['@J7H61]D]^FS9'%:H*@UHNUPW?,R^T4@N
MY>X1JV/OMV".[VVI=8,_&KHAI>U5J":Q[9;^9E+MDAE^EG\+'$$4UXL-'Y.;
M+FZ&)ZKJHJ064(?P:NZ+J#$K^<>80XL;3H]\6 U!?&SPFF/@\O)4D*7FUV_O
MD/>O^?4S?."0)G+)GJ^)Y;-ZUI>&P98)MOXVA<0R9*Q$!1>H@Q888/':J-59
M2*U=>&8(%QJDU2FNY13CL)A+8-VI*BU050'U<E1SHP,*VGP*@S(\Q]S;9*XS
M=C.F,U%5FXE+!#;BVV(K0F6[?.E<'"#XB_OPL@%:!V8?--?R"<1,KW1L.J"$
MXWUK6S!1)J2I21E4LFY*^3&(3'2CO J4K?$:6S#PK#D BR2V(:$3QDUE6#?>
M-##7)3F6W\[<20A8^8:93B@%^9VDG>$()2RA8\/OL5"I>QHCCVUHF5('$.TD
MR=8-%>%SMCES;R!>L3'+P;>^;^T2(X#Z\M1L*..V)'32KWEE(I03T8**VX+M
MQIF4+IAA.A!CHQUP)9Q]Y4(D-3X[R4H:2VM5Y"6_62")6H1/#U\GZS:>;W-3
M+,PJ$^?,F^5EZ*ZLC@57!/N\I%F)$EJL&'X58FW,6M1#(_UQ>!>*XM>U,M[
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M*1-N'N^=,-,$&QG',KA.4 W0Q,55(S4@99#/VA7'GE8P*)K6+))#'N%(U8N
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ME 1.4V# #I#R12L2D#@CYN&;EL$Y8P3CSCEWHC0NP+G+-JX ;Y51X]JSS61
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MA=OS*[]1L2M/87(:E-I.VAE'F I49##M(L 7&8]^2X[$'S]SAC73FS?D#2L
MGC9HPR8!OKPWOE0)\ .7Q"[Y$/(*E^W /94>J+1TE<9D1#,DVWOV09]^;\F9
M(&B#+2PYHY-%+=&CQ:7\_CK26Y5I&?Y^P6$X"C>_0.WFR*D&]%0+WQ^_G(.L
M0DM3:LAWT$K%2;&G9-Z ^TA*:.8),,_E+1=9U2Q579KUEN5 BUT8W-;Y_0IB
MM4\Z5KY83LJF8TZ/C,QO]$LCJ'.;H)77^*<-IBA\,:B95$A+@C5-TMH)TCL*
MG7&36!Q:CXDG%B7=)FSM!6GL]'KRS8S4D1(>K9<@R<'>.43-9#]R<?Z0 NO(
M[I#)BDO5+9B.B_[E^H1I_1] "*W$5*!4R$9/6; 0JLTJL&BZ0944/D1)XUUA
M$2"#PS 78BWM0I@M\4BDY4JNW2F.3J0)S#Q:M!0YG:9JR^\,8:/3H1V%K:<Q
M2CYNA.@(G>CY_,W]Q]J_Q1RBE!7F3B[%5#' K62!LA,+4X.^&8I>C0_-AN!Y
MWK4D%K7$:$F]:9^C*0E.<+-27N(OFSO?HOC)+A<!KMW?MUTTQH58V;H^C]WP
MILQ>KKC<?IA41!>LSN6U@S//H4&J9CNTD]#DS$,7M]2B>R?9F"B\!U>\FJ$D
M".::,KO)'.]ZFG1Y8 C?PI[E;E:.SJWC6&!Z4)HG,4,S2F.EQFXL-]^%C*LY
MG.]Z X[%0G0K8;<(J+(4 0$&"40D_"0"5*JXQ"%$%6T9X0N\8NPM$7 >(R7X
M#?1F&<2]$?B#(:\%IA3NFFPF6O/KF"E5D<+I\!DT[K9T(</2B+JZO?R:)A3)
MU-4/*$*J^I6^R>J^O"UK 2I;5 #%(6D;OK=@'W=TVIYO AI5TMYA:P/Z0IFF
M4Y&<!1X%O$"5X-(2Y@-NK9X@;.0FW1'HL6 26,9R?A+@'W(-44M&>. NN_H0
MMG BH&SFM/41VBVY  QGOJYX^+56/L>=!PD?$U""U7!$0V!]P2Q)XNC5HJR$
MN?2D<@\NOZKORBG4AX 8K#RDB MUI(*Y 4/])_H.V3+H6JNXU3CB4%<=.3ZM
MQ2&3A8R?4W>/B[,X6GT0$8E^%T#']+KP4CBCT\5\&_Q182Q!28#D8*80CPF?
MD,H"34Y9-=6"8Q>%TB)6T\#4E^"H/5?GIL";C57H&U?1TN@>[<HI[RDF*XV=
MTOK0JDVA<+H*HLCVV[),\F@<3$"O9Q6T&LR'-;N$$"[QWD0M>$>6HUKB[;DV
MN5,O**M]ED@UF!CMD^W&,XKXBUR[&AF'_3/&;X>P=[!%9\JX^E,9_J\S,+>+
M9I:#H8XEL8NY!D$>BT3L^B#ZXMF*-;1KX3R,D 89$[JH*\%HK@R&,S/5P0X
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M"_')%#C,!!\1<!,N#R/98S-FQ,_$ZJ1?+37P3X9=^_>!0?\/Z/Y/@F[YZ;W
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M5N :.PYVK,7OBSE8=$>P-S3$../@0E!_E7)7"6%>8NC[VH\2HXD/1Q?GES+
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M6Q=_M*:AJ6IY:H=.M-6O??09V1_",S>O'3KD(=2[B=CYY@WFYH/S0F_)E,+
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MTL_S:%U=SW0,IMTYQ@&#DFU6WL&+1J0PB6@L@'( 2;N#S]3$M B7[%BP6OD
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M?Z)KDK+V-&FFU5B51W@1'/8=8]EMM^1%_,!8E$VA<]/0!$7 TJ<&T>9WF>'
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M'^W<I_W5]>ZY%3<WG3\?H_DC9B]&\T)<S['"]9K3YW?%$J-]MRX14U6I^^H
M^BTP<)?1KL3,5^,)/H,W(JAS0U]7P&Q54T[_RDO#R4)(%4H,6M;.[)7=\S=4
MR- #)8;@$9408_@I,??';Q!#61(@QT"A)F=U]#?AGK"1ZX+J1 7++)4WNP]]
M<UPFG\%]!IQ(VHP6WK0]8P0GH^=;*C&]2^1[O7MXP[NQ8!!NON*1+=0YPT)_
M93Y_4) RNO6O<_SJ^!<7+5D[[G+^DM$T/N[!;&N,;FLZ:2J8><"57=P77YCZ
M]&)L]*5R:83_]Y/=AU>0[S\/"B,$!&U5C!4V,?#P3R0CNCY<+#Q!=WP(9Q$,
M:(9-^5ANQXSQQ39^P(:>".;JL:.?<E[1POQZ=G"T;-VAM5U3Y^YUL#EK5[\Q
M]K(G5@:<;-'Z$_?K/'/R I3:' WPL1@D@#38)F%-0N#1)H$F?CV-J%)SJ1 @
M8_1$E(6?A,,>Y04+>T8<8%8QW1P<;0'2]+F:T)KR=#&0A&K#5R C&LF]U]I_
ME^10'VKU\OY^2LQ\G%R%RW;!#?X^PCG^:WT/DTUPF\J2[2<F")8C.\Z<X<34
M>FR4-W%W0[SD(*)@$#87]5^+J!5H3W0-E6;[]&L4?;JXM3KZT;O](.\Z3U@@
MT,8O!1H\&<L9#3Q#NIHP&W:7N](WQ'FIH/)[VMF))F^?7^F4FMSF0KX2LX*Q
M\9-OFM>G ,,ZZ .33UHW MMYV,W/QWI_G9%N?S/\.HM] >L8:O/(X]7:R>-K
M1\:MLXQ+I&>?Z):8&?I_*C0?G'[J%OWU8E!<P^FBQ.8S>\]>V.;QRN8)G-:M
M9:<=^BIO^Z4 ,VQB1NI 3]$6Q8!]C?5OW!_ANRK,'(!\FC@*=IUY00B+H]^(
MO4:J+@W8J,3$R^4$NIWB#D/#"21ZP>UE P.N8D$::@AA4]%E,$\<Q?<W;ZYA
MY))7ED2)-))+ZX"2SQ50=H.YO]U6SI[N9XIXKJ,SY"Y);,%B:?VRELY9+)-7
MX9/ "XX-=^+V*S$_Q0)'NE UFJ%3KP-!5&_Y-DR B0QF2?+S #%N=:C,38S5
MGT -(,?[/(OV-(>8;VK.I8OJ">,DV%P-T3W:+'B,O8S7*&X0Q ?@X)=0L834
MPD[$K9C!:='X_CWTW4+2TA"2ML/I(MI2_ 9D?_^,.>7H\<Z(M4B0F+2"=O95
MR,^62S\7EM1L/-MUAA ZS.@"EN'UPU@:7!VT \ 1@G$8M&/$OG,F+,PJ\2C=
M$U3%A$/0IV6!K<&15%#0@-KT6]0%EX_I^]80 PLRJ1:*[GO>4SK#3^+/T^Q>
MA_T>&%P2-NBT^*MWW2.'9R'6.7 W]9;@Q)?=W<5-)X/VW'MFGGCTX KW"<1]
MLY? X*%TM_JYH8]NFTFNOMTI5 GNK:O,&<X%L:Z*7*[1N& -(=1=E8A/71M9
MJY$M8/"U.A*D(\PO!$?%47&<-HK^03@L4!*K+VIM4&(6A>9;]*M<B9-3"M\%
M\N]E7YUUW.U7P^UF;X8S?P9$EL]G!4/5LF4LV00'/EXP@:N<:FF_:K*PN!C7
M0%@[P]1 MH-3+^I]^?[P$[#;#[\>CI7@= +H*GD+Z7OR*D$%.@"(UB2,MS7.
M-X&^[J5DVXJA$@.&CJ(8W3J\<'T>:H.V<C=R0 N>JCR)@B?,1NJ@3Z/O9U9P
MB2_\Q ; T4_ <>#HB6[ZT4<C :\+Z[/RL/S:UP=U*QX__D'8>V?U.M\N<:2L
MGB ;5Z1PJ!IT=Z@O6TYBM UF7V5HM06I-0O6D948$X;>,"U8Y-]2\L#RUKT&
M".=?#1T;!.)(1WD9YEK?3O3;_4+RUZ^.V[V\@/''45GH2%^1_[F\'[J]W.]1
M#^_TZO8>]*C]E/GT*^(??>*V\\&9\]_]7/7;UU/G3QR$7\'1>U(\CCY,OSTQ
MZ+'7^L-9Q>BE5X7 'E5G_:8KK@5G@FHQ5#*NLE]Z6GZ T8/:*6Y;UGF6,=JY
M)G#</40#Q#4*XO/M(&^F9?P%:)=5(F\I8Q7=MA(JOCY3JWZO"D0?2MH$JT]^
MNGJ61>R^4WOB7.#7DH6[G-:?".,M9FQEM/NRI6-R[P":F7A*BN=5J:66,Z_P
MSIC'7N#N=9/D[193T(KBUX%R6U]R#9 XQ5T?DF.;7 PV5V7D'-,A=X[ID2FB
MVGI7ESJ%+6F(*".P&G%:^/5.<F_TC0Z,E1#35*T*4EM ) RFF,7C=] ^BZ$9
MV$$+E#2%B2,[ZRZ(Y26<L*T.CJ*V-H7'Y\<WANI2'T?DJ]I8)?NGD@+V0,5\
MJX4MH]_0R9"5".KAB?:"^M>X6VFF38S=H(_,,RGT**VB<?YLO>63.ULR-SW9
M4J(HHX9D%4E2+OV8=2QMX$^ZNH0$;S+C4W5H);*"?L1\00+SU.MVRZDT Y(F
MVL?3Q!M.$-0G'19!0*LM7HOY8I#=:FYL'@"?9 \CN^ R,45O*ZG%1Z#)P6K0
MPEMT&M0A_?@IL?R0/L&?OEJ1F2DD):-&XW@36(F1[X=S7P":A+.D%>AK7_T&
MEB&MEI_3S[<X0%@^H3VN1S#@U!H"ZN3YV=&6DO0M;[H;^O'K/1@"_E.:[]ZR
M]FMOBL_GE'&I?/:@4P-K)1 TM9C^D^*12G(*!KQE_4?0[@J5\@FA+H?Y?-Y*
M()B])M1"''NNVXW9,,A+=:"4D[=95-T,IA:,:P.-?L!F09+UZZ"R^ <6@60U
MJ8;\Q"?",OQ*6K#L60=]O[ ]F?#T8^Z6Q(>(+T2-BXPAK=I?1-\*'2X,O(>[
M;J(.X1(_]$:TZW["+ZIY7M7G0"STO=0Y'K#<9&.?=?T!C\#OGW9%:F,YDK7[
MATR_>VD*"C&.BQ^Q"U)BCSU^7EU?>76ZZ^/(=-_GK>5EY65F*1_[Q"-BZYR1
MF)@DUYL..@V;PIUVG+EWXX_RM%=.AA$83V==C-<_W_?MHL0TSP *C$\SJ<('
MN<U#=%W1MKD&MB*0.O"&VPN(YPGH97,Q>Z $/4Q"5Y@J,4'RA4.&JR='C\?#
M.P&9!E9Q8J-9O15$4&SYO[[A^[3JI[[1V=/Q]INJ%E-,_FUPT;J]TM8[ZW.^
MYLH>@KOI1V%]R%14UIY(]Q-3U%JC';CKH,.WP"]-50P-.(V^^]'K%:'9C*60
MR1U&PVEQ[M8;0=W%S^J[@M/KAO((WH][RBB;,L<^.E/K=NU,,[D6<WUVVJ=%
MB1E<UMT Z#.T&*_S-3FI)^!>:,1*+RS'0?_0TY"197"8T-S/CV6$>$ .]AF7
M)BOE>4ZNX%3B3$P@CP1MX023-S>GY]5_>&\QH>ZRZ^:V@X*ZJVE%79_?O)HH
M$CBSP^YN[6KJ9-M9/[$>.[@K?S7GD+_!\1[_=V9^2[P3MF?;S05Z_Z:HTB-)
M3WA#ZLYH1)M\&T*%K%+Q*T,!XT2IC=P9QLFH<+*(E,1;CFK3#\ EX#JZQCWZ
M2?!-6A9I!1(K9AG3[(53U[B6='(WHD6)B2P)F^]OFM(.$(0$V&=-?T%7$9*F
M3A>'DK^,)A&$V='Y3X16Z< BQ/ZT_"SBJ+C%^ XYUH42VN0V-!])^XM:(!'0
M0K?!@6)F(M<*?O/EA<G6?CR6QA(GQD?@#.%N_C2<VY"_^#F4F(K'P84!]34L
MWTY4S]^=#!0K;HIP\-;6-&LJO+TZC2#,49D@K@F-P(^VY(&L@RJ'NQ<) 8N4
MF.1<#SA9O*G[?1_B!A8W9T5_*!B+-F/.*#$:)\-,=CSNGO$G>EZ7[^_Z\.Q
MAIO1 2MX6]3"^EOB)!,BR:P75E($3\5SE\-WH1)9-2P18>-]?-E-TO"F?!,X
M$,SFY]MDGNJB6[!AWA&P*+^HG%@"MP9T.CCI7XNPU[B4Z]/MH";Y6I0Q$)$T
M0B2,_Y[N([M/*"O3Y'9.9N-7>UWPR<K\C<6_.!F[HP(I\/)28CSA4+M-(B-
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M\B=.377*?MFM&]Q#*FQ)I '".6F#?!\Z(*CP:1 P2<N#%$\8.HQ7O*>\9L'
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M&P3+N38T']%5.*OU6(]T2Q<=*VQSI(\SK*&T)IKI06BT*?8L>=:#<+1?2OF
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M5P567UU;L'AM854*8:-U\H%+H7%G0AY?]?7/_FN$ 3L!KBK^Q_'U_SD^H;;
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M^77[JU+OC+2RUUN*R&9;:P/L=CXC9;QYLZ*_"@6NXE6:X=H4ND(E[UUX\G6
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MMRL'_@=02P$"% ,4    " !"K_=:]]0&55(S  ",-   #@
M@ $     86YN97AC7S P,2YJ<&=02P$"% ,4    " !"K_=:GS01I!\#  #&
M P  #@              @ %^,P  86YN97AC7S P,BYJ<&=02P$"% ,4
M" !"K_=:"=UC*>L$  !_!0  #@              @ ')-@  86YN97AC7S P
M,RYJ<&=02P$"% ,4    " !"K_=:;.AK-A@)  !&"@  #@
M@ '@.P  86YN97AC7S P-"YJ<&=02P$"% ,4    " !"K_=:%V1PY.$(  "G
M"0  "P              @ $D10  875D7S P,2YJ<&=02P$"% ,4    " !"
MK_=:*^O+OT :  !L, $ $0              @ $N3@  8WEC8RTR,#(U,#,S
M,2YX<V102P$"% ,4    " !"K_=:##/ET/87  ">&0$ %0
M@ &=:   8WEC8RTR,#(U,#,S,5]C86PN>&UL4$L! A0#%     @ 0J_W6DJ^
M>.4;5   _)$% !4              ( !QH   &-Y8V,M,C R-3 S,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( $*O]UJ_C9DJ_9,  %^@"  5              "
M 135  !C>6-C+3(P,C4P,S,Q7VQA8BYX;6Q02P$"% ,4    " !"K_=:.#\Z
M%K!E  ![Z08 %0              @ %$:0$ 8WEC8RTR,#(U,#,S,5]P<F4N
M>&UL4$L! A0#%     @ 0J_W6B)[\<;_%0  R7\   L              ( !
M)\\! &5X,3 M,C@N:'1M4$L! A0#%     @ 0J_W6C@M^=<+%@  1'\   L
M             ( !3^4! &5X,3 M,CDN:'1M4$L! A0#%     @ 0J_W6@@"
M9^'<%0  8WX   L              ( !@_L! &5X,3 M,S N:'1M4$L! A0#
M%     @ 0J_W6KC+^HS3%0  -WX   L              ( !B!$" &5X,3 M
M,S$N:'1M4$L! A0#%     @ 0J_W6GWY&07K%0  X'T   L
M ( !A"<" &5X,3 M,S(N:'1M4$L! A0#%     @ 0J_W6LZ:&ZW5$   $G(
M  D              ( !F#T" &5X,3 W+FAT;5!+ 0(4 Q0    ( $*O]UI&
M3:>)K@,  %X4   *              "  91. @!E>#(S+3$N:'1M4$L! A0#
M%     @ 0J_W6AB>$O.6 P  31$   H              ( !:E(" &5X,C,M
M,BYH=&U02P$"% ,4    " !"K_=:9%'GW.D#  "R$0  "@
M@ $H5@( 97@R,RTS+FAT;5!+ 0(4 Q0    ( $*O]UI.NV[5[PP  ,P\   )
M              "  3E: @!E>#4M,2YH=&U02P$"% ,4    " !"K_=:+;76
M#<4!   $!@  "@              @ %/9P( 97@Y.2TQ+FAT;5!+ 0(4 Q0
M   ( $*O]UK0TP^DK ,   P3   *              "  3QI @!E>#DY+3,N
M:'1M4$L! A0#%     @ 0J_W6EC;.D"I P   Q,   H              ( !
M$&T" &5X.3DM-"YH=&U02P$"% ,4    " !"K_=:%J?N]K,#   %$P  "@
M            @ 'A< ( 97@Y.2TU+FAT;5!+ 0(4 Q0    ( $*O]UJ6%G4C
MFZX( /#N8  +              "  ;QT @!F;W)M<RTT+FAT;5!+ 0(4 Q0
M   ( $*O]UK89A#VEZT  -_*   /              "  8 C"P!F;W)M<RTT
M7S P,2YJ<&=02P$"% ,4    " !"K_=:I:Q*>A)X  ">EP  #P
M    @ %$T0L 9F]R;7,M-%\P,#(N:G!G4$L! A0#%     @ 0J_W6OA%7R_C
M$@  TQ,   \              ( !@TD, &9O<FUS+31?,# S+FIP9U!+ 0(4
M Q0    ( $*O]UIJR8"T<@X  -L/   /              "  9-<# !F;W)M
M<RTT7S P-"YJ<&=02P$"% ,4    " !"K_=:\],AV.(.  !F$   #P
M        @ $R:PP 9F]R;7,M-%\P,#4N:G!G4$L! A0#%     @ 0J_W6A$S
M4J=V 0$ 8Q$!  \              ( !07H, &9O<FUS+31?,# V+FIP9U!+
M 0(4 Q0    ( $*O]UH2EX$N04T! "9> 0 /              "  >1[#0!F
M;W)M<RTT7S P-RYJ<&=02P$"% ,4    " !"K_=:&I$ _!HE 0#W- $ #P
M            @ %2R0X 9F]R;7,M-%\P,#@N:G!G4$L! A0#%     @ 0J_W
M6H3DX'-;O0  ^MT   \              ( !F>X/ &9O<FUS+31?,# Y+FIP
M9U!+ 0(4 Q0    ( $*O]UH@=*6""A@! "8> 0 /              "  2&L
M$ !F;W)M<RTT7S Q,"YJ<&=02P$"% ,4    " !"K_=:;@%]MQCM  "^\P
M#P              @ %8Q!$ 9F]R;7,M-%\P,3$N:G!G4$L! A0#%     @
M0J_W6E8=&M@>'P  4B0   \              ( !G;$2 &9O<FUS+31?,#$R
M+FIP9U!+ 0(4 Q0    ( $*O]UI@(]4T<B(  *XJ   /              "
M >C0$@!F;W)M<RTT7S Q,RYJ<&=02P$"% ,4    " !"K_=:8-S#!,LN  #$
M-@  #P              @ &'\Q( 9F]R;7,M-%\P,30N:G!G4$L! A0#%
M  @ 0J_W6G*X&OR_,   C3@   \              ( !?R(3 &9O<FUS+31?
M,#$U+FIP9U!+ 0(4 Q0    ( $*O]UHF!K#A$88! *W9 0 /
M  "  6M3$P!F;W)M<RTT7S Q-BYJ<&=02P$"% ,4    " !"K_=:J4E$GE;:
M  !7W0  #P              @ &IV10 9F]R;7,M-%\P,3<N:G!G4$L! A0#
M%     @ 0J_W6A7OE8,=T@  #=@   \              ( !++05 &9O<FUS
M+31?,#$X+FIP9U!+ 0(4 Q0    ( $*O]UJ^JAX6;IX  *BQ   /
M      "  7:&%@!F;W)M<RTT7S Q.2YJ<&=02P$"% ,4    " !"K_=:UL@-
M3$E:  !I:P  #P              @ $1)1< 9F]R;7,M-%\P,C N:G!G4$L!
M A0#%     @ 0J_W6OR"A>O%2P  VW4   \              ( !AW\7 &9O
M<FUS+31?,#(Q+FIP9U!+ 0(4 Q0    ( $*O]UK,]&B6'(4  !B(   /
M          "  7G+%P!F;W)M<RTT7S R,BYJ<&=02P$"% ,4    " !"K_=:
M4TVL0E'&  "%S   #P              @ '"4!@ 9F]R;7,M-%\P,C,N:G!G
M4$L! A0#%     @ 0J_W6A5M).TMP0  #>4   \              ( !0!<9
F &9O<FUS+31?,#(T+FIP9U!+!08     ,0 Q '@+  ":V!D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>forms-4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CYCC="http://cyclacel.com/20250331"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cycc-20250331.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SixPercentConvertibleExchangeablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SixPercentConvertibleExchangeablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SixPercentConvertibleExchangeablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SixPercentConvertibleExchangeablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SixPercentConvertibleExchangeablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ClinicalTrialSupplyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CYCC:ClinicalTrialSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialSupplyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CYCC:ClinicalTrialSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ClinicalTrialSupplyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CYCC:ClinicalTrialSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_ClinicalTrialSupplyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CYCC:ClinicalTrialSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-292025-01-29_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-29</startDate>
            <endDate>2025-01-29</endDate>
        </period>
    </context>
    <context id="From2025-01-022025-01-02_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="From2025-01-022025-01-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-02</instant>
        </period>
    </context>
    <context id="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="From2025-01-312025-01-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-31</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-02-042025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-04</startDate>
            <endDate>2025-02-04</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-04</instant>
        </period>
    </context>
    <context id="From2025-02-052025-02-05_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_custom_HelenaSpecialOpportunitiesOneLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:HelenaSpecialOpportunitiesOneLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-05</startDate>
            <endDate>2025-02-05</endDate>
        </period>
    </context>
    <context id="From2025-02-062025-02-06_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="From2025-02-112025-02-11_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-11_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="From2025-02-112025-02-11_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-11_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="From2025-02-112025-02-11_custom_SeriesCAndDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCAndDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="From2025-02-262025-02-26_custom_SeriesCAndDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCAndDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="From2025-02-262025-02-26_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="From2025-02-262025-02-26_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="From2025-02-262025-02-26_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="From2025-03-102025-03-10_us-gaap_SubsequentEventMember_custom_CyclacelLimitedUnitedKingdomMember_custom_AssetsOfCyclacelLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CyclacelLimitedUnitedKingdomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CYCC:AssetsOfCyclacelLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-10</startDate>
            <endDate>2025-03-10</endDate>
        </period>
    </context>
    <context id="From2025-03-212025-03-21_custom_SeriesEConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-21_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_custom_SeriesEConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_RombotisSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:RombotisSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_McBarronSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:McBarronSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_RombotisSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:RombotisSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-02</instant>
        </period>
    </context>
    <context id="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_McBarronSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:McBarronSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-02</instant>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2023-12-182023-12-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="From2025-01-242025-01-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2025-01-24</startDate>
            <endDate>2025-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2025-01-24</instant>
        </period>
    </context>
    <context id="From2021-09-012021-09-30_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:ClinicalCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CYCC:ClinicalCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OfficeEquipmentAndFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CYCC:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OfficeEquipmentAndFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CYCC:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_custom_OfficeEquipmentAndFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CYCC:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_custom_OfficeEquipmentAndFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CYCC:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnitedKingdomSubsidiaryCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CYCC:UnitedKingdomSubsidiaryCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_UnitedKingdomSubsidiaryCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CYCC:UnitedKingdomSubsidiaryCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_BerkeleyHeightsFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:BerkeleyHeightsFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DundeeScotlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:DundeeScotlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DundeeScotlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:DundeeScotlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BerkeleyHeightsFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:BerkeleyHeightsFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsAndCommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsAndCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="From2024-05-022024-05-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2024-05-02</startDate>
            <endDate>2024-05-02</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="AsOf2024-04-29_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="AsOf2024-03-14_custom_RothCapitalPartnersLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:RothCapitalPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="AsOf2023-10-30_custom_LadenburgThalmannCo.IncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:LadenburgThalmannCo.IncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember54201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-26_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CYCC:ChiefFinancialOfficerAndChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CYCC:ChiefFinancialOfficerAndChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2021-08-122021-08-12_custom_CantorFitzgeraldCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CantorFitzgeraldCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CantorFitzgeraldCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:August2021ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CantorFitzgeraldCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:August2021ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-12</instant>
        </period>
    </context>
    <context id="From2022-08-152022-08-15_custom_CantorFitzgeraldCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CYCC:CantorFitzgeraldCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesCWarrantsMember_custom_November2024WarrantExerciseAndReloadAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAWarrantsMember_custom_April2024WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:April2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_custom_April2024WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:April2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_December2023PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DecemberTwoThousandTwentyThreePrivatePlacementMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_December2023PrivatePlacementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_December2023PlacementAgencyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_December2023PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DecemberTwoThousandTwentyWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyWarrantMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DecemberTwoThousandTwentyWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AprilTwoThousandTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-07-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PlacementAgentWarrantsMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SeriesCWarrantsMember_custom_November2024WarrantExerciseAndReloadAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:November2024WarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SeriesAWarrantsMember_custom_April2024WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:April2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_custom_April2024WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:April2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_December2023PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_DecemberTwoThousandTwentyThreePrivatePlacementMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyThreePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_December2023PrivatePlacementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_December2023PlacementAgencyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_December2023PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_December2023PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:December2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_DecemberTwoThousandTwentyWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_DecemberTwoThousandTwentyWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_DecemberTwoThousandTwentyWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:DecemberTwoThousandTwentyWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_AprilTwoThousandTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_AprilTwoThousandTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:AprilTwoThousandTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CYCC:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-24_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_srt_MinimumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_srt_MaximumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CYCC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CYCC:InsiderPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-21_custom_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="AsOf2023-06-13_custom_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-13</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EquityIncentivePlan2018Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-10-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:InducementEquityIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:InducementEquityIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_OptionsVestingOnThirdAnniversaryOfGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">CYCC:OptionsVestingOnThirdAnniversaryOfGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-02-06_custom_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-06</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_EquityIncentivePlan2018Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CYCC:InducementEquityIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Plan401KMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">CYCC:Plan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_Plan401KMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">CYCC:Plan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember54207625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember54207640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember54207656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember54207656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember54207671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember54207671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember54207671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember54207687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockWarrantsMember54207703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_GB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_GB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_country_GB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_GB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SingleReportableSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CYCC:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SingleReportableSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CYCC:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember54208953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember54208968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember54208968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember54208984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_SixPercentConvertibleExchangeablePreferredMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:SixPercentConvertibleExchangeablePreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_SixPercentConvertibleExchangeablePreferredMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:SixPercentConvertibleExchangeablePreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember54209000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember54209015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember54209015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CommonStockWarrantsMember54209031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CYCC:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_DundeeScotlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:DundeeScotlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_DundeeScotlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:DundeeScotlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_KualaLumpurFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CYCC:KualaLumpurFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-192025-04-19_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-19</startDate>
            <endDate>2025-04-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-02</instant>
        </period>
    </context>
    <context id="From2025-04-022025-04-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-02</startDate>
            <endDate>2025-04-02</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-29_us-gaap_SeriesEPreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-29</instant>
        </period>
    </context>
    <context id="From2025-04-292025-04-29_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-29</startDate>
            <endDate>2025-04-29</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2025-04-24</instant>
        </period>
    </context>
    <context id="AsOf2025-04-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="AsOf2025-05-06_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-06</instant>
        </period>
    </context>
    <context id="AsOf2025-05-06_custom_FittersDiversifiedBerhadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">CYCC:FittersDiversifiedBerhadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-06</instant>
        </period>
    </context>
    <context id="From2025-05-072025-05-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>CYCC:Integer</measure>
    </unit>
    <unit id="GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="Segment">
        <measure>CYCC:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-03-31" id="Fact000004">0001130166</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0101"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueConversionOfConvertibleExchangeablePreferred
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:AccrualOfPreferredStockDividends
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0708"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0949"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0951"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0977"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0989"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1005"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1097"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1134"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:EffectiveIncomeTaxRateReconciliationOtherItemsAmount
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1137"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1153"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1163"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1194"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember54207687"
      id="xdx2ixbrl1222"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31_country_US"
      id="xdx2ixbrl1269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      id="xdx2ixbrl1362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      id="xdx2ixbrl1363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl1376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl1377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl1381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl1382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl1386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl1387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl1393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl1399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-01-012025-03-31_custom_ClinicalTrialSupplyMember"
      id="xdx2ixbrl1427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl1458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl1476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1498"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1509"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1510"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1512"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl1523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1533"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1536"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1537"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1538"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1579"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1590"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1591"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1593"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1601"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1609"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1610"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1611"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1618"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1620"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1621"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1629"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1630"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1631"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1638"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1640"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1641"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1646"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1647"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1648"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1649"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1650"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueIssueOnWarrantExercise
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1664"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1668"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1671"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1672"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1673"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1676"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1678"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1679"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1680"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1682"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueTranslationAdjustment
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1685"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueTranslationAdjustment
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1686"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueTranslationAdjustment
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1687"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:StockIssuedDuringPeriodValueTranslationAdjustment
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1692"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1693"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1695"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1702"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1713"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1730"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl1755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1757"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl1758"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl1767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1790"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl1797"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1799"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:AccrualOfPreferredStockDividends
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1805"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:AccrualOfPreferredStockDividends
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl1806"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl1837"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl1857"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl1860"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1882"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:AccruedResearchAndDevelopmentCostCurrent
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1889"
      unitRef="USD"
      xsi:nil="true"/>
    <CYCC:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1919"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1971"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1977"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1979"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1990"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl2001"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-03-31" id="Fact000013">S-4</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-03-31" id="Fact000014">CYCLACEL PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-03-31" id="Fact000015">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-03-31" id="Fact000016">93-2403210</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-03-31" id="Fact000017">Level 10, Tower 11</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-03-31" id="Fact000018">Avenue 5, The Horizon</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2025-01-01to2025-03-31" id="Fact000019">Bangsar South City, No. 8, Jalan Kerinchi</dei:EntityAddressAddressLine3>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-03-31" id="Fact000020">59200</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-03-31" id="Fact000021">Kuala Lumpur</dei:EntityAddressCityOrTown>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-03-31" id="Fact000022">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-03-31" id="Fact000023">517-7330</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000024">Datuk Dr. Doris Wong</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000025">Level 10, Tower 11</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000026">Avenue 5, The Horizon</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000027">Bangsar South City, No. 8, Jalan Kerinchi</dei:EntityAddressAddressLine3>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000028">59200</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000029">Kuala Lumpur</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000030">MY</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000031">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2025-01-012025-03-31_dei_BusinessContactMember"
      id="Fact000032">517-7330</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-03-31" id="Fact000033">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-03-31" id="Fact000034">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-03-31" id="Fact000035">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000043"
      unitRef="USD">3137000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000044"
      unitRef="USD">3378000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000046"
      unitRef="USD">537000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">4066000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000049"
      unitRef="USD">3674000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000050"
      unitRef="USD">7444000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000052"
      unitRef="USD">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000055"
      unitRef="USD">5000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000056"
      unitRef="USD">93000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000058"
      unitRef="USD">412000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000059"
      unitRef="USD">1259000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000061"
      unitRef="USD">4094000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000062"
      unitRef="USD">8805000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">4599000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">3543000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">1669000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">4618000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">6268000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">8161000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">37000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">6268000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">8198000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000087"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000088"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000089"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000090"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="INF"
      id="Fact000094"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="INF"
      id="Fact000095"
      unitRef="Shares">135273</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="INF"
      id="Fact000096"
      unitRef="Shares">335273</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="INF"
      id="Fact000097"
      unitRef="Shares">335273</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">1697676000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2023-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">4006512000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000103"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000104"
      unitRef="Shares">264</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000108"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000109"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000110"
      unitRef="Shares">119000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000117"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000118"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000119"
      unitRef="Shares">36913</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000120"
      unitRef="Shares">4412</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">438211000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">429797000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">-891000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">-908000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">-439494000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">-428282000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">-2174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">607000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">4094000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">8805000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_ClinicalTrialSupplyMember"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">43000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialSupplyMember"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">420000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">43000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">420000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">6655000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">19155000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">5392000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">6718000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000155"
      unitRef="USD">12047000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">25873000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">-12004000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">-25453000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">-54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">-414000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">12000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">266000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">52000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">50000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">10000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000177"
      unitRef="USD">-98000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">-11994000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000180"
      unitRef="USD">-25551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">-782000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000183"
      unitRef="USD">-2996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">-11212000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000186"
      unitRef="USD">-22555000</us-gaap:ProfitLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000189"
      unitRef="USD">201000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000191"
      unitRef="USD">-11212000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000192"
      unitRef="USD">-22756000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000196"
      unitRef="USDPShares">-502.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000197"
      unitRef="USDPShares">-6419.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">-11212000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">-22555000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">2916000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">-12142000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000205"
      unitRef="USD">-2899000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">12550000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">-11195000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">-22147000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">573282</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">2617</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">422982000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000214"
      unitRef="USD">-1316000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">-405727000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">15939000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <CYCC:IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">735</CYCC:IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">1049000</CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">1049000</CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000238"
      unitRef="Shares">-118745</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">165</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <CYCC:ReclassificationOfRedeemableCommonStockShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">866</CYCC:ReclassificationOfRedeemableCommonStockShares>
    <CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">-4494000</CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock>
    <CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">-4494000</CYCC:IncreaseInCarryingAmountOfRedeemableCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000253"
      unitRef="USD">1473000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">1473000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">201000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000265"
      unitRef="USD">201000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">12550000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">12550000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">-12142000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">-12142000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">-22555000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">-22555000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">454537</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">4412</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000289"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">429797000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">-908000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">-428282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">454537</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000308"
      unitRef="Shares">4412</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000301"
      unitRef="USD">429797000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">-908000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">-428282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <CYCC:IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000317"
      unitRef="Shares">2944</CYCC:IssueOfCommonStockPreferredStockSharesPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">0</CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">6209000</CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses>
    <CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000315"
      unitRef="USD">6209000</CYCC:IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000326"
      unitRef="Shares">-119000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000328"
      unitRef="Shares">165</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000336"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <CYCC:StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">-200000</CYCC:StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred>
    <CYCC:StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">0</CYCC:StockIssuedDuringPeriodSharesConversionOfConvertibleExchangeablePreferred>
    <CYCC:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">29391</CYCC:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <CYCC:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000343"
      unitRef="USD">0</CYCC:StockIssuedDuringPeriodValueWarrantsExercised>
    <CYCC:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">1613000</CYCC:StockIssuedDuringPeriodValueWarrantsExercised>
    <CYCC:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">1613000</CYCC:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000353"
      unitRef="USD">592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000356"
      unitRef="USD">592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">-2899000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">-2899000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">2916000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000370"
      unitRef="USD">2916000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">-11212000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000377"
      unitRef="USD">-11212000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000386"
      unitRef="Shares">135537</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000388"
      unitRef="Shares">36913</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000380"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">438211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">-891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">-439494000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">-2174000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">135537</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">36913</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000391"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000392"
      unitRef="USD">438211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000393"
      unitRef="USD">-891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">-439494000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000395"
      unitRef="USD">-2174000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">-11212000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">-22555000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000410"
      unitRef="USD">6000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">31000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000413"
      unitRef="USD">592000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000414"
      unitRef="USD">1473000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">-37000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">-69000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000422"
      unitRef="USD">-4472000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">-4712000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">-1811000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000426"
      unitRef="USD">296000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">-7990000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">-16112000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">6000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000438"
      unitRef="USD">-6000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">6209000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">1049000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <CYCC:ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">1613000</CYCC:ProceedsFromExerciseOfStockOptionsAndWarrantExercisesNetOfIssuanceCosts>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">201000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">7822000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">848000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000458"
      unitRef="USD">-73000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">303000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">-241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000462"
      unitRef="USD">-14967000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000464"
      unitRef="USD">3378000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">18345000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">3137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">3378000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">96000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000474"
      unitRef="USD">266000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000476"
      unitRef="USD">3715000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">4846000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000482"
      unitRef="USD">4000</us-gaap:InterestPaidNet>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000485"
      unitRef="USD">2000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">2000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <CYCC:AccrualOfPreferredStockDividends
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000492"
      unitRef="USD">50000</CYCC:AccrualOfPreferredStockDividends>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-292025-01-29_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000493"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-022025-01-02_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000494"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-022025-01-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000495"
      unitRef="Shares">2100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000496"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_JanuaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000497"
      unitRef="USD">3100000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <CYCC:StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary
      contextRef="From2025-01-312025-01-31_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000498"
      unitRef="USD">5600000</CYCC:StockholderSEquityIncreaseFromDeConsolidationOfSubsidiary>
    <CYCC:CommonStockValueAgreedToBeIssued
      contextRef="From2025-02-042025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000499"
      unitRef="USD">8000000</CYCC:CommonStockValueAgreedToBeIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000500"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <CYCC:SharePurchaseAgreementIncrementExerciseLotOneValue
      contextRef="From2025-02-042025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">1000000</CYCC:SharePurchaseAgreementIncrementExerciseLotOneValue>
    <CYCC:SharePurchaseAgreementIncrementExerciseLotTwoValue
      contextRef="From2025-02-042025-02-04_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">2000000</CYCC:SharePurchaseAgreementIncrementExerciseLotTwoValue>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-02-052025-02-05_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_custom_HelenaSpecialOpportunitiesOneLtdMember"
      decimals="-6"
      id="Fact000503"
      unitRef="USD">25000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2025-02-062025-02-06_us-gaap_SubsequentEventMember"
      id="Fact000504">reverse
stock split at a ratio not less than 1:4 and not more than 1:16</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-02-112025-02-11_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000505"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-02-11_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000506"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-02-112025-02-11_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000507"
      unitRef="Shares">2100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-02-11_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000508"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <CYCC:PercentageOfOutstandingCommonStock
      contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000509"
      unitRef="Pure">0.70</CYCC:PercentageOfOutstandingCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-02-112025-02-11_custom_SeriesCAndDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000510"
      unitRef="Shares">1745262</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-02-262025-02-26_custom_SeriesCAndDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000511"
      unitRef="Shares">1000000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-02-262025-02-26_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000512"
      unitRef="Shares">11041</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-02-262025-02-26_custom_SeriesDConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000513"
      unitRef="Shares">1745262</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-02-262025-02-26_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_custom_FebruaryTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000514"
      unitRef="Shares">799911</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="From2025-03-102025-03-10_us-gaap_SubsequentEventMember_custom_CyclacelLimitedUnitedKingdomMember_custom_AssetsOfCyclacelLimitedMember"
      decimals="0"
      id="Fact000515"
      unitRef="GBP">250000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-212025-03-21_custom_SeriesEConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000516"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-03-21_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_custom_SeriesEConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000517"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-03-212025-03-21_custom_SeriesEConvertiblePreferredStockMember_us-gaap_SubsequentEventMember_custom_MarchTwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000518"
      unitRef="USD">1000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <CYCC:SettlementPaymentSettlementAgreement
      contextRef="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_RombotisSettlementAgreementMember"
      decimals="2"
      id="Fact000519"
      unitRef="USD">279415.50</CYCC:SettlementPaymentSettlementAgreement>
    <CYCC:SettlementPaymentSettlementAgreement
      contextRef="From2025-01-022025-01-02_us-gaap_SubsequentEventMember_custom_McBarronSettlementAgreementMember"
      decimals="2"
      id="Fact000520"
      unitRef="USD">165164.50</CYCC:SettlementPaymentSettlementAgreement>
    <CYCC:FutureOneTimeSettlementPaymentSettlementAgreement
      contextRef="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_RombotisSettlementAgreementMember"
      decimals="2"
      id="Fact000521"
      unitRef="USD">279415.50</CYCC:FutureOneTimeSettlementPaymentSettlementAgreement>
    <CYCC:FutureOneTimeSettlementPaymentSettlementAgreement
      contextRef="AsOf2025-01-02_us-gaap_SubsequentEventMember_custom_McBarronSettlementAgreementMember"
      decimals="2"
      id="Fact000522"
      unitRef="USD">165164.50</CYCC:FutureOneTimeSettlementPaymentSettlementAgreement>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000524">&lt;p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_znfds40WrRDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
Organization of the Company and Basis of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_82C_z9TCUACedVif" style="display: none"&gt;Company
Overview&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cyclacel
Pharmaceuticals, Inc. (&#x201c;Cyclacel&#x201d; or &#x201c;the Company&#x201d;) is a clinical-stage biopharmaceutical company developing
innovative cancer medicines based on cell cycle and mitosis control biology. Cyclacel is a pioneer company in the field of cancer cell
cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome
resistance and ultimately increase a patient&#x2019;s overall survival.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, substantially all efforts of the Company to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited
to, the fact that drug candidates developed by the Company typically will require approvals or clearances from the U.S. Food and Drug
Administration, the European Medicines Agency or other similar regulatory agencies in other countries prior to commercial sales. There
can be no assurance that the Company&#x2019;s drug candidates will receive any of the required approvals or clearances. If any of the
Company&#x2019;s drug candidates are denied approval or clearance or such approval is delayed, or if the Company is unable to obtain the
necessary financing to complete development and approval, there will be a material adverse impact on the Company&#x2019;s financial condition
and results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Through
December 31, 2024, the Company has funded all of its operations and capital expenditures with proceeds from the issuance of public equity
securities, private placements of securities, government grants, research and development tax credits, interest on investments, royalty
income, product revenue and licensing revenue. The Company has incurred recurring losses since its inception, including net losses of
$&lt;span id="xdx_901_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_z7CYLlOgcdd8"&gt;11.2&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
and $&lt;span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zk9yXx1P6kE"&gt;22.6&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company had an accumulated deficit of $&lt;span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zRTcx8aPX5F6"&gt;439.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. The Company expects to continue to generate operating
losses for the foreseeable future due to, among other things, costs related to the clinical development of its drug candidate, its preclinical
programs and its administrative organization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the requirements of Accounting Standard Codification (ASC) 205-40, &lt;i&gt;Presentation of Financial Statements-Going Concern&lt;/i&gt;, management
is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial
doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are
issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s plans that have
not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,
management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company&#x2019;s
ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#x2019;s ability to continue as a going concern for one year after the date that these financial statements are issued. In
performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40,
the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered
probable at this time because these plans are not entirely within the Company&#x2019;s control nor have they been approved by the Board
of Directors as of the date of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the Company&#x2019;s current operating plan, it is anticipated that cash and cash equivalents of $&lt;span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zdm8vsc8Mgnc"&gt;3.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million as of December 31, 2024 will allow it to meet liquidity
requirements into the second quarter of 2025. The Company continues to work to raise additional capital, however, as of the date of these
financial statements there is no guarantee that the Company will be able to raise additional funds to extend operations beyond the second
quarter of 2025. The Company&#x2019;s history of losses, negative cash flows from operations, liquid resources currently on hand, and
dependence on the ability to obtain additional financing to fund its operations, about which there can be no certainty, have resulted
in the assessment that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of at
least twelve months from the issuance date of these financial statements. While the Company has plans in place to mitigate this risk,
which primarily consist of raising additional capital through a combination of public or private equity or debt financings or by entering
into partnership agreements for further development of our drug candidates, there is no guarantee that it will be successful in these
mitigation efforts. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates
realization of assets and the satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America, or GAAP and include the financial statements of Cyclacel Pharmaceuticals, Inc. and all of the Company&#x2019;s
wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company effected a &lt;span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20231218__20231218_zE0NtuWg5gx"&gt;15:1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reverse stock split of the Company&#x2019;s common stock on
December 18, 2023 (the &#x201c;Reverse Stock Split&#x201d;). All share and per share information has been adjusted to give effect to the
Reverse Stock Split for all periods presented, unless otherwise indicated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company held a special meeting of stockholders (the &#x201c;Special Meeting&#x201d;) on February 6, 2025 at which, among other matters,
the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation to effect
a &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20250206__20250206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5x4FQ6t8Hd1"&gt;reverse
stock split at a ratio not less than 1:4 and not more than 1:16&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(the
&#x201c;2025 Reverse Stock Split&#x201d;) such ratio and the implementation and timing of such Reverse Stock Split to be determined in
the discretion of the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;). The 2025 Reverse Stock Split is expected to be implemented
by the Board in or around May 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBvZiB0aGUgQ29tcGFueSBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd7x1WMim2fg"&gt;All references to issued and outstanding shares
all periods reflect: the 1-for-16 reverse stock split effective May 12, 2025, and the 1-for-15 reverse stock split effective July 7,
2025. As a result, all share numbers for all periods, including the number of shares underlying warrants, options, and other convertible
securities, and all exercise prices applicable to such warrants, options and convertible securities have been adjusted retrospectively
to give effect to the 1-for-16 and 1-for-15 reverse stock splits&lt;/span&gt;.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact000525"
      unitRef="USD">-11200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000526"
      unitRef="USD">-22600000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000527"
      unitRef="USD">-439500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000528"
      unitRef="USD">3100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-12-182023-12-18" id="Fact000529">15:1</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2025-02-062025-02-06_us-gaap_SubsequentEventMember"
      id="Fact000530">reverse
stock split at a ratio not less than 1:4 and not more than 1:16</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember"
      id="Fact000531">All references to issued and outstanding shares
all periods reflect: the 1-for-16 reverse stock split effective May 12, 2025, and the 1-for-15 reverse stock split effective July 7,
2025. As a result, all share numbers for all periods, including the number of shares underlying warrants, options, and other convertible
securities, and all exercise prices applicable to such warrants, options and convertible securities have been adjusted retrospectively
to give effect to the 1-for-16 and 1-for-15 reverse stock splits</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-012024-12-31" id="Fact000533">&lt;p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zkPOm8snEPCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_824_zBrTlNiBQtY1"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zf22ZbzN9hBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_860_zORo9d23eFii" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and
the reported expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals and stock-based
compensation expense. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various
other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates.
Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the
Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zTsyEQTmcUjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_867_zzBt6yywtCb9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
Currency and Currency Translation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets and liabilities of the Company&#x2019;s international subsidiary are translated from its functional currency into United States
dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the
statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising
on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses
arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable future and that
are of a long-term-investment nature, are recorded in other comprehensive loss. As discussed in the subsequent events note, the foreign
subsidiary will be liquidated. Upon loss of control of the foreign subsidiary, the accumulated translation adjustments currently recorded
in other comprehensive income within equity will be reversed and recorded as part of the gain/loss from deconsolidation of the subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhPazvbBRD2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_868_zg5mNVQtEq1k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The objectives of the Company&#x2019;s cash management policy are to safeguard and preserve funds, to maintain sufficient
liquidity to meet Cyclacel&#x2019;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial
institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is
exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s cash and cash equivalents balance at December 31, 2024 was $&lt;span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z8mXOaPoUwya"&gt;3.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and it maintains its cash accounts in several entities
both within the United States and the United Kingdom. The cash balances for amounts held in the United States are insured by the Federal
Deposit Insurance Corporation, or FDIC up to $&lt;span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20241231__srt--RangeAxis__srt--MaximumMember_ztFkYdx0KeVa"&gt;250,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per account. The Company has cash balances exceeding the balance
insured by the FDIC that totaled approximately $&lt;span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zRYaqA6cTC64"&gt;2.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million at December 31, 2024. The cash balances for amounts
held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme, or FSCS up to &#xa3;&lt;span id="xdx_907_ecustom--CashFinancialServicesCompensationSchemeInsuredAmount_iI_uGBP_c20241231__srt--RangeAxis__srt--MaximumMember_z8induwTekb5"&gt;85,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per account. The Company does not have cash balances exceeding
the balance insured by the FSCS at December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8XV9i7HEWC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_867_zJXr7MejXSGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of
the related assets, which are generally three &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zKERt8IxurR8" style="display: none"&gt;3 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zS7NMRj7zts8"&gt;five
years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. Amortization of leasehold
improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life
of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are
removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss.
Expenditures for maintenance and repairs are charged to operating expenses as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zSYMxV5D0yt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_862_zqSOuNl91Gt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets
by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment,
if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrUHKJjdqFV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86B_zqNibifhTxSh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy,
of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#x25cf; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1&#x2009;&#x2014;&#x2009;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 2&#x2009;&#x2014;&#x2009;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that
are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 3&#x2009;&#x2014;&#x2009;Unobservable inputs that are supported by little or no market activity that are significant to determining
the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values
due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZSdFDq0EjRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_867_z0RohBEsyXM9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is managed and operated as &lt;span id="xdx_902_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zTSW8xTZfz6a"&gt;one&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;business which is focused on using cell cycle, transcriptional
regulation and mitosis control biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire
business is managed by a single management team that reports to the Chief Executive Officer. Historically, the Company has not operated
separate lines of business with respect to any of its products or product candidates and the Company did not prepare discrete financial
information with respect to separate products or product candidates or by location through December 31, 2024. Accordingly, the Company
has viewed its business historically as &lt;span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zWLd0JQd0Sx3"&gt;one&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reportable operating segment with development operations in
&lt;span id="xdx_909_eus-gaap--NumberOfCountriesInWhichEntityOperates_iI_dc_uInteger_c20241231_zEdDnnew2oul"&gt;two&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;geographic
areas, namely the United States and the United Kingdom. With the commencement of the liquidation of the Subsidiary, the Company will
no longer be considered to have control over the Subsidiary and the financial results of the Subsidiary will be deconsolidated from those
of the Company commencing with its first quarter 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zyfbuT5pdDSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_862_zr7bBrD150F5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not generated any revenues from product sales to date. However, the Company recognized $&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zdRogL4upoDl"&gt;43,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of revenue for the year ended December 31, 2024. This revenue
relates to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center
(&#x201c;CSMC&#x201d;). There was $&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230101__20231231_zJpEFhhMydod"&gt;420,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of revenues recognized for the comparative period in 2023.
All revenues from this customer are recognized at the point in time that the related clinical supply are transferred to CSMC and CSMC
obtains control over the goods. The arrangements with CSMC comprise a single performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not recognized any other sources of revenue during the years ended December 31 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company invoices CSMC following the transfer of the clinical supply and provides CSMC with typical payment terms. The Company has collected
all amounts due from CSMC. As of December 31, 2024, December 31, 2023, and January, 1, 2023, the Company has not recognized any accounts
receivable from CSMC, credit loss allowances, contract assets, contract liabilities, or warranty provisions. There were &lt;span id="xdx_905_eus-gaap--RevenueRemainingPerformanceObligation_iI_do_c20241231_zyystFxOLx5"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining performance obligations outstanding as of December
31, 2024; however, CSMC may place additional orders for clinical supply in 2025 and beyond.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--OtherIncomePolicyTextBlock_z48CGyEtEVP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_864_zpPxy3yffl8d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Income&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part
of the Company&#x2019;s ongoing operations and activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIW8polrH7g2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_869_zhV5KtObiUm7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses consist primarily of costs associated with the development of the Company&#x2019;s product candidates, including
upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials,
costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development
are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--ClinicalTrialAccountingPolicyTextBlock_zz39pDabBkt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86D_zboMqvkHKNq2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Clinical
Trial Accounting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Data
management and monitoring of the Company&#x2019;s clinical trials are performed with the assistance of contract research organizations,
or CROs or clinical research associates, or CRAs in accordance with the Company&#x2019;s standard operating procedures. Typically, CROs
and CRAs bill monthly for services performed, and others bill based upon milestones achieved. The Company accrues unbilled clinical trial
expenses based on estimates of the level of services performed each period. Clinical trial costs related to patient enrollment are accrued
as patients are entered into and progress through the trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zghWh5wi7XVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_861_zGXaAhljvi39" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patent
Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patent
prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zaElcefeAcl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_867_zBP3UW2DZHD" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for lease contracts in accordance with ASC 842. As of December 31, 2024 and 2023, all of the Company&#x2019;s leases
are classified as operating leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#x2019;s obligation to make lease payments under the lease. As the Company&#x2019;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how a loan would be repaid (e.g.,
amortizing versus bullet), and the Company&#x2019;s credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of
exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether
it is reasonably certain that the Company will exercise an option, the Company considers factors such as:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease payments due in any optional period;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Penalties
    for failure to exercise (or not exercise) the option;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market
    factors, such as the availability of similar assets and current rental rates for such assets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    nature of the underlying leased asset and its importance to the Company&#x2019;s operations; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    remaining useful lives of any related leasehold improvements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term and is reported as a component
of general and administrative expense. Variable lease payments, if any, are recognized in the period when the obligation to make those
payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed
lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw7hrtGvrsh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86C_zqnZce9J5QU" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date
of the grant and recognizes compensation expense of those awards over the requisite service period, which for the Company is the period
between the grant date and the date the award vests or becomes exercisable. Many awards granted by the Company vest ratably over three&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z2zvqtVyXwXj" style="display: none"&gt;3&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;or &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zJTSjJa78iD3"&gt;four
years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. However, certain awards granted to members
of the Company&#x2019;s Board of Directors vest in their entirety on the one&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_z8fUbfdTSME4" style="display: none"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-year
anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only
service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain years,
the Company will grant share-based payment awards to employees that are dependent upon the fulfillment of certain clinical and financial
conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes compensation
expense when the award is probable of vesting (See Note 12&#x2009;&#x2014;&#x2009;Stock-Based Compensation).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies stock-based compensation expenses in its statement of operations in the same manner in which the award recipient&#x2019;s
payroll costs are classified. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of restricted stock and restricted stock units is determined based on the number of shares granted and the quoted price of
the Company&#x2019;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated
using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#x2019;s share price, expected
term of the award, interest rates, and dividend yields.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on its historical volatility as an input to the option pricing model as management believes that this rate will be representative
of future volatility over the expected term of the options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average risk-free interest rate represents the interest rate for treasury constant maturities published by the Federal Reserve
Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel
interpolates a discount rate based on the two Federal Reserve securities closest to the expected term of the employee option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected dividend yield is zero, as the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends
on common stock in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z54Xjh3qPW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86C_zqR9Wghh5rvd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based
on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year
in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred
tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the
amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained
upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not-to be sustained, the tax position
is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized
is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes
includes the effects of any resulting tax reserves for unrecognized tax benefits that are considered appropriate as well as the related
net interest and penalties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records research and development tax credits within income taxes. Credit is taken in the accounting period for research and development
tax credits, when claimed from H.M. Revenue &amp;amp; Customs, or HMRC, the United Kingdom&#x2019;s taxation and customs authority, in respect
of qualifying research and development costs incurred in the same accounting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zg7mEvChTDKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_862_zfnnR38qNFEf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net
Loss Per Common Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates net loss per common share in accordance with ASC 260 &#x201c;Earnings Per Share&#x201d;. Basic and diluted net loss
per common share was determined by dividing the net loss applicable to common stockholders by the weighted average number of common shares
outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common
stockholders is the same as basic net loss per share attributable to common stockholders since potentially dilutive common shares are
not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders
for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z1D5SLfGoCwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86F_zHxZvlU9nSie" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Comprehensive
Income (Loss)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported to arrive at comprehensive income (loss). There were &lt;span id="xdx_905_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20230101__20231231_zgku0Qy7OIg9"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reclassifications out of other comprehensive income (loss)
during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_z4CYFimM2Iy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_866_zzVz1m4j8wpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB has issued ASU 2024-03, &#x201c;&lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;&#x201d;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB has issued ASU 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#x201d;. This standard will require
all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage
and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received)
disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions
for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods
beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation
of that information.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85E_zSxsf6fBNRa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-012024-12-31" id="Fact000535">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zf22ZbzN9hBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_860_zORo9d23eFii" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and
the reported expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals and stock-based
compensation expense. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various
other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates.
Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the
Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000537">&lt;p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zTsyEQTmcUjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_867_zzBt6yywtCb9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
Currency and Currency Translation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets and liabilities of the Company&#x2019;s international subsidiary are translated from its functional currency into United States
dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the
statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising
on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses
arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable future and that
are of a long-term-investment nature, are recorded in other comprehensive loss. As discussed in the subsequent events note, the foreign
subsidiary will be liquidated. Upon loss of control of the foreign subsidiary, the accumulated translation adjustments currently recorded
in other comprehensive income within equity will be reversed and recorded as part of the gain/loss from deconsolidation of the subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000539">&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhPazvbBRD2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_868_zg5mNVQtEq1k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The objectives of the Company&#x2019;s cash management policy are to safeguard and preserve funds, to maintain sufficient
liquidity to meet Cyclacel&#x2019;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial
institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is
exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s cash and cash equivalents balance at December 31, 2024 was $&lt;span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z8mXOaPoUwya"&gt;3.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and it maintains its cash accounts in several entities
both within the United States and the United Kingdom. The cash balances for amounts held in the United States are insured by the Federal
Deposit Insurance Corporation, or FDIC up to $&lt;span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20241231__srt--RangeAxis__srt--MaximumMember_ztFkYdx0KeVa"&gt;250,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per account. The Company has cash balances exceeding the balance
insured by the FDIC that totaled approximately $&lt;span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zRYaqA6cTC64"&gt;2.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million at December 31, 2024. The cash balances for amounts
held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme, or FSCS up to &#xa3;&lt;span id="xdx_907_ecustom--CashFinancialServicesCompensationSchemeInsuredAmount_iI_uGBP_c20241231__srt--RangeAxis__srt--MaximumMember_z8induwTekb5"&gt;85,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per account. The Company does not have cash balances exceeding
the balance insured by the FSCS at December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000540"
      unitRef="USD">3100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="0"
      id="Fact000541"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000542"
      unitRef="USD">2800000</us-gaap:CashUninsuredAmount>
    <CYCC:CashFinancialServicesCompensationSchemeInsuredAmount
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="0"
      id="Fact000543"
      unitRef="GBP">85000</CYCC:CashFinancialServicesCompensationSchemeInsuredAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000545">&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8XV9i7HEWC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_867_zJXr7MejXSGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of
the related assets, which are generally three &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zKERt8IxurR8" style="display: none"&gt;3 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zS7NMRj7zts8"&gt;five
years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. Amortization of leasehold
improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life
of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are
removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss.
Expenditures for maintenance and repairs are charged to operating expenses as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentMember"
      id="Fact000546">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentMember"
      id="Fact000547">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000549">&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zSYMxV5D0yt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_862_zqSOuNl91Gt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets
by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment,
if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-012024-12-31" id="Fact000551">&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrUHKJjdqFV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86B_zqNibifhTxSh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy,
of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#x25cf; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1&#x2009;&#x2014;&#x2009;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 2&#x2009;&#x2014;&#x2009;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that
are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 3&#x2009;&#x2014;&#x2009;Unobservable inputs that are supported by little or no market activity that are significant to determining
the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values
due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000553">&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZSdFDq0EjRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_867_z0RohBEsyXM9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is managed and operated as &lt;span id="xdx_902_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zTSW8xTZfz6a"&gt;one&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;business which is focused on using cell cycle, transcriptional
regulation and mitosis control biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire
business is managed by a single management team that reports to the Chief Executive Officer. Historically, the Company has not operated
separate lines of business with respect to any of its products or product candidates and the Company did not prepare discrete financial
information with respect to separate products or product candidates or by location through December 31, 2024. Accordingly, the Company
has viewed its business historically as &lt;span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zWLd0JQd0Sx3"&gt;one&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reportable operating segment with development operations in
&lt;span id="xdx_909_eus-gaap--NumberOfCountriesInWhichEntityOperates_iI_dc_uInteger_c20241231_zEdDnnew2oul"&gt;two&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;geographic
areas, namely the United States and the United Kingdom. With the commencement of the liquidation of the Subsidiary, the Company will
no longer be considered to have control over the Subsidiary and the financial results of the Subsidiary will be deconsolidated from those
of the Company commencing with its first quarter 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000554"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000555"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000556"
      unitRef="Integer">2</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000558">&lt;p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zyfbuT5pdDSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_862_zr7bBrD150F5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not generated any revenues from product sales to date. However, the Company recognized $&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zdRogL4upoDl"&gt;43,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of revenue for the year ended December 31, 2024. This revenue
relates to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center
(&#x201c;CSMC&#x201d;). There was $&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230101__20231231_zJpEFhhMydod"&gt;420,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of revenues recognized for the comparative period in 2023.
All revenues from this customer are recognized at the point in time that the related clinical supply are transferred to CSMC and CSMC
obtains control over the goods. The arrangements with CSMC comprise a single performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not recognized any other sources of revenue during the years ended December 31 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company invoices CSMC following the transfer of the clinical supply and provides CSMC with typical payment terms. The Company has collected
all amounts due from CSMC. As of December 31, 2024, December 31, 2023, and January, 1, 2023, the Company has not recognized any accounts
receivable from CSMC, credit loss allowances, contract assets, contract liabilities, or warranty provisions. There were &lt;span id="xdx_905_eus-gaap--RevenueRemainingPerformanceObligation_iI_do_c20241231_zyystFxOLx5"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining performance obligations outstanding as of December
31, 2024; however, CSMC may place additional orders for clinical supply in 2025 and beyond.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">43000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">420000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">0</us-gaap:RevenueRemainingPerformanceObligation>
    <CYCC:OtherIncomePolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000563">&lt;p id="xdx_84D_ecustom--OtherIncomePolicyTextBlock_z48CGyEtEVP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_864_zpPxy3yffl8d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Income&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part
of the Company&#x2019;s ongoing operations and activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</CYCC:OtherIncomePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-012024-12-31" id="Fact000565">&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIW8polrH7g2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_869_zhV5KtObiUm7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses consist primarily of costs associated with the development of the Company&#x2019;s product candidates, including
upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials,
costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development
are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <CYCC:ClinicalTrialAccountingPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000567">&lt;p id="xdx_84F_ecustom--ClinicalTrialAccountingPolicyTextBlock_zz39pDabBkt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86D_zboMqvkHKNq2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Clinical
Trial Accounting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Data
management and monitoring of the Company&#x2019;s clinical trials are performed with the assistance of contract research organizations,
or CROs or clinical research associates, or CRAs in accordance with the Company&#x2019;s standard operating procedures. Typically, CROs
and CRAs bill monthly for services performed, and others bill based upon milestones achieved. The Company accrues unbilled clinical trial
expenses based on estimates of the level of services performed each period. Clinical trial costs related to patient enrollment are accrued
as patients are entered into and progress through the trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</CYCC:ClinicalTrialAccountingPolicyTextBlock>
    <CYCC:PatentCostsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000569">&lt;p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zghWh5wi7XVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_861_zGXaAhljvi39" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patent
Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patent
prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CYCC:PatentCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000571">&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zaElcefeAcl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_867_zBP3UW2DZHD" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for lease contracts in accordance with ASC 842. As of December 31, 2024 and 2023, all of the Company&#x2019;s leases
are classified as operating leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#x2019;s obligation to make lease payments under the lease. As the Company&#x2019;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how a loan would be repaid (e.g.,
amortizing versus bullet), and the Company&#x2019;s credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of
exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether
it is reasonably certain that the Company will exercise an option, the Company considers factors such as:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease payments due in any optional period;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Penalties
    for failure to exercise (or not exercise) the option;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market
    factors, such as the availability of similar assets and current rental rates for such assets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    nature of the underlying leased asset and its importance to the Company&#x2019;s operations; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    remaining useful lives of any related leasehold improvements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term and is reported as a component
of general and administrative expense. Variable lease payments, if any, are recognized in the period when the obligation to make those
payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed
lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-012024-12-31" id="Fact000573">&lt;p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw7hrtGvrsh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86C_zqnZce9J5QU" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date
of the grant and recognizes compensation expense of those awards over the requisite service period, which for the Company is the period
between the grant date and the date the award vests or becomes exercisable. Many awards granted by the Company vest ratably over three&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z2zvqtVyXwXj" style="display: none"&gt;3&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;or &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zJTSjJa78iD3"&gt;four
years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. However, certain awards granted to members
of the Company&#x2019;s Board of Directors vest in their entirety on the one&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_z8fUbfdTSME4" style="display: none"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-year
anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only
service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain years,
the Company will grant share-based payment awards to employees that are dependent upon the fulfillment of certain clinical and financial
conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes compensation
expense when the award is probable of vesting (See Note 12&#x2009;&#x2014;&#x2009;Stock-Based Compensation).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies stock-based compensation expenses in its statement of operations in the same manner in which the award recipient&#x2019;s
payroll costs are classified. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of restricted stock and restricted stock units is determined based on the number of shares granted and the quoted price of
the Company&#x2019;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated
using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#x2019;s share price, expected
term of the award, interest rates, and dividend yields.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on its historical volatility as an input to the option pricing model as management believes that this rate will be representative
of future volatility over the expected term of the options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average risk-free interest rate represents the interest rate for treasury constant maturities published by the Federal Reserve
Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel
interpolates a discount rate based on the two Federal Reserve securities closest to the expected term of the employee option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected dividend yield is zero, as the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends
on common stock in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact000574">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact000575">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_srt_DirectorMember"
      id="Fact000576">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000578">&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z54Xjh3qPW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86C_zqR9Wghh5rvd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based
on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year
in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred
tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the
amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained
upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not-to be sustained, the tax position
is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized
is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes
includes the effects of any resulting tax reserves for unrecognized tax benefits that are considered appropriate as well as the related
net interest and penalties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records research and development tax credits within income taxes. Credit is taken in the accounting period for research and development
tax credits, when claimed from H.M. Revenue &amp;amp; Customs, or HMRC, the United Kingdom&#x2019;s taxation and customs authority, in respect
of qualifying research and development costs incurred in the same accounting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000580">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zg7mEvChTDKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_862_zfnnR38qNFEf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net
Loss Per Common Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates net loss per common share in accordance with ASC 260 &#x201c;Earnings Per Share&#x201d;. Basic and diluted net loss
per common share was determined by dividing the net loss applicable to common stockholders by the weighted average number of common shares
outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common
stockholders is the same as basic net loss per share attributable to common stockholders since potentially dilutive common shares are
not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders
for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000582">&lt;p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z1D5SLfGoCwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_86F_zHxZvlU9nSie" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Comprehensive
Income (Loss)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported to arrive at comprehensive income (loss). There were &lt;span id="xdx_905_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20230101__20231231_zgku0Qy7OIg9"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reclassifications out of other comprehensive income (loss)
during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000583"
      unitRef="USD">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <CYCC:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000585">&lt;p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_z4CYFimM2Iy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_866_zzVz1m4j8wpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB has issued ASU 2024-03, &#x201c;&lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;&#x201d;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB has issued ASU 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#x201d;. This standard will require
all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage
and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received)
disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions
for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods
beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation
of that information.&lt;/span&gt;&lt;/p&gt;

</CYCC:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <CYCC:SignificantContractsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000587">&lt;p id="xdx_80B_ecustom--SignificantContractsDisclosureTextBlock_zG5SVzWD8z2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_82A_zrJx7x7nmhb8"&gt;Significant Contracts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Distribution,
Licensing and Research Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into licensing and similar agreements with academic and research organizations. Under the terms of these agreements,
the Company has received licenses to technology and patent applications. The Company may be required to pay royalties on future sales
of products employing the technology or falling under claims of patent applications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
a 2003 license agreement, the Company licensed certain patent rights for sapacitabine. The Company will not be pursuing further development
of sapacitabine and the license agreement was terminated effective as of March 23, 2023 for commercial reasons.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three&lt;span id="xdx_902_ecustom--TermOfAgreement_dtY_c20210901__20210930__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zJN1Y8Vra9Z6" style="display: none"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-year
term of the Clinical Collaboration Agreement, or CCA with The University of Texas MD Anderson Cancer Center, or MD Anderson ended in
September 2021, in accordance with its terms. The main objective of the CCA was to clinically evaluate the safety and efficacy of three
Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic
syndromes and other advanced leukemias. Under the terms of the CCA, MD Anderson conducted &lt;span id="xdx_907_ecustom--ConductClinicalStudies_dc_uInteger_c20210901__20210930__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zX8BqBaVQNI5"&gt;four&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;clinical studies and under the risk-sharing agreement MD Anderson
assumed the patient costs for all studies and Cyclacel, who is the sponsor, provided investigational drugs and other limited support.
The agreement provided that the Company would make certain payments to MD Anderson upon first commercial sale in specific indications
studied in the alliance. There were &lt;span id="xdx_909_ecustom--LicenseAgreementPaymentEarned_iI_do_c20231231__srt--CounterpartyNameAxis__custom--MdAndersonMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalCollaborationAgreementMember_zXvQVl3uVxs4"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;such payments earned in 2024 or 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</CYCC:SignificantContractsDisclosureTextBlock>
    <CYCC:TermOfAgreement
      contextRef="From2021-09-012021-09-30_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember"
      id="Fact000588">P3Y</CYCC:TermOfAgreement>
    <CYCC:ConductClinicalStudies
      contextRef="From2021-09-012021-09-30_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember"
      decimals="INF"
      id="Fact000589"
      unitRef="Integer">4</CYCC:ConductClinicalStudies>
    <CYCC:LicenseAgreementPaymentEarned
      contextRef="AsOf2023-12-31_custom_MdAndersonMember_custom_ClinicalCollaborationAgreementMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">0</CYCC:LicenseAgreementPaymentEarned>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000592">&lt;p id="xdx_808_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zYZBZ7Fszs8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_82B_zbwIypBARO7e"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zKGCPiHTH0vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of cash and cash equivalents at December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zSET5jeIuAFb" style="display: none"&gt;Summary
of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zCrSHJ6cUOUa" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_z3X01H23zeu9" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Cash_iI_pn3n3_maCACEAzyS5_zOQ4QyfcCAj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,303&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_maCACEAzyS5_ztNzonajCXL9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtCACEAzyS5_ztcDYgnqRxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zlpBK3rZKgqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
equivalents are made up entirely of money market funds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000594">&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zKGCPiHTH0vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of cash and cash equivalents at December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zSET5jeIuAFb" style="display: none"&gt;Summary
of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zCrSHJ6cUOUa" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_z3X01H23zeu9" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Cash_iI_pn3n3_maCACEAzyS5_zOQ4QyfcCAj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,303&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_maCACEAzyS5_ztNzonajCXL9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_pn3n3_mtCACEAzyS5_ztcDYgnqRxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000596"
      unitRef="USD">93000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">3303000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000599"
      unitRef="USD">3044000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000600"
      unitRef="USD">75000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000602"
      unitRef="USD">3137000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">3378000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-01-012024-12-31" id="Fact000605">&lt;p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zeQ0gULVRKzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_825_zPqp0YORJTqh"&gt;Fair Value of Financial Assets and Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zQMBDnQxiAIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zfWV7hPOTay2" style="display: none"&gt;Schedule
of Financial Assets and Liabilities Measured on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwX5DJUCfoAc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level
    1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgjTt48bL3B6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level
    2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zfavjkQ0qZS8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level
    3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z03y08eOqvN3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; font-weight: bold"&gt;Fair Value Measurements&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;as of December 31, 2024 Using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zoNhzn6SrTel" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0611"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zI3MZ1GRH2td" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0615"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVw0fayAHRdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level
    1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zljm8svDHA5a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level
    2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxVo90jidCB1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level
    3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCFgvYNLB1Nd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value Measurements&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;as of December 31, 2023 Using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zz6uWUGiipWl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0620"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0621"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zs7yLDFJFqs1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AB_z4BNglRLtnA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000607">&lt;p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zQMBDnQxiAIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zfWV7hPOTay2" style="display: none"&gt;Schedule
of Financial Assets and Liabilities Measured on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwX5DJUCfoAc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level
    1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgjTt48bL3B6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level
    2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zfavjkQ0qZS8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level
    3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z03y08eOqvN3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; font-weight: bold"&gt;Fair Value Measurements&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;as of December 31, 2024 Using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zoNhzn6SrTel" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0611"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zI3MZ1GRH2td" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0615"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVw0fayAHRdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level
    1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zljm8svDHA5a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level
    2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxVo90jidCB1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level
    3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCFgvYNLB1Nd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value Measurements&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;as of December 31, 2023 Using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_zz6uWUGiipWl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0620"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0621"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iTI_pn3n3_zs7yLDFJFqs1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">3044000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000612"
      unitRef="USD">3044000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000614"
      unitRef="USD">3044000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">3044000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">75000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000622"
      unitRef="USD">75000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">75000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">75000</us-gaap:AssetsFairValueDisclosure>
    <CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="From2024-01-012024-12-31" id="Fact000629">&lt;p id="xdx_809_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zJiNGqNYU9Ca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
Prepaid Expenses and Other Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_829_zPuB703Js7B" style="display: none"&gt;Prepaid
Expenses and Other Current Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zQgaOlf1dqf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of prepaid expenses and other current assets at December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B3_zoCIaaOCdeBb" style="display: none"&gt;Schedule
of prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_z7lf3DnBHndi" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zKUsKElCmOml" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxesAndOtherTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zNaZJS6qlveb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development tax credit receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zfR5pVGM24T6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepayments and VAT receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQOL_zcBXTXszRPd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;341&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQOL_z5PJ3bmEwOj2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zulAoQBuRbql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000631">&lt;p id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zQgaOlf1dqf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of prepaid expenses and other current assets at December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B3_zoCIaaOCdeBb" style="display: none"&gt;Schedule
of prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_z7lf3DnBHndi" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zKUsKElCmOml" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxesAndOtherTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zNaZJS6qlveb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development tax credit receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPEAOAzQOL_zfR5pVGM24T6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepayments and VAT receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQOL_zcBXTXszRPd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;341&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQOL_z5PJ3bmEwOj2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000634"
      unitRef="USD">2933000</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
    <CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000636"
      unitRef="USD">237000</CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent>
    <CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000637"
      unitRef="USD">792000</CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000639"
      unitRef="USD">300000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000640"
      unitRef="USD">341000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000642"
      unitRef="USD">537000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">4066000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <CYCC:NonCurrentAssetsTextBlock contextRef="From2024-01-012024-12-31" id="Fact000645">&lt;p id="xdx_805_ecustom--NonCurrentAssetsTextBlock_zeJZXRYmhcki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_825_zKmxr92m22H"&gt;Non-Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
at December 31, 2024, the Company had non-current assets of $&lt;span id="xdx_90A_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20241231_zm2zxTjof2Z6"&gt;0.4&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, which comprised clinical trial deposits held by a
contract research organization in relation to the Company&#x2019;s Phase 1/2 clinical trials. As at December 31, 2023, the Company had
non-current assets of $&lt;span id="xdx_901_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20231231_zblFozQVrCq"&gt;1.3&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million,
which was wholly attributable to clinical trial deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</CYCC:NonCurrentAssetsTextBlock>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000646"
      unitRef="USD">400000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000647"
      unitRef="USD">1300000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000649">&lt;p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRAliyO6pFj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_82F_zUSzh6bAoghk"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5FwiODQbG4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following at December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zA2wcsohQTJ3" style="display: none"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_zwww3daVkxr1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zApi9l4rFhx3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;Lives in&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zDPi9ChoS2B7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 14%"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVSyesfIk2Xj"&gt;2&lt;/span&gt;
    to &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z60zWO360104"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zP0tiNECtJP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment and furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zwbT4afEWMY2"&gt;3&lt;/span&gt;
    to &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_ztazAMISFTch"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_maPPAENzWpG_zblZiY2R2G18" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzWpG_zWafk7wLbO2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(424&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzWpG_zSnlF9zZX9a9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zL4k8x7IAF6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-012024-12-31" id="Fact000651">&lt;p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5FwiODQbG4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following at December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zA2wcsohQTJ3" style="display: none"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_zwww3daVkxr1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zApi9l4rFhx3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;Lives in&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zDPi9ChoS2B7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 14%"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVSyesfIk2Xj"&gt;2&lt;/span&gt;
    to &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z60zWO360104"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zP0tiNECtJP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment and furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zwbT4afEWMY2"&gt;3&lt;/span&gt;
    to &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_ztazAMISFTch"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_maPPAENzWpG_zblZiY2R2G18" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzWpG_zWafk7wLbO2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(424&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzWpG_zSnlF9zZX9a9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_LeaseholdImprovementsMember"
      id="Fact000655">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_LeaseholdImprovementsMember"
      id="Fact000656">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">6000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">6000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember_custom_OfficeEquipmentAndFurnitureMember"
      id="Fact000660">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember_custom_OfficeEquipmentAndFurnitureMember"
      id="Fact000661">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_OfficeEquipmentAndFurnitureMember"
      decimals="-3"
      id="Fact000658"
      unitRef="USD">420000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_OfficeEquipmentAndFurnitureMember"
      decimals="-3"
      id="Fact000659"
      unitRef="USD">423000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000663"
      unitRef="USD">427000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000664"
      unitRef="USD">429000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">424000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000667"
      unitRef="USD">420000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000669"
      unitRef="USD">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000670"
      unitRef="USD">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-01-012024-12-31" id="Fact000672">&lt;p id="xdx_80F_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zHc4nHN70Xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
Accrued and Other Current Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_822_zzyIFd8uN2gb" style="display: none"&gt;Accrued
and Other Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaF3qBcqwcx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
and other current liabilities consisted of the following at December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zbG35D6tYoFb" style="display: none"&gt;Schedule
of Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zaNSbn7pGCEe" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zWyxteIAyah1" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_pn3n3_maALCzjWX_zxdCwQ5F9Xhg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,299&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzjWX_zYEd45USEZVb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued legal and professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--OtherCurrentLiabilities_iI_pn3n3_maALCzjWX_zNaqeuRnK0Oj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzjWX_zdKU4QmktAa4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zkwCvpwKGGCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
at December 31, 2024, the Company had accounts payables of $&lt;span id="xdx_902_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20241231_z0nvYC2wo6Ba"&gt;4.6&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, of which $&lt;span id="xdx_90C_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--UnitedKingdomSubsidiaryCompanyMember_zdj93MkE06j5"&gt;4.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million related to the UK subsidiary. As at December 31, 2023,
the Company had accounts payables of $&lt;span id="xdx_901_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20231231_zQFCi6UqWH2b"&gt;3.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, of which $&lt;span id="xdx_909_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--UnitedKingdomSubsidiaryCompanyMember_zONXGAeXRTO"&gt;3.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million related to the UK subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000674">&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zaF3qBcqwcx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
and other current liabilities consisted of the following at December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zbG35D6tYoFb" style="display: none"&gt;Schedule
of Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zaNSbn7pGCEe" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zWyxteIAyah1" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_pn3n3_maALCzjWX_zxdCwQ5F9Xhg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,299&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzjWX_zYEd45USEZVb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued legal and professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--OtherCurrentLiabilities_iI_pn3n3_maALCzjWX_zNaqeuRnK0Oj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzjWX_zdKU4QmktAa4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <CYCC:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000676"
      unitRef="USD">1299000</CYCC:AccruedResearchAndDevelopmentCostsCurrent>
    <CYCC:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000677"
      unitRef="USD">3668000</CYCC:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000679"
      unitRef="USD">87000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000680"
      unitRef="USD">570000</us-gaap:AccruedProfessionalFeesCurrent>
    <CYCC:OtherCurrentLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000682"
      unitRef="USD">283000</CYCC:OtherCurrentLiabilities>
    <CYCC:OtherCurrentLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000683"
      unitRef="USD">380000</CYCC:OtherCurrentLiabilities>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">1669000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000686"
      unitRef="USD">4618000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000687"
      unitRef="USD">4600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31_custom_UnitedKingdomSubsidiaryCompanyMember"
      decimals="-5"
      id="Fact000688"
      unitRef="USD">4100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000689"
      unitRef="USD">3500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_custom_UnitedKingdomSubsidiaryCompanyMember"
      decimals="-5"
      id="Fact000690"
      unitRef="USD">3100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000692">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAEWNduzmAte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_821_zNIoIndDsXm1"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Please
refer to &lt;i&gt;Note 3&#x2009;&#x2014;&#x2009;Significant Contracts&lt;/i&gt; for further discussion of certain of the Company&#x2019;s commitments
and contingencies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2022, the Company extended the lease for its corporate headquarters facility in Berkeley Heights, New Jersey for a further &lt;span id="xdx_90A_ecustom--LesseeOperatingLeaseTermOfContractExtension_dc_c20220401__20220430__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_z9dGR3SGzIS8"&gt;three
years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;, expiring in July 2025. In December 2024,
the Company terminated this lease, effective as of January 31, 2025. Effective March 1, 2025, the Company entered into a &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20241231__srt--StatementGeographicalAxis__custom--CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember_zxR258m07qDb"&gt;two
year&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;lease agreement for our corporate headquarters
at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia, which we believe will be adequate to accommodate
our business needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and December 31, 2023, the Company recognized operating lease expenses of $&lt;span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zmXNvBr5nk46"&gt;82,830&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zeMeGg0KHhKi"&gt;74,218&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively, including $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zbWfZnQMwJb6"&gt;9,104&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20230101__20231231__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zs9wSo2B9ce4"&gt;10,851&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively relating to a short term lease for offices in
Dundee, Scotland. The remaining lease term as of December 31, 2024 is &lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dc_c20241231__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_zzfOXMvQYFUl"&gt;one
month&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the Berkeley Heights facility and no
remaining lease term for Dundee, Scotland. The discount rate used by the Company in determining the lease liability was &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20241231__srt--StatementGeographicalAxis__custom--BerkeleyHeightsFacilityMember_zzSwAo6pIW29"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z440AH7tNQMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s future contractual obligations and commitments relating to its facilities lease as at December
31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8BC_zB11ngH9qKE2" style="display: none"&gt;Schedule
of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zrvqNs2ZDnBg" style="text-align: center; font-weight: bold"&gt;Operating Lease&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Obligation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zYSfO3aFolH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zwF0630Vo0yb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_zFHUvGgprMR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0708"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zXdwuRZhI9kd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z3kbC3utV7Md" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z148Y2pkKCnc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zMqrRRcp51j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <CYCC:LesseeOperatingLeaseTermOfContractExtension
      contextRef="From2022-04-012022-04-30_custom_BerkeleyHeightsFacilityMember"
      id="Fact000693">P3Y</CYCC:LesseeOperatingLeaseTermOfContractExtension>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2024-12-31_custom_CorporateHeadquarters.Tower11KualaLumpurMalaysiaMember"
      id="Fact000694">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000695"
      unitRef="USD">82830</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000696"
      unitRef="USD">74218</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_custom_DundeeScotlandMember"
      decimals="0"
      id="Fact000697"
      unitRef="USD">9104</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31_custom_DundeeScotlandMember"
      decimals="0"
      id="Fact000698"
      unitRef="USD">10851</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2024-12-31_custom_BerkeleyHeightsFacilityMember"
      id="Fact000699">P1M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2024-12-31_custom_BerkeleyHeightsFacilityMember"
      decimals="INF"
      id="Fact000700"
      unitRef="Pure">0.12</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000702">&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z440AH7tNQMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s future contractual obligations and commitments relating to its facilities lease as at December
31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8BC_zB11ngH9qKE2" style="display: none"&gt;Schedule
of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zrvqNs2ZDnBg" style="text-align: center; font-weight: bold"&gt;Operating Lease&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Obligation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zYSfO3aFolH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zwF0630Vo0yb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_zFHUvGgprMR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0708"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zXdwuRZhI9kd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z3kbC3utV7Md" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z148Y2pkKCnc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000704"
      unitRef="USD">5000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000710"
      unitRef="USD">5000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000714"
      unitRef="USD">5000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000716">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zalWS0btNRB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_82F_zOaHl5fSNiFg"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has completed the following equity issuances during the periods presented in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;November
2024 Warrant Exercise and Reload Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 13, 2024, Cyclacel Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) entered into a letter agreement (the &#x201c;Warrant Exercise
and Reload Agreement&#x201d;) with the holder (the &#x201c;Holder&#x201d;) of its issued and outstanding Series B Warrants (the &#x201c;Prior
Warrants&#x201d;) to purchase an aggregate of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_zIthoNGmdFGf"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock of the Company offering the Holder the
opportunity to exercise all of its Prior Warrants for cash at a reduced exercise price equal to $&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zIw77kU1BSQj"&gt;99.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share provided the Prior Warrants were exercised in full
for cash on or before 12:30 P.M. Eastern Time on the date of the Warrant Exercise and Reload Agreement. In consideration for the exercise
of the Prior Warrants, the Holder received new unregistered Series C Warrants (the &#x201c;Series C Warrants&#x201d;) exercisable for up
to an aggregate of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MaximumMember_z2nJt8iIEQ98"&gt;41,408&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock (the &#x201c;Series C Warrant Shares&#x201d;)
and new unregistered Series D Warrants (the &#x201c;Series D Warrants&#x201d; and, together with the Series C Warrants, the &#x201c;New
Warrants&#x201d;) exercisable for up to an aggregate of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember__srt--RangeAxis__srt--MaximumMember_z7P5lyeVpbA3"&gt;41,408&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock (the &#x201c;Series D Warrant Shares&#x201d;
and, together with the Series C Warrant Shares, the &#x201c;New Warrant Shares&#x201d;). The Series C Warrants are exercisable beginning
on the date upon which the Company receives stockholder approval of the issuance of the New Warrant Shares and the Placement Agent Warrant
Shares (as defined below) (the &#x201c;Stockholder Approval Date&#x201d;) for a period of five and one-half (&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zwphBe7Sx8v9"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
years following the Stockholder Approval Date and the Series D Warrants are exercisable beginning on the Stockholder Approval Date for
a period of eighteen (&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zaK6EsTtSSx5"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
months following the Stockholder Approval Date. The New Warrants each have an exercise price of $&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights_iI_c20241113__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zwleHMtS4Yqf"&gt;99.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The shares of common stock issued upon exercise
of the Prior Warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-279157).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;April
2024 Securities Purchase Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 30, 2024, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional
investor (the &#x201c;Purchaser&#x201d;) for the issuance and sale in a private placement (the &#x201c;Private Placement&#x201d;) of (i)
&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_zaKIA9oBY35f"&gt;604&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock, (ii) pre-funded
warrants to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z5erFSmnQjh7"&gt;20,100&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;),
(iii) series A warrants to purchase up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_ztG73B9rt8jc"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock (the &#x201c;Series A Warrants&#x201d;),
and (iv) series B warrants to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zcItD1sBQpn4"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock (the &#x201c;Series B Warrants&#x201d;
and together with the Series A Warrants, the &#x201c;Common Warrants&#x201d;). The purchase price of each share of common stock and associated
Common Warrants was $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNXTFLy0SvWi"&gt;386.40&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and the purchase price of each Pre-Funded Warrant and associated
Common Warrants was $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsAndCommonWarrantsMember_zCo8viJY06Ch"&gt;386.376&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Common Warrants are exercisable immediately upon issuance at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zMYaDXFUgKg6"&gt;326.40&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The Series A Warrants will expire five and one-half
years&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zUiLe2DtvpE2" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the date of issuance and the Series B Warrants will expire
eighteen months from the date of issuance. The Pre-Funded Warrants are exercisable immediately upon issuance at an exercise price of
$&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_znxWUrSAWMI3"&gt;0.024&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share and may be exercised at any time until the Pre-Funded
Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its affiliates) may not exercise any
portion of such warrants to the extent that the holder would own more than &lt;span id="xdx_902_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zP1rZsr56qjb"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
(or, at the election of the holder &lt;span id="xdx_907_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zsnWwNxkiFPi"&gt;9.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%)
of the Company&#x2019;s outstanding common stock immediately after exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Private Placement, the Company entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;),
dated as of April 30, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with
the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) registering the resale of the securities issued in the Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Private Placement closed on May 2, 2024. The gross proceeds to the Company from the Private Placement were approximately $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240502__20240502_zSzPTAYzb5m8"&gt;8.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, before deducting placement agent fees and estimated
offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;H.C.
Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;) acted as the Company&#x2019;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of April 29, 2024, between the Company and Wainwright (as amended, the
&#x201c;Engagement Letter&#x201d;). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to &lt;span id="xdx_902_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20240429_zD4yCmuXVAf1"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate gross proceeds of the Private Placement and (ii) a management fee of &lt;span id="xdx_90D_ecustom--ManagementFeePercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240429_zhsfS6elTY21"&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued
to Wainwright or its designees warrants (the &#x201c;Placement Agent Warrants&#x201d;) to purchase up to an aggregate of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zJEJFIefpf0j"&gt;1,242&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock at an exercise price equal to $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z2k13njyoMgh"&gt;124.512&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The Placement Agent Warrants are exercisable immediately
upon issuance and have a term of exercise equal to five and a half years&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zS5z7m5Zd4J3" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with this transaction, the Company was required to compensate Roth Capital Partners, LLC, pursuant to a tail provision contained
in an engagement letter entered into on March 14, 2024, in an amount equal to &lt;span id="xdx_90D_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240314__srt--CounterpartyNameAxis__custom--RothCapitalPartnersLlcMember_zDxCywiasD27"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate proceeds of the Private Placement plus the reimbursement of certain expenses. The Company was also required to compensate
Ladenburg Thalmann &amp;amp; Co. Inc, pursuant to a tail provision contained in an engagement letter entered into on October 30, 2023, in
an amount equal to &lt;span id="xdx_907_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20231030__srt--CounterpartyNameAxis__custom--LadenburgThalmannCo.IncMember_zclQRSY20Kw1"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate proceeds of the Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
of the instruments issued in the Private Placement have been classified and recorded as part of shareholders&#x2019; equity (deficit).
The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective
instruments as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_z7m7v6VBOkz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_z6NUgLOQ9Vi8" style="display: none"&gt;Schedule
of Fair Value of Instruments Issued in Offering&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zBIhHSrSJReb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Allocated
    Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq3QwXNUjED6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Common shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;72,108&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zpODY3vap7N4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prefunded warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,398,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWUkBjHcDr4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,819,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_zCzqzHT8J5V4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net proceeds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,290,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z25frHlhgXC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate fair value of the Placement Agent Warrants was $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zKhQ2wTFXwo5"&gt;609,179&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
These have been accounted for as a direct cost of the Private Placement, resulting in no net effect to overall shareholders&#x2019; equity
(deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjUMBilXRxKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8BE_zH2Kn3OlToH6" style="display: none"&gt;Schedule
of Fair value of Warrants Valuation Assumption&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Pre-Funded Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Common Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Placement Agent Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zQlb4fHHvBn"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zfxP64rao9gd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;103&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
                                            - &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zmZIGElcjLW2"&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z3gwiYo35EJ6"&gt;103&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Contractual term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGismNVQlp66" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUPPyBSjAiy9" style="display: none"&gt;1.5&lt;/span&gt;&lt;/span&gt;1&#xbd;
                                            - 5&#xbd; years&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zXeVsP78Db5d" style="display: none"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuHIcIE3sdjd" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.5&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#xbd;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zn43bSaXZy6a"&gt;5.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zXt0T5Dj3Kec" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.57&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
                                            - &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ztk2p9BCs8ig"&gt;5.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZ1tCBxmj8l3"&gt;4.57&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zSpvZGyUq6h4"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJMWTO3OuCFf"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMBjP67BlMnj"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zKTss7DXffqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the common stock was determined using the closing price of the Company&#x2019;s common stock as of May 2, 2024, which is
the date that the Private Placement closed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;December
2023 Registered Direct Offering Securities Purchase Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 21, 2023, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain
institutional investors (&#x201c;Purchasers&#x201d;). Pursuant to the Securities Purchase Agreement, the Company agreed to sell in a registered
direct offering (&#x201c;Registered Direct Offering&#x201d;) &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUSvaUf0eOp7"&gt;702&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares (&#x201c;Shares&#x201d;) of the Company&#x2019;s common
stock and pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;) to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z8f25EwLQJtl"&gt;915&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock. The Pre-Funded Warrants have an exercise
price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z3cYy5VF96pf"&gt;0.24&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share and are immediately exercisable and can be exercised
at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each Share is being sold at an offering
price of $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z696kwAm0G3e"&gt;795.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and each Pre-Funded Warrant is being sold at an offering price
of $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zO3rfrOkVtii"&gt;795.36&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(equal to the purchase price per Share minus the exercise price
of the Pre-Funded Warrant).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the &#x201c;Offerings&#x201d;),
the Company also agreed to issue to the Purchasers unregistered warrants (&#x201c;Common Warrants&#x201d;) to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zfhbyd13R8R"&gt;1,617&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock. Each Common Warrant has an exercise
price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zxyKxYf2JjZf"&gt;765.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, is exercisable immediately following their original
issuance and will expire &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zLBW1gBg5sD"&gt;seven
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the original issuance date. The closing
of the offering occurred on December 26, 2023, and the net proceeds to the Company were approximately $&lt;span id="xdx_90E_ecustom--AggregateProceedsFromSaleOfStock_iI_pn5n6_c20231226__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zJHQ1MXWzG76"&gt;1.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, after deducting placement agent fees and other offering
expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 21, 2023, in a separate concurrent insider private placement (the &#x201c;Insider Private Placement&#x201d;), the Company also
entered into a Securities Purchase Agreement with certain of its executive officers (the &#x201c;Insider Securities Purchase Agreement&#x201d;)
pursuant to which the Company agreed to sell in a private placement (i) &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDbEsQKu9cN4"&gt;25&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock and warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_z3l9jhhwa6Th"&gt;25&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Spiro Rombotis, the Company&#x2019;s Chief Executive Officer, and (ii) &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember_zzfWOP4FHBU3"&gt;8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock and warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zQcDV3K7eude"&gt;8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Paul McBarron, the Company&#x2019;s Executive Vice President-Finance, Chief Financial Officer
and Chief Operating Officer. Each such share of common stock and accompanying warrant was sold at a purchase price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_z59qt1SSJDYk"&gt;795.60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which was the same purchase price for the Shares sold in the Registered Direct Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ladenburg
Thalmann &amp;amp; Co. Inc. (the &#x201c;Placement Agent&#x201d;) acted as the exclusive placement agent for the Offerings, pursuant to a placement
agency agreement (the &#x201c;Placement Agency Agreement&#x201d;), dated December 21, 2023, by and between the Company and the Placement
Agent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Placement Agency Agreement, the Company paid the Placement Agent a cash placement fee equal to &lt;span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zxyTpFX2Zh2f"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate gross proceeds raised in the Offerings from sales arranged for by the Placement Agent. Subject to certain conditions,
the Company also agreed to reimburse all reasonable travel and other out-of-pocket expenses of the Placement Agent in connection with
the Offerings, including but not limited to legal fees, up to a maximum of $&lt;span id="xdx_90A_eus-gaap--ProfessionalFees_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zrNaBYwgRAFk"&gt;85,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
In addition, the Placement Agent also received warrants that have substantially the same terms as the Warrants issued in the concurrent
private placement to the Purchasers in the Offerings to purchase that number of shares of common stock equal to &lt;span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zoYkp4PnmHTl"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate number of shares of common stock and Prefunded Warrants sold in the Offerings, or an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zpU5LIm5eA24"&gt;99&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z9Jp8Gp4Tmda"&gt;994.50&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (the &#x201c;Placement Agent Warrants&#x201d;). The
Placement Agent Warrants will be exercisable immediately following the date of issuance and will expire &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zNfBBPfsUow9"&gt;five
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from issuance. The Placement Agency Agreement
contains customary representations, warranties and agreements by the Company and customary conditions to closing. The Company has agreed
to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and liabilities arising
from breaches of representations and warranties contained in the Placement Agency Agreement, or to contribute to payments that the Placement
Agent may be required to make in respect of those liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
of the instruments issued in the Offerings and the Insider Private Placement have been classified and recorded as part of shareholders&#x2019;
equity. The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values
of the respective instruments as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4OcU6YuX39i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zY381SfL0bfd" style="display: none"&gt;Schedule
of Fair Value of Instruments Issued in Offering&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zyjBGzo64avj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Allocated
    Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHUGbPFf2sba" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Common Shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;258,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSZmexFaegDa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Pre-Funded Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzNFN989B3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Regular Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;470,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zQqPN6pWrAzk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net Proceeds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,049,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zb4MaUITsIzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate fair value of the Placement Agent Warrants was $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zFMPYS5N4FH9"&gt;47,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
These have been accounted for as a direct cost of the Offerings and Inside Private Placement, resulting in no net effect to overall shareholders&#x2019;
equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4JNxJDtzfie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zWpLB9du8iUi" style="display: none"&gt;Schedule
of Fair value of Warrants Valuation Assumption&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Pre-Funded Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Regular Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Placement Agent Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zgIRxBJJrZac"&gt;134&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zymclqOdcvj7"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_ztxHj2RvY8S1"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Contractual/expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z70PhkHMtHj5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;month&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zKVZgEYRcRl8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zdZmDyp6Len2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAoG8yfczVX5"&gt;5.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z6gjOzFvrbt5"&gt;3.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zrQBxpZsYiS6"&gt;3.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zVXETncroDmk"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zvysFIElhW06"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIppfgQqqL54"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zdarbiT7nGxh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the common shares was determined using the closing price of the Company&#x2019;s common stock as of December 26, 2023, which
is the date that the Offerings and the Insider Private Placement closed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;August
2021 Controlled Equity Offering Sales Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 12, 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor
Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;), pursuant to which the Company could issue and sell, from time to time, shares of its common
stock having an aggregate offering price of up to $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210812__20210812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_zJMdMEFhmXR9"&gt;50.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million through Cantor as the sales agent. Cantor could sell
the Company&#x2019;s common stock by any method permitted by law deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule
415(a)(4) of the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 12, 2022, the Company became aware that the shelf registration statement on Form S-3 (file number 333-231923) (the &#x201c;Registration
Statement&#x201d;) associated with this Sales Agreement had expired on June 21, 2022. Prior to becoming aware of the expiration, the Company
sold an aggregate of &lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zsPeJM7cseI8"&gt;552&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of its common stock at the market price, following the
expiration of the Registration Statement and through August 12, 2022, for aggregate proceeds of approximately $&lt;span id="xdx_902_ecustom--AggregateProceedsFromSaleOfStock_iI_c20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zopApQOCgqQ5"&gt;2,721,187&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
There was no sale of shares post August 12, 2022. The sale of these shares were subject to potential rescission rights by certain shareholders.
As a result of these potential rescission rights, the Company reclassified &lt;span id="xdx_901_ecustom--ReclassificationOfCommonStockShares_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zv03kIgeoAE2"&gt;866&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares (including &lt;span id="xdx_90B_ecustom--ReclassificationOfCommonStockSharesNoProceedsReceived_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_zHuX4PF4IDH4"&gt;314&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares sold for which the Company did not receive any proceeds),
with an aggregate purchase price of $&lt;span id="xdx_90C_ecustom--ReclassificationOfCommonStockValue_c20220812__20220812__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember__us-gaap--SubsidiarySaleOfStockAxis__custom--August2021ControlledEquityOfferingSalesAgreementMember_z0sRpDI1mmYa"&gt;4,494,496&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of its common stock outside stockholders&#x2019; equity as of
December 31, 2022. These shares have been treated as issued and outstanding for financial reporting purposes. The rescission rights for
these shares lapsed and the shares were reclassified back to permanent equity as of December 31, 2023. As of December 31, 2024, there
have been no claims or demands to exercise such rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 15, 2022, the Sales Agreement was mutually terminated. A total of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220815__20220815__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_z1l7eIi8F1pk"&gt;911&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares, for gross proceeds of approximately $&lt;span id="xdx_908_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20220815__20220815__srt--CounterpartyNameAxis__custom--CantorFitzgeraldCoMember_zSEwHJLzhdM5"&gt;7.6&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, had been sold pursuant to the Sales Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;November
2024 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, warrants to purchase a total of &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_z5ioFWcPrz2e"&gt;82,816&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock issued pursuant to a securities purchase
agreement in a November 2024 financing transaction (the &#x201c;November 2024 Warrant Exercise and Reload Agreement&#x201d;) remained outstanding.
A total of &lt;span id="xdx_903_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zupPvhXsoch9"&gt;82,816&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants were issued in pursuant to the November 2024 Warrant
Exercise and Reload Agreement. This consisted of i) series C warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zO0lcJxyhHN5"&gt;41,408&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_z0hd0si37Pki" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_z2FwheneL143"&gt;99.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share, ii) series D warrants to purchase up to
&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zU3LMLXpr5Ya"&gt;41,408&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, exercisable immediately from the date
of issuance for a period of &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zUVO9AuNCVq1"&gt;eighteen
months&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise
price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zadW48rwEWAi"&gt;99.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_pid_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zOsFWFPc3GB8"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercises of these warrants during the years ended December
31, 2024 or December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;April
2024 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, warrants to purchase a total of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zoJySxMJhdyf"&gt;31,934&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock issued pursuant to a securities purchase
agreement in an April 2024 financing transaction (the &#x201c;April 2024 Securities Purchase Agreement&#x201d;) remained outstanding. A
total of &lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zZXZ2TKx37kf"&gt;62,750&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants were issued in pursuant to the April 2024 Securities
Purchase Agreement. This consisted of i) pre-funded warrants to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zEb1Z3rQ8K8d"&gt;20,100&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of common stock, exercisable immediately from the date of issuance,
and with no expiry date, at an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zDZWOZonCYFa"&gt;0.24&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share, ii) series A warrants to purchase up to
&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPCecdUahTjj"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zsisPXuun5yi" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zByQEcmurQsh"&gt;326.40&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share, iii) series B warrants to purchase up to
&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zcsaiDPTj29"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, exercisable immediately from the date
of issuance for a period of &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zxZ3QjgQ4aRl"&gt;eighteen
months&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise
price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zN6BwN8MCAZ7"&gt;326.40&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share. A further &lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightsExercisable_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zsZi8sUXM4Z6"&gt;1,242&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of five and a half years&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zgIk9ZfIUNl" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zaZ6gP9cddB4"&gt;124.512&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercised_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zJvVogHkTsQk"&gt;20,100&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;pre-funded warrants and &lt;span id="xdx_901_ecustom--ClassOfWarrantOrRightExercised_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_zSuLSN8a4tU8"&gt;10,716&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series B warrants were exercised during the year ended December
31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;December
2023 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, warrants to purchase a total of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zFDZ84J9sTpg"&gt;1,750&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock issued pursuant to a securities purchase
agreement in a December 2023 financing transaction remained outstanding. A total of &lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zOCDhAz0VnX6"&gt;1,651&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants, including &lt;span id="xdx_901_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreePrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zkRorAjArK25"&gt;33&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued in a concurrent private placement, are exercisable
immediately from the date of issuance for a period of &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zy80jv03DSm9"&gt;seven
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise
price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zGDvXea7VShe"&gt;765.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share. A further &lt;span id="xdx_902_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcZWXIlfGF9"&gt;99&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zkzgA2wgcZNh"&gt;five
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise
price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zHvYGsHpLMV2"&gt;994.50&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_z1pM3Xf04aQd"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercises of these warrants during the years ended December
31, 2024 or December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;December
2020 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, warrants to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z0PZl1O7TLQa"&gt;186&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock issued pursuant to a securities purchase
agreement in a December 2020 financing transaction remained outstanding. Each warrant shall be exercisable beginning on the 12-month
anniversary of the date of issuance for a period of &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z2hbvJdrqlgk"&gt;five
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise
price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zjRA4NuhW6w2"&gt;14,868.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share. The exercise price of the warrants will
be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar
transaction, as described in the warrants. The warrants may be exercised on a &#x201c;cashless&#x201d; basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, &lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercised_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfzBNRAkfqy1"&gt;65&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants lapsed upon conversion of the associated Series B
Preferred Stock. There were &lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_z3Rwgk9BzASg"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercises of these warrants during the year ended December
31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;April
2020 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zcg8CHGkLTfh"&gt;497&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued in connection with an April 2020 equity financing
remained outstanding, each with an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zQmvWkjnxcYj"&gt;18,000.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The common warrants are immediately exercisable and will expire on the fifth anniversary of the original issuance date. The exercise
price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting the Company&#x2019;s common stock. The common warrants were issued separately
from the common stock and were eligible for transfer immediately after issuance. A common warrant to purchase one share of common stock
was issued for every share of common stock purchased in this offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise
notice accompanied by payment in full for the number of shares of the Company&#x2019;s common stock purchased upon such exercise (except
in the case of a cashless exercise). &lt;span id="xdx_90E_eus-gaap--DebtInstrumentDescription_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zjHjUmnK3Cg9"&gt;A
holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more
than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days prior notice from the holder
to the Company, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#x2019;s common warrants
up to 9.99% of the number of shares of the Company&#x2019;s common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the common warrants.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, the
Company will round down to the next whole share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRightExercised_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_z3cX5KcR4pDc"&gt;111&lt;/span&gt; warrants were exercised during the year ended December 31, 2024. &lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightExercised_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zIxfkqhLW8zg"&gt;No&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants were exercised during the year ended December 31,
2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
B Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNid3PIJiCs1"&gt;237,745&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s Series B Preferred Stock were
issued in a December 2020 Securities Purchase Agreement. Each share of Series B Preferred Stock shall initially be convertible into one
third (1/3) share of common stock (the &#x201c;Conversion Shares&#x201d;), subject to adjustment in accordance with the Certificate of
Designation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock
basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series
B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company
will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a)
alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Certificate
of Designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights
of the holders of Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, (e) pay certain
dividends or (f) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock does not have a preference
upon any liquidation, dissolution or winding-up of the Company. The Purchaser may convert shares of Series B Preferred Stock through
a conversion into shares of common stock if and solely to the extent that such conversion would not result in the Purchaser beneficially
owning in excess of &lt;span id="xdx_90B_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbrVB1A6kuJk"&gt;9.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of then-outstanding common stock or aggregate voting power of the Company (such limitation, the &#x201c;Ownership Limitation&#x201d;) and
any portion in excess of such limitation will remain outstanding as Series B Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, &lt;span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z80ypU7lmqX3"&gt;119,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Series B Preferred Stock was converted, at the option
of the holder, into &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zocqvnwoQRD6"&gt;165&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock. As of December 31, 2024, there were
&lt;span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlostzkFR6zg"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining shares of the Series B Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
A Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYBA5ymp05Hg"&gt;8,872&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s Series A Preferred Stock were
issued in a July 2017 Underwritten Public Offering. Each share of Series A Preferred Stock is convertible at any time at the option of
the holder thereof, into a number of shares of common stock determined by dividing $&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHzzSK2nIpO6"&gt;1,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;by the initial conversion price of $&lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2IYGWDYiHw4"&gt;144,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, subject to a &lt;span id="xdx_90D_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLJFziQuW93g"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
blocker provision, or, upon election by a holder prior to the issuance of shares of Series A Preferred Stock, &lt;span id="xdx_907_ecustom--ConvertiblePreferredStockConversionPercentage_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2BPEAHa2UZ2"&gt;9.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, &lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0cm0Sof4318"&gt;264&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Series A Preferred Stock remain issued and outstanding.
The &lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zw6z4u0mehFa"&gt;264&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Series A Preferred Stock issued and outstanding at
December 31, 2024, are convertible into &lt;span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zoedssE9uV12"&gt;2&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock
basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends
in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted
basis. There is no restriction on the Company&#x2019;s ability to repurchase shares of Series A Preferred Stock while there is an arrearage
in the payment of dividends on such shares, and there are no sinking fund provisions applicable to Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subject
to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder
of the Series A Preferred Stock to convert all or part of such holder&#x2019;s Series A Preferred Stock in the event that (i) the volume
weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds &lt;span id="xdx_906_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKvYphkB3ODl"&gt;300&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations,
stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $&lt;span id="xdx_900_eus-gaap--ConversionOfStockAmountConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSkscOcyJSWf"&gt;500,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per trading day and (iii) the holder is not in possession of
any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to
cause each holder of Series A Preferred Stock to convert all or part of such holder&#x2019;s Series A Preferred Stock shall be exercised
ratably among the holders of the then outstanding preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains
no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common
stock in the distribution of assets, to the extent legally available for distribution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6%
Convertible Exchangeable Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there were &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zmW1tAtLncpl"&gt;135,273&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s &lt;span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z2XPeCSRRKtd"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
Convertible Exchangeable, or Preferred Stock issued and outstanding at an issue price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zLGOPcPZlrKc"&gt;10.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. Dividends on the Preferred Stock are cumulative
from the date of original issuance at the annual rate of &lt;span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zOSxPD0ojie9"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the liquidation preference of the Preferred Stock, and if declared, payable quarterly on the first day of February, May, August and
November, commencing February 1, 2005. Any dividends must be declared by the Company&#x2019;s Board of Directors and must come from funds
that are legally available for dividend payments. The Preferred Stock has a liquidation preference of $&lt;span id="xdx_90E_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zLKfEnzExJoh"&gt;10.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, plus accrued and unpaid dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Board of Directors considers numerous factors in determining whether to declare the quarterly dividend pursuant to the
Certificate of Designations governing the terms of the Company&#x2019;s Preferred Stock, including the requisite financial analysis and
determination of a surplus. Accumulated but unpaid dividends in arrears on preferred stock were $&lt;span id="xdx_901_eus-gaap--PreferredStockAmountOfPreferredDividendsInArrears_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zIKtoRIgiTQ7"&gt;0.3&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, or $&lt;span id="xdx_90F_eus-gaap--PreferredStockPerShareAmountsOfPreferredDividendsInArrears_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zHVTZio9m3j"&gt;2.55&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, of preferred stock, as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Preferred Stock is convertible at the option of the holder at any time into the Company&#x2019;s shares of common stock at a conversion
rate of approximately &lt;span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zOGNhn7UbHV"&gt;0.0000001&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for each share of Preferred Stock based
on a price of $&lt;span id="xdx_90F_ecustom--ConvertiblePreferredStockConversionPricePerShare_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ztBeBzRoU1Ej"&gt;142,128,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The Company has reserved &lt;span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3IEihCHsAbi"&gt;6&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for issuance upon conversion of the
remaining shares of Preferred Stock outstanding at December 31, 2024. The shares of previously converted Preferred Stock have been retired,
cancelled and restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors
as shares of Preferred Stock of one or more series.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&#x2019;s common stock has
exceeded $&lt;span id="xdx_90D_ecustom--CommonStockClosingPriceThreshold_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zZTyEkWeG0jb"&gt;213,192,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which is &lt;span id="xdx_901_ecustom--PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zH3UxVhle3bb"&gt;150&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the conversion price of the Preferred Stock, for at least &lt;span id="xdx_90D_ecustom--PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zq3xaJ5siC7a"&gt;20&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;trading days during any &lt;span id="xdx_90B_ecustom--PreferredStockConversionObligationNumberOfTradingDays_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ziudvZhBorI5"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-day
trading period, ending within &lt;span id="xdx_909_ecustom--PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_dtD_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z7qW4QFrgAj9" style="display: none"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;five
trading days prior to notice of automatic conversion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock
for &lt;span id="xdx_904_ecustom--DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends_dc_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z0ty4fIsJuX9"&gt;six&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;quarterly periods, holders of Preferred Stock are entitled
to nominate and elect two directors to the Company&#x2019;s Board of Directors. This right accrued to the holders of Preferred Stock as
of August 2, 2010 and two directors were nominated and elected at the annual meeting held on May 24, 2011.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption price of
$&lt;span id="xdx_904_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zQ53MohjAj38"&gt;10.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November
1, 2005, or Exchange Date for the Company&#x2019;s &lt;span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zphZvKjMwR6b"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
Convertible Subordinated Debentures, or Debentures at the rate of $&lt;span id="xdx_908_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zK8Wfzuii8Rl"&gt;10.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;principal amount of Debentures for each share of Preferred
Stock. The Debentures, if issued, will mature &lt;span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zkuYmJjsUAAf"&gt;25&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years after the Exchange Date and have terms substantially
similar to those of the Preferred Stock. No such exchanges have taken place as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2023, the company declared dividends of $&lt;span id="xdx_90A_eus-gaap--PreferredStockDividendsPerShareDeclared_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zoIeHqACcAB8"&gt;0.15&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share quarterly on its &lt;span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zUWFr7Wm18E7"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
Convertible Exchangeable Preferred Stock. These dividends were paid on February 1, 2024. No further dividends were declared or paid subsequent
to this.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CYCC:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights
      contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000718"
      unitRef="USDPShares">99.60</CYCC:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000719"
      unitRef="Shares">41408</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000720"
      unitRef="Shares">41408</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember"
      id="Fact000721">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember"
      id="Fact000722">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CYCC:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights
      contextRef="AsOf2024-11-13_custom_November2024WarrantExerciseAndReloadAgreementMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000723"
      unitRef="USDPShares">99.60</CYCC:ClassOfWarrantOrRightReducedExercisePriceOfWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000724"
      unitRef="Shares">604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">20100</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Shares">386.40</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsAndCommonWarrantsMember"
      decimals="INF"
      id="Fact000729"
      unitRef="Shares">386.376</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000730"
      unitRef="USDPShares">326.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-04-30_custom_SeriesAWarrantsMember"
      id="Fact000731">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000732"
      unitRef="USDPShares">0.024</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:PercentageOfOutstandingCommonStock
      contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000733"
      unitRef="Pure">0.0499</CYCC:PercentageOfOutstandingCommonStock>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000734"
      unitRef="Pure">0.0999</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-05-022024-05-02"
      decimals="-5"
      id="Fact000735"
      unitRef="USD">8000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <CYCC:CashPlacementFeePercentage
      contextRef="AsOf2024-04-29"
      decimals="INF"
      id="Fact000736"
      unitRef="Pure">0.070</CYCC:CashPlacementFeePercentage>
    <CYCC:ManagementFeePercentageToAggregateGrossProceeds
      contextRef="AsOf2024-04-29"
      decimals="INF"
      id="Fact000737"
      unitRef="Pure">0.010</CYCC:ManagementFeePercentageToAggregateGrossProceeds>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000738"
      unitRef="Shares">1242</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000739"
      unitRef="USDPShares">124.512</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember"
      id="Fact000740">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CYCC:CompensationPercentageToAggregateGrossProceeds
      contextRef="AsOf2024-03-14_custom_RothCapitalPartnersLlcMember"
      decimals="INF"
      id="Fact000741"
      unitRef="Pure">0.070</CYCC:CompensationPercentageToAggregateGrossProceeds>
    <CYCC:CompensationPercentageToAggregateGrossProceeds
      contextRef="AsOf2023-10-30_custom_LadenburgThalmannCo.IncMember"
      decimals="INF"
      id="Fact000742"
      unitRef="Pure">0.080</CYCC:CompensationPercentageToAggregateGrossProceeds>
    <CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000744">&lt;p id="xdx_893_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_z7m7v6VBOkz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_z6NUgLOQ9Vi8" style="display: none"&gt;Schedule
of Fair Value of Instruments Issued in Offering&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zBIhHSrSJReb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Allocated
    Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq3QwXNUjED6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Common shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;72,108&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zpODY3vap7N4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prefunded warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,398,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWUkBjHcDr4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,819,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_pn3n3_zCzqzHT8J5V4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net proceeds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,290,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000746"
      unitRef="USD">72108000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_PreFundedWarrantsMember"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">2398831000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember"
      decimals="-3"
      id="Fact000750"
      unitRef="USD">3819274000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000752"
      unitRef="USD">6290213000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsMember"
      decimals="0"
      id="Fact000753"
      unitRef="USD">609179</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000755">&lt;p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjUMBilXRxKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8BE_zH2Kn3OlToH6" style="display: none"&gt;Schedule
of Fair value of Warrants Valuation Assumption&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Pre-Funded Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Common Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Placement Agent Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zQlb4fHHvBn"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zfxP64rao9gd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;103&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
                                            - &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zmZIGElcjLW2"&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z3gwiYo35EJ6"&gt;103&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Contractual term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGismNVQlp66" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUPPyBSjAiy9" style="display: none"&gt;1.5&lt;/span&gt;&lt;/span&gt;1&#xbd;
                                            - 5&#xbd; years&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zXeVsP78Db5d" style="display: none"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuHIcIE3sdjd" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.5&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#xbd;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zn43bSaXZy6a"&gt;5.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zXt0T5Dj3Kec" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.57&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
                                            - &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ztk2p9BCs8ig"&gt;5.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZ1tCBxmj8l3"&gt;4.57&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zSpvZGyUq6h4"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJMWTO3OuCFf"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMBjP67BlMnj"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000756"
      unitRef="Pure">100</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000757"
      unitRef="Pure">103</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000758"
      unitRef="Pure">121</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000759"
      unitRef="Pure">103</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact000760"
      unitRef="Pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_srt_MinimumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Pure">1.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_srt_MaximumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact000762"
      unitRef="Pure">5.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Pure">5.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000764"
      unitRef="Pure">5.51</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000765"
      unitRef="Pure">4.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000766"
      unitRef="Pure">5.51</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000767"
      unitRef="Pure">4.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact000768"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact000770"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000771"
      unitRef="Shares">702</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">915</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000773"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember54201031"
      decimals="INF"
      id="Fact000774"
      unitRef="USDPShares">795.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000775"
      unitRef="USDPShares">795.36</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">1617</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000777"
      unitRef="USDPShares">765.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      id="Fact000778">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CYCC:AggregateProceedsFromSaleOfStock
      contextRef="AsOf2023-12-26_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="-5"
      id="Fact000779"
      unitRef="USD">1000000.0</CYCC:AggregateProceedsFromSaleOfStock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000780"
      unitRef="Shares">25</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">25</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember"
      decimals="INF"
      id="Fact000782"
      unitRef="Shares">8</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">8</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000784"
      unitRef="USDPShares">795.60</us-gaap:SharesIssuedPricePerShare>
    <CYCC:CashPlacementFeePercentage
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000785"
      unitRef="Pure">0.080</CYCC:CashPlacementFeePercentage>
    <us-gaap:ProfessionalFees
      contextRef="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact000786"
      unitRef="USD">85000</us-gaap:ProfessionalFees>
    <CYCC:PercentageOfOutstandingCommonStock
      contextRef="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000787"
      unitRef="Pure">0.060</CYCC:PercentageOfOutstandingCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000788"
      unitRef="Shares">99</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000789"
      unitRef="USDPShares">994.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      id="Fact000790">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember"
      id="Fact000792">&lt;p id="xdx_89F_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4OcU6YuX39i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zY381SfL0bfd" style="display: none"&gt;Schedule
of Fair Value of Instruments Issued in Offering&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zyjBGzo64avj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Allocated
    Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHUGbPFf2sba" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Common Shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;258,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSZmexFaegDa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Pre-Funded Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzNFN989B3uc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Regular Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;470,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zQqPN6pWrAzk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net Proceeds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,049,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000794"
      unitRef="USD">258000000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_custom_PreFundedWarrantsMember"
      decimals="-3"
      id="Fact000796"
      unitRef="USD">321000000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember_custom_CommonStockWarrantsMember"
      decimals="-3"
      id="Fact000798"
      unitRef="USD">470000000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember"
      decimals="-3"
      id="Fact000800"
      unitRef="USD">1049000000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsMember_custom_InsiderPrivatePlacementMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">47000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_InsiderPrivatePlacementMember"
      id="Fact000803">&lt;p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z4JNxJDtzfie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zWpLB9du8iUi" style="display: none"&gt;Schedule
of Fair value of Warrants Valuation Assumption&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Pre-Funded Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Regular Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Placement Agent Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zgIRxBJJrZac"&gt;134&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zymclqOdcvj7"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_ztxHj2RvY8S1"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Contractual/expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z70PhkHMtHj5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;month&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zKVZgEYRcRl8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zdZmDyp6Len2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAoG8yfczVX5"&gt;5.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_z6gjOzFvrbt5"&gt;3.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zrQBxpZsYiS6"&gt;3.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zVXETncroDmk"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zvysFIElhW06"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIppfgQqqL54"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000804"
      unitRef="Pure">134</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Pure">96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000806"
      unitRef="Pure">99</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000807"
      unitRef="Pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000808"
      unitRef="Pure">7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000810"
      unitRef="Pure">5.53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Pure">3.91</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000812"
      unitRef="Pure">3.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000814"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-08-122021-08-12_custom_CantorFitzgeraldCoMember"
      decimals="0"
      id="Fact000816"
      unitRef="USD">50.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Shares">552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <CYCC:AggregateProceedsFromSaleOfStock
      contextRef="AsOf2022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember"
      decimals="0"
      id="Fact000818"
      unitRef="USD">2721187</CYCC:AggregateProceedsFromSaleOfStock>
    <CYCC:ReclassificationOfCommonStockShares
      contextRef="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember"
      decimals="INF"
      id="Fact000819"
      unitRef="Shares">866</CYCC:ReclassificationOfCommonStockShares>
    <CYCC:ReclassificationOfCommonStockSharesNoProceedsReceived
      contextRef="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">314</CYCC:ReclassificationOfCommonStockSharesNoProceedsReceived>
    <CYCC:ReclassificationOfCommonStockValue
      contextRef="From2022-08-122022-08-12_custom_CantorFitzgeraldCoMember_custom_August2021ControlledEquityOfferingSalesAgreementMember"
      decimals="0"
      id="Fact000821"
      unitRef="USD">4494496</CYCC:ReclassificationOfCommonStockValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-08-152022-08-15_custom_CantorFitzgeraldCoMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Shares">911</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <CYCC:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2022-08-152022-08-15_custom_CantorFitzgeraldCoMember"
      decimals="-5"
      id="Fact000823"
      unitRef="USD">7600000</CYCC:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember"
      decimals="INF"
      id="Fact000824"
      unitRef="Shares">82816</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Shares">82816</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Shares">41408</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_SeriesCWarrantsMember_custom_November2024WarrantExerciseAndReloadAgreementMember"
      id="Fact000827">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000828"
      unitRef="USDPShares">99.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember"
      decimals="INF"
      id="Fact000829"
      unitRef="Shares">41408</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember"
      id="Fact000830">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember"
      decimals="INF"
      id="Fact000831"
      unitRef="USDPShares">99.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2023-01-012023-12-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact000833"
      unitRef="Shares">31934</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact000834"
      unitRef="Shares">62750</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Shares">20100</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000836"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000837"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_SeriesAWarrantsMember_custom_April2024WarrantsMember"
      id="Fact000838">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000839"
      unitRef="USDPShares">326.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember"
      id="Fact000841">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000842"
      unitRef="USDPShares">326.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Shares">1242</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsMember_custom_April2024WarrantsMember"
      id="Fact000844">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000845"
      unitRef="USDPShares">124.512</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Shares">20100</CYCC:ClassOfWarrantOrRightExercised>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Shares">10716</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact000848"
      unitRef="Shares">1750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact000849"
      unitRef="Shares">1651</CYCC:ClassOfWarrantOrRightsExercisable>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyThreePrivatePlacementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Shares">33</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember"
      id="Fact000851">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact000852"
      unitRef="USDPShares">765.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2024-12-31_custom_December2023PrivatePlacementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">99</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_December2023PlacementAgencyAgreementMember"
      id="Fact000854">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_December2023PlacementAgencyAgreementMember"
      decimals="INF"
      id="Fact000855"
      unitRef="USDPShares">994.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2023-01-012023-12-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyWarrantMember"
      decimals="INF"
      id="Fact000857"
      unitRef="Shares">186</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyWarrantMember"
      id="Fact000858">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyWarrantMember"
      decimals="INF"
      id="Fact000859"
      unitRef="USDPShares">14868.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyWarrantMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">65</CYCC:ClassOfWarrantOrRightExercised>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2023-01-012023-12-31_custom_DecemberTwoThousandTwentyWarrantMember"
      decimals="INF"
      id="Fact000861"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyWarrantsMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">497</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyWarrantsMember"
      decimals="INF"
      id="Fact000863"
      unitRef="USDPShares">18000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyWarrantsMember"
      id="Fact000864">A
holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more
than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days prior notice from the holder
to the Company, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#x2019;s common warrants
up to 9.99% of the number of shares of the Company&#x2019;s common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the common warrants.</us-gaap:DebtInstrumentDescription>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2024-01-012024-12-31_custom_AprilTwoThousandTwentyWarrantsMember"
      decimals="INF"
      id="Fact000865"
      unitRef="Shares">111</CYCC:ClassOfWarrantOrRightExercised>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2023-01-012023-12-31_custom_AprilTwoThousandTwentyWarrantsMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000867"
      unitRef="Shares">237745</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000868"
      unitRef="Pure">0.0999</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Shares">119000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">165</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000871"
      unitRef="Shares">0</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000872"
      unitRef="Shares">8872</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000873"
      unitRef="USD">1000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2017-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000874"
      unitRef="USDPShares">144000</us-gaap:PreferredStockConvertibleConversionPrice>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000875"
      unitRef="Pure">0.0499</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <CYCC:ConvertiblePreferredStockConversionPercentage
      contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000876"
      unitRef="Pure">0.0999</CYCC:ConvertiblePreferredStockConversionPercentage>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000877"
      unitRef="Shares">264</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">264</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000879"
      unitRef="Shares">2</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000880"
      unitRef="Pure">3</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000881"
      unitRef="USD">500000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">135273</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000883"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000884"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000885"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000886"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="-5"
      id="Fact000887"
      unitRef="USD">300000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
    <us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000888"
      unitRef="USDPShares">2.55</us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000889"
      unitRef="Shares">0.0000001</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <CYCC:ConvertiblePreferredStockConversionPricePerShare
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000890"
      unitRef="USDPShares">142128000</CYCC:ConvertiblePreferredStockConversionPricePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">6</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <CYCC:CommonStockClosingPriceThreshold
      contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000892"
      unitRef="USD">213192000</CYCC:CommonStockClosingPriceThreshold>
    <CYCC:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000893"
      unitRef="Pure">1.50</CYCC:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice>
    <CYCC:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      id="Fact000894">P20D</CYCC:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays>
    <CYCC:PreferredStockConversionObligationNumberOfTradingDays
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      id="Fact000895">P30D</CYCC:PreferredStockConversionObligationNumberOfTradingDays>
    <CYCC:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      id="Fact000896">P5D</CYCC:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion>
    <CYCC:DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000897"
      unitRef="Segment">6</CYCC:DirectorElectionTriggerNumberOfQuarterlyPeriodsWithNoDividends>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000898"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000899"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000900"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      id="Fact000901">P25Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000902"
      unitRef="USDPShares">0.15</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000903"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-012024-12-31" id="Fact000905">&lt;p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_znQWdRcu69i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
Stock-Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_821_zEM0MRbmF4ef" style="display: none"&gt;Stock
Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zXCK22xGcJEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the years ended 2024 and
2023 as shown in the following table (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zW9fimmMO287" style="display: none"&gt;Schedule
of Stock Based Compensation Expense&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z5J1LKCuPOd6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_zoBc2yGOwLFk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; font-weight: bold"&gt;Year Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zG7j9d9M17T4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;498&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5qIKuYJsX7d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zUb79rLOxow5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zyYSPO1y2Ai9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2018
Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2018, the Company&#x2019;s stockholders approved the 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), under which Cyclacel
may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan replaced the 2015 Equity Incentive
Plan (the &#x201c;2015 Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2018 Plan allows for various types of award grants, including stock options and restricted stock units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 21, 2024, the Company&#x2019;s stockholders approved an additional &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240621__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zeFiU61TQvt"&gt;160,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock that may be issued under the 2018 Plan.
On June 13, 2023, the Company&#x2019;s stockholders approved an additional &lt;span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230613__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z6ms7IFo8Lij"&gt;60,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock that may be issued under the 2018 Plan.
As of December 31, 2024, the Company has reserved approximately &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z9agf1Z10yx5"&gt;196,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock under the 2018 Plan
for future issuances. Stock option awards granted under the Company&#x2019;s equity incentive plans have a maximum life of &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member__srt--RangeAxis__srt--MaximumMember_zgbuIy9LIkuf"&gt;10&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years and generally &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240101__20241231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_z27qR6ke1CFl"&gt;vest
over a one to four-year period from the date of grant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2020
Inducement Equity Incentive Plan &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), became effective. Under the Inducement Plan,
Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder
approval). The Inducement Plan allows for the issuance of up to &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20201031__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zy9d7OagRbpd"&gt;55&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock (or the equivalent
of such number). As of December 31, 2024, the reserve remains at &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zVvOaQTEFAYk"&gt;55&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Option
Grants and Exercises&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeIIfNY9BWz4"&gt;52&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options granted during the year ended December 31, 2024, all
issued under the 2018 Plan. These options had a grant date fair value of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr01DMLhwYbe"&gt;424.80&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per option. There were &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCLNscJVcAu1"&gt;181&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options granted during the year ended December 31, 2023. These
options had a grant date fair value ranging between $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zNpnvqTKb2te"&gt;1,516.80&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-$&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zpp49O0UskSl"&gt;2,635.20&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Of
the options granted during the year ended December 31, 2024, all vested &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0KzoUypebxi"&gt;six
months&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from their date of grant. Of the options
granted during the year ended December 31, 2023, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--OptionsVestingOnThirdAnniversaryOfGrantMember_zScAeDCVQIA5"&gt;71&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;awards shall vest on the third anniversary of their date of
grant, or earlier if either of the certain performance conditions are met relating to enrollment goals for various clinical studies.
A further &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV64TXIKVcYc"&gt;36&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options granted during the year ended December 31, 2023 were
forfeited during 2024 due to the holders&#x2019; termination of employment with the Company. The Company had assumed that these awards
will vest after &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dc_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--OptionsVestingOnThirdAnniversaryOfGrantMember_zZuZYVw122Q1"&gt;three
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as satisfaction of the performance conditions
is not probable at this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the total remaining unrecognized compensation cost related to the non-vested stock options with service conditions
amounted to approximately $&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231_zKgpLL0nXbzc"&gt;0.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, which will be amortized over the weighted-average
remaining requisite service period of &lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_z8HmQwph5sce"&gt;1.30&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Outstanding
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zYaETrg97Iuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the share option activity and related information is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zYiLYeCPA6tk" style="display: none"&gt;Schedule
of Share Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Aggregate&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Price Per&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Term (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Value ($000)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;Options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZba66nJpzr1" style="width: 10%; text-align: right" title="Number of Options Outstanding, Balance"&gt;447&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpPSaXrFwvVa" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;21,049.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6ihu0t7sqTc"&gt;8.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKlyebtltsKg" style="width: 10%; text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4uBx3qaHJJj" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG6lVgIsPxrf" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2,117.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjZg89pcq0ce" style="text-align: right" title="Number of Options Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4rlVdRnM6O9" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0951"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zei0oYx5BAD2" style="text-align: right" title="Number of Options Outstanding, Cancelled/forfeited"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAp2gYljl4z3" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited"&gt;79,737.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW6MdwH7khT8" style="text-align: right" title="Number of Options Outstanding, Balance"&gt;595&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxNXXZznHXje" style="text-align: right" title="Weighted Average Exercise Price, Balance"&gt;12,048.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmJ5D0fqqkT3"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1THMMqemkLb" style="text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTDEG35BHJkf" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKNNH2gjtHA2" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;547.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z45Oa4VM7lp9" style="text-align: right" title="Number of Options Outstanding, Cancelled/forfeited"&gt;(153&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqB5l4LngxRl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited"&gt;12327.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1aMINQMRCJc" style="text-align: right" title="Number of Options Outstanding, Balance"&gt;494&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvHykPYxeNHh" style="text-align: right" title="Weighted Average Exercise Price, Balance"&gt;10,658.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgOqXuyCcwD2"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXPhzx6MQkGi" style="text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3wxdHLU6Wd4" style="text-align: right" title="Number of Options Outstanding, Unvested"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjrVZ71REUt4" style="text-align: right" title="Weighted Average Exercise Price, Unvested"&gt;2,250.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmh8LOODM46c"&gt;8.45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and exercisable at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTSjcDWGjEBi" style="text-align: right" title="Number of Options Outstanding, Vested and exercisable"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7JzNxuMInj7" style="text-align: right" title="Weighted Average Exercise Price, Vested and exercisable"&gt;12,141.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwcSRTTunONf"&gt;6.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDlk1p37R0C7" style="text-align: right" title="Aggregrate Intrinsic Value, Vested and Exerciseable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zHpzs7E0GNpb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLk6BC2Yaog5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B7_zuL5AUzeIOG2" style="display: none"&gt;Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Year ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Year ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdy05diIKDd6"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zi4hnL1Nbi65" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;- &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zWa2OUYvebgi"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr79fZTdLQOe"&gt;3.995&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zPj9fqVcqaJ2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.660&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
                                            &#x2009;&#x2013;&#x2009;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTCRQ6XLrwv5"&gt;4.160&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6AtZ7wEbaLk"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHPdnGuNw9Z6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&#x2009;&#x2013;&#x2009;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zD8iL2fdMt72"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield over expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSyMhqwDeVMb"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDBGHpXkRUOe"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Resulting weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqLTmwaaiAih"&gt;424.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjDlkN8WLLZ5"&gt;1,591.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zkuTqvoTGAA" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSbXS9y0d0S9" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;stock options exercised during each of the years ended December
31, 2024 and 2023, respectively. The Company does not expect to be able to benefit from the deduction for stock option exercises that
may occur because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK3tmfhPqMs9"&gt;52&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock units during the year ended December 31, 2024.
These restricted stock units vest monthly over a six-month&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtM_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbiwy96lLcQb" style="display: none"&gt;6&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;service period. These restricted stock units were valued at
$&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdQNw50UDo8d"&gt;547.20&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at the date of grant, which was equivalent to the market price
of a share of the Company&#x2019;s common stock on that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbKBK3EXdol5"&gt;71&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock units were issued in January 2023 vest on
the third anniversary of their date of grant, or earlier if certain defined clinical trial related performance targets are met. A three-year&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1s54avrM6Ee" style="display: none"&gt;3&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vesting assumption was applied to these restricted stock units
as satisfaction of the performance conditions is not probable at this time. Each of these restricted stock units was valued at $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgQdUy0iVF2e"&gt;3,240.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at the date of grant, which was equivalent to the market price
of a share of the Company&#x2019;s common stock on that date. During 2023, &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0krSL20mtli"&gt;1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of these restricted stock units were forfeited as the recipient
voluntarily terminated employment with the Company. A further &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSdTTweCTRNh"&gt;35&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock units issued in June 2023 vest on the first
anniversary of the date of grant. Each of these restricted stock units were valued at $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pp2d_c20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWLOO99AkOpg"&gt;2,121.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at the date of grant, which was equivalent to the market price
of a share of the Company&#x2019;s common stock on that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, an additional &lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGyHbUH9o1x3"&gt;32&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of these restricted stock units have been forfeited due to
the holders&#x2019; termination of employment with the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z0y5of2jRFW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summarized
information for restricted stock units as of December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z3I6sU64j9Ca" style="display: none"&gt;Schedule
of Restricted Stock Units Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Restricted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;Remaining&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Stock Units&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 51%; text-align: left"&gt;Restricted Stock Units outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4bnpsxRNzp5" style="width: 14%; text-align: right" title="Restricted Stock Units outstanding, Beginning balance"&gt;38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5vmvcpilDg8" style="width: 10%; text-align: right" title="Restricted Stock Units, Grant Date Value Per Share"&gt;6,768.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFYiu1O9hNg" style="text-align: right" title="Granted"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zARNwFuag36h" style="text-align: right" title="Granted"&gt;2,870.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdkJjVayPsI5" style="text-align: right" title="Cancelled/forfeited"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRFRVJA2uDT2" style="text-align: right" title="Cancelled/forfeited"&gt;3,240.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrWRPQXoR4yd" style="text-align: right" title="Restricted Stock Units outstanding, Beginning balance"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBGAA1hpRkl1" style="text-align: right" title="Restricted Stock Units, Grant Date Value Per Share"&gt;3,902.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPxTjzhMzzX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.96&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRomSdcQm0g8" style="text-align: right" title="Granted"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJFqXxPzH1Ej" style="text-align: right" title="Granted"&gt;547.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkqh0qcxHcUi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.03&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAfRIpbwJTIk" style="text-align: right" title="Cancelled/forfeited"&gt;(32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD5MLF0pZK74" style="text-align: right" title="Cancelled/forfeited"&gt;3,675.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZrTIw89T5rl" style="text-align: right" title="Restricted Stock Units outstanding, Ending balance"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6AnS530vm5j" style="text-align: right" title="Restricted Stock Units, Grant Date Value Per Share"&gt;2,881.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdrTMg2j6Qw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.30&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzrxrQL9jip3" style="text-align: right" title="Unvested"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztEIEWKXLf67" style="text-align: right" title="Unvested, Weighted Average Grant Date Value Per Share"&gt;3,280.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8A61gEZ9Bf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.06&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb6xI7zGQfe6" style="text-align: right" title="Vested"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQYuj9KVPi75" style="text-align: right" title="Vested"&gt;2,747.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdKSrMuFyqBb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.39&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z6vaINvgkkf5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-01-012024-12-31" id="Fact000907">&lt;p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zXCK22xGcJEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the years ended 2024 and
2023 as shown in the following table (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zW9fimmMO287" style="display: none"&gt;Schedule
of Stock Based Compensation Expense&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z5J1LKCuPOd6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_zoBc2yGOwLFk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; font-weight: bold"&gt;Year Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zG7j9d9M17T4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;498&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5qIKuYJsX7d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zUb79rLOxow5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000909"
      unitRef="USD">498000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000910"
      unitRef="USD">1039000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000912"
      unitRef="USD">94000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000913"
      unitRef="USD">434000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000915"
      unitRef="USD">592000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000916"
      unitRef="USD">1473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-06-21_custom_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact000917"
      unitRef="Shares">160000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-06-13_custom_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">60000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact000919"
      unitRef="Shares">196000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_EquityIncentivePlan2018Member_srt_MaximumMember"
      id="Fact000920">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2024-01-012024-12-31_custom_EquityIncentivePlan2018Member"
      id="Fact000921">vest
over a one to four-year period from the date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-10-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember"
      decimals="INF"
      id="Fact000922"
      unitRef="Shares">55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember"
      decimals="INF"
      id="Fact000923"
      unitRef="Shares">55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000924"
      unitRef="Shares">52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000925"
      unitRef="USDPShares">424.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000926"
      unitRef="Shares">181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000927"
      unitRef="USDPShares">1516.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000928"
      unitRef="USDPShares">2635.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact000929">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_OptionsVestingOnThirdAnniversaryOfGrantMember"
      decimals="INF"
      id="Fact000930"
      unitRef="Shares">71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000931"
      unitRef="Shares">36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_OptionsVestingOnThirdAnniversaryOfGrantMember"
      id="Fact000932">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000933"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2024-01-012024-12-31" id="Fact000934">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000936">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zYaETrg97Iuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the share option activity and related information is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zYiLYeCPA6tk" style="display: none"&gt;Schedule
of Share Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Aggregate&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Price Per&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Term (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Value ($000)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;Options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZba66nJpzr1" style="width: 10%; text-align: right" title="Number of Options Outstanding, Balance"&gt;447&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpPSaXrFwvVa" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;21,049.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6ihu0t7sqTc"&gt;8.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKlyebtltsKg" style="width: 10%; text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4uBx3qaHJJj" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG6lVgIsPxrf" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2,117.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjZg89pcq0ce" style="text-align: right" title="Number of Options Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4rlVdRnM6O9" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0951"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zei0oYx5BAD2" style="text-align: right" title="Number of Options Outstanding, Cancelled/forfeited"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAp2gYljl4z3" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited"&gt;79,737.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW6MdwH7khT8" style="text-align: right" title="Number of Options Outstanding, Balance"&gt;595&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxNXXZznHXje" style="text-align: right" title="Weighted Average Exercise Price, Balance"&gt;12,048.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmJ5D0fqqkT3"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1THMMqemkLb" style="text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTDEG35BHJkf" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKNNH2gjtHA2" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;547.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z45Oa4VM7lp9" style="text-align: right" title="Number of Options Outstanding, Cancelled/forfeited"&gt;(153&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqB5l4LngxRl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited"&gt;12327.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1aMINQMRCJc" style="text-align: right" title="Number of Options Outstanding, Balance"&gt;494&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvHykPYxeNHh" style="text-align: right" title="Weighted Average Exercise Price, Balance"&gt;10,658.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgOqXuyCcwD2"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXPhzx6MQkGi" style="text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3wxdHLU6Wd4" style="text-align: right" title="Number of Options Outstanding, Unvested"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjrVZ71REUt4" style="text-align: right" title="Weighted Average Exercise Price, Unvested"&gt;2,250.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmh8LOODM46c"&gt;8.45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and exercisable at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTSjcDWGjEBi" style="text-align: right" title="Number of Options Outstanding, Vested and exercisable"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7JzNxuMInj7" style="text-align: right" title="Weighted Average Exercise Price, Vested and exercisable"&gt;12,141.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwcSRTTunONf"&gt;6.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDlk1p37R0C7" style="text-align: right" title="Aggregrate Intrinsic Value, Vested and Exerciseable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000938"
      unitRef="Shares">447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000940"
      unitRef="USDPShares">21049.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact000941">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000945"
      unitRef="Shares">181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000947"
      unitRef="USDPShares">2117.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000953"
      unitRef="Shares">33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000955"
      unitRef="USDPShares">79737.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Shares">595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000959"
      unitRef="USDPShares">12048.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact000960">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000964"
      unitRef="Shares">52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000966"
      unitRef="USDPShares">547.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000968"
      unitRef="Shares">153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000970"
      unitRef="USDPShares">12327.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000972"
      unitRef="Shares">494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000974"
      unitRef="USDPShares">10658.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact000975">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000979"
      unitRef="Shares">74</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000981"
      unitRef="USDPShares">2250.91</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact000982">P8Y5M12D</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000984"
      unitRef="Shares">420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000986"
      unitRef="USDPShares">12141.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact000987">P6Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000991">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLk6BC2Yaog5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B7_zuL5AUzeIOG2" style="display: none"&gt;Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Year ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Year ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdy05diIKDd6"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zi4hnL1Nbi65" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;- &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zWa2OUYvebgi"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr79fZTdLQOe"&gt;3.995&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zPj9fqVcqaJ2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.660&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
                                            &#x2009;&#x2013;&#x2009;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTCRQ6XLrwv5"&gt;4.160&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6AtZ7wEbaLk"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHPdnGuNw9Z6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&#x2009;&#x2013;&#x2009;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zD8iL2fdMt72"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield over expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSyMhqwDeVMb"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDBGHpXkRUOe"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Resulting weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqLTmwaaiAih"&gt;424.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjDlkN8WLLZ5"&gt;1,591.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact000992">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      id="Fact000993">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      id="Fact000994">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000995"
      unitRef="Pure">0.03995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000996"
      unitRef="Pure">0.03660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Pure">0.04160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Pure">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000999"
      unitRef="Pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001000"
      unitRef="Pure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001002"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001003"
      unitRef="USDPShares">424.80</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001004"
      unitRef="USDPShares">1591.20</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001007">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001008"
      unitRef="USDPShares">547.20</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001009"
      unitRef="Shares">71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001010">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-01-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001011"
      unitRef="USDPShares">3240.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001012"
      unitRef="Shares">1</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001013"
      unitRef="Shares">35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact001014"
      unitRef="USDPShares">2121.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001015"
      unitRef="Shares">32</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001017">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z0y5of2jRFW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summarized
information for restricted stock units as of December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z3I6sU64j9Ca" style="display: none"&gt;Schedule
of Restricted Stock Units Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Restricted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;Remaining&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Stock Units&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 51%; text-align: left"&gt;Restricted Stock Units outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4bnpsxRNzp5" style="width: 14%; text-align: right" title="Restricted Stock Units outstanding, Beginning balance"&gt;38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5vmvcpilDg8" style="width: 10%; text-align: right" title="Restricted Stock Units, Grant Date Value Per Share"&gt;6,768.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFYiu1O9hNg" style="text-align: right" title="Granted"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zARNwFuag36h" style="text-align: right" title="Granted"&gt;2,870.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdkJjVayPsI5" style="text-align: right" title="Cancelled/forfeited"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRFRVJA2uDT2" style="text-align: right" title="Cancelled/forfeited"&gt;3,240.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrWRPQXoR4yd" style="text-align: right" title="Restricted Stock Units outstanding, Beginning balance"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBGAA1hpRkl1" style="text-align: right" title="Restricted Stock Units, Grant Date Value Per Share"&gt;3,902.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPxTjzhMzzX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.96&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRomSdcQm0g8" style="text-align: right" title="Granted"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJFqXxPzH1Ej" style="text-align: right" title="Granted"&gt;547.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkqh0qcxHcUi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.03&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAfRIpbwJTIk" style="text-align: right" title="Cancelled/forfeited"&gt;(32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD5MLF0pZK74" style="text-align: right" title="Cancelled/forfeited"&gt;3,675.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZrTIw89T5rl" style="text-align: right" title="Restricted Stock Units outstanding, Ending balance"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6AnS530vm5j" style="text-align: right" title="Restricted Stock Units, Grant Date Value Per Share"&gt;2,881.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdrTMg2j6Qw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.30&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzrxrQL9jip3" style="text-align: right" title="Unvested"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztEIEWKXLf67" style="text-align: right" title="Unvested, Weighted Average Grant Date Value Per Share"&gt;3,280.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8A61gEZ9Bf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.06&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb6xI7zGQfe6" style="text-align: right" title="Vested"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQYuj9KVPi75" style="text-align: right" title="Vested"&gt;2,747.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdKSrMuFyqBb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.39&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001019"
      unitRef="Shares">38000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001021"
      unitRef="USDPShares">6768.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001023"
      unitRef="Shares">107000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001025"
      unitRef="USDPShares">2870.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001027"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001029"
      unitRef="USDPShares">3240.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001031"
      unitRef="Shares">144000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001033"
      unitRef="USDPShares">3902.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001034">P8Y11M15D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001036"
      unitRef="Shares">52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001038"
      unitRef="USDPShares">547.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001039">P9Y10D</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsDuringPeriodWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001041"
      unitRef="Shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001043"
      unitRef="USDPShares">3675.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001045"
      unitRef="Shares">164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001047"
      unitRef="USDPShares">2881.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001048">P8Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001050"
      unitRef="Shares">41000</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001052"
      unitRef="USDPShares">3280.09</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001053">P8Y21D</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001055"
      unitRef="Shares">123000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001057"
      unitRef="USDPShares">2747.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001058">P8Y4M20D</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001060">&lt;p id="xdx_80E_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z4JEEJEo67V9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_82E_zqDEuSLYSI8i"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Pension
Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates a defined contribution group personal pension plan for all of its UK based employees. Company contributions to the plan
totaled approximately $&lt;span id="xdx_907_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20240101__20241231_z2dd5cvF5pd7"&gt;51,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_z2Whnnugw6F"&gt;52,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;401(k)
Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
401(k) Plan provides for matching contributions by the Company in an amount equal to the lesser of &lt;span id="xdx_907_ecustom--DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_pid_dp_uPure_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zsBo8GLJzrd4"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the employee&#x2019;s deferral or &lt;span id="xdx_901_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pid_dp_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_z9kCUlpY4w7e"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the U.S. employee&#x2019;s qualifying compensation. The 401(k) Plan is intended to qualify under Section 401(k) of the Internal Revenue
Code, so that contributions to the 401(k) Plan by employees or by the Company, and the investment earnings thereon, are not taxable to
the employees until they are withdrawn. Company matching contributions are tax deductible by the Company when made. In 2024, Company
employees could elect to reduce their current compensation by up to the statutorily prescribed annual limit of $&lt;span id="xdx_90E_ecustom--DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_z2wXwLdjHdV"&gt;23,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;if under 50 years old and $&lt;span id="xdx_90C_ecustom--DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zFq0vlBb6pQ5"&gt;30,500&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;if over 50 years old and to have those funds contributed to
the 401(k) Plan. The Company made contributions of approximately $&lt;span id="xdx_906_eus-gaap--DefinedContributionPlanCostRecognized_pp0d_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_zNkj37no1lpl"&gt;40,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pp0d_c20230101__20231231__us-gaap--RetirementPlanTypeAxis__custom--Plan401KMember_ztTBMIszXbdc"&gt;103,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to the 401(k) Plan for the years ended December 31, 2024 and
2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001061"
      unitRef="USD">51000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001062"
      unitRef="USD">52000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <CYCC:DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral
      contextRef="From2024-01-012024-12-31_custom_Plan401KMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Pure">1</CYCC:DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="From2024-01-012024-12-31_custom_Plan401KMember"
      decimals="INF"
      id="Fact001064"
      unitRef="Pure">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <CYCC:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge
      contextRef="From2024-01-012024-12-31_custom_Plan401KMember"
      decimals="0"
      id="Fact001065"
      unitRef="USD">23000</CYCC:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge>
    <CYCC:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge
      contextRef="From2024-01-012024-12-31_custom_Plan401KMember"
      decimals="0"
      id="Fact001066"
      unitRef="USD">30500</CYCC:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2024-01-012024-12-31_custom_Plan401KMember"
      decimals="0"
      id="Fact001067"
      unitRef="USD">40000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2023-01-012023-12-31_custom_Plan401KMember"
      decimals="0"
      id="Fact001068"
      unitRef="USD">103000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001070">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_z0l3rkrmF2o1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
&lt;span id="xdx_82C_z9ds2jaJjJoa"&gt;Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zi2SGX2EgT35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Loss)
income from continuing operations before taxes is comprised of the following components for the years ended December 31, 2024 and 2023
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_ziPhwKKQ7QD9" style="display: none"&gt;Schedule
of Components of (Loss) Income Before Taxes from Continuing Operations&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z40s8ijn56Sg" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_z6hypnLtSc9c" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_zpbZuNxDOIb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 62%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_zn0TTtefFfZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,030&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(24,745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztT40wwpCbvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from continuing operations before taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,994&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zgXzGKTTjWei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zP6uKjErOoEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
benefit (provision) for income taxes from continuing operations consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zzIQKg3SheM1" style="display: none"&gt;Schedule
of Benefit (Provision) for Income Taxes from Continuing Operations&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 62%"&gt;Current&#x2009;&#x2009;&#x2013;&#x2009;&#x2009;domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20240101__20241231_zHkvjHh0ciX7" style="width: 15%; text-align: right" title="Current - domestic"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230101__20231231_zDspSsLfAIQe" style="width: 15%; text-align: right" title="Current - domestic"&gt;(2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current&#x2009;&#x2009;&#x2013;&#x2009;&#x2009;foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20240101__20241231_z9oZ5jhlCOdj" style="text-align: right" title="Current - foreign"&gt;803&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20230101__20231231_z6Hfu5Pnc17b" style="text-align: right" title="Current - foreign"&gt;2,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current&#x2009;&#x2009;&#x2013;&#x2009;&#x2009;total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zloeSjLyuHY7" style="text-align: right" title="Current - total"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_z9VgN91v53Lk" style="text-align: right" title="Current - total"&gt;2,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred&#x2009;&#x2009;&#x2013;&#x2009;&#x2009;domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20240101__20241231_zQ2kfkKvaYm5" style="text-align: right" title="Deferred  -  domestic"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20230101__20231231_zSiCUsFkQC8k" style="text-align: right" title="Deferred  -  domestic"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1099"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20240101__20241231_z1GEgQ9Enx3h" style="text-align: right" title="Income tax benefit"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20230101__20231231_zwWKMtcDwWP7" style="text-align: right" title="Income tax benefit"&gt;2,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z0hVNo1lu5Ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred a taxable loss in each of the operating periods since incorporation. The income tax credits of $&lt;span id="xdx_90A_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231_zKVJoKduiR1d"&gt;0.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20231231_zWcBYe3D7Oyk"&gt;3.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million for the years ended December 31, 2024 and 2023, respectively,
represent UK research and development (&#x201c;R&amp;amp;D&#x201d;) tax credits for expenditures in the United Kingdom.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zIXbJHNN5g85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory
federal tax rate to loss from continuing operations before income taxes is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8BD_zGLXvuCpGWSa" style="display: none"&gt;Schedule
of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory
Federal Tax Rate to Loss Before Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z8pHbjV9u6k3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zHIcFpd8tN45" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_z4J0PexTZVJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Loss from continuing operations before taxes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(11,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(25,551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_z6JAAMhrd20f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income tax expense computed at statutory federal tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,527&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,366&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_zV1GNveNkmd4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additional research and development tax relief&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,409&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_zyhfrwmzo8hf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss surrendered to generate R&amp;amp;D credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_zZ68zSJfuL25" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_zdz7HvdWK7cj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other foreign items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_pn3n3_zvxQ78xJhSSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Disallowed expenses and non-taxable income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_zocg3OA9DKb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock Compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_zkjIlTHWkJAc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign items, including change in tax rates, and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1134"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationOtherItemsAmount_pn3n3_zI4jzmlThK9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zrvdoTqNWRlb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current - total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(782&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,996&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zWX1gTWRmRj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTQBA6wBlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
components of the Company&#x2019;s deferred tax assets are shown below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zaRTNnpL4Wy7" style="display: none"&gt;Schedule
of Significant Components of the Entity's Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zYKpNA6rzTgb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zXMGekTlL4Cl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzNQW_z9WHoQsvbAp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Net operating loss and tax credit carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;59,417&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;57,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_iI_pn3n3_maDTAGzNQW_zgSYHJggyol" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Depreciation, amortization and impairment of property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzNQW_zkSqryKkSQNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_iI_pn3n3_maDTAGzNQW_zeB95xzQFgza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseRightOfUseAsset_iI_pn3n3_maDTAGzNQW_zUcW5ieyLWNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right of use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsLeaseRightOfUseLiability_iI_pn3n3_maDTAGzNQW_zudO5YVuNRlc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzNQW_zqg5xGjm4Fmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzNQW_maDTANzSsl_z8fPaw5CXOh7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzSsl_zlMJjZXNVAXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance for deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(59,820&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57,323&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzSsl_zET7nPL47GL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zJQF0WqlpXk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
valuation allowance has been established, as realization of such assets is uncertain. The Company&#x2019;s management evaluated the positive
and negative evidence bearing upon the realizability of its deferred assets, and has determined that, at present, the Company may not
be able to recognize the benefits of the deferred tax assets under the more likely than not criteria. Accordingly, a valuation allowance
of approximately $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20241231_zVgt0vwS60J6"&gt;59.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million has been established at December 31, 2024. The valuation
allowance increased by approximately $&lt;span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zjQ2QYDP92g1"&gt;2.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
specified in the Tax Reform Act of 1986, due to ownership changes, the Company&#x2019;s ability to utilize its net operating loss (&#x201c;NOL&#x201d;)
carryforwards may be limited. Utilization of the NOLs may be subject to a substantial annual limitation under Section 382 of the Internal
Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership
changes may limit the amount of NOL and R&amp;amp;D credit carryforwards that can be utilized annually to offset future taxable income and
tax, respectively. The Company completed a Section 382 study and has concluded that an ownership change occurred on March 4, 2015 and
July 21, 2017. As a result of the ownership changes, the NOLs are limited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company has federal NOLs of $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zjWiNCg79XT7"&gt;3.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zswJqJgLAcXf"&gt;3.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respectively. The federal NOLs have an indefinite
life. As of December 31, 2024 and 2023, the Company has state NOLs of&#x2009;$&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zcg5ohylH34"&gt;16.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ziCVmlso24De"&gt;17.3&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respectively, which will begin to expire in 2028.
As of December 31, 2024 and 2023, the Company had foreign NOLs of $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zJgjQM3J2bcc"&gt;230.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zcWSGz9BC0jk"&gt;220.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respectively. The Company&#x2019;s foreign NOL&#x2019;s
do not expire under UK tax law however the use of these NOLs is restricted to an annual &#xa3;&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn6n6_uGBP_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zET1OBwkf7Zd"&gt;5.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million allowance in each standalone company or group and above
this allowance, there will be a &lt;span id="xdx_90A_ecustom--PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_pid_dp_uPure_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z7JNT7IuFkw1"&gt;50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
restriction in the profits that can be covered by losses brought forward.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated all significant tax positions at December 31, 2024 and 2023 and concluded that there are no material uncertain tax positions.
The Company would recognize both interest and penalties related to unrecognized benefits in income tax expense. The Company has not recorded
any interest and penalties on any unrecognized tax benefits since its inception.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
years 2020 - 2023 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the
United Kingdom and the United States, as carryforward attributes generated in years past may still be adjusted upon examination by the
United Kingdom&#x2019;s H.M. Revenue &amp;amp; Customs, the Internal Revenue Service (&#x201c;IRS&#x201d;) or state tax authorities. The Company
is currently not under examination by the IRS or any other jurisdictions for any tax years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have not provided a deferred tax liability on the cumulative amount of unremitted foreign earnings of international subsidiaries because
it is our intent to permanently reinvest such earnings outside of the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has an aggregate deficit in foreign earnings and therefore has not provided any deferred tax liability on its outside book-tax
basis difference in its foreign subsidiaries and because it is also our intent to permanently reinvest any earnings outside of the United
States. We would recognize this deferred tax liability if we were to experience a change in circumstances producing a change in that
intention. As a result of the repeal of Section 902 foreign tax credit under the Tax Act, future distributions would not be offset by
a foreign tax credit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental
to research and experimentation (R&amp;amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting
these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;amp;E expenses
for tax years tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;amp;E activities in the US must be
amortized over a 5-year period if incurred, and R&amp;amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;amp;E
activities are broader in scope than qualified research activities that are considered under IRC Section 41 (relating to the research
tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that
the company does not have any R&amp;amp;E expenses in the US. The company will continue to monitor this issue for future developments, but
it does not expect R&amp;amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001072">&lt;p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zi2SGX2EgT35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Loss)
income from continuing operations before taxes is comprised of the following components for the years ended December 31, 2024 and 2023
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_ziPhwKKQ7QD9" style="display: none"&gt;Schedule
of Components of (Loss) Income Before Taxes from Continuing Operations&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z40s8ijn56Sg" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_z6hypnLtSc9c" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_zpbZuNxDOIb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 62%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_zn0TTtefFfZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,030&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(24,745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztT40wwpCbvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from continuing operations before taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,994&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001074"
      unitRef="USD">36000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">-806000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001077"
      unitRef="USD">-12030000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001078"
      unitRef="USD">-24745000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001080"
      unitRef="USD">-11994000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001081"
      unitRef="USD">-25551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001083">&lt;p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zP6uKjErOoEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
benefit (provision) for income taxes from continuing operations consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zzIQKg3SheM1" style="display: none"&gt;Schedule
of Benefit (Provision) for Income Taxes from Continuing Operations&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 62%"&gt;Current&#x2009;&#x2009;&#x2013;&#x2009;&#x2009;domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20240101__20241231_zHkvjHh0ciX7" style="width: 15%; text-align: right" title="Current - domestic"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230101__20231231_zDspSsLfAIQe" style="width: 15%; text-align: right" title="Current - domestic"&gt;(2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current&#x2009;&#x2009;&#x2013;&#x2009;&#x2009;foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20240101__20241231_z9oZ5jhlCOdj" style="text-align: right" title="Current - foreign"&gt;803&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20230101__20231231_z6Hfu5Pnc17b" style="text-align: right" title="Current - foreign"&gt;2,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current&#x2009;&#x2009;&#x2013;&#x2009;&#x2009;total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zloeSjLyuHY7" style="text-align: right" title="Current - total"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_z9VgN91v53Lk" style="text-align: right" title="Current - total"&gt;2,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred&#x2009;&#x2009;&#x2013;&#x2009;&#x2009;domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20240101__20241231_zQ2kfkKvaYm5" style="text-align: right" title="Deferred  -  domestic"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20230101__20231231_zSiCUsFkQC8k" style="text-align: right" title="Deferred  -  domestic"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1099"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20240101__20241231_z1GEgQ9Enx3h" style="text-align: right" title="Income tax benefit"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_c20230101__20231231_zwWKMtcDwWP7" style="text-align: right" title="Income tax benefit"&gt;2,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001085"
      unitRef="USD">-21000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001087"
      unitRef="USD">-2000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001089"
      unitRef="USD">803000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001091"
      unitRef="USD">2998000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001093"
      unitRef="USD">782000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001095"
      unitRef="USD">2996000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001101"
      unitRef="USD">-782000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001103"
      unitRef="USD">-2996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001104"
      unitRef="USD">800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001105"
      unitRef="USD">3000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001107">&lt;p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zIXbJHNN5g85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory
federal tax rate to loss from continuing operations before income taxes is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8BD_zGLXvuCpGWSa" style="display: none"&gt;Schedule
of Reconciliation of the (Benefit) Provision for Income Taxes from Continuing Operations with the Amount Computed by Applying the Statutory
Federal Tax Rate to Loss Before Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z8pHbjV9u6k3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zHIcFpd8tN45" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_z4J0PexTZVJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Loss from continuing operations before taxes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(11,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(25,551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_z6JAAMhrd20f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income tax expense computed at statutory federal tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,527&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,366&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_zV1GNveNkmd4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additional research and development tax relief&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,409&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_zyhfrwmzo8hf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss surrendered to generate R&amp;amp;D credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_zZ68zSJfuL25" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_zdz7HvdWK7cj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other foreign items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_pn3n3_zvxQ78xJhSSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Disallowed expenses and non-taxable income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_zocg3OA9DKb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock Compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_zkjIlTHWkJAc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign items, including change in tax rates, and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1134"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationOtherItemsAmount_pn3n3_zI4jzmlThK9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zrvdoTqNWRlb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current - total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(782&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,996&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001109"
      unitRef="USD">-11994000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001110"
      unitRef="USD">-25551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001112"
      unitRef="USD">-2527000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001113"
      unitRef="USD">-5366000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001116"
      unitRef="USD">-5409000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001119"
      unitRef="USD">4865000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001121"
      unitRef="USD">2798000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001122"
      unitRef="USD">1261000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001124"
      unitRef="USD">-1158000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001125"
      unitRef="USD">809000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <CYCC:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001127"
      unitRef="USD">35000</CYCC:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome>
    <CYCC:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001128"
      unitRef="USD">782000</CYCC:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001130"
      unitRef="USD">30000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001131"
      unitRef="USD">62000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <CYCC:EffectiveIncomeTaxRateReconciliationOtherItemsAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001136"
      unitRef="USD">40000</CYCC:EffectiveIncomeTaxRateReconciliationOtherItemsAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001139"
      unitRef="USD">-782000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001140"
      unitRef="USD">-2996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001142">&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTQBA6wBlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
components of the Company&#x2019;s deferred tax assets are shown below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zaRTNnpL4Wy7" style="display: none"&gt;Schedule
of Significant Components of the Entity's Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zYKpNA6rzTgb" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zXMGekTlL4Cl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzNQW_z9WHoQsvbAp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Net operating loss and tax credit carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;59,417&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;57,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_iI_pn3n3_maDTAGzNQW_zgSYHJggyol" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Depreciation, amortization and impairment of property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzNQW_zkSqryKkSQNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndDevelopmentCredits_iI_pn3n3_maDTAGzNQW_zeB95xzQFgza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseRightOfUseAsset_iI_pn3n3_maDTAGzNQW_zUcW5ieyLWNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right of use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsLeaseRightOfUseLiability_iI_pn3n3_maDTAGzNQW_zudO5YVuNRlc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzNQW_zqg5xGjm4Fmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzNQW_maDTANzSsl_z8fPaw5CXOh7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzSsl_zlMJjZXNVAXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance for deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(59,820&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57,323&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzSsl_zET7nPL47GL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001144"
      unitRef="USD">59417000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001145"
      unitRef="USD">57074000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <CYCC:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001147"
      unitRef="USD">39000</CYCC:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses>
    <CYCC:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001148"
      unitRef="USD">39000</CYCC:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001150"
      unitRef="USD">250000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001151"
      unitRef="USD">210000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <CYCC:DeferredTaxAssetsLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001156"
      unitRef="USD">-1000</CYCC:DeferredTaxAssetsLeaseRightOfUseAsset>
    <CYCC:DeferredTaxAssetsLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001157"
      unitRef="USD">-26000</CYCC:DeferredTaxAssetsLeaseRightOfUseAsset>
    <CYCC:DeferredTaxAssetsLeaseRightOfUseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001159"
      unitRef="USD">1000</CYCC:DeferredTaxAssetsLeaseRightOfUseLiability>
    <CYCC:DeferredTaxAssetsLeaseRightOfUseLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001160"
      unitRef="USD">26000</CYCC:DeferredTaxAssetsLeaseRightOfUseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001162"
      unitRef="USD">114000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001165"
      unitRef="USD">59820000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001166"
      unitRef="USD">57323000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001168"
      unitRef="USD">59820000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001169"
      unitRef="USD">57323000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001173"
      unitRef="USD">59800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001174"
      unitRef="USD">2500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Fact001175"
      unitRef="USD">3500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Fact001176"
      unitRef="USD">3800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001177"
      unitRef="USD">16800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001178"
      unitRef="USD">17300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="Fact001179"
      unitRef="USD">230000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="Fact001180"
      unitRef="USD">220100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      decimals="-6"
      id="Fact001181"
      unitRef="GBP">5000000.0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <CYCC:PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      decimals="INF"
      id="Fact001182"
      unitRef="Pure">0.50</CYCC:PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-012024-12-31" id="Fact001184">&lt;p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zzhzGbR1nhnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15.
Net Loss Per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_823_zj1AqnScSNpl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaPgmkrAWcSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zmPAJzP3Lbrl" style="display: none"&gt;Schedule
of Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zApuHLCLafz8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zosuHDqHoUu3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_iB_zkye7KFpM8v1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pn3n3_zbSYFLhOBBbd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(11,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(22,555&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PreferredStockDividendsIncomeStatementImpact_i01N_pn3n3_di_zWwGMIonyOHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend on convertible exchangeable preferred shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1194"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(201&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01_pn3n3_zZDaggpx6Wfg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to common shareholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,756&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zpuiu0OGIyBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average number of common shares used in loss per share&#x2009;&#x2013;&#x2009;basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_z2K08zwrNZj9"&gt;22,314&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zU4gHRANFRC2"&gt;3,545&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss per share - basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zPueyGER5C51"&gt;(502.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zHsdxXBu0y1h"&gt;(6,419.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zBdjnzCqCrA6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potential
dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss
per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per
share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on
amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the
periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8A5qjK8ZPL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zMnLkR0Etvvg" style="display: none"&gt;Schedule
of antidilutive shares excluded from computation of diluted net loss per share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zk6Kqj4vAPUe" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zlAdyJ4k5uG7" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrCtIDMllqvh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;494&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zR6bOlwu5J4h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zyDexCfFVXUh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20231231_zrUem3V7owIj"&gt;6&lt;/span&gt;%
    convertible exchangeable preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zRFaUHnu69b4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series A preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zCe0VYxg8vfi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series B preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1222"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_ziemC2QSOQWa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zVCB9AnJJVy5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total shares excluded from calculation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zP6iQB9a6Ofh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001186">&lt;p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaPgmkrAWcSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zmPAJzP3Lbrl" style="display: none"&gt;Schedule
of Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zApuHLCLafz8" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zosuHDqHoUu3" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_iB_zkye7KFpM8v1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pn3n3_zbSYFLhOBBbd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(11,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;(22,555&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PreferredStockDividendsIncomeStatementImpact_i01N_pn3n3_di_zWwGMIonyOHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend on convertible exchangeable preferred shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1194"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(201&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01_pn3n3_zZDaggpx6Wfg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to common shareholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,756&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zpuiu0OGIyBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average number of common shares used in loss per share&#x2009;&#x2013;&#x2009;basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_z2K08zwrNZj9"&gt;22,314&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zU4gHRANFRC2"&gt;3,545&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss per share - basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zPueyGER5C51"&gt;(502.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zHsdxXBu0y1h"&gt;(6,419.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001191"
      unitRef="USD">-11212000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001192"
      unitRef="USD">-22555000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001195"
      unitRef="USD">201000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001197"
      unitRef="USD">-11212000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001198"
      unitRef="USD">-22756000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001202"
      unitRef="Shares">22314</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001203"
      unitRef="Shares">3545</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001204"
      unitRef="USDPShares">-502.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001205"
      unitRef="USDPShares">-6419.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-012024-12-31" id="Fact001207">&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8A5qjK8ZPL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zMnLkR0Etvvg" style="display: none"&gt;Schedule
of antidilutive shares excluded from computation of diluted net loss per share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zk6Kqj4vAPUe" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zlAdyJ4k5uG7" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrCtIDMllqvh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;494&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zR6bOlwu5J4h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zyDexCfFVXUh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20231231_zrUem3V7owIj"&gt;6&lt;/span&gt;%
    convertible exchangeable preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zRFaUHnu69b4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series A preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zCe0VYxg8vfi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series B preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1222"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_ziemC2QSOQWa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zVCB9AnJJVy5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total shares excluded from calculation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember54207625"
      decimals="-3"
      id="Fact001209"
      unitRef="Shares">494000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember54207640"
      decimals="-3"
      id="Fact001210"
      unitRef="Shares">595000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember54207656"
      decimals="-3"
      id="Fact001212"
      unitRef="Shares">164000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember54207656"
      decimals="-3"
      id="Fact001213"
      unitRef="Shares">144000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001217"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember54207671"
      decimals="-3"
      id="Fact001215"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember54207671"
      decimals="-3"
      id="Fact001216"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember54207671"
      decimals="-3"
      id="Fact001219"
      unitRef="Shares">2000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact001220"
      unitRef="Shares">2000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact001223"
      unitRef="Shares">165000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember54207703"
      decimals="-3"
      id="Fact001225"
      unitRef="Shares">117182000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember"
      decimals="-3"
      id="Fact001226"
      unitRef="Shares">2648000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001228"
      unitRef="Shares">117842000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001229"
      unitRef="Shares">3554000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001231">&lt;p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zFvFF9ZiFIz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16.
&lt;span id="xdx_827_zCY0RQhiwx5l"&gt;Geographic and Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zhvSlWLPSFni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Geographic
information for the years ended December 31, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zjd4R6VCOs8i" style="display: none"&gt;Schedule
of Geographic Information&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revenue&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;United Kingdom&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z31mrJ5xVR5f" style="width: 15%; text-align: right" title="Revenue"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zYpp0Btyfs8h" style="width: 15%; text-align: right" title="Revenue"&gt;420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231_zmcpsLEtp13f" style="text-align: right" title="Revenue"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231_zkaLebsGMq57" style="text-align: right" title="Revenue"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;United States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z93MITdRGmJg" style="text-align: right" title="Net Loss"&gt;(37&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zB8d1IKB0Y7b" style="text-align: right" title="Net Loss"&gt;(808&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;United Kingdom&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z9oQ8kHoVvNf" style="text-align: right" title="Net Loss"&gt;(11,175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zRJ0Tzg31Vwf" style="text-align: right" title="Net Loss"&gt;(21,747&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Net Loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231_z9ia6vKOwEye" style="text-align: right" title="Net Loss"&gt;(11,212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231_zBLG7QHpFici" style="text-align: right" title="Net Loss"&gt;(22,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_z4mkAC6qKjjd" style="width: 15%; text-align: right" title="Total Assets"&gt;3,285&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_z3BUwgBWuDD3" style="width: 15%; text-align: right" title="Total Assets"&gt;2,938&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;United Kingdom&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zIbAgLrDsWP9" style="text-align: right" title="Total Assets"&gt;809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zsxWshuvtgH" style="text-align: right" title="Total Assets"&gt;5,867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20241231_zUlx5ZeC1M8j" style="text-align: right" title="Total Assets"&gt;4,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20231231_zAJ7AObNigng" style="text-align: right" title="Total Assets"&gt;8,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long Lived Assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;United States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_zCpCcEUOJzub" style="text-align: right" title="Long Lived Assets, net"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_zJfAm2BtN2of" style="text-align: right" title="Long Lived Assets, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;United Kingdom&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zSuaHLMaO2Nc" style="text-align: right" title="Long Lived Assets, net"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zKbX2ASHevdk" style="text-align: right" title="Long Lived Assets, net"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total Long Lived Assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231_zTND4cTeXCu1" style="text-align: right" title="Long Lived Assets, net"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231_zRyQfY2EJ2Nf" style="text-align: right" title="Long Lived Assets, net"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zsP8HMlkbOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as a single segment engaged in the development of innovative cancer medicines based on cell cycle, transcriptional regulation
and mitosis control biology. Consistent with our operational structure, our Chief Executive Officer (CEO), as the chief operating decision
maker, makes resource allocation and business process decisions globally across our consolidated business. Managing and allocating resources
at the consolidated level enables our CEO to assess the overall level of resources available and how to best deploy these resources across
functions, and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on
a geographic or some other basis. Consistent with this decision-making process, our CEO considers consolidated net loss, which is our
single segment&#x2019;s principal measure of segment profit and loss, when evaluating performance and allocating company-wide resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
expenses are amounts that are regularly provided to our CEO and included in consolidated net loss, our primary measure of our single
segment&#x2019;s profit or loss. Our CEO regularly reviews reported consolidated revenues, significant expenses and consolidated net loss,
in addition to forecasted revenues, significant expenses and net loss amounts for future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zKx9LsphFx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of our consolidated net loss for the years ended December 31, 2024 and 2023 is as follows, including the significant expenses
provided to and regularly reviewed by our CEO:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B0_z7QwPwziIp66" style="display: none"&gt;Schedule
of Summary of Consolidated Net Loss&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zGDczUfPKtg" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zp3qrFRvlZzk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zWylEmRgvbF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 62%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zMpaKm9T8JXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzPoy_zyBHG2eEx5zf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pn3n3_maOEzPoy_zmCmaBoierR" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEzPoy_z6BXTAH0TEac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingIncomeLoss_pn3n3_maILFCOzkrX_z5BrWNbJ2yTb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,004&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,453&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_maILFCOzkrX_z30IvRkRIle8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total other income (expense), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(98&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzkrX_maNILz14R_zBwzAszUDlab" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss before taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,994&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_di_msNILz14R_zQ2xcxeqceca" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz14R_zb1OinZBvAt1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zHmoeihOuKli" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001233">&lt;p id="xdx_89C_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zhvSlWLPSFni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Geographic
information for the years ended December 31, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zjd4R6VCOs8i" style="display: none"&gt;Schedule
of Geographic Information&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revenue&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;United Kingdom&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z31mrJ5xVR5f" style="width: 15%; text-align: right" title="Revenue"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zYpp0Btyfs8h" style="width: 15%; text-align: right" title="Revenue"&gt;420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20240101__20241231_zmcpsLEtp13f" style="text-align: right" title="Revenue"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20230101__20231231_zkaLebsGMq57" style="text-align: right" title="Revenue"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;United States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z93MITdRGmJg" style="text-align: right" title="Net Loss"&gt;(37&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zB8d1IKB0Y7b" style="text-align: right" title="Net Loss"&gt;(808&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;United Kingdom&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--GB_z9oQ8kHoVvNf" style="text-align: right" title="Net Loss"&gt;(11,175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zRJ0Tzg31Vwf" style="text-align: right" title="Net Loss"&gt;(21,747&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Net Loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231_z9ia6vKOwEye" style="text-align: right" title="Net Loss"&gt;(11,212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20231231_zBLG7QHpFici" style="text-align: right" title="Net Loss"&gt;(22,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_z4mkAC6qKjjd" style="width: 15%; text-align: right" title="Total Assets"&gt;3,285&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_z3BUwgBWuDD3" style="width: 15%; text-align: right" title="Total Assets"&gt;2,938&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;United Kingdom&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zIbAgLrDsWP9" style="text-align: right" title="Total Assets"&gt;809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zsxWshuvtgH" style="text-align: right" title="Total Assets"&gt;5,867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20241231_zUlx5ZeC1M8j" style="text-align: right" title="Total Assets"&gt;4,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20231231_zAJ7AObNigng" style="text-align: right" title="Total Assets"&gt;8,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long Lived Assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;United States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_zCpCcEUOJzub" style="text-align: right" title="Long Lived Assets, net"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_zJfAm2BtN2of" style="text-align: right" title="Long Lived Assets, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;United Kingdom&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GB_zSuaHLMaO2Nc" style="text-align: right" title="Long Lived Assets, net"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GB_zKbX2ASHevdk" style="text-align: right" title="Long Lived Assets, net"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total Long Lived Assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20241231_zTND4cTeXCu1" style="text-align: right" title="Long Lived Assets, net"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20231231_zRyQfY2EJ2Nf" style="text-align: right" title="Long Lived Assets, net"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31_country_GB"
      decimals="-3"
      id="Fact001235"
      unitRef="USD">43000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_GB"
      decimals="-3"
      id="Fact001237"
      unitRef="USD">420000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001239"
      unitRef="USD">43000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001241"
      unitRef="USD">420000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_country_US"
      decimals="-3"
      id="Fact001243"
      unitRef="USD">-37000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_country_US"
      decimals="-3"
      id="Fact001245"
      unitRef="USD">-808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_country_GB"
      decimals="-3"
      id="Fact001247"
      unitRef="USD">-11175000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_country_GB"
      decimals="-3"
      id="Fact001249"
      unitRef="USD">-21747000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001251"
      unitRef="USD">-11212000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001253"
      unitRef="USD">-22555000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_country_US"
      decimals="-3"
      id="Fact001255"
      unitRef="USD">3285000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_country_US"
      decimals="-3"
      id="Fact001257"
      unitRef="USD">2938000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_country_GB"
      decimals="-3"
      id="Fact001259"
      unitRef="USD">809000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_country_GB"
      decimals="-3"
      id="Fact001261"
      unitRef="USD">5867000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001263"
      unitRef="USD">4094000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001265"
      unitRef="USD">8805000</us-gaap:Assets>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31_country_US"
      decimals="-3"
      id="Fact001267"
      unitRef="USD">1000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31_country_GB"
      decimals="-3"
      id="Fact001271"
      unitRef="USD">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31_country_GB"
      decimals="-3"
      id="Fact001273"
      unitRef="USD">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001275"
      unitRef="USD">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001277"
      unitRef="USD">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-012024-12-31" id="Fact001279">&lt;p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zKx9LsphFx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of our consolidated net loss for the years ended December 31, 2024 and 2023 is as follows, including the significant expenses
provided to and regularly reviewed by our CEO:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B0_z7QwPwziIp66" style="display: none"&gt;Schedule
of Summary of Consolidated Net Loss&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zGDczUfPKtg" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zp3qrFRvlZzk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zWylEmRgvbF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 62%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zMpaKm9T8JXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzPoy_zyBHG2eEx5zf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pn3n3_maOEzPoy_zmCmaBoierR" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEzPoy_z6BXTAH0TEac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingIncomeLoss_pn3n3_maILFCOzkrX_z5BrWNbJ2yTb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,004&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,453&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_maILFCOzkrX_z30IvRkRIle8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total other income (expense), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(98&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzkrX_maNILz14R_zBwzAszUDlab" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss before taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,994&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_di_msNILz14R_zQ2xcxeqceca" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz14R_zb1OinZBvAt1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001281"
      unitRef="USD">43000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001282"
      unitRef="USD">420000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001287"
      unitRef="USD">6655000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001288"
      unitRef="USD">19155000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001290"
      unitRef="USD">5392000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001291"
      unitRef="USD">6718000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001293"
      unitRef="USD">12047000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001294"
      unitRef="USD">25873000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001296"
      unitRef="USD">-12004000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001297"
      unitRef="USD">-25453000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001299"
      unitRef="USD">10000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001300"
      unitRef="USD">-98000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001302"
      unitRef="USD">-11994000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001303"
      unitRef="USD">-25551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001305"
      unitRef="USD">-782000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001306"
      unitRef="USD">-2996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001308"
      unitRef="USD">-11212000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SingleReportableSegmentMember"
      decimals="-3"
      id="Fact001309"
      unitRef="USD">-22555000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001317"
      unitRef="USD">3450000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001318"
      unitRef="USD">3137000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001320"
      unitRef="USD">264000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001321"
      unitRef="USD">537000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001323"
      unitRef="USD">3714000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001324"
      unitRef="USD">3674000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001326"
      unitRef="USD">1000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001327"
      unitRef="USD">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001329"
      unitRef="USD">19000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001330"
      unitRef="USD">5000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001333"
      unitRef="USD">412000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001335"
      unitRef="USD">3734000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001336"
      unitRef="USD">4094000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001344"
      unitRef="USD">114000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001345"
      unitRef="USD">4599000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001347"
      unitRef="USD">549000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001348"
      unitRef="USD">1669000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001350"
      unitRef="USD">663000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001351"
      unitRef="USD">6268000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001353"
      unitRef="USD">9000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001356"
      unitRef="USD">672000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001357"
      unitRef="USD">6268000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001364"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001365"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="INF"
      id="Fact001366"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="INF"
      id="Fact001367"
      unitRef="Shares">135273</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2025-03-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="-3"
      id="Fact001368"
      unitRef="USD">1717967000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2024-12-31_custom_SixPercentConvertibleExchangeablePreferredStockMember"
      decimals="-3"
      id="Fact001369"
      unitRef="USD">1697676000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001373"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001374"
      unitRef="Shares">264</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001378"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001379"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001383"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001384"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact001388"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact001389"
      unitRef="Shares">354738</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact001390"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact001394"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact001396"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="-3"
      id="Fact001392"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="-3"
      id="Fact001398"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001403"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001404"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001405"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001406"
      unitRef="Shares">863902</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001407"
      unitRef="Shares">36913</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001401"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001402"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001409"
      unitRef="USD">443521000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001410"
      unitRef="USD">438211000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001413"
      unitRef="USD">-891000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001415"
      unitRef="USD">-440461000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001416"
      unitRef="USD">-439494000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001418"
      unitRef="USD">3062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001419"
      unitRef="USD">-2174000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001421"
      unitRef="USD">3734000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001422"
      unitRef="USD">4094000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-03-31_custom_ClinicalTrialSupplyMember"
      decimals="-3"
      id="Fact001428"
      unitRef="USD">29000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001431"
      unitRef="USD">29000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001436"
      unitRef="USD">822000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001437"
      unitRef="USD">2802000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001439"
      unitRef="USD">4214000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001440"
      unitRef="USD">1582000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001442"
      unitRef="USD">5036000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001443"
      unitRef="USD">4384000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001445"
      unitRef="USD">-5036000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001446"
      unitRef="USD">-4355000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001451"
      unitRef="USD">-8000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001452"
      unitRef="USD">1000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001454"
      unitRef="USD">6000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001455"
      unitRef="USD">2000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001457"
      unitRef="USD">4947000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001460"
      unitRef="USD">10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001461"
      unitRef="USD">52000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001463"
      unitRef="USD">4955000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001464"
      unitRef="USD">55000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001466"
      unitRef="USD">-81000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001467"
      unitRef="USD">-4300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001470"
      unitRef="USD">-1354000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001472"
      unitRef="USD">-81000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001473"
      unitRef="USD">-2946000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001478"
      unitRef="USD">-81000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001479"
      unitRef="USD">-2946000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact001483"
      unitRef="USDPShares">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact001484"
      unitRef="USDPShares">-545.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001486"
      unitRef="USD">-81000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001487"
      unitRef="USD">-2946000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001489"
      unitRef="USD">3272000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001490"
      unitRef="USD">2140000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001492"
      unitRef="USD">-2380000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001493"
      unitRef="USD">-2130000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001495"
      unitRef="USD">811000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001496"
      unitRef="USD">-2936000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Shares">454537</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Shares">4412</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001499"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001500"
      unitRef="USD">429797000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001501"
      unitRef="USD">-908000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001502"
      unitRef="USD">-428282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001503"
      unitRef="USD">607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <CYCC:StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001516"
      unitRef="Shares">915</CYCC:StockIssuedDuringPeriodSharesUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001511"
      unitRef="USD">-80000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001514"
      unitRef="USD">-80000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001525"
      unitRef="Shares">-119000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001527"
      unitRef="Shares">165</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001531"
      unitRef="USD">203000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001534"
      unitRef="USD">203000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001539"
      unitRef="USD">-2130000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001541"
      unitRef="USD">-2130000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001546"
      unitRef="USD">2140000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001548"
      unitRef="USD">2140000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001554"
      unitRef="USD">-2946000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001555"
      unitRef="USD">-2946000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001564"
      unitRef="Shares">335537</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001566"
      unitRef="Shares">5493</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001558"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001559"
      unitRef="USD">429920000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001560"
      unitRef="USD">-898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001561"
      unitRef="USD">-431228000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001562"
      unitRef="USD">-2206000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001575"
      unitRef="Shares">135537</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001577"
      unitRef="Shares">36913</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001569"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001570"
      unitRef="USD">438211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001571"
      unitRef="USD">-891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001572"
      unitRef="USD">-439494000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001573"
      unitRef="USD">-2174000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001586"
      unitRef="Shares">135537</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001588"
      unitRef="Shares">36913</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001580"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001581"
      unitRef="USD">438211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001582"
      unitRef="USD">-891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001583"
      unitRef="USD">-439494000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001584"
      unitRef="USD">-2174000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001592"
      unitRef="USD">-248000</CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses>
    <CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001595"
      unitRef="USD">-248000</CYCC:StockIssuedDuringPeriodValueIssueCostsOnIssuanceOfCommonStockPreferredStockAndAssociatedWarrantsOnUnderwrittenOfferingNetOfExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001604"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact001597"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001599"
      unitRef="USD">999000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001602"
      unitRef="USD">1000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <CYCC:StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001613"
      unitRef="Shares">-1000000</CYCC:StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact001606"
      unitRef="USD">-1000</CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001615"
      unitRef="Shares">11042</CYCC:StockIssuedDuringPeriodSharesSeriesCPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001607"
      unitRef="USD">0</CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001608"
      unitRef="USD">-1000</CYCC:StockIssuedDuringPeriodValueSeriesCPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001624"
      unitRef="Shares">2100000</CYCC:StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact001617"
      unitRef="USD">2000</CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001619"
      unitRef="USD">1892000</CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001622"
      unitRef="USD">1894000</CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreement>
    <CYCC:StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001633"
      unitRef="Shares">-1745262</CYCC:StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact001626"
      unitRef="USD">-2000</CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001635"
      unitRef="Shares">799912</CYCC:StockIssuedDuringPeriodSharesSeriesDPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001627"
      unitRef="USD">1000</CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001628"
      unitRef="USD">-1000</CYCC:StockIssuedDuringPeriodValueSeriesDPreferredStockConversions>
    <CYCC:StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001644"
      unitRef="Shares">1000000</CYCC:StockIssuedDuringPeriodSharesIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact001637"
      unitRef="USD">1000</CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001639"
      unitRef="USD">999000</CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne>
    <CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001642"
      unitRef="USD">1000000</CYCC:StockIssuedDuringPeriodValueIssueOfSeriesDPreferredStockInSecuritiesPurchaseAgreementOne>
    <CYCC:StockIssuedDuringPeriodSharesIssueOnWarrantExercise
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001653"
      unitRef="Shares">15277</CYCC:StockIssuedDuringPeriodSharesIssueOnWarrantExercise>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001662"
      unitRef="Shares">758</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001666"
      unitRef="USD">1666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001669"
      unitRef="USD">1666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001674"
      unitRef="USD">886000</CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary>
    <CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001675"
      unitRef="USD">-886000</CYCC:StockIssuedDuringPeriodValueDeconsolidationOfSubsidiary>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001681"
      unitRef="USD">-2380000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001683"
      unitRef="USD">-2380000</CYCC:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
    <CYCC:StockIssuedDuringPeriodValueTranslationAdjustment
      contextRef="From2025-01-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact001688"
      unitRef="USD">2385000</CYCC:StockIssuedDuringPeriodValueTranslationAdjustment>
    <CYCC:StockIssuedDuringPeriodValueTranslationAdjustment
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001690"
      unitRef="USD">2385000</CYCC:StockIssuedDuringPeriodValueTranslationAdjustment>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001696"
      unitRef="USD">-81000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001697"
      unitRef="USD">-81000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001706"
      unitRef="Shares">1490275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact001699"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001708"
      unitRef="Shares">863902</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001700"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001701"
      unitRef="USD">443521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001703"
      unitRef="USD">-440461000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001704"
      unitRef="USD">3062000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001717"
      unitRef="Shares">1490275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact001710"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001719"
      unitRef="Shares">863902</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001711"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact001712"
      unitRef="USD">443521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact001714"
      unitRef="USD">-440461000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001715"
      unitRef="USD">3062000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001724"
      unitRef="USD">-81000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001725"
      unitRef="USD">-2946000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001731"
      unitRef="USD">2000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001733"
      unitRef="USD">1666000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001734"
      unitRef="USD">203000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001736"
      unitRef="USD">9000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001737"
      unitRef="USD">-16000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001742"
      unitRef="USD">-658000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001743"
      unitRef="USD">-2020000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001745"
      unitRef="USD">-5499000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001746"
      unitRef="USD">254000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001748"
      unitRef="USD">-3247000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001749"
      unitRef="USD">-483000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001763"
      unitRef="USD">248000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001764"
      unitRef="USD">79000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001766"
      unitRef="USD">3894000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001769"
      unitRef="USD">3646000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001770"
      unitRef="USD">-79000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001772"
      unitRef="USD">-86000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001773"
      unitRef="USD">-18000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001775"
      unitRef="USD">313000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001776"
      unitRef="USD">-580000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001778"
      unitRef="USD">3137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001779"
      unitRef="USD">3378000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001781"
      unitRef="USD">3450000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001782"
      unitRef="USD">2798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001787"
      unitRef="USD">9000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001788"
      unitRef="USD">1000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001791"
      unitRef="USD">2925000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001796"
      unitRef="USD">4000</us-gaap:InterestPaidNet>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001800"
      unitRef="USD">2000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001808">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z4QVIQpJaImf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_825_z7y7QvXuEHO7"&gt;Company Overview&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nature
of Operations&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cyclacel
Pharmaceuticals, Inc. (&#x201c;Cyclacel&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company developing
innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis control biology. Cyclacel is a pioneer
company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology
into medicines that can overcome resistance and ultimately increase a patient&#x2019;s overall survival.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 24, 2025, the Company&#x2019;s wholly owned United Kingdom subsidiary Cyclacel Limited entered into a creditors voluntary liquidation.
Upon the commencement of the liquidation of the Cyclacel Limited, the Company lost operational and strategic control over the Cyclacel
Limited and the financial results of Cyclacel Limited have been deconsolidated from Company as of January 24, 2025. The deconsolidation
of the subsidiary resulted in a gain on deconsolidation of approximately $&lt;span id="xdx_900_eus-gaap--DeconsolidationGainOrLossAmount_pn5n6_c20250124__20250124_zjpz5YHCYdUc"&gt;5.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million shown as other income within the income statement for
the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Through
March 31, 2025, substantially all efforts of the Company to date have been devoted to performing research and development, conducting
clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2025-01-242025-01-24"
      decimals="-5"
      id="Fact001809"
      unitRef="USD">5000000.0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001811">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zJwWmGnpsfP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_828_zTZG0jPxPjta"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z5SC1TKoNBg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_86B_zkCZdtJqw1A2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated balance sheet as of March 31, 2025, the consolidated statements of operations, comprehensive loss, and stockholders&#x2019;
equity (deficit) for the three months ended March 31, 2025 and 2024 and the consolidated statements of cash flows for the three months
ended March 31, 2025 and 2024, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance
sheet as of December 31, 2024 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K
for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on April 2, 2025.
The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States
(&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they
do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete
set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary
to present fairly the consolidated balance sheet as of March 31, 2025, and the results of operations, comprehensive loss, and changes
in stockholders&#x2019; equity (deficit) for the three months ended March 31, 2025, and cash flows for the three months ended March 31,
2025, have been made. The interim results for three months ended March 31, 2025 are not necessarily indicative of the results to be expected
for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2024 that are included
in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on April 2, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_z3jJ9Fw35e6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_860_zXCLHemlLPI" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the requirements of Accounting Standard Codification (ASC) 205-40, &lt;i&gt;Presentation of Financial Statements-Going Concern&lt;/i&gt;, management
is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial
doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are
issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s plans that have
not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,
management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company&#x2019;s
ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#x2019;s ability to continue as a going concern for one year after the date that these financial statements are issued. In
performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40,
the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered
probable at this time because these plans are not entirely within the Company&#x2019;s control nor have they been approved by the Board
of Directors as of the date of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the Company&#x2019;s current operating plan, it is anticipated that cash and cash equivalents of $&lt;span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zymioRMWspyf"&gt;3.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million as of March 31, 2025, will allow it to meet its liquidity
requirements into the second quarter of 2025. The Company&#x2019;s history of losses, negative cash flows from operations, liquidity resources
currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources
are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company&#x2019;s
ability to &lt;span id="xdx_90F_eus-gaap--SubstantialDoubtAboutGoingConcernWithinOneYear_pn5n6_dbTp_c20250101__20250331_zOlc6k16dxaj"&gt;continue&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as a going concern for a period of at least twelve months from
the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist
of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will
be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations,
delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 25, 2025, Nasdaq notified the Company that it has regained compliance with the equity requirement in Listing Rule 5550(b)(1)
(the &#x201c;Equity Rule&#x201d;), as required by the Nasdaq Hearing Panel&#x2019;s decision dated October 22, 2024. Following the Company&#x2019;s
regaining compliance with the Equity Rule, the Company will be subject to a Mandatory Panel Monitor for a period of one year from February
25, 2025 pursuant to Listing Rule 5815(d)(4)(B).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets
and the satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9NhsWiwFzV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_86F_zNiNRgXykyMj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Newly
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2025, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (Topic 740): Improvements
to Income Tax Disclosures&#x201d;. This standard requires all entities to include specified captions when reconciling the statutory income
tax rate to the effective tax rate, on both a percentage and absolute dollar basis, in the annual financial statements. ASU 2023-09 also
requires entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and
foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts
from, exceed a defined threshold. The company does not anticipate the adoption of ASU 2023-09 will require significant adjustments to
the presentation of that information in the Company&#x2019;s annual financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zxj2fc1u1Yq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_867_z8XQNyu0LXFb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB has issued ASU 2024-03, &#x201c;&lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;&#x201d;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKMAUBis1ymd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_86B_zSjmyuNmHdNa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts
payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zbBtUWjxgeO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86A_zKuGX21dU0w7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). &lt;span id="xdx_90E_eus-gaap--OtherComprehensiveIncomeLossTax_do_c20250101__20250331_zKmQocSIJAh8"&gt;No&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;taxes were recorded on items of other comprehensive income
(loss). There were &lt;span id="xdx_90F_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20250101__20250331_zmEZIzVWNKMf"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reclassifications out of other comprehensive income (loss)
during the three months ended March 31, 2024. However, upon deconsolidation of the Company&#x2019;s formerly wholly-owned subsidiary on
January 24, 2025, $&lt;span id="xdx_901_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_pn5n6_do_c20250124_zKO3BurNZ4G5"&gt;0.9&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of accumulated comprehensive income (loss) was reclassified
into earnings as part of the gain on deconsolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z9r0BdZUBTpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_86D_ztLasLFOULI3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign
Currency and Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied
to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable
future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Through
January 24, 2025, the assets and liabilities of the Company&#x2019;s international subsidiary were translated from its functional currency
into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used
to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation
adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign
exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable
future and that are of a long-term-investment nature, were recorded in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zvYatxd84zDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_860_zSNBLpn78rl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for lease contracts in accordance with ASC 842. As of March 31, 2025, the Company&#x2019;s outstanding leases are classified
as operating leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#x2019;s obligation to make lease payments under the lease. As the Company&#x2019;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing
versus bullet), and the Company&#x2019;s credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect
the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In
assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease payments due in any optional period;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Penalties
    for failure to exercise (or not exercise) the option;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market
    factors, such as the availability of similar assets and current rental rates for such assets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    nature of the underlying leased asset and its importance to the Company&#x2019;s operations; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    remaining useful lives of any related leasehold improvements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized
in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded
as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and
the right-of-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z0Y03lbdDMUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_864_znXMbcaOvK78" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company enters into contracts with customers, the Company recognizes revenue using the five step-model provided in ASC 606, &lt;i&gt;Revenue
from Contracts with Customers &lt;/i&gt;(&#x201c;ASC 606&#x201d;):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the contract with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine
    the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate
    the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize
    revenue when, or as, the Company satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines
the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then
applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the
Company considers:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Whether
    achievement of a development milestone is highly susceptible to factors outside the entity&#x2019;s influence, such as milestones
    involving the judgment or actions of third parties, including regulatory bodies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Whether
    the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Whether
    the Company can reasonably predict that a milestone will be achieved based on previous experience; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    complexity and inherent uncertainty underlying the achievement of the milestone.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The
best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions,
entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment
due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part
satisfied) performance obligations. Once the right to receive consideration is unconditional, that amount is presented as a receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grant
revenue received from organizations that are not the Company&#x2019;s customers, such as charitable foundations or government agencies,
is presented as a reduction against the related research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_851_zISaSAnOQu58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001813">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z5SC1TKoNBg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_86B_zkCZdtJqw1A2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated balance sheet as of March 31, 2025, the consolidated statements of operations, comprehensive loss, and stockholders&#x2019;
equity (deficit) for the three months ended March 31, 2025 and 2024 and the consolidated statements of cash flows for the three months
ended March 31, 2025 and 2024, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance
sheet as of December 31, 2024 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K
for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on April 2, 2025.
The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States
(&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they
do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete
set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary
to present fairly the consolidated balance sheet as of March 31, 2025, and the results of operations, comprehensive loss, and changes
in stockholders&#x2019; equity (deficit) for the three months ended March 31, 2025, and cash flows for the three months ended March 31,
2025, have been made. The interim results for three months ended March 31, 2025 are not necessarily indicative of the results to be expected
for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2024 that are included
in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on April 2, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <CYCC:GoingConcernPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001815">&lt;p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_z3jJ9Fw35e6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_860_zXCLHemlLPI" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the requirements of Accounting Standard Codification (ASC) 205-40, &lt;i&gt;Presentation of Financial Statements-Going Concern&lt;/i&gt;, management
is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial
doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are
issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s plans that have
not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology,
management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company&#x2019;s
ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it
is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and
(2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about
the entity&#x2019;s ability to continue as a going concern for one year after the date that these financial statements are issued. In
performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40,
the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered
probable at this time because these plans are not entirely within the Company&#x2019;s control nor have they been approved by the Board
of Directors as of the date of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the Company&#x2019;s current operating plan, it is anticipated that cash and cash equivalents of $&lt;span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zymioRMWspyf"&gt;3.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million as of March 31, 2025, will allow it to meet its liquidity
requirements into the second quarter of 2025. The Company&#x2019;s history of losses, negative cash flows from operations, liquidity resources
currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources
are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company&#x2019;s
ability to &lt;span id="xdx_90F_eus-gaap--SubstantialDoubtAboutGoingConcernWithinOneYear_pn5n6_dbTp_c20250101__20250331_zOlc6k16dxaj"&gt;continue&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as a going concern for a period of at least twelve months from
the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist
of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will
be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations,
delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 25, 2025, Nasdaq notified the Company that it has regained compliance with the equity requirement in Listing Rule 5550(b)(1)
(the &#x201c;Equity Rule&#x201d;), as required by the Nasdaq Hearing Panel&#x2019;s decision dated October 22, 2024. Following the Company&#x2019;s
regaining compliance with the Equity Rule, the Company will be subject to a Mandatory Panel Monitor for a period of one year from February
25, 2025 pursuant to Listing Rule 5815(d)(4)(B).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets
and the satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CYCC:GoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact001816"
      unitRef="USD">3500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear contextRef="From2025-01-01to2025-03-31" id="Fact001817">true</us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001819">&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9NhsWiwFzV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_86F_zNiNRgXykyMj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Newly
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2025, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (Topic 740): Improvements
to Income Tax Disclosures&#x201d;. This standard requires all entities to include specified captions when reconciling the statutory income
tax rate to the effective tax rate, on both a percentage and absolute dollar basis, in the annual financial statements. ASU 2023-09 also
requires entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and
foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts
from, exceed a defined threshold. The company does not anticipate the adoption of ASU 2023-09 will require significant adjustments to
the presentation of that information in the Company&#x2019;s annual financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <CYCC:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001821">&lt;p id="xdx_848_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zxj2fc1u1Yq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_867_z8XQNyu0LXFb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB has issued ASU 2024-03, &#x201c;&lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;&#x201d;. This standard will require all public entities to disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027. ASU 2024-03 will not change the way in which expenses are recognized or measured. However, the Company
is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CYCC:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-03-31" id="Fact001823">&lt;p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKMAUBis1ymd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_86B_zSjmyuNmHdNa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts
payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001825">&lt;p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zbBtUWjxgeO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86A_zKuGX21dU0w7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation
adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). &lt;span id="xdx_90E_eus-gaap--OtherComprehensiveIncomeLossTax_do_c20250101__20250331_zKmQocSIJAh8"&gt;No&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;taxes were recorded on items of other comprehensive income
(loss). There were &lt;span id="xdx_90F_eus-gaap--ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_do_c20250101__20250331_zmEZIzVWNKMf"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reclassifications out of other comprehensive income (loss)
during the three months ended March 31, 2024. However, upon deconsolidation of the Company&#x2019;s formerly wholly-owned subsidiary on
January 24, 2025, $&lt;span id="xdx_901_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_pn5n6_do_c20250124_zKO3BurNZ4G5"&gt;0.9&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of accumulated comprehensive income (loss) was reclassified
into earnings as part of the gain on deconsolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact001826"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact001827"
      unitRef="USD">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-01-24"
      decimals="-5"
      id="Fact001828"
      unitRef="USD">900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001830">&lt;p id="xdx_842_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z9r0BdZUBTpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_86D_ztLasLFOULI3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign
Currency and Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the
transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates,
with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied
to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable
future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Through
January 24, 2025, the assets and liabilities of the Company&#x2019;s international subsidiary were translated from its functional currency
into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used
to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation
adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign
exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable
future and that are of a long-term-investment nature, were recorded in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001832">&lt;p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zvYatxd84zDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_860_zSNBLpn78rl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for lease contracts in accordance with ASC 842. As of March 31, 2025, the Company&#x2019;s outstanding leases are classified
as operating leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on
the present value of the Company&#x2019;s obligation to make lease payments under the lease. As the Company&#x2019;s leases do not indicate
an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company
estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the
lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing
versus bullet), and the Company&#x2019;s credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect
the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In
assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease payments due in any optional period;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Penalties
    for failure to exercise (or not exercise) the option;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market
    factors, such as the availability of similar assets and current rental rates for such assets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    nature of the underlying leased asset and its importance to the Company&#x2019;s operations; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    remaining useful lives of any related leasehold improvements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized
in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded
as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and
the right-of-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001834">&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z0Y03lbdDMUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_864_znXMbcaOvK78" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company enters into contracts with customers, the Company recognizes revenue using the five step-model provided in ASC 606, &lt;i&gt;Revenue
from Contracts with Customers &lt;/i&gt;(&#x201c;ASC 606&#x201d;):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the contract with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine
    the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate
    the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize
    revenue when, or as, the Company satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines
the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then
applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the
Company considers:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Whether
    achievement of a development milestone is highly susceptible to factors outside the entity&#x2019;s influence, such as milestones
    involving the judgment or actions of third parties, including regulatory bodies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Whether
    the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Whether
    the Company can reasonably predict that a milestone will be achieved based on previous experience; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    complexity and inherent uncertainty underlying the achievement of the milestone.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The
best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions,
entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment
due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part
satisfied) performance obligations. Once the right to receive consideration is unconditional, that amount is presented as a receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grant
revenue received from organizations that are not the Company&#x2019;s customers, such as charitable foundations or government agencies,
is presented as a reduction against the related research and development expenses.&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001836">&lt;p id="xdx_804_eus-gaap--RevenueFromContractWithCustomerTextBlock_zpHZwylWVeue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_820_zHz5eSwZwLtd"&gt;Revenue&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized $&lt;span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_dxL_c20250101__20250331_zoY26LBzUa2l" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1837"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;revenue for the three months ended March 31, 2025 and $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20240331_z4IUS3sB0iXe"&gt;29,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the three months ended March 31, 2024. This revenue is
related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact001838"
      unitRef="USD">29000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001840">&lt;p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zpofJ7nei8Zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_824_zRM4uZwVOCvk"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates net loss per common share in accordance with ASC 260 &#x201c;Earnings Per Share&#x201d; (&#x201c;ASC 260&#x201d;). Basic
and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number
of shares of common stock outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zbzAXbJny5Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months
ended March 31, 2025 and 2024, as the result would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_z43J4DXcFng7" style="display: none"&gt;Schedule
of Earnings Per Share, Basic and Diluted&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250331_zSVobvtRXP52" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240331_zZJFVDt0iGye" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWpMgCBotake" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;p style="margin: 0"&gt;25,259&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;619&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuyEMv5nfs8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SixPercentConvertibleExchangeablePreferredMember_zYxhTPDB1Uue" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6% convertible exchangeable preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zmOM5NfdY59d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series&#160;A preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesDPreferredStockMember_zOhr2In2vgyg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series&#160;D preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;162,588&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1857"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zRfDUYCbGV05" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series&#160;E preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;458,333&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1860"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zXNf4hOm0ZY4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101,905&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,648&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zs36fcpXjAL4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total shares excluded
    from calculation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;748,224&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,456&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z4RvWrHKJQIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001842">&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zbzAXbJny5Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months
ended March 31, 2025 and 2024, as the result would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_z43J4DXcFng7" style="display: none"&gt;Schedule
of Earnings Per Share, Basic and Diluted&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250331_zSVobvtRXP52" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240331_zZJFVDt0iGye" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWpMgCBotake" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;p style="margin: 0"&gt;25,259&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;619&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuyEMv5nfs8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SixPercentConvertibleExchangeablePreferredMember_zYxhTPDB1Uue" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6% convertible exchangeable preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zmOM5NfdY59d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series&#160;A preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesDPreferredStockMember_zOhr2In2vgyg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series&#160;D preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;162,588&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1857"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zRfDUYCbGV05" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series&#160;E preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;458,333&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1860"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zXNf4hOm0ZY4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101,905&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,648&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zs36fcpXjAL4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total shares excluded
    from calculation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;748,224&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,456&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember54208953"
      decimals="INF"
      id="Fact001844"
      unitRef="Shares">25259</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember54208968"
      decimals="INF"
      id="Fact001845"
      unitRef="Shares">619</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember54208968"
      decimals="INF"
      id="Fact001847"
      unitRef="Shares">136</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember54208984"
      decimals="INF"
      id="Fact001848"
      unitRef="Shares">187</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_custom_SixPercentConvertibleExchangeablePreferredMember"
      decimals="INF"
      id="Fact001850"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_custom_SixPercentConvertibleExchangeablePreferredMember"
      decimals="INF"
      id="Fact001851"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember54209000"
      decimals="INF"
      id="Fact001853"
      unitRef="Shares">2</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001854"
      unitRef="Shares">2</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember54209015"
      decimals="INF"
      id="Fact001856"
      unitRef="Shares">162588</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember54209015"
      decimals="INF"
      id="Fact001859"
      unitRef="Shares">458333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_custom_CommonStockWarrantsMember54209031"
      decimals="INF"
      id="Fact001862"
      unitRef="Shares">101905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001863"
      unitRef="Shares">2648</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact001865"
      unitRef="Shares">748224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact001866"
      unitRef="Shares">3456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001868">&lt;p id="xdx_80A_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_za2ce6ncCEFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_820_zeGrSPn69j39"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zaAfOm0GuBpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following (in $000s):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zrrHepcxb5El" style="display: none"&gt;Schedule
of Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250331_zfFI1ZvlaPic" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zETxqZSOI6q3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPECzxNf_zZhhBXB2luka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;237&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPECzxNf_zhNtmZdVkIt9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;194&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidExpenseCurrent_iTI_pn3n3_mtPECzxNf_zon8974OLUTa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and
    other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;537&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z9IxNttGV2P8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CYCC:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001870">&lt;p id="xdx_898_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zaAfOm0GuBpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following (in $000s):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zrrHepcxb5El" style="display: none"&gt;Schedule
of Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250331_zfFI1ZvlaPic" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zETxqZSOI6q3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaymentsAndValueAddedTaxReceivableCurrent_iI_pn3n3_maPECzxNf_zZhhBXB2luka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;237&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPECzxNf_zhNtmZdVkIt9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;194&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidExpenseCurrent_iTI_pn3n3_mtPECzxNf_zon8974OLUTa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and
    other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;537&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001872"
      unitRef="USD">70000</CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent>
    <CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001873"
      unitRef="USD">237000</CYCC:PrepaymentsAndValueAddedTaxReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001875"
      unitRef="USD">194000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001876"
      unitRef="USD">300000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001878"
      unitRef="USD">264000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001879"
      unitRef="USD">537000</us-gaap:PrepaidExpenseCurrent>
    <CYCC:NonCurrentAssetsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001881">&lt;p id="xdx_80A_ecustom--NonCurrentAssetsTextBlock_z5UduPuSn50f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_828_zNbPBkrz68y9"&gt;Non-Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had $&lt;span id="xdx_907_eus-gaap--DepositsAssetsNoncurrent_iI_dxL_c20250331_zzx61uyaNAXh" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1882"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;non-current
assets as of March 31, 2025 and $&lt;span id="xdx_908_eus-gaap--DepositsAssetsNoncurrent_iI_pn5n6_c20241231_zZBshIPL6pF6"&gt;0.4&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million as of December 31, 2024. The balance at December 31,
2024 primarily comprised of deposits held by a contract research organization in relation to the Company&#x2019;s clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CYCC:NonCurrentAssetsTextBlock>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001883"
      unitRef="USD">400000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001885">&lt;p id="xdx_80E_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zvOj8T2jVOqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_82F_znSHTrXHVLJl"&gt;Accrued and Other Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_ztbudYMeSXQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
and other current liabilities consisted of the following (in $000s):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zi8hNVrt2Rpc" style="display: none"&gt;Schedule
of Accrued and Other Current Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250331_zZRyuple1Nz1" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_z6ahcDahe2xj" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCostCurrent_iI_pn3n3_zLff99MwH0ji" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1889"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_zBMIXPiwxp6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued legal and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;532&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_zP40xWtPhJ6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;284&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_zl7SdYb7Ozl6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued and other current
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;549&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,671&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zqtmuHxKFHN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001887">&lt;p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_ztbudYMeSXQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
and other current liabilities consisted of the following (in $000s):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zi8hNVrt2Rpc" style="display: none"&gt;Schedule
of Accrued and Other Current Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250331_zZRyuple1Nz1" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_z6ahcDahe2xj" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCostCurrent_iI_pn3n3_zLff99MwH0ji" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1889"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_zBMIXPiwxp6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued legal and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;532&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_zP40xWtPhJ6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;284&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_zl7SdYb7Ozl6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued and other current
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;549&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,671&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <CYCC:AccruedResearchAndDevelopmentCostCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001890"
      unitRef="USD">1300000</CYCC:AccruedResearchAndDevelopmentCostCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001892"
      unitRef="USD">532000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001893"
      unitRef="USD">87000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001895"
      unitRef="USD">17000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001896"
      unitRef="USD">284000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001898"
      unitRef="USD">549000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001899"
      unitRef="USD">1671000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001901">&lt;p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zV3IkZxjpg3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_82E_zNdrso9qbDLh"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently has an operating lease liability relating to its facilities in Kuala Lumpur, Malaysia. The Company terminated its lease
agreement for its previous headquarters in Berkely Heights, New Jersey, effective January 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended March 31, 2025 and 2024, the Company recognized operating lease expenses of $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20250101__20250331_zfafTDQdbiAf"&gt;1,176&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20240331_z2xbsuVlcEK5"&gt;19,039&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively, including $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20250101__20250331__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_znOi1ut4nW03"&gt;0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240101__20240331__srt--StatementGeographicalAxis__custom--DundeeScotlandMember_zMBdCNNRjAoe"&gt;3,011&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively relating to a short term lease for offices in
Dundee, Scotland. Cash payments made during the three months ended March 31, 2025 and 2024 totaled $&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20250101__20250331_zi1fw9t1Hfh1"&gt;0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90E_eus-gaap--OperatingLeasePayments_c20240101__20240331_zXpJey0GUjUg"&gt;19,037&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, and were presented within cash outflows from operating activities. The remaining lease term as of March 31, 2025 is approximately
&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331__srt--StatementGeographicalAxis__custom--KualaLumpurFacilityMember_zZcGgK6QrlAe"&gt;1.9&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years for the Kuala Lumpur facility. The discount rate used
by the Company in determining the lease liability was &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20250331_zJl1vjsFJsVh"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z7uw9TXndB96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Remaining
lease payments for both facilities are as follows (in $000s):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zVNt5lnBaftk" style="display: none"&gt;Schedule
of Remaining Lease Payments&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20250331_zn4xLC10bj1e" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzo6M_zxqWjMRO59ug" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_pn3n3_maLOLLPzo6M_z9ML6eh0b3T1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_pn3n3_maLOLLPzo6M_z4w1j7Zt1rL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maLOLLPzo6M_zsCZr4fNrUng" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1919"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzo6M_zDO9QjtMUjIj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future minimum
    lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zRRwrwyyhI1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact001902"
      unitRef="USD">1176</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact001903"
      unitRef="USD">19039</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-012025-03-31_custom_DundeeScotlandMember"
      decimals="0"
      id="Fact001904"
      unitRef="USD">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-03-31_custom_DundeeScotlandMember"
      decimals="0"
      id="Fact001905"
      unitRef="USD">3011</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact001906"
      unitRef="USD">0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact001907"
      unitRef="USD">19037</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2025-03-31_custom_KualaLumpurFacilityMember"
      id="Fact001908">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001909"
      unitRef="Pure">0.12</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001911">&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z7uw9TXndB96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Remaining
lease payments for both facilities are as follows (in $000s):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zVNt5lnBaftk" style="display: none"&gt;Schedule
of Remaining Lease Payments&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20250331_zn4xLC10bj1e" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzo6M_zxqWjMRO59ug" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_pn3n3_maLOLLPzo6M_z9ML6eh0b3T1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_pn3n3_maLOLLPzo6M_z4w1j7Zt1rL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maLOLLPzo6M_zsCZr4fNrUng" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1919"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzo6M_zDO9QjtMUjIj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future minimum
    lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001913"
      unitRef="USD">8000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001915"
      unitRef="USD">11000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001917"
      unitRef="USD">3000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001921"
      unitRef="USD">22000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001923">&lt;p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z0M8qK40nSn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_826_zmTnXRsUqxkd"&gt;Stock Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the
Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based
awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods
when they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYtfZyMeRNhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended
March 31, 2025 and 2024 as shown in the following table (in $000s):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zKQAAO8uuGuh" style="display: none"&gt;Schedule
of Stock Based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250331_zpby0g2Vqtmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240331_zxKy2IqfCBvg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYy8HPBaUKN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,592&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zInBf5ZVuUYd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zu8nndUTR1i1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,666&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;203&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zfbzK3CbrNwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2018
Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2018, the Company&#x2019;s stockholders approved the 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), under which Cyclacel
may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan allows for various types of award
grants, including stock options and restricted stock units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 6, 2025, the Company&#x2019;s stockholders approved an amendment to the 2018 Plan to reserve an additional &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zOP6vKFv9OK1"&gt;500,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock for issuance thereunder, which number
would not be adjusted as a result of the Reverse Stock Split. As of March 31, 2025, the Company has reserved approximately &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zWr9O94r64a3"&gt;468,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock under the 2018 Plan
for future issuances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option awards granted under the Company&#x2019;s equity incentive plans have a maximum life of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member__srt--RangeAxis__srt--MaximumMember_z1HQAHZ8ao32"&gt;10&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years and generally &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20250101__20250331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2018Member_zD8btxalzYGl"&gt;vest
over a one to four-year period from the date of grant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2020
Inducement Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), became effective. Under the Inducement Plan,
Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder
approval). The Inducement Plan allows for the issuance of up to &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20201031__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zenVrPqMNLYh"&gt;55&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock (or the equivalent
of such number). As of March 31, 2025, there were no shares issued under the Inducement Plan, leaving a remaining reserve of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--InducementEquityIncentivePlanTwoThousandTwentyMember_zECb1czm6h26"&gt;55&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Option
Awards Granted Outside of the 2018 Plan and Inducement Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
February 2025, the Company issued stock option awards to employees and consultants outside of the 2018 Plan and the Inducement Plan.
The shares underlying these options are not registered for resale. All of the options granted outside of the 2018 Plan and Inducement
Plan vest immediately upon grant and can be exercised beginning three months from the recipient&#x2019;s Termination Date through the
expiry of the option awards, which is ten years from the grant date. The Termination Date is defined as the date on which an award recipient
ceases to be an employee, director or consultant of the Company or of an Affiliate for any reason other than the death or disability,
or termination of the recipient for cause.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Option
Grants and Exercises&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpvnHevrbHue"&gt;24,818&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options granted during the three months ended March 31, 2025.
Of these awards, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmNdTSemosNj"&gt;1,068&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were issued under the 2018 Plan and the rest were issued outside
of the 2018 Plan and the Inducement Plan. Options granted during the three months ended March 31, 2025 had a grant date fair value ranging
between $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxMFXKlbm1q1"&gt;60.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__srt--RangeAxis__srt--MaximumMember_zB252Sjpw7Qd"&gt;72.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSywSSjd0i1b"&gt;52&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options granted under the 2018 Plan during the three months
ended March 31, 2024. These options had a grant date fair value of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuwfH12Fjlq4"&gt;424.80&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zk3oxX36nWv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span id="xdx_8BE_zYhg4KfeWeV2" style="display: none"&gt;Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three months
    ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three months
    ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqFUkCdCtZWf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;- &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTjpv8bpNTi5"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwUUjiySqPj" style="font-family: Times New Roman, Times, Serif"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zKsRwGExvwIf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.060&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
                                            &#x2009;&#x2013;&#x2009;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zse7pFP0qWPl"&gt;4.250&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztCBFHieoNN" style="font-family: Times New Roman, Times, Serif"&gt;3.995&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zJNe79AcKKUc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&#x2009;&#x2013;&#x2009;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zepvyxBHtzrc"&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlentDg6UWHh" style="font-family: Times New Roman, Times, Serif"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield over expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrx1L8kJHrYh" style="font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaXlxtGKKdpd" style="font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Resulting weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj7mjJsL01uf" style="font-family: Times New Roman, Times, Serif"&gt;69.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNK8Lp6rs0V2" style="font-family: Times New Roman, Times, Serif"&gt;424.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zOU16x43Y1g3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_do_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5Hk5HSFpwW4"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;stock options exercised during each of the three months ended
March 31, 2025 and 2024, respectively. The Company does not expect to be able to benefit from the deduction for stock option exercises
that may occur because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable
income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Outstanding
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zQQmAYU3aYkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the share option activity and related information is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zoZ4fKD31OYc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Share Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price
    Per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&#160;($000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstwfN5m9aj6" style="width: 12%; text-align: right" title="Number of Options Outstanding, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;494&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zytlelT6Ae67" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,658.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9kHDuWSUJ9" style="font-family: Times New Roman, Times, Serif"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaEZNWTN3Ty1" style="width: 12%; text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1971"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z29rIEzredui" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,818&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztxQ9q4xeaZ3" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zktzPgOv4HSh" style="text-align: right" title="Number of Options Outstanding, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1977"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQqUjyUxUUkh" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1979"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLjl4YGhFYG1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(53&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZfT3AMOY5Ld" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,238.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNELwZ9Cktb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,259&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMdsAc4XTAV9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276.67&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv863YW7rCB1" style="font-family: Times New Roman, Times, Serif"&gt;9.76&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zorV9XJzvHS1" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1990"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYWebtg3xGp3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1PDNg7ypaj1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,094.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and exercisable
    at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpqjbPFISF37" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Vested and exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,238&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsebhVlWTaRe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;275.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zProbUO1VJKc" style="font-family: Times New Roman, Times, Serif"&gt;9.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlEDaTXVzfdl" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregrate Intrinsic Value, Vested and Exerciseable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2001"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zvFMNAb2hnYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxZJr4GZCzJb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock units were issued during the three months
ended March 31, 2025. The Company issued &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze5Ema5bMKsf"&gt;52&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock units during the three months ended March
31, 2024. These restricted stock units vested monthly over a six-month &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtM_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zT5g5dA4dah1" style="display: none"&gt;6&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;service period. These restricted stock units were valued at
$&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1_iI_c20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9WPBZCBmJH7"&gt;547.20&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at the date of grant, which was equivalent to the market price
of a share of the Company&#x2019;s common stock on that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze3MYAgYX9Gb"&gt;71.36&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock units were issued in January 2023. These units
vest on the third anniversary of their date of grant, or earlier if certain defined clinical trial related performance targets are met.
A three-year &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLLZ7NDCWYqd" style="display: none"&gt;3&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vesting assumption was applied to these restricted stock units
as satisfaction of the performance conditions is not probable at this time. Each restricted stock unit was valued at $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20230131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbOWdnDFImp7"&gt;3,240.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at the date of grant, which was equivalent to the market price
of a share of the Company&#x2019;s common stock on that date. As of March 31, 2025, all but &lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM4bwDq1qFh3"&gt;13&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of the original awards granted have been forfeited due to the
recipient&#x2019;s termination of service with the Company. In the three months ended March 31, 2025, the Company reduced stock compensation
cost, a component of selling general, and administrative expense, by approximately $&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAWh4Ot3BwK4"&gt;61,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as a result of forfeitures of these awards during that period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zIlyBKat9Eci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summarized
information for restricted stock units as of March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zlz1nvtipnN9" style="display: none"&gt;Schedule
of Restricted Stock Units Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    Units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value
    per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted Stock Units outstanding
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zccoDBjfXf64" style="width: 14%; text-align: right" title="Restricted Stock Units, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAVbyDwPg9b" style="width: 14%; text-align: right" title="Weighted Average Grant Date Value per share, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,882.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJBQIK9FaNrb" style="font-family: Times New Roman, Times, Serif"&gt;8.30&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zitdVZA2rNjd" style="text-align: right" title="Restricted Stock Units, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zylkNtvV5h7e" style="text-align: right" title="Weighted Average Grant Date Value per share, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbmenNYJpFbl" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted Stock Units, Cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQf3PvJrKsG2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Value per share, Cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,300.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted Stock Units
    outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC6Pc9nonvbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted Stock Units, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4ngbjnxOPEb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Value per share, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,795.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEq554owd7ha" style="font-family: Times New Roman, Times, Serif"&gt;8.09&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAhgUkCLGvL3" style="text-align: right" title="Restricted Stock Units, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgEvQltVVBR4" style="text-align: right" title="Weighted Average Grant Date Value per share, Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,240.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTZDNVuDP0Oh" style="font-family: Times New Roman, Times, Serif"&gt;7.82&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2aBmLd5Wzh" style="text-align: right" title="Restricted Stock Units, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;123&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zU0TV8voZ7ze" style="text-align: right" title="Weighted Average Grant Date Value per share, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,747.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlBhulV3rLeb" style="font-family: Times New Roman, Times, Serif"&gt;8.12&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AD_zkCzJRcHThC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001925">&lt;p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYtfZyMeRNhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended
March 31, 2025 and 2024 as shown in the following table (in $000s):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zKQAAO8uuGuh" style="display: none"&gt;Schedule
of Stock Based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250331_zpby0g2Vqtmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240331_zxKy2IqfCBvg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYy8HPBaUKN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,592&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zInBf5ZVuUYd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zu8nndUTR1i1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,666&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;203&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001927"
      unitRef="USD">1592000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001928"
      unitRef="USD">149000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001930"
      unitRef="USD">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001931"
      unitRef="USD">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact001933"
      unitRef="USD">1666000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact001934"
      unitRef="USD">203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-02-06_custom_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact001935"
      unitRef="Shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-03-31_custom_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact001936"
      unitRef="Shares">468000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-03-31_custom_EquityIncentivePlan2018Member_srt_MaximumMember"
      id="Fact001937">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2025-01-012025-03-31_custom_EquityIncentivePlan2018Member"
      id="Fact001938">vest
over a one to four-year period from the date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-10-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember"
      decimals="INF"
      id="Fact001939"
      unitRef="Shares">55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-31_custom_InducementEquityIncentivePlanTwoThousandTwentyMember"
      decimals="INF"
      id="Fact001940"
      unitRef="Shares">55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001941"
      unitRef="Shares">24818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001942"
      unitRef="Shares">1068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001943"
      unitRef="USDPShares">60.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001944"
      unitRef="USDPShares">72.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001945"
      unitRef="Shares">52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001946"
      unitRef="USDPShares">424.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001948">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zk3oxX36nWv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the
following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span id="xdx_8BE_zYhg4KfeWeV2" style="display: none"&gt;Schedule
of Assumptions Used for Fair Value of the Stock Options Granted Using Black-Scholes Option-Pricing Model&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three months
    ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three months
    ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqFUkCdCtZWf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;- &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zTjpv8bpNTi5"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwUUjiySqPj" style="font-family: Times New Roman, Times, Serif"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zKsRwGExvwIf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.060&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
                                            &#x2009;&#x2013;&#x2009;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zse7pFP0qWPl"&gt;4.250&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztCBFHieoNN" style="font-family: Times New Roman, Times, Serif"&gt;3.995&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zJNe79AcKKUc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&#x2009;&#x2013;&#x2009;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zepvyxBHtzrc"&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlentDg6UWHh" style="font-family: Times New Roman, Times, Serif"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield over expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrx1L8kJHrYh" style="font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaXlxtGKKdpd" style="font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Resulting weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj7mjJsL01uf" style="font-family: Times New Roman, Times, Serif"&gt;69.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue_pid_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNK8Lp6rs0V2" style="font-family: Times New Roman, Times, Serif"&gt;424.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember"
      id="Fact001949">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      id="Fact001950">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001951">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001952"
      unitRef="Pure">0.04060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001953"
      unitRef="Pure">0.04250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001954"
      unitRef="Pure">0.03995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-012025-03-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001955"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001956"
      unitRef="Pure">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001957"
      unitRef="Pure">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001958"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001959"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001960"
      unitRef="USDPShares">69.60</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001961"
      unitRef="USDPShares">424.80</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001962"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact001964">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zQQmAYU3aYkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the share option activity and related information is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zoZ4fKD31OYc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Share Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price
    Per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&#160;($000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstwfN5m9aj6" style="width: 12%; text-align: right" title="Number of Options Outstanding, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;494&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zytlelT6Ae67" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,658.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9kHDuWSUJ9" style="font-family: Times New Roman, Times, Serif"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaEZNWTN3Ty1" style="width: 12%; text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1971"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z29rIEzredui" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,818&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztxQ9q4xeaZ3" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zktzPgOv4HSh" style="text-align: right" title="Number of Options Outstanding, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1977"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQqUjyUxUUkh" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1979"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLjl4YGhFYG1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(53&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZfT3AMOY5Ld" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,238.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNELwZ9Cktb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,259&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMdsAc4XTAV9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276.67&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv863YW7rCB1" style="font-family: Times New Roman, Times, Serif"&gt;9.76&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zorV9XJzvHS1" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregrate Intrinsic Value, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1990"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYWebtg3xGp3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1PDNg7ypaj1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,094.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and exercisable
    at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpqjbPFISF37" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Vested and exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,238&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsebhVlWTaRe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;275.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zProbUO1VJKc" style="font-family: Times New Roman, Times, Serif"&gt;9.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlEDaTXVzfdl" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregrate Intrinsic Value, Vested and Exerciseable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2001"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001966"
      unitRef="Shares">494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001968"
      unitRef="USDPShares">10658.40</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001969">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001973"
      unitRef="Shares">24818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001975"
      unitRef="USDPShares">70.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001981"
      unitRef="Shares">53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001983"
      unitRef="USDPShares">2238.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001985"
      unitRef="Shares">25259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001987"
      unitRef="USDPShares">276.67</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001988">P9Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001992"
      unitRef="Shares">21</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001994"
      unitRef="USDPShares">2094.84</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001996"
      unitRef="Shares">25238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001998"
      unitRef="USDPShares">275.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001999">P9Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002002"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002003"
      unitRef="Shares">52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact002004">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002005"
      unitRef="USDPShares">547.20</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002006"
      unitRef="Shares">71.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2023-01-012023-01-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact002007">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-01-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002008"
      unitRef="USDPShares">3240.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002009"
      unitRef="Shares">13</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentOrginalAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact002010"
      unitRef="USD">61000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact002012">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zIlyBKat9Eci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summarized
information for restricted stock units as of March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zlz1nvtipnN9" style="display: none"&gt;Schedule
of Restricted Stock Units Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    Units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value
    per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted Stock Units outstanding
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zccoDBjfXf64" style="width: 14%; text-align: right" title="Restricted Stock Units, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAVbyDwPg9b" style="width: 14%; text-align: right" title="Weighted Average Grant Date Value per share, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,882.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJBQIK9FaNrb" style="font-family: Times New Roman, Times, Serif"&gt;8.30&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zitdVZA2rNjd" style="text-align: right" title="Restricted Stock Units, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zylkNtvV5h7e" style="text-align: right" title="Weighted Average Grant Date Value per share, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbmenNYJpFbl" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted Stock Units, Cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQf3PvJrKsG2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Value per share, Cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,300.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted Stock Units
    outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC6Pc9nonvbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted Stock Units, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4ngbjnxOPEb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Value per share, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,795.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEq554owd7ha" style="font-family: Times New Roman, Times, Serif"&gt;8.09&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAhgUkCLGvL3" style="text-align: right" title="Restricted Stock Units, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgEvQltVVBR4" style="text-align: right" title="Weighted Average Grant Date Value per share, Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,240.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTZDNVuDP0Oh" style="font-family: Times New Roman, Times, Serif"&gt;7.82&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2aBmLd5Wzh" style="text-align: right" title="Restricted Stock Units, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;123&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zU0TV8voZ7ze" style="text-align: right" title="Weighted Average Grant Date Value per share, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,747.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlBhulV3rLeb" style="font-family: Times New Roman, Times, Serif"&gt;8.12&lt;/span&gt;
                                            &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002014"
      unitRef="Shares">164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <CYCC:ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002016"
      unitRef="USDPShares">2882.40</CYCC:ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact002017">P8Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002019"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002021"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002023"
      unitRef="Shares">28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002025"
      unitRef="USDPShares">3300.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002027"
      unitRef="Shares">136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <CYCC:ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002029"
      unitRef="USDPShares">2795.37</CYCC:ShareBasedCompensationArrangementByStockBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact002030">P8Y1M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002032"
      unitRef="Shares">13</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002034"
      unitRef="USDPShares">3240.00</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact002035">P7Y9M25D</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002037"
      unitRef="Shares">123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002039"
      unitRef="USDPShares">2747.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact002040">P8Y1M13D</CYCC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact002042">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs4GUMLb48n9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_82F_zBtRPV7o9WC9"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Equity Offerings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;April
2024 Securities Purchase Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 30, 2024, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional
investor (the &#x201c;Purchaser&#x201d;) for the issuance and sale in a private placement (the &#x201c;Private Placement&#x201d;) of (i)
&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_zmVqw0jjT8y3"&gt;604&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock, (ii) pre-funded
warrants to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zuymfjDHeJk1"&gt;20,100&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;),
(iii) series A warrants to purchase up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zxgh8A3yNQFg"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock (the &#x201c;Series A Warrants&#x201d;),
and (iv) series B warrants to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z4wlJtWOymT8"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock (the &#x201c;Series B Warrants&#x201d;
and together with the Series A Warrants, the &#x201c;Common Warrants&#x201d;). The purchase price of each share of common stock and associated
Common Warrants was $386.40 and the purchase price of each Pre-Funded Warrant and associated Common Warrants was $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsAndCommonWarrantsMember_zni0dunyKQna"&gt;386.376&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Common Warrants are exercisable immediately upon issuance at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zFt1UcVulfog"&gt;326.40&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The Series A Warrants will expire five and one-half
years&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zeyPH0DhQ0uj" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the date of issuance and the Series B Warrants will expire
&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_z3Y1WYKLO0k1"&gt;eighteen
months&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the date of issuance. The Pre-Funded
Warrants are exercisable immediately upon issuance at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zgo6sIDf7gT8"&gt;0.024&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share and may be exercised at any time until the Pre-Funded
Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its affiliates) may not exercise any
portion of such warrants to the extent that the holder would own more than &lt;span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zp7eFIdS9X19"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
(or, at the election of the holder &lt;span id="xdx_907_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20240430__20240430__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zhBWHyy6vAGb"&gt;9.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%)
of the Company&#x2019;s outstanding common stock immediately after exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Private Placement, the Company entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;),
dated as of April 30, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with
the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) registering the resale of the securities issued in the Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Private Placement closed on May 2, 2024. The gross proceeds to the Company from the Private Placement were approximately $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240502__20240502_zfXWsPjyzQxg"&gt;8.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, before deducting placement agent fees and estimated
offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;H.C.
Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;) acted as the Company&#x2019;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of April 29, 2024, between the Company and Wainwright (as amended, the
&#x201c;Engagement Letter&#x201d;). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to &lt;span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20240429_zBrA9gHcwGs"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate gross proceeds of the Private Placement and (ii) a management fee of &lt;span id="xdx_90E_ecustom--ManagementFeePercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240429_zByJDqWP4oP5"&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued
to Wainwright or its designees warrants (the &#x201c;Placement Agent Warrants&#x201d;) to purchase up to an aggregate of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zmhBLE2axGt8"&gt;1,242&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock at an exercise price equal to $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zKb8wEowljf"&gt;124.512&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The Placement Agent Warrants are exercisable immediately
upon issuance and have a term of exercise equal to five and a half years&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240429__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zuD3aEBuYzLa" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with this transaction, the Company was required to compensate Roth Capital Partners, LLC, pursuant to a tail provision contained
in an engagement letter entered into on March 14, 2024, in an amount equal to &lt;span id="xdx_902_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20240314__srt--CounterpartyNameAxis__custom--RothCapitalPartnersLlcMember_z5vZ5JiKyDN9"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate proceeds of the Private Placement plus the reimbursement of certain expenses. The Company was also required to compensate
Ladenburg Thalmann &amp;amp; Co. Inc, pursuant to a tail provision contained in an engagement letter entered into on October 30, 2023, in
an amount equal to &lt;span id="xdx_907_ecustom--CompensationPercentageToAggregateGrossProceeds_iI_pid_dp_uPure_c20231030__srt--CounterpartyNameAxis__custom--LadenburgThalmannCo.IncMember_zPS9NG1TTRLf"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the aggregate proceeds of the Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
of the instruments issued in the Private Placement have been classified and recorded as part of shareholders&#x2019; equity (deficit).
The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective
instruments as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_zA78XcnVP3d9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zoHcCeHWglHg" style="display: none"&gt;Schedule
of Fair Value of Instruments Issued in Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250331_zGjcrW70H7G8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated
    Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuojg1Le9Ry5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common shares&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72,108&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSSPmw9N1rvj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prefunded warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,398,831&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYpsat2GSfXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,819,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zs3KLuTxpE01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net proceeds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,290,213&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zyL72AZbeih7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate fair value of the Placement Agent Warrants was $&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zO9gzZVzzPmj" title="Warrants exercise price"&gt;609,179&lt;/span&gt;. These have been accounted for as a direct cost of the Private Placement,
resulting in no net effect to overall shareholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zTUa68Prla6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zxPcTvzLnbz2" style="display: none"&gt;Schedule of Fair value of Warrants Valuation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-Funded
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Placement
    Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKuoTFVcMyZ1" title="Warrants and rights outstanding"&gt;100&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zDnR00CKxMGj" title="Warrants and rights outstanding"&gt;103&lt;/span&gt;% - &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zzNklfHgkJNh" title="Warrants and rights outstanding"&gt;121&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0huGRbp6ax3" title="Warrants and rights outstanding"&gt;103&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0cu2bRSDefd" title="Warrants and rights outstanding"&gt;1&lt;/span&gt; year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 7pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zENaCO5e8ZGh" title="Contractual term"&gt;1.5&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&#xbd;&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif"&gt;- 5&#xbd;&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years &lt;span style="display: none; font-size: 7pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zO0bmRuNgBzl" title="Contractual term"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&#xbd;&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years &lt;span style="display: none; font-size: 7pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPcIKiW6chD8"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztL9uwwXw2Z9" title="Warrants and rights outstanding"&gt;5.51&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z6AfpudEkteh" title="Warrants and rights outstanding"&gt;4.57&lt;/span&gt;% - &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zWqD4S4fITBk" title="Warrants and rights outstanding"&gt;5.51&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zF6xSJIXdgW8" title="Warrants and rights outstanding"&gt;4.57&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxxy4WOQ6Ip" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zb3qu8Q9Wg4e" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcVi1mljH135" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zIYAZP4KnbVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the common shares was determined using the closing price of the Company&#x2019;s common stock as of May 2, 2024, which is
the date that the Private Placement closed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;December
2023 Registered Direct Offering Securities Purchase Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 21, 2023, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with
certain institutional investors (&#x201c;Purchasers&#x201d;). Pursuant to the Securities Purchase Agreement, the Company agreed to
sell in a registered direct offering (&#x201c;Registered Direct Offering&#x201d;) &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z7KSS8HvQImj"&gt;702&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
(&#x201c;Shares&#x201d;) of the Company&#x2019;s common stock, $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXgX3pF9BFr5"&gt;0.001&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;par
value per share (&#x201c;Common Stock&#x201d;), and pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;) to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z9GBVwRk7evk"&gt;915&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Common Stock. The Pre-Funded Warrants have an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zmbSw9wXVz5a"&gt;0.24 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share and can be exercised at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each
Share is being sold at an offering price of $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI7XvSgnZLP9"&gt;795.60&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
each Pre-Funded Warrant is being sold at an offering price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zPmArmRugOCe"&gt;795.36&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(equal
to the purchase price per Share minus the exercise price of the Pre-Funded Warrant). The Pre-Funded Warrants have been included in
the calculation of basic and diluted loss per share for all periods outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the &#x201c;Offerings&#x201d;),
the Company also agreed to issue to the Purchasers unregistered warrants (&#x201c;Common Warrants&#x201d;) to purchase up to &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zcGGNLguUNC7"&gt;1,617&lt;/span&gt;
shares of Common Stock. Each Common Warrant has an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zj0bFuWECwe3"&gt;765.60&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, is exercisable immediately following their original
issuance and will expire &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zlPI0n1FE893"&gt;seven
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the original issuance date. The closing
of the offering occurred on December 26, 2023, and the net proceeds to the Company were approximately $&lt;span id="xdx_907_ecustom--AggregateProceedsFromSaleOfStock_iI_pn5n6_c20231226__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zbokclLNzJ2g"&gt;1.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, after deducting placement agent fees and other offering
expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 21, 2023, in a separate concurrent insider private placement (the &#x201c;Insider Private Placement&#x201d;), the Company also
entered into a Securities Purchase Agreement with certain of its executive officers (the &#x201c;Insider Securities Purchase Agreement&#x201d;)
pursuant to which the Company agreed to sell in a private placement (i) &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJ5yYlv0H2Ec"&gt;25&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock and warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zFknP8RvmKu"&gt;25&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Spiro Rombotis, the Company&#x2019;s Chief Executive Officer, and (ii) &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember_zrbeLsRQlMMe"&gt;8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock and warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerAndChiefOperatingOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zhPBpDu4Boik"&gt;8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock on the same terms as the Common Warrants
issued to the Purchasers in the Offerings to Paul McBarron, the Company&#x2019;s Executive Vice President-Finance, Chief Financial Officer
and Chief Operating Officer. Each such share of Common Stock and accompanying warrant was sold at a purchase price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zafyPJ2aQeXa"&gt;795.60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which was the same purchase price for the Shares sold in the Registered Direct Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ladenburg
Thalmann &amp;amp; Co. Inc. (the &#x201c;Placement Agent&#x201d;) acted as the exclusive placement agent for the Offerings, pursuant to a placement
agency agreement (the &#x201c;Placement Agency Agreement&#x201d;), dated December 21, 2023, by and between the Company and the Placement
Agent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Placement Agency Agreement, the Company paid the Placement Agent a cash placement fee equal to &lt;span id="xdx_906_ecustom--CashPlacementFeePercentage_iI_pid_dp_uPure_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_zzaZoE0raod1" title="Cash placement fee, percentage"&gt;8.0&lt;/span&gt;% of the aggregate gross proceeds
raised in the Offerings from sales arranged for by the Placement Agent. Subject to certain conditions, the Company also agreed to reimburse
all reasonable travel and other out-of-pocket expenses of the Placement Agent in connection with the Offerings, including but not limited
to legal fees, up to a maximum of $&lt;span id="xdx_90A_eus-gaap--ProfessionalFees_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zuCzCsxkXyD1" title="Professional fees"&gt;85,000&lt;/span&gt;. In addition, the Placement Agent also received warrants that have substantially the same terms
as the Warrants issued in the concurrent private placement to the Purchasers in the Offerings to purchase that number of shares of Common
Stock equal to &lt;span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20231221__20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zhiD8vh866p5" title="Percentage of outstanding common stock"&gt;6.0&lt;/span&gt;% of the aggregate number of shares of Common Stock and Prefunded Warrants sold in the Offerings, or an aggregate of
&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zL0ufWmxoJl9" title="Warrants outstanding"&gt;99&lt;/span&gt; shares of Common Stock, at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zRZ2qm2L5R0j" title="Warrant exercise price"&gt;994.50&lt;/span&gt; per share (the &#x201c;Placement Agent Warrants&#x201d;). The Placement
Agent Warrants will be exercisable immediately following the date of issuance and will expire &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231221__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zgX4pa6bSZx4" title="Warrant outstanding Term"&gt;five years&lt;/span&gt; from issuance. The Placement
Agency Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The
Company has agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and
liabilities arising from breaches of representations and warranties contained in the Placement Agency Agreement, or to contribute to
payments that the Placement Agent may be required to make in respect of those liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
of the instruments issued in the Offerings and the Insider Private Placement have been classified and recorded as part of shareholders&#x2019;
equity (deficit). The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying
values of the respective instruments as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;/p&gt;&lt;p id="xdx_89C_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zZ8211qrMUHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zRuUJ2cLdkP8" style="display: none"&gt;Schedule
of Fair Value of Instruments Issued in Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPyX9aCkusHa" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated
    Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjgcPPPJlqXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;258,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zlthtXzj474i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;321,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGaGssgFOYu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regular Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;470,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zbraQ6ny1bE9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,049,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z7Nfb6onCP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate fair value of the Placement Agent Warrants was $&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_znWVI7GjaHId" title="Warrants exercise price"&gt;47,000&lt;/span&gt;. These have been accounted for as a direct cost of the Offerings and
Inside Private Placement, resulting in no net effect to overall shareholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIfFlUzMp4s4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zOuAHdkHrU5l" style="display: none"&gt;Schedule of Fair value of Warrants Valuation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-Funded
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regular Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Placement
    Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zxKTq7hZhrd2" title="Warrants and rights outstanding"&gt;134&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zFEVlJ8CHIyc" title="Warrants and rights outstanding"&gt;96&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zpB6jZiLkPt7" title="Warrants and rights outstanding"&gt;99&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual/ expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAkLJTwKcqFl" title="Warrants and rights outstanding"&gt;1&lt;/span&gt; month&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zs4ti35RRENe" title="Contractual term"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zc3OwhDykApd" title="Contractual term"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zJ5dZf57aYed" title="Warrants and rights outstanding"&gt;5.53&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zfYtLFqlCxH9" title="Warrants and rights outstanding"&gt;3.91&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPGIqLtKCXz1" title="Warrants and rights outstanding"&gt;3.89&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zP2XHomOv7Xj" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zGU7TLCKdSU4" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zSfRb5M2gZ3e" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zSGN6mLcGGn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the common shares was determined using the closing price of the Company&#x2019;s common stock as of December 26, 2023, which
is the date that the Offerings and the Insider Private Placement closed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;November
2024 Warrants (As Amended)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, warrants to purchase a total of &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zkcMv1Hg4Pzj" title="Warrants to purchase shares"&gt;77,526&lt;/span&gt; shares of common stock issued pursuant to a securities purchase agreement
in a November 2024 financing transaction (the &#x201c;November 2024 Warrant Exercise and Reload Agreement&#x201d;) and as amended in a
January 2, 2025 Warrant Exchange Agreement, remained outstanding. A total of &lt;span id="xdx_904_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_ziWMN0bG94Y1" title="Exercisable warrants"&gt;82,816&lt;/span&gt; warrants were issued in pursuant to the November
2024 Warrant Exercise and Reload Agreement. This consisted of i) series C warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zUvaaA4Bzeyb" title="Warrants to purchase shares"&gt;41,408&lt;/span&gt; shares of common stock,
exercisable immediately from the date of issuance for a period of five and a half years&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2024WarrantExerciseAndReloadAgreementMember_zK1HsjILzh9a" style="display: none" title="Warrant outstanding Term"&gt;5.5&lt;/span&gt; after the date of issuance, at an exercise price
of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zKj2kuaJpwWf" title="Warrant exercise price"&gt;99.60&lt;/span&gt; per warrant share, ii) series D warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zO2cbLs6sHJk" title="Warrants to purchase shares"&gt;41,408&lt;/span&gt; shares of common stock, exercisable immediately from the
date of issuance for a period of &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zJCntURLdsp7" title="Warrant term"&gt;eighteen months&lt;/span&gt; after the date of issuance, at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zet3ZEStQ8il" title="Warrant exercise price"&gt;99.60&lt;/span&gt; per warrant share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_pid_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_zd2eb2Y4cayb" title="Warrants exercised"&gt;5,289&lt;/span&gt; of these warrants were exercised during the three months ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;April
2024 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, warrants to purchase a total of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zX6nfLCSawN9"&gt;31,934&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock issued pursuant to a securities purchase
agreement in an April 2024 financing transaction (the &#x201c;April 2024 Securities Purchase Agreement&#x201d;) remained outstanding. A
total of &lt;span id="xdx_908_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember_zR2Zh0SwJdKg"&gt;62,750&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants were issued in pursuant to the April 2024 Securities
Purchase Agreement. This consisted of i) pre-funded warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zeboZxC2BIsc"&gt;20,100&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of common stock, exercisable immediately from the date of issuance,
and with no expiry date, at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zHitqqljdRM6"&gt;0.24&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share, ii) series A warrants to purchase up to
&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zWlbvYD8z0P9"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, exercisable immediately from the date
of issuance for a period of five and a half years&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zPpXhQ9L5Zce" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zRlUHfrKaXyd"&gt;326.40&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share, iii) series B warrants to purchase up to
&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zuQAmXLNEec2"&gt;20,704&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, exercisable immediately from the date
of issuance for a period of &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zJWatDmblluh"&gt;eighteen
months&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise
price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zsqKtwHR50Bh"&gt;326.40&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share. A further &lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zts2BaHIU36j"&gt;1,242&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued in a concurrent placement agency agreement,
are exercisable immediately from the date of issuance for a period of five and a half years&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--April2024WarrantsMember_zUKwuRMeFo6l" style="display: none"&gt;5.5&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;after the date of issuance, at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxpGjAhPERKk"&gt;124.512&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per warrant share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercised_pid_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_z7Q8K41fr22e" title="Warrants exercised"&gt;9,988&lt;/span&gt; Series B warrants were exercised during the three months ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;December
2023 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, warrants to purchase a total of &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zHgpj8Ogb3ol" title="Warrants to purchase shares"&gt;1,750&lt;/span&gt; shares of common stock issued pursuant to a securities purchase agreement
in a December 2023 financing transaction remained outstanding. A total of &lt;span id="xdx_901_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zNIZl9MpeXn7" title="Warrants exerciseable"&gt;1,651&lt;/span&gt; warrants, including &lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyThreePrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zYetQAMjqvn3" title="Warrants exerciseable"&gt;33&lt;/span&gt; warrants issued in a concurrent
private placement, are exercisable immediately from the date of issuance for a period of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zftguHdWf4H3" title="Warrant term"&gt;seven years&lt;/span&gt; after the date of issuance, at an
exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zmYARZA6K7Zc" title="Warrant exercise price"&gt;765.60&lt;/span&gt; per warrant share. A further &lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightsExercisable_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPxWoeO6a9c3" title="Warrants exercisable"&gt;99&lt;/span&gt; warrants issued in a concurrent placement agency agreement, are exercisable
immediately from the date of issuance for a period of &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_z8V30rblwKr5" title="Warrant term"&gt;five years&lt;/span&gt; after the date of issuance, at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PlacementAgencyAgreementMember_zqSJ6PU1vsJg" title="Warrant exercise price"&gt;994.50&lt;/span&gt; per warrant
share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zRANP317UFZb" title="Warrants exercised"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--December2023PrivatePlacementMember_zpV4ybVDiICk" title="Warrants exercised"&gt;no&lt;/span&gt;&lt;/span&gt; exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;December
2020 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, warrants to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zYUBqq4swWmd" title="Warrants to purchase shares"&gt;186&lt;/span&gt; shares of common stock issued pursuant to a securities purchase agreement in a December
2020 financing transaction remained outstanding (the &#x201c;December 2020 Securities Purchase Agreement&#x201d;). Each warrant shall be
exercisable beginning on the 12-month anniversary of the date of issuance for a period of &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zX8zGeFh6K3i" title="Warrant term"&gt;five years&lt;/span&gt; after the date of issuance, at an
exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zPYRsqvitn9j" title="Warrant exercise price"&gt;14,868&lt;/span&gt; per warrant share. The exercise price of the warrants will be subject to adjustment in the event of any stock
dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the warrants. The
warrants may be exercised on a &#x201c;cashless&#x201d; basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zupY5LG7oIA1" title="Warrants exercised"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyWarrantMember_zr5RfpDPtfk5" title="Warrants exercised"&gt;no&lt;/span&gt;&lt;/span&gt; exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;April
2020 Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zS3hgIxDurTj" title="Warrant outstanding"&gt;497&lt;/span&gt; warrants issued pursuant to a securities purchase agreement in connection with an April 2020 equity financing
remained outstanding, each with an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_z0kzxT9mVZG1" title="Warrant exercise price"&gt;18,000.00&lt;/span&gt;. The common warrants are immediately exercisable and will expire on the fifth
anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject
to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company&#x2019;s
common stock. The common warrants were issued separately from the common stock and were eligible for transfer immediately after issuance.
A common warrant to purchase one share of common stock was issued for every share of common stock purchased in this offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise
notice accompanied by payment in full for the number of shares of the Company&#x2019;s common stock purchased upon such exercise (except
in the case of a cashless exercise). &lt;span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zwoDOH4r2sX8" title="Debt description"&gt;A holder (together with its affiliates) may not exercise any portion of the common warrant to the
extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least
61 days prior notice from the holder to the Company, the holder may increase the amount of ownership of outstanding stock after exercising
the holder&#x2019;s common warrants up to 9.99% of the number of shares of the Company&#x2019;s common stock outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants.&lt;/span&gt; No fractional
shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, the Company
will round down to the next whole share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightExercised_do_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_zvGypY5H1Vq8" title="Warrants exercised"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantOrRightExercised_do_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyWarrantsMember_znF2EDkHduS8" title="Warrants exercised"&gt;no&lt;/span&gt;&lt;/span&gt; exercises of these warrants during the three months ended March 31, 2025 or March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
E Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zpYmcvRxdd22" title="Number of share sold"&gt;1,000,000&lt;/span&gt; shares of the Company&#x2019;s Series E Preferred Stock were issued pursuant to a March 2025 Securities Purchase Agreement
with certain accredited investors. The Company received proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zORkeXYmqnYi" title="Gross proceeds"&gt;1.0&lt;/span&gt; million, net of issuance costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
share of Series E Preferred Stock is convertible into &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zPE19G3De40c"&gt;0.45833&lt;/span&gt;
shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zFYuxC1XNDC8"&gt;0.001&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (&#x201c;Common Stock&#x201d;). In no event will the
Series E Preferred Stock be convertible into Common Stock in a manner that would result in each Investor or their transferees or their
affiliates holding more than the lower of (i) the maximum percentage of the number of shares of Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series E Preferred Stock that can be issued
to the holder without requiring a vote of the stockholders of the Company under the rules and regulations of The Nasdaq Capital Market
(&#x201c;Nasdaq&#x201d;); and (ii) &lt;span id="xdx_900_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zJc8SRYs2dQa"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the number of shares of Common Stock outstanding immediately before the original issue date (the &#x201c;Series E Ownership Limitation&#x201d;),
prior to the date that the Company&#x2019;s stockholders approve the issuance of shares of Common Stock to the Investors upon conversion
of the Series E Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Purchase Agreement, the Company filed a certificate of designations (the &#x201c;Series E Certificate of Designations&#x201d;) with
the Secretary of State of Delaware designating the rights, preferences and limitations of the shares of the Series E Preferred Stock
on March 21, 2025. The Series E Certificate of Designations provides, in particular, that the Series E Preferred Stock will vote together
with the Common Stock on an as-converted basis, subject to the Series E Ownership Limitation, subject further to adjustments for any
stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series E Preferred Stock will be entitled to participate in any dividends made on shares of Common Stock (on an as-converted
basis) if and when such dividends are declared. Upon any liquidation or sale of the Company or all or substantially all of its assets,
the holders of the Series E Preferred Stock will be entitled to receive pari passu with the other holders of preferred stock, prior to
and in preference to any distribution to holders of Common Stock, an amount equal to $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zSkwpv9KbYka" title="Share price"&gt;1.00&lt;/span&gt; per share, the stated value of the Series
E Preferred Stock, then held by them plus any accrued but unpaid dividends. Thereafter, the remaining assets of the Company will be distributed
to the holders of Common Stock until such holders receive a return of their capital originally contributed, and thereafter, any remaining
assets will be distributed to all holders of Common Stock and preferred stock pro rata based on the number of shares held on an as-converted
basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, &lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z1tjIWXFGAW3" title="Preferred stock shares issued"&gt;1,000,000&lt;/span&gt; shares of the Series E Preferred Stock remain issued and outstanding. The &lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zjgMHtKDXS6g" title="Preferred stock shares outstanding"&gt;1,000,000&lt;/span&gt; shares of Series E Preferred
Stock issued and outstanding at March 31, 2025, are convertible into &lt;span id="xdx_908_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zbG7ge5i7Wz" title="Conversion of shares"&gt;458,333&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
C and Series D Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zb4CxxZfbd95" title="Number of share sold"&gt;1,000,000&lt;/span&gt; shares of the Company&#x2019;s Series C Preferred Stock and &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zutCw4YoU4Nf" title="Number of share sold"&gt;2,100,000&lt;/span&gt; shares of the Company&#x2019;s Series D Preferred
Stock were issued pursuant to a January 2025 Securities Purchase Agreement with David E. Lazar, pursuant to which he agreed to purchase
from the Company &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zQU0TJCDrbA2" title="Number of share sold"&gt;1,000,000&lt;/span&gt; shares of Series C Convertible Preferred Stock (the &#x201c;Series C Preferred Stock&#x201d;) and &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z0cVsNfTWDH6" title="Number of share sold"&gt;2,100,000&lt;/span&gt;
shares of Series D Convertible Preferred Stock (the &#x201c;Series D Preferred Stock&#x201d; and, together with the Series C Preferred
Stock, the &#x201c;Preferred Stock&#x201d;) of the Company at a purchase price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zLNqQfQwzW1f" title="Share price"&gt;1.00&lt;/span&gt; per share for aggregate gross proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_ziSnJURRTme8" title="Gross proceeds"&gt;3.1&lt;/span&gt;
million, subject to the terms and conditions of the Purchase Agreement. The proceeds of the transaction were used to repay and settle
outstanding liabilities of the Company and for other general corporate and operating purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;Each share of
Series C Preferred Stock is convertible into &lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7ysKNX5ZqXg" title="Conversion of shares"&gt;0.011&lt;/span&gt;
shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250331_zYU2fJn9LU1j" title="Common stock par value"&gt;0.001&lt;/span&gt;
per share (&#x201c;Common Stock&#x201d;), and each share of Series D Preferred Stock is convertible into &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z722kWYFLCmf" title="Conversion of shares"&gt;0.45833&lt;/span&gt;
shares of Common Stock. In no event will the Series C Preferred Stock be convertible into Common Stock in a manner that would result
in Mr. Lazar or his transferees or their affiliates holding more than the lower of (i) the maximum percentage of the number of
shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
conversion of the Preferred Stock that can be issued to the holder without requiring a vote of the stockholders of the Company under
the rules and regulations of The Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;); and (ii) &lt;span id="xdx_90A_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zVLbTH6plbRc" title="Outstanding common stock at election of purchaser"&gt;5&lt;/span&gt;%
of the number of shares of Common Stock outstanding immediately before the original issue date (the &#x201c;Series C Ownership
Limitation&#x201d;), prior to the date that the Company&#x2019;s stockholders approve the issuance of shares of Common Stock to Mr.
Lazar upon conversion of the Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, prior to a Fundamental Transaction (as defined below), in no event will the Series D Preferred Stock be convertible into Common
Stock in a manner that would result in Mr. Lazar or his transferees or their affiliates holding more than the lower of (i) the maximum
percentage of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon conversion of the Preferred Stock that can be issued to the Holder without requiring a vote of the stockholders of
the Company under the rules and regulations of Nasdaq; and, (ii) &lt;span id="xdx_904_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zk70bDflPDbl" title="Outstanding common stock at election of purchaser"&gt;49.99&lt;/span&gt;% of the number of shares of the Common Stock outstanding immediately
before the original issue date (the &#x201c;Series D Ownership Limitation&#x201d;). The term &#x201c;Fundamental Transaction,&#x201d; means
when (i) the Company effects any merger of the Company with or into another entity and the Company is not the surviving entity, (ii)
any tender offer or exchange offer (whether by the Company or by another individual or entity, and approved by the Company) is completed
pursuant to which holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash
or property and the holders of at least 50% of the Common Stock accept such offer, or (iii) the Company effects any reclassification
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock). The certificate
of designations for each of the Series C Preferred Stock and Series D Preferred Stock further provide that even following a vote of the
stockholders of the Company in accordance with the rules and regulations of the trading market on which the Common Stock trades on such
date and applicable securities laws to approve the removal of the Series C Ownership Limitation, the Company shall not affect any conversion
of the Preferred Stock, and a holder of the Preferred Stock shall not have the right to convert any portion of the Preferred Stock, to
the extent that, after giving effect to the conversion, such holder (together with any other shares of Common Stock otherwise held by
such holder(s) or their affiliates) would beneficially own the number of shares of Common Stock, which would be in excess of any statutory
threshold pursuant to which the acquisition of such shares would trigger a compulsory offer requirement under applicable federal or state
tender offer rules for the holder and its affiliates to make a tender offer for all the shares of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 24, 2025, all of the Series C preferred shares were converted in conjunction with the Purchase Agreement. As of March 31, 2025
there were no remaining shares of the Series C Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 24, 2025, &lt;span id="xdx_90F_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250224__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zMCO5G34RGRb" title="Conversion of shares"&gt;1,745,262&lt;/span&gt; of the Series D preferred shares were converted in conjunction with the Purchase Agreement. As of March
31, 2025, &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zN3mCOEZFIu2" title="Preferred stock shares issued"&gt;354,738&lt;/span&gt; shares of the Series D Preferred Stock remain issued and outstanding. The &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zCH8jksCD2B9" title="Preferred stock shares outstanding"&gt;354,738&lt;/span&gt; shares of Series D Preferred Stock
issued and outstanding at March 31, 2025, are convertible into &lt;span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z6hjriCr2rc8" title="Conversion of shares"&gt;162,588&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
B Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLsRIdlcPqab" title="Number of share sold"&gt;237,745&lt;/span&gt; shares of the Company&#x2019;s Series B Preferred Stock were issued pursuant to a December 2020 Securities Purchase Agreement.
Each share of Series B Preferred Stock was initially convertible into one third (1/3) share of common stock (the &#x201c;Conversion Shares&#x201d;),
subject to adjustment in accordance with the Certificate of Designation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, &lt;span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPu9HnRo13u2" title="Number of shares converted"&gt;119,000&lt;/span&gt; shares of Series B Preferred Stock were converted, at the option of the holder, into &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zeyl6WJF2ak7"&gt;165&lt;/span&gt;
shares of common stock. As of March 31, 2025, there were &lt;span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_do_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkj3mD0PFwli" title="Conversion of shares"&gt;no&lt;/span&gt; remaining shares of the Series&#160;B Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
A Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
total of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOOlbNWOJTJ3" title="Number of share sold"&gt;8,872&lt;/span&gt; shares of the Company&#x2019;s Series A Preferred Stock were issued in a July 2017 Underwritten Public Offering. Each share
of Series A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined
by dividing $&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqBCZjQGWjf3" title="Stock value"&gt;1,000&lt;/span&gt; by the initial conversion price of $&lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsTURdQmFgKa" title="Conversion price of convertible preferred stock"&gt;144,000.00&lt;/span&gt; per share, subject to a &lt;span id="xdx_90D_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAESJnthatX" title="Outstanding common stock at election of purchaser"&gt;4.99&lt;/span&gt;% blocker provision, or, upon election by a
holder prior to the issuance of shares of Series A Preferred Stock, &lt;span id="xdx_90B_ecustom--ConvertiblePreferredStockConversionPercentage_pid_dp_uPure_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3PoyIUtBKNe" title="Conversion percentage"&gt;9.99&lt;/span&gt;%, and is subject to adjustment for stock splits, stock dividends,
distributions, subdivisions and combinations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025 and December 31, 2024, &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4mei2YiKrAd" title="Preferred stock shares issued"&gt;264&lt;/span&gt; shares of the Series A Preferred Stock remain issued and outstanding. The &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_za8mkKWMRoOg" title="Preferred stock shares outstanding"&gt;264&lt;/span&gt; shares of
Series A Preferred Stock issued and outstanding at March 31, 2025, are convertible into &lt;span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVmvgQBjVWUa" title="Conversion of shares"&gt;2&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock
basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends
in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted
basis. There is no restriction on the Company&#x2019;s ability to repurchase shares of Series A Preferred Stock while there is an arrearage
in the payment of dividends on such shares, and there are no sinking fund provisions applicable to Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subject
to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder
of the Series A Preferred Stock to convert all or part of such holder&#x2019;s Series A Preferred Stock in the event that (i) the volume
weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds &lt;span id="xdx_908_ecustom--PercentageOfOutstandingCommonStockAtElectionOfPurchaser_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcTrwOmPwfBg" title="Outstanding common stock at election of purchaser"&gt;300&lt;/span&gt;% of the initial conversion
price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends
and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $&lt;span id="xdx_908_eus-gaap--ConversionOfStockAmountConverted1_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVyAW3bRuw8i" title="Conversion of amount"&gt;500,000&lt;/span&gt; per trading
day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information
which was provided by the Company. The right to cause each holder of Series A Preferred Stock to convert all or part of such holder&#x2019;s
Series A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains
no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common
stock in the distribution of assets, to the extent legally available for distribution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;6%
Convertible Exchangeable Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, there were &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3WdMmP29BVd" title="Preferred stock shares issued"&gt;135,273&lt;/span&gt; shares of the Company&#x2019;s &lt;span id="xdx_907_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ze6pXP3PNsi2" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Convertible Exchangeable Preferred Stock (the &#x201c;&lt;span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zjsOuoDx1f7b" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred
Stock&#x201d;) issued and outstanding at an issue price of $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_ztLikzfrwhWg" title="Share issue price per share"&gt;10.00&lt;/span&gt; per share. Dividends on the &lt;span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zeKGc9t23jmk" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred Stock are cumulative from the
date of original issuance at the annual rate of &lt;span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z5ldLMp0Zw1a" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% of the liquidation preference of the &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zCeU7ykmoW3d" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred Stock, payable quarterly on the
first day of February, May, August and November, commencing February 1, 2005. Any dividends must be declared by the Company&#x2019;s board
of directors and must come from funds that are legally available for dividend payments. The &lt;span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zt7IYqiOti9d" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred Stock has a liquidation preference
of $&lt;span id="xdx_902_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zkradnCESYi1" title="Liquidation preference"&gt;10.00&lt;/span&gt; per share, plus accrued and unpaid dividends. As of March 31, 2024, there were no accrued and unpaid dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may automatically convert the 6% Preferred Stock into common stock if the per share closing price of the Company&#x2019;s common
stock has exceeded $&lt;span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zinJmwiIaa2l" title="Conversion amount"&gt;213,192,000&lt;/span&gt;, which is &lt;span id="xdx_90D_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zm7PD695dYbg" title="Conversion price percentage"&gt;150&lt;/span&gt;% of the conversion price of the &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zU2NIHGoSfde" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred Stock, for at least 20 trading days during any
30 day trading period, ending within five trading days prior to notice of automatic conversion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
&lt;span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zJGsK7OFNHo" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may, at its option, redeem the &lt;span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z4Jwz1yauNbf" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred Stock in whole or in part, out of funds legally available at the redemption price
of $&lt;span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zaxlBPAqB1C3" title="Redemption price per share"&gt;10.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
6% Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on
November&#160;1, 2005 (the &#x201c;Exchange Date&#x201d;) for the Company&#x2019;s &lt;span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zFYZg4Hm6QEj" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Convertible Subordinated Debentures (the &#x201c;Debentures&#x201d;)
at the rate of $&lt;span id="xdx_908_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zVrdSenLYaai" title="Redemption price per share"&gt;10.00&lt;/span&gt; principal amount of Debentures for each share of &lt;span id="xdx_908_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z1xGOnD8mM64" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred Stock. The Debentures, if issued, will mature &lt;span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zzRktYzy60nl" title="Debt instrument, term"&gt;25&lt;/span&gt;
years after the Exchange Date and have substantially similar terms to those of the &lt;span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zY3klpZtJJWj" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Preferred Stock. No such exchanges have taken place
to date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact002043"
      unitRef="Shares">604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002044"
      unitRef="Shares">20100</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact002045"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact002046"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsAndCommonWarrantsMember"
      decimals="INF"
      id="Fact002047"
      unitRef="Shares">386.376</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact002048"
      unitRef="USDPShares">326.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-04-30_custom_SeriesAWarrantsMember"
      id="Fact002049">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_SeriesBWarrantsMember"
      id="Fact002050">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002051"
      unitRef="USDPShares">0.024</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:PercentageOfOutstandingCommonStock
      contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact002052"
      unitRef="Pure">0.0499</CYCC:PercentageOfOutstandingCommonStock>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2024-04-302024-04-30_custom_AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact002053"
      unitRef="Pure">0.0999</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-05-022024-05-02"
      decimals="-5"
      id="Fact002054"
      unitRef="USD">8000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <CYCC:CashPlacementFeePercentage
      contextRef="AsOf2024-04-29"
      decimals="INF"
      id="Fact002055"
      unitRef="Pure">0.070</CYCC:CashPlacementFeePercentage>
    <CYCC:ManagementFeePercentageToAggregateGrossProceeds
      contextRef="AsOf2024-04-29"
      decimals="INF"
      id="Fact002056"
      unitRef="Pure">0.010</CYCC:ManagementFeePercentageToAggregateGrossProceeds>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002057"
      unitRef="Shares">1242</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002058"
      unitRef="USDPShares">124.512</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-04-29_custom_PlacementAgentWarrantsMember"
      id="Fact002059">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CYCC:CompensationPercentageToAggregateGrossProceeds
      contextRef="AsOf2024-03-14_custom_RothCapitalPartnersLlcMember"
      decimals="INF"
      id="Fact002060"
      unitRef="Pure">0.070</CYCC:CompensationPercentageToAggregateGrossProceeds>
    <CYCC:CompensationPercentageToAggregateGrossProceeds
      contextRef="AsOf2023-10-30_custom_LadenburgThalmannCo.IncMember"
      decimals="INF"
      id="Fact002061"
      unitRef="Pure">0.080</CYCC:CompensationPercentageToAggregateGrossProceeds>
    <CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact002063">&lt;p id="xdx_897_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_zA78XcnVP3d9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zoHcCeHWglHg" style="display: none"&gt;Schedule
of Fair Value of Instruments Issued in Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250331_zGjcrW70H7G8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated
    Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuojg1Le9Ry5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common shares&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72,108&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zSSPmw9N1rvj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prefunded warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,398,831&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYpsat2GSfXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,819,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zs3KLuTxpE01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net proceeds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,290,213&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact002065"
      unitRef="USD">72108000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_PreFundedWarrantsMember"
      decimals="-3"
      id="Fact002067"
      unitRef="USD">2398831000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_CommonStockWarrantsMember"
      decimals="-3"
      id="Fact002069"
      unitRef="USD">3819274000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2025-01-01to2025-03-31"
      decimals="-3"
      id="Fact002071"
      unitRef="USD">6290213000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-03-31_custom_PlacementAgentWarrantsMember"
      decimals="0"
      id="Fact002073"
      unitRef="USD">609179</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact002075">&lt;p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zTUa68Prla6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zxPcTvzLnbz2" style="display: none"&gt;Schedule of Fair value of Warrants Valuation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-Funded
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Placement
    Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKuoTFVcMyZ1" title="Warrants and rights outstanding"&gt;100&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zDnR00CKxMGj" title="Warrants and rights outstanding"&gt;103&lt;/span&gt;% - &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zzNklfHgkJNh" title="Warrants and rights outstanding"&gt;121&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0huGRbp6ax3" title="Warrants and rights outstanding"&gt;103&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0cu2bRSDefd" title="Warrants and rights outstanding"&gt;1&lt;/span&gt; year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 7pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zENaCO5e8ZGh" title="Contractual term"&gt;1.5&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&#xbd;&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif"&gt;- 5&#xbd;&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years &lt;span style="display: none; font-size: 7pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zO0bmRuNgBzl" title="Contractual term"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&#xbd;&lt;/span&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif"&gt;years &lt;span style="display: none; font-size: 7pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPcIKiW6chD8"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztL9uwwXw2Z9" title="Warrants and rights outstanding"&gt;5.51&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z6AfpudEkteh" title="Warrants and rights outstanding"&gt;4.57&lt;/span&gt;% - &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zWqD4S4fITBk" title="Warrants and rights outstanding"&gt;5.51&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zF6xSJIXdgW8" title="Warrants and rights outstanding"&gt;4.57&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxxy4WOQ6Ip" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zb3qu8Q9Wg4e" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcVi1mljH135" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact002077"
      unitRef="Pure">100</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002079"
      unitRef="Pure">103</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002081"
      unitRef="Pure">121</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact002083"
      unitRef="Pure">103</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact002085"
      unitRef="Pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_srt_MinimumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact002087"
      unitRef="Pure">1.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_srt_MaximumMember_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact002089"
      unitRef="Pure">5.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact002090"
      unitRef="Pure">5.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact002092"
      unitRef="Pure">5.51</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002094"
      unitRef="Pure">4.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002096"
      unitRef="Pure">5.51</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact002098"
      unitRef="Pure">4.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact002100"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact002102"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact002104"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002105"
      unitRef="Shares">702</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember54201031"
      decimals="INF"
      id="Fact002106"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002107"
      unitRef="Shares">915</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002108"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember54201031"
      decimals="INF"
      id="Fact002109"
      unitRef="USDPShares">795.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002110"
      unitRef="USDPShares">795.36</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact002111"
      unitRef="Shares">1617</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact002112"
      unitRef="USDPShares">765.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      id="Fact002113">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CYCC:AggregateProceedsFromSaleOfStock
      contextRef="AsOf2023-12-26_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="-5"
      id="Fact002114"
      unitRef="USD">1000000.0</CYCC:AggregateProceedsFromSaleOfStock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact002115"
      unitRef="Shares">25</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact002116"
      unitRef="Shares">25</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember"
      decimals="INF"
      id="Fact002117"
      unitRef="Shares">8</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_ChiefFinancialOfficerAndChiefOperatingOfficerMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact002118"
      unitRef="Shares">8</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact002119"
      unitRef="USDPShares">795.60</us-gaap:SharesIssuedPricePerShare>
    <CYCC:CashPlacementFeePercentage
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact002121"
      unitRef="Pure">0.080</CYCC:CashPlacementFeePercentage>
    <us-gaap:ProfessionalFees
      contextRef="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact002123"
      unitRef="USD">85000</us-gaap:ProfessionalFees>
    <CYCC:PercentageOfOutstandingCommonStock
      contextRef="From2023-12-212023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002125"
      unitRef="Pure">0.060</CYCC:PercentageOfOutstandingCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002127"
      unitRef="Shares">99</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002129"
      unitRef="USDPShares">994.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-21_custom_DecemberTwoThousandTwentyThreeSecuritiesPurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      id="Fact002131">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock
      contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember"
      id="Fact002133">&lt;p id="xdx_89C_ecustom--ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zZ8211qrMUHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zRuUJ2cLdkP8" style="display: none"&gt;Schedule
of Fair Value of Instruments Issued in Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPyX9aCkusHa" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated
    Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjgcPPPJlqXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;258,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zlthtXzj474i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;321,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGaGssgFOYu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regular Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;470,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts_zbraQ6ny1bE9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,049,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CYCC:ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact002135"
      unitRef="USD">258000000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_custom_PreFundedWarrantsMember"
      decimals="-3"
      id="Fact002137"
      unitRef="USD">321000000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember_custom_CommonStockWarrantsMember"
      decimals="-3"
      id="Fact002139"
      unitRef="USD">470000000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
      contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember"
      decimals="-3"
      id="Fact002141"
      unitRef="USD">1049000000</CYCC:StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-03-31_custom_PlacementAgentWarrantsMember_custom_InsiderPrivatePlacementMember"
      decimals="0"
      id="Fact002143"
      unitRef="USD">47000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2025-01-012025-03-31_custom_InsiderPrivatePlacementMember"
      id="Fact002145">&lt;p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zIfFlUzMp4s4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes
Option Pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zOuAHdkHrU5l" style="display: none"&gt;Schedule of Fair value of Warrants Valuation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-Funded
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regular Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Placement
    Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zxKTq7hZhrd2" title="Warrants and rights outstanding"&gt;134&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zFEVlJ8CHIyc" title="Warrants and rights outstanding"&gt;96&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zpB6jZiLkPt7" title="Warrants and rights outstanding"&gt;99&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual/ expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zAkLJTwKcqFl" title="Warrants and rights outstanding"&gt;1&lt;/span&gt; month&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zs4ti35RRENe" title="Contractual term"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zc3OwhDykApd" title="Contractual term"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zJ5dZf57aYed" title="Warrants and rights outstanding"&gt;5.53&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zfYtLFqlCxH9" title="Warrants and rights outstanding"&gt;3.91&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zPGIqLtKCXz1" title="Warrants and rights outstanding"&gt;3.89&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zP2XHomOv7Xj" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zGU7TLCKdSU4" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InsiderPrivatePlacementMember_zSfRb5M2gZ3e" title="Warrants and rights outstanding"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002147"
      unitRef="Pure">134</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002149"
      unitRef="Pure">96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002151"
      unitRef="Pure">99</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002153"
      unitRef="Pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002155"
      unitRef="Pure">7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedTermMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002157"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002159"
      unitRef="Pure">5.53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002161"
      unitRef="Pure">3.91</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002163"
      unitRef="Pure">3.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PreFundedWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002165"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_CommonStockWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002167"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_InsiderPrivatePlacementMember"
      decimals="INF"
      id="Fact002169"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember"
      decimals="INF"
      id="Fact002171"
      unitRef="Shares">77526</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember"
      decimals="INF"
      id="Fact002173"
      unitRef="Shares">82816</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact002175"
      unitRef="Shares">41408</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_custom_SeriesCWarrantsMember_custom_November2024WarrantExerciseAndReloadAgreementMember"
      id="Fact002177">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact002179"
      unitRef="USDPShares">99.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember"
      decimals="INF"
      id="Fact002181"
      unitRef="Shares">41408</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember"
      id="Fact002183">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember_custom_SeriesDWarrantsMember"
      decimals="INF"
      id="Fact002185"
      unitRef="USDPShares">99.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2025-01-012025-03-31_custom_NovemberTwoThousandTwentyFourWarrantExerciseAndReloadAgreementMember"
      decimals="INF"
      id="Fact002187"
      unitRef="Shares">5289</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact002188"
      unitRef="Shares">31934</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact002189"
      unitRef="Shares">62750</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002190"
      unitRef="Shares">20100</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact002191"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact002192"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_custom_SeriesAWarrantsMember_custom_April2024WarrantsMember"
      id="Fact002193">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact002194"
      unitRef="USDPShares">326.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact002195"
      unitRef="Shares">20704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember"
      id="Fact002196">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact002197"
      unitRef="USDPShares">326.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002198"
      unitRef="Shares">1242</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_custom_PlacementAgentWarrantsMember_custom_April2024WarrantsMember"
      id="Fact002199">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002200"
      unitRef="USDPShares">124.512</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyFourWarrantsMember_custom_SeriesBWarrantMember"
      decimals="INF"
      id="Fact002202"
      unitRef="Shares">9988</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact002204"
      unitRef="Shares">1750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact002206"
      unitRef="Shares">1651</CYCC:ClassOfWarrantOrRightsExercisable>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2025-03-31_custom_DecemberTwoThousandTwentyThreePrivatePlacementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact002208"
      unitRef="Shares">33</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember"
      id="Fact002210">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact002212"
      unitRef="USDPShares">765.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightsExercisable
      contextRef="AsOf2025-03-31_custom_December2023PrivatePlacementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002214"
      unitRef="Shares">99</CYCC:ClassOfWarrantOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_custom_December2023PlacementAgencyAgreementMember"
      id="Fact002216">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_December2023PlacementAgencyAgreementMember"
      decimals="INF"
      id="Fact002218"
      unitRef="USDPShares">994.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2025-01-012025-03-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact002220"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2024-01-012024-03-31_custom_December2023PrivatePlacementMember"
      decimals="INF"
      id="Fact002222"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-31_custom_DecemberTwoThousandTwentyWarrantMember"
      decimals="INF"
      id="Fact002224"
      unitRef="Shares">186</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_custom_DecemberTwoThousandTwentyWarrantMember"
      id="Fact002226">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_DecemberTwoThousandTwentyWarrantMember"
      decimals="INF"
      id="Fact002228"
      unitRef="USDPShares">14868</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2025-01-012025-03-31_custom_DecemberTwoThousandTwentyWarrantMember"
      decimals="INF"
      id="Fact002230"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2024-01-012024-03-31_custom_DecemberTwoThousandTwentyWarrantMember"
      decimals="INF"
      id="Fact002232"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyWarrantsMember"
      decimals="INF"
      id="Fact002234"
      unitRef="Shares">497</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_AprilTwoThousandTwentyWarrantsMember"
      decimals="INF"
      id="Fact002236"
      unitRef="USDPShares">18000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyWarrantsMember"
      id="Fact002238">A holder (together with its affiliates) may not exercise any portion of the common warrant to the
extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least
61 days prior notice from the holder to the Company, the holder may increase the amount of ownership of outstanding stock after exercising
the holder&#x2019;s common warrants up to 9.99% of the number of shares of the Company&#x2019;s common stock outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants.</us-gaap:DebtInstrumentDescription>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2025-01-012025-03-31_custom_AprilTwoThousandTwentyWarrantsMember"
      decimals="INF"
      id="Fact002240"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <CYCC:ClassOfWarrantOrRightExercised
      contextRef="From2024-01-012024-03-31_custom_AprilTwoThousandTwentyWarrantsMember"
      decimals="INF"
      id="Fact002242"
      unitRef="Shares">0</CYCC:ClassOfWarrantOrRightExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact002244"
      unitRef="Shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="-5"
      id="Fact002246"
      unitRef="USD">1000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact002247"
      unitRef="Shares">0.45833</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact002248"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact002249"
      unitRef="Pure">0.0499</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact002251"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact002253"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact002255"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-03-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact002257"
      unitRef="Shares">458333</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact002259"
      unitRef="Shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact002261"
      unitRef="Shares">2100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-31_custom_SeriesCConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002263"
      unitRef="Shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002265"
      unitRef="Shares">2100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact002267"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="-5"
      id="Fact002269"
      unitRef="USD">3100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact002271"
      unitRef="USDPShares">0.011</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact002273"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact002275"
      unitRef="Shares">0.45833</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact002277"
      unitRef="Pure">0.05</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact002279"
      unitRef="Pure">0.4999</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-02-24_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact002281"
      unitRef="Shares">1745262</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact002283"
      unitRef="Shares">354738</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact002285"
      unitRef="Shares">354738</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-03-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact002287"
      unitRef="Shares">162588</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002289"
      unitRef="Shares">237745</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002291"
      unitRef="Shares">119000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002292"
      unitRef="Shares">165</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002294"
      unitRef="Shares">0</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002296"
      unitRef="Shares">8872</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact002298"
      unitRef="USD">1000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2017-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002300"
      unitRef="USDPShares">144000.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002302"
      unitRef="Pure">0.0499</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <CYCC:ConvertiblePreferredStockConversionPercentage
      contextRef="From2017-07-012017-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002304"
      unitRef="Pure">0.0999</CYCC:ConvertiblePreferredStockConversionPercentage>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002306"
      unitRef="Shares">264</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002308"
      unitRef="Shares">264</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002310"
      unitRef="Shares">2</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002312"
      unitRef="Pure">3</CYCC:PercentageOfOutstandingCommonStockAtElectionOfPurchaser>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2025-01-012025-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002314"
      unitRef="USD">500000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002316"
      unitRef="Shares">135273</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002318"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002320"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002322"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002324"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002326"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002328"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002330"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002332"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002334"
      unitRef="USD">213192000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002336"
      unitRef="Pure">1.50</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002338"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002340"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002342"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002344"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002346"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002348"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002350"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      id="Fact002352">P25Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-01-012025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact002354"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact002356">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zKLzuswfrDM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_822_zKfc4OaQw7g3"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividends
on 6% Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 19, 2025, the board of directors of the Company declared a quarterly cash dividend on the Company&#x2019;s &lt;span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250419__20250419__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zerVJoSVrM8b" title="Preferred stock, dividend rate"&gt;6&lt;/span&gt;% Convertible Exchangeable
Preferred Stock scheduled for May 1, 2025. The cash dividend was paid on May 1, 2025, to Preferred Stock stockholders of record as of
the close of business on April 29, 2025. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on
a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Preferred
Stock Conversions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 2, 2025, all of the remaining &lt;span id="xdx_909_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250402__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXp45eGMmaEa" title="Number of common shares issued upon conversion"&gt;354,738&lt;/span&gt; shares of the Company&#x2019;s Series D Preferred Stock was converted into &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250402__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zumQM22wlBZk" title="Number of shares converted"&gt;162,588&lt;/span&gt; shares
of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 29, 2025, all of the &lt;span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20250429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv2zE2pslVTg" title="Number of common shares issued upon conversion"&gt;1,000,000&lt;/span&gt; shares of the Company&#x2019;s Series E Preferred Stock was converted into &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250429__20250429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBBonK5PAX64" title="Number of shares converted"&gt;45,833&lt;/span&gt; shares of
common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;i&gt;Amendment to Amended and Restated
Certificate of Incorporation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 25, 2025, after obtaining the
approval of the Board of Directors and the Company&#x2019;s majority stockholder, the Company filed a Certificate of Amendment to its Amended
and Restated Certificate of Incorporation to increase the number of authorized shares of the Company&#x2019;s common stock from two hundred
fifty million (&lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20250424_zAc9tKH6mDb8" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt;) to six hundred million (&lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20250425_zlbcXLeMvJT7" title="Common stock, shares authorized"&gt;600,000,000&lt;/span&gt;). The amendment did not result in any changes to the issued and outstanding
shares of the Company&#x2019;s common stock, and only affects the number of shares that may be issued by the Company in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Proposed
Business Combination of FITTERS Diversified Berhad&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 6, 2025, the Company entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; &#x201c;FITTERS&#x201d;), an investment
holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention
systems, &#x201c;Waste-To-Resource&#x201d; services and real estate development and construction. Pursuant to the Exchange Agreement, all
of the ordinary shares owned by FITTERS of FITTERS&#x2019; subsidiary, Fitters Sdn. Bhd., a Malaysia-based private limited company (&#x201c;Fitters
Sub&#x201d;) shall be exchanged for common stock, par value $&lt;span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250506__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8rn5pZbpNz2"&gt;0.001&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
of the Company (the &#x201c;Purchaser Stock&#x201d;), and Fitters Sub shall be continuing as a wholly-owned subsidiary of the Company (the
&#x201c;Transaction&#x201d;). As part of the Transaction, Cyclacel shall issue an amount of Purchaser Stock equal to 19.99% percent, which
percentage may be subject to adjustment, of the issued and outstanding shares of Purchaser Stock as of the closing date to FITTERS. At
the closing, it is expected that Cyclacel stockholders will own approximately &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20250506__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FittersDiversifiedBerhadMember_zKEj4G1rxi17"&gt;80.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the combined company. Cyclacel expects that at the closing of the Transaction, its common shares will continue to be listed on the
Nasdaq Capital Market under a new ticker symbol and Cyclacel will be renamed Bio Green Med Solution, Inc. Among the termination rights,
both Cyclacel and FITTERS have the right to terminate the Exchange Agreement if the closing date of the Transaction has not occurred
on or before September 30, 2025. It is currently anticipated that at least one of the officers or directors of FITTERS or Fitters Sub
will be appointed to Cyclacel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Transaction is subject to approval from Cyclacel stockholders and FITTERS shareholders. The Exchange Agreement has been unanimously approved
by the Boards of Directors of each of Cyclacel, FITTERS and Fitters Sub.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 7, 2025, the Company filed an amendment to its Certificate of Incorporation (&#x201c;Certificate of Amendment&#x201d;)
to implement a &lt;span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20250507__20250507_zOr33nZ0KVag" title="Reverse stock split"&gt;one-for-sixteen&lt;/span&gt; reverse stock split. The effective date of the Certificate of Amendment is May 12, 2025 (the &#x201c;Effective
Date&#x201d;). The Company&#x2019;s common stock began trading on a split-adjusted basis when the market opened on the Effective Date. The
Board of Directors of the Company approved the amendment to the Company&#x2019;s Certificate of Incorporation primarily to meet the share
bid price requirements of The Nasdaq Capital Market. The Company&#x2019;s stockholders approved the Certificate of Amendment at a special
meeting of its stockholders held on February 6, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As a result of the
reverse stock split, on the Effective Date, every sixteen shares of common stock then issued and outstanding automatically was combined
into one share of common stock, with no change in par value per share. No fractional shares were outstanding following the reverse stock
split, and any fractional shares that would have resulted from the reverse stock split have been (a) rounded up to the nearest whole
number for any shareholder who would otherwise be entitled to receive one-half or more of a fractional split-adjusted share, and (b)
rounded down to the nearest whole number for any shareholder who would otherwise be entitled to receive less than one-half of a fractional
split-adjusted share.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-04-192025-04-19_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002358"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-04-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002360"
      unitRef="Shares">354738</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-04-022025-04-02_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002362"
      unitRef="Shares">162588</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-04-29_us-gaap_SeriesEPreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002364"
      unitRef="Shares">1000000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-04-292025-04-29_us-gaap_SeriesDPreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002366"
      unitRef="Shares">45833</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-04-24"
      decimals="INF"
      id="Fact002368"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-04-25"
      decimals="INF"
      id="Fact002370"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-05-06_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002371"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-05-06_custom_FittersDiversifiedBerhadMember"
      decimals="INF"
      id="Fact002372"
      unitRef="Pure">0.8001</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-05-072025-05-07" id="Fact002374">one-for-sixteen</us-gaap:StockholdersEquityReverseStockSplit>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>ex107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"
      xlink:type="simple"/>
    <context id="AsOf2025-07-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-07-23" id="Fact000003">0001130166</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp contextRef="AsOf2025-07-23" id="xdx2ixbrl0009">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:MaxOfferingPricPerScty
      contextRef="From2025-07-232025-07-23_1"
      id="xdx2ixbrl0016"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ffd:SubmissnTp contextRef="AsOf2025-07-23" id="Fact000010">S-4</ffd:SubmissnTp>
    <ffd:FormTp contextRef="AsOf2025-07-23" id="Fact000011">S-4</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="AsOf2025-07-23" id="Fact000012">Cyclacel Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="From2025-07-232025-07-23_1" id="Fact000013">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2025-07-232025-07-23_1" id="Fact000014">Class A common stock, par value $0.00001 per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2025-07-232025-07-23_1" id="Fact000024">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="From2025-07-232025-07-23_1"
      decimals="INF"
      id="Fact000015"
      unitRef="Shares">1118282</ffd:AmtSctiesRegd>
    <ffd:MaxAggtOfferingPric
      contextRef="From2025-07-232025-07-23_1"
      decimals="INF"
      id="Fact000017"
      unitRef="USD">2578304</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="From2025-07-232025-07-23_1"
      decimals="INF"
      id="Fact000018"
      unitRef="Ratio">0.00015310</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="From2025-07-232025-07-23_1"
      decimals="INF"
      id="Fact000019"
      unitRef="USD">394.74</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="AsOf2025-07-23"
      decimals="0"
      id="Fact000025"
      unitRef="USD">2578304</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="AsOf2025-07-23"
      decimals="INF"
      id="Fact000026"
      unitRef="USD">394.74</ffd:TtlFeeAmt>
    <ffd:PrevslyPdFlg contextRef="From2025-07-232025-07-23_1" id="Fact000027">false</ffd:PrevslyPdFlg>
    <ffd:TtlPrevslyPdAmt
      contextRef="AsOf2025-07-23"
      decimals="0"
      id="Fact000028"
      unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt
      contextRef="AsOf2025-07-23"
      decimals="0"
      id="Fact000029"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="AsOf2025-07-23"
      decimals="INF"
      id="Fact000030"
      unitRef="USD">394.74</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="From2025-07-232025-07-23_1" id="Fact000033">Represents the maximum number of shares of Common Stock, par value $0.001 per share (&#x201c;Cyclacel Common Stock&#x201d;),
of Cyclacel Pharmaceuticals, Inc. (the &#x201c;Registrant&#x201d;), issuable to securityholders of Fitters Sdn. Bhd. (&#x201c;Fitters&#x201d;)
pursuant to the Exchange and related transactions contemplated by the Exchange Agreement, dated as of May 6, 2025, as amended on July
7, 2025, by and among the Registrant, FITTERS Diversified Berhad and Fitters.Estimated solely for the purpose of calculating the registration fee under Rule 457(f)(2)
under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). As Fitters is a private company, there is no market
for its securities, therefore, the proposed maximum aggregate offering price per share was calculated based on the book value as of July
10, 2025 of the Fitters Ordinary Shares that will be exchanged in the Transaction, which amount equals $2,578,304.The registration fee is determined in accordance with Section 6(b) of the
Securities Act and calculated by multiplying the estimated aggregate offering price of securities to be registered by 0.00015310.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
